PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Carter, J; Gragerov, A; Konvicka, K; Elder, G; Weinstein, H; Lazzarini, RA				Carter, J; Gragerov, A; Konvicka, K; Elder, G; Weinstein, H; Lazzarini, RA			Neurofilament (NF) assembly; Divergent characteristics of human and rodent NF-L subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; TRIPLET PROTEINS; ALPHA-INTERNEXIN; TRANSGENIC MICE; NERVOUS-SYSTEM; EXPRESSION; INVITRO; CELLS; GENE; RAT	Previous studies have shown that rodent neurofilaments (NF) are obligate heteropolymers requiring NF-L plus either NF-M or NF-H for filament formation, We have assessed the competence of human NF-L and NF-M to assemble and find that unlike rat NF-L, human NF-L is capable of self-assembly, However, human NF-M cannot form homopolymers and requires the presence of NF-L for incorporation into filaments, To investigate the stage at which filament formation is blocked, the rod domains or the full-length subunits of human NF-L, human NF-RI, and rodent NF-L were analyzed in the yeast "interaction trap" system, These studies demonstrated that the fundamental block to filament formation in those neurofilaments that do not form homopolymers is at the level of dimer formation, Based on theoretical biophysical considerations of the requirements for the formation of coiled-coil structures, we predicted which amino acid differences were likely to be responsible for the differing dimerization potentials of the rat and human NF-L rod domains, We tested these predictions using site-specific mutagenesis, Interestingly, single amino acid changes in the rod domains designed to restore or eliminate the coiled-coil propensity were found respectively to convert rat NF-L into a subunit capable of homopolymerization and human NF-L into a protein that is no longer able to self-assemble, Our results additionally suggest that the functional properties of the L12 linker region of human NF-L, generally thought to assume an extended beta-sheet conformation, are consonant with an alpha-helix that positions the heptad repeats before and after it in an orientation that allows coiled-coil dimerization, These studies reveal an important difference between the assembly properties of the human and rodent NF-L subunits possibly suggesting that the initiating events in neurofilament assembly may differ in the two species.	CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biophys, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Lazzarini, RA (corresponding author), CUNY Mt Sinai Sch Med, Brookdale Ctr Dev & Mol Biol, POB 1126, New York, NY 10029 USA.		WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818	NIA NIH HHS [P50 AGO 5138-11] Funding Source: Medline; NIDA NIH HHS [DA 00060] Funding Source: Medline; NIDDK NIH HHS [DK4 6943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046943, R01DK046943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005138] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALIN BJ, 1991, BRAIN RES, V556, P181, DOI 10.1016/0006-8993(91)90306-G; BALIN BJ, 1991, BRAIN RES, V556, P196, DOI 10.1016/0006-8993(91)90307-H; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BALLESTEROS JA, 1992, BIOPHYS J, V62, P110, DOI 10.1016/S0006-3495(92)81795-2; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BROWN BA, 1981, J NEUROCHEM, V36, P143, DOI 10.1111/j.1471-4159.1981.tb02389.x; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHIU FC, 1982, J NEUROCHEM, V39, P1252, DOI 10.1111/j.1471-4159.1982.tb12562.x; COCHARD P, 1984, J NEUROSCI, V4, P2080; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; EAGLES PAM, 1990, CELLULAR MOL BIOL IN, P37; ELDER GA, 1994, MOL BRAIN RES, V26, P177, DOI 10.1016/0169-328X(94)90089-2; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLIEGNER KH, 1994, J COMP NEUROL, V342, P161, DOI 10.1002/cne.903420202; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GARDNER EE, 1984, J NEUROSCI RES, V11, P145, DOI 10.1002/jnr.490110204; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; *GEN COMP GROUP, 1996, WISC PACK VERS 9 0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE VMY, 1992, MOL BRAIN RES, V15, P76, DOI 10.1016/0169-328X(92)90154-4; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P199; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Leung CL, 1996, J BIOL CHEM, V271, P14041, DOI 10.1074/jbc.271.24.14041; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; LIFSICS MR, 1984, BIOCHEMISTRY-US, V23, P2866, DOI 10.1021/bi00308a004; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; MINAMI Y, 1984, J BIOCHEM-TOKYO, V96, P1481, DOI 10.1093/oxfordjournals.jbchem.a134977; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MOON HM, 1981, J CELL BIOL, V89, P560, DOI 10.1083/jcb.89.3.560; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; PARYSEK LM, 1988, NEURON, V1, P395, DOI 10.1016/0896-6273(88)90189-4; SANKARARAMAKRISHNAN R, 1993, PROTEINS, V15, P26, DOI 10.1002/prot.340150105; SANKARARAMAKRISHNAN R, 1992, INT J PEPT PROT RES, V39, P356; SANKARARAMAKRISHNAN R, 1990, BIOPOLYMERS, V30, P287, DOI 10.1002/bip.360300307; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; SCOTT D, 1985, J BIOL CHEM, V260, P736; SHECKET G, 1980, J NEUROCHEM, V35, P1335, DOI 10.1111/j.1471-4159.1980.tb09007.x; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; ZACKROFF RV, 1982, P NATL ACAD SCI-BIOL, V79, P754, DOI 10.1073/pnas.79.3.754	50	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5101	5108		10.1074/jbc.273.9.5101	http://dx.doi.org/10.1074/jbc.273.9.5101			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478962	hybrid			2022-12-27	WOS:000072310400046
J	Gohla, A; Harhammer, R; Schultz, G				Gohla, A; Harhammer, R; Schultz, G			The G-protein G(13) but not G(12) mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; BETA-GAMMA-SUBUNITS; TYROSINE PHOSPHORYLATION; FOCAL ADHESIONS; GENE-PRODUCT; RAT-BRAIN; KINASE; ACTIVATION; IDENTIFICATION; P21(RAS)	Lysophosphatidic acid (LPA) utilizes a G-protein-coupled receptor to activate the small GTP-binding protein Rho and to induce rapid remodeling of the actin cytoskeleton, We studied the signal transduction from LPA receptors to Rho activation, Analysis of the G-protein-coupling pattern of LPA receptors by labeling activated G-proteins with [alpha-P-32]GTP azidoanilide revealed interaction with proteins of the G(q), G(i), and G(12) subfamilies, We could show that in COS 7 cells, expression of GTPase-deficient mutants of G alpha(12) and G alpha(13) triggered Rho activation as measured by increased Rho-GTP levels. In Swiss 3T3 cells, incubation with LPA or microinjection of constitutively active mutants of G alpha(12) and G alpha(13) induced formation of actin stress fibers and assembly of focal adhesions in a Rho-dependent manner, Interestingly, the LPA dependent cytoskeletal reorganization was suppressed by microinjected antibodies directed against G alpha(13), whereas G alpha(12)-specific antibodies showed no inhibition, The tyrosine kinase inhibitor tyrphostin A 25 and the epidermal growth factor (EGF) receptor-specific tyrphostin AG 1478 completely blocked actin stress fiber formation caused by LPA or activated G alpha(13) but not the effects of activated G alpha(12). Also, expression of the dominant negative EGF receptor mutant EGFR-CD533 markedly prevented the LPA- and G alpha(13)-induced actin polymerization, Coexpression of EGFR CD533 and activated G alpha(13) in COS-7 cells resulted in decreased Rho-GTP levels compared with expression of activated G alpha(13) alone, These data indicate that in Swiss 3T3 cells, G(13) but not G(12) is involved in the LPA-induced activation of Rho, Moreover, our results suggest an involvement of the EGF receptor in this pathway.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schultz, G (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 67-73, D-14195 Berlin, Germany.			Gohla, Antje/0000-0002-7442-1487				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BARRY ST, 1994, J CELL SCI, V107, P2033; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; HARHAMMER R, 1994, BIOCHEM J, V303, P135, DOI 10.1042/bj3030135; Harhammer R, 1996, BIOCHEM J, V319, P165, DOI 10.1042/bj3190165; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; THOMSON FJ, 1994, MOL PHARMACOL, V45, P718; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WOLBRING G, 1994, J BIOL CHEM, V269, P22470	35	232	240	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4653	4659		10.1074/jbc.273.8.4653	http://dx.doi.org/10.1074/jbc.273.8.4653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468525	hybrid			2022-12-27	WOS:000072115000053
J	Woska, JR; Morelock, MM; Jeanfavre, DD; Caviness, GO; Bormann, BJ; Rothlein, R				Woska, JR; Morelock, MM; Jeanfavre, DD; Caviness, GO; Bormann, BJ; Rothlein, R			Molecular comparison of soluble intercellular adhesion molecule (sICAM)-1 and sICAM-3 binding to lymphocyte function-associated antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD11A I-DOMAIN; CELL-ADHESION; T-LYMPHOCYTES; AMINO-ACIDS; MONOCLONAL-ANTIBODIES; NEUTROPHIL ADHERENCE; COUNTER-RECEPTOR; INTEGRIN LFA-1; ICAM-1; ACTIVATION	The interactions of intercellular adhesion molecules-1 and -3 (ICAM-1 and ICAM-3) with lymphocyte function-associated antigen-1 (LFA-1) have been characterized and compared on the molecular and cellular level, Enzyme linked immunosorbent-based molecular assays have been utilized to calculate the binding affinities of soluble ICAM-1 (sICAM-1) and soluble ICAM-3 (sICAM-3) for LFA-1. Consistent with previously published data, we found that sICAM-1 binds to LFA-1 with an affinity of similar to 60 nM. In contrast, sICAM-3 binds to LFA-1 with an affinity similar to 9 times weaker (similar to 550 nM). Both sICAM-1 and sICAM-3 require divalent cations for binding, Specifically, both Mg2+ and Mn2+ support high affinity adhesion, although interestingly, high concentrations of Ca2+ decrease the affinity of each molecule for LFA-1 substantially, Furthermore, a panel of anti-LFA-1 monoclonal antibodies were characterized for their ability to block sICAM-1 and sICAM-3/LFA-1 interactions in molecular and cellular assays to help distinguish binding sites on LFA-1 for both molecules, Finally, molecular and cellular competition experiments demonstrate that sICAM-1 and sICAM-3 compete with each other for binding to LFA-1. The above data demonstrate that sICAM-1 and sICAM-3 share a common binding site or an overlapping binding site on LFA-1 and that the apparent differences in binding sites can be attributed to different affinities of sICAM-1 and sICAM-3 for LFA-1.	Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, Cell Adhes Grp, Ridgefield, CT 06877 USA; Boehringer Ingelheim Pharmaceut Inc, Dept Inflammatory Dis, Biophys Grp, Ridgefield, CT 06877 USA	Boehringer Ingelheim; Boehringer Ingelheim	Woska, JR (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, Cell Adhes Grp, 900 Ridgebury Rd,POB 368, Ridgefield, CT 06877 USA.	jwoska@bi-pharm.com						ARGENBRIGHT LW, 1991, J LEUKOCYTE BIOL, V49, P253, DOI 10.1002/jlb.49.3.253; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; Binnerts ME, 1996, J BIOL CHEM, V271, P9962, DOI 10.1074/jbc.271.17.9962; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; BOSSY D, 1995, EUR J IMMUNOL, V25, P459, DOI 10.1002/eji.1830250223; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DELPOZO MA, 1994, CELL ADHES COMMUN, V2, P211, DOI 10.3109/15419069409004439; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; HERNANDEZCASELLES T, 1993, EUR J IMMUNOL, V23, P2799, DOI 10.1002/eji.1830231112; HOGG N, 1993, STRUCTURE, FUNCTION, AND REGULATION OF MOLECULES INVOLVED IN LEUKOCYTE ADHESION, P3; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; JUAN M, 1993, EUR J IMMUNOL, V23, P1508, DOI 10.1002/eji.1830230717; Kishimoto T K, 1994, Adv Pharmacol, V25, P117, DOI 10.1016/S1054-3589(08)60431-7; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LORENZ HM, 1993, CELL IMMUNOL, V147, P110, DOI 10.1006/cimm.1993.1052; MA XL, 1992, CIRCULATION, V86, P937, DOI 10.1161/01.CIR.86.3.937; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SAS Institute Inc, 1989, SAS STAT US GUID VER; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STARLING GC, 1995, EUR J IMMUNOL, V25, P2528, DOI 10.1002/eji.1830250918; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Stewart MP, 1996, J IMMUNOL, V156, P1810; TEUNISSEN MBM, 1995, J INVEST DERMATOL, V104, P995, DOI 10.1111/1523-1747.ep12606235; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; Woska JR, 1996, J IMMUNOL, V156, P4680	44	29	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4725	4733		10.1074/jbc.273.8.4725	http://dx.doi.org/10.1074/jbc.273.8.4725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468535	hybrid			2022-12-27	WOS:000072115000063
J	Kretz-Remy, C; Bates, EEM; Arrigo, AP				Kretz-Remy, C; Bates, EEM; Arrigo, AP			Amino acid analogs activate NF-kappa B through redox-dependent I kappa B-alpha degradation by the proteasome without apparent I kappa B-alpha phosphorylation - Consequence on HIV-1 long terminal repeat activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; UNFOLDED-PROTEIN-RESPONSE; GLUCOSE-REGULATED PROTEINS; HEAT-SHOCK INDUCTION; TRANSCRIPTION FACTOR; MULTICATALYTIC PROTEINASE; TYROSINE PHOSPHORYLATION; PROTEOLYTIC DEGRADATION; GLUTATHIONE-PEROXIDASE	We report here that amino acid analogs, which activate hsp70 promoter, are powerful transcriptional activators of human immunodeficiency virus 1 (HIV-1) long terminal repeat (LTR), an activation which was impaired when the two kappa B sites present in the LTR were mutated or deleted. Amino acid analogs also stimulated the transcription of a kappa B-controlled reporter gene. Upon treatment with amino acid analogs, the two NF-kappa B subunits (p65 and p50), which are characterized by a relatively long half-life, redistributed into the nucleus where they bound to kappa B elements. This phenomenon, which began to be detectable after 1 h of treatment, was concomitant with the degradation of the short lived inhibitory subunit I kappa B-alpha by the proteasome. However, contrasting with other NF-kappa B inducers that trigger I kappa B-alpha degradation through a phosphorylation step, amino acid analogs did not change I kappa B-alpha isoform composition. Antioxidant conditions inhibited amino acid analog stimulatory action toward NF-kappa B. This suggests that aberrant protein conformation probably generates a prooxidant state that is necessary for I kappa B-alpha proteolysis by the proteasome. Moreover, this activation of NF-kappa B appeared different from that mediated by endoplasmic reticulum overload as it was not inhibited by calcium chelation.	Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Stress Cellulaire, CNRS,UMR 5534, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Arrigo, AP (corresponding author), Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Stress Cellulaire, CNRS,UMR 5534, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.		Kretz-Remy, Carole/J-7850-2019	Kretz-Remy, Carole/0000-0002-9553-5598				ANATHAN J, 1986, SCIENCE, V232, P522; ARRIGO AP, 1993, BIOCHEM BIOPH RES CO, V194, P1387, DOI 10.1006/bbrc.1993.1978; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BAUERLE PA, 1988, SCIENCE, V242, P540; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN FL, 1993, MOL CELL BIOL, V13, P5245, DOI 10.1128/MCB.13.9.5245; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Castano JG, 1996, BIOCHEMISTRY-US, V35, P3782, DOI 10.1021/bi952540s; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GEELEN JLMC, 1988, J GEN VIROL, V69, P2913, DOI 10.1099/0022-1317-69-11-2913; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HIROMI Y, 1986, CELL, V44, P293, DOI 10.1016/0092-8674(86)90763-4; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; KRETZREMY C, 1994, FEBS LETT, V353, P337; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LIM K, 1989, BIOTECHNIQUES, V7, P576; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LYLE R, 1994, GENE, V138, P265, DOI 10.1016/0378-1119(94)90823-0; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIRAULT ME, 1992, MOLECULAR BASIS OF OXIDATIVE DAMAGE BY LEUKOCYTES, P303; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MORIMOTO R I, 1990, P1; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RE MC, 1989, J VIROL METHODS, V26, P313, DOI 10.1016/0166-0934(89)90113-4; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STANLEY SK, 1990, J IMMUNOL, V145, P1120; STEFFY K, 1991, MICROBIOL REV, V55, P193, DOI 10.1128/MMBR.55.2.193-205.1991; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMAS GP, 1984, MOL CELL BIOL, V4, P1063, DOI 10.1128/MCB.4.6.1063; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; ZABEL U, 1991, J BIOL CHEM, V266, P252	86	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3180	3191		10.1074/jbc.273.6.3180	http://dx.doi.org/10.1074/jbc.273.6.3180			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452429	hybrid			2022-12-27	WOS:000071822300014
J	Kireeva, ML; Lam, SCT; Lau, LF				Kireeva, ML; Lam, SCT; Lau, LF			Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alpha(v)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PHAGE DISPLAY LIBRARY; GROWTH-FACTOR-I; EXTRACELLULAR-MATRIX; ALPHA-V-BETA-3 INTEGRIN; SIGNAL-TRANSDUCTION; EXPRESSION; BINDING; LIGAND; CYCLE	Cyr61 is a member of a family of growth factor-inducible immediate-early gene products thought to act cooperatively with the activities of growth factors, Upon synthesis, Cyr61 is secreted and is predominantly incorporated into the extracellular matrix, Recently, we demonstrated that Cyr61 promotes cell adhesion and migration and augments growth factor-induced DNA synthesis (Kireeva, M, L., Mo, F.-E,, Yang, G, P., and Lau, L, F. (1996) Mol, Cell. Biol. 16, 1326-1334), In the present study, we investigated possible candidate receptor(s) on human umbilical vein endothelial cells (HUVECs) mediating adhesion to Cyr61. Under both serum-containing and serum-free conditions, adhesion of HUVECs to Cyr61 was dose-dependent, saturable, and abolished by affinity-purified anti-Cyr61 antibodies, Cell adhesion to Cyr61 was divalent cation-dependent and specifically inhibited by the peptide RGDS and LM609, a monoclonal antibody against integrin alpha(v) beta(3) Furthermore, purified alpha(v) beta(3) bound directly to an affinity matrix of Cyr61-coupled Sepharose 4B, and this interaction was specifically blocked by anti-Cyr61 antibodies, Additionally, in a solid phase binding assay, soluble Cyr61 bound to immobilized gp, in a dose-dependent manner, and half-saturation binding occurred at approximately 5 nM Cyr61, As expected, the interaction of Cyr61 with immobilized alpha(v) beta(3) was blocked by RGDS and LM609. In sum, these results identified Cyr61 as a novel ligand for alpha(v) beta(3) and indicate that the adhesion of HUVECs to Cyr61 is mediated through interaction with this integrin, The possibility that integrin alpha(v) eta(3) functions as a signaling receptor for Cyr61 accounts for most if not all activities that can be ascribed to Cyr61 to date and suggests a mechanism of action discussed herein.	Univ Illinois, Dept Mol Genet MC 669, Coll Med, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kireeva, ML (corresponding author), Univ Illinois, Dept Mol Genet MC 669, Coll Med, 900 S Ashland Ave, Chicago, IL 60607 USA.		Kireeva, Maria/B-4391-2018	Kireeva, Maria/0000-0003-0527-3182; Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA46565] Funding Source: Medline; NHLBI NIH HHS [HL41793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041793, R01HL041793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; CUMMINGS RD, 1992, BIOESSAYS, V14, P849, DOI 10.1002/bies.950141210; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IUPAC-IUB commission on biochemical nomenclature, 1968, J BIOL CHEM, V243, P3557; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LATINKIC BV, 1994, THESIS U ILLINOIS CH; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; MEREDITH J, 1995, SCIENCE, V269, P1570, DOI 10.1126/science.7545312; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEPP NT, 1994, J INVEST DERMATOL, V103, P295, DOI 10.1111/1523-1747.ep12394617; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; WOODS VL, 1994, ARTHRITIS RHEUM, V37, P537, DOI 10.1002/art.1780370414; Yamada T, 1996, FEBS LETT, V387, P11, DOI 10.1016/0014-5793(96)00409-7; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	57	187	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3090	3096		10.1074/jbc.273.5.3090	http://dx.doi.org/10.1074/jbc.273.5.3090			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446626	hybrid			2022-12-27	WOS:000071736600081
J	Takasawa, S; Akiyama, T; Nata, K; Kuroki, M; Tohgo, A; Noguchi, N; Kobayashi, S; Kato, I; Katada, T; Okamoto, H				Takasawa, S; Akiyama, T; Nata, K; Kuroki, M; Tohgo, A; Noguchi, N; Kobayashi, S; Kato, I; Katada, T; Okamoto, H			Cyclic ADP-ribose and inositol 1,4,5-trisphosphate as alternate second messengers for intracellular Ca2+ mobilization in normal and diabetic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; INSULIN-SECRETION; PANCREATIC-ISLETS; PROINSULIN SYNTHESIS; RYANODINE RECEPTOR; MOLECULAR-CLONING; SURFACE-MOLECULE; CYCLASE ACTIVITY; CD38; RELEASE	Intracellular Ca2+ mobilization occurs in a variety of cellular processes and is mediated by two major systems, the inositol 1,4,5-trisphosphate (IP3) and cyclic ADP-ribose (cADPR) systems, cADPR has been proposed to be a second messenger for insulin secretion induced by glucose in pancreatic beta-cells (Takasawa, S., Nata, K., Yonekura, H., and Okamoto, H. (1993) Science 259, 370-373). Here we show that the cADPR signal system for insulin secretion is replaced by the IP3 system in diabetic beta-cells such as ob/ob mouse islets and RINm5F cells. We measured the cADPR content in these beta-cells by radioimmunoassay and found that the increase of the cADPR content by glucose did not occur in ob/ob mouse islets and RINm5F cells, whereas the increased cADPR level by glucose was observed in normal rat and mouse islets, Microsomes of these diabetic beta-cells released Ca2+ in response to IP3 but not to cADPR. In the diabetic beta-cells, CD38 (ADP-ribosyl cyclase/cADPR hydrolase) and type 2 ryanodine receptor mRNAs were scarcely detected and, in contrast, an increased expression of IP3 receptor mRNAs was observed, The diabetic beta-cells secreted insulin rather by carbamylcholine than by glucose.	Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 98077, Japan; Univ Tokyo, Fac Pharmaceut Sci, Dept Physiol Chem, Tokyo 113, Japan	Tohoku University; University of Tokyo	Okamoto, H (corresponding author), Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, 2-1 Sieryo Machi, Sendai, Miyagi 98077, Japan.							ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DONG C, 1994, INT IMMUNOL, V6, P1353, DOI 10.1093/intimm/6.9.1353; Ebihara S, 1997, J BIOL CHEM, V272, P16023, DOI 10.1074/jbc.272.25.16023; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUYA Y, 1995, GENE, V165, P329, DOI 10.1016/0378-1119(95)00540-M; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GOTO Y, 1975, P JPN ACAD, V51, P80, DOI 10.2183/pjab1945.51.80; HARADA N, 1993, J IMMUNOL, V151, P3111; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; ISLAM MS, 1993, SCIENCE, V262, P584, DOI 10.1126/science.8211188; ITOH M, 1994, BIOCHEM BIOPH RES CO, V203, P1309, DOI 10.1006/bbrc.1994.2325; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Kajimoto Y, 1996, BIOCHEM BIOPH RES CO, V219, P941, DOI 10.1006/bbrc.1996.0327; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Malaisse WJ, 1997, BIOCHEM BIOPH RES CO, V231, P546, DOI 10.1006/bbrc.1996.5715; MATSUOKA TA, 1995, BIOCHEM BIOPH RES CO, V214, P239, DOI 10.1006/bbrc.1995.2280; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; OKAMOTO H, 1995, BIOCHIMIE, V77, P356, DOI 10.1016/0300-9084(96)88146-6; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; ROJAS E, 1994, ENDOCRINOLOGY, V134, P1771, DOI 10.1210/en.134.4.1771; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESUE S, 1970, J BIOCHEM-TOKYO, V67, P259, DOI 10.1093/oxfordjournals.jbchem.a129249; Tohgo A, 1997, J BIOL CHEM, V272, P3879, DOI 10.1074/jbc.272.7.3879; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074	42	107	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2497	2500		10.1074/jbc.273.5.2497	http://dx.doi.org/10.1074/jbc.273.5.2497			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446548	hybrid			2022-12-27	WOS:000071736600003
J	Wu, HJ; MacLeod, AR; Lima, WF; Crooke, ST				Wu, HJ; MacLeod, AR; Lima, WF; Crooke, ST			Identification and partial purification of human double strand RNase activity - A novel terminating mechanism for oligoribonucleotide antisense drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; ESCHERICHIA-COLI; GENE-EXPRESSION; III CLEAVAGE; OLIGONUCLEOTIDES; REPLICATION; TRANSLATION; INHIBITION; INVITRO; INVIVO	We have identified a double strand RNase (dsRNase) activity that can serve as a novel mechanism for chimeric antisense oligonucleotides comprised of 2'-methoxy 5' and 3' "wings" on either side of an oligoribonucleotide gap. Antisense molecules targeted to the point mutation in codon 12 of Harvey Ras (Ha-Ras) mRNA resulted in a dose-dependent reduction in Ha-Ras RNA, Reduction in Ha-Ras RNA was dependent on the oligoribonucleotide gap size with the minimum gap size being four nucleotides, An antisense oligonucleotide of the same composition, but containing four mismatches, was inactive. When chimeric antisense oligonucleotides were prehybridized with 17-mer oligoribonucleotides, extracts prepared from T24 cells, cytosol, and nuclei resulted in cleavage in the oligoribonucleotide gap, Both strands were cleaved. Neither mammalian nor Escherichia coli RNase HI cleaved the duplex, nor did single strand nucleases. The dsRNase activity resulted in cleavage products with 5'-phosphate and 8'-hydroxyl termini. Partial purification of dsRNase from rat liver cytosolic and nuclear fractions was effected, The cytosolic enzyme was purified approximately 165-fold. It has an approximate molecular weight of 50,000-65,000, a pH optimum of approximately 7.0, requires divalent cations, and is inactivated by approximately 300 mM NaCl. It is inactivated by heat, proteinase K, and also by a number of detergents and several organic solvents.	ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Crooke, ST (corresponding author), ISIS Pharmaceut, Dept Mol Pharmacol, 2292 Faraday Ave, Carlsbad, CA 92008 USA.							AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; Crooke ST, 1996, J PHARMACOL EXP THER, V277, P923; CROOKE ST, 1995, THERAPEUTICS APPL OL, P1; CROUCH RJ, 1982, RIBONUCLEASE H NUCL, P211; CROUCH RJ, 1982, NUCLEASES, P21; CRUM C, 1988, NUCLEIC ACIDS RES, V16, P4569, DOI 10.1093/nar/16.10.4569; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DUNN JJ, 1975, J MOL BIOL, V99, P487, DOI 10.1016/S0022-2836(75)80140-9; GERDES K, 1992, J MOL BIOL, V226, P637, DOI 10.1016/0022-2836(92)90621-P; KRINKE L, 1990, GENE DEV, V4, P2223, DOI 10.1101/gad.4.12a.2223; MEEGAN JM, 1989, SCIENCE, V244, P1089, DOI 10.1126/science.2471268; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NELLEN W, 1992, BIOCHEM SOC T, V20, P750, DOI 10.1042/bst0200750; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; SANKAR S, 1989, EUR J BIOCHEM, V184, P39, DOI 10.1111/j.1432-1033.1989.tb14987.x; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; STOLT P, 1993, MOL MICROBIOL, V7, P875, DOI 10.1111/j.1365-2958.1993.tb01178.x; SZYF M, 1991, J BIOL CHEM, V266, P10027; WANG M, 1994, P NATL ACAD SCI USA, V91, P10591, DOI 10.1073/pnas.91.22.10591; WEINBERG RA, 1988, CANCER-AM CANCER SOC, V61, P1963, DOI 10.1002/1097-0142(19880515)61:10<1963::AID-CNCR2820611005>3.0.CO;2-8	33	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2532	2542		10.1074/jbc.273.5.2532	http://dx.doi.org/10.1074/jbc.273.5.2532			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446554	hybrid			2022-12-27	WOS:000071736600009
J	Abu-Abed, SS; Beckett, BR; Chiba, H; Chithalen, JV; Jones, G; Metzger, D; Chambon, P; Petkovich, M				Abu-Abed, SS; Beckett, BR; Chiba, H; Chithalen, JV; Jones, G; Metzger, D; Chambon, P; Petkovich, M			Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor gamma and retinoid X receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA STEM-CELLS; EMBRYONAL CARCINOMA-CELLS; INVITRO METABOLISM; DIFFERENTIATION; INDUCTION; KERATINOCYTES; 4-HYDROXYLASE; BIOSYNTHESIS; KETOCONAZOLE; DISRUPTION	We have cloned a mouse cDNA homolog of P450RAI, a cytochrome P450 belonging to a new family (CYP26), which has previously been isolated from zebrafish and human cDNAs and found to encode a retinoic acid-inducible retinoic acid hydroxylase activity. The cross-species conservation of the amino acid sequence is high, particularly between the mouse and the human enzymes, in which it is over 90%. Like its human and zibrafish counterparts, the mouse P450RAI cDNA catalyzes metabolism of retinoic acid into 4-OH-retinoic acid, 4-oxo-retinoic acid, 18-OH-retinoic acid, and unidentified water-soluble metabolites when transfected into COS-1 cells. Retinoic acid-inducible retinoic acid metabolism has previously been observed in F9 murine embryonal carcinoma cells and some derivatives lacking retinoid receptors. We were interested in determining whether P450RAI could be responsible for retinoic acid metabolism in F9 cells and in studying the effect of retinoid receptor ablation on P450RAI expression. In wild-type F9 cells and derivatives lacking RAR gamma, RAR alpha, and/or RXR alpha, we observed a direct relationship between the level of retinoic acid metabolic activity and retinoic acid-induced P450RAI mRNA. These experiments, as well as others using synthetic receptor subtype-specific retinoids, suggest that the RAR gamma and RXR alpha receptors mediate the effects of retinoic acid on the expression of the P450RAI gene.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ Strasbourg 1, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Petkovich, M (corresponding author), Queens Univ, Canc Res Labs, Rm 355,Botterell Hall, Kingston, ON K7L 3N6, Canada.	petkovic@post.queensu.ca		Metzger, Daniel/0000-0002-5555-046X				Achkar CC, 1996, P NATL ACAD SCI USA, V93, P4879, DOI 10.1073/pnas.93.10.4879; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DeCoster R, 1996, J STEROID BIOCHEM, V56, P133, DOI 10.1016/0960-0760(95)00230-8; Duell EA, 1996, J INVEST DERMATOL, V106, P316, DOI 10.1111/1523-1747.ep12342972; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; FISHER C, 1995, CRIT REV ORAL BIOL M, V6, P284, DOI 10.1177/10454411950060040201; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; GUBLER ML, 1985, J BIOL CHEM, V260, P9552; GUDAS LJ, 1994, RETINOIDS BIOL CHEM, V2, P443; Han IS, 1996, J CLIN ENDOCR METAB, V81, P2069, DOI 10.1210/jc.81.6.2069; Hofmann Clementine, 1994, P387; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Kurlandsky SB, 1996, J BIOL CHEM, V271, P15346, DOI 10.1074/jbc.271.26.15346; LAMPRON C, 1995, DEVELOPMENT, V121, P539; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Li CY, 1996, J BIOL CHEM, V271, P6810, DOI 10.1074/jbc.271.12.6810; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MEYSKENS FL, 1995, AM J CLIN NUTR, V62, P1417, DOI 10.1093/ajcn/62.6.1417S; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; RIGAS JR, 1993, J NATL CANCER I, V85, P1921, DOI 10.1093/jnci/85.23.1921; ROBERTS AB, 1979, J BIOL CHEM, V254, P6303; ROBERTS AB, 1979, J BIOL CHEM, V254, P6296; Ross SA, 1996, NUTR REV, V54, P355; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Saari John C., 1994, P351; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Taimi M, 1997, BIOCHEM BIOPH RES CO, V232, P432, DOI 10.1006/bbrc.1997.6309; Takatsuka J, 1996, CANCER RES, V56, P675; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; Warrell RP, 1996, ANNU REV MED, V47, P555, DOI 10.1146/annurev.med.47.1.555; WHITE JA, 1994, DEVELOPMENT, V120, P1861; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658	52	159	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2409	2415		10.1074/jbc.273.4.2409	http://dx.doi.org/10.1074/jbc.273.4.2409			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442090	hybrid			2022-12-27	WOS:000071595200079
J	Huang, CH				Huang, CH			The human Rh50 glycoprotein gene - Structural organization and associated splicing defect resulting in Rh-null disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENCY SYNDROME; MOLECULAR-CLONING; DUFFY GENE; EXPRESSION; PROTEIN; ANTIGENS; PHENOTYPE; MEMBRANE; DELETION; LOCUS	The Rh (Rhesus) protein family comprises Rh50 glycoprotein and Rh30 polypeptides, which form a complex essential for Rh antigen expression and erythrocyte membrane integrity, This article describes the structural organization of Rh50 gene and identification of its associated splicing defect causing Rh-null disease, The Rh50 gene, which maps at chromosome 6p11-21.1, has an exon/intron structure nearly identical to Rh30 genes, which map at 1p34-36, Of the 10 exons assigned, conservation of size and sequence is confined mainly to the region from exons 2 to 9, suggesting that RH50 and RH30 were formed as two separate genetic loci from a common ancestor via a transchromosomal insertion event, The available information on the structure of RH50 facilitated search for candidate mutations underlying the Rh deficiency syndrome, an autosomal recessive disorder characterized by mild to moderate chronic hemolytic anemia and spherostomatocytosis. In one patient with the Rh-null disease of regulator type, a shortened Rh50 transcript lacking the sequence of exon 7 was detected, while no abnormality was found in transcripts encoding Rh30 polypeptides and Rh-related CD47 glycoprotein, Amplification and sequencing of the genomic region spanning exon 7 revealed a G --> A transition in the invariant GT motif of the donor splice site in both Rh50 alleles, This splicing mutation caused not only a total skipping of exon 7 but also a frameshift and premature chain termination, Thus, the deduced translation product contained 351 instead of 409 amino acids, with an entirely different C-terminal sequence following Thr(315), These results identify the donor splicing defect, for the first time, as a loss-of-function mutation at the RH50 locus and pinpoint the importance of the C-terminal region of Rh50 in Rh complex formation via protein-protein interactions.	New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, New York, NY 10021 USA	New York Blood Center	Huang, CH (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, 310 E 67th St, New York, NY 10021 USA.				NHLBI NIH HHS [HL54459] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054459] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSTEE DJ, 1993, BAILLIERE CLIN HAEM, V6, P401, DOI 10.1016/S0950-3536(05)80152-0; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; Avent ND, 1996, J BIOL CHEM, V271, P14233, DOI 10.1074/jbc.271.24.14233; CAMPBELL IG, 1992, CANCER RES, V52, P5416; CARRITT B, 1993, ANN HUM GENET, V57, P273, DOI 10.1111/j.1469-1809.1993.tb00900.x; CARTRON JP, 1994, BLOOD REV, V8, P199, DOI 10.1016/0268-960X(94)90108-2; CARTRON JP, 1995, BLOOD CEL B, V6, P189; CHERIFZAHAR B, 1994, GENOMICS, V19, P68, DOI 10.1006/geno.1994.1014; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; CHERIFZAHAR B, 1993, BLOOD, V82, P656, DOI 10.1182/blood.V82.2.656.bloodjournal822656; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; Goossens M, 1981, Methods Enzymol, V76, P805; Hermand P, 1996, BLOOD, V87, P2962, DOI 10.1182/blood.V87.7.2962.bloodjournal8772962; Huang C H, 1997, Curr Opin Hematol, V4, P94; Huang CH, 1996, AM J HUM GENET, V58, P133; HUANG CH, 1987, BLOOD, V70, P1830; HUANG CH, 1991, BLOOD, V77, P381; Huang CH, 1996, BLOOD, V88, P2326, DOI 10.1182/blood.V88.6.2326.bloodjournal8862326; Huang CH, 1996, AM J HUM GENET, V59, P825; KRAWCZAK M, 1992, HUM GENET, V90, P41; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; MALLINSON G, 1995, BRIT J HAEMATOL, V90, P823, DOI 10.1111/j.1365-2141.1995.tb05202.x; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; NASH R, 1987, AM J HEMATOL, V24, P267, DOI 10.1002/ajh.2830240306; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RACE RR, 1975, BLOOD GROUPS MAN, P78; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7156; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224	34	53	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2207	2213		10.1074/jbc.273.4.2207	http://dx.doi.org/10.1074/jbc.273.4.2207			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442063	hybrid			2022-12-27	WOS:000071595200052
J	Davoodi, J; Drown, PM; Bledsoe, RK; Wallin, R; Reinhart, GD; Hutson, SM				Davoodi, J; Drown, PM; Bledsoe, RK; Wallin, R; Reinhart, GD; Hutson, SM			Overexpression and characterization of the human mitochondrial and cytosolic branched-chain aminotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID AMINOTRANSFERASE; MONO-VALENT CATIONS; CIRCULAR-DICHROISM; QUATERNARY STRUCTURE; MONOVALENT CATIONS; ESCHERICHIA-COLI; C-MYC; TRYPTOPHANASE; PURIFICATION; PYRIDOXAL	We have developed overexpression systems for the human branched-chain aminotransferase isoenzymes. The enzymes function as dimers and have substrate specificity comparable with the rat enzymes, The human cytosolic enzyme appears to turn over 2-5 times faster than the mitochondrial enzyme, and there may be anion and cation effects on the kinetics of both enzymes. The two proteins demonstrate similar absorption profiles, and the far UV circular dichroism spectra show that no global structural changes occur when the proteins are converted from the pyridoxal to pyridoxamine form, On the other hand, the near UV circular dichroism spectra suggest differences in the local environment surrounding tyrosines within these proteins, Both enzymes require a reducing environment for maximal activity, but the mitochondrial enzyme can be inhibited by nickel ions in the presence of reducing agents, while the cytosolic enzyme is unaffected, Chemical denaturation profiles of the proteins show that there are differences in structural stability, Titration of -SH groups with 5,5'-dithiobis(2-nitrobenzoic acid) suggests that no disulfide bonds are present in the mitochondrial enzyme and that at least two disulfide bonds are present in the cytosolic enzyme, Two -SH groups are titrated in the native form of the mitochondrial enzyme, leading to complete inhibition of activity, while only one -SH group is titrated in the cytosolic enzyme with no effect on activity, Although these proteins share 58% identity in primary amino acid sequence, the local environment surrounding the active site appears unique for each isoenzyme.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Glaxo Wellcome Res & Dev Ltd, Res Triangle Pk, NC 27709 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Wake Forest University; Wake Forest University; GlaxoSmithKline; Texas A&M University System; Texas A&M University College Station	Hutson, SM (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.	shutson@bgsm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK034738, R01DK034738] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34738] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTSON AA, 1994, ADV LIF SCI-SERIES, P187; BenKasus T, 1996, BBA-PROTEIN STRUCT M, V1294, P147, DOI 10.1016/0167-4838(96)00004-0; Bledsoe RK, 1997, BBA-PROTEIN STRUCT M, V1339, P9, DOI 10.1016/S0167-4838(97)00044-7; CHENG S, 1971, J BIOL CHEM, V246, P3623; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DEMIDKINA TV, 1989, BIOCHIMIE, V71, P565, DOI 10.1016/0300-9084(89)90188-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Eden A, 1996, J BIOL CHEM, V271, P20242, DOI 10.1074/jbc.271.34.20242; FIELD MJ, 1989, BIOCHEMISTRY-US, V28, P5306, DOI 10.1021/bi00438a058; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HALL TR, 1993, J BIOL CHEM, V268, P3092; HARRUFF RC, 1978, ARCH BIOCHEM BIOPHYS, V188, P37, DOI 10.1016/0003-9861(78)90353-3; HONDA T, 1986, J BIOCHEM-TOKYO, V100, P679, DOI 10.1093/oxfordjournals.jbchem.a121760; HUTSON SM, 1992, J BIOL CHEM, V267, P15681; HUTSON SM, 1988, J BIOL CHEM, V263, P3618; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; ICHIHARA A, 1966, J BIOCHEM-TOKYO, V59, P160, DOI 10.1093/oxfordjournals.jbchem.a128277; Ichihara A, 1985, TRANSAMINASES, P430; INOUE K, 1988, J BIOCHEM-TOKYO, V104, P777, DOI 10.1093/oxfordjournals.jbchem.a122549; ISUPOV M, 1994, ADV LIF SCI-SERIES, P183; KANDA M, 1995, J NUTR SCI VITAMINOL, V41, P51; Kispal G, 1996, J BIOL CHEM, V271, P24458, DOI 10.1074/jbc.271.40.24458; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1992, ANAL ULTRACENTRIFUGA, P97; LEEPENG FC, 1979, J BACTERIOL, V139, P339, DOI 10.1128/JB.139.2.339-345.1979; LIPSCOMB EL, 1974, BIOCHEMISTRY-US, V13, P2070, DOI 10.1021/bi00707a011; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; MICHUDA CM, 1970, J BIOL CHEM, V245, P262; Okada K, 1997, J BIOCHEM-TOKYO, V121, P637; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SUGIO S, 1995, BIOCHEMISTRY-US, V34, P9661, DOI 10.1021/bi00030a002; TANIZAWA K, 1989, J BIOL CHEM, V264, P2450; TAYLOR RT, 1966, J BIOL CHEM, V241, P4396; TOKUSHIGE M, 1989, BIOCHIMIE, V71, P711, DOI 10.1016/0300-9084(89)90087-4; TONEY MD, 1995, J MOL BIOL, V245, P151, DOI 10.1006/jmbi.1994.0014; TORAYA T, 1976, EUR J BIOCHEM, V69, P411, DOI 10.1111/j.1432-1033.1976.tb10925.x; WALLIN R, 1990, J BIOL CHEM, V265, P6019; WELTY DF, 1995, ANN PHARMACOTHER, V29, P1164, DOI 10.1177/106002809502901118; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YOSHIMURA T, 1993, J AM CHEM SOC, V115, P3897, DOI 10.1021/ja00063a007	46	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4982	4989		10.1074/jbc.273.9.4982	http://dx.doi.org/10.1074/jbc.273.9.4982			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478945	hybrid			2022-12-27	WOS:000072310400029
J	Miech, C; Dierks, T; Selmer, T; von Figura, K; Schmidt, B				Miech, C; Dierks, T; Selmer, T; von Figura, K; Schmidt, B			Arylsulfatase from Klebsiella pneumoniae carries a formylglycine generated from a serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GENOME; DNA-SEQUENCE; PROTEIN; REGION; ATSA; GENE	Eukaryotic sulfatases share an unusual posttranslational protein modification, which converts a cysteine into alpha-formylglycine. The alpha-formylglycine is essential for the catalytic activity. Klebsiella pneumoniae expresses an inducible arylsulfatase for which the DNA predicts a serine at the position occupied by the alpha-formylglycine residue in eukaryotic sulfatases. Structural analysis showed that the majority of the arylsulfatase polypeptides from K. pneumoniae carries the alpha-formylglycine, whereas the remaining arylsulfatase polypeptides contain the predicted serine residue. This demonstrates the evolutionary conservation between prokaryotes and eukaryotes of this novel protein modification that so far has been found only in sulfatases. alpha-Formylglycine in Klebsiella is generated from a serine and not from a cysteine as in eukaryotes.	Univ Gottingen, Biochem Abt 2, D-37073 Gottingen, Germany	University of Gottingen	Schmidt, B (corresponding author), Univ Gottingen, Biochem Abt 2, Gosslerstr 12D, D-37073 Gottingen, Germany.	bschmidt@ukb2-00.uni-bc.gwdg.de	Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				BEIL S, 1995, EUR J BIOCHEM, V229, P385, DOI 10.1111/j.1432-1033.1995.0385k.x; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; BROOKS DA, 1995, BIOCHEM J, V307, P457, DOI 10.1042/bj3070457; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; Dierks T, 1997, P NATL ACAD SCI USA, V94, P11963, DOI 10.1073/pnas.94.22.11963; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; FITZGERALD JW, 1976, BACTERIOL REV, V40, P698, DOI 10.1128/MMBR.40.3.698-721.1976; LUKATELA G, 1998, IN PRESS BIOCHEMISTR; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; OKAMURA H, 1976, AGR BIOL CHEM TOKYO, V40, P2071, DOI 10.1080/00021369.1976.10862350; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selmer T, 1996, EUR J BIOCHEM, V238, P341, DOI 10.1111/j.1432-1033.1996.0341z.x; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576	15	72	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4835	4837		10.1074/jbc.273.9.4835	http://dx.doi.org/10.1074/jbc.273.9.4835			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478923	hybrid			2022-12-27	WOS:000072310400007
J	Pessler, F; Hernandez, N				Pessler, F; Hernandez, N			The HIV-1 inducer of short transcripts activates the synthesis of 5,6-dichloro-1-beta-D-benzimidazole-resistant short transcripts in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; C-MYC GENE; PROTEIN-KINASE; ELONGATION; PROMOTERS; ELEMENT; INVITRO; REPEAT	The HIV-1 inducer of short transcripts (IST) is an unusual promoter element that activates the synthesis of short transcripts from the HIV-1 promoter as well as from heterologous promoters. While the DNA sequences constituting IST have been characterized in some detail, little is known about the biochemical mechanisms underlying IST activity. Here, we describe a cell-free transcription assay that faithfully reproduces the synthesis of IST-dependent HIV-1 short transcripts. As in vivo, formation of these short transcripts requires a functional IST element and is repressed in the presence of the viral trans-activator Tat, Short transcript and full-length transcript synthesis respond differently to variations in several reaction parameters, suggesting that the short and full-length transcripts are synthesized by transcription complexes with distinct biochemical properties, In particular, short transcript synthesis is resistant to the action of 5,6-dichloro-1-beta-D-benzimidazole, an inhibitor of transcript elongation. Formation of transcription complexes directed by the IST element may, therefore, not require the activity of a factor inhibited by 5,6-dichloro-1-beta-D-benzimidazole, such as the TFIIH-associated or pTEFb kinases.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Pessler, F (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Stangel, Martin/AAH-5345-2020	Hernandez, Nouria/0000-0003-1465-4585				BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; Blackburn P, 1982, ENZYMES B, VXV; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KESSLER M, 1992, J VIROL, V66, P4488, DOI 10.1128/JVI.66.7.4488-4496.1992; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Pendergrast PS, 1996, J VIROL, V70, P5025, DOI 10.1128/JVI.70.8.5025-5034.1996; Pendergrast PS, 1997, J VIROL, V71, P910, DOI 10.1128/JVI.71.2.910-917.1997; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; PIRAS G, 1994, J VIROL, V68, P6170, DOI 10.1128/JVI.68.10.6170-6179.1994; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOOHEY MG, 1989, GENE DEV, V3, P265, DOI 10.1101/gad.3.3.265; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	26	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5375	5384		10.1074/jbc.273.9.5375	http://dx.doi.org/10.1074/jbc.273.9.5375			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478998	hybrid			2022-12-27	WOS:000072310400082
J	Willars, GB; Nahorski, SR; Challiss, RAJ				Willars, GB; Nahorski, SR; Challiss, RAJ			Differential regulation of muscarinic acetylcholine receptor-sensitive polyphosphoinositide pools and consequences for signaling in human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED PHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPASE-C ISOZYMES; HAMSTER OVARY CELLS; SK-N-SH; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR CA2+; TYROSINE KINASE; GTP ANALOGS; SH-SY5Y	In this study we have quantitatively assessed the basal turnover of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) and M-3-muscarinic receptor-mediated changes in phosphoinositides in the human neuroblastoma cell line, SH-SY5Y. We demonstrate that the polyphosphoinositides represent a minor fraction of the total cellular phosphoinositide pool and that in addition to rapid, sustained increases in [H-3]inositol phosphates dependent upon the extent of receptor activation by carbachol, there are equally rapid and sustained reductions in the levels of polyphosphoinositides. Compared with phosphatidylinositol 4-phosphate (PtdIns(4)P), PtdIns(4,5)P-2 was reduced with less potency by carbachol and recovered faster following agonist removal suggesting protection of PtdIns(4,5)P-2 at the expense of PtdIns(4)P and indicating specific regulatory mechanism(s). This does not involve a pertussis toxin-sensitive G-protein regulation of PtdIns(4)P 5-kinase. Using wortmannin to inhibit PtdIns I-kinase activity, we demonstrate that the immediate consequence of blocking the supply of PtdIns(4)P (and therefore PtdIns(4,5)P-2) is a failure of agonist-mediated phosphoinositide and Ca2+ signaling. The use of wortmannin also indicated that PtdIns is not a substrate for receptor-activated phospholipase C and that 15% of the basal level of PtdIns(4,5)P-2 is in an agonist-insensitive pool. We estimate that the agonist-sensitive pool of PtdIns(4,5)P-2 turns over every 5 s (0.23 fmol/cell/min) during sustained receptor activation by a maximally effective concentration of carbachol, Immediately following agonist addition, PtdIns(4,5)P-2 is consumed >3 times faster (0.76 fmol/cell/min) than during sustained receptor activation which represents, therefore, utilization by a partially desensitized receptor. These data indicate that resynthesis of PtdIns(4,5)P-2 is required to allow full early and sustained phases of receptor signaling Despite the critical dependence of phosphoinositide and Ca2+ signaling on PtdIns(4,5)P-2 resynthesis, we find no evidence that this rate resynthesis is limiting for agonist-mediated responses.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Willars, GB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.		Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLANK JL, 1991, J BIOL CHEM, V266, P18206; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUNG HC, 1995, PFLUG ARCH EUR J PHY, V429, P789, DOI 10.1007/BF00374802; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; CONWAY BR, 1993, MOL PHARMACOL, V43, P286; DOWNES CP, 1986, BIOCHEM J, V234, P199, DOI 10.1042/bj2340199; DOWNES CP, 1989, INOSITOL LIPIDS CELL, P3; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; DRUMMOND AH, 1984, BIOCHEM J, V224, P129, DOI 10.1042/bj2240129; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HELMS JB, 1991, J BIOL CHEM, V266, P21368; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JENKINSON S, 1994, MOL PHARMACOL, V46, P1138; KOREH K, 1986, J BIOL CHEM, V261, P88; LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555; LAMBERT DG, 1989, EUR J PHARMACOL, V165, P71, DOI 10.1016/0014-2999(89)90771-1; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; NAKANISHI S, 1994, J BIOL CHEM, V269, P6528; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; OKADA T, 1994, J BIOL CHEM, V269, P3563; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Schmidt M, 1996, MOL PHARMACOL, V50, P1038; SMITH CD, 1989, J BIOL CHEM, V264, P3206; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STUBBS EB, 1993, J NEUROCHEM, V60, P1292, DOI 10.1111/j.1471-4159.1993.tb03289.x; VAUGHAN PFT, 1995, GEN PHARMACOL-VASC S, V26, P1191, DOI 10.1016/0306-3623(94)00312-B; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WILLARS GB, 1995, MOL PHARMACOL, V47, P509; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; Zhang CY, 1996, MOL PHARMACOL, V50, P864	51	146	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5037	5046		10.1074/jbc.273.9.5037	http://dx.doi.org/10.1074/jbc.273.9.5037			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478953	hybrid			2022-12-27	WOS:000072310400037
J	Elomaa, O; Sankala, M; Pikkarainen, T; Bergmann, U; Tuuttila, A; Raatikainen-Ahokas, A; Sariola, H; Tryggvason, K				Elomaa, O; Sankala, M; Pikkarainen, T; Bergmann, U; Tuuttila, A; Raatikainen-Ahokas, A; Sariola, H; Tryggvason, K			Structure of the human macrophage MARCO receptor and characterization of its bacteria-binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; SCAVENGER RECEPTOR; LIGAND-BINDING; ADHESION; COLLAGEN; CLONING; RECOGNITION; EXPRESSION; CONTAINS; PROTEIN	The primary structure of human macrophage receptor with collagenous structure (MARCO) was determined from cDNA clones and shown to be highly similar to that of mouse (Elomaa, O., Kangas, M., Sahlberg, C., Tuukkanen, J., Sormunen, R., Liakka, A., Thesleff, I., Kraal, G., and Tryggvason, H. (1995) Cell 80, 603-609), Features such as potential carbohydrate attachment sites in the extracellular spacer domain III and the interruption of Gly-Xaa-Yaa repeats in the collagenous domain IV were conserved between the two species, However, the human MARCO polypeptide chain lacked the intracellular cysteine present in mouse, as well as two extracellular cysteines that form interchain disulfide bonds in the murine protein, fit situ hybridization showed MARCO to be strongly expressed in macrophages of several tissues of human individuals with sepsis, No expression was observed in other cell types. The bacteria-binding region of MARCO was determined in binding studies with full-length and truncated variants of MARCO, and localized to a region proximal to the cysteine-rich part of the COOH-terminal domain V, The intrachain disulfide bond pattern of domain V was established showing that these bonds are between cysteine pairs C1-C5, C2-C6, and C3-C4.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Karolinska Institutet; University of Helsinki	Tryggvason, K (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden.							ASHKENAS J, 1993, J LIPID RES, V34, P983; Ausubel FM, 1988, MOL REPROD DEV; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; Bodian DL, 1997, BIOCHEMISTRY-US, V36, P2637, DOI 10.1021/bi962560+; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOI T, 1993, J BIOL CHEM, V268, P2126; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; EMI M, 1993, J BIOL CHEM, V268, P2120; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HUGHES DA, 1994, IMMUNOL LETT, V43, P7, DOI 10.1016/0165-2478(94)00143-X; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MAYER WE, 1995, GENE, V164, P267, DOI 10.1016/0378-1119(95)94092-Z; NAITO M, 1992, AM J PATHOL, V141, P591; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Sambrook J., 2002, MOL CLONING LAB MANU; SUMMERS MD, 1986, TEX AGR EXP STN B, V1555; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TURPIN JA, 1993, MONONUCLEAR PHAGOCYT, P71; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155	32	109	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4530	4538		10.1074/jbc.273.8.4530	http://dx.doi.org/10.1074/jbc.273.8.4530			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468508	hybrid			2022-12-27	WOS:000072115000036
J	Sano, H; Kuroki, Y; Honma, T; Ogasawara, Y; Sohma, H; Voelker, DR; Akino, T				Sano, H; Kuroki, Y; Honma, T; Ogasawara, Y; Sohma, H; Voelker, DR; Akino, T			Analysis of chimeric proteins identifies the regions in the carbohydrate recognition domains of rat lung collectins that are essential for interactions with phospholipids, glycolipids, and alveolar type II cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT-ASSOCIATED PROTEIN; SITE-DIRECTED MUTAGENESIS; APOPROTEIN SP-A; PULMONARY SURFACTANT; HIGH-AFFINITY; PNEUMOCYSTIS-CARINII; SPECIFICALLY BINDS; TERMINAL DOMAIN; SECRETION; PHOSPHATIDYLINOSITOL	Pulmonary surfactant proteins A (SP-A) and D (SP-D) are collectins in the C-type lectin superfamily, SP-A binds to dipalmitoylphosphatidylcholine and galactosylceramide, and it regulates the uptake and secretion of surfactant lipids by alveolar type II cells, In contrast, SP-D binds to phosphatidylinositol (PI) and glucosylceramide (GlcCer). We investigated the functional region in the carbohydrate recognition domain of rat SP-A and SP-D that is involved in binding lipids and interacting with alveolar type II cells by using chimeric proteins, Chimeras ad3, ad4, and ad5 were constructed with SP-A/SP-D splice junctions at Gly(194)/Glu(321), Gln(173)/Thr(300), and Met(134)/Cys(261), respectively, All three chimeras lost SP-A-specific functions, Chimeras ad3, ad4, and ad5 bound to PI with increasing activity, In contrast, chimeras ad3 and ad4 did not bind to GlcCer, whereas ad5 avidly bound this lipid, From these results, we conclude that 1) the SP-A region of Glu(195)-phe(228) is required for lipid and type II cell interactions, 2) the SP-D region of Cys(261)-Phe(355) is required for optimal lipid interactions, and 3) the structural requirement for the binding of SP-D to PI is different from that for GlcCer.	Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 060, Japan; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Sapporo Medical University; National Jewish Health	Kuroki, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South-1 West-17, Sapporo, Hokkaido 060, Japan.	kurokiy@sapmed.ac.jp						BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1979, J CLIN INVEST, V63, P378, DOI 10.1172/JCI109313; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Honna T, 1997, BIOCHEMISTRY-US, V36, P7176, DOI 10.1021/bi962967e; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUAN SF, 1995, J CLIN INVEST, V95, P2699; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1992, ARCH BIOCHEM BIOPHYS, V299, P261, DOI 10.1016/0003-9861(92)90273-Y; KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V187, P963, DOI 10.1016/0006-291X(92)91291-W; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeVine AM, 1997, J IMMUNOL, V158, P4336; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; O'Reilly DR, 1992, BACULOVIRUS EXPRESSI, P139; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; OGASAWARA Y, 1995, J BIOL CHEM, V270, P19052, DOI 10.1074/jbc.270.32.19052; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; PISON U, 1992, AM J PHYSIOL, V262, pL412, DOI 10.1152/ajplung.1992.262.4.L412; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; VANIWAARDEN JF, 1992, J BIOL CHEM, V267, P25039; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	48	52	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4783	4789		10.1074/jbc.273.8.4783	http://dx.doi.org/10.1074/jbc.273.8.4783			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468543	hybrid			2022-12-27	WOS:000072115000071
J	Brandsch, M; Thunecke, F; Kullertz, G; Schutkowski, M; Fischer, G; Neubert, K				Brandsch, M; Thunecke, F; Kullertz, G; Schutkowski, M; Fischer, G; Neubert, K			Evidence for the absolute conformational specificity of the intestinal H+/peptide symporter, PEPT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTERS	This study was initiated to determine whether the intestinal H+/peptide symporter PEPT1 differentiates between the peptide bond conformers of substrates, We synthesized a modified dipeptide where the peptide bond is replaced by the isosteric thioxo peptide bond, The Ala-Pro derivative Ala-psi[CS-N]-Pro exists as a mixture of cis and trans conformation in aqueous solution and is characterized by a low cis/trans isomerization rate, The compound was recognized by PEPT1 with high affinity, The K-i value of Ala-psi[CS-N]-Pro for the inhibition of the uptake of radiolabeled glycylsarcosine in Caco-2 cells was 0.30 +/- 0.02 mM, determined in solution with 96% trans conformation, In contrast, the Ri value was 0.51 +/- 0.02 mM when uptake media with 62% trans conformer were used, We conclude that only the trans conformer interacts with the transport system. From our data, a significant affinity of the cis conformer at PEPT1 cannot be derived, In a second approach, conformer-specific uptake of Ala-psi[CS-N]-Pro was studied by analyzing the intracellular content of Caco-2 cells following transport as well as the composition of the extracellular medium using capillary electrophoresis. The percentage of trans conformer that was 62% in the uptake medium increased to 92% inside the cells, This is the first direct evidence that an H+/peptide cotransport system selectively binds and transports the trans conformer of a peptide derivative.	Univ Halle Wittenberg, Inst Biochem, Dept Biochem Biotechnol, D-06120 Halle, Germany; Univ Halle Wittenberg, Biozentrum, D-06120 Halle, Germany; Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Max Planck Society	Brandsch, M (corresponding author), Univ Halle Wittenberg, Inst Biochem, Dept Biochem Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Germany.			Schutkowski, MIke/0000-0003-0919-7076				Adibi SA, 1997, GASTROENTEROLOGY, V113, P332, DOI 10.1016/S0016-5085(97)70112-4; AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321; Brandsch M, 1997, BBA-BIOMEMBRANES, V1324, P251, DOI 10.1016/S0005-2736(96)00231-3; Daniel H, 1996, J MEMBRANE BIOL, V154, P197, DOI 10.1007/s002329900144; DANIEL H, 1992, J BIOL CHEM, V267, P9565; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; GANAPATHY ME, 1995, J BIOL CHEM, V270, P25672, DOI 10.1074/jbc.270.43.25672; Ganapathy Vadivel, 1994, P1773; Leibach FH, 1996, ANNU REV NUTR, V16, P99, DOI 10.1146/annurev.nu.16.070196.000531; Merker MP, 1996, AM J PHYSIOL-LUNG C, V270, pL251, DOI 10.1152/ajplung.1996.270.2.L251; Ottleben H, 1997, EUR J BIOCHEM, V244, P471, DOI 10.1111/j.1432-1033.1997.00471.x; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SCHUTKOWSKI M, 1995, BIOCHEMISTRY-US, V34, P13016, DOI 10.1021/bi00040a012; Schutkowski M, 1997, EUR J BIOCHEM, V245, P381, DOI 10.1111/j.1432-1033.1997.00381.x; Thunecke F, 1996, J CHROMATOGR A, V744, P259, DOI 10.1016/0021-9673(96)00241-5; Tsuji A, 1995, PEPTIDE BASED DRUG D, P101; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P186; YAMAZAKI T, 1993, J MED CHEM, V36, P708, DOI 10.1021/jm00058a007; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	19	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3861	3864		10.1074/jbc.273.7.3861	http://dx.doi.org/10.1074/jbc.273.7.3861			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461567	hybrid			2022-12-27	WOS:000072048400009
J	Dibirdik, I; Kristupaitis, D; Kurosaki, T; Tuel-Ahlgren, L; Chu, A; Pond, D; Tuong, D; Luben, R; Uckun, FM				Dibirdik, I; Kristupaitis, D; Kurosaki, T; Tuel-Ahlgren, L; Chu, A; Pond, D; Tuong, D; Luben, R; Uckun, FM			Stimulation of Src family protein-tyrosine kinases as a proximal and mandatory step for SYK kinase-dependent phospholipase C gamma 2 activation in lymphoma B cells exposed to low energy electromagnetic fields	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; OCCUPATIONAL EXPOSURE; CLONAL PROLIFERATION; PHOSPHORYLATION; LEUKEMIA; CANCER; LYN; PRECURSORS; APOPTOSIS	Here, we present evidence that exposure of DT40 lymphoma B cells to low energy electromagnetic field (EMF) results in a tyrosine kinase-dependent activation of phospholipase C gamma 2 (PLC-gamma 2) leading to increased inositol phospholipid turnover, B cells rendered PLC-gamma 2-deficient by targeted disruption of the PLC-gamma 2 gene as well as PLC-gamma 2-deficient cells reconstituted with Src homology domain 2 (SH2) domain mutant PLC-gamma 2 did not show any increase in inositol-1,4,5-trisphosphate levels after EMF exposure, providing direct evidence that PLC-gamma 2 is responsible for EMF-induced stimulation of inositol phospholipid turnover, and its SH2 domains are essential for this function, B cells rendered SYK-deficient by targeted disruption of the syk gene did not show PLC-gamma 2 activation in response to EMF exposure, The C-terminal SH2 domain of SYK kinase is essential for its ability to activate PLC-gamma 2, SYK-deficient cells reconstituted with a C-terminal SH2 domain mutant syk gene failed to elicit increased inositol phospholipid turnover after EMF exposure, whereas SYK deficient cells reconstituted with an N-terminal SH2 domain mutant syk gene showed a normal EMF response, LYN kinase is essential for the initiation of this biochemical signaling cascade, Lymphoma B cells rendered LYN-deficient through targeted disruption of the lyn gene did not elicit enhanced inositol phospholipid turnover after EMF exposure, Introduction of the wild-type (but not a kinase domain mutant) mouse fyn gene into LYN-deficient B cells restored their EMF responsiveness, B cells reconstituted with a SH2 domain mutant fyn gene showed a normal EMF response, whereas no increase in inositol phospholipid turnover in response to EMF was noticed in LYN-deficient cells reconstituted with a SH3 domain mutant fyn gene, Taken together, these results indicate that EMF-induced PLC-gamma 2 activation is mediated by LYN-regulated stimulation of SYK, which acts downstream of LYN kinase and upstream of PLC-gamma 2.	Univ Minnesota, Biotherapy Program, Minneapolis, MN 55417 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Wayne Hughes Inst, Roseville, NSW 55113, Australia; Kansai Med Univ, Inst Hepat Res, Dept Mol Genet, Osaka 570, Japan	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Riverside; Kansai Medical University	Uckun, FM (corresponding author), Wayne Hughes Inst, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Uckun, Fatih M./0000-0001-9334-183X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007175] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES-07175] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CARTWRIGHT RA, 1989, BRIT J CANCER, V60, P649, DOI 10.1038/bjc.1989.332; DEMERS PA, 1991, AM J EPIDEMIOL, V134, P340, DOI 10.1093/oxfordjournals.aje.a116095; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; GUENEL P, 1993, BRIT J IND MED, V50, P758; KOBAYASHI H, 1994, ANU RES NAGOYA U HOS, V28, P39; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Linet MS, 1997, NEW ENGL J MED, V337, P1, DOI 10.1056/NEJM199707033370101; Norimura Toshiyuki, 1993, Journal of UOEH, V15, P103; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TORNQVIST S, 1991, British Journal of Industrial Medicine, V48, P597; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; UEKUN FM, 1997, BLOOD, V89, P3769; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; Zhang X R, 1995, Nagoya J Med Sci, V58, P157	28	57	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4035	4039		10.1074/jbc.273.7.4035	http://dx.doi.org/10.1074/jbc.273.7.4035			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461594	hybrid			2022-12-27	WOS:000072048400036
J	Mathias, N; Steussy, CN; Goebl, MG				Mathias, N; Steussy, CN; Goebl, MG			An essential domain within Cdc34p is required for binding to a complex containing Cdc4p and Cdc53p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; YEAST-CELL CYCLE; PROTEOLYTIC PATHWAY; IN-VIVO; UBC3; DEGRADATION; INHIBITOR; TRANSITION; PROTEINS; FAMILY	The CDC34 gene of the yeast Saccharomyces cerevisiae encodes a ubiquitin-conjugating protein that transfers ubiquitin onto substrates to signal rapid degradation via the proteasome, Cdc34p has been implicated in signaling the destruction of a variety of substrates including the cyclin-dependent kinase inhibitor, Sic1p, which must be degraded for cells to enter S-phase, Mutants lacking CDC34 activity fail to degrade Sic1p and fail to enter S-phase, a phenotype that is also shared with cells lacking CDC4 and CDC53 activity, Here we demonstrate that Cdc4p, Cdc34p, and Cdc53p interact in vivo. We have mapped a Cdc4p/Cdc53p-binding region on Cdc34p; this region is essential for S-phase entry and thus the association of these three proteins is required for Sic1p degradation, All three proteins migrate in gel filtration to sizes that greatly exceed their actual size suggesting that they form stable associations with other proteins and we observe Cdc4p, Cdc34p, and Cdc53p fractionating into overlapping families of high molecular weight complexes. Finally, we demonstrate that Cdc4p, Cde34p, and Cdc53p are stable throughout the cell cycle and that Cdc34p permanently resides as part of a complex throughout the cell cycle, This suggests that all Cdc34p substrates are ubiquitinated by a similar high molecular weight complex.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Mathias, N (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	neal@biochem4.iupui.edu						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Candau R, 1996, J BIOL CHEM, V271, P5237; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; Elbe R, 1992, BIOTECHNIQUES, V13, P18; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LIU Y, 1995, MOL CELL BIOL, V15, P5635; MACKINNEY JD, 1993, GENE DEV, V7, P833; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; PTAK C, 1994, J BIOL CHEM, V269, P26539; Rose MD., 1990, METHODS YEAST GENETI; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2	42	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4040	4045		10.1074/jbc.273.7.4040	http://dx.doi.org/10.1074/jbc.273.7.4040			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461595	hybrid			2022-12-27	WOS:000072048400037
J	Ribon, V; Herrera, R; Kay, BK; Saltiel, AR				Ribon, V; Herrera, R; Kay, BK; Saltiel, AR			A role for CAP, a novel, multifunctional Src homology 3 domain-containing protein in formation of actin stress fibers and focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; TYROSINE PHOSPHORYLATION; SH3 DOMAINS; KINASE; P130(CAS); IDENTIFICATION; CORTACTIN; SUBSTRATE; BINDING; RHO	c-Cbl-associated protein, CAP, was originally cloned from a 3T3-L1 adipocyte cDNA expression library using full-length c-Cbl as a bait, CAP contains a unique structure, with three adjacent Src homology-3 (SH3) domains in the COOH terminus and a region sharing significant sequence similarity with the peptide hormone sorbin, Expression of CAP in NIH-3T3 cells overexpressing the insulin receptor induced the formation of stress fibers and focal adhesions, This effect of CAP expression on the organization of the actin-based cytoskeleton was independent of the type of integrin receptors engaged with extracellular matrix, whereas membrane ruffling and decreased actin stress fibers induced by insulin were not affected by expression of CAP. Immunofluorescence microscopy demonstrated that CAP colocalized with actin stress fibers. Moreover, CAP interacted with the focal adhesion kinase, p125FAK, both in vitro and in vivo through one of the SH3 domains of CAP, The increased formation of stress fibers and focal adhesions in CAP-expressing cells was correlated with decreased tyrosine phosphorylation of p125FAK in growing cells or upon integrin-mediated cell adhesion, These results suggest that CAP may mediate signals for the formation of stress fibers and focal adhesions.	Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Div Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	Pfizer; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison	Saltiel, AR (corresponding author), Warner Lambert Parke Davis, Parke Davis Pharmaceut Res Div, Div Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ANDERSON JR, 1990, SCIENCE, V250, P360, DOI 10.1126/science.250.4979.360; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILIE D, 1995, NATURE, V37, P539; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIBON V, 1998, IN PRESS MOL CELL BI, V18; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	91	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4073	4080		10.1074/jbc.273.7.4073	http://dx.doi.org/10.1074/jbc.273.7.4073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461600	hybrid			2022-12-27	WOS:000072048400042
J	Delvig, AA; Robinson, JH				Delvig, AA; Robinson, JH			Different endosomal proteolysis requirements for antigen processing of two T-cell epitopes of the M5 protein from viable Streptococcus pyogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; GROUP-A STREPTOCOCCI; CYSTEINE PROTEINASES; CATHEPSIN-S; RAT-LIVER; MOLECULES; ACIDIFICATION; PROTEASES; COMPLEX; INHIBITION	We studied endosomal proteolysis of the surface fibrillar M5 protein from viable Streptococcus pyogenes as an essential step involved in major histocompatibility complex class II-restricted antigen processing of two immunodominant CD4(+) T-cell epitopes (17-31/E-d and 308-319/A(d)). Intracellular proteolysis of viable streptococci for presentation of 17-31, bound by serine proteinase cleavage sites, was mediated by serine proteinases, whereas processing of soluble recombinant M5 protein required in addition cysteine proteinases. Furthermore, processing of 17-31 was resistant to ammonium chloride and thus was not dependent on endosome acidification. Cysteine and serine proteinase cleavage sites were located adjacent to 308-319, and its processing was dependent on serine, cysteine, and aspartic proteinases, as well as on endosomal acidification. The data suggest that antigen processing of two major T-cell epitopes on streptococcal M5 protein occurred in different endosomal compartments by different classes of intracellular proteinases.	Univ Newcastle Upon Tyne, Sch Med, Sch Microbiol Virol & Immunol Sci, Dept Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robinson, JH (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Microbiol Virol & Immunol Sci, Dept Immunol, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			von Delwig, Alexei/0000-0003-2978-4761	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRETT AJ, 1975, PROTEASES BIOL CONTR, P467; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BROMME D, 1989, BIOCHEM J, V264, P475; Busch R, 1996, CURR OPIN IMMUNOL, V8, P51, DOI 10.1016/S0952-7915(96)80105-1; BUUS S, 1986, J IMMUNOL, V136, P452; CHAIN BM, 1989, CLIN EXP IMMUNOL, V75, P87; Conte MP, 1996, J MED MICROBIOL, V44, P418, DOI 10.1099/00222615-44-6-418; Delvig AA, 1997, BIOCHEM SOC T, V25, pS205, DOI 10.1042/bst025205s; DIMENT S, 1990, J IMMUNOL, V145, P417; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; HARDING CV, 1997, MHC MOL ANTIGEN PROC; JACQUIERSARLIN MR, 1995, IMMUNOLOGY, V84, P164; KEHOE MA, 1985, INFECT IMMUN, V48, P190, DOI 10.1128/IAI.48.1.190-197.1985; MCCOY K, 1988, J CELL BIOL, V106, P1879, DOI 10.1083/jcb.106.6.1879; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MELLMAN I, 1995, CURR OPIN CELL BIOL, V7, P564, DOI 10.1016/0955-0674(95)80014-X; METZLER DE, 1977, BIOCHEMISTRY-US, P353; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pieters J, 1997, CURR OPIN IMMUNOL, V9, P89, DOI 10.1016/S0952-7915(97)80164-1; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; PINET V, 1994, J IMMUNOL, V152, P4852; PURI J, 1988, J IMMUNOL, V141, P3313; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROBINSON JH, 1991, INFECT IMMUN, V59, P4324, DOI 10.1128/IAI.59.12.4324-4331.1991; ROBINSON JH, 1993, INFECT IMMUN, V61, P1062, DOI 10.1128/IAI.61.3.1062-1068.1993; ROSSITER BA, 1994, EUR J IMMUNOL, V24, P1244, DOI 10.1002/eji.1830240537; STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831; TAKAHASHI H, 1989, J IMMUNOL, V142, P2221; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; ZIEGLER K, 1994, BBA-BIOMEMBRANES, V1196, P209, DOI 10.1016/0005-2736(94)00228-2	34	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3291	3295		10.1074/jbc.273.6.3291	http://dx.doi.org/10.1074/jbc.273.6.3291			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452445	hybrid			2022-12-27	WOS:000071822300030
J	Lai, A; Gibson, A; Hopkins, CR; Trowbridge, IS				Lai, A; Gibson, A; Hopkins, CR; Trowbridge, IS			Signal-dependent trafficking of beta-amyloid precursor protein-transferrin receptor chimeras in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MDCK CELLS; CYTOPLASMIC DOMAIN; ENDOCYTIC PATHWAY; EPITHELIAL-CELLS; MEMBRANE; LYSOSOMES; SECRETION; CLEAVAGE; DETERMINANTS	We have investigated the intracellular trafficking of a chimeric molecule consisting of the cytoplasmic domain of the beta-amyloid precursor protein (APP) and the transmembrane region and external domain of the human transferrin receptor (TR) in Madin-Darby canine kidney cells. Newly synthesized APP-TR chimeras are selectively targeted to the basolateral surface by a tyrosine-dependent sorting signal in the APP cytoplasmic tail. APP-TR chimeras are then rapidly internalized from the basolateral surface and a significant fraction (similar to 20-30%) are degraded. Morphological studies show that APP-TR chimeras internalized from the basolateral surface are found in tubulo-vesicular endosomal elements, internal membranes of multivesicular bodies, and lysosomes. APP-TR chimeras are also found in 60-nm diameter vesicles previously shown to selectively deliver wild-type TR to the basolateral surface; this result is consistent with the fact that 90% of internalized chimeras that are not degraded are selectively recycled back to the basolateral surface. APP-TR chimeras internalized from the apical surface are selectively transcytosed to the basolateral surface underscoring the importance of basolateral sorting in the endocytic pathway for maintaining the polarized phenotype. Tyr-653, an important element of the YTSI internalization signal in the APP cytoplasmic domain, is required for basolateral sorting in the biosynthetic and endocytic pathways. However, the structural features for basolateral sorting differ from those required for internalization.	Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92037 USA; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England	Salk Institute; University of California System; University of California San Diego; University of London; University College London	Trowbridge, IS (corresponding author), Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035489] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS35489] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DeStrooper B, 1995, J BIOL CHEM, V270, P30310, DOI 10.1074/jbc.270.51.30310; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GOTTLIEB TA, 1986, J CELL BIOL, V102, P1242, DOI 10.1083/jcb.102.4.1242; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; HOPKINS CR, 1983, J CELL BIOL, V94, P1265; HUGHES SH, 1990, J REPROD FERTIL, P39; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; LO ACY, 1994, J BIOL CHEM, V269, P30966; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; NORSTEDT C, 1993, J BIOL CHEM, V268, P608; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; ODORIZZI G, 1994, METHOD CELL BIOL, V43, P79; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; OMARY MB, 1981, J BIOL CHEM, V256, P2888; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Yamazaki T, 1996, J CELL SCI, V109, P999	44	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3732	3739		10.1074/jbc.273.6.3732	http://dx.doi.org/10.1074/jbc.273.6.3732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452505	hybrid			2022-12-27	WOS:000071822300090
J	Ostrowski, J; Roalsvig, T; Hammer, L; Marinier, A; Starrett, JE; Yuo, KL; Reczek, PR				Ostrowski, J; Roalsvig, T; Hammer, L; Marinier, A; Starrett, JE; Yuo, KL; Reczek, PR			Serine 232 and methionine 272 define the ligand binding pocket in retinoic acid receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; DOMAIN; ALPHA; GAMMA; RECOGNITION; SITE; BETA	The transcriptional response mediated by retinoic acid involves a complex series of events beginning with ligand recognition by a nuclear receptor. To dissect the amino acid contacts important for receptor-specific ligand recognition, a series of retinoic acid receptor (RAR) mutants were constructed. Transcriptional studies revealed that serine 232 (Ser(232)) in RAR alpha and methionine 272 (Met(272)) in RAR gamma are critical residues for the recognition of their respective receptor-selective analogs. The identification of these key amino acids in the ligand binding pocket is confirmed by the reported crystal structure of RAR gamma. Interestingly, the serine at position 232 in RAR alpha gives an explanation for the observed differences in the affinity of the naturally occurring ligand, all-trans-retinoic acid (t-RA), in this receptor compared with that for the other receptors, since hydrogen bonding would not be permitted between the hydroxyl of serine and the hydrophobic linker of t-RA. Using this model, a molecular mechanism for the transcriptional antagonism of a synthetic analog is suggested that involves an alteration in the structure of the receptor protein in the region around the AF2 domain in helix 12.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Cell & Mol Biol, Buffalo, NY 14213 USA; Dept Chem, Candiac, PQ J5R 1J1, Canada; Dept Cent Chem, Wallingford, CT 06492 USA	Bristol-Myers Squibb	Reczek, PR (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Cell & Mol Biol, 100 Forest Ave, Buffalo, NY 14213 USA.							BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Driscoll JE, 1996, J BIOL CHEM, V271, P22969, DOI 10.1074/jbc.271.38.22969; GIQUERE V, 1994, ENDOCR REV, V15, P61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; LUPISELLA JA, 1995, J BIOL CHEM, V270, P24884, DOI 10.1074/jbc.270.42.24884; Mangelsdorf David J., 1994, P319; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; Reczek PR, 1995, SKIN PHARMACOL, V8, P292, DOI 10.1159/000211360; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sasaki T, 1996, BIOL PHARM BULL, V19, P659; SASAKI T, 1995, BIOCHEM BIOPH RES CO, V207, P444, DOI 10.1006/bbrc.1995.1208; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; STROMSTEDT PE, 1990, J BIOL CHEM, V265, P12973; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yu KL, 1996, J MED CHEM, V39, P2411, DOI 10.1021/jm9502293	22	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3490	3495		10.1074/jbc.273.6.3490	http://dx.doi.org/10.1074/jbc.273.6.3490			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452473	hybrid			2022-12-27	WOS:000071822300058
J	Robinson, NA; Eckert, RL				Robinson, NA; Eckert, RL			Identification of transglutaminase-reactive residues in S100A11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; CROSS-LINKED ENVELOPE; PLASMA FACTOR-XIIIA; HUMAN EPIDERMAL-KERATINOCYTES; PIG LIVER-ENZYME; STRUCTURAL FEATURES; TISSUE TRANSGLUTAMINASE; LIPOCORTIN-I; ANNEXIN-I; LINKING	The recent finding that S100A11 is a component of the keratinocyte cornified envelope (CE) (Robinson, N. A., Lapic, S., Welter, J. F., and Eckert, R. L. (1997) J. Biol. Chern, 272, 12035-12046) suggests that S100A11 is a transglutaminase (TG) substrate, In the present study we show that S100All forms multimers when cultured keratinocytes are challenged by increased levels of intracellular calcium and that multimer formation is inhibited by the TG inhibitor, cystamine, These S100All multimers appear to be incorporated into the CE, as immunoreactive S100A11 is detected in purified envelopes prepared from cultured cells and from foreskin epidermis, To study S100A11 as a transglutaminase substrate, recombinant human S100All (rhS100A11) was used in a cell-free cross linking system, [C-14]Putrescine, a primary amine, labels rhS100A11 in a TG-dependent manner. Trypsin digestion of [C-14]putrescine-labeled rhS100A11 releases one radiolabeled peptide, Ala(98)-Lys(103). The glutamine residue in this segment, Gln(102), is the site of radiolabel incorporation indicating that Gln(102) functions as an amine acceptor, The ability of S100All to form multimers indicates that it also has a reactive lysine residue that functions as an amine donor, To identify the reactive residue, we compared the high pressure liquid chromatography profile of trypsin-digested rhS100A11 monomer to that of cross-linked rhS100A11, A unique cross linked peptide was purified and identified as Met-Ala-Lys(3)-Ilu-Ser-Ser-Pro-Thr-Glu-Thr-Glu-Arg cross-linked via an Lys(3)-Gln(102) isopeptide bond to Ala-Val-Pro-Ser-Gln(102)-Lys. These studies show that S100All is post-translationally modified by transglutaminase, that it can be cross linked to form multimers, that it is present in CEs from cultured keratinocytes and in vivo epidermis, and that Lys(3) and Gln(102) are specific sites of cross link formation.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.				NCI NIH HHS [P30 CA443703] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NIGMS NIH HHS [GM43751] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BG, 1996, BIOCHEM CELL BIOL, V74, P687, DOI 10.1139/o96-075; ANDO Y, 1989, BIOCHEM BIOPH RES CO, V163, P944, DOI 10.1016/0006-291X(89)92313-9; ANDO Y, 1991, J BIOL CHEM, V266, P1101; BHOWN AS, 1986, ADV METHODS PROTEIN, P208; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GERKE V, 1991, NOVEL CALCIUM BINDIN, P139; GOLDSMITH LA, 1983, J INVEST DERMATOL S, V80, P39; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; Jensen PH, 1996, J BIOL CHEM, V271, P26892, DOI 10.1074/jbc.271.43.26892; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KLOTZ AV, 1993, ANAL BIOCHEM, V100, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; MOORE KG, 1992, EXP CELL RES, V200, P186, DOI 10.1016/S0014-4827(05)80087-4; NAKA M, 1994, BBA-MOL CELL RES, V1223, P348, DOI 10.1016/0167-4889(94)90094-9; OGAWA H, 1976, J BIOL CHEM, V251, P7281; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; ROBINSON NA, 1991, J BIOCHEM TOXICOL, V6, P171, DOI 10.1002/jbt.2570060303; RORKE EA, 1991, J INVEST DERMATOL, V97, P543, DOI 10.1111/1523-1747.ep12481579; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; ROTHNAGEL JA, 1984, MOL CELL BIOCHEM, V58, P113, DOI 10.1007/BF00240610; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIZEMORE N, 1993, DIFFERENTIATION, V54, P219, DOI 10.1111/j.1432-0436.1993.tb01603.x; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; TA BM, 1990, J CELL SCI, V95, P631; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; vandenBos C, 1996, J IMMUNOL, V156, P1247; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	56	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2721	2728		10.1074/jbc.273.5.2721	http://dx.doi.org/10.1074/jbc.273.5.2721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446578	hybrid			2022-12-27	WOS:000071736600033
J	Vitale, N; Moss, J; Vaughan, M				Vitale, N; Moss, J; Vaughan, M			Molecular characterization of the GTPase-activating domain of ADP-ribosylation factor domain protein 1 (ARD1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; BINDING-PROTEIN; CHOLERA-TOXIN; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-D; ACID PHOSPHOLIPIDS; CHROMAFFIN CELLS; GOLGI MEMBRANES; ALPHA-SUBUNIT; FACTOR-I	ADP-ribosylation factors (ARFs) are similar to 20-kDa guanine nucleotide-binding proteins recognized as critical components in intracellular vesicular transport and phospholipase D activation, Both guanine nucleotide-exchange proteins and GTPase-activating proteins (GAPs) for ARFs have been cloned recently. A zinc finger motif near the amino terminus of the ARF1 GAP was required for stimulation of GTP hydrolysis. ARD1 is an ARF family member that differs from other ARFs by the presence of a 46-kDa amino-terminal extension, We had reported that the ARF domain of ARD1 binds specifically GDP and GTP and that the amino-terminal extension acts as a GAP for the ARF domain of ARD1 but not for ARF proteins, The GAP domain of ARD1, synthesized in Escherichia coli, stimulated hydrolysis of GTP bound to the ARF domain of ARD1, Using ARD1 truncations, it appears that amino acids 101-190 are critical for GAP activity, whereas residues 190-333 are involved in physical interaction between the two domains of ARD1 and are required for GTP hydrolysis. The GAP function of the amino-terminal extension of ARD1 required two arginines, an intact zinc finger motif, and a group of residues which resembles a sequence present in Rho/Pac GAPs, Interaction between the two domains of ARD1 required two negatively charged residues (Asp(427) and Glu(428)) located in the effector region of the ARF domain and two basic amino acids (Arg(249) and Lys(250)) found in the amino-terminal extension, The GAP domain of ARD1 thus is similar to ARF GAPs but differs from other GAPs in its covalent association with the GTP-binding domain.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vitale, N (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Room 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.	vitalen@fido.nhlbi.nih.gov	Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907				Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Burton JL, 1997, J BIOL CHEM, V272, P3663, DOI 10.1074/jbc.272.6.3663; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HONG JX, 1995, P NATL ACAD SCI USA, V92, P3056, DOI 10.1073/pnas.92.7.3056; HONG JX, 1994, J BIOL CHEM, V269, P9743; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TERUI T, 1994, J BIOL CHEM, V269, P28130; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TSAI SC, 1988, J BIOL CHEM, V263, P1768; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1993, J BIOL CHEM, V268, P10820; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; Vitale N, 1997, J BIOL CHEM, V272, P3897, DOI 10.1074/jbc.272.7.3897; Vitale N, 1997, J BIOL CHEM, V272, P25077, DOI 10.1074/jbc.272.40.25077; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; VITALE N, 1993, J BIOL CHEM, V268, P14715; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	55	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2553	2560		10.1074/jbc.273.5.2553	http://dx.doi.org/10.1074/jbc.273.5.2553			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446556	hybrid			2022-12-27	WOS:000071736600011
J	Henriksen, A; Welinder, KG; Gajhede, M				Henriksen, A; Welinder, KG; Gajhede, M			Structure of barley grain peroxidase refined at 1.9-angstrom resolution - A plant peroxidase reversibly inactivated at neutral pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COPRINUS-CINEREUS PEROXIDASE; CRYSTAL-STRUCTURE; HORSERADISH-PEROXIDASE; PHANEROCHAETE-CHRYSOSPORIUM; ANGSTROM RESOLUTION; ASP245->ASN MUTANT; FUNGAL PEROXIDASE; LIGNIN PEROXIDASE; RESONANCE RAMAN	The crystal structure of the major peroxidase of barley grain (BP 1) has been solved by molecular replacement and phase combination and refined to an R-factor of 19.2% for all data between 38 and 1.9 Angstrom, The refined model includes amino acid residues 1-309, one calcium ion, one sodium ion, iron-protoporphyrin IX, and 146 solvent molecules, BP 1 has the apparently unique property of being unable to catalyze the reaction with the primary substrate hydrogen peroxide to form compound I at pH values > 5, a feature investigated by obtaining crystal structure data at pH 5.5, 7.5, and 8.5, Structural comparison shows that the overall fold of inactive barley grain peroxidase at these pH values resembles that of both horseradish peroxidase C and peanut peroxidase, The key differences between the structures of active horseradish peroxidase C and inactive BP 1 include the orientation of the catalytic distal histidine, disruption of a hydrogen bond between this histidine and a conserved asparagine, and apparent substitution of calcium at the distal cation binding site with sodium at pH 7.5. These profound changes are a result of a dramatic structural rearrangement to the loop region between helices B and C, This is the first time that structural rearrangements linked to active site chemistry have been observed by crystallography in the peroxidase domain distal to heme.	Univ Copenhagen, Inst Chem, Dept Phys Chem, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Dept Prot Chem, DK-1353 Copenhagen K, Denmark	University of Copenhagen; University of Copenhagen	Henriksen, A (corresponding author), Univ Copenhagen, Inst Chem, Dept Phys Chem, Univ Pk 5, DK-2100 Copenhagen O, Denmark.	anette@jerne.ki.ku.dk		Welinder, Karen Gjesing/0000-0002-5409-0131; Henriksen, Anette/0000-0003-4051-5079; Gajhede, Michael/0000-0001-9864-2287				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Greppin H., 1993, PLANT PEROXIDASES BI, P35; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; HENRIKSEN A, 1992, J MOL BIOL, V228, P690, DOI 10.1016/0022-2836(92)90851-A; JOHANSSON A, 1992, PLANT MOL BIOL, V18, P1151, DOI 10.1007/BF00047718; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; MORISHIMA I, 1986, J BIOL CHEM, V261, P9391; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RASMUSSEN CB, 1993, FEBS LETT, V321, P102, DOI 10.1016/0014-5793(93)80630-D; Rasmussen CB, 1997, PHYSIOL PLANTARUM, V100, P102, DOI 10.1034/j.1399-3054.1997.1000110.x; Rasmussen CB, 1998, J BIOL CHEM, V273, P2232, DOI 10.1074/jbc.273.4.2232; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; VEITCH NC, 1995, EUR J BIOCHEM, V233, P650, DOI 10.1111/j.1432-1033.1995.650_2.x; Veitch NC, 1996, BIOCHEMISTRY-US, V35, P14370, DOI 10.1021/bi961582t; Welinder K.G, 1992, PLANT PEROXIDASES, P1; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]	36	80	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2241	2248		10.1074/jbc.273.4.2241	http://dx.doi.org/10.1074/jbc.273.4.2241			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442067	hybrid			2022-12-27	WOS:000071595200056
J	Rustaeus, S; Stillemark, P; Lindberg, K; Gordon, D; Olofsson, SO				Rustaeus, S; Stillemark, P; Lindberg, K; Gordon, D; Olofsson, SO			The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; APO-B; B-100-CONTAINING LIPOPROTEINS; PULSE-CHASE; SECRETION; ABETALIPOPROTEINEMIA; TRANSPORT; MEMBRANE	In cells in which the lipoprotein assembly process had been inactivated by brefeldin A (BFA), membrane-associated apoB-100 disappeared without forming lipoproteins or being secreted, indicating that it was degraded, Reactivation of the assembly process by chasing the cells in the absence of BFA, gave rise to a quantitative recovery of the membrane-associated apoB-100 in the very low density lipoprotein (VLDL) fraction in the medium, These results indicate that the membrane-associated apoB-100 can be converted to VLDL. A new method was developed by which the major amount (88%) of microsomal apoB-100 but not integral membrane proteins could be extracted, The major effect of this method was to increase the recovery of apoB-100 that banded in the LDL and HDL density regions, suggesting that the membrane-associated form of apoB-100 is partially lipidated, We also investigated the role of the microsomal triglyceride transfer protein (MTP) in the assembly of apoB-100 VLDL using a photoactivatable MTP inhibitor (BMS-192951), This compound strongly inhibited the assembly and secretion of apoB-100 VLDL when present during the translation of the protein, To investigate the importance of MTP during the later stages in the assembly process, the cells were preincubated with BFA (to reversibly inhibit the assembly of apoB-100 VLDL) and pulse-labeled (+BFA) and chased (+BFA) for 30 min to obtain full length apoB-100 associated with the microsomal membrane, Inhibition of MTP after the 30-min chase blocked assembly of VLDL, This indicates that MTP is important for the conversion of full-length apoB-100 into VLDL, Results from experiments in which a second chase (-BFA) was introduced before the inactivation of MTP indicated that only early events in this conversion of full-length apoB-100 into VLDL were blocked by the MTP inhibitor, Together these results indicate that there is a MTP-dependent "window" in the VLDL assembly process that occurs after the completion of apoB-100 but before the major amount of lipids is added to the VLDL particle, Thus the assembly of apoB-100 VLDL from membrane-associated apoB-100 involves an early MTP-dependent phase and a late MTP-independent phase, during which the major amount of lipid is added.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden; Gothenburg Univ, Wallenberg Lab, S-41390 Gothenburg, Sweden; Bristol Myers Squibb Co, Div Metab Dis, Princeton, NJ 08543 USA	University of Gothenburg; University of Gothenburg; Bristol-Myers Squibb	Olofsson, SO (corresponding author), Gothenburg Univ, Dept Med Biochem, Medicinaregatan 9, S-41390 Gothenburg, Sweden.		Adiels, Martin/C-9278-2011	Andersson, Karin/0000-0002-9475-3040				ATZEL A, 1993, BIOCHEMISTRY-US, V32, P10444, DOI 10.1021/bi00090a021; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CRESSWELL P, 1997, CURR BIOL, V7, P552; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GLICKMAN RM, 1986, P NATL ACAD SCI USA, V83, P5296, DOI 10.1073/pnas.83.14.5296; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KREIBICH G, 1973, J CELL BIOL, V58, P436, DOI 10.1083/jcb.58.2.436; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Sjoberg A, 1996, J LIPID RES, V37, P275; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277	34	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5196	5203		10.1074/jbc.273.9.5196	http://dx.doi.org/10.1074/jbc.273.9.5196			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478974	hybrid			2022-12-27	WOS:000072310400058
J	Shuang, RQ; Zhang, L; Fletcher, A; Groblewski, GE; Pevsner, J; Stuenkel, EL				Shuang, RQ; Zhang, L; Fletcher, A; Groblewski, GE; Pevsner, J; Stuenkel, EL			Regulation of Munc-18 syntaxin 1A interaction by cyclin-dependent kinase 5 in nerve endings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED PROTEIN-KINASE; UNC-18 GENE ENCODES; MEMBRANE-FUSION; BINDING PROTEIN; SEC1 HOMOLOG; YEAST SEC1; BRAIN; ROP; TRAFFICKING; SPECIFICITY	The Munc-18-syntaxin 1A complex has been postulated to act as a negative control on the regulated exocytotic process because its formation blocks the interaction of syntaxin with vesicle SNARE proteins, However, the formation of this complex is simultaneously essential for the final stages of secretion as evidenced by the necessity of Munc-18's homologues in Saccharomyces cerevisiae (Sec1p), Drosophila (ROP), and Caenorhabditis elegans (Unc-18) for proper secretion in these organisms, As such, any event that regulates the interaction of these two proteins is important for the control of secretion, One candidate for such regulation is cyclin-dependent kinase 5 (Cdk5), a member of the Cdc2 family of cell division cycle kinases that has recently been copurified with Munc-18 from rat brain, The present study shows that Cdk5 bound to its neural specific activator p35 not only binds to Munc-18 but utilizes it as a substrate for phosphorylation, Furthermore, it is demonstrated that Munc-18 that has been phosphorylated by Cdk5 has a significantly reduced affinity for syntaxin Ik Finally, it is shown that Cdk5 can also bind to syntaxin 1A and that a complex of Cdk5, p35, Munc-18, and syntaxin 1A can be fashioned in the absence of ATP and promptly disassembled upon the addition of ATP, These results suggest a model in which p35-activated Cdk5 becomes localized to the Munc-18-syntaxin 1A complex by its affinity for both proteins so that it may phosphorylate Munc-18 and thus permit the positive interaction of syntaxin 1A with upstream protein effecters of the secretory mechanism.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Kennedy Krieger Res Inst, Baltimore, MD 21205 USA	University of Michigan System; University of Michigan; Kennedy Krieger Institute	Stuenkel, EL (corresponding author), Univ Michigan, Dept Physiol, 7804 Med Sci 2 Bldg, Ann Arbor, MI 48109 USA.			Stuenkel, Edward/0000-0001-8225-5725	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031888, R01NS036227] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31888, NS36227] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; COWLES CR, 1994, J CELL SCI, V107, P3449; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HODEL A, 1994, J BIOL CHEM, V269, P8623; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PEVSNER J, 1997, GENE AMST, V183, P7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHELLER RH, 1995, NEURON, V14, P893; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1993, CELL, V75, P1; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	46	134	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4957	4966		10.1074/jbc.273.9.4957	http://dx.doi.org/10.1074/jbc.273.9.4957			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478941	hybrid			2022-12-27	WOS:000072310400025
J	Ahmad, M; Theofanidis, P; Medford, RM				Ahmad, M; Theofanidis, P; Medford, RM			Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR AP-1; MOUSE FIBROBLAST CELLS; DNA-BINDING DOMAINS; C-FOS EXPRESSION; ENDOTHELIAL-CELLS; LEUCINE ZIPPERS; NUCLEAR FACTOR; JUN; PROMOTER	Endothelial cell surface expression of VCAM-1 is one of the initial steps in the pathogenesis of atherosclerosis, The inflammatory response transcription factor nuclear factor (NF)-kappa B plays an important role in the regulation of VCAM-1 expression by various stimuli including tumor necrosis factor (TNF)-alpha. Other transcription factors may modulate this response through interaction with NF-kappa B factors. Since c-Fos/c-Jun (activating protein-1 (AP-1)) are expressed in vascular endothelium during proinflammatory conditions, pie investigated the role of AP-1 proteins in the expression of VCAM-1 by TNF-alpha in SV40 immortalized human microvascular endothelial cells (HMEC), TNF-alpha induced expression of both early protooncogenes, c-fos and c-jun. The ability of TNF-alpha to activate the kappa B-motif (kappa L-kappa R)-dependent VCAM-1 promoter-chloramphenicol acetyltransferase (CAT) reporter gene lacking a consensus AP-I element was markedly inhibited by co-transfection of the expression vector encoding c-fos ribozyme, which decreases the level of c-fos by degrading c-fos mRNA, or c-fos or c-jun oligonucleotides. Conversely, co-transfection of c-Fos and c-Jun encoding expression vectors potentiated the p65/NF-kappa B-mediated transactivation of the VCAM-1 promoter-CAT reporter gene, Furthermore the c-Fos encoding expression vector potentiated by a-fold the transactivation activity of a chimeric transcriptional factor Gal/P65 (containing the transactivation domain of p65 and the DNA binding domain of the yeast transcriptional factor Gal-4). Consistent with the promoter studies, curcumin and. NDGA, inhibitors of AP-I activation, markedly inhibited the ability of TNF-alpha to activate the expression of VCAM-1 mRNA levels at concentration that; did not inhibit the activation of NF-kappa B, In gel mobility supershift assays, the antibodies to c-Fos or c-Jun inhibited the binding of TNF-alpha-activated nuclear NF-kappa B to the kappa L-kappa R, suggesting that both e-Fos and c-Jun interacted with NF-kappa B. These results suggest that AP-I proteins may mediate the effect of TNF-alpha in the regulation of VCAM-1 expression through interaction with NF-kappa B factors in endothelial cells.	Emory Univ, Dept Med, Div Cardiol, Sch Med, Atlanta, GA 30322 USA	Emory University	Ahmad, M (corresponding author), Emory Univ, Dept Med, Div Cardiol, Sch Med, 1639 Pierce Dr,WMB 319, Atlanta, GA 30322 USA.	mahmad@emory.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048667] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL48667] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; AHMAD M, 1994, J CELL BIOCHEM, V18, P268; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLLINS T, 1993, LAB INVEST, V68, P499; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1476; GAMBLE JR, 1991, J IMMUNOL, V146, P1149; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; HUANG TS, 1995, CANCER LETT, V96, P1, DOI 10.1016/0304-3835(95)03918-M; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN JX, 1987, J BIOL CHEM, V262, P11908; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Sambrook J., 2002, MOL CLONING LAB MANU; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047	50	174	182	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4616	4621		10.1074/jbc.273.8.4616	http://dx.doi.org/10.1074/jbc.273.8.4616			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468519	hybrid			2022-12-27	WOS:000072115000047
J	Arkonac, BM; Foster, LC; Sibinga, NES; Patterson, C; Lai, KH; Tsai, JC; Lee, ME; Perrella, MA; Haber, E				Arkonac, BM; Foster, LC; Sibinga, NES; Patterson, C; Lai, KH; Tsai, JC; Lee, ME; Perrella, MA; Haber, E			Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR MESSENGER-RNA; FACTOR GENE; ATHEROSCLEROTIC PLAQUES; RECEPTOR EXPRESSION; PHORBOL ESTER; ANGIOGENESIS; EGF; HYPOXIA; INDUCTION	Although several cytokines and growth factors have been shown to regulate vascular endothelial growth factor (VEGF) production, little is known about how VEGF may regulate growth factors that have known mitogenic and chemotactic actions on mesenchymal cells (which are involved in the maturation of the angiogenic process). We investigated the effect of VEGF on heparin-binding epidermal growth factor-like growth factor (HB-EGF) expression in human umbilical vein endothelial cells. HB-EGF mRNA was induced by 8-fold after 2 h of VEGF stimulation, and it returned to base line within 6 h. VEGF did not alter the half-life of HB-EGF mRNA (55 min). Nuclear run-on experiments showed a 4.9-fold increase in HB-EGF gene transcription within 2 h of VEGF stimulation, and Western analysis demonstrated an associated increase in cellular HB-EGF protein. We found that platelet-derived growth factor-BB (PDGF-BB) mRNA was also induced 3-fold after 5 h of VEGF stimulation, whereas neither endothelin 1 nor transforming growth factor-beta 1 was regulated by VEGF. Finally, conditioned medium from VEGF-stimulated endothelial cells produced an increase in DNA synthesis in vascular smooth muscle cells, and this effect was blocked by a neutralizing antibody to PDGF. The induction of HB-EGF an PDGF-BB expression in endothelial cells may represent the mechanism by which VEGF recruits mesenchymal cells to form the medial and adventitial layers of arterioles and venules during the course of angiogenesis.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Kaohsiung Med Coll, Dept Med, Kaohsiung, Taiwan; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Kaohsiung Medical University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Arkonac, BM (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.		Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03274, HL03194] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS GF, 1994, J BIOL CHEM, V269, P10112; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BREIER G, 1992, DEVELOPMENT, V114, P521; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; D'Amore P A, 1992, Semin Cancer Biol, V3, P49; DAMORE PA, 1993, GROWTH FACTORS, V8, P61, DOI 10.3109/08977199309029135; DAS SK, 1994, DEVELOPMENT, V120, P1071; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FREEMAN MR, 1995, CANCER RES, V55, P4140; GIAID A, 1995, TRANSPLANTATION, V59, P1308; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; KUZUYA M, 1995, J CELL PHYSIOL, V164, P658, DOI 10.1002/jcp.1041640324; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; MORITA T, 1993, BIOCHEM BIOPH RES CO, V197, P256, DOI 10.1006/bbrc.1993.2469; NEHLS V, 1994, MICROVASC RES, V48, P349, DOI 10.1006/mvre.1994.1061; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; NICOSIA RF, 1995, LAB INVEST, V73, P658; NOMURA M, 1995, J BIOL CHEM, V270, P28316; OBRIEN ER, 1994, AM J PATHOL, V145, P883; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Ruef J, 1997, CIRC RES, V81, P24, DOI 10.1161/01.RES.81.1.24; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	50	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4400	4405		10.1074/jbc.273.8.4400	http://dx.doi.org/10.1074/jbc.273.8.4400			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468491	hybrid			2022-12-27	WOS:000072115000019
J	Marx, UC; Adermann, K; Bayer, P; Meyer, M; Forssmann, WG; Rosch, P				Marx, UC; Adermann, K; Bayer, P; Meyer, M; Forssmann, WG; Rosch, P			Structure-activity relation of NH2-terminal human parathyroid hormone fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; NUCLEAR-MAGNETIC-RESONANCE; NMR CHEMICAL-SHIFTS; HELIX DIPOLE MODEL; CIRCULAR-DICHROISM; PEPTIDE-FRAGMENTS; AQUEOUS-SOLUTION; ALPHA-HELICES; DYNAMICS CALCULATIONS; H-1-NMR SPECTROSCOPY	Human parathyroid hormone (hPTH) is involved in the regulation of the calcium level in blood. This hormone function is located in the NH2-terminal 34 amino acids of the 84-amino acid peptide hormone and is transduced via the adenylate cyclase and the phosphatidylinositol signaling pathways. it is well known that truncation of the two NH2-terminal amino acids of the hormone leads to complete loss of in vivo normocalcemic function. To correlate loss of calcium level regulatory activity after stepwise NH2-terminal truncation and solution structure, we studied the conformations of fragments hPTH-(2-37), hPTH-(3-37), and hPTH-(4-37) in comparison to hPTH-(1-37) in aqueous buffer solution under near physiological conditions by circular dichroism spectroscopy, two-dimensional nuclear magnetic resonance spectroscopy, and restrained molecular dynamics calculations, All peptides show helical structures and hydrophobic interactions between Leu-15 and Trp-23 that lead to a defined loop region from His-14 to Ser-17. A COOH-terminal helix from Met-18 to at least Leu-28 was found for all peptides. The helical structure in the NH2-terminal part of the peptides was lost in parallel with the NH2-terminal truncation and can be correlated with the loss of calcium regulatory activity.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95440 Bayreuth, Germany; Niedersachs Inst Peptid Forsch, D-30625 Hannover, Germany	University of Bayreuth	Rosch, P (corresponding author), Univ Bayreuth, Lehrstuhl Struktur & Chem Biopolymere, POB 101251, D-95440 Bayreuth, Germany.		Rösch, Paul/I-5445-2014; Bayer, Peter/B-8803-2009	Rösch, Paul/0000-0003-3330-2446; Bayer, Peter/0000-0003-0435-7202; Marx, Ute C./0000-0002-7077-9940				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; Atherton E., 1990, SOLID PHASE PEPTIDE; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1993, X PLOR VERSION 3 1; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chorev Michael, 1994, P139; Coleman Daniel T., 1994, P239; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; Ernst R.R., 1992, ANGEW CHEM, V104, P817; FAIRMAN R, 1989, PROTEINS, V5, P1, DOI 10.1002/prot.340050102; FORSSMANN WG, 1993, PEPTIDE CHEMISTRY 1992, P553; FORSSMANN WG, 1995, PEPTIDES CHEM STRUCT, P225; GANS PJ, 1991, BIOPOLYMERS, V31, P1605, DOI 10.1002/bip.360311315; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Gronwald W, 1996, BIOL CHEM H-S, V377, P175, DOI 10.1515/bchm3.1996.377.3.175; Hock D, 1997, FEBS LETT, V400, P221, DOI 10.1016/S0014-5793(96)01390-7; JIMENEZ MA, 1994, BIOPOLYMERS, V34, P647, DOI 10.1002/bip.360340507; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karle IL, 1996, BIOPOLYMERS, V40, P157, DOI 10.1002/(SICI)1097-0282(1996)40:1<157::AID-BIP7>3.0.CO;2-V; KARLE IL, 1990, BIOCHEMISTRY-US, V29, P6747, DOI 10.1021/bi00481a001; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P976; LANCELIN JM, 1994, FEBS LETT, V343, P261, DOI 10.1016/0014-5793(94)80568-7; Lee MS, 1996, PROTEIN ENG, V9, P15, DOI 10.1093/protein/9.1.15; LOPEZHILKER S, 1992, J LAB CLIN MED, V119, P738; MANNING MC, 1991, BIOPOLYMERS, V31, P569, DOI 10.1002/bip.360310511; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; MILLHAUSER GL, 1995, BIOCHEMISTRY-US, V34, P3873, DOI 10.1021/bi00012a001; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; MORTON CJ, 1994, EUR J BIOCHEM, V219, P97, DOI 10.1111/j.1432-1033.1994.tb19919.x; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NEUGEBAUER W, 1995, BIOCHEMISTRY-US, V34, P8835, DOI 10.1021/bi00027a035; PARSONS JA, 1973, ENDOCRINOLOGY, V92, P454, DOI 10.1210/endo-92-2-454; Petukhov M, 1996, BIOCHEMISTRY-US, V35, P387, DOI 10.1021/bi9513766; POTTS JT, 1982, ADV PROTEIN CHEM, V35, P323, DOI 10.1016/S0065-3233(08)60471-4; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROSENBLATT M, 1977, J BIOL CHEM, V252, P5847; SAYLE R, 1995, RASMOL VERSION 2 6 M; SCHLUTER KD, 1989, J BIOL CHEM, V264, P11087; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; Segre Gino V., 1994, P213; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SOMJEN D, 1990, BIOCHEM J, V272, P781; SOMJEN D, 1991, BIOCHEM J, V277, P863; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woody R. W., 1994, CIRCULAR DICHROISM P, P473; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YANG JT, 1986, METHOD ENZYMOL, V130, P208	69	30	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4308	4316		10.1074/jbc.273.8.4308	http://dx.doi.org/10.1074/jbc.273.8.4308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468478	hybrid			2022-12-27	WOS:000072115000006
J	Sutherland, PJ; Tobin, AE; Rutherford, CL; Price, NPJ				Sutherland, PJ; Tobin, AE; Rutherford, CL; Price, NPJ			Dictyostelium discoideum fatty-acyl amidase II has deacylase activity on Rhizobium nodulation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPO-OLIGOSACCHARIDE SIGNALS; NOD FACTORS; LINKED OLIGOSACCHARIDES; STRUCTURAL-ANALYSIS; STRAIN NGR234; N-METHYL; ACID; BIOSYNTHESIS; PROTEIN	Dictyostelium discoideum (Amoebidae) secretes cell-lysing enzymes: esterases, amidases, and glycosylases, many of which degrade soil bacteria to provide a source of nutrients, Two of these enzymes, fatty-acyl amidases FAA I and FAA II, act sequentially on the N-linked long chain acyl groups of lipid A, the lipid anchor of Gramnegative bacterial lipopolysaccharide, FAA I selectively hydrolyzes the 3-hydroxymyristoyl group N-linked to the proximal glucosamine residue of de-O-acylated lipid A, Substrate specificity for FAA II is less selective, but does require prior de-N-acylation of the proximal sugar, i.e. bis-N-acylated lipid A is not a substrate, We have synthesized a C-14-labeled substrate analog for FAA II and used this in a novel assay to monitor its purification, Inhibitory studies indicate that FAA II is not a serine protease, but may have a catalytic mechanism similar to metalloprotein de-N-acetylases such as LpxC, Interestingly, rhizobial Nod factor signal oligosaccharides that induce root nodules on leguminous plants have many of the structural requirements for substrate recognition by FAA II, In vitro evidence indicates that Rhizobium fredii Nod factors are selectively de-N-acylated by purified FAA II, suggesting that the enzyme may reduce the N-2-fixing efficiency of Rhizobium-legume symbioses, In contrast, N-methylated Nod factors from transgenic R, fredii carrying the rhizobial nodS gene were resistant to FAA II, suggesting a mechanism by which Nod factors may be protected from enzymatic de-N-acylation, Since FAA II and Nod factors are both secreted, and Nod factors that lack the N-acyl group are unable to induce nodules, dictyostelial FAA II may decrease the efficiency of symbiotic nitrogen fixation in the environment by reducing the available biologically active nodule inducer signal.	SUNY Syracuse, Coll Environm Sci & Forestry, Dept Chem, Syracuse, NY 13210 USA; Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA	State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry; Virginia Polytechnic Institute & State University	Sutherland, PJ (corresponding author), SUNY Syracuse, Coll Environm Sci & Forestry, Dept Chem, Syracuse, NY 13210 USA.				NIA NIH HHS [AG00678] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ATKINSON EM, 1994, P NATL ACAD SCI USA, V91, P8418, DOI 10.1073/pnas.91.18.8418; BECFERTE MP, 1994, BIOCHEMISTRY-US, V33, P11782, DOI 10.1021/bi00205a014; CARLSON RW, 1994, MOL PLANT MICROBE IN, V7, P684, DOI 10.1094/MPMI-7-0684; DELMONT N, 1993, J BIOL CHEM, V268, P20134; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; Hyland SA, 1997, J BACTERIOL, V179, P2029, DOI 10.1128/jb.179.6.2029-2037.1997; JABBOURI S, 1995, J BIOL CHEM, V270, P22968, DOI 10.1074/jbc.270.39.22968; KRISHNAN HB, 1992, MOL MICROBIOL, V6, P3321, DOI 10.1111/j.1365-2958.1992.tb02200.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERGAERT P, 1993, P NATL ACAD SCI USA, V90, P1551, DOI 10.1073/pnas.90.4.1551; POUPOT R, 1993, BIOCHEMISTRY-US, V32, P10430, DOI 10.1021/bi00090a019; Price NPJ, 1996, CARBOHYD RES, V289, P115, DOI 10.1016/0008-6215(96)00119-X; PRICE NPJ, 1992, MOL MICROBIOL, V6, P3575, DOI 10.1111/j.1365-2958.1992.tb01793.x; PRICE NPJ, 1995, GLYCOBIOLOGY, V5, P233, DOI 10.1093/glycob/5.2.233; ROHRIG H, 1994, P NATL ACAD SCI USA, V91, P3122, DOI 10.1073/pnas.91.8.3122; ROSNER MR, 1979, J BIOL CHEM, V254, P5926; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VERRET CR, 1982, J BIOL CHEM, V257, P222; VERRET CR, 1982, J BIOL CHEM, V257, P228	23	5	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4459	4464		10.1074/jbc.273.8.4459	http://dx.doi.org/10.1074/jbc.273.8.4459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468498	hybrid			2022-12-27	WOS:000072115000026
J	Xu, G; Marshall, CA; Lin, TA; Kwon, G; Munivenkatappa, RB; Hill, JR; Lawrence, JC; McDaniel, ML				Xu, G; Marshall, CA; Lin, TA; Kwon, G; Munivenkatappa, RB; Hill, JR; Lawrence, JC; McDaniel, ML			Insulin mediates glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells - An insulin-receptor mechanism for autoregulation of protein synthesis by translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; GENE-EXPRESSION; MESSENGER-RNA; CYCLIC-AMP; RAT ISLETS; KINASE; BIOSYNTHESIS; RAPAMYCIN; SECRETION; LINE	Although glucose regulates the biosynthesis of a variety of beta cell proteins at the level of translation, the mechanism responsible for this effect is unknown, We demonstrate that incubation of pancreatic islets with elevated glucose levels results in rapid and concentration-dependent phosphorylation of PHAS-I, an inhibitor of mRNA cap-binding protein, eukaryotic initiation factor (eIF)-4E. Our initial approach was to determine if this effect is mediated by the metabolism of glucose and activation of islet cell protein kinases, or whether insulin secreted from the beta cell stimulates phosphorylation of PHAS-I via an insulin-receptor mechanism as described for insulin sensitive cells, In support of the latter mechanism, inhibitors of islet cell protein kinases A and C exert no effect on glucose-stimulated phosphorylation of PHAS-I, whereas the phosphatidylinositol 3-kinase inhibitor, wortmannin, the immunosuppressant, rapamycin, and theophylline, a phosphodiesterase inhibitor, promote marked dephosphorylation of PHAS-I. In addition, exogenous insulin and endogenous insulin secreted by the beta cell line, beta TC6-F7, increase phosphorylation of PHAS-I, suggesting that beta cells of the islet, in part, mediate this effect, Studies with beta cell lines and islets indicate that amino acids are required for glucose or exogenous insulin to stimulate the phosphorylation of PHAS-I, and amino acids alone dose-dependently stimulate the phosphorylation of PHAS-I, which is further enhanced by insulin, Furthermore, rapamycin inhibits by similar to 62% the increase in total protein synthesis stimulated by high glucose concentrations. These results indicate that glucose stimulates PHAS-I phosphorylation via insulin interacting with its own receptor on the beta cell which may serve as an important mechanism for autoregulation of protein synthesis by translation.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	Washington University (WUSTL); University of Virginia	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.				NIAMS NIH HHS [AR41189] Funding Source: Medline; NIDDK NIH HHS [DK50628, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZICAR041189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ESCOLAR JC, 1987, J ENDOCRINOL, V115, P225, DOI 10.1677/joe.0.1150225; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GAZZANO H, 1985, BIOCHEM J, V226, P867, DOI 10.1042/bj2260867; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; ISHIHARA F, 1994, J ENDOCRINOL, V143, P497, DOI 10.1677/joe.0.1430497; KNAACK D, 1994, DIABETES, V43, P1413, DOI 10.2337/diabetes.43.12.1413; Krueger KA, 1997, J BIOL CHEM, V272, P27464, DOI 10.1074/jbc.272.43.27464; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; PATTI ME, 1997, DIABETES S1, V46; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; PERMUTT MA, 1974, J BIOL CHEM, V249, P2738; Persaud SJ, 1996, BIOCHEM J, V313, P119, DOI 10.1042/bj3130119; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Renstrom E, 1996, J PHYSIOL-LONDON, V494, P41, DOI 10.1113/jphysiol.1996.sp021474; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Thompson MG, 1996, BBA-MOL CELL RES, V1311, P37, DOI 10.1016/0167-4889(95)00194-8; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5	40	90	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4485	4491		10.1074/jbc.273.8.4485	http://dx.doi.org/10.1074/jbc.273.8.4485			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468502	hybrid			2022-12-27	WOS:000072115000030
J	DeMattos, RB; Curtiss, LK; Williams, DL				DeMattos, RB; Curtiss, LK; Williams, DL			A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; CENTRAL NERVOUS-SYSTEM; ALZHEIMER-DISEASE; CEREBROSPINAL-FLUID; A-I; PERIPHERAL-TISSUES; NONHUMAN-PRIMATES; E GENOTYPE; EXPRESSION; MOUSE	Within the central nervous system,;apolipoprotein E (apoE) synthesis Is increased in response to nerve injury, a finding that may reflect a role for apoE in neuronal remodeling.,, Recent studies show that apoE3 promotes and apoE4 inhibits neurite outgrowth in cultured neuronal cells, interestingly, these isoform-specific effects are observed only when apoE is presented to cells in the presence of an exogenous lipid source such as rabbit beta-very low density lipoprotein (beta-VLDL, making, it difficult to discern the biologically active form of apoE or to understand the role of the lipid source. In the present study we tested whether a cell-derived lipidated form of apoE can alter neurite outgrowth in the? absence of beta-VLDL by constructing Neuro-2a cell lines expressing high levels of apoE. Our results showed that endogenous apoE3 stimulated neurite outgrowth, whereas the endogenous apoE4 isoform was neutral, Furthermore, beta-VLDL antagonized the stimulatory effects of the endogenous apoE3, Characterization of the secreted apoE3 indicated that the neurite outgrowth-stimulating activity could be recovered,from culture medium with an anti-apoE immunoaffinity column and was present in a poorly lipidated particle with a density between 1.19 and 1.26 g/ml. These results indicated that the biological activity of apoE3 in stimulating neurite outgrowth was inherent in the cell-derived apoE particle and was not dependent on either (a) an interaction of apoE3 with an artificial lipid source or (b) independent actions of apoE3 and beta-VLDL.	SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Scripps Research Institute; Scripps Research Institute	Williams, DL (corresponding author), SUNY Stony Brook, Med Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA.				NHLBI NIH HHS [HL 32868, HL 35297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032868, R01HL035297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; GOEDERT M, 1994, NATURE, V372, P45, DOI 10.1038/372045a0; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; HUANG DY, 1995, EXP NEUROL, V136, P251, DOI 10.1006/exnr.1995.1101; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; KIM DH, 1996, J BIOL CHEM, V271, P8873; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Narita M, 1997, J NEUROCHEM, V68, P587; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Puttfarcken PS, 1997, J NEUROCHEM, V68, P760; REYLAND ME, 1991, P NATL ACAD SCI USA, V88, P2375, DOI 10.1073/pnas.88.6.2375; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHORE V, 1967, BIOCHEMISTRY-US, V6, P1962, DOI 10.1021/bi00859a012; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	41	109	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4206	4212		10.1074/jbc.273.7.4206	http://dx.doi.org/10.1074/jbc.273.7.4206			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461617	hybrid			2022-12-27	WOS:000072048400059
J	Gesbert, F; Garbay, C; Bertoglio, J				Gesbert, F; Garbay, C; Bertoglio, J			Interleukin-2 stimulation induces tyrosine phosphorylation of p120-Cbl and CrkL and formation of multimolecular signaling complexes in T lymphocytes and natural killer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CBL PROTOONCOGENE; EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; IL-2 RECEPTOR; ANTIGEN RECEPTOR; PROTEIN PRODUCT; ADAPTER PROTEIN; SH3 DOMAIN; V-CBL; EGF STIMULATION	Interleukin (IL)-2, a major growth and differentiation factor far T lymphocytes, was found to induce tyrosine phosphorylation of the proto-oncogene products p120-Cbl and CrkL in IL-2-dependent cell lines, We established that, in unstimulated lymphocytes, the Src homology 2 (SH2) and SH3 domain-containing protein Grb2 and the p85 subunit of phosphatidylinositol 3-kinase, associate constitutively with Cbl via their SPPS domains, Furthermore, IL-2 stimulation increased the level of interaction of phosphorylated Cbl with the p85 SH2 domains, and we provide evidence that the preformed Cbl-Grb2 complex recruits the phosphorylated p52 Shc adaptor protein, In addition, we demonstrate that the SH2-SH3-SH3 adaptor protein CrkL is tyrosine-phosphorylated in an IL-2-dependent manner and, via its SH2 domain, associates with a large proportion of phosphorylated Cbl, We also show that p85 is preassociated with the CrkL SH3 domain, Furthermore, the association of CrkL and p85 is increased after IL-2 treatment by a mechanism involving intermediary tyrosine-phosphorylated proteins that remain to be identified, Our results show that CrkL associates independently with Cbl or p85 and suggest that it salse participates in larger complexes containing Cbl and p85. Although the precise roles of Cbl and CrkL remain to be elucidated, their tyrosine phosphorylation, in addition to the multiple protein interactions described here, strongly suggest that Cbl and CrkL may play pivotal roles in the early steps of IL-2 signal transduction.	Fac Pharm Paris 11, INSERM U461, F-92296 Chatenay Malabry, France; Fac Pharm Paris 5, INSERM U266, F-75720 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bertoglio, J (corresponding author), Fac Pharm Paris 11, INSERM U461, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.	j.bertoglio@cep.u-psud.fr		Gesbert, Franck/0000-0002-5800-8385				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HORI T, 1987, BLOOD, V70, P1069; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; Kontani K, 1996, J BIOL CHEM, V271, P1534; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Liu YC, 1997, J BIOL CHEM, V272, P168; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Matsuo T, 1996, FEBS LETT, V382, P11, DOI 10.1016/0014-5793(96)00122-6; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MERIDA I, 1991, J IMMUNOL, V147, P2202; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Robertson MJ, 1996, EXP HEMATOL, V24, P406; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3986	3993		10.1074/jbc.273.7.3986	http://dx.doi.org/10.1074/jbc.273.7.3986			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461587	hybrid			2022-12-27	WOS:000072048400029
J	Liberator, P; Anderson, J; Feiglin, M; Sardana, M; Griffin, P; Schmatz, D; Myers, RW				Liberator, P; Anderson, J; Feiglin, M; Sardana, M; Griffin, P; Schmatz, D; Myers, RW			Molecular cloning and functional expression of mannitol-1-phosphatase from the apicomplexan parasite Eimeria tenella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC-ACID-PHOSPHATASE; SITE-DIRECTED MUTAGENESIS; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; MANNITOL CYCLE; ACTIVE-SITE; RAT-LIVER; SEQUENCE; IDENTIFICATION; PROTEINS; ENZYME	A metabolic pathway responsible for the biosynthesis and utilization of mannitol is present in the seven species of Eimeria that infect chickens, but is not in the avian host, Mannitol-l-phosphatase (M1Pase), a key enzyme for mannitol biosynthesis, is a highly substrate-specific phosphatase and, accordingly, represents an attractive chemotherapeutic target, Amino acid sequence of tryptic peptides obtained from biochemically purified Eimeria tenella M1Pase was used to synthesize degenerate oligonucleotide hybridization probes, Using these reagents, a partial genomic clone and full-length cDNA clones have been isolated and characterized, The de deduced amino acid sequence of E. tenella M1Pase shows limited overall homology to members of the phosphohistidine family of phosphatases, This limited homology to other histidine phosphatases does, however, include several conserved residues that have been shown to be essential for their catalytic activity, Kinetic parameters of recombinant M1Pase expressed in bacteria are essentially identical to those of the biochemically purified preparation from E., tenella, Moreover, recombinant M1Pase is subject to active site directed, hydroxylamine-reversible inhibition by the histidine-selective acylating reagent diethyl pyrocarbonate. These results indicate the presence of an essential histidine residue(s) at the M1Pase active site, as predicted for a histidine phosphatase.	Merck Res Labs, Dept Parasite Biochem & Cell Biol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Design & Divers, Rahway, NJ 07065 USA; Merck Res Labs, Dept Biol Chem, West Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company	Liberator, P (corresponding author), Merck Res Labs, Dept Parasite Biochem & Cell Biol, POB 2000,Mail Locat R80Y-265, Rahway, NJ 07065 USA.	paul_liberator@merck.com						BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOTHERGILLGILMO.LA, 1990, ADV ENZYMOLOGY RELAT, V62, P227; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HULT K, 1978, EUR J BIOCHEM, V88, P607, DOI 10.1111/j.1432-1033.1978.tb12487.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee YH, 1996, BIOCHEMISTRY-US, V35, P6010, DOI 10.1021/bi9600613; Levine N.D., 1982, P1; LIBERATOR PA, 1989, NUCLEIC ACIDS RES, V17, P7104, DOI 10.1093/nar/17.17.7104; LIN K, 1992, J BIOL CHEM, V267, P19163; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P422, DOI 10.1016/0005-2744(78)90044-X; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; OSTANIN K, 1993, J BIOL CHEM, V268, P20778; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; OSTANIN K, 1994, J BIOL CHEM, V269, P8971; OSTROWSKI W, 1978, BIOCHIM BIOPHYS ACTA, V526, P147, DOI 10.1016/0005-2744(78)90299-1; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; PILKIS SJ, 1987, J BIOL CHEM, V262, P12672; PROFOUSJUCHELKA H, 1988, MOL BIOCHEM PARASIT, V30, P233, DOI 10.1016/0166-6851(88)90092-8; Rose Z B, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P211; SAINI MS, 1979, BIOCHIM BIOPHYS ACTA, V568, P370, DOI 10.1016/0005-2744(79)90305-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMATZ DM, 1989, MOL BIOCHEM PARASIT, V32, P263, DOI 10.1016/0166-6851(89)90075-3; SCHMATZ DM, 1988, MOL BIOCHEM PARASIT, V29, P29, DOI 10.1016/0166-6851(88)90116-8; SCHMATZ DM, 1989, PARASITOL TODAY, V5, P205, DOI 10.1016/0169-4758(89)90268-8; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; TAULER A, 1990, J BIOL CHEM, V265, P15617; THORNBERRY NA, 1991, J BIOL CHEM, V266, P21657; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27	38	31	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4237	4244		10.1074/jbc.273.7.4237	http://dx.doi.org/10.1074/jbc.273.7.4237			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461622	hybrid			2022-12-27	WOS:000072048400064
J	Huang, L; Grammatikakis, N; Toole, BP				Huang, L; Grammatikakis, N; Toole, BP			Organization of the chick CDC37 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSFORMING PROTEIN; BINDING PROTEIN; HEPARAN-SULFATE; CELL-DIVISION; KINASE; GLYCOSAMINOGLYCANS; LOCALIZATION; REPRESSOR; RECEPTOR; COMPLEX	CDC37 and the chaperone protein, Hsp90, form a complex that binds to several kinases, resulting in stabilization and promotion of their activity. CDC37 also binds DNA and glycosaminoglycans in a sequence-specific manner. In this study, we further characterize chick CDC37 and examine the organization of the CDC37 gene. Chick CDC37 is a similar to 50-kDa protein encoded by an mRNA of similar to 1.7 kilobases. The CDC37 gene is similar to 8.5 kilobases and contains 8 exons and 7 introns of various sizes. The presumptive promoter and 5'-flanking regions contain an E2 box and consensus binding sites for SP1, for the S8 homeodomain protein, and for two zinc finger clusters within the myeloid progenitor transcription factor, MZF1. Particularly striking is a similar to 470-base pair region composed of a highly repetitive 10-11-base pair sequence, (T/C)gCTAT(A/G)GGG(A/T) (where g represents the additional G present in the 11-base pair sequence). This region includes 15 copies of the sequence, TAT-GGGGA, which conforms to the DNA consensus sequence recognized by one of the zinc finger clusters in MZF1. These findings emphasize the potential importance of CDC37 in regulation of cellular behavior during tissue development and reorganization.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Toole, BP (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, 136 Harrison Ave, Boston, MA 02111 USA.	btoole@infonet.tufts.edu			NICHD NIH HHS [HD23681] Funding Source: Medline; NIDCR NIH HHS [DE05838] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005838] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1982, NATURE, V295, P250, DOI 10.1038/295250a0; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DEJONG R, 1993, NUCLEIC ACIDS RES, V21, P4711, DOI 10.1093/nar/21.20.4711; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; HISCOCK DRR, 1994, J BIOL CHEM, V269, P4539; ISHIHARA M, 1989, J CELL PHYSIOL, V138, P467, DOI 10.1002/jcp.1041380305; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; OCHMAN H, 1988, GENETICS, V120, P621; Ozaki T, 1996, DNA CELL BIOL, V15, P975, DOI 10.1089/dna.1996.15.975; Ozaki T, 1995, DNA CELL BIOL, V14, P1017, DOI 10.1089/dna.1995.14.1017; Ozaki T, 1996, BIOCHEM BIOPH RES CO, V226, P237, DOI 10.1006/bbrc.1996.1339; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REED SI, 1980, GENETICS, V95, P561; RIPELLINO JA, 1989, J CELL BIOL, V108, P1899, DOI 10.1083/jcb.108.5.1899; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	39	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3598	3603		10.1074/jbc.273.6.3598	http://dx.doi.org/10.1074/jbc.273.6.3598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452487	hybrid			2022-12-27	WOS:000071822300072
J	Reilly, BA; Brostrom, MA; Brostrom, CO				Reilly, BA; Brostrom, MA; Brostrom, CO			Regulation of protein synthesis in ventricular myocytes by vasopressin - The role of sarcoplasmic/endoplasmic reticulum Ca2+ stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; NUCLEOTIDE EXCHANGE FACTOR; INITIATION-FACTOR 2-ALPHA; VASCULAR SMOOTH-MUSCLE; KINASE-C; RAT-LIVER; TRANSLATIONAL INITIATION; ENDOPLASMIC-RETICULUM; EUKARYOTIC CELLS; PHORBOL ESTER	Protein synthesis in H9c2 ventricular myocytes was subject to rapid inhibition by agents that release Ca2+ from the sarcoplasmic/endoplasmic reticulum, including thapsigargin, ionomycin, caffeine, and arginine vasopressin. Inhibitions were attributable to the suppression of translational initiation and were coupled to the mobilization of cell-associated Ca2+ and the phosphorylation of eIF2 alpha. Ionomycin and thapsigargin produced relatively stringent degrees of Ca2+ mobilization that produced an endoplasmic reticulum (ER) stress response, Translational recovery was associated with the induction of ER chaperones and resistance to translational inhibition by Ca2+-mobilizing agents. Vasopressin at physiologic concentrations mobilized 60% of cell-associated Ca2+ and decreased protein synthesis by 50% within 20-30 min. The inhibition of protein synthesis was exerted through an interaction at the V1 vascular receptor, was imposed at physiologic extracellular Ca2+ concentrations, and became refractory to hormonal washout within 10 min of treatment. Inhibition was found to attenuate after 30 min, with full recovery occurring in 2 h. Translational recovery did not involve an ER stress response but rather was derived from the partial repletion of intracellular Ca2+ stores. Longer exposures to vasopressin were invariably accompanied by increased rates of protein synthesis. Translational inhibition by vasopressin, but not by Ca2+-mobilizing drugs, was both preventable and reversible by treatment with phorbol ester, which reduced the extent of Ca2+ mobilization occurring in response to the hormone. Larger and more prolonged translational inhibitions occurred after down-regulation of protein kinase C. This report provides the first compelling evidence that hormonally induced mobilization of sarcoplasmic/endoplasmic reticulum Ca2+ stores is regulatory upon mRNA translation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Brostrom, MA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brostrom@umdnj.edu						Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; Bogoyevitch MA, 1996, INT J BIOCHEM CELL B, V28, P1, DOI 10.1016/1357-2725(95)00142-5; BRINER VA, 1992, P NATL ACAD SCI USA, V89, P2854, DOI 10.1073/pnas.89.7.2854; BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM CO, 1986, MOL PHARMACOL, V29, P104; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHIN KV, 1987, J BIOL CHEM, V262, P16509; CHIN KV, 1988, INT J BIOCHEM, V20, P1313, DOI 10.1016/0020-711X(88)90236-4; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CULPEPPER RM, 1985, TXB ENDOCRINOLOGY, P619; DECKER RS, 1995, CIRC RES, V77, P544, DOI 10.1161/01.RES.77.3.544; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; JARVIS WD, 1994, CANCER RES, V54, P1707; JOHNSON JA, 1995, LIFE SCI, V57, P1027, DOI 10.1016/0024-3205(95)02048-N; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KIMBALL SR, 1992, AM J PHYSIOL, V263, pE958, DOI 10.1152/ajpendo.1992.263.5.E958; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LUTZ W, 1991, AM J PHYSIOL, V261, pF1, DOI 10.1152/ajprenal.1991.261.1.F1; MENAYA J, 1988, BIOCHEM J, V254, P773, DOI 10.1042/bj2540773; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; PALAZZO AJ, 1991, AM J PHYSIOL, V260, pH604, DOI 10.1152/ajpheart.1991.260.2.H604; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SCHOPF G, 1986, BIOCHIM BIOPHYS ACTA, V884, P319, DOI 10.1016/0304-4165(86)90180-7; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; TRAN K, 1995, MOL CELL BIOCHEM, V151, P69, DOI 10.1007/BF01076898; Tran K, 1995, BBA-LIPID LIPID MET, V1259, P283, DOI 10.1016/0005-2760(95)00175-1; VANDERBENT V, 1994, AM J PHYSIOL, V266, pH597, DOI 10.1152/ajpheart.1994.266.2.H597; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZHANG ST, 1995, CIRC RES, V76, P592, DOI 10.1161/01.RES.76.4.592; ZU YJ, 1991, CIRC RES, V69, P239	48	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3747	3755		10.1074/jbc.273.6.3747	http://dx.doi.org/10.1074/jbc.273.6.3747			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452507	hybrid			2022-12-27	WOS:000071822300092
J	Apergis, GA; Crawford, N; Ghosh, D; Steppan, CM; Vorachek, WR; Wen, P; Locker, J				Apergis, GA; Crawford, N; Ghosh, D; Steppan, CM; Vorachek, WR; Wen, P; Locker, J			A novel nk-2-related transcription factor associated with human fetal liver and hepatocellular carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; HOMEO BOX GENE; FACTOR-I; CELL-LINES; DNA; HOMEODOMAIN; EXPRESSION; PROMOTER; BINDING; ENHANCER	A novel cDNA was partially isolated from a HepG2 cell expression library by screening with the promoter-linked coupling element (PCE), a site from the alpha-fetoprotein (AFP) gene promoter, The remainder of the cDNA was cloned from fetal liver RNA using random amplification of cDNA ends, The cDNA encodes a 239-amino acid peptide with domains closely related to the Drosophila factor nk-2. The new factor is the eighth vertebrate factor related to nk-2, hence nkx-2. 8. Northern blot and reverse transcriptase polymerase chain reaction analysis demonstrated mRNA in HepG2, two other AFP-expressing human cell lines, and human fetal liver, Transcripts were not detected in adult liver. Cell-free translation produced DNA binding activity that gel shifted a PCE oligonucleotide. Cotransfection of nkx-2.8 expression and PCE reporter plasmids into HeLa cells demonstrated transcriptional activation; NH2-terminal deletion eliminated this activity. Cotransfection into AFP-producing hepatocytic cells repressed AFP reporter expression, suggesting that endogenous activity was already present in these cells. In contrast, cotransfection into an AFP-negative hepatocytic line produced moderate activation of the AFP gene, The cardiac developmental factor nkx-2.5 could substitute for nkx-2.8 in all transfection assays, whereas another related factor, thyroid transcription factor 1, showed a more limited range of substitution, Although the studies have yet to establish definitively that nkx-2.8 is the AFP gene regulator PCF, the two factors share a common DNA binding site, gel shift behavior, migration on SDS-acrylamide gels, and cellular distribution, Moreover, the nk-2-related genes are developmental regulators, and nkx-2.8 is the first such factor associated with liver development.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Locker, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, BST S405, Pittsburgh, PA 15261 USA.	loc@med.pitt.edu			NCI NIH HHS [CA68440] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068440] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; EVANS SM, 1995, DEVELOPMENT, V121, P3889; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FINKE J, 1993, BIOTECHNIQUES, V14, P448; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; Hentsch B, 1996, GENE DEV, V10, P70, DOI 10.1101/gad.10.1.70; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; JIN JR, 1995, DNA CELL BIOL, V14, P267, DOI 10.1089/dna.1995.14.267; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Lee KH, 1996, DEV BIOL, V180, P722, DOI 10.1006/dbio.1996.0341; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Minoo P, 1995, DEV BIOL, V172, P694, DOI 10.1006/dbio.1995.8080; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUGLIA L, 1984, NUCLEIC ACIDS RES, V12, P6751, DOI 10.1093/nar/12.17.6751; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULZ WA, 1988, EXP CELL RES, V174, P433, DOI 10.1016/0014-4827(88)90313-8; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STORTO PD, 1990, GENE CHROMOSOME CANC, V2, P300, DOI 10.1002/gcc.2870020408; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231	44	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2917	2925		10.1074/jbc.273.5.2917	http://dx.doi.org/10.1074/jbc.273.5.2917			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446603	hybrid			2022-12-27	WOS:000071736600058
J	Nabirochkin, S; Ossokina, M; Heidmann, T				Nabirochkin, S; Ossokina, M; Heidmann, T			A nuclear matrix/scaffold attachment region co-localizes with the gypsy retrotransposon insulator sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-WING PROTEIN; DNA-BINDING PROTEIN; METAPHASE CHROMOSOME STRUCTURE; SCAFFOLD-ASSOCIATED REGIONS; ZINC FINGER PROTEIN; TOPOISOMERASE-II; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENT; CHROMATIN INSULATOR; MOLECULAR ANALYSIS	The 5'-untranslated region of the Drosophila gypsy retrotransposon contains an "insulator," which disrupts the interactions between enhancer and promoter elements located apart, The insulator effect is dependent on the suppressor of Hairy-wing (su(Hw)) protein, which binds to reiterated sites within the 350 base pairs of the gypsy insulator, whereby it additionally acts as a transcriptional activator of gypsy, Here, we show that the 350 base pair su(Hw) binding site containing gypsy insulator behaves in addition as a matrix/scaffold attachment region (MAR/SAR), involved in interactions with the nuclear matrix. In vitro experiments using nuclear matrices from Drosophila, murine, and human cells demonstrate specific binding of the gypsy insulator, not observed with any other sequence within the retrotransposon, Moreover, we show that the gypsy insulator, like previously characterized MAR/SARs, specifically interacts with topoisomerase II and histone H1, i.e. with two essential components of the nuclear matrix, Finally, experiments within cells in culture demonstrate differential effects of the gypsy MAR sequence on reporter genes, namely no effect under conditions of transient transfection and a repressing effect in stable transformants, as expected for a sequence involved in chromatin structure and organization, A model for the gypsy insulator, which combines within a short "compacted" retroviral sequence three functional domains (insulator, enhancer, and the presently unraveled MAR/SAR) dispersed within more extended regions in other "boundary" domains, is discussed in relation to previously proposed models for insulation.	Inst Gustave Roussy, Unite Physicochim & Pharmacol Macromol Biol, CNRS URA147, F-94805 Villejuif, France	UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, Unite Physicochim & Pharmacol Macromol Biol, CNRS URA147, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.							ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BAYEV AA, 1984, NUCLEIC ACIDS RES, V12, P3707, DOI 10.1093/nar/12.8.3707; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cai HN, 1997, EMBO J, V16, P1732, DOI 10.1093/emboj/16.7.1732; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; Coffin JM, 1996, FIELDS VIROLOGY, P1767; CORCES VG, 1995, NATURE, V376, P462, DOI 10.1038/376462a0; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HANCOCK R, 1982, BIOL CELL, V44, P201; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Iarovaia O, 1996, MOL CELL BIOL, V16, P302; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1993, EMBO J, V12, P115, DOI 10.1002/j.1460-2075.1993.tb05637.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Kim J, 1996, MOL CELL BIOL, V16, P3381; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; Maniatis T., 1989, MOL CLONING LAB MANU; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MODOLELL J, 1983, P NATL ACAD SCI-BIOL, V80, P1678, DOI 10.1073/pnas.80.6.1678; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; Neznanov N, 1996, MOL BIOL CELL, V7, P541, DOI 10.1091/mbc.7.4.541; NICOLAS JF, 1983, COLD SPRING HARBOR C, V10, P469; PARKHURST SM, 1986, MOL CELL BIOL, V6, P47, DOI 10.1128/MCB.6.1.47; PAULSON JR, 1977, CELL, V12, P815; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PhiVan L, 1996, BIOCHEMISTRY-US, V35, P10735, DOI 10.1021/bi9603783; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SCHEDL P, 1995, CHROMATIN STRUCTURE, P172; Schubeler D, 1996, BIOCHEMISTRY-US, V35, P11160, DOI 10.1021/bi960930o; Scott KS, 1995, EMBO J, V14, P6258, DOI 10.1002/j.1460-2075.1995.tb00316.x; SMITH PA, 1995, GENETICS, V139, P215; SPANA C, 1988, GENE DEV, V2, P1414, DOI 10.1101/gad.2.11.1414; SPANA C, 1990, GENE DEV, V4, P1505, DOI 10.1101/gad.4.9.1505; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; VAZQUEZ J, 1994, EMBO J, V13, P5984, DOI 10.1002/j.1460-2075.1994.tb06944.x; VAZQUEZ J, 1993, COLD SPRING HARB SYM, V58, P45, DOI 10.1101/SQB.1993.058.01.008; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195	67	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2473	2479		10.1074/jbc.273.4.2473	http://dx.doi.org/10.1074/jbc.273.4.2473			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442099	hybrid			2022-12-27	WOS:000071595200088
J	Blackburn, MR; Datta, SK; Kellems, RE				Blackburn, MR; Datta, SK; Kellems, RE			Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; MOUSE; 2'-DEOXYADENOSINE; DEOXYADENOSINE; EXPRESSION; APOPTOSIS; RECEPTOR; DEOXYNUCLEOTIDES; INACTIVATION; LYMPHOCYTES	Adenosine deaminase (ADA) deficiency in humans leads to a combined immunodeficiency. The mechanisms involved in the lymphoid specificity of the disease are not fully understood due to the inaccessibility of human tissues for detailed analysis and the absence of an adequate animal model for the disease. We report the use of a two-stage genetic engineering strategy to generate ADA-deficient mice that retain many features associated with ADA deficiency in humans, including a combined immunodeficiency. Severe T and B cell lymphopenia was accompanied by a pronounced accumulation of 2'-deoxyadenosine and dATP in the thymus and spleen, and a marked inhibition of S-adenosylhomocysteine hydrolase in these organs, Accumulation of adenosine was widespread among all tissues examined. ADA-deficient mice also exhibited severe pulmonary insufficiency, bone abnormalities, and kidney pathogenesis. These mice have provided in vivo information into the metabolic basis for the immune phenotype associated with ADA deficiency.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	University of Texas System; Baylor College of Medicine	Kellems, RE (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St, Houston, TX 77030 USA.	rkellems@utmmg.med.uth.tmc.edu		Blackburn, Michael/0000-0002-1394-9966	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034130] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R56HD034130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34130, HD07843] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apasov SG, 1997, J IMMUNOL, V158, P5095; BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Blackburn MR, 1996, J BIOL CHEM, V271, P15203, DOI 10.1074/jbc.271.25.15203; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BLAESE RM, 1995, PEDIATR RES, V33, pS49; BLAESE RM, 1995, METABOLIC MOL BASIS, V3, P3895; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; CEDERBAUM SD, 1976, J PEDIATR-US, V89, P737, DOI 10.1016/S0022-3476(76)80793-7; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; DOHERTY PJ, 1991, SCAND J IMMUNOL, V33, P405, DOI 10.1111/j.1365-3083.1991.tb01788.x; DONOFRIO J, 1978, J CLIN INVEST, V62, P884, DOI 10.1172/JCI109201; DOOLEY T, 1987, PRENATAL DIAG, V7, P561, DOI 10.1002/pd.1970070806; GAO X, 1994, TERATOLOGY, V49, P1, DOI 10.1002/tera.1420490103; GIBLETT ER, 1972, LANCET, V2, P1067; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1993, PEDIATR RES, V33, pS35; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; KAMINSKA JE, 1980, J LAB CLIN MED, V96, P141; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; LUI X, 1996, CELL, V86, P147; Malanchere E, 1997, EUR J IMMUNOL, V27, P788, DOI 10.1002/eji.1830270330; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MORGAN G, 1987, CLIN EXP IMMUNOL, V70, P491; PUFFINBARGER NK, 1995, MOL PHARMACOL, V47, P1126; RATECH H, 1981, CLIN IMMUNOL IMMUNOP, V21, P119, DOI 10.1016/0090-1229(81)90200-2; RATECH H, 1985, AM J PATHOL, V120, P157; Ratter F, 1996, INT IMMUNOL, V8, P1139, DOI 10.1093/intimm/8.7.1139; Resta R, 1997, IMMUNOL TODAY, V18, P371, DOI 10.1016/S0167-5699(97)01047-5; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; STILES GL, 1992, J BIOL CHEM, V267, P6451; SZONDY Z, 1994, BIOCHEM J, V304, P877, DOI 10.1042/bj3040877; ULLMAN B, 1981, J BIOL CHEM, V256, P848; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673	43	136	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5093	5100		10.1074/jbc.273.9.5093	http://dx.doi.org/10.1074/jbc.273.9.5093			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478961	hybrid			2022-12-27	WOS:000072310400045
J	McEwen, DG; Ornitz, DM				McEwen, DG; Ornitz, DM			Regulation of the fibroblast growth factor receptor 3 promoter and intron I enhancer by Sp1 family transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; OSTEONECTIN PROMOTER; FACTOR-BINDING; GENE PROMOTER; LESS PROMOTER; FGF RECEPTOR; BONE-CELLS; ACTIVATION; DNA; EXPRESSION	Fibroblast growth factor receptor 3 (FGFR3) has a complex spatial and temporal pattern of expression and is essential for the normal development of a diverse set of tissues. Recently, mutations have been identified in FGFR3 that result in constitutive tyrosine kinase activity and cause a number of different human skeletal disorders. To examine the regulatory mechanisms governing FGFR3 expression, the promoter for the FGFR3 gene was identified and characterized. It resides in a CpG island, which encompasses the 5' end of the FGFR3 gene and lacks classical cis-regulatory motifs. As little as 100 base pairs of sequence 5' to the initiation site can confer a 20-40-fold increase in transcriptional activity upon a promoter-less vector. The transcriptional activity of these cia-regulatory sequences is further stimulated by elements found within the first intron. Mapping of the enhancer activity found within intron I identified two purine-rich sequence moths between +340 and +395. Electrophoretic mobility shift assays demonstrated that sequences within this region bind members of the Spl family of transcription factors. In a background lacking Spl-like activity, we demonstrate that Spl can enhance transcription of the minimal promoter (which contains five classical Spl sites), whereas both Spl and Sp3 can enhance transcription through the elements found in intron I. Although these transcription factors are ubiquitously expressed, we demonstrate that the sequences between -220 and +609 of the FGFR3 gene are sufficient to promote the tissue-specific expression of a reporter gene in transgenic mice.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Ornitz, DM (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.			Ornitz, David/0000-0003-1592-7629	NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER; NCI NIH HHS [CA60673] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CHEN XR, 1992, ONCOGENE, V7, P1805; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISEMANN A, 1991, ONCOGENE, V6, P1195; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; Iannello RC, 1997, MOL CELL BIOL, V17, P612, DOI 10.1128/MCB.17.2.612; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; McEwen DG, 1997, BIOTECHNIQUES, V22, P1068, DOI 10.2144/97226bm12; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MORGAN WD, 1989, MOL CELL BIOL, V9, P4099, DOI 10.1128/MCB.9.9.4099; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sambrook J., 2002, MOL CLONING LAB MANU; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Simon TC, 1997, J BIOL CHEM, V272, P10652; Skaer H, 1997, CURR BIOL, V7, pR238, DOI 10.1016/S0960-9822(06)00110-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILKIE AOM, 1995, CURR BIOL, V5, P500; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; YOUNG MF, 1989, J BIOL CHEM, V264, P450	61	47	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5349	5357		10.1074/jbc.273.9.5349	http://dx.doi.org/10.1074/jbc.273.9.5349			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478995	hybrid			2022-12-27	WOS:000072310400079
J	Ong, E; Yeh, JC; Ding, YL; Hindsgaul, O; Fukuda, M				Ong, E; Yeh, JC; Ding, YL; Hindsgaul, O; Fukuda, M			Expression cloning of a human sulfotransferase that directs the synthesis of the HNK-1 glycan on the neural cell adhesion molecule and glycolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY HNK-1; MYELIN-ASSOCIATED GLYCOPROTEIN; SULFOGLUCURONYL GLYCOLIPIDS; NERVOUS-SYSTEM; CARBOHYDRATE EPITOPE; HUMAN POLYSIALYLTRANSFERASE; CDNA CLONING; N-CAM; BIOSYNTHESIS; ANTIGEN	The HNK-1 carbohydrate is expressed on various adhesion molecules in the nervous system and is suggested to play a role in cell-cell and cell-substratum interactions, Here we describe the isolation and functional expression of a cDNA encoding a human sulfotransferase that synthesizes the HNK-1 carbohydrate epitope, A mutant Chinese hamster ovary cell line, Lec2, which stably expresses human neural cell adhesion molecule (N-CAM) (Lec2-NCAM), was first established, Lec2-NCAM was co transfected with a human fetal brain cDNA library, a cDNA encoding the rat glucuronyltransferase that forms a precursor of the HNK-1 carbohydrate, and a vector encoding the polyoma large T antigen, The transfected Lec2-NCAM cells expressing the HNK-1 glycan were enriched by fluorescence-activated cell sorting, Sibling selection of recovered plasmids resulted in a cDNA encoding a sulfotransferase, HNK-1ST, that directs the expression of the HNK-1 carbohydrate epitope on the cell surface, The deduced amino acid sequence indicates that the enzyme is a type II membrane protein, Sequence analysis revealed that there is a short amino acid sequence in the presumed catalytic domain, which is highly homologous to the corresponding sequence in other Gels-associated sulfotransferases so far cloned, The amount of HNK-1ST transcript is high in fetal brain compared with fetal lung, kidney, and liver, Expression of HNK-1ST resulted in the formation of the HNK-1 epitope on N-CAM and a soluble chimeric form of HNK-1ST was shown to add a sulfate group to a precursor, GlcA beta 1-->3Gal beta 1-->4GlcNAc beta 1-->R, forming sulfo-->3GlcA beta 1-->3Gal beta 1-->4GlcNAc beta 1-->R. The results combined together indicate that the cloned HNK-1ST directs the synthesis of the HNK-1 carbohydrate epitope on both glycoproteins and glycolipids in the nervous tissues.	Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham-inst.org			NCI NIH HHS [R01 CA33895, P01 CA71932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895, P01CA071932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO T, 1981, J IMMUNOL, V127, P1024; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; ARIGA T, 1987, J BIOL CHEM, V262, P848; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BOURNE SP, 1991, J NEURO-ONCOL, V10, P111, DOI 10.1007/BF00146871; BRONNERFRASER M, 1986, DEV BIOL, V115, P44, DOI 10.1016/0012-1606(86)90226-5; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CUMMINGS L, 1993, BIOCHEM BIOPH RES CO, V195, P814, DOI 10.1006/bbrc.1993.2118; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; Ding YL, 1996, BIOORGAN MED CHEM, V4, P683, DOI 10.1016/0968-0896(96)00064-8; EISENMAN LM, 1993, J COMP NEUROL, V335, P586, DOI 10.1002/cne.903350410; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GENNARINI G, 1989, J NEUROSCI RES, V22, P1, DOI 10.1002/jnr.490220102; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Isogai Y, 1996, J CARBOHYD CHEM, V15, P1119, DOI 10.1080/07328309608006501; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; OBATA K, 1988, NEUROSCI RES, V6, P131, DOI 10.1016/0168-0102(88)90015-6; OKA S, 1992, J BIOL CHEM, V267, P22711; ONG E, 1998, IN PRESS GLYCOBIOLOG, V8; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160	45	87	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5190	5195		10.1074/jbc.273.9.5190	http://dx.doi.org/10.1074/jbc.273.9.5190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478973	hybrid			2022-12-27	WOS:000072310400057
J	Revilla, Y; Callejo, M; Rodriguez, JM; Culebras, E; Nogal, ML; Salas, ML; Vinuela, E; Fresno, M				Revilla, Y; Callejo, M; Rodriguez, JM; Culebras, E; Nogal, ML; Salas, ML; Vinuela, E; Fresno, M			Inhibition of nuclear factor kappa B activation by a virus-encoded I kappa B-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWINE FEVER VIRUS; TUMOR-NECROSIS-FACTOR; C-TERMINAL DOMAIN; TRANSCRIPTION FACTORS; ALPHA; DEGRADATION; CYTOKINE; GENE; VIVO; REL	Certain viruses have evolved mechanisms to counteract innate immunity, a host response in which nuclear factor kappa B (NF-kappa B) transcription factors play a central role. African swine fever virus encodes a protein of 28.2 kDa containing ankyrin repeats similar to those of cellular I kappa B proteins, which are inhibitors of NF-kappa B. Transfection of the African swine fever virus I kappa B gene inhibited tumor necrosis factor-or phorbol ester-induced activation of kappa B- but not AP-l-driven reporter genes. Moreover, African swine fever virus I kappa B co-immunoprecipitated with p65 NF-kappa B, and the purified recombinant protein prevented the binding of p65-p50 NF-kappa B proteins to their target sequences in the DNA. NF-kappa B activation induced by tumor necrosis factor, as detected by mobility shift assays or by transfection of kappa B-driven reporter genes, is impaired in African swine fever virus-infected cells. These results indicate that the African swine fever virus I kappa B gene homologue interferes with NF-kappa B activation, likely representing a new mechanism to evade the immune response during viral infection.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Vinuela, E (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Culebras, ESTHER/AAA-3865-2019; Rodriguez Martinez, Javier Maria/A-5478-2017	Fresno Escudero, Manuel/0000-0002-9223-5477; Culebras, Esther/0000-0001-7395-2684; Yolanda, Revilla/0000-0001-6555-6331; Rodriguez Martinez, Javier Maria/0000-0003-0146-9903				ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CARRERA AC, 1992, J IMMUNOL, V149, P3142; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; ENJUANES L, 1976, J GEN VIROL, V32, P471, DOI 10.1099/0022-1317-32-3-471; ESPARZA I, 1988, J GEN VIROL, V69, P2973, DOI 10.1099/0022-1317-69-12-2973; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GANCHI PA, 1992, MOL CELL BIOL, V12, P1339; GOODING LR, 1992, CELL, V71, P5; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARADA EN, 1992, P NATL ACAD SCI USA, V89, P2489; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INOUE J, 1992, P NATL ACAD SCI USA, V99, P4333; KOPF EB, 1995, ADV IMMUNOL, V58, P1; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEY V, 1984, VIROLOGY, V133, P249, DOI 10.1016/0042-6822(84)90392-1; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; PALUMBO GJ, 1994, J VIROL, V68, P1737, DOI 10.1128/JVI.68.3.1737-1749.1994; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Rodriguez MS, 1996, ONCOGENE, V12, P2425; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; SALAS ML, 1986, VIROLOGY, V152, P228, DOI 10.1016/0042-6822(86)90387-9; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SPRIGGS MK, 1994, CURR OPIN IMMUNOL, V6, P526, DOI 10.1016/0952-7915(94)90136-8; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Vinuela E., 1987, African swine fever, P31; Wilkinson P. J., 1989, Virus infections of porcines., P17; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	47	106	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5405	5411		10.1074/jbc.273.9.5405	http://dx.doi.org/10.1074/jbc.273.9.5405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9479002	Green Published, hybrid			2022-12-27	WOS:000072310400086
J	Bernstein, HS; Coughlin, SR				Bernstein, HS; Coughlin, SR			A mammalian homolog of fission yeast Cdc5 regulates G2 progression and mitotic entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEE1 TYROSINE KINASE; NEGATIVE REGULATION; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; PROTEIN PHOSPHATASE; MITOSIS; PHOSPHORYLATION; INACTIVATION; EXPRESSION; TRANSITION	Progression through G2/M of the mammalian cell division cycle requires the coordinated expression of many gene products, but little is known of the transcriptional regulators involved. Schizosaccharomyces pombe Cdc5 is a putative transcription factor implicated in G2/M transit, me recently identified a cDNA encoding a putative human transcription factor, now designated human Cdc5 (hCdc5), with homology to S. pombe Cdc5. Widespread expression of hCdc5 in human tissues and homology with expressed sequences in other eukaryotes suggested an evolutionarily conserved general function, Nuclear import of hCdc5 upon serum stimulation of mammalian cells suggested a possible role in cell proliferation, We now report that overexpression of hCdc5 in mammalian cells shortened G2 and reduced cell size, A dominant negative mutant of hCdc5 lacking the carboxyl-terminal activation domain slowed G2 progression and delayed entry into mitosis, Thus, hCdc5 is the first transcriptional regulator shown to affect G2 progression and mitotic entry in mammalian cells.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bernstein, HS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 513 Parnassus Ave,Box 0632, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL03228, HL43821, HL44907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R21HL103228, R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Fleig U N, 1991, Semin Cell Biol, V2, P195; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; Iavarone A, 1997, NATURE, V387, P417; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KREK W, 1995, METHOD ENZYMOL, V254, P114; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1993, CELL CYCLE; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	32	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4666	4671		10.1074/jbc.273.8.4666	http://dx.doi.org/10.1074/jbc.273.8.4666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468527	hybrid			2022-12-27	WOS:000072115000055
J	Frischholz, S; Beier, F; Girkontaite, I; Wagner, K; Poschl, E; Turnay, J; Mayer, U; von der Mark, K				Frischholz, S; Beier, F; Girkontaite, I; Wagner, K; Poschl, E; Turnay, J; Mayer, U; von der Mark, K			Characterization of human type X procollagen and its NC-1 domain expressed as recombinant proteins in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-PLATE CARTILAGE; SCHMID METAPHYSEAL CHONDRODYSPLASIA; SHORT-CHAIN COLLAGEN; ENDOCHONDRAL OSSIFICATION; OSTEOARTHRITIC CARTILAGE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; TERMINAL DOMAIN; ALGINATE BEADS; CHONDROCYTES	Type X collagen is a short-chain, network-forming collagen found in hypertrophic cartilage in the growth zones of long bones, vertebrae, and ribs. To obtain information about the structure and assembly of mammalian type X collagen, we generated recombinant human type collagen X by stable expression of full-length human alpha 1(X) cDNA in the human embryonal kidney cell line HEK293 and the fibrosarcoma cell line HT1080, Stable clones were obtained secreting recombinant human type X collagen (hrColX) in amounts of 50 mu g/ml with alpha 1(X)-chains of apparent molecular mass of 75 kDa, Pepsin digestion converted the native protein to a molecule migrating as one band at 65 kDa, while bands of 55 and 43 kDa were generated by trypsin digestion, Polyclonal antibodies prepared against purified hrColX reacted specifically with type X collagen in sections of human fetal growth cartilage, Circular dichroism spectra and trypsin/chymotrypsin digestion experiments of hrColX at increasing temperatures indicated triple helical molecules with a reduced melting temperature of 31 degrees C as a result of partial underhydroxylation. Ultrastructural analysis of hrColX by rotary shadowing demonstrated rodlike molecules with a length of 130 nm, assembling into aggregates via the globular noncollagenous (NC)-1 domains as reported for chick type X collagen, NC-1 domains generated by collagenase digestion of hrColX migrated as multimers of apparent mass of 40 kDa on SDS polyacrylamide gel electrophoresis, even after reduction and heat denaturation, and gave rise to monomers of 18-20 kDa after treatment with trichloroacetic acid, The NC-1 domains prepared by collagenase digestion comigrated with NC-1 domains prepared as recombinant protein in HEK293 cells, both in the multimeric and monomeric form. These studies demonstrate the potential of the pCMVsis expression system to produce recombinant triple helical type X collagens in amounts sufficient for further studies on its structural and functional domains.	Univ Erlangen Nurnberg, Inst Expt Med, D-91054 Erlangen, Germany; Univ Complutense Madrid, Fac Chem Sci, Dept Biochem & Mol Biol, Madrid, Spain; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Erlangen Nuremberg; Complutense University of Madrid; Max Planck Society	von der Mark, K (corresponding author), Univ Erlangen Nurnberg, Inst Expt Med, Schwabachanlage 10, D-91054 Erlangen, Germany.	kvdmark@expmed.uni-erlangen.de	Turnay, Javier/K-4551-2014; Girkontaite, Irute/K-9017-2013; Beier, Frank/T-4734-2019; Beier, Frank/G-4595-2013; Turnay, Javier/AAB-1497-2022	Turnay, Javier/0000-0002-6135-2179; Girkontaite, Irute/0000-0002-3659-3202; Beier, Frank/0000-0002-8505-7537; Beier, Frank/0000-0002-8505-7537; Turnay, Javier/0000-0002-6135-2179; Mayer, Ulrike/0000-0003-2328-0052				AIGNER T, 1993, VIRCHOWS ARCH B, V63, P205, DOI 10.1007/BF02899263; AYAD S, 1987, FEBS LETT, V220, P181, DOI 10.1016/0014-5793(87)80899-2; BONAVENTURE J, 1995, HUM GENET, V96, P58, DOI 10.1007/BF00214187; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; CAPASSO O, 1984, EMBO J, V3, P823, DOI 10.1002/j.1460-2075.1984.tb01891.x; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; Fukuda K, 1997, BIOCHEM BIOPH RES CO, V231, P178, DOI 10.1006/bbrc.1997.6069; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; GIBSON GJ, 1984, J CELL BIOL, V99, P208, DOI 10.1083/jcb.99.1.208; Girkontaite I, 1996, MATRIX BIOL, V15, P231, DOI 10.1016/S0945-053X(96)90114-6; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRANT WT, 1987, J BIOL CHEM, V262, P9844; GRANT WT, 1985, J BIOL CHEM, V260, P3798; GUNSON DE, 1976, IMMUNOLOGY, V31, P577; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; HARWOOD R, 1976, BIOCHEM J, V156, P81, DOI 10.1042/bj1560081; HAUSELMANN HJ, 1992, MATRIX, V12, P116; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; HOYLAND JA, 1991, BONE MINER, V15, P151, DOI 10.1016/0169-6009(91)90005-K; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; JIMENEZ SA, 1986, BIOCHEM BIOPH RES CO, V138, P835, DOI 10.1016/S0006-291X(86)80572-1; Kielty Cay M., 1993, P103; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; KIRSCH T, 1992, DIFFERENTIATION, V52, P89, DOI 10.1111/j.1432-0436.1992.tb00503.x; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KIRSCH T, 1991, EUR J BIOCHEM, V196, P575, DOI 10.1111/j.1432-1033.1991.tb15852.x; KIRSCH T, 1992, BONE MINER, V18, P107, DOI 10.1016/0169-6009(92)90851-4; KIRSCH T, 1994, J BIOL CHEM, V269, P11462; KIRSCH T, 1991, FEBS LETT, V294, P149, DOI 10.1016/0014-5793(91)81363-D; KIRSCH T, 1992, FEBS LETT, V310, P143, DOI 10.1016/0014-5793(92)81316-E; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; KWAN APL, 1986, FEBS LETT, V206, P267, DOI 10.1016/0014-5793(86)80994-2; KWAN APL, 1986, BIOSCIENCE REP, V6, P155, DOI 10.1007/BF01115001; KWAN APL, 1989, J CELL BIOL, V109, P1849, DOI 10.1083/jcb.109.4.1849; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; MARRIOTT A, 1991, J CELL SCI, V99, P641; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MCINTOSH I, 1995, HUM MUTAT, V5, P121, DOI 10.1002/humu.1380050204; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MING KK, 1997, J CELL BIOL, V136, P459; MULLER PK, 1974, BIOCHIM BIOPHYS ACTA, V365, P158, DOI 10.1016/0005-2795(74)90260-8; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; QUARTO N, 1985, EUR J BIOCHEM, V147, P397, DOI 10.1111/j.1432-1033.1985.tb08763.x; REGINATO AM, 1988, J BIOL CHEM, V263, P9938; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REMINGTON MC, 1984, BIOCHEM J, V224, P227, DOI 10.1042/bj2240227; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SCHMID TM, 1984, J ULTRA MOL STRUCT R, V86, P186, DOI 10.1016/S0022-5320(84)80057-X; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; SCHMID TM, 1984, BIOCHEMISTRY-US, V23, P553, DOI 10.1021/bi00298a024; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; SCHMID TM, 1987, STRUCTURE FUNCTION C, P223; Schmid TM, 1994, EXTRACELLULAR MATRIX, P171; Schulte S, 1998, J BIOL CHEM, V273, P1551, DOI 10.1074/jbc.273.3.1551; SUMMERS TA, 1988, J BIOL CHEM, V263, P581; SWOBODA B, 1989, J CELL BIOL, V109, P1363, DOI 10.1083/jcb.109.3.1363; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WALKER GD, 1995, J ORTHOPAED RES, V13, P4, DOI 10.1002/jor.1100130104; WALLIS GA, 1994, AM J HUM GENET, V54, P169; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	68	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4547	4555		10.1074/jbc.273.8.4547	http://dx.doi.org/10.1074/jbc.273.8.4547			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468510	hybrid			2022-12-27	WOS:000072115000038
J	Scholz, A; Truss, M; Beato, M				Scholz, A; Truss, M; Beato, M			Hormone-induced recruitment of Sp1 mediates estrogen activation of the rabbit uteroglobin gene in endometrial epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-DEPENDENT INTERACTION; II PROMOTER INVIVO; TRANSCRIPTION FACTORS; GLUCOCORTICOID RECEPTOR; HYPERSENSITIVE SITES; BINDING-PROTEINS; RESPONSE ELEMENT; MAMMALIAN-CELLS; TFIID COMPLEX; DNA	Steroid hormones activate gene expression by interaction of their receptors with hormone-responsive DNA elements and tissue-specific or ubiquitous factors. To monitor the molecular changes on the promoter of the rabbit uteroglobin gene during early pseudopregnancy in vitro, we have applied the genomic footprinting methodology to endometrial tissue, Estrogen induction results in the simultaneous occupancy of an estrogen-re sponsive element and an adjacent GC/GT box in the promoter, DNA binding assays demonstrate that the corresponding regulatory factors are the ligand-induced estrogen receptor and the ubiquitous transcription factor Sp1, Both factors functionally synergize in primary endometrial cells, showing that the GC/GT box is an essential part of a composite estrogen-responsive unit, However, the estrogen receptor and Sp1 do not bind cooperatively to their sites in vitro, suggesting that other mechanisms might be responsible for the hormone-dependent binding of Sp1 in vivo. Since hormone treatment leads to the appearance of a distinct DNase I-hypersensitive site over the promoter chromatin, an estrogen-induced change in the local chromatin structure could facilitate binding of Sp1 in vivo.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg	Beato, M (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	beato@imt.uni-marburg.de	Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BEIER HM, 1968, BIOCHIM BIOPHYS ACTA, V160, P289, DOI 10.1016/0005-2795(68)90108-6; BONDY KL, 1993, NUCLEIC ACIDS RES, V21, P5277, DOI 10.1093/nar/21.22.5277; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Eisfeld K, 1997, NUCLEIC ACIDS RES, V25, P3733, DOI 10.1093/nar/25.18.3733; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JANTZEN K, 1987, NUCLEIC ACIDS RES, V15, P4535, DOI 10.1093/nar/15.11.4535; KOK K, 1985, NUCLEIC ACIDS RES, V13, P5189, DOI 10.1093/nar/13.14.5189; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; MULLER H, 1980, EUR J BIOCHEM, V112, P235, DOI 10.1111/j.1432-1033.1980.tb07199.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Saceda M, 1996, ENDOCRINOLOGY, V137, P4322, DOI 10.1210/en.137.10.4322; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHAUER M, 1989, P NATL ACAD SCI USA, V86, P1123, DOI 10.1073/pnas.86.4.1123; SCHIPPERS IJ, 1994, EUR J BIOCHEM, V221, P43, DOI 10.1111/j.1432-1033.1994.tb18713.x; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Suske Guntram, 1992, Gene Expression, V2, P339; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WIJNHOLDS J, 1991, NUCLEIC ACIDS RES, V19, P33, DOI 10.1093/nar/19.1.33; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x	49	52	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4360	4366		10.1074/jbc.273.8.4360	http://dx.doi.org/10.1074/jbc.273.8.4360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468485	hybrid			2022-12-27	WOS:000072115000013
J	McCormick, KA; Isom, LL; Ragsdale, D; Smith, D; Scheuer, T; Catterall, WA				McCormick, KA; Isom, LL; Ragsdale, D; Smith, D; Scheuer, T; Catterall, WA			Molecular determinants of Na+ channel function in the extracellular domain of the beta 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; RAT-BRAIN; SKELETAL-MUSCLE; ALPHA-SUBUNIT; AMINO-ACIDS; INACTIVATION; EXPRESSION; PROTEIN; MUTAGENESIS; RECOGNITION	The rat brain voltage-gated Na+ channel is composed of three glycoprotein subunits: the pore-forming cu subunit and two auxiliary subunits, beta 1 and beta 2, which contain immunoglobulin (Ig)-like folds in their extracellular domains, When expressed in Xenopus oocytes, beta 1 modulates the gating properties of the channel-forming type IIA alpha subunit, resulting in an acceleration of inactivation, We have used a combination of deletion, alanine-scanning, site-directed, and chimeric mutagenesis strategies to examine the importance of different structural features of the beta 1 subunit in the modulation of alpha(IIA), function, with an emphasis on the extracellular domain, Deletion analysis revealed that the extracellular domain is required for function, but the intracellular domain is not, The mutation of four putative sites of N-linked glycosylation showed that they are not required for beta 1 function. Mutations of hydrophobic residues in the core beta sheets of the Ig fold disrupted beta 1 function, whereas substitution of amino acid residues in connecting segments had no effect, Mutations of acidic residues in the A/A' strand of the Ig fold reduced the effectiveness of the beta 1 subunit in modulating the rate of inactivation hut did not significantly affect the association of the mutant beta 1 subunit with the alpha(IIA) subunit or its effect on recovery from inactivation, Our data suggest that the Ig fold of the beta 1 extracellular domain serves as a scaffold that presents the charged residues of the A/A' strands for interaction with the pore-forming alpha subunit.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.			Isom, Lori/0000-0002-9479-6729	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25704] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FILHIN MT, 1993, J CELL BIOL, V122, P451; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JANIN J, 1990, J BIOL CHEM, V265, P16027; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Makita N, 1996, J NEUROSCI, V16, P7117; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PATTON DE, 1994, J BIOL CHEM, V269, P17649; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; TONG JF, 1993, BIOCHEM BIOPH RES CO, V195, P679, DOI 10.1006/bbrc.1993.2099; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; WELLS CA, 1993, J NEUROCHEM, V61, P1987, DOI 10.1111/j.1471-4159.1993.tb07434.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	34	129	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3954	3962		10.1074/jbc.273.7.3954	http://dx.doi.org/10.1074/jbc.273.7.3954			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461582	hybrid			2022-12-27	WOS:000072048400024
J	Olsthoorn, MMA; Petersen, BO; Schlecht, S; Haverkamp, J; Bock, K; Thomas-Oates, JE; Holst, O				Olsthoorn, MMA; Petersen, BO; Schlecht, S; Haverkamp, J; Bock, K; Thomas-Oates, JE; Holst, O			Identification of a novel core type in Salmonella lipopolysaccharide - Complete structural analysis of the core region of the lipopolysaccharide from Salmonella enterica sv. Arizonae 062	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENUS-SPECIFIC EPITOPE; BOMBARDMENT MASS-SPECTROMETRY; MURINE MONOCLONAL-ANTIBODY; MINNESOTA ROUGH MUTANTS; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; OUTER CORE; CHLAMYDIA LIPOPOLYSACCHARIDE; NMR-SPECTROSCOPY; VIBRIO-CHOLERAE	For the first time, the complete structure of a lipopolysaccharide (LPS) core region from Salmonella enterica has been identified that is different from the Ra core type generally thought to be present in all Salmonella LPS. The LPSs from two rough mutants and the smooth form of S, enterica sv, Arizonae IIIa 062, which all failed to react with an Ra core type-specific monoclonal antibody and were resistant to phage F01, were analyzed after chemical modification using monosaccharide analysis, mass spectrometry, and NMR spectroscopy, In the novel core type, the terminal D-GlcNAc residue present in the Ra core type, is replaced by a D-Glc residue, The O-specific polysaccharide is alpha 1-->4-linked to the second distal Glc residue of the core, Furthermore, phosphoryl substituents attached to 0-4 of L-glycero-D-manno-heptose (Hep) I and II were identified as a-aminoethyl diphosphate (on Hep I) and phosphate (Hep II), GRAPHICS Abbreviations in Structure I are as follows: Hepp, L-glycero-D-manno-heptopyranose; Kdo, 3-deoxy-D-manno-oct-2-ulopyranosonic acid; PPEA, 2-aminoethyl diphosphate; R, O-specific polysaccharide, The presence of this novel core type in LPS of S, enterica should be taken into account in the development of a general antibody-based diagnostic system for Salmonella.	Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, D-23845 Borstel, Germany; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Mass Spectrometry, NL-3508 TB Utrecht, Netherlands; Carlsberg Lab, Dept Chem, DK-2500 Valby, Denmark; Max Planck Inst Immunbiol, D-79108 Freiburg, Germany	Forschungszentrum Borstel; Utrecht University; Max Planck Society	Holst, O (corresponding author), Res Ctr Borstel, Ctr Med & Biosci, Div Med & Biochem Microbiol, Parkallee 22, D-23845 Borstel, Germany.	oholst@fz-borstel.de						BAX A, 1983, J MAGN RESON, V52, P330, DOI 10.1016/0022-2364(83)90206-8; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BRADE H, 1983, EUR J BIOCHEM, V131, P195, DOI 10.1111/j.1432-1033.1983.tb07249.x; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brull LP, 1997, J AM SOC MASS SPECTR, V8, P43, DOI 10.1016/S1044-0305(96)00134-1; DELL A, 1983, BIOMED MASS SPECTROM, V10, P50, DOI 10.1002/bms.1200100110; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Duus JO, 1996, CARBOHYD RES, V288, P25, DOI 10.1016/S0008-6215(96)90773-9; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GALANOS C, 1977, INT REV BIOCH BIOC 2, V14, P238; HAISHIMA Y, 1992, EUR J BIOCHEM, V207, P1129; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HOFINGER A, 1993, CARBOHYD RES, V243, P273, DOI 10.1016/0008-6215(93)87033-O; Holst O, 1996, FEMS IMMUNOL MED MIC, V16, P83, DOI 10.1111/j.1574-695X.1996.tb00126.x; HOLST O, 1995, EUR J BIOCHEM, V229, P194, DOI 10.1111/j.1432-1033.1995.tb20455.x; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; HOLST O, 1994, EUR J BIOCHEM, V222, P183, DOI 10.1111/j.1432-1033.1994.tb18856.x; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KACA W, 1988, CARBOHYD RES, V179, P289, DOI 10.1016/0008-6215(88)84125-9; KJAER M, 1994, METHODS ENZYMOL, V239, P288; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; KOVACIK V, 1995, J MASS SPECTROM, V30, P949, DOI 10.1002/jms.1190300704; LERNER L, 1987, CARBOHYD RES, V166, P35, DOI 10.1016/0008-6215(87)80042-3; LOPEZLARA IM, 1995, MOL MICROBIOL, V15, P627, DOI 10.1111/j.1365-2958.1995.tb02372.x; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MCNEIL M, 1983, CARBOHYD RES, V123, P31, DOI 10.1016/0008-6215(83)88378-5; MCNICHOLAS PA, 1987, CARBOHYD RES, V165, P17, DOI 10.1016/0008-6215(87)80073-3; PATIRRE SV, 1996, ANAL CHEM, V68, pA740; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; SCHLECHT S, 1986, ZBL BAKT-INT J MED M, V261, P147; SCHLECHT S, 1992, ZBL BAKT-INT J MED M, V277, P288; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TACKEN A, 1986, CARBOHYD RES, V149, P279, DOI 10.1016/S0008-6215(00)90051-X; TSANG RSW, 1991, ZBL BAKT-INT J MED M, V274, P446; TSANG RSW, 1987, INFECT IMMUN, V55, P211, DOI 10.1128/IAI.55.1.211-216.1987; TSANG RSW, 1991, RES MICROBIOL, V142, P521, DOI 10.1016/0923-2508(91)90185-D; TSANG RSW, 1992, ZBL BAKT-INT J MED M, V276, P330, DOI 10.1016/S0934-8840(11)80539-6; TSANG RSW, 1990, RES MICROBIOL, V141, P671, DOI 10.1016/0923-2508(90)90061-T; VINOGRADOV EV, 1992, EUR J BIOCHEM, V210, P491, DOI 10.1111/j.1432-1033.1992.tb17447.x; VINOGRADOV EV, 1994, CARBOHYD RES, V253, P101, DOI 10.1016/0008-6215(94)80058-8; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5	47	42	44	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3817	3829		10.1074/jbc.273.7.3817	http://dx.doi.org/10.1074/jbc.273.7.3817			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461562	hybrid, Green Submitted			2022-12-27	WOS:000072048400004
J	Capell, A; Grunberg, J; Pesold, B; Diehlmann, A; Citron, M; Nixon, R; Beyreuther, K; Selkoe, DJ; Haass, C				Capell, A; Grunberg, J; Pesold, B; Diehlmann, A; Citron, M; Nixon, R; Beyreuther, K; Selkoe, DJ; Haass, C			The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; IN-VIVO; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; GENE; PEPTIDE	Mutations in the presenilin (PS) genes are linked to early onset familial Alzheimer's disease (FAD). PS-1 proteins are proteolytically processed by an unknown protease to two stable fragments of similar to 30 kDa (N-terminal fragment (NTF)) and similar to 20 kDa (C-terminaI fragment (CTF)) (Thinakaran, G., Borchelt, D. R., Lee, M. K. Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., Hardy, J., Levey, A. I., Candy, S. E., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. (1996) Neuron 17, 181-190). Here we show that the CTF and NTF of PS-1 bind to each other. Fractionating proteins from 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid-extracted membrane preparations by velocity sedimentation reveal a high molecular mass SDS and Triton X-100-sensitive complex of approximately 100-150 kDa. To prove if both proteolytic fragments of PS-1 are bound to the same complex, we performed co-immunoprecipitations using multiple antibodies specific to the CTF and NTF of PS-1. These experiments revealed that both fragments of PS-1 occur as a tightly bound non-covalent complex. Upon overexpression, unclipped wild type PS-1 sediments at a lower molecular weight in glycerol velocity gradients than the endogenous fragments. In contrast, the non-cleavable, PAD-associated PS-1 Delta exon 9 sediments at a molecular weight similar to that observed for the endogenous proteolytic fragments. This result may indicate that the Delta exon 9 mutation generates a mutant protein that exhibits biophysical properties similar to the naturally occurring PS-1 fragments. This could explain the surprising finding that the Delta exon 9 mutation is functionally active, although it cannot be proteolytically processed (Baumeister, R., Leimer, U., Zweckbronner, I., Jakubek, C., Grunberg, J., and Haass, C. (1997) Genes & Function 1, 149-159; Levitan, D., Doyle, T., Brousseau, D., Lee, M., Thinakaran, G., Slunt, H., Sisodia, S., and Greenwald, I, (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14940-14944). Formation of a high molecular weight complex of PS-1 composed of both endogenous PS-1 fragments may also explain the recent finding that PAD-associated mutations within the N-terminal portion of PS-1 result in the hyperaccumulation not only of the NTF but also of the CTF (Lee, M. K., Borchelt, D. R., Kim, G., Thinakaran, G., Slunt, H. H., Ratovitski, T., Martin, L. J., Kittur, A., Gandy, S., Levey, A. I., Jenkins, N., Copeland, N., Price, D. L., and Sisodia, S. S. (1997) Not. Med 3, 756-760). Moreover, these results provide a model to understand the highly regulated expression and processing of PS proteins.	Cent Inst Mental Hlth, Dept Mol Biol, D-68159 Mannheim, Germany; Zentrum Mol Biol, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; NYU, Med Ctr, Dept Psychiat, Orangeburg, NY 10962 USA	Central Institute of Mental Health; Ruprecht Karls University Heidelberg; Harvard University; Harvard Medical School; New York University	Haass, C (corresponding author), Cent Inst Mental Hlth, Dept Mol Biol, J5, D-68159 Mannheim, Germany.							Baumeister R, 1997, Genes Funct, V1, P149; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BURDICK D, 1992, J BIOL CHEM, V267, P546; Capell A, 1997, J NEUROCHEM, V69, P2432; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GRUNBERG J, 1998, IN PRESS BIOCHEMISTR; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	45	301	311	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3205	3211		10.1074/jbc.273.6.3205	http://dx.doi.org/10.1074/jbc.273.6.3205			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452432	hybrid			2022-12-27	WOS:000071822300017
J	Shieh, HL; Chiang, HL				Shieh, HL; Chiang, HL			In vitro reconstitution of glucose-induced targeting of fructose-1,6-bisphosphatase into the vacuole in semi-intact yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-TRANSPORT; ENDOPLASMIC-RETICULUM; SORTING RECEPTOR; SELECTIVE UPTAKE; PLASMA-MEMBRANE; GOLGI MEMBRANES; DEGRADATION; ENDOCYTOSIS; MUTANTS	Fructose-1,6-bisphosphatase (FBPase), the key enzyme in gluconeogenesis in the yeast Saccharomyces cerevisiae, is induced when cells are grown in medium containing poor carbon sources. FBPase is targeted from the cytosol to the vacuole for degradation when glucose-starved yeast cells are replenished with fresh glucose. In this study, we report the reconstitution of the glucose-induced import of FBPase into the vacuole in semi-intact yeast cells using radiolabeled FBPase, an ATP regenerating system and cytosol. The import of FBPase was defined as the fraction of the FBPase that was sequestered inside a membrane-sealed compartment. FBPase import requires ATP hydrolysis and is stimulated by cytosolic proteins. Furthermore, the import of FBPase is a saturable process. FBPase import is low in the glucose-starved cells and is stimulated in the glucose-replenished cells, FBPase accumulates to a higher level in the pep4 cell, suggesting that FBPase is targeted to the vacuole for degradation. Indirect immunofluorescence microscopy studies demonstrate that the imported FBPase is localized to the vacuole in the permeabilized cells. Thus, the glucose-induced targeting of FBPase into the vacuole can be reproduced in our in vitro system.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Chiang, HL (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049267] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM49267] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hoffman M, 1996, GENETICS, V143, P1555; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, J BIOL CHEM, V266, P7963; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Murdock D. G., 1994, CELLULAR PROTEOLYTIC, P115; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; RIBALLO E, 1995, J BACTERIOL, V177, P5622, DOI 10.1128/jb.177.19.5622-5627.1995; RITTENHOUSE J, 1986, J BIOL CHEM, V261, P3939; ROGERS DT, 1988, J BIOL CHEM, V263, P6051; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCANDEL K, 1994, MOL CELL BIOL, V14, P7245; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TUTTLE DL, 1995, J CELL SCI, V108, P25; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	46	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3381	3387		10.1074/jbc.273.6.3381	http://dx.doi.org/10.1074/jbc.273.6.3381			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452458	hybrid			2022-12-27	WOS:000071822300043
J	Sundaram, M; Sivaprasadarao, A; DeSousa, MM; Findlay, JBC				Sundaram, M; Sivaprasadarao, A; DeSousa, MM; Findlay, JBC			The transfer of retinol from serum retinol-binding protein to cellular retinol-binding protein is mediated by a membrane receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; VITAMIN-A; TRANSPORT PROTEINS; ESCHERICHIA-COLI; PLASMA; PURIFICATION; BOVINE	The hypothesis that the cellular uptake of retinol involves the specific interaction of a plasma membrane receptor with serum retinol-binding protein (RBP) at the extracellular surface followed by ligand transfer to cytoplasmic cellular retinol-binding protein (CRBP) has been investigated. The experimental system consisted of the [H-3]retinol-RBP complex, Escherichia coli-expressed recombinant apo-CRBP containing the 10 amino acid long streptavidin-binding peptide sequence at its C terminus (designated as CRBP Strep) and permeabilized human placental membranes, [H-3]Retinol transfer from REP to CRBP-Strep was monitored by measuring the radioactivity associated with CRBP-Strep retained by an immobilized streptavidin resin. Using this assay system, we have demonstrated that optimal retinol uptake is achieved with holo-RBP, the membrane receptor and apo-CRBP. The effects are specific: other binding proteins, including beta-lactoglobulin and serum albumin, despite their ability to bind retinol, failed to substitute for either REP or apo-CRBP. The process is facilitated by membranes containing the native receptor suggesting that this protein is an important component in the transfer mechanism. Taken together, the data suggest that the REP receptor, through specific interactions with the binding proteins, participates (either directly or via associated proteins) in the mechanism which mediates the transfer of retinol from extracellular REP to intracellular CRBP.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Dept Pharmacol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Sivaprasadarao, A (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	a.sivaprasadarao@leeds.ac.uk	Sousa, Monica/K-4367-2013	Sousa, Monica/0000-0002-4524-2260; Sivaprasadarao, Asipu/0000-0002-6755-3502				BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BOOTH AG, 1980, PLACENTA, V1, P327, DOI 10.1016/S0143-4004(80)80034-8; CHEN CC, 1977, J BIOL CHEM, V252, P5216; CHEN WYJ, 1986, BIOCHEM SOC T, V14, P925, DOI 10.1042/bst0140925; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COLANTUONI V, 1983, NUCLEIC ACIDS RES, V11, P7769, DOI 10.1093/nar/11.22.7769; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HELLER J, 1975, J BIOL CHEM, V250, P3613; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATARESE V, 1993, J BIOL CHEM, V268, P18859; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NOY N, 1990, BIOCHEMISTRY-US, V29, P3613; ONG DE, 1994, NUTR REV, V52, P524; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; RASK L, 1976, J BIOL CHEM, V251, P6360; SANI BP, 1979, BIOCHEM BIOPH RES CO, V91, P502, DOI 10.1016/0006-291X(79)91550-X; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SENOO H, 1990, J LIPID RES, V31, P1229; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIVAPRASADARAO A, 1993, BIOCHEM SOC T, V21, P619, DOI 10.1042/bst0210619; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P571; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SIVAPRASADARAO A, 1994, BIOCHEM J, V300, P437, DOI 10.1042/bj3000437; SIVAPRASADARAO A, 1994, BIOCHEM J, V302, P245, DOI 10.1042/bj3020245; SIVAPRASADARAO A, 1993, BIOCHEM J, V296, P209, DOI 10.1042/bj2960209; Sivaprasadarao A., 1994, Vitamin A in health and disease., P87	33	90	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3336	3342		10.1074/jbc.273.6.3336	http://dx.doi.org/10.1074/jbc.273.6.3336			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452451	hybrid			2022-12-27	WOS:000071822300036
J	Tanaka, T; Kohno, T; Kinoshita, S; Mukai, H; Itoh, H; Ohya, M; Miyazawa, T; Higashijima, T; Wakamatsu, K				Tanaka, T; Kohno, T; Kinoshita, S; Mukai, H; Itoh, H; Ohya, M; Miyazawa, T; Higashijima, T; Wakamatsu, K			alpha helix content of G protein or subunit is decreased upon activation by receptor mimetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; BETA-ADRENERGIC-RECEPTOR; HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; SECONDARY STRUCTURE; SYNTHETIC PEPTIDES; CIRCULAR-DICHROISM; WASP VENOM; BOUND CONFORMATION; ADENYLATE-CYCLASE	To elucidate the mechanism whereby liganded receptor molecules enhance nucleotide exchange of GTP-binding regulatory proteins (G proteins), changes in the secondary structure of the recombinant G(i1) alpha subunit (G(i1)alpha) upon binding with receptor mimetics, compound 48/80 and mastoparan, were analyzed by circular dichroism spectroscopy. Compound 48/80 enhanced the initial rate of GTP gamma S binding to soluble G(i1)alpha 2.6-fold with an EC50 of 30 mu g/ml. With the same EC50, the mimetic decreased the magnitude of ellipticity, which is ascribed to a reduction in a helix content of the G(i1)alpha by 7%. Likewise, mastoparan also enhanced the rate of GTP gamma S binding by 3.0-fold and decreased the magnitude of ellipticity of G(i1)alpha similar to compound 48/80. In corresponding experiments using a K349P-G(i1)alpha, a G(i1)alpha counterpart of the une mutant in G(s) alpha in which Pro was substituted for Lys(349), enhancement of the GTP gamma S binding rate by both activators was quite small. In addition, compound 48/80 showed a negligible effect on the circular dichroism spectrum of the mutant. On the other hand, a proteolytic fragment of G(i1)alpha lacking the N-terminal 29 residues was activated and showed decreased ellipticity upon interaction with the compound, as did the wild-type C(i1)alpha. Taken together, our results strongly suggest that the activator-induced unwinding of the alpha helix of the G protein alpha subunit is mechanically coupled to the enhanced release of bound GDP from the alpha subunit.	Gunma Univ, Fac Engn, Dept Biochem Sci, Kiryu, Gumma 376, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 194, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Kanagawa 226, Japan; Prot Engn Res Inst, Osaka 565, Japan; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; RIKEN, Inst Phys & Chem Res, Wako, Saitama 35101, Japan	Gunma University; University of Tsukuba; Tokyo Institute of Technology; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; RIKEN	Wakamatsu, K (corresponding author), Gunma Univ, Fac Engn, Dept Biochem Sci, Kiryu, Gumma 376, Japan.	wakamats@bce.gunma-u.ac.jp	Wakamatsu, Kaori/AAQ-9690-2020	Wakamatsu, Kaori/0000-0003-1412-5691				BOURNE HR, 1995, SCIENCE, V270, P933, DOI 10.1126/science.270.5238.933; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; ITOH H, 1991, J BIOL CHEM, V266, P16226; KATSU T, 1983, FEBS LETT, V151, P219, DOI 10.1016/0014-5793(83)80073-8; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1991, METHOD ENZYMOL, V195, P202; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SAITO K, 1984, CHEM PHARM BULL, V32, P2187; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUKUMAR M, 1992, J BIOL CHEM, V267, P21421; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P184, DOI 10.1093/oxfordjournals.jbchem.a123342; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WAKAMATSU K, 1992, BIOCHEMISTRY-US, V31, P5654, DOI 10.1021/bi00139a032; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0	53	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3247	3252		10.1074/jbc.273.6.3247	http://dx.doi.org/10.1074/jbc.273.6.3247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452438	hybrid			2022-12-27	WOS:000071822300023
J	Ye, Q; Koltchine, VV; Mihic, SJ; Mascia, MP; Wick, MJ; Finn, SE; Harrison, NL; Harris, RA				Ye, Q; Koltchine, VV; Mihic, SJ; Mascia, MP; Wick, MJ; Finn, SE; Harrison, NL; Harris, RA			Enhancement of glycine receptor function by ethanol is inversely correlated with molecular volume at position alpha 267	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELINATED NERVE; SODIUM CURRENTS; PROTEIN; ACID; INHIBITION; ALCOHOLS; NEURONS; BRAIN; ANESTHETICS; SUPERFAMILY	Glycine and gamma-aminobutyric acid (GABA)(A) receptors are members of the "superfamily" of ion channels, and are sensitive to allosteric modulation by n-alcohols such as ethanol and butanol. We recently demonstrated that the mutation of Ser-267 to Ile in the alpha 1 subunit abolished ethanol regulation of glycine receptors (Gly-R). In the present study, a pair of chimeric receptors was studied, in which a 45-amino acid domain comprising transmembrane domains 2 and 3 was exchanged between the Gly-R alpha 1 and gamma-aminobutyric acid rho 1 subunits. Detailed pharmacologic analysis of these chimeras confirmed that this domain of the Gly-R confers enhancement of recep tor function by ethanol and butanol. An extensive series of mutations at Ser-267 in the Gly-R alpha 1 subunit was also prepared, and the resulting homomeric receptors were expressed and tested for sensitivity to glycine, and allosteric modulation by alcohols. All of the mutant receptors expressed successfully in Xenopus oocytes. Mutation of Ser-267 to small amino acid residues such as Gly or Ala produced receptors in which glycine responses were potentiated by ethanol. As we have reported previously, the mutant Gly-R alpha 1 (Ser-267 --> Ile) was completely insensitive to ethanol; mutation of Ser-267 to Val had a similar effect. Mutation of Ser-267 to large residues such as His, Cys, or Tyr resulted in inhibition of Gly-R function by ethanol. These results demonstrate that the size of the amino acid residue at position alpha 267 plays a crucial role in determining the functional consequences of allosteric modulation of the Gly-R by alcohols.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Alcohol Res Ctr, Denver, CO 80262 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Chicago; University of Chicago; Wake Forest University; Wake Forest Baptist Medical Center	Harris, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th St, Denver, CO 80262 USA.				NIAAA NIH HHS [AA 03527, AA 11428, AA 06399] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011428, R37AA006399, R01AA006399, P50AA003527] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AGUAYO LG, 1994, J PHARMACOL EXP THER, V270, P61; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; CELENTANO JJ, 1988, BRAIN RES, V455, P377, DOI 10.1016/0006-8993(88)90098-4; COURTNEY KR, 1975, J PHARMACOL EXP THER, V195, P225; CURRY S, 1991, BRIT J PHARMACOL, V102, P167, DOI 10.1111/j.1476-5381.1991.tb12148.x; DEITRICH RA, 1989, PHARMACOL REV, V41, P491; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162; ENGBLOM AC, 1991, J NEUROCHEM, V57, P384, DOI 10.1111/j.1471-4159.1991.tb03764.x; Gready JE, 1997, PROTEIN SCI, V6, P983, DOI 10.1002/pro.5560060504; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Koltchine VV, 1996, NEUROPHARMACOLOGY, V35, P1445, DOI 10.1016/S0028-3908(96)00088-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1993, NEUROSCI LETT, V159, P83, DOI 10.1016/0304-3940(93)90804-T; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1996, MOL PHARMACOL, V50, P402; MCCLAVE JT, 1979, STATISTICS, P492; Mihic S.J., 1996, PHARMACOLOGICAL EFFE, P51; Mihic SJ, 1996, J PHARMACOL EXP THER, V277, P411; MIHIC SJ, 1994, EUR J PHARM-MOLEC PH, V268, P209; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Mihic SJ, 1996, BIOTECHNIQUES, V20, P802; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; SAMSON HH, 1992, TRENDS PHARMACOL SCI, V13, P206, DOI 10.1016/0165-6147(92)90065-E; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; VANDENBERG RJ, 1994, HDB MEMBRANE CHANNEL, P317; WILLIAMS KL, 1995, PHARMACOL BIOCHEM BE, V50, P199, DOI 10.1016/0091-3057(94)00288-T; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; [No title captured]	34	116	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3314	3319		10.1074/jbc.273.6.3314	http://dx.doi.org/10.1074/jbc.273.6.3314			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452448	hybrid			2022-12-27	WOS:000071822300033
J	Chien, YT; Cheung, AL				Chien, YT; Cheung, AL			Molecular interactions between two global regulators, sar and agr, in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRULENCE; LOCUS; EXPRESSION; SEQUENCES; RNA	The expression of many virulence determinants in Staphylococcus aureus is controlled by regulatory loci such as agr and sar, We have previously shown that the SarA protein is required for optimal transcription of RNAII and RNAIII in the agr locus, To define the specific molecular interaction, we overexpressed SarA as a glutathione S-transferase (GST) fusion protein by cloning the 372-base pair (bp) sarA gene into the vector, The purified GST-SarA as well as cleaved SarA were able to bind specifically to the P2, P3, and the combined P2-P3 promoter fragments of agr in gel shift assays, Using monoclonal antibodies to SarA, we found that SarA is a part of the retarded protein-DNA complex as evidenced by the formation of a supershifted band, The SarA binding site on the agr promoter, mapped by DNase I footprinting assay, covered a 29-bp region between the P2 and P3 promoters devoid of any direct repeats, A synthetic 45-bp fragment encompassing the 29-bp sequence also bound the SarA protein in band shift assays, Serial in-frame deletion analysis of sarA revealed that, with the exception of 15 residues in the N terminus, almost all of SarA (residues 16-124) is essential for agr binding activity. Northern analysis confirmed that only the sar mutant clone containing a truncated sarA gene with a 15-residue deletion in the N terminus (SarA(16-124)) could activate agr transcription to a level approaching that of the full-length counterpart (SarA(1-124)), Taken together, these data indicated that SarA is a DNA-binding protein with binding specificity to the P2 and P3 interpromoter region of agr, thereby activating RNAII and RNAIII transcription.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA	Rockefeller University	Cheung, AL (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA.	cheunga@rockvax.rockefeller.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030061, R01AI037142] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37142, AI30061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bayer MG, 1996, J BACTERIOL, V178, P4563, DOI 10.1128/jb.178.15.4563-4570.1996; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CHEUNG AL, 1992, P NATL ACAD SCI USA, V89, P6462, DOI 10.1073/pnas.89.14.6462; Cheung AL, 1997, J BACTERIOL, V179, P3963, DOI 10.1128/jb.179.12.3963-3971.1997; Cheung AL, 1997, INFECT IMMUN, V65, P2243, DOI 10.1128/IAI.65.6.2243-2249.1997; CHEUNG AL, 1994, J BACTERIOL, V176, P4168, DOI 10.1128/JB.176.13.4168-4172.1994; CHEUNG AL, 1994, J CLIN INVEST, V94, P1815, DOI 10.1172/JCI117530; CHEUNG AL, 1994, ANAL BIOCHEM, V222, P511, DOI 10.1006/abio.1994.1528; CHEUNG AL, 1997, 37 ICAAC TOR CAN; CROSSLEY KB, 1997, STAPHYLOCOCCI HUMAN; FLUCIGER U, 1997, ANN M AM SOC MICR MI; Giraudo AT, 1997, ARCH MICROBIOL, V168, P53, DOI 10.1007/s002030050469; Heinrichs JH, 1996, J BACTERIOL, V178, P418, DOI 10.1128/jb.178.2.418-423.1996; JONES KF, 1986, J EXP MED, V164, P1226, DOI 10.1084/jem.164.4.1226; Kornblum J., 1990, MOL BIOL STAPHYLOCOC, P373; Maniatis T., 1989, MOL CLONING LAB MANU; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; Morfeldt E, 1996, MOL MICROBIOL, V21, P1227, DOI 10.1046/j.1365-2958.1996.751447.x; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENESCH F, 1991, J BACTERIOL, V173, P6313, DOI 10.1128/jb.173.20.6313-6320.1991; VANDENESCH F, 1993, FEMS MICROBIOL LETT, V111, P115, DOI 10.1016/0378-1097(93)90191-4; VANWAMEL W, 1996, ANN M AM SOC MICR NE; [No title captured]	25	120	130	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2645	2652		10.1074/jbc.273.5.2645	http://dx.doi.org/10.1074/jbc.273.5.2645			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446568	hybrid			2022-12-27	WOS:000071736600023
J	Coqueret, O; Martin, N; Berube, G; Rabbat, M; Litchfield, DW; Nepveu, A				Coqueret, O; Martin, N; Berube, G; Rabbat, M; Litchfield, DW; Nepveu, A			DNA binding by cut homeodomain proteins is down-modulated by casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CELL TYPE SPECIFICATION; EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; DROSOPHILA CUT; HOMEO DOMAIN; GENE; EXPRESSION; PHOSPHORYLATION; SITE	The Drosophila and mammalian Cut homeodomain proteins contain, in addition to the homeodomain, three other DNA binding regions called Cut repeats. Cut-related proteins thus belong to a distinct class of homeodomain proteins with multiple DNA binding domains. Using nuclear extracts from mammalian cells, Cut-specific DNA binding was increased following phosphatase treatment, suggesting that endogenous Cut proteins are phosphorylated in vivo. Sequence analysis of Cut repeats revealed the presence of sequences that match the consensus phosphorylation site for casein kinase II (CKII), Therefore, we investigated whether CKII can modulate the activity of mammalian Cut proteins. In vitro, a purified preparation of CKII efficiently phosphorylated Cut repeats causing an inhibition of DNA binding. In vivo, overexpression of the CKII alpha and beta caused a decrease in DNA binding by Cut. The CKII phosphorylation sites within the murine Cut (mCut) protein were identified by in vitro mutagenesis as residues Ser(400) Ser(789), and Ser(972) within Cut repeat 1, 2, and 3, respectively. Cut homeodomain proteins were previously shown to function as transcriptional repressors. Overexpression of CKII reduced transcriptional repression by mCut, whereas a mutant mCut protein containing alanine substitutions at these sites was not affected. Altogether our results indicate that the transcriptional activity of Cut proteins is modulated by CKII.	McGill Univ, Royal Victoria Hosp, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Oncol, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Biochem, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Western University (University of Western Ontario)	Coqueret, O (corresponding author), McGill Univ, Mol Oncol Grp, Room H-508,687 Pine Ave W, Quebec City, PQ H3A 1A1, Canada.	alain@lan1.molonc.mcgill.ca	Litchfield, David/E-4636-2015; /AAB-8315-2020; Coqueret, Olivier/K-9660-2015	Litchfield, David/0000-0002-2425-6620; Coqueret, Olivier/0000-0002-2843-7867				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; Blanc Richard, 1942, UNIV CALIFORNIA PUBL ZOOL, V49, P1; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; Braun W, 1940, J EXP ZOOL, V84, P325, DOI 10.1002/jez.1400840302; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; Hertweck H, 1931, Z WISS ZOOL ABT A, V139, P559; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JACK J, 1991, DEVELOPMENT, V113, P735; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LIU S, 1991, GENETICS, V127, P151; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MANAK JR, 1993, ONCOGENE, V8, P703; MARSHAK DR, 1994, CELL MOL BIOL RES, V40, P513; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Quaggin SE, 1996, J BIOL CHEM, V271, P22624, DOI 10.1074/jbc.271.37.22624; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STURM RA, 1988, CELL, V64, P475; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VALARCHE I, 1993, DEVELOPMENT, V119, P881; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; YOON SO, 1994, J BIOL CHEM, V269, P18453	56	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2561	2566		10.1074/jbc.273.5.2561	http://dx.doi.org/10.1074/jbc.273.5.2561			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446557	hybrid			2022-12-27	WOS:000071736600012
J	Gitt, MA; Colnot, C; Poirier, F; Nani, KJ; Barondes, SH; Leffler, H				Gitt, MA; Colnot, C; Poirier, F; Nani, KJ; Barondes, SH; Leffler, H			Galectin-4 and galectin-6 are two closely related lectins expressed in mouse gastrointestinal tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTINS; ADHERENS JUNCTION PROTEIN; RAT SMALL-INTESTINE; CRYSTAL-STRUCTURE; GENE FAMILY; S-LECTIN; LACTOSE; SEQUENCE; CLONING; MEMBER	Galectins are a family of carbohydrate-binding proteins that share a conserved sequence and affinity for beta-galactosides. Some, such as galectin-1, are isolated as dimers and have a single carbohydrate recognition domain (CRD) in each monomer, whereas others, such as galectin-4, are isolated as monomers and have two CRDs in a single polypeptide chain. In the course of studying mouse colon mRNA for galectin-4, we detected a related mRNA that encodes a new galectin that also has two CRDs in a single peptide chain. The new galectin, galectin-6, lacks a 24-amino acid stretch in the link region between the two CRDs that is present in galectin-4. Otherwise, these two galectins have 83% amino acid identity. Expression of both galectin-4 and galectin-6 is confined to the epithelial cells of the embryonic and adult gastrointestinal tract. Galectin-4 is expressed at about equal levels in colon and small intestine but much less in stomach, whereas galectin-6 is expressed at about equal levels throughout the gastrointestinal tract.	Univ Calif San Francisco, Ctr Neurobiol & Psychiat, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Inst Cochin Genet Mol, U257 INSERM, F-75014 Paris, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Leffler, H (corresponding author), Inst Med Microbiol, Dept Clin Immunol, Solvegatan 23, S-22362 Lund, Sweden.		Colnot, Celine/D-4997-2017; Leffler, Hakon/A-2416-2019	Colnot, Celine/0000-0001-8423-8718; Leffler, Hakon/0000-0003-4482-8945	NHLBI NIH HHS [HL38627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; BARILA D, 1995, BBA-GENE STRUCT EXPR, V1263, P133, DOI 10.1016/0167-4781(95)00090-4; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; CHIU ML, 1994, J BIOL CHEM, V269, P31770; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Huflejt ME, 1997, J BIOL CHEM, V272, P14294, DOI 10.1074/jbc.272.22.14294; KLION AD, 1994, MOL BIOCHEM PARASIT, V65, P305, DOI 10.1016/0166-6851(94)90081-7; Leffler H, 1997, TRENDS GLYCOSCI GLYC, V9, P9, DOI 10.4052/tigg.9.9; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADARA JL, 1981, DEV BIOL, V86, P170, DOI 10.1016/0012-1606(81)90327-4; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; ODA Y, 1993, J BIOL CHEM, V268, P5929; POIRIER F, 1992, DEVELOPMENT, V115, P143; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; TARDY F, 1995, FEBS LETT, V359, P169, DOI 10.1016/0014-5793(95)00025-5; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WASANO K, 1995, CELL TISSUE RES, V281, P77, DOI 10.1007/BF00307960	30	91	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2954	2960		10.1074/jbc.273.5.2954	http://dx.doi.org/10.1074/jbc.273.5.2954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446608	hybrid			2022-12-27	WOS:000071736600063
J	Vega, MC; Walsh, SB; Mantle, TJ; Coll, M				Vega, MC; Walsh, SB; Mantle, TJ; Coll, M			The three-dimensional structure of Cys-47-modified mouse liver glutathione S-transferase P1-1 - Carboxymethylation dramatically decreases the affinity for glutathione and is associated with a loss of electron density in the alpha B-3(10)B region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-PI; 3-DIMENSIONAL STRUCTURE; CATALYTIC MECHANISM; HUMAN PLACENTA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; GSH TRANSFERASE; RAT; INACTIVATION; COMPLEX	The three-dimensional structure of mouse liver glutathione S-transferase P1-1 carboxymethylated at Cys-47 and its complex with S-(p-nitrobenzyl)glutathione have been determined by x-ray diffraction analysis, The structure of the modified enzyme described here is the first structural report for a P-i class glutathione S-transferase with no glutathione, glutathione S-conjugate, or inhibitor bound, It shows that part of the active site area, which includes helix alpha B and helix 3(10)B, is disordered. However, the environment of Tyr-7, an essential residue for the catalytic reaction, remains unchanged, The position of the sulfur atom of glutathione is occupied in the ligand-free enzyme by a water molecule that is at H-bond distance from Tyr-7, We do not find any structural evidence for a tyrosinate form, and therefore our results suggest that Tyr-7 is not acting as a general base abstracting the proton from the thiol group of glutathione, The binding of the inhibitor S-(p-nitrobenzyl)glutathione to the carboxymethylated enzyme results in a partial restructuring of the disordered area. The modification of Cys-47 sterically hinders structural organization of this region, and although it does not prevent glutathione binding, it significantly reduces the affinity, A detailed kinetic study of the modified enzyme indicates that the carboxymethylation increases the K-m for glutathione by 3 orders of magnitude, although the enzyme can function efficiently under saturating conditions.	CSIC, Ctr Invest & Desenvolupament, Dept Mol & Cellular Biol, ES-08034 Barcelona, Spain; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Consejo Superior de Investigaciones Cientificas (CSIC); Trinity College Dublin	Coll, M (corresponding author), CSIC, Ctr Invest & Desenvolupament, Dept Mol & Cellular Biol, Jordi Girona 18-26, ES-08034 Barcelona, Spain.	mcccri@cid.csic.es	Coll, Miquel/L-5999-2014; Vega, M. Cristina/C-3640-2011	Coll, Miquel/0000-0003-4471-8674; Vega, M. Cristina/0000-0003-0628-8378	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; ATKINS WM, 1993, J BIOL CHEM, V268, P19188; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; DIRR H, 1994, J MOL BIOL, V243, P72, DOI 10.1006/jmbi.1994.1631; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HAYES JD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P3; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LoBello M, 1997, BIOCHEMISTRY-US, V36, P6207, DOI 10.1021/bi962813z; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MEYER DJ, 1993, BIOCHEM J, V293, P351, DOI 10.1042/bj2930351; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIHARA T, 1991, BIOCHEM BIOPH RES CO, V174, P580, DOI 10.1016/0006-291X(91)91456-M; Oakley AJ, 1997, BIOCHEMISTRY-US, V36, P576, DOI 10.1021/bi962316i; Orozco M, 1997, PROTEINS, V28, P530, DOI 10.1002/(SICI)1097-0134(199708)28:4<530::AID-PROT7>3.3.CO;2-U; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PHILLIPS MF, 1993, BIOCHEM J, V294, P57, DOI 10.1042/bj2940057; PHILLIPS MF, 1992, THESIS U DUBLIN DUBL; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROUSELL A, 1991, SILICON GRAPHICS DIR; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STEIGEMANN W, 1991, PROTEIN VERSION 3 1; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TURK D, 1996, MAIN 96; WALSH SB, 1995, BIOCH SOC T, V23; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	43	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2844	2850		10.1074/jbc.273.5.2844	http://dx.doi.org/10.1074/jbc.273.5.2844			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446594	hybrid			2022-12-27	WOS:000071736600049
J	Hu, XQ; Singh, N; Mukhopadhyay, D; Akbarali, HI				Hu, XQ; Singh, N; Mukhopadhyay, D; Akbarali, HI			Modulation of voltage-dependent Ca2+ channels in rabbit colonic smooth muscle cells by c-Src and focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; ANGIOTENSIN-II; SH3 DOMAIN; FACTOR RECEPTOR; FACTOR BB; ASSOCIATION; ACTIVATION; FAMILY; PP125(FAK)	There is emerging evidence indicating that smooth muscle contraction and Ca2+ influx through voltage-dependent L-type Ca2+ channels are regulated by tyrosine kinases; however, the specific kinases involved are largely unknown, In rabbit colonic muscularis mucosae cells, tyrosine-phosphorylated proteins of similar to 60 and 125 kDa were observed served in immunoblots using an anti-phosphotyrosine antibody and were identified as c-Src and focal adhesion kinase (FAK) by immunoblotting with specific antibodies, FAK co-immunoprecipitated with c-Src, and the phosphorylation of the c-Src.FAK complex was markedly enhanced by platelet-derived growth factor (PDGF) BE. The presence of activated c-Src in unstimulated cells was identified in cell lysates by immunoblotting with an antibody recognizing the autophosphorylated site (P416Y). In whole-cell patch-clamp studies, intracellular dialysis of a Src substrate peptide and anti-c-Src and anti-FAK antibodies suppressed Ca2+ currents by 60, 62, and 43%, respectively, In contrast, intracellular dialysis of an anti-mouse IgG or anti-Kv1.5 antibody did not inhibit Ca2+ currents, Co-dialysis of anti-cSrc and anti-FAK antibodies inhibited Ca2+ currents (63%) equivalent to dialysis with the anti-c-Src antibody alone, PDGF-BB enhanced Ca2+ currents by 43%, which was abolished by the anti-c-Src and anti-FAK antibodies, Neither the MER inhibitor PD 098059 nor an anti-Ras antibody inhibited basal Ca2+ currents or PDGF-stimulated Ca2+ currents, The alpha(1C) subunit of the L-type Ca2+ channel co-immunoprecipitated with anti-c-Src and anti-phosphotyrosine antibodies, indicating direct association of c-Src kinase with the Ca2+ channel, These data suggest that c-Src and FAK, but not the Ras/mitogen-activated protein kinase cascade, modulate basal Ca2+ channel activity and mediate the PDGF-induced enhancement of L-type Ca2+ currents in differentiated smooth muscle cells.	Harvard Univ, Sch Med, Beth Israel Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Med Ctr, Div Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Akbarali, HI (corresponding author), Harvard Univ, Sch Med, Beth Israel Med Ctr, Div Gastroenterol, 330 Brookline Ave, Boston, MA 02215 USA.		Akbarali, Hamid I/B-3236-2012; Akbarali, Hamid/Q-9344-2019	Singh, Namita/0000-0002-6782-4288; Akbarali, Hamid/0000-0003-1423-0774	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046367, R29DK046367] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-46367] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DISALVO J, 1993, BIOCHEM BIOPH RES CO, V190, P968, DOI 10.1006/bbrc.1993.1144; DISALVO J, 1989, J BIOL CHEM, V264, P10773; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hatakeyama N, 1996, AM J PHYSIOL-CELL PH, V270, pC1780, DOI 10.1152/ajpcell.1996.270.6.C1780; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KURIYAMA H, 1995, PHARMACOL REV, V47, P387; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Ma HP, 1996, J CLIN INVEST, V97, P2332, DOI 10.1172/JCI118676; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PAVALKO FM, 1995, AM J PHYSIOL-CELL PH, V268, pC563, DOI 10.1152/ajpcell.1995.268.3.C563; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	37	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5337	5342		10.1074/jbc.273.9.5337	http://dx.doi.org/10.1074/jbc.273.9.5337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478993	hybrid			2022-12-27	WOS:000072310400077
J	Ratner, JN; Balasubramanian, B; Corden, J; Warren, SL; Bregman, DB				Ratner, JN; Balasubramanian, B; Corden, J; Warren, SL; Bregman, DB			Ultraviolet radiation-induced ubiquitination and proteasomal degradation of the large subunit of RNA polymerase II - Implications for transcription-coupled DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; INVITRO TRANSCRIPTION; ALPHA-AMANITIN; ACTIVE GENES; KAPPA-B; PHOSPHORYLATION; PROTEIN; CELLS; ELONGATION; ENCODES	We have shown previously that UV radiation and other DNA-damaging agents induce the ubiquitination of a portion of the RNA polymerase II large subunit (Pol II LS), In the present study UV irradiation of repair competent fibroblasts induced a transient reduction of the Pol II LS level; new protein synthesis restored Pol II LS to the base-line level within 16-24 h. In repair-deficient xeroderma pigmentosum cells, UV radiation-induced ubiquitination of Pol II LS was followed by a sustained reduction of Pol II LS level, In both normal and xeroderma pigmentosum cells, the ubiquitinated Pol II LS had a hyperphosphorylated COOH-terminal domain (CTD), which is characteristic of elongating Pol II, The portion of Pol II LS whose steady-state level diminished most quickly had a relatively hypophosphorylated CTD, The ubiquitinated residues did not map to the CTD, Importantly, UV-induced reduction of Pol II LS level in repair-competent or -deficient cells was inhibited by the proteasome inhibitors lactacystin or MG132. These data demonstrate that UV-induced ubiquitination of Pol II LS is followed by its degradation in the proteasome, These results suggest, contrary to a current model of transcription-coupled DNA repair, that elongating Pol II complexes which arrest at intragenic DNA lesions may be aborted rather than resuming elongation after repair takes place.	Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; NeXstar Pharmaceut, Boulder, CO 80301 USA	Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University	Ratner, JN (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave,F717N, Bronx, NY 10461 USA.	bregman@aecom.yu.edu			NATIONAL CANCER INSTITUTE [K08CA073549] Funding Source: NIH RePORTER; NCI NIH HHS [CA73549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Coin F., 1997, Mutation Research, V379, pS33, DOI 10.1016/S0027-5107(97)82704-2; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; Dahmus ME, 1996, METHOD ENZYMOL, V273, P185; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DALLEY BK, 1993, GENETICS, V133, P237; Damgaard J, 1996, BIOCHEM BIOPH RES CO, V227, P677, DOI 10.1006/bbrc.1996.1568; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Ikehata H, 1997, MOL CELL BIOL, V17, P1484, DOI 10.1128/MCB.17.3.1484; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; Maki CG, 1996, CANCER RES, V56, P2649; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Verhage RA, 1997, MOL GEN GENET, V254, P284, DOI 10.1007/s004380050417; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; WINTZERITH M, 1992, NUCLEIC ACIDS RES, V20, P910, DOI 10.1093/nar/20.4.910; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZHANG J, 1991, J BIOL CHEM, V266, P2290	56	188	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5184	5189		10.1074/jbc.273.9.5184	http://dx.doi.org/10.1074/jbc.273.9.5184			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478972	hybrid			2022-12-27	WOS:000072310400056
J	Shi, ZQ; Lu, W; Feng, GS				Shi, ZQ; Lu, W; Feng, GS			The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAINS; SYP; TRANSDUCTION; INSULIN; SH-PTP2; PHOSPHORYLATION; SEVENLESS; BINDING; RAS	Shp-2 is a widely expressed cytoplasmic tyrosine phosphatase with two SH2 domains, A targeted mutant allele of the Shp-2 gene with a deletion of 65 amino acids in the NH2-terminal SH2 domain was created that leads to embryonic lethality at mid-gestation in homozygous mutant mice, To define the Shp-2 function in cell signaling, we have established mutant fibroblast cell lines, and have examined the effect of the Shp-2 mutation on extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) mitogen-activated protein (MAP) kinase pathways, Insulin-like growth factor (IGF)-I-induced ERK activation was completely abolished, while ERK activity upon platelet-derived growth factor and epidermal growth factor stimulation was significantly reduced and shortened in mutant cells. Stimulation of ERK by phorbol la-myristate 13-acetate was not affected in mutant cells, but the phorbol 12-myristate Is-acetate induced ERK activity decayed much faster compared with that in wild-type cells, In contrast, JNK activation upon heat shock was significantly enhanced in Shp-2 mutant cells, Based on these results, we conclude that Shp-2 plays differential positive regulatory roles in various mitogenic signaling pathways leading to ERK activation, and that Shp-2 is a negative effector in JNK activation by cellular stress, This is the first evidence that a tyrosine phosphatase has opposite effects in mediating the activation of ERK and JNK MAP kinases.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Walther Oncol Ctr, 1044 W Walnut St,Rm 302, Indianapolis, IN 46202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM53660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FIJIOKA Y, 1996, MOL CELL BIOL, V16, P6887; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; XIAO S, 1994, J BIOL CHEM, V269, P21244	23	103	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4904	4908		10.1074/jbc.273.9.4904	http://dx.doi.org/10.1074/jbc.273.9.4904			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478933	hybrid			2022-12-27	WOS:000072310400017
J	Ueki, K; Yamamoto-Honda, R; Kaburagi, Y; Yamauchi, T; Tobe, K; Burgering, BMT; Coffer, PJ; Komuro, I; Akanuma, Y; Yazaki, Y; Kadowaki, T				Ueki, K; Yamamoto-Honda, R; Kaburagi, Y; Yamauchi, T; Tobe, K; Burgering, BMT; Coffer, PJ; Komuro, I; Akanuma, Y; Yazaki, Y; Kadowaki, T			Potential role of protein kinase B in insulin-induced glucose transport, glycogen synthesis, and protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE; RABBIT SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; SYNTHASE KINASE-3; PLASMA-MEMBRANE; SER/THR KINASE; GROWTH-FACTOR; IN-VIVO; PHAS-I; TRANSLOCATION	Various biological responses stimulated by insulin have been thought to be regulated by phosphatidylinositol 3-kinase, including glucose transport, glycogen synthesis, and protein synthesis. However, the molecular link between phosphatidylinositol 3-kinase and these biological responses has been poorly understood. Recently, it has been shown that protein kinase B (PKB/c-Akt/Rac) lies immediately downstream from phosphatidylinositol 3-kinase. Here, we show that expression of a constitutively active form of PKB induced glucose uptake, glycogen synthesis, and protein synthesis in L6 myotubes downstream of phosphatidylinositol 3-kinase and independent of Ras and mitogen-activated protein kinase activation. Introduction of constitutively active PKB induced glucose uptake and protein synthesis but not glycogen synthesis in 3T3L-1 adipocytes, which lack expression of glycogen synthase kinase 3 different from L6 myotubes. Furthermore, we show that deactivation of glycogen synthase kinase 3 and activation of rapamycin-sensitive serine/threonine kinase by PKB in L6 myotubes might be involved in the enhancement of glycogen synthesis and protein synthesis, respectively. These results suggest that PKB acts as a key enzyme linking phosphatidylinositol 3-kinase activation to multiple biological functions of insulin through regulation of downstream kinases in skeletal muscle, a major target tissue of insulin.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Chiyoda Ku, Tokyo 100, Japan; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Univ Utrecht Hosp, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	University of Tokyo; Asahi Life Foundation; Utrecht University; Utrecht University; Utrecht University Medical Center	Kadowaki, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; COHEN P, 1991, METHOD ENZYMOL, V201, P153; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Fadden P, 1997, J BIOL CHEM, V272, P10240; FINKELMAN HE, 1996, P NATL ACAD SCI USA, V93, P10228; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FROST SC, 1985, J BIOL CHEM, V260, P2646; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KANAMOTO R, 1988, EUR J BIOCHEM, V154, P539; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; STIREWAL.WS, 1967, P NATL ACAD SCI USA, V57, P1885, DOI 10.1073/pnas.57.6.1885; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; UEKI K, 1994, J BIOL CHEM, V269, P15756; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; YU JS, 1994, J BIOL CHEM, V269, P14341	56	318	330	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5315	5322		10.1074/jbc.273.9.5315	http://dx.doi.org/10.1074/jbc.273.9.5315			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478990	hybrid, Green Published			2022-12-27	WOS:000072310400074
J	Holtz-Heppelmann, CJ; Algeciras, A; Badley, AD; Paya, CV				Holtz-Heppelmann, CJ; Algeciras, A; Badley, AD; Paya, CV			Transcriptional regulation of the human FasL promoter-enhancer region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-MEDIATED CYTOTOXICITY; RECEPTOR TRANSGENIC MICE; NF-KAPPA-B; T-CELLS; LYMPHOPROLIFERATIVE SYNDROME; ALLOGRAFT-REJECTION; LIGAND EXPRESSION; INDUCED APOPTOSIS	The human FasL enhancer region was cloned and functionally characterized in transformed and primary T cells, Within the 2.3 kilobase pairs of the FasL, untranslated region, the distal 3' 300-base pair portion contains a single transcription initiation site and confers basal and inducible transcriptional activity. Stimuli that increase [Ca2+](i) such as CD3 cross-linking or ionomycin, but not activation of protein kinase C, were found to induce FasL enhancer transcription in a cyclosporin-sensitive manner. Moreover, calcineurin and NFAT, but not AP1, were identified as necessary and sufficient effectors in driving FasL, transcription through an NFAT cis-acting motif (GGAAA), Additional modes of T cell activation such as CD4 cross-linking were also found to induce NFAT binding to the FasL enhancer region and to functionally transactivate its transcription, These results indicate that the induction of FasL gene transcription in T cells after CD3 or CD4 activation is selectively mediated by calcineurin and NFAT.	Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Paya, CV (corresponding author), Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, 200 1st St SW,Guggenheim 501, Rochester, MN 55905 USA.		badley, andrew d/O-9022-2014	Badley, Andrew/0000-0001-7796-7680				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; Badley AD, 1996, J VIROL, V70, P199, DOI 10.1128/JVI.70.1.199-206.1996; Badley AD, 1997, J EXP MED, V185, P55, DOI 10.1084/jem.185.1.55; BALDARI CT, 1995, EUR J IMMUNOL, V25, P1843, DOI 10.1002/eji.1830250708; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Eischen CM, 1996, J IMMUNOL, V156, P2693; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Latinis KM, 1997, J IMMUNOL, V158, P4602; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; Mitra D, 1996, IMMUNOLOGY, V87, P581, DOI 10.1046/j.1365-2567.1996.510589.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OYAIZU N, 1995, J CLIN IMMUNOL, V15, P217, DOI 10.1007/BF01540879; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Seino K, 1996, INT IMMUNOL, V8, P1347, DOI 10.1093/intimm/8.9.1347; SEKIGAWA I, 1995, J CLIN IMMUNOL, V15, P312, DOI 10.1007/BF01541321; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; TWIGG HL, 1992, J IMMUNOL, V149, P1462; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673	51	136	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4416	4423		10.1074/jbc.273.8.4416	http://dx.doi.org/10.1074/jbc.273.8.4416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468493	hybrid			2022-12-27	WOS:000072115000021
J	Larsen, M; Ressler, SJ; Lu, B; Gerdes, MJ; McBride, L; Dang, TD; Rowley, DR				Larsen, M; Ressler, SJ; Lu, B; Gerdes, MJ; McBride, L; Dang, TD; Rowley, DR			Molecular cloning and expression of ps20 growth inhibitor - A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL INTERACTIONS; UROGENITAL SINUS MESENCHYME; ELASTASE-SPECIFIC INHIBITOR; RODENT URINARY-BLADDER; CELL-SURFACE; DIFFERENTIAL EXPRESSION; PROSTATIC DEVELOPMENT; CULTURED FIBROBLASTS; NEGATIVE REGULATION; ENDOTHELIAL-CELLS	We previously reported the purification of ps20 (Rowley, D. R,, Dang, T, D., Larsen, IM,, Gerdes, M. J,, McBride, L., and Lu, B, (1995) J. Biol. Chem. 270, 22058-22065), a urogenital sinus mesenchymal cell, secreted protein having growth-inhibitory properties, We report here cloning of the 1.03-kilobase rat ps20 cDNA clone from the PS-1 (adult rat prostate smooth muscle) cDNA library. Partial clones were obtained by nested polymerase chain reaction with degenerate primers, and full-length ps20 cDNA clones were isolated by plaque hybridization. Sequence analysis revealed that ps20 protein contains a WAP-type "four-disulfide core" motif and is a novel member of the WAP signature protein family composed primarily of secreted serine protease inhibitors. Native ps20 immunoprecipitated from smooth muscle cells and recombinant ps20 both resolved on SDS-polyacrylamide gel electrophoresis with apparent molecular mass of 27-29 kDa under reducing conditions and 21-23 kDa under non-reducing conditions, respectively, Stable ps20-transfectant COS-7 cell lines secreted ps20 and were growth-inhibited relative to mock transfectants. In addition, COS-7 and prostate carcinoma PC-3 cells were growth-inhibited by bacterially expressed ps20, Northern analysis indicated differential expression by tissue with highest, expression in the heart, Immunohistochemical localization of ps20 protein showed cell-specific expression by both visceral and vascular smooth muscle in all tissues, including the prostate gland. These results indicate ps20 is a novel growth-regulatory member of the WAP signature family expressed by smooth muscle cells.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Program Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Rowley, DR (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	drowley@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA058093, P50CA058204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045909] Funding Source: NIH RePORTER; NCI NIH HHS [CA58093, CA58204] Funding Source: Medline; NIDDK NIH HHS [DK45909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CUNHA GR, 1983, J CELL BIOL, V96, P1662, DOI 10.1083/jcb.96.6.1662; CUNHA GR, 1972, ANAT REC, V172, P179, DOI 10.1002/ar.1091720206; CUNHA GR, 1980, ENDOCRINOLOGY, V107, P1767, DOI 10.1210/endo-107-6-1767; DEAR TN, 1988, CANCER RES, V48, P5203; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; DOW KE, 1983, CELL TISSUE RES, V231, P83; FREY P, 1979, P NATL ACAD SCI USA, V76, P6294, DOI 10.1073/pnas.76.12.6294; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; Gerdes MJ, 1996, ENDOCRINOLOGY, V137, P864, DOI 10.1210/en.137.3.864; GERDES MJ, 1998, IN PRESS J HISTOCHEM; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HASLAM SZ, 1991, ENDOCRINOLOGY, V129, P2017, DOI 10.1210/endo-129-4-2017; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; JAHNKE GD, 1994, ENDOCRINOLOGY, V135, P2022, DOI 10.1210/en.135.5.2022; KATO I, 1979, FED PROC, V38, P832; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; KNOTH K, 1988, NUCLEIC ACIDS RES, V16, P109; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KUROKI J, 1995, J BIOL CHEM, V270, P22428, DOI 10.1074/jbc.270.38.22428; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; LACROIX B, 1984, DIFFERENTIATION, V28, P129, DOI 10.1111/j.1432-0436.1984.tb00276.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAJMUDAR G, 1994, MOL CARCINOGEN, V11, P29, DOI 10.1002/mc.2940110106; NEUBAUER BL, 1983, J CELL BIOL, V96, P1671, DOI 10.1083/jcb.96.6.1671; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PONGOR S, 1994, NUCLEIC ACIDS RES, V22, P3610; POST M, 1984, BIOCHIM BIOPHYS ACTA, V793, P297, DOI 10.1016/0005-2760(84)90332-1; ROWLEY DR, 1992, IN VITRO CELL DEV-AN, V28A, P29; ROWLEY DR, 1995, J BIOL CHEM, V270, P22058, DOI 10.1074/jbc.270.37.22058; ROWLEY DR, 1987, CANCER RES, V47, P2955; Rugarli EI, 1996, HUM MOL GENET, V5, P1109, DOI 10.1093/hmg/5.8.1109; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAWYER RH, 1984, DEV BIOL, V101, P8, DOI 10.1016/0012-1606(84)90111-8; SHEUG S, 1996, P NATL ACAD SCI USA, V93, P11669; SMITH BT, 1983, P NATL ACAD SCI-BIOL, V80, P1951, DOI 10.1073/pnas.80.7.1951; SMITH BT, 1979, SCIENCE, V204, P1094, DOI 10.1126/science.582216; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; THORSEN S, 1987, FUNDAMENTAL CLIN FIB, P83; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WILSON MJ, 1995, MICROSC RES TECHNIQ, V30, P305, DOI 10.1002/jemt.1070300406; ZHANG M, 1995, CANCER RES, V55, P2537	56	62	65	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4574	4584		10.1074/jbc.273.8.4574	http://dx.doi.org/10.1074/jbc.273.8.4574			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468514	hybrid			2022-12-27	WOS:000072115000042
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Coexpression of ligand-gated P-2X and G protein-coupled P-2Y receptors in smooth muscle - Preferential activation of P-2Y receptors coupled to phospholipase C (PLC)-beta 1 via and the PLC-beta 3 via G beta gamma(i3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; INTESTINAL MUSCLE; ION CHANNELS; EXTRACELLULAR ATP; FUNCTIONAL EXPRESSION; NUCLEOTIDE RECEPTOR; SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDES; MOLECULAR-CLONING; ADENYLYL-CYCLASE	P-2 receptor subtypes and their signaling mechanisms were characterized in dispersed smooth muscle cells. UTP and ATP stimulated inositol 1,4,5-triphosphate formation, Ca2+ release, and contraction that were abolished by U-73122 and guanosine 5'-O-(3-thio) diphosphate, and partly inhibited (50-60%) by pertussis toxin (PTX). ATP analogs (adenosine 5'-(alpha,beta-methylene)triphosphate, adenosine 5'-(beta, gamma-methylene)triphosphate, and 2-methylthio-ATP) stimulated Ca2+ influx and contraction that were abolished by nifedipine and in Ca2+-free medium, Micromolar concentrations of ATP stimulated both Ca2+ influx and Ca2+ release. ATP and UTP activated G(q/11) and G(i3) in gastric and aortic smooth muscle and heart membranes, G(q/11) and G(i1) acid/or G(i2) in liver membranes, and G(o) and G(i1-3) in brain membranes. Phosphoinositide hydrolysis stimulated by ATP and UTP was mediated concurrently by G alpha(q/11)-dependent activation of phospholipase (PL) C-beta 1 and G beta gamma(i3)-dependent activation of PLC-beta 3. Phosphoinositide hydrolysis was partially inhibited by PTX or by antibodies to G alpha(q/11), G(beta), PLC-beta 1, or PLC-beta 3, and completely inhibited by the following combinations (PLC-beta 1 and PLC-beta 3 antibodies; G alpha(q/11) and G(beta) antibodies; PLC-beta 1 and G(beta) antibodies; PTX with either PLC-beta 1 or G alpha(q/11) antibody). The pattern of responses implied that P-2Y2 receptors in visceral, and probably vascular, smooth muscle are coupled to PLC-beta 1 via G alpha(q/11) and to PLC-beta 3 via G beta gamma(i3). These receptors co-exist with ligand-gated P-2X1 receptors activated by ATP analogs and high levels of ATP.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Makhlouf, GM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, POB 980711, Richmond, VA 23298 USA.				NIDDK NIH HHS [DK-28300] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028300] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; BITAR KN, 1986, J BIOL CHEM, V261, P6591; BITAR KN, 1982, NATURE, V297, P72, DOI 10.1038/297072a0; BITAR KN, 1982, SCIENCE, V216, P531, DOI 10.1126/science.6176025; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Collo G, 1996, J NEUROSCI, V16, P2495; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; COWEN DS, 1990, BIOCHIM BIOPHYS ACTA, V1053, P195, DOI 10.1016/0167-4889(90)90014-5; CRACK BE, 1994, BRIT J PHARMACOL, V113, P1432, DOI 10.1111/j.1476-5381.1994.tb17157.x; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GERWINS P, 1992, J BIOL CHEM, V267, P16081; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Harden TK, 1997, TRENDS PHARMACOL SCI, V18, P43, DOI 10.1016/S0165-6147(97)89795-7; IRVING HR, 1987, J BIOL CHEM, V262, P3440; KUEMMERLE JF, 1992, AM J PHYSIOL, V263, pG269, DOI 10.1152/ajpgi.1992.263.2.G269; KUEMMERLE JF, 1992, MOL PHARMACOL, V42, P1090; LANZAROWSKI ER, 1994, AM J PHYSIOL, V266, pC406; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MORINI G, 1993, J PHARMACOL EXP THER, V264, P598; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1997, J BIOL CHEM, V272, P21317, DOI 10.1074/jbc.272.34.21317; Murthy KS, 1996, MOL PHARMACOL, V50, P870; MURTHY KS, 1995, AM J PHYSIOL-CELL PH, V269, pC969, DOI 10.1152/ajpcell.1995.269.4.C969; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; MURTHY KS, 1995, J PHARMACOL EXP THER, V274, P300; MURTHY KS, 1993, AM J PHYSIOL, V265, pG660, DOI 10.1152/ajpgi.1993.265.4.G660; Najbar AT, 1996, BRIT J PHARMACOL, V118, P537, DOI 10.1111/j.1476-5381.1996.tb15435.x; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; OKOMOTO T, 1992, FEBS LETT, V305, P125; PACAUD P, 1995, AM J PHYSIOL-HEART C, V269, pH30, DOI 10.1152/ajpheart.1995.269.1.H30; Post SR, 1996, J BIOL CHEM, V271, P2029, DOI 10.1074/jbc.271.4.2029; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SIMON J, 1995, PHARMACOL TOXICOL, V76, P302, DOI 10.1111/j.1600-0773.1995.tb00151.x; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; TREZISE DJ, 1995, N-S ARCH PHARMACOL, V351, P603; UHING RJ, 1986, J BIOL CHEM, V261, P2140; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	57	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4695	4704		10.1074/jbc.273.8.4695	http://dx.doi.org/10.1074/jbc.273.8.4695			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468531	hybrid			2022-12-27	WOS:000072115000059
J	Aguado, B; Campbell, RD				Aguado, B; Campbell, RD			Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; GLYCOSYLATION END-PRODUCTS; PHOSPHATIDIC-ACID; 1-ACYLGLYCEROPHOSPHORYLCHOLINE ACYLTRANSFERASE; 1-ACYL-SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; 1-ACYLGLYCEROLPHOSPHATE ACYLTRANSFERASE; PROTEIN; RECEPTOR; IDENTIFICATION; SPECIFICITIES	Sequence analysis of cDNA clones corresponding to a number of genes located in the class III region of the human major histocompatibility complex (MHC), in the chromosome band 6p21.3, has shown that the G15 gene encodes a 283-amino acid polypeptide with significant homology over the entire polypeptide with the enzyme lysophosphatidic acid acyltransferase (LPAAT) from different yeast, plant, and bacterial species, The amino acid sequence of the MHC-encoded human LPAAT (hLPAAT alpha) is 48% identical to the recently described hLPAAT (Eberhardt, C., Gray, P. W., and Tjoelker, L. W. (1991) J, Biol. Chem. 272, 20299 - 20305), which is encoded by a gene located on chromosome 9p34.3, LPAAT is the enzyme that in lipid metabolism converts lysophosphatidic acid (LPA) into phosphatidic acid (PA), The expression of the hEPAAT alpha polypeptide in the baculovirus system and in mammalian cells has shown that it is an intracellular protein that contains LPAAT activity. Cell extracts from insect cells overexpressing hLPAAT alpha were analyzed in different LPAAT enzymatic assays using as substrates, different acyl acceptors and acyl donors, These cell extracts were found to contain up to 5-fold more LPAAT activity compared with control cell extracts, indicating that the hLPAAT alpha specifically converts LPA into PA, incorporating different acyl-CoAs with different affinities, The hLPAAT alpha polypeptide expressed in the mammalian Chinese hamster ovary cell Pine was found, by confocal immunofluorescence, to be localized in the endoplasmic reticulum, Due to the known role of EPA anti PA in intracellular signaling and inflammation, the hLPAAT alpha gene represents a candidate gene for some MHC-associated diseases.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	University of Oxford	Campbell, RD (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.		Aguado, Begoña/R-4496-2019	Aguado, Begona/0000-0003-4043-6944	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUADO B, 1995, GENOMICS, V25, P650, DOI 10.1016/0888-7543(95)80007-9; Aguado B, 1996, HLA MHC GENES MOL FU, P39; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; Bell RM, 1983, ENZYMES, V16, P87; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; BURSTEN S, 1994, CIRC SHOCK, V44, P14; BURSTEN SL, 1992, AM J PHYSIOL, V262, pC328, DOI 10.1152/ajpcell.1992.262.2.C328; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; CAMPBELL RD, 1997, IMMUNOL TODAY, V18; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; COLEMAN RA, 1983, ENZYMES, V16, P605; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; Katsanis N, 1996, GENOMICS, V35, P101, DOI 10.1006/geno.1996.0328; KENDALL E, 1990, NUCLEIC ACIDS RES, V18, P7251, DOI 10.1093/nar/18.24.7251; Khanna A, 1996, BIOCHEM J, V319, P81, DOI 10.1042/bj3190081; KNUTZON DS, 1995, PLANT PHYSIOL, V109, P999, DOI 10.1104/pp.109.3.999; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LASSNER MW, 1995, PLANT PHYSIOL, V109, P1389, DOI 10.1104/pp.109.4.1389; LIVINGSTONE C, 1989, NUCLEIC ACIDS RES, V17, P2366, DOI 10.1093/nar/17.6.2366; Lodish H., 1995, MOL CELL BIOL; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MIKI Y, 1977, EUR J BIOCHEM, V81, P433, DOI 10.1111/j.1432-1033.1977.tb11968.x; MIN J, 1995, GENOMICS, V30, P149, DOI 10.1006/geno.1995.9891; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; NEEPER M, 1992, J BIOL CHEM, V267, P14998; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROST B, 1995, PROTEIN SCI, V4, P521; Singer J. W., 1994, EXPERT OPIN INV DRUG, V3, P631; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; Stamps AC, 1997, BIOCHEM J, V326, P455, DOI 10.1042/bj3260455; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; SWARTLEY JS, 1995, MOL MICROBIOL, V18, P401, DOI 10.1111/j.1365-2958.1995.mmi_18030401.x; TOU JS, 1991, BIOCHEM J, V280, P625, DOI 10.1042/bj2800625; Voet D., 1995, BIOCHEMISTRY; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; YAMASHIT.S, 1973, EUR J BIOCHEM, V38, P25, DOI 10.1111/j.1432-1033.1973.tb03028.x; YAMASHITA S, 1975, P NATL ACAD SCI USA, V72, P600, DOI 10.1073/pnas.72.2.600; Yamashita S, 1981, Methods Enzymol, V71 Pt C, P528	44	85	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4096	4105		10.1074/jbc.273.7.4096	http://dx.doi.org/10.1074/jbc.273.7.4096			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461603	hybrid			2022-12-27	WOS:000072048400045
J	Yu, NJ; Spremulli, LL				Yu, NJ; Spremulli, LL			Regulation of the activity of chloroplast translational initiation factor 3 by NH2- and COOH-terminal extensions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; EUGLENA-GRACILIS; MESSENGER-RNA; FACTOR IF3; CHLAMYDOMONAS-REINHARDTII; FACTOR-III; PROKARYOTIC TRANSLATION; COMPLEX FORMS; SH3 DOMAINS; IN-VITRO	The mature form of the chloroplast translational initiation factor 3 (IF3(chl)) from Euglena gracilis consists of an internal region homologous to prokaryotic IF3 flanked by long NH2- and COOH-terminal extensions. Sequences in these extensions reduce the activity of the homology domain in promoting initiation complex formation with chloroplast mRNAs and 30 S ribosomal sub units. A series of deletions of the NH2- and COOH-terminal extensions of IF3(chl) were constructed and tested for their effects on the activity of the homology domain. About half of the inhibitory effect arises from sequences within 9 residues of the junction between the NH2-terminal extension and the homology domain. The remaining inhibitory effect is the result of sequences in the COOH-terminal extension. The equilibrium constant governing the binding of the homology domain of IF3(chl) to 30 S subunits is estimated to be 1.3 x 10(7) M-1. Sequences close to the junction of the NH2-terminal extension and the homology domain reduce this binding constant about 10-fold. Sequences in the COOH-terminal extension have a similar negative effect. The negative effects of these two regions are cumulative, resulting in a 100-fold reduction of the binding constant. The 9 residues at the NH2-terminal extension effectively prevent the proofreading activity of IF3(chl). The entire COOH-terminal extension reduces the proofreading ability by about half. These results are discussed in terms of the proposed three-dimensional structure of the homology domain of IF3(chl).	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	Linda_Spremulli@unc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BERKHOUT B, 1986, BIOCHIM BIOPHYS ACTA, V866, P144, DOI 10.1016/0167-4781(86)90111-9; BETTS L, 1994, J BIOL CHEM, V269, P26456; BIOU V, 1995, EMBO J, V14, P4056, DOI 10.1002/j.1460-2075.1995.tb00077.x; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BUTLER JS, 1987, P NATL ACAD SCI USA, V84, P4022, DOI 10.1073/pnas.84.12.4022; CANONACO MA, 1989, EUR J BIOCHEM, V182, P501, DOI 10.1111/j.1432-1033.1989.tb14856.x; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; DOTTAVIOMARTIN D, 1979, FEBS LETT, V97, P105, DOI 10.1016/0014-5793(79)80062-9; FORTIER PL, 1994, BIOCHIMIE, V76, P376, DOI 10.1016/0300-9084(94)90111-2; GARCIA C, 1995, J MOL BIOL, V254, P247, DOI 10.1006/jmbi.1995.0615; GARCIA C, 1995, EUR J BIOCHEM, V228, P395, DOI 10.1111/j.1432-1033.1995.tb20276.x; GOLD JC, 1985, J BIOL CHEM, V260, P4897; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; GUALERZI C, 1979, J BIOL CHEM, V254, P44; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUALERZI CO, 1990, RIBOSOME, P281; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; KINI RM, 1995, BIOCHEM BIOPH RES CO, V212, P1115, DOI 10.1006/bbrc.1995.2084; KOO JS, 1994, J BIOL CHEM, V269, P7494; KRAUS BL, 1988, PLANT PHYSIOL, V88, P993, DOI 10.1104/pp.88.4.993; KYCIA JH, 1995, BIOCHEMISTRY-US, V34, P6183, DOI 10.1021/bi00018a022; LAMMI M, 1987, FEBS LETT, V215, P115, DOI 10.1016/0014-5793(87)80124-2; Lin Q, 1996, PLANT MOL BIOL, V32, P937, DOI 10.1007/BF00020490; LIN Q, 1994, J BIOL CHEM, V269, P9436; MA L, 1990, J BIOL CHEM, V265, P13560; MA L, 1992, ARCH BIOCHEM BIOPHYS, V267, P18356; Mangroo D, 1995, BIOCHEM CELL BIOL, V73, P1023, DOI 10.1139/o95-109; MCCARTHY JEG, 1994, TRENDS GENET, V10, P402, DOI 10.1016/0168-9525(94)90057-4; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; PACI M, 1984, J BIOL CHEM, V259, P9628; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Pon C L, 1979, Methods Enzymol, V60, P230; PON CL, 1974, P NATL ACAD SCI USA, V71, P4950, DOI 10.1073/pnas.71.12.4950; RISULEO G, 1976, EUR J BIOCHEM, V67, P603, DOI 10.1111/j.1432-1033.1976.tb10726.x; SAKAMOTO W, 1994, PLANT J, V6, P503, DOI 10.1046/j.1365-313X.1994.6040503.x; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STAUB JM, 1994, PLANT J, V6, P547, DOI 10.1046/j.1365-313X.1994.6040547.x; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sussman JK, 1996, MOL MICROBIOL, V21, P347, DOI 10.1046/j.1365-2958.1996.6371354.x; TEANA A, 1996, J MOL BIOL, V256, P667; VANKNIPPENBERG PH, 1990, RIBOSOME, P265; WANG CC, 1989, NUCLEIC ACIDS RES, V17, P9735, DOI 10.1093/nar/17.23.9735; WANG CC, 1991, J BIOL CHEM, V266, P17079; WEIEL J, 1978, FEBS LETT, V87, P103, DOI 10.1016/0014-5793(78)80144-6; WU HY, 1995, CURR GENET, V27, P263, DOI 10.1007/BF00326159; ZERGES W, 1994, MOL CELL BIOL, V14, P5268, DOI 10.1128/MCB.14.8.5268	53	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3871	3877		10.1074/jbc.273.7.3871	http://dx.doi.org/10.1074/jbc.273.7.3871			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461569	hybrid			2022-12-27	WOS:000072048400011
J	Corey, SJ; Dombrosky-Ferlan, PM; Zuo, S; Krohn, E; Donnenberg, AD; Zorich, P; Romero, G; Takata, M; Kurosaki, T				Corey, SJ; Dombrosky-Ferlan, PM; Zuo, S; Krohn, E; Donnenberg, AD; Zorich, P; Romero, G; Takata, M; Kurosaki, T			Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; NECROSIS-FACTOR-ALPHA; FACTOR-RECEPTOR; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; LEUKEMIA-CELLS; DEFICIENT MICE; GM-CSF; ACTIVATION; FAMILY	Treatment of cells with granulocyte colony-stimulating factor (G-CSF) leads to tyrosine phosphorylation of cellular proteins, G-CSF stimulates both the activation of protein tyrosine kinases Lyn, Jak1, and Jak2 and the association of these enzymes with the G-CSF receptor, Wild-type, lyn-deficient, and syk-deficient chicken B lymphocyte cell lines were transfected with the human G-CSF receptor, and stable transfectants were studied, G-CSF-dependent tyrosyl phosphorylation of Jak1 and Jak2 occurred in all three cell lines, Wild-type and syk-deficient transfectants responded to G-CSF in a dose-responsive fashion with increased thymidine incorporation, but none of the clones of lyn-deficient transfectants did, Ectopic expression of Lyn, but not that of c-Src, in the lyn-deficient cells restored their mitogenic responsiveness to G-CSF, Ectopic expression in wild-type cells of the kinase inactive form of Lyn, but not of the kinase-inactive form of Jak2, inhibited thymidine incorporation in response to G-CSF. These studies show that the absence of Lyn results in the loss of mitogenic signaling in the G-CSF signaling pathway and that activation of Jak1 or Jak2 is not sufficient to cause mitogenesis.	Childrens Hosp Pittsburgh, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Amer Cyanamid Co, Div Cardiovasc Med, Pearl River, NY 10965 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Corey, SJ (corresponding author), Childrens Hosp Pittsburgh, Div Hematol Oncol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	corey@med.pitt.edu		Takata, Minoru/0000-0002-4926-3675	NHLBI NIH HHS [HL02303] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIMARU K, 1992, ARCH BIOCHEM BIOPHYS, V298, P703, DOI 10.1016/0003-9861(92)90469-D; BOLEN JB, 1991, ADV CANCER RES, V57, P103; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DEMETRI GD, 1991, BLOOD, V78, P2791; DHAR A, 1991, J BIOL CHEM, V266, P18797; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; EVANS JPM, 1990, BLOOD, V75, P88; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LI Y, 1995, J IMMUNOL, V155, P2165; LIESCHKE GJ, 1994, BLOOD, V84, P1737; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NICOLA NA, 1985, J CELL PHYSIOL, V124, P313, DOI 10.1002/jcp.1041240222; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TIAN SS, 1994, BLOOD, V84, P1760; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Wilkinson L., 1990, SYSTAT SYSTEM STAT; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	39	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3230	3235		10.1074/jbc.273.6.3230	http://dx.doi.org/10.1074/jbc.273.6.3230			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452436	hybrid			2022-12-27	WOS:000071822300021
J	Dominguez, DI; Ryabova, LA; Pooggin, MM; Schmidt-Puchta, W; Futterer, J; Hohn, T				Dominguez, DI; Ryabova, LA; Pooggin, MM; Schmidt-Puchta, W; Futterer, J; Hohn, T			Ribosome shunting in cauliflower mosaic virus - Identification of an essential, and sufficient structural element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCISTRONIC MESSENGER-RNA; ENCEPHALOMYOCARDITIS VIRUS; PROTEIN-SYNTHESIS; TRANSLATION; INITIATION; SEQUENCE; PLANTS; CODONS; CELLS; CAULIMOVIRUS	A wheat germ cell-free system was used to study details of ribosome shunting promoted by the cauliflower mosaic virus 35 S RNA leader. By testing a dicistronic construct with the leader placed between two coding regions, we confirmed that the 35 S RNA leader does not include an internal ribosome entry site of the type observed with picornavirus RNAs. A reporter gene fused to the leader was shown to be expressed by ribosomes that had followed the bypass route (shunted) and, with lower efficiency, by ribosomes that had scanned through the whole region. Stem section 1, the most stable of the three stem sections of the leader, was shown to be an important structural element for shunting. Mutations that abolished formation of this stem section drastically reduced reporter gene expression, whereas complementary mutations that restored stem section 1 also restored shunting. A micro-leader capable of shunting consisting of stem section 1 and flanking sequences could be defined. A small open reading frame preceding stem section 1 enhances shunting.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; ETH Zurich, CH-8902 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; Swiss Federal Institutes of Technology Domain; ETH Zurich	Hohn, T (corresponding author), Friedrich Miescher Inst, CH-4002 Basel, Switzerland.			Pooggin, Mikhail/0000-0003-2308-393X				ALTMANN M, 1994, BIOCHIMIE PARIS, V76, P835; BAUGHMAN G, 1988, VIROLOGY, V167, P125, DOI 10.1016/0042-6822(88)90061-X; BONNEVILLE JM, 1989, CELL, V59, P1135, DOI 10.1016/0092-8674(89)90769-1; BONNEVILLE JM, 1993, REVERSE TRANSCRIPTAS, P357; Browning K. S., 1996, POST TRANSCRIPTIONAL, P107; Cao JH, 1996, MOL CELL BIOL, V16, P7109; CURRAN J, 1989, EMBO J, V8, P521, DOI 10.1002/j.1460-2075.1989.tb03406.x; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; DIXON LK, 1984, EMBO J, V3, P2731, DOI 10.1002/j.1460-2075.1984.tb02203.x; Dominguez DI, 1996, VIROLOGY, V226, P374, DOI 10.1006/viro.1996.0665; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; FUTTERER J, 1988, NUCLEIC ACIDS RES, V16, P8377, DOI 10.1093/nar/16.17.8377; FUTTERER J, 1990, EMBO J, V9, P1697, DOI 10.1002/j.1460-2075.1990.tb08293.x; Futterer J, 1989, Virus Genes, V3, P45, DOI 10.1007/BF00301986; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; GEBALLE AP, 1995, TRANSLATIONAL CONTRO, P173; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GORDON K, 1992, PLANT J, V2, P809, DOI 10.1046/j.1365-313X.1992.t01-17-00999.x; HemmingsMieszczak M, 1997, J MOL BIOL, V267, P1075, DOI 10.1006/jmbi.1997.0929; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HOHN T, 1989, UCLA S MOL CELLULAR, V101, P153; HULL R, 1984, PLANT MOL BIOL, V3, P121, DOI 10.1007/BF00016059; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; JOSHI B, 1994, J BIOL CHEM, V269, P2048; KISSLASZLO Z, 1995, EMBO J, V14, P3552, DOI 10.1002/j.1460-2075.1995.tb07361.x; KissLaszlo Z, 1996, TRENDS MICROBIOL, V4, P480, DOI 10.1016/S0966-842X(97)82909-5; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LI J, 1996, THESIS U GIESSEN GIE; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MESNARD J, 1996, VIROLOGY, V213, P1; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; ROBERTS BE, 1973, P NATL ACAD SCI USA, V70, P2330, DOI 10.1073/pnas.70.8.2330; ROTHNIE HM, 1994, ADV VIRUS RES, V44, P1, DOI 10.1016/S0065-3527(08)60327-9; ROTHNIE HM, 1994, EMBO J, V13, P2200, DOI 10.1002/j.1460-2075.1994.tb06497.x; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SANFACON H, 1990, NATURE, V346, P81, DOI 10.1038/346081a0; SchmidtPuchta W, 1997, NUCLEIC ACIDS RES, V25, P2854, DOI 10.1093/nar/25.14.2854; SCHOLTHOF HB, 1992, J VIROL, V66, P3131, DOI 10.1128/JVI.66.5.3131-3139.1992; SIMPSON GG, 1995, EMBO J, V14, P4540, DOI 10.1002/j.1460-2075.1995.tb00133.x; THOMAS AAM, 1992, NEW BIOL, V4, P404; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; ZUCKER M, 1989, SCIENCE, V244, P48	50	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3669	3678		10.1074/jbc.273.6.3669	http://dx.doi.org/10.1074/jbc.273.6.3669			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452497	hybrid			2022-12-27	WOS:000071822300082
J	Worby, CA; Vega, QC; Chao, HHJ; Seasholtz, AF; Thompson, RC; Dixon, JE				Worby, CA; Vega, QC; Chao, HHJ; Seasholtz, AF; Thompson, RC; Dixon, JE			Identification and characterization of GFR alpha-3, a novel co-receptor belonging to the glial cell line-derived neurotrophic receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE; TYROSINE KINASE; MICE LACKING; GDNF; NEURONS; EXPRESSION; MUTATIONS; PHOSPHATIDYLINOSITOL; SUPERFAMILY; SURVIVAL	A new family of neuronal survival factors comprised of glial cell line-derived neurotrophic factor (GDNF) and neurturin has recently been described (Kotzbauer, P. T., Lampe, P. A., Heuckeroth, R. O., Golden, J. P., Creedon, D. J., Johnson, E. M., Jr., and Milbrandt, J. (1997) Nature 384, 467-470), These molecules, which are related to transforming growth factor-beta, are important in embryogenesis and in the survival of distinct neuronal populations, These molecules signal through a novel receptor system that includes the Ret receptor tyrosine kinase, a ligand (i.e. GDNF or neurturin), and an accessory glycosyl-phosphatidylinositol-linked molecule that is responsible for high affinity binding of the ligand, Two accessory molecules denoted GDNF family receptor 1 and 2 (GFR alpha-1 and GFR alpha-2) have been described that function in GDNF and neurturin signaling complexes, We have identified a novel co-receptor belonging to this family based on similarity to GFR alpha-1, which we have named GFR alpha-3. GFR alpha-3 displays 33% amino acid identity with GFR alpha-1 and 36% identity with GFR alpha-2. Despite the similarity of GFR alpha-3 to GFR alpha-1 and GFR alpha-2, it is unable to activate Ret in conjunction with GDNF, suggesting that there are likely additional undiscovered ligands and/or Ret-like receptors to be identified, GFR alpha-3 is anchored to the cell membrane by a phosphatidylinositol-specific phospholipase C-resistant glycosyl-phosphatidylinositol linkage, GFR alpha-3 is highly expressed by embryonic day 11 but is not appreciably expressed in the adult mouse, In situ hybridization analyses demonstrate that GFR alpha-3 is located in dorsal root ganglia and the superior cervical sympathetic ganglion. Comparison of the expression patterns of GFR alpha-3 and Ret suggests that these molecules could form a receptor pair and interact with GDNF family members to play unique roles in development.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Reprod Sci Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dixon, JE (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.				PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KEEGAN CE, 1994, ENDOCRINOLOGY, V134, P2547, DOI 10.1210/en.134.6.2547; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LOW MG, 1986, TRENDS BIOCHEM SCI, V11, P212, DOI 10.1016/0968-0004(86)90009-5; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1997, J NEUROSCI, V17, P3554; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	37	86	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3502	3508		10.1074/jbc.273.6.3502	http://dx.doi.org/10.1074/jbc.273.6.3502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452475	hybrid			2022-12-27	WOS:000071822300060
J	Yu, ZB; Su, LC; Hoglinger, O; Jaramillo, ML; Banville, D; Shen, SH				Yu, ZB; Su, LC; Hoglinger, O; Jaramillo, ML; Banville, D; Shen, SH			SHP-1 associates with both platelet-derived growth factor receptor and the p85 subunit of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GTPASE-ACTIVATING PROTEIN; SRC HOMOLOGY-2 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; MITOGENIC SIGNAL; SYP PHOSPHATASE; BETA-SUBUNIT; PHOSPHORYLATION; KINASE; INSULIN	The Src homology 2 (SH2)-containing protein tyrosine phosphatase 1, SHP-1, is highly expressed in all hematopoietic cells as well as in many non-hematopoietic cells, particularly in some malignant epithelial cell lines. In hematopoietic cells, SHP-1 negatively regulates multiple cytokine receptor pathways. The precise function and the targets of SHP-1 in non-hematopoietic cells, however, are largely unknown. Here we demonstrate that SHP-1 associates with both the tyrosine-phosphorylated platelet-derived growth factor (PDGF) receptor and the p85 subunit of phosphatidylinositol 3-kinase in MCF-7 and TRMP cells. Through the use of mutant PDGF receptors and performing peptide competition for immunoprecipitation, it was determined that SHP-1 independently associates with the PDGF receptor and p85 and that its N-terminal SH2 domain is directly responsible for the interactions. Overexpression of SHP-1 in TRMP cells transfected with the PDGF receptor markedly inhibited PDGF-induced c-fos promoter activation, whereas the expression of three catalytically inactive SHP-1 mutants increased the c-fos promoter activation in response to PDGF stimulation. These results indicate that SHP-1 might negatively regulate PDGF receptor-mediated signaling in these cells. Identification of the association of SHP-1 with the PDGF receptor and p85 in MCF-7 and TRMP cells furthers our understanding of the function of SHP-1 in non-hematopoietic cells.	Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	National Research Council Canada; McGill University	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							Adachi M, 1996, CELL, V85, P15; Allard JD, 1996, DEVELOPMENT, V122, P1137; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Liu L, 1997, J BIOL CHEM, V272, P10998; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; REEVES SA, 1995, EUR J BIOCHEM, V233, P55, DOI 10.1111/j.1432-1033.1995.055_1.x; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	50	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3687	3694		10.1074/jbc.273.6.3687	http://dx.doi.org/10.1074/jbc.273.6.3687			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452499	hybrid			2022-12-27	WOS:000071822300084
J	Skrzypek, MS; Nagiec, MM; Lester, RL; Dickson, RC				Skrzypek, MS; Nagiec, MM; Lester, RL; Dickson, RC			Inhibition of amino acid transport by sphingoid long chain bases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; PROTEIN-KINASE-C; TRANSLATIONAL CONTROL; BAKERS-YEAST; PERMEASES; SPHINGOLIPIDS; CERAMIDE; GENE; METABOLISM; STRAINS	Sphingoid long chain bases have many effects on cells including inhibition or stimulation of growth, The physiological significance of these effects is unknown in most cases, To bean to understand how these compounds inhibit growth, we have studied Saccharomyces cerevisiae cells. Growth of tryptophan (Trp(-)) auxotrophs was more strongly inhibited by phytosphingosine (PHS) than was growth of Trp(+) strains, suggesting that PHS diminishes tryptophan uptake and starves cells for this amino acid, This hypothesis is supported by data showing that growth inhibition is relieved by increasing concentrations of tryptophan in the culture medium and by multiple copies of the TAT2 gene, encoding a high affinity tryptophan transporter, Measurement of tryptophan uptake shows that it is inhibited by PHS. Finally, PHS treatment induces the general control response, indicating starvation for amino acids, Multiple copies of TAT2 do not protect cells against two other cationic lipids, stearylamine, and sphingosine, indicating that the effect of PHS on tryptophan utilization is specific, Other data demonstrate that PHS reduces uptake of leucine, histidine, and proline by specific transporters, Our data suggest that PHS targets proteins in the amino acid transporter family but not other distantly related membrane transporters, including those necessary for uptake of adenine and uracil.	Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Dickson, RC (corresponding author), Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA.	bobd@pop.uky.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; COURCHESNE WE, 1983, MOL CELL BIOL, V3, P672, DOI 10.1128/MCB.3.4.672; Ella KM, 1997, ARCH BIOCHEM BIOPHYS, V340, P101, DOI 10.1006/abbi.1997.9897; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GIETZ RD, 1992, NUCLEIC ACIDS RES, V8, P1425; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HORAK J, 1986, BIOCHIM BIOPHYS ACTA, V864, P223, DOI 10.1016/0304-4157(86)90001-8; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; JOHNSTON SA, 1982, P NATL ACAD SCI USA, V79, P6871; LESTER RL, 1993, ADV LIPID RES, V26, P253; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AHJ, 1996, LIPID 2 MESSENGERS, V8, P205; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NELISSEN B, 1995, FEBS LETT, V377, P22; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH SW, 1974, J BIOL CHEM, V249, P3395; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; WILSON E, 1986, J BIOL CHEM, V261, P2616	36	73	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2829	2834		10.1074/jbc.273.5.2829	http://dx.doi.org/10.1074/jbc.273.5.2829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446592	hybrid			2022-12-27	WOS:000071736600047
J	Song, Y; Withers, DA; Hakomori, S				Song, Y; Withers, DA; Hakomori, S			Globoside-dependent adhesion of human embryonal carcinoma cells, based on carbohydrate-carbohydrate interaction, initiates signal transduction and induces enhanced activity of transcription factors AP1 and CREB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-INDUCED DIFFERENTIATION; HUMAN TERATOCARCINOMA CELLS; NF-KAPPA-B; MONOCLONAL-ANTIBODY; PREIMPLANTATION EMBRYOS; MOUSE EMBRYOS; GLYCOSPHINGOLIPIDS; EXPRESSION; ANTIGEN; PROTEIN	Undifferentiated human embryonal carcinoma cells are characterized by high expression of lactoneotetraosylceramide (nLc(4)), globoside (Gb4), and extended globe-series glycosphingolipids (GSLs) termed "stage-specific embryonic antigens 3 and 4" (SSEA-3 and -4), Expression of these GSLs declines in association with a decline of homotypic adhesion during the differentiation process, Therefore, these GSLs may play an essential role in adhesion among these cells, As an example, human embryonal carcinoma 2102 cells display strong adhesion to plates coated with Gb4 ("Gb4-dependent cell adhesion"), This adhesion, which simulates homotypic 2102 cell aggregation, is based on interaction between Gb4 and nLc(4), or between Gb4 and GalGb4 (IV(3)GalGb4; the major SSEA-3 epitope), as indicated by the following observations: (i) adhesion of 2102 cells or GSL-liposomes to GSL-coated plates in various combinations; (ii) inhibition of Gb4-dependent 2102 cell adhesion by preincubation of cells with anti-SSEA-3 or anti-nLc(4) antibodies, or by pretreatment of Gb4-coated plates with aqueous micellar solution of nLc(4) or GalGb4; (iii) decline of the cell adhesion in association with retinoic acid-induced differentiation, whereby SSEA-3 and nLc(4) levels are reduced, Since cell adhesion is an essential prerequisite for induction of differentiation, as observed at each step of embryogenesis, expression of seven transcription fac tors following adhesion of 2102 cells to Gb4-coated plates, and to detergent-insoluble substrate adhesion matrix prepared from 2102 cells, were studied, In both types of adhesion, a strong enhancement of AP1 and CREB site binding activity was observed during the early stage (15-60 min following initial adhesion), Although 2102 cells showed strong adhesion to Gg3-coated plates, based on interaction between Gg3 and Gb4, adhesion of the cells to Gg3 did not cause changes of AP1 and CREB activity, No other transcription factors showed changes induced by Gg3- or Gb4-dependent adhesion.	Pacific NW Res Fdn, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Song, Y (corresponding author), NIDDK, Lab Cell Biochem, NIH, MSC 0850,Bldg 8,Rm 402, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1982, INT J CANCER, V29, P523, DOI 10.1002/ijc.2910290507; ANDREWS PW, 1987, INT J ANDROL, V10, P95, DOI 10.1111/j.1365-2605.1987.tb00170.x; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; Boubelik M, 1996, BIOCHEM BIOPH RES CO, V224, P283, DOI 10.1006/bbrc.1996.1022; Bovin N. V., 1997, GLYCOSCIENCES STATUS, P277; Buck C A, 1992, Semin Cell Biol, V3, P179; CARTER WG, 1981, J BIOL CHEM, V256, P6953; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Grobstein C., 1975, EXTRACELLULAR MATRIX, P9; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAKOMORI S, 1992, TOHOKU J EXP MED, V168, P211, DOI 10.1620/tjem.168.211; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANDA K, 1995, INT J ONCOL, V6, P773; HERRLICH P, 1995, EUR J CANCER, V31A, P1110, DOI 10.1016/0959-8049(95)00252-E; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ITO K, 1994, GLYCOCONJUGATE J, V11, P232, DOI 10.1007/BF00731223; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOJIMA N, 1991, Glycobiology, V1, P623, DOI 10.1093/glycob/1.6.623; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KOSCIELAK J, 1968, IMMUNOCHEMISTRY, V5, P441, DOI 10.1016/0019-2791(68)90181-X; Koshy KM, 1996, J BIOL CHEM, V271, P3496; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SMYTH SS, 1993, BLOOD, V81, P2827; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STROUD MR, 1991, J BIOL CHEM, V266, P8439; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VESTWEBER D, 1987, DEV BIOL, V124, P451, DOI 10.1016/0012-1606(87)90498-2; VONDEMBORNE AEG, 1986, BR J HAEMATOL, V63; WILLISON KR, 1982, J IMMUNOL, V129, P603; YAMAKAWA T, 1952, J BIOCHEM-TOKYO, V39, P393, DOI 10.1093/oxfordjournals.jbchem.a126309; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; YOUNG WW, 1979, J EXP MED, V150, P1008, DOI 10.1084/jem.150.4.1008; YOUNG WW, 1981, J BIOL CHEM, V256, P967	56	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2517	2525		10.1074/jbc.273.5.2517	http://dx.doi.org/10.1074/jbc.273.5.2517			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446552	hybrid			2022-12-27	WOS:000071736600007
J	Bloemers, SM; Verheule, S; Peppelenbosch, MP; Smit, MJ; Tertoolen, LGJ; de Laat, S				Bloemers, SM; Verheule, S; Peppelenbosch, MP; Smit, MJ; Tertoolen, LGJ; de Laat, S			Sensitization of the histamine H-1 receptor by increased ligand affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; INHALED LEUKOTRIENE-D4; PROTEIN; CELLS; EXOCYTOSIS; INTERNALIZATION; RESPONSIVENESS; EXPRESSION; PATHWAYS; MEMBRANE	Histamine regulates a variety of physiological processes including inflammation, gastric acid secretion, and neurotransmission. The cellular response to histamine is subject to dynamic control, and exaggerated histamine reactivity in response to cysteinyl leukotrienes and other stimuli is important in a variety of different pathological conditions, The molecular mechanisms controlling histamine responsiveness are still unresolved, In investigating histamine responses in embryonic stem (ES5) and F9 embryonic carcinoma cells, we encountered a novel mechanism controlling the cellular reaction to histamine, Unstimulated cells displayed neither [H-3]pyrilamine binding nor histamine-induced increases in cytosolic Ca2+ levels, Pretreatment of these cells, however, with leukotriene D-4, leukotriene E-4, serotonin, or fetal calf serum induced an immediate and transient ability of these cells to respond to histamine with an increase in cytosolic Ca2+ levels, This effect could be inhibited by pertussis toxin and was mimicked by GTP analogues, Importantly, the latter compounds also provoked immediate high affinity [H-3]pyrilamine binding, We conclude that in these cells histamine responsiveness is directly controlled by pertussis toxin-sensitive G protein-coupled receptors, whose activation enables the H-1 receptor to bind its ligand, These findings define a novel mechanism for regulating histamine H-1 receptor activity and provide for the first time molecular insight into the mechanism by which cysteinyl leukotrienes and other external stimuli can increase histamine responsiveness.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Vrije Univ Amsterdam, Fac Chem, Dept Pharmacochem, NL-1081 HV Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Peppelenbosch, MP (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.			Peppelenbosch, Maikel/0000-0001-9112-6028; Smit, Martine/0000-0003-2713-0238; Verheule, Sander/0000-0001-5196-5425				ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BLOEMERS SM, 1992, BIOCHEM BIOPH RES CO, V191, P118; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1506, DOI 10.1164/ajrccm/146.6.1506; CIVITELLI R, 1987, J CELL PHYSIOL, V131, P434, DOI 10.1002/jcp.1041310316; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gerthoffer WT, 1996, J PHARMACOL EXP THER, V278, P800; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILL SJ, 1990, PHARMACOL REV, V42, P45; KAHLSON G, 1968, PHYSIOL REV, V48, P155, DOI 10.1152/physrev.1968.48.1.155; KAYE MG, 1990, AM REV RESPIR DIS, V141, P993, DOI 10.1164/ajrccm/141.4_Pt_1.993; KERN R, 1986, AM REV RESPIR DIS, V133, P1127; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; Krueger KM, 1997, J BIOL CHEM, V272, P5; LANG JC, 1993, EMBO J, V12, P2671, DOI 10.1002/j.1460-2075.1993.tb05928.x; LAW GJ, 1993, FEBS LETT, V333, P56, DOI 10.1016/0014-5793(93)80374-4; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; OHICKEY SP, 1991, AM REV RESPIR DIS, V144, P1053, DOI 10.1164/ajrccm/144.5.1053; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEPPELENBOSCH MP, 1995, J NEUROSCI METH, V58, P49, DOI 10.1016/0165-0270(94)00158-D; SAKURAI T, 1994, PROSTAG LEUKOTR ESS, V51, P95, DOI 10.1016/0952-3278(94)90084-1; SMIT MJ, 1992, BRIT J PHARMACOL, V107, P448, DOI 10.1111/j.1476-5381.1992.tb12766.x; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; THIEN FCK, 1995, PROSTAG LEUKOTR ESS, V52, P271, DOI 10.1016/0952-3278(95)90027-6; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; VITALE N, 1994, BIOCHEM J, V300, P217, DOI 10.1042/bj3000217; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Werle E, 1936, BIOCHEM Z, V288, P292; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	30	10	10	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2249	2255		10.1074/jbc.273.4.2249	http://dx.doi.org/10.1074/jbc.273.4.2249			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442068	Green Published, hybrid			2022-12-27	WOS:000071595200057
J	Kim, SO; Jiang, J; Yi, WS; Feng, GS; Frank, SJ				Kim, SO; Jiang, J; Yi, WS; Feng, GS; Frank, SJ			Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; GH RECEPTOR; IM-9 CELLS; IN-VIVO; PHOSPHORYLATION; JAK2	Growth hormone (GH) signaling requires activation of the GH receptor (GHR)-associated tyrosine kinase, JAK2. JAK2 activation by GH is believed to facilitate initiation of various pathways including the Ras, mitogen-activated protein kinase, STAT, insulin receptor substrate (IRS), and phosphatidylinositol 3-kinase systems. In the present study, we explore the biochemical and functional involvement of the Src homology 2 (SH2)-containing protein-tyrosine phosphatase, SHP-2, in GH signaling. GH stimulation of murine NIH 3T3-F442A fibroblasts, cells that homologously express GHRs, resulted in tyrosine phosphorylation of SHP-2. As assessed specifically by anti-SHP-2 coimmunoprecipitation and by affinity precipitation with a glutathione S-transferase fusion protein incorporating the SH2 domains of SHP-2, GI-I induced formation of a complex of tyrosine phosphoproteins including SHP-2, GHR, JAK2, and a glycoprotein with properties consistent with being a SIRP-alpha-like molecule. A reciprocal binding assay using IM-9 cells as a source of SHP-1 and SHP-2 revealed specific association of SHP-2 (but not SHP-1) with a glutathione S-transferase fusion incorporating GHR cytoplasmic domain residues 485-620, but only if the fusion was first rendered tyrosine-phosphorylated. GH-dependent tyrosine phosphorylation of SHP-2 was also observed in murine 32D cells (which lack IRS-1 and -2) stably transfected with the GHR. Further, GH-dependent anti-SHP-2 coimmunoprecipitation of the Grb2 adapter protein was detected in both 3T3-F442A and 32D-rGHR cells, indicating that biochemical involvement of SHP-2 in GH signaling may not require IRS-1 or -2. Finally, GH-induced transactivation of a c-Fos enhancer-driven luciferase reporter in GHR-and JAK2-transfected COS-7 cells was significantly reduced when a catalytically inactive SHP-2 mutant (but not wild-type SHP-2) was coexpressed; in contrast, expression of a catalytically inactive SHP-1 mutant allowed modestly enhanced GH-induced transactivation of the reporter in comparison with that found with expression of wildtype SHP-1, Collectively, these biochemical and functional data imply a positive role for SHP-2 in GH signaling.	Univ Alabama, DREB, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35294 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Frank, SJ (corresponding author), Univ Alabama, DREB, Dept Med, Div Endocrinol & Metab, Room 756,UAB Stn, Birmingham, AL 35294 USA.	frank@endo.dom.uab.edu			NIDDK NIH HHS [DK46395] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R01DK046395, R29DK046395] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COLOSI P, 1993, J BIOL CHEM, V268, P12617; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Hackett RH, 1997, J BIOL CHEM, V272, P11128; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LESNIAK MA, 1974, J BIOL CHEM, V249, P1661; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yu ZB, 1997, J BIOL CHEM, V272, P7519, DOI 10.1074/jbc.272.11.7519; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	69	131	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2344	2354		10.1074/jbc.273.4.2344	http://dx.doi.org/10.1074/jbc.273.4.2344			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442080	hybrid			2022-12-27	WOS:000071595200069
J	Rasmussen, CB; Hiner, ANP; Smith, AT; Welinder, KG				Rasmussen, CB; Hiner, ANP; Smith, AT; Welinder, KG			Effect of calcium, other ions, and pH on the reactions of barley peroxidase with hydrogen peroxide and fluoride - Control of activity through conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COMPOUND-I FORMATION; HORSERADISH-PEROXIDASE; ARTHROMYCES-RAMOSUS; ANGSTROM RESOLUTION; PEANUT PEROXIDASE; SUBSTRATE-BINDING; FUNGAL PEROXIDASE; CRYSTAL-STRUCTURE; HEME CAVITY	Transient-state kinetic analysis of compound I formation for barley grain peroxidase (BP 1) has revealed properties that are highly unusual for a heme peroxidase but which may be relevant to its biological function. The enzyme shows very little reaction with H2O2 at pH > 5 and exhibited saturation kinetics at higher H2O2 concentrations (k(cat)(app) increases from 1.1 s(-1) at pH 4.5 to 4.5 s(-1) at pH 3.1 with an enzyme-linked pK(a) < 3.7 (Rasmussen, C. B., Bakovic, M., Welinder, K. G., and Dunford, H. B. (1993) FEES Lett. 321, 102-105)). In the present paper, it is shown that the presence of Ca2+ gives rise to biphasic kinetics for compound I formation, with a slow phase as described above and a fast phase that exhibits a second order rate constant more typical of a classical peroxidase (k(1)(app) = 1.5 x 10(7) M-1 s(-1), which is pH-independent between 3.3 and 5.0). The amount of enzyme reacting in the fast phase increases with Ca2+ concentration (K-d = 4 +/- 1 mM at pH 4.0), although it is also moderately inhibited by Cl-. The absorption spectrum of BP-1, which appears to be a five-coordinate high spin ferric in the resting state changes insignificantly in the presence of Ca2+. In the presence of Cl-, it becomes six-coordinate high spin (K-d approximately 60 mM at pH 4.0) but only if Ca2+ is also present. Fluoride binds to BP 1 with monophasic kinetics in the presence of 0-5 mM Ca2+. The activating effect of Ca2+ can be mimicked only by replacing it with Sr2+ and Ba2+ ions. Comparing these data with the crystal structure of the inactive neutral form of BP 1 (Henriksen, k, Welinder, K. G., and Gajhede, M. (1997) J. Biol. Chem. 273, 2241-2248) and similar data for wild-type and mutant peroxidases of plant and fungal origin suggests (i) a proton-induced conformational change from an inactive BP 1 at neutral pH to a low activity BP 1 form with a functional distal histidine and (ii) a Ca2+-induced slow conformational change (at least compared with compound I formation) of this low activity form to a high activity BP 1 with a typical peroxidase reactivity. BP 1 is the first example of a plant peroxidase whose activity can be reversibly controlled at the enzyme level by pH-and Ca2+-induced conformational changes.	Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, DK-1353 Copenhagen K, Denmark	University of Copenhagen	Welinder, KG (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.	welinder@biobase.dk		Welinder, Karen Gjesing/0000-0002-5409-0131; Smith, Andrew/0000-0002-0926-1878				ANDERSEN MB, 1991, BIOCH MOL PHYSL ASPE, P169; BARBER KR, 1995, EUR J BIOCHEM, V232, P825, DOI 10.1111/j.1432-1033.1995.tb20879.x; Dalton DA., 1991, PEROXIDASES CHEM BIO, V2, P139; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FARHANGRAZI ZS, 1995, BIOCHEMISTRY-US, V34, P14970, DOI 10.1021/bi00046a003; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Henriksen A, 1998, J BIOL CHEM, V273, P2241, DOI 10.1074/jbc.273.4.2241; HU CF, 1987, PHYSIOL PLANTARUM, V70, P99, DOI 10.1111/j.1399-3054.1987.tb08703.x; Jespersen HM, 1997, BIOCHEM J, V326, P305, DOI 10.1042/bj3260305; JOHANSSON A, 1992, PLANT MOL BIOL, V18, P1151, DOI 10.1007/BF00047718; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; MAKINO R, 1973, ARCH BIOCHEM BIOPHYS, V157, P3576; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; MIYAKE C, 1991, PLANT CELL PHYSIOL, V32, P33; Neri F, 1997, BIOCHEMISTRY-US, V36, P8947, DOI 10.1021/bi970248+; NERI F, 1998, IN PRESS BIOCHEMISTR; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RASMUSSEN CB, 1993, FEBS LETT, V321, P102, DOI 10.1016/0014-5793(93)80630-D; Rasmussen CB, 1997, PHYSIOL PLANTARUM, V100, P102, DOI 10.1034/j.1399-3054.1997.1000110.x; RASMUSSEN CB, 1995, BIOCHEMISTRY-US, V34, P4022, DOI 10.1021/bi00012a021; RASMUSSEN SK, 1991, PLANT MOL BIOL, V16, P317, DOI 10.1007/BF00020562; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; Welinder K. G., 1996, PLANT PEROXIDASES BI, P173; WELINDER KG, PLANT PEROXIDASES BI, P35; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; WINK M, 1993, J EXP BOT, V44, P231; YONETANI T, 1987, J BIOL CHEM, V262, P9547	39	31	31	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2232	2240		10.1074/jbc.273.4.2232	http://dx.doi.org/10.1074/jbc.273.4.2232			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442066	hybrid			2022-12-27	WOS:000071595200055
J	Reedquist, KA; Bos, JL				Reedquist, KA; Bos, JL			Costimulation through CD28 suppresses T cell receptor-dependent activation of the ras-like small GTPase Rap1 in human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASES; EXCHANGE FACTOR; IN-VIVO; PROTEIN; GRB2; CRK; STIMULATION; DOMAIN	Members of the Ras superfamily of small molecular weight GTPases play diverse and critical roles in mediating cellular responses to extracellular stimuli, including mitogenesis, cytoskeletal maintenance and rearrangement, and integrin activation. In T lymphocytes, biochemical and genetic evidence demonstrate that Ras plays an essential role in coupling T cell receptor ligation to signaling cascades required for T cell proliferation and development. Recent observations that C3G, a guanine nucleotide exchange factor specific for the Ras-related GTPase Rap1, is recruited into tyrosine-phosphorylated protein signaling complexes in activated T cells have suggested that Rap1 may also play a role in T cell activation, Utilizing a recently developed technique for detection of endogenous, GTP-bound Rap1, we have found that Rap1, but not Rapa, is transiently activated following T cell receptor stimulation of normal human T lymphocytes, Increases in intracellular calcium is both necessary and sufficient to induce Rap1 activation, Remarkably, costimulation of T cells with mitogenic anti-CD28 antibody completely abolished T cell receptor-dependent activation of Rap1, This report demonstrates a potential role for Rap1 in T cell receptor signaling and suggests inactivation of Rap1 as a candidate target of CD28-dependent costimulatory signals required for T cell antigen responsiveness.	Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands	Utrecht University	Reedquist, KA (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	k.a.reedquist@med.ruu.nl						ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BADWEY JA, 1991, BIOCHEM BIOPH RES CO, V178, P423, DOI 10.1016/0006-291X(91)90124-P; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FRENCH M, 1990, SCIENCE, V249, P169; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HATA Y, 1990, J BIOL CHEM, V265, P7104; HATTORI M, 1995, MOL CELL BIOL, V15, P552, DOI 10.1128/MCB.15.1.552; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MALY FE, 1994, J BIOL CHEM, V269, P18743; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; ODA T, 1994, J BIOL CHEM, V269, P22925; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; VANDEGRIEND RJ, 1984, J IMMUNOL, V133, P1222; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VANLIER RAW, 1989, LEUKOCYTE TYPING, V4, P353; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	56	91	92	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4944	4949		10.1074/jbc.273.9.4944	http://dx.doi.org/10.1074/jbc.273.9.4944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478939	hybrid			2022-12-27	WOS:000072310400023
J	Yamaguchi, K; Kinosaki, M; Goto, M; Kobayashi, F; Tsuda, E; Morinaga, T; Higashio, K				Yamaguchi, K; Kinosaki, M; Goto, M; Kobayashi, F; Tsuda, E; Morinaga, T; Higashio, K			Characterization of structural domains of human osteoclastogenesis inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH-DOMAIN; CELL-SURFACE; CONTAINING RECEPTOR; SOLUBLE FORM; APOPTOSIS; PROTEIN; FAS; DIFFERENTIATION; MODULATION; PROTECTION	Osteoclastogenesis inhibitory factor (OCIF) is a heparin-binding secretary glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) family. OCIF is present both as a similar to 60-kDa monomer and a disulfide-linked homodimer, We attempted to characterize the seven structural domains of OCIF by determining the capabilities of various OCIF mutants to inhibit osteoclastogenesis, to interact with heparin, and to form dimers. We also examined a potential of domains 5 and 6, death domain homologous regions (DDHs), for inducing cell death by expressing OCIF/Fas fusion proteins, Our results show that: (i) the N-terminal portion of OCIF containing domains 1-4, which have structural similarity to the extracellular domains of the TNFR family proteins, is sufficient to inhibit osteoclastogenesis; (ii) a heparin-binding site is located in domain 7, and affinity for heparin does not correlate with the inhibitory activity; (iii) Cys-400 in domain 7 is the residue responsible for dimer formation; and (iv) the C-terminal portion containing domains 5 and 6, DDHs, has a high potential for mediating a cytotoxic signal when it is expressed in cells as an OCIF/Fas fusion protein in which the transmembrane region of Fas is inserted in front of DDHs.				fvbd7042@mb.infoweb.or.jp						ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAMBERS TJ, 1991, VITAM HORM, V46, P41; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; HARTMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; SANDSTROM J, 1994, J BIOL CHEM, V269, P19163; Schreiber M, 1996, J BIOL CHEM, V271, P13333, DOI 10.1074/jbc.271.23.13333; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH C, 1991, CYTOKINE, V3, P448; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756-3282(95)00185-G; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; YASUDA H, 1998, IN PRESS ENDOCRINOLO; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	29	180	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5117	5123		10.1074/jbc.273.9.5117	http://dx.doi.org/10.1074/jbc.273.9.5117			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478964	hybrid			2022-12-27	WOS:000072310400048
J	Kim, A; Kim, J; Martin, BM; Dunaway-Mariano, D				Kim, A; Kim, J; Martin, BM; Dunaway-Mariano, D			Isolation and characterization of the carbon-phosphorus bond-forming enzyme phosphoenolpyruvate mutase from the mollusk Mytilus edulis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-C BOND; TRYPANOSOMA-CRUZI; STREPTOMYCES-HYGROSCOPICUS; TETRAHYMENA-PYRIFORMIS; NUCLEOTIDE-SEQUENCE; EPIMASTIGOTE FORMS; BIOSYNTHETIC GENES; BIALAPHOS SF-1293; APLYSIA-KURODAI; PHOSPHOMUTASE	The enzyme phosphoenolpyruvate mutase was purified to homogeneity from the mollusk Mytilus edulis. The subunit size of the native homotetramer was determined to be 34,000 Da, The steady state kinetic constants for catalysis of the conversion of phosphonopyruvate to phosphoenolpyruvate at pH 7.5 and 25 degrees C were measured at k(cat) = 34 s(-1), phosphonopyruvate K-m = 3 mu M, and Mg2+ K-m = 4 mu M. The enzyme displayed a broad specificity for divalent metal ion activation; Co2+, Mn2+, Zn2+, and Ni2+ are activators, whereas Ca2+ is not. Analysis of the pH dependence of the Mg2+-activated mutase-catalyzed reaction of phosphonopyruvate revealed one residue that must be protonated (apparent pK(a) = 8.3) and a second residue that must be unprotonated (apparent pK(a) = 7.7) for maximal catalytic activity.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; NIMH, Mol Neurogenet Unit, Clin Neurosci Branch, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.		Kim, Jaebong/AAV-1986-2021	Kim, Jaebong/0000-0003-1609-338X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28688] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE S, 1991, J BIOL CHEM, V266, P9939; ALHADELFF JA, 1970, J BIOCH, V9, P4866; BARRY RJ, 1988, BIOCHEM BIOPH RES CO, V153, P177, DOI 10.1016/S0006-291X(88)81205-1; BAUMANN H, 1992, BIOCHEMISTRY-US, V31, P4081, DOI 10.1021/bi00131a026; BOWMAN E, 1988, J AM CHEM SOC, V110, P5575, DOI 10.1021/ja00224a054; BOWMAN ED, 1990, BIOCHEMISTRY-US, V29, P7059, DOI 10.1021/bi00482a016; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; HAMMERSCHMIDT F, 1991, J ORG CHEM, V56, P2364, DOI 10.1021/jo00007a022; HARA O, 1991, J GEN MICROBIOL, V137, P351, DOI 10.1099/00221287-137-2-351; HARD K, 1993, BIOCHEMISTRY-US, V32, P766, DOI 10.1021/bi00054a005; HIDAKA T, 1989, J ANTIBIOT, V42, P491, DOI 10.7164/antibiotics.42.491; HIDAKA T, 1989, J AM CHEM SOC, V111, P8012, DOI 10.1021/ja00202a051; HIDAKA T, 1992, J ANTIBIOT, V45, P1977, DOI 10.7164/antibiotics.45.1977; HIDAKA T, 1995, MOL GEN GENET, V249, P274, DOI 10.1007/BF00290527; HILDERBRAND RL, 1983, ROLES PHOSPHONATES L; KAHAN FM, 1974, ANN NY ACAD SCI, V235, P364, DOI 10.1111/j.1749-6632.1974.tb43277.x; KENNEDY KE, 1970, SCIENCE, V168, P989, DOI 10.1126/science.168.3934.989; KILBY PM, 1991, NATURWISSENSCHAFTEN, V78, P514, DOI 10.1007/BF01131402; MASTELERZ P, 1984, NATURAL PRODUCTS CHE, P171; MATSUBARA T, 1990, BIOCHIM BIOPHYS ACTA, V1042, P280, DOI 10.1016/0005-2760(90)90154-P; NAKASHITA H, 1992, J BACTERIOL, V174, P6857, DOI 10.1128/JB.174.21.6857-6861.1992; NAKASHITA H, 1991, AGR BIOL CHEM TOKYO, V55, P2825, DOI 10.1080/00021369.1991.10871050; OGAWA Y, 1973, Scientific Reports of Meiji Seika Kaisha, V13, P42; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; SEIDEL HM, 1992, BIOCHEMISTRY-US, V31, P2598, DOI 10.1021/bi00124a021; SEIDEL HM, 1988, NATURE, V335, P457, DOI 10.1038/335457a0; STEINER S, 1973, J BACTERIOL, V116, P1199, DOI 10.1128/JB.116.3.1199-1211.1973; WASSEF MK, 1977, BIOCHIM BIOPHYS ACTA, V922, P78; WHITE RW, 1970, BIOCHEM J, V116, P767, DOI 10.1042/bj1160767; YAMADA S, 1995, J BIOCHEM-TOKYO, V117, P794, DOI 10.1093/oxfordjournals.jbchem.a124778	33	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4443	4448		10.1074/jbc.273.8.4443	http://dx.doi.org/10.1074/jbc.273.8.4443			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468496	hybrid			2022-12-27	WOS:000072115000024
J	Wegner, SA; Ehrenberg, PK; Chang, G; Dayhoff, DE; Sleeker, AL; Michael, NL				Wegner, SA; Ehrenberg, PK; Chang, G; Dayhoff, DE; Sleeker, AL; Michael, NL			Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-TRANSMEMBRANE DOMAIN RECEPTOR; HIV-1 ENTRY; TROPIC HIV-1; INFECTION; CLONING; MIP-1-ALPHA; MIP-1-BETA; FUSION; RANTES; CELLS	CXCR4 is both a chemokine receptor and entry co-preceptor for T cell lime-adapted human immunodeficiency virus type 1. The genomic organization and promoter function for the entire transcription unit of CXCR4 were determined, The gene contains 2 exons of 103 and 1563 base pairs (bp) interrupted by a 2132-bp intron precisely between codons 5 and 6 of the coding sequences. a transcription start site was identified 88 bp upstream of the initiation codon, and a polyadenylate addition sits was identified 22 bp 3' to a polyadenylation signal, Transient expression assays defined a minimal promoter at positions -114 to +43 relative to the transcription start site. This region contains a TATA box, a nuclear respiratory factor-1 (NRF-1) site, and two GC boxes. Specific factor binding to the NRF-1 site and GC boxes were demonstrated by gel mobility shifts and DNase I footprinting. Site-directed mutagenesis showed that the NRF-1 site is crucial for promoter activity providing the first evidence for the regulation of a signal transduction gene by NRF-1. Sequences between -691 and -191 repress CXCR4 promoter activity. Further study of these regulatory elements will be important to understanding how CXCR4 functions as both a chemokine receptor and human immunodeficiency virus type 1 entry co-receptor.	Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Henry M Jackson Fdn, Rockville, MD 20850 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	Michael, NL (corresponding author), Walter Reed Army Inst Res, Div Retrovirol, 1600 E Gude Dr, Rockville, MD 20850 USA.	nmichael@pasteur.hjf.org		Ehrenberg, Philip/0000-0002-8695-4301				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; Clapham PR, 1997, NATURE, V388, P230, DOI 10.1038/40758; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; GRANELLIPIPERNO A, 1995, P NATL ACAD SCI USA, V92, P10944, DOI 10.1073/pnas.92.24.10944; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUSSO P, 1995, J VIROL, V69, P3712, DOI 10.1128/JVI.69.6.3712-3720.1995; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; MICHAEL NL, 1995, J VIROL, V69, P6758, DOI 10.1128/JVI.69.11.6758-6769.1995; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; Moriuchi M, 1997, J IMMUNOL, V159, P4322; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; REESE MG, 1996, P PAC S BIOC KON HAW, P74; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMPSON M, 1996, BIOCHEMISTRY-US, V35, P3362; SAMPSON M, 1996, NATURE, V382, P722; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZOUBAK S, 1999, GENE AMST, V174, P95	48	96	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4754	4760		10.1074/jbc.273.8.4754	http://dx.doi.org/10.1074/jbc.273.8.4754			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468539	hybrid			2022-12-27	WOS:000072115000067
J	Yan, H; Piazza, F; Krishnan, K; Pine, R; Krolewski, JJ				Yan, H; Piazza, F; Krishnan, K; Pine, R; Krolewski, JJ			Definition of the interferon-alpha receptor-binding domain on the TYK2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; SIGNAL-TRANSDUCTION; JAK FAMILY; PHOSPHORYLATION; P135(TYK2); SUBUNIT; CELLS; FORM; ASSOCIATION; ACTIVATION	Interferons and cytokines modulate gene expression via a simple, direct signaling pathway containing receptors, JAK tyrosine kinases, and STAT transcription factors, The interferon-alpha pathway is a model for these cascades. Two receptors, IFNaR1 and IFNaR2, associate exclusively in a constitutive manner with two JAK proteins, TYK2 and JAK1, respectively; Defining the molecular interface between JAK proteins and their receptors is critical to understanding the signaling pathway and may contribute to the development of novel therapeutics. This report defines the IFNaR1 interaction domain on TYK2. In vitro binding studies demonstrate that the amino-terminal half of TYK2, which is similar to 600 amino acids long and contains JAK homology (JH) domains 3-7, comprises the maximal binding domain for IFNaR1, A fragment containing amino acids 171-601 (JH3-6) also binds IFNaR1, but with reduced affinity. Glutathione S-transferase-TYK2 fusion proteins approximating either the JH6 or JH3 domain affinity-precipitate IFNaR1, suggesting that these are major sites of interaction within the larger binding domain. TYK2 amino acids 1-601 act in a dominant manner to inhibit the transcription of an interferon-alpha-dependent reporter gene, presumably by displacing endogenous TYK2 from the receptor, This same fragment inhibits interferon-alpha-dependent tyrosine phosphorylation of TYK2, STAT1, and STAT2.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Irving Comprehens Canc Ctr, New York, NY 10032 USA; Publ Hlth Res Inst, New York, NY 10016 USA	Columbia University; Columbia University	Krolewski, JJ (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.	jjk5@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Davis E, 1996, LEUKEMIA, V10, P543; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HARPUR AG, 1992, ONCOGENE, V7, P1347; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; Krishnan K, 1996, ONCOGENE, V13, P125; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	36	37	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4046	4051		10.1074/jbc.273.7.4046	http://dx.doi.org/10.1074/jbc.273.7.4046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461596	hybrid			2022-12-27	WOS:000072048400038
J	Dai, RM; Chen, EY; Longo, DL; Gorbea, CM; Li, CCH				Dai, RM; Chen, EY; Longo, DL; Gorbea, CM; Li, CCH			Involvement of valosin-containing protein, an ATPase co-purified with I kappa B alpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA CELL-LINES; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEIN; ESCHERICHIA-COLI; RAT-LIVER; SIGNAL; PROTEOLYSIS; ACTIVATION; SUBUNIT	The inactivation of the prototype NF-kappa B inhibitor, I kappa B alpha, occurs through a series of ordered processes including phosphorylation, ubiquitin conjugation, and proteasome-mediated degradation. We identify valosin-containing protein (VCP), an AAA (ATPases associated with a variety of cellular activities) family member, that co-precipitates with I kappa B alpha immune complexes, The ubiquitinated I kappa B alpha conjugates readily associate with VCP both in vivo and in vitro, and this complex appears dissociated from NF-kappa B. In ultracentrifugation analysis, physically associated VCP and ubiquitinated I kappa B alpha complexes sediment in the 19 S fractions, while the unmodified I kappa B alpha sediments in the 4.5 S fractions deficient in VCP, Phosphorylation and ubiquitination of I kappa B alpha are critical for VCP binding, which in turn is necessary but not sufficient for I kappa B alpha degradation; while the N-terminal domain of I kappa B alpha is required in all three reactions, both N- and C-terminal domains are required in degradation, Further, VCP co-purifies with the 26 S proteasome on two-dimensional gels and co-immunoprecipitates with subunits of the 26 S proteasome. Our results suggest that VCP may provide a physical and functional link between I kappa B alpha and the 26 S proteasome and play an important role in the proteasome-mediated degradation of I kappa B alpha.	NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NIA, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Utah System of Higher Education; University of Utah	Li, CCH (corresponding author), NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.		Longo, Dan L./F-6022-2011					ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECKWITH M, 1990, J NATL CANCER I, V82, P501, DOI 10.1093/jnci/82.6.501; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; COUX L, 1996, ANN REV BIOCH, V65, P801; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; DEVEREAUX Q, 1994, J BIOL CHEM, V26, P7059; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EGERTON M, 1994, J BIOL CHEM, V269, P11435; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; OCONNOR PM, 1993, CANCER RES, V53, P4776; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	58	272	282	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3562	3573		10.1074/jbc.273.6.3562	http://dx.doi.org/10.1074/jbc.273.6.3562			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452483	hybrid			2022-12-27	WOS:000071822300068
J	Vanden Berghe, W; Plaisance, S; Boone, E; De Bosscher, K; Schmitz, ML; Fiers, W; Haegeman, G				Vanden Berghe, W; Plaisance, S; Boone, E; De Bosscher, K; Schmitz, ML; Fiers, W; Haegeman, G			p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor kappa B p65 transactivation mediated by tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; INTERLEUKIN-6 GENE-EXPRESSION; TRANSCRIPTION FACTOR; HUMAN-FIBROBLASTS; CYCLIC-AMP; CELL-LINES; IN-VIVO; INDUCTION; PROMOTER; DNA	Interleukin-6 (IL-6) is a pleiotropic cytokine, which is involved in inflammatory and immune responses, acute phase reactions, and hematopoiesis. In the mouse fibrosarcoma cell line L929, the nuclear factor (NF)-kappa B plays a crucial role in IL-6 gene expression mediated by tumor necrosis factor (TNF). The levels of the activated factor do not, however, correlate with the variations of IL-6 gene transcription; therefore, other factors and/or regulatory mechanisms presumably modulate the levels of IL-6 mRNA production, Upon analysis of various deletion and point-mutated variants of the human IL-6 gene promoter coupled to a reporter gene, we screened for possible cooperating transcription factors. Even the smallest deletion variant, containing almost exclusively a NF-kappa B-responsive sequence preceding the IL-6 minimal promoter, as well as a recombinant construction containing multiple kappa B-motifs, could still be stimulated with TNF. We observed that the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 was able to repress TNF-stimulated expression of the IL-6 gene, as well as of a kappa B-dependent reporter gene construct, without affecting the levels of NF-kappa B binding to DNA. Furthermore, we clearly show that, using a nuclear Gal4 "one-hybrid" system, the MAPK inhibitors SB203580 and PD0980589 have a direct repressive effect on the transactivation potential of the p65 kappa B subunit. Therefore, we conclude that, in addition to cytoplasmic activation and DNA binding of NF-kappa B, the p38 and extracellular signal-regulated kinase MAPK pathways act as necessary cooperative mechanisms to regulate TNF-induced IL-6 gene expression by modulating the transactivation machinery.	Univ Ghent, Mol Biol Lab, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Mol Biol Lab, Ghent, Belgium; German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany	Ghent University; Helmholtz Association; German Cancer Research Center (DKFZ)	Haegeman, G (corresponding author), Univ Ghent, Mol Biol Lab, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	chrish@mb.rug.ac.be	Plaisance, Stephane/B-3488-2009; Plaisance, Stephane/ABI-6307-2020; Berghe, Wim Vanden/S-6425-2018; Schmitz, M. Lienhard/D-9328-2017; Vanden Berghe, Wim/HGE-4696-2022	Plaisance, Stephane/0000-0002-1651-241X; Plaisance, Stephane/0000-0002-1651-241X; Berghe, Wim Vanden/0000-0003-0161-7355; Schmitz, M. Lienhard/0000-0002-6984-7192; De Bosscher, Karolien/0000-0001-5059-9718				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bellier S, 1997, MOL CELL BIOL, V17, P1434, DOI 10.1128/MCB.17.3.1434; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HAEGEMAN G, 1995, SIGNALLING MECH TRAN, P375; HIRANO T, 1992, RES IMMUNOL, V143, P689; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Keller Evan T., 1996, Frontiers in Bioscience (online), V1, pD340; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PATESTOS NP, 1993, BIOCHIMIE, V75, P1007, DOI 10.1016/0300-9084(93)90153-J; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHOENACKER P, 1994, EUR CYTOKINE NETW, V5, P283; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	47	593	600	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3285	3290		10.1074/jbc.273.6.3285	http://dx.doi.org/10.1074/jbc.273.6.3285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452444	hybrid			2022-12-27	WOS:000071822300029
J	Wang, J; Riedel, H				Wang, J; Riedel, H			Insulin-like growth factor-I receptor and insulin receptor association with a Src homology-2 domain-containing putative adapter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; SIGNAL-TRANSDUCTION; SH2 DOMAIN; GLUT4 TRANSLOCATION; 2-HYBRID SYSTEM; BINDING-SITES; PROTEINS P85; GRB-IR; KINASE; CELLS	Insulin receptor (IR) and the related insulin-like growth factor-I (IGF-I) receptor (IGF-IR) mediate a variety of metabolic and mitogenic cellular responses, some of which may involve unidentified receptor tar gets, A Src homology-a (SH2) domain-coding region of a mouse protein was cloned based on its interaction with IR. It was designated mSH2-B based on its high similarity to an earlier reported rat sequence SH2-B. A role of mSH2-B in IGF-I and insulin action was suggested by the interaction of the SH2 domain with activated IGF-IR and IR catalytic fragments but not with an inactive IR catalytic fragment in the yeast two-hybrid system in vivo and by the hormone-dependent association of a glutathione S-transferase (GST) SH2 domain fusion protein of mSH2-B with both receptors in cell extracts, A comparison of IGF-IR and IR mutants lacking individual Tyr autophosphorylation sites for association with GST; mSH2-B showed that homologous juxtamembrane (IR960/IGF-IR950) and C-terminal (IR1322/IGF-IR1316) receptor motifs were required. Synthetic phosphopeptides representing IR960 and IR1322 competed for GST mSH2-B binding to the receptor, suggesting that both motifs participate in the association with mSH2-B. Antibodies raised against GST mSH2-B identified a cellular protein of 92 kDa that was not found to be phosphorylated on Tyr. It co-immunoprecipitated with IGF-IR or IR, which was strictly dependent on receptor activation, IR and IGF IR Tyr phosphorylation motifs were not identified in the complete SH2-B primary structure, suggesting that it may participate as an adapter rather than a substrate in the IGF-I and insulin signaling pathways.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48202 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Mol Biol Sect, Boston, MA 02215 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Riedel, H (corresponding author), Wayne State Univ, Dept Biol Sci, 2171 BSB,5047 Gullen Mall, Detroit, MI 48202 USA.	hriedel@sun.science.wayne.edu						ANDO A, 1992, J BIOL CHEM, V267, P12788; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Carel K, 1996, ENDOCRINOLOGY, V137, P2362, DOI 10.1210/en.137.6.2362; CARTER WG, 1995, BIOCHEMISTRY-US, V34, P9488, DOI 10.1021/bi00029a025; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAN M, 1995, DIABETES, V44, P1081, DOI 10.2337/diabetes.44.9.1081; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Matozaki T, 1996, CELL SIGNAL, V8, P13, DOI 10.1016/0898-6568(95)02015-2; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MYERS MG, 1991, J BIOL CHEM, V266, P10616; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Najjar SM, 1997, BIOCHEMISTRY-US, V36, P6827, DOI 10.1021/bi962634h; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; RIEDEL H, 1994, J VIROL, V68, P411, DOI 10.1128/JVI.68.1.411-424.1994; Rocchi S, 1996, ENDOCRINOLOGY, V137, P4944, DOI 10.1210/en.137.11.4944; RUBIN R, 1995, LAB INVEST, V73, P311; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; Smith RM, 1997, INT REV CYTOL, V173, P243; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163	48	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3136	3139		10.1074/jbc.273.6.3136	http://dx.doi.org/10.1074/jbc.273.6.3136			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452421	hybrid			2022-12-27	WOS:000071822300006
J	Roy, SK; Yoko-o, T; Ikenaga, H; Jigami, Y				Roy, SK; Yoko-o, T; Ikenaga, H; Jigami, Y			Functional evidence for UDP-galactose transporter in Saccharomyces cerevisiae through the in vivo galactosylation and in vitro transport assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SCHIZOSACCHAROMYCES-POMBE; GUANOSINE DIPHOSPHATASE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; OUTER CHAIN; YEAST; PURIFICATION; VESICLES; GALACTOSYLTRANSFERASE	The oligosaccharide profiles in glycoproteins are determined by a series of processing reactions catalyzed by Golgi glycosyltransferases and glycosidases. Recently in vivo galactose incorporation in Saccharomyces cerevisiae has been demonstrated through the expression of human beta-1,4-galactosyltransferase in an alg1 mutant, suggesting the presence of a UDP-galactose transporter in S. cerevisiae (Schwientek, T., Narimatsu, H., and Ernst, J. F. (1996) J. Biol. Chem. 271, 3398-3405). However, this is quite unexpected, because S. cerevisiae does not have galactose residues in its glycoproteins. To address this question we have constructed S. cerevisiae mnn1 mutant strains expressing Schizosaccharomyces pombe alpha-1,2-galactosyltransferase. The mnn1 mutant of S. cerevisiae provides endogenous accepters for galactose transfer by the expressed alpha-1,2-galactosyltransferase. We present here three lines of evidences for the existence of UDP-galactose transporter in S. cerevisiae. (i) About 15-20% of the total transformed mnn1 cells grown in a galactose medium were stained with fluorescein isothiocyanate-conjugated alpha-galactose-specific lectin, indicating the presence of Lu-galactose residues on the cell surface. (ii) Galactomannan proteins can be precipitated with agarose-immobilized cu-galactose-specific lectin from a whole cell lysate prepared from transformed mnn1 cells grown in a galactose medium. (iii) The presence of UDP-galactose transporter was demonstrated by direct transport assay. This transport in S. cerevisiae is dependent on time, temperature, and protein concentration and is inhibited by nucleotide monophosphate and Triton X-100. The overall UDP-galactose transport in S. cerevisiae is comparable with that in S. pombe, indicating a more or less similar reaction velocity, while the rate of GDP-mannose transport is higher in S. pombe than in S. cerevisiae.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanagawa 236, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Kirin Brewery Company Limited	Jigami, Y (corresponding author), Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.	jigami@nibh.go.jp	Yoko-o, Takehiko/L-7093-2018	Yoko-o, Takehiko/0000-0003-0291-8299				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BALLOU CE, 1994, P NATL ACAD SCI USA, V91, P9327, DOI 10.1073/pnas.91.20.9327; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; BOSSUYT X, 1994, EUR J BIOCHEM, V223, P981, DOI 10.1111/j.1432-1033.1994.tb19076.x; BUSSEY H, 1991, MOL MICROBIOL, V5, P2339, DOI 10.1111/j.1365-2958.1991.tb02079.x; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; CHAPPELL TG, 1994, MOL BIOL CELL, V5, P519, DOI 10.1091/mbc.5.5.519; Eckart MR, 1996, CURR OPIN BIOTECH, V7, P525, DOI 10.1016/S0958-1669(96)80056-5; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; ICHIKAWA Y, 1992, ANAL BIOCHEM, V202, P215, DOI 10.1016/0003-2697(92)90099-S; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLEENE R, 1994, BIOCHEM BIOPH RES CO, V201, P160, DOI 10.1006/bbrc.1994.1683; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREZDORN CH, 1993, EUR J BIOCHEM, V212, P113, DOI 10.1111/j.1432-1033.1993.tb17640.x; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1995, GLYCOPROTEINS, P475; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MASON TL, 1973, J BIOL CHEM, V248, P1346; MUDGAPALLI A, 1994, J BIOL CHEM, V269, P11327; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Odani T, 1996, GLYCOBIOLOGY, V6, P805, DOI 10.1093/glycob/6.8.805; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PEAT S, 1961, J CHEM SOC, P29, DOI 10.1039/jr9610000029; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROY SK, 1989, ENZYME MICROB TECH, V11, P431, DOI 10.1016/0141-0229(89)90138-5; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; Schwientek T, 1996, J BIOL CHEM, V271, P3398; SHERMAN F, 1986, LAB COURSE MANNUAL M; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TRIMBLE RB, 1995, TRENDS GLYCOSCI GLYC, V7, P1, DOI 10.4052/tigg.7.1; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZIEGLER FD, 1994, J BIOL CHEM, V269, P12527	43	27	27	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2583	2590		10.1074/jbc.273.5.2583	http://dx.doi.org/10.1074/jbc.273.5.2583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446560	hybrid			2022-12-27	WOS:000071736600015
J	Stevens, J; Wiesmuller, KH; Barker, PJ; Walden, P; Butcher, GW; Joly, E				Stevens, J; Wiesmuller, KH; Barker, PJ; Walden, P; Butcher, GW; Joly, E			Efficient generation of major histocompatibility complex class I-peptide complexes using synthetic peptide libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; ESCHERICHIA-COLI; HEAVY-CHAIN; 3-DIMENSIONAL STRUCTURE; LONG PEPTIDES; RAT; MOLECULES; TRANSPORTER; TRANSLOCATION; BINDING	The use of synthetic random peptide libraries is a powerful technology for the study of many aspects of antigen presentation and peptide selection by major histocompatibility complex (MHC) molecules, Here we have used them in conjunction with a recombinant system to determine the peptide binding motifs of three classical class I MHC molecules of the laboratory rat: RT1-A(a), RT1-A(u), and RT1-A1(c), Described is a method for producing large amounts of soluble class I heavy and light chains in bacteria, Refolding RT1-A(a) heavy chain (HC) with rat beta(2)-microglobulin (beta(2)m) in the presence of a specific peptide and the subsequent purification of the complex yielded conformationally correct material, This was assessed by gel chromatography, SDS-polyacrylamide gel electrophoresis, isoelectric focussing gel electrophoresis, enzyme-linked immunosorbent assay, and fluorescence-activated cell sorter analysis employing a previously unreported method utilizing a His-Tag affinity silica. By refolding RT1-A(a) RC and rat beta(2)m around a random nonapeptide library and subjecting the resulting complex to acid elution of the bound peptides and pool sequencing, the peptide binding motif for this MHC class I molecule was determined. Results corresponded well with those previously determined from naturally bound peptides and in addition gave a clear and unambiguous signal for the C-terminal anchor residue. This method was then applied to determine the previously undescribed binding motifs for RT1-A(u) and RT1-A1(c), For both molecules, the whole motif was confirmed from naturally bound peptides, We propose this method as an alternative way to obtain the whole class I MHC peptide motif, particularly when a specific antibody is unavailable and/or natural expression of the class I molecule of interest is low.	Babraham Inst, Dept Immunol, Cambridge CB2 4AT, England; Univ Tubingen, Nat Wissensch & Med Inst, D-72762 Reutlingen, Germany; Babraham Inst, Microchem Facil, Cambridge CB2 4AT, England; Humboldt Univ, Dermatol Klin, D-10117 Berlin, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Eberhard Karls University of Tubingen; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Humboldt University of Berlin	Stevens, J (corresponding author), Babraham Inst, Dept Immunol, Cambridge CB2 4AT, England.	james.stevens@bbsrc.ac.uk	Joly, Etienne/A-5644-2009	Joly, Etienne/0000-0002-7264-2681				Bhuyan PK, 1997, J IMMUNOL, V158, P3753; COLLINS EJ, 1995, P NATL ACAD SCI USA, V92, P1218, DOI 10.1073/pnas.92.4.1218; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; Davenport MP, 1997, J EXP MED, V185, P367, DOI 10.1084/jem.185.2.367; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FUKUMOTO T, 1982, EUR J IMMUNOL, V12, P237, DOI 10.1002/eji.1830120313; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HEEMELS MT, 1994, IMMUNITY, V1, P775, DOI 10.1016/S1074-7613(94)80019-7; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; Joly E, 1996, J IMMUNOL, V157, P1551; JOLY E, 1994, IMMUNOGENETICS, V40, P45, DOI 10.1007/BF00163963; JOYCE S, 1994, P NATL ACAD SCI USA, V91, P4145, DOI 10.1073/pnas.91.10.4145; Koopmann JO, 1996, EUR J IMMUNOL, V26, P1720, DOI 10.1002/eji.1830260809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; METZGER JW, 1994, ANAL BIOCHEM, V219, P261, DOI 10.1006/abio.1994.1266; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; PARKER KC, 1992, J BIOL CHEM, V267, P5451; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PEITSCH MC, 1995, TRENDS BIOCHEM SCI, V20, P82, DOI 10.1016/S0968-0004(00)88963-X; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; POWIS SJ, 1993, TRANSPLANT P, V25, P2752; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; Reid SW, 1996, FEBS LETT, V383, P119, DOI 10.1016/0014-5793(96)00226-8; Reizis B, 1997, IMMUNOGENETICS, V45, P278, DOI 10.1007/s002510050204; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; STEPHENSON SP, 1985, J IMMUNOGENET, V12, P101; STET RJM, 1987, TRANSPLANT P, V19, P3004; STEVANOVIC S, 1993, ANAL BIOCHEM, V212, P212, DOI 10.1006/abio.1993.1314; STEVANOVIC S, 1993, BIOORG MED CHEM LETT, V3, P431, DOI 10.1016/S0960-894X(01)80226-2; UDAKA K, 1995, J EXP MED, V181, P2097, DOI 10.1084/jem.181.6.2097; Uebel S, 1997, P NATL ACAD SCI USA, V94, P8976, DOI 10.1073/pnas.94.17.8976; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; Walden P, 1996, CURR OPIN IMMUNOL, V8, P68, DOI 10.1016/S0952-7915(96)80107-5; WALDEN P, 1995, BIOCHEM SOC T, V23, P678, DOI 10.1042/bst0230678; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; [No title captured]	51	32	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2874	2884		10.1074/jbc.273.5.2874	http://dx.doi.org/10.1074/jbc.273.5.2874			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446598	hybrid			2022-12-27	WOS:000071736600053
J	Wang, ZG; Ackerman, SH				Wang, ZG; Ackerman, SH			Mutational studies with Atp12p, a protein required for assembly of the mitochondrial F-1-ATPase in yeast - Identification of domains important for Atp12p function and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; F1-ATPASE; SYNTHASE; SUBUNIT; GENES; F1; DISRUPTION; MECHANISM	The Atp12p protein of Saccharomyces cerevisiae is required for assembly of the F-1 moiety of the mitochondrial ATP synthase, The current work has used mutant forms of Atp12p in an effort to learn about amino acids and/or domains that are important for the action of the protein, In one set of studies, the mutant atp12 genes were cloned and sequenced from 13 independent isolates of chemically mutagenized yeast, Of the 10 different mutant alleles that were identified, 9 (8 nonsense and 1 frameshift) lead to the early termination of the protein. A single missense mutation that substitutes lysine for Glu-289 was identified in two of the atp12 strains. Analysis of several Atp12p variants, each with different substitutions at Glu-289, showed that the functional activity of Atp12p is compromised when non-acidic residues are introduced at position 289 in the sequence, In other work, deletion analysis led to the assignment of two domains in Atp12p; the functional domain of the protein was mapped to the sequence between Gln-181 and Val-306, and a structural domain (Asp-307 through Gln-325) was identified that confers Atp12p the ability to oligomerize with other proteins in mitochondria.	Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Ackerman, SH (corresponding author), Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA.	sackerm@med.wayne.edu			NIGMS NIH HHS [GM48157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; BIANCHET M, 1994, BBA-BIOENERGETICS, V1187, P163, DOI 10.1016/0005-2728(94)90103-1; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BURNS DJ, 1986, J BIOL CHEM, V261, P2066; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUTAI M, 1988, J BIOENERG BIOMEMBR, V20, P41, DOI 10.1007/BF00762137; GIRAUD MF, 1994, EUR J BIOCHEM, V222, P851, DOI 10.1111/j.1432-1033.1994.tb18932.x; GUELIN E, 1993, J BIOL CHEM, V268, P161; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; PAUL MF, 1994, J BIOL CHEM, V269, P26158; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; RICHARME G, 1982, BIOCHEM BIOPH RES CO, V105, P476, DOI 10.1016/0006-291X(82)91459-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; Wang ZG, 1996, J BIOL CHEM, V271, P4887; WHITE M, 1995, ARCH BIOCHEM BIOPHYS, V319, P299, DOI 10.1006/abbi.1995.1296; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	36	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2993	3002		10.1074/jbc.273.5.2993	http://dx.doi.org/10.1074/jbc.273.5.2993			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446613	hybrid			2022-12-27	WOS:000071736600068
J	Warwicker, J				Warwicker, J			Modeling charge interactions and redox properties in DsbA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; FORMATION IN-VIVO; ACTIVE-SITE; IONIZABLE GROUPS; PROTEIN; THIOREDOXIN; ELECTROSTATICS; ISOMERASE; RESIDUES	Accurate prediction of charge interactions in macromolecules presents a significant challenge for computational biology, A model for the low Cys(30) pK(a), and oxidizing power of DsbA (Gane, P.J., Freedman, R. B., and Warwicker, J. (1995) J. Mol. Biol. 249, 376-387) has been investigated experimentally (Hennecke, J., Spleiss, C., and Glockshuber, R. (1997) J. Biol. Chem. 272, 189-195), with substitutions for Glu(37) and Glu(38) and with residues 38-40 removed, Measured changes in Cys(30) pK(a) and redox potential were relatively small and reported to be in contrast to model predictions, It is now shown, particularly with calculations of wild-type:mutant differences for a range of salt concentrations, that the data are consistent with the model and support the key finding that a number of different factors contribute to the oxidizing power of DsbA, so that any particular one need not necessarily be large, A feature of the model is a low protein dielectric, and higher values (which are becoming popular in predictions of pH dependence) are inconsistent with both the difference data and the wild-type Cys(30) pK(a).	Inst Food Res, Reading Lab, Reading RG6 6BZ, Berks, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute	Warwicker, J (corresponding author), Inst Food Res, Reading Lab, Earley Gate,Whiteknights Rd, Reading RG6 6BZ, Berks, England.			Warwicker, Jim/0000-0002-1302-0815				ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BEROZA P, 1991, P NATL ACAD SCI USA, V88, P5804, DOI 10.1073/pnas.88.13.5804; Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; Demchuk E, 1996, J PHYS CHEM-US, V100, P17373, DOI 10.1021/jp960111d; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Hennecke J, 1997, J BIOL CHEM, V272, P189; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hu SH, 1997, J MOL BIOL, V268, P137, DOI 10.1006/jmbi.1997.0940; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Ruddock LW, 1996, BIOCHEM J, V315, P1001, DOI 10.1042/bj3151001; VANGUNSTEREN WF, 1987, GROMOS MANUAL; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WARWICKER J, 1986, J THEOR BIOL, V121, P199, DOI 10.1016/S0022-5193(86)80093-5; WARWICKER J, 1987, PROTEINS, V2, P283, DOI 10.1002/prot.340020404; Warwicker J, 1996, FEBS LETT, V385, P105, DOI 10.1016/0014-5793(96)00358-4; Warwicker J, 1997, PROTEIN ENG, V10, P809, DOI 10.1093/protein/10.7.809	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2501	2504		10.1074/jbc.273.5.2501	http://dx.doi.org/10.1074/jbc.273.5.2501			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446549	hybrid			2022-12-27	WOS:000071736600004
J	Allan, BW; Beechem, JM; Lindstrom, WM; Reich, NO				Allan, BW; Beechem, JM; Lindstrom, WM; Reich, NO			Direct real time observation of base flipping by the EcoRI DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC RECOGNITION; S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; TARGET BASE; MECHANISM; METHYLASE; BINDING; NMR; ADENINE; 2-AMINOPURINE	DNA methyltransferases are excellent prototypes for investigating DNA distortion and enzyme specificity because catalysis requires the extrahelical stabilization of the target base within the enzyme active site, The energetics and kinetics of base flipping by the EcoRI DNA methyltransferase were investigated by two methods, First, equilibrium dissociation constants (K-D(DNA)) were determined for the binding of the methyltransferase to DNA containing abasic sites or base analogs incorporated at the target base. Consistent with a base flipping mechanism, tighter binding-to oligonucleotides containing destabilized target base pairs was observed, Second, total intensity stopped flow fluorescence measurements of DNA containing a-aminopurine allowed presteady-state real time observation of the base flipping transition, Following the rapid formation of an enzyme-DNA collision complex, a biphasic increase in total intensity was observed, The fast phase dominated the total intensity increase with a rate nearly identical to k(methylation) determined by rapid chemical quench-flow techniques (Reich, N. O., and Mashoon, N. (1993) J. Biol. Chem. 268, 9191-9193). The restacking of the extrahelical base also revealed biphasic kinetics with the recovered amplitudes from these off-rate experiments matching very closely to those observed during the base unstacking process, These results provide the first direct and continuous observation of base flipping and show that at least two distinct conformational transitions occurred at the flipped base subsequent to complex formation, Furthermore, our results suggest that the commitment to catalysis during the methylation of the target site is not determined at the level of the chemistry step but rather is mediated by prior intramolecular isomerization within the enzyme-DNA complex.	Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Vanderbilt University	Reich, NO (corresponding author), Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA.	reich@sbmm1.ucsb.edu						Adams GM, 1997, BIOCHEMISTRY-US, V36, P8284, DOI 10.1021/bi961885n; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BLOOM LB, 1993, BIOCHEMISTRY-US, V32, P11247, DOI 10.1021/bi00092a039; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; BRENNAN CA, 1985, NUCLEIC ACIDS RES, V13, P8665, DOI 10.1093/nar/13.24.8665; Cal S, 1996, J BIOL CHEM, V271, P1008, DOI 10.1074/jbc.271.2.1008; CHAZIN WJ, 1991, NUCLEIC ACIDS RES, V19, P5507, DOI 10.1093/nar/19.20.5507; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; COLL M, 1986, J BIOMOL STRUCT DYN, V4, P157, DOI 10.1080/07391102.1986.10506337; Dunkak KS, 1996, ANAL BIOCHEM, V243, P234, DOI 10.1006/abio.1996.0511; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FAZAKERLEY GV, 1985, BIOCHEMISTRY-US, V24, P4540, DOI 10.1021/bi00338a009; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; HO DK, 1991, ARCH BIOCHEM BIOPHYS, V284, P264, DOI 10.1016/0003-9861(91)90294-S; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LYCKSELL PO, 1987, NUCLEIC ACIDS RES, V15, P9011, DOI 10.1093/nar/15.21.9011; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Menger M, 1996, BIOCHEMISTRY-US, V35, P14710, DOI 10.1021/bi960440w; MOE JG, 1992, BIOCHEMISTRY-US, V31, P8421, DOI 10.1021/bi00151a005; NORDLUND TM, 1989, BIOCHEMISTRY-US, V28, P9095, DOI 10.1021/bi00449a021; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; POGOLOTTI AL, 1988, J BIOL CHEM, V263, P7461; QUIGNARD E, 1985, EUR J BIOCHEM, V152, P99, DOI 10.1111/j.1432-1033.1985.tb09168.x; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V91, P10957; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1992, J BIOL CHEM, V267, P15802; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REICH NO, 1992, BIOCHEMISTRY-US, V31, P1937, DOI 10.1021/bi00122a006; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Sastry SS, 1996, BIOCHEMISTRY-US, V35, P15715, DOI 10.1021/bi960729d; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WARD DC, 1969, J BIOL CHEM, V244, P1228; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	51	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2368	2373		10.1074/jbc.273.4.2368	http://dx.doi.org/10.1074/jbc.273.4.2368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442083	hybrid			2022-12-27	WOS:000071595200072
J	Baskakov, I; Bolen, DW				Baskakov, I; Bolen, DW			Forcing thermodynamically unfolded proteins to fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSACTIVATION DOMAIN; CONFORMATION; DNA; RIBONUCLEASE-T1; ISOMERIZATION; SOLUBILITY; OSMOLYTE; BINDING; ALPHA	A growing number of biologically important proteins have been identified as fully unfolded or partially disordered, Thus, an intriguing question is whether such proteins can be forced to fold by adding solutes found in the cells of some organisms, Nature has not ignored the powerful effect that the solution can have on protein stability and has developed the strategy of using specific solutes (called organic osmolytes) to maintain the structure and function cellular proteins in organisms exposed to denaturing environmental stresses (Yancey, P. H., Clark, M. E., Hand, S. C., Bowlus, R. D., and Somero, G. N. (1982) Science 217, 1214-1222), Here, we illustrate the extraordinary capability of one such osmolyte, trimethylamine N-oxide (TMAO), to force two thermodynamically unfolded proteins to fold to nativelike species having significant functional activity, In one of these examples, TMAO is shown to increase the population of native state relative to the denatured ensemble by nearly five orders of magnitude, The ability of TMAO to force thermodynamically unstable proteins to fold presents an opportunity for structure determination and functional studies of an important emerging class of proteins that have little or no structure without the presence of TMAO.	Univ Texas, Med Branch, Sealy Ctr Struct Biol, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Bolen, DW (corresponding author), Univ Texas, Med Branch, Sealy Ctr Struct Biol, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	wbolen@hbcg.utmb.edu			PHS HHS [49760] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; BUCHE A, 1993, J BIOMOL STRUCT DYN, V11, P95, DOI 10.1080/07391102.1993.10508712; Cho HS, 1996, PROTEIN SCI, V5, P262; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GAST K, 1995, BIOCHEMISTRY-US, V34, P13211, DOI 10.1021/bi00040a037; HOY MV, 1993, CELL, V72, P587; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; MUCKE M, 1992, BIOCHEMISTRY-US, V31, P7848; Nelson JC, 1997, SCIENCE, V277, P1793, DOI 10.1126/science.277.5333.1793; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OOBATAKE M, 1979, J BIOCHEM-TOKYO, V86, P65; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PACE CN, 1988, J BIOL CHEM, V263, P11820; Pan B, 1997, PROTEIN SCI, V6, P1237, DOI 10.1002/pro.5560060612; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TIMASHEFF SN, 1970, ACCOUNTS CHEM RES, V3, P62, DOI 10.1021/ar50026a004; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zurdo J, 1997, BIOCHEMISTRY-US, V36, P9625, DOI 10.1021/bi9702400	31	304	315	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4831	4834		10.1074/jbc.273.9.4831	http://dx.doi.org/10.1074/jbc.273.9.4831			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478922	hybrid			2022-12-27	WOS:000072310400006
J	Kulzer, R; Pils, T; Kappl, R; Huttermann, J; Knappe, J				Kulzer, R; Pils, T; Kappl, R; Huttermann, J; Knappe, J			Reconstitution and characterization of the polynuclear iron-sulfur cluster in pyruvate formate-lyase-activating enzyme - Molecular properties of the holoenzyme form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; PROTEIN; GLYCINE-734; ACONITASE; FE3S4	The glycyl radical (Gly-734) contained in the active form of pyruvate formate-lyase (PFL) of Escherichia coli is generated by the S-adenosylmethionine-dependent pyruvate formate-lyase-activating enzyme (PFL activase), A 5'-deoxyadenosyl radical intermediate produced by the activase has been suggested as the species that abstracts the pro-S hydrogen of the glycine 734 residue in PFL (Frey, M., Rothe, M., Wagner, A. F. V., and Knappe, J. (1994) J. Biol. Chem. 269, 12432-12437). To enable mechanistic investigations of this system we have worked out a convenient large scale preparation of functionally competent PFL activase from its apoform, The previously inferred metallic cofactor was identified as redox-interconvertible polynuclear iron-sulfur cluster, most probably of the [4Fe-4S] type, according to W-visible and EPR spectroscopic information, Cys --> Ser replacements by site-directed mutagenesis determined Cys-29, Cys-33, and Cys-36 to be essential to yield active holoenzyme, Gel filtration chromatography showed a monomeric structure (28 kDa) for both the apoenzyme and holoenzyme form, The iron-sulfur cluster complement proved to be a prerequisite for effective binding of adenosylmethionine, which induces a characteristic shift of the EPR signal shape of the reduced enzyme form ([4Fe-4S](+)) from axial to rhombic symmetry.	Univ Heidelberg, Inst Biol Chem, D-69120 Heidelberg, Germany; Univ Saarland, Inst Biophys & Phys Grundlagen Med, D-66421 Homburg, Germany	Ruprecht Karls University Heidelberg; Saarland University	Knappe, J (corresponding author), Univ Heidelberg, Inst Biol Chem, Neuenheimer Feld 501, D-69120 Heidelberg, Germany.	knappe@sun0.urz.uni-heidelberg.de		Kappl, Reinhard/0000-0003-0223-6642				Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; DEPAMPHILIS BV, 1974, J AM CHEM SOC, V96, P4159, DOI 10.1021/ja00820a017; FREY M, 1994, J BIOL CHEM, V269, P12432; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; HAGEN KS, 1983, J AM CHEM SOC, V105, P3905, DOI 10.1021/ja00350a028; KING TE, 1967, METHOD ENZYMOL, V10, P634; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KNAPPE J, 1974, EUR J BIOCHEM, V50, P253, DOI 10.1111/j.1432-1033.1974.tb03894.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNAPPE J, 1993, BIOCHEM SOC T, V21, P731, DOI 10.1042/bst0210731; Knappe J, 1975, Methods Enzymol, V41, P508; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; PARAST CV, 1995, BIOCHEMISTRY-US, V34, P2393, DOI 10.1021/bi00008a001; Penefsky H S, 1979, Methods Enzymol, V56, P527; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; RODEL W, 1988, EUR J BIOCHEM, V177, P151; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; SAYERS JR, 1991, DIRECTED MUTAGENESIS, P49; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SURERUS KK, 1989, P NATL ACAD SCI USA, V86, P9846, DOI 10.1073/pnas.86.24.9846; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WONG KK, 1993, BIOCHEMISTRY-US, V32, P14102, DOI 10.1021/bi00214a005; YOUNG P, 1994, J BIOL CHEM, V269, P27815	28	125	125	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4897	4903		10.1074/jbc.273.9.4897	http://dx.doi.org/10.1074/jbc.273.9.4897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478932	hybrid			2022-12-27	WOS:000072310400016
J	Mustafa, SB; Olson, MS				Mustafa, SB; Olson, MS			Expression of nitric-oxide synthase in rat Kupffer cells is regulated by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYCLIC-AMP; BACTERIAL LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; ACTIVATION; INDUCTION	Treatment of cultured rat Kupffer cells with lipopolysaccharide (LPS) resulted in a time-dependent increase in the expression of the inducible isoform of nitric-oxide synthase (iNOS). Agents that elevated intracellular cAMP levels (e.g, forskolin, dibutyryl cAMP, cholera toxin, and isoproterenol) markedly decreased nitrite production and iNOS protein formation by LPS-stimulated Kupffer cells, Furthermore, inhibition of LPS-induced nitrite formation and iNOS protein levels by these agents was enhanced in the presence of the phosphodiesterase inhibitor 5-isobutyl-1-methylxanthine. Forskolin, the most potent inhibitor of LPS-induced nitrite formation by Kupffer cells, decreased iNOS mRNA levels in a time-dependent manner. Time course studies indicated that forskolin was most effective at inhibiting LPS-induced nitrite formation and iNOS mRNA levels by Kupffer cells when added before LPS. Message stability studies established that forskolin did not enhance the rate of decay of LPS-induced iNOS mRNA Nuclear run-on assays revealed that forskolin decreased LPS-induced transcription of the iNOS gene, Treatment of Kupffer cells with LPS induced the translocation of the p65 subunit of nuclear factor kappa B (NF-kappa B) into the nucleus, and this process was abolished by forskolin, In addition, the LPS-dependent degradation of I kappa B alpha was not observed in forskolin-treated cells; the levels of the p65 subunit of NF-kappa B were minimal in the nucleus at the same time. Also, we observed that forskolin induced transcription of the I kappa B alpha gene in a time-dependent manner and in addition up-regulated LPS-induced I kappa B alpha mRNA levels. Taken together, this study indicates that the attenuation of LPS-induced iNOS formation in Kupffer cells by elevated intracellular cAMP levels occurs by preventing the degradation of I kappa B alpha which suppresses the activation of NF-kappa B and inhibits the onset of transcription of the iNOS gene.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Olson, MS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NIDDK NIH HHS [DK-33538] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033538] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bellezzo JM, 1996, AM J PHYSIOL-GASTR L, V270, pG956, DOI 10.1152/ajpgi.1996.270.6.G956; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BULUT V, 1993, BIOCHEM BIOPH RES CO, V195, P1134, DOI 10.1006/bbrc.1993.2162; CHAO W, 1990, J BIOL CHEM, V265, P17576; CURRAN RD, 1990, ANN SURG, V212, P462, DOI 10.1097/00000658-199010000-00009; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; Essani NA, 1996, J IMMUNOL, V156, P2956; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Grisham MB, 1996, METHOD ENZYMOL, V268, P237; HARBRECHT BG, 1995, ENDOTHELIUM, V3, pS95; Ikeda K, 1996, PHYSIOL CHEM PHYS, V28, P239; Jeon YJ, 1996, MOL PHARMACOL, V50, P334; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KUNZ D, 1994, BIOCHEM J, V304, P337, DOI 10.1042/bj3040337; Kurose I, 1997, J CLIN INVEST, V99, P867, DOI 10.1172/JCI119251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKIN DL, 1995, HEPATOLOGY, V22, P223, DOI 10.1002/hep.1840220133; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUSTAFA SB, 1996, HEPATOLOGY, V23, P1662; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NeuschwanderTetri BA, 1996, BIOCHEM J, V320, P1005, DOI 10.1042/bj3201005; Nisoli E, 1997, ENDOCRINOLOGY, V138, P676, DOI 10.1210/en.138.2.676; NUSSLER AK, 1995, HEPATOLOGY, V21, P1552, DOI 10.1016/0270-9139(95)90459-X; Oddis CV, 1995, AM J PHYSIOL-HEART C, V269, pH2044, DOI 10.1152/ajpheart.1995.269.6.H2044; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Szabo C, 1997, IMMUNOLOGY, V90, P95, DOI 10.1046/j.1365-2567.1997.00137.x; SZABO C, 1993, CIRC RES, V73, P991, DOI 10.1161/01.RES.73.6.991; TRANTHI TA, 1995, HEPATOLOGY, V22, P613, DOI 10.1016/0270-9139(95)90587-1; WANG MH, 1994, J BIOL CHEM, V269, P14027; West M A, 1996, New Horiz, V4, P168; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	45	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5073	5080		10.1074/jbc.273.9.5073	http://dx.doi.org/10.1074/jbc.273.9.5073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478958	hybrid			2022-12-27	WOS:000072310400042
J	Bae, YS; Cantley, LG; Chen, CS; Kim, SR; Kwon, KS; Rhee, SG				Bae, YS; Cantley, LG; Chen, CS; Kim, SR; Kwon, KS; Rhee, SG			Activation of phospholipase C-gamma by phosphatidylinositol 3,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE-3 KINASE; 3-KINASE; SYSTEM; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; PHOSPHATES; WORTMANNIN; RECEPTOR; DOMAINS; CLONING	Signal transduction across cell membranes often involves the activation of both phosphatidylinositol (PI)-specific phospholipase C (PLC) and phosphoinositide 3-kinase (PI 3-kinase). Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2), a substrate for both enzymes, is converted to phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3) by the action of PI 3-kinase. Here, we show that PI(3,4,5)P-3 activates purified PLC-gamma isozymes by interacting with their Src homology 2 domains, Furthermore, the expression of an activated catalytic subunit of PI 3-kinase in COS-7 cells resulted in an increase in inositol phosphate formation, whereas platelet-derived growth factor-induced PLC activation in NIH 3T3 cells was markedly inhibited by the specific PI 3-kinase inhibitor LY294002. These results suggest that receptors coupled to PI 3-kinase may activate PLC-gamma isozymes indirectly, in the absence of PLC-gamma tyrosine phosphorylation, through the generation of PI(3,4,5)P-3.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02115 USA; Univ Kentucky, Coll Pharm, Div Med Chem & Pharmaceut, Lexington, KY 40506 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Kentucky	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 3,Rm 122,3 Ctr Dr,MSC 0320, Bethesda, MD 20892 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48871] Funding Source: Medline; NIGMS NIH HHS [GM53448] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER S, 1995, MOL BIOL CELL, V6, P1145; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; FALASCA M, 1998, IN PRESS EMBO J; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1994, J BIOL CHEM, V269, P6528; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PARK D, 1992, J BIOL CHEM, V267, P16048; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOKER A, 1994, J BIOL CHEM, V269, P32358; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x	34	292	296	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4465	4469		10.1074/jbc.273.8.4465	http://dx.doi.org/10.1074/jbc.273.8.4465			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468499	hybrid			2022-12-27	WOS:000072115000027
J	Knodler, LA; Sekyere, EO; Stewart, TS; Schofield, PJ; Edwards, MR				Knodler, LA; Sekyere, EO; Stewart, TS; Schofield, PJ; Edwards, MR			Cloning and expression of a prokaryotic enzyme, arginine deiminase, from a primitive eukaryote Giardia intestinalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT GLUTAMATE-DEHYDROGENASE; TRICHOMONAS-VAGINALIS; MYCOPLASMA-ARGININI; NUCLEOTIDE-SEQUENCE; LAMBLIA; GENE; METABOLISM; PATHWAY; LOCALIZATION; CATABOLISM	Arginine deiminase (EC 3.5.3.6) catalyzes the irreversible catabolisn: of arginine to citrulline in the arginine dihydrolase pathway, This pathway has been regarded as restricted to prokaryotic organisms but if an important source of energy to the primitive protozoan Giardia intestinalis. In this paper we report the cloning and expression of the arginine deiminase gene from this parasite, Degenerate oligonucleotides based on amino acid sequences of tryptic peptides from the purified protein were used to amplify a portion of the arginine deiminase gene. This was then used as a probe to screen HindIII and PstI "mini" libraries to obtain two overlapping clones that contained the arginine deiminase gene, The open reading frame encoded 581 amino acids including all of the tryptic peptides that were sequenced and corresponded to a molecular mass of 67 kDa. Northern blot analysis identified a single 1.8-kilobase transcript in both trophozoites and encysting cells. Arginine deiminase was successfully expressed in Escherichia coli and purified to homogeneity. The recombinant protein was found to have characteristics comparable with those of the native enzyme.	Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Edwards, MR (corresponding author), Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia.	m.edwards@unsw.edu.au		Knodler, Leigh/0000-0002-3028-2198				BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; EDWARDS MR, 1992, MOL BIOCHEM PARASIT, V53, P97, DOI 10.1016/0166-6851(92)90011-8; HARASAWA R, 1992, MICROBIOL IMMUNOL, V36, P661, DOI 10.1111/j.1348-0421.1992.tb02068.x; KABNICK KS, 1991, AM SCI, V79, P34; Knodler LA, 1997, EXP PARASITOL, V85, P77, DOI 10.1006/expr.1996.4099; KNODLER LA, 1995, MICROBIOL-UK, V141, P2063, DOI 10.1099/13500872-141-9-2063; KNODLER LA, 1994, EXP PARASITOL, V79, P117, DOI 10.1006/expr.1994.1071; KONDO K, 1990, MOL GEN GENET, V221, P81, DOI 10.1007/BF00280371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSTEAD D, 1983, MOL BIOCHEM PARASIT, V8, P241, DOI 10.1016/0166-6851(83)90046-4; MISAWA S, 1994, J BIOTECHNOL, V36, P145, DOI 10.1016/0168-1656(94)90050-7; OHNO T, 1990, INFECT IMMUN, V58, P3788, DOI 10.1128/IAI.58.11.3788-3795.1990; PEATTIE DA, 1989, J CELL BIOL, V109, P2323, DOI 10.1083/jcb.109.5.2323; Que XC, 1996, MOL BIOCHEM PARASIT, V81, P101, DOI 10.1016/0166-6851(96)02698-9; SCHOFIELD PJ, 1992, MOL BIOCHEM PARASIT, V51, P29, DOI 10.1016/0166-6851(92)90197-R; SCHOFIELD PJ, 1991, MOL BIOCHEM PARASIT, V45, P39, DOI 10.1016/0166-6851(91)90025-2; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; UPCROFT JA, 1993, INT J PARASITOL, V23, P609, DOI 10.1016/0020-7519(93)90167-W; YARLETT N, 1994, J EUKARYOT MICROBIOL, V41, P554, DOI 10.1111/j.1550-7408.1994.tb01516.x; YEE J, 1992, J BIOL CHEM, V267, P7539; YEE J, 1994, SYST APPL MICROBIOL, V16, P759, DOI 10.1016/S0723-2020(11)80350-4	22	66	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4470	4477		10.1074/jbc.273.8.4470	http://dx.doi.org/10.1074/jbc.273.8.4470			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468500	hybrid			2022-12-27	WOS:000072115000028
J	Martin, DA; Siegel, RM; Zheng, LX; Lenardo, MJ				Martin, DA; Siegel, RM; Zheng, LX; Lenardo, MJ			Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACH alpha 1) death signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOPROLIFERATIVE SYNDROME; INDUCED APOPTOSIS; CRYSTAL-STRUCTURE; CD95 FAS/APO-1; T-CELLS; PROTEASE; RECEPTOR; FAS; PROTEINS; DOMAIN	Many forms of apoptosis, including that caused by the death receptor CD95/Fas/APO-1, depend on the activation of caspases, which are proteases that cleave specific intracellular proteins to cause orderly cellular disintegration. The requirements for activating these. crucial enzymatic mediators of death are not well understood. Using molecular chimeras with either CD8 or Tac, we find that oligomerization at the cell membrane powerfully induces caspase-8 autoactivation and apoptosis. Death induction was abrogated by the z-VAD-fmk, z-IETD-fmk, or p35 enzyme inhibitors or by a mutation in the active site cysteine but was surprisingly unaffected by death inhibitor Bcl-2, Amino acid substitutions that prevent the proteolytic separation of the caspase from its membrane-associated domain completely blocked apoptosis. Thus, oligomerization at the membrane is sufficient for caspase-8 autoactivation, but apoptosis could involve a death signal conveyed by the proteolytic release of the enzyme into the cytoplasm.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lenardo, MJ (corresponding author), NIAID, Immunol Lab, NIH, Rm 11N311,Bldg 10,10 Ctr Dr,MSC1892, Bethesda, MD 20892 USA.	lenardo@nih.gov	Siegel, Richard/C-7592-2009	Siegel, Richard/0000-0001-5953-9893				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brinkmann U, 1997, APOPTOSIS, V2, P192, DOI 10.1023/A:1026468532413; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hu SM, 1997, J BIOL CHEM, V272, P9621; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LACAL PM, 1988, ONCOGENE, V2, P533; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEMON SA, 1995, J IMMUNOL, V155, P4644; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Tomita Y, 1996, INT J CANCER, V68, P132, DOI 10.1002/(SICI)1097-0215(19960927)68:1<132::AID-IJC23>3.0.CO;2-C; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	32	314	336	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4345	4349		10.1074/jbc.273.8.4345	http://dx.doi.org/10.1074/jbc.273.8.4345			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468483	hybrid			2022-12-27	WOS:000072115000011
J	English, JM; Pearson, G; Baer, R; Cobb, MH				English, JM; Pearson, G; Baer, R; Cobb, MH			Identification of substrates and regulators of mitogen-activated protein kinase ERK5 using chimeric protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHOSPHORYLATION SITES; MYC; PATHWAYS; CASCADES; INSULIN; FAMILY; YEAST; CELLS; AUTOPHOSPHORYLATION	Extracellular signal-regulated protein kinase 5 (ERK5) is a recently discovered orphan mitogen-activated protein kinase for which no substrates or strong activators have? been described. Two ERK5 chimeras were created as a novel approach to discover its substrates and upstream regulators, One chimeric protein contained the N-terminal domain of the ERK5 catalytic core (subdomains I-IV) and the C-terminal domain of the ERK2 catalytic core (subdomains V-XI), This chimera a was highly responsive to stimuli that regulate ERK2 in vitro and in cells, A second chimeric protein consisted of the N-terminal domain of ERK2 (subdomains I-IV) and the C-terminal domain of the ERK5 catalytic core (subdomains V-XI). This chimera was activated in bacteria by coexpression with a constitutively active mutant of MEK1. Using the activated chimera, we identified three in vitro substrates of ERK5, Assaying ERK5 activity in immune complexes with one of these substrates, c-Myc, wet determined that the ERK5 catalytic domain is activated by V-12 H-Ras and to a lesser extent by phorbol ester but not by constitutively active mutants of Raf-1. Thus, ERK5 is a target of a novel Ras effector pathway that may communicate with c-Myc.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [T32CA066187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA66187] Funding Source: Medline; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEWIS TS, IN PRESS ADV CANC RE; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; XIA Y, 1994, ONCOGENE, V9, P1437; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	64	134	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3854	3860		10.1074/jbc.273.7.3854	http://dx.doi.org/10.1074/jbc.273.7.3854			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461566	hybrid			2022-12-27	WOS:000072048400008
J	Hata, K; Ito, T; Takeshige, K; Sumimoto, H				Hata, K; Ito, T; Takeshige, K; Sumimoto, H			Anionic amphiphile-independent activation of the phagocyte NADPH oxidase in a cell-free system by p47(phox) and p67(phox), both in C terminally truncated forms - Implication for regulatory Src homology 3 domain-mediated interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SUPEROXIDE PRODUCTION; SH3 DOMAINS; COMPONENT P47(PHOX); PROTEIN-KINASE; P67-PHOX; BINDING; COMPLEX	Anionic amphiphiles, such as arachidonate, activate the superoxide-producing phagocyte NADPH oxidase in a cell-free system with human neutrophil membrane, which contains cytochrome b(558) comprising gp91(phox) and p22(phox), and three cytosolic proteins: p47(phox) and p67(phox), each harboring two SH3 domains, and the small GTPase Rac. Here we show that, even without the amphiphiles, the oxidase is activated in vitro by a C terminally truncated p47(phox)., retaining the N-terminal and the two SH3 domains, and the N terminus of p67(phox). When either truncated p47(phox) or, p67(phox) is replaced by the respective full-length one, the activation absolutely requires the amphiphiles. The results indicate that both p47(phox) and p67(phox) are the primary targets of the amphiphiles, and that their C-terminal regions play negative regulatory roles. We also find that the truncated p47(phox), but not the full-length one, can bind to p22(phox), a binding required for the oxidase activation. The N-terminal SH3 domain of p47(phox) is responsible for the binding not only to p22(phox), but also to the p47(phox) C terminus. Thus the SH3 domain is accessible in the active p47(phox) but is normally masked in the full-length one probably via intramolecularly interacting with the C terminus. The present findings support our previous proposal of regulatory SH3 domain-mediated interactions.	Kyushu Univ, Sch Med, Dept Biochem, Higashi Ku, Fukuoka 81282, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 108, Japan	Kyushu University; University of Tokyo	Sumimoto, H (corresponding author), Kyushu Univ, Sch Med, Dept Biochem, Higashi Ku, 3-1-1 Maidashi, Fukuoka 81282, Japan.	hsumi@mailserver.med.kyushu-u.ac.jp		Ito, Takashi/0000-0001-6097-2803				Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHEN JK, 1995, ANGEW CHEM INT EDIT, V34, P953, DOI 10.1002/anie.199509531; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS AR, 1990, FREE RADICAL BIO MED, V8, P71, DOI 10.1016/0891-5849(90)90147-B; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; NISHIMOTO Y, 1997, J BIOL CHEM, V272, P18834; Park JW, 1997, J BIOL CHEM, V272, P11035; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Roos D, 1996, BLOOD, V87, P1663; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Sumimoto H, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P235; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Wang DS, 1996, P NATL ACAD SCI USA, V93, P13182, DOI 10.1073/pnas.93.23.13182; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	40	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4232	4236		10.1074/jbc.273.7.4232	http://dx.doi.org/10.1074/jbc.273.7.4232			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461621	hybrid			2022-12-27	WOS:000072048400063
J	Spangler, NJ; Meyers, MR; Gierke, KL; Kerby, RL; Roberts, GP; Ludden, PW				Spangler, NJ; Meyers, MR; Gierke, KL; Kerby, RL; Roberts, GP; Ludden, PW			Substitution of valine for histidine 265 in carbon monoxide dehydrogenase from Rhodospirillum rubrum affects activity and spectroscopic states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; CLOSTRIDIUM-THERMOACETICUM; COA SYNTHASE; NICKEL; SITE; IDENTIFICATION; ACTIVATION; SEQUENCE; CLUSTER; CYANIDE	In carbon monoxide dehydrogenase (CODH) from Rhodospirillum rubrum, histidine 265 was replaced with valine by site-directed mutagenesis of the cooS gene, The altered form of CODH (H265V) had a low nickel content and a dramatically reduced level of catalytic activity, Although treatment with NiCl2 and CoCl2 increased the activity of H265V CODH by severalfold, activity levels remained more than 1000-fold lower than that of wild-type CODH. Histidine 265 was not essential for the formation and stability of the Fe4S4 clusters, The K-m and K-D for CO as well as the K-D for cyanide were relatively unchanged as a result of the amino acid substitution in CODH. The time-dependent reduction of the [Fe4S4](2+) clusters by CO occurred on a time scale of hours, suggesting that, as a consequence of the mutation, a rate-limiting step had been introduced prior to the transfer of electrons from CO to the cubanes in centers B and C. EPR spectra of H265V CODH lacked the g(av) = 1.86 and g(av) = 1.87 signals characteristic of reduced forms of the active site (center C) of wild-type CODH, This indicates that the electronic properties of center C have been modified possibly by the disruption or alteration of the ligand-mediated interaction between the nickel site and Fe4S4 chromophore.	Univ Wisconsin, Dept Biochem, Coll Agr & Life Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Coll Agr & Life Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Dept Biochem, Coll Agr & Life Sci, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson ME, 1996, BIOCHEMISTRY-US, V35, P8371, DOI 10.1021/bi952902w; ANDERSON ME, 1993, J AM CHEM SOC, V115, P12204, DOI 10.1021/ja00078a085; BONAM D, 1988, P NATL ACAD SCI USA, V85, P31, DOI 10.1073/pnas.85.1.31; BONAM D, 1987, J BIOL CHEM, V262, P2980; BONAM D, 1984, J BACTERIOL, V159, P693, DOI 10.1128/JB.159.2.693-699.1984; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGGEN RIL, 1991, J BIOL CHEM, V266, P6883; ENSIGN SA, 1990, BIOCHEMISTRY-US, V29, P2162, DOI 10.1021/bi00460a029; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4973, DOI 10.1021/bi00438a011; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4968, DOI 10.1021/bi00438a010; ENSIGN SA, 1995, BIOCHEMISTRY-US, V34, P5372, DOI 10.1021/bi00016a008; ENSIGN SA, 1991, J BIOL CHEM, V266, P18395; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MaupinFurlow JA, 1996, J BACTERIOL, V178, P6849, DOI 10.1128/jb.178.23.6849-6856.1996; MORTON TA, 1991, J BIOL CHEM, V266, P23824; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; Seravalli J, 1997, BIOCHEMISTRY-US, V36, P11241, DOI 10.1021/bi970590m; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spangler NJ, 1996, J BIOL CHEM, V271, P7973, DOI 10.1074/jbc.271.14.7973; STEPHENS PJ, 1989, J BIOL CHEM, V264, P16347; TAN GO, 1992, P NATL ACAD SCI USA, V89, P4427, DOI 10.1073/pnas.89.10.4427; XIA JQ, 1995, BIOCHEMISTRY-US, V34, P6037, DOI 10.1021/bi00018a005; Zhang YP, 1996, J BACTERIOL, V178, P2948, DOI 10.1128/jb.178.10.2948-2953.1996	28	27	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4059	4064		10.1074/jbc.273.7.4059	http://dx.doi.org/10.1074/jbc.273.7.4059			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461598	hybrid			2022-12-27	WOS:000072048400040
J	Turner, PR; Mefford, S; Bambino, T; Nissenson, RA				Turner, PR; Mefford, S; Bambino, T; Nissenson, RA			Transmembrane residues together with the amino terminus limit the response of the parathyroid hormone (PTH) 2 receptor to PTH-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LINKED RECEPTOR; EXPRESSION; ACTIVATION; BINDING	The mechanisms of ligand binding and receptor activation for G-protein-coupled receptors in the secretin/parathyroid hormone (PTH) receptor subfamily are not understood, The PTH1 receptor (PTH1R) signals in response to both PTH and parathyroid hormone-related peptide (PTHrP), whereas the PTH2 receptor (PTH2R) responds only to PTB, not to PTHrP, To locate PTHrP discriminatory domains in the PTH2R, we generated PTH1R/PTH2R chimeras in which the extracellular ami no-terminal domains were exchanged. Production of cAMP in response to 1 mu M PTHrP or PTH was identical in cells expressing the PTH1R with the PTH2R amino terminus and in cells expressing the PTH2R with the PTH1R amino terminus. The ability of the chimeric receptor with the PTH2R amino terminus to respond fully to PTHrP showed that the body of the PTH2R, must contain sites that limit the response to PTHrP. Mutations to PTH1R sequence were therefore made in each of the seven transmembrane domains of the PTH2R. Mutations in transmembrane domains 3 and 7 resulted in receptors able to respond to PTHrP Thus, residues in more than one domain form a barrier or filter, allowing the receptor to discriminate between different ligands.	Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Turner, PR (corresponding author), Univ Calif San Francisco, Vet Affairs Med Ctr, Endocrine Unit, 111N,4150 Clement St, San Francisco, CA 94121 USA.				NIDDK NIH HHS [DK 35323] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035323] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Behar V, 1996, ENDOCRINOLOGY, V137, P2748, DOI 10.1210/en.137.7.2748; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; NISSENSON RA, 1985, CANCER RES, V45, P5358; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Schipani E, 1997, MOL ENDOCRINOL, V11, P851, DOI 10.1210/me.11.7.851; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	16	47	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3830	3837		10.1074/jbc.273.7.3830	http://dx.doi.org/10.1074/jbc.273.7.3830			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461563	hybrid			2022-12-27	WOS:000072048400005
J	Caspi, S; Halimi, M; Yanai, A; Ben Sasson, S; Taraboulos, A; Gabizon, R				Caspi, S; Halimi, M; Yanai, A; Ben Sasson, S; Taraboulos, A; Gabizon, R			The anti-prion activity of Congo red - Putative mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; NEURO-BLASTOMA CELLS; CULTURED-CELLS; CONFORMATIONAL TRANSITIONS; NEUROBLASTOMA-CELLS; AGENT REPLICATION; PRP ACCUMULATION; SCRAPIE PRIONS; INCUBATION PERIOD; PROTEIN	PrPSc, an abnormal conformational isoform of the normal prion protein, PrPC, is the only known component of the prion, a proteinacious agent that causes fatal neurodegenerative disorders in humans and other animals. The hallmark properties of PrPSc are its insolubility in nondenaturing detergents and its resistance to digestion by proteases. Anions such as Congo red (CR) have been shown to reduce the accumulation of PrPSc in a neuroblastoma cell line permanently infected with prions as well as to delay disease onset in rodents when administrated prophylactically. The mechanism by which such anti prion agents operate is unknown. We show here that in vitro incubation with CR renders native PrPSc resistant to denaturation by boiling SDS, This resulted from PrPSc conformation, since neither the properties of PrPC nor those of predenatured PrPSc were changed by the addition of CR. CR-PrPSc could only be denatured by the addition of acidic 3 M guanidine thiocyanate. Since in vitro conversion experiments have suggested that partial denaturation may be required for PrPSc to serve as template in the PrPC --> PrPSc conversion, we propose that CR inhibits prion propagation by overstabilizing the conformation of PrPSc molecules.	Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Gabizon, R (corresponding author), Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel.	gabizonr@hadassah.org.il		Yanai, Anat/0000-0002-0792-6901				BALDWIN MA, 1995, J BIOL CHEM, V270, P19197, DOI 10.1074/jbc.270.33.19197; BARRY RA, 1986, J INFECT DIS, V154, P518, DOI 10.1093/infdis/154.3.518; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1994, ANN NY ACAD SCI, V724, P290, DOI 10.1111/j.1749-6632.1994.tb38918.x; CAUGHEY B, 1994, PHILOS T R SOC B, V343, P399, DOI 10.1098/rstb.1994.0035; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1993, J VIROL, V67, P6270, DOI 10.1128/JVI.67.10.6270-6272.1993; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Harrison PM, 1997, CURR OPIN STRUC BIOL, V7, P53, DOI 10.1016/S0959-440X(97)80007-3; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lindquist S, 1995, COLD SPRING HARB SYM, V60, P451, DOI 10.1101/SQB.1995.060.01.050; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1994, PHILOS T R SOC B, V343, P443, DOI 10.1098/rstb.1994.0042; Ovadia H, 1996, J BIOL CHEM, V271, P16856, DOI 10.1074/jbc.271.28.16856; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; PRIOLA SA, 1994, INFECT AGENT DIS, V3, P54; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1996, CURR TOP MICROBIOL, V207, P1; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; Safar J, 1996, CURR TOP MICROBIOL, V207, P69; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SNOW AD, 1990, LAB INVEST, V63, P601; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; TASHIMA T, 1986, BRAIN RES, V399, P80, DOI 10.1016/0006-8993(86)90602-5; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Wille H, 1996, J MOL BIOL, V259, P608, DOI 10.1006/jmbi.1996.0343	52	112	119	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3484	3489		10.1074/jbc.273.6.3484	http://dx.doi.org/10.1074/jbc.273.6.3484			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452472	hybrid			2022-12-27	WOS:000071822300057
J	Redwood, C; Davies, SL; Wells, NJ; Fry, AM; Hickson, ID				Redwood, C; Davies, SL; Wells, NJ; Fry, AM; Hickson, ID			Casein kinase II stabilizes the activity of human topoisomerase II alpha in a phosphorylation-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; CYCLE-DEPENDENT PHOSPHORYLATION; DNA TOPOISOMERASE; CELL-CYCLE; IN-VITRO; SACCHAROMYCES-CEREVISIAE; MOLECULAR-COMPLEX; GROWTH-STATE; YEAST TOP2; M-PHASE	Previous reports have indicated that topoisomerase II (topo II) co-purifies with and is a substrate for casein kinase II. We have carried out a detailed study of the effect that purified casein kinase II has on the activity of purified recombinant human topo II alpha. Co-incubation of topo II alpha and casein kinase II led to an apparent activation of the topo II alpha; however, in experiments in which topo II alpha was preincubated at 37 degrees C with or without native casein kinase II prior to assaying for decatenation activity, it emerged that the kinase was exerting its "activating" function via a decrease in the rate of topo II alpha enzyme inactivation during the incubation period. This stabilization of topo II alpha by casein kinase II was ATP-independent and was observed in both mutated and truncated derivatives of topo II alpha lacking the major casein kinase II phospho-acceptor sites, indicating the lack of a requirement for phosphorylation. Consistent with a nonenzymatic role for casein kinase II, stoichiometric quantities of kinase were required for topo II alpha stabilization. These data indicate that casein kinase II plays a significant role in regulating human topo II alpha protein action via stabilization against thermal inactivation.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Hickson, ID (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England.	hickson@icrf.icnet.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI N, 1992, NUCLEIC ACIDS RES, V20, P5297, DOI 10.1093/nar/20.20.5297; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DANDREA MR, 1994, APPL IMMUNOHISTOCHEM, V2, P177; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GOSWAMI P, 1996, MOL CELL BIOL, V116, P1500; GOTO T, 1984, EMBO J, V3, P1737; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; Jensen S, 1996, MOL GEN GENET, V252, P79, DOI 10.1007/BF02173207; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Kimura K, 1996, J BIOL CHEM, V271, P10990, DOI 10.1074/jbc.271.18.10990; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; PARK SH, 1993, BIOCHEM BIOPH RES CO, V193, P787, DOI 10.1006/bbrc.1993.1694; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1995, J BIOL CHEM, V270, P28357; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209	50	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3635	3642		10.1074/jbc.273.6.3635	http://dx.doi.org/10.1074/jbc.273.6.3635			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452492	hybrid			2022-12-27	WOS:000071822300077
J	Reverter, D; Ventura, S; Villegas, V; Vendrell, J; Aviles, FX				Reverter, D; Ventura, S; Villegas, V; Vendrell, J; Aviles, FX			Overexpression of human procarboxypeptidase A2 in Pichia pastoris and detailed characterization of its activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-A; 3-DIMENSIONAL STRUCTURE; EXPRESSION; SECRETION; PROTEINS; CLONING; PANCREAS; ENZYME; GENES	The cDNA of human procarboxypeptidase A2 has been overexpressed in the methylotrophic yeast Pichia pastoris and secreted into the culture medium by means of the alpha-mating factor signal sequence, yielding a major protein of identical size and N-terminal sequence as the wild-type form, Two other forms containing the proenzyme have also been overexpressed: one of them resulted from an incomplete processing of the signal peptide, whereas the other was a glycosylated derivative. Recombinant procarboxypeptidase A2 was purified to homogeneity, and it was shown that its mature active form displays functional properties similar to those of the enzyme directly isolated from human pancreas, The overall yield was similar to 250 mg of proenzyme or 180 mg of mature enzyme/liter of cell culture. The proteolysis-promoted activation process of the recombinant proenzyme has been studied in detail. During maturation by trypsin, the increase in activity of the enzyme is a rapid and monotonic event, which reflects the rate of the proteolytic release of the inhibitory pro-segment and the weaker nature of its interactions with the enzyme moiety compared with procarboxypeptidases of the A1 type, Three main forms of the pro-segment (96, 94, and 92 amino acids), with no inhibitory capability in the severed state, and a single mature carboxypeptidase A2 are produced during this process. No further proteolysis of these pro-segments by the generated carboxypeptidase A2 occurs, in contrast with observations made in other procarboxypeptidases (A1 and B), This differential behavior is a result of the extreme specificity of carboxypeptidase A2.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Ciencies, Bellaterra 08193, Spain; Univ Autonoma Barcelona, Inst Biol Fonamental, Bellaterra 08193, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Ciencies, Bellaterra 08193, Spain.	FX.Aviles@blues.uab.es	Ventura, Salvador/C-7021-2008; Vendrell, Josep/A-6731-2010; Aviles, Francesc Xavier/F-3482-2019; Villegas, Sandra/ABF-8206-2021; Villegas, Sandra/D-8789-2011; Reverter, David/H-5360-2015; Ventura, Salvador/AAY-3170-2021; Avilés, Francesc Xavier/A-2664-2015	Ventura, Salvador/0000-0002-9652-6351; Vendrell, Josep/0000-0002-9378-4742; Aviles, Francesc Xavier/0000-0002-1399-6789; Villegas, Sandra/0000-0001-8644-4304; Villegas, Sandra/0000-0001-8644-4304; Reverter, David/0000-0002-5347-0992; Ventura, Salvador/0000-0002-9652-6351; Avilés, Francesc Xavier/0000-0002-1399-6789				AULD DS, 1987, NEW COMPR BIOCH, V16, P201; AVILES FX, 1993, EUR J BIOCHEM, V211, P391; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4092; CATASUS L, 1995, J BIOL CHEM, V270, P6651, DOI 10.1074/jbc.270.12.6651; COLL M, 1991, EMBO J, V9, P1; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; FAMMING Z, 1991, J BIOL CHEM, V266, P24606; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; GOMISRUTH FX, 1995, EMBO J, V14, P4387, DOI 10.1002/j.1460-2075.1995.tb00117.x; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HUENNEKENS FM, 1994, TRENDS BIOTECHNOL, V12, P234, DOI 10.1016/0167-7799(94)90122-8; KJELDSEN T, 1996, GENE, V170, P97; Laethem RM, 1996, ARCH BIOCHEM BIOPHYS, V332, P8, DOI 10.1006/abbi.1996.0310; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; NORMANT E, 1995, J BIOL CHEM, V270, P20543, DOI 10.1074/jbc.270.35.20543; Ohi H, 1996, YEAST, V12, P31, DOI 10.1002/(SICI)1097-0061(199601)12:1<31::AID-YEA877>3.0.CO;2-S; OPPEZZO O, 1994, EUR J BIOCHEM, V222, P55, DOI 10.1111/j.1432-1033.1994.tb18841.x; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; Phillips MA, 1996, BIOCHEMISTRY-US, V35, P6771, DOI 10.1021/bi960113o; PUIGSERVER A, 1986, MOL CELLULAR BASIS D, P235; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; Rowsell S, 1997, STRUCTURE, V5, P337, DOI 10.1016/S0969-2126(97)00191-3; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Skidgel R. A., 1996, ZINC METALLOPROTEASE, P241; Song LX, 1997, J BIOL CHEM, V272, P10543; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; VEDVICK T, 1991, J IND MICROBIOL, V7, P197, DOI 10.1007/BF01575883; VENDRELL J, 1986, J CHROMATOGR, V358, P401, DOI 10.1016/S0021-9673(01)90354-1; VENDRELL J, 1990, J BIOL CHEM, V265, P6949; VENDRELL J, 1993, INNOVATIONS PROTEASE, P279; VILLEGAS V, 1995, BIOCHEMISTRY-US, V34, P15105, DOI 10.1021/bi00046a017; VILLEGAS V, 1995, PROTEIN SCI, V4, P1792, DOI 10.1002/pro.5560040914; VILLEGAS V, 1995, THESIS U AUTONOMA BA; VITOLS KS, 1995, CANCER RES, V55, P478; Vozza LA, 1996, BIO-TECHNOL, V14, P77, DOI 10.1038/nbt0196-77; WAGNER SL, 1992, BIOCHEM BIOPH RES CO, V196, P1139; Zhu A, 1995, ARCH BIOCHEM BIOPHYS, V324, P65, DOI 10.1006/abbi.1995.9928	39	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3535	3541		10.1074/jbc.273.6.3535	http://dx.doi.org/10.1074/jbc.273.6.3535			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452479	hybrid			2022-12-27	WOS:000071822300064
J	Forsberg, LS; Carlson, RW				Forsberg, LS; Carlson, RW			The structures of the lipopolysaccharides from Rhizobium etli strains CE358 and CE359 - The complete structure of the core region of R-etli lipopolysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEGUMINOSARUM BIOVAR PHASEOLI; GRAM-NEGATIVE BACTERIA; LIPID-A; BRADYRHIZOBIUM-JAPONICUM; ESCHERICHIA-COLI; FATTY-ACIDS; BIOSYNTHESIS; COMPONENT; MUTANTS; PLANT	The structural arrangement of oligosaccharides comprising the core region of Rhizobium etli CE3 lipopolysaccharide (LPS) has been elucidated through the characterization of the LPSs from two R. etli mutants, One mutant, CE358, completely lacks the O-chain polysaccharide, while the second mutant, CE359, contains a truncated portion of this polysaccharide. This structural arrangement of the core oligosaccharides in these LPSs was determined using electrospray ionization mass spectrometry, tandem mass spectrometry, and methylation analysis, Mild acid hydrolysis of the CE359 LPS produces two major core oligosaccharides: a tetrasaccharide (I) with the structure alpha-D-Galp-(1-->6)-[alpha-D-GalpA-(1-->4)]-alpha-D-Manp-(1-->5)-Kdop (where Kdo represents 3-deoxy-D-manno-2-octulosonic acid) and a trisaccharide (2) having the structure alpha-D-GalpA-(1-->4)-[alpha-D-GalpA-(1-->5)]-Kdop. Structure 1 in CE358 LPS lacks the galacturonosyl residue, Glycosyl linkage and tandem mass spectrometry analyses show that the intact LPS core region consists of trisaccharide (2) attached to O-4 of the Kdo residue in tetrasaccharide 1, and that an additional Kdo residue is attached to O-6 of the galactosyl residue of 1. [GRAPHICS] SCHEME 1. R. etli core structure. The additional terminally linked Kdo residue is not in close proximity to the lipid A moiety, a unique location for a core Kdo residue. The mutant LPS preparations also contain minor LPS species, one of which lacks the Kdo linked to O-6 of the galactosyl residue, another that lacks the galacturonic acid attached to O-5 of Kdo, and a third that lacks two galacturonosyl residues and one Kdo residue, Thus, in addition to lacking both heptose and phosphate, the R. etli LPS core region differs substantially from the typical enterobacterial cores, The abundance of galacturonosyl residues in the R. etli core might serve as a suitable functional replacement for phosphate, such as would be predicted for Ca2+ binding.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Carlson, RW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 220 Riverbend Rd, Athens, GA 30602 USA.	RCARLSON@ccrc.uga.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHAT UR, 1992, J BACTERIOL, V174, P2230, DOI 10.1128/JB.174.7.2230-2235.1992; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BHAT UR, 1992, GLYCOBIOLOGY, V2, P535, DOI 10.1093/glycob/2.6.535; BOCK K, 1994, EUR J BIOCHEM, V225, P1029, DOI 10.1111/j.1432-1033.1994.1029b.x; BREWIN NJ, 1986, J GEN MICROBIOL, V132, P1959; BREWIN NJ, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P227; BRINK BA, 1990, J BACTERIOL, V172, P548, DOI 10.1128/jb.172.2.548-555.1990; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; CARLSON RW, 1989, CARBOHYD RES, V195, P101, DOI 10.1016/0008-6215(89)85092-X; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CARLSON RW, 1988, CARBOHYD RES, V176, P127, DOI 10.1016/0008-6215(88)84064-3; CARLSON RW, 1978, PLANT PHYSIOL, V62, P912, DOI 10.1104/pp.62.6.912; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; Duelli DM, 1997, MOL PLANT MICROBE IN, V10, P903, DOI 10.1094/MPMI.1997.10.7.903; HOLLINGSWORTH RI, 1990, J BIOL CHEM, V265, P12752; HOLLINGSWORTH RI, 1989, J BIOL CHEM, V264, P9294; Hong M, 1997, MOL MICROBIOL, V24, P779, DOI 10.1046/j.1365-2958.1997.3731744.x; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kannenberg EL, 1996, PLANT SOIL, V186, P161, DOI 10.1007/BF00035070; KANNENBERG EL, 1994, J BACTERIOL, V176, P2021, DOI 10.1128/jb.176.7.2021-2032.1994; Kannenberg Elmar L., 1994, Trends in Microbiology, V2, P277, DOI 10.1016/0966-842X(94)90004-3; KONDO S, 1993, FEMS MICROBIOL LETT, V106, P93, DOI 10.1016/0378-1097(93)90061-6; KRAUSS JH, 1988, INT J SYST BACTERIOL, V38, P157, DOI 10.1099/00207713-38-2-157; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; Noel KD, 1996, BIOLOGY OF PLANT-MICROBE INTERACTIONS, P337; Noel KD., 1992, MOL SIGNALS PLANT MI, P341; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RICHTER WJ, 1990, METHOD ENZYMOL, V193, P607, DOI 10.1016/0076-6879(90)93441-M; ROTH LE, 1989, EUR J CELL BIOL, V49, P24; RYAN JM, 1974, ARCH BIOCHEM BIOPHYS, V162, P530, DOI 10.1016/0003-9861(74)90213-6; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; Selvendran R.R, 1987, METHODS BIOCH ANAL, V32, P25; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; STACEY G, 1991, MOL PLANT MICROBE IN, V4, P332, DOI 10.1094/MPMI-4-332; SZABO L, 1991, J CHEM SOC P1, V1, P509; SZABO L, 1982, J CHEM SOC P1, V1, P1275; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030; Whitfield C, 1997, MOL MICROBIOL, V23, P629, DOI 10.1046/j.1365-2958.1997.2571614.x; WOOD EA, 1989, J BACTERIOL, V171, P4549, DOI 10.1128/jb.171.9.4549-4555.1989; YORK WS, 1986, METHOD ENZYMOL, V118, P3; ZHANG Y, 1992, CARBOHYD RES, V231, P261, DOI 10.1016/0008-6215(92)84024-M	51	98	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2747	2757		10.1074/jbc.273.5.2747	http://dx.doi.org/10.1074/jbc.273.5.2747			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446581	hybrid			2022-12-27	WOS:000071736600036
J	Tamarit, J; Cabiscol, E; Ros, J				Tamarit, J; Cabiscol, E; Ros, J			Identification of the major oxidatively damaged proteins in Escherichia coli cells exposed to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-CATALYZED OXIDATION; ELONGATION-FACTOR-G; HYDROGEN-PEROXIDE; RNASE-E; IRON; ENZYME; IONS; DEHYDROGENASES; ACCUMULATION; INACTIVATION	In the present study we have analyzed protein oxidation on Escherichia coli when these cells were submitted to different stress conditions such as hydrogen peroxide, superoxide-generating compounds, and iron overloading, Carbonyl groups on oxidized cell proteins were examined by Western blot immunoassay. When anaerobically grown E, coli cells were exposed to hydrogen peroxide stress, alcohol dehydrogenase E, elongation factor G, the heat shock protein DNA K, oligopeptide-binding protein A, enolase, and the outer membrane protein A were identified as the major protein targets, A similar immunostained band pattern was found when cells were shifted from anaerobic to aerobic conditions in the presence of different concentrations of iron; it is relevant to note that oxidation of outer membrane protein C, not observed in peroxide stress conditions, was clearly detected as the concentration of iron was increased in the culture media, The hydrogen peroxide stress performed under aerobic conditions affected the beta-subunit of F0F1-ATPase; the rest of the oxidized protein pattern was very similar to that found for anaerobic conditions, with the exception of alcohol dehydrogenase E, a protein not synthesized aerobically, Cells submitted to superoxide stress using menadione showed a more specific pattern in which elongation factor G and the beta-subunit of F0F1-ATPase were affected significantly, When paraquat was used, although the degree of oxidative damage was lower, the same two modified proteins were detected, and DNA K was also clearly damaged, Cell. viability was affected to different extents depending on the type of stress exerted, The results described in this paper provide data about the in vivo effects of oxidative stress on protein oxidation and give insights into understanding how such modifications can affect cellular functions.	Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Lleida 25198, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Dept Ciencies Med Basiques, Fac Med, Avda Rovira Roure 44, Lleida 25198, Spain.	joaquim.ros@cmb.udl.es	ROS, Joaquim/ABG-7487-2020; Ros, Joaquim/A-7507-2010; Tamarit, Jordi/C-6316-2008; Cabiscol, Elisa/A-4584-2009	ROS, Joaquim/0000-0003-0901-8648; Tamarit, Jordi/0000-0003-3227-6928; Cabiscol, Elisa/0000-0003-2795-7999				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; Belogrudov GI, 1996, ARCH BIOCHEM BIOPHYS, V335, P131, DOI 10.1006/abbi.1996.0490; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; Crawford DR, 1997, FREE RADICAL BIO MED, V22, P551, DOI 10.1016/S0891-5849(96)00380-2; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dean RT, 1997, BIOCHEM J, V324, P1; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; Demple B., 1996, REGULATION GENE EXPR, P433; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GonzalezFlecha B, 1997, J BACTERIOL, V179, P382, DOI 10.1128/jb.179.2.382-388.1997; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; GREENBERG JT, 1989, J BACTERIOL, V171, P3933, DOI 10.1128/jb.171.7.3933-3939.1989; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HOLMSEN H, 1977, J BIOL CHEM, V252, P1752; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LIPPE G, 1991, BIOCHEM BIOPH RES CO, V181, P764, DOI 10.1016/0006-291X(91)91256-C; MAITRA PK, 1971, J BIOL CHEM, V246, P475; MCPHEDRAN P, 1961, J BACTERIOL, V81, P852, DOI 10.1128/JB.81.6.852-857.1961; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MISRA TK, 1979, J BIOL CHEM, V254, P1154; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; SCHNAITMAN CA, 1981, MANUAL METHODS GENER, P52; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; STARKE PE, 1985, J BIOL CHEM, V260, P99; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; VERHOEVEN AJM, 1985, J BIOL CHEM, V260, P2621; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	56	216	223	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3027	3032		10.1074/jbc.273.5.3027	http://dx.doi.org/10.1074/jbc.273.5.3027			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446617	hybrid, Green Published			2022-12-27	WOS:000071736600072
J	Young, KC; Shi, GY; Wu, DH; Chang, LC; Chang, BI; Ou, CP; Wu, HL				Young, KC; Shi, GY; Wu, DH; Chang, LC; Chang, BI; Ou, CP; Wu, HL			Plasminogen activation by streptokinase via a unique mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX; BINDING; MICROPLASMINOGEN; FRAGMENTS; CLEAVAGE; AFFINITY; ANTIBODY; PROTEINS; ACID	The mechanism of human plasminogen (HPlg) activation by streptokinase (SK)-type activator was investigated with recombinant truncated SR peptides. An enzyme substrate intermediate of HPlg SK HPlg ternary complex was demonstrated by a sandwich-binding experiment. Formation of the ternary complex was saturable, HPlg-specific, and inhibited by 6-aminocaproic acid. Three interaction sites between SK and HPlg were demonstrated. SK-(220-414) bound to HPlg with two binding sites: one to the micro-HPlg region, the catalytic domain of HPlg, and one to the kringle 1-5 region, with K-d values of 1.50 x 10(-7) and 2.44 x 10(-6) M, respectively. SK-(16-251) bound to a single site on the kringle 1-5 region of HPlg with a K-d of 4.09 x 10(-7) M. SK-(220-414) and SK-(16-251) competed for binding on the same or nearby location on the human kringle 1-5 domain. Combination of SK-(220-414) and SK-(16-251), but not either peptide alone, could effectively activate HPlg. In addition, SK-(16-251) dose-dependently enhanced the activation of HPlg by SK-(16-414), while the HPlg activation by SK-(16-414) was inhibited by SK-(220-414). We conclude that the HPlg that binds to the COOH-terminal domains of SK functions as an enzyme to catalyze the conversion of substrate HPlg that binds to the NH2-terminal domain of SK to human plasmin.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University	Wu, HL (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 70101, Taiwan.		Young, Kung-Chia/G-1529-2011					ALKJAERSIG N, 1959, J BIOL CHEM, V234, P832; BAJAJ SP, 1977, J BIOL CHEM, V252, P492; BROCKWAY WJ, 1972, ARCH BIOCHEM BIOPHYS, V151, P194, DOI 10.1016/0003-9861(72)90488-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DAMASCHUN G, 1992, EUR BIOPHYS J BIOPHY, V20, P355; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DAVIES MC, 1964, J BIOL CHEM, V239, P2651; DAWSON KM, 1994, BIOCHEMISTRY-US, V33, P12042, DOI 10.1021/bi00206a005; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; GONZALEZGRONOW M, 1978, J BIOL CHEM, V253, P1090; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING CM, 1965, J BIOL CHEM, V240, P4213; LING CM, 1967, J BIOL CHEM, V242, P1419; MARKUS G, 1976, J BIOL CHEM, V251, P6495; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NAGENDRA K, 1974, J BIOL CHEM, V249, P4851; Nihalani D, 1995, BIOCHEM BIOPH RES CO, V217, P1245, DOI 10.1006/bbrc.1995.2902; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1988, ENZYME, V40, P79, DOI 10.1159/000469149; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; REED GL, 1993, J IMMUNOL, V150, P4407; SCHICK LA, 1973, BIOCHEMISTRY-US, V12, P4315, DOI 10.1021/bi00746a003; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SHI GY, 1994, BIOCHEM J, V304, P235, DOI 10.1042/bj3040235; SHI GY, 1988, J BIOL CHEM, V263, P17071; SHI GY, 1993, BIOCHEM BIOPH RES CO, V195, P192, DOI 10.1006/bbrc.1993.2029; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; SUMMARIA L, 1987, THROMB HAEMOSTASIS, V58, P772; SUMMARIA L, 1982, BIOCHEMISTRY-US, V21, P2056, DOI 10.1021/bi00538a012; SUMMARIA L, 1974, J BIOL CHEM, V249, P4760; TEUTEN AJ, 1993, BIOCHEM J, V290, P313, DOI 10.1042/bj2900313; Tillett WS, 1933, J EXP MED, V58, P485, DOI 10.1084/jem.58.4.485; TOMAR RH, 1971, BIOCHEM J, V125, P793, DOI 10.1042/bj1250793; WANG JY, 1995, PROTEIN SCI, V4, P1758, DOI 10.1002/pro.5560040911; WANG JY, 1995, PROTEIN SCI, V4, P1768, DOI 10.1002/pro.5560040912; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5; WU HL, 1990, J BIOL CHEM, V265, P19658; WULF RJ, 1969, CAN J BIOCHEM CELL B, V47, P927, DOI 10.1139/o69-145; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	41	56	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3110	3116		10.1074/jbc.273.5.3110	http://dx.doi.org/10.1074/jbc.273.5.3110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446629	hybrid			2022-12-27	WOS:000071736600084
J	Diep, DB; Nelson, KL; Raja, SM; Pleshak, EN; Buckley, JT				Diep, DB; Nelson, KL; Raja, SM; Pleshak, EN; Buckley, JT			Glycosylphosphatidylinositol anchors of membrane glycoproteins are binding determinants for the channel-forming toxin aerolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; CELL-LINE; PROTEIN; RECEPTOR; ACTIVATION; PURIFICATION; LYMPHOCYTES; EXPRESSION; ENDOTOXIN	Cells that are sensitive to the channel-forming toxin aerolysin contain surface glycoproteins that bind the toxin with high affinity, Here we show that a common feature of aerolysin receptors is the presence of a glycosylphosphatidylinositol anchor, and we present evidence that the anchor itself is an essential part of the toxin binding determinant, The glycosylphosphatidylinositol (GPI)-anchored T-lymphocyte protein Thy-1 is an example of a protein that acts as an aerolysin recep tor, This protein retained its ability to bind aerolysin when it was expressed in Chinese hamster ovary cells, but could not bind the toxin when expressed in Escherichia coli, where the GPI anchor is absent, An unrelated GPI-anchored protein, the variant surface glycoprotein of trypanosomes, was shown to bind aerolysin with similar affinity to Thy-1, and this binding ability was significantly reduced when the anchor was removed chemically, Cathepsin D, a protein with no affinity for aerolysin, was converted to an aerolysin binding form when it was expressed as a GPI-anchored hybrid in COS cells, Not all GPI-anchored proteins bind aerolysin, In some cases this may be due to differences in the structure of the anchor itself. Thus the GPI-anchored proteins procyclin of Trypanosoma congolense and gp63 of Leishmania major did not bind aerolysin, but when gp63 was expressed with a mammalian GPI anchor in Chinese hamster ovary cells, it bound the toxin.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Buckley, JT (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.		Diệp, Dzũng/ABG-9262-2020; Diep, Dzung B./AAK-1419-2021	Diep, Dzung/0000-0001-7661-5501				AMES BN, 1960, J BIOL CHEM, V235, P769; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; CLISSOLD PM, 1992, BIOCHEM J, V281, P129, DOI 10.1042/bj2810129; Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; ENGLUND PT, 1993, ANN REV BIOCH, V62, P12; EVANS GA, 1987, IMMUNOGENETICS, V25, P28, DOI 10.1007/BF00768830; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FUJITA N, 1995, CELL GROWTH DIFFER, V6, P355; GRUBER HJ, 1994, MOL MICROBIOL, V14, P1093, DOI 10.1111/j.1365-2958.1994.tb01341.x; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HIROSE S, 1995, METHOD ENZYMOL, V250, P582; HORST M, 1991, BIOCHEM J, V273, P355, DOI 10.1042/bj2730355; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; HUEBER AO, 1994, J EXP MED, V179, P785, DOI 10.1084/jem.179.3.785; KINGSTON RE, 1988, CURRENT PROTOCOLS MO; KNIGHT PJK, 1995, J BIOL CHEM, V270, P17765, DOI 10.1074/jbc.270.30.17765; KROCZEK RA, 1986, J IMMUNOL, V136, P4379; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LETARTEMUIRHEAD M, 1975, BIOCHEM J, V151, P685, DOI 10.1042/bj1510685; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; LUNDJOHANSEN F, 1993, EUR J IMMUNOL, V23, P2782, DOI 10.1002/eji.1830231110; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MISUMI Y, 1990, EUR J BIOCHEM, V191, P563, DOI 10.1111/j.1432-1033.1990.tb19158.x; Morrison CJ, 1997, BIOTECHNOL BIOENG, V53, P594, DOI 10.1002/(SICI)1097-0290(19970320)53:6<594::AID-BIT7>3.3.CO;2-M; MUKASA R, 1995, ARCH BIOCHEM BIOPHYS, V318, P182, DOI 10.1006/abbi.1995.1219; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; OGIERDENIS E, 1995, BIOCHEM BIOPH RES CO, V221, P935; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PaturiauxHanocq F, 1997, BIOCHEM J, V324, P885, DOI 10.1042/bj3240885; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PU MY, 1995, FEBS LETT, V361, P295, DOI 10.1016/0014-5793(95)00193-D; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; Solomon KR, 1996, P NATL ACAD SCI USA, V93, P6053, DOI 10.1073/pnas.93.12.6053; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Wang X, 1996, BIOCHEMISTRY-US, V35, P16305, DOI 10.1021/bi961098q; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZANG F, 1992, P NATL ACAD SCI USA, V89, P5231	48	158	164	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2355	2360		10.1074/jbc.273.4.2355	http://dx.doi.org/10.1074/jbc.273.4.2355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442081	hybrid			2022-12-27	WOS:000071595200070
J	Zhang, JW; Lesort, M; Guttmann, RP; Johnson, GVW				Zhang, JW; Lesort, M; Guttmann, RP; Johnson, GVW			Modulation of the in situ activity of tissue transglutaminase by calcium and GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; PIG LIVER TRANSGLUTAMINASE; RETINOIC ACID; CROSS-LINKING; SH-SY5Y NEUROBLASTOMA; PROMYELOCYTIC LEUKEMIA; II TRANSGLUTAMINASE; BINDING PROTEIN; EXPRESSION; APOPTOSIS	Tissue transglutaminase (tTG) is a calcium-dependent enzyme that catalyzes the posttranslational modification of proteins by transamidation of specific polypeptide-bound glutamine residues. Previous in vitro studies have demonstrated that the transamidating activity of tTG requires calcium and is inhibited by GTP, To investigate the endogenous regulation of tTG, a quantitative in situ transglutaminase (TG) activity assay was developed, Treatment of human neuroblastoma SH-SY5Y cells with retinoic acid (RA) resulted in a significant increase in tTG levels and in vitro TG activity. In contrast, basal in situ TG activity did not increase concurrently with RA-induced increased tTG levels. However, stimulation of cells with the calcium-mobilizing drug maitotoxin (MTX) resulted in increases in in situ TG activity that correlated (r(2) = 0.76) with increased tTG levels. To examine the effects of GTP on in situ TG; activity, tiazofurin, a drug that selectively decreases GTP levels, was used. Depletion of GTP resulted in a significant increase in in situ TG activity; however, treatment of SH-SY5Y cells with a combination of MTX and tiazofurin resulted in significantly less in situ TG activity compared with treatment with MTX alone, This raised the possibility of calcium-dependent proteolysis due to the effects of tiazofurin, because in vitro GTP protects tTG against proteolysis by trypsin. Studies with a selective membrane permeable calpain inhibitor indicated that tTG is likely to be an endogenous substrate of calpain, and that depletion of GTP increases tTG degradation after elevation of intracellular calcium levels. TG activity was also increased in response to activation of muscarinic cholinergic receptors, which increases intracellular calcium through inositol 1,4,5-trisphosphate generation. The results of these experiments demonstrate that selective changes in calcium and GTP regulate the activity and levels of tTG in situ.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012; guttmann, rodney/AAN-8880-2021	Johnson, Gail V.W./0000-0003-3464-0404; guttmann, rodney/0000-0001-5553-3099	NIA NIH HHS [AG12396] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Baek KJ, 1996, BIOCHEMISTRY-US, V35, P2651, DOI 10.1021/bi9522965; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Benedetti L, 1996, BLOOD, V87, P1939; Beninati S, 1988, Adv Exp Med Biol, V250, P411; BIEDLER JL, 1973, CANCER RES, V33, P2643; Borge L, 1996, BBA-MOL CELL RES, V1312, P117, DOI 10.1016/0167-4889(96)00028-6; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CORDELLAMIELE E, 1993, J BIOCHEM-TOKYO, V113, P164, DOI 10.1093/oxfordjournals.jbchem.a124021; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FINCH RA, 1993, J BIOL CHEM, V268, P5823; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1972, ANN NY ACAD SCI, V202, P59, DOI 10.1111/j.1749-6632.1972.tb16322.x; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; HAND D, 1993, J NEUROCHEM, V61, P1064, DOI 10.1111/j.1471-4159.1993.tb03621.x; Hettasch JM, 1996, LAB INVEST, V75, P637; HOHENADL C, 1995, J BIOL CHEM, V270, P23415, DOI 10.1074/jbc.270.40.23415; Hwang KC, 1996, CIRCULATION, V94, P718, DOI 10.1161/01.CIR.94.4.718; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; JOHNSON TS, 1994, ONCOGENE, V9, P2935; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; Kojima S, 1997, J BIOL CHEM, V272, P9410; KOSA K, 1995, CANCER RES, V55, P4850; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Li XH, 1996, J NEUROSCI, V16, P5914; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MEUCCI O, 1992, J NEUROCHEM, V59, P679, DOI 10.1111/j.1471-4159.1992.tb09422.x; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; MILLER ML, 1995, J NEUROCHEM, V65, P1760; Mitrovic DM, 1995, J CHEMOTHERAPY, V7, P543, DOI 10.1179/joc.1995.7.6.543; MORTON AJ, 1992, MOL BRAIN RES, V13, P53, DOI 10.1016/0169-328X(92)90044-C; Nagy L, 1996, J BIOL CHEM, V271, P4355; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PAYNE SM, 1982, ANAL BIOCHEM, V123, P151, DOI 10.1016/0003-2697(82)90636-4; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PIACENTINI M, 1988, J BIOL CHEM, V263, P3790; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; ROSS RA, 1983, J NATL CANCER I, V71, P741; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; SUTO N, 1993, J BIOL CHEM, V268, P7469; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Weber G, 1996, ANTICANCER RES, V16, P3313; WEBER G, 1992, ADV ENZYME REGUL, V32, P57; Xie HQ, 1997, J NEUROCHEM, V69, P1020	63	180	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2288	2295		10.1074/jbc.273.4.2288	http://dx.doi.org/10.1074/jbc.273.4.2288			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442073	hybrid			2022-12-27	WOS:000071595200062
J	Crombie, R; Silverstein, R				Crombie, R; Silverstein, R			Lysosomal integral membrane protein II binds thrombospondin-1 - Structure-function homology with the cell adhesion molecule CD36 defines a conserved recognition motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; PLATELET SURFACE GLYCOPROTEIN; CARBOXYL CYTOPLASMIC TAIL; LOW-DENSITY-LIPOPROTEIN; LIMP-II; SEQUENCE ALIGNMENT; SR-BI; SIGNAL TRANSDUCTION; SCAVENGER RECEPTOR; FUSION PROTEINS	LIMPII (lysosomal integral membrane protein II) is one of a family of proteins structurally related to the cell surface glycoprotein CD36. We recently defined a single structural domain on CD36 that mediates binding to adhesive glycoprotein thrombospondin-l (TSP1). The CD36-TSP1 interaction is known to play a role in platelet-tumor and platelet-monocyte adhesion, angiogenesis, and in monocyte uptake of apoptotic cells. To test whether LIMPII also binds TSP1, a LIMPII peptide corresponding to the TSP1 binding domain of CD36 was expressed as a recombinant glutathione S-transferase (GST) fusion protein. In solid phase binding assays, purified I-125-TSP1 bound to immobilized GST/LIMPII in a time-dependent and saturable manner. Inhibition by excess unlabeled TSP1 or EDTA demonstrated specificity. LIMPII.TSP1 complex formation was specifically blocked by soluble LIMPII fusion protein, by monospecific rabbit IgG directed against the LIMPII peptide and by CD36 fusion proteins containing the TSP1 binding domain. Transfection of Bowes melanoma cells with a chimeric LIMPII cDNA that targets expression to the plasma membrane conferred the ability to bind I-125-TSP1 and to adhere to TSP1-coated surfaces. This study defines a TSP1 binding site conserved between LIMPII and CD36 and suggests that cell surface LIMPII may function in some circumstances as an adhesion receptor for TSP1. Computer-assisted homology searches suggest that the TSP1 recognition motif identified from study of CD36 family members may be widely expressed in nature.	Cornell Univ, Coll Med, Dept Med,Program Cell Biol & Genet, Div Hematol Oncol,Grad Sch Med Sci, New York, NY 10021 USA; New York Hosp, Cornell Med Ctr, Div Hematol Oncol, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University; NewYork-Presbyterian Hospital	Silverstein, R (corresponding author), Cornell Univ, Coll Med, Dept Med,Program Cell Biol & Genet, Div Hematol Oncol,Grad Sch Med Sci, Rm C606,1300 York Ave, New York, NY 10021 USA.				NHLBI NIH HHS [HL46403, HL18828] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, P50HL018828] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BORNSTEIN P, 1992, FASEB J, V6, P3222; CALVO D, 1993, J BIOL CHEM, V268, P18929; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CLEZARDIN P, 1993, CANCER RES, V53, P1421; CLEZARDIN P, 1985, BRIT J HAEMATOL, V60, P331, DOI 10.1111/j.1365-2141.1985.tb07419.x; Crombie R, 1998, J EXP MED, V187, P25, DOI 10.1084/jem.187.1.25; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FEBBRAIO M, 1990, J BIOL CHEM, V265, P18531; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; FUJITA H, 1992, BIOCHEM BIOPH RES CO, V184, P604, DOI 10.1016/0006-291X(92)90632-U; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GARRIGUES J, 1994, J CELL BIOL, V125, P129, DOI 10.1083/jcb.125.1.129; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GREENWALT DE, 1992, BLOOD, V80, P1105; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; HENIKOFF S, 1995, GENE, V163, P17; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; KAIN R, 1995, J EXP MED, V181, P585, DOI 10.1084/jem.181.2.585; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LAFERTE S, 1988, CANCER RES, V48, P4743; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAHAV J, 1993, THROMBOSPONDIN, P1; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; OGATA S, 1994, J BIOL CHEM, V269, P5210; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; PEARCE SFA, 1995, J BIOL CHEM, V270, P2981, DOI 10.1074/jbc.270.7.2981; PEARCE SFA, 1994, BLOOD, V84, P384; PECHOUX C, 1994, DIFFERENTIATION, V57, P133, DOI 10.1046/j.1432-0436.1994.5720133.x; PRATT D, 1987, EUR J CANC CLIN ONCO, V25, P343; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RYEOM SW, 1994, CLIN RES, V42, pA113; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SILVERSTEIN RL, 1986, ARTERIOSCLEROSIS, V6, P245, DOI 10.1161/01.ATV.6.3.245; SILVERSTEIN RL, 1992, BLOOD, V80, P1470; SILVERSTEIN RL, 1985, J CLIN INVEST, V75, P2065, DOI 10.1172/JCI111926; SILVERSTEIN RL, 1984, J CLIN INVEST, V74, P1625, DOI 10.1172/JCI111578; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VEGA MA, 1991, J BIOL CHEM, V266, P16269; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	79	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4855	4863		10.1074/jbc.273.9.4855	http://dx.doi.org/10.1074/jbc.273.9.4855			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478926	hybrid			2022-12-27	WOS:000072310400010
J	Fang, BL; Ji, L; Bouvet, M; Roth, JA				Fang, BL; Ji, L; Bouvet, M; Roth, JA			Evaluation of GAL4/TATA in vivo - Induction of transgene expression by adenovirally mediated gene codelivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT ADENOVIRUS; MAMMALIAN-CELLS; GAL4-VP16; SYSTEM; GAL4; TRANSCRIPTION; THERAPY; YEAST; MICE; P53	A synthetic GAL4-responsive promoter consisting of five GAL4-binding sites and a TATA box (GAL4/TATA) was evaluated for its transcriptional activity in an adenoviral backbone using luciferase as the reporter, Basal luciferase activities in vitro were the same for cells infected with either adenovirus-containing luciferase cDNA driven by GAL4/TATA (Ad/GT-Luc) or adenovirus-containing luciferase cDNA not driven by a promoter (Ad/PO-Luc), In vitro induction of GAL4/TATA by coinfection of cells with adenovirus expressing the GAL4/VP16 fusion protein (Ad/3-phosphoglycerate kinase (PGK)-GV16) was dose-dependent and reached as high as 4 x 10(4)- to 9 x 10(4)-fold above basal levels when GAL4/TATA and GAL4/VP16 were delivered at a ratio of 10:1, In vivo studies in Balb/c mice showed no detectable luciferase activities in liver or other tissues examined in mice infused with either Ad/GT-Luc or Ad/PO-Luc, High levels of luciferase activity were, however, elicited when animals were infused with Ad/GT-Luc and Ad/PGK-GV16, Together, these results suggest that combination of the GAL4 gene regulatory system with adenovirally mediated in vivo gene delivery may be applicable to the in vivo evaluation of promoter activities and in vivo targeting of gene expression.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAND AH, 1993, DEVELOPMENT, V118, P401; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; Fang B, 1996, GENE THER, V3, P217; FANG B, 1994, GENE THER, V1, P247; Fang BL, 1997, J VIROL, V71, P4798, DOI 10.1128/JVI.71.6.4798-4803.1997; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; Oligino T, 1996, GENE THER, V3, P892; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sadowski I, 1995, Genet Eng (N Y), V17, P119; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; ZHANG WW, 1994, CANCER GENE THER, V1, P5	17	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4972	4975		10.1074/jbc.273.9.4972	http://dx.doi.org/10.1074/jbc.273.9.4972			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478943	hybrid			2022-12-27	WOS:000072310400027
J	Garner, J; Durrer, P; Kitchen, J; Brunner, J; Crooke, E				Garner, J; Durrer, P; Kitchen, J; Brunner, J; Crooke, E			Membrane-mediated release of nucleotide from all initiator of chromosomal replication, Escherichia coli DnaA, occurs with insertion of a distinct region of the protein into the lipid bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; ANIONIC PHOSPHOLIPIDS; ACIDIC PHOSPHOLIPIDS; ORIGIN; BINDING; DOMAIN; DIACYLGLYCEROL; QUANTITIES; ATP	DnaA protein, the initiator protein of E. coli chromosomal replication, can be rejuvenated from an inactive ADP form to active ATP-DnaA protein by acidic phospholipids in a fluid bilayer. Cross-linking studies with the photoactivable phospholipid analog 1-O-hexadecanoyl-2-O-[9-[[[2-[I-125]iodo-4-(trifluoromethyl-3H-diazirin-3-yl)benzyl]oxy]carbonyl]nonanoyl]-sn-glycero-3-phosphocholine reveal insertion of DnaA protein into the hydrophobic region of the bilayer; this insertion is accompanied by membrane-mediated dissociation of the tightly bound allosteric nucleotides ADP and ATP. Photolabeling of DnaA protein occurred with membrane properties that resembled those needed for reactivation of ADP-DnaA protein; efficient labeling of DnaA protein was observed only when the lipid analog was incorporated into anionic vesicles and the temperature during treatment was above the gel to Liquid crystalline phase transition. Predominant hydrophobic photolabeling was localized within a single region of DnaA protein, a region that contains putative amphipathic helices and has been shown to contain information essential for functional interaction with membranes.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; ETH Zurich, Dept Biochem, CH-8092 Zurich, Switzerland	Georgetown University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Crooke, E (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049700] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16042-20] Funding Source: Medline; NIGMS NIH HHS [R01-GM49700, R01 GM049700] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CROOKE E, 1992, J BIOL CHEM, V267, P16779; Durrer P, 1996, J BIOL CHEM, V271, P13417, DOI 10.1074/jbc.271.23.13417; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Gennis R. B., 1989, BIOMEMBRANES MOL STR, DOI [10.1007/978-1-4757-2065-5, DOI 10.1007/978-1-4757-2065-5]; HEACOCK PN, 1987, J BIOL CHEM, V262, P13044; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; KOGOMA T, 1983, EMBO J, V2, P463, DOI 10.1002/j.1460-2075.1983.tb01445.x; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSER W, 1996, INITIATION CHROMOSOM, P1579; Mizushima T, 1996, J BIOL CHEM, V271, P3633; ORR JW, 1992, J BIOL CHEM, V267, P15263; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schaper S, 1997, PROTEINS, V28, P1; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P1724; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	38	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5167	5173		10.1074/jbc.273.9.5167	http://dx.doi.org/10.1074/jbc.273.9.5167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478970	hybrid			2022-12-27	WOS:000072310400054
J	Breen, JJ; Agulnick, AD; Westphal, S; Dawid, IB				Breen, JJ; Agulnick, AD; Westphal, S; Dawid, IB			Interactions between LIM domains and the LIM domain-binding protein Ldb1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENE; SYNERGISTIC ACTIVATION; ORGANIZER; XENOPUS; HOMEODOMAIN; DIFFERENTIATION; TRANSCRIPTION; REQUIREMENT; SPECIFICITY; ELEGANS	LIM domains mediate protein-protein interactions and, within LIM-homeodomain proteins, act as negative regulators of the transcriptional activation function of the protein, The recently described protein Ldb1 (also known as NLI; LIM domain-binding protein) binds LIM domains in vitro and synergizes with the LIM-homeodomain protein Xlim-1 in frog embryo microinjection experiments. Hn this study we localized the transcriptional activation domain of Xlim-1 to its carboxyl-terminal region, and characterized the interactions of the amino-terminally located LIM domains with Ldb1. Ldb1 binds LIM domains through its carboxyl-terminal region, and can form homodimers via its amino-terminal region. Optimal binding to Ldb1 required tandem LIM domains, while single domains could bind at lower but clearly reasonable efficiency. In animal explant experiments, synergism of Ldb1 with Xlim-1 in the activation of downstream genes required both the region containing the dimerization domain of Ldb1 and time region containing the LIM-binding domain. The role of Ldb1 may be to recruit other transcriptional activators depending on the promoter context and LIM-homeodomain partner involved.	NICHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA; NICHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dawid, IB (corresponding author), NICHD, Genet Mol Lab, NIH, Bldg 6B,Rm 413, Bethesda, MD 20892 USA.							Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; LICHTSTEINER S, 1995, EMBO J, V14, P3937, DOI 10.1002/j.1460-2075.1995.tb00065.x; MENZEL R, 1989, ANAL BIOCHEM, V181, P40, DOI 10.1016/0003-2697(89)90391-6; MOEHLE CM, 1991, MOL CELL BIOL, V11, P2723, DOI 10.1128/MCB.11.5.2723; PANNESE M, 1995, DEVELOPMENT, V121, P707; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; RICHTER K, 1990, New Biologist, V2, P556; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934	33	82	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4712	4717		10.1074/jbc.273.8.4712	http://dx.doi.org/10.1074/jbc.273.8.4712			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468533	hybrid			2022-12-27	WOS:000072115000061
J	Isobe, K; Ito, S; Hosaka, H; Iwamura, Y; Kondo, H; Kagawa, Y; Hayashi, JI				Isobe, K; Ito, S; Hosaka, H; Iwamura, Y; Kondo, H; Kagawa, Y; Hayashi, JI			Nuclear-recessive mutations of factors involved in mitochondrial translation are responsible for age-related respiration deficiency of human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA DELETIONS; HUMAN BRAIN; HUMAN-CELLS; GENOME; DYSFUNCTION; SENESCENCE; INTEGRITY; INCREASE; DISEASE	We addressed the question of whether both mitochondrial and cytoplasmic translation activities decreased simultaneously in human skin fibroblasts with the age of the donors and found that the age-related reduction was limited to mitochondrial translation. Then, to determine which genome, mitochondrial or nuclear, was responsible for this age-related, mitochondria-specific reduction, pure nuclear transfer was carried out from mitochondrial DNA (mtDNA)-less HeLa cells to four fibroblast lines, two from aged subjects, one from a fetus, and one from a patient with cardiomyopathy, and their nuclear hybrid clones were isolated. A normal fibroblast line from the fetus and a respiration-deficient fibroblast line from the patient were used as a positive and a negative control, respectively, Subsequently, the mitochondrial translation and respiration properties of the nuclear hybrid clones were compared, A negative control experiment showed that this procedure could be used to isolate even nuclear hybrids expressing overall mitochondrial respiration deficiency, whereas no respiration deficiencies were observed in any nuclear hybrids irrespective of whether their mtDNAs were exclusively derived from aged or fetal donors. These observations suggest that nuclear recessive mutations of factors involved in mitochondrial translation but not mtDNA mutations are responsible for age-related respiration deficiency of human fibroblasts.	Univ Tsukuba, Inst Biol Sci, Ibaraki, Osaka 305, Japan; Ibaraki Prefectural Univ Hlth Sci, Ctr Arts & Humanities, Ibaraki, Osaka 30003, Japan; Tokyo Metropolitan Inst Gerontol, Dept Biol, Tokyo 103, Japan; Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 32904, Japan	University of Tsukuba; Tokyo Metropolitan Institute of Gerontology; Jichi Medical University	Hayashi, JI (corresponding author), Univ Tsukuba, Inst Biol Sci, Ibaraki, Osaka 305, Japan.	jih45@sakura.cc.tsukuba.ac.jp						ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; GOLDSTEIN S, 1982, J CELL PHYSIOL, V112, P419, DOI 10.1002/jcp.1041120316; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAYASHI JI, 1986, CANCER RES, V46, P4001; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; Isobe K, 1997, J BIOL CHEM, V272, P12606, DOI 10.1074/jbc.272.19.12606; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Kubota N, 1997, RADIAT RES, V148, P395, DOI 10.2307/3579525; Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MIQUEL J, 1991, ARCH GERONTOL GERIAT, V12, P99, DOI 10.1016/0167-4943(91)90022-I; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; REIS RJS, 1983, J BIOL CHEM, V258, P9078; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; SOONG NW, 1992, NAT GENET, V2, P318; Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E	33	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4601	4606		10.1074/jbc.273.8.4601	http://dx.doi.org/10.1074/jbc.273.8.4601			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468517	hybrid			2022-12-27	WOS:000072115000045
J	Laurberg, M; Mansilla, F; Clark, BFC; Knudsen, CR				Laurberg, M; Mansilla, F; Clark, BFC; Knudsen, CR			Investigation of functional aspects of the N-terminal region of elongation factor Tu from Escherichia coli using a protein engineering approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; AMINOACYL-TRANSFER-RNA; CRYSTAL-STRUCTURE; STEP PURIFICATION; TERNARY COMPLEX; GTPASE; EFFECTOR; BINDING; DNA	The function of the N-terminal region of elongation factor Tu is still unexplained, Until recently, it has not been visible in electron density maps from xray crystallography studies, but the presence of several well conserved basic residues suggest that this part of the molecule is of structural importance for the factor to function properly, In this study, two lysines at positions 4 and 9 were mutated separately to alanine or glutamate, The resulting four point mutants were expressed and purified using the pGEX system, The untagged products were characterized with regard to guanine-nucleotide interaction, intrinsic GTPase activity, and binding of aminoacyl-tRNA (aa-tRNA), The results show that Lys(9) is especially strongly involved in the association with guanine nucleotides and the binding of aa-tRNA. Also Lys(4) plays a role in the association of GDP and GTP and is also of some importance in aa-tRNA binding, Our results are discussed in structural terms with the conclusion that a complex network of interactions across the interface between domains 1 and 2 with Lys(9) being a key residue seems to be important for the fine tuning of the dimensions of the cleft accommodating the acceptor end of aa-tRNA as well as delineating the structure of the effector region.	Aarhus Univ, Biostruct Chem IMSB, DK-8000 Aarhus C, Denmark; Lund Univ, S-22100 Lund, Sweden	Aarhus University; Lund University	Knudsen, CR (corresponding author), Aarhus Univ, Biostruct Chem IMSB, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	crk@imsb.au.dk		Knudsen, Charlotte/0000-0003-2356-4821				Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; ANDERSEN C, 1994, EUR J BIOCHEM, V220, P739, DOI 10.1111/j.1432-1033.1994.tb18674.x; ANTONSSON B, 1984, EUR J BIOCHEM, V141, P483, DOI 10.1111/j.1432-1033.1984.tb08218.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Knudsen CR, 1995, PROTEIN ENG, V8, P1267, DOI 10.1093/protein/8.12.1267; KNUDSEN CR, 1995, EUR J BIOCHEM, V228, P176; KNUDSEN CR, 1992, BIOCHEM INT, V28, P353; Mansilla F, 1997, PROTEIN ENG, V10, P927, DOI 10.1093/protein/10.8.927; Miller D L, 1974, Methods Enzymol, V30, P219; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nissen P, 1996, BIOCHIMIE, V78, P921, DOI 10.1016/S0300-9084(97)86714-4; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; von der Haar F, 1979, Methods Enzymol, V59, P257	24	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4387	4391		10.1074/jbc.273.8.4387	http://dx.doi.org/10.1074/jbc.273.8.4387			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468489	hybrid			2022-12-27	WOS:000072115000017
J	Yamauchi, E; Kiyonami, R; Kanai, M; Taniguchi, H				Yamauchi, E; Kiyonami, R; Kanai, M; Taniguchi, H			The C-terminal conserved domain of MARCKS is phosphorylated in vivo by proline-directed protein kinase - Application of ion trap mass spectrometry to the determination of protein phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE MARCKS; CELLULAR SUBSTRATE; FAMILY; CALMODULIN; PEPTIDES; BINDING; CLONING; GAP-43; 80-KDA; BRAIN	MARCKS, the major protein kinase C substrate in various cells and tissues, binds to calmodulin, acidic membrane phospholipids, and actin filaments, and these in teractions are regulated by protein phosphorylation. We have previously shown that MARCKS purified from bovine brain is phosphorylated not only by protein kinase C but also by so-called proline-directed protein kinases in the well conserved N-terminal half of the molecule (Taniguchi, H., Manenti, S., Suzuki, M., and Titani, K. (1994) J, Biol, Chem, 269, 18299-18302), Although the presence of other phosphorylation sites in the C-terminal peptide was also noticed, the ambiguity in the C-terminal domain of the bovine protein hampered a more detailed analysis, In the present study, we analyzed MARCKS purified from rat brain by electrospray ionization/ion trap mass spectrometry, The results obtained revealed two additional novel phosphorylation sites in the C-terminal region, Both phosphorylation sites (Ser(291) and Ser(299)) are immediately followed by proline, suggesting that these sites are also phosphorylated by the proline-directed protein kinase(s), Since Ser(299) is within the C-terminal domain, which is well conserved among various species, the function of the domain, whatever it is, seems to be controlled by phosphorylation.	Fujita Hlth Univ, Inst Comprehens Med Sci, Div Biomed Polymer Sci, Aichi 47011, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Dept Biol Chem, Mizuho Ku, Nagoya, Aichi 467, Japan; ThermoQuest KK, Shibuya Ku, Tokyo 151, Japan	Fujita Health University; Nagoya City University	Taniguchi, H (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Div Biomed Polymer Sci, Aichi 47011, Japan.		Kanai, Motomu/J-6807-2016; Taniguchi, Hisaaki/I-9171-2012	Kanai, Motomu/0000-0003-1977-7648; 				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HERGET T, 1992, EUR J BIOCHEM, V209, P7, DOI 10.1111/j.1432-1033.1992.tb17255.x; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; KIM JY, 1994, J BIOL CHEM, V269, P28214; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; MANENTI S, 1992, J BIOL CHEM, V267, P22310; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; Yates JR, 1996, METHOD ENZYMOL, V271, P351	20	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4367	4371		10.1074/jbc.273.8.4367	http://dx.doi.org/10.1074/jbc.273.8.4367			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468486	hybrid			2022-12-27	WOS:000072115000014
J	Brown, MR; Graf, R; Swiderek, KM; Fendley, D; Stracker, TH; Champagne, DE; Lea, AO				Brown, MR; Graf, R; Swiderek, KM; Fendley, D; Stracker, TH; Champagne, DE; Lea, AO			Identification of a steroidogenic neurohormone in female mosquitoes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; AEDES-AEGYPTI; MICROSEQUENCE ANALYSIS; PEPTIDES; PROTEINS; VITELLOGENIN; HORMONE; SYSTEM	In the female mosquito, Aedes aegypti, neurohormones are released from the brain in response to a blood meal and stimulate the ovaries to secrete ecdysteroid hormones, which modulate yolk protein synthesis in the fat body. Neuropeptides with this bioactivity were isolated from head extracts, and partial sequences from these peptides when aligned gave a 31-residue sequence at the amino terminus. Oligonucleotide primers for this sequence were used to amplify with the polymerase chain reaction a genomic DNA product that hybridized to a clone from a head cDNA library. The cDNA encodes a 149-residue preprohormone that is processed into an 86-residue peptide, as indicated by the mass value obtained from the native peptide, with the expected amino-terminal sequence, After modification, the cDNA for the putative neurohormone was expressed in a bacterial system, and the purified peptide had high specific activity in bioassays, thus confirming that it is a steroidogenic gonadotropin, the first to be identified for invertebrates.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Zurich Hosp, Dept Chirurg, CH-8091 Zurich, Switzerland; City Hope Natl Med Ctr, Div Immunol, Duarte, CA 91010 USA	University System of Georgia; University of Georgia; University of Zurich; University Zurich Hospital; City of Hope	Brown, MR (corresponding author), Univ Georgia, Dept Entomol, Athens, GA 30602 USA.		Stracker, Travis H/I-2815-2015	Stracker, Travis H/0000-0002-8650-2081; Graf, Rolf/0000-0001-7449-7302	NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033108] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NIAID NIH HHS [AI33108, AI17927, R01 AI033108] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN MR, 1988, J COMP NEUROL, V270, P606, DOI 10.1002/cne.902700413; DAVIS MT, 1995, J AM SOC MASS SPECTR, V6, P571, DOI 10.1016/1044-0305(95)00192-G; DEITSCH KW, 1995, INSECT BIOCHEM MOLEC, V25, P449, DOI 10.1016/0965-1748(94)00082-A; FOURNIER B, 1994, BBA-MOL CELL RES, V1220, P181, DOI 10.1016/0167-4889(94)90133-3; Girardie J, 1996, J INSECT PHYSIOL, V42, P107, DOI 10.1016/0022-1910(95)00092-5; Girardie J, 1996, J INSECT PHYSIOL, V42, P215, DOI 10.1016/0022-1910(95)00097-6; GIRARDIE J, 1993, MOL COMP PHYSL, V12, P67; Graf R, 1997, INSECT MOL BIOL, V6, P151, DOI 10.1111/j.1365-2583.1997.tb00083.x; HAWKE DH, 1985, ANAL BIOCHEM, V147, P315, DOI 10.1016/0003-2697(85)90278-7; Hua YJ, 1997, ARCH INSECT BIOCHEM, V35, P125, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<125::AID-ARCH11>3.3.CO;2-A; ISHIZAKI H, 1994, INT J DEV BIOL, V38, P301; Kim AJ, 1997, P NATL ACAD SCI USA, V94, P1130, DOI 10.1073/pnas.94.4.1130; KINGAN TG, 1989, ANAL BIOCHEM, V183, P283, DOI 10.1016/0003-2697(89)90481-8; Klowden MJ, 1997, ARCH INSECT BIOCHEM, V35, P491, DOI 10.1002/(SICI)1520-6327(1997)35:4<491::AID-ARCH10>3.3.CO;2-5; KOLLER CN, 1991, J INSECT PHYSIOL, V37, P703, DOI 10.1016/0022-1910(91)90048-5; LEA AO, 1967, J INSECT PHYSIOL, V13, P419, DOI 10.1016/0022-1910(67)90082-0; LEA AO, 1972, GENERAL COMPAR END S, V3, P602; MASLER EP, 1995, EUR J ENTOMOL, V92, P113; MATSUMOTO S, 1989, INSECT BIOCHEM, V19, P651, DOI 10.1016/0020-1790(89)90100-5; MUEHLEISEN DP, 1994, EXPERIENTIA, V50, P159, DOI 10.1007/BF01984956; Raikhel A.S., 1992, Advances in Disease Vector Research, V9, P1; Sambrook J, 1989, MOL CLONING LABORATO, p1 25; SHIVELY JE, 1987, ANAL BIOCHEM, V163, P517, DOI 10.1016/0003-2697(87)90257-0; Swiderek KM, 1996, METHOD ENZYMOL, V271, P68; WHEELOCK GD, 1991, J CHROMATOGR, V542, P508, DOI 10.1016/S0021-9673(01)88785-9	25	124	128	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3967	3971		10.1074/jbc.273.7.3967	http://dx.doi.org/10.1074/jbc.273.7.3967			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461584	hybrid			2022-12-27	WOS:000072048400026
J	Kundra, A; Kornfeld, S				Kundra, A; Kornfeld, S			Wortmannin retards the movement of the mannose 6-phosphate/insulin-like growth factor II receptor and its ligand out of endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; SYNTHESIZED LYSOSOMAL-ENZYMES; TRANS-GOLGI NETWORK; 6-PHOSPHATE RECEPTOR; ENDOCYTIC PATHWAY; PHOSPHOINOSITIDE 3-KINASE; CYTOPLASMIC DOMAIN; CELLS; TRAFFICKING; BIOGENESIS	The effect of wortmannin on the trafficking of the mannose 6-phosphate/insulin-like growth factor II receptor (Man-6-P/IGF-II receptor) and its ligand beta-glucuronidase has been determined in murine L cells and normal rat kidney cells, The drug induced a 90% decrease in the steady-slate level of the Man-6-P/IGF-II receptor at the plasma membrane without affecting the rate of internalization, indicating that the return of receptor from endosomes to the plasma membrane is retarded. Wortmannin also slowed the movement of receptor from endosomes to the trans-Golgi network by about 60%, Such a kinetic block would dramatically reduce the number of Man-6-P/IGF-II receptors in the trans-Golgi network, which could account for the previously described hypersecretion of procathepsin D induced by wortmannin, In addition, the drug slowed delivery of endocytosed beta-glucuronidase from endosomes to dense lysosomes. These data, taken together with the published reports of others, indicate that wortmannin inhibits membrane trafficking out of multiple compartments of the endosomal system and suggest a role for phosphatidylinositol 3-kinase in regulating these processes.	Washington Univ, Sch Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08759-30] Funding Source: Medline; NHLBI NIH HHS [T32 HL07088] Funding Source: Medline; NIGMS NIH HHS [T32 GM07200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BENNETT G, 1981, J CELL BIOL, V88, P1, DOI 10.1083/jcb.88.1.1; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gaffet P, 1997, J BIOL CHEM, V272, P24170, DOI 10.1074/jbc.272.39.24170; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; JADOT M, 1992, J BIOL CHEM, V267, P11069; JIN M, 1989, J BIOL CHEM, V264, P7675; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Korner C, 1996, MOL CELL ENDOCRINOL, V118, P201, DOI 10.1016/0303-7207(96)03785-9; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Nakajima Y, 1997, MOL BIOL CELL, V8, P577, DOI 10.1091/mbc.8.4.577; NATOWICZ M, 1982, J BIOL CHEM, V257, P4412; OKADA T, 1994, J BIOL CHEM, V269, P3568; Reaves BJ, 1996, J CELL SCI, V109, P749; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P533; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; TAIT JF, 1981, J BIOL CHEM, V256, P1086; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WILSON RB, 1993, J BIOL CHEM, V268, P25357	46	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3848	3853		10.1074/jbc.273.7.3848	http://dx.doi.org/10.1074/jbc.273.7.3848			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461565	hybrid			2022-12-27	WOS:000072048400007
J	Hartmann, R; Norby, PL; Martensen, PM; Jorgensen, P; James, MC; Jacobsen, C; Moestrup, SK; Clemens, MJ; Justesen, J				Hartmann, R; Norby, PL; Martensen, PM; Jorgensen, P; James, MC; Jacobsen, C; Moestrup, SK; Clemens, MJ; Justesen, J			Activation of 2 '-5 ' oligoadenylate synthetase by single-stranded and double-stranded RNA aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; TREATED HELA-CELLS; PROTEIN-KINASE; 2',5'-OLIGO(A) POLYMERASE; RESPONSE ELEMENT; BINDING DOMAIN; VAI RNA; INTERFERON; RECOGNITION; LIGANDS	A number of small RNA molecules that are high affinity ligands for the 46-kDa form of human 2'-5' oligoadenylate synthetase have been identified by the SELEX method, Surface plasmon resonance analysis indicates that these RNAs bind to the enzyme with dissociation constants in the nanomolar range, Competition experiments indicate that the binding site for the small RNAs on the 2'-5' oligoadenylate synthetase molecule at least partially overlaps that for the synthetic double-stranded RNA, poly(I). poly(C). Several of the RNAs function as potent activators of 2'-5' oligoadenylate synthetase in vitro, although there is no correlation between binding affinity and ability to activate, The RNA aptamers having the strongest activation potential appear to have few base-paired regions. This suggests that 2'-5' oligoadenylate synthetase, which has previously been believed to be activated only by double-stranded RNA, can also be activated by RNA ligands with little secondary structure, Since 2'-5' oligoadenylate synthetase possesses no homology to other known RNA-binding proteins, the development of small specific ligands by SELEX should facilitate studies of RNA-protein interactions and may reveal novel features of the structure-function relationships involving this enzyme.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Sci, Div Biochem, London SW17 0RE, England; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark	Aarhus University; St Georges University London; Aarhus University	Justesen, J (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.	jj@mbio.aau.dk	Martensen, Pia/I-3996-2012; Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Hartmann, Rune/0000-0003-1159-066X; Martensen, Pia Moller/0000-0002-1259-0226				BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEBATH J, 1992, INTERFERON PRINCIPLE, P225; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CLEMENS MJ, 1984, TRANSCRIPTION TRANSL, P270; DESAI SY, 1995, J BIOL CHEM, V270, P3454, DOI 10.1074/jbc.270.7.3454; FERBUS D, 1984, MOL CELL BIOCHEM, V62, P51; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GUNNERY S, 1990, P NATL ACAD SCI USA, V87, P8687, DOI 10.1073/pnas.87.22.8687; JOHNSTON MI, 1984, MECH PRODUCTION ACTI, P189; JUSTESEN J, 1992, ANAL BIOCHEM, V207, P90, DOI 10.1016/0003-2697(92)90506-3; JUSTESEN J, 1980, NUCLEIC ACIDS RES, V8, P3073, DOI 10.1093/nar/8.14.3073; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KING CA, 1991, BACULOVIRUS EXPRESSI; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; Lund AH, 1996, NUCLEIC ACIDS RES, V24, P800, DOI 10.1093/nar/24.4.800; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MELLITS KH, 1990, NUCLEIC ACIDS RES, V18, P5401, DOI 10.1093/nar/18.18.5401; MINKS MA, 1980, J BIOL CHEM, V255, P6403; MINKS MA, 1979, J BIOL CHEM, V254, P180; MORDECHAI E, 1995, VIROLOGY, V206, P913, DOI 10.1006/viro.1995.1014; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PETERSON ET, 1994, J MOL BIOL, V242, P186, DOI 10.1006/jmbi.1994.1571; PRATT G, 1988, NUCLEIC ACIDS RES, V16, P3497, DOI 10.1093/nar/16.8.3497; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P; SENGUPTA DN, 1989, NUCLEIC ACIDS RES, V17, P969, DOI 10.1093/nar/17.3.969; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, 1993, GENE, V137, P33, DOI 10.1016/0378-1119(93)90248-2; Zuker M, 1994, Methods Mol Biol, V25, P267	36	71	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3236	3246		10.1074/jbc.273.6.3236	http://dx.doi.org/10.1074/jbc.273.6.3236			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452437	hybrid			2022-12-27	WOS:000071822300022
J	Iordanov, MS; Magun, BE				Iordanov, MS; Magun, BE			Loss of cellular K+ mimics ribotoxic stress - Inhibition of protein synthesis and activation of the stress kinases SEK1/MKK4, stress-activated protein kinase c-Jun NH2-terminal kinase 1, and p38/HOG1 by palytoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; ARACHIDONIC-ACID METABOLISM; TUMOR PROMOTER PALYTOXIN; MAMMALIAN SODIUM-PUMP; PROSTAGLANDIN PRODUCTION; MOUSE SKIN; CELLS; INDUCTION; FOS	The tumor promoter palytoxin has been found to activate the stress-activated protein kinase/c-Jun NH2-terminal kinase 1 (SAPK/JNK1), and it also potentiates, as demonstrated here, the p38/HOG1 mitogen-activated protein kinase and the upstream activator of SAPK/JNK1, SEK1/MKK4. In search of possible mechanisms for both the cytotoxicity and the activation of stress kinases by palytoxin, we found that palytoxin is a potent inhibitor of cellular protein synthesis. The inhibition of translation by palytoxin does not result from its direct binding to the translational apparatus. We have previously demonstrated that ribotoxic stressors (Iordanov, M. S., Pribnow, D., Magun, J. L., Dinh, T.-H., Pearson, J. A., Chen, S. L.-Y., and Magun, B. E. (1997) Mol. Cell. Biol. 17, 3373-3381) signal the activation of SAPK/JNK1 by binding to or covalently modifying 28 S rRNA in ribosomes that are active at the time of exposure to the stressor, Palytoxin acted as a ribotoxic stressor, inasmuch as it required actively translating ribosomes at the time of exposure to activate SAPK/JNK1. Palytoxin has been shown to augment ion fluxes by binding to the Na+/K+-ATPase in the plasma membrane of cells. To determine whether altered fluxes of either Na+ or K+ could be responsible for the effects of palytoxin on translation and on activation of SAPK/JNK1, cells were exposed to palytoxin in modified culture medium in which a major portion of the Na+ was replaced by either K+ or by choline(+). The substitution of Na+ by K+ strongly inhibited the ability of palytoxin both to inhibit protein translation and to activate SAPK/JNK1, whereas the substitution of Na+ by choline(+) did not. These results suggest that palytoxin-induced efflux of cellular K+ mimics ribotoxic stress by provoking both translational inhibition and activation of protein kinases associated with cellular defense against stress.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Magun, BE (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA.	magunb@OHSU.edu			NCI NIH HHS [CA-39360] Funding Source: Medline; NIEHS NIH HHS [ES-08456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AIZU E, 1990, EUR J PHARMACOL, V182, P19; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FISCHER SM, 1980, ARACHIDONIC ACID MET; Fujiki H, 1983, Princess Takamatsu Symp, V14, P37; FUJIKI H, 1986, CARCINOGENESIS, V7, P707, DOI 10.1093/carcin/7.5.707; FURSTENBERGER G, 1981, P NATL ACAD SCI-BIOL, V78, P7722, DOI 10.1073/pnas.78.12.7722; FURSTENBERGER G, 1994, CARCINOGENESIS, V15, P2823, DOI 10.1093/carcin/15.12.2823; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HABERMANN E, 1989, TOXICON, V27, P1171, DOI 10.1016/0041-0101(89)90026-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Kuroki DW, 1996, CANCER RES, V56, P637; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAZZARO M, 1987, ENDOCRINOLOGY, V120, P1338, DOI 10.1210/endo-120-4-1338; LEVINE L, 1986, PROSTAGLANDINS, V31, P669, DOI 10.1016/0090-6980(86)90173-5; LEVINE L, 1986, CARCINOGENESIS, V7, P99, DOI 10.1093/carcin/7.1.99; LEVINE L, 1991, PROSTAG OTH LIPID M, V41, P7, DOI 10.1016/0090-6980(91)90100-T; LEWIS JG, 1987, CARCINOGENESIS, V8, P889, DOI 10.1093/carcin/8.7.889; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAGUN BE, 1995, CELL GROWTH DIFFER, V6, P891; Marks F, 1995, TOXICOL LETT, V82-3, P907, DOI 10.1016/0378-4274(95)03529-X; MARTINSGREEN M, 1994, CANCER RES, V54, P4334; MCGAUGHEY C, 1983, J TOXICOL ENV HEALTH, V11, P467, DOI 10.1080/15287398309530359; Michiel D F, 1992, Semin Cancer Biol, V3, P3; OHUCHI K, 1985, BIOCHIM BIOPHYS ACTA, V834, P42, DOI 10.1016/0005-2760(85)90174-2; PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415; Redondo J, 1996, MOL PHARMACOL, V49, P49; Rodland KD, 1997, MOL ENDOCRINOL, V11, P281, DOI 10.1210/me.11.3.281; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHEINERBOBIS G, 1994, MOL PHARMACOL, V45, P1132; SCHOOF RA, 1986, INT J IMMUNOPHARMACO, V8, P455, DOI 10.1016/0192-0561(86)90132-3; SCRIBNER JD, 1972, EUR J CANCER, V8, P617, DOI 10.1016/0014-2964(72)90142-9; SEGAL A, 1978, CANCER RES, V38, P921; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANBOGELEN RA, 1990, P NATL ACAD SCI USA, V87, P5589, DOI 10.1073/pnas.87.15.5589; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vazquez D., 1979, INHIBITORS PROTEIN B; WATTENBERG EV, 1989, J BIOL CHEM, V264, P213; WATTENBERG EV, 1987, CANCER RES, V47, P4618; WATTENBERG EV, 1989, J BIOL CHEM, V264, P14668; WATTENBERG EV, 1989, CANCER RES, V49, P5837; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOOL IG, 1992, TRENDS BIOCHEM SCI, V17, P266, DOI 10.1016/0968-0004(92)90407-Z; YAN MH, 1994, NATURE, V372, P798	51	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3528	3534		10.1074/jbc.273.6.3528	http://dx.doi.org/10.1074/jbc.273.6.3528			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452478	hybrid			2022-12-27	WOS:000071822300063
J	Shimabukuro, M; Zhou, YT; Lee, Y; Unger, RH				Shimabukuro, M; Zhou, YT; Lee, Y; Unger, RH			Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; INSULIN-RESISTANCE; OBESITY; LIPOTOXICITY; PATHOGENESIS; BIOSYNTHESIS; SECRETION; DEPLETION; CS-045; ACIDS	The thiazolidinedione compound troglitazone, which is used to treat non-insulin-dependent diabetes mellitus (NIDDM) in man, is also effective in the adipogenic NIDDM of Zucker diabetic fatty (ZDF) rats, To test the "lipotoxicity hypothesis," which attributes the beta cell dysfunction of adipogenic NIDDM to an excessive accumulation of fat in the pancreatic islets, we sought to determine if troglitazone-mediated amelioration of beta cell function in islets of ZDF rats might be associated with a reduction in their elevated triglyceride (TG) content. Troglitazone (10 mu M) in the culture medium reduced the TG content of ZDF rats by 52%; this was reflected by decreased esterification and increased oxidation of [H-3]palmitate, Glycerol-3-phosphate acyltransferase mRNA fell by 57% and acyl-CoA synthetase mRNA by 67% (brain isoform) and 38% (liver isoform), all consistent with the effects of troglitazone on TG metabolism, The 52% decrease in islet TG was accompanied by >30- and 2-fold improvements in glucose- and arginine-stimulated insulin secretion, respectively. We conclude that troglitazone exerts direct lipopenic activity in normal islets and in islets of obese prediabetic ZDF rats; in the latter, this correlated with improvement in beta cell function, The results are consistent with the lipotoxicity hypothesis for adipogenic diabetes.	Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Vet Adm Med Ctr, Dallas, TX 75216 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Shimabukuro, Michio/0000-0001-7835-7665	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02700-37] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAPITO K, 1992, ACTA DIABETOL, V28, P193, DOI 10.1007/BF00778997; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; Iida M, 1996, BIOCHEM BIOPH RES CO, V222, P19, DOI 10.1006/bbrc.1996.0691; IWAOTO Y, 1994, DIABETES CARE, V14, P1083; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; McDaniel ML, 1996, P SOC EXP BIOL MED, V211, P24; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OHNEDA M, 1995, DIABETOLOGIA, V38, P173, DOI 10.1007/BF00400091; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Shimabukuro M, 1997, J CLIN INVEST, V100, P1750, DOI 10.1172/JCI119700; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Sreenan S, 1996, AM J PHYSIOL-ENDOC M, V271, pE742, DOI 10.1152/ajpendo.1996.271.4.E742; Unger RH, 1997, TRENDS ENDOCRIN MET, V8, P276, DOI 10.1016/S1043-2760(97)00094-5; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; YOSHIOKA S, 1993, METABOLISM, V42, P75, DOI 10.1016/0026-0495(93)90175-N; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	26	214	226	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3547	3550		10.1074/jbc.273.6.3547	http://dx.doi.org/10.1074/jbc.273.6.3547			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452481	hybrid			2022-12-27	WOS:000071822300066
J	Nichols, BL; Eldering, J; Avery, S; Hahn, D; Quaroni, A; Sterchi, E				Nichols, BL; Eldering, J; Avery, S; Hahn, D; Quaroni, A; Sterchi, E			Human small intestinal maltase-glucoamylase cDNA cloning - Homology to sucrase-isomaltase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LYSOSOMAL ALPHA-GLUCOSIDASE; BRUSH-BORDER MEMBRANE; NEUTRAL MALTASE; MOLECULAR-CLONING; AMINOPEPTIDASE-N; SUCKLING RAT; EXPRESSION; COMPLEX; GENE	It has been hypothesized that human mucosal glucoamylase (EC 3.2.1.20 and 3.2.1.3) activity serves as an alternate pathway for starch digestion when luminal cu-amylase activity is reduced because of immaturity or malnutrition and that maltase-glucoamylase plays a unique role in the digestion of malted dietary oligosaccharides used in food manufacturing, As a first step toward the testing of this hypothesis, we have cloned human small intestinal maltase-glucoamylase cDNA to permit study of the individual catalytic and binding sites for maltose and starch enzyme hydrolase activities in subsequent expression experiments, Human maltase-glucoamylase was purified by immunoisolation and partially sequenced, Maltase-glucoamylase cDNA was amplified from human intestinal RNA using degenerate and gene-specific primers with the reverse transcription-polymerase chain reaction. The 6,513-base pair cDNA contains an open reading frame that encodes a 1,857-amino acid protein (molecular mass 209,702 Da). Maltase-glucoamylase has two catalytic sites identical to those of sucrase-isomaltase, but the proteins are only 59% homologous, Both are members of glycosyl hydrolase family 31, which has a variety of substrate specificities, Our findings suggest that divergences in the carbohydrate binding sequences must determine the substrate specificities for the four different enzyme activities that share a conserved catalytic site.	Baylor Coll Med, Dept Pediat, Childrens Nutr Res Ctr, USDA, Houston, TX 77030 USA; Cornell Univ, Sch Vet Med, Dept Physiol, Ithaca, NY 14853 USA; Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland	Baylor College of Medicine; United States Department of Agriculture (USDA); Cornell University; University of Bern	Nichols, BL (corresponding author), Baylor Coll Med, Dept Pediat, Childrens Nutr Res Ctr, USDA, 1100 Bates St, Houston, TX 77030 USA.							ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; AURICCHIO S, 1965, BIOCHIM BIOPHYS ACTA, V96, P498, DOI 10.1016/0005-2787(65)90566-6; AZAD MAK, 1990, PEDIATR RES, V28, P166, DOI 10.1203/00006450-199028020-00017; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BAYER DP, 1989, BIOCHEM J, V263, P647; CHANDRASENA G, 1994, GENE, V150, P355, DOI 10.1016/0378-1119(94)90452-9; CHANTRET I, 1992, BIOCHEM J, V285, P915, DOI 10.1042/bj2850915; COWELL GM, 1986, BIOCHEM J, V237, P455, DOI 10.1042/bj2370455; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DANIELSEN EM, 1983, BIOCHEM J, V210, P389, DOI 10.1042/bj2100389; DANUS VO, 1970, J PEDIATR-US, V77, P334; DOHMEN RJ, 1990, GENE, V95, P111, DOI 10.1016/0378-1119(90)90421-M; EGGERMONT E, 1981, TXB GASTROENTEROLOGY, P966; FORSTNER G, 1982, CAN J BIOCHEM CELL B, V60, P1007, DOI 10.1139/o82-129; FORSTNER G, 1979, BIOCHIM BIOPHYS ACTA, V586, P250, DOI 10.1016/0304-4165(79)90097-7; GALAND G, 1986, COMP BIOCHEM PHYS A, V85, P109, DOI 10.1016/0300-9629(86)90470-6; GALLUSER M, 1991, J COMP PHYSIOL B, V161, P357; Genetic Computer Group, 1994, PROGR MAN WISC PACK; HASSID WZ, 1957, CARBOHYDRATES CHEM B, P501; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HENIKOFF S, 1994, J MOL BIOL, V243, P574, DOI 10.1016/0022-2836(94)90032-9; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HU CB, 1987, BIOCHIM BIOPHYS ACTA, V896, P275, DOI 10.1016/0005-2736(87)90188-X; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; IWANAMI S, 1995, BIOSCI BIOTECH BIOCH, V59, P459, DOI 10.1271/bbb.59.459; JAMES WPT, 1971, ARCH DIS CHILD, V46, P218, DOI 10.1136/adc.46.246.218; KELLY JJ, 1973, J BIOL CHEM, V248, P8216; KELLY JJ, 1973, BIOCHIM BIOPHYS ACTA, V315, P113, DOI 10.1016/0005-2744(73)90135-6; KIMURA A, 1992, BIOSCI BIOTECH BIOCH, V56, P1368, DOI 10.1271/bbb.56.1368; LAWRENCE CB, 1989, SAM SOFTWARE PACKAGE; LEBENTHAL E, 1994, J PEDIATR-US, V124, P541, DOI 10.1016/S0022-3476(05)83131-2; LEE L, 1990, BIOCHEM CELL BIOL, V68, P1103, DOI 10.1139/o90-165; LEE L, 1983, CAN J BIOCHEM, V62, P36; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NOREN O, 1986, J BIOL CHEM, V261, P2306; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINSLOO JG, 1971, ARCH DIS CHILD, V46, P474, DOI 10.1136/adc.46.248.474; QUARONI A, 1992, INT J CANCER, V51, P404, DOI 10.1002/ijc.2910510312; QUARONI A, 1974, J BIOL CHEM, V249, P6424; QUEZADACALVILLO R, 1993, AM J PHYSIOL, V265, pG1150, DOI 10.1152/ajpgi.1993.265.6.G1150; REISS U, 1981, ARCH BIOCHEM BIOPHYS, V209, P342, DOI 10.1016/0003-9861(81)90290-3; ROSSITER MA, 1974, ACTA PAEDIATR SCAND, V63, P389, DOI 10.1111/j.1651-2227.1974.tb04815.x; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SEMENZA G, 1989, METABOLIC BASIS INHE, V2, P2975; SHULMAN RJ, 1983, J PEDIATR-US, V103, P23, DOI 10.1016/S0022-3476(83)80769-0; SORENSEN SH, 1982, EUR J BIOCHEM, V126, P559, DOI 10.1111/j.1432-1033.1982.tb06817.x; Sugimoto M, 1996, J BIOCHEM, V119, P500; Tibbot BK, 1996, PLANT MOL BIOL, V30, P229, DOI 10.1007/BF00020110; WHISTLER RL, 1957, CARBOHYDRATES CHEM B, P644; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187	53	91	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3076	3081		10.1074/jbc.273.5.3076	http://dx.doi.org/10.1074/jbc.273.5.3076			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446624	hybrid			2022-12-27	WOS:000071736600079
J	Wang, J; Villeneuve, S; Zhang, J; Lei, PS; Miller, CE; Lafaye, P; Nato, F; Szu, SSC; Karpas, A; Bystricky, S; Robbins, JB; Kovac, P; Fournier, JM; Glaudemans, CPJ				Wang, J; Villeneuve, S; Zhang, J; Lei, PS; Miller, CE; Lafaye, P; Nato, F; Szu, SSC; Karpas, A; Bystricky, S; Robbins, JB; Kovac, P; Fournier, JM; Glaudemans, CPJ			On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O : 1, serotypes Ogawa and Inaba	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL ALPHA-GLYCOSIDE; MONOSACCHARIDE REPEATING UNIT; O-POLYSACCHARIDE; STRUCTURAL-ANALYSIS; IMMUNOGLOBULIN-A; CORE REGION; O139; ANTIBODIES; BINDING; O/1	Monoclonal, murine IgG(1)s S-20-4, A-20-6, and IgA 2D6, directed against Vibrio cholerae O:1 Ogawa-lipopolysaccharide exhibited the same fine specificities and similar affinities for the synthetic methyl a glycosides of the (oligo)saccharide fragments mimicking the Ogawa O-polysaccharide (O-PS). They did not react with the corresponding synthetic fragments of Inaba O-PS. IgG(1)s S-20-4 and A-20-6 have absolute affinity constants for synthetic Ogawa mono-to hexasaccharides of from similar to 10(5) to similar to 10(6) M-1. For IgG(1)s S-20-4, A-20-6, and IgA 2D6, the nonreducing terminal residue of Ogawa O-PS is the dominant determinant, accounting for similar to 90% of the maximal binding energy shown by these antibodies. finding studies of derivatives of the Ogawa monosaccharide and IgGs S-20-4 and A-20-6 revealed that the C-2 O-methyl group fits into a somewhat flexible antibody cavity and that hydrogen bonds involving the oxygen and, respectively, the OH at the 2- and 3-position of the sugar moiety as well as the 2'-position in the amide side chain are required. Monoclonal IgA ZAC-3 and IgG(3) I-24-2 are specific for V. cholerae O:1 serotypes Ogawa/lnaba-LPS.(1) The former did not show binding with members of either series of the synthetic ligands related to the O-antigens of the Ogawa or Inaba serotypes, in agreement with its reported specificity for the lipid/core region (1). Inhibition studies revealed that the binding of purified IgG, I-24-2 to Ogawa-LPS might be mediated by a region in the junction of the OPS to the lipid-core region of the LPS. cDNA cloning and analysis of the anti-Ogawa antibodies S-20-4, A-20-6, and 2D6 revealed a very high degree of homology among the heavy chains. Among the light chains, no such homology between S-20-4 and A-20-6 on the one hand, and 2D6 on the other hand, exists. For the anti-Inaba/Ogawa antibodies I-24-2 and ZAC-3, their heavy chains are completely different, with some homology among the light chains.	NIDDK, Med Chem Lab, NIH, Bethesda, MD 20892 USA; NICHD, Dev & Mol Immun Lab, NIH, Bethesda, MD 20892 USA; Ctr Natl Reference Vibr & Cholera, Unite Cholera & Bivr, F-75724 Paris 15, France; Inst Pasteur, Hybridolab, F-75724 Paris 15, France	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Glaudemans, CPJ (corresponding author), NIDDK, Med Chem Lab, NIH, Bethesda, MD 20892 USA.	glau@helix.nih.gov		Zhang, Jian/0000-0002-6192-4632				Bougoudogo F, 1995, B I PASTEUR, V93, P273, DOI 10.1016/0020-2452(96)85762-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cox AD, 1996, CARBOHYD RES, V290, P59, DOI 10.1016/0008-6215(96)00131-0; Cox AD, 1996, CARBOHYD RES, V290, P43, DOI 10.1016/0008-6215(96)00135-8; DAS MK, 1978, CARBOHYD RES, V62, P165, DOI 10.1016/S0008-6215(00)83388-1; FATTOM A, 1990, INFECT IMMUN, V58, P2367, DOI 10.1128/IAI.58.7.2367-2374.1990; Glaudemans CPJ, 1997, CARBOHYD RES, V300, P169, DOI 10.1016/S0008-6215(97)00042-6; GLAUDEMANS CPJ, 1991, CHEM REV, V91, P25, DOI 10.1021/cr00001a002; GLAUDEMANS CPJ, 1977, IMMUNOCHEMISTRY, V14, P675, DOI 10.1016/0019-2791(77)90140-9; GOTOH M, 1995, CARBOHYD RES, V268, P73, DOI 10.1016/0008-6215(94)00319-B; GOTOH M, 1994, J CARBOHYD CHEM, V13, P1193, DOI 10.1080/07328309408011859; HISATSUNE K, 1993, BIOCHEM BIOPH RES CO, V190, P302, DOI 10.1006/bbrc.1993.1046; HITSATSUNE K, 1989, J GEN MICROBIOL, V135, P1901; ITO T, 1994, CARBOHYD RES, V256, P113, DOI 10.1016/0008-6215(94)84231-0; JOLLEY ME, 1974, CARBOHYD RES, V33, P377, DOI 10.1016/S0008-6215(00)82819-0; KANG A S, 1991, Methods (Orlando), V2, P111, DOI 10.1016/S1046-2023(05)80211-7; KENNE L, 1982, CARBOHYD RES, V100, P341, DOI 10.1016/S0008-6215(00)81047-2; KNIREL YA, 1995, EUR J BIOCHEM, V232, P391, DOI 10.1111/j.1432-1033.1995.tb20823.x; KOVAC P, 1988, CARBOHYD RES, V184, P87, DOI 10.1016/0008-6215(88)80008-9; Lei PS, 1996, CARBOHYD RES, V281, P47, DOI 10.1016/0008-6215(95)00331-2; LEI PS, 1995, CARBOHYD RES, V275, P117, DOI 10.1016/0008-6215(95)00147-L; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; Miller CE, 1996, MOL IMMUNOL, V33, P1217, DOI 10.1016/S0161-5890(96)00105-8; OGAWA Y, 1995, CARBOHYD RES, V277, P327, DOI 10.1016/0008-6215(95)00213-D; PARK JT, 1949, J BIOL CHEM, V181, P149; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; PRESTON LM, 1995, J BACTERIOL, V177, P835, DOI 10.1128/jb.177.3.835-838.1995; STEIN KE, 1982, J IMMUNOL, V128, P1283; STROEHER UH, 1995, P NATL ACAD SCI USA, V92, P10374, DOI 10.1073/pnas.92.22.10374; SZU SC, 1994, INDUCTION SERUM VIBR, P381; VINOGRADOV EV, 1995, EUR J BIOCHEM, V233, P152, DOI 10.1111/j.1432-1033.1995.152_1.x; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991; Zhang J, 1997, CARBOHYD RES, V300, P329, DOI 10.1016/S0008-6215(97)00070-0; ZHANG J, 1997, IN PRESS J CARBOHYDR	35	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2777	2783		10.1074/jbc.273.5.2777	http://dx.doi.org/10.1074/jbc.273.5.2777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446585	hybrid			2022-12-27	WOS:000071736600040
J	Merino, G; Shuman, HA				Merino, G; Shuman, HA			Truncation of MalF results in lactose transport via the maltose transport system of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; MEMBRANE-PROTEIN; P-GLYCOPROTEIN; CYTOPLASMIC MEMBRANE; ACTIVE-TRANSPORT; NUCLEOTIDE-BINDING; SITE; RECOGNITION; MUTAGENESIS; EXPRESSION	The active accumulation of maltose and maltodextrins by Escherichia coli is dependent on the maltose transport system. Several lines of evidence suggest that the substrate specificity of the system is not only determined by the periplasmic maltose-binding protein but that a further level of substrate specificity is contributed by the inner membrane integral membrane components of the system, MalF and MalG. We have isolated and characterized an altered substrate specificity mutant that transports lactose. The mutation responsible for the altered substrate specificity results in an amber stop codon at position 99 of MalF. The mutant requires functional MalK-ATPase activity and hydrolyzes ATP constitutively. It also requires MalG. The data suggest that in this mutant the MalG protein is capable of forming a low affinity transport path for substrate.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University	Shuman, HA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.							BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BIBI E, 1992, P NATL ACAD SCI USA, V89, P3180, DOI 10.1073/pnas.89.8.3180; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHAPON C, 1982, EMBO J, V1, P369, DOI 10.1002/j.1460-2075.1982.tb01176.x; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DENGEN DA, 1974, J BACTERIOL, V117, P477; Ehrle R, 1996, J BACTERIOL, V178, P2255, DOI 10.1128/jb.178.8.2255-2262.1996; EHRMANN M, 1991, J BIOL CHEM, V266, P16530; FERENCI T, 1980, EUR J BIOCHEM, V108, P631, DOI 10.1111/j.1432-1033.1980.tb04758.x; FERENCI T, 1986, BIOCHIM BIOPHYS ACTA, V860, P44, DOI 10.1016/0005-2736(86)90496-7; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HEKSTRA D, 1993, J BACTERIOL, V175, P6546, DOI 10.1128/jb.175.20.6546-6552.1993; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HOR LI, 1991, THESIS COLUMBIA U; KABACK HR, 1994, J EXP BIOL, V196, P183; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miller J.H., 1972, EXPT MOL GENETICS; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; REYES M, 1986, J BACTERIOL, V165, P918, DOI 10.1128/jb.165.3.918-922.1986; SADOSKY B, 1994, J BACTERIOL, V176, P3790, DOI 10.1128/JB.176.12.3790-3799.1994; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SILHAVY TJ, 1979, MOL GEN GENET, V174, P249, DOI 10.1007/BF00267797; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; WALTER C, 1992, J BIOL CHEM, V267, P8863; ZHANG F, 1993, J BIOL CHEM, V268, P19889; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	49	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2435	2444		10.1074/jbc.273.4.2435	http://dx.doi.org/10.1074/jbc.273.4.2435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442094	hybrid			2022-12-27	WOS:000071595200083
J	Chang, DJ; Ji, C; Kim, KK; Casinghino, S; McCarthy, TL; Centrella, M				Chang, DJ; Ji, C; Kim, KK; Casinghino, S; McCarthy, TL; Centrella, M			Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; OSTEOPOROSIS; PHENOTYPE; CULTURES; COMPLEX; GENE	Glucocorticoid in excess suppresses bone formation in. vivo and disrupts bone matrix protein synthesis by osteoblasts in vitro, In contrast, transforming growth factor beta (TGF-beta) potently enhances bone matrix apposition. The rat TGF-beta type I receptor gene promoter contains cis-acting elements for transcription factor CBFa1, which increases in parallel with osteoblast differentiation, Here we present molecular data linking these events. We show that previously unexplained effects of glucocorticoid on bone loss may be mediated in part by suppression of CBFa1, with a resultant decrease in the expression and activity of the TGF-beta type I receptor on matrix-producing bone cells.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA	Yale University	Centrella, M (corresponding author), Yale Univ, Sch Med, Dept Surg Plast Surg, 333 Cedar St,POB 208041, New Haven, CT 06520 USA.				NIAMS NIH HHS [AR39201] Funding Source: Medline; NIDDK NIH HHS [DK47421] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039201, R29AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER RA, 1994, ENDOCRIN METAB CLIN, V23, P641, DOI 10.1016/S0889-8529(18)30090-2; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985, DOI 10.1210/endo-121-6-1985; Centrella M, 1997, J CELL BIOCHEM, V67, P528, DOI 10.1002/(SICI)1097-4644(19971215)67:4<528::AID-JCB10>3.3.CO;2-5; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Centrella M, 1996, J BIOL CHEM, V271, P18616, DOI 10.1074/jbc.271.31.18616; CENTRELLA M, 1995, HORMONAL REGULATION, P211; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lukert Barbara P., 1996, P278; MAJORS J, 1983, P NATL ACAD SCI USA, V80, P5066; Meyers S, 1996, ONCOGENE, V13, P303; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x	24	150	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4892	4896		10.1074/jbc.273.9.4892	http://dx.doi.org/10.1074/jbc.273.9.4892			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478931	hybrid			2022-12-27	WOS:000072310400015
J	Hazen, SL; d'Avignon, A; Anderson, MM; Hsu, FF; Heinecke, JW				Hazen, SL; d'Avignon, A; Anderson, MM; Hsu, FF; Heinecke, JW			Human neutrophils employ the myeloperoxidase hydrogen peroxide chloride system to oxidize alpha-amino acids to a family of reactive aldehydes - Mechanistic studies identifying labile intermediates along the reaction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DEFICIENT MICE; OXIDATION; OXIDANTS; AUTOANTIBODIES; CHLORINATION; EOSINOPHILS; GENERATION; EPITOPES; TAURINE	We have recently demonstrated that neutrophils oxidize nearly all of the amino acids commonly found in plasma to a corresponding family of aldehydes in high yield. The reaction is mediated by hypochlorous acid (HOCl), the major oxidant generated by the myeloperoxidase-H2O2-Cl- system of phagocytes, We now present evidence for the underlying mechanism of this reaction, including the structural requirements and reaction intermediates formed, Utilizing mass spectrometry and isotopically labeled amino acids, we rule out hydrogen atom abstraction from the alpha-carbon as the initial event in aldehyde formation during amino acid oxidation, a pathway known to occur with ionizing radiation, Aldehyde generation from amino acids required the presence of an alpha-amino moiety; beta- and epsilon-amino acids did not form aldehydes upon oxidation by either the myeloperoxidase system or HOCl, generating stable monochloramines instead, UV difference spectroscopy, high pressure liquid chromatography, and multinuclear (H-1,N-15) NMR spectroscopy established that the conversion of alpha-amino acids into aldehydes begins with generation of an unstable alpha-monochloramine, which subsequently decomposes to yield an aldehyde, Precursor product relationships between alpha-amino acid and alpha-monochloramine, and alpha-monochloramine and aldehyde were confirmed by high pressure liquid chromatography purification of the reaction intermediate and subsequent H-1 and N-15 NMR spectroscopy. Collectively, these results detail the chemical mechanism and reaction intermediates generated during conversion of amino acids into aldehydes by myeloperoxidase-generated HOCl.	Washington Univ, Dept Mol Biol & Pharmacol, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA; Washington Univ, Dept Chem, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Heinecke, JW (corresponding author), Washington Univ, Dept Mol Biol & Pharmacol, Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.	heinecke@im.wustl.edu	Hazen, Stanley L/ABD-5845-2021	Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015013, R01AG012293] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NIA NIH HHS [R01 AG12293, R01 AG15013] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH J, 1982, P NATL ACAD SCI USA, V78, P210; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BASS DA, 1985, CECIL TXB MED, P1011; Dakin HD, 1906, J BIOL CHEM, V1, P171; Dakin HD, 1908, J BIOL CHEM, V5, P409; Dakin HD, 1908, J BIOL CHEM, V4, P63; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; FURUKAWA J, 1963, POLYM ALDEHYDES OXIM, P43; GARRISON WARREN M., 1968, CURR TOP RADIAT RES, VVol. 4-4, P43; GARRISON WM, 1964, RADIATION RES      S, V4, P158; GRISHAM MB, 1984, J BIOL CHEM, V259, P6575; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HAZEN SL, 1998, IN PRESS BIOCHEMISTR; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; KNAPP DR, 1979, HDB ANAL DERIVATIZAT, P485; LINDER M, 1992, NUTR BIOCH METABOLIS, P98; MAXWELL CR, 1955, RADIAT RES, V2, P431, DOI 10.2307/3570188; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MONNIER VM, 1991, GERONTOLOGY, V37, P152; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Palinski W, 1996, J CLIN INVEST, V98, P800, DOI 10.1172/JCI118853; RAPER, 1932, BIOCH J, V266, P2000; ROWBOTTOM J, 1955, J BIOL CHEM, V212, P877; Schauenstein E, 1978, Ciba Found Symp, P225; SHARPLESS NE, 1955, RADIAT RES, V2, P135, DOI 10.2307/3570317; SHRINER RL, 1980, SYSTEMATIC IDENTIFIC, P161; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, P NATL ACAD SCI USA, V87, P389; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; SWALLOW AJ, 1960, RAD CHEM ORGANIC COM, P200; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; THOMAS EL, 1985, J BIOL CHEM, V260, P3321; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6	42	160	173	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4997	5005		10.1074/jbc.273.9.4997	http://dx.doi.org/10.1074/jbc.273.9.4997			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478947	hybrid			2022-12-27	WOS:000072310400031
J	Pei, L				Pei, L			Genomic organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; EMBRYONIC-DEVELOPMENT; CELL-DIFFERENTIATION; EGR FAMILY; EXPRESSION; PROMOTER; SP1; HOX-1.4; DOMAINS; TESTIS	The rat pituitary tumor transforming gene (PTTG) genomic structure was characterized in this study. Northern blot analysis showed that PTTG mRNA is highly expressed in testicular cell lines. Transfection of testicular cell lines with fusion constructs containing various portions of PTTG 5'-flanking sequences linked to luciferase showed that at least 745 base-pair (bp(s)) 5'-flanking sequences are required for PTTG transcriptional activation. DNaseI footprinting assays indicated that nuclear protein(s) from testicular cell lines interacts with PTTG 5'-flanking sequence between -509 and -624 bp, including two consensus Spl binding sites. Western and Southwestern blot analysis showed that three nuclear proteins in addition to Spl protein specifically interact with this DNA sequence and that two of these proteins are testicular cell-specific. Deletion of this 115-bp sequence from PTTG promoter resulted in complete loss of promoter function. Site-directed mutagenesis within the Spl consensus sequences indicated that the Spl binding sites are not critical components of the enhancer sequence for PTTG trancriptional activation in testicular cell lines. Finally, the 115-bp enhancer sequence was shown to be able to activate transcription from a heterologous promoter. These results suggest that PTTG transcriptional activation in testicular cell lines involves interactions of multiple nuclear factors with the PTTG 5' enhancer sequence.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Endocrinol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Endocrinol, 8700 Beverly Blvd,D-3066, Los Angeles, CA 90048 USA.	Pei@CSMC.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02346] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DITTMER J, 1994, J BIOL CHEM, V269, P21428; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PROPST F, 1988, ONCOGENE, V2, P227; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WATRIN F, 1993, DEV BIOL, V156, P136, DOI 10.1006/dbio.1993.1064; WILKINSON MF, 1990, DEV BIOL, V141, P451, DOI 10.1016/0012-1606(90)90400-D; WOLGEMUTH DJ, 1991, ANN NY ACAD SCI, V637, P300, DOI 10.1111/j.1749-6632.1991.tb27317.x; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YU CY, 1991, J BIOL CHEM, V266, P8907; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	29	33	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5219	5225		10.1074/jbc.273.9.5219	http://dx.doi.org/10.1074/jbc.273.9.5219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478977	hybrid			2022-12-27	WOS:000072310400061
J	Banghart, LR; Chamberlain, CW; Velarde, J; Korobko, IV; Ogg, SL; Jack, LJW; Vakharia, VN; Mather, IH				Banghart, LR; Chamberlain, CW; Velarde, J; Korobko, IV; Ogg, SL; Jack, LJW; Vakharia, VN; Mather, IH			Butyrophilin is expressed in mammary epithelial cells from a single-sized messenger RNA as a type I membrane glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-GLOBULE-MEMBRANE; MILK LIPID GLOBULES; IMMUNOGLOBULIN SUPERFAMILY; BOVINE BUTYROPHILIN; ENDOPLASMIC-RETICULUM; APICAL GLYCOPROTEIN; CYTOPLASMIC DOMAIN; XANTHINE-OXIDASE; PROTEIN; SURFACE	We investigated the expression of butyrophilin in eukaryotic cells with a view to determining the number of mRNA species, the incorporation of the peptide chain into microsomes, and the topology of the processed protein in biological membranes, Butyrophilin is synthesized from a single sized mRNA in both bovine and murine lactating mammary tissue and associates with microsomal membranes with a type I topology (N-exo.C-cyto) via a single hydrophobic anchor in the middle of the sequence. Several isoelectric variants of the protein were detected in cellular membranes from lactating bovine mammary tissue and in the milk-fat-globule membrane. We found no evidence for soluble forms of butyrophilin in postmicrosomal supernatants, The 66-kDa protein appears to be subjected to limited proteolysis, giving rise to a 62-kDa fragment lacking the C terminus and to other more minor fragments of lower M-r, in the milk-fat-globule membrane. Antipeptide antibodies to epitopes within the N- nd C-terminal domains were used to show that butyrophilin retains a type I topology in plasma membranes when expressed in insect cells from a baculovirus vector, and in secreted milk-fat globules, These data do not agree with previous suggestions that butyrophilin may exist in cytoplasmic soluble forms, or be reorganized in the plane of the lipid bilayer during secretion in lipid droplets from mammary cells. The results are discussed with reference to the role butyrophilin may play as the principal scaffold for the assembly of a complex with xanthine oxidase and other proteins that functions in the budding and release of milk-fat globules from the apical surface during lactation.	Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA; Univ Maryland, Agr Biotechnol Ctr, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Mather, IH (corresponding author), Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA.	im2@umail.umd.edu		Vakharia, Vikram/0000-0002-0955-3010	FOGARTY INTERNATIONAL CENTER [F06TW001508] Funding Source: NIH RePORTER; FIC NIH HHS [FO6TWO1508-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BANGHART LR, 1992, MOL BIOL CELL, V3, pA208; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BUCHHEIM W, 1982, NATURWISSENSCHAFTEN, V69, P505, DOI 10.1007/BF00365826; BUCHHEIM W, 1988, BIOL HUMAN MILK, V15, P27; Davey HW, 1997, GENE, V199, P57, DOI 10.1016/S0378-1119(97)00346-6; DEENEY JT, 1985, EUR J CELL BIOL, V38, P16; DYLEWSKI DP, 1984, EUR J CELL BIOL, V35, P99; FRANKE WW, 1981, J CELL BIOL, V89, P485, DOI 10.1083/jcb.89.3.485; FREUDENSTEIN C, 1979, EXP CELL RES, V118, P277, DOI 10.1016/0014-4827(79)90153-8; GARDINIER MV, 1992, J NEUROSCI RES, V33, P177, DOI 10.1002/jnr.490330123; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; HEID HW, 1983, BIOCHIM BIOPHYS ACTA, V728, P228, DOI 10.1016/0005-2736(83)90476-5; HINK WF, 1991, IN VITRO CELL DEV B, V27, P397, DOI 10.1007/BF02630959; Ishii T, 1995, BBA-GEN SUBJECTS, V1245, P285, DOI 10.1016/0304-4165(95)00102-6; JACK LJW, 1990, J BIOL CHEM, V265, P14481; JARASCH ED, 1981, CELL, V25, P67, DOI 10.1016/0092-8674(81)90232-4; Jensen R. G., 1995, HDB MILK COMPOSITION, P5; Keenan T. W., 1988, Fundamentals of dairy chemistry., P511; KEON BH, 1994, BBA-LIPID LIPID MET, V1215, P327, DOI 10.1016/0005-2760(94)90061-2; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LINSLEY PS, 1994, PROTEIN SCI, V3, P1341, DOI 10.1002/pro.5560030820; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mather I. H., 1987, The mammary gland. Development, regulation, and function., P217; MATHER IH, 1975, J MEMBRANE BIOL, V21, P65, DOI 10.1007/BF01941062; MATHER IH, 1993, J DAIRY SCI, V76, P3832, DOI 10.3168/jds.S0022-0302(93)77726-7; MATHER IH, 1978, BIOCHIM BIOPHYS ACTA, V514, P25, DOI 10.1016/0005-2736(78)90074-3; MATHER IH, 1980, EUR J BIOCHEM, V110, P327, DOI 10.1111/j.1432-1033.1980.tb04871.x; MELANCON P, 1986, EMBO J, V5, P1551, DOI 10.1002/j.1460-2075.1986.tb04396.x; MONDY BL, 1993, PROTOPLASMA, V177, P32, DOI 10.1007/BF01403396; NEIRA LM, 1990, PROTOPLASMA, V159, P168, DOI 10.1007/BF01322599; NIELSEN CS, 1977, BIOCHIM BIOPHYS ACTA, V466, P496, DOI 10.1016/0005-2736(77)90342-X; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ogg SL, 1996, MAMM GENOME, V7, P900, DOI 10.1007/s003359900265; PACIOTTI GF, 1992, PROG NEUROENDOCRINIM, V5, P21; PATTON S, 1986, LIPIDS, V21, P170, DOI 10.1007/BF02534441; PATTON S, 1975, BIOCHIM BIOPHYS ACTA, V415, P273, DOI 10.1016/0304-4157(75)90011-8; PINTODASILVA P, 1980, EXP CELL RES, V125, P127, DOI 10.1016/0014-4827(80)90197-4; Ruddy DA, 1997, GENOME RES, V7, P441, DOI 10.1101/gr.7.5.441; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147, DOI 10.1093/oxfordjournals.jbchem.a124702; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TaziAhnini R, 1997, IMMUNOGENETICS, V47, P55, DOI 10.1007/s002510050326; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNET C, 1993, J MOL EVOL, V37, P600; WARD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695; WELSCH U, 1988, HISTOCHEMISTRY, V88, P357; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOODING FBP, 1975, CELL TISSUE RES, V165, P113, DOI 10.1007/BF00222804; ZERBAN H, 1978, CELL BIOL INT REP, V2, P87, DOI 10.1016/0309-1651(78)90088-7; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x; [No title captured]	54	53	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4171	4179		10.1074/jbc.273.7.4171	http://dx.doi.org/10.1074/jbc.273.7.4171			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461613	hybrid			2022-12-27	WOS:000072048400055
J	Yao, GQ; Sun, BH; Hammond, EE; Spencer, EN; Horowitz, MC; Insogna, KL; Weir, EC				Yao, GQ; Sun, BH; Hammond, EE; Spencer, EN; Horowitz, MC; Insogna, KL; Weir, EC			The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I CSF-1; OP OP MOUSE; PARATHYROID-HORMONE; OSTEOBLASTIC CELLS; MOLECULAR-CLONING; MESSENGER-RNA; BONE-RESORPTION; C-FMS; EXPRESSION; RECEPTORS	Colony-stimulating factor-1 (CSF-1) is a hematopoietic growth factor that is released by osteoblasts and is recognized to play a critical role in bone remodeling in vivo and in vitro. CSF-1 is synthesized as a soluble or cell-surface protein. It is unclear, however, whether human osteoblasts express both molecular forms of CSF-1, and whether these isoforms can independently mediate osteoclastogenesis. In the present study, using a combination of quantitative reverse transcriptase polymerase chain reaction, flow cytometry, and Western immunoblot analysis, we have demonstrated that human osteoblast-like cells as well as primary human osteoblasts express the cell-surface form of CSF-1 both constitutively and in response to parathyroid hormone and tumor necrosis factor. Furthermore, using an in vitro coculture system, we have shown that cell-surface CSF-1 alone is sufficient to support osteoclast formation. These findings may be especially significant in view of evidence that direct cell-to-cell contact is critical for osteoclast formation, and suggest that differential regulation of expression of the CSF-1 isoforms may influence osteoclast function modulated by osteotropic hormones.	Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Orthopaed & Rehabil, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Weir, EC (corresponding author), Yale Univ, Sch Med, Comparat Med Sect, POB 208016, New Haven, CT 06520 USA.	eleanor.weir@yale.edu		Insogna, Karl/0000-0001-6973-5679	NIAMS NIH HHS [AR39571] Funding Source: Medline; NIDDK NIH HHS [DK45228, DK50859] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050859, R01DK045228] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONIOLICORBOZ V, 1992, ENDOCRINOLOGY, V130, P437; BARON R, 1983, BONE HISTOMORPHOMETR, P31; BEGG SK, 1993, J EXP MED, V177, P237, DOI 10.1084/jem.177.1.237; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIVITELLI R, 1994, J BONE MINER RES, V9, P1407; DAITER E, 1992, J CLIN ENDOCR METAB, V74, P850, DOI 10.1210/jc.74.4.850; DIVIACCO S, 1992, GENE, V122, P3013; ELFORD PR, 1987, CALCIFIED TISSUE INT, V41, P151, DOI 10.1007/BF02563795; ELIAS JA, 1995, ENDOCRINOLOGY, V136, P489, DOI 10.1210/en.136.2.489; Felix R, 1996, J CELL PHYSIOL, V166, P311, DOI 10.1002/(SICI)1097-4652(199602)166:2<311::AID-JCP9>3.0.CO;2-S; FELIX R, 1989, CALCIFIED TISSUE INT, V44, P356, DOI 10.1007/BF02556317; HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006-291X(91)92015-C; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; HUME DA, 1995, J INTERF CYTOK RES, V15, P279, DOI 10.1089/jir.1995.15.279; JIN CF, 1994, PCR METH APPL, V3, P252; Kaplan DL, 1996, J CELL PHYSIOL, V168, P199; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; MAHAFFEY JE, 1979, J BIOL CHEM, V254, P6496; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MOROHASHI T, 1994, J BONE MINER RES, V9, P401; PAMPFER S, 1991, MOL ENDOCRINOL, V5, P1931, DOI 10.1210/mend-5-12-1931; Perkins SL, 1995, AM J PHYSIOL-ENDOC M, V269, pE1024, DOI 10.1152/ajpendo.1995.269.6.E1024; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; RETTENMIER CW, 1989, CURR TOP MICROBIOL, V149, P129; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; ROULEAU MF, 1988, ENDOCRINOLOGY, V123, P187, DOI 10.1210/endo-123-1-187; Rubin J, 1996, CALCIFIED TISSUE INT, V59, P291, DOI 10.1007/s002239900125; Sarma U, 1996, BLOOD, V88, P2531, DOI 10.1182/blood.V88.7.2531.bloodjournal8872531; SHADLE PJ, 1989, J CELL BIOCHEM, V40, P91, DOI 10.1002/jcb.240400110; SHIINAISHIMI Y, 1986, BIOCHEM BIOPH RES CO, V134, P400, DOI 10.1016/0006-291X(86)90577-2; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; TAKAHASHI N, 1991, J BONE MINER RES, V6, P977; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; WEIR EC, 1993, J BONE MINER RES, V8, P1507; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WIKTORJEDRZEJCZAK W, 1982, J EXP MED, V156, P1516, DOI 10.1084/jem.156.5.1516; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; Yao GQ, 1996, BIOCHEM PHARMACOL, V51, P431, DOI 10.1016/0006-2952(95)02198-1; YAO GQ, 1995, VIRUS GENES, V9, P247, DOI 10.1007/BF01702880	44	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4119	4128		10.1074/jbc.273.7.4119	http://dx.doi.org/10.1074/jbc.273.7.4119			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461606	hybrid			2022-12-27	WOS:000072048400048
J	Barylko, B; Binns, D; Lin, KM; Atkinson, MAL; Jameson, DM; Yin, HL; Albanesi, JP				Barylko, B; Binns, D; Lin, KM; Atkinson, MAL; Jameson, DM; Yin, HL; Albanesi, JP			Synergistic activation of dynamin GTPase by Grb2 and phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; CRYSTAL-STRUCTURE; ACIDIC PHOSPHOLIPIDS; MICROTUBULES; BINDING; KINASE; PHOSPHORYLATION; ENDOCYTOSIS; SUBUNITS; VESICLES	Hydrolysis of GTP by dynamin is essential for budding clathrin-coated vesicles from the plasma membrane. Two distinct domains of dynamin are implicated in the interactions with dynamin GTPase activators. Microtubules and Grb2 bind to the carboxyl-terminal proline/arginine-rich domain (PRD), whereas phosphoinositides bind to the pleckstrin homology (PH) domain. In this study we tested the effect of different phosphoinositides on dynamin GTPase activity and found that the best activator is phosphatidylinositol 4,5-bisphosphate followed by 1-O-(1,2-di-O-palmitoyl-sn-glycerol-3-benzyloxyphosphoryl)-D-myo-inositol 3,4,5-triphosphate. Phosphatidylinositol 4-phosphate was a weak activator and phosphatidylinositol 3,4-bisphosphate did not activate GTPase at all. We then addressed the question of whether both domains of dynamin, PRD and PH, can be engaged simultaneously, and determined the effects of dual occupancy on dynamin GTPase activity. We found that Grb2 and phosphatidylinositol 4,5-bisphosphate together increased the dynamin GTPase activity up to 4-fold higher than that obtained by these activators tested separately, and also reduced the dynamin concentration required for half-maximal activities by 3-fold. These results indicate that both stimulators can bind to dynamin simultaneously resulting in superactivation of dynamin GTPase activity. We propose that SH3-containing proteins such as Grb2 bind to the dynamin PRD to target it to clathrin-coated pits and prime it for superactivation by phosphoinositides.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, Tyler, TX 75708 USA; Univ Hawaii, Dept Biochem & Biophys, Honolulu, HI 96822 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); University of Hawaii System	Albanesi, JP (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031430] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM5112] Funding Source: Medline; NINDS NIH HHS [NS31430] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohn E. J., 1943, PROTEINS AMINO ACIDS; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P59; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOOD LE, 1984, IMMUNOLOGY, P48; KORN ED, 1982, METHOD ENZYMOL, V85, P357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Lin HC, 1997, J BIOL CHEM, V272, P25999, DOI 10.1074/jbc.272.41.25999; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P357; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	47	109	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3791	3797		10.1074/jbc.273.6.3791	http://dx.doi.org/10.1074/jbc.273.6.3791			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452513	hybrid			2022-12-27	WOS:000071822300098
J	Brasier, AR; Jamaluddin, M; Casola, A; Duan, WL; Shen, Q; Garafalo, RP				Brasier, AR; Jamaluddin, M; Casola, A; Duan, WL; Shen, Q; Garafalo, RP			A promoter recruitment mechanism for tumor necrosis factor-alpha-induced interleukin-8 transcription in type II pulmonary epithelial cells - Dependence of nuclear abundance of Rel A, NF-kappa B1 and c-Rel transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RESPIRATORY SYNCYTIAL VIRUS; UBIQUITIN-PROTEASOME PATHWAY; TATA-BINDING PROTEIN; GENE-EXPRESSION; MMTV PROMOTER; IN-VIVO; ACTIVATION; DNA; INFECTION	The alveolar macrophage-derived peptide tumor necrosis factor-alpha (TNF alpha) initiates pulmonary inflammation through its ability to stimulate interleukin-8 (IL-8) synthesis in alveolar epithelial cells through an incompletely described transcriptional mechanism. In this study, we use the technique of ligation-mediated polymerase chain reaction (LMPCR) to record changes in transcription factor occupancy of the IL-8 promoter after TNF alpha stimulation of A549 human alveolar cells. Using dimethylsulfate/LMPCR, no detectable proteins bind the TATA box in unstimulated cells. By contrast, TNF alpha rapidly induces protection of G residues at -79 and -80 coincident with endogenous IL-8 gene transcription. Using DNase I/LMPCR, we observe inducible protection of nucleotides -60 to -99 (the TNF response element) and nucleotides -3 to -32 (containing the TATA box). Surprisingly, extensive TATA box protection is only seen after TNF alpha stimulation Using a two-step microaffinity isolation/Western immunoblot DNA binding assay, we observe that the NF-kappa B subunits Rel A, NF-kappa B1, and c-Rel inducibly bind the TNF response element; these proteins undergo rapid TNF alpha-inducible increases in nuclear abundance as a consequence of I kappa B alpha proteolysis. Furthermore, the peptide aldehyde N-acetyl-Leu-Leu-norleucinal, an agent that blocks both I kappa B alpha proteolysis and NF-kappa B subunit translocation, abrogates recombinant human TNF alpha-inducible IL-8 gene transcription. These studies demonstrate that IL-8 is activated by a promoter recruitment mechanism in alveolar epithelial cells, where NF-kappa B subunit translocation is required for (and coincident with) binding of the constitutively active TATA box-binding proteins.	Univ Texas, Med Branch, Div Endocrinol, Dept Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Div Endocrinol, Dept Med, MRB 8-138,301 Univ Blvd, Galveston, TX 77555 USA.	arbrasie@utmb.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015939, R01AI040218] Funding Source: NIH RePORTER; NIAID NIH HHS [1 R01 AI40218-01A1, AI/HL 15939-14A1] Funding Source: Medline; NICHD NIH HHS [R30HD 27841] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARNOLD R, 1994, IMMUNOLOGY, V82, P126; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Beato M, 1996, J MOL MED, V74, P711, DOI 10.1007/s001090050076; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEUTLER B, 1995, J INVEST MED, V43, P227; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; BRASIER AR, 1991, METHODS NEUROSCIENCE, P108; BRASIER AR, 1990, CURRENT PROTOCOLS MO; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOI AMK, 1992, FEBS LETT, V309, P327, DOI 10.1016/0014-5793(92)80799-M; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Han YQ, 1997, J BIOL CHEM, V272, P9825; HAYES PJ, 1994, J MED VIROL, V42, P323, DOI 10.1002/jmv.1890420402; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jamaluddin M, 1996, J VIROL, V70, P1554, DOI 10.1128/JVI.70.3.1554-1563.1996; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Khair OA, 1996, EUR RESPIR J, V9, P1913, DOI 10.1183/09031936.96.09091913; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KWON J, 1994, AM J PHYSIOL, V267, pL398; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; LI Z, 1989, GENE DEV, V3, P1814, DOI 10.1101/gad.3.11.1814; Liu L, 1996, AM J RESP CELL MOL, V15, P771, DOI 10.1165/ajrcmb.15.6.8969272; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MASSION PP, 1994, J CLIN INVEST, V93, P26, DOI 10.1172/JCI116954; MUELLER P R, 1991, Methods (Orlando), V2, P20, DOI 10.1016/S1046-2023(05)80122-7; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STADNYK AW, 1994, FASEB J, V8, P1041, DOI 10.1096/fasebj.8.13.7926369; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	56	149	153	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3551	3561		10.1074/jbc.273.6.3551	http://dx.doi.org/10.1074/jbc.273.6.3551			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452482	hybrid			2022-12-27	WOS:000071822300067
J	Justice, MC; Hsu, MJ; Tse, B; Ku, T; Balkovec, J; Schmatz, D; Nielsen, J				Justice, MC; Hsu, MJ; Tse, B; Ku, T; Balkovec, J; Schmatz, D; Nielsen, J			Elongation factor 2 as a novel target for selective inhibition of fungal protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; EF-G; TRANSLATION; RESISTANT; SYSTEM; GDP	Elongation factor 2 (EF2) is an essential protein catalyzing ribosomal translocation during protein synthesis and is highly conserved in all eukaryotes. It is largely interchangeable in translation systems reconstituted from such divergent organisms as human, wheat, and fungi, We have identified the sordarins as selective inhibitors of fungal protein synthesis acting via a specific interaction with EF2 despite the high degree of amino acid sequence homology exhibited by EF2s from various eukaryotes, In vitro reconstitution assays using purified components from human, yeast, and plant cells demonstrate that sordarin sensitivity is dependent on fungal EF2, Genetic analysis of sordarin-resistant mutants of Saccharomyces cerevisiae shows that resistance to the inhibitor is linked to the genes EFT1 and EFT2 that encode EF2, Sordarin blocks ribosomal translocation by stabilizing the fungal EF2-ribosome complex in a manner similar to that of fusidic acid, The fungal specificity of the sordarins, along with a detailed understanding of its mechanism of action, make EF2 an attractive antifungal target, These findings are of particular significance due to the need for new antifungal agents.	Merck Res Labs, Dept Basic Anim Sci Res, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Nielsen, J (corresponding author), Merck Res Labs, Dept Basic Anim Sci Res, Rahway, NJ 07065 USA.	jennifer_nielsen_kahn@merck.com						BELFIELD GP, 1993, MOL MICROBIOL, V9, P411, DOI 10.1111/j.1365-2958.1993.tb01702.x; BODLEY JW, 1970, FEBS LETT, V11, P153, DOI 10.1016/0014-5793(70)80516-6; COLLINS JF, 1971, J BIOL CHEM, V246, P1049; COVAL SJ, 1995, J ANTIBIOT, V48, P1171, DOI 10.7164/antibiotics.48.1171; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; Evarsson A., 1994, EMBO J, V13, P3669; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HAUSER D, 1971, HELV CHIM ACTA, V54, P1178, DOI 10.1002/hlca.19710540427; HUSSAIN I, 1986, GENE, V46, P13, DOI 10.1016/0378-1119(86)90162-9; Johanson U, 1996, J MOL BIOL, V258, P420, DOI 10.1006/jmbi.1996.0259; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; JURNAK F, 1994, STRUCTURE, V2, P785, DOI 10.1016/S0969-2126(94)00078-6; LAUER SJ, 1984, J BIOL CHEM, V259, P1644; PHAN LD, 1993, J BIOL CHEM, V268, P8665; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; Skogerson L, 1979, Methods Enzymol, V60, P676	19	134	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3148	3151		10.1074/jbc.273.6.3148	http://dx.doi.org/10.1074/jbc.273.6.3148			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452424	hybrid			2022-12-27	WOS:000071822300009
J	Siddiqui, AA; Garland, JR; Dalton, MB; Sinensky, M				Siddiqui, AA; Garland, JR; Dalton, MB; Sinensky, M			Evidence for a high affinity, saturable, prenylation-dependent p21(Ha-ras) binding site in plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYBASIC DOMAIN; RAS PROTEINS; PURIFICATION; PALMITOYLATION; INSULIN	Oncogenic p21(ras) proteins can only exert their stimulation of cellular proliferation when plasma membrane-associated. This membrane association has an absolute requirement for post-translational modification with isoprenoids. The mechanism by which isoprenoids participate in the specific association of p21(ras) with plasma membranes is the subject of this report. We present in vitro evidence for a plasma membrane binding protein for p21(ras) that can recognize the isoprenoid substituent and, therefore, may facilitate the localization of p21(ras).	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Sinensky, M (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Box 70581, Johnson City, TN 37614 USA.	sinensky@etsu-tn.edu						Bylund D.B., 1990, METHODS NEUROTRANSMI, P1; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CAMP LA, 1993, J BIOL CHEM, V268, P22566; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; FLEISCHER S, 1975, METHOD ENZYMOL, V3, P299; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GHOMASCHI F, 1995, BIOCHEMISTRY-US, V35, P11910; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KHOSRAVIFAR R, 1995, METHOD ENZYMOL, V255, P56; Kilic F, 1997, J BIOL CHEM, V272, P5298, DOI 10.1074/jbc.272.8.5298; LOWE PN, 1990, ONCOGENE, V5, P1045; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PFENNING MA, 1990, METHODS NEUROTRANSMI, P156; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SIDDIQUI AA, 1985, J HELMINTHOL, V59, P263, DOI 10.1017/S0022149X00008063; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Summers MD, 1987, MANUAL METHODS BACUL; TAN EW, 1991, J BIOL CHEM, V266, P10719; WHITTENBERGER B, 1977, P NATL ACAD SCI USA, V74, P2251, DOI 10.1073/pnas.74.6.2251; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	29	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3712	3717		10.1074/jbc.273.6.3712	http://dx.doi.org/10.1074/jbc.273.6.3712			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452502	hybrid			2022-12-27	WOS:000071822300087
J	Kadrmas, JL; Raetz, CRH				Kadrmas, JL; Raetz, CRH			Enzymatic synthesis of lipopolysaccharide in Escherichia coli - Purification and properties of heptosyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; T7 RNA-POLYMERASE; SALMONELLA-TYPHIMURIUM; LIPID-A; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; ANTIBACTERIAL AGENTS; CLONED GENES; BIOSYNTHESIS; EXPRESSION; ENDOTOXIN	Heptosyltransferase I, encoded by the rfaC(waaC) gene of Escherichia coli, is thought to add L-glycero-D-manno-heptose to the inner 3-deoxy-D-manno-octulosonic acid (Kdo) residue of the lipopolysaccharide core. Lipopolysaccharide isolated from mutants defective in rfaC lack heptose and all other sugars distal to heptose. The putative donor, ADP-L-glycero-D-manno-heptose, has never been fully characterized and is not readily available, In cell extracts, the analog ADP-mannose can serve as an alternative donor for RfaC-catalyzed glycosylation of the acceptor, Kdo(2)-lipid IVA. Using a T7 promoter construct that overexpresses RfaC similar to 15,000-fold, the enzyme has been purified to near homogeneity. NH2-terminal sequencing confirms that the purified enzyme is the rfaC gene product. The subunit molecular mass is 36 kDa, Enzymatic activity is dependent upon the presence of Triton X-100 and is maximal at pH 7.5. The apparent K-m (determined at near saturating concentrations of the second substrate) is 1.5 mM for ADP-mannose and 4.5 mu M for Kdo(2)-lipid IVA. Chemical hydrolysis of the RfaC reaction product at 100 degrees C in the presence of sodium acetate and 1% sodium dodecyl sulfate generates fragments consistent with the inner Kdo residue of Kdo(2)-lipid IVA as the site of mannosylation, The analog, Kdo-lipid IVA, functions as an acceptor, but is mannosylated at less than 1% the rate of Kdo(2)-lipid IVA. The purified enzyme displays no activity with ADP-glucose, GDP-mannose, UDP-glucose, or UDP-galactose. Mannosylation of Kdo(2)-lipid IVA catalyzed by RfaC proceeds in high yield and may be useful for the synthesis of lipopolysaccharide analogs. Pure RfaC can also be used together with Kdo(2)-[4'P-32]lipid IVA to assay for the physiological donor (presumably ADP-L-glycero-D-manno-heptose) in a crude, low molecular weight fraction isolated from wild type cells.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007105, R37GM051796, R01GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07105, GM-51796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; BEHUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BOWMAN HG, 1968, GENET RES, V12, P169; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAROFF M, 1991, J BIOL CHEM, V266, P18543; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CREEGER ES, 1979, J BIOL CHEM, V254, P804; DANKERT M, 1964, BIOCHEM BIOPH RES CO, V14, P358, DOI 10.1016/S0006-291X(64)80010-3; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DING L, 1994, J BIOL CHEM, V269, P24384; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GRUNDSTROM T, 1980, J BACTERIOL, V143, P1127; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; HAVEKES L, 1977, J BACTERIOL, V129, P1; Hood DW, 1996, MOL MICROBIOL, V22, P951, DOI 10.1046/j.1365-2958.1996.01545.x; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1997, FASEB J, V11, pA1421; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN V, 1973, EUR J BIOCHEM, V32, P268, DOI 10.1111/j.1432-1033.1973.tb02607.x; Makela P. H., 1984, HDB ENDOTOXIN, P59; Miller J.H., 1972, EXPT MOL GENETICS; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; NISHIMURA A, 1992, MICROBIOL REV, V56, P137, DOI 10.1128/MMBR.56.1.137-151.1992; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; PASSERON S, 1964, BIOCHIM BIOPHYS ACTA, V89, P372, DOI 10.1016/0926-6569(64)90233-0; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; REEVES PR, 1994, BACTERIAL CELL WALL, V27, P281; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROANTREE RJ, 1977, J GEN MICROBIOL, V103, P223, DOI 10.1099/00221287-103-2-223; RONCERO C, 1992, J BACTERIOL, V174, P3250, DOI 10.1128/jb.174.10.3250-3260.1992; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANDERSON KE, 1974, CAN J MICROBIOL, V20, P1127, DOI 10.1139/m74-175; SANDERSON KE, 1988, MICROBIOL REV, V52, P485, DOI 10.1128/MMBR.52.4.485-532.1988; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHNAITMAN CA, 1991, J BACTERIOL, V173, P7410, DOI 10.1128/jb.173.23.7410-7411.1991; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALENGA RW, 1980, J BIOL CHEM, V255, P4257; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555	54	61	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2799	2807		10.1074/jbc.273.5.2799	http://dx.doi.org/10.1074/jbc.273.5.2799			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446588	hybrid			2022-12-27	WOS:000071736600043
J	Pahan, K; Sheikh, FG; Khan, M; Namboodiri, AMS; Singh, I				Pahan, K; Sheikh, FG; Khan, M; Namboodiri, AMS; Singh, I			Sphingomyelinase and ceramide stimulate the expression of inducible nitric-oxide synthase in rat primary astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; C6 GLIOMA-CELLS; PROTEIN-KINASE; ACTIVATION; APOPTOSIS; INDUCTION; PATHWAY; ALPHA	The sphingomyelin signal transduction pathway is known to play a role in mediating the action of various cytokines, Here we examined the possible role of the sphingomyelin signaling pathway on lipopolysaccharide (LPS)- and cytokine-mediated production of NO and the expression of inducible nitric-oxide synthase (iNOS). Sphingomyelinase (SMase) treatment of astrocytes increased the cellular levels of ceramide without the induction of NO production, However, incubation of LPS or cytokine-stimulated astrocytes with SMase or by increasing intracellular ceramide by cell-permeable ceramide analogs (C-2- or C-6-ceramide) or inhibitor of ceramidase (N-oleoyl ethanolamine) led to a time-and dose-dependent increase in the production of NO, This increase in NO production was accompanied by an increase in iNOS activity, MOS protein, and iNOS mRNA, Similar to astrocytes, SMase or ceramide analogs also stimulated the LPS-and cytokine-mediated expression of iNOS in the C-6 glial cell line, Since activation of NF-kappa B is necessary for the induction of MOS, we examined the effect of SMase and C-2-ceramide on the activation of NF-kappa B. Although SMase or C-2-ceramide alone was ineffective in activating NF-kappa B, both stimulated the LPS-mediated activation of NF-kappa B in LPS-activated astrocytes, Inhibition of ceramide and LPS-mediated induction of iNOS by antioxidant inhibitors of NF-kappa B (N-acetylcysteine and pyrrolidine dithiocarbamate) suggest that the stimulatory effect of ceramide on the induction of iNOS is due to the stimulation of NF-kappa B activation and that cellular redox plays a role in the activation of NF-kappa B and induction of iNOS, Inhibition of LPS-mediated as well as LPS and ceramide-mediated induction of iNOS and activation of NF-kappa B by PD98059, a specific inhibitor of activation of mitogen activated protein (MAP) kinase kinase (MEK), and FPT inhibitor II, a selective inhibitor of Ras farnesyl protein transferase, indicate that the Ras-MAP kinase pathway is involved in LPS-ceramide induced activation of NF-kappa B and induction of iNOS, and that ceramide-mediated signaling events probably converge into the LPS-modulated MAP kinase signaling pathway resulting in greater activation of NF-KB and iNOS induction, This study illustrates a novel role of the sphingomyelin-ceramide signaling pathway in stimulating the expression of iNOS via LPS-or cytokine-mediated activation of NF-KB in astrocytes.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA	Medical University of South Carolina	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	singhi@musc.edu			NINDS NIH HHS [NS-34741, NS-22576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS034741, R01NS022576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brugg B, 1996, J NEUROCHEM, V66, P733; CAIRA F, 1995, BIOCHEM PHARMACOL, V49, P611, DOI 10.1016/0006-2952(94)00480-A; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobashi K, 1997, J NEUROCHEM, V68, P1896; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KANTEY H, 1995, J BIOL CHEM, V270, P23780; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NISHIYA T, 1995, FEBS LETT, V371, P333, DOI 10.1016/0014-5793(95)00933-Z; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; PRIESS J, 1986, J BIOL CHEM, V261, P8597; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wiesner DA, 1996, GLYCOCONJUGATE J, V13, P327, DOI 10.1007/BF00731508; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; XIE QW, 1994, J BIOL CHEM, V269, P4705; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	37	152	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2591	2600		10.1074/jbc.273.5.2591	http://dx.doi.org/10.1074/jbc.273.5.2591			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446561	hybrid			2022-12-27	WOS:000071736600016
J	Louis, JM; Martin, RG; Clore, GM; Gronenborn, AM				Louis, JM; Martin, RG; Clore, GM; Gronenborn, AM			Preparation of uniformly isotope-labeled DNA oligonucleotides for NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-DIMENSIONAL HETERONUCLEAR NMR; PROTEIN NMR; RNA; C-13; ENHANCEMENT; OLIGOMERS; DODECAMER; LARGER	Two methods for the large scale preparation of uniformly isotope-labeled DNA for NMR studies have been developed, The first method comprises the growth of a suitable plasmid harboring multiple copies of the desired oligonucleotide in a medium based on N-15 and C-13 nutrients. The second method uses a polymerase chain reaction (PCR)-based approach with N-15-and/or C-13-labeled deoxynucleoside triphosphates. The novelty of our PCR strategy over existing ones is that the primer and template are the identical molecule, resulting in an exponential growth in the length of the double strand that contains tandem repeats of the target DNA sequence. This novel PCR approach, which we have termed ESRA for endonuclease-sensitive repeat amplification, is easy to use, results in high fields, and can be accomplished at low costs, The utility of both methods is demonstrated for the preparation of a double-stranded 21-mer uniformly labeled with N-15 and a double-stranded 17-mer DNA uniformly labeled with N-15 and C-13.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bldg 5, Bethesda, MD 20892 USA.		Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Louis, John M/0000-0002-0052-1899; Gronenborn, Angela M/0000-0001-9072-3525				ASHCROFT J, 1991, BIOPOLYMERS, V31, P45, DOI 10.1002/bip.360310105; Batey RT, 1995, METHOD ENZYMOL, V261, P300; BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Chen W, 1997, J IND MICROBIOL BIOT, V18, P43, DOI 10.1038/sj.jim.2900355; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; FOLDESI A, 1992, TETRAHEDRON, V48, P9033, DOI 10.1016/S0040-4020(01)82001-9; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; Michalczyk R, 1996, MAGN RESON CHEM, V34, pS97; MICHNICKA MJ, 1993, BIOCHEMISTRY-US, V32, P395, DOI 10.1021/bi00053a002; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NIKONOWICZ EP, 1992, NATURE, V355, P184, DOI 10.1038/355184a0; NIKONOWICZ EP, 1992, J AM CHEM SOC, V114, P1082, DOI 10.1021/ja00029a043; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; ONO A, 1994, J BIOMOL NMR, V4, P581, DOI 10.1007/BF00156622; Pardi A, 1995, METHOD ENZYMOL, V261, P350; Puglisi JD, 1995, METHOD ENZYMOL, V261, P323; QUANT S, 1994, TETRAHEDRON LETT, V35, P6649, DOI 10.1016/S0040-4039(00)73458-7; Radha PK, 1996, MAGN RESON CHEM, V34, pS18, DOI 10.1002/(SICI)1097-458X(199612)34:13<S18::AID-OMR48>3.0.CO;2-K; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIEDER P, 1992, NUCLEIC ACIDS RES, V20, P4747, DOI 10.1093/nar/20.18.4747; Smith DE, 1997, J BIOMOL NMR, V10, P245, DOI 10.1023/A:1018358602001; TATE S, 1994, J AM CHEM SOC, V116, P5977, DOI 10.1021/ja00092a062; Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Zimmer DP, 1996, MAGN RESON CHEM, V34, pS177, DOI 10.1002/(SICI)1097-458X(199612)34:13<S177::AID-OMR76>3.0.CO;2-S; ZIMMER DP, 1995, P NATL ACAD SCI USA, V92, P3091, DOI 10.1073/pnas.92.8.3091	32	54	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2374	2378		10.1074/jbc.273.4.2374	http://dx.doi.org/10.1074/jbc.273.4.2374			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442084	hybrid			2022-12-27	WOS:000071595200073
J	Okamoto, T; Schlegel, A; Scherer, PE; Lisanti, MP				Okamoto, T; Schlegel, A; Scherer, PE; Lisanti, MP			Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NITRIC-OXIDE SYNTHASE; CELL-SURFACE; IN-VITRO; DOMAINS; PALMITOYLATION; LOCALIZATION; EXPRESSION; TYROSINE; VIP21-CAVEOLIN; CHOLESTEROL		Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012; Lisanti, Michael/B-6131-2018	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382; Schlegel, Amnon/0000-0003-4060-2252	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443, T32GM007288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH056036] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07288, GM-50443] Funding Source: Medline; NIMH NIH HHS [MH-56036] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MOLDOVAN NI, 1995, EXP CELL RES, V219, P309, DOI 10.1006/excr.1995.1233; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Puertollano R, 1997, J BIOL CHEM, V272, P18311, DOI 10.1074/jbc.272.29.18311; Raposo G, 1994, Trends Cell Biol, V4, P418, DOI 10.1016/0962-8924(94)90096-5; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Scherer PE, 1997, J BIOL CHEM, V272, P20698, DOI 10.1074/jbc.272.33.20698; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187	72	1312	1348	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	1998	273	10					5419	5422		10.1074/jbc.273.10.5419	http://dx.doi.org/10.1074/jbc.273.10.5419			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ZA256	9488658	hybrid			2022-12-27	WOS:000072345000001
J	Gaudin, P; Maoret, JJ; Couvineau, A; Rouyer-Fessard, C; Laburthe, M				Gaudin, P; Maoret, JJ; Couvineau, A; Rouyer-Fessard, C; Laburthe, M			Constitutive activation of the human vasoactive intestinal peptide 1 receptor, a member of the new class II family of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; HORMONE (PTH)/PTH-RELATED PEPTIDE; TERMINAL EXTRACELLULAR DOMAIN; VIP RECEPTOR; THYROTROPIN-RECEPTOR; ADENYLATE-CYCLASE; LIGAND-BINDING; SECRETIN; MUTATION; MUTAGENESIS	The human vasoactive intestinal peptide (VIP) 1 receptor belongs to the new class II subfamily of G protein-coupled receptors, Specific change by mutagenesis of a strictly conserved histidine into arginine at position 178 of the human VIP1 receptor resulted in its constitutive activation with respect to cAMP production. Transfection of the H178R mutant into COS cells resulted in a 3.5-fold increase in the cAMP level as compared with cells transfected with the wild type receptor or the vector alone. This increase was proportional to the amount of transfected cDNA The H178R mutant exhibited an otherwise normal cAMP response to VIP as well as a dissociation constant similar to that of the wild type receptor. Other mutants at position 178 such as H178K, H178A, and H178D were not constitutively activated. They were otherwise expressed at the cell surface of transfected nonpermeabilized cells. Double mutants were then constructed in which the H178R mutation was associated with a point mutation in the the N-terminal extracellular domain that totally abolished VIP binding or VIP-stimulated cAMP production, i.e. E36A or D68A. The corresponding double mutants H178R/E36A and H178R/D68A were no longer constitutively activated, A control double mutant (H178R/D132A) with an unaltered dissociation constant for VIP and cAMP response to VIP was still constitutively activated. Our findings demonstrate that constitutive activation of the VIP1 receptor by mutation of His(178) into R requires the functional integrity of the N-terminal extracellular VIP binding domain. They might provide interesting generalities about the activation process of G protein-coupled receptors.	Fac Med Xavier Bichat, INSERM, U410, F-75870 Paris 18, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Laburthe, M (corresponding author), Fac Med Xavier Bichat, INSERM, U410, BP 416, F-75870 Paris 18, France.	laburthe@bichat.inserm.fr	couvineau, alain/T-3466-2019; couvineau, alain/G-3641-2013; LABURTHE, Marc/C-1875-2012	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168; 				BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; BRADFORD M, 1979, ANAL BIOCHEM, V78, P248; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; COUVINEAU A, 1986, J BIOL CHEM, V261, P14882; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Graziano MP, 1996, RECEPTOR CHANNEL, V4, P9; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HAGER J, 1995, NAT GENET, V9, P299, DOI 10.1038/ng0395-299; HAMMAN J, 1995, J IMMUNOL, V155, P1942; Heller RS, 1996, BIOCHEM BIOPH RES CO, V223, P624, DOI 10.1006/bbrc.1996.0945; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LABURTHE M, 1978, P NATL ACAD SCI USA, V75, P2772, DOI 10.1073/pnas.75.6.2772; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; LABURTHE M, 1993, HDB EXPT PHARM, V106, P133; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLE P, 1996, REGUL PEPTIDES, V64, P139; PARMA J, 1994, MOL CELL ENDOCRINOL, V100, P159, DOI 10.1016/0303-7207(94)90296-8; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Unson CG, 1996, P NATL ACAD SCI USA, V93, P310, DOI 10.1073/pnas.93.1.310; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; Wilmen A, 1996, FEBS LETT, V398, P43, DOI 10.1016/S0014-5793(96)01214-8; ZHANG ML, 1995, BIOCHEM BIOPH RES CO, V211, P205, DOI 10.1006/bbrc.1995.1797	47	53	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4990	4996		10.1074/jbc.273.9.4990	http://dx.doi.org/10.1074/jbc.273.9.4990			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478946	hybrid			2022-12-27	WOS:000072310400030
J	Mukhopadhyay, B; Stoddard, SF; Wolfe, RS				Mukhopadhyay, B; Stoddard, SF; Wolfe, RS			Purification, regulation, and molecular and biochemical characterization of pyruvate carboxylase from Methanobacterium thermoautotrophicum strain Delta H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONYL-COA CARBOXYLASE; FULL-LENGTH CDNA; ESCHERICHIA-COLI; ACETYL-COA; AFFINITY-CHROMATOGRAPHY; ACETATE ASSIMILATION; NUCLEOTIDE-SEQUENCE; RHIZOBIUM-ETLI; BIOTIN ENZYMES; SUBUNIT	We discovered that Methanobacterium thermoautotrophicum strain Delta H possessed pyruvate carboxylase (PYC), and this biotin prototroph required exogenously supplied biotin to exhibit detectable amounts of PYC activity, The enzyme was highly labile and was stabilized by 10% inositol in buffers to an extent that allowed purification to homogeneity and characterization. The purified enzyme was absolutely dependent on ATP, Mg2+ (or Mn2+ or Co2+), pyruvate, and bicarbonate for activity; phosphoenolpyruvate could not replace pyruvate, and acetyl-CoA was not required, The enzyme was inhibited by ADP and alpha-ketoglutarate but not by aspartate or glutamate. ATP was inhibitory at high concentrations, The enzyme, unlike other PYCs, exhibited non-linear kinetics with respect to bicarbonate and was inhibited by excess Mg2+, Mn2+, or Co2+, Th, 540-kDa enzyme of A(4)B(4) composition contained a non-biotinylated 52-kDa subunit (PYCA) and a 75-kDa biotinylated subunit (PYCB), The pycB gene was probably monocistronic and followed by a putative gene of a DNA-binding protein on the opposite strand, The pycA was about 727 kilobase pairs away from pycB on the chromosome and was probably co-transcribed with the biotin ligase gene (birA), PYCA and PYCB showed substantial sequence identities (33-62%) to, respectively, the biotin carboxylase and biotin carboxyl carrier + carboxyltransferase domains or subunits of known biotin-dependent carboxylases/decarboxylases. We discovered that PYCB and probably the equivalent domains or subunits of all biotin-dependent carboxylases harbored the serine/threonine dehydratase types of pyridoxal-phosphate attachment site, Our results and the existence of an alternative oxaloacetate synthesizing enzyme phosphoenolpyruvate carboxylase in M. thermoautotrophicum strain Delta H (Kenealy, W. R., and Zeikus, J. G. (1982) FEMS Microbiol. Lett, 14, 7-10) raise several questions for future investigations.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Mukhopadhyay, B (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	biswarup_mukhopadhyay@qms1.life.uiuc.edu		Mukhopadhyay, Biswarup/0000-0003-0736-0298	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051334] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALCH WE, 1976, APPL ENVIRON MICROB, V32, P781, DOI 10.1128/AEM.32.6.781-791.1976; Becker A, 1995, MOL GEN GENET, V249, P487, DOI 10.1007/BF00290574; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDIS A, 1981, ZBL BAKT MIK HYG I C, V2, P311, DOI 10.1016/S0721-9571(81)80023-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAZZULO JJ, 1969, BIOCHEM J, V112, P747, DOI 10.1042/bj1120747; CAZZULO JJ, 1970, PROC R SOC SER B-BIO, V176, P1, DOI 10.1098/rspb.1970.0030; CAZZULO JJ, 1969, NATURE, V223, P1137, DOI 10.1038/2231137a0; Cleland W. W, 1970, ENZYMES, V2, P1; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; Dunn MF, 1996, J BACTERIOL, V178, P5960, DOI 10.1128/jb.178.20.5960-5970.1996; EISENBERG MA, 1985, ANN NY ACAD SCI, V447, P335, DOI 10.1111/j.1749-6632.1985.tb18449.x; EKIEL I, 1983, J BACTERIOL, V156, P316, DOI 10.1128/JB.156.1.316-326.1983; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ENCARNACION S, 1995, J BACTERIOL, V177, P3058, DOI 10.1128/jb.177.11.3058-3066.1995; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUCHS G, 1986, SYST APPL MICROBIOL, V7, P364; GOSS JA, 1981, J BIOL CHEM, V256, P1819; Gottschalk G., 1986, BACTERIAL METABOLISM; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; JANSEN K, 1982, ARCH MICROBIOL, V132, P355, DOI 10.1007/BF00413389; Jitrapakdee S, 1996, BIOCHEM J, V316, P631, DOI 10.1042/bj3160631; Kaneko T, 1996, DNA Res, V3, P109; KANO Y, 1985, MOL GEN GENET, V201, P360, DOI 10.1007/BF00425687; KENEALY WR, 1982, FEMS MICROBIOL LETT, V14, P7, DOI 10.1016/0378-1097(82)90032-5; KOHANSKI RA, 1990, METHOD ENZYMOL, V184, P194; Kondo H, 1997, GENE, V191, P47, DOI 10.1016/S0378-1119(97)00027-9; KORNBERG H. L., 1966, ESSAYS BIOCHEM, V2, P1; KUMAR GK, 1988, BIOCHEMISTRY-US, V27, P5978, DOI 10.1021/bi00416a022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMHONWAH AM, 1994, GENOMICS, V19, P500, DOI 10.1006/geno.1994.1099; LAMHONWAH AM, 1989, NUCLEIC ACIDS RES, V17, P4396, DOI 10.1093/nar/17.11.4396; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; LIM F, 1988, J BIOL CHEM, V263, P11493; MILRADDEFORCHETTI SR, 1976, J GEN MICROBIOL, V93, P75, DOI 10.1099/00221287-93-1-75; MODAK HV, 1995, MICROBIOL-UK, V141, P2619, DOI 10.1099/13500872-141-10-2619; MUKHOPADHYAY B, 1995, J BIOL CHEM, V270, P2827, DOI 10.1074/jbc.270.6.2827; MUKHOPADHYAY B, 1993, THESIS U IOWA IOWA C; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; NOLL KM, 1988, J BACTERIOL, V170, P4315, DOI 10.1128/jb.170.9.4315-4321.1988; NORMAN E, 1994, J BACTERIOL, V176, P2525, DOI 10.1128/JB.176.9.2525-2531.1994; OBRIEN RW, 1977, J BIOL CHEM, V252, P1257; POST LE, 1990, J BIOL CHEM, V265, P7742; Purcell AW, 1996, ANAL BIOCHEM, V238, P213, DOI 10.1006/abio.1996.0280; Reeve John N., 1993, P493; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SCHWARZ E, 1988, J BIOL CHEM, V263, P9640; SCRUTTON MC, 1974, ARCH BIOCHEM BIOPHYS, V164, P641, DOI 10.1016/0003-9861(74)90076-9; SHIEH JS, 1987, J BACTERIOL, V169, P5327, DOI 10.1128/jb.169.11.5327-5329.1987; STODDARD SF, 1991, GEN M AM SOC MICR WA; SUNDARAM TK, 1973, J BACTERIOL, V113, P549, DOI 10.1128/JB.113.2.549-557.1973; TAYLOR BL, 1975, J BIOL CHEM, V250, P2376; THORNTON CG, 1993, J BACTERIOL, V175, P5301, DOI 10.1128/JB.175.17.5301-5308.1993; THORNTON CG, 1993, FEBS LETT, V330, P191, DOI 10.1016/0014-5793(93)80271-U; TOSAKA O, 1979, AGR BIOL CHEM TOKYO, V43, P1513, DOI 10.1080/00021369.1979.10863663; VAL DLH, 1995, THESIS U ADELAIDE S; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; WALLACE JC, 1985, PYRUVATE CARBOXYLASE, P6; WEIMER PJ, 1979, J BACTERIOL, V137, P332, DOI 10.1128/JB.137.1.332-339.1979; WEXLER ID, 1994, BBA-MOL BASIS DIS, V1227, P46, DOI 10.1016/0925-4439(94)90105-8; WURTELE ES, 1990, ARCH BIOCHEM BIOPHYS, V278, P179, DOI 10.1016/0003-9861(90)90246-U; ZEIKUS JG, 1977, J BACTERIOL, V132, P604, DOI 10.1128/JB.132.2.604-613.1977; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	66	47	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5155	5166		10.1074/jbc.273.9.5155	http://dx.doi.org/10.1074/jbc.273.9.5155			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478969	hybrid			2022-12-27	WOS:000072310400053
J	Plonk, SG; Park, SK; Exton, JH				Plonk, SG; Park, SK; Exton, JH			The alpha-subunit of the heterotrimeric G protein G(13) activates a phospholipase D isozyme by a pathway requiring Rho family GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COS-7 CELLS; G-ALPHA(12); MUTANT; IDENTIFICATION; TRANSFORMATION; FIBROBLASTS; SUBFAMILY; EXCHANGE; KINASE; RAC	G(13) belongs to the G(12) family of heterotrimeric G proteins, whose effecters are poorly defined. The present study was designed to test if phospholipase D (PLD) is regulated by G(13) and if Rho-type small GTPases are involved. Expression of the constitutively active Q226L mutant of the alpha-subunit of G(13) in COS-7 cells stimulated the activity of a rat brain phospholipase D isozyme (rPLD1) co-expressed in the cells. Wild type G alpha(13) was ineffective unless the cells were incubated with AlF4-. rPLD1 was previously shown to be activated by constitutively active V14RhoA in COS-7 cells (Park, S. K., Provost, J. J., Bae, C. D., Ho, W. T., and Exton, J. H. (1997) J. Biol. Chem. 272, 29263-29272). When the endogenous Rho proteins of the cells were inactivated by treatment with C3 exoenzyme from Clostridium botulinum, the ability of G alpha(13)Q226L to activate rPLD1 was greatly attenuated. Co-transfection of dominant negative N19RhoA and N17Rac-1, but not N17Cdc42Hs or N17Ras, also inhibited the activation. Expression of constitutively active G alpha(q) in COS-7 cells also activated rPLD1, but constitutively active forms of G alpha(i2) and G alpha(s) were without effect. These findings support an effector role for PLD in G(13) signaling and demonstrate a requirement for Rho GTPases in this response.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.	john.exton@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47448, DK 07563] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Harhammer R, 1996, BIOCHEM J, V319, P165, DOI 10.1042/bj3190165; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Liscovitch M, 1996, CHEM PHYS LIPIDS, V80, P37, DOI 10.1016/0009-3084(96)02544-3; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MILLIGAN G, 1992, FEBS LETT, V297, P186, DOI 10.1016/0014-5793(92)80357-M; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	34	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4823	4826		10.1074/jbc.273.9.4823	http://dx.doi.org/10.1074/jbc.273.9.4823			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478920	hybrid			2022-12-27	WOS:000072310400004
J	Sullam, PM; Hyun, WC; Szollosi, J; Dong, JF; Foss, WM; Lopez, JA				Sullam, PM; Hyun, WC; Szollosi, J; Dong, JF; Foss, WM; Lopez, JA			Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor Fc gamma RIIA on the platelet plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; VIRIDANS GROUP STREPTOCOCCI; IMMUNOGLOBULIN-G; CELL-SURFACES; VONWILLEBRAND-FACTOR; FLOW-CYTOMETRY; FACTOR BINDING; AGGREGATION; ACTIVATION; THROMBOCYTOPENIA	Although the glycoprotein (GP) Ib-IX-V complex and Fc gamma RIIA are distinct platelet membrane receptors, previous studies have suggested that these structures may be co-localized. To determine more directly the proximity of GP Ib-IX-V and Fc gamma RIIA, we assessed the effects of anti-GP Ib alpha monoclonal antibodies on Fc gamma RIIA-mediated platelet aggregation and on the direct binding of polymeric IgG to human platelets. In addition, we directly examined the proximity of Fc gamma RII and GP Ib-IX-V using flow cytometric fluorescence energy transfer and immunoprecipitation studies. Preincubation of platelets with either of two monoclonal antibodies (AN51 or SZ2) directed against GP Ib alpha completely blocked platelet aggregation by polymeric IgG. Similarly, these antibodies totally inhibited platelet aggregation by two strains of viridans group streptococci known to induce aggregation via Fc gamma RIIA, In addition, AN51 and SZ2 significantly reduced the binding of polymeric IgG to washed fixed platelets, When assessed by flow cytometry, significant levels of bidirectional energy transfer were detected between Fc gamma RIIA and GP Ib alpha, indicating a physical proximity of less than 10 nm between these receptors, This energy transfer was not due to high receptor density, because no homoassociative energy transfer was seen, Moreover, immunoprecipitation of Fc gamma RIIA from platelet lysates also co-precipitated GP Ib alpha. These results indicate that GP Ib alpha and Fc gamma RIIA are co-localized on the platelet membrane and that this association is not random.	Vet Affairs Med Ctr, Div Infect Dis 111W, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Ctr Canc, Lab Cell Anal, San Francisco, CA 94143 USA; Debrecen Univ Med, Sch Med, Dept Biophys & Cell Biol, H-4012 Debrecen, Hungary; Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Debrecen; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Sullam, PM (corresponding author), Vet Affairs Med Ctr, Div Infect Dis 111W, 4150 Clement St, San Francisco, CA 94121 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041513] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02463] Funding Source: Medline; NIAID NIH HHS [AI41513, AI32506] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELMAN B, 1989, J LAB CLIN MED, V113, P204; ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; Andrews RK, 1996, BIOCHEMISTRY-US, V35, P12629, DOI 10.1021/bi960704e; BECKER RC, 1994, CORONARY ARTERY DIS, V5, P339, DOI 10.1097/00019501-199404000-00010; BENE L, 1994, EUR J IMMUNOL, V24, P2115, DOI 10.1002/eji.1830240928; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; CHONG BH, 1989, BRIT J HAEMATOL, V73, P235, DOI 10.1111/j.1365-2141.1989.tb00258.x; CORASH L, 1990, BLOOD CELLS, V16, P97; DU XP, 1994, J BIOL CHEM, V269, P18287; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FORD I, 1993, BRIT J HAEMATOL, V84, P95, DOI 10.1111/j.1365-2141.1993.tb03030.x; Ford I, 1997, BRIT J HAEMATOL, V97, P737, DOI 10.1046/j.1365-2141.1997.1342950.x; Harlow E., 1988, ANTIBODIES LAB MANUA; JUNG SM, 1983, BIOCHIM BIOPHYS ACTA, V761, P152, DOI 10.1016/0304-4165(83)90224-6; KARAS SP, 1982, BLOOD, V60, P1277; KOKSCH M, 1995, J IMMUNOL METHODS, V187, P53, DOI 10.1016/0022-1759(95)00166-8; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LIEGLER T, 1991, P NATL ACAD SCI USA, V88, P6755, DOI 10.1073/pnas.88.15.6755; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MATYUS L, 1992, J PHOTOCH PHOTOBIO B, V12, P323, DOI 10.1016/1011-1344(92)85039-W; MOORE A, 1978, J CLIN INVEST, V62, P1053, DOI 10.1172/JCI109210; ODA A, 1995, THROMB HAEMOSTASIS, V74, P736; RAZDAN K, 1994, BIOCHEM J, V302, P681, DOI 10.1042/bj3020681; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SULLAM PM, 1988, INFECT IMMUN, V56, P2907, DOI 10.1128/IAI.56.11.2907-2911.1988; SULLAM PM, 1987, INFECT IMMUN, V55, P1743, DOI 10.1128/IAI.55.8.1743-1750.1987; SZOLLOSI J, 1987, P NATL ACAD SCI USA, V84, P7246, DOI 10.1073/pnas.84.20.7246; SZOLLOSI J, 1984, CYTOMETRY, V5, P210, DOI 10.1002/cyto.990050216; TOMIYAMA Y, 1992, BLOOD, V80, P2261; TRON L, 1984, BIOPHYS J, V45, P939, DOI 10.1016/S0006-3495(84)84240-X; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471	32	117	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5331	5336		10.1074/jbc.273.9.5331	http://dx.doi.org/10.1074/jbc.273.9.5331			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478992	hybrid			2022-12-27	WOS:000072310400076
J	Witt, H; Malatesta, F; Nicoletti, F; Brunori, M; Ludwig, B				Witt, H; Malatesta, F; Nicoletti, F; Brunori, M; Ludwig, B			Tryptophan 121 of subunit II is the electron entry site to cytochrome-c oxidase in Paracoccus denitrificans - Involvement of a hydrophobic patch in the docking reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2.8 ANGSTROM; BINDING; KINETICS; IDENTIFICATION; RESIDUES; PROTEINS; MUTANTS; ENZYME; GENE	To investigate the contribution of hydrophobic residues to the molecular recognition of cytochrome c with cytochrome oxidase, we mutated several hydrophobic amino acids exposed on subunit II of the Paracoccus denitrificans oxidase, K-M and k(cat) values and the bimolecular rate constant were determined under steady-or presteady-state conditions, respectively, We present evidence that Trp-121 which is surrounded by a hydrophobic patch is the electron entry site to oxidase. Mutations in this cluster do not affect the binding of cytochrome c as the K-M remains largely unchanged, Rather, the k(cat) is reduced, proposing that these hydrophobic residues are required for a fine tuning of the redox partners in the initial collisional complex to obtain a configuration optimal for electron transfer.	Biozentrum, Inst Biochem, D-60439 Frankfurt, Germany; Univ Aquila, Dept Basic & Appl Biol, I-67100 Laquila, Italy; Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Rome La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy	University of L'Aquila; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Ludwig, B (corresponding author), Biozentrum, Inst Biochem, N200 1-OG,Marie Curie Str 9, D-60439 Frankfurt, Germany.	ludwig@em.uni-frankfurt.de	Malatesta, Francesco/AAT-4757-2020	Brunori, Maurizio/0000-0002-7795-1635				Bendall D. S., 1996, P43; BUSE G, 1978, H-S Z PHYSIOL CHEM, V359, P1011; CAFFREY MS, 1994, BIOCHIMIE, V76, P622, DOI 10.1016/0300-9084(94)90139-2; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P14035, DOI 10.1021/bi961577p; DEGIER JWL, 1994, MOL MICROBIOL, V13, P183, DOI 10.1111/j.1365-2958.1994.tb00414.x; ERREDE B, 1976, P NATL ACAD SCI USA, V73, P113, DOI 10.1073/pnas.73.1.113; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; GARBER EAE, 1990, BIOCHIM BIOPHYS ACTA, V1015, P279, DOI 10.1016/0005-2728(90)90032-Y; GERHUS E, 1990, J BACTERIOL, V172, P2392, DOI 10.1128/jb.172.5.2392-2400.1990; HARRIS TK, 1994, BIOCHEMISTRY-US, V33, P12600, DOI 10.1021/bi00208a010; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; LAPPALAINEN P, 1995, BIOCHEMISTRY-US, V34, P5824, DOI 10.1021/bi00017a014; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Overholtzer MH, 1996, J BIOL CHEM, V271, P7719, DOI 10.1074/jbc.271.13.7719; RICHTER OMH, 1994, J BIOL CHEM, V269, P23079; RIEDER R, 1980, J BIOL CHEM, V255, P4732; STAUDENMAYER N, 1977, BIOCHEMISTRY-US, V16, P600, DOI 10.1021/bi00623a007; STEINRUCKE P, 1991, J BIOL CHEM, V266, P7676; TOLLIN G, 1991, ARCH BIOCHEM BIOPHYS, V287, P1, DOI 10.1016/0003-9861(91)90380-2; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; WITT H, 1995, BBA-BIOENERGETICS, V1230, P74, DOI 10.1016/0005-2728(95)00050-S; Witt H, 1998, EUR J BIOCHEM, V251, P367, DOI 10.1046/j.1432-1327.1998.2510367.x	32	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5132	5136		10.1074/jbc.273.9.5132	http://dx.doi.org/10.1074/jbc.273.9.5132			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478966	hybrid			2022-12-27	WOS:000072310400050
J	Chow, JC; Condorelli, G; Smith, RJ				Chow, JC; Condorelli, G; Smith, RJ			Insulin-like growth factor-1 receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I-RECEPTOR; MEDIATED ENDOCYTOSIS; PHOSPHATIDYLINOSITOL 3'-KINASE; TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; SHC PROTEINS; TRANSDUCTION; CELLS; SRC; ASSOCIATION	Insulin like growth factor-I (IGF-I) receptors activate divergent signaling pathways by phosphorylation multiple cellular proteins, including insulin receptor substrate-1 (IRS-1) and the Shc proteins. Following hormone binding, IGF-I receptors cluster into clathrin-coated pits and are internalized via an endocytotic mechanism, This study investigates the relationship between IGF-I receptor internalization and signaling via IRS-1 and Shc. A mutation in the C terminus of the IGF-I receptor decreased both the rate of receptor internalization and IGF-I-stimulated Shc phosphorylation by more than 50%, but did not affect IRS-1 phosphorylation. Low temperature (15 degrees C) decreased IGF-I receptor internalization and completely inhibited Shc phosphorylation. Although receptor and IRS-1 phosphorylation were decreased in accordance with delayed binding kinetics at 15 degrees C, the ratio of IRS-1 to receptor phosphorylation was increased more than 2-fold. Dansylcadaverine de creased receptor internalization and Shc phosphorylation, but did not change receptor or IRS-1 phosphorylation, Consistent with these findings, dansylcadaverine inhibited IGF-I stimulated Shc-Grb2 association, mitogen activated protein kinase phosphorylation, and p90 ribosomal S6 kinase activation, but did not affect the association of phosphatidylinositide 3-kinase with IRS-1 or activation of p70 S6 kinase, These data support the concept that Shc/mitogen-activated protein kinase pathway activation requires IGF-I receptor internalization, whereas the IRS-1 pathway is activated by both cell surface and endosomal receptors.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Smith, RJ (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.		Condorelli, Gerolama/AAC-3472-2022	Condorelli, Gerolama/0000-0003-0177-8829	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043038, P30DK036836, T32DK007260] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43038, DK07260, DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADASHI EY, 1988, ENDOCRINOLOGY, V122, P194, DOI 10.1210/endo-122-1-194; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARPENTIER JL, 1994, DIABETOLOGIA, V37, pS117, DOI 10.1007/BF00400835; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CONDORELLI G, 1994, FRONT ENDOCRINOL, V9, P373; CONDORELLI G, 1994, J BIOL CHEM, V269, P8510; Dardevet D, 1996, ENDOCRINOLOGY, V137, P4087, DOI 10.1210/en.137.10.4087; DAVIES PJA, 1984, DIABETES CARE, V7, P35; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; FURLANETTO RW, 1988, ENDOCRINOLOGY, V122, P2044, DOI 10.1210/endo-122-5-2044; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HSU D, 1994, ENDOCRINOLOGY, V134, P744, DOI 10.1210/en.134.2.744; HSU D, 1993, ENDOCRINOLOGY, V133, P1247, DOI 10.1210/en.133.3.1247; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAMPS MP, 1988, ONCOGENE, V2, P305; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; LUND KA, 1990, J BIOL CHEM, V265, P15713; MOEHLYROSEN D, 1995, SCIENCE, V268, P247; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NORIEGA AG, 1980, J CELL BIOL, V85, P839; OLEFSKY JM, 1982, J BIOL CHEM, V257, P8667; PEAVY DE, 1984, ENDOCRINOLOGY, V114, P753, DOI 10.1210/endo-114-3-753; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1997, TRENDS BIOCHEM SCI, V21, P312; SMITH RJ, 1996, EXP CLIN ENDOCR S2, V104, P42; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	49	139	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4672	4680		10.1074/jbc.273.8.4672	http://dx.doi.org/10.1074/jbc.273.8.4672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468528	hybrid			2022-12-27	WOS:000072115000056
J	Inoue, D; Reid, M; Lum, L; Kratzschmar, J; Weskamp, G; Myung, YM; Baron, R; Blobel, CP				Inoue, D; Reid, M; Lum, L; Kratzschmar, J; Weskamp, G; Myung, YM; Baron, R; Blobel, CP			Cloning and initial characterization of mouse meltrin beta and analysis of the expression of four metalloprotease-disintegrins in bone cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-EGG FUSION; PROTEIN; DIFFERENTIATION; OSTEOCLAST; DOMAIN; FAMILY; GENE; ACID; IDENTIFICATION; RECEPTOR	Here Ne report the cloning and initial biochemical characterization of the mouse metalloprotease/disintegrin/cysteine-rich (MDC) protein meltrin beta and the analysis of the mRNA expression of four MDC genes (meltrin alpha, meltrin beta, mdc9, and mdc15) in bone cells, including osteoclasts and osteoblasts. Like most other MDC proteins, the predicted meltrin beta protein consists of a signal sequence, prodomain, metalloprotease domain with a predicted catalytic site, disintegrin domain, cysteine-rich region, epidermal growth factor repeat, transmembrane domain, and cytoplasmic domain with putative signaling motifs, such as potential SH3 ligand domains. Northern blot analysis indicates that meltrin beta is widely expressed, with the highest expression in bone, heart, and lung. RNase protection studies revealed expression of all four MDC genes analyzed here in osteoblasts, whereas only mdc9 and mdc15 mRNAs were detectable in osteoclast like cells generated in vitro. Treatment of primary osteoblasts with 10 nM calcitriol increased meltrin beta expression more than 3-fold, and both meltrin alpha and meltrin beta expression is apparently regulated in a differentiation associated manner in a mouse osteoblastic cell line, MC3T3E1. Collectively, these results suggest that meltrin alpha and meltrin beta may play a role in osteoblast differentiation and/or function but are not likely to be involved in osteoclast fusion.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Orthopaed & Cell Biol, New Haven, CT 06510 USA	Memorial Sloan Kettering Cancer Center; Yale University	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, Box 368,1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051988] Funding Source: NIH RePORTER; NCI NIH HHS [NCI-P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [R55GM51988] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; EVANS JP, 1995, J CELL SCI, V108, P3267; FAMBROUGH D, 1996, P NATL ACAD SCI USA, V93, P13223; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; KRATZSCHMAR J, 1991, GENE, V105, P229, DOI 10.1016/0378-1119(91)90155-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Podbilewicz B, 1996, MOL BIOL CELL, V7, P1877, DOI 10.1091/mbc.7.12.1877; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YAMIN M, 1994, ENDOCRINOLOGY, V135, P2635, DOI 10.1210/en.135.6.2635; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	47	90	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4180	4187		10.1074/jbc.273.7.4180	http://dx.doi.org/10.1074/jbc.273.7.4180			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461614	hybrid			2022-12-27	WOS:000072048400056
J	Auchus, RJ; Lee, TC; Miller, WL				Auchus, RJ; Lee, TC; Miller, WL			Cytochrome b(5) augments the 17,20-lyase activity of human P450c17 without direct electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; RAT-LIVER MICROSOMES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; YEAST-CELLS; NADPH-P450 REDUCTASE; CATALYTIC ACTIVITIES; APOCYTOCHROME B(5); MESSENGER-RNA; PIG TESTIS	In the biosynthesis of steroid hormones, P450c17 is the single enzyme that catalyzes both the 17 alpha-hydroxylation of al-carbon steroids and the 17,20-lyase activity that cleaves the C-17,-C-20,, bond to produce C-19, sex steroids. Cytochrome b(5), augments the 17,20-lyase activity of cytochrome P450c17 in vitro, but this has not been demonstrated in membranes, and the mechanism of this action is unknown. We expressed human P450c17, human P450-oxidoreductase (OR), and/or human cytochrome b(5) in Saccharomyces cerevisiae and analyzed the 17 alpha-hydroxylase and 17,20-lyase activities of the resulting yeast microsomes. Yeast expressing only P450c17 have 17 alpha-hydroxylase and trace 17,20 lyase activities toward both Delta(4) and Delta(5) steroids. Coexpression of human OR with P450c17 increases the V-max,,, of both the 17 alpha-hydroxylase and 17,20-lyase reactions B-fold; coexpression of human b(5), with P450c17 also increases the V-max,, of the 17,20-lyase reactions but not of the 17 alpha-hydroxylase reactions. Simultaneous expression of human b(5), with P450c17 and OR, or addition of purified human b(5), to microsomes from yeast coexpressing human P450c17 and OR, further increases the V-max,, of the 17,20-lyase reaction without altering 17 alpha-hydroxylase activity. Genetically engineered yeast and mixing experiments demonstrate that OR is both necessary and sufficient for microsomal 17,20-lyase activity. Addition of purified human holo-b(5),, apo-b(5),, or cytochrome c to microsomes containing both human P450c17 and OR demonstrate that the stimulatory action of b(5), does not require electron transfer from b(5), to P450c17. These data suggest that human b(5), acts principally as an allosteric effector that interacts primarily with the P450c17 OR complex to stimulate 17,20-lyase activity.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Bldg MR-IV,Box 0978, San Francisco, CA 94143 USA.		Miller, Walter L/J-3696-2012		NICHD NIH HHS [U54-HD34449] Funding Source: Medline; NIDDK NIH HHS [DK37922, DK42154] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042154, R01DK037922] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BARNES HJ, 1994, ARCH BIOCHEM BIOPHYS, V315, P489, DOI 10.1006/abbi.1994.1530; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; Conley AJ, 1997, BIOL REPROD, V56, P789, DOI 10.1095/biolreprod56.4.789; CUTLER GB, 1978, ENDOCRINOLOGY, V103, P2112, DOI 10.1210/endo-103-6-2112; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; Falzone CJ, 1996, BIOCHEMISTRY-US, V35, P6519, DOI 10.1021/bi960501q; Geller DH, 1997, NAT GENET, V17, P201, DOI 10.1038/ng1097-201; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILLETTE JR, 1957, J PHARMACOL EXP THER, V119, P532; GIORDANO SJ, 1994, HUM GENET, V93, P568; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; HALL PF, 1985, VITAM HORM, V42, P315; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HIGUCHI A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P240, DOI 10.1016/0005-2760(91)90064-O; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; KATAGIRI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P343, DOI 10.1006/abbi.1995.1173; KOMINAMI S, 1992, J STEROID BIOCHEM, V42, P57, DOI 10.1016/0960-0760(92)90011-7; KUMA F, 1976, ARCH BIOCHEM BIOPHYS, V172, P600, DOI 10.1016/0003-9861(76)90113-2; LeeRobichaud P, 1997, BIOCHEM J, V321, P857, DOI 10.1042/bj3210857; LIN D, 1991, J BIOL CHEM, V266, P15992; LIN D, 1993, ENDOCRINOLOGY, V132, P2498, DOI 10.1210/en.132.6.2498; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; Miller WL, 1997, STEROIDS, V62, P133, DOI 10.1016/S0039-128X(96)00172-9; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Modi S, 1997, BIOCHEMISTRY-US, V36, P4461, DOI 10.1021/bi962633p; Muskett FW, 1996, J MOL BIOL, V258, P172, DOI 10.1006/jmbi.1996.0241; NAKAJIN S, 1981, J BIOL CHEM, V256, P3871; NAKAJIN S, 1985, BIOCHEM BIOPH RES CO, V132, P708, DOI 10.1016/0006-291X(85)91190-8; OMURA T, 1964, J BIOL CHEM, V239, P2370; ONODA M, 1982, BIOCHEM BIOPH RES CO, V108, P454, DOI 10.1016/0006-291X(82)90850-6; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; OSHINO N, 1971, J BIOCHEM, V69, P155, DOI 10.1093/oxfordjournals.jbchem.a129444; PARIKH A, 1997, NAT BIOTECHNOL, V15, P346; PEYRONNEAU MA, 1993, EUR J BIOCHEM, V218, P355, DOI 10.1111/j.1432-1033.1993.tb18384.x; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; POMPON D, 1984, J BIOL CHEM, V259, P5377; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; SHET MS, 1994, ARCH BIOCHEM BIOPHYS, V311, P402, DOI 10.1006/abbi.1994.1255; Storch EM, 1996, BIOCHEMISTRY-US, V35, P11596, DOI 10.1021/bi960598g; SWART P, 1993, J CLIN ENDOCR METAB, V77, P98, DOI 10.1210/jc.77.1.98; TAGASHIRA H, 1995, BIOCHEMISTRY-US, V34, P10939, DOI 10.1021/bi00034a028; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; URBAN P, 1993, BIOCHEM SOC T, V21, P1028, DOI 10.1042/bst0211028; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V342, P329, DOI 10.1006/abbi.1997.0125; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; YANAGIBASHI K, 1986, J BIOL CHEM, V261, P8429; YOO M, 1988, BIOCHEM BIOPH RES CO, V156, P576, DOI 10.1016/S0006-291X(88)80881-7; ZHANG LH, 1995, P NATL ACAD SCI USA, V92, P10619, DOI 10.1073/pnas.92.23.10619	54	436	446	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3158	3165		10.1074/jbc.273.6.3158	http://dx.doi.org/10.1074/jbc.273.6.3158			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452426	hybrid			2022-12-27	WOS:000071822300011
J	Domanski, P; Nadeau, OW; Platanias, LC; Fish, E; Kellum, M; Pitha, P; Colamonici, OR				Domanski, P; Nadeau, OW; Platanias, LC; Fish, E; Kellum, M; Pitha, P; Colamonici, OR			Differential use of the beta(L) subunit of the type I interferon (IFN) receptor determines signaling specificity for IFN alpha 2 and IFN beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CYTOPLASMIC DOMAIN; ALPHA RECEPTOR; TARGETED DISRUPTION; TYROSINE KINASE; BINDING; GENE; TRANSDUCTION; EXPRESSION; CLONING; CELLS	The signaling specificity for cytokines that have common receptor subunits is achieved by the presence of additional cytokine-specific receptor components. In the type I interferon (IFN) family, all 14 subtypes of IFN alpha, IFN beta, and IFN omega bind to the same alpha and beta(L), subunits of the type I IFN-R, yet differences in signaling and biological effects exist among them. Our data demonstrate that IFN alpha 2 and IFN beta utilize different regions of the beta(L), subunit for signaling, Thus, in contrast to other cytokine systems, signal diversity in the type I IFN system can be accomplished within the same receptor complex by utilizing different regions of the same receptor subunits.	Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA; Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Affairs Hosp, Chicago, IL 60607 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; Johns Hopkins University; Johns Hopkins Medicine	Colamonici, OR (corresponding author), Univ Tennessee, Dept Pathol, 899 Madison Ave,M-576, Memphis, TN 38163 USA.				NCI NIH HHS [CA73381, CA55079] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073381, R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BENOIT P, 1993, J IMMUNOL, V150, P707; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; CHEUNG SC, 1991, J IMMUNOL, V146, P121; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COOK JR, 1996, J BIOL CHEM, V271, P13488; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; GROUP AR, 1989, J NEUROL NEUROSUR PS, V52, P566; JOHNSON K P, 1990, Neurology, V40, P261; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; SCHINDLER S, 1995, ANNU REV BIOCHEM, V64, P621; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Yan H, 1996, MOL CELL BIOL, V16, P2074	36	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3144	3147		10.1074/jbc.273.6.3144	http://dx.doi.org/10.1074/jbc.273.6.3144			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452423	hybrid			2022-12-27	WOS:000071822300008
J	Haas, TL; Davis, SJ; Madri, JA				Haas, TL; Davis, SJ; Madri, JA			Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGELATINASE-A; GROWTH-FACTOR; ANGIOGENESIS INVITRO; VITRO ANGIOGENESIS; TISSUE INHIBITOR; GENE-EXPRESSION; TUBE FORMATION; MEMBRANE; ACTIVATION; MODULATION	Matrix metalloproteinases (MMPs) are hypothesized to play a key role in the processes of endothelial cell migration and matrix remodeling during angiogenesis. We utilized an in vitro model of microvascular endothelial cell angiogenesis, cells cultured within a collagen matrix, to investigate the MMP profile of endothelial cells undergoing angiogenesis. We demonstrated by gelatin zymography that monolayer cultures (two-dimensional) of endothelial cells constitutively expressed low levels of latent MMP-2, but that culture in a three-dimensional collagen matrix increased the total amount of MMP-2 mRNA and protein, Furthermore, 51% of total MMP-2 protein was activated in the three-dimensional culture lysates, compared with 3.5% in two-dimensional culture, The mRNA and protein of MT1-MMP, the putative activator of MMP-2, were up-regulated in endothelial cells cultured in three-dimensional as compared with two dimensional culture, Treatment of cultures with MMP inhibitors blocked activation of MMP-2 and inhibited formation of endothelial cell networks within the collagen gel, Induction of MT1-MMP and MMP-2 appeared to be specific to collagen, inasmuch as culture of the endothelial cells on top of, or within, a Matrigel(R) matrix neither increased total MMP-2 nor increased activation of MMP-2. These results suggest that MT1-MMP activation of MMP-2 occurs in endothelial cells undergoing angiogenesis, that this activation has a functional role in endothelial cell organization, and that specific matrix interactions may be critical for the increased expression of MT1-MMP and MMP-2.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, LH115,310 Cedar St, New Haven, CT 06510 USA.	joseph.madri@yale.edu	Haas, Tara/F-6788-2013	Haas, Tara/0000-0001-8559-9574	NHLBI NIH HHS [R01 HL-5108] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CANFIELD AE, 1995, J CELL SCI, V108, P797; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Clark, 1996, MOL CELLULAR BIOL WO, P355; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; CORNELIUS LA, 1995, J INVEST DERMATOL, V105, P170, DOI 10.1111/1523-1747.ep12317080; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Foda HD, 1996, LAB INVEST, V74, P538; Folkman J, 1997, EXS, V79, P1; Gilles C, 1997, LAB INVEST, V76, P651; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; JACKSON CJ, 1994, CELL BIOL INT, V18, P859, DOI 10.1006/cbir.1994.1122; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MADRI JA, 1986, J HISTOCHEM CYTOCHEM, V34, P85, DOI 10.1177/34.1.2416801; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MERWIN JR, 1990, J CELL PHYSIOL, V142, P117, DOI 10.1002/jcp.1041420115; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1992, EUR J CLIN INVEST, V22, P504, DOI 10.1111/j.1365-2362.1992.tb01498.x; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Senger DR, 1996, AM J PATHOL, V149, P293; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132	47	294	309	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3604	3610		10.1074/jbc.273.6.3604	http://dx.doi.org/10.1074/jbc.273.6.3604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452488	hybrid			2022-12-27	WOS:000071822300073
J	Ratovitski, EA; Kotzbauer, PT; Milbrandt, J; Lowenstein, CJ; Burrow, CR				Ratovitski, EA; Kotzbauer, PT; Milbrandt, J; Lowenstein, CJ; Burrow, CR			Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; ACID-RESPONSIVE GENE; EPITHELIAL-MESENCHYMAL INTERACTIONS; I INTERFERON RECEPTOR; N-SYNDECAN SYNDECAN-3; RETINOIC ACID; LIGAND-BINDING; HB-GAM; DIFFERENTIAL EXPRESSION	The G401 cell line derived from a rhabdoid tumor of the kidney secretes the heparin-binding growth factors midkine and pleiotrophin. Both proteins act as mitogens for diverse cells, but only midkine serves as an autocrine mitogen for G401 tumor cells. We show that midkine specifically binds a protein or complex of molecular mass greater than 200 kDa with high affinity (K-d = 0.07 +/- 0.01 nM). Midkine, but not pleiotrophin, stimulates tyrosine phosphorylation of several cellular proteins with molecular mass of 100, 130, and 200+ kDa. Upon midkine binding, the midkine-receptor complex associates with the Janus tyrosine kinases, JAK1 and JAK2. MK stimulates tyrosine phosphorylation of JAK1, JAK2, and STAT1 alpha. Our initial characterization of the midkine receptor suggests that midkine autocrine stimulation of tumor cell proliferation is mediated by a cell-surface receptor which in turn might activate the JAK/STAT pathway.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA	Johns Hopkins University; Johns Hopkins University; Washington University (WUSTL); Icahn School of Medicine at Mount Sinai	Ratovitski, EA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 972 Rutland Ave,950 Ross Bldg, Baltimore, MD 21205 USA.	erat@welchlink.welch.jhu.edu		Lowenstein, Charles/0000-0003-0485-7514; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL52315, R01 HL5361] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Ausubel FM, 1988, MOL REPROD DEV; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWDY SF, 1991, J CELL PHYSIOL, V147, P248, DOI 10.1002/jcp.1041470209; EKBLOM P, 1992, KIDNEY PHYSL PATHOPH, P475; ELENIUS K, 1994, J CELL SCI, V107, P2975; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; GARVIN AJ, 1993, AM J PATHOL, V142, P375; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KAREY KP, 1988, IN VITRO CELL DEV B, V24, P1107; KIKUCHI S, 1993, NEUROSCI LETT, V160, P9, DOI 10.1016/0304-3940(93)90904-Y; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOJIMA S, 1995, J BIOL CHEM, V270, P9590, DOI 10.1074/jbc.270.16.9590; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; KUO MD, 1992, BIOCHEM BIOPH RES CO, V182, P188, DOI 10.1016/S0006-291X(05)80129-9; KUO MD, 1990, J BIOL CHEM, V265, P18749; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; LANGER JA, 1986, J BIOL CHEM, V261, P9801; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; LI YS, 1993, BIOCHEM BIOPH RES CO, V195, P1089, DOI 10.1006/bbrc.1993.2156; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; Mehler MF, 1997, TRENDS NEUROSCI, V20, P357, DOI 10.1016/S0166-2236(96)01045-4; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MICHIKAWA M, 1993, J NEUROSCI RES, V35, P530, DOI 10.1002/jnr.490350509; MICHIKAWA M, 1993, BIOCHEM BIOPH RES CO, V192, P1312, DOI 10.1006/bbrc.1993.1559; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MITSIADIS TA, 1995, J CELL BIOL, V129, P267, DOI 10.1083/jcb.129.1.267; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU T, 1994, DEV GROWTH DIFFER, V36, P1; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAMOTO M, 1992, J BIOCHEM-TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SATOH J, 1993, DEV BRAIN RES, V75, P201, DOI 10.1016/0165-3806(93)90024-5; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHWABE M, 1988, EUR J IMMUNOL, V18, P2009, DOI 10.1002/eji.1830181221; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; TSUTSUI J, 1993, CANCER RES, V53, P1281; VANDERWINDEN J, 1932, ANAT EMBRYOL, V186, P387; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	61	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3654	3660		10.1074/jbc.273.6.3654	http://dx.doi.org/10.1074/jbc.273.6.3654			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452495	hybrid			2022-12-27	WOS:000071822300080
J	Schmid-Alliana, A; Menou, L; Manie, S; Schmid-Antomarchi, H; Millet, MA; Giuriato, S; Ferrua, B; Rossi, B				Schmid-Alliana, A; Menou, L; Manie, S; Schmid-Antomarchi, H; Millet, MA; Giuriato, S; Ferrua, B; Rossi, B			Microtubule integrity regulates Src-like and extracellular signal-regulated kinase activities in human pro-monocytic cells - Importance for interleukin-1 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; EPIDERMAL GROWTH-FACTOR; TYROSINE-PHOSPHORYLATION; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; TRANSDUCTION; MACROPHAGES; INHIBITOR; FAMILY	We have demonstrated previously that microtubule depolymerization by colchicine in human monocytes induces selective production of interleukin-1 (IL-1) (Manie, S., Schmid-Alliana, A., Kubar, J., Ferrua, B., and Rossi, B. (1993) J. Biol. Chem. 268, 13675-13681), Here, we provide evidence that disruption of the microtubule structure rapidly triggers extracellular signal-regulated kinase (ERK) activation, whereas it was without effect on SAPK2 activity, which is commonly acknowledged to control pro-inflammatory cytokine production, This process involves the activation of the entire cascade including Ras, Raf-1, MEK1/2, ERK1, and ERK2, Activation of ERKs is followed by their nuclear translocation, Although other SAPK congeners might be activated upon microtubule depolymerization, the activation of ERK1 and ERK2 is mandatory for IL-1 production as shown by the blocking effect of PD 98059, a specific MEK1/2 inhibitor, Additionally, we provide evidence that microtubule disruption also induces the activation of c-Src and Hck activities, The importance of Src kinases in the mediation of the colchicine effect is underscored by the fact that CP 118556, a specific inhibitor of Src like kinase, abrogates both the colchicine-induced ERK activation and IL-1 production. This is the first evidence that ERK activation is an absolute prerequisite for induction of this cytokine, Altogether, our data lend support to a model where the status of microtubule integrity controls the level of Src activities that subsequently activate the ERK kinase cascade, thus leading to IL-1 production.	Fac Med Pasteur, INSERM, U364, F-06107 Nice 02, France; Fac Med Pasteur, Parasitol Lab, Grp Rech Immunopathol Leishmaniose, F-06107 Nice 02, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Rossi, B (corresponding author), Fac Med Pasteur, INSERM, U364, Ave Valombrose, F-06107 Nice 02, France.	rossi@unice.fr	Giuriato, Sylvie/A-9113-2010; SCHMID-ALLIANA, Annie/P-4366-2016; Manie, Serge/ABC-8331-2021	Giuriato, Sylvie/0000-0003-3274-3397; SCHMID-ALLIANA, Annie/0000-0003-2321-7408; manie, serge/0000-0002-9168-1977				AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALLEN NN, 1991, AM J PHYSIOL, V261, pL315; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BURDERING BMT, 1991, EMBO J, V10, P1103; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DING A, 1993, J IMMUNOL, V151, P5596; DING AH, 1990, J EXP MED, V171, P715, DOI 10.1084/jem.171.3.715; DOGLIO A, 1988, BIOCHEM J, V238, P123; FERRUA B, 1988, J IMMUNOL METHODS, V114, P41, DOI 10.1016/0022-1759(88)90151-2; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; JASPER JR, 1995, J PHARMACOL EXP THER, V274, P937; KATAGIRI K, 1993, J IMMUNOL, V150, P585; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANIE S, 1993, J BIOL CHEM, V268, P13675; MANIE S, 1993, EUR CYTOKINE NETW, V4, P51; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; MOLONY L, 1991, EXP CELL RES, V196, P40, DOI 10.1016/0014-4827(91)90454-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PARK JH, 1993, BLOOD, V82, P2470; Park RK, 1996, J BIOL CHEM, V271, P13342, DOI 10.1074/jbc.271.23.13342; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; ROBERGE CJ, 1993, J CLIN INVEST, V92, P1722, DOI 10.1172/JCI116759; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SchmidAntomarchi H, 1996, EUR J IMMUNOL, V26, P717, DOI 10.1002/eji.1830260331; SETH A, 1992, J BIOL CHEM, V267, P24796; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	47	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3394	3400		10.1074/jbc.273.6.3394	http://dx.doi.org/10.1074/jbc.273.6.3394			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452460	hybrid			2022-12-27	WOS:000071822300045
J	De Angelis, J; Gastel, J; Klein, DC; Cole, PA				De Angelis, J; Gastel, J; Klein, DC; Cole, PA			Kinetic analysis of the catalytic mechanism of serotonin N-acetyltransferase (EC 2.3.1.87)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-ENZYME INTERMEDIATE; PINEAL-GLAND; ESCHERICHIA-COLI; COENZYME-A; EXPRESSION; RHYTHM; SITE; RAT	Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT, EC 2.3.1.87) is the penultimate enzyme in melatonin biosynthesis. This enzyme is of special biological interest because large changes in its activity drive the large night/day rhythm in circulating melatonin in vertebrates, In this study the kinetic mechanism of AANAT action was studied using bacterially expressed glutathione S-transferase (GST)-AANAT fusion protein, The enzymologic behavior of GST-AANAT and cleaved AANAT was essentially identical, Two-substrate kinetic analysis generated an intersecting line pattern characteristic of a ternary complex mechanism, The dead end inhibitor analog desulfo-CoA was competitive versus acetyl-CoA and noncompetitive versus tryptamine. Tryptophol was not an alternative substrate but was a dead end competitive inhibitor versus tryptamine and an uncompetitive inhibitor versus acetyl-CoA, indicative of an ordered binding mechanism requiring binding of acetyl-CoA first, N-Acetyl-tryptamine, a reaction product, was a noncompetitive inhibitor versus tryptamine and uncompetitive with respect to acetyl-CoA, Taken together these results support an ordered BiBi ternary complex (sequential) kinetic mechanism for AANAT and provide a framework for inhibitor design.	Rockefeller Univ, Bioorgan Chem Lab, New York, NY 10021 USA; NICHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	Rockefeller University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Cole, PA (corresponding author), Rockefeller Univ, Bioorgan Chem Lab, 1230 York Ave, New York, NY 10021 USA.			Klein, David/0000-0002-1792-5806				ARENDT J, 1996, MELATONIN MAMMALIAN; BERGES DA, 1986, J BIOL CHEM, V261, P6160; Bernard M, 1997, J NEUROCHEM, V68, P213; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; CHENN HG, 1992, BIOCHEM PHARMACOL, V43, P2255; Cleland W W, 1979, Methods Enzymol, V63, P103; COLUCCI WJ, 1988, BIOORG CHEM, V16, P307, DOI 10.1016/0045-2068(88)90018-1; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 1996, GENOMICS, V34, P76, DOI 10.1006/geno.1996.0243; DEGUCHI T, 1975, J NEUROCHEM, V24, P1083, DOI 10.1111/j.1471-4159.1975.tb03682.x; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; FAJARDO N, 1992, J PINEAL RES, V13, P80, DOI 10.1111/j.1600-079X.1992.tb00058.x; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; JENCKS WP, 1972, J BIOL CHEM, V247, P3756; JENKINS DL, 1985, J BIOL CHEM, V260, P4748; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; Klein DC, 1996, TRENDS ENDOCRIN MET, V7, P106, DOI 10.1016/1043-2760(96)00033-1; MORRISSEY JJ, 1977, BIOCHEM BIOPH RES CO, V77, P118, DOI 10.1016/S0006-291X(77)80172-1; RIDDLE B, 1971, J BIOL CHEM, V246, P3250; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Segel IH, 1975, ENZYME KINETICS BEHA; SHAW WV, 1991, ANNU REV BIOPHYS BIO, V20, P363, DOI 10.1146/annurev.biophys.20.1.363; SIM E, 1992, BIOCHEM SOC T, V20, P304, DOI 10.1042/bst0200304; SOBER HA, 1970, HDB BIOCH SELECTED D, pJ184; THOMAS KB, 1990, ANAL BIOCHEM, V184, P228, DOI 10.1016/0003-2697(90)90673-W; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; VOISIN P, 1984, J BIOL CHEM, V259, P913; WEBER WW, 1967, MOL PHARMACOL, V3, P266; WOLFE MS, 1995, BRAIN RES, V669, P100, DOI 10.1016/0006-8993(94)01267-L; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	32	108	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3045	3050		10.1074/jbc.273.5.3045	http://dx.doi.org/10.1074/jbc.273.5.3045			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446620	hybrid			2022-12-27	WOS:000071736600075
J	Soltoff, SP; Avraham, H; Avraham, S; Cantley, LC				Soltoff, SP; Avraham, H; Avraham, S; Cantley, LC			Activation of P-2Y2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; EXTRACELLULAR ATP; GROWTH-FACTOR; EPITHELIAL-CELLS; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; CALCIUM INFLUX; SUBSTANCE-P; MAP KINASE; DELTA	We examined downstream signaling events that followed the exposure of PC12 cells to extracellular ATP and UTP, and we compared the effects of these P-2 receptor agonists with those of growth factors and other stimuli, Based on early findings, we focused particular attention on the mitogen-activated protein (MAP) kinase pathway, ATP and/or UTP produced increases in tyrosine phosphorylation of multiple proteins, including p42 MAP (ERK2) kinase, related adhesion focal tyrosine kinase (RAFTK) (PYK2, CAK beta), focal adhesion kinase (FAK), Shc, and protein kinase C delta (PKC delta). MAP (ERK2) kinase activity (quantified by substrate phosphorylation) was increased by UTP, ATP, phorbol la-myristate 13-acetate, ionomycin, and growth factors, UTP and ATP were equipotent (EC50 similar to 25 mu M) in stimulating MAP kinase activity, suggesting that these effects were mediated via the G(i)-linked P-2Y2 (P-2U) receptor. Consistent with this, the UTP-and ATP-promoted activation of MAP kinase was diminished in pertussis toxin-treated cells, Treatment of cells with pertussis toxin also reduced both the UTP-dependent increases in intracellular calcium ion concentration ([Ca2+](i)) and the tyrosine phosphorylation of RAFTK, Similarly, when [Ca2+](i) elevation was prevented using BAPTA and EGTA, the activation of MAP kinase by UTP and ionomycin was blocked, and the tyrosine phosphorylation of RAFTK was reduced, The UTP-promoted increase in MAP kinase activity was partially reduced in cells in which PKC was down-regulated, suggesting that both PKC-dependent and PKC independent pathways were involved, PKC delta, which increases MAP kinase activity in some systems, became tyrosine-phosphorylated within 15 s of exposure of cells to ATP or UTP; but epidermal growth factor, nerve growth factor, and insulin had little effect, UTP also promoted the association of Shc with Grb2. These results suggest that the P,,, receptor-initiated activation of MAP kinase was dependent on the elevation of [Ca2+](i), involved the recruitment of Shc and Grb2, and was mediated by RAFTK and PKC.	Harvard Univ, Beth Israel Med Ctr, Div Signal Transduct, Harvard Inst Med,Dept Med,Sch Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Med Ctr, Dept Med,Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Soltoff, SP (corresponding author), Harvard Univ, Beth Israel Med Ctr, Div Signal Transduct, Harvard Inst Med,Dept Med,Sch Med, 330 Brookline Ave, Boston, MA 02215 USA.	ssoltoff@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Avraham, Hava/0000-0002-7545-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55445] Funding Source: Medline; NIDCR NIH HHS [DE10877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BANBIESEN T, 1995, NATURE, V270, P781; BARRY VA, 1994, J CELL SCI, V107, P451; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BROWN HA, 1991, MOL PHARMACOL, V40, P648; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; COWEN DS, 1990, BIOCHIM BIOPHYS ACTA, V1053, P195, DOI 10.1016/0167-4889(90)90014-5; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; ERB L, 1993, P NATL ACAD SCI USA, V90, P10449, DOI 10.1073/pnas.90.22.10449; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HAAS M, 1995, J BIOL CHEM, V270, P28955, DOI 10.1074/jbc.270.48.28955; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; INOUE K, 1989, NEUROSCI LETT, V106, P294, DOI 10.1016/0304-3940(89)90179-1; Kadotani M, 1997, J BIOCHEM-TOKYO, V121, P1047; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; KIM WK, 1994, J BIOL CHEM, V269, P6471; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MAJID MA, 1993, BIOCHEM BIOPH RES CO, V195, P415, DOI 10.1006/bbrc.1993.2059; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MURRIN RJA, 1992, MOL PHARMACOL, V41, P561; ODRISCOLL KR, 1995, MOL BIOL CELL, V6, P449, DOI 10.1091/mbc.6.4.449; Palmer RK, 1996, AM J PHYSIOL-CELL PH, V271, pC43, DOI 10.1152/ajpcell.1996.271.1.C43; RAPAPORT E, 1983, CANCER RES, V43, P4402; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHULZELOHOFF E, 1992, AM J PHYSIOL, V263, pF374, DOI 10.1152/ajprenal.1992.263.3.F374; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SELA D, 1991, J BIOL CHEM, V266, P17990; SIPMA H, 1994, EUR J PHARM-MOLEC PH, V268, P431, DOI 10.1016/0922-4106(94)90069-8; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WOLKOFF LI, 1995, CELL CALCIUM, V17, P375, DOI 10.1016/0143-4160(95)90111-6	46	155	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2653	2660		10.1074/jbc.273.5.2653	http://dx.doi.org/10.1074/jbc.273.5.2653			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446569	hybrid			2022-12-27	WOS:000071736600024
J	Li, AC; Guidez, FRB; Collier, JG; Glass, CK				Li, AC; Guidez, FRB; Collier, JG; Glass, CK			The macrosialin promoter directs high levels of transcriptional activity in macrophages dependent on combinatorial interactions between PU.1 and c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; LOW-DENSITY-LIPOPROTEIN; PROTEIN-KINASE-C; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; CELL-SURFACE EXPRESSION; SCAVENGER RECEPTOR; INTERFERON-GAMMA; DIFFERENTIAL EXPRESSION; SEQUENCE SIMILARITY; HEMATOPOIETIC-CELLS	Macrosialin is a transmembrane glycoprotein that is highly expressed in macrophages. In the present studies, macrosialin mRNA levels are shown to be markedly up-regulated during macrophage differentiation of bone marrow progenitor cells in response to macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. To investigate the mechanisms responsible for regulation of macrosialin expression, we have isolated the macrosialin gene and performed an initial analysis of its transcriptional regulatory elements. The macrosialin promoter and 7.0 kilobase pairs of 5'-flanking information direct high levels of reporter gene activity in monocyte/macrophage-like cells, but little or no expression in nonmyeloid cells. This pattern of expression is dependent on regulatory elements located between -7.0 and -2.5 kilobase pairs from the transcriptional start site that exhibit strong enhancer activity in macrophages and repressor activity in nonmyeloid cells. Analysis of the proximal macrosialin promoter indicates that combinatorial interactions between at least four classes of transcriptional activators, including PU.1/Spi-1 and members of the AP-1 family are required for basal promoter function. PU.1/Spi-1 and c-Jun act synergistically to activate the macrosialin promoter in a nonmyeloid cell line, suggesting that combinatorial interactions between these proteins are involved in regulating macrosialin expression during macrophage differentiation.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Cardiol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	cglass@ucsd.edu	Glass, Christopher/AAI-3933-2021; Guidez, Fabien/P-4220-2019; Guidez, Fabien/B-3750-2009	Glass, Christopher/0000-0003-4344-3592; Guidez, Fabien/0000-0003-1380-4473; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003625, P50HL014197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000353] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14197, 1K08HL03625-01] Funding Source: Medline; NIA NIH HHS [2K12AG00353-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKESON AL, 1991, J LIPID RES, V32, P1699; ATHANASOU NA, 1986, J PATHOL, V150, P239, DOI 10.1002/path.1711500403; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN JW, 1988, J BIOL CHEM, V263, P8754; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLLINS SJ, 1987, BLOOD, V70, P1233; daSilva RP, 1996, BIOCHEM SOC T, V24, P220, DOI 10.1042/bst0240220; DATTA R, 1992, BLOOD, V79, P904; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRACH J, 1994, CANCER RES, V54, P1746; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HOLNESS CL, 1993, BLOOD, V81, P1607; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAJL HL, 1993, J BIOL CHEM, V268, P5014; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PULFORD KAF, 1990, INT IMMUNOL, V2, P973, DOI 10.1093/intimm/2.10.973; RABINOWITZ S, 1989, J CELL SCI, V93, P623; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; RAY D, 1990, ONCOGENE, V5, P663; ROUSSEL MF, 1994, J CELL SCI, P105; SAITO N, 1991, AM J PATHOL, V139, P1053; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SMITH MJ, 1987, J CELL SCI, V87, P113; STROBL H, 1995, BRIT J HAEMATOL, V90, P774, DOI 10.1111/j.1365-2141.1995.tb05195.x; WARNKE RA, 1989, AM J PATHOL, V135, P1089; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YOUNG HA, 1995, J LEUKOCYTE BIOL, V58, P373, DOI 10.1002/jlb.58.4.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	58	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5389	5399		10.1074/jbc.273.9.5389	http://dx.doi.org/10.1074/jbc.273.9.5389			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9479000	hybrid			2022-12-27	WOS:000072310400084
J	Martens, JS; Reiner, NE; Herrera-Velit, P; Steinbrecher, UP				Martens, JS; Reiner, NE; Herrera-Velit, P; Steinbrecher, UP			Phosphatidylinositol 3-kinase is involved in the induction of macrophage growth by oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HERITABLE HYPERLIPIDEMIC RABBIT; COLONY-STIMULATING FACTORS; PLATELET-ACTIVATING-FACTOR; ENDOTHELIAL-CELLS; HUMAN-MONOCYTES; PROTEIN-KINASE; LINE THP-1; ATHEROSCLEROSIS; LDL	Early atherosclerotic lesions are characterized by the presence of cholesterol-rich, macrophage-derived foam cells. It has recently been shown that macrophage proliferation occurs during the development of early lesions and that oxidized low density lipoprotein (LDL) stimulates macrophage growth, Possible mechanisms for this induction of macrophage growth include potentiation of mitogenic signal transduction by a component of oxidized LDL following internalization and degradation, interaction with integral plasma membrane proteins coupled to signaling pathways, or direct or indirect activation of growth factor receptors on the cell surface (e.g. GM-CSF receptor) through an autocrine/paracrine mechanism, The present study was undertaken to characterize some of the early intracellular signaling events by which oxidized LDL mediates macrophage cell growth. Extensively oxidized LDL increased protein-tyrosine phosphorylation and caused a 2-fold increase in phosphatidylinositol (PI) 3-kinase activity in phorbol ester-pretreated THP-1 cells (a human monocyte-like cell line). Similar concentrations of native LDL had no effect. Oxidized LDL also stimulated growth of resident mouse peritoneal macrophages, and this effect was reduced by 40-50% in cells treated with PI 3-kinase inhibitors (100 nM wortmannin or 20 mu M LY294002), These results suggest that PI 3-kinase mediates part of the mitogenic effect of oxidized LDL, but parallel pathways involving other receptors and signal transduction pathways are likely also involved.	Univ British Columbia, Dept Med, Div Gastroenterol, Vancouver, BC V5Z 4E3, Canada; Univ British Columbia, Dept Med, Div Infect Dis, Vancouver, BC V5Z 4E3, Canada	University of British Columbia; University of British Columbia	Steinbrecher, UP (corresponding author), Univ British Columbia, Dept Med, Div Gastroenterol, 3300-950 W 10th Ave, Vancouver, BC V5Z 4E3, Canada.	usteinbr@unixg.ubc.ca		Herrera, Patricia/0000-0001-8754-9335				AagaardTillery KM, 1996, J IMMUNOL, V156, P4543; BERLINER JA, 1993, ADV EXP MED BIOL, V351, P13; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; FOWLER S, 1979, LAB INVEST, V41, P372; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GERRITY RG, 1981, AM J PATHOL, V103, P181; GERRITY RG, 1985, SWINE BIOMEDICAL RES, P1497; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; Iwama A., 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS318, DOI 10.1111/j.1440-1681.1995.tb02935.x; KATSUDA S, 1993, AM J PATHOL, V142, P1787; KIM JA, 1994, ARTERIOSCLER THROMB, V14, P427, DOI 10.1161/01.ATV.14.3.427; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Miki S, 1996, FEBS LETT, V399, P241, DOI 10.1016/S0014-5793(96)01332-4; NATARAJAN V, 1995, J LIPID RES, V36, P2005; OKADA T, 1994, J BIOL CHEM, V269, P3563; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PLIEMAN CM, 1993, J MOL CELL BIOL, V13, P5877; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; REKHTER MD, 1995, AM J PATHOL, V147, P668; RESINK TJ, 1992, ARTERIOSCLER THROMB, V12, P278, DOI 10.1161/01.ATV.12.3.278; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; SCHWARTZ D, 1994, J CLIN INVEST, V94, P1968, DOI 10.1172/JCI117548; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VENABLE ME, 1993, J LIPID RES, V34, P691; VIA DP, 1989, J LIPID RES, V30, P1515; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331; YUSOFF P, 1994, GROWTH FACTORS, V10, P181, DOI 10.3109/08977199409000236	56	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4915	4920		10.1074/jbc.273.9.4915	http://dx.doi.org/10.1074/jbc.273.9.4915			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478935	hybrid			2022-12-27	WOS:000072310400019
J	Yamaji, A; Sekizawa, Y; Emoto, K; Sakuraba, H; Inoue, K; Kobayashi, H; Umeda, M				Yamaji, A; Sekizawa, Y; Emoto, K; Sakuraba, H; Inoue, K; Kobayashi, H; Umeda, M			Lysenin, a novel sphingomyelin-specific binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; EARTHWORM CELOMIC FLUID; NIEMANN-PICK DISEASE; MONOCLONAL-ANTIBODY; CELL-SURFACE; HUMAN FIBROBLASTS; EISENIA-FOETIDA; PLASMA-MEMBRANE; RAT CEREBELLUM; CROSS-LINKING	Lysenin, a novel 41-kDa protein purified from coelomic fluid of the earthworm Eisenia foetida, induced erythrocyte lysis. Preincubation of lysenin with vesicles containing sphingomyelin inhibited lysenin-induced hemolysis completely, whereas vesicles containing phospholipids other than sphingomyelin showed no inhibitory activity, suggesting that lysenin bound specifically to sphingomyelin on erythrocyte membranes. The specific binding of lysenin to sphingomyelin was confirmed by enzyme-linked immunosorbent assay, TLC immunostaining, and liposome lysis assay. In these assays, lysenin bound specifically to sphingomyelin and did not show any cross-reaction with other phospholipids including sphingomyelin analogs such as sphingosine, ceramide, and sphingosylphosphorylcholine, indicating that it recognized a precise molecular structure of sphingomyelin. Kinetic analysis of the lysenin-sphingo-myelin interaction by surface plasmon resonance measurements using BIAcore(TM) system showed that lysenin associated with membrane surfaces composed of sphingomyelin (k(on) = 3.2 x 10(4) M-1 s(-1)) and dissociated extremely slowly (k(off) = 1.7 x 10(-4) s(-1)), giving a low dissociation constant (K-D = 5.3 x 10(-9) M). Incorporation of cholesterol into the sphingomyelin membrane significantly increased the total amount of lysenin bound to the membrane, whereas it did not change the kinetic parameters of the lysenin-membrane interaction, suggesting that lysenin specifically recognized sphingomyelin and cholesterol incorporation changed the topological distribution of sphingomyelin in the membranes, thereby increasing the accessibility of sphingomyelin to lysenin. Immunofluorescence staining of fibroblasts derived from a patient with Niemann-Pick disease type A showed that lysenin stained the surfaces of the fibroblasts uniformly, whereas intense lysosomal staining was observed when the cells were permeabilized by digitonin treatment, Preincubation of lysenin with vesicles containing sphingomyelin abolished lysenin immunostaining. This study demonstrated that lysenin bound specifically to sphingomyelin on cellular membranes and should be a useful tool to probe the molecular motion and function of sphingomyelin in biological membranes.	Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, Tokyo 113, Japan; Tokyo Metropolitan Inst Med Sci, Dept Clin Genet, Bunkyo Ku, Tokyo 113, Japan; Zenyaku Kogyo Co Ltd, Res Lab, Nerima Ku, Tokyo 178, Japan; Univ Tokyo, Fac Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Umeda, M (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 113, Japan.	umeda@rinshoken.or.jp	EMOTO, KAZUO/G-4992-2014					ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7; DAVIES AA, 1984, BIOCHEM J, V219, P301, DOI 10.1042/bj2190301; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; Emoto K, 1997, EXP CELL RES, V232, P430, DOI 10.1006/excr.1997.3521; ESTEP TN, 1979, BIOCHEMISTRY-US, V18, P2112, DOI 10.1021/bi00577a042; Fujimoto K, 1996, J CELL SCI, V109, P2453; Fujimoto T, 1996, J HISTOCHEM CYTOCHEM, V44, P929, DOI 10.1177/44.8.8756764; HAGMANN J, 1982, BIOCHIM BIOPHYS ACTA, V720, P181, DOI 10.1016/0167-4889(82)90010-6; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HIROTA K, 1995, J BIOCHEM, V118, P4, DOI 10.1093/oxfordjournals.jbchem.a124890; IGARASHI K, 1995, J BIOCHEM-TOKYO, V117, P452, DOI 10.1093/jb/117.2.452; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; IKEZAWA H, 1980, ARCH BIOCHEM BIOPHYS, V199, P572, DOI 10.1016/0003-9861(80)90315-X; ITO E, 1991, NEUROSCI RES, V11, P179, DOI 10.1016/0168-0102(91)90041-V; JIANG LW, 1990, J BIOL CHEM, V265, P4775; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; Lange S, 1997, J BIOL CHEM, V272, P20884, DOI 10.1074/jbc.272.33.20884; LANGE S, 1995, 23 M FEBS AUG 13 18; LEVADE T, 1987, BIOCHIM BIOPHYS ACTA, V918, P250, DOI 10.1016/0005-2760(87)90228-1; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Maulik PR, 1996, BIOCHEMISTRY-US, V35, P8025, DOI 10.1021/bi9528356; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MIYAZAWA A, 1988, MOL IMMUNOL, V25, P1025; MIYAZAWA A, 1992, J NEUROCHEM, V59, P1547, DOI 10.1111/j.1471-4159.1992.tb08472.x; OKU N, 1987, J BIOCHEM-TOKYO, V102, P1303, DOI 10.1093/oxfordjournals.jbchem.a122168; OSHIMA A, 1990, HUM GENET, V85, P505; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PLANT AL, 1995, ANAL BIOCHEM, V226, P342, DOI 10.1006/abio.1995.1234; ROCH P, 1989, BIOCHIM BIOPHYS ACTA, V983, P193, DOI 10.1016/0005-2736(89)90233-2; ROCH P, 1984, J CHROMATOGR, V290, P231, DOI 10.1016/S0021-9673(01)93578-2; ROCH PH, 1984, J CHROMATOGR, V983, P193; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; Sekizawa Y, 1996, BIOMED RES-TOKYO, V17, P197, DOI 10.2220/biomedres.17.197; Sekizawa Y, 1997, GENE, V191, P97, DOI 10.1016/S0378-1119(97)00047-4; Sekizawa Y, 1996, BIOMED RES-TOKYO, V17, P327, DOI 10.2220/biomedres.17.327; SLOAN HR, 1972, METHOD ENZYMOL, V28, P874; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; STREULI CH, 1981, EXP CELL RES, V136, P247, DOI 10.1016/0014-4827(81)90002-1; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; UMEDA M, 1989, J IMMUNOL, V143, P2273; VAILLIER J, 1985, DEV COMP IMMUNOL, V9, P11, DOI 10.1016/0145-305X(85)90055-2; VANIER MT, 1983, BIOCHIM BIOPHYS ACTA, V750, P178, DOI 10.1016/0005-2760(83)90218-7; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	53	266	285	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5300	5306		10.1074/jbc.273.9.5300	http://dx.doi.org/10.1074/jbc.273.9.5300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478988	hybrid			2022-12-27	WOS:000072310400072
J	Fieschi, F; Torrents, E; Toulokhonova, L; Jordan, A; Hellman, U; Barbe, J; Gibert, I; Karlsson, M; Sjoberg, BM				Fieschi, F; Torrents, E; Toulokhonova, L; Jordan, A; Hellman, U; Barbe, J; Gibert, I; Karlsson, M; Sjoberg, BM			The manganese-containing ribonucleotide reductase of Corynebacterium ammoniagenes is a class Ib enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BACILLUS-SUBTILIS; BREVIBACTERIUM-AMMONIAGENES; NRDEF ENZYME; CLONING; PROTEIN; ENTEROBACTERIACEAE; THIOREDOXIN; EXPRESSION	Ribonucleotide reductases (RNRs) are key enzymes in living cells that provide the precursors of DNA synthesis, The three characterized classes of RNRs differ by their metal cofactor and their stable organic radical. We have purified to near homogeneity the enzymatically active Mn-containing RNR of Corynebacterium ammoniagenes, previously claimed to represent a fourth RNR class, N-terminal and internal peptide sequence analyses clearly indicate that the C. ammoniagenes RNR is a class Ib enzyme. In parallel, we have cloned a 10-kilobase pair fragment from C. ammoniagenes genomic DNA, using primers specific for the known class Ib RNR, The cloned class Ib locus contains the nrdHIEF genes typical for class Ib RNR operon, The deduced amino acid sequences of the nrdE and nrdF genes matched the peptides from the active enzyme, demonstrating that C. ammoniagenes RNR is composed of R1E and R2F components typical of class Ib. We also show that the Mn-containing RNR has a specificity for the NrdH-redoxin and a response to allosteric effecters that are typical of class Ib RNRs. Electron paramagnetic resonance and atomic absorption analyses confirm the presence of Mn as a cofactor and show, for the first time, insignificant amounts of iron and cobalt found in the other classes of RNR. Our discovery that C. ammoniagenes RNR is a class Ib enzyme and possesses all the highly conserved amino acid side chains that are known to ligate two ferric ions in other class I RNRs evokes new, challenging questions about the control of the metal site specificity in RNR. The cloning of the entire NrdHIEF locus of C, ammoniagenes will facilitate further studies along these lines.	Univ Stockholm, Dept Biol Mol, S-10691 Stockholm, Sweden; Autonomous Univ Barcelona, Fac Sci, Dept Genet & Microbiol, E-08193 Barcelona, Spain; Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Stockholm University; Autonomous University of Barcelona; Ludwig Institute for Cancer Research	Sjoberg, BM (corresponding author), Univ Stockholm, Dept Biol Mol, S-10691 Stockholm, Sweden.	Britt-Marie.Sjoberg@molbio.su.se	Torrents, Eduard/C-7184-2008; jordan, albert/ABC-8229-2020; jordan, albert/K-4678-2014; Gibert, Isidre/L-9834-2014; Fieschi, Franck/W-2748-2019	Torrents, Eduard/0000-0002-3010-1609; jordan, albert/0000-0002-3970-8693; jordan, albert/0000-0002-3970-8693; Gibert, Isidre/0000-0003-1442-2258; FIESCHI, Franck/0000-0003-1194-8107; Sjoberg, Britt-Marie/0000-0001-5953-3360				ATTA M, 1992, J BIOL CHEM, V267, P20682; Bathe B, 1996, MOL GEN GENET, V252, P255, DOI 10.1007/s004380050227; Boldt YR, 1997, BIOCHEMISTRY-US, V36, P2147, DOI 10.1021/bi962362i; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; Eliasson R, 1996, J BIOL CHEM, V271, P26582, DOI 10.1074/jbc.271.43.26582; FraOsto da Silva Williams, 1991, BIOL CHEM ELEMENTS I; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FURUYA A, 1976, MICROBIAL PRODUCTION, P125; Griepenburg U, 1996, FREE RADICAL RES, V24, P473, DOI 10.3109/10715769609088046; Hellman U, 1997, SPRING LAB MAN, P97; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HOCH JA, 1991, METHOD ENZYMOL, V204, P305; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, J BACTERIOL, V176, P3420, DOI 10.1128/jb.176.11.3420-3427.1994; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1995, GENE, V167, P75, DOI 10.1016/0378-1119(95)00656-7; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LUNN CA, 1984, J BIOL CHEM, V259, P469; MALUMBRES M, 1993, GENE, V134, P15, DOI 10.1016/0378-1119(93)90169-4; MORIYA S, 1985, NUCLEIC ACIDS RES, V13, P2251, DOI 10.1093/nar/13.7.2251; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; OKA T, 1968, J BACTERIOL, V96, P1760, DOI 10.1128/JB.96.5.1760-1767.1968; Patek M, 1996, MICROBIOL-SGM, V142, P1297, DOI 10.1099/13500872-142-5-1297; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLONZIG J, 1987, ARCH MICROBIOL, V146, P396, DOI 10.1007/BF00410942; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIMPFFWEILAND G, 1981, BIOCHEM BIOPH RES CO, V102, P1276, DOI 10.1016/S0006-291X(81)80149-0; Schmidt M, 1996, J BIOL INORG CHEM, V1, P532, DOI 10.1007/s007750050089; Scotti C, 1996, MICROBIOL-SGM, V142, P2995, DOI 10.1099/13500872-142-11-2995; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; Thelander L, 1978, Methods Enzymol, V51, P227; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEBLEY DM, 1962, J GEN MICROBIOL, V29, P179, DOI 10.1099/00221287-29-1-179; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x; WILLING A, 1988, EUR J BIOCHEM, V175, P167, DOI 10.1111/j.1432-1033.1988.tb14179.x; YANG FD, 1994, J BACTERIOL, V176, P6738, DOI 10.1128/JB.176.21.6738-6743.1994; Yang FD, 1997, J BACTERIOL, V179, P6408, DOI 10.1128/jb.179.20.6408-6415.1997	49	45	47	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4329	4337		10.1074/jbc.273.8.4329	http://dx.doi.org/10.1074/jbc.273.8.4329			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468481	hybrid, Green Published			2022-12-27	WOS:000072115000009
J	Librizzi, MD; Brenowitz, M; Willis, IM				Librizzi, MD; Brenowitz, M; Willis, IM			The TATA element and its context affect the cooperative interaction of TATA-binding protein with the TFIIB-related factor, TFIIIB70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; CRYSTAL-STRUCTURE; MINOR-GROOVE; BOX COMPLEX; IN-VIVO; YEAST; DNA; TBP; PROMOTER	We have conducted a quantitative thermodynamic study of the effects of the TATA element and TATA-flanking sequences on the assembly of complexes containing TATA-binding protein (TBP) and the TFIIB-related factor, TFIIIB70. TBP binds to the sequence TATAAAAG in the context of the yeast U6 gene (yU6 hybrid TATA) or the adenovirus major late promoter (AdMLP) with different affinities demonstrating that the sequence context of a TATA element contributes to TBP binding, We also determined the cooperative free energies of formation of TBP.TFIIIB70.DNA complexes on the yU6 TATA element, the yU6 hybrid TATA element and a nonconsensus TATA element, The yU6 hybrid TATA displayed a moderate, less than 5-fold, increase in TBP affinity similar to the 3-fold increase observed for the AdMLP. In contrast, the nonconsensus and yU6 TATAs increased the affinity of TBP for DNA 12- and 17-fold, respectively. Since the TBP-TFIIIB70 cooperativity is greater on lower affinity TATA boxes and most polymerase III genes contain low affinity "TATA boxes," we conclude that the cooperative binding of TFIIIB70 and TBP to DNA represents an important driving force in the assembly of polymerase III-specific transcription complexes, An effect of the sequences surrounding the TATA box was also observed on TBP-TFIIIB70 cooperativity, The mechanistic implications of the thermodynamic linkage between DNA sequence and binding cooperativity are discussed.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Willis, IM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	willis@aecom.yu.edu		Willis, Ian/0000-0001-6599-2395	NIGMS NIH HHS [GM51506, GM42728, GM07491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051506, R01GM042728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; BRENOWITZ M, 1993, FOOTPRINTING TECHNIQ, P1; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHOISNE N, 1998, IN PRESS PLANT MOL B; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; Daugherty MA, 1997, FASEB J, V11, pA1207; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; GARBER ME, 1994, MOL CELL BIOL, V14, P339, DOI 10.1128/MCB.14.1.339; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Huang WB, 1996, NUCLEIC ACIDS RES, V24, P1158, DOI 10.1093/nar/24.6.1158; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; Librizzi MD, 1996, J BIOL CHEM, V271, P32695, DOI 10.1074/jbc.271.51.32695; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; PETRI V, 1996, FASEB J, V10, pA1123; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STARR DB, 1995, J MOL BIOL, V250, P434; VERRIJZER CP, 1996, TRENDS BIOCHEM SCI, V21, P325; Wang Y, 1996, NUCLEIC ACIDS RES, V24, P3100, DOI 10.1093/nar/24.15.3100; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890	37	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4563	4568		10.1074/jbc.273.8.4563	http://dx.doi.org/10.1074/jbc.273.8.4563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468512	hybrid			2022-12-27	WOS:000072115000040
J	Underwood, KW; Jacobs, NL; Howley, A; Liscum, L				Underwood, KW; Jacobs, NL; Howley, A; Liscum, L			Evidence for a cholesterol transport pathway from lysosomes to endoplasmic reticulum that is independent of the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; ACYL-COENZYME-A; INTRACELLULAR CHOLESTEROL; CULTURED FIBROBLASTS; HEPATOMA-CELLS; GOLGI-COMPLEX; BREFELDIN-A; ESTERIFICATION; MACROPHAGES	We have studied the movement of low density lipoprotein (LDL)-derived cholesterol in cultured Chinese hamster ovary cells, Our hypothesis is that when LDL cholesterol is effluxed from lysosomes, the bulk of LDL cholesterol is mobilized to the plasma membrane, while another pathway delivers LDL cholesterol from lysosomes to acyl-CoA/cholesterol acyltransferase (ACAT) in the endoplasmic reticulum. Three lines of evidence support this model, First, LDL cholesterol transport to ACAT can be blocked without inhibiting the movement of cholesterol from lysosomes to plasma membrane or from plasma membrane to endoplasmic reticulum, Second, LDL cholesterol transport to ACAT is normal in a Chinese hamster ovary mutant with defective plasma membrane-to-ACAT movement, Third, LDL cholesterol is not diluted by the plasma. membrane cholesterol pool before reaching ACAT, Our evidence supports a vesicular model of cholesterol transport from lysosomes to the endoplasmic reticulum that is independent; of the plasma membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Liscum, L (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049564, T32DK007542, P30DK034928] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34928, DK49564, DK07542] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; COXEY RA, 1993, J LIPID RES, V34, P1165; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAHL NK, 1994, J LIPID RES, V35, P1839; DEKRUIJFF B, 1990, BIOSCIENCE REP, V10, P127; FAUST JR, 1977, J BIOL CHEM, V252, P4861; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; Jacobs NL, 1997, J LIPID RES, V38, P1973; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KINSKY SC, 1970, ANNU REV PHARMACOLOG, V10, P119, DOI 10.1146/annurev.pa.10.040170.001003; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORTING HC, 1994, LIFE SCI, V55, P533, DOI 10.1016/0024-3205(94)00746-2; LANGE Y, 1983, J BIOL CHEM, V258, P5130; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1995, J LIPID RES, V36, P1092; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J LIPID RES, V32, P329; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; PORN MI, 1995, BIOCHEM J, V308, P269; RALSTON E, 1993, J CELL BIOL, V120, P399, DOI 10.1083/jcb.120.2.399; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1994, J BIOL CHEM, V269, P22547; Underwood KW, 1996, J LIPID RES, V37, P1556; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; XU XX, 1991, J BIOL CHEM, V266, P17040	41	137	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4266	4274		10.1074/jbc.273.7.4266	http://dx.doi.org/10.1074/jbc.273.7.4266			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461625	hybrid			2022-12-27	WOS:000072048400067
J	Makhina, EN; Nichols, CG				Makhina, EN; Nichols, CG			Independent trafficking of K-ATP channel subunits to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; ENDOPLASMIC-RETICULUM; POTASSIUM CHANNELS; PROTEIN; EXPRESSION; CLONING; CELLS	K-ATP channels are unique in requiring two distinct subunits (Kir6.2, a potassium channel subunit) and SUR1 (an ABC protein) for generation of functional channels, To examine the cellular trafficking of K-ATP channel subunits, green fluorescent protein (GFP) was tagged to the cytoplasmic N or C terminus of SUR1 and Kir6.2 subunits and to the C terminus of a dimeric fusion between SUR1 and Kir6.2 (SUR1-Kir6.2). AU tagged constructs generated functional channels with essentially normal properties when coexpressed with the relevant other subunit. GFP-tagged Kir6.2 (Kir6.2-GFP) showed perinuclear and plasma membrane fluorescence patterns when expressed alone or with SUR1, and a very similar pattern was observed when channel-forming SUR1-Kir6.2-GFP was expressed on its own. In contrast, whereas SUR1 (SUR1-GFP) also showed a perinuclear and plasma membrane fluorescence pattern when expressed alone, an apparently cytoplasmic fluorescence was observed when coexpressed with Kir6.2 subunits, The results indicate that Kir6.2 subunits traffic to the plasma membrane in the presence or absence of SUR1, in contradiction to the hypothesis that homomeric Kir6.2 channels are not observed because SUR1 is required as a chaperone to guide Kir6.2 subunits through the secretory pathway.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Nichols, Colin/D-6336-2012		NHLBI NIH HHS [HL54171, HL451231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ammala C, 1996, NATURE, V379, P545, DOI 10.1038/379545a0; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MAKHINA EN, 1997, BIOPHYS J, V72, P253; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; SHYNG SL, 1997, J GEN PHYSIOL, V110, P654; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0	23	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3369	3374		10.1074/jbc.273.6.3369	http://dx.doi.org/10.1074/jbc.273.6.3369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452456	hybrid			2022-12-27	WOS:000071822300041
J	Schultz, RA; Swoap, SJ; McDaniel, LD; Zhang, BQ; Koon, EC; Garry, DJ; Li, K; Williams, RS				Schultz, RA; Swoap, SJ; McDaniel, LD; Zhang, BQ; Koon, EC; Garry, DJ; Li, K; Williams, RS			Differential expression of mitochondrial DNA replication factors in mammalian tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; CONTRACTILE ACTIVITY; POLYMERASE-GAMMA; STRIATED-MUSCLE; GENE-EXPRESSION; SKELETAL-MUSCLE; NUCLEAR; CLONING; SSB; RNA	Mitochondrial biogenesis and mitochondrial DNA (mtDNA) replication are regulated during development and in response to physiological stresses, but the regulatory events that control the abundance of mtDNA in cells of higher eukaryotes have not been defined at a molecular level, In this study, we observed that expression of the catalytic subunit of DNA polymerase gamma (POL gamma(CAT)) mRNA varies little among different tissues and is not increased by continuous neural activation of skeletal muscle, a potent stimulus to mitochondrial bio genesis, Increased copy number for the POL gamma locus in a human cell line bearing a partial duplication of chromosome 15 increased the abundance of POL gamma(CAT) mRNA without up-regulation of mtDNA, In contrast, expression of mitochondrial single-stranded DNA-binding (mtSSB) mRNA is regulated coordinately with variations in the abundance of mtDNA among tissues of mammalian organisms and is up-regulated in association with the enhanced mitochondrial biogenesis that characterizes early postnatal development of the heart and the adaptive response of skeletal myofibers to motor nerve stimulation, In addition, we noted that expression of mtSSB is concentrated within perinuclear mitochondria that constitute active sites of mtDNA replication, We conclude that constitutive expression of the gene encoding the catalytic subunit of mitochondrial DNA polymerase is sufficient to support physiological variations in mtDNA replication among specialized cell types, whereas expression of the mtSSB gene is controlled by molecular mechanisms acting to regulate mtDNA replication or stability in mammalian cells.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol Oncol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, NB11-200, Dallas, TX 75235 USA.				NATIONAL CANCER INSTITUTE [R01CA052121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054794, P01HL006296] Funding Source: NIH RePORTER; NCI NIH HHS [CA52121] Funding Source: Medline; NHLBI NIH HHS [HL54794, HL06296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ANNEX BH, 1990, MOL CELL BIOL, V10, P5671, DOI 10.1128/MCB.10.11.5671; ANNEX BH, 1991, AM J PHYSIOL, V260, pC266, DOI 10.1152/ajpcell.1991.260.2.C266; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753; FOURY F, 1989, J BIOL CHEM, V264, P20552; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; ORDWAY GA, 1993, AM J PHYSIOL, V265, pC1511, DOI 10.1152/ajpcell.1993.265.6.C1511; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Saltin B, 2010, COMPR PHYSIOL, P555; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; Walker RL, 1997, GENOMICS, V40, P376, DOI 10.1006/geno.1996.4580; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	22	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3447	3451		10.1074/jbc.273.6.3447	http://dx.doi.org/10.1074/jbc.273.6.3447			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452467	hybrid			2022-12-27	WOS:000071822300052
J	Katoh, H; Aoki, J; Ichikawa, A; Negishi, M				Katoh, H; Aoki, J; Ichikawa, A; Negishi, M			p160 RhoA-binding kinase ROK alpha induces neurite retraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; SMALL GTPASE-RHO; PROTEIN-RHO; SERINE/THREONINE KINASE; PUTATIVE TARGET; ADP-RIBOSYLTRANSFERASE; ACTIVATION; CELLS; RIBOSYLATION; CYTOSKELETON	We previously reported that the activation of prostaglandin E receptor EP3 subtype caused neurite retraction via small GTPase Rho in the EP3B receptor-expressing PC12 cells (Katoh, H., Negishi, M., and Ichikawa, A. (1996) J. Biol. Chem. 271, 29780-29784). However, a potential downstream effector of Rho that induces neurite retraction was not identified, Here we examined the morphological effect of p160 RhoA-binding kinase ROK alpha, a target for RhoA recently identified, on the nerve growth factor-differentiated PC12 cells. Microinjection of the catalytic domain of ROK alpha rapidly induced neurite retraction similar to that induced by microinjection of a constitutively active Rho, Rho(V14) whereas microinjection of the kinase-deficient catalytic domain of ROK alpha did not induce neurite retraction. This morphological change was observed even though C3 exoenzyme, which was known to inactivate Rho, had been preinjected. On the other hand, microinjection of the Rho-binding domain or the pleckstrin homology domain of ROK alpha inhibited the EP3 receptor-induced neurite retraction, These results demonstrate that ROK alpha induces neurite retraction acting downstream of Rho in neuronal cells.	Kyoto Univ, Fac Pharmaceut Sci, Dept Mol Neurobiol, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Fac Pharmaceut Sci, Dept Mol Neurobiol, Sakyo Ku, Kyoto 606, Japan.							AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Hasegawa H, 1997, BIOCHEM BIOPH RES CO, V234, P631, DOI 10.1006/bbrc.1997.6655; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 1997, J BIOL CHEM, V272, P10333; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TAKAISHI K, 1994, ONCOGENE, V9, P273; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 1996, J NEUROCHEM, V66, P537; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044	31	161	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2489	2492		10.1074/jbc.273.5.2489	http://dx.doi.org/10.1074/jbc.273.5.2489			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446546	hybrid			2022-12-27	WOS:000071736600001
J	Lopez-Ilasaca, M; Gutkind, JS; Wetzker, R				Lopez-Ilasaca, M; Gutkind, JS; Wetzker, R			Phosphoinositide 3-kinase gamma is a mediator of G beta gamma-dependent Jun kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNALING PATHWAY; SUBUNITS; CDC42; RAS	Jun kinases (JNK) are involved in the stress response of mammalian cells, Stimulation of JNK can be induced by stress factors and by agonists of tyrosine kinase and G protein coupled receptors, G protein-dependent receptors stimulate JNK via G beta gamma subunits of heterotrimeric G proteins, but the subsequent signaling reaction has been undefined. Here we demonstrate JNK activation in COS-7 cells by G beta gamma-stimulated phosphoinositide S-kinase gamma (PI3K gamma). Signal transduction from PI3K gamma to JNK can be suppressed by dominant negative mutants of Ras, Rac, and the protein kinase PAK. These results identify PI3K gamma as a mediator of G beta gamma-dependent regulation of JNK activity.	Univ Jena, Fac Med, Max Planck Res Unit Mol Cell Biol, D-07747 Jena, Germany; NIH, Mol Signaling Unit, Cellular Dev & Oncol Lab, NIDR, Bethesda, MD 20892 USA	Friedrich Schiller University of Jena; Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Wetzker, R (corresponding author), Univ Jena, Fac Med, Max Planck Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5rewe@rz.uni-jena.de	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Wetzker, Reinhard/AAD-8713-2019	Gutkind, J. Silvio/0000-0002-5150-4482; 				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731	16	88	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2505	2508		10.1074/jbc.273.5.2505	http://dx.doi.org/10.1074/jbc.273.5.2505			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446550	hybrid			2022-12-27	WOS:000071736600005
J	Srivastava, SP; Kumar, KU; Kaufman, RJ				Srivastava, SP; Kumar, KU; Kaufman, RJ			Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; MALIGNANT TRANSFORMATION; FACTOR-II; SIGNAL-TRANSDUCTION; MESSENGER-RNAS; P68 KINASE; 3T3 CELLS; INTERFERON; PKR	The interferon-inducible, double-stranded (ds) RNA-dependent serine/threonine protein kinase (PKR) plays a role in viral pathogenesis, cell growth, and differentiation and is implicated as a tumor suppressor gene. Expression of a trans-dominant negative, catalytically inactive mutant PKR protected NIH3T3 cells from apoptosis in response to either treatment with tumor necrosis factor alpha (TNF alpha), serum deprivation. In cells expressing mutant PKR, TNF alpha, but not dsRNA induced transcription from a nuclear factor kappa B-dependent promoter, demonstrating specificity for dsRNA in signaling through the PKR pathway. Serum or platelet-derived growth factor addition to serum-deprived mutant PI(R-expressing cells induced transcription of the early response genes c-fos and c-jun, indicating that the immediate early response signaling was intact. Overexpression of wild-type PKR in a transient DNA transfection system was sufficient to induce apoptosis. TNF alpha-induced apoptosis correlated with increased phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2 alpha), the primary physiological substrate of the PKR Furthermore, forced expression of a nonphosphorylatable S51A mutant eIF-2 alpha partially protected cells from TNF alpha-induced apoptosis, and expression of a S51D mutant eIF-2 alpha, a mutant that mimics phosphorylated eIF-2 alpha, was sufficient to induce apoptosis. Taken together, these studies identify a novel requirement for PKR in stress-induced apoptosis that is mediated through eIF-2 alpha phosphorylation.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA.							ANTWERP DJV, 1996, SCIENCE, V274, P787; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HUISMANS H, 1976, VIROLOGY, V70, P411, DOI 10.1016/0042-6822(76)90282-8; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; KATZE MG, 1993, SEMIN VIROL, V4, P259, DOI 10.1006/smvy.1993.1022; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LANGLAND JO, 1994, J VIROL, V68, P3821, DOI 10.1128/JVI.68.6.3821-3829.1994; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LLOYD RM, 1992, J VIROL, V66, P6878, DOI 10.1128/JVI.66.12.6878-6884.1992; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; PROTSKO CR, 1995, J BIOL CHEM, V270, P6211; RAMAIAH KVA, 1994, MOL CELL BIOL, V14, P4546, DOI 10.1128/MCB.14.7.4546; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WARING P, 1990, J BIOL CHEM, V265, P14476; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wong GHW, 1992, TUMOR NECROSIS FACTO, P371; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	70	315	325	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2416	2423		10.1074/jbc.273.4.2416	http://dx.doi.org/10.1074/jbc.273.4.2416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442091	hybrid			2022-12-27	WOS:000071595200080
J	Brickman, YG; Ford, MD; Gallagher, JT; Nurcombe, V; Bartlett, PF; Turnbull, JE				Brickman, YG; Ford, MD; Gallagher, JT; Nurcombe, V; Bartlett, PF; Turnbull, JE			Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDURONATE 2-SULFATE RESIDUES; FACTOR RECEPTOR; MOLECULAR-ORGANIZATION; PRECURSOR CELLS; FINE-STRUCTURE; HIGH-AFFINITY; FGF-2; PROTEOGLYCANS; SEQUENCE; DEPOLYMERIZATION	Heparan sulfate (HS) glycosaminoglycans are essential modulators of fibroblast growth factor (FGF) activity and appear to act by coupling particular forms of FGF to appropriate FGF receptors, During neural development, one particular HS proteoglycan is able to rapidly switch its potentiating activity from FGF-2, as neural precursor cell proliferation occurs, to FGF-1, as neuronal differentiation occurs, Using various analytical techniques, including chemical and enzymatic cleavage, low pressure chromatography, and strong anion-exchange high performance Liquid chromatography, we have analyzed the different HSs expressed during these crucial developmental stages, There are distinct alterations in patterns of 6-O-sulfation, total chain length, and the number of sulfated domains of the HS from the more mature embryonic brain, These changes correlate with a switch in the ability of the HS to potentiate the actions of FGF-1 in triggering: cell differentiation It thus appears that each HS pool is designed to function in the modulation of an intricate interaction with a specific growth factor and its cognate receptor, and suggests tightly regulated expression of specific, bioactive disaccharide sequences, The data can be used to construct a simple model of controlled variations in HS chain structure which have functional consequences at a crucial stage of neuronal maturation.	Univ Melbourne, Dept Anat & Cell Biol, Melbourne, Vic 3052, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Manchester, CRC, Dept Med Oncol, Christie Res Ctr, Manchester M20 4BX, Lancs, England	University of Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Manchester	Brickman, YG (corresponding author), Monash Univ, Alfred Hosp, Dept Med, Dept Neurosci,Van Cleef Roet Ctr Nervous Dis, Commercial Rd, Prahran, Vic 3181, Australia.		Bartlett, Perry/F-3813-2012					BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; BRICKMAN YG, 1997, IN PRESS GLYCOBIOLOG, V7; CHALLACOMBE JF, 1995, NEUROCHEM RES, V20, P253, DOI 10.1007/BF00969540; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FORD MD, 1994, NEUROREPORT, V5, P565, DOI 10.1097/00001756-199401000-00008; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HISCOCK DRR, 1995, BBA-GEN SUBJECTS, V1244, P104, DOI 10.1016/0304-4165(94)00206-D; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATO M, 1994, J BIOL CHEM, V269, P18881; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT R, 1991, BIOCHEMISTRY-US, V29, P2611; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PYE DA, 1995, BBA-MOL CELL RES, V1266, P235, DOI 10.1016/0167-4889(95)00012-H; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; Turnbulll Jeremy E., 1993, V19, P253; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	47	157	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4350	4359		10.1074/jbc.273.8.4350	http://dx.doi.org/10.1074/jbc.273.8.4350			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468484	hybrid			2022-12-27	WOS:000072115000012
J	Natochin, M; Artemyev, NO				Natochin, M; Artemyev, NO			Substitution of transducin Ser(202) by Asp abolishes G-protein/RGS interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; ALPHA-SUBUNITS; MECHANISM; BINDING; FAMILY; HYDROLYSIS; DOMAIN; GAIP; RGS4	Known RGS proteins stimulate GTPase activity of G(i) and G(q) family members, but do not interact with G(s) alpha and G(12)alpha. To determine the role of specific G alpha residues for RGS protein recognition, six RGS contact residues of chimeric transducin alpha-subunit (G(t) alpha) corresponding to the residues that differ between G(i) alpha and G(s) alpha have been replaced by G(s) alpha residues, The ability of human retinal RGS (hRGSr) to bind mutant G(t) alpha subunits and accelerate their GTPase activity was investigated Substitutions Thr(178) --> Ser, Ile(181) --> Phe, and Lys(205) --> Arg of G(t) alpha did not alter its interaction with hRGSr. The Lys(176) --> Leu mutant had the same affinity for hRGSr as G(t) alpha, but the maximal GTPase stimulation by hRGSr was reduced by similar to 2.5-fold, The substitution His(209) --> Gln led to a 3-fold decrease in the affinity of hRGSr for the G(t) alpha mutant without significantly affecting the maximal GTPase enhancement. The Ser(202) --> Asp mutation abolished G(t) alpha recognition by hRGSr. A counteracting replacement of Glu(129) by Ala in hRGSr did not restore the interaction of hRGSr with the G(t) alpha Ser(202) --> Asp mutant. Our data suggest that the Ser residue at position 202 of G(t) alpha is critical for the specificity of RGS proteins toward G(i) and G(q) families of G-proteins. Consequently, the corresponding residue, Asp(229) of G(s) alpha, is likely responsible for the inability of RGS proteins to interact with G(s) alpha.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, 5-660 Bowen Sci Bldg, Iowa City, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; KLEUSS C, 1987, J CHROMATOGR, V407, P281, DOI 10.1016/S0021-9673(01)92625-1; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Natochin M, 1997, FEBS LETT, V411, P179, DOI 10.1016/S0014-5793(97)00687-X; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; NATOCHIN M, 1998, IN PRESS J BIOL CHEM, V273; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039	26	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4300	4303		10.1074/jbc.273.8.4300	http://dx.doi.org/10.1074/jbc.273.8.4300			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468476	hybrid			2022-12-27	WOS:000072115000004
J	Muranjan, M; Nussenzweig, V; Tomlinson, S				Muranjan, M; Nussenzweig, V; Tomlinson, S			Characterization of the human serum trypanosome toxin, haptoglobin-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; 21-KDA PROTEIN; GENE; BRUCEI; IDENTIFICATION; COMPLEX; PLASMA; TUMORS	Haptoglobin-related protein (HPR) is a serum protein that is > 90% homologous to the acute-phase reactant haptoglobin (Hp). Haptoglobin binds and removes free hemoglobin (Hb) from the circulation, Hpr levels are elevated with tumor progression in the serum of some cancer patients, but the relevance of this observation is not understood. HPR is an integral part of two distinct high molecular weight complexes (trypanosome lytic factor 1 (TLF1) and TLF2) that are lytic for the African parasite Tryanosoma brucei brucei. Previous data indicate that HPR represents the toxic component of both trypanosoma lytic factors. It has been proposed that after uptake by the parasite, Hb bound to HPR causes lysis in a peroxidase-dependent process, We report that the molecular architecture of HPR in normal human serum is different from that of Rp and that HPR does not bind Hb in normal human serum. Immunodepletion of all detectable Hb from TLF1 does not deplete TLF1 of HPR or trypanolytic activity, suggesting that; the mechanism of parasite lysis is Hb-independent.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA	New York University	Tomlinson, S (corresponding author), NYU, Med Ctr, Dept Pathol, MSB 127,550 1st Ave, New York, NY 10016 USA.	tomlis01@popmail.med.nyu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040206, R21AI040206] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40206] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; FAWCETT HAC, 1990, BIOCHIM BIOPHYS ACTA, V1048, P187, DOI 10.1016/0167-4781(90)90055-7; GRUNDNERCULEMANN E, 1993, J CANCER RES CLIN, V119, P685, DOI 10.1007/BF01215988; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAWKING F, 1973, T ROY SOC TROP MED H, V67, P501, DOI 10.1016/0035-9203(73)90081-3; HWANG PK, 1980, J BIOL CHEM, V255, P3038; JENNINGS FW, 1983, T ROY SOC TROP MED H, V77, P693, DOI 10.1016/0035-9203(83)90207-9; KUHAJDA FP, 1989, NEW ENGL J MED, V321, P636, DOI 10.1056/NEJM198909073211003; KUHAJDA FP, 1989, P NATL ACAD SCI USA, V86, P1188, DOI 10.1073/pnas.86.4.1188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MAEDA N, 1985, J BIOL CHEM, V260, P6698; MCEVOY SM, 1988, J BIOL CHEM, V263, P15740; OH SK, 1992, HYBRIDOMA, V11, P1, DOI 10.1089/hyb.1992.11.1; PINTERA J, 1971, BIOCH GENETIC CLINIC; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; Raper J, 1996, J EXP MED, V183, P1023, DOI 10.1084/jem.183.3.1023; SEED JR, 1990, J PROTOZOOL, V37, P393, DOI 10.1111/j.1550-7408.1990.tb01163.x; SHALITIN C, 1991, INT J CANCER, V49, P861, DOI 10.1002/ijc.2910490610; SMITH AB, 1995, P NATL ACAD SCI USA, V92, P10262, DOI 10.1073/pnas.92.22.10262; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; Tabak S, 1996, DNA CELL BIOL, V15, P1001, DOI 10.1089/dna.1996.15.1001; TOMLINSON S, 1995, MOL BIOCHEM PARASIT, V70, P131, DOI 10.1016/0166-6851(95)00019-W; Tomlinson S, 1997, MOL BIOCHEM PARASIT, V86, P117, DOI 10.1016/S0166-6851(97)90013-X	25	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3884	3887		10.1074/jbc.273.7.3884	http://dx.doi.org/10.1074/jbc.273.7.3884			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461571	hybrid			2022-12-27	WOS:000072048400013
J	Ralton, JE; McConville, MJ				Ralton, JE; McConville, MJ			Delineation of three pathways of glycosylphosphatidylinositol biosynthesis in Leishmania mexicana - Precursors from different pathways are assembled on distinct pools of phosphatidylinositol and undergo fatty acid remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMASTIGOTE SURFACE PROTEASE; MEMBRANE ANCHORS; GLYCOSYL-PHOSPHATIDYLINOSITOLS; GLYCOINOSITOL-PHOSPHOLIPIDS; AFRICAN TRYPANOSOMES; GLUCOSAMINYL PHOSPHATIDYLINOSITOL; INOSITOL ACYLATION; MYRISTIC ACID; LIPOPHOSPHOGLYCAN; GLYCOLIPIDS	Glycosylphosphatidylinositol (GPI) glycolipids are major cell surface constituents in the Leishmania parasites. Distinct classes of GPI are present as membrane anchors for several surface glycoproteins and an abundant lipophosphoglycan as well as being the major glycolipids (GIPLs) in the plasma membrane. In this study we have identified putative precursors for the protein and lipophosphoglycan anchors and delineated the complete pathway for GIPL biosynthesis in Leishmania mexicana promastigotes. Based on the structural analyses of these GPI intermediates and their kinetics of labeling in vivo and in cell-free systems, we provide evidence that the GIPLs are the products of an independent biosynthetic pathway rather than being excess precursors of the anchor pathways, First, we show that the similar glycan head groups of the GIPL and protein/lipophosphoglycan anchor precursors are assembled on two distinct pools of PI corresponding to 1-O-(C18:0)alkyl-2-stearoyl-PI and 1-O-(C24:0/C26:0)-2-stearoyl-PI, respectively, These PI species account for 20 and 1% of the total PI pool, respectively, indicating a remarkable specificity in their selection, Second, analysis of the flux of intermediates through these pathways in vivo and in a cell-free system suggests that the GIPL and anchor pathways are independently regulated. We also show that GIPL biosynthesis requires fatty acid remodeling, in which the sn-2 stearoyl chains are replaced with myristoyl or lauroyl chains, Fatty acid remodeling is dependent on CoA and ATP and occurs on pre-existing but not on de novo synthesized GIPLs. We suggest that the compartmentalization of different GPI pathways may be important in regulating the species and stage-specific expression of different GPI structures in these parasites.	Univ Melbourne, Dept Biochem, Parkville, Vic 3052, Australia	University of Melbourne	McConville, MJ (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia.							BABR V, 1993, MOL BIOCHEM PARASIT, V58, P107; BAUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; BUTOKOFER P, 1992, EUR J BIOCHEM, V208, P677; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DOERING TL, 1994, P NATL ACAD SCI USA, V91, P9735, DOI 10.1073/pnas.91.21.9735; DOERING TL, 1994, BIOCHEM J, V299, P741, DOI 10.1042/bj2990741; DOERING TL, 1993, J BIOL CHEM, V268, P9215; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; GEROLD P, 1994, J BIOL CHEM, V269, P2597; Giorgione JR, 1996, P NATL ACAD SCI USA, V93, P11634, DOI 10.1073/pnas.93.21.11634; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; ILG T, 1992, J BIOL CHEM, V267, P6834; Ma DQ, 1996, BIOCHEM BIOPH RES CO, V227, P885, DOI 10.1006/bbrc.1996.1600; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; MENON AK, 1990, J BIOL CHEM, V265, P9033; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; PROUDFOOT L, 1995, EUR J IMMUNOL, V25, P745, DOI 10.1002/eji.1830250318; REDMAN CA, 1995, BIOCHEM J, V311, P495, DOI 10.1042/bj3110495; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; SEVLEVER D, 1995, EUR J BIOCHEM, V233, P384, DOI 10.1111/j.1432-1033.1995.384_1.x; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Smith TK, 1997, BIOCHEM J, V326, P393, DOI 10.1042/bj3260393; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; STEVENS VL, 1995, BIOCHEM J, V310, P361, DOI 10.1042/bj3100361; Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VANTHOF W, 1995, J BIOL CHEM, V270, P24150; WINTER G, 1994, J CELL SCI, V107, P2471	44	97	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4245	4257		10.1074/jbc.273.7.4245	http://dx.doi.org/10.1074/jbc.273.7.4245			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461623	hybrid			2022-12-27	WOS:000072048400065
J	Vorgia, P; Zannis, VI; Kardassis, D				Vorgia, P; Zannis, VI; Kardassis, D			A short proximal promoter and the distal hepatic control region-1 (HCR-1) contribute to the liver specificity of the human apolipoprotein C-II gene - Hepatic enhancement by HCR-1 requires two proximal hormone response elements which have different binding specificities for orphan receptors HNF-4, ARP-1, and EAR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOCIII GENE; TRANSCRIPTIONAL ACTIVATION; INTESTINAL TRANSCRIPTION; TRANSGENIC MICE; MESSENGER-RNA; B GENE; APO-B; A-I; EXPRESSION; DNA	We have identified the regulatory elements, some of the factors and potential regulatory mechanisms which determine the tissue specificity of the human apoC-II gene. The -545/+18 apoC-II promoter directs high levels of expression of the reporter CAT gene in cells of hepatic origin (NepG2), low levels of expression in cells of intestinal origin (CaCo-2) and basal expression in HeLa cells, Deletion analysis identified negative regulatory elements within the -545/-388 region and positive regulatory elements within the -388/-55 region. Linkage of different apoC-II promoter segments to the hepatic control region-1 (HCR-1) enhanced the promoter activity 2.5-11-fold in HepG2 cells but did not affect its activity in CaCo-2 or COS-1 cells. DNase I footprinting analysis using rat liver nuclear extracts identified five protected regions within the -545/+18 apoC-II promoter as follows: CIIA (-74/-44), CIIB (-102/-81), CIIC (-159/-116), CIID (-288/-265), and CIIE (-497/-462), Elements CIIB and CIIC: contain hormone response elements. CIIB is recognized by hepatic nuclear factor-4 (HNF-4) but not ARP-I or EAR-2, whereas CIIC is recognized by ARP-1 and EAR-2 but not by HNF-4, HNF-4 transactivated the apoC-II promoter or the apoC-II promoter linked. to the HCR-1 in COS-1 cells, A double mutation in elements CIIB and CIIC that eliminated binding of HNF-4 or ARP-1 and EAR-2, respectively, to these sites abolished the enhancer activity of HCR-1. The combined data suggest that the apoC-II: promoter/HCR-1. cluster can direct expression In cells of hepatic origin and that optimal enhancer activity requires synergistic interactions between factors bound Let the distal HCR-1 and nuclear receptors bound to the two proximal hormone response elements.	Univ Crete, Dept Med, Biochem Sect, Div Basic Sci, Heraklion 71110, Crete, Greece; Inst Mol Biol & Biotechnol, Heraklion 71110, Crete, Greece	University of Crete	Kardassis, D (corresponding author), Univ Crete, Dept Med, Biochem Sect, Div Basic Sci, POB 1393, Heraklion 71110, Crete, Greece.		Vorgia, Pelagia/ABK-2455-2022; VORGIA, PELAGIA/W-8793-2018	Vorgia, Pelagia/0000-0002-7061-146X; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; JACKSON RL, 1977, P NATL ACAD SCI USA, V74, P1942, DOI 10.1073/pnas.74.5.1942; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LENICH C, 1988, J LIPID RES, V29, P755; LUSIS AJ, 1986, P NATL ACAD SCI USA, V83, P3929, DOI 10.1073/pnas.83.11.3929; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Malik S, 1996, MOL CELL BIOL, V16, P1824; MANGELSDORF DJ, 1994, RETINOIDS BIOL CHEM, V8, P319; METZGER S, 1993, J BIOL CHEM, V268, P16831; MILLER AL, 1973, J BIOL CHEM, V248, P3359; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; OGAMI K, 1990, J BIOL CHEM, V265, P9808; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SAYER F, 1995, SCIENCE, V270, P1825; SAYER F, 1995, SCIENCE, V270, P1783; SCHACHTER NS, 1993, J LIPID RES, V34, P1699; SCHACHTER NS, 1994, J CLIN INVEST, V93, P1688; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRONCHE F, 1994, LIVER GENE EXPRESSIO, P157; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WEI CF, 1985, J BIOL CHEM, V260, P5211; WU AL, 1979, J BIOL CHEM, V254, P7316; ZANNIS VI, 1993, ADV HUM GENET, V21, P145; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	55	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4188	4196		10.1074/jbc.273.7.4188	http://dx.doi.org/10.1074/jbc.273.7.4188			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461615	hybrid			2022-12-27	WOS:000072048400057
J	Yang, CZ; Heimberg, H; D'Souza-Schorey, C; Mueckler, MM; Stahl, PD				Yang, CZ; Heimberg, H; D'Souza-Schorey, C; Mueckler, MM; Stahl, PD			Subcellular distribution and differential expression of endogenous ADP-ribosylation factor 6 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; GUANINE-NUCLEOTIDE; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; BREFELDIN-A; ARF; LOCALIZATION; MECHANISM; TRANSPORT	ADP-ribosylation factor (ARF) 6 has been shown to play a role in vesicular transport; however, the expression and subcellular localization of the endogenous protein have not been clearly delineated, In this study, an ARF6-specific monoclonal antibody was raised and used to examine the subcellular distribution and expression of ARF6 in various tissues and during the differentiation of several well characterized cell types, We found that ARF6 localizes in both the cytosol and membranes of all tissues and cells tested, Moreover, ARF6 in 3T3-L1 adipocytes is principally localized on the plasma membrane, but substantial amounts are detected in the cytosolic and intracellular membrane fractions, We observed an increased expression of ARF6 during the differentiation of B lymphocytes to plasmocytes, However, the expression of ARF6 decreased during adipogenesis and monocyte differentiation. In contrast, the expression of other ARFs, detected by the monoclonal antibody 1D9, did not significantly change during differentiation of the aforementioned cell types, Taken together, our results indicate that ARF6 is a broadly expressed, differentially regulated GTPase that is present in cytoplasm and on both cell-surface and intracellular membranes and whose functions may include tissue-specific effects on vesicular trafficking during cellular differentiation.	Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL)	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Physiol & Cell Biol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012; Stahl, Philip/D-6315-2012	Heimberg, Harry/0000-0003-1954-7375	NIDDK NIH HHS [DK38495, DRTC DK2057] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038495, K08DK002057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Shisheva A, 1997, BIOCHEMISTRY-US, V36, P6564, DOI 10.1021/bi970202g; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; YANG CZ, 1992, BIOCHEM BIOPH RES CO, V182, P1499, DOI 10.1016/0006-291X(92)91903-4	28	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4006	4011		10.1074/jbc.273.7.4006	http://dx.doi.org/10.1074/jbc.273.7.4006			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461590	hybrid			2022-12-27	WOS:000072048400032
J	Chang, WSW; Lomas, DA				Chang, WSW; Lomas, DA			Latent alpha(1)-antichymotrypsin - A molecular explanation for the inactivation of alpha(1)-antichymotrypsin in chronic bronchitis and emphysema	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN ALPHA-1-PROTEINASE INHIBITOR; HUMAN ALPHA-1-ANTICHYMOTRYPSIN; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; REACTIVE CENTER; HUMAN-PLASMA; PURIFICATION; LOOP; CLEAVAGE	alpha(1)-Antichymotrypsin is an acute phase protein that protects the tissues from damage by proteolytic enzymes, but previous studies have shown that alpha(1)-antichymotrypsin within the lungs of patients with chronic bronchitis and emphysema is intact but inactive as an inhibitor. Ammonium sulfate fractionation followed by blue Sepharose and DNA-Sepharose chromatography was used to isolate small amounts of intact, monomeric but inactive alpha(1)-antichymotrypsin from the plasma of 30 healthy blood donors. This species had a higher DNA binding affinity with more anodal electrophoretic mobility than native alpha(1)-antichymotrypsin and was conformationally stable against thermal denaturation, 8 M urea, and 7 M guanidinium chloride. The protein was unable to accept synthetic reactive loop peptides, and the reactive loop was resistant to proteolytic cleavage at the P-5-P-4 bond but could be cleaved between P-1' and P-3'. These data suggest that this new alpha(1)-antichymotrypsin species was in a conformation similar to those of the crystallographically determined latent serpins, plasminogen activator inhibitor-1 and antithrombin. alpha(1)-Antichymotrypsin from lung lavage migrated with the same electrophoretic mobility as the putative latent alpha(1)-antichymotrypsin, suggesting that this is the inactive conformation described previously in the lungs of patients with chronic bronchitis and emphysema. This conformational transition of alpha(1)-antichymotrypsin, from an active to an inactive state, within the lung may play an important role in the pathogenesis of chronic lung disease.	Univ Cambridge, Ctr Mrc, Dept Haematol, Cambridge CB2 2QH, England; Univ Cambridge, Ctr Mrc, Dept Med, Cambridge CB2 2QH, England	University of Cambridge; University of Cambridge	Lomas, DA (corresponding author), Univ Cambridge, Ctr Mrc, Dept Haematol, Hills Rd, Cambridge CB2 2QH, England.	dal16@cam.ac.uk	Chang, Wun-Shaing Wayne/C-1202-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARONSEN KF, 1972, SCAND J CLIN LAB INV, V29, P127, DOI 10.3109/00365517209102760; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BERMAN G, 1986, J BIOL CHEM, V261, P14095; CALVERLEY PMA, 1995, CHRONIC OBSTRUCTIVE; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1996, BIOCHEM J, V314, P647, DOI 10.1042/bj3140647; CICHY J, 1995, J CLIN INVEST, V95, P2729, DOI 10.1172/JCI117975; GAFFAR SA, 1980, J BIOL CHEM, V255, P8334; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HEIMBURG.N, 1965, CLIN CHIM ACTA, V12, P116, DOI 10.1016/0009-8981(65)90118-X; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KILPATRICK L, 1991, J IMMUNOL, V146, P2388; KRESS LF, 1984, COMP BIOCHEM PHYS B, V77, P431, DOI 10.1016/0305-0491(84)90255-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE A, 1981, BIOCHIM BIOPHYS ACTA, V668, P429, DOI 10.1016/0005-2795(81)90177-X; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN EG, 1987, BLOOD, V70, P1090; LINDMARK B, 1989, BIOCHIM BIOPHYS ACTA, V997, P90, DOI 10.1016/0167-4838(89)90139-8; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; LOMAS DA, 1995, J BIOL CHEM, V270, P23437, DOI 10.1074/jbc.270.40.23437; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MORII M, 1983, BIOCHEM BIOPH RES CO, V111, P438, DOI 10.1016/0006-291X(83)90325-X; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; STOCKLEY RA, 1992, BOICH PULMONARY EMPH, P47; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5647, DOI 10.1021/bi00619a010; TRAVIS J, 1981, METHOD ENZYMOL, V80, P765; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1978, BIOCHEMISTRY-US, V17, P5651, DOI 10.1021/bi00619a011; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; WEEKE B, 1973, SCAND J IMMUNOL, V2, P37, DOI 10.1111/j.1365-3083.1973.tb03777.x; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	49	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3695	3701		10.1074/jbc.273.6.3695	http://dx.doi.org/10.1074/jbc.273.6.3695			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452500	hybrid			2022-12-27	WOS:000071822300085
J	Schreiber, M; Wei, AG; Yuan, A; Gaut, J; Saito, M; Salkoff, L				Schreiber, M; Wei, AG; Yuan, A; Gaut, J; Saito, M; Salkoff, L			Slo3, a novel pH-sensitive K+ channel from mammalian spermatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; INTRACELLULAR PH; ZONA-PELLUCIDA; ACROSOMAL EXOCYTOSIS; SKELETAL-MUSCLE; CA2+ CHANNELS; BETA-SUBUNIT; MOUSE SPERM; CONDUCTANCE; CELLS	Potassium channels have evolved to play specialized roles in both excitable and inexcitable tissues, Here we describe the cloning and expression of Slo3, a novel potassium channel abundantly expressed in mammalian spermatocytes. Slo3 represents a new and unique type of potassium channel regulated by both intracellular pH and membrane voltage, Reverse transcription-polymerase chain reaction, Northern analysis, and in situ hybridization show that Slo3 is primarily expressed in testis in both mouse and human, Because of its sensitivity to both pH and voltage, Slo3 could be involved in sperm capacitation and/or the acrosome reaction, essential steps in fertilization where changes in both intracellular pH and membrane potential are Imo cvn to occur, The protein sequence of mSlo3 (the mouse Slo3 homologue) is similar to Slo1, the large conductance, calcium-and voltage-gated potassium channel. These results suggest that Slo channels comprise a multigene family, defined by a combination of sensitivity to voltage and a variety of intracellular factors, Northern analysis from human testis indicates that a Slo3 homologue is present in humans and conserved with regard to sequence, transcript size, and tissue distribution, Because of its high testis-specific expression, pharmacological agents that target human Slo3 channels may be useful in both the study of fertilization as well as in the control or enhancement of fertility.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Salkoff, L (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.	salkoffl@thalamus.wustl.edu	Gaut, Joseph/ABD-4600-2021; Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Yuan, Alex/0000-0003-0191-8035				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Arnoult C, 1996, J CELL BIOL, V134, P637, DOI 10.1083/jcb.134.3.637; ART JJ, 1995, J GEN PHYSIOL, V105, P49, DOI 10.1085/jgp.105.1.49; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BABCOCK DF, 1987, J BIOL CHEM, V262, P15041; BABCOCK DF, 1983, P NATL ACAD SCI-BIOL, V80, P1327, DOI 10.1073/pnas.80.5.1327; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Chan HC, 1997, BBA-BIOMEMBRANES, V1323, P117, DOI 10.1016/S0005-2736(96)00127-7; COOK SP, 1993, J BIOL CHEM, V268, P22402; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; FLORMAN HM, 1992, DEV BIOL, V152, P304, DOI 10.1016/0012-1606(92)90137-6; Fuchs P A, 1992, Curr Opin Neurobiol, V2, P457, DOI 10.1016/0959-4388(92)90180-S; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; Knaus HG, 1996, J NEUROSCI, V16, P955; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURIDO C, 1991, J GEN PHYSIOL, V98, P1025, DOI 10.1085/jgp.98.5.1025; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; Santi CM, 1996, AM J PHYSIOL-CELL PH, V271, pC1583, DOI 10.1152/ajpcell.1996.271.5.C1583; SASAKI S, 1992, BIOCHIM BIOPHYS ACTA, V1137, P45, DOI 10.1016/0167-4889(92)90098-V; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0; TABCHARANI JA, 1989, BIOCHIM BIOPHYS ACTA, V982, P62, DOI 10.1016/0005-2736(89)90174-0; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VREDENBURGHWILBERG WL, 1995, MOL REPROD DEV, V40, P490, DOI 10.1002/mrd.1080400413; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; Zeng Y, 1996, DEV BIOL, V173, P510, DOI 10.1006/dbio.1996.0044	50	173	187	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3509	3516		10.1074/jbc.273.6.3509	http://dx.doi.org/10.1074/jbc.273.6.3509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452476	hybrid			2022-12-27	WOS:000071822300061
J	Zuscik, MJ; Porter, JE; Gaivin, R; Perez, DM				Zuscik, MJ; Porter, JE; Gaivin, R; Perez, DM			Identification of a conserved switch residue responsible for selective constitutive activation of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-H EXCHANGE; BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; ADENYLATE-CYCLASE; G-PROTEIN; AFFINITY; BINDING; TRANSIENTS; PATHWAYS; STATE	A cysteine-to-phenylalanine mutation of residue 116 in the third transmembrane domain of the beta(2)-adrenergic receptor caused selective constitutive activation of Na+/H+ exchange through a pathway not involving cAMP. This selectivity was identified by comparing binding and signaling characteristics of wild-type (WT) versus C116F mutant receptors transiently transfected into COS-1 cells, Indicating constitutive activity, ligand binding to the C116F mutant showed a 78-fold higher than WT affinity for isoproterenol and a 40-fold lower than WT affinity for ICI 118551, Although agonist-independent activation of cAMP production was not exhibited by the C116F mutant, a constitutive stimulation of the Na+/H+ exchanger (NHE1) was observed. This was identified by measuring either basal intracellular pH (pH(i)) or rate of pH(i) recovery from cellular acid load. Due to a higher rate of H+ efflux through NHE1, C116F transfectants exhibited a significantly higher pH(i) (7.42) than did WT transfectants (7.1). Furthermore, the rate of pH(i) recovery from acid load facilitated by NHE1 was 8.1-fold faster in mutant transfectants than in WT transfectants. The lower rate seen in the WT case was stimulated by epinephrine, and the higher rate seen in the mutant case was inhibited by ICI 118551. These findings, which show that a C116F mutation of the beta(2)-adrenergic receptor evokes selective constitutive coupling to NHE1 over cAMP, form the basis of our prediction that multiple and distinct activation states can exist in G protein-coupled receptors.	Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Perez, DM (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, 9500 Euclid Ave,FF3-01, Cleveland, OH 44195 USA.	perexd@cesmtp.ccf.org		Zuscik, Michael/0000-0003-0461-8708	PHS HHS [R01152544] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FRASER CM, 1988, P NATL ACAD SCI USA, V85, P5478, DOI 10.1073/pnas.85.15.5478; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HARDMAN JG, 1996, PHARMACOL BASIS THER, P125; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA B, 1991, TRENDS CARDIOVAS MED, V1, P189, DOI 10.1016/1050-1738(91)90036-E; KOHMOTO O, 1990, CIRC RES, V66, P622, DOI 10.1161/01.RES.66.3.622; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; NODA K, 1994, J BIOL CHEM, V269, P6743; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1991, J BIOL CHEM, V266, P5; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721	34	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3401	3407		10.1074/jbc.273.6.3401	http://dx.doi.org/10.1074/jbc.273.6.3401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452461	hybrid			2022-12-27	WOS:000071822300046
J	Bevans, CG; Kordel, M; Rhee, SK; Harris, AL				Bevans, CG; Kordel, M; Rhee, SK; Harris, AL			Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; MARIE-TOOTH DISEASE; CROSS-LINKING; HORIZONTAL CELLS; HELA-CELLS; UNITARY CONDUCTANCE; XENOPUS-OOCYTES; LIPID BILAYERS; RAT-LIVER; PROTEINS	Intercellular connexin channels (gap junction channels) have long been thought to mediate molecular signaling between cells, but the nature of the signaling has been unclear. This study shows that connexin channels from native tissue have selective permeabilities, partially based on pore diameter, that discriminate among cytoplasmic second messenger molecules, Permeability was assessed by measurement of selective loss/retention of tracers from liposomes containing reconstituted connexin channels. The tracers employed were tritiated cyclic nucleotides and a series of oligomaltosaccharides derivatized with a small uncharged fluorescent moiety, The data define different size cut-off limits for permeability through homomeric connexin-32 channels and through heteromeric connexin-32/connexin-26 channels, Connexin-26 contributes to a narrowed pore, Both cAMP and cGMP were permeable through the homomeric connexin-32 channels. cAMP was permeable through only a fraction of the heteromeric channels, Surprisingly, cGMP was permeable through a substantially greater fraction of the heteromeric channels than was cAMP. The data suggest that isoform stoichiometry and/or arrangement within a connexin channel determines whether cyclic nucleotides can permeate, and which ones, This is the first evidence for connexin-specific selectivity among biological signaling molecules.	Johns Hopkins Univ, Thomas C Jenkins Dept Biophys, Baltimore, MD 21218 USA; Gesell Biotechnol Forsch mbH, Dept Enzyme Technol, D-38124 Braunschweig, Germany; Yeungnam Univ, Dept Biochem, Kyongsan 712749, South Korea	Johns Hopkins University; Gesellschaft fur Biotechnologische Forschung mbH; Yeungnam University	Harris, AL (corresponding author), Johns Hopkins Univ, Thomas C Jenkins Dept Biophys, Baltimore, MD 21218 USA.		Bevans, Carville/C-6651-2009	Bevans, Carville/0000-0001-7389-2124; Harris, Andrew/0000-0002-3782-0550	NIGMS NIH HHS [GM36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TS, 1983, J CELL BIOL, V96, P204, DOI 10.1083/jcb.96.1.204; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Bevans C. G., 1995, Biophysical Journal, V68, pA204; Bevans C. G., 1995, Molecular Biology of the Cell, V6, p190A; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; Brink PR, 1997, AM J PHYSIOL-CELL PH, V273, pC1386, DOI 10.1152/ajpcell.1997.273.4.C1386; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BUEHLER LK, 1995, BIOPHYS J, V68, P1767, DOI 10.1016/S0006-3495(95)80353-X; BUKAUSKAS FF, 1995, BIOPHYS J, V68, P2289, DOI 10.1016/S0006-3495(95)80411-X; BUKAUSKAS FF, 1995, PFLUG ARCH EUR J PHY, V429, P870, DOI 10.1007/BF00374812; Cao F., 1994, Molecular Biology of the Cell, V5, p198A; CASCIO M, 1995, J BIOL CHEM, V270, P18643, DOI 10.1074/jbc.270.31.18643; Chanson M., 1994, Journal of Physiology (Cambridge), V479P, p117P; CHEN YH, 1996, AM J PHYSIOL, V39, pC276; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; Donaldson P, 1997, HISTOL HISTOPATHOL, V12, P219; DOWNER NW, 1985, BIOPHYS J, V47, P285, DOI 10.1016/S0006-3495(85)83918-7; EBIHARA L, 1995, BIOPHYS J, V68, P1796, DOI 10.1016/S0006-3495(95)80356-5; EBIHARA L, 1993, J GEN PHYSIOL, V102, P59, DOI 10.1085/jgp.102.1.59; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; EHIHARA L, 1996, BIOPHYS J, V71, P742; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; FRENCH AD, 1979, BAKERS DIG, V53, P39; FRENCH AD, 1978, J JPN SOC STARCH SCI, V25, P171, DOI 10.5458/jag1972.25.171; Ghosh S., 1995, Molecular Biology of the Cell, V6, p189A; Gingalewski C, 1996, J CELL PHYSIOL, V166, P461; GOLDIN SM, 1978, J BIOL CHEM, V253, P2575; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; GOODENOU.DA, 1974, J CELL BIOL, V61, P557, DOI 10.1083/jcb.61.2.557; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GUPTA VK, 1994, INVEST OPHTH VIS SCI, V35, P3747; HARRIS AL, 1989, J MEMBRANE BIOL, V109, P243, DOI 10.1007/BF01870281; HARRIS RM, 1992, DATABASE, V15, P69; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HENNEMANN H, 1992, EUR J CELL BIOL, V58, P81; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; HOGER JH, 1985, J BIOL CHEM, V260, P6932; JANSSENTIMMEN U, 1986, CARCINOGENESIS, V7, P1475, DOI 10.1093/carcin/7.9.1475; JEFFREY GA, 1978, MOL STRUCTURE DIFFRA, P183; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KORDEL M, 1993, BIOPHYS J, V64, pA192; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KURAOKA A, 1993, J HISTOCHEM CYTOCHEM, V41, P971, DOI 10.1177/41.7.8390496; KWAK BR, 1995, MOL BIOL CELL, V6, P1707, DOI 10.1091/mbc.6.12.1707; KWAK BR, 1995, PFLUG ARCH EUR J PHY, V430, P770, DOI 10.1007/BF00386175; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LUDWIG FR, 1985, EUR J BIOCHEM, V151, P83, DOI 10.1111/j.1432-1033.1985.tb09071.x; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MAKOWSKI L, 1984, J MOL BIOL, V174, P449, DOI 10.1016/0022-2836(84)90331-0; MALCHOW RP, 1993, J NEUROSCI RES, V35, P237, DOI 10.1002/jnr.490350303; MESNIL M, 1995, CANCER RES, V55, P629; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORENO AP, 1992, BIOPHYS J, V62, P51, DOI 10.1016/S0006-3495(92)81775-7; MORENO AP, 1994, BIOPHYS J, V67, P113, DOI 10.1016/S0006-3495(94)80460-6; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; NEVEU MJ, 1994, J CELL SCI, V107, P83; NEVEU MJ, 1994, MOL CARCINOGEN, V11, P145, DOI 10.1002/mc.2940110305; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; NICHOLSON BJ, 1988, MODERN CELL BIOL, V7, P207; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; OLLIVON M, 1986, ANAL BIOCHEM, V152, P262, DOI 10.1016/0003-2697(86)90408-2; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; PERICAKVANCE MA, 1995, HUM HERED, V45, P121, DOI 10.1159/000154272; Perkins G, 1997, BIOPHYS J, V72, P533, DOI 10.1016/S0006-3495(97)78693-4; PICCOLINO M, 1984, J NEUROSCI, V4, P2477; Rhee SK, 1996, BIOCHEMISTRY-US, V35, P9212, DOI 10.1021/bi960295m; RISEK B, 1995, J CELL SCI, V108, P1017; RIVKIN RB, 1981, LIMNOL OCEANOGR, V26, P780, DOI 10.4319/lo.1981.26.4.0780; SOSINSKY G, 1995, P NATL ACAD SCI USA, V92, P9210, DOI 10.1073/pnas.92.20.9210; SOUMARMON A, 1986, BIOCHIM BIOPHYS ACTA, V860, P109, DOI 10.1016/0005-2736(86)90504-3; Spray David C., 1994, P195; STAROS JV, 1989, METHOD ENZYMOL, V172, P609; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; Suchyna Thomas M., 1994, Molecular Biology of the Cell, V5, p199A; TAKENSKWAK BR, 1992, PFLUG ARCH EUR J PHY, V422, P198, DOI 10.1007/BF00370421; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; Unger VM, 1997, NAT STRUCT BIOL, V4, P39, DOI 10.1038/nsb0197-39; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; VEENSTRA RD, 1995, CIRC RES, V77, P1156, DOI 10.1161/01.RES.77.6.1156; Veenstra RD, 1996, BIOPHYS J, V70, P1082, DOI 10.1016/S0006-3495(96)79654-6; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; VEENSTRA RD, 1994, CIRC RES, V75, P483, DOI 10.1161/01.RES.75.3.483; White TW, 1996, J BIOENERG BIOMEMBR, V28, P339, DOI 10.1007/BF02110110; WILCOX MD, 1992, BIOCHEMISTRY-US, V31, P10458, DOI 10.1021/bi00158a007; Yamasaki H, 1995, MUTAT RES-FUND MOL M, V333, P181, DOI 10.1016/0027-5107(95)00144-1; ZAMBROWICZ EB, 1993, BIOPHYS J, V65, P1093, DOI 10.1016/S0006-3495(93)81148-2; ZHANG JT, 1994, J MEMBRANE BIOL, V139, P15; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4	98	255	266	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2808	2816		10.1074/jbc.273.5.2808	http://dx.doi.org/10.1074/jbc.273.5.2808			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446589	hybrid			2022-12-27	WOS:000071736600044
J	Meyer, SC; Sanan, DA; Fox, JEB				Meyer, SC; Sanan, DA; Fox, JEB			Role of actin-binding protein in insertion of adhesion receptors into the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IB-IX COMPLEX; DYSTROPHIN-ASSOCIATED PROTEINS; 4.1(-) HEREDITARY ELLIPTOCYTOSIS; PLATELET GLYCOPROTEIN-IB; VON-WILLEBRAND-FACTOR; GLYCOPHORIN-C; CYTOPLASMIC DOMAIN; ERYTHROCYTE-MEMBRANE; MUSCULAR-DYSTROPHIES; EXTRACELLULAR-MATRIX	The goal of this study was to determine whether actin-binding protein (ABP) regulates membrane composition, ABP-deficient and ABP-containing cells were transfected with the cDNAs coding for glycoprotein (GP) Ib-IX, a platelet receptor that interacts with ABP, Most of the GP Ib-IX remained inside the ABP-deficient cells, When ABP was present, functional GP Ib-IX was inserted into the membrane, GP Ib-IX lacking the domain that interacts with ABP also showed increased membrane insertion in ABP-expressing cells. Furthermore, a fragment of ABP that lacks the dimerization and GP Ib-IX-binding sites restored the spreading of the cells and increased the amount of GP Ib-IX in the membrane, Finally, expression of ABP also increased endogenous beta(1) integrin in the membrane, These results indicate that 1) ABP maintains the properties of the cell such that adhesion receptors can be efficiently expressed in the membrane; 2) increased receptor expression is accompanied by increased ability of the cell to spread; and 3) ABP exerts its effect by a mechanism that does not appear to involve direct cross-linking of actin filaments or direct interaction with receptors.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol FF 20, Cleveland, OH 44195 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	Cleveland Clinic Foundation; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes	Fox, JEB (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol FF 20, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030657, R37HL030657, R23HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AAKHUS AM, 1992, THROMB HAEMOSTASIS, V67, P252; ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; ALLOISIO N, 1985, BIOCHIM BIOPHYS ACTA, V816, P57, DOI 10.1016/0005-2736(85)90392-X; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1984, PROG HEMOST THROMB, V7, P111; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MATSUMURA K, 1993, FEBS LETT, V320, P276, DOI 10.1016/0014-5793(93)80602-Q; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MEYER S, 1993, J BIOL CHEM, V268, P20555; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; REID ME, 1990, BLOOD, V75, P2229; REID ME, 1989, RED CELL, P553; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SOLUM NO, 1983, BIOCHIM BIOPHYS ACTA, V729, P53, DOI 10.1016/0005-2736(83)90455-8; SONDAG D, 1987, BRIT J HAEMATOL, V65, P43, DOI 10.1111/j.1365-2141.1987.tb06133.x; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; TRUGLIA JA, 1981, BIOCHEM BIOPH RES CO, V100, P814, DOI 10.1016/S0006-291X(81)80247-1; VENEZIA ND, 1992, J CLIN INVEST, V90, P1713, DOI 10.1172/JCI116044; WEIHING RR, 1988, BIOCHEMISTRY-US, V27, P1865, DOI 10.1021/bi00406a011; ZHANG J, 1992, J BIOL CHEM, V267, P4686	48	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3013	3020		10.1074/jbc.273.5.3013	http://dx.doi.org/10.1074/jbc.273.5.3013			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446615	hybrid			2022-12-27	WOS:000071736600070
J	Chestkov, VV; Radko, SP; Cho, MS; Chrambach, A; Vogel, SS				Chestkov, VV; Radko, SP; Cho, MS; Chrambach, A; Vogel, SS			Reconstitution of calcium-triggered membrane fusion using "reserve" granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; MEDIATING CELL-ADHESION; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; BIOLOGICAL-MEMBRANES; REGULATED SECRETION; VESICLE EXOCYTOSIS; YOLK PLATELETS; PROTEINS; ATP	Calcium-gated secretion of proteins involves the transfer of "reserve" granules, exocytotic vesicles that are cytoplasmic and, hence, plasma membrane-naive, from the cell interior to the surface membrane where they dock prior to fusion. Docking and subsequent priming steps are thought to require cytoplasmic factors. These steps are believed to induce fusion competence. We have tested this hypothesis by isolating reserve granules from sea urchin eggs and determining under which conditions these granules will fuse, We find that isolated reserve granules, lacking soluble cofactors, support calcium-dependent membrane fusion in vitro, Preincubation with adenosine 5'-3-O-(thio)triphosphate and guanosine 5'-3-O-(thio)triphosphate did not prevent fusion, Thus, isolated reserve granules have all the necessary components required for calcium-gated fusion prior to docking.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; NINDS, Synapt Mechanisms Sect, NIH, Bethesda, MD 20892 USA; NICHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; Russian Acad Med Sci, Ctr Genet Med, Moscow, Russia	University System of Georgia; Augusta University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Russian Academy of Medical Sciences	Vogel, SS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St CB 2803, Augusta, GA 30912 USA.		Vogel, Steven/A-3585-2012; Oka, Yoshitaka/C-9670-2010; Radko, Sergey P/G-1783-2017	Oka, Yoshitaka/0000-0002-3482-3051; Radko, Sergey P/0000-0002-0519-1745; Vogel, Steven/0000-0002-3005-2667				ALLIEGRO MC, 1988, DEV BIOL, V125, P208, DOI 10.1016/0012-1606(88)90074-7; ANDERSON E, 1968, J CELL BIOL, V37, P514, DOI 10.1083/jcb.37.2.514; ARMANT DR, 1986, DEV BIOL, V113, P342, DOI 10.1016/0012-1606(86)90169-7; BAKER PF, 1978, NATURE, V276, P513, DOI 10.1038/276513a0; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Bauer J, 1996, ELECTROPHORESIS, V17, P526, DOI 10.1002/elps.1150170319; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; BISGROVE BW, 1991, DEV BIOL, V146, P89, DOI 10.1016/0012-1606(91)90449-D; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; Calakos N, 1996, PHYSIOL REV, V76, P1; CAZALIS M, 1987, J PHYSIOL-LONDON, V390, P71, DOI 10.1113/jphysiol.1987.sp016687; CERVELLO M, 1989, CELL DIFFER DEV, V26, P67, DOI 10.1016/0922-3371(89)90784-3; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; CRABB JH, 1985, J CELL BIOL, V101, P2263, DOI 10.1083/jcb.101.6.2263; EPEL D, 1977, SCI AM, V237, P128, DOI 10.1038/scientificamerican1177-128; FISHKIND DJ, 1990, DEV BIOL, V142, P439, DOI 10.1016/0012-1606(90)90366-Q; FISHKIND DJ, 1990, DEV BIOL, V142, P453, DOI 10.1016/0012-1606(90)90367-R; Gallant PE, 1995, J NEUROCYTOL, V24, P943, DOI 10.1007/BF01215644; GRATWOHL EKM, 1991, MECH DEVELOP, V33, P127, DOI 10.1016/0925-4773(91)90079-L; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; JACKSON RC, 1990, J MEMBRANE BIOL, V115, P83, DOI 10.1007/BF01869108; JAFFE LA, 1986, ANNU REV PHYSIOL, V48, P191, DOI 10.1146/annurev.ph.48.030186.001203; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; KAST C, 1994, J BIOL CHEM, V269, P5179; KRAUSE TL, 1994, J NEUROSCI, V14, P6638; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE MC, 1993, DEVELOPMENT, V117, P1049; MATESE J, 1997, DEV BIOL, V186, P12; MATRANGA V, 1986, EMBO J, V5, P3125, DOI 10.1002/j.1460-2075.1986.tb04619.x; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MORRE DJ, 1994, J CHROMATOGR A, V668, P201, DOI 10.1016/0021-9673(94)80110-X; NOLL H, 1985, P NATL ACAD SCI USA, V82, P8062, DOI 10.1073/pnas.82.23.8062; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PAULIK M, 1988, J BIOL CHEM, V263, P17738; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SASAKI H, 1983, DEV BIOL, V98, P327, DOI 10.1016/0012-1606(83)90363-9; Schmid S L, 1993, Subcell Biochem, V19, P1; SCOTT LB, 1990, DEV BIOL, V137, P368, DOI 10.1016/0012-1606(90)90261-G; Shafi Nadeem I., 1994, Methods (Orlando), V6, P82, DOI 10.1006/meth.1994.1010; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; VACQUIER VD, 1975, DEV BIOL, V43, P62, DOI 10.1016/0012-1606(75)90131-1; VATER CA, 1989, DEV BIOL, V135, P111, DOI 10.1016/0012-1606(89)90162-0; VIDAL M, 1995, J BIOL CHEM, V270, P17823, DOI 10.1074/jbc.270.30.17823; VILMARTSEUWEN J, 1986, J CELL BIOL, V103, P1279, DOI 10.1083/jcb.103.4.1279; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; Vogel SS, 1996, J CELL BIOL, V134, P329, DOI 10.1083/jcb.134.2.329; VOGEL SS, 1992, J BIOL CHEM, V267, P25640; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; WHALLEY T, 1995, J CELL BIOL, V131, P1183, DOI 10.1083/jcb.131.5.1183; WHALLEY T, 1988, BIOSCIENCE REP, V8, P335, DOI 10.1007/BF01115224; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245; ZIMMERBERG J, 1985, J CELL BIOL, V101, P2398, DOI 10.1083/jcb.101.6.2398	60	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2445	2451		10.1074/jbc.273.4.2445	http://dx.doi.org/10.1074/jbc.273.4.2445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442095	hybrid			2022-12-27	WOS:000071595200084
J	Qi, Z; Tang, DM; Zhu, XD; Fujita, DJ; Wang, JH				Qi, Z; Tang, DM; Zhu, XD; Fujita, DJ; Wang, JH			Association of neurofilament proteins with neuronal Cdk5 activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; BRAIN-SPECIFIC ACTIVATOR; PAIRED HELICAL FILAMENTS; TAU-PROTEIN; CDC2-LIKE KINASE; RAT CEREBELLUM; BOVINE BRAIN; INTERMEDIATE FILAMENTS; DEVELOPMENTAL-CHANGES; PHOSPHORYLATES TAU	Cdk5 exists in brain extracts in multiple forms, one of which is a macromolecular protein complex comprising Cdk5, neuron-specific Cdk5 activator p35(nck5a) and other protein components (Lee, K.-Y., Resales, J. L., Tang, D., and Wang, J. H. (1996) J. Biol. Chem. 271, 1538-1543). The yeast two-hybrid system was employed to identify p35(nck5a)-interacting proteins from a human brain cDNA library. One of the isolated clones encodes a fragment of glial fibrillary acidic protein, which is a glial-specific protein. Sequence alignment revealed significant homology between the p35(nck5a)-binding fragment of glial fibrillary acidic protein and corresponding regions in neurofilaments. The association between p35(nck5a) and neurofilament medium molecular weight subunit (NF-M) was confirmed by both the yeast two-hybrid assay and direct binding of the bacteria-expressed proteins. The p35(nck5a) binding site on NF-M was mapped to a carboxyl-terminal region of the rod domain, in close proximity to the putative Cdk5 phosphorylation sites in NF-M, A region immediately amino-terminal to the kinase-activating domain in p35(nck5a) is required for its binding with NF-M. In in vitro binding assays, NF-M binds both monomeric p35(nck5a) and the Cdk5/p35(nck5a) complex. The binding of NF-M has no effect on the kinase activity of Cdk5/p35(nck5a).	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong; Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	Hong Kong University of Science & Technology; University of Calgary	Wang, JH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong.		Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Betts JC, 1997, J BIOL CHEM, V272, P12922, DOI 10.1074/jbc.272.20.12922; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; FLIEGNER KH, 1991, INT REV CYTOL, V131, P109, DOI 10.1016/S0074-7696(08)62018-5; Guidato S, 1996, J NEUROCHEM, V66, P1698; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hirooka K, 1996, J NEUROCHEM, V67, P2478; HISANAGA S, 1993, J BIOL CHEM, V268, P15056; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazaro JB, 1996, NEUROSCI LETT, V218, P21; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; Matsushita M, 1996, BRAIN RES, V734, P319, DOI 10.1016/S0006-8993(96)00702-0; MATSUSHITA M, 1995, NEUROREPORT, V6, P1267, DOI 10.1097/00001756-199506090-00009; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Pant HC, 1995, BIOCHEM CELL BIOL, V73, P575, DOI 10.1139/o95-063; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; QI Z, 1995, MOL CELL BIOCHEM, V149, P35, DOI 10.1007/BF01076561; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tomizawa K, 1996, NEUROSCIENCE, V74, P519, DOI 10.1016/0306-4522(96)00136-4; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VULLIET R, 1992, J BIOL CHEM, V267, P22570	41	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2329	2335		10.1074/jbc.273.4.2329	http://dx.doi.org/10.1074/jbc.273.4.2329			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442078	hybrid			2022-12-27	WOS:000071595200067
J	Zhang, F; Subbaramaiah, K; Altorki, N; Dannenberg, AJ				Zhang, F; Subbaramaiah, K; Altorki, N; Dannenberg, AJ			Dihydroxy bile acids activate the transcription of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FAMILIAL ADENOMATOUS POLYPOSIS; PROSTAGLANDIN-H SYNTHASE-2; CAMP RESPONSE ELEMENT; HUMAN COLON-CANCER; PHORBOL-ESTER; EPITHELIAL-CELLS; ESOPHAGEAL-CARCINOMA; MESSENGER-RNA; CARCINOGENESIS	Bile acids, endogenous promoters of gastrointestinal cancer, activate protein kinase C (PKC) and the activator protein-1 (AP-1) transcription factor. Because other activators of PKC and AP-1 induce cyclooxygenase-a (COX-2), we determined the effects of bile acids on the expression of COX-2 in human esophageal adenocarcinoma cells. Treatment with the dihydroxy bile acids chenodeoxycholate and deoxycholate resulted in an similar to 10-fold increase in the production of prostaglandin E-2 (PGE(2)). Enhanced synthesis of PGE, was associated with a marked increase in the levels of COX-2 mRNA and protein, with maximal effects at 8-12 and 12-24 h, respectively. In contrast, neither cholic acid nor conjugated bile acids affected the levels of COX-2 or the synthesis of PGE(2). Nuclear run-off assays and transient transfections with a human COX-2 promoter construct showed that induction of COX-2 mRNA by chenodeoxycholate and deoxycholate was due to increased transcription. Bile acid-mediated induction of COX-2 was blocked by inhibitors of PI(C activity, including calphostin C and staurosporine. Treatment with bile acid enhanced the phosphorylation of c-Jun and increased binding of AP-1 to DNA. These data are important because dihydroxy bile acid-mediated induction of COX-2 may explain, at least in part, the tumor-promoting effects of bile acids.	New York Hosp, Cornell Med Ctr, Div Digest Dis, Dept Med, New York, NY 10021 USA; New York Hosp, Cornell Med Ctr, Dept Surg, New York, NY 10021 USA; New York Hosp, Cornell Med Ctr, Dept Cardiothorac Surg, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital	Dannenberg, AJ (corresponding author), New York Hosp, Cornell Med Ctr, Div Digest Dis, Dept Med, Room F-231,1300 York Ave, New York, NY 10021 USA.							ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ATTWOOD SEA, 1992, SURGERY, V111, P503; BENNETT A, 1986, PROG LIPID RES, V25, P539, DOI 10.1016/0163-7827(86)90109-8; BENNETT A, 1987, GUT, V28, P315, DOI 10.1136/gut.28.3.315; Boolbol SK, 1996, CANCER RES, V56, P2556; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; FITZER CJ, 1987, CARCINOGENESIS, V8, P217, DOI 10.1093/carcin/8.2.217; FUNKHOUSER EM, 1995, CANCER-AM CANCER SOC, V76, P1116, DOI 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GILLEN P, 1988, BRIT J SURG, V75, P540, DOI 10.1002/bjs.1800750612; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GUILLEM JG, 1987, ARCH SURG-CHICAGO, V122, P1475; HILL MJ, 1991, EUROPEAN JOURNAL OF CANCER PREVENTION, VOL 1, SUPPLEMENT 2, OCTOBER 1991, P69, DOI 10.1097/00008469-199110002-00012; Hirano F, 1996, CARCINOGENESIS, V17, P427, DOI 10.1093/carcin/17.3.427; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; HUANG XP, 1992, INT J CANCER, V52, P444, DOI 10.1002/ijc.2910520319; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES DA, 1993, J BIOL CHEM, V268, P9049; KAIBARA N, 1984, CANCER RES, V44, P5482; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATOBA N, 1986, J LIPID RES, V27, P1154; MCJUNKIN B, 1981, GASTROENTEROLOGY, V80, P1454; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; Miller BW, 1997, AM J PHYSIOL-CELL PH, V273, pC130, DOI 10.1152/ajpcell.1997.273.1.C130; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PERA M, 1993, ANN THORAC SURG, V55, P1386, DOI 10.1016/0003-4975(93)91077-Z; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RAMPTON DS, 1981, CLIN SCI, V61, P641, DOI 10.1042/cs0610641; RAO CV, 1995, CANCER RES, V55, P1464; REDDY BS, 1977, CANCER RES, V37, P3238; REDDY BS, 1973, J NATL CANCER I, V50, P1437, DOI 10.1093/jnci/50.6.1437; Ristimaki A, 1997, CANCER RES, V57, P1276; RUBIO CA, 1984, J NATL CANCER I, V72, P705; RUBIO CA, 1986, CANCER, V58, P1029, DOI 10.1002/1097-0142(19860901)58:5<1029::AID-CNCR2820580508>3.0.CO;2-D; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TIANO H, 1997, P AM ASSOC CANC RES, V38, P1727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	57	187	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2424	2428		10.1074/jbc.273.4.2424	http://dx.doi.org/10.1074/jbc.273.4.2424			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442092	hybrid			2022-12-27	WOS:000071595200081
J	Zhao, XY; Huang, J; Khani, SC; Palczewski, K				Zhao, XY; Huang, J; Khani, SC; Palczewski, K			Molecular forms of human rhodopsin kinase (GRK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; CONE PHOTORECEPTORS; CHROMOSOMAL LOCALIZATION; GUANYLYL CYCLASE; ENCODING GENE; PROTEIN; FAMILY; IDENTIFICATION; EXPRESSION; CLONING	The G protein-coupled receptor kinases (GRKs) are critical enzymes in the desensitization of activated G protein-coupled receptors. Six members of the GRK family have been identified to date. Among these enzymes, GRK1 (rhodopsin kinase) is involved in phototransduction and is the most specialized of the family. GRK1 phosphorylates photoactivated rhodopsin, initiating steps in its deactivation. In this study, we found that human retina expressed all GRKs except GRK4. Based on results of molecular cloning and immunolocalization, it appears that both rod and cone photoreceptors express GRK1. This conclusion was supported by the cloning of only GRK1 from cone-dominated chicken retina. Human photoreceptors also transcribe a splice variant of GRK1, which differs in its C-terminal region next to the catalytic domain. This novel variant, GRK1b, is produced by retention of the last intron. mRNA encoding GRK1b is exported to the cytosol; however, the level of the protein is relatively low compared with GRK1 (now called GRK1a), and GRK1b appears to have very low catalytic activity. Thus, Obese studies suggest that rods and cones, express the same form of GRK1.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; SUNY Buffalo, Dept Ophthalmol, Buffalo, NY 14215 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.				NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061] Funding Source: NIH RePORTER; NEI NIH HHS [EY08061] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; Campbell AM, 1984, LAB TECHNIQUES BIOCH, V13; CHIU MI, 1994, VISUAL NEUROSCI, V11, P773, DOI 10.1017/S0952523800003072; Cideciyan AV, 1998, P NATL ACAD SCI USA, V95, P328, DOI 10.1073/pnas.95.1.328; CRAFT CM, 1994, J BIOL CHEM, V269, P4613; CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Firsov D, 1997, AM J PHYSIOL-CELL PH, V273, pC953, DOI 10.1152/ajpcell.1997.273.3.C953; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; Jia GQ, 1995, EUR CYTOKINE NETW, V6, P253; Kawamura S, 1996, J BIOL CHEM, V271, P21359, DOI 10.1074/jbc.271.35.21359; Khani SC, 1996, GENOMICS, V35, P571, DOI 10.1006/geno.1996.0399; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAI SP, 1995, GENE, V153, P301, DOI 10.1016/0378-1119(94)00674-H; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; Lovett PS, 1996, GENE, V179, P157, DOI 10.1016/S0378-1119(96)00420-9; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MACLEOD JN, 1991, AM J HUM GENET, V48, P1168; MATSUMURA Y, 1995, J PATHOL, V177, P11, DOI 10.1002/path.1711770104; MAX M, 1995, SCIENCE, V267, P1502, DOI 10.1126/science.7878470; Milam AH, 1997, VISUAL NEUROSCI, V14, P601, DOI 10.1017/S0952523800012256; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; OttoBruc A, 1997, P NATL ACAD SCI USA, V94, P4727, DOI 10.1073/pnas.94.9.4727; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; POLANS AS, 1993, INVEST OPHTH VIS SCI, V34, P81; PORTER S, 1991, GENE, V97, P277, DOI 10.1016/0378-1119(91)90063-H; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sallese M, 1997, J BIOL CHEM, V272, P10188; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; VASCONCELOS O, 1995, P NATL ACAD SCI USA, V92, P10322, DOI 10.1073/pnas.92.22.10322; WANG YC, 1992, J BIOL CHEM, V267, P2728; Yamamoto S, 1997, NAT GENET, V15, P175, DOI 10.1038/ng0297-175; Zama M, 1995, Nucleic Acids Symp Ser, P97; Zhao XY, 1997, VISUAL NEUROSCI, V14, P225, DOI 10.1017/S0952523800011366	54	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5124	5131		10.1074/jbc.273.9.5124	http://dx.doi.org/10.1074/jbc.273.9.5124			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478965	hybrid			2022-12-27	WOS:000072310400049
J	Andersson, E; Hellman, L; Gullberg, U; Olsson, I				Andersson, E; Hellman, L; Gullberg, U; Olsson, I			The role of the propeptide for processing and sorting of human myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA HL-60 CELLS; HUMAN RECOMBINANT MYELOPEROXIDASE; HUMAN CATHEPSIN-G; LINE RBL; PROGENITOR-CELL; BREFELDIN-A; BIOSYNTHESIS; GRANULES; HEME; SITE	Myeloperoxidase (MPO), stored in azurophil granules of neutrophils, is critical for an optimal oxygen-dependent microbicidal activity of these cells. Pro-MPO goes through a stepwise proteolytic trimming with elimination of an amino-terminal propeptide to yield one heavy and one light polypeptide chain. The propeptide of MPO may have a role in retention and folding of the nascent protein into its tertiary structure or in targeting of pro-MPO for processing and storage in granules, A propeptide-deleted pro-MPO mutant (MPO Delta pro) was constructed to determine if deletion of the propeptide interferes with processing and targeting after transfection to the myeloid 32D cell line. Transfection of full-length cDNA for human MPO results in normal processing and targeting of MPO to cytoplasmic dense organelles. Although the efficiency of incorporation was lower for MPO Delta pro, both pro-MPO and MPO Delta pro showed heme incorporation indicating that the propeptide is not critical for this process. Deletion of the propeptide results in synthesis of a protein that lacks processing into mature two-chain forms but rather is degraded intracellularly or secreted, The finding of continued degradation of MPO Delta pro in the presence of lysosomotrophic agents or brefeldin A rules out that the observed degradation takes place after transfer to granules, Intracellular pro-MPO has high mannose oligosaccharide side chains, whereas stored mature MPO was found to have both high mannose and complex oligosaccharide side chains as judged by only partial sensitivity to endoglycosidase H. The propeptide may normally interfere with the generation of certain complex oligosaccharide chain(s) supported by the finding of high mannose side chains in secreted pro-MPO and lack of them in MPO Delta pro that contained complex oligosaccharide side chains only. In conclusion, elimination of the propeptide of pro-MPO blocks the maturation process and abolishes accumulation of the final product in granules suggesting a critical role of the propeptide for late processing of pro-MPO and targeting for storage in granules.	Univ Lund Hosp, Res Dept 2, Dept Hematol, S-22185 Lund, Sweden; Univ Uppsala, Ctr Biomed, Dept Immunol & Med Microbiol, S-75123 Uppsala, Sweden	Lund University; Skane University Hospital; Uppsala University	Olsson, I (corresponding author), Univ Lund Hosp, Res Dept 2, Dept Hematol, E Blocket, S-22185 Lund, Sweden.	inge.olsson@hematologi.lu.se						AKIN DT, 1987, ARCH BIOCHEM BIOPHYS, V255, P428, DOI 10.1016/0003-9861(87)90411-5; AKIN DT, 1986, J BIOL CHEM, V261, P8370; ANDREWS PC, 1981, J BIOL CHEM, V256, P4211; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; CASTANEDA VL, 1992, EXP HEMATOL, V20, P916; CONNER GE, 1992, J BIOL CHEM, V267, P21738; CULLY J, 1989, EXP CELL RES, V180, P440, DOI 10.1016/0014-4827(89)90070-0; GARWICZ D, 1995, J BIOL CHEM, V270, P28413; Garwicz D, 1997, J LEUKOCYTE BIOL, V61, P113, DOI 10.1002/jlb.61.1.113; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; Gullberg U, 1997, EUR J HAEMATOL, V58, P137; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HASILIK A, 1984, EMBO J, V3, P2671, DOI 10.1002/j.1460-2075.1984.tb02192.x; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; JACQUET A, 1991, ARCH BIOCHEM BIOPHYS, V291, P132, DOI 10.1016/0003-9861(91)90115-Y; JACQUET A, 1992, FEBS LETT, V302, P189, DOI 10.1016/0014-5793(92)80437-L; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P; KOEFFLER HP, 1985, BLOOD, V65, P484; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LINDMARK A, 1990, BLOOD, V76, P2374; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; LIU LD, 1995, J IMMUNOL METHODS, V181, P253, DOI 10.1016/0022-1759(95)00009-Y; MOGUILEVSKY N, 1991, EUR J BIOCHEM, V197, P605, DOI 10.1111/j.1432-1033.1991.tb15950.x; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; NAUSEEF WM, 1986, BLOOD, V67, P865; Nauseef WM, 1996, J BIOL CHEM, V271, P9546, DOI 10.1074/jbc.271.16.9546; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NAUSEEF WM, 1987, BLOOD, V70, P1143; NAUSEEF WM, 1992, BLOOD, V80, P2622; OLSSON I, 1984, BIOCHEM J, V223, P911, DOI 10.1042/bj2230911; OLSSON I, 1972, SCAND J HAEMATOL, V9, P483; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; STROMBERG K, 1986, EUR J CELL BIOL, V39, P424; TAYLOR KL, 1992, J BIOL CHEM, V267, P25282; TAYLOR KL, 1992, BIOCHEM BIOPH RES CO, V187, P1572, DOI 10.1016/0006-291X(92)90482-Z; VALTIERI M, 1987, J IMMUNOL, V138, P3829; YAMADA M, 1982, J BIOL CHEM, V257, P5980; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	44	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4747	4753		10.1074/jbc.273.8.4747	http://dx.doi.org/10.1074/jbc.273.8.4747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468538	hybrid			2022-12-27	WOS:000072115000066
J	Lain, B; Yanez, A; Iriarte, A; Martinez-Carrion, M				Lain, B; Yanez, A; Iriarte, A; Martinez-Carrion, M			Aminotransferase variants as probes for the role of the N-terminal region of a mature protein in mitochondrial precursor import and processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE TRANSLATION SYSTEM; ASPARTATE-AMINOTRANSFERASE; YEAST MITOCHONDRIA; RAT-LIVER; PHOSPHOLIPID-VESICLES; MOLECULAR CHAPERONES; PROTEOLYTIC CLEAVAGE; TARGETING SEQUENCES; STRUCTURAL FEATURES; PEPTIDASE	Of the two homologous isozymes of aspartate aminotransferase that are also nearly identical in their folded structures, only the mitochondrial form (mAAT) is synthesized as a precursor (pmAAT). After its in vitro synthesis in rabbit reticulocyte lysate, it can also be efficiently imported into isolated rat liver mitochondria, where it is processed to its native form by removal of the N-terminal presequence. The homologous cytosolic isoenzyme (cAAT) is not imported into mitochondria, even after fusion of the mitochondrial presequence from pmAAT to its N-terminal end. Substitution of the 30-residue N-terminal peptide of the mature portion of pmAAT with the corresponding sequence from the homologous, import-incompetent cytosolic isozyme (pc-mAAT) does not prevent import but reduces substantially its processing in the matrix. A detectable amount of the pcmAAT chimera is found associated with the inner mitochondrial membrane. Single and double substitution mutants of Trp-5 and Trp-6 at the N-terminal end of the mature protein are imported into mitochondria with efficiency similar to that of wild type. However, replacement of Trp-5 with proline, or of both tryptophans with either alanine (W5A/W6A mutant) or valine and aline (W5V/W6A mutant), allows import but interferes with the correct processing of the imported protein despite the presence of an intact cleavage site for the processing peptidase. Similar cleavage results were obtained using newly synthesized proteins and mitochondrial matrix extracts. These results indicate that translocation and processing for a precursor are independent events and that sequences C-terminal to the cleavage site are indeed important for the correct maturation of pmAAT in the matrix, probably because of their contribution to the conformation and flexibility of the peptide region surrounding the cleavage site required for efficient processing. The same region from the mature component of the passenger protein to complete its translocation into the matrix.	Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; ARRETZ M, 1991, BIOMED BIOCHIM ACTA, V50, P403; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; Artigues A, 1997, TECH PROT CHEM, V8, P481, DOI 10.1016/S1080-8914(97)80048-8; Berezov A, 1996, ARCH BIOCHEM BIOPHYS, V336, P173, DOI 10.1006/abbi.1996.0546; BEREZOV A, 1994, J BIOL CHEM, V269, P22222; CHRISTEN P, 1985, TRANSAMINASES, V2, P173; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1985, P NATL ACAD SCI USA, V82, P4930, DOI 10.1073/pnas.82.15.4930; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; HUYNH QK, 1981, J BIOCHEM-TOKYO, V90, P863, DOI 10.1093/oxfordjournals.jbchem.a133543; IRIARTE A, 1984, CHEM BIOL ASPECTS B, P269; JAUSSI R, 1985, J BIOL CHEM, V260, P6060; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1994, J BIOL CHEM, V269, P15588; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; LALORAYA S, 1995, MOL CELL BIOL, V15, P7098; LIN LN, 1985, BIOCHEMISTRY-US, V24, P6533, DOI 10.1021/bi00344a034; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; NGUYEN M, 1987, J CELL BIOL, V104, P1193, DOI 10.1083/jcb.104.5.1193; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; OBARU K, 1986, J BIOL CHEM, V261, P6976; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1994, J BIOL CHEM, V269, P24673; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PARSONS DF, 1967, METHOD ENZYMOL, V10, P443; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; PFANNER N, 1995, CURR BIOL, V5, P132; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; RILERS M, 1988, CELL, V52, P481; ROISE D, 1988, J BIOL CHEM, V263, P4509; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SRINIVASAN M, 1995, J BIOL CHEM, V270, P1191, DOI 10.1074/jbc.270.3.1191; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; THORNTON K, 1993, J BIOL CHEM, V268, P19906; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VASSAROTTI A, 1987, J BIOL CHEM, V262, P411; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; WALTNER M, 1995, J BIOL CHEM, V270, P26311, DOI 10.1074/jbc.270.44.26311; YANG M, 1991, J BIOL CHEM, V266, P6416	58	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4406	4415		10.1074/jbc.273.8.4406	http://dx.doi.org/10.1074/jbc.273.8.4406			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468492	hybrid			2022-12-27	WOS:000072115000020
J	Cover, CM; Hsieh, SJ; Tran, SH; Hallden, G; Kim, GS; Bjeldanes, LF; Firestone, GL				Cover, CM; Hsieh, SJ; Tran, SH; Hallden, G; Kim, GS; Bjeldanes, LF; Firestone, GL			Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G(1) cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURALLY OCCURRING INDOLES; DIETARY INDOLE-3-CARBINOL; ESTRADIOL METABOLISM; GENE-EXPRESSION; GROWTH-FACTOR; INDUCTION; RAT; PROGRESSION; TAMOXIFEN; BINDING	Indole-3-carbinol (I3C), a naturally occurring component of Brassica vegetables such as cabbage, broccoli, and Brussels sprouts, has been shown to reduce the incidence of spontaneous and carcinogen-induced mammary tumors, Treatment of cultured human MGF7 breast cancer cells with I36 reversibly suppresses the incorporation of [H-3]thymidine without affecting cell viability or estro,aem receptor (ER) responsiveness, Flow cytometry of propidium iodide stained cells revealed that I3C induces a G(1) cell cycle arrest, Concurrent with the I3C-induced growth inhibition, Northern blot and Western blot analyses demonstrated that I3C selectively abolished the expression of cyclin-dependent kinase 6 (CDK6) in a dose-and time-dependent manner. Furthermore, I3C inhibited the endogenous retinoblastoma protein phosphorylation and CDK6 phosphorylation of retinoblastoma in vi;ro to the same extent, After the MCF7 cells reached their maximal growth arrest, the levels of the p21 and p27 CDK inhibitors increased by 50%, The antiestrogen tamoxifen also suppressed MCF7 cell DNA synthesis but had no effect on CDK6 expression, while a combination of I3C and tamoxifen inhibited MCF7 cell growth more stringently than either agent alone. The I3C-mediated cell cycle arrest and repression of CDK6 production were also observed in estrogen receptor-deficient MDA-MB-231 human breast cancer cells, which demonstrates that this indole can suppress the growth of mammary tumor cells independent of estrogen receptor signaling Thus, our observations have uncovered a previously undefined antiproliferative pathway for I3C that implicates CDK6 as a target for cell cycle control in human breast cancer cells, Moreover, our results establish for the first time that CDK6 gene expression can be inhibited in response to an extracellular antiproliferative signal.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@mendel.berkeley.edu		Hsieh, S. Jean/0000-0002-2716-4609	NCI NIH HHS [CA-09041] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALDWIN WS, 1992, CHEM-BIOL INTERACT, V83, P155, DOI 10.1016/0009-2797(92)90043-K; BARDON S, 1984, MOL CELL ENDOCRINOL, V35, P89, DOI 10.1016/0303-7207(84)90004-2; Bergan R, 1996, CLIN EXP METASTAS, V14, P389, DOI 10.1007/BF00123398; Birt DF, 1996, PROG CLIN BIOL RES, V395, P223; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BRADFIELD CA, 1984, FOOD CHEM TOXICOL, V22, P977, DOI 10.1016/0278-6915(84)90147-9; BRADLOW HL, 1994, CANCER EPIDEM BIOMAR, V3, P591; BRADLOW HL, 1991, CARCINOGENESIS, V12, P1571, DOI 10.1093/carcin/12.9.1571; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHEN YH, 1995, J BIOL CHEM, V270, P22548, DOI 10.1074/jbc.270.38.22548; Costello JF, 1997, CANCER RES, V57, P1250; DE KC, 1991, CHEM-BIOL INTERACT, V80, P303; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Forbes JF, 1997, SEMIN ONCOL, V24, pS5; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; Hirokawa M, 1996, IMMUNOL LETT, V50, P95, DOI 10.1016/0165-2478(96)02526-6; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ISHIDA T, 1995, J IMMUNOL, V155, P5527; JELLINCK PH, 1993, BIOCHEM PHARMACOL, V45, P1129, DOI 10.1016/0006-2952(93)90258-X; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; LEGHA SS, 1988, ANN INTERN MED, V109, P219, DOI 10.7326/0003-4819-109-3-219; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU H, 1994, JNCI-J NATL CANCER I, V86, P1758, DOI 10.1093/jnci/86.23.1758; LOUB WD, 1975, J NATL CANCER I, V54, P985; MCDANELL R, 1989, FOOD CHEM TOXICOL, V27, P289, DOI 10.1016/0278-6915(89)90130-0; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHNOVICZ JJ, 1990, J NATL CANCER I, V82, P947, DOI 10.1093/jnci/82.11.947; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORSE MA, 1990, CANCER RES, V50, P2613; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Norberg T, 1996, ACTA ONCOL, V35, P96, DOI 10.3109/02841869609083980; Pennisi E, 1996, SCIENCE, V273, P1171, DOI 10.1126/science.273.5279.1171; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POWL, 1997, SEMIN ONCOL S1, V24, P48; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; SCHUURING E, 1992, ONCOGENE, V7, P355; SHARMA S, 1994, CANCER RES, V54, P5848; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERTZER HG, 1984, CHEM-BIOL INTERACT, V48, P81, DOI 10.1016/0009-2797(84)90008-5; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; TIWARI RK, 1994, J NATL CANCER I, V86, P126, DOI 10.1093/jnci/86.2.126; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang QM, 1997, CANCER RES, V57, P2851; WATTENBERG LW, 1978, CANCER RES, V38, P1410; WATTENBERG LW, 1990, BASIC LIFE SCI, V52, P155; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIEBE VJ, 1993, CRIT REV ONCOL HEMAT, V14, P173, DOI 10.1016/1040-8428(93)90008-R; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65	68	223	231	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3838	3847		10.1074/jbc.273.7.3838	http://dx.doi.org/10.1074/jbc.273.7.3838			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461564	hybrid			2022-12-27	WOS:000072048400006
J	Kordula, T; Rydel, RE; Brigham, EF; Horn, F; Heinrich, PC; Travis, J				Kordula, T; Rydel, RE; Brigham, EF; Horn, F; Heinrich, PC; Travis, J			Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha(1)-antichymotrypsin expression in human cortical astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE PATIENTS; NECROSIS-FACTOR-ALPHA; ACUTE-PHASE RESPONSE; INFLAMMATORY CYTOKINES; CEREBROSPINAL-FLUID; TRANSGENIC MICE; NERVOUS-SYSTEM; CELLS; TRANSCRIPTION; BRAIN	alpha(1)-Antichymotrypsin (ACT) is an acute phase protein expressed in the brain which specifically colocalizes with amyloid-beta during Alzheimer's disease, We analyzed ACT synthesis in cultured human cortical astrocytes in response to various cytokines and growth factors. Oncostatin M (OSM) and interleukin (IL)-1 beta were potent stimulators of ACT mRNA expression, whereas tumor necrosis factor-alpha had modest activity, and IL-6 and leukemia inhibitory factor (LIF) were ineffective. The finding that OSM, but not LIF or IL-6, stimulated ACT expression suggests that human astrocytes express a "specific" OSM receptor, but not IL-6 or LIF receptors, However, cotreatment of human, astrocytes with soluble IL-6 receptor (sIL-6R).IL-6 complex did result In potent stimulation of ACT expression. When the human ACT gene was cloned, two elements binding STAT1 and STAT3 (signal transducer and activator of transcription) in response to OSM or IL-6.sIL-6R complexes could be identified and characterized, Taken together, these findings indicate that OSM or IL-6.sIL-6 complexes may regulate ACT expression in human astrocytes and thus directly or indirectly contribute to title pathogenesis of Alzheimer's disease.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Inst Mol Biol, PL-31120 Krakow, Poland; Athena Neurosci Inc, S San Francisco, CA 94080 USA; Rhein Westfal TH Aachen, Inst Biochem, D-5100 Aachen, Germany	University System of Georgia; University of Georgia; Jagiellonian University; RWTH Aachen University	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Life Sci Bldg, Athens, GA 30602 USA.	JTravis@uga.cc.uga.edu			NHLBI NIH HHS [HL37090, HL26148] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL137090, R01HL037090, R01HL026148, R37HL037090] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ALOISI F, 1994, J IMMUNOL, V152, P5022; ATSUMI T, 1995, ACTA HAEMATOL-BASEL, V94, P90; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BENVENISTE JA, 1992, AM J PHYSIOL, V263, pC1; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; CADMAN ED, 1994, J NEUROCHEM, V63, P980; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CICHY J, 1995, J CLIN INVEST, V95, P2729, DOI 10.1172/JCI117975; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HUELL M, 1995, ACTA NEUROPATHOL, V89, P544; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Koj A, 1985, ACUTE PHASE RESPONSE, P139; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; LEE SC, 1993, J IMMUNOL, V150, P2659; Lieb K, 1996, J NEUROCHEM, V67, P2039; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; MERILL JE, 1992, J IMMUNOTHER, V12, P167; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NAEMURA JR, 1993, LYMPHOKINE CYTOK RES, V12, P187; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; PASTERNACK JM, 1989, AM J PATHOL, V135, P827; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHERRER K, 1962, BIOCHEM BIOPH RES CO, V7, P486, DOI 10.1016/0006-291X(62)90341-8; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STRAUSS S, 1992, LAB INVEST, V66, P223; THOMA B, 1994, J BIOL CHEM, V269, P6215; VADENABEELE P, 1991, IMMUNOL TODAY, V12, P217; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	55	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4112	4118		10.1074/jbc.273.7.4112	http://dx.doi.org/10.1074/jbc.273.7.4112			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461605	hybrid			2022-12-27	WOS:000072048400047
J	Noel, LS; Champion, BR; Holley, CL; Simmons, CJ; Morris, DC; Payne, JA; Lean, JM; Chambers, TJ; Zaman, G; Lanyon, LE; Suva, LJ; Miller, LR				Noel, LS; Champion, BR; Holley, CL; Simmons, CJ; Morris, DC; Payne, JA; Lean, JM; Chambers, TJ; Zaman, G; Lanyon, LE; Suva, LJ; Miller, LR			RoBo-1, a novel member of the urokinase plasminogen activator receptor/CD59/Ly-6/snake toxin family selectively expressed in rat bone and growth plate cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE A(2) INHIBITOR; CANCELLOUS BONE; MECHANICAL STIMULATION; OSTEOGENIC RESPONSE; OVARIECTOMIZED RATS; GENE-EXPRESSION; THAILAND COBRA; MESSENGER-RNA; RECEPTOR; PROTEINS	Using differential display polymerase chain reaction, we cloned a novel cDNA named RoBo-1 from rat tibia, RoBo-1 is abundantly expressed in bone, including the hypertrophic chondrocytes of the growth plate where cartilage is remodeled into bone. RoBo-1 mRNA expression increased in response to two modulators of bone metabolism, estradiol and intermittent mechanical loading, suggesting a role in bone homeostasis. The 1.6-kilobase cDNA encodes a 240-amino acid protein with a cysteine spacing pattern, suggesting that RoBo-1 is a novel member of the urokinase plasminogen activator a receptor/Cd59/Ly-6/snake toxin family. Furthermore, the C-terminal contains glycosyl-phosphatidylinositol attachment site, suggesting that it is a cell surface protein similar to other mammalian members of this family, The strongest homology of RoBo-1 is to the snake serum-derived phospholipase A2 inhibitors, which uniquely contain two of the cysteine domains but are secreted proteins, interestingly, RoBo-1 is likely the first membrane-anchored member of this family containing two cysteine domains. Thus, the tissue specificity, responsiveness bane protective mediators, along with its relationship to the multifunctional urokinase plasminogen activator receptor/CD59/Ly-6/snake toxin family suggests that RoBo-1 may play a novel role in the growth or remodeling of bone.	Glaxo Wellcome Inc, Res, Dept Mol Pharmacol, Res Triangle Pk, NC 27709 USA; Univ London St Georges Hosp, Sch Med, Dept Histopathol, London SW17 0RE, England; Univ London Royal Vet Coll, London NW1 0TU, England; Harvard Univ, Beth Israel Hosp, Div Bone & Mineral Metab, Beth Israel Deaconess Med Ctr,Med Sch, Boston, MA 02215 USA	GlaxoSmithKline; St Georges University London; University of London; University of London Royal Veterinary College; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Miller, LR (corresponding author), Glaxo Wellcome Inc, Res, Dept Mol Pharmacol, Rm 3-3084,5 Moore Dr, Res Triangle Pk, NC 27709 USA.	LRM11241@glaxowellcome.com	Holley, Christopher/ABB-6677-2020; Holley, Christopher/T-1312-2019	Holley, Christopher/0000-0002-2870-3352; Suva, Larry/0000-0002-2892-9757				Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; BIKLE DD, 1994, AM J PHYSIOL-ENDOC M, V267, pE822, DOI 10.1152/ajpendo.1994.267.6.E822; Canalis E, 1996, REGULATION BONE REMO, P29; CASEY JR, 1994, BLOOD, V84, P1151; CHOW JWM, 1993, AM J PHYSIOL, V265, pE340, DOI 10.1152/ajpendo.1993.265.2.E340; FORTESDIAS CL, 1994, J BIOL CHEM, V269, P15646; FROST HM, 1988, CALCIFIED TISSUE INT, V42, P145, DOI 10.1007/BF02556327; HENDRIKS W, 1987, NUCLEIC ACIDS RES, V15, P9093, DOI 10.1093/nar/15.21.9093; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; Jagger CJ, 1996, J CLIN INVEST, V98, P2351, DOI 10.1172/JCI119047; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952-3278(90)90081-U; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V200, P784, DOI 10.1006/bbrc.1994.1519; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V204, P1212, DOI 10.1006/bbrc.1994.2592; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; RIEK RP, 1995, J THEOR BIOL, V172, P245; SALIH MA, 1993, BONE MINER, V23, P285, DOI 10.1016/S0169-6009(08)80104-3; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V122, P2191, DOI 10.1210/endo-122-5-2191; SCHWARTZ Z, 1992, BONE, V13, P51, DOI 10.1016/8756-3282(92)90361-Y; SUVA LJ, 1993, J BONE MINER RES, V8, P379; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686; WRONSKI TJ, 1988, ENDOCRINOLOGY, V123, P681, DOI 10.1210/endo-123-2-681; Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769; [No title captured]	31	35	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3878	3883		10.1074/jbc.273.7.3878	http://dx.doi.org/10.1074/jbc.273.7.3878			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461570	hybrid			2022-12-27	WOS:000072048400012
J	Zrihan-Licht, S; Deng, BJ; Yarden, Y; McShan, G; Keydar, I; Avraham, H				Zrihan-Licht, S; Deng, BJ; Yarden, Y; McShan, G; Keydar, I; Avraham, H			Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASES; MAMMARY-TUMORS; C-SRC; C-ERBB-2 PROTEIN; TRANSGENIC MICE; NEU RECEPTOR; EXPRESSION; GENE; INDUCTION	Substantial evidence exists supporting direct roles for ErbB-2/neu and Src kinase activation in breast cancer, The Csk homologous kinase (CHK) is a recently identified tyrosine kinase which, like Csk, phosphorylates the C-terminal tyrosine of Src kinases, resulting in inactivation of these enzymes, Recently, we observed that CHK is associated with the ErbB-2/neu receptor upon heregulin stimulation of breast cancer cells, Here, we report that CHK expression was observed in 70 out of 80 primary breast cancer specimens but not in normal breast tissues (0/19), Confocal microscopy analysis revealed colocalization of CHK with ErbB-2 in these primary specimens (6/6), In addition, we observed that the cytoplasmic domain of the ErbB-2/neu receptor is sufficient for its interaction with the CHKSH2 domain, Phosphopeptide inhibition of the in vitro interaction of CHKSH2 or native CHK with ErbB-2/neu, as well as site-directed mutagenesis of ErbB-2/neu, indicated that CHKSH2 binds to Tyr(1253) of ErbB-2/neu, Interestingly, autophosphorylation at this site confers oncogenicity to this receptor, Moreover, CHK was able to down-regulate ErbB-2/neu-activated Src kinases, Overexpression of CHK in MCF-7 breast cancer cells markedly inhibited cell growth and proliferative response to heregulin as well as decreased colony formation in soft agar, These studies indicate that CHK binds, via its SH2 domain, to Tyr(1253) Of the activated ErbB-2/neu and down-regulates the ErbB-2/neu-mediated activation of Src kinases, thereby inhibiting breast cancer cell growth, These data strongly suggest that CHK is a novel negative growth regulator in human breast cancer.	Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; Weizmann Inst Sci, Dept Chem Immunol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Weizmann Institute of Science; Tel Aviv University	Avraham, H (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.		YARDEN, YOSEF/K-1467-2012	Avraham, Hava/0000-0002-7545-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELOFF MD, 1996, CURR OPIN ONCOL, V8, P447; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; Blackwood M. Anne, 1996, Current Opinion in Oncology, V8, P449; BOLEN JB, 1993, ONCOGENE, V8, P2025; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COHEN JA, 1989, ONCOGENE, V4, P81; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HAMAGUCHI I, 1994, ONCOGENE, V9, P3371; Hirao A, 1997, EMBO J, V16, P2342, DOI 10.1093/emboj/16.9.2342; Hoskins Kent, 1995, Current Opinion in Oncology, V7, P495, DOI 10.1097/00001622-199511000-00003; JHUN BH, 1995, J BIOL CHEM, V270, P9661, DOI 10.1074/jbc.270.16.9661; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN G, 1993, P NATL ACAD SCI USA, V9, P1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1990, REGULATORY MECH BREA, P25; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHAU HE, 1990, MOL CARCINOGEN, V3, P254, DOI 10.1002/mc.2940030503; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	47	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4065	4072		10.1074/jbc.273.7.4065	http://dx.doi.org/10.1074/jbc.273.7.4065			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461599	hybrid			2022-12-27	WOS:000072048400041
J	Brazil, BT; Ybarra, J; Horowitz, PM				Brazil, BT; Ybarra, J; Horowitz, PM			Divalent cations can induce the exposure of GroEL hydrophobic surfaces and strengthen GroEL hydrophobic binding interactions - Novel effects of Zn2+ GroEL interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; CHAPERONIN GROEL; PROTEINS; ATP; OLIGOMER	Fluorescent and non-fluorescent probes have been used to show that divalent cations (Ca2+, Mg2+, Mn2+, and Zn2+) significantly increase hydrophobic exposure on GroEL, whereas monovalent cations (K+ and Na+) have little effect, Zn2+ always induced the largest amount of hydrophobic exposure on GroEL, By using a new method based on interactions of GroEL with octyl-Sepharose, it was demonstrated that Zn2+ binding strengthens GroEL hydrophobic binding interactions and increases the efficiency of substrate release upon the addition of MgATP and GroES. The binding of 4,4'-bis(1-anilino-8-naphthalenesulfonic acid) to GroEL in the presence of Zn2+ has a K-d congruent to 1 mu M, which is similar to that observed previously for the GroEL 4,4'-bis(1-anilino-8-naphthalenesulfonic acid) complex, Urea denaturation, sedimentation velocity ultracentrifugation, and electron microscopy revealed that the quaternary structure of GroEL in the presence of Zn2+ had a stability and morphology equivalent to unliganded GroEL. In contrast, circular dichroism suggested some loss in both alpha-helical and beta-sheet secondary structure in the presence of Zn2+. These data suggest that divalent cations can modulate the amount of hydrophobic surface presented by GroEL, Furthermore, the influence of Zn2+ on GroEL hydrophobic surface exposure as well as substrate binding and release appears to be distinct from the stabilizing effects of Mg2+ on GroEL quaternary structure.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Horowitz, PM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.	Horowitz@bioc09.uthscsa.edu			NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brazil BT, 1997, J BIOL CHEM, V272, P5105, DOI 10.1074/jbc.272.8.5105; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566	26	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3257	3263		10.1074/jbc.273.6.3257	http://dx.doi.org/10.1074/jbc.273.6.3257			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452440	hybrid			2022-12-27	WOS:000071822300025
J	Jurata, LW; Pfaff, SL; Gill, GN				Jurata, LW; Pfaff, SL; Gill, GN			The nuclear LIM domain interactor NLI mediates homo- and heterodimerization of LIM domain transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HOMEOBOX GENE LHX3; NEUROENDOCRINE TISSUES; TRANSGENIC MICE; INSULIN GENE; EXPRESSION; CELL; HOMEODOMAIN; PROTEIN; RHOMBOTIN	LIM domain-containing transcription factors are required for embryonic survival and for the determination of many cell types. The combinatorial expression of the LIM homeodomain proteins Isl1, Isl2, Lhx1, and Lhx3 in subsets of developing motor neurons correlates with the future organization of these neurons into motor columns with distinct innervation targets, implying a functional role for LIM homeodomain protein combinations in the specification of neuronal identity, NLI is a widely expressed, dimeric protein that has been shown to specifically interact with the LIM domains of LIM domain-containing transcription factors, The present studies demonstrate that NLI mediates home-and heteromeric complex formation between LIM domain transcription factors, requiring both the N-terminal dimerization and C-terminal LIM interaction domains of NLI, Although the interaction between most LIM homeodomain proteins is dependent on NLI, a direct interaction between the LIM domains of Lhx3 and the homeodomains of Isl1 and Isl2 was also observed. This interaction was disrupted by NLI, demonstrating that the conformational state of Lhx3-Isl1/Isl2 complexes is modified by NLI, Evidence indicating that NLI facilitates long range enhancer-promoter interactions suggests that NLI-dependent LIM domain transcription factor complexes are involved in communication between transcriptional control elements.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute	Gill, GN (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13149, DK 07541] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Appel B, 1995, DEVELOPMENT, V121, P4117; Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHEN CA, 1990, CURRENT PROTOCOLS MO; DANDOYDRON F, 1993, EXP CELL RES, V209, P58, DOI 10.1006/excr.1993.1285; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DONG JL, 1991, MOL ENDOCRINOL, V5, P1633, DOI 10.1210/mend-5-11-1633; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; Johnson JD, 1997, MOL CELL BIOL, V17, P3488, DOI 10.1128/MCB.17.7.3488; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; Morcillo P, 1997, GENE DEV, V11, P2729, DOI 10.1101/gad.11.20.2729; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; TOSNEY KW, 1995, BIOESSAYS, V17, P379, DOI 10.1002/bies.950170503; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; Yamashita T, 1997, GENOMICS, V44, P144, DOI 10.1006/geno.1997.4852; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	40	138	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3152	3157		10.1074/jbc.273.6.3152	http://dx.doi.org/10.1074/jbc.273.6.3152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452425	hybrid			2022-12-27	WOS:000071822300010
J	Reynolds, MG; Roos, DS				Reynolds, MG; Roos, DS			A biochemical and genetic model for parasite resistance to antifolates - Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-THYMIDYLATE SYNTHASE; DIHYDROFOLATE-REDUCTASE; ESCHERICHIA-COLI; POINT MUTATIONS; HUMAN MALARIA; DRUG-RESISTANCE; HETEROLOGOUS EXPRESSION; DEFICIENT MUTANT; SYNTHETASE GENE; MOLECULAR-BASIS	We have exploited the experimental accessibility of the protozoan parasite Toxoplasma gondii and its similarity to Plasmodium falciparum to investigate the influence of specific dihydrofolate reductase polymorphisms known from field isolates of drug-resistant malaria. By engineering appropriate recombinant shuttle vectors, it is feasible to examine mutations by transient or stable transformation of T. gondii parasites, in bacterial and yeast complementation assays, and through biochemical analysis of purified enzyme, A series of mutant alleles that mirror P. falciparum variants reveals that the key mutation Asn-108 (Asn-83 in T. gondii) probably confers resistance to pyrimethamine by affecting critical interactions in the ternary complex, Mutations such as Arg-59 (T. gondii 36) have limited effect in isolation, but in combination with other mutations they enhance the competitive ability of folate by increasing the speed of product turnover. Val-16 (T. gondii 10) confers low level resistance to cycloguanil but hypersensitivity to pyrimethamine, This mutation precludes Asn-108, probably because compression of the folate binding pocket introduced by this combination is incompatible with enzyme function. These studies permit detailed biochemical, kinetic, and structural analysis of drug resistance mutations and reconstruction of the probable phylogeny of antifolate resistance in malaria.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Roos, DS (corresponding author), Univ Penn, Dept Biol, 415 S Univ Ave, Philadelphia, PA 19104 USA.	droos@sas.upenn.edu		Reynolds, Mary/0000-0001-7882-4614; Roos, David Siker/0000-0001-6725-4089	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028724, R37AI028724] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28724] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACCANARI DP, 1982, BIOCHEMISTRY-US, V21, P5068, DOI 10.1021/bi00263a034; BACCANARI DP, 1981, BIOCHEMISTRY-US, V20, P1710, DOI 10.1021/bi00510a002; BASCO LK, 1995, MOL BIOCHEM PARASIT, V69, P135, DOI 10.1016/0166-6851(94)00207-4; BASCO LK, 1994, AM J TROP MED HYG, V50, P193, DOI 10.4269/ajtmh.1994.50.193; BROOKS RG, 1987, ANTIMICROB AGENTS AN, V2, P267; BROWN KA, 1992, FARADAY DISCUSS, V93, P217, DOI 10.1039/fd9929300217; BZIK DJ, 1987, P NATL ACAD SCI USA, V84, P8360, DOI 10.1073/pnas.84.23.8360; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHEN GX, 1987, MOL PHARMACOL, V31, P430; CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P361, DOI 10.1016/0166-6851(94)90087-6; Cowman AF, 1995, AUST NZ J MED, V25, P837, DOI 10.1111/j.1445-5994.1995.tb02889.x; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DONALD RGK, 1994, MOL BIOCHEM PARASIT, V63, P243, DOI 10.1016/0166-6851(94)90060-4; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; EYLES DON E., 1955, ANTIBIOT AND CHEMOTHER, V5, P529; EYLES DON E., 1955, ANTIBIOT AND CHEMOTHER, V5, P731; FILMAN DJ, 1982, J BIOL CHEM, V257, P13663; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; HALL SJ, 1991, MOL BIOCHEM PARASIT, V45, P317, DOI 10.1016/0166-6851(91)90100-K; HekmatNejad M, 1997, EXP PARASITOL, V85, P303, DOI 10.1006/expr.1997.4145; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; HITCHINGS GH, 1983, INHIBITION FOLATE ME, P1; HOLFELS E, 1994, ANTIMICROB AGENTS CH, V38, P1392, DOI 10.1128/AAC.38.6.1392; HOWELL EE, 1988, J BACTERIOL, V170, P3040, DOI 10.1128/jb.170.7.3040-3045.1988; HYDE JE, 1990, PHARMACOL THERAPEUT, V48, P45, DOI 10.1016/0163-7258(90)90017-V; ITZSCH MH, 1993, J EUKARYOT MICROBIOL, V40, P24; IVANETICH KM, 1990, EXP PARASITOL, V70, P367, DOI 10.1016/0014-4894(90)90119-W; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; Le Bras Jacques, 1996, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V190, P471; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEVINE ND, 1988, J PROTOZOOL, V35, P518, DOI 10.1111/j.1550-7408.1988.tb04141.x; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; PENNER MH, 1987, J BIOL CHEM, V262, P15908; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PFEFFERKORN ER, 1977, J PROTOZOOL, V24, P449, DOI 10.1111/j.1550-7408.1977.tb04774.x; Prapunwattana P, 1996, MOL BIOCHEM PARASIT, V83, P93, DOI 10.1016/S0166-6851(96)02756-9; Reeder JC, 1996, AM J TROP MED HYG, V55, P209, DOI 10.4269/ajtmh.1996.55.209; REYES P, 1982, MOL BIOCHEM PARASIT, V5, P275, DOI 10.1016/0166-6851(82)90035-4; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; ROOS DS, 1993, J BIOL CHEM, V268, P6269; SANO G, 1994, MOL BIOCHEM PARASIT, V63, P265, DOI 10.1016/0166-6851(94)90062-0; SCHWARTZMAN JD, 1981, J PARASITOL, V67, P150, DOI 10.2307/3280627; SINGER S, 1985, J BACTERIOL, V164, P470, DOI 10.1128/JB.164.1.470-472.1985; SIRAWARAPORN W, 1993, J BIOL CHEM, V268, P21637; Sirawaraporn W, 1997, P NATL ACAD SCI USA, V94, P1124, DOI 10.1073/pnas.94.4.1124; SIRAWARAPORN W, 1990, BIOCHEMISTRY-US, V29, P10779, DOI 10.1021/bi00500a009; SNEWIN VA, 1989, GENE, V76, P41, DOI 10.1016/0378-1119(89)90006-1; STONE SR, 1986, BIOCHIM BIOPHYS ACTA, V869, P275, DOI 10.1016/0167-4838(86)90067-1; TANAKA M, 1990, MOL BIOCHEM PARASIT, V39, P127, DOI 10.1016/0166-6851(90)90015-E; TENANTFLOWERS M, 1991, AIDS, V5, P311, DOI 10.1097/00002030-199103000-00011; THAITHONG S, 1992, MOL BIOCHEM PARASIT, V52, P149, DOI 10.1016/0166-6851(92)90047-N; THILLET J, 1990, BIOCHEMISTRY-US, V29, P5195, DOI 10.1021/bi00473a028; Trujillo M, 1996, BIOCHEMISTRY-US, V35, P6366, DOI 10.1021/bi952923q; vanderWel AM, 1997, J EXP MED, V185, P1499, DOI 10.1084/jem.185.8.1499; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Zindrou S, 1996, EXP PARASITOL, V84, P56, DOI 10.1006/expr.1996.0089; ZOLG JW, 1989, MOL BIOCHEM PARASIT, V36, P253, DOI 10.1016/0166-6851(89)90173-4	62	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3461	3469		10.1074/jbc.273.6.3461	http://dx.doi.org/10.1074/jbc.273.6.3461			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452469	hybrid			2022-12-27	WOS:000071822300054
J	Xie, Z; Price, DH				Xie, Z; Price, DH			Unusual nucleic acid binding properties of factor 2, an RNA polymerase II transcript release factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR COUPLING FACTOR; ELONGATION COMPLEXES; DEPENDENT ATPASE; TERMINATION; GENE; DNA; DROSOPHILA; PURIFICATION; EXPRESSION; ETHIDIUM	Drosophila factor 2, an RNA polymerase II transcript release factor, exhibits a DNA-dependent ATPase activity (Xie, Z., and Price D. H. (1997) J. Biol. Chem. 272, 31902-31907). We examined the nucleic acid requirement and found that only double-stranded DNA (dsDNA) effectively activated the ATPase. Single-stranded DNA (ssDNA) not only failed to activate the ATPase, but suppressed the dsDNA-dependent ATPase. Gel mobility shift assays showed that factor 2 formed stable complexes with dsDNA or ssDNA in the absence of ATP. However, in the presence of ATP, the interaction of factor 2 with dsDNA was destabilized, while the ssDNA-factor 2 complexes were not affected. The interaction of factor 2 with dsDNA was sensitive to increasing salt concentrations and was competed by ssDNA. In both cases, loss of binding of factor 2 to dsDNA was mirrored by a decrease in ATPase and transcript release activity, suggesting that the interaction of factor 2 with dsDNA is important in coupling the ATPase with the transcript release activity. Although the properties of factor 2 suggested that it might have helicase activity, we were unable to detect any DNA unwinding activity associated with factor 2.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NIGMS NIH HHS [R01-GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Deng L, 1996, J BIOL CHEM, V271, P29386, DOI 10.1074/jbc.271.46.29386; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Guzder SN, 1996, J BIOL CHEM, V271, P18314, DOI 10.1074/jbc.271.31.18314; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HANAWALT PC, 1994, CURR BIOL, V4, P18; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MATSON SW, 1986, J BIOL CHEM, V261, P169; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PRICE DH, 1987, J BIOL CHEM, V262, P3244; PULLEYBLANK DE, 1975, J MOL BIOL, V91, P1, DOI 10.1016/0022-2836(75)90368-X; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SPENCER CA, 1990, ONCOGENE, V5, P777; Tong J, 1996, J BACTERIOL, V178, P2695, DOI 10.1128/jb.178.9.2695-2700.1996; WANG JC, 1974, J MOL BIOL, V89, P783, DOI 10.1016/0022-2836(74)90053-9; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Xie Z, 1997, J BIOL CHEM, V272, P31902, DOI 10.1074/jbc.272.50.31902; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	32	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3771	3777		10.1074/jbc.273.6.3771	http://dx.doi.org/10.1074/jbc.273.6.3771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452510	hybrid			2022-12-27	WOS:000071822300095
J	Fujiwara, T; Takami, N; Misumi, Y; Ikehara, Y				Fujiwara, T; Takami, N; Misumi, Y; Ikehara, Y			Nordihydroguaiaretic acid blocks protein transport in the secretory pathway causing redistribution of Golgi proteins into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; DIPEPTIDYL PEPTIDASE-IV; BREFELDIN-A CAUSES; INTRACELLULAR-TRANSPORT; ORGANELLE STRUCTURE; GUANINE-NUCLEOTIDE; MEMBRANE-PROTEIN; NETWORK; COMPLEX; EXPRESSION	We have investigated the effect of nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenase, on the intracellular protein transport and the structure of the Golgi complex. Pulse-chase experiments and immuno-electron microscopy showed that NDGA strongly inhibits the transport of newly synthesized secretory proteins to the Golgi complex resulting in their accumulation in the endoplasmic reticulum (ER). Despite their retention in the ER, oligosaccharides of secretory and ED-resident proteins were processed to endoglycosidase H-resistant forms, raising the possibility that oligosaccharide-processing enzymes are redistributed from the Golgi to the ER. Morphological observations further revealed that a-mannosidase II (a cis/medial-Golgi marker), but not TGN38 (a trans-Golgi network marker), rapidly redistributes to the ER in the presence of NDGA, resulting in the disappearance of the characteristic Golgi structure. Upon removal of the drug, the Golgi complex was reassembled into the normal structure as judged by perinuclear staining of alpha-mannosidase II and by restoration of the secretion. These effects of NDGA are quite similar to those of brefeldin A. However, unlike brefeldin A, NDGA did not cause a dissociation of beta-coatomer protein, a subunit of coatomer, from the Golgi membrane. On the contrary, NDGA exerted the stabilizing effect on beta-coatomer protein/membrane interaction against the dissociation caused by brefeldin A and ATP depletion. Taken together, these results indicate that NDGA is a potent agent disrupting the structure and function of the Golgi complex with a mechanism different from those known for other drugs reported so far.	Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 81480, Japan; Fukuoka Univ, Sch Med, Radioistope Lab, Jonan Ku, Fukuoka 81480, Japan	Fukuoka University; Fukuoka University	Ikehara, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 81480, Japan.	mm031321@cc.fukuoka-u.ac.jp						ARMOUR CL, 1981, EUR J PHARMACOL, V72, P93, DOI 10.1016/0014-2999(81)90302-2; BALCH WE, 1986, J BIOL CHEM, V261, P4681; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; CARMANKRZAN M, 1993, J NEUROSCI RES, V34, P225, DOI 10.1002/jnr.490340210; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1992, BIOCHEM BIOPH RES CO, V185, P776, DOI 10.1016/0006-291X(92)91693-K; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HIROSE S, 1988, J BIOL CHEM, V263, P7426; HORRUM MA, 1987, AGE, V10, P58, DOI 10.1007/BF02432287; KINOUCHI T, 1995, BIOCHEM BIOPH RES CO, V209, P841, DOI 10.1006/bbrc.1995.1576; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIM J, 1996, ANN OTO RHINOL LARYN, V105, P916; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORRIS HR, 1979, BRIT J PHARMACOL, V66, P452; ODA K, 1990, BIOCHEM J, V265, P161, DOI 10.1042/bj2650161; OGATA S, 1989, J BIOL CHEM, V264, P3596; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PARDINI RS, 1970, BIOCHEM PHARMACOL, V19, P2695, DOI 10.1016/0006-2952(70)90095-X; PAVANI M, 1994, BIOCHEM PHARMACOL, V48, P1935, DOI 10.1016/0006-2952(94)90592-4; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PERSSON R, 1988, J CELL BIOL, V107, P2503, DOI 10.1083/jcb.107.6.2503; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SEGUCHI T, 1992, J BIOL CHEM, V267, P11626; SIMONS K, 1987, EMBO J, V6, P2241, DOI 10.1002/j.1460-2075.1987.tb02496.x; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Tagaya M, 1996, J BIOCHEM, V119, P863; TAGAYA M, 1993, FEBS LETT, V324, P210; TAKAMI N, 1988, J BIOL CHEM, V263, P3016; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; TSUJI E, 1992, BIOCHEMISTRY-US, V31, P11921, DOI 10.1021/bi00162a035; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Yamaguchi T, 1997, J BIOL CHEM, V272, P25260, DOI 10.1074/jbc.272.40.25260	57	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3068	3075		10.1074/jbc.273.5.3068	http://dx.doi.org/10.1074/jbc.273.5.3068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446623	hybrid			2022-12-27	WOS:000071736600078
J	Hofmann, A; Escherich, A; Lewit-Bentley, A; Benz, J; Raguenes-Nicol, C; Russo-Marie, F; Gerke, V; Moroder, L; Huber, R				Hofmann, A; Escherich, A; Lewit-Bentley, A; Benz, J; Raguenes-Nicol, C; Russo-Marie, F; Gerke, V; Moroder, L; Huber, R			Interactions of benzodiazepine derivatives with annexins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; MEMBRANE-BINDING; CALCIUM; VESICLES; PROTEIN; CRYSTAL; REPLICATION; INHIBITION; CHANNELS; INVITRO	Human annexins III and V, members of the annexin family of calcium-and membrane-binding proteins, were complexed within the crystals with BDA452, a new 1,4-benzodiazepine derivative by soaking and co-crystallization methods, The crystal structures of the complexes were analyzed by x-ray crystallography and refined to 2.3- and 3.0-Angstrom resolution, BDA452 binds to a cleft which is located close to the N-terminus opposite to the membrane binding side of the proteins. Biophysical studies of the interactions of various benzodiazepine derivatives with annexins were performed to analyze the binding of benzodiazepines to annexins and their effects on the annexin-induced calcium influx into phosphatidylserine/phosphatidylethanolamine liposomes, Different effects were observed with a variety of benzodiazepines and different annexins depending on both the ligand and the protein, Almost opposite effects on annexin function are elicited by BDA250 and diazepam, its 7-chloro-derivative. We conclude that benzodiazepines modulate the calcium influx activity of annexins allosterically by stabilizing or destabilizing the conducting state of peripherally bound annexins in agreement with suggestions by Kaneko.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Abt Bioorgan Chem, D-82152 Martinsried, Germany; Ctr Univ Paris Sud, LURE, F-91405 Orsay, France; Inst Cochin Genet Mol, U332, INSERM, F-75014 Paris, France; Univ Munster, Inst Med Biochem, D-48149 Munster, Germany	Max Planck Society; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munster	Hofmann, A (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hofmann, Andreas/M-9870-2019; Hofmann, Andreas/B-9515-2008; Raguenes-Nicol, Celine/I-2693-2015	Hofmann, Andreas/0000-0003-4408-5467; Hofmann, Andreas/0000-0003-4408-5467; Raguenes-Nicol, Celine/0000-0001-8428-9558; Moroder, Luis/0000-0001-9570-5713				Arispe N, 1996, BIOPHYS J, V71, P1764, DOI 10.1016/S0006-3495(96)79377-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Benz J, 1996, J MOL BIOL, V260, P638, DOI 10.1006/jmbi.1996.0426; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BERENDES R, 1993, FEBS LETT, V317, P131, DOI 10.1016/0014-5793(93)81507-V; BOCK MG, 1989, J MED CHEM, V32, P13, DOI 10.1021/jm00121a004; BONDINELL WE, 1993, Patent No. 00095; BRISSON A, 1991, J MOL BIOL, V220, P199, DOI 10.1016/0022-2836(91)90002-N; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Eghbali M, 1997, NATURE, V388, P71, DOI 10.1038/40404; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FavierPerron B, 1996, BIOCHEMISTRY-US, V35, P1740, DOI 10.1021/bi952092o; FORTH W, 1996, ALLGEMEINE SPEZIELLE, P304; Garcia DA, 1997, BBA-BIOMEMBRANES, V1324, P76, DOI 10.1016/S0005-2736(96)00210-6; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; *GEN COMP GROUP, 1996, WISC PACK VERS 9 0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann A, 1997, BBA-BIOMEMBRANES, V1330, P254, DOI 10.1016/S0005-2736(97)00150-8; Hommer DW, 1987, PSYCHOPHARMACOLOGY 3, P977; HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko N, 1997, J MOL BIOL, V274, P16, DOI 10.1006/jmbi.1997.1375; KANEKO N, 1994, DRUG DEVELOP RES, V33, P429, DOI 10.1002/ddr.430330406; KORNECKI E, 1984, SCIENCE, V226, P1454, DOI 10.1126/science.6150550; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; LASKOWSKI RA, 1994, PROCHECK PROGRAMS CH; LESLIE AGW, 1994, MOSFLM VERSION 5 20; Liu L, 1997, FASEB J, V11, P3227; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; Meers P., 1996, ANNEXINS MOL STRUCTU, P97; MINOR W, 1993, XDISPLAYF PROGRAMME; MUTSCHLER E, 1986, ARZNEIMITTELWIRKUNGE, P145; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; OTWINOVSKI Z, 1993, P CCP4 STUDY WEEKEND; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; Perron B, 1997, J BIOL CHEM, V272, P11321; PLAGER DA, 1994, BIOCHEMISTRY-US, V33, P13239, DOI 10.1021/bi00249a010; RANG HP, 1991, PHARMACOLOGY, P634; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROMER D, 1982, NATURE, V298, P759, DOI 10.1038/298759a0; Seemann J, 1996, MOL BIOL CELL, V7, P1359, DOI 10.1091/mbc.7.9.1359; STERNBACH LH, 1979, J MED CHEM, V22, P1, DOI 10.1021/jm00187a001; SWAIRJO MA, 1994, BIOCHEMISTRY-US, V33, P10944, DOI 10.1021/bi00202a013; THIEL C, 1991, J BIOL CHEM, V266, P14732; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011	55	24	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2885	2894		10.1074/jbc.273.5.2885	http://dx.doi.org/10.1074/jbc.273.5.2885			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446599	hybrid			2022-12-27	WOS:000071736600054
J	Jarpe, MB; Knall, C; Mitchell, FM; Buhl, AM; Duzic, E; Johnson, GL				Jarpe, MB; Knall, C; Mitchell, FM; Buhl, AM; Duzic, E; Johnson, GL			[D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P acts as a biased agonist toward neuropeptide and chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ACTIVATED PROTEIN-KINASE; SWISS 3T3 CELLS; STRESS FIBER FORMATION; LUNG-CANCER CELLS; SUBSTANCE-P; INVERSE AGONISTS; TYROSINE KINASE; IN-VITRO; BOMBESIN	Substance P derivatives are potential therapeutic compounds for the treatment of small cell lung cancer and can cause apoptosis in small cell lung cancer cells in culture. These peptides act as broad spectrum neuropeptide antagonists, blocking calcium mobilization induced by gastrin-releasing peptide, bradykinin, cholecystokinin, and other neuropeptides. We show that [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P has unique agonist activities in addition to this described antagonist function, At doses that block calcium mobilization by neuropeptides, this peptide causes activation of c-Jun N-terminal kinase and cytoskeletal changes in Swiss 3T3 fibroblasts and stimulates migration and calcium flux in human neutrophils. Activation of c-Jun N-terminal kinase is dependent on the expression of the gastrin-releasing peptide receptor in rat 1A fibroblasts, demonstrating that the responses to the peptide are receptor-mediated. me hypothesize that [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]substance P acts as a biased agonist on neuropeptide and related receptors, activating certain guanine nucleotide-binding proteins through the receptor, but not others.	Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, Denver, CO 80206 USA; Cadus Pharmaceut, Tarrytown, NY 10591 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jarpe, MB (corresponding author), Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.	jarpem@njc.org			NATIONAL CANCER INSTITUTE [P50CA058187, F32CA073037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NCI NIH HHS [CA73037, CA58187] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY SJ, 1984, BRIT J PHARMACOL, V82, P441, DOI 10.1111/j.1476-5381.1984.tb10779.x; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUNN PA, 1994, CANCER RES, V54, P3602; BURBACH JPH, 1992, EUR J PHARM-MOLEC PH, V227, P1, DOI 10.1016/0922-4106(92)90136-J; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DUZIC E, 1992, J BIOL CHEM, V267, P9844; FAURE M, 1994, J BIOL CHEM, V269, P7851; Fruh T, 1996, BIOORG MED CHEM LETT, V6, P2323, DOI 10.1016/0960-894X(96)00421-0; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GU XH, 1991, BIOCHEM BIOPH RES CO, V179, P1991; HAWCOCK AB, 1982, EUR J PHARMACOL, V80, P135, DOI 10.1016/0014-2999(82)90189-3; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; PONG L, 1993, BIOCHEM J, V289, P283; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; SERRA MC, 1988, J IMMUNOL, V141, P2118; SETHI T, 1992, CANCER RES, V52, pS2737; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; TAKENOUCHI T, 1995, PEPTIDES, V16, P1019, DOI 10.1016/0196-9781(95)00084-W; TSOU K, 1985, EUR J PHARMACOL, V110, P155, DOI 10.1016/0014-2999(85)90047-0; Wang JL, 1996, BIOCHEM J, V320, P87, DOI 10.1042/bj3200087; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	42	83	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3097	3104		10.1074/jbc.273.5.3097	http://dx.doi.org/10.1074/jbc.273.5.3097			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446627	hybrid			2022-12-27	WOS:000071736600082
J	Liliental, J; Chang, DD				Liliental, J; Chang, DD			Rack1, a receptor for activated protein kinase C, interacts with integrin beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CYTOPLASMIC DOMAIN; CELL-ADHESION; SIGNAL-TRANSDUCTION; ALPHA-ACTININ; BINDING; CALRETICULIN; POLYPEPTIDE; AFFINITY; ICAM-1	The integrin beta subunit cytoplasmic domains are important for activation-dependent cell adhesion and adhesion-dependent signaling events. We report an interaction between integrin beta subunit cytoplasmic domain and Rack1, a Trp-Asp (WD) repeat protein that has been shown to bind activated protein kinase C, The Rack1-binding site on integrin beta(2) subunit resides within a conserved, membrane proximal region. In the yeast two-hybrid assay, WD repeats five to seven of Rack1 (Rack1-WD5/7) interact with integrin beta(1), beta(2), and beta(5) cytoplasmic domain, In eukaryotic cells, Rack1 co-immunoprecipitates with at least two different beta integrins, beta(1) integrins in 293T cells and beta(1) integrins in JY lymphoblastoid cells, Whereas Rack1-WD5/7 binds integrins constitutively, the association of full length Rack1 to integrins in vivo requires a treatment with phorbol esters, which promotes cell spreading and adhesion, These findings suggest that Rack1 may link protein kinase C directly to integrins and participate in the regulation of integrin functions.	Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Dept Med Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Dept Med Microbiol & Immunol, Factor 11-934,10833 Le Conte Ave, Los Angeles, CA 90095 USA.							AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, P911; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COPPOLINO GG, 1997, NATURE, V386, P843; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stewart MP, 1996, J IMMUNOL, V156, P1810; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3	34	296	303	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2379	2383		10.1074/jbc.273.4.2379	http://dx.doi.org/10.1074/jbc.273.4.2379			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442085	hybrid			2022-12-27	WOS:000071595200074
J	Scheel, AA; Pelham, HRB				Scheel, AA; Pelham, HRB			Identification of amino acids in the binding pocket of the human KDEL receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RETENTION; PROTEINS; TOPOLOGY; YEAST; GOLGI; ERD2; LOCALIZATION; SPECIFICITY	Retention of soluble proteins in the endoplasmic reticulum is dependent on their interaction with the KDEL (Lys-Asp-Glu-Leu) receptor in the Golgi apparatus and their subsequent retrieval back to the endoplasmic reticulum. We have studied the three-dimensional organization of the human KDEL receptor using site-directed mutagenesis and sulfhydryl-specific labeling, We have identified four amino acid residues, Arg-5, Asp-50, Tyr-162, and Asn-165, which we suggest participate in the formation of the ligand binding pocket. Arg-5 and Asp-50 are shown to be located on the lumenal side of the membrane and are inaccessible from the cytoplasm, In addition, our results strongly support a topology of the KDEL receptor similar to the family of G-protein-coupled receptors with seven transmembrane domains, Furthermore, Asp-50 plays a crucial role in the binding of His/Lys-Asp-Glu-Leu ligands, but is not required for Asp-Asp-Glu-Leu binding, suggesting that this residue forms an ion pair with the positively charged amino acid residue positioned 4 residues from the carboxyl terminus of the ligand.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Pelham, HRB (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							ELMENDORF HG, 1993, EMBO J, V12, P4763, DOI 10.1002/j.1460-2075.1993.tb06165.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE HI, 1993, P NATL ACAD SCI USA, V90, P11433, DOI 10.1073/pnas.90.23.11433; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Scheel AA, 1996, BIOCHEMISTRY-US, V35, P10203, DOI 10.1021/bi960807x; SEMENZA JC, 1992, J MOL BIOL, V224, P1, DOI 10.1016/0022-2836(92)90571-Z; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; Summers MD, 1987, MANUAL METHODS BACUL; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WILSON DW, 1993, J BIOL CHEM, V268, P7465	20	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2467	2472		10.1074/jbc.273.4.2467	http://dx.doi.org/10.1074/jbc.273.4.2467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442098	hybrid			2022-12-27	WOS:000071595200087
J	De Reggi, M; Gharib, B; Patard, L; Stoven, V				De Reggi, M; Gharib, B; Patard, L; Stoven, V			Lithostathine, the presumed pancreatic stone inhibitor, does not interact specifically with calcium carbonate crystals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC CALCIFYING PANCREATITIS; AMINO-ACID SEQUENCE; REG PROTEIN; LIQUID-CHROMATOGRAPHY; REGENERATING GENE; THREAD PROTEIN; MESSENGER-RNA; EXPRESSION; PRODUCT; GROWTH	Lithostathine (pancreatic stone protein, Peg protein) is, in addition to albumin, the major nonenzymatic protein of the pancreatic juice. It has been assumed to inhibit calcium carbonate precipitation and therefore to prevent stone formation in the pancreatic ducts. This function is, however, debatable, The assumption is based on the inhibition of in vitro crystal nucleation and growth by lithostathine, Considering that these phenomena occur only under certain critical conditions, we re-examined the question using a protein preparation where the purity and folding have been tested by mass spectroscopy and NMR in the absence of nonprotein contaminants, Under these conditions, we showed conclusively that lithostathine does not inhibit calcium carbonate nucleation and crystal growth, We demonstrated that previous findings on the alleged inhibition can be attributed to the uncontrolled presence of salts in the protein preparation used, Moreover, the affinity of lithostathine to calcite crystals, expressed as the half-life of bound iodinated protein in the presence of unlabeled competitor, was significantly lower than that of bovine serum albumin (8.8 and 11.2 h, respectively). Using glass microspheres instead of crystals did not significantly change the half-life of bound lithostathine (8.0 h), These findings are incompatible with the hypothesis of a specific interaction of lithostathine with calcium carbonate crystals, In conclusion, considering that components of pancreatic juice such as NaCl and phosphate ions are powerful inhibitors of calcium carbonate crystal growth, the mechanism of stone formation in pancreatic ducts must be reconsidered, The presence in normal pancreatic juice of small amounts of the 133-residue isoform of lithostathine (PSP-S-1), which precipitates at physiological pH, should be noted, and the possibility should be considered that they form micro-precipitates that aggregate and are progressively calcified.	INSERM, U399, F-13385 Marseille 5, France; Ecole Polytech, CNRS, URA 1308, Synth Organ Lab,Lab Resonance Magnet Nucl, F-91128 Palaiseau, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	De Reggi, M (corresponding author), INSERM, U399, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.							BACHRA BN, 1963, ARCH BIOCHEM BIOPHYS, V103, P124, DOI 10.1016/0003-9861(63)90018-3; Baeza N, 1996, DIABETES METAB, V22, P229; BARTOLI C, 1993, FEBS LETT, V327, P289, DOI 10.1016/0014-5793(93)81006-L; BERNARD JP, 1995, GUT, V36, P630, DOI 10.1136/gut.36.4.630; BERNARD JP, 1992, GASTROENTEROLOGY, V103, P1277, DOI 10.1016/0016-5085(92)91516-7; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Bimmler D, 1997, J BIOL CHEM, V272, P3073, DOI 10.1074/jbc.272.5.3073; *CIB GEIG, 1985, GEIG SCI TABL, P662; DECARO A, 1979, BIOCHEM BIOPH RES CO, V87, P1176, DOI 10.1016/S0006-291X(79)80031-5; DECARO AM, 1987, EUR J BIOCHEM, V168, P201; DEREGGI M, 1995, EUR J BIOCHEM, V230, P503; FredjReygrobellet D, 1996, OPHTHALMIC RES, V28, P130, DOI 10.1159/000267885; Geider S, 1996, J BIOL CHEM, V271, P26302, DOI 10.1074/jbc.271.42.26302; HANEIN D, 1993, LANGMUIR, V9, P1058, DOI 10.1021/la00028a030; HAY DI, 1986, CALCIFIED TISSUE INT, V39, P151, DOI 10.1007/BF02555111; KIMURA N, 1992, CANCER, V70, P1857, DOI 10.1002/1097-0142(19921001)70:7<1857::AID-CNCR2820700708>3.0.CO;2-8; MARIANI A, 1995, GUT, V36, P622, DOI 10.1136/gut.36.4.622; MONTALTO G, 1986, BIOCHEM J, V238, P227, DOI 10.1042/bj2380227; Moriscot C, 1996, PEDIATR RES, V39, P349, DOI 10.1203/00006450-199602000-00026; OKIDO M, 1992, HEPATOLOGY, V15, P1079, DOI 10.1002/hep.1840150618; Patard L, 1996, PROTEIN ENG, V9, P949, DOI 10.1093/protein/9.11.949; PERFETTI R, 1994, TRANSPLANT P, V26, P733; ROUQUIER S, 1991, J BIOL CHEM, V266, P786; SARLES H, 1992, B ACAD NAT MED PARIS, V176, P153; SARLES H, 1974, GASTROENTEROLOGY, V66, P604, DOI 10.1016/s0016-5085(74)80050-8; SOKAL RR, 1981, BIOMETRY, P454; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; WATANABE T, 1990, J BIOL CHEM, V265, P7432; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; Zenilman ME, 1996, SURGERY, V119, P576, DOI 10.1016/S0039-6060(96)80270-4; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	31	32	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4967	4971		10.1074/jbc.273.9.4967	http://dx.doi.org/10.1074/jbc.273.9.4967			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478942	hybrid			2022-12-27	WOS:000072310400026
J	Genestier, L; Prigent, AF; Paillot, R; Quemeneur, L; Durand, I; Banchereau, J; Revillard, JP; Bonnefoy-Berard, N				Genestier, L; Prigent, AF; Paillot, R; Quemeneur, L; Durand, I; Banchereau, J; Revillard, JP; Bonnefoy-Berard, N			Caspase-dependent ceramide production in Fas- and HLA class I-mediated peripheral T cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; RESONANCE ENERGY-TRANSFER; ICE-LIKE PROTEASE; ICE/CED-3 PROTEASE; PHOSPHOLIPASE-C; RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; SURFACE ANTIGEN; DEATH; PATHWAY	We recently demonstrated that the engagement of HLA class I alpha 1 domain induced Fas-independent apoptosis in human T and B lymphocytes. We analyzed the signaling pathway involved in HLA class I-mediated apoptosis in comparison with Fas (APO-1, CD95)-dependent apoptosis. The mouse mAb90 or the rat YTH862 monoclonal antibodies which bind the human HLA class I alpha 1 domain induced the production of ceramide which was blocked by addition of the phosphatidylcholine-dependent phospholipase C inhibitor, D609. Furthermore, HLA class I-mediated apoptosis involved at least two different caspases, an interleukin-1 converting enzyme-like protease and another protease inhibited by the CPP32-like protease inhibitor Ac-DEVD-CHO. Despite similarity between Fas and HLA class I signaling pathways, we failed to demonstrate any physical association between these two molecules. We also report that the pan-caspase inhibitory peptide zVAD-fmk, but not Ac-DEVD-CHO and Ac-YVAD-CHO, inhibited decrease of mitochondrial transmembrane potential and generation of ceramide induced by anti-HLA class I and anti-Fas monoclonal antibodies, whereas all three peptides efficiently inhibited apoptosis. Altogether these results suggest that signaling through Fas and HLA class I involve caspase(s), targeted by zVAD-fmk, which act upstream of ceramide generation and mitochondrial events, whereas interleukin-1 converting enzyme-like and CPP32-like proteases act downstream of the mitochondria.	Hop Edouard Herriot, INSERM, Immunol Lab, U80,UCBL, F-69437 Lyon, France; Inst Natl Sci Appl Lyon, Lab Biochem & Pharmacol, U352, INSERM, F-69621 Villeurbanne, France; Schering Plough, Lab Immunol Res, F-69571 Dardilly, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Merck & Company	Bonnefoy-Berard, N (corresponding author), Hop Edouard Herriot, INSERM, Immunol Lab, U80,UCBL, F-69437 Lyon, France.	bonnefoy@inserm.lyon151.fr	Bonnefoy, Nathalie/J-2536-2012; Genestier, Laurent/H-6443-2016	Bonnefoy, Nathalie/0000-0003-4814-6722; Genestier, Laurent/0000-0002-0527-4583; PAILLOT, Romain/0000-0003-3081-2037				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BEIER DC, 1994, J IMMUNOL, V152, P3862; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FOURNEL S, 1995, FEBS LETT, V367, P188, DOI 10.1016/0014-5793(95)00532-E; Genestier L, 1997, BLOOD, V90, P3629, DOI 10.1182/blood.V90.9.3629; Genestier L, 1997, BLOOD, V90, P726, DOI 10.1182/blood.V90.2.726.726_726_735; GORVEL JP, 1989, J CELL BIOL, V108, P2193, DOI 10.1083/jcb.108.6.2193; GOTTSCHALK AR, 1995, EUR J IMMUNOL, V25, P1032, DOI 10.1002/eji.1830250426; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Klaus SJ, 1996, J IMMUNOL, V156, P2743; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Mollereau B, 1996, J IMMUNOL, V156, P3184; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OEHM A, 1992, J BIOL CHEM, V267, P10709; PENNINGTON MW, 1994, PEPTIDE RES, V7, P72; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; PREISS J, 1986, J BIOL CHEM, V261, P8597; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHOWRONSKI EW, 1996, CELL DEATH DIFFER, V3, P171; Skov S, 1997, J IMMUNOL, V158, P3189; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SZOLLOSI J, 1987, P NATL ACAD SCI USA, V84, P7246, DOI 10.1073/pnas.84.20.7246; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSHERNING T, 1994, SCAND J IMMUNOL, V39, P117; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESSELBORG S, 1993, EUR J IMMUNOL, V23, P2707, DOI 10.1002/eji.1830231050; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOODLE SE, 1997, J IMMUNOL, V158, P2156; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	57	64	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5060	5066		10.1074/jbc.273.9.5060	http://dx.doi.org/10.1074/jbc.273.9.5060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478956	hybrid			2022-12-27	WOS:000072310400040
J	Montemartini, M; Nogoceke, E; Singh, M; Steinert, P; Flohe, L; Kalisz, HM				Montemartini, M; Nogoceke, E; Singh, M; Steinert, P; Flohe, L; Kalisz, HM			Sequence analysis of the tryparedoxin peroxidase gene from Crithidia fasciculata and its functional expression in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; THIOL-SPECIFIC ANTIOXIDANT; SALMONELLA-TYPHIMURIUM; GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; TRYPANOSOMA-BRUCEI; HYDROGEN-PEROXIDE; PURIFICATION; HOMOLOGY; CLONING	Tryparedoxin peroxidase from Crithidia fasciculata is an essential component of the trypanothione-dependent hydroperoxide metabolism in the trypanosomatids (Nogoceke, E., Gommel, D, U,, Kie beta, M,, Kalisz, H. M,, and Flohe, L, (1997) Biol. Chem, 378, 827-836), The tryparedoxin peroxidase gene and its flanking regions have been isolated and sequenced from a C, fasciculata genomic DNA library, It consists of an open reading frame of 564 base pairs encoding a protein of 188 amino acid residues, The gene, modified to encode 6 additional histidine residues, was expressed in Escherichia coli and the recombinant protein was purified to homogeneity by metal chelating chromatography, Recombinant tryparedoxin peroxidase has a subunit molecular mass of 21884 +/- 22 and contains two isoforms of pi 6.2 and 6.3, It exhibits a kinetic pattern identical to that of the authentic tryparedoxin peroxidase and has a similar specific activity of 2.51 units mg-l, The enzyme unequivocally belongs to the peroxiredoxin family of proteins, whose members have been found in all phyla, A phylo genetic tree comprising 47 protein and DNA sequences showed tryparedoxin peroxidase and a homologous Trypanosoma blucei sequence to form a distinct molecular clade, The consensus sequence: x(n)Ax(5-6)Fx(9)Gx(3)Vx(2)Fx(1)Px(2)Fx(1)FVCPTEx(21)Sx(1)Dx(7)Wx(16-19)Dx(15-16)Gx(3)Rx(2)Fx(2)Dx(27)Ax(1)Qx(4-11)Cx(1-3)Wx(n) was demonstrated by alignment of the sequences of tryparedoxin peroxidase and 8 other peroxiredoxins with established peroxidase function.	Gesell Biotechnol Forsch GmbH, D-38124 Braunschweig, Germany; Tech Univ Braunschweig, Dept Physiol Chem, D-38124 Braunschweig, Germany	Gesellschaft fur Biotechnologische Forschung mbH; Braunschweig University of Technology	Kalisz, HM (corresponding author), Gesell Biotechnol Forsch GmbH, Mascheroder Weg 1, D-38124 Braunschweig, Germany.							Bsat N, 1996, J BACTERIOL, V178, P6579, DOI 10.1128/jb.178.22.6579-6586.1996; Calonge M, 1996, BIOL CHEM H-S, V377, P233, DOI 10.1515/bchm3.1996.377.4.233; Cazzulo JJ, 1997, BIOL CHEM, V378, P1; Cha MK, 1995, BIOCHEM BIOPH RES CO, V217, P900, DOI 10.1006/bbrc.1995.2856; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAE HZ, 1994, BIOFACTORS, V4, P177; DOCAMPO R, 1990, CHEM-BIOL INTERACT, V73, P1, DOI 10.1016/0009-2797(90)90106-W; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; FAIRLAMB AH, 1996, BIOCHEMIST, V18, P11; FERRANTE AA, 1995, P NATL ACAD SCI USA, V92, P7617, DOI 10.1073/pnas.92.17.7617; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; GONNET GH, 1997, TUTORIAL INTRO COMPU; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; HENZE K, 1995, P NATL ACAD SCI USA, V92, P9122, DOI 10.1073/pnas.92.20.9122; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; Jacoby EM, 1996, PROTEINS, V24, P73, DOI 10.1002/(SICI)1097-0134(199601)24:1&lt;73::AID-PROT5&gt;3.0.CO;2-P; Koenig K, 1997, J BIOL CHEM, V272, P11908, DOI 10.1074/jbc.272.18.11908; Krauth-Siegel RL, 1987, FLAVINS FLAVOPROTEIN, P69; LOHRER H, 1990, EUR J BIOCHEM, V194, P863, DOI 10.1111/j.1432-1033.1990.tb19480.x; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Navas IM, 1996, BIOL CHEM, V377, P833, DOI 10.1515/bchm3.1996.377.12.833; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; SAURI H, 1995, BIOCHEM BIOPH RES CO, V208, P964, DOI 10.1006/bbrc.1995.1428; Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641; SHIM H, 1988, J GEN MICROBIOL, V134, P807; TAI SS, 1995, J BACTERIOL, V177, P3512, DOI 10.1128/jb.177.12.3512-3517.1995; Tamura T, 1995, BIOFACTORS, V5, P99; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; WONG S, 1993, MOL CELL BIOL, V13, P207, DOI 10.1128/MCB.13.1.207	34	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4864	4871		10.1074/jbc.273.9.4864	http://dx.doi.org/10.1074/jbc.273.9.4864			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478927	hybrid			2022-12-27	WOS:000072310400011
J	Nagai, T; Igarashi, K; Akasaka, J; Furuyama, K; Fujita, H; Hayashi, N; Yamamoto, M; Sassa, S				Nagai, T; Igarashi, K; Akasaka, J; Furuyama, K; Fujita, H; Hayashi, N; Yamamoto, M; Sassa, S			Regulation of NF-E2 activity in erythroleukemia cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; PORPHOBILINOGEN DEAMINASE GENE; LEUCINE ZIPPER PROTEIN; SUBSTRATE RECOGNITION; ERYTHROID PROMOTER; EXPRESSION; KINASE; IDENTIFICATION; HEMATOPOIESIS; ACTIVATION	The erythroid transcription factor NF-ES is an obligate heterodimer composed of two different subunits (p45 and p18), each containing a basic region-leucine zipper DNA binding domain, and it plays a critical role in erythroid differentiation as an enhancer-binding protein for expression of the beta-globin gene. We show here that dimethyl sulfoxide treatment of wild-type murine erythroleukemia cells, but not a mutant clone of dimethyl sulfoxide-resistant cells, increases NF-E2 activity significantly, which involves both up-regulation of DNA binding and transactivation activities, Both activities were reduced markedly by treatment of cells with a-aminopurine but not by genistein, Activation of the Ras-Raf-MAP kinase signaling cascade increased NF-E2 activity significantly, but this was suppressed when MafK was overexpressed, Domain analysis revealed an activation domain in the NH2-terminal region of p45 and a suppression domain in the basic region-leucine zipper of MafK. These findings indicate that induction of NF-ES activity is essential for erythroid differentiation of murine erythroleukemia cells, and serine/threonine phosphorylation may be involved in this process. In addition, they also suggest that a MafK homodimer can suppress transcription, not only by competition for the DNA binding site, but also by direct inhibition of transcription, Hence, MafK may function as an active transcription repressor.	Rockefeller Univ, New York, NY 10021 USA; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan	Rockefeller University; University of Tsukuba; University of Tsukuba; Tohoku University	Sassa, S (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Furuyama, Kazumichi/0000-0002-1376-4080; Igarashi, Kazuhiko/0000-0002-2470-2475	NIDDK NIH HHS [DK32890] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032890] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHANG CS, 1982, J BIOL CHEM, V257, P3650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; EISEN H, 1978, P277; FUJITA H, 1991, BIOCHIM BIOPHYS ACTA, V1090, P311, DOI 10.1016/0167-4781(91)90195-R; FUJITA H, 1991, J BIOL CHEM, V266, P17494; GARINGO AD, 1995, J BIOL CHEM, V270, P9169, DOI 10.1074/jbc.270.16.9169; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IGARASHI K, 1995, J BIOL CHEM, V270, P7915; KISHI A, 1993, BIOCHEM BIOPH RES CO, V192, P1131, DOI 10.1006/bbrc.1993.1534; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LU SJ, 1995, CANCER RES, V55, P1139; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MEGURO K, 1995, BLOOD, V86, P940; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; OHTA Y, 1976, P NATL ACAD SCI USA, V73, P1232, DOI 10.1073/pnas.73.4.1232; SASSA S, 1983, REGULATION HEMOGLOBI, P359; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	32	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5358	5365		10.1074/jbc.273.9.5358	http://dx.doi.org/10.1074/jbc.273.9.5358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478996	hybrid			2022-12-27	WOS:000072310400080
J	Yee, KSY; Yu, VC				Yee, KSY; Yu, VC			Isolation and characterization of a novel member of the neural zinc finger factor myelin transcription factor family with transcriptional repression activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; GENE; DOMAINS; DROSOPHILA; KRUPPEL; IDENTIFICATION; EXPRESSION; ACTIVATION; HUNCHBACK; SEQUENCE	Myelin transcription factor 1 (MyT1) and neural zinc finger factor 1 (NZF-1) represent the first two members of an emerging family of neural specific, zinc finger-containing DNA-binding proteins, MyT1 has been shown recently to play a critical role in neuronal cell differentiation during development, We have cloned the third member of the NZF/MyT family, referred to as neural zinc finger factor 3 (NZF-3), The cDNA sequence predicts a protein of 1,032 amino acids which contains two clusters of zinc fingers similar to MyT1 and NZF-1, Unlike MyT1 and NZF-1, NZF-3 does not contain an acidic domain at the amino terminus or a serine/threonine-rich region between the two finger clusters. NZF-3 binds to a DNA element containing a single copy of the previously described AAAGTTT consensus motif for these factors but exhibits a marked enhancement in relative affinity to a bipartite element containing two copies of the consensus motif, In contrast to MyT1 and NZF-1, which are known to activate transcription, cotransfection experiments revealed that NZF-3 confers repression on the basal activity of promoters containing the consensus binding elements. The identification of an additional member of the NZF/MyT family provides an opportunity to investigate the relative contribution of members of this family of transcription factors to the complex regulatory processes in neural development and homeostasis.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Yu, VC (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Yu, Victor/A-7899-2015	Yu, Victor/0000-0003-3270-4734				ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; LABOUESSE M, 1994, DEVELOPMENT, V120, P2359; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOUNT SM, 1985, MOL CELL BIOL, V5, P1630, DOI 10.1128/MCB.5.7.1630; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	33	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5366	5374		10.1074/jbc.273.9.5366	http://dx.doi.org/10.1074/jbc.273.9.5366			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478997	hybrid			2022-12-27	WOS:000072310400081
J	Zhang, ZQ; Simons, AM; Prabhu, VP; Chen, JH				Zhang, ZQ; Simons, AM; Prabhu, VP; Chen, JH			Strand exchange protein 1 (Sep1) from Saccharomyces cerevisiae does not promote branch migration in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UVSX PROTEIN; RECA PROTEIN; IN-VITRO; DNA; RECOMBINATION; GENE; EXONUCLEASE; CELLS; XRN1; BETA	It has been shown in vitro that Saccharomyces cerevisiae strand exchange protein 1 (Sep1) promotes the transfer of one strand of a linear duplex DNA to a homologous single-stranded DNA circle, Sep1 also has an exonuclease active on DNA and RNA. By using exonuclease III-treated linear duplex DNA with various lengths of single-stranded tail as well as Ca2+ to inhibit the exonuclease activity of Sep1, we show that the processivity of exonuclease activity of Sep1 is greater than previously reported. The results in this work also demonstrate that the joint molecule between the linear duplex and single-stranded circle observed from the Sep1-promoted strand transfer reaction is just the pairing between the long single-stranded tail of the linear duplex DNA (generated by the exonuclease activity of Sep1) and the single-stranded circular DNA. When a synthetic Holliday junction was used as substrate, branch migration facilitated by Sep1 could not be detected. Finally, using electron microscopy no alpha-structure, a joint molecule with displaced single-stranded DNA tail that indicates branch migration could be observed. The results imply that Sep1 cannot promote branch migration in vitro. Further investigation is needed to determine the role of Sep1 in recombination in vivo.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Chen, JH (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.		Chen, Junghuei/B-5217-2011					BASHKIROV VI, 1995, CHROMOSOMA, V104, P215, DOI 10.1007/s004120050110; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CHEN JH, 1994, GENE DEV, V8, P1356, DOI 10.1101/gad.8.11.1356; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HEYER WD, 1995, MOL CELL BIOL, V15, P2728; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; INTERTHAL H, 1995, EMBO J, V14, P1057, DOI 10.1002/j.1460-2075.1995.tb07088.x; JOHNSON AW, 1994, J BIOL CHEM, V269, P3664; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JOHNSON AW, 1994, J BIOL CHEM, V269, P3673; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KASLIN E, 1994, J BIOL CHEM, V269, P14094; KERSEY S, 1991, TRENDS CELL BIOL, V1, P110; KIM JM, 1990, GENETICS, V126, P799; KIPLING D, 1991, NUCLEIC ACIDS RES, V19, P1385, DOI 10.1093/nar/19.7.1385; KMIEC EB, 1994, J BIOL CHEM, V269, P10163; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOLODNER R, 1994, MOL MICROBIOL, V11, P23, DOI 10.1111/j.1365-2958.1994.tb00286.x; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PEREZMORGA DL, 1993, NUCLEIC ACIDS RES, V21, P1327, DOI 10.1093/nar/21.5.1327; Sambrook J., 2002, MOL CLONING LAB MANU; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; STEVENS A, 1980, J BIOL CHEM, V255, P3080; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TISHKOFF DX, 1995, GENETICS, V139, P495; YU X, 1993, J MOL BIOL, V232, P1, DOI 10.1006/jmbi.1993.1363	36	2	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4950	4956		10.1074/jbc.273.9.4950	http://dx.doi.org/10.1074/jbc.273.9.4950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478940	Green Published, hybrid			2022-12-27	WOS:000072310400024
J	Frenkel, C; Peters, JS; Tieman, DM; Tiznado, ME; Handa, AK				Frenkel, C; Peters, JS; Tieman, DM; Tiznado, ME; Handa, AK			Pectin methylesterase regulates methanol and ethanol accumulation in ripening tomato (Lycopersicon esculentum) fruit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE; METHYL ESTERASE; EXPRESSION; GENE	We provide genetic evidence that the production of methanol in tomato fruit is regulated by pectin methylesterase (PME, EC 3.1.1.11), an enzyme that catalyzes demethoxylation of pectins, The role of PME in methanol production in tomato fruit was examined by relating the tissue methanol content to the PME enzymatic activity in wild-type Rutgers and isogenic PME antisense fruits with lowered PME activity, In the wild-type, fruit development and ripening were accompanied by an increase in the abundance of PME protein and activity and a corresponding ripening-related increase in methanol content, In the PME antisense pericarp, the level of methanol was greatly reduced in unripe fruit, and diminished methanol content persisted throughout the ripening process, The close correlation between PME activity and levels of methanol in fruit tissues from wildtype and a PME antisense mutant indicates that PME is the primary biosynthetic pathway for methanol production in tomato fruit, Interestingly, ethanol levels that were low and unchanged during ripening of wild-type tomatoes increased progressively with the ripening of PME antisense fruit, In vitro studies indicate that methanol is a competitive inhibitor of the tomato alcohol dehydrogenase (ADH, EC 1.1.1.1) activity suggesting that ADH-catalyzed production of ethanol may be arrested by methanol accumulation in the wild-type but not in the PME mutant where methanol levels remain low.	Rutgers State Univ, Dept Plant Sci, New Brunswick, NJ 08901 USA; Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA	Rutgers State University New Brunswick; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Frenkel, C (corresponding author), Rutgers State Univ, Dept Plant Sci, 59 Dudley Rd, New Brunswick, NJ 08901 USA.							BICSAK TA, 1982, ARCH BIOCHEM BIOPHYS, V216, P605, DOI 10.1016/0003-9861(82)90250-8; BIGGS MS, 1989, PLANT PHYSIOL, V89, P117, DOI 10.1104/pp.89.1.117; DAVIES DD, 1980, BIOCH PLANTS COMPREH, V2, P581, DOI DOI 10.1016/B978-0-12-675402-5.50020-9; FISCHER RL, 1991, ANNU REV PLANT PHYS, V42, P675, DOI 10.1146/annurev.pp.42.060191.003331; GAFFE J, 1994, PLANT PHYSIOL, V105, P199, DOI 10.1104/pp.105.1.199; GOLDBERG R, 1984, PHYSIOL PLANTARUM, V61, P58, DOI 10.1111/j.1399-3054.1984.tb06100.x; HARRIMAN RW, 1991, PLANT PHYSIOL, V97, P80, DOI 10.1104/pp.97.1.80; KIMMERER TW, 1982, PLANT PHYSIOL, V69, P840, DOI 10.1104/pp.69.4.840; LONGHURST TJ, 1990, J FOOD BIOCHEM, V14, P421, DOI 10.1111/j.1745-4514.1990.tb00804.x; MOUSTACAS AM, 1986, EUR J BIOCHEM, V155, P191, DOI 10.1111/j.1432-1033.1986.tb09476.x; NEMECEKMARSHALL M, 1995, PLANT PHYSIOL, V108, P1359, DOI 10.1104/pp.108.4.1359; NURSTEN HE, 1967, CHEM IND-LONDON, P486; OBENDORF RL, 1990, J EXP BOT, V41, P489, DOI 10.1093/jxb/41.4.489; Sajjaanantakul T., 1991, CHEM TECHNOLOGY PECT, P135; TIEMAN DM, 1992, PLANT CELL, V4, P667, DOI 10.1105/tpc.4.6.667; TIEMAN DM, 1994, PLANT PHYSIOL, V106, P429, DOI 10.1104/pp.106.2.429; WOOD PJ, 1971, ANAL BIOCHEM, V39, P418, DOI 10.1016/0003-2697(71)90432-5	17	87	91	4	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4293	4295		10.1074/jbc.273.8.4293	http://dx.doi.org/10.1074/jbc.273.8.4293			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468474	hybrid			2022-12-27	WOS:000072115000002
J	Jacob, KK; Sap, J; Stanley, FM				Jacob, KK; Sap, J; Stanley, FM			Receptor-like protein-tyrosine phosphatase alpha specifically inhibits insulin-increased prolactin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; R-PTP-KAPPA; PHOSPHATIDYLINOSITOL 3-KINASE; RAS ACTIVATION; DOMAIN; SIGNAL; KINASE; PATHWAYS; GRB2; STIMULATION	A physiologically relevant response to insulin, stimulation of prolactin promoter activity in GH4 pituitary cells, was used as an assay to study the specificity of protein-tyrosine phosphatase function. Receptor-like protein-tyrosine phosphatase alpha (RPTP alpha) blocks the effect of insulin to increase prolactin gene expression but potentiates the effects of epidermal growth factor and cAMP on prolactin promoter activity. RPTP alpha was the only protein-tyrosine phosphatase tested that did this, Thus, the effect of RPTP alpha on prolactin-chloramphenicol acetyltransferase (CAT) promoter activity is specific by two criteria. A number of potential RPTP alpha targets were ruled out by finding (a) that they are not affected or (b) that they are not on the pathway to insulin-increased prolactin-CAT activity, The negative effect of RPTP alpha on insulin activation of the prolactin promoter is not due to reduced phosphorylation or kinase activity of the insulin receptor or to reduced phosphorylation of insulin. receptor substrate-1 or Shc. Inhibitor studies suggest that insulin-increased prolactin gene expression is mediated by a Ras-like GTPase but is not mitogen-activated protein kinase dependent. Experiments with inhibitors of phosphatidylinositol 3-kinase suggest that insulin-increased prolactin-CAT expression is phosphatidylinositol 3-kinase-independent. These results suggest that RPTP alpha may be a physiological regulator of insulin action.	NYU, Med Ctr, Dept Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University	Stanley, FM (corresponding author), NYU, Med Ctr, Dept Med, TH 450,550 1st Ave, New York, NY 10016 USA.			Stanley, Frederick/0000-0002-3684-2168	NCI NIH HHS [R29CA68365] Funding Source: Medline; NIDDK NIH HHS [DK43365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarcon CM, 1996, GENE DEV, V10, P279, DOI 10.1101/gad.10.3.279; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BRUDER J, 1992, GENE DEV, V6, P546; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; IRANMANESH A, 1990, J CLIN ENDOCR METAB, V71, P73, DOI 10.1210/jcem-71-1-73; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; JACOB K, 1995, J BIOL CHEM, V270, P2773; JACOB KK, 1995, MOL CELL ENDOCRINOL, V109, P175, DOI 10.1016/0303-7207(95)03500-7; JACOB KK, 1994, J BIOL CHEM, V269, P25515; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Myers MG, 1996, MOL CELL BIOL, V16, P4147; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PRAGER D, 1988, ENDOCRINOLOGY, V122, P2946, DOI 10.1210/endo-122-6-2946; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SAP J, 1994, MOL CELL BIOL, V14, P1; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SU J, 1994, J BIOL CHEM, V269, P18731; TESONE M, 1985, MOL CELL ENDOCRINOL, V43, P135, DOI 10.1016/0303-7207(85)90076-0; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	50	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4800	4809		10.1074/jbc.273.8.4800	http://dx.doi.org/10.1074/jbc.273.8.4800			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468545	hybrid			2022-12-27	WOS:000072115000073
J	Marathe, S; Schissel, SL; Yellin, MJ; Beatini, N; Mintzer, R; Williams, KJ; Tabas, I				Marathe, S; Schissel, SL; Yellin, MJ; Beatini, N; Mintzer, R; Williams, KJ; Tabas, I			Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase - Implication for early atherogenesis and ceramide-mediated cell signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ACID SPHINGOMYELINASE; NIEMANN-PICK DISEASE; MATRIX METALLOPROTEINASES; ATHEROSCLEROTIC LESIONS; MACROPHAGE UPTAKE; PLASMA-MEMBRANE; DEFICIENT MICE; PROPOSED ROLE; CHOLESTEROL	We recently reported that macrophages and fibroblasts secrete a Zn2+-dependent sphingomyelinase (S-SMase), which, like lysosomal SMase, is a product of the acid SMase gene. S-SMase may cause subendothelial retention and aggregation of lipoproteins during athero genesis, and the acid SMase gene has been implicated in ceramide-mediated cell signaling, especially involving apoptosis of endothelial cells, Because of the central importance of the endothelium in each of these pro cesses, we now sought to examine the secretion and regulation of S-SMase by vascular endothelial cells, Herein we show that cultured human coronary artery and umbilical vein endothelial cells secrete massive amounts of S-SMase (up to 20-fold more than macrophages). Moreover, whereas S-SMase secreted by macrophages and fibroblasts is almost totally dependent on the addition of exogenous Zn2+, endothelium-derived S-SMase was partially active even in the absence of added Zn2+. Secretion of S-SMase by endothelial cells occurred both apically and basolaterally, suggesting an endothelial contribution to both serum and arterial wall SMase. When endothelial cells were incubated with inflammatory cytokines, such as interleukin-1 beta and interferon-gamma, S-SMase secretion by endothelial cells was increased 2-3-fold above the already high level of basal secretion, whereas lysosomal SMase activity was decreased. The mechanism of interleukin-1 beta-stimulated secretion appears to be through increased routing of a SMase precursor protein through the secretory pathway. In summary, endothelial cells are a rich and regulatable source of enzymatically active S-SMase, suggesting physiologic and pathophysiologic roles for this enzyme.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Berlex Biosci, Richmond, CA 94804 USA; Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Columbia University; Columbia University; Jefferson University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu		Yellin, Michael/0000-0002-1164-7614; Williams, Kevin Jon/0000-0002-0000-2159	NHLBI NIH HHS [HL39703, HL56984, HL38956] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, R29HL038956, P50HL056984, R01HL038956] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD TY, 1985, J LIPID RES, V26, P1160; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CORNICELLI JA, 1983, ARTERIOSCLEROSIS, V3, P560, DOI 10.1161/01.ATV.3.6.560; COUSINS RJ, 1988, FASEB J, V2, P2884, DOI 10.1096/fasebj.2.13.2458983; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DONANGELO CM, 1981, CLIN CHIM ACTA, V113, P201, DOI 10.1016/0009-8981(81)90154-6; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LIBBY P, 1991, LAB INVEST, V64, P5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mantovani A, 1997, THROMB HAEMOSTASIS, V78, P406; MAROUDAS A, 1988, BIOPHYS CHEM, V32, P257, DOI 10.1016/0301-4622(88)87012-1; MENDIS S, 1989, BIOL TRACE ELEM RES, V22, P251, DOI 10.1007/BF02916613; Menkin V, 1934, AM J PATHOL, V10, P193; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MILANINO R, 1988, AGENTS ACTIONS, V24, P365, DOI 10.1007/BF02028295; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; OKWU AK, 1994, J LIPID RES, V35, P644; Perregaux DG, 1996, J BIOL CHEM, V271, P29830, DOI 10.1074/jbc.271.47.29830; POBER JS, 1991, ADV IMMUNOL, V50, P261; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SMITH EB, 1979, ADV EXP MED BIOL, V115, P245; SORBI D, 1993, KIDNEY INT, V44, P1266, DOI 10.1038/ki.1993.378; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SRIPADA PK, 1987, J LIPID RES, V28, P710; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; URADE R, 1988, BIOCHIM BIOPHYS ACTA, V946, P151, DOI 10.1016/0005-2736(88)90468-3; VARKI A, 1983, J BIOL CHEM, V258, P2808; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857; Zhang P, 1997, J BIOL CHEM, V272, P9609	65	199	209	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4081	4088		10.1074/jbc.273.7.4081	http://dx.doi.org/10.1074/jbc.273.7.4081			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461601	hybrid			2022-12-27	WOS:000072048400043
J	Palaniappan, C; Kim, JK; Wisniewski, M; Fay, PJ; Bambara, RA				Palaniappan, C; Kim, JK; Wisniewski, M; Fay, PJ; Bambara, RA			Control of initiation of viral plus strand DNA synthesis by HIV reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; SEQUENCE FEATURES IMPORTANT; RNASE-H; POLYPURINE TRACT; CLEAVAGE SPECIFICITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; RIBONUCLEASE-H; POLYMERASE	Human immunodeficiency virus reverse transcribes its single-stranded RNA genome making a DNA copy. As synthesis proceeds, the RNA is simultaneously degraded to oligomers; one of these, the polypurine tract, primers synthesis of a plus strand DNA. The viral reverse transcriptase (Ra) degrades all of the non-polypurine tract oligomers, We show that until ie other DNA polymerases the retroviral RT can bind either end of an annealed RNA primer, the 5'-end for degradation and the 3'-end for synthesis, The competition between the two binding modes at any primer determines whether it will be extended or degraded. The 5'-end binding can be suppressed in at least two ways, The sequence of the primer can be such that a region at the 5'-end is unannealed or a DNA primer can be annealed just adjacent to the 5'-end of the RNA primer. This promotes binding of RT to the RNA 3'-end, allowing a primer that; would normally be degraded to be extended. implications for human immunodeficiency virus replication and antiviral therapy are discussed.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, POB 712,601 Elmwood Ave, Rochester, NY 14642 USA.				NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOONE LR, 1993, REVERSE TRANSCRIPTAS, P119; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; Fuentes GM, 1996, NUCLEIC ACIDS RES, V24, P1719, DOI 10.1093/nar/24.9.1719; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUNGNES O, 1992, VIROLOGY, V190, P440, DOI 10.1016/0042-6822(92)91230-R; HUNGNES O, 1991, ARCH VIROL, V116, P133, DOI 10.1007/BF01319237; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LITVAK S, 1996, RETROVIRAL REVERSE T, P83; Lu YN, 1997, J BIOL CHEM, V272, P14523, DOI 10.1074/jbc.272.23.14523; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P4207, DOI 10.1021/bi00067a007; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; Schultz SJ, 1996, J VIROL, V70, P8630, DOI 10.1128/JVI.70.12.8630-8638.1996; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	48	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3808	3816		10.1074/jbc.273.7.3808	http://dx.doi.org/10.1074/jbc.273.7.3808			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461561	hybrid			2022-12-27	WOS:000072048400003
J	Haltiwanger, RS; Grove, K; Philipsberg, GA				Haltiwanger, RS; Grove, K; Philipsberg, GA			Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION; PHOSPHORYLATION; BINDING; IDENTIFICATION; GLCNACYLATION; TRANSCRIPTION; GLYCOPROTEINS; PURIFICATION	O-Linked N-acetylglucosamine (O-GlcNAc) is a ubiquitous and abundant post-translational modification found on nuclear and cytoplasmic proteins and is thought to be a dynamically regulated modification much like phosphorylation. In this study we have demonstrated that O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc), a potent in vitro inhibitor of the enzyme responsible for the removal of O-GlcNAc from proteins (peptide O-GlcNAc-beta-N-acetylglucosaminidase), can be used to increase O-GlcNAc levels on nuclear and cytoplasmic proteins in vivo. Overall, PUGNAc caused approximately a 2-fold increase in O-GlcNAc levels in the human colon cancer cells, HT29, although the effects on individual proteins varied, The increase appeared to be the result of the direct inhibition of the peptide O-GlcNAc-beta-N-acetylglucosaminidase since neither the O-GlcNAc transferase nor UDP-GlcNAc levels were affected by the treatment. O-GlcNAc levels in other cell lines tested (NIH 3T3, CV-1, and HeLa) were also affected by PUGNAc, although the effects on HeLa cells were minimal. At the concentrations tested, PUGNAc was non-toxic and had no affect on the growth rate of any of the cell lines examined, Interestingly, we demonstrated that an increase in O-GlcNAc levels on the transcription factor Sp1 resulted in a reciprocal decrease in its level of phosphorylation, supporting the hypothesis that O-GlcNAc competes with phosphate on some proteins, These studies demonstrate that PUGNAc is an effective inhibitor of O-GlcNAc turnover within cells and can be used to selectively alter the extent of O-GlcNAc on cellular proteins.	SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048666] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48666] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; DONG DLY, 1994, J BIOL CHEM, V269, P19321; FELIN M, 1994, J CELL BIOCHEM, V56, P527, DOI 10.1002/jcb.240560413; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; Haltiwanger RS, 1997, BIOCHEM BIOPH RES CO, V231, P237, DOI 10.1006/bbrc.1997.6110; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lubas WA, 1997, J BIOL CHEM, V272, P9316; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; Shaw P, 1996, ONCOGENE, V12, P921; SNOW DM, 1996, MOL BIOL CELL, V6, pA357; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WICE BM, 1985, J BIOL CHEM, V260, P139	29	230	255	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3611	3617		10.1074/jbc.273.6.3611	http://dx.doi.org/10.1074/jbc.273.6.3611			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452489	hybrid			2022-12-27	WOS:000071822300074
J	Marcu, MG; Zhang, L; Elzagallaai, A; Trifaro, JM				Marcu, MG; Zhang, L; Elzagallaai, A; Trifaro, JM			Localization by segmental deletion analysis and functional characterization of a third actin-binding site in domain 5 of scinderin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN CELL SCINDERIN; FILAMENT-SEVERING PROTEIN; BOVINE ADRENAL-MEDULLA; PERMEABILIZED PLATELETS; RECOMBINANT SCINDERIN; PLASMA GELSOLIN; CALCIUM; EXPRESSION; PURIFICATION; EXOCYTOSIS	Scinderin is a Ca2+-dependent actin filament severing protein present in a variety of secretory cells. Previous work suggests that scinderin-evoked cortical F-actin disassembly is required for secretion because local disassembly of cortical cytoskeleton allows secretory vesicle exocytosis (Vitale, M. L., Rodriguez Del Castillo, A., Tchakarov, L., and Trifaro, J.-M. (1991) J. Cell Biol. 113, 1057-1067). Scinderin has six domains each containing three internal sequence motifs, two actin, and two phosphatidylinositol disphosphate-binding sites in domains 1 and 2. In this paper we report the presence of another actin-binding site at the NH2-terminal of domain 5 (Sc511-518). This site binds actin in a Ca2+-independent manner and a recombinant fragment (Sc5-6 or Sc502-715) containing this site binds to actin-DNase-I-Sepharose 4B beads, co-sediments with actin and is able to nucleate actin assembly. Recombinant Sc(L)5-6, a fusion protein devoid of the actin-binding site (Sc519-715), did not exhibit these properties, Moreover, Sc-ABP(3), a peptide constructed with sequence (RLFQVRRNLASIT) identical to Sc511-523 blocked the binding of Sc5-6 to actin. Sc5-6 and Sc-ABP(3) also prevented the actin severing activity of recombinant full-length scinderin (r-Sc) and inhibited the potentiation by r-Sc of Ca2+-evoked release of serotonin from permeabilized platelets. On the other hand, Sc(L)5-6 failed to block the effect of r-Sc on platelet serotonin release. Sc1-4,6, a construct devoid of domain 5, was able to sever but unable to nucleate actin, indicating that an actin nucleation site of scinderin was in domain 5. The results suggest that scinderin, in addition to binding actin on sites present in domains 1 and 2, must bind actin on a third site in domain 5 to sever and nucleate actin effectively.	Univ Ottawa, Fac Med, Dept Pharmacol, Secretory Proc Res Program, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Trifaro, JM (corresponding author), Univ Ottawa, Fac Med, Dept Pharmacol, Secretory Proc Res Program, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.							ASHINO N, 1987, J BIOCHEM-TOKYO, V101, P609, DOI 10.1093/jb/101.3.609; BADER MF, 1986, J CELL BIOL, V102, P643; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; DELCASTILLO AR, 1990, EMBO J, V9, P43, DOI 10.1002/j.1460-2075.1990.tb08078.x; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; EDMONDS CG, 1990, METHOD ENZYMOL, V193, P412, DOI 10.1016/0076-6879(90)93430-S; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FECHHEIMER M, 1984, J BIOL CHEM, V259, P4514; HASLAM RJ, 1984, BIOCHEM J, V222, P351, DOI 10.1042/bj2220351; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; LAPETINA EG, 1985, J BIOL CHEM, V260, P7078; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MAEKAWA S, 1990, J BIOL CHEM, V265, P10940; Marcu MG, 1996, BLOOD, V87, P20; MARCU MG, 1994, MOL CELL BIOCHEM, V141, P153, DOI 10.1007/BF00926179; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NAKAMURA S, 1994, J BIOL CHEM, V269, P5890; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; SAKURAI T, 1990, NEUROSCIENCE, V38, P743, DOI 10.1016/0306-4522(90)90067-E; SAKURAI T, 1991, J BIOL CHEM, V266, P15979; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TCHAKAROV L, 1990, FEBS LETT, V268, P209, DOI 10.1016/0014-5793(90)81010-L; TRIFARO JM, 1985, CAN J BIOCHEM CELL B, V63, P661, DOI 10.1139/o85-084; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; TRIFARO JM, 1995, PHARM SCI PERSPECTIV, P282; TRIFARO JM, 1989, J CELL BIOL, V109, P274; VanTroys M, 1996, FEBS LETT, V397, P191, DOI 10.1016/S0014-5793(96)01086-1; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YU FX, 1991, J BIOL CHEM, V266, P19269; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	38	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3661	3668		10.1074/jbc.273.6.3661	http://dx.doi.org/10.1074/jbc.273.6.3661			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452496	hybrid			2022-12-27	WOS:000071822300081
J	Sutherland, C; Waltner-Law, M; Gnudi, L; Kahn, BB; Granner, DK				Sutherland, C; Waltner-Law, M; Gnudi, L; Kahn, BB; Granner, DK			Activation of the Ras mitogen-activated protein kinase ribosomal protein kinase pathway is not required for the repression of phosphoenolpyruvate carboxykinase gene transcription by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; DEPENDENT ACTIVATION; EXPRESSION; CAMP; PHOSPHORYLATION; CONVERGENCE; INHIBITION; SEQUENCE; CASCADE	Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the first committed step in hepatic gluconeogenesis. Glucagon and glucocorticoids stimulate PEPCK gene transcription, whereas insulin has a dominant inhibitory effect. We have shown that inhibitors of 1-phosphatidylinositol 3-kinase (PI 3-kinase) block this action of insulin, In contrast, three distinct agents, all of which prevent activation of p42/p44 mitogen-activated protein (MAP) kinase, have no effect on the regulation of PEPCK transcription by insulin. However, a subsequent report has suggested that this pathway is involved in the inhibition of cAMP induced PEPCK gene transcription by insulin, To address these conflicting data, we re-examined the Ras MAP kinase pathway, not only with respect to regulation of PEPCK gene transcription, but also for regulation of PI 3-kinase and p42/p44 MAP kinase, Overexpression of constitutively active Ras (V61) (or Raf-1 (RafCAAX)) partially represses PEPCK transcription in hepatoma cells. However, an inhibitor of MAP kinase kinase blocks this action of RafCAAX but has no effect on regulation of PEPCK gene transcription by insulin. Second, the action of a dominant negative Ras (N17Ras) on PEPCK gene transcription correlates more closely with the inhibition of PI 3-kinase than with the inhibition of p42/p44 MAP kinase. Third, insulin cannot activate p42/p44 MAP kinase in the presence of cAMP even though cAMP-induced PEPCK gene transcription is inhibited by insulin. This data confirms that the Pas MAP kinase pathway is not required for the regulation of PEPCK gene transcription by insulin and demonstrates the importance of employing multiple techniques when investigating the function of signaling pathways.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Diabet Unit, Boston, MA 02215 USA	Vanderbilt University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 707 Light Hall, Nashville, TN 37232 USA.			Sutherland, Calum/0000-0003-4398-7434; gnudi, luigi/0000-0002-6353-630X	NIDDK NIH HHS [R01 DK043051, DK20593, DK43051, DK35107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, R01DK043051, R37DK043051, R01DK035107, R37DK035107, P60DK020593] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHU DTW, 1986, J BIOL CHEM, V261, P6848; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Gines P, 1996, HEPATOLOGY, V23, P1167; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; Sutherland C, 1996, PHILOS T ROY SOC B, V351, P191, DOI 10.1098/rstb.1996.0016; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TEBBEY PW, 1995, BIOCHEM BIOPH RES CO, V215, P1006, DOI 10.1006/bbrc.1995.2564; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	36	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3198	3204		10.1074/jbc.273.6.3198	http://dx.doi.org/10.1074/jbc.273.6.3198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452431	hybrid			2022-12-27	WOS:000071822300016
J	Coda, L; Salcini, AE; Confalonieri, S; Pelicci, G; Sorkina, T; Sorkin, A; Pelicci, PG; Di Fiore, PP				Coda, L; Salcini, AE; Confalonieri, S; Pelicci, G; Sorkina, T; Sorkin, A; Pelicci, PG; Di Fiore, PP			Eps15R is a tyrosine kinase substrate with characteristics of a docking protein possibly involved in coated pits-mediated internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ASYMMETRIC LOCALIZATION; TRANSFORMING ACTIVITY; ACTIN CYTOSKELETON; BINDING DOMAIN; SH3 DOMAIN; GENE; NUMB; DROSOPHILA; CONFERS	eps15R was identified because of its relatedness to eps15, a gene encoding a tyrosine kinase substrate bearing a novel protein-protein interaction domain, called EH, In this paper, we report a biochemical characterization of the eps15R gene product(s). In NIH-3T3 cells, three proteins of 125, 108, and 76 kDa were specifically recognized by anti-eps15R sera, The 125-kDa species is a bona fide product of the eps15R gene, whereas p108 and p76 are most likely products of alternative splicing events. Eps15R protein(s) are tyrosine-phosphorylated following epidermal growth factor receptor activation in NIH-3T3 cells overexpressing the receptor, even at low levels of receptor occupancy, thus behaving as physiological substrates, A role for eps15R in clathrin-mediated endocytosis is suggested by its localization in plasma membrane-coated pits and in vivo association to the coated pits' adapter protein AP-2. Finally, we demonstrate that a sizable fraction of eps15R exists in the cell as a complex with eps15 and that its EH domains exhibit binding specificities that are partially distinct from those of eps15, We propose that eps15 and eps15R are multifunctional binding proteins that serve pleiotropic functions within the cell.	Ist Europeo Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Parma, Ist Patol Speciale Med, I-43100 Parma, Italy; Univ Bari, Ist Microbiol, I-70124 Bari, Italy	IRCCS European Institute of Oncology (IEO); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Parma; Universita degli Studi di Bari Aldo Moro	Di Fiore, PP (corresponding author), Ist Europeo Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Confalonieri, Stefano/AAQ-6786-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Pelicci, Giuliana/AAA-8921-2022; Di Fiore, Pier Paolo/K-2130-2012; Salcini, Anna Elisabetta/G-4472-2017	Confalonieri, Stefano/0000-0001-6886-9851; Pelicci, Giuliana/0000-0003-0986-8255; Di Fiore, Pier Paolo/0000-0002-2252-0950; Sorkin, Alexander/0000-0002-4446-1920; Salcini, Anna Elisabetta/0000-0001-5828-2512	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVANTAGGIATO V, 1995, ONCOGENE, V11, P1191; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Iannolo G, 1997, CANCER RES, V57, P240; Matoskova B, 1996, ONCOGENE, V12, P2679; Matoskova B, 1996, ONCOGENE, V12, P2563; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SPANA EP, 1995, DEVELOPMENT, V121, P3489; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WONG WT, 1994, ONCOGENE, V9, P1591; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	34	70	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3003	3012		10.1074/jbc.273.5.3003	http://dx.doi.org/10.1074/jbc.273.5.3003			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446614	hybrid			2022-12-27	WOS:000071736600069
J	Fernandes, ND; Kolattukudy, PE				Fernandes, ND; Kolattukudy, PE			A newly identified methyl-branched chain fatty acid synthesizing enzyme from Mycobacterium tuberculosis var. bovis BCG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; MULTIFUNCTIONAL ENZYME; SYNTHASE; PURIFICATION; GENE; BIOSYNTHESIS; PROTEINS; CLONING	Mycobacterium bovis BCG produces a variety of methyl-branched fatty acids. They include C-28 to C-32 mycocerosic acids esterified to phthiocerol and phenolphthiocerol and the shorter (C-22 to C-26) mycocerosic acids esterified to phthiocerol. A mycocerosic acid synthase gene-disrupted mutant was still able to produce the shorter mycocerosic acids. The enzyme short chain mycocerosic acid synthase (SMAS), that catalyzes the synthesis of such acids, was purified using anion exchange and red-agarose chromatography. Gel filtration showed the native enzyme to be a 537-kDa protein. Since SDS-polyacrylamide gel electrophoresis of the purified enzyme showed a 280-, 170-, and 100-kDa protein and they cross-reacted with antibodies prepared against the 280- or 100-kDa protein, this enzyme is composed of the three subunits or two 280-kDa monomers with an unusual susceptibility to a proteolytic nick. SMAS utilizes methylmalonyl-CoA with C-12 to C-20 acyl CoA as primers and with either NADH or NADPH as the reductant to synthesize the short mycocerosic acids. The K-m values for NADH and NADPH were 93 and 90 mu M, respectively. Antibodies raised against either the 280- or 100-kDa protein inhibited the incorporation of methylmalonyl-CoA into fatty acids by SMAS, The enzyme is not immunologically closely related to mycocerosic acid synthase or fatty acid synthase.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Med Biochem, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Kolattukudy, PE (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA.		kolattukudy, pappachan e/A-1350-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035272] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35272] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1984, FATTY ACID METABOLIS, P29; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; BESRA GS, 1992, BIOCHEMISTRY-US, V31, P9832, DOI 10.1021/bi00155a040; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BUCKNER JS, 1976, BIOCHEMISTRY-US, V15, P1948, DOI 10.1021/bi00654a024; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Fernandes ND, 1996, GENE, V170, P95, DOI 10.1016/0378-1119(95)00842-X; Fernandes ND, 1997, J BACTERIOL, V179, P7538, DOI 10.1128/jb.179.23.7538-7543.1997; HARLOW E, 1989, ANTIBODIES LAB MANUA, P103; Hart CA, 1996, J MED MICROBIOL, V44, P1, DOI 10.1099/00222615-44-1-1; HUNTER SW, 1983, J BIOL CHEM, V258, P481; KIKUCHI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P318, DOI 10.1016/0003-9861(92)90524-Z; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; NAJIMA H, 1996, WHO REPORT, P27; PETERSON DO, 1977, J BIOL CHEM, V252, P5735; RAFIDINARIVO E, 1982, BIOCHIM BIOPHYS ACTA, V711, P266, DOI 10.1016/0005-2760(82)90035-2; RAINWATER DL, 1985, J BIOL CHEM, V260, P616; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WHEELER PR, 1990, J GEN MICROBIOL, V136, P211, DOI 10.1099/00221287-136-1-211	24	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2823	2828		10.1074/jbc.273.5.2823	http://dx.doi.org/10.1074/jbc.273.5.2823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446591	hybrid			2022-12-27	WOS:000071736600046
J	Stauffer, DR; Chukwumezie, BN; Wilberding, JA; Rosen, ED; Castellino, FJ				Stauffer, DR; Chukwumezie, BN; Wilberding, JA; Rosen, ED; Castellino, FJ			Characterization of transcriptional regulatory elements in the promoter region of the murine blood coagulation factor VII gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-IX; ENHANCER BINDING-PROTEIN; HEMOPHILIA-B LEYDEN; LIVER-SPECIFIC EXPRESSION; NUCLEAR FACTOR-III; HUMAN FACTOR-X; TISSUE FACTOR; NUCLEOTIDE-SEQUENCE; FUNCTIONAL-CHARACTERIZATION; CATALYTIC DOMAIN	To identify the 5' sequences of the murine coagulation factor VII (fVII) gene that resulted in its efficient transcription, a variety of 5'-flanking sequences up to 7 kilobase pairs upstream of the translation ATG initiation codon were fused to the reporter gene, bacterial chloramphenicol acetyltransferase, and relative expression levels of this gene in mouse Hepa 1-6 cells were determined. It was found that the 5' region extending approximately 85 base pairs (bp) upstream of the transcriptional initiation site served as the minimal DNA region that provided full relative promoter activity for chloramphenicol acetyltransferase expression, This region of the gene also contains consensus sequences for liver-enriched transcription factors, C/EBP beta and HNF4, as well as for the ubiquitous protein factors, AP1, H4TF1, NF1, and Spl, In vitro DNase I footprinting of the 200-bp proximal region of the promoter with a murine Hepa 1-6 cell nuclear extract revealed a clear footprint of a region corresponding to -80 to -28 bp of the murine fVII gene, suggesting that liver factors interact with this region of the DNA. Competitive gel shift and supershift assays with different synthetic oligonucleotide probes demonstrate that proteins contained in the nuclear extract, identified as C/EBP beta, H4TF1, and HNF4, bind to a region of the murine fVII DNA from 85 to 32 bp upstream of the transcription start site, Purified Spl also interacts with this region of the DNA at a site that substantially overlaps, but is not identical to, the H4TF1 binding locus, Binding of Spl to the mouse DNA was not observed with the nuclear extract as the source of the transcription factors, suggesting that Spl is likely displaced from its binding site by H4TF1 in the crude extract. In vivo dimethyl sulfate footprint analysis confirmed the existence of these sites and additionally revealed two other binding regions slightly upstream of the CCAAT/enhancer-binding protein (C/EBP) binding locus that are homologous to NF1 binding sequences, The data demonstrate that appropriate transcription factor binding sites exist in the proximal promoter region of the murine fVII gene that are consistent with its strong liver-based expression in a highly regulated manner.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Ctr Transgene Res, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	castellino.1@nd.edu			NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, BIOCHEMISTRY-US, V31, P1928, DOI 10.1021/bi00122a005; Arbini AA, 1997, BLOOD, V89, P176, DOI 10.1182/blood.V89.1.176.176_176_182; Arenzana N, 1996, J IMMUNOL, V156, P168; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bernardi F, 1996, HUM MUTAT, V8, P108; BERNARDI F, 1994, HUM MOL GENET, V3, P1175, DOI 10.1093/hmg/3.7.1175; Bhardwaj D, 1996, J BIOL CHEM, V271, P30685, DOI 10.1074/jbc.271.48.30685; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOM VJJ, 1991, THROMB HAEMOSTASIS, V66, P283; BROZE GJ, 1987, P NATL ACAD SCI USA, V84, P1886, DOI 10.1073/pnas.84.7.1886; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAING S, 1994, BLOOD, V83, P3524; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; ESCOFFRE M, 1995, BRIT J HAEMATOL, V91, P739, DOI 10.1111/j.1365-2141.1995.tb05378.x; FEO S, 1995, MOL CELL BIOL, V15, P5991; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; HUANG MN, 1992, J BIOL CHEM, V267, P15440; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; Idusogie E, 1996, THROMB HAEMOSTASIS, V76, P957; ISSHIKI H, 1991, NEW BIOL, V3, P63; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Junker R, 1997, ARTERIOSCL THROM VAS, V17, P1539, DOI 10.1161/01.ATV.17.8.1539; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; KAZAMA Y, 1992, BLOOD COAGUL FIBRIN, V3, P697, DOI 10.1097/00001721-199212000-00001; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LANE A, 1992, ATHEROSCLEROSIS, V94, P43, DOI 10.1016/0021-9150(92)90186-K; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; MADHUSUDHAN KT, 1995, BIOCHEMISTRY-US, V34, P1288, DOI 10.1021/bi00004a023; MARIANI G, 1983, HAEMOSTASIS, V13, P169; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; Maxam A M, 1980, Methods Enzymol, V65, P499; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MIAO CH, 1992, J BIOL CHEM, V267, P7395; Miao CH, 1996, J BIOL CHEM, V271, P9587, DOI 10.1074/jbc.271.16.9587; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; Patthy L, 1996, MATRIX BIOL, V15, P301, DOI 10.1016/S0945-053X(96)90131-6; PICKETTS DJ, 1994, BLOOD, V84, P2992; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REITSMA PH, 1989, BLOOD, V73, P743; Rosen ED, 1997, NATURE, V390, P290, DOI 10.1038/36862; RUF W, 1991, J BIOL CHEM, V266, P15719; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Singh M, 1996, P NATL ACAD SCI USA, V93, P4392, DOI 10.1073/pnas.93.9.4392; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TANABE S, 1991, J BIOCHEM-TOKYO, V109, P924, DOI 10.1093/oxfordjournals.jbchem.a123481; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TRONCHE F, 1991, J MOL BIOL, V222, P31, DOI 10.1016/0022-2836(91)90735-O; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; ZIMMERMANN R, 1979, BLUT, V38, P119, DOI 10.1007/BF01007952	79	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2277	2287		10.1074/jbc.273.4.2277	http://dx.doi.org/10.1074/jbc.273.4.2277			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442072	hybrid			2022-12-27	WOS:000071595200061
J	Boumans, H; Grivell, LA; Berden, JA				Boumans, H; Grivell, LA; Berden, JA			The respiratory chain in yeast behaves as a single functional unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDOREDUCTASE; MITOCHONDRIAL ELECTRON-TRANSPORT; 17-KDA SUBUNIT-VI; SACCHAROMYCES-CEREVISIAE; LATERAL DIFFUSION; PLASTOQUINONE COMPARTMENTATION; PARACOCCUS-DENITRIFICANS; REACTION CENTERS; BC1 COMPLEX; UBIQUINOL	Inhibitor titrations using antimycin have been used to study the pool behavior of ubiquinone and cytochrome c in the respiratory chain of the yeast Saccharomyces cerevisiae, If present in a homogeneous pool, these carriers should be able to diffuse freely through or along the membrane respectively and accept and subsequently donate electrons to an infinite number of the respective respiratory complex, However, we show that under physiological conditions neither ubiquinone nor cyto chrome c exhibits pool behavior, implying that the respiratory chain in yeast is one functional unit, Pool behavior can be introduced for both small carriers by adding chaotropic agents to the reaction medium. We conclude that these agents disrupt the interaction between the respiratory complexes, thereby causing them to become randomly arranged in the membrane, In such a situation, ubiquinone and cytochrome c become mobile carriers, shuttling between the large respiratory complexes. Furthermore, we conclude from the respiratory activities found for different substrates that the respiratory units in yeast vary in composition with respect to the ubiquinone reducing enzyme, All units contain the cytochrome chain, supplemented with either succinate dehydrogenase or the internal or the external NADH dehydrogenase. This implies that when only one substrate is available, only a certain fraction of the cytochrome chain is used in respiration, The molecular organization of the respiratory chain in yeast is compared with that of higher eukaryotes and to the electron transfer systems of photosynthetic membranes, Differences between the organization of the respiratory chain of yeast and that of higher eukaryotes are discussed in terms of the ability of yeast to radically alter its metabolism in response to change of the available carbon source.	Univ Amsterdam, EC Slater Inst, Bioctr, Dept Mol Cell Biol, NL-1018 TV Amsterdam, Netherlands; Univ Amsterdam, Bioctr, Dept Mol Cell Biol, Mol Biol Sect, NL-1018 TV Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam	Berden, JA (corresponding author), Univ Amsterdam, EC Slater Inst, Bioctr, Dept Mol Cell Biol, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.							BEATTIE DS, 1992, ARCH BIOCHEM BIOPHYS, V292, P499, DOI 10.1016/0003-9861(92)90022-O; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; Bonnefoy N, 1996, MOL GEN GENET, V251, P204; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; Bruel C, 1996, J BIOENERG BIOMEMBR, V28, P59; BRYLA J, 1969, BIOCHIM BIOPHYS ACTA, V189, P317; CHAZOTTE B, 1989, J BIOL CHEM, V264, P4978; DEGIER JWL, 1994, MOL MICROBIOL, V13, P183, DOI 10.1111/j.1365-2958.1994.tb00414.x; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GUPTE S, 1984, P NATL ACAD SCI-BIOL, V81, P2606, DOI 10.1073/pnas.81.9.2606; GUPTE SS, 1988, J BIOL CHEM, V263, P5241; GUPTE SS, 1988, J BIOL CHEM, V263, P5248; HEMRIKA W, 1993, EUR J BIOCHEM, V215, P601, DOI 10.1111/j.1432-1033.1993.tb18071.x; HERON C, 1978, BIOCHEM J, V174, P791, DOI 10.1042/bj1740791; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; JOLIOT P, 1992, BIOCHIM BIOPHYS ACTA, V1101, P1, DOI 10.1016/0167-4838(92)90460-U; JOLIOT P, 1993, BIOCHIM BIOPHYS ACTA, V1141, P151, DOI 10.1016/0005-2728(93)90039-I; JOLIOT P, 1989, BIOCHIM BIOPHYS ACTA, V975, P336, DOI 10.1016/S0005-2728(89)80341-X; KROGER A, 1973, EUR J BIOCHEM, V39, P313, DOI 10.1111/j.1432-1033.1973.tb03129.x; LAVERGNE J, 1992, BIOCHIM BIOPHYS ACTA, V1101, P13, DOI 10.1016/0167-4838(92)90461-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; PRIETO S, 1992, EUR J BIOCHEM, V208, P487, DOI 10.1111/j.1432-1033.1992.tb17212.x; RAGAN CI, 1978, BIOCHEM J, V174, P783, DOI 10.1042/bj1740783; RAGAN CI, 1985, BIOCHIM BIOPHYS ACTA, V811, P13; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; ROSEN D, 1980, BIOCHEMISTRY-US, V19, P5687, DOI 10.1021/bi00566a004; SCHNEIDER H, 1980, J BIOL CHEM, V255, P3748; SCHNEIDER H, 1982, FUNCTION QUINONES EN, P125; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; SONE N, 1987, J BIOL CHEM, V262, P15386; WALLACE PG, 1994, ANAL BIOCHEM, V222, P404, DOI 10.1006/abio.1994.1509	37	129	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4872	4877		10.1074/jbc.273.9.4872	http://dx.doi.org/10.1074/jbc.273.9.4872			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478928	hybrid			2022-12-27	WOS:000072310400012
J	Schmidt, C; Pommerenke, H; Durr, F; Nebe, B; Rychly, J				Schmidt, C; Pommerenke, H; Durr, F; Nebe, B; Rychly, J			Mechanical stressing of integrin receptors induces enhanced tyrosine phosphorylation of cytoskeletally anchored proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; GENE-EXPRESSION; KINASE; CALCIUM; STIMULATION; ACTIVATION; INDUCTION; PROLIFERATION	Physical forces play a fundamental role in the regulation of cell function in many tissues, but little is known about how cells are able to sense mechanical loads and realize signal transduction, Adhesion receptors like integrins are candidates for mechanotransducers. We used a magnetic drag force device to apply forces on integrin receptors in an osteoblastic cell line and studied the effect on tyrosine phosphorylation as a biochemical event in signal transduction. Mechanical stressing of both the beta 1 and the alpha 2 integrin subunit induced an enhanced tyrosine phosphorylation of proteins compared with integrin clustering. Application of cyclic forces with a frequency of 1 Hz was more effective than a continuous stress. Using Triton X-100 for cell extraction, we found that tyrosine-phosphorylated proteins became physically anchored to the cytoskeleton due to mechanical integrin loading. This cytoskeletal linkage was dependent on intracellular calcium, To see if mechanical integrin stressing induced further downstream signaling, we analyzed the activation of mitogen-activated protein (MAP) kinases and found an increased phosphorylation of MAP kinases due to mechanical stress. We conclude that integrins sense physical forces that control gene expression by activation of the MAP kinase pathway. The cytoskeleton may play a key role in the physical anchorage of activated signaling molecules, which enables the switch of physical forces to biochemical signaling events.	Univ Rostock, Innere Med Klin, Dept Internal Med, D-18055 Rostock, Germany	University of Rostock	Rychly, J (corresponding author), Univ Rostock, Innere Med Klin, Dept Internal Med, Ernst Heydemann Str 6, D-18055 Rostock, Germany.	joachim.rychly@med.uni-rostock.de	Nebe, Barbara -/C-3577-2015	Nebe, Barbara -/0000-0003-2662-0905; Schmidt, Christian/0000-0002-1260-9732				BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HASEGAWA S, 1985, CALCIFIED TISSUE INT, V37, P431, DOI 10.1007/BF02553714; HERT J, 1971, Folia Morphologica (Prague), V19, P290; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KORNBERG L, 1992, J BIOL CHEM, V267, P23499; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LANYON LE, 1984, CALCIFIED TISSUE INT, V36, pS56, DOI 10.1007/BF02406134; LANYON LE, 1984, J BIOMECH, V17, P897, DOI 10.1016/0021-9290(84)90003-4; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NEBE B, 1995, EXP CELL RES, V218, P479, DOI 10.1006/excr.1995.1181; Nebe B, 1996, EXP CELL RES, V229, P100, DOI 10.1006/excr.1996.0348; NEIDLINGERWILKE C, 1994, J ORTHOP RES, V12, P70, DOI 10.1002/jor.1100120109; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pommerenke H, 1996, EUR J CELL BIOL, V70, P157; RAABCULLEN DM, 1994, J BONE MINER RES, V9, P1143; RUBIN CT, 1995, J BONE MINER RES, V10, P488; SANDY JR, 1989, BONE MINER, V5, P155, DOI 10.1016/0169-6009(89)90093-7; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; WANG DL, 1995, CIRC RES, V77, P294, DOI 10.1161/01.RES.77.2.294; WANG N, 1994, BIOPHYS J, V66, P2181, DOI 10.1016/S0006-3495(94)81014-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WIRTZ HRW, 1990, SCIENCE, V250, P1266, DOI 10.1126/science.2173861	42	169	173	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5081	5085		10.1074/jbc.273.9.5081	http://dx.doi.org/10.1074/jbc.273.9.5081			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478959	hybrid			2022-12-27	WOS:000072310400043
J	McLaurin, J; Franklin, T; Fraser, PE; Chakrabartty, A				McLaurin, J; Franklin, T; Fraser, PE; Chakrabartty, A			Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; FIBRIL FORMATION; DISEASE; PROTEIN; MEMBRANES; CELLS; NEUROTOXICITY; CONFORMATION; PATHOGENESIS; SUBSTITUTION	Alzheimer's disease is characterized pathologically by the presence of neurofibrillary tangles and amyloid plaques. The principal component of the plaque is the beta-amyloid peptide (A beta), a 39-43-resiure peptide. The conformational change required for the conversion of soluble peptide into amyloid fabrils is modulated by pH, A beta concentration, addition of kinetic and thermodynamic enhancers, and alterations in the primary sequence of A beta. We report here the ability of gangliosides to induce an alpha-helical structure in A beta and thereby diminish fibrillogenesis, Circular dichroism and a fluorescence dye release assay data indicate that gangliosides interact with and induce alpha-helix formation in A beta. We find that the sialic acid moiety of gangliosides is necessary for the induction of alpha-helical structure. Differences in the amount and the position of the sialic acid on the carbohydrate backbone also affect the conformational switch. The A beta-ganglioside interaction at pH 7.0, monitored by CD, is stable over time and resistant to high concentrations of NaCl. The induction of alpha-helical structure is greater with A beta 1-40 than A beta 1-42. The ability of gangliosides to sequester A beta from fibril formation was also evaluated by electron microscopy.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto	Chakrabartty, A (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Chakrabartty, Avi/0000-0001-7002-8381				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Avdulov NA, 1997, J NEUROCHEM, V68, P2086; Barlett G.R., 1959, J BIOL CHEM, V234, P466; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Blanc EM, 1997, J NEUROCHEM, V68, P1870; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P883; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KOHN LD, 1980, STRUCTURE FUNCTION G, P333; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MAESTRE GE, 1992, BRAIN RES, V599, P64, DOI 10.1016/0006-8993(92)90853-2; MAESTRE GE, 1993, BRAIN RES, V621, P145, DOI 10.1016/0006-8993(93)90311-A; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; MCLEAN LR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P1, DOI 10.1016/0005-2736(90)90201-X; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757; RAHMANN H, 1992, NEUROCHEM INT, V20, P323, DOI 10.1016/0197-0186(92)90047-U; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; SARTI P, 1990, BIOCHEM J, V267, P413, DOI 10.1042/bj2670413; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SNOW AD, 1988, AM J PATHOL, V133, P456; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SOTO C, 1995, NEUROSCI LETT, V186, P115, DOI 10.1016/0304-3940(95)11299-C; TATE B, 1992, B CLIN NEUROSCI, V56, P131; TERRY RD, 1994, PROG BRAIN RES, V101, P383; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; WEIGEL J, 1990, ACTA NEUROPATHOL, V81, P116; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YAMAGUCHI H, 1989, AM J PATHOL, V135, P593; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062	49	153	156	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4506	4515		10.1074/jbc.273.8.4506	http://dx.doi.org/10.1074/jbc.273.8.4506			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468505	hybrid			2022-12-27	WOS:000072115000033
J	Nakamura, T; Jamieson, GA; Okuma, M; Kambayashi, J; Tandon, NN				Nakamura, T; Jamieson, GA; Okuma, M; Kambayashi, J; Tandon, NN			Platelet adhesion to native type I collagen fibrils - Role of GPVI in divalent cation-dependent and -independent adhesion and thromboxane A(2) generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACKING GLYCOPROTEIN-IV; INDUCED AGGREGATION; DEFICIENCY; BLOOD; CD36; PATIENT; SUBENDOTHELIUM; IDENTIFICATION; INHIBITION; RECEPTOR	Three glycoproteins (GPs), namely GPIa-IIa, GPVI, and GPIV, have been recently implicated in platelet-collagen adhesive interactions, We have employed antibodies to these GPs to investigate further their role in platelet adhesion to immobilized monomeric and polymeric fibrillar collagen under static conditions in the presence and the absence of Mg2+, In the presence of Mg2+, each antibody inhibited platelet adhesion to fibrillar collagen from 70 to 85%, especially during the early phase (<15 min), but the inhibitory effects diminished dramatically to 25% or less by 60 min, Combination of anti-GPVI with anti-GPIa-IIa antibodies completely inhibited platelet adhesion at 60 min, Anti-GPIV and anti-GPIa-IIa or anti-GPVI antibodies in combinations were more effective in inhibiting adhesion than was anti-GPIa-IIa or anti-GPVI alone, In the absence of Mg2+, anti-GPVI completely inhibited adhesion at 60 min, while anti-GPIV antibody inhibited adhesion by about 50% and minimal effects were seen with anti-GPIa-IIa, suggesting that GPIa-IIa does not play a significant role in the divalent cation-independent platelet adhesion to immobilized fibrillar collagen, Under either divalent cation-dependent or -independent conditions, platelets adhered to fibrillar collagen were able to secrete contents of both alpha-granules and dense granules and generate thromboxane A(2) (TXA(2)), but platelets adhering to acid soluble monomeric collagen neither secreted their granular contents nor generated TXA(2). Although anti-GPVI antibodies were not able to inhibit Mg2+-dependent adhesion, they completely inhibited TXA(2) generation under both divalent cation-dependent and -independent conditions. With the other antibodies, TXA(2) generation corresponded with the amount of adhesion observed, These results suggest that GPVI is directly associated with the TXA(2) generating system during platelet collagen interaction.	Otsuka Amer Pharmaceut Inc, Maryland Res Labs, Rockville, MD 20850 USA; Amer Red Cross, Rockville, MD 20855 USA; Takashima Gen Hosp, Shiga 52011, Japan	American Red Cross	Nakamura, T (corresponding author), Otsuka Amer Pharmaceut Inc, Maryland Res Labs, 9900 Med Ctr Dr, Rockville, MD 20850 USA.							ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; BRASS LF, 1974, J CLIN INVEST, V54, P1480, DOI 10.1172/JCI107896; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; COLLER BS, 1989, BLOOD, V74, P182; DECKMYN H, 1990, THROMB HAEMOSTASIS, V64, P74; DIAZRICART M, 1993, BLOOD, V82, P491; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; JAFFE R, 1974, J CLIN INVEST, V53, P875, DOI 10.1172/JCI107628; KEHREL B, 1988, BLOOD, V71, P1074; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MCKEOWN L, 1994, BLOOD, V83, P2866, DOI 10.1182/blood.V83.10.2866.2866; MOROI M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P1, DOI 10.1016/0167-4889(92)90092-P; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON L F, 1991, Biochemical Society Transactions, V19, p439S; MUGGLI R, 1973, Thrombosis Research, V3, P715, DOI 10.1016/0049-3848(73)90018-2; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; PACKHAM MA, 1984, THROMB HAEMOSTASIS, V51, P140; PETRONI A, 1995, THROMB RES, V78, P151, DOI 10.1016/0049-3848(95)00043-7; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SAELMAN EUM, 1994, BLOOD, V83, P3240, DOI 10.1182/blood.V83.11.3240.bloodjournal83113240; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SANTORO SA, 1988, MOL BASIS PLATELET A, P291; SUGIYAMA T, 1987, BLOOD, V69, P1712; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; YAMAMOTO N, 1990, BLOOD, V76, P1698; ZIJENAH LS, 1990, BIOCHEM J, V268, P481, DOI 10.1042/bj2680481; ZUCKER WH, 1974, AM J PATHOL, V77, P255	31	70	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4338	4344		10.1074/jbc.273.8.4338	http://dx.doi.org/10.1074/jbc.273.8.4338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468482	hybrid			2022-12-27	WOS:000072115000010
J	Ulrix, W; Swinnen, JV; Heyns, W; Verhoeven, G				Ulrix, W; Swinnen, JV; Heyns, W; Verhoeven, G			Identification of the phosphatidic acid phosphatase type 2a isozyme as an androgen-regulated gene in the human prostatic adenocarcinoma cell line LNCaP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; MESSENGER-RNA; CANCER CELLS; ENDOPLASMIC-RETICULUM; PHOSPHOHYDROLASE; RECEPTOR; PROTEIN; DIFFERENTIATION; PROLIFERATION; EXPRESSION	Differential display wars used to identify novel and androgen-regulated genes in the human prostatic adenocarcinoma cell line LNCaP. A 322-base pair cDNA fragment that, was consistently induced by the synthetic androgen R1881 revealed 100% homology with the human phosphatidic acid phosphatase type 2a isozyme very recently reported by Kai Et al; (PAP-2a; Kai., Wa., Wada, I., Imai, S.-i., Sakane, F., and Kanoh, H. (1997) J. Biol. Chem. 272, 24572-24578). The fragment was used to clone the corresponding cDNA from a human prostate library. The deduced amino acid sequence confirmed the identity with human PAP-2a. The inducibility of PAP-2a mRNA by androgens was confirmed by Northern blot hybridization, The effect was time-and dose-dependent Math a maximal stimulation (4-fold) after 24 h of treatment with 10(-9) M R1881. The steroid specificity of PAP-2a mRNA regulation was found to be in agreement with the aberrant ligand specificity of the mutated androgen receptor in LNCaP cells, supporting the involvement of the androgen receptor in the induction process. Furthermore, low basal levels of PAP-2a mRNA and absence of androgen inducibility were observed in the poorly differentiated and androgen receptor-negative cell lines PC-3 and DU-145. Induction of PaP-2a mRNA was not affected by the protein synthesis inhibitor cycloheximide and was accompanied by a marked increase in PAP-2 activity as measured by the conversion of phosphatidic acid into diacylglycerol in membrane fractions of LNCaP. Comparison of the expression of PAP-2a mRNA in 50 different human tissues revealed ubiquitous expression. The highest levels, however, were observed in the prostate, Since PAP-2 plays a pivotal role in the control of signal transduction by lipid mediators such as phosphatidate, lysophosphatidate, and ceramide-1-phosphate, the ability off androgens to stimulate the expression and activity of this enzyme in prostatic cells may provide an important opportunity for cross-talk between signaling pathways involving lipid mediators and androgens.	Catholic Univ Louvain, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium	KU Leuven; Universite Catholique Louvain	Verhoeven, G (corresponding author), LEGENDO, Herestr 49, B-3000 Louvain, Belgium.	guido.verhoeven@med.kuleuven.ac.be	Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barila D, 1996, J BIOL CHEM, V271, P29928, DOI 10.1074/jbc.271.47.29928; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BRINDLEY DN, 1988, PHOSPHATIDATE PHOSPH, V1, P21; CARTER HB, 1990, PROSTATE, V16, P39; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DAVIES P, 1995, J ENDOCRINOL, V131, P5; EGAWA K, 1995, FEBS LETT, V372, P74, DOI 10.1016/0014-5793(95)00957-B; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Esquenet M, 1996, PROSTATE, V28, P182, DOI 10.1002/(SICI)1097-0045(199603)28:3<182::AID-PROS5>3.0.CO;2-H; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HOER A, 1994, ARCH PHARM, V349, P653; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KAIGHN ME, 1979, INVEST UROL, V17, P16; KANOH H, 1992, J BIOL CHEM, V267, P25309; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOKONTIS J, 1994, CANCER RES, V54, P1566; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MCCONNELL JD, 1991, J ANDROL, V12, P356; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NEGRICESI P, 1994, J STEROID BIOCHEM, V51, P89, DOI 10.1016/0960-0760(94)90119-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SCHUURMANS ALG, 1988, INT J CANCER, V42, P917, DOI 10.1002/ijc.2910420622; SOZZANI S, 1992, J BIOL CHEM, V267, P20481; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; SUGIMOTO K, 1994, J STEROID BIOCHEM, V51, P167, DOI 10.1016/0960-0760(94)90090-6; SWILNNEN JV, 1997, CANCER RES, V57, P1086; SWINNEN JV, 1994, MOL CELL ENDOCRINOL, V104, P153, DOI 10.1016/0303-7207(94)90118-X; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VERHOEVEN G, 1995, INT J ANDROL, V18, P23, DOI 10.1111/j.1365-2605.1995.tb00931.x; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WILDING G, 1990, PROSTATE, V16, P15, DOI 10.1002/pros.2990160103; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	44	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4660	4665		10.1074/jbc.273.8.4660	http://dx.doi.org/10.1074/jbc.273.8.4660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468526	hybrid			2022-12-27	WOS:000072115000054
J	Saberan-Djoneidi, D; Picart, R; Escalier, D; Gelman, M; Barret, A; Tougard, C; Glowinski, J; Levi-Strauss, M				Saberan-Djoneidi, D; Picart, R; Escalier, D; Gelman, M; Barret, A; Tougard, C; Glowinski, J; Levi-Strauss, M			A 21-kDa polypeptide belonging to a new family of proteins is expressed in the Golgi apparatus of neural and germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCEPHALIC DOPAMINERGIC-NEURONS; MEMBRANE-PROTEINS; MESSENGER-RNA; GENE; RECEPTORS; SPERM; RESISTANCE; SEQUENCES; PEPTIDES; VESICLES	We have isolated a full-length murine clone corresponding to the rat neuronal p1A75 partial cDNA (Sutcliffe, J. G., Milner, R. J., Shinnick, T. M., and Bloom, F, E. (1983) Cell 33, 671-682). It encodes a 185-residue polypeptide that displays 56% identity with p19, a protein selectively expressed in the Golgi apparatus of neural cells (Saberan-Djoneidi, D., Marey-Semper, I., Picart, R., Studler, J.-M., Tougard, C., Glowinski, J., and Levi-Strauss, M. (1995) J. Biol. Chem. 270, 1888-1893). An antibody directed against the recombinant polypeptide allowed us to demonstrate the existence of the natural 21-kDa protein (p21) in brain and its prominent juxtanuclear Golgi-like localization in cultured neurons. Ultrastructural observation of cultured neurons and analysis of transfected COS cells revealed a specific labeling of the Golgi apparatus, suggesting, as for p19, the presence of a Golgi targeting signal in its primary sequence. Surprisingly, p21, which is much more strongly expressed in the olfactory epithelium than p19, is also present in the Golgi complex of spermatocytes and in the flagellar middle piece of late spermatids.	Coll France, INSERM, U114, Chaire Neuropharmacol, F-75005 Paris, France; Coll France, INSERM, U36, Grp Biol Cellule Neuroendocrine, F-75005 Paris, France; Hop Necker Enfants Malad, INSERM, U25, F-75743 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Saberan-Djoneidi, D (corresponding author), INSERM, U406, 27 Bd Jean Moulin, F-13385 Marseille 5, France.		Saberan-Djoneidi, Delara/AAD-7820-2022	Saberan-Djoneidi, Delara/0000-0002-2757-6419				BALZI E, 1994, J BIOL CHEM, V269, P2206; BRINKLEY BR, 1967, J CELL BIOL, V35, P279, DOI 10.1083/jcb.35.1.279; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHENDAYAG A, 1995, P NATL ACAD SCI USA, V92, P11039, DOI 10.1073/pnas.92.24.11039; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DENISDONINI S, 1984, NATURE, V307, P641, DOI 10.1038/307641a0; DIPORZIO U, 1980, NATURE, V288, P370, DOI 10.1038/288370a0; DIRIONG S, 1994, HUM GENET, V93, P703; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; Russell L.D., 1990, HISTOLOGICAL HISTOPA, P120; SABERANDJONEIDI D, 1995, J BIOL CHEM, V270, P1888, DOI 10.1074/jbc.270.4.1888; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TOUGARD C, 1986, AM J ANAT, V175, P161, DOI 10.1002/aja.1001750206; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALENSKY LD, 1995, MOL MED, V1, P130, DOI 10.1007/BF03401561	37	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3909	3914		10.1074/jbc.273.7.3909	http://dx.doi.org/10.1074/jbc.273.7.3909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461575	hybrid			2022-12-27	WOS:000072048400017
J	Kamitani, T; Nguyen, HP; Kito, K; Fukuda-Kamitani, T; Yeh, ETH				Kamitani, T; Nguyen, HP; Kito, K; Fukuda-Kamitani, T; Yeh, ETH			Covalent modification of PML by the sentrin family of ubiquitin-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; TRANSLOCATION; SUPPRESSOR; TRANSFORMATION; LOCALIZATION; T(15-17); GROWTH; CELLS; GENE	PML, a RING finger protein with tumor suppressor activity, has been implicated in the pathogenesis of acute promyelocytic leukemia that arises following a reciprocal chromosomal translocation that fuses the PML gene with the retinoic acid receptor alpha (RAR alpha) gene. Immunocytochemical analysis has demonstrated that PML is co-localized with a novel ubiquitin-like protein in the nuclear bodies, which could be disrupted by the PML-RAR alpha: fusion protein. The physical nature of this co-localization is unknown. Using a COS cell expression system, we show that PML is covalently modified by all three members of the sentrin family of ubiquitin-like proteins. Covalent modification of PML requires the conserved Gly residue near the C termini of sentrin proteins. Sentrinization of PML is highly specific because neither NEDD8 nor ubiquitin could modify PML. Similar specificity is also observed for the covalent modification of RanGAP1 by the sentrin member of ubiquitin-like proteins, These observations highlight the fine substrate specificity of the sentrinization pathway. In acute promyelocytic leukemia, two forms of PML-RAR alpha fusion proteins have been reported, Remarkably, both forms of PML-RAR alpha fusion proteins could not be sentrinized, Thus differential sentrinization of PML and PML-RAR alpha could play an important role in regulating the biological function of PML and in the pathogenesis of acute promyelocytic leukemia.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Yeh, ETH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Mol Med, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.		Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boddy MN, 1996, ONCOGENE, V13, P971; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Lapenta V, 1997, GENOMICS, V40, P362, DOI 10.1006/geno.1996.4556; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Okura T, 1996, J IMMUNOL, V157, P4277; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	19	180	184	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3117	3120		10.1074/jbc.273.6.3117	http://dx.doi.org/10.1074/jbc.273.6.3117			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452416	hybrid			2022-12-27	WOS:000071822300001
J	Low, SH; Roche, PA; Anderson, HA; van Ijzendoorn, SCD; Zhang, M; Mostov, KE; Weimbs, T				Low, SH; Roche, PA; Anderson, HA; van Ijzendoorn, SCD; Zhang, M; Mostov, KE; Weimbs, T			Targeting of SNAP-23 and SNAP-25 in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; SYNAPTOSOMAL-ASSOCIATED PROTEIN; NERVE GROWTH-FACTOR; POLYMERIC IMMUNOGLOBULIN RECEPTOR; SYNTAXIN-BINDING PROTEIN; PRIMARY CILIA; CLOSTRIDIAL NEUROTOXINS; BASOLATERAL TRANSPORT; NONNEURONAL TISSUES; NEURITE OUTGROWTH	SNAP-23 is the ubiquitously expressed homologue of the neuronal SNAP-25, which functions in synaptic vesicle fusion, We have investigated the subcellular localization of SNAP-23 in polarized epithelial cells, In hepatocyte-derived HepG2 cells and in Madin-Darby canine kidney (MDCK) cells, the majority of SNAP-23 was present at both the basolateral and apical plasma membrane domains with little intracellular localization, This suggests that SNAP-23 does not function in intracellular fusion events but rather as a general plasma membrane t-SNARE, Canine SNAP-23 is efficiently cleaved by the botulinum neurotoxin E, suggesting that it is the toxin-sensitive factor previously found to be involved in plasma membrane fusion in MDCK cells, The localization of SNAP-25 in transfected MDCK cells was studied for comparison and was found to be identical to SNAP-23 with the exception that SNAP-25 was transported to the primary cilia protruding from the apical plasma membrane, which suggests that subtle differences in the targeting signals of both proteins exist. In contrast to its behavior in neurons, the distribution of SNAP-25 in MDCK cells remained unaltered by treatment with dibutyryl cAMP or forskolin, which, however, caused an increased growth of the primary cilia, Finally, we found that SNAP-23/25 and syntaxin 1A, when coexpressed in MDCK cells, do not stably interact with each other but are independently targeted to the plasma membrane and lysosomes, respectively.	Univ Calif San Francisco, Dept Anat, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Inst Cardiovasc Res, San Francisco, CA 94143 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Univ Groningen, Dept Physiol Chem, NL-9713 AV Groningen, Netherlands	University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Groningen	Weimbs, T (corresponding author), Univ Calif San Francisco, Dept Anat, Inst Cardiovasc Res, 513 Parnassus Ave, San Francisco, CA 94143 USA.	weimbs@itsa.ucsf.edu		Roche, Paul/0000-0002-8949-9172; Weimbs, Thomas/0000-0001-9423-5561; mostov, keith/0000-0002-8123-6247	NIAID NIH HHS [R01 AI25144, AI36953, AI39161] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039161, R01AI025144, R01AI036953] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn J, 1996, J BIOL CHEM, V271, P6917, DOI 10.1074/jbc.271.12.6917; Apodaca G, 1996, EMBO J, V15, P1471, DOI 10.1002/j.1460-2075.1996.tb00491.x; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BINZ T, 1994, J BIOL CHEM, V269, P1617; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Brandstatter JH, 1996, EUR J NEUROSCI, V8, P823, DOI 10.1111/j.1460-9568.1996.tb01268.x; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Calakos N, 1996, PHYSIOL REV, V76, P1; CASANOVA JE, 1991, J BIOL CHEM, V266, P24428; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; DEHOOP MJ, 1993, J CELL SCI, P85; EKER P, 1994, J BIOL CHEM, V269, P18607; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; Gu HH, 1996, J BIOL CHEM, V271, P18100, DOI 10.1074/jbc.271.30.18100; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; HohneZell B, 1996, FEBS LETT, V394, P109, DOI 10.1016/0014-5793(96)00931-3; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; LOW SH, 1991, J BIOL CHEM, V266, P13391; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Mostov KE, 1995, COLD SPRING HARB SYM, V60, P775, DOI 10.1101/SQB.1995.060.01.083; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OYLER GA, 1991, P NATL ACAD SCI USA, V88, P5247, DOI 10.1073/pnas.88.12.5247; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Pelham HRB, 1995, COLD SPRING HARB SYM, V60, P105, DOI 10.1101/SQB.1995.060.01.013; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; POOLE CA, 1985, CELL MOTIL CYTOSKEL, V5, P175, DOI 10.1002/cm.970050302; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; RICHTERLANDSBERG C, 1986, J CELL BIOL, V102, P821, DOI 10.1083/jcb.102.3.821; ROTH KE, 1988, J CELL SCI, V89, P457; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SANNA PP, 1991, DEV BRAIN RES, V59, P104, DOI 10.1016/0165-3806(91)90035-H; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; ULLRICH B, 1994, J PHYSIOL-PARIS, V88, P249, DOI 10.1016/0928-4257(94)90088-4; Valentich J D, 1981, Ann N Y Acad Sci, V372, P384, DOI 10.1111/j.1749-6632.1981.tb15490.x; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Wheatley DN, 1995, PATHOBIOLOGY, V63, P222, DOI 10.1159/000163955; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011; ZAAL KJM, 1994, EUR J CELL BIOL, V63, P10	63	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3422	3430		10.1074/jbc.273.6.3422	http://dx.doi.org/10.1074/jbc.273.6.3422			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452464	hybrid			2022-12-27	WOS:000071822300049
J	Martina, JA; Daniotti, JL; Maccioni, HJF				Martina, JA; Daniotti, JL; Maccioni, HJF			Influence of N-glycosylation and N-glycan trimming on the activity and intracellular traffic of GD3 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-SUGAR PYROPHOSPHATASE; SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; MOUSE-BRAIN; RAT RETINA; EXPRESSION; GANGLIOSIDES; PROTEINS; CELLS; PHOSPHORYLATION	GD3 synthase (ST8Sia I) transfers a sialic acid in alpha-2-->8 linkage to the sialic acid moiety of GM3 to form the ganglioside GD3. The cDNAs of GD3 synthases predict several putative N-glycosylation sites. In this work we have examined the occupancy of these sites in a chicken GD3 synthase and how they affect its activity and intracellular traffic. COS-7 cells were transfected with an influenza virus hemagglutinin (HA) epitope-tagged form of GD3 synthase (GD3 synthase-HA). Cells acquired GD3 synthase activity, cell surface GD3 immunoexpression, and GD3 synthase-HA immunoreactivity in the Golgi complex, In Western blots, a main GD3 synthase-HA band of 47 kDa was detected, which was radioactive upon metabolic labeling with [2-H-3] mannose. Tunicamycin prevented the incorporation of [2-H-3]mannose into GD3 synthase-HA, blocked the enzyme activity, and promoted a reduction of the enzyme molecular mass of 6-7 kDa. Timed deglycosylation with N-glycosidase F showed that all three potential N-glycosylation sites of GD3 synthase-HA were glycosylated. The deglycosylated forms were enzymatically more unstable than the native form. Tunicamycin treatment of cells led to retention of GD3 synthase-HA immunoreactivity in the endoplasmic reticulum (ER). Castanospermine and deoxynojirimycin, inhibitors of the ER-processing enzymes Lu-glucosidases I and II, also prevented the exit from the ER but did not essentially affect the enzyme specific activity. 1-Deoxymannojirimycin and swainsonine, inhibitors of mannosidases, did not affect either the enzyme activity or the Golgi localization, Results indicate that (a) N-glycosylation is necessary for GD3 synthase to attain and to maintain a catalytically active folding, and for exiting the ER; and (b) N-glycan trimming in the ER, while not required for enzyme activity, is necessary for proper trafficking of GD3 synthase to the Golgi complex.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, RA-5000 Cordoba, Argentina	National University of Cordoba	Maccioni, HJF (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, AP 4,CC 61, RA-5000 Cordoba, Argentina.		Martina, Jose A/C-2772-2013	Martina, Jose/0000-0001-5814-8807				Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Daniotti JL, 1997, INT J DEV NEUROSCI, V15, P767, DOI 10.1016/S0736-5748(97)00027-0; Daniotti JL, 1997, NEUROCHEM INT, V31, P11, DOI 10.1016/S0197-0186(97)00002-8; DeAngelis DA, 1996, J NEUROCHEM, V67, P943; FAST DG, 1993, BIOCHIM BIOPHYS ACTA, V1202, P325, DOI 10.1016/0167-4838(93)90023-K; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; Glombitza GJ, 1997, J BIOL CHEM, V272, P5199, DOI 10.1074/jbc.272.8.5199; GU XB, 1995, J NEUROCHEM, V64, P2295; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HARAGUCHI M, 1995, BIOCHEM J, V312, P273, DOI 10.1042/bj3120273; Kaetzel DM, 1996, BBA-PROTEIN STRUCT M, V1298, P250, DOI 10.1016/S0167-4838(96)00136-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LABRIOLA C, 1995, J CELL BIOL, V130, P771, DOI 10.1083/jcb.130.4.771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martina JA, 1996, J NEUROSCI RES, V46, P485, DOI 10.1002/(SICI)1097-4547(19961115)46:4<485::AID-JNR10>3.0.CO;2-Y; MARTINA JA, 1995, J NEUROCHEM, V64, P1274; Maxzud MK, 1997, NEUROCHEM RES, V22, P455, DOI 10.1023/A:1027311811334; MAXZUD MK, 1995, J BIOL CHEM, V270, P20207, DOI 10.1074/jbc.270.34.20207; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; Nagai K, 1997, GLYCOBIOLOGY, V7, P769, DOI 10.1093/glycob/7.6.769; Nguyen TT, 1996, J NEUROCHEM, V67, P645; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; PANZETTA P, 1980, J NEUROCHEM, V35, P100, DOI 10.1111/j.1471-4159.1980.tb12494.x; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SCHEIDELER MA, 1986, J NEUROCHEM, V46, P1639, DOI 10.1111/j.1471-4159.1986.tb01787.x; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; WEITZ G, 1992, J BIOL CHEM, V267, P10039; Yamamoto A, 1996, J NEUROCHEM, V66, P26; Yamamoto A, 1996, GLYCOCONJUGATE J, V13, P471, DOI 10.1007/BF00731480; YAMASHIRO S, 1993, CANCER RES, V53, P5395; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670; Zeng GC, 1996, BIOCHEM BIOPH RES CO, V226, P319, DOI 10.1006/bbrc.1996.1354	35	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3725	3731		10.1074/jbc.273.6.3725	http://dx.doi.org/10.1074/jbc.273.6.3725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452504	hybrid			2022-12-27	WOS:000071822300089
J	Na, SY; Kim, HJ; Lee, SK; Choi, HS; Na, DS; Lee, MO; Chung, M; Moore, DD; Lee, JW				Na, SY; Kim, HJ; Lee, SK; Choi, HS; Na, DS; Lee, MO; Chung, M; Moore, DD; Lee, JW			I kappa B beta interacts with the retinoid X receptor and inhibits retinoid-dependent transactivation in lipopolysaccharide-treated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; PROTEINS; ACTIVATION; FAMILY	To elucidate the molecular action of the NF kappa B inhibitor I kappa B beta, we isolated a number of I kappa B beta interactors using the yeast two-hybrid system, These include the retinoid X receptor (RXR), whose interaction with I kappa B beta is significantly stimulated by the RXR ligand g-cis-retinoic acid, as shown in the yeast system as well as the glutathione S-transferase pull down assays. RXR is a nuclear protein, whereas I kappa B beta accumulates in the nucleus only in cells stimulated with lipopolysaccharide or other inducers that result in prolonged activation of NF kappa beta. Consistent with this, cotransfection with I kappa B beta specifically repressed the 9-cis-RA-induced transcriptional activities of RXR in an lipopolysaccharide-dependent manner. These results suggest a novel I kappa B beta-mediated antagonism between the signaling pathways of NF kappa B and RXR.	Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Univ Ulsan, Coll Med, Dept Biochem, Seoul 138040, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Chonnam National University; Chonnam National University; Chonnam National University; University of Ulsan; Yonsei University; Yonsei University Health System; Harvard University; Massachusetts General Hospital	Lee, JW (corresponding author), Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.	jlee@chonnam.chonnam.ac.kr			NIDDK NIH HHS [R01 DK43382] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043382] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOLLNICK H, 1987, Dermatologica (Basel), V175, P182; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Moore DD, 1995, GLOB MOB SURV; ORFANOS CE, 1983, BRIT J DERMATOL, V109, P55; ORFANOS CE, 1987, DRUGS, V34, P459, DOI 10.2165/00003495-198734040-00003; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Weil R, 1997, J BIOL CHEM, V272, P9942	24	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3212	3215		10.1074/jbc.273.6.3212	http://dx.doi.org/10.1074/jbc.273.6.3212			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452433	hybrid			2022-12-27	WOS:000071822300018
J	Bertrand, F; Atfi, A; Cadoret, A; L'Allemain, G; Robin, H; Lascols, O; Capeau, J; Cherqui, G				Bertrand, F; Atfi, A; Cadoret, A; L'Allemain, G; Robin, H; Lascols, O; Capeau, J; Cherqui, G			A role for nuclear factor kappa B in the antiapoptotic function of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; RECEPTOR TYROSINE RESIDUE-1162; CASEIN KINASE-II; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; CELL-DEATH; SUPPRESSES APOPTOSIS; SIGNALING PATHWAY; GLUCOSE-TRANSPORT; EPITHELIAL-CELLS	We previously reported that insulin activates nuclear factor kappa B (NF-kappa B) in Chinese hamster ovary (CHO)-R cells overexpressing wild-type insulin receptors (IRs) through a pathway requiring IR tyrosine kinase and Raf-1 kinase activities, We now investigated whether the activation of NF-kappa B by insulin could serve an antiapoptotic function. Insulin (10(-9)-10(-7) M) inhibited apoptosis induced by serum withdrawal in CHO-R cells in a concentration-dependent manner. Insulin antiapoptotic signaling: (i) was dependent on IR number and IR tyrosine kinase activity since it was reduced in parental CHO cells and was abolished in CHO-YB cells overexpressing IRs mutated at Tyr(1162/1163); (ii) was, like insulin activation of NF-KB, dependent on Raf-1 but not on mitogen activated protein kinase activity since both processes were decreased by the dominant-negative Raf-1 mutant Raf-C4 whereas they persisted in mitogen-activated protein kinase-depleted cells; and (iii) required NF-kappa B activation since it was decreased by proteasome inhibitors and the dominant-negative I kappa B-alpha (A32/36) mutant and was mimicked by overexpression of the NF-KB c-Rel subunit, We also show that insulin antiapoptotic signaling but not insulin activation of NF-kappa B involved phosphatidylinositol 3-kinase (PI 3-kinase), as supported by the inhibition of the former but not of the latter process by the PI S-kinase inhibitor LY294002. Inhibition of both NF-kappa B and PI 3-kinase totally abolished insulin antiapoptotic signaling, Thus insulin exerts a specific antiapoptotic function which is dependent on IR tyrosine kinase activity and is mediated by both a Raf-1-dependent pathway that leads to NF-kappa B activation and a PI 3-kinase-dependent pathway.	Fac Med St Antoine, INSERM U402, Inst Fed Rech 65, Biol Cellulaire Lab, F-75571 Paris 12, France; Hop St Antoine, Inst Fed Rech 65, INSERM U482, F-75571 Paris, France; Fac Sci, F-06108 Nice, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Cherqui, G (corresponding author), Fac Med St Antoine, INSERM U402, Inst Fed Rech 65, Biol Cellulaire Lab, 27 Rue Chaligny, F-75571 Paris 12, France.		Cadoret, Axelle/L-2529-2017	Cadoret, Axelle/0000-0002-4283-6864				Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Chappell D, 1997, CELL DEATH DIFFER, V4, P105, DOI 10.1038/sj.cdd.4400219; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DESBOIS C, 1992, J BIOL CHEM, V267, P13488; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KAUFMANZEH A, 1997, NATURE, V385, P5444; KOONG AC, 1994, CANCER RES, V54, P5273; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; Menke AL, 1997, CANCER RES, V57, P1353; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Miller TM, 1997, J BIOL CHEM, V272, P9847; Minshall C, 1996, J IMMUNOL, V156, P939; MUNOZ E, 1994, J VIROL, V68, P8035; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Parrizas M, 1997, J BIOL CHEM, V272, P154; RAMPALLI AM, 1995, CELL GROWTH DIFFER, V6, P945; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rudin CM, 1997, ANNU REV MED, V48, P267; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	70	94	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2931	2938		10.1074/jbc.273.5.2931	http://dx.doi.org/10.1074/jbc.273.5.2931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446605	hybrid			2022-12-27	WOS:000071736600060
J	Faussner, A; Proud, D; Towns, M; Bathon, JM				Faussner, A; Proud, D; Towns, M; Bathon, JM			Influence of the cytosolic carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MEDIATED INTERNALIZATION; BRADYKININ RECEPTOR; HUMAN-FIBROBLASTS; MECHANISMS; CLONING	To determine the role of the cytoplasmic carboxyl termini of human B1 and B2 kinin receptors (B1KR and B2KR, respectively) in the internalization of their respective ligands, des-Arg(10)-kallidin and bradykinin (BK), both wild type receptors, as well as truncated B2KRs, a mutated B2KR, and chimeric receptors were stably expressed in Chinese hamster ovary cells. Incubation of [H-3]BK at 37 degrees C with cells expressing wild type B2KR resulted in pronounced and rapid ligand internalization (similar to 80% after 10 min), By contrast, incubation of H-3-labeled des-Arg(10)-kallidin with cells expressing B1KR resulted in a modest, slow internalization of the Ligand (<20% after 10 min), Replacement, from Cys(324), Of the cytoplasmic carboxyl terminus of the B2KR with that of the B1KR from Cys(330) (both Cys residues are putative palmitoylation sites) greatly reduced ligand internalization (similar to 40% after 10 min) without significantly altering K-d or ligand-induced signal activation, By marked contrast, the corresponding replacement, of the sequence from Cys(330) Of the cytoplasmic carboxyl terminus of the B1KR with the segment of the B2KR, led to a striking increase of ligand internalization (similar to 75% within 10 min) without altering K-d Or ligand-induced signal activation. Truncation of the B2KR to within three amino acids of Cys(324) (truncation at Gly(327)) led to strongly reduced ligand internalization (similar to 40% after 10 min), Truncation of the B2KR up to Lys(315) almost completely abolished internalization of [H-3]BK (10% after 10 min). This additional reduction is apparently not caused by the loss of the potential palmitoylation site at Cys(324), since a B2KR with a point mutation of Cys(324) to Ala internalized [H-3]BK as rapidly as the wild type B2KR, From these results we conclude that the cytoplasmic carboxyl terminus of the human B2KR contains sequences that are necessary and sufficient to permit rapid ligand-induced sequestration of human kinin receptors and internalization of their agonists.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Faussner, A (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001856] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32272] Funding Source: Medline; NIAMS NIH HHS [AR01856] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Austin CE, 1997, J BIOL CHEM, V272, P11420; BATHON JM, 1991, ANNU REV PHARMACOL, V31, P129; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Bohm SK, 1997, J BIOL CHEM, V272, P2363; FARMER GS, 1992, ANN REV PHARM TOXICO, V32, P511; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; MENKE JG, 1994, J BIOL CHEM, V269, P21583; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Petrou C, 1997, J BIOL CHEM, V272, P2326; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; ROSCHER AA, 1984, J CLIN INVEST, V74, P552, DOI 10.1172/JCI111452; ROSCHER AA, 1990, J CARDIOVASC PHARM, V15, pS39, DOI 10.1097/00005344-199015061-00008; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; YU SS, 1993, J BIOL CHEM, V268, P337	34	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2617	2623		10.1074/jbc.273.5.2617	http://dx.doi.org/10.1074/jbc.273.5.2617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446564	hybrid			2022-12-27	WOS:000071736600019
J	Gitt, MA; Xia, YR; Atchison, RE; Lusis, AJ; Barondes, SH; Leffler, H				Gitt, MA; Xia, YR; Atchison, RE; Lusis, AJ; Barondes, SH; Leffler, H			Sequence, structure, and chromosomal mapping of the mouse Lgals6 gene, encoding galectin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING-PROTEIN; LEYDEN CRYSTAL PROTEIN; NEGATIVE GROWTH-FACTOR; S-LAC LECTIN; NUCLEOTIDE-SEQUENCE; 2 MEMBERS; FAMILY; EXPRESSION; DNA; ORGANIZATION	In the accompanying paper (Gitt, M, A., Colnot, C., Poirier, F., and Barondes, S. H., and Leffler, H. (1998) J. Biol. Chem. 273, 2954-2960), we reported that mouse gastrointestinal tract specifically expresses two closely related galectins, galectins-4 and -6, each with two carbohydrate recognition domains in the same peptide. Here, we report the isolation, characterization, and chromosomal mapping of the complete mouse Lgals6 gene, which encodes galectin-6, and of a fragment of a distinct gene, Lgals4, which encodes galectin-4, The coding sequence of galectin-6 is specified by eight exons. The upstream region contains two putative promoters. Both Lgals6 and the closely related Lgals4 are clustered together about 3.2 centimorgans proximal to the apoE gene on mouse chromosome 7. The syntenic human region is 19q13.1-13.3.	Univ Calif San Francisco, Dept Psychiat, Ctr Neurobiol & Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Leffler, H (corresponding author), Inst Med Microbiol, Dept Clin Immunol, Solvegatan 23, S-22362 Lund, Sweden.		Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945	NHLBI NIH HHS [HL38627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1992, CURRENT PROTOCOLS S, V20; BALDINI A, 1993, GENOMICS, V15, P216, DOI 10.1006/geno.1993.1039; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; CASASNOVAS JM, 1987, NUCLEIC ACIDS RES, V15, P8899, DOI 10.1093/nar/15.21.8899; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hurlin PJ, 1995, ONCOGENE, V11, P2487; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Leffler H, 1997, TRENDS GLYCOSCI GLYC, V9, P9, DOI 10.4052/tigg.9.9; LEITH IR, 1988, NUCLEIC ACIDS RES, V16, P8277, DOI 10.1093/nar/16.17.8277; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LIAO, 1994, P NATL ACAD SCI US, V91, P1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Maniatis T., 1982, MOL CLONING LAB MANU; MASTRIANNI DM, 1992, GENOMICS, V13, P240, DOI 10.1016/0888-7543(92)90237-M; McCrea Kirk W., 1993, Biotechniques, V15, P843; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MEHRABIAN M, 1993, GENOMICS, V15, P418, DOI 10.1006/geno.1993.1078; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; ODA Y, 1993, J BIOL CHEM, V268, P5929; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Raimond J, 1997, MAMM GENOME, V8, P706, DOI 10.1007/s003359900548; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOVYEV VV, 1995, P 3 INT C INT SYST M, P367; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; TABOURY JA, 1985, NUCLEIC ACIDS RES, V13, P4469, DOI 10.1093/nar/13.12.4469; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; VOSS PG, 1994, GLYCOCONJUGATE J, V11, P353, DOI 10.1007/BF00731209; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WHEELER MB, 1992, MOL CELL BIOL, V12, P3531, DOI 10.1128/MCB.12.8.3531; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8	52	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2961	2970		10.1074/jbc.273.5.2961	http://dx.doi.org/10.1074/jbc.273.5.2961			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446609	hybrid			2022-12-27	WOS:000071736600064
J	Kitamoto, T; Wang, WY; Salvaterra, PM				Kitamoto, T; Wang, WY; Salvaterra, PM			Structure and organization of the Drosophila cholinergic locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR ACETYLCHOLINE TRANSPORTER; ACETYLTRANSFERASE MESSENGER-RNA; TEMPERATURE-SENSITIVE MUTANTS; CAENORHABDITIS-ELEGANS; FUNCTIONAL IDENTIFICATION; DEVELOPMENTAL EXPRESSION; MONOAMINE TRANSPORTER; REGULATORY ELEMENTS; MOLECULAR-CLONING; GENE-EXPRESSION	The Drosophila cholinergic locus is composed of two distinct genetic functions: choline acetyltransferase (ChAT; EC 2.3.1.6), the enzyme catalyzing biosynthesis of neurotransmitter acetylcholine (ACh), and the vesicular ACh transporter (VAChT), the synaptic vesicle membrane protein which pumps transmitter into vesicles. Both genes share a common first exon and the remainder of the VAChT gene contains a single coding exon residing entirely within the first intron of ChAT. RNase protection analysis indicates that all Drosophila VAChT specific transcripts contain the shared first exon and suggests common transcriptional control for ChAT and VAChT. Similar types of genomic organization have been evolutionarily conserved for cholinergic loci in nematodes and vertebrates, and may operate to ensure coordinate expression of these functionally related genes in the same cells. The relative levels of Drosophila ChAT and VAChT mRNA differ, however, in different tissues or in Cha mutants, indicating that independent regulation of ChAT and VAChT transcripts may occur post-transcriptionally. The predicted Drosophila VAChT protein is composed of 578 amino acids and contains 12 conserved putative transmembrane domains, Full-length VAChT cDNA is 7.2 kilobase long and has unusually long 5'- and 3'-untranslated regions (UTR), The 5'-UTR contains a GTG ChAT translational initiation codon along with three other potential ATG initiation codons, These features of the VAChT 5'-UTR region suggest that a ribosome scanning model may not be used for VAChT translation initiation.	City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Salvaterra, PM (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, 1450 E Duarte Rd, Duarte, CA 91010 USA.	psalv@coh.org		Kitamoto, Toshihiro/0000-0003-0863-8466				ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BERRARD S, 1995, J NEUROCHEM, V65, P939; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BEVERLEY SM, 1992, CURRENT PROTOCOLS MO; BRENNER S, 1974, GENETICS, V77, P71; CARBINI LA, 1990, NEUROCHEM RES, V15, P1089, DOI 10.1007/BF01101709; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CERVINI R, 1995, J BIOL CHEM, V270, P24654, DOI 10.1074/jbc.270.42.24654; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; GILMAN M, 1992, CURRENT PROTOCOLS MO; GREENSPAN RJ, 1980, J COMP PHYSIOL, V137, P83, DOI 10.1007/BF00656920; Harlow E., 1988, ANTIBODIES LAB MANUA; Holler T, 1996, NEUROSCI LETT, V212, P107, DOI 10.1016/0304-3940(96)12808-1; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; KITAMOTO T, 1993, ROUX ARCH DEV BIOL, V202, P159, DOI 10.1007/BF00365306; KITAMOTO T, 1992, J NEUROSCI, V12, P1628; KITAMOTO T, 1995, J NEUROSCI, V15, P3509; KITAMOTO T, 1995, J NEUROBIOL, V28, P70, DOI 10.1002/neu.480280107; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LORENZI MV, 1992, DNA CELL BIOL, V11, P593, DOI 10.1089/dna.1992.11.593; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MISAWA H, 1995, NEUROREPORT, V6, P965, DOI 10.1097/00001756-199505090-00004; RAND JB, 1984, GENETICS, V106, P227; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUBIN GM, 1994, DROSOPHILA INFORMATI, V75, P200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; SUGIHARA H, 1991, J NEUROCHEM, V57, P1636, DOI 10.1111/j.1471-4159.1991.tb06362.x; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; TAJIMA Y, 1990, NEUROSCIENCE, V39, P245, DOI 10.1016/0306-4522(90)90237-X; TAJIMA Y, 1992, MOL BRAIN RES, V13, P213, DOI 10.1016/0169-328X(92)90029-B; TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; Yasuyama K, 1996, J NEUROBIOL, V30, P205, DOI 10.1002/(SICI)1097-4695(199606)30:2<205::AID-NEU3>3.0.CO;2-9	47	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2706	2713		10.1074/jbc.273.5.2706	http://dx.doi.org/10.1074/jbc.273.5.2706			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446576	hybrid			2022-12-27	WOS:000071736600031
J	Leask, A; Stearns, T				Leask, A; Stearns, T			Expression of amino- and carboxyl-terminal gamma- and alpha-tubulin mutants in cultured epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; SACCHAROMYCES-CEREVISIAE; MICROTUBULE NUCLEATION; ASPERGILLUS-NIDULANS; FISSION YEAST; COMPONENT; CENTROSOME; PROTEIN; COMPLEX; TUB4P	Three distinct tubulin proteins are essential for microtubule function: alpha-, beta-, and gamma-tubulin. After translation, alpha- and beta-tubulin proteins combine into a soluble, 7 S heterodimer that is multimerized to form the microtubule filament. Conversely, gamma-tubulin combines with several proteins into a soluble, 25 S multi-protein particle, the gammasome that is essential for nucleating microtubule filaments at the centrosome. The proteins that assist tubulins in executing their specific functions are largely unknown. As an initial approach to address this issue, we first decided to identify domains of mammalian alpha- and gamma-tubulin necessary for their function by creating mutant mammalian alpha- and gamma-tubulin (both deletion and hybrid mutants) and assaying their behavior in stably transfected Chinese hamster ovary epithelial cells. First, we demonstrated that addition of a carboxyl-terminal epitope tag had no effect on the subcellular localization of either alpha- and gamma-tubulin, Second, we found that both the amino and carboxyl termini of gamma-tubulin were essential for its incorporation into the gammasome, Third, we found that the amino and carboxyl termini of alpha-tubulin were necessary for incorporation of the alpha-beta-tubulin heterodimer into the microtubule filament network. In general, alpha-tubulin sequences could not replace those of gamma-tubulin and vice versa. Taken together, these results suggest that the amino and carboxyl termini of alpha- and gamma-tubulin and perhaps regions throughout these proteins were necessary for their specif, functions.	FibroGen Inc, S San Francisco, CA 94080 USA; Stanford Univ, Dept Sci Biol, Stanford, CA 94030 USA	FibroGen; Stanford University	Leask, A (corresponding author), FibroGen Inc, 260 Littlefield Ave, S San Francisco, CA 94080 USA.	aleask@fibrogen.com	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015	Stearns, Tim/0000-0002-0671-6582				AMOS LA, 1974, J CELL SCI, V14, P523; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERGEN LG, 1980, J CELL BIOL, V84, P141, DOI 10.1083/jcb.84.1.141; BURNS RG, 1995, J CELL SCI, V108, P2123; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; Geissler S, 1996, EMBO J, V15, P3899, DOI 10.1002/j.1460-2075.1996.tb00764.x; HIROSE K, 1995, J MOL BIOL, V251, P329, DOI 10.1006/jmbi.1995.0437; HORIO T, 1994, J CELL BIOL, V126, P1465, DOI 10.1083/jcb.126.6.1465; HORIO T, 1991, J CELL SCI, V99, P693; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KIKKAWA M, 1995, NATURE, V376, P271; KIRSCHNER K, 1985, EMBO J, V4, P2397; Knop M, 1997, EMBO J, V16, P1550, DOI 10.1093/emboj/16.7.1550; KubeGranderath E, 1997, EUR J CELL BIOL, V72, P287; Leask A, 1997, NEUROSCI LETT, V229, P17, DOI 10.1016/S0304-3940(97)00412-6; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LIU B, 1994, PLANT CELL, V6, P303, DOI 10.1105/tpc.6.2.303; LOPEZ I, 1995, PLANT PHYSIOL, V107, P309, DOI 10.1104/pp.107.1.309; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Marschall LG, 1996, J CELL BIOL, V134, P443, DOI 10.1083/jcb.134.2.443; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Moudjou M, 1996, J CELL SCI, V109, P875; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; Pickett-Heaps J.D., 1969, CYTOBIOS, V3, P257; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; Sobel SG, 1995, J CELL BIOL, V131, P1775, DOI 10.1083/jcb.131.6.1775; SOSA H, 1996, J MOL BIOL, V260, P742; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Wade RH, 1997, CURR OPIN CELL BIOL, V9, P12, DOI 10.1016/S0955-0674(97)80146-9; Wade RH, 1995, PROTEINS, V23, P502, DOI 10.1002/prot.340230405; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	35	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2661	2668		10.1074/jbc.273.5.2661	http://dx.doi.org/10.1074/jbc.273.5.2661			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446570	hybrid			2022-12-27	WOS:000071736600025
J	Sato, C; Kitajima, K; Inoue, S; Inoue, Y				Sato, C; Kitajima, K; Inoue, S; Inoue, Y			Identification of oligo-N-glycolylneuraminic acid residues in mammal-derived glycoproteins by a newly developed immunochemical reagent and biochemical methods	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; FISH EGG POLYSIALOGLYCOPROTEINS; NEURO-BLASTOMA CELLS; GROUP-B-MENINGOCOCCI; ESCHERICHIA-COLI K1; POLYSIALIC ACID; MONOCLONAL-ANTIBODY; SIALIC ACIDS; 2-KETO-3-DEOXY-D-GLYCERO-D-GALACTONONONIC ACID; POLY(ALPHA-2,8-DEAMINONEURAMINIC ACID)	The occurrence of the alpha 2-->8-linked oligomeric form of N-glycolylneuraminic acid (oligo-Neu5Gc) residues in mammalian glycoproteins was unequivocally demonstrated using a nea ly developed anti-oligo/poly-Neu5Gc monoclonal antibody as well as by chemical and biochemical methods, First, the antibody, designated mAb.2-4B, which specifically recognized oligo/poly-Neu5Gc with a degree of polymerization of >2, was developed by establishing a hybridoma cell line from P3U1 myeloma cells fused with splenocytes from an MRL autoimmune mouse immunized with dipalmitoylphosphatidylethanolamine-conjugated oligo/poly-Neu5Gc. Second, oligo-Neu5Gc was shown to occur in glycoproteins derived from pig spleen by Western blot analysis using mAb.2-4B, which was also confirmed by fluorometric high performance liquid chromatographic analysis of the product of periodate oxidation/reduction/acid hydrolysis of the purified glycopeptide fractions and by TLC and 600-MHz H-1 NMR spectroscopic analysis of their mild acid hydrolysates. Finally, the ubiquitous occurrence of oligo-Neu5Gc chains as glycoproteinaceous components in Wistar rat tissue was immunochemically indicated. This is the first example demonstrating the diversity in oligo/poly-Sia structure in mammalian glycoproteins, where only poly-N-acetylneuraminic acid is known to occur, Such diversity in oligo/poly-Sia structure also implicates a diverged array of biological functions of this glycan unit in glycoproteins.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan; Nagoya Univ, Sch Agr Sci, Dept Appl Biol Sci, Chikusa Ku, Nagoya, Aichi 46401, Japan	Academia Sinica - Taiwan; University of Tokyo; Nagoya University	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	syinoue@gate.sinica.edu.tw	SATO, Chihiro/B-7396-2014; Naganawa, Shinji/I-1572-2012	Naganawa, Shinji/0000-0002-0214-613X				AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANGATA T, 1994, GLYCOCONJUGATE J, V11, P493, DOI 10.1007/BF00731286; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CORFIELD AP, 1982, SIALIC ACIDS, P6; DEVI SJN, 1991, P NATL ACAD SCI USA, V88, P7175, DOI 10.1073/pnas.88.16.7175; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; FINNE J, 1983, LANCET, V2, P355; FINNE J, 1987, J IMMUNOL, V138, P4402; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Funakoshi Y, 1997, GLYCOBIOLOGY, V7, P195, DOI 10.1093/glycob/7.2.195; GALANOS C, 1971, EUR J BIOCHEM, V24, P116; HAKOMORI S, 1985, CANCER RES, V45, P2405; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; HaraYokoyama M, 1996, J BIOL CHEM, V271, P12951, DOI 10.1074/jbc.271.22.12951; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HIGASHI H, 1985, CANCER RES, V45, P3796; HUSMANN M, 1990, J HISTOCHEM CYTOCHEM, V38, P209, DOI 10.1177/38.2.1688896; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; INOUE Y, 1993, POLYSIALIC ACID MICR, P171; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; KANAMORI A, 1994, HISTOCHEMISTRY, V101, P333, DOI 10.1007/BF00268994; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAJIMA K, 1988, J BIOL CHEM, V263, P18269; KITAJIMA K, 1994, J BIOL CHEM, V269, P21415; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MCLEAN RL, 1971, J BIOL CHEM, V246, P803; NAKAMURA K, 1995, J BIOL CHEM, V270, P3876, DOI 10.1074/jbc.270.8.3876; NAKAYAMA J, 1993, J HISTOCHEM CYTOCHEM, V41, P1563, DOI 10.1177/41.10.8245415; Nishino S, 1996, J BIOL CHEM, V271, P2909, DOI 10.1074/jbc.271.6.2909; OZAWA H, 1992, ARCH BIOCHEM BIOPHYS, V294, P427, DOI 10.1016/0003-9861(92)90707-4; Qu BX, 1996, P NATL ACAD SCI USA, V93, P8995, DOI 10.1073/pnas.93.17.8995; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1971; ROTH J, 1993, POLYSIALIC ACID MICR, P335; SATO C, 1993, J BIOL CHEM, V268, P23675; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; Schauer R, 1997, TRENDS GLYCOSCI GLYC, V9, P315, DOI 10.4052/tigg.9.315; SEYFRIED TN, 1985, MOL CELL BIOCHEM, V68, P3; SHIMAMURA M, 1984, BIOCHEMISTRY-US, V23, P317, DOI 10.1021/bi00297a022; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TSUJI S, 1983, J BIOCHEM-TOKYO, V94, P303, DOI 10.1093/oxfordjournals.jbchem.a134344; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; Varki A, 1996, GLYCOBIOLOGY, V6, P707, DOI 10.1093/glycob/6.7.707; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; VIMR ER, 1984, P NATL ACAD SCI-BIOL, V81, P1971, DOI 10.1073/pnas.81.7.1971; YU S, 1993, GLYCOBIOLOGY, V3, P31; Ziak M, 1996, P NATL ACAD SCI USA, V93, P2759, DOI 10.1073/pnas.93.7.2759; ZUBER C, 1992, J BIOL CHEM, V267, P9965	62	32	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2575	2582		10.1074/jbc.273.5.2575	http://dx.doi.org/10.1074/jbc.273.5.2575			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446559	hybrid			2022-12-27	WOS:000071736600014
J	von Mollard, GF; Stevens, TH				von Mollard, GF; Stevens, TH			A human homolog can functionally replace the yeast vesicle-associated SNARE Vti1p in two vesicle transport pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SORTING RECEPTOR; GOLGI-COMPLEX; CARBOXYPEPTIDASE-Y; SEQUENCE ALIGNMENT; SECRETORY PATHWAY; MEMBRANE-FUSION; GENE-PRODUCTS; COILED COILS	Membrane traffic in eukaryotic cells requires the interaction of a vesicle-associated soluble NSF attachment protein receptor (v-SNARE) on transport vesicles with a SNARE on the target membrane (t-SNARE). Recently, we identified the yeast protein Vti1p as a v-SNARE that is involved in two transport reactions. Vti1p interacts with the prevacuolar t-SNARE Pep12p in Golgi to prevacuolar transport and with the cis-Golgi t-SNARE Sed5p in traffic to the cis-Golgi. Here we describe a human Vti1p homolog, hVti1, Whereas vti1 Delta cells are inviable, expression of hVti1 allows vti1 Delta cells to grow at nearly the wild-type growth rate. When expressed in yeast hVti1 can replace Vti1p in both Golgi to prevacuolar transport and in traffic to the cis-Golgi, Sequence comparisons with a Schizosaccharomyces pombe and two different mouse Vti1 homologs led to the identification of a very conserved predicted alpha-helix. Amino acid exchanges in vti1 mutant alleles defective either in one or both trafficking steps cluster in this domain, suggesting that this structure is probably the binding site for effector proteins.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Stevens, TH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	stevens@molbio.uoregon.edu	von Mollard, Gabriele Fischer/A-3935-2012; von Mollard, Gabriele Fischer/O-9778-2019	von Mollard, Gabriele Fischer/0000-0003-3236-1401; von Mollard, Gabriele Fischer/0000-0003-3236-1401; Stevens, Tom/0000-0001-6427-6848	NIGMS NIH HHS [GM32448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032448, R01GM032448] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JONES EW, 1977, GENETICS, V85, P23; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Regazzi R, 1996, EMBO J, V15, P6951, DOI 10.1002/j.1460-2075.1996.tb01087.x; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SIKORSKI RS, 1989, GENETICS, V122, P19; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; SWAROOP A, 1993, CYTOGENET CELL GENET, V64, P292, DOI 10.1159/000133595; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803	50	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2624	2630		10.1074/jbc.273.5.2624	http://dx.doi.org/10.1074/jbc.273.5.2624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446565	hybrid			2022-12-27	WOS:000071736600020
J	Hughes, BW; King, SA; Allan, PW; Parker, WB; Sorscher, EJ				Hughes, BW; King, SA; Allan, PW; Parker, WB; Sorscher, EJ			Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUICIDE GENES; CANCER; THERAPY; PROLIFERATION; CARCINOMA; TUMORS	Expression of Escherichia coli purine nucleoside phosphorylase (PNP) activates prodrugs and kills entire populations of mammalian cells, even when as few as 1% of the cells express this gene. This phenomenon of bystander billing has been previously investigated for herpes simplex virus-thymidine kinase (HSV-TR) and has been shown to require cell to cell contact. Using silicon rings to separate E. coli PNP expressing cells from non-expressing cells sharing the same medium, we demonstrate that bystander cell killing by E. coli PNP does not require cell-cell contact. Initially, cells expressing E. coli PNP convert the non-toxic prodrug, 6-methylpurine-2'-deoxyriboside (MeP-dR) to the highly toxic membrane permeable toxin, 6-methylpurine (MeP). As the expressing cells die, E. coli PNP is released into the culture medium, retains activity, and continues precursor conversion extracellularly (as determined by reverse phase high performance liquid chromatography of both prodrug and toxin). Bystander killing can also be observed in the absence of extracellular E. coli PNP by removing the MeP-dR prior to death of the expressing cells. In this case, 100% of cultured cells die when as few as 3% of the cells of a population express E. coli PNP. Blocking nucleoside transport with nitrobenzylthioinosine reduces MeP-dR mediated cell killing but not MeP cell killing. These mechanisms differ fundamentally from those previously reported for the HSV-TK gene.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; So Res Inst, Birmingham, AL 35255 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sorscher, EJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, Basic Hlth Sci Bldg,Rm 796,1918 Univ Blvd, Birmingham, AL 35294 USA.			Sorscher, Eric J./0000-0001-9341-3354	NCI NIH HHS [U19-CA67763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan P. W., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P379; Beck C, 1995, HUM GENE THER, V6, P1525, DOI 10.1089/hum.1995.6.12-1525; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BOTH GW, 1997, MOL CELLULAR BIOL GE, P26; Caruso M, 1996, P NATL ACAD SCI USA, V93, P11302, DOI 10.1073/pnas.93.21.11302; CHANG MW, 1995, MOL MED, V1, P172, DOI 10.1007/BF03401565; Connors TA, 1995, GENE THER, V2, P702; DaCosta LT, 1996, P NATL ACAD SCI USA, V93, P4192, DOI 10.1073/pnas.93.9.4192; DENNIG CN, 1997, MOL CELLULAR BIOL GE; Freeman SM, 1996, SEMIN ONCOL, V23, P31; GIVENS KT, 1990, INVEST OPHTH VIS SCI, V31, P1856; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Hall SJ, 1997, INT J CANCER, V70, P183, DOI 10.1002/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO;2-T; HUGHES BW, 1995, CANCER RES, V55, P3339; KEINKELEIN M, 1997, MOL CELLULAR BIOL GE, P32; MESNIL M, 1997, MOL CELLULAR BIOL GE, P67; MONTGOMERY JA, 1968, J MED CHEM, V11, P48, DOI 10.1021/jm00307a010; MOOLTEN FL, 1994, CANCER GENE THER, V1, P279; Parker WB, 1997, HUM GENE THER, V8, P1637, DOI 10.1089/hum.1997.8.14-1637; RAM Z, 1993, CANCER RES, V53, P83; ROBERTS B, 1997, MOL CELLULAR BIOL GE, P68; Sacco MG, 1996, GENE THER, V3, P1151; Smith SM, 1996, P NATL ACAD SCI USA, V93, P7955, DOI 10.1073/pnas.93.15.7955; SORSCHER EJ, 1994, GENE THER, V1, P233; Wygoda MR, 1997, CANCER RES, V57, P1699	25	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2322	2328		10.1074/jbc.273.4.2322	http://dx.doi.org/10.1074/jbc.273.4.2322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442077	hybrid			2022-12-27	WOS:000071595200066
J	Bellocq, A; Suberville, S; Philippe, C; Bertrand, F; Perez, J; Fouqueray, B; Cherqui, G; Baud, L				Bellocq, A; Suberville, S; Philippe, C; Bertrand, F; Perez, J; Fouqueray, B; Cherqui, G; Baud, L			Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages - Evidence for involvement of nuclear factor-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR NF-KAPPA; RENAL EPITHELIAL-CELLS; MESSENGER-RNA LEVELS; TRANSCRIPTION FACTOR; PERITONEAL-MACROPHAGES; PROTEASOME PATHWAY; INTERFERON-GAMMA; MAMMALIAN-CELLS; DNA-BINDING; LIPOPOLYSACCHARIDE	Stimulation of macrophages with endotoxin and/or cytokines is responsible for the expression of the inducible isoform of nitric oxide synthase (MOS). Because macrophages are exposed to low pH within the microenvironment of inflammatory lesions, the potential role of acidic pH as an additional regulator of iNOS was investigated, Substitution of the culture medium of rat peritoneal macrophages at pH 7.4 with medium at pH 7.0 up-regulated iNOS activity, as reflected by a 2.5-fold increase in nitrite accumulation, The increase in iNOS activity was associated with a similar increase in iNOS mRNA expression that reflected an increase in iNOS mRNA synthesis rather than stability, Low environmental pH-induced iNOS gene transcription involved the activation of nuclear factor-kappa B (NF-kappa B) transcription factor since exposure of macrophages to low environmental pH both increased NF-kappa B binding activity in the nucleus and enhanced NF-kappa B-driven reporter gene expression, In addition, treatment of macrophages with pyrrolidine dithiocarbamate or n-acetyl-leucinyl-leucinyl-norleucinal, two drugs preventing NF-kappa B translocation to the nucleus, canceled low pH-induced nitrite accumulation, The overall mechanism required the synthesis of tumor necrosis factor alpha (TNF alpha). Indeed, 1) elevated TNF alpha bioactivity was observed in the medium of macrophages exposed to pH 7.0, and 2) incubation of macrophages with a neutralizing anti-TNF alpha antibody impaired both NF-kappa B activation and nitrite accumulation in response to acid challenge, In summary, exposure of macrophages to acidic microenvironment in inflammatory lesions leads to the up-regulation of iNOS activity through the activation of NF-kappa B.	Hop Tenon, INSERM, U64, F-75020 Paris, France; Hop St Antoine, INSERM, U402, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Baud, L (corresponding author), Hop Tenon, INSERM, U64, 4 Rue Chine, F-75020 Paris, France.	laurent.baud@tnn.ap-hop-paris.fr		BELLOCQ, Agnes/0000-0002-9297-7534				ALARD P, 1993, BIOTECHNIQUES, V15, P730; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BAUD L, 1988, J CELL PHYSIOL, V136, P355, DOI 10.1002/jcp.1041360220; BAUD L, 1989, AM J PHYSIOL, V257, pC232, DOI 10.1152/ajpcell.1989.257.2.C232; BAYDOUN AR, 1994, BRIT J PHARMACOL, V112, P487, DOI 10.1111/j.1476-5381.1994.tb13099.x; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BOUTARD V, 1995, J IMMUNOL, V155, P2077; BRYANT RE, 1980, J INFECT DIS, V142, P594, DOI 10.1093/infdis/142.4.594; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DOUVDEVANI A, 1995, KIDNEY INT, V47, P1537, DOI 10.1038/ki.1995.217; GAO J, 1977, J BIOL CHEM, V272, P1226; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; KAISER S, 1991, J BIOL CHEM, V266, P9397; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MELLERGARD P, 1994, AM J PHYSIOL, V267, pC581, DOI 10.1152/ajpcell.1994.267.2.C581; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; PHILIPPE C, 1993, AM J PATHOL, V143, P1713; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELDEN RF, 1996, CURRENT PROTOCOLS MO; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; SWALLOW CJ, 1991, J EXP MED, V174, P1009, DOI 10.1084/jem.174.5.1009; WEINBERG JM, 1991, KIDNEY INT, V39, P476, DOI 10.1038/ki.1991.58; WRIGHT J, 1986, J CLIN INVEST, V77, P782, DOI 10.1172/JCI112375; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YAMAJI Y, 1994, J CLIN INVEST, V94, P1297, DOI 10.1172/JCI117448; Yaqoob M, 1996, KIDNEY INT, V49, P1314, DOI 10.1038/ki.1996.187; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	38	172	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5086	5092		10.1074/jbc.273.9.5086	http://dx.doi.org/10.1074/jbc.273.9.5086			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478960	hybrid			2022-12-27	WOS:000072310400044
J	Kanda, Y; Mitani, K; Kurokawa, M; Yamagata, T; Yazaki, Y; Hirai, H				Kanda, Y; Mitani, K; Kurokawa, M; Yamagata, T; Yazaki, Y; Hirai, H			Overexpression of the MEN/ELL protein, an RNA polymerase II elongation factor, results in transformation of Rat1 cells with dependence on the lysine-rich region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; C-FOS; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; MYELOID-LEUKEMIA; GENE; TRANSCRIPTION; CLONING; T(11-19)(Q23-P13.1); ONCOGENE	The MEN gene (also called ELL) encodes an RNA polymerase II elongation factor that has been implicated in t(11;19)(q23;p13.1) translocation in myeloid leukemias. The function of another elongation factor, elongin, is known to be inhibited by VHL tumor suppressor protein in vitro, suggesting the possible relationship of aberrant transcriptional elongation to oncogenesis. We overexpressed the MEN protein in Rat1 fibroblasts to evaluate its transforming activity, MEN-overexpressing cells acquired the capacity for anchorage-independent growth, In addition, the growth factor requirement was decreased in these cells, However, cells expressing a deletion mutant of MEN lacking the lysine-rich region did not exhibit such biological abilities, c-Fos protein expression and AP-1 activity were elevated in the MEN-expressing cells, which might be part of the mechanism responsible for the transformation, The c-fos mRNA, the expression of which is known to be regulated partly at the stage of transcriptional elongation, appeared earlier in the MEN-expressing cells than in cells transfected with an empty vector or the deletion mutant lacking the lysine-rich region after stimulation with epidermal growth factor, The RNA polymerase II elongation factor MEN may play an important role in the regulation of cell proliferation.	Univ Tokyo, Fac Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.							Ausubel FM, 1992, CURRENT PROTOCOLS MO; BALSALOBRE A, 1995, ONCOGENE, V11, P455; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Kanda Y, 1997, INT J HEMATOL, V66, P189; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PRASAD R, 1993, CANCER RES, V53, P5624; REINES D, 1994, TRANSCRIPTION MECHAN, P263; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDERSCHAULIES J, 1987, EUR J IMMUNOL, V17, P713, DOI 10.1002/eji.1830170521; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; TAN SY, 1994, J BIOL CHEM, V269, P25684; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Thirman MJ, 1997, P NATL ACAD SCI USA, V94, P1408, DOI 10.1073/pnas.94.4.1408; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	25	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5248	5252		10.1074/jbc.273.9.5248	http://dx.doi.org/10.1074/jbc.273.9.5248			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478981	hybrid			2022-12-27	WOS:000072310400065
J	Petruska, J; Hartenstine, MJ; Goodman, MF				Petruska, J; Hartenstine, MJ; Goodman, MF			Analysis of strand slippage in DNA polymerase expansions of CAG/CTG triplet repeats associated with neurodegenerative disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; TRINUCLEOTIDE REPEATS; MUTATIONS; CTG	Lengthy expansions of trinucleotide repeats are found in DNA of patients suffering severe neurodegenerative age-related diseases, Using a synthetic self-priming DNA, containing CAG and CTG repeats implicated in Huntington's disease and several other neurological disorders, we measure the equilibrium distribution of hairpin folding and generate triplet repeat expansions by polymerase-catalyzed extensions of the hairpin folds, Expansions occur by slippage in steps of two CAG triplets when the self priming sequence (CTG)(16)(CAG)(4) is extended with proofreading-defective Klenow fragment (KF exo(-)) from Escherichia coli DNA polymerase I. Slippage by two triplets is 20 times more frequent than by one triplet, in accordance with our finding that hairpin loops with even numbers of triplets are 1-2 kcal/mol more stable than their odd-numbered counterparts, By measuring triplet repeat expansions as they evolve over time, individual rate constants for expansion from 4 to 18 CAG repeats are obtained, An empirical expression is derived from the data, enabling the prediction of slippage rates from the ratio of hairpin CTG/CTG interactions to CAG/CTG interactions, Slippage is initiated internally in the hairpin folds in preference to melting inward from the 3' terminus, The same triplet expansions are obtained using proofreading-proficient KF exo(+), provided 10-100-fold higher dNTP concentrations are present to counteract the effect of 3'-exonucleolytic proofreading.	Univ So Calif, Hedco Mol Biol Labs, Dept Biol Sci, Los Angeles, CA 90089 USA	University of Southern California	Petruska, J (corresponding author), Univ So Calif, Hedco Mol Biol Labs, Dept Biol Sci, Los Angeles, CA 90089 USA.				NIA NIH HHS [AG 11398] Funding Source: Medline; NIGMS NIH HHS [GM 21422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Cossee M, 1997, P NATL ACAD SCI USA, V94, P7452, DOI 10.1073/pnas.94.14.7452; DARLOW JM, 1995, GENETICS, V141, P825; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; GACY AM, 1995, CELL, V81, P533; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Ji JP, 1996, NUCLEIC ACIDS RES, V24, P2835, DOI 10.1093/nar/24.14.2835; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; YU A, 1995, NUCLEIC ACIDS RES, V23, P4055, DOI 10.1093/nar/23.20.4055	22	89	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5204	5210		10.1074/jbc.273.9.5204	http://dx.doi.org/10.1074/jbc.273.9.5204			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478975	hybrid			2022-12-27	WOS:000072310400059
J	Xie, WF; Kondo, S; Sandell, LJ				Xie, WF; Kondo, S; Sandell, LJ			Regulation of the mouse cartilage-derived retinoic acid-sensitive protein gene by the transcription factor AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALIGNANT MELANOMA; CLONING; DIFFERENTIATION; ACTIVATION; EXPRESSION; BINDING; CELLS; MIA	The expression of cartilage-derived retinoic acid-sensitive protein (CD-RAP) is initiated at the beginning of chondrogenesis and continues throughout the cartilage development, In chondrocytes, CD-RAP is down-regulated by retinoic acid, To understand the molecular mechanism underlying this regulation and the cell-specific expression, the deletion constructs of the mouse CD-RAP promoter were transfected into chondrocytes and a melanoma cell line, The results revealed a domain that demonstrated high levels of expression specifically in chondrocytes. In this functional domain, we show that a cis-acting element, 5'-GCCTGAGGC-3', binds to the trans-acting factor protein AP-2, Mutation of the AP-2 site on the CD-RAP promoter led to decreased transcription in C5.18 chondrocytes, indicating that this site may act as an activator of transcription, In contrast, increased concentration of AP-2, stimulated by retinoic acid, led to decreased transcription of the CD RAP promoter, an effect that was abolished by mutation of the AP-2 binding site, The effect of AP-2 was further examined by co-transfection of C5.18 and HepG2 cells with the CD-RAP promoter constructs and an AP-2 expression plasmid, In a dose-dependent manner, cotransfection with AP-2 elevated and then decreased CD-RAP promoter activity, Taken together, these results suggest that AP-2 is involved in the biphasic regulation of CD-RAP transcription.	Univ Washington, Dept Orthopaed, Seattle, WA 98108 USA; Univ Washington, Dept Biochem, Seattle, WA 98108 USA; Vet Adm Puget Sound Hlth Care Syst, Seattle, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sandell, LJ (corresponding author), Washington Univ, Sch Med, Dept Orthopaed Surg, Yalem Res Bldg,Room 704,216 S Kingshighway, St Louis, MO 63110 USA.	sandelll@msnotes.wustl.edu			PHS HHS [R0136994] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; BLESCH A, 1994, CANCER RES, V54, P5695; BOGDAHN U, 1989, CANCER RES, V49, P5358; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 1997, DEV DYNAM, V208, P516, DOI 10.1002/(SICI)1097-0177(199704)208:4<516::AID-AJA7>3.0.CO;2-L; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; COVERT J, 1995, VET IMMUNOL IMMUNOP, V49, P39, DOI 10.1016/0165-2427(95)05451-B; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRIGORIADIS AE, 1989, ENDOCRINOLOGY, V125, P2103, DOI 10.1210/endo-125-4-2103; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IWAMOTO M, 1993, EXP CELL RES, V205, P213, DOI 10.1006/excr.1993.1079; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; KONDO S, 1998, ORTHOP T, V21, P28; KUETTNER KE, 1982, J CELL BIOL, V93, P743, DOI 10.1083/jcb.93.3.743; LANGMAN J, 1967, J COMP NEUROL, V131, P15, DOI 10.1002/cne.901310103; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Mangelsdorf David J., 1994, P319; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MOSER M, 1995, DEVELOPMENT, V121, P2779; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SNAPE AM, 1991, DEVELOPMENT, V113, P283; TAMARIN A, 1984, J EMBRYOL EXP MORPH, V84, P105; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	34	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5026	5032		10.1074/jbc.273.9.5026	http://dx.doi.org/10.1074/jbc.273.9.5026			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478951	hybrid			2022-12-27	WOS:000072310400035
J	Coombs, GS; Bergstrom, RC; Madison, EL; Corey, DR				Coombs, GS; Bergstrom, RC; Madison, EL; Corey, DR			Directing sequence-specific proteolysis to new targets - The influence of loop size and targets sequence on selective proteolysis by tissue-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL NUCLEASE; SUBSTRATE-SPECIFICITY; OMEGA-LOOP; SITE; PROTEIN; IDENTIFICATION; MUTAGENESIS; EXPRESSION; CATALYSIS; MECHANISM	We have previously used substrate phage display to identify peptide sequences that are efficiently and selectively cleaved by tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA), We demonstrate that this information can be used to direct selective proteolysis to new protein targets, Sequences that were labile to selective cleavage by t-PA or u-PA when in the context of a peptide were introduced into the 43-52 (or Omega) loop of staphylococcal nuclease, Both t-PA and u-PA hydrolyze the engineered proteins at the inserted target sequences, and K-m values for protein cleavage were reduced up to 200-fold relative to values for cleavage of analogous sequences within 15 residue peptides, Variation of loop size surrounding a target sequence affects the efficiency of t-PA approximately 5-fold more strongly than that of trypsin, suggesting that cleavage by t-PA is more dependent on target site mobility, Cleavage of proteins by t-PA and u-PA is sequence selective, u-PA is 47-fold more active than t-PA for cleavage of a sequence known to be u-PA selective within small peptide substrates, whereas t-PA is 230-fold more active toward a t-PA-selective sequence.	Scripps Res Inst, Dept Vasc Biol VB1, La Jolla, CA 92037 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Corey, DR (corresponding author), Scripps Res Inst, Dept Vasc Biol VB1, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Corey@howie.swmed.edu		Coombs, Gary/0000-0002-0711-185X	NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline; NIGMS NIH HHS [T32GM08203] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDISSERI DM, 1991, BIOCHEMISTRY-US, V30, P3628, DOI 10.1021/bi00229a006; BUNTON CA, 1960, J CHEM SOC, P3293, DOI 10.1039/jr9600003293; CHAPMAN KT, 1993, J MED CHEM, V36, P4293, DOI 10.1021/jm00078a019; CHATTERJEE S, 1995, J MOL BIOL, V245, P311, DOI 10.1006/jmbi.1994.0025; Coombs GS, 1996, J BIOL CHEM, V271, P4461; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; GUTHRIE JP, 1977, J AM CHEM SOC, V99, P3391; HALE SP, 1993, BIOCHEMISTRY-US, V32, P7479, DOI 10.1021/bi00080a020; HAMILTON RT, 1991, MOL REPROD DEV, V30, P285, DOI 10.1002/mrd.1080300402; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JUDICE JK, 1993, SCIENCE, V261, P1578, DOI 10.1126/science.8103944; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Ke SH, 1997, J BIOL CHEM, V272, P20456, DOI 10.1074/jbc.272.33.20456; KUMAMOTO J, 1956, J AM CHEM SOC, V78, P4858, DOI 10.1021/ja01600a012; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Niedbala M J, 1993, Agents Actions Suppl, V42, P179; POOLE LB, 1991, BIOCHEMISTRY-US, V30, P3621, DOI 10.1021/bi00229a005; RYPNIEWSKI WR, 1994, PROTEIN ENG, V7, P57, DOI 10.1093/protein/7.1.57; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SHORTLE D, 1986, J CELL BIOCHEM, V30, P281, DOI 10.1002/jcb.240300402; Sim R B, 1993, Int Rev Immunol, V10, P65, DOI 10.3109/08830189309051172; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; TANIUCHI H, 1967, P NATL ACAD SCI USA, V58, P1235, DOI 10.1073/pnas.58.3.1235; TANIUCHI H, 1968, J BIOL CHEM, V243, P4778; Taylor J. R., 1982, INTRO ERROR ANAL STU; TORCHIA DA, 1989, BIOCHEMISTRY-US, V28, P5509, DOI 10.1021/bi00439a028; Werb Z, 1992, Matrix Suppl, V1, P337	38	27	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4323	4328		10.1074/jbc.273.8.4323	http://dx.doi.org/10.1074/jbc.273.8.4323			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468480	hybrid			2022-12-27	WOS:000072115000008
J	Hoffman, GR; Nassar, N; Oswald, RE; Cerione, RA				Hoffman, GR; Nassar, N; Oswald, RE; Cerione, RA			Fluoride activation of the Rho family GTP-binding protein Cdc42Hs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GS-ALPHA; TRANSDUCIN; MECHANISM; DOMAIN; IDENTIFICATION; KINASE; SPECTROSCOPY; HYDROLYSIS; MUTATIONS	Aluminum tetrafluoride (AlF4-) activation of heterotrimeric G-protein alpha-subunits is a well established aspect of the biochemistry of these proteins; however, until recently it has been thought that AlF4- does not mediate effects on the Ras superfamily of low molecular weight GTP-binding proteins. Recent work demonstrating aluminum fluoride-induced complex formation between Ras and its GTPase-activating proteins (RasGAP and NF1) has provided important insights into the mechanism of GAP-stimulated GTP hydrolysis. We have characterized the AlF4--induced complex formation between the GDP-bound form of the Rho subfamily G-protein Cdc42Hs and a limit functional domain of the Cdc42-GAP using a variety of biochemical techniques. Our results indicate that the apparent affinity of GAP for the AlF4--mediated complex ids similar to the affinity observed for the activated (GTP-bound) form of Cdc42 and that beryllium (Be) can replace aluminum in mediating fluoride-induced complex formation. Additionally, the AlF4--induced interaction is weakened significantly by the catalytically compromised GAP(R305A) mutant, indicating that this arginine is critical in transition state stabilization. Unlike Ras, we find that AlF4- and BeF3- mediate complex formation between Cdc42Hs.GDP and downstream target/effector molecules, indicating that there are important differences in the mechanism of effector binding between the Ras and Rho subfamily G-proteins.	Cornell Univ, Dept Pharmacol, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Pharmacol, Ithaca, NY 14853 USA.				NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; AHMED S, 1994, J BIOL CHEM, V269, P17642; ANTONNY B, 1992, J BIOL CHEM, V267, P6710; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DARWISH AA, 1981, J LIQ CHROMATOGR, V4, P1511, DOI 10.1080/01483918108064826; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HART MJ, 1991, J BIOL CHEM, V266, P20840; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOP C, 1984, J BIOL CHEM, V259, P696	35	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4392	4399		10.1074/jbc.273.8.4392	http://dx.doi.org/10.1074/jbc.273.8.4392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468490	hybrid			2022-12-27	WOS:000072115000018
J	Ishikawa, K; Matera, KM; Zhou, H; Fujii, H; Sato, M; Yoshimura, T; Ikeda-Saito, M; Yoshida, T				Ishikawa, K; Matera, KM; Zhou, H; Fujii, H; Sato, M; Yoshimura, T; Ikeda-Saito, M; Yoshida, T			Identification of histidine 45 as the axial heme iron ligand of heme oxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; CARBON-MONOXIDE; ESCHERICHIA-COLI; CATALYTIC SITE; DEGRADATION; EXPRESSION; COMPLEX; CDNA; SYSTEM; PURIFICATION	A truncated, soluble, and enzymatically active form of human heme oxygenase-2 (Delta HHO2) was expressed in Escherichia coli, To identify the axial heme ligand of HO-2, His-45 to Ala (Delta H45A) and His-152 to Ala (Delta H152A) mutants have been prepared using this expression system. Delta H45A could form a 1:1 complex with hemin but was completely devoid of the heme degradation activity, A 5-coordinate-type ferrous NO EPR spectrum was ob served for the heme-Delta H45A complex, The Delta H152A mutant was expressed as an inclusion body and was recovered from the lysis pellet by dissolution in urea followed by dialysis. The solubilized fraction obtained, however, was composed of a mixture of a functional enzyme and an inactive fraction. The inactive fraction was removed by Sephadex G-75 column chromatography since it eluted out of the column at the void volume, The gel filtration-purified Delta H152A exhibited spectroscopic and enzymatic properties identical to those of wild-type. We conclude, in contrast to the previous reports (McCoubrey and Maines (1993) Arch. Biochem. Biophys. 302, 402-408; McCoubrey, W, K., Jr., Huang, T, J., and Maines, M. (1997) J. Biol, Chem. 272, 12568-12574), that His 45, but not His-152, in heme oxygenase isoform-a is the proximal ligand of the heme and is essential for the heme degradation activity of the enzyme, His-152 appears to play a structural role in stabilization of the heme oxygenase protein.	Yamagata Univ, Sch Med, Dept Biochem, Yamagata 99023, Japan; Yamagata Univ, Sch Med, Cent Lab Res & Educ, Yamagata 99023, Japan; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Yamagata Techonopolis Fdn, Inst Life Support Technol, Yamagata 990, Japan	Yamagata University; Yamagata University; Case Western Reserve University	Yoshida, T (corresponding author), Yamagata Univ, Sch Med, Dept Biochem, Yamagata 99023, Japan.		Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051588] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05659] Funding Source: Medline; NIGMS NIH HHS [GM51588] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNE B, 1987, MOL PHARMACOL, V32, P497; HARGROVE M, 1994, BIOCHEMISTRY-US, V33, P11676; ISHIKAWA K, 1991, EUR J BIOCHEM, V202, P161, DOI 10.1111/j.1432-1033.1991.tb16357.x; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KIKUCHI G, 1980, TRENDS BIOCHEM SCI, V5, P323, DOI 10.1016/0968-0004(80)90141-3; KON H, 1975, BIOCHIM BIOPHYS ACTA, V379, P103, DOI 10.1016/0005-2795(75)90012-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARSTON FAO, 1984, BIO-TECHNOL, V2, P800, DOI 10.1038/nbt0984-800; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NOGUCHI M, 1983, J BIOCHEM, V93, P1027, DOI 10.1093/oxfordjournals.jbchem.a134226; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SPRINGER BA, 1994, CHEM REV, V94, P69; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x	33	19	19	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4317	4322		10.1074/jbc.273.8.4317	http://dx.doi.org/10.1074/jbc.273.8.4317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468479	hybrid			2022-12-27	WOS:000072115000007
J	Tibbs, GR; Liu, DT; Leypold, BG; Sigelbaum, SA				Tibbs, GR; Liu, DT; Leypold, BG; Sigelbaum, SA			A state-independent interaction between ligand and a conserved arginine residue in cyclic nucleotide-gated channels reveals a functional polarity of the cyclic nucleotide binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; REGULATORY SUBUNIT; POTASSIUM CHANNEL; K+ CHANNEL; ARABIDOPSIS-THALIANA; MOLECULAR MECHANISM; ION-CHANNEL; CAMP	Activation of cyclic nucleotide-gated channels is thought to involve two distinct steps: a recognition event in which a ligand binds to the channel and a conformational change that both opens the channel and increases the affinity of the channel for an agonist, Sequence similarity with the cyclic nucleotide binding sites of cAMP- and cGMP-dependent protein kinases and the bacterial catabolite activating protein (CAP) suggests that the channel ligand binding site consists of a beta-roll and three alpha-helices, Recent evidence has demonstrated that the third (or C) alpha-helix moves relative to the agonist upon channel activation, forming additional favorable contacts with the purine ring, Here we ask if channel activation also involves structural changes in the beta-roll by investigating the contribution of a conserved arginine residue that, in CAP and the kinases, forms an important ionic interaction with the cyclized phosphate of the bound ligand, Mutations that conserve, neutralize, or reverse the charge on this arginine decreased the apparent affinity for ligand over four orders of magnitude but had little effect on the ability of bound ligand to open the channel, These data indicate that the cyclized phosphate of the nucleotide approaches to within 2-4 Angstrom of the arginine, forming a favorable ionic bond that is largely unaltered upon activation, Thus, the binding site appears to be polarized into two distinct structural and functional domains: the beta-roll stabilizes the ligand in a state-independent manner, whereas the C-helix selectively stabilizes the ligand in the open state of the channel. It is likely that these distinct contributions of the nucleotide/C-helix and nucleotide/beta-roll interactions may also be a general feature of the mechanism of activation of other cyclic nucleotide-binding proteins.	Columbia Univ, Dept Pharmacol, Ctr Neurobiol & Behav, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Tibbs, GR (corresponding author), Columbia Univ, Dept Pharmacol, Ctr Neurobiol & Behav, 722 W 168th St, New York, NY 10032 USA.							AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BELDUZ AO, 1993, NUCLEIC ACIDS RES, V21, P1827, DOI 10.1093/nar/21.8.1827; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; GRONENBORN AM, 1988, BIOCHEM J, V253, P801, DOI 10.1042/bj2530801; GRONENBORN AM, 1982, BIOCHEMISTRY-US, V21, P4040, DOI 10.1021/bi00260a020; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kramer RH, 1996, J NEUROSCI, V16, P1285; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOORE J, 1992, J BACTERIOL, V174, P8030, DOI 10.1128/JB.174.24.8030-8035.1992; OGREID D, 1988, J BIOL CHEM, V263, P17397; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; Scott SP, 1996, PROTEIN ENG, V9, P333, DOI 10.1093/protein/9.4.333; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHEN NV, 1993, NEURON, V11, P67; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	44	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4497	4505		10.1074/jbc.273.8.4497	http://dx.doi.org/10.1074/jbc.273.8.4497			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468504	hybrid			2022-12-27	WOS:000072115000032
J	Brink, R; Lodish, HF				Brink, R; Lodish, HF			Tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a TRAF2 splice variant with an extended RING finger domain that inhibits TNFR2-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; CELL-DEATH; CYTOPLASMIC DOMAIN; SIGNALING PROTEINS; INDUCED APOPTOSIS; FACTOR FAMILY; CONTAINS 2; CD40; INTERACTS	We describe here the identification and characterization of tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a splice variant of the TRAF2 molecule utilized for signal transduction by members of the TNFR family. TRAF2A and TRAF2 cDNAs are identical in sequence with the exception of an extra 21 base pairs of sequence encoding a 7-amino acid insert within the TRAF2A RING finger domain. TRAF2A mRNA expression is regulated in a tissue-specific manner, with relative TRAF2A mRNA levels being highest in spleen and lowest in brain. TRAF2A protein is capable of binding to the cytoplasmic domain of TNFR2 (p75) and is detectable in T-lymphoma cells stably transfected with the TRAF2A cDNA. Unlike TRAF2, TRAF2A has a short half-life (similar to 100 min) in these cells and is expressed at only low levels in transiently transfected COS-7 cells. However, TRAF2A levels in transiently transfected COS-7 cells approach those of TRAF2 upon coexpression with TRAF1 and/or TRAF2, indicating that TRAF2A stability is regulated by the binding of other TRAF family proteins. Also in contrast to TRAF2, TRAF2A is unable to stimulate NF-kappa B activity when overexpressed in 293 cells and acts as a dominant inhibitor of TNFR2-dependent NF-kappa B activation. TRAF2A thus represents a novel signal transduction protein, the expression of which can act to inhibit TRAF2-dependent NF-kappa B activation.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Brink, R (corresponding author), Centenary Inst Canc Med & Cell Biol, Locked Bag 6, Newtown, NSW 2042, Australia.	R.Brink@centenary.usyd.edu.au	Brink, Robert/B-7910-2010	Brink, Robert/0000-0002-9586-3655	NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xu Y, 1996, IMMUNITY, V5, P407, DOI 10.1016/S1074-7613(00)80497-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	37	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4129	4134		10.1074/jbc.273.7.4129	http://dx.doi.org/10.1074/jbc.273.7.4129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461607	hybrid			2022-12-27	WOS:000072048400049
J	Gupta, SK; Lysko, PG; Pillarisetti, K; Ohlstein, E; Stadel, JM				Gupta, SK; Lysko, PG; Pillarisetti, K; Ohlstein, E; Stadel, JM			Chemokine receptors in human endothelial cells - Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; PLATELET FACTOR-IV; X-C CHEMOKINE; MOLECULAR-CLONING; IMMUNODEFICIENCY-VIRUS; HIV-1 ENTRY; LYMPHOCYTE CHEMOATTRACTANT; CHROMOSOMAL LOCALIZATION; INTERLEUKIN-8 RECEPTORS; FOAM CELLS	Chemokines play an important role in the regulation of endothelial cell (EC) function, including proliferation, migration and differentiation during angiogenesis, and re-endothelialization after injury. In this study, reverse transcriptase-polymerase chain reaction was used to reveal expression of various CXC and CC chemokine receptors in human umbilical vein EC, Northern analysis showed. that CXCR4 was selectively expressed in vascular EC, but not in smooth muscle cells. Compared with other chemokines, stromal cell derived factor-1 alpha (SDF-1 alpha), the known CXCR4 ligand, was an efficacious chemoattractant. for EC, causing the migration of similar to 40% input cells with an EC50 of 10-20 nM., Of the chemokines tested, only SDF-1 alpha induced a rapid, though variable mobilization of intracellular Ca2+ in EC. Experiments with actinomycin D demonstrated that CXCR4 transcripts were short-lived, indicating a rapid mRNA turnover. Interferon-gamma (IFN-gamma) caused a pronounced downregulation of CXCR4 mRNA in a concentration-and time-dependent manner, In a striking functional correlation, IFN-gamma treatment also attenuated the chemotactic response of EC to SDF-1 alpha, IL-1 beta, tumor necrosis factor-al and lipopolysaccharide produced a time course-dependent biphasic effect on CXCR4 transcription Expression of CXCR4 in EC is significant, more so as it and several CC chemokine receptors have been shown to serve as fusion ca-receptors along with CD4 during human immunodeficiency virus infection. Taken together, these findings provide evidence of chemokine receptor expression in EC and offer an explanation for the action of chemokines like SDF-1 alpha on the vascular endothelium.	SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA	GlaxoSmithKline	Gupta, SK (corresponding author), SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, Mail Code UW2511, King Of Prussia, PA 19406 USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CORBEIL J, 1995, IMMUNOL CELL BIOL, V73, P140, DOI 10.1038/icb.1995.22; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GERRITY RG, 1981, AM J PATHOL, V103, P181; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; GUPTA SK, 1993, GENE, V124, P287, DOI 10.1016/0378-1119(93)90407-T; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH AE, 1995, SCIENCE, V268, P448, DOI 10.1126/science.268.5209.448; LABRANCHE CC, 1994, J VIROL, V68, P5509, DOI 10.1128/JVI.68.9.5509-5522.1994; LEE J, 1992, J BIOL CHEM, V267, P16283; LLOYD AR, 1995, J BIOL CHEM, V270, P28188; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LYSKO PG, 1994, STROKE, V25, P2476, DOI 10.1161/01.STR.25.12.2476; MACIAG T, 1988, ENDOTHELIAL CELLS, V2, P3; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; Murray HW, 1996, INTENS CARE MED, V22, pS456, DOI 10.1007/BF01743724; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Rot A, 1996, J LEUKOCYTE BIOL, V59, P39, DOI 10.1002/jlb.59.1.39; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; STARY HC, 1987, ATHEROSCLEROSIS, V64, P91, DOI 10.1016/0021-9150(87)90234-6; STEFFAN AM, 1992, P NATL ACAD SCI USA, V89, P1582, DOI 10.1073/pnas.89.5.1582; STOECKLE M Y, 1990, New Biologist, V2, P313; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; Tangirala RK, 1997, J BIOL CHEM, V272, P8050, DOI 10.1074/jbc.272.12.8050; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553	54	384	402	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4282	4287		10.1074/jbc.273.7.4282	http://dx.doi.org/10.1074/jbc.273.7.4282			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461627	hybrid			2022-12-27	WOS:000072048400069
J	Ichimura, T; Bonventre, JV; Bailly, V; Wei, H; Hession, CA; Cate, RL; Sanicola, M				Ichimura, T; Bonventre, JV; Bailly, V; Wei, H; Hession, CA; Cate, RL; Sanicola, M			Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING GDNF; RHINOVIRUS RECEPTOR; GROWTH-FACTOR; EXPRESSION; MADCAM-1; FAILURE; VIMENTIN; ANTIGEN; CLONING; BINDING	We report the identification of rat and human cDNAs for a type 1 membrane protein that contains a novel six-cysteine immunoglobulin-like domain and a mucin domain; it is named kidney injury molecule-1 (KIM-1). Structurally, KIM-1 is a member of the immunoglobulin gene superfamily most reminiscent of mucosal addressin cell adhesion molecule 1 (MAdCAM-1). Human KIM-1 exhibits homology to a monkey gene, hepatitis A virus cell receptor 1 (HAVcr-1), which was identified recently as a receptor for the hepatitis A virus, KIM-1 mRNA and protein are expressed at a low level in normal kidney but are increased dramatically in postischemic kidney, In situ hybridization and immunohistochemistry revealed that KIM-1 is expressed in proliferating bromodeoxyuridine-positive and dedifferentiated vimentin-positive epithelial cells in regenerating proximal tubules, Structure and expression data suggest that KIM-1 is an epithelial cell adhesion molecule up-regulated in the cells, which are dedifferentiated and undergoing replication, KIM-1 may play an important role in the restoration of the morphological integrity and function to postischemic kidney.	Biogen Inc, Cambridge Ctr 14, Cambridge, MA 01242 USA; Massachusetts Gen Hosp East, Renal Unit, Med Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02129 USA	Biogen; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Sanicola, M (corresponding author), Biogen Inc, Cambridge Ctr 14, Cambridge, MA 01242 USA.		Wilson, Matthew H/K-3193-2013		NIDDK NIH HHS [DK 39773] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039773, R01DK039773] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLIGORSKY MS, 1993, P NATL ACAD SCI USA, V90, P5700, DOI 10.1073/pnas.90.12.5700; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAMMERMAN MR, 1994, J AM SOC NEPHROL, V5, P1; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; ICHIMURA T, 1995, AM J PHYSIOL-RENAL, V269, pF653, DOI 10.1152/ajprenal.1995.269.5.F653; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Kaplan G, 1996, EMBO J, V15, P4282, DOI 10.1002/j.1460-2075.1996.tb00803.x; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; MALIS CD, 1983, AM J PHYSIOL, V245, pF735, DOI 10.1152/ajprenal.1983.245.6.F735; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SHI SR, 1993, J HISTOCHEM CYTOCHEM, V41, P1599, DOI 10.1177/41.11.7691930; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; Shyjan AM, 1996, J IMMUNOL, V156, P2851; SIGEL MB, 1983, METHOD ENZYMOL, V93, P3; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALLIN A, 1992, LAB INVEST, V66, P474; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214	42	895	985	3	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4135	4142		10.1074/jbc.273.7.4135	http://dx.doi.org/10.1074/jbc.273.7.4135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461608	hybrid			2022-12-27	WOS:000072048400050
J	Munch-Petersen, B; Piskur, J; Sondergaard, L				Munch-Petersen, B; Piskur, J; Sondergaard, L			Four deoxynucleoside kinase activities from Drosophila melanogaster are contained within a single monomeric enzyme, a new multifunctional deoxynucleoside kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYMIDINE KINASE; DEOXYGUANOSINE KINASE; DEOXYCYTIDINE KINASE; CELL-CYCLE; AFFINITY-CHROMATOGRAPHY; SUBSTRATE-SPECIFICITY; MOLECULAR-FORMS; DNA POLYMERASE; CLONING; EXPRESSION	In mammalian cells, there are three pyrimidine nucleoside salvage enzymes with the capacity to phosphorylate all four deoxynucleosides, the two thymidine kinase isoenzymes, TK1 and TK2, and two deoxycytidine kinase, dCK. TK1 is cell cycle-regulated; TK2 is expressed constitutively and can phosphorylate deoxycytidine to the same extent as thymidine. dCK phosphorylates deoxycytidine, deoxyadenosine, and deoxyguanosine, but not thymidine. In addition, the three kinases can phosphorylate a number of medically important analogs. In cultured Drosophila melanogaster embryonic cells, only one pyrimidine deoxynucleoside kinase was present, This kinase was purified and showed a broad substrate specificity, since it was able to phosphorylate all four deoxynucleosides with high efficiency, as compared with the kinases in mammalian cells. Additionally, a number of nucleoside analogs such as arabinofuranosyl pyrimidines, deoxyuridine, and 5'-fluorodeoxyuridine, were phosphorylated. There was negligible 3'-azidothymidine and no dTMP phosphorylation. The enzyme was active as a monomer of about 30 kDA. We suggest the name D. melanogaster deoxynucleoside kinase for this multifunctional kinase. The substrate specificity, size, and other characteristics show that this enzyme is more related to human TK2 than to the other mammalian deoxyribonucleoside kinases, but is unique with respect to the capacity to phosphorylate all four deoxynucleosides.	Roskilde Univ, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Tech Univ Denmark, Dept Microbiol, DK-2800 Lyngby, Denmark; Univ Copenhagen, Dept Genet, DK-1353 Copenhagen, Denmark	Roskilde University; Technical University of Denmark; University of Copenhagen	Munch-Petersen, B (corresponding author), Roskilde Univ, Dept Chem & Life Sci, POB 260, DK-4000 Roskilde, Denmark.							ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BLACK ME, 1991, MOL MICROBIOL, V5, P373, DOI 10.1111/j.1365-2958.1991.tb02119.x; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW HD, 1983, P NATL ACAD SCI-BIOL, V80, P5588, DOI 10.1073/pnas.80.18.5588; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; EGER K, 1993, PHARMACEUT RES, V10, P771, DOI 10.1023/A:1018980304519; GOWER WR, 1979, J BIOL CHEM, V254, P2180; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258; KAGUNI LS, 1983, P NATL ACAD SCI-BIOL, V80, P2221, DOI 10.1073/pnas.80.8.2221; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KIT S, 1974, BIOCHEM GENET, V11, P231, DOI 10.1007/BF00486058; KOWAL EP, 1976, PREP BIOCHEM, V6, P369, DOI 10.1080/00327487608061625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM FK, 1988, BIOCHEM CELL BIOL, V66, P318, DOI 10.1139/o88-041; MUNCHPETERSEN B, 1993, J BIOL CHEM, V268, P15621; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; Sondergaard L, 1996, BIOTECHNOL TECH, V10, P161, DOI 10.1007/BF00158939; WANG LY, 1993, J BIOL CHEM, V268, P22847; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764	26	87	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3926	3931		10.1074/jbc.273.7.3926	http://dx.doi.org/10.1074/jbc.273.7.3926			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461577	hybrid			2022-12-27	WOS:000072048400019
J	Hill, JR; Kwon, G; Marshall, CK; McDaniel, ML				Hill, JR; Kwon, G; Marshall, CK; McDaniel, ML			Hyperglycemic levels of glucose inhibit interleukin 1 release from RAW 264.7 murine macrophages by activation of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET CELL TUMOR; DIABETIC RATS; LINES; IDENTIFICATION; GLYCOLYSIS; METABOLISM; GLUTAMINE; GLOMERULI; INSULIN; ENZYME	Diabetic patients with hyperglycemia (high blood glucose) have frequent and persistent bacterial infections linked to significantly diminished bactericidal activity and macrophage function, Interleukin-1 (IL-1), released primarily from activated macrophages, is a key mediator of effective host defense against microorganisms. We observe that hyperglycemic levels of D-glucose (8-20 mM) inhibit the release of IL-1 by lipopolysaccharide-stimulated RAW 264.7 murine macrophage cells. An inhibitor of glucose transport and metabolism, 2-deoxyglucose, prevents this inhibition of IL-1 release, High levels (8-20 mM) of fructose and mannose (but not galactose or L-glucose) also inhibit the release of IL-1 activity, suggesting that metabolism is required for IL-1 inhibition. Immunoprecipitation and activity measurements demonstrate that high glucose levels block the release of IL-1 but do not inhibit IL-1 production, High glucose levels (20 mM) increase protein kinase C (PKC) activity, and inhibitors of PKC block the inhibitory effects of glucose. Phorbol 12-myristate 13-acetate, an agonist of PKC, mimics glucose-induced inhibition of IL-1 release. These results demonstrate that high glucose levels inhibit IL-1 release (but not production) by RAW 264.7 murine macrophages, and this inhibition is mediated by PKC activation. These studies suggest that persistent infections in hyperglycemic patients may be due to an inhibition of IL-1 release from macrophages.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL)	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.				NIDDK NIH HHS [F32 DK-08748, DK-06181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008748, R01DK006181, R56DK006181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bessman Alice N., 1992, Journal of Diabetes and its Complications, V6, P258, DOI 10.1016/1056-8727(92)90062-P; BHATHENA SJ, 1982, DIABETES, V31, P521, DOI 10.2337/diabetes.31.6.521; BUSTOS R, 1992, BIOCHEM J, V282, P299, DOI 10.1042/bj2820299; CALAME W, 1995, J INFECTION, V30, P227, DOI 10.1016/S0163-4453(95)90762-9; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CRAVEN PA, 1994, J CLIN INVEST, V93, P311, DOI 10.1172/JCI116961; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DOUVDEVANI A, 1992, PERITON DIALYSIS INT, V13, P112; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GILKES AF, 1994, BIOCHEM BIOPH RES CO, V204, P1318, DOI 10.1006/bbrc.1994.2607; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Hill JR, 1996, J BIOL CHEM, V271, P22672, DOI 10.1074/jbc.271.37.22672; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; JONES CA, 1982, P SOC EXP BIOL MED, V170, P298; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; MAYHAN WG, 1995, AM J PHYSIOL-HEART C, V269, pH1297, DOI 10.1152/ajpheart.1995.269.4.H1297; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; NEWSHOLME P, 1986, BIOCHEM J, V239, P121, DOI 10.1042/bj2390121; NIELSON CP, 1989, DIABETES, V38, P1031, DOI 10.2337/diabetes.38.8.1031; ORLINSKA U, 1993, J CELL PHYSIOL, V157, P201, DOI 10.1002/jcp.1041570126; POTTER LR, 1994, J BIOL CHEM, V269, P14636; RALPH P, 1977, J IMMUNOL, V119, P950; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; RAYFIELD EJ, 1982, AM J MED, V72, P439, DOI 10.1016/0002-9343(82)90511-3; RUBARTELLI A, 1991, BIOCHEM SOC T, V19, P255, DOI 10.1042/bst0190255; SCHACHTELE C, 1988, BIOCHEM BIOPH RES CO, V151, P542, DOI 10.1016/0006-291X(88)90628-6; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; SMITHERMAN KO, 1995, MED CLIN N AM, V79, P53, DOI 10.1016/S0025-7125(16)30084-0; WHEAT LJ, 1980, DIABETES CARE, V3, P187, DOI 10.2337/diacare.3.1.187; WILLIAMS B, 1992, DIABETES, V41, P1464, DOI 10.2337/diabetes.41.11.1464; WU GY, 1991, BIOCHIM BIOPHYS ACTA, V1115, P166, DOI 10.1016/0304-4165(91)90026-D	37	28	28	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3308	3313		10.1074/jbc.273.6.3308	http://dx.doi.org/10.1074/jbc.273.6.3308			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452447	hybrid			2022-12-27	WOS:000071822300032
J	Jonassen, T; Proft, M; Randez-Gil, F; Schultz, JR; Marbois, BN; Entian, KD; Clarke, CF				Jonassen, T; Proft, M; Randez-Gil, F; Schultz, JR; Marbois, BN; Entian, KD; Clarke, CF			Yeast clk-1 homologue (Coq7/Cat5) is a mitochondrial protein in coenzyme Q synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; CAENORHABDITIS-ELEGANS; GLUCOSE REPRESSION; GLUCONEOGENIC ENZYMES; ENDOPLASMIC-RETICULUM; HYDROPHOBIC MOMENT; HYDROGEN-PEROXIDE	Mutations in the clk-1 gene result in slower development and increased life span in Caenorhabditis elegans. The Saccharomyces cerevisiae homologue COQ7/CAT5 is essential for several metabolic pathways including ubiquinone biosynthesis, respiration, and gluconeogenic gene activation. We show here that Coq7p/Cat5p is a mitochondrial inner membrane protein directly involved in ubiquinone biosynthesis, and that the defect in gluconeogenic gene activation in coq7/cat5 null mutants is a general consequence of a defect in respiration. These results obtained in the yeast model suggest that the effects on development and life span in C. elegans clk-1 mutants may relate to changes in the amount of ubiquinone, an essential electron transport component and a lipid soluble antioxidant.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Goethe Univ Frankfurt, Biozentrum, Inst Mikrobiol, D-60439 Frankfurt, Germany	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Goethe University Frankfurt	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	cathy@ewald.mbi.ucla.edu	Randez-Gil, Francisca/H-2868-2012; Entian, Karl-Dieter/D-3080-2011; Proft, Markus/K-2323-2014	Randez-Gil, Francisca/0000-0001-8217-3156; Proft, Markus/0000-0002-6788-5830	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07185, GM45952] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; ANDREE P, 1996, THESIS KAROLINSKA I, P9; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHER E B, 1989, Molecular and General Genetics, V215, P517, DOI 10.1007/BF00427051; Austriaco NR, 1996, YEAST, V12, P623, DOI 10.1002/(SICI)1097-0061(19960615)12:7<623::AID-YEA968>3.0.CO;2-G; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BROWN TA, 1995, J BACTERIOL, V177, P1380, DOI 10.1128/jb.177.5.1380-1382.1995; CALDER KM, 1991, MOL MICROBIOL, V5, P1769, DOI 10.1111/j.1365-2958.1991.tb01926.x; CARLSON M, 1981, GENETICS, V98, P25; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CIRIACY M, 1975, MOL GEN GENET, V138, P157, DOI 10.1007/BF02428119; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; Dibrov E, 1997, J BIOL CHEM, V272, P9175; DIXON GH, 1959, BIOCHEM J, V72, pP3; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; ENTIAN KD, 1982, J BACTERIOL, V151, P1123, DOI 10.1128/JB.151.3.1123-1128.1982; ERNSTER L, 1993, CLIN INVESTIGATOR, V71, pS60, DOI 10.1007/BF00226842; ESTORNELL E, 1992, FEBS LETT, V311, P107, DOI 10.1016/0014-5793(92)81378-Y; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; ForsmarkAndree P, 1997, FREE RADICAL BIO MED, V22, P391, DOI 10.1016/S0891-5849(96)00330-9; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Glinn MA, 1997, BBA-BIOENERGETICS, V1318, P246, DOI 10.1016/S0005-2728(96)00142-9; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; HANSEN RJ, 1976, ANAL BIOCHEM, V74, P576, DOI 10.1016/0003-2697(76)90240-2; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEDGES D, 1995, MOL CELL BIOL, V15, P1915; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Lemmon MA., 1992, CURR OPIN STRUC BIOL, V2, P511; LENAZ G, 1993, CLIN INVESTIGATOR, V71, pS66; Lithgow GJ, 1996, BIOESSAYS, V18, P809, DOI 10.1002/bies.950181007; MARBOIS BN, 1994, GENE, V138, P213; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Murakami S, 1996, GENETICS, V143, P1207; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; NEIGEBORN L, 1984, GENETICS, V108, P845; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; OHASHI A, 1982, J BIOL CHEM, V257, P3042; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; PROFT M, 1997, THESIS JW GOETHE U F; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; SantosOcana C, 1995, J BIOENERG BIOMEMBR, V27, P597, DOI 10.1007/BF02111657; SIKORSKI RS, 1989, GENETICS, V122, P19; SIPPEL CJ, 1983, J BIOL CHEM, V258, P1057; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1986, J BIOL CHEM, V261, P7163; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975; WONG A, 1995, GENETICS, V139, P1247; WONG S, 1986, BIOCHEMISTRY-US, V25, P6294, DOI 10.1021/bi00368a069; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Yu BP, 1996, ANN NY ACAD SCI, V786, P1, DOI 10.1111/j.1749-6632.1996.tb39047.x; ZIMMERMANN FK, 1977, MOL GEN GENET, V151, P95, DOI 10.1007/BF00446918; [No title captured]	87	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3351	3357		10.1074/jbc.273.6.3351	http://dx.doi.org/10.1074/jbc.273.6.3351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452453	hybrid			2022-12-27	WOS:000071822300038
J	Kim, MJ; Min, DS; Ryu, SH; Suh, PG				Kim, MJ; Min, DS; Ryu, SH; Suh, PG			A cytosolic, G alpha(q)- and beta gamma-insensitive splice variant of phospholipase C-beta 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; DROSOPHILA-MELANOGASTER; INOSITOL TRISPHOSPHATE; BOVINE CEREBELLUM; HUMAN PLATELETS; GROWTH-FACTOR; NORPA GENE; C ISOZYME; ACTIVATION; PURIFICATION	Phospholipase C (PLC)-beta 4 has been considered to be a mammalian homolog of the NorpA PLC, which is responsible for visual signal transduction in Drosophila. We reported previously the cloning of a cDNA encoding rat phospholipase C-beta 4 (PLC-beta 4) (Kim, M.J., Bahk, Y.Y., Min, D.S., Lee, S.J., Ryu, S.H., and Suh, P.-G. (1993) Biochem. Biophys. Res. Commun. 194, 706-712), We report now the isolation and characterization of a splice variant (PLC-beta 4b). PLC-beta 4b is identical to the 130-kDa PLC-beta 4 (PLC-beta 4a) except that the carboxyl-terminal 162 amino acids of PLC-beta 4a are replaced by 10 distinct amino acids, The existence of PLC-beta 4b transcripts in the rat brain was demonstrated by reverse transcription-polymerase chain reaction analysis. Immunological analysis using polyclonal antibody specific for PLC-beta 4b revealed that this splice variant exists in rat brain cytosol. To investigate functional differences between the two forms of PLC-beta 4, transient expression studies in COS-7 cells were conducted, We found that PLC-beta 4a was localized mainly in the particulate fraction of the cell, and it could be activated by G alpha(q), whereas PLC-beta 4b was localized exclusively in the soluble fraction, and it could not be activated by G alpha(q). In addition, both PLC-beta 4a and PLC-beta 4b were not activated by G-protein beta gamma-subunits purified from rat brain. These results suggest that PLC-beta 4b may be regulated by a mechanism different from that of PLC-beta 4a, and therefore it may play a distinct role in PLC mediated signal transduction.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Suh, PG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.	pgs@pop.postech.ac.kr	Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				BAHK YY, 1994, J BIOL CHEM, V269, P8240; BANNO Y, 1994, FEBS LETT, V340, P185, DOI 10.1016/0014-5793(94)80134-7; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FERREIRA PA, 1994, J BIOL CHEM, V269, P3129; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KIM S, 1995, J BIOL CHEM, V270, P14376, DOI 10.1074/jbc.270.24.14376; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE CW, 1994, J BIOL CHEM, V269, P25335; LEE SB, 1993, J BIOL CHEM, V268, P25952; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; MIN DS, 1993, FEBS LETT, V331, P38, DOI 10.1016/0014-5793(93)80293-4; MIN DS, 1993, J BIOL CHEM, V268, P12207; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROUSTAN P, 1995, NEUROREPORT, V6, P1837, DOI 10.1097/00001756-199510020-00004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UEDA N, 1994, J BIOL CHEM, V269, P4388; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P1811; YEO EJ, 1994, J BIOL CHEM, V269, P27823	45	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3618	3624		10.1074/jbc.273.6.3618	http://dx.doi.org/10.1074/jbc.273.6.3618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452490	hybrid			2022-12-27	WOS:000071822300075
J	Nadanaka, S; Clement, A; Masayama, K; Faissner, A; Sugahara, K				Nadanaka, S; Clement, A; Masayama, K; Faissner, A; Sugahara, K			Characteristic hexasaccharide sequences in octasaccharides derived from shark cartilage chondroitin sulfate D with a neurite outgrowth promoting activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; HEPARAN-SULFATE; FLAVOBACTERIUM-HEPARINUM; MONOCLONAL-ANTIBODIES; STRUCTURAL-ANALYSIS; OLIGOSACCHARIDES; PROTEOGLYCANS; ABC; SPECTROSCOPY; TETRASACCHARIDES	A mouse brain chondroitin sulfate (CS) proteoglycan, DSD-1-PG, bears the DSD-1 epitope and has neurite out-growth promoting properties. Shark cartilage CS-C inhibits the interactions between the DSD-1-specific monoclonal antibody 473HD and the CS chains of the DSD-1-PG, which is expressed on the mouse glial cells (Faissner, A., Clement, A., Lochter, A., Streit, A., Mandl, C., and Schachner, M. (1994) J. Cell Biol. 126, 783-799), On the other hand, several hexasaccharides isolated from commercial shark cartilage CS-D, which contains a higher proportion of characteristic D units (GlcUA(2-sulfate)beta 1-3GalNAc(6-sulfate)) as compared with CS-C, has the A-D tetrasaccharide sequence composed of an A disaccharide unit (GlcUA beta 1-3GalNAc(4-sulfate)) and a D disaccharide unit (Nadanaka, S. and Sugahara, K. (1997) Glycobiology 7, 253-263). In this study, the biological activities and the structure of shark cartilage CS-D were investigated. CS-D inhibited the interactions between monoclonal antibody 473HD and DSD-1-PG and also promoted neurite outgrowth of embryonic day 18 hippocampal neurons. Eight octasaccharide fractions were isolated from CS-D after partial digestion with bacterial chondroitinase ABC by means of gel filtration chromatography and anion-exchange high performance liquid chromotography to investigate the frequency and the arrangement of the A-D tetrasaccharide unit in the polymer sequence. Structural analysis performed by a combination of enzymatic digestions with 500-MHz H-1 NMR spectroscopy demonstrated that the isolated octasaccharides shared the common core structure Delta HexA alpha 1-3GalNAc beta 1-4(GlcUA beta 1-3GalNAc)(3) with four, five, and six sulfate esters at various hydroxyl groups in different combinations, In the structure, Delta HexA and GlcUA represent 4-deoxy-alpha-L-threo-hex-4-enepyranosyluronic acid and glucuronic acid, respectively. No D-D tetrasaccharide sequence was found, and discrete D disaccharide units were demonstrated exclusively as A-D tetrasaccharide units in either an A-D-A or an A-D-C hexasaccharide sequence in the five octasaccharides that represented about 5.0% (w/w) of the starting polysaccharides (C denotes the disaccharide GlcUA beta 1-3GalNAc(6-sulfate)). It remains to be determined whether such characteristic hexasaccharide sequences present in shark cartilage CS-D serve as functional domain structures recognized by some protein ligands.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan; Univ Heidelberg, Dept Neurobiol, D-69120 Heidelberg, Germany	Kobe Pharmaceutical University; Ruprecht Karls University Heidelberg	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan.		Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Goslin K., 1991, CULTURING NERVE CELL, P251; Gotz B, 1996, J CELL BIOL, V132, P681, DOI 10.1083/jcb.132.4.681; Hamai A, 1997, J BIOL CHEM, V272, P9123; HARDINGHAM TE, 1994, CARBOHYD RES, V255, P241, DOI 10.1016/S0008-6215(00)90982-0; HARRIS MJ, 1970, CARBOHYD RES, V15, P57, DOI 10.1016/S0008-6215(00)80294-3; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MICHELACCI YM, 1987, BIOCHIM BIOPHYS ACTA, V923, P291, DOI 10.1016/0304-4165(87)90016-X; Nadanaka S, 1997, GLYCOBIOLOGY, V7, P253, DOI 10.1093/glycob/7.2.253; NADANAKA S, 1997, GLYCONJUGATE J, V14, pS15; SORRELL JM, 1993, MATRIX, V13, P351, DOI 10.1016/S0934-8832(11)80040-5; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 1996, GLYCOCONJUGATE J, V13, P609, DOI 10.1007/BF00731449; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Sugahara K, 1996, EUR J BIOCHEM, V239, P865, DOI 10.1111/j.1432-1033.1996.0865u.x; SUZUKI S, 1960, J BIOL CHEM, V235, P3580; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; YOSHIDA K, 1995, GLYCOCONJUGATE J, V12, P488	33	144	152	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3296	3307		10.1074/jbc.273.6.3296	http://dx.doi.org/10.1074/jbc.273.6.3296			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452446	hybrid			2022-12-27	WOS:000071822300031
J	Banhegyi, G; Marcolongo, P; Puskas, F; Fulceri, R; Mandl, J; Benedetti, A				Banhegyi, G; Marcolongo, P; Puskas, F; Fulceri, R; Mandl, J; Benedetti, A			Dehydroascorbate and ascorbate transport in rat liver microsomal vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6-PHOSPHATASE SYSTEM; ENDOPLASMIC-RETICULUM; VITAMIN-C; ACID; GLUCOSE; PROTEIN; IDENTIFICATION; ACCUMULATION; PERMEABILITY; EXPRESSION	Ascorbate and dehydroascorbate transport was investigated in rat liver microsomal vesicles using radiolabeled compounds and a rapid filtration method, The uptake of both compounds was time-and temperature-dependent, and saturable. Ascorbate uptake did not reach complete equilibrium, it had low affinity and high capacity, Ascorbate influx could not be inhibited by glucose, dehydroascorbate, or glucose transport inhibitors (phloretin, cytochalasin B) but it was reduced by the anion transport inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid and by the alkylating agent N-ethylmaleimide, Ascorbate uptake could be stimulated by ferric iron and could be diminished by reducing agents (dithiothreitol, reduced glutathione). In contrast, dehydroascorbate uptake exceeded the level of passive equilibrium, it had high affinity and low capacity, Glucose cis inhibited and trans stimulated the uptake. Glucose transport inhibitors were also effective. The presence of intravesicular reducing compounds increased, while extravesicular reducing environment decreased dehydroascorbate influx. Our results suggest that dehydroascorbate transport is preferred in hepatic endoplasmic reticulum and it is mediated by a GLUT-type transporter, The intravesicular reduction of dehydroascorbate leads to the accumulation of ascorbate and contributes to the low intraluminal reduced/oxidized glutathione ratio.	Semmelweis Univ, Dept Med Chem, H-1444 Budapest, Hungary; Univ Siena, Ist Patol Gen, I-53100 Siena, Italy	Semmelweis University; University of Siena	Banhegyi, G (corresponding author), Semmelweis Univ, Dept Med Chem, POB 260, H-1444 Budapest, Hungary.	banhegyi@puskin.sote.hu	Bánhegyi, Gábor/A-1476-2014; Marcolongo, Paola/AAG-5260-2019	Marcolongo, Paola/0000-0001-9330-8570				Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Banhegyi G, 1997, FREE RADICAL BIO MED, V23, P793, DOI 10.1016/S0891-5849(97)00062-2; BERGSTEN P, 1994, J BIOL CHEM, V269, P1041; Braun L, 1996, FEBS LETT, V390, P183, DOI 10.1016/0014-5793(96)00654-0; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Chen Y-T, 1995, METABOLIC MOL BASES, P935; DELBELLO B, 1994, BIOCHEM J, V304, P385, DOI 10.1042/bj3040385; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; FULCERI R, 1992, BIOCHEM J, V286, P813, DOI 10.1042/bj2860813; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HARAPANHALLI RS, 1993, J CHROMATOGR-BIOMED, V614, P233, DOI 10.1016/0378-4347(93)80314-T; HENNE V, 1986, FEBS LETT, V202, P267, DOI 10.1016/0014-5793(86)80699-8; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; Marcolongo P, 1996, BIOCHEM BIOPH RES CO, V219, P916, DOI 10.1006/bbrc.1996.0333; MEISSNER G, 1988, METHOD ENZYMOL, V157, P417; Ngkeekwong FC, 1997, BIOCHEM J, V324, P225, DOI 10.1042/bj3240225; NJUS D, 1993, BIOCHIM BIOPHYS ACTA, V1144, P235, DOI 10.1016/0005-2728(93)90108-R; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; Price KD, 1996, MED HYPOTHESES, V46, P119, DOI 10.1016/S0306-9877(96)90011-0; Rowling P J, 1993, Subcell Biochem, V21, P41; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WADDELL ID, 1991, BIOCHEM J, V275, P363, DOI 10.1042/bj2750363; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584	30	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2758	2762		10.1074/jbc.273.5.2758	http://dx.doi.org/10.1074/jbc.273.5.2758			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446582	hybrid			2022-12-27	WOS:000071736600037
J	Flynn, P; Mellor, H; Palmer, R; Panayotou, G; Parker, PJ				Flynn, P; Mellor, H; Palmer, R; Panayotou, G; Parker, PJ			Multiple interactions of PRK1 with RhoA - Functional assignment of the HR1 repeat motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-D ACTIVITY; GTP-BINDING PROTEIN; AMINO-TERMINAL REGION; ZIPPER-LIKE SEQUENCES; PUTATIVE TARGET; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; HA-RAS; ACTIVATION; FAMILY	PRK1 (PKN) is a serine/threonine kinase that has been shown to be activated by RhoA (Amano, M., Mukai, H., One, Y., Chihara, K., Matsui, T., Hamajima, Y., Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) Science 271, 648-650), Detailed analysis of the PRK1 region involved in RhoA binding has revealed that two homologous sequences within the HR1 domain (HR1a and HR1b) both bind to RhoA; the third repeat within this domain, HR1c(PRK1), does not bind RhoA, The related HR1 motif is also found to confer RhoA binding activity to the only other fully cloned member of this kinase family, PRK2, Furthermore, the predictive value of this motif is established for an HR1a sequence derived from a Caenorhabditis elegans open reading frame encoding a protein kinase of unknown function, Interestingly, the HR1a(PRK1) and HR1b(PRK1) subdomains are shown to display a distinctive nucleotide dependence for RhoA binding, HR1a(PRK1) is entirely GTP-dependent, while HR1b(PRK1) binds both GTP-and GDP-bound forms of RhoA. This distinction indicates that there are two sites of contact between RhoA and PRK1, one contact through a region that is conformationally dependent upon the nucleotide-bound state of RhoA and one that is not, Analysis of binding to Rho/Rac chimera provides evidence for a HR1a(PRK1) but not HR1b(PRK1) interaction in the central third of Rho, Additionally, it is observed that the V14RhoA mutant binds HR1a but does not bind HR1b, This distinct binding behavior corroborates the conclusion that there are independent contacts on RhoA for the HR1a(PRK1) and HR1b(PRK1) motifs.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London	Parker, PJ (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	Mellor, Harry/0000-0003-3894-0623; parker, peter/0000-0002-6218-2933				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; ISHIZAKI T, 1996, EMBO J, V15, P4885; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Ponting CP, 1996, PROTEIN SCI, V5, P162; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Shimooku K, 1996, FEBS LETT, V387, P141, DOI 10.1016/0014-5793(96)00483-8; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOLONTE C, 1992, J BIOL CHEM, V267, P21663; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Yokozeki T, 1996, J NEUROCHEM, V66, P1234; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	43	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2698	2705		10.1074/jbc.273.5.2698	http://dx.doi.org/10.1074/jbc.273.5.2698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446575	hybrid			2022-12-27	WOS:000071736600030
J	Mohanty, BK; Sahoo, T; Bastia, D				Mohanty, BK; Sahoo, T; Bastia, D			Mechanistic studies on the impact of transcription on sequence-specific termination of DNA replication and vice versa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TRANSCRIBING POLYMERASE; POLAR CONTRAHELICASE; BINDING PROTEIN; TUS PROTEIN; FORK; ARREST; IDENTIFICATION	Since DNA replication and transcription often temporally and spatially overlap each other, the impact of one process on the other is of considerable interest. We have reported previously that transcription is impeded at the replication termini of Escherichia coli and Bacillus subtilis in a polar mode and that, when transcription is allowed to invade a replication terminus from the permissive direction, arrest of replication fork at the terminus is abrogated. In the present report, we have addressed four significant questions pertaining to the mechanism of transcription impedance by the replication terminator proteins, Is transcription arrested at the replication terminus or does RNA polymerase dissociate from the DNA causing authentic transcription termination? How does transcription cause abrogation of replication fork arrest at the terminus? Are the points of arrest of the replication fork and transcription the same or are these different? Are eukaryotic RNA polymerases also arrested at prokaryotic replication termini? Our results show that replication terminator proteins of E, coli and B. subtilis arrest but do not terminate transcription, Passage of an RNA transcript through the replication terminus causes the dissociation of the terminator protein from the terminus DNA, thus causing abrogation of replication fork arrest. DNA and RNA chain elongation are arrested at different locations on the terminator sites, Finally, although bacterial replication terminator proteins blocked yeast RNA polymerases in a polar fashion, a yeast transcription terminator protein (Reb1p) was unable to block T7 RNA polymerase and E, coli DnaB helicase.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University	Bastia, D (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.	bastia@abacus.mc.duke.edu						Bastia D, 1997, Genet Eng (N Y), V19, P101; BASTIA D, 1996, EUKARYOTIC DNA REPLI, P177; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BRUAND C, 1990, GENETICS BIOTECHNOLO, V3, P117; BUSSIERE DE, 1995, CELL, V80, P651; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; DHAR V, 1988, MOL CELL BIOL, V8, P4958, DOI 10.1128/MCB.8.11.4958; DILLIN A, 1995, TRENDS BIOCHEM SCI, V20, P231, DOI 10.1016/S0968-0004(00)89023-4; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; FURTH ME, 1978, J MOL BIOL, V126, P195, DOI 10.1016/0022-2836(78)90359-5; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; Kamada K, 1996, NATURE, V383, P598, DOI 10.1038/383598a0; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEVINE A, 1995, MOL MICROBIOL, V15, P287, DOI 10.1111/j.1365-2958.1995.tb02243.x; LEWIS PJ, 1989, J BACTERIOL, V171, P1402, DOI 10.1128/jb.171.3.1402-1408.1989; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; Manna AC, 1996, CELL, V87, P881, DOI 10.1016/S0092-8674(00)81995-9; Manna AC, 1996, P NATL ACAD SCI USA, V93, P3253, DOI 10.1073/pnas.93.8.3253; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; Pai KS, 1996, EMBO J, V15, P3164, DOI 10.1002/j.1460-2075.1996.tb00679.x; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RICHARDSON JP, 1966, J MOL BIOL, V21, P115, DOI 10.1016/0022-2836(66)90083-0; ROCKLEIN BA, 1992, MOL MICROBIOL, V6, P1655, DOI 10.1111/j.1365-2958.1992.tb00890.x; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; YOUNG PA, 1994, J MOL BIOL, V240, P275, DOI 10.1006/jmbi.1994.1444	54	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3051	3059		10.1074/jbc.273.5.3051	http://dx.doi.org/10.1074/jbc.273.5.3051			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446621	hybrid			2022-12-27	WOS:000071736600076
J	Rotenberg, SA; Sun, XG				Rotenberg, SA; Sun, XG			Photoinduced inactivation of protein kinase C by dequalinium identifies the RACK-1-binding domain as a recognition site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR RECEPTORS; BETA-SUBUNIT; INHIBITION; REGION; AGENT	1,1'-Decamethylenebis-4-aminoquinaldinium diiodide (DECA; dequalinium) is an anti-tumor agent and protein kinase C (PKC) inhibitor whose mechanism of action with PKC is unknown, This study reports that with human PKC alpha, DECA exhibited competitive inhibition (K-i = 11.5 +/- 5 mu M) with respect to RACK-1 (receptor for activated C kinase-1), an adaptor protein that has been proposed to bind activated PKC following translocation (Ron, D., Luo, J., and Mochly-Rosen, D. (1995) J. Biol. Chem. 270, 24180-24187), When exposed to UV light, DECA covalently modified and irreversibly inhibited PKC (alpha or beta), with IC50 = 7-18 mu M. UV/DECA treatment of synthetic peptides modeled after the RACK-1-binding site in the C2 region of PKC beta induced modification of Ser(218)-Leu-Asn-Pro-Glu-Trp-Asn-Glu-Thr(226), but not of a control peptide, This modification occurred ata tryptophan residue (Trp(223)) that is conserved in all conventional PKC isoforms. In overlay assays with native RACK-1 that had been immobilized on nitrocellulose, UV-treated control PKC alpha bound well to RACK-1, whereas UV/DECA-inactivated PKC alpha had reduced binding activity, The significance of these findings is shown with adenocarcinoma cells, which, when pretreated with 10 mu M DECA and UV light, exhibited diminished 12-O-tetradecanoylphorbol-13-acetate-induced PKC alpha translocation. Overall, this work identifies DECA as a tool that prevents PKC translocation by inhibiting formation of the PRC RACK-1 complex.	CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	City University of New York (CUNY) System; Queens College NY (CUNY)	Rotenberg, SA (corresponding author), CUNY Queens Coll, Dept Chem & Biochem, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	rotenber@qcvaxa.acc.qc.edu		Rotenberg, Susan/0000-0002-6618-686X	NCI NIH HHS [CA60618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; HELIGE C, 1993, EUR J CANCER, V29A, P124, DOI 10.1016/0959-8049(93)90589-8; LESTER DS, 1992, PROTEIN KINASE C CUR, P80; MANETTA A, 1993, GYNECOL ONCOL, V50, P38, DOI 10.1006/gyno.1993.1161; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; ORR JW, 1994, J BIOL CHEM, V269, P8383; Parker P.J., 1992, PROTEIN KINASE C CUR, P3; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROSENBERG IM, 1996, PROTEIN ANAL PURIFIC, P38; ROTENBERG SA, 1990, CANCER RES, V50, P677; ROTENBERG SA, 1991, BIOCH MOL ASPECTS SE, V1, P25; SEGEL IH, 1975, ENZYME KINETICS, P110; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAYLOR EP, 1951, J CHEM SOC, P1150, DOI 10.1039/jr9510001150; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS MJ, 1987, P NATL ACAD SCI USA, V84, P5444, DOI 10.1073/pnas.84.15.5444; YOUNG P M, 1990, Peptide Research, V3, P287; ZHUO SQ, 1988, BIOCHEM BIOPH RES CO, V152, P968, DOI 10.1016/S0006-291X(88)80378-4; ZHUO SQ, 1993, BIOCHEMISTRY-US, V32, P2219, DOI 10.1021/bi00060a013	29	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2390	2395		10.1074/jbc.273.4.2390	http://dx.doi.org/10.1074/jbc.273.4.2390			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442087	hybrid			2022-12-27	WOS:000071595200076
J	Lawler, JF; Yin, M; Diehl, AM; Roberts, E; Chatterjee, S				Lawler, JF; Yin, M; Diehl, AM; Roberts, E; Chatterjee, S			Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; HUMAN FIBROBLASTS; ACTIVATION; CERAMIDE; CELLS; TURNOVER; VESICLES	The mechanism by which genes involved in cholesterol biosynthesis and import are preferentially up-regulated in response to sterol depletion was elucidated with the cloning of sterol regulatory element binding protein-1 (SREBP-1), SREBP-1 is a transcription factor whose entry into the nucleus is gated by sterol-regulated proteolysis. We have investigated the role of tumor necrosis factor-alpha (TNF-alpha) as a mediator of SREBP-1 maturation in human hepatocytes. TNF-alpha is capable of inducing SREBP-1 maturation in a time-and dose-dependent manner that is consistent with the kinetics of TNF-alpha-mediated activation of neutral sphingomyelinase (N-SMase). Antibodies to N-SMase inhibit TNF-alpha-induced SREBP-1 maturation suggesting that N-SMase is a necessary component of this signal transduction pathway, Ceramide, a product of sphingomyelin hydrolysis, is also capable of inducing SREBP-1 maturation, The mature form of SREBP-1 generated by TNF-alpha, sphingomyelinase or ceramide treatment translocates to the nucleus and binds the sterol regulatory element. This promotes transcription of the gene upstream of the sterol regulatory element. A unique finding of our studies is that ceramide stimulated SREBP-1 maturation even in the presence of cholesterol and 25-hydroxycholesterol both of which are known suppressors of SREBP-1 maturation, Our findings indicate that ceramide-mediated maturation of SREBP-1 maturation is a novel sterol-independent mechanism by which cholesterol homeostasis may be regulated.	Johns Hopkins Univ, Sch Med, Dept Pediat, Lipid Res Atherosclerosis Unit, Baltimore, MD 21287 USA; Univ Toronto, Toronto, ON M5G 1X8, Canada	Johns Hopkins University; University of Toronto	Chatterjee, S (corresponding author), Johns Hopkins Hosp, CMSC-604,600 N Wolfe St, Baltimore, MD 21287 USA.				NHLBI NIH HHS [P50-HL47212] Funding Source: Medline; NIDDK NIH HHS [R0-1 DK-31722] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEJAN S, 1984, J BIOL CHEM, V259, P823; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; KAN C, 1991, BIOCHEMISTRY-US, V30, P10746; KIM MY, 1991, J BIOL CHEM, V266, P484; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	23	130	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5053	5059		10.1074/jbc.273.9.5053	http://dx.doi.org/10.1074/jbc.273.9.5053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478955	hybrid			2022-12-27	WOS:000072310400039
J	Lewis, SD; Lucas, BJ; Brady, SF; Sisko, JT; Cutrona, KJ; Sanderson, PEJ; Freidinger, RM; Mao, SS; Gardell, SJ; Shafer, JA				Lewis, SD; Lucas, BJ; Brady, SF; Sisko, JT; Cutrona, KJ; Sanderson, PEJ; Freidinger, RM; Mao, SS; Gardell, SJ; Shafer, JA			Characterization of the two-step pathway for inhibition of thrombin by alpha-ketoamide transition state analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ARG CHLOROMETHYLKETONE; CYCLOTHEONAMIDE-A; CRYSTAL-STRUCTURE; BINDING INHIBITION; SLOW-BINDING; DESCRIBES; KINETICS	The interaction of thrombin with several potent and selective alpha-ketoamide transition state analogs was characterized. L-370,518 (H-N-Me-D-Phe-Pro-t-4-aminocyclohexylglycyl N-methylcarboxamide) a potent (K-i = 90 pd and selective (>10(4)-fold versus trypsin) ketoamide thrombin inhibitor was shown to bind thrombin via a two-step reaction wherein the initially formed thrombin-inhibitor complex (EI1) rearranges to a more stable, final complex (EI2). A novel sequential stopped-Row analysis showed that k(-1), the rate constant for dissociation of EI1, was comparable to k(2), the rate constant for conversion of EI1 to EI2 (0.049 and 0.035 s(-1), respectively) indicating that formation of the initial complex EI1 is partially rate controlling. Replacement of the N-terminal methylamino group in L-370,518 with a hydrogen (L-372,051) resulted in a 44-fold loss in potency (K-i = 4 nM) largely due to an increase in k(-1). Consequently in the reaction of L-372,051 with thrombin formation of EI1 was not rate controlling. Replacement of the P1' N-methylcarboxamide group of L-370,518 with an azetidylcarboxamido (L-372,228) produced a 58-fold increase in the value of the equilibrium constant (K(-)1) for dissociation of EI1. Nevertheless, L-372,228 was a 2-fold more potent thrombin inhibitor (K-i = 40 pM) than L-370,518 due to its 18-fold higher k(2) and 10-fold lower k(-2) values. The desketoamide analogs of L-370,518 and L-372,051, namely L-371,912 and L-372,011, inhibited thrombin via a one-step process. The K-i value for L-371,912 and the K-1 value for its alpha-ketoamide analog, L-370,518, were similar (5 and 14 nM, respectively). Likewise, the K-i value for L-372,011 and the K-1 value for its alpha-ketoamide analog, L-372,051, were similar (330 and 285 nM, respectively). These observations are consistent with the view that the alpha-ketoamides L-370,518 and L-372,051 form initial complexes with thrombin that are similar to the complexes formed by their desketoamide analogs, and in a second step the alpha-ketoamides react with the active site serine residue of thrombin to form a more stable hemiketal adduct.	Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA	Merck & Company; Merck & Company	Lewis, SD (corresponding author), Merck Res Labs, Dept Biol Chem, WP 42-300,Sumneytown Pike, W Point, PA 19486 USA.							BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; BRADY SF, 1995, BIOORGAN MED CHEM, V3, P1063, DOI 10.1016/0968-0896(95)00105-P; BRADY SF, 1995, PEPTIDES CHEM STRUCT, P331; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHEN ZG, 1995, ARCH BIOCHEM BIOPHYS, V322, P198, DOI 10.1006/abbi.1995.1452; Cutrona KJ, 1996, TETRAHEDRON LETT, V37, P5045, DOI 10.1016/0040-4039(96)01013-1; FUSETANI N, 1990, J AM CHEM SOC, V112, P7053, DOI 10.1021/ja00175a045; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6570, DOI 10.1021/ja00042a053; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; LEWIS SD, 1993, THROMB RES, V70, P173, DOI 10.1016/0049-3848(93)90158-K; LEWIS SD, 1995, THROMB HAEMOSTASIS, V74, P1107; Lyle TA, 1997, BIOORG MED CHEM LETT, V7, P67, DOI 10.1016/S0960-894X(96)00583-5; MARYANOFF BE, 1995, J AM CHEM SOC, V117, P1225, DOI 10.1021/ja00109a006; MARYANOFF BE, 1993, P NATL ACAD SCI USA, V90, P8048, DOI 10.1073/pnas.90.17.8048; MEHDI S, 1993, BIOORG CHEM, V21, P249, DOI 10.1006/bioo.1993.1021; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Sculley MJ, 1996, BBA-PROTEIN STRUCT M, V1298, P78, DOI 10.1016/S0167-4838(96)00118-5; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; Williams J W, 1979, Methods Enzymol, V63, P437; WIPF P, 1993, J ORG CHEM, V58, P5592, DOI 10.1021/jo00073a010	24	19	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4843	4854		10.1074/jbc.273.9.4843	http://dx.doi.org/10.1074/jbc.273.9.4843			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478925	hybrid			2022-12-27	WOS:000072310400009
J	Borsch-Haubold, AG; Bartoli, F; Asselin, J; Dudler, T; Kramer, RM; Apitz-Castro, R; Watson, SP; Gelb, MH				Borsch-Haubold, AG; Bartoli, F; Asselin, J; Dudler, T; Kramer, RM; Apitz-Castro, R; Watson, SP; Gelb, MH			Identification of the phosphorylation sites of cytosolic phospholipase A(2) in agonist-stimulated human platelets and HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; MAP KINASE; DEPENDENT PHOSPHORYLATION; ARACHIDONIC-ACID; NUCLEAR-ENVELOPE; THROMBIN; TRANSLOCATION; INHIBITION; MEMBRANE	The present study identifies the phosphorylation sites of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)) in human platelets and HeLa cells, Tryptic digests of P-32-phosphorylated and -immunoprecipitated cPLA(2) were analyzed by microbore high performance liquid chromatography and two-dimensional phosphopeptide mapping against synthetic phosphopeptide standards, Thrombin stimulated significant phosphorylation of platelet cPLA(2) at two sites, Ser-505 and Ser-727. Exclusive phosphorylation on these two sites was also seen in collagen-stimulated platelets and HeLa cells stimulated with interferon-alpha or arsenite; no tyrosine phosphorylation was detected. The inhibitor of the 38-kDa stress-activated protein kinase (p38(mapk)), SB 203580, reduced phosphorylation of both Ser-505 and Ser-727 by 50 and 60%, respectively, in thrombin-stimulated platelets. An additional p38(mapk) inhibitor SB 202190 also partially (60%) inhibited the phosphorylation of cPLA(2) in arsenite-stimulated HeLa cells, These studies extend the previous work on the identification of multiple phosphorylation sites on cPLA(2) expressed in a baculovirus/insect cell system to cPLA(2) in mammalian cells stimulated with physiological agonists, They also underscore the necessity of high resolution phosphopeptide mapping combined with microbore high performance liquid chromatography for quantification of phosphorylation levels, which has lead to the conclusion that Ser-505 and Ser-727 are common phosphorylation sites on cPLA(2) in different mammalian cells stimulated with multiple agonists.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; IVIC, Ctr Biofis & Bioquim, Lab Thrombosis, Caracas, Venezuela; Lilly Res Labs, Indianapolis, IN 46285 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Oxford; Venezuelan Institute Science Research; Eli Lilly	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL50040] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KAST R, 1993, J BIOL CHEM, V268, P16795; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIU LL, 1993, CELL, V72, P269; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; QIU ZH, 1994, J BIOL CHEM, V269, P19480; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SMITH MC, 1988, J BIOL CHEM, V263, P7211; VANDERGEER P, 1993, PROTEIN PHOSPHORYLAT, P35; XING MZ, 1994, J BIOL CHEM, V269, P3117	35	138	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4449	4458		10.1074/jbc.273.8.4449	http://dx.doi.org/10.1074/jbc.273.8.4449			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468497	hybrid			2022-12-27	WOS:000072115000025
J	Ferre, S; Torvinen, M; Antoniou, K; Irenius, E; Civelli, O; Arenas, E; Fredholm, BB; Fuxe, K				Ferre, S; Torvinen, M; Antoniou, K; Irenius, E; Civelli, O; Arenas, E; Fredholm, BB; Fuxe, K			Adenosine A(1) receptor-mediated modulation of dopamine D-1 receptors in stably cotransfected fibroblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERTUSSIS TOXIN; ADENYLATE-CYCLASE; PROTEIN-KINASE; BINDING; RAT; HIPPOCAMPUS; CLONING; BRAIN; CAMP	The antagonistic interactions between adenosine A(1) and dopamine D-1 receptors were studied in a mouse Ltk(-) cell hue stably cotransfected with human adenosine A(1) receptor and dopamine D-1 receptor cDNAs, In membrane preparations, both the adenosine A(1) receptor agonist N-6-cyclopentyladenosine and the GTP analogue guanyl-5'-yl imidodiphospate induced a decrease in the proportion of dopamine D-1 receptors in a high affinity state, In the cotransfect-ed cells, the adenosine A(1) agonist induced a concentration-dependent inhibition of dopamine-induced cAMP accumulation, Blockade of adenosine A(1) receptor signal transduction with the adenosine A(1) receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine or with pertussis toxin pretreatment increased both basal and dopamine-stimulated cAMP levels, indicating the existence of tonic adenosine A(1) receptor activation, Pretreatment with pertussis toxin also counteracted the effects of low concentrations of the A(1) agonist on D-1 receptor-agonist binding The results suggest that adenosine A(1) receptors antagonistically modulate dopamine D-1 receptors at the level of receptor binding and the generation of second messengers.	Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Biochem & Mol Biophys, S-17177 Stockholm, Sweden; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of California System; University of California Irvine	Ferre, S (corresponding author), Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden.		Civelli, Olivier/A-8392-2012; Ferre, Sergi/K-6115-2014; Arenas, Ernest/AAO-5231-2020	Ferre, Sergi/0000-0002-1747-1779; Arenas, Ernest/0000-0003-0197-6577; Fuxe, Kjell/0000-0001-8491-4288				ABBRACCHIO MP, 1987, PHARMACOL RES COMMUN, V19, P275, DOI 10.1016/0031-6989(87)90085-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTE TE, 1984, J BIOL CHEM, V259, P8693; CUNHA RA, 1995, NEUROREPORT, V6, P1583, DOI 10.1097/00001756-199507310-00029; Dasgupta S, 1996, EUR J PHARMACOL, V316, P325, DOI 10.1016/S0014-2999(96)00665-6; Ferre S, 1996, EUR J NEUROSCI, V8, P1545, DOI 10.1111/j.1460-9568.1996.tb01617.x; FERRE S, 1994, NEUROREPORT, V6, P73, DOI 10.1097/00001756-199412300-00020; FERRE S, 1992, NEUROSCIENCE, V51, P501, DOI 10.1016/0306-4522(92)90291-9; Ferre S, 1997, TRENDS NEUROSCI, V20, P482, DOI 10.1016/S0166-2236(97)01096-5; FERRE S, 1991, P NATL ACAD SCI USA, V88, P7238, DOI 10.1073/pnas.88.16.7238; FREDHOLM BB, 1989, EUR J PHARM-MOLEC PH, V172, P249, DOI 10.1016/0922-4106(89)90055-2; HERVE D, 1992, NEUROSCIENCE, V46, P687, DOI 10.1016/0306-4522(92)90155-U; HSIA JA, 1984, J BIOL CHEM, V259, P1086; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; KUROSE H, 1983, J BIOL CHEM, V258, P4870; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; LIU YF, 1992, MOL ENDOCRINOL, V6, P1815, DOI 10.1210/me.6.11.1815; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; UHLER MD, 1987, J BIOL CHEM, V262, P15202; ZOLI M, 1993, MOL NEUROBIOL, V7, P293, DOI 10.1007/BF02769180	21	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4718	4724		10.1074/jbc.273.8.4718	http://dx.doi.org/10.1074/jbc.273.8.4718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468534	hybrid			2022-12-27	WOS:000072115000062
J	Klann, E; Roberson, ED; Knapp, LT; Sweatt, JD				Klann, E; Roberson, ED; Knapp, LT; Sweatt, JD			A role for superoxide in protein kinase C activation and induction of long-term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; FREE-RADICALS; SYNAPTIC TRANSMISSION; PERSISTENT ACTIVATION; RETROGRADE MESSENGER; HIPPOCAMPAL SLICES; ARACHIDONIC-ACID; PHOSPHORYLATION; MAINTENANCE; RAT	The induction of several forms of long-term potentiation (LTP) of synaptic transmission in the CA1 region of the mammalian hippocampus is dependent on N-methyl-D-aspartate receptor activation and the subsequent activation of protein kinase C (PKC), but the mechanisms that underlie the regulation of PKC in this context are largely unknown. It is known that reactive oxygen species, including superoxide, are produced by N-methyl-D-aspartate receptor activation in neurons, and recent studies have suggested that some reactive oxygen species can modulate PKC in vitro. Thus, we have investigated the role of superoxide in both the induction of LTP and the activation of PKC during LTP. We found that incubation of hippocampal slices with superoxide scavengers inhibited the induction of LTP. The effects of superoxide on LTP induction may involve PKC, as we observed that superoxide was required for appropriate modulation of PKC activation during the induction of LTP. In this respect, superoxide appears to work in conjunction with nitric oxide, which was required for a portion of the LTP-associated changes in PKC activity as well. Our observations indicate that superoxide and nitric oxide together regulate PKC in a physiologic context and that this type of regulation occurs during the induction of LTP in the hippocampus.	Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15260 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine	Klann, E (corresponding author), Univ Pittsburgh, Dept Neurosci, 446 Crawford Hall, Pittsburgh, PA 15260 USA.		Roberson, Erik/A-5718-2009	Roberson, Erik/0000-0002-1810-9763; Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034007, R01NS034007, R37NS034007, F32NS008950] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48186] Funding Source: Medline; NINDS NIH HHS [NS34007, NS08950] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Chen SJ, 1997, BRAIN RES, V749, P181, DOI 10.1016/S0006-8993(96)01159-6; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DIONISI O, 1975, BIOCHIM BIOPHYS ACTA, V403, P292, DOI 10.1016/0005-2744(75)90059-5; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; GONZALEZ A, 1993, ANAL BIOCHEM, V215, P184, DOI 10.1006/abio.1993.1574; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LARSSON R, 1989, CANCER RES, V49, P5627; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH MA, 1991, BIOCHEM SOC T, V19, P391, DOI 10.1042/bst0190391; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; Osten P, 1996, J NEUROSCI, V16, P2444; OTANI S, 1993, BRAIN RES, V613, P1, DOI 10.1016/0006-8993(93)90446-T; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; PELLEGRINIGIAMPIETRO DE, 1988, J NEUROCHEM, V51, P1960, DOI 10.1111/j.1471-4159.1988.tb01187.x; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; PELLMAR TC, 1992, BRAIN RES, V569, P189, DOI 10.1016/0006-8993(92)90630-R; POU S, 1992, J BIOL CHEM, V267, P24173; RADI R, 1991, J BIOL CHEM, V266, P4244; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUZUKI T, 1992, BIOCHEM BIOPH RES CO, V189, P1515, DOI 10.1016/0006-291X(92)90247-I; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; WILLIAMS JH, 1989, NEUROSCI LETT, V107, P301, DOI 10.1016/0304-3940(89)90835-5	55	151	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4516	4522		10.1074/jbc.273.8.4516	http://dx.doi.org/10.1074/jbc.273.8.4516			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468506	hybrid			2022-12-27	WOS:000072115000034
J	Weis, MA; Wilkin, DJ; Kim, HJ; Wilcox, WR; Lachman, RS; Rimoin, DL; Cohn, DH; Eyre, DR				Weis, MA; Wilkin, DJ; Kim, HJ; Wilcox, WR; Lachman, RS; Rimoin, DL; Cohn, DH; Eyre, DR			Structurally abnormal type II collagen in a severe form of Kniest dysplasia caused by an exon 24 skipping mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LETHAL OSTEOGENESIS IMPERFECTA; CROSS-LINKING SITES; TRIPLE-HELIX; SPONDYLOEPIPHYSEAL DYSPLASIA; PRO-ALPHA-1(I) CHAIN; ALTER CLEAVAGE; N-PROTEINASE; AMINO-ACIDS; XI COLLAGEN; CARTILAGE	Type II collagen mutations have been identified in a phenotypic continuum of chondrodysplasias that range widely in clinical severity. They include achondrogenesis type II, hypochondrogenesis, spondyloepiphyseal dysplasia congenita, spondyloepimetaphyseal dysplasia, Kniest dysplasia, and Stickler syndrome. We report here results that define the underlying genetic defect and consequent altered structure of assembled type II collagen in a neonatal lethal form of Kniest dysplasia, Electrophoresis of a cyanogen bromide (CNBr) (CB) digest of sternal cartilage revealed an alpha 1(II)CB11 peptide doublet and a slightly retarded mobility for all major CB peptides, which implied post-translational overmodification. Further peptide mapping and sequence analysis of CB11 revealed equal amounts of a normal alpha 1(II) sequence and a chain lacking the 18 residues (361-378 of the triple helical domain) corresponding to exon 24. Sequence analysis of an amplified genomic DNA fragment identified a G to A transition in the +5 position of the splice donor consensus sequence of intron 24 in one allele. Cartilage matrix analysis showed that the short alpha 1(II) chain was present in collagen molecules that had become cross-linked into fibrils. Trypsin digestion of the pepsin-extracted native type II collagen selectively cleaved the normal length alpha 1(II) chains within the exon 24 domain, These findings support a hypothesis that normal and short alpha-chains had combined to form hetero trimeric molecules in which the chains were in register in both directions from the deletion site, accommodated effectively by a loop out of the normal chain exon 24 domain. Such an accommodation, with potential overall shortening of the helical domain and hence misalignment of intermolecular relationships within fibrils, offers a common molecular mechanism by which a group of different mutations might act to produce the Kniest phenotype.	Univ Washington, Dept Orthopaed, Orthopaed Res Labs, Seattle, WA 98195 USA; Cedars Sinai Med Ctr, Burns & Allen Cedars Sinai Res Inst, Steven Spielberg Pediat Res Ctr, Ahmanson Dept Pediat, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Radiol, Los Angeles, CA 90048 USA; Ajou Univ, Coll Med, Dept Med Genet, Suwon 441749, South Korea	University of Washington; University of Washington Seattle; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Ajou University	Eyre, DR (corresponding author), Univ Washington, Dept Orthopaed, Orthopaed Res Labs, POB 356500, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD022657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037318, R37AR037318, R01AR036794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016219] Funding Source: NIH RePORTER; NIAMS NIH HHS [R37 AR037318, AR37318, R01 AR036794] Funding Source: Medline; NICHD NIH HHS [HD22657] Funding Source: Medline; NIGMS NIH HHS [GM16219] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BALDWIN CT, 1989, J CLIN INVEST, V81, P521; BATEMAN JF, 1986, ANAL BIOCHEM, V154, P338, DOI 10.1016/0003-2697(86)90534-8; BOGAERT R, 1992, J BIOL CHEM, V267, P22522; BOGAERT R, 1994, AM J HUM GENET, V55, P1128; Byers Peter H., 1993, P317; Chen LP, 1996, J ORTHOPAED RES, V14, P712, DOI 10.1002/jor.1100140506; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CHIPMAN SD, 1992, J BONE MINER RES, V7, P793; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EYRE D, 1987, METHOD ENZYMOL, V144, P115; EYRE D R, 1990, P188; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; EYRE DR, 1975, BIOCHEM J, V151, P595, DOI 10.1042/bj1510595; FERNANDES RJ, 1995, T ORTHO RES SOC, V20, P30; Fertala A, 1996, J BIOL CHEM, V271, P14864, DOI 10.1074/jbc.271.25.14864; HORTON WA, 1979, PEDIATR RES, V13, P1266, DOI 10.1203/00006450-197911000-00012; Horton William A., 1993, P641; KNIEST W, 1952, Z Kinderheilkd, V70, P633, DOI 10.1007/BF00438870; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LACHMAN RS, 1975, AM J ROENTGENOL, V123, P805, DOI 10.2214/ajr.123.4.805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; LIGHTFOOT SJ, 1994, J BIOL CHEM, V269, P30352; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; Mundlos S, 1996, J BIOL CHEM, V271, P21068, DOI 10.1074/jbc.271.35.21068; POOLE AR, 1988, J CLIN INVEST, V81, P579, DOI 10.1172/JCI113356; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; RIMOIN DL, 1975, ADV HUM GENET, V5, P1; RIMOIN DL, 1996, PRINCIPLES PRACTICE, P2779; SOKOLOV B P, 1988, Biokhimiya, V53, P1828; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/BF01959208; Spranger J, 1997, AM J MED GENET, V69, P79, DOI 10.1002/(SICI)1096-8628(19970303)69:1<79::AID-AJMG15>3.0.CO;2-L; STEGEMANN H, 1958, H-S Z PHYSIOL CHEM, V311, P41, DOI 10.1515/bchm2.1958.311.1.41; TILLER GE, 1995, AM J HUM GENET, V56, P388; WALLIS GA, 1992, J BIOL CHEM, V267, P25529; WILKIN DJ, 1994, HUM MOL GENET, V3, P1999; WILLING MC, 1988, J BIOL CHEM, V263, P8398; Winterpacht A, 1996, J MED GENET, V33, P649, DOI 10.1136/jmg.33.8.649; WINTERPACHT A, 1994, HUM MOL GENET, V3, P1891, DOI 10.1093/hmg/3.10.1891; WINTERPACHT A, 1993, NAT GENET, V3, P323, DOI 10.1038/ng0493-323; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041	45	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4761	4768		10.1074/jbc.273.8.4761	http://dx.doi.org/10.1074/jbc.273.8.4761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468540	hybrid			2022-12-27	WOS:000072115000068
J	Santolini, J; Haraux, F; Sigalat, C; Munier, L; Andre, F				Santolini, J; Haraux, F; Sigalat, C; Munier, L; Andre, F			Interrelation between high and low affinity tentoxin binding sites in chloroplast F-1-ATPase revealed by synthetic analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; COUPLING FACTOR-I; ATP SYNTHASE; SPINACH CHLOROPLAST; ELECTRON-MICROSCOPY; CYCLIC TETRAPEPTIDE; SUBUNITS; ROTATION; CF1; MITOCHONDRIA	Eight synthetic analogues of tentoxin (cyclo-(L-N-Me-Glu(1)-L-Leu(2)-N-Me Delta(z)Phe(3)-Gly(4))) modified in residues 1, 2, and 3 were checked for their ability to inhibit and reactivate the ATPase activity of the activated soluble part of chloroplast ATP synthase. The data were consistent with a model involving two binding sites of different affinities for the toxins. The occupancy of the high affinity site (or tight site) gave rise to an inactive complex, whereas filling both sites (tight + loose) gave rise to a complex of variable activity, dependent on the toxin analogue. Competition experiments between tentoxin and nonreactivating analogues allowed discrimination between the absence of binding and a nonproductive binding to the site of lower affinity (or loose site). The affinity for the loose site was not affected significantly by the modifications of the tentoxin molecule, whereas the affinity for the tight site was found notably changed. Increasing the size of side chain 1 or 2 and introducing a net electrical charge both resulted in a decrease of affinity for the tight site, but the second change dominated the first one. The activity of different ternary complexes enzyme-tentoxin-analogue depended on the nature of the toxin bound on each site and not only on that bound on the loose site. This demonstrates that the reactivation process results from an interaction, direct or not, between these two binding sites. Possible molecular mechanisms are discussed.	CEA Saclay, Sect Bioenerget, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France; CEA Saclay, DBCM, CNRS, URA 2096, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Andre, F (corresponding author), CEA Saclay, Sect Bioenerget, Dept Biol Cellulaire & Mol, Batiment 532, F-91191 Gif Sur Yvette, France.	andre@dsvidf.cea.fr	ANDRE, François/E-5555-2015	Santolini, Jerome/0000-0001-8919-112X				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; BERGER G, 1987, J LIQ CHROMATOGR, V10, P1507, DOI 10.1080/01483918708066783; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1020, P49, DOI 10.1016/0005-2728(90)90092-I; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DAHSE I, 1994, J PLANT PHYSIOL, V143, P615, DOI 10.1016/S0176-1617(11)81147-8; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DURBIN RD, 1977, PHYTOPATHOLOGY, V67, P602, DOI 10.1094/Phyto-67-602; FROMME P, 1992, Z NATURFORSCH C, V47, P239; HU NM, 1993, J BIOL CHEM, V268, P8536; LIEBERMANN B, 1983, Z ALLG MIKROBIOL, V23, P503, DOI 10.1002/jobm.3630230810; MEYER W L, 1971, Tetrahedron Letters, V25, P2357; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Pinet E, 1996, FEBS LETT, V395, P217, DOI 10.1016/0014-5793(96)01043-5; Pinet E, 1996, BIOCHEMISTRY-US, V35, P12804, DOI 10.1021/bi960955n; PINET E, 1995, BIOPOLYMERS, V36, P135, DOI 10.1002/bip.360360204; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SIGALAT C, 1995, FEBS LETT, V368, P253, DOI 10.1016/0014-5793(95)00664-U; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Sokolov M, 1996, BIOCHEMISTRY-US, V35, P1242, DOI 10.1021/bi9511189; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V504, P136, DOI 10.1016/0005-2728(78)90012-9; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHEM BIOPH RES CO, V84, P215, DOI 10.1016/0006-291X(78)90284-X; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; VIK SB, 1994, J BIOL CHEM, V269, P30364; WANG JH, 1987, BIOCHEMISTRY-US, V26, P5527, DOI 10.1021/bi00391a047; YOSHIMURA H, 1990, ULTRAMICROSCOPY, V32, P265, DOI 10.1016/0304-3991(90)90004-6	33	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3343	3350		10.1074/jbc.273.6.3343	http://dx.doi.org/10.1074/jbc.273.6.3343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452452	hybrid			2022-12-27	WOS:000071822300037
J	Berry, H; Debat, H; Garde, VL				Berry, H; Debat, H; Garde, VL			Oxygen concentration determines regiospecificity in soybean lipoxygenase-1 reaction via a branched kinetic scheme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; STEADY-STATE KINETICS; LINOLEIC-ACID; OXIDATION; HYDROPEROXIDES; PEROXIDATION; CATALYSIS; MECHANISM; RADICALS; CAROTENE	The effect of oxygen concentration on the regiospecificity of the soybean lipoxygenase-l dioxygenation reaction was studied, At low oxygen concentrations (<5 mu M), a dramatic change in the regiospecificity of the enzyme was observed with the hydroperoxy-octadecadienoic acid (HPOD) 13:9 ratio closer to 50:50 instead of the generally reported 95:5. This alteration of regiospecificity is not an isolated phenomenon, since it occurs during a reaction carried out under "classical" conditions, i.e. in a buffer saturated with air before the reaction. beta-carotene bleaching and electronic paramagnetic resonance findings provided evidence that substrate-derived free radical species are released from the enzyme. The kinetic scheme proposed by Schilstra et al, (Schilstra, M. J., Veldink, G. A. & Vliegenthart, J. F. G. (1994) Biochemistry 33, 3974-3979) was thus expanded to account for the observed variations in specificity, The equations describing the branched scheme show two different kinetic pathways: a fully enzymatic one leading to a regioisomeric composition of 13-HPOD:9-HPOD = 95:5, and a semienzymatic one leading to a regio-isomeric composition of 13-HPOD:9-HPOD = 50:50, The ratio between the two different pathways depends on oxygen concentration, which thus determines the overall specificity of the reaction.	Univ Cergy Pontoise, Dept Life Sci, F-95302 Cergy Pontoise, France; Univ Technol Compiegne, Lab Enzyme Technol, CNRS, UPRES A 6022, F-60205 Compiegne, France	CY Cergy Paris Universite; Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Garde, VL (corresponding author), Univ Cergy Pontoise, Dept Life Sci, 2 Ave Adolphe Chauvin, F-95302 Cergy Pontoise, France.	larreta@u-cergy.fr	Berry, Hugues/C-2321-2011; larreta garde, veronique/E-9356-2013	Berry, Hugues/0000-0003-3470-683X; larreta garde, veronique/0000-0003-3500-1364; DEBAT, Helene/0000-0003-0020-2748				AOSHIMA H, 1977, BIOCHIM BIOPHYS ACTA, V486, P121; ARAI H, 1995, LIPIDS, V30, P135, DOI 10.1007/BF02538266; Axelrod B., 1981, METH ENZYMOL, V441, P451, DOI [10.1016/0076-6879(81)71055-3, DOI 10.1016/0076-6879(81)71055-3]; CHRISTOPHER JP, 1972, BIOCHIM BIOPHYS ACTA, V289, P81; DEGROOT JJM, 1975, BIOCHIM BIOPHYS ACTA, V377, P71, DOI 10.1016/0005-2744(75)90287-9; EGMOND MR, 1976, EUR J BIOCHEM, V61, P93, DOI 10.1111/j.1432-1033.1976.tb10001.x; FRANKEL E N, 1980, Progress in Lipid Research, V19, P1, DOI 10.1016/0163-7827(80)90006-5; GALEY JB, 1988, BIOCHEMISTRY-US, V27, P1058, DOI 10.1021/bi00403a031; GARDNER HW, 1989, BIOCHIM BIOPHYS ACTA, V1001, P274, DOI 10.1016/0005-2760(89)90111-2; GARDNER HW, 1989, FREE RADICAL BIO MED, V7, P65, DOI 10.1016/0891-5849(89)90102-0; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GARSSEN GJ, 1971, BIOCHEM J, V122, P327, DOI 10.1042/bj1220327; GIBIAN MJ, 1976, BIOCHEMISTRY-US, V15, P4209, DOI 10.1021/bi00664a012; Glickman MH, 1996, BIOCHEMISTRY-US, V35, P12882, DOI 10.1021/bi960985q; GLICKMAN MH, 1995, BIOCHEMISTRY-US, V34, P14077, DOI 10.1021/bi00043a013; HONN KV, 1994, CANCER METAST REV, V13, P365, DOI 10.1007/BF00666105; Jones GD, 1996, BIOCHEMISTRY-US, V35, P7197, DOI 10.1021/bi952425h; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; LUDWIG P, 1987, EUR J BIOCHEM, V61, P93; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; NIKOLAEV V, 1990, BIOCHEM BIOPH RES CO, V170, P491, DOI 10.1016/0006-291X(90)92118-J; PORTER NA, 1984, J AM CHEM SOC, V106, P2626, DOI 10.1021/ja00321a022; POURPLANCHE C, 1994, J BIOL CHEM, V269, P31585; POURPLANCHE C, 1991, ANAL BIOCHEM, V198, P160, DOI 10.1016/0003-2697(91)90522-U; RAMADOSS CS, 1978, ARCH BIOCHEM BIOPHYS, V190, P549, DOI 10.1016/0003-9861(78)90309-0; ROGINSKII VA, 1990, MOL BIOL+, V24, P1262; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHEWE T, 1991, TRENDS BIOCHEM SCI, V16, P369, DOI 10.1016/0968-0004(91)90153-M; SCHILSTRA MJ, 1994, BIOCHEMISTRY-US, V33, P3974, DOI 10.1021/bi00179a025; SCHILSTRA MJ, 1993, BIOCHEMISTRY-US, V32, P7686, DOI 10.1021/bi00081a012; SCHNURR K, 1995, BIOCHIM BIOPHYS ACTA, V1254, P109; SCHONEICH C, 1992, ARCH BIOCHEM BIOPHYS, V292, P456, DOI 10.1016/0003-9861(92)90016-P; WANG ZX, 1993, BIOCHEMISTRY-US, V32, P1500, DOI 10.1021/bi00057a014; ZAMORA R, 1988, NAHRUNG, V32, P965, DOI 10.1002/food.19880321013	34	35	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2769	2776		10.1074/jbc.273.5.2769	http://dx.doi.org/10.1074/jbc.273.5.2769			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446584	Green Published, hybrid			2022-12-27	WOS:000071736600039
J	Boehmer, PE				Boehmer, PE			The herpes simplex virus type-1 single-strand DNA-binding protein, ICP8, increases the processivity of the UL9 protein DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP PROTEIN; ESCHERICHIA-COLI; POLYMERASE-ALPHA; CALF THYMUS; DUPLEX DNA; ORIGIN; REPLICATION; PRIMASE; ANTIGEN; ENZYME	Herpes simplex virus type-1 UL9 protein is a sequence-specific DNA-binding protein that recognizes elements in the viral origins of DNA replication and possesses DNA helicase activity, It forms an essential complex with its cognate single-strand DNA-binding protein, ICPS, The DNA helicase activity of the UL9 protein is greatly stimulated as a consequence of this interaction, A complex of these two proteins is thought to be responsible for unwinding the viral origins of DNA replication, The aim of this study was to identify the mechanism by which ICPS stimulates the translocation of the UL9 protein along DNA, The data show that the association of the UL9 protein with DNA substrate is slow and that its dissociation from the DNA substrate is fast, suggesting that it is nonprocessive. ICP8 caused maximal stimulation of DNA unwinding activity at equimolar UL9 protein concentrations, indicating that the active species is a complex that contains UL9 protein and ICP8 in I:1 ratio. ICP8 prevented dissociation of UL9 protein from the DNA substrate, suggesting that it increases its processivity, ICPS specifically stimulated the DNA-dependent ATPase activity of the UL9 protein with DNA cofactors that allow translocation of UL9 protein and those with secondary structure, These data suggest that UL9 protein and ICP8 form a specific complex that translocates along DNA. Within this complex, ICP8 tethers the UL9 protein to the DNA substrate, thereby preventing its dissociation, and participates directly in the assimilation and stabilization of the unwound DNA strand, thus facilitating translocation of the complex through regions of duplex DNA.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Boehmer, PE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA.			Boehmer, Paul/0000-0003-4479-0529	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; BISWAS EE, 1995, BIOCHEM BIOPH RES CO, V206, P850, DOI 10.1006/bbrc.1995.1121; BISWAS EE, 1993, BIOCHEMISTRY-US, V32, P13393, DOI 10.1021/bi00212a003; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BOROWIEC JA, 1996, DNA REPLICATION EUKA, P545; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHIOU HC, 1985, VIROLOGY, V145, P213, DOI 10.1016/0042-6822(85)90155-2; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DODSON MS, 1993, J BIOL CHEM, V268, P1213; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GEORGAKI A, 1994, NUCLEIC ACIDS RES, V22, P1128, DOI 10.1093/nar/22.7.1128; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; Kornberg A., 1992, DNA REPLICATION; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LITTLER E, 1983, J GEN VIROL, V64, P983, DOI 10.1099/0022-1317-64-5-983; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SEO YS, 1991, J BIOL CHEM, V266, P13161; SEO YS, 1993, J BIOL CHEM, V268, P10282; THOMMES P, 1992, J BIOL CHEM, V267, P6063; VAUGHAN PJ, 1984, J GEN VIROL, V65, P2033, DOI 10.1099/0022-1317-65-11-2033; VILLANI G, 1994, J BIOL CHEM, V269, P21676; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; YANCEYWRONA JE, 1992, EUR J BIOCHEM, V207, P479, DOI 10.1111/j.1432-1033.1992.tb17074.x; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; ZHANG SS, 1992, FEBS LETT, V312, P143, DOI 10.1016/0014-5793(92)80922-4	44	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2676	2683		10.1074/jbc.273.5.2676	http://dx.doi.org/10.1074/jbc.273.5.2676			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446572	hybrid			2022-12-27	WOS:000071736600027
J	Ogata, H; Inoue, N; Podolsky, DK				Ogata, H; Inoue, N; Podolsky, DK			Identification of a goblet cell-specific enhancer element in the rat intestinal trefoil factor gene promoter bound by a goblet cell nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC SPASMOLYTIC POLYPEPTIDE; EPIDERMAL GROWTH-FACTOR; SUCRASE-ISOMALTASE GENE; MOLECULAR-CLONING; BINDING-PROTEINS; REPORTER GENE; DNA-BINDING; P-DOMAIN; EXPRESSION; PS2	Intestinal trefoil factor (ITF) is selectively expressed in goblet cells of the small and large intestinal mucosa. Detailed analysis of the rat ITF (RITF) promoter was undertaken by transient transfection and gel mobility shift assays (GMSAs) using the goblet cell-like LS174T colon cancer-derived cell line. Various lengths of wild-type or mutant constructs of the 5'-flanking region were linked to the pXP2 reporter gene luciferase. Expression of -118 RITF was significantly decreased compared with -154 RITF, and transfection with an 18-base pair construct (-141 to -124) resulted in more than 5-fold greater expression than transfection with the promoterless pXP2 gene construct alone. Using various synthetic oligonucleotide mutants, GMSAs revealed that only a 9-base pair sequence (CCCCTCCCC) in this element was required for specific binding, overlapping but distinct from a Spl-like element. GMSA demonstrated that this element was specifically bound by nuclear proteins from intestinal cells with a goblet cell-like phenotype. These studies demonstrate that a 9-base pair element (goblet cell response element) between -154 and -118 in the RITF promoter gene is a cis-active element bound by a distinct nuclear transcription factor and is capable of directing intestine and goblet cell-specific expression.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Podolsky, DK (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Fruit St, Boston, MA 02114 USA.	Podolsky.Daniel@mgh.harvard.edu	Ogata, H/B-3964-2014		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK046906] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43351, DK46906] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BOLL W, 1991, AM J HUM GENET, V48, P889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARR MD, 1992, BIOCHEMISTRY-US, V31, P1998, DOI 10.1021/bi00122a015; CHANTRET I, 1992, BIOCHEM J, V285, P915, DOI 10.1042/bj2850915; CHINERY R, 1992, BIOCHEM J, V285, P5, DOI 10.1042/bj2850005; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; HAUSER F, 1992, J BIOL CHEM, V267, P24620; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; JEFFREY GP, 1994, GASTROENTEROLOGY, V106, P336, DOI 10.1016/0016-5085(94)90590-8; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; JORGENSEN KH, 1982, REGUL PEPTIDES, V3, P207, DOI 10.1016/0167-0115(82)90126-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; LEFEBVRE O, 1993, J CELL BIOL, V122, P191, DOI 10.1083/jcb.122.1.191; MASHIMO H, 1995, BIOCHEM BIOPH RES CO, V210, P31, DOI 10.1006/bbrc.1995.1623; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; MILLAN JL, 1987, NUCLEIC ACIDS RES, V15, P10599, DOI 10.1093/nar/15.24.10599; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6; PLAYFORD RJ, 1995, GASTROENTEROLOGY, V108, P108, DOI 10.1016/0016-5085(95)90014-4; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; QUARONI A, 1979, J CELL BIOL, V80, P245; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; SANDS BE, 1995, J BIOL CHEM, V270, P9353, DOI 10.1074/jbc.270.16.9353; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIB T, 1995, BIOCHEM BIOPH RES CO, V214, P195, DOI 10.1006/bbrc.1995.2274; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; THIM L, 1988, BIOCHEM J, V253, P309; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; TOMITA M, 1995, BIOCHEM J, V311, P293, DOI 10.1042/bj3110293; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402	42	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3060	3067		10.1074/jbc.273.5.3060	http://dx.doi.org/10.1074/jbc.273.5.3060			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446622	hybrid			2022-12-27	WOS:000071736600077
J	Roy, K; Tolner, B; Chiao, JH; Sirotnak, FM				Roy, K; Tolner, B; Chiao, JH; Sirotnak, FM			A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues - Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHOTREXATE TRANSPORT; CARRIER ACTIVITY; CDNA; EXPRESSION; CANCER; NITROCELLULOSE; SENSITIVITY; INHIBITORS; DEFICIENT; VARIANTS	The apparent K-m, but not V-max, for influx of methotrexate (MTX) mediated through the plasma membrane of S180 cells by the one-carbon, reduced folate transporter as well as the K-D for binding to the transporter were 4-fold higher than in L1210 cells correlating with the greater intrinsic resistance of the former to this folate analogue, In contrast, no difference was observed between each cell type with regard to efflux of [H-3]MTX mediated by this same transporter in ATP-depleted cells, The difference in influx K-m in the case of this 10-methyl substituted N10 analogue of folic acid was not seen with more effective permeants, such as the unsubstituted N10 aminopterin or C10 analogues, Thus, values for influx K-m, for aminopterin, which were 1-1.2 mu M in each cell type, increased as a result of substitution at NIO (MTX) 3-fold in L1210 cells but 12-fold in S180 cells. Nucleotide sequencing of reverse transcriptase-polymerase chain reaction-generated cDNA and of polymerase chain reaction-generated genomic DNA identified a single nucleotide difference between each cell type at +890 within exon 3 of the RFC-1 gene, This was in the form of a G (L1210 cells) to A (S180 cells) transition, Codon 297, the site of this transition, encodes either Ser or Asn in L1210 or S180 cells, respectively, which is located between the seventh and eight membrane-spanning helices, This amino acid difference had no effect on the electrophoretic mobility or amount of the transporter in each cell type that was shown by Western blotting with anti-RFC-1 peptide antibodies to migrate as 46 kDa in each case, Proof that this nucleotide difference alone accounted for the alteration in influx between each cell type was obtained by S180 RFC-1 cDNA versus L1210 RFC-1 cDNA transfection of an L1210 cell variant with undetectable MTX influx and RFC-1 gene expression, In this case, the higher K-m for MTX influx associated with S180 cells was duplicated only in the S180 RFC-1 transfectants. These results appear to document the first example of a nucleotide alteration within the RFC-1 gene, which influences the interaction of MTX with the encoded plasma membrane transporter, An analysis of topology, in addition to other considerations, suggests that the site of the amino acid difference found in the transporter from L1210 and S180 cells occurs within or near the binding site on the external plasma membrane surface.	Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol Mem, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Sirotnak, FM (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol Mem, New York, NY 10021 USA.	sirotnaf@mskcc.org			NATIONAL CANCER INSTITUTE [P30CA008748, R35CA056517] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748, CA56517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BLAKLEY RL, 1964, BIOCH FOLIC ACID REL, P3; Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165; CHIAO JH, 1995, J BIOL CHEM, V270, P29698; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; DIXON KH, 1994, J BIOL CHEM, V269, P17; GOLDMAN ID, 1986, PHARMACOL THERAPEUT, V118, P293; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V202, P144, DOI 10.1016/0003-9861(80)90416-6; KESSEL D, 1965, SCIENCE, V150, P752, DOI 10.1126/science.150.3697.752; KESSEL D, 1968, CANCER RES, V28, P562; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P2; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1991, CANCER RES, V51, P3420; MOSCOW JA, 1995, CANCER RES, V55, P3790; Persson B, 1996, PROTEIN SCI, V5, P363; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; RATNAM M, 1987, CONT ISSUES CLIN NUT, P91; SAMUELS LL, 1985, CANCER RES, V45, P1488; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1976, CANCER RES, V36, P1151; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1991, CANCER RES, V51, P1412; SIROTNAK FM, 1980, PHARMACOL THERAPEUT, V8, P71, DOI 10.1016/0163-7258(80)90060-1; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Tolner B, 1997, GENE, V189, P1, DOI 10.1016/S0378-1119(96)00676-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; YANG CH, 1988, J BIOL CHEM, V263, P9703	39	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2526	2531		10.1074/jbc.273.5.2526	http://dx.doi.org/10.1074/jbc.273.5.2526			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446553	hybrid			2022-12-27	WOS:000071736600008
J	Takamura, T; Kato, I; Kimura, N; Nakazawa, T; Yonekura, H; Takasawa, S; Okamoto, H				Takamura, T; Kato, I; Kimura, N; Nakazawa, T; Yonekura, H; Takasawa, S; Okamoto, H			Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; DNA STRAND BREAKS; POLY(ADP-RIBOSE) SYNTHETASE; PROINSULIN SYNTHESIS; ISLET CELLS; NICK TRANSLATION; STREPTOZOTOCIN; INHIBITION; SECRETION; TOXICITY	We generated transgenic mice carrying the mouse type 2 nitric oxide synthase (NOS2) cDNA under the control of the insulin promoter. Western and immunohistochemical analyses revealed that NOS2 was expressed abundantly in transgenic islets but not in control islets. When islets were isolated and cultured, high levels of nitrite were released from the transgenic islets, In transgenic mice, the beta cell mass was markedly reduced without the infiltration of macrophages or lymphocytes, and extensive DNA strand breaks were detected in the islets by in situ nick translation, All the transgenic mice developed hypoinsulinemic diabetes by 4 weeks of age, and treatment with an inhibitor of NOS2, aminoguanidine (200 mg/kg body weight every 12 h), prevented or delayed the development of diabetes. The present study shows that the production of nitric oxide by beta cell NOS2 plays an essential role in the beta cell degeneration.	Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 98077, Japan; Tohoku Univ, Sch Med, Dept Pathol, Aoba Ku, Sendai, Miyagi 98077, Japan	Tohoku University; Tohoku University	Okamoto, H (corresponding author), Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 98077, Japan.							AKABANE A, 1995, BIOCHEM BIOPH RES CO, V215, P524, DOI 10.1006/bbrc.1995.2496; BOWMAN M, 1994, DIABETES, V43, pA235; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; DELANEY CA, 1993, FEBS LETT, V333, P291, DOI 10.1016/0014-5793(93)80673-I; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; FAJANS S, 1990, ELLENBERG RIFKINS DI, P346; Faust A, 1996, LESSONS ANIMAL DIABE, P47; FEHSEL K, 1993, DIABETES, V42, P496, DOI 10.2337/diabetes.42.3.496; FOULIS AK, 1987, J PATHOL, V152, P141, DOI 10.1002/path.1711520302; GEPTS W, 1985, DIABETIC PANCREAS, P337; GREEN IC, 1994, BIOCHEM SOC T, V22, P30, DOI 10.1042/bst0220030; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HOLSTAD M, 1993, AUTOIMMUNITY, V15, P211; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; KATO I, 1994, J BIOL CHEM, V269, P21223; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MONCADA S, 1991, PHARMACOL REV, V43, P109; NOSE K, 1983, BIOCHEM BIOPH RES CO, V111, P383, DOI 10.1016/0006-291X(83)90317-0; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; OKAMOTO H, 1995, BIOCHIMIE, V77, P356, DOI 10.1016/0300-9084(96)88146-6; Okamoto H., 1996, LESSONS ANIMAL DIABE, P97; Okamoto H., 2008, MOL BIOL ISLETS LANG, P209; PENDINO KJ, 1995, AM J RESP CELL MOL, V13, P125, DOI 10.1165/ajrcmb.13.2.7542894; Rabinovitch A, 1996, ENDOCRINOLOGY, V137, P2093, DOI 10.1210/en.137.5.2093; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; SHIBATA S, 1995, PANCREAS, V10, P354, DOI 10.1097/00006676-199505000-00006; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; UCHIGATA Y, 1982, J BIOL CHEM, V257, P6084; UCHIGATA Y, 1983, DIABETES, V32, P316, DOI 10.2337/diabetes.32.4.316; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; YONEMURA Y, 1988, INT J PANCREATOL, V3, P73	36	112	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2493	2496		10.1074/jbc.273.5.2493	http://dx.doi.org/10.1074/jbc.273.5.2493			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446547	hybrid			2022-12-27	WOS:000071736600002
J	Yasuda, T; Takeshita, H; Iida, R; Nakajima, T; Hosomi, O; Nakashima, Y; Kishi, K				Yasuda, T; Takeshita, H; Iida, R; Nakajima, T; Hosomi, O; Nakashima, Y; Kishi, K			Molecular cloning of the cDNA encoding human deoxyribonuclease II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SPLEEN DEOXYRIBONUCLEASE; DNASE-II; GENETIC-POLYMORPHISM; CATHEPSIN-D; ACID DEOXYRIBONUCLEASES; NUCLEOTIDE SUBSTITUTION; ESCHERICHIA-COLI; HUMAN TISSUES; BODY-FLUIDS; ACTIVE-SITE	A rapid amplification of cDNA ends method, using degenerate oligonucleotides based upon the N-terminal amino acid sequence of human hepatic deoxyribonuclease II (DNase II), allowed a novel cDNA encoding DNase II to be constructed from thyroid gland RNA. The composite nucleotide sequence (1593 bases) included an open reading frame of 1080 bases, which encoded a single polypeptide of 360 amino acids (signal peptide, 16; propeptide, 91; mature protein, 253), Although the sequence of DNase II showed no significant homology to other mammalian proteins, its cDNA structural organization resembled those of the lysosomal cathepsin families. The two parts of the cDNA corresponding to the propeptide and the mature protein were expressed in Escherichia coli, and the recombinant polypeptides thus obtained were strongly stained with an anti-DNase II antibody on Western blotting. DNase II is ubiquitously expressed in human tissues, and the DNase II gene (DNASE2) was assigned to chromosome 19.	Gunma Univ, Sch Med, Dept Legal Med, Gunma 371, Japan; Fukui Med Sch, Dept Legal Med, Fukui 91011, Japan	Gunma University; University of Fukui	Kishi, K (corresponding author), Gunma Univ, Sch Med, Dept Legal Med, Gunma 371, Japan.	kkoichi@news.sb.gunma-u.ac.jp						ALLFREY V, 1952, J GEN PHYSIOL, V36, P227, DOI 10.1085/jgp.36.2.227; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Bernardi G., 1971, HYDROLYSIS, P271; BROOK JD, 1984, HUM GENET, V68, P282, DOI 10.1007/BF00292584; BRUNS G A P, 1979, Journal of Cell Biology, V83, p444A; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONNI.C, 1968, CAN J BIOCHEM CELL B, V46, P989, DOI 10.1139/o68-148; DULANEY JT, 1972, J BIOL CHEM, V247, P1424; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAROSH I, 1991, EUR J BIOCHEM, V202, P479, DOI 10.1111/j.1432-1033.1991.tb16397.x; IIDA R, 1990, ELECTROPHORESIS, V11, P852, DOI 10.1002/elps.1150111014; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; KISHI K, 1990, AM J HUM GENET, V47, P121; KOIZUMI T, 1995, EXP ANIM TOKYO, V44, P323, DOI 10.1538/expanim.44.323; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUHELJ R, 1995, EUR J BIOCHEM, V229, P533, DOI 10.1111/j.1432-1033.1995.0533k.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESCA P, 1976, J BIOL CHEM, V251, P116; LIAO TH, 1989, BIOCHIM BIOPHYS ACTA, V1007, P15, DOI 10.1016/0167-4781(89)90124-3; LIAO TH, 1985, J BIOL CHEM, V260, P708; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; MURAI K, 1980, J BIOCHEM-TOKYO, V87, P1097; NADANO D, 1993, CLIN CHEM, V39, P448; NEWTON CR, 1994, PCR, P27; OOSTHUIZEN MMJ, 1984, INT J BIOCHEM, V16, P1207, DOI 10.1016/0020-711X(84)90218-0; OSHIMA RG, 1973, J BIOL CHEM, V248, P7522; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; Takeshita H, 1997, BIOCHEM MOL BIOL INT, V42, P65; TAKESHITA H, 1994, INT J BIOCHEM, V26, P1025, DOI 10.1016/0020-711X(94)90074-4; TORRIGLIA A, 1995, J BIOL CHEM, V270, P28579, DOI 10.1074/jbc.270.48.28579; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMANAKA M, 1974, J BIOL CHEM, V249, P3884; Yasuda T, 1996, J FORENSIC SCI, V41, P862; Yasuda T, 1997, BIOCHEM J, V325, P465, DOI 10.1042/bj3250465; YASUDA T, 1995, CYTOGENET CELL GENET, V70, P221, DOI 10.1159/000134038; YASUDA T, 1995, FEBS LETT, V359, P211, DOI 10.1016/0014-5793(95)00037-A; YASUDA T, 1990, J BIOCHEM-TOKYO, V108, P393, DOI 10.1093/oxfordjournals.jbchem.a123212; YASUDA T, 1993, CLIN CHIM ACTA, V218, P5, DOI 10.1016/0009-8981(93)90217-R; YASUDA T, 1992, ANN HUM GENET, V56, P1, DOI 10.1111/j.1469-1809.1992.tb01125.x; YASUDA T, 1995, ANN HUM GENET, V59, P1, DOI 10.1111/j.1469-1809.1995.tb01601.x; YASUDA T, 1992, BIOCHIM BIOPHYS ACTA, V1119, P185, DOI 10.1016/0167-4838(92)90390-Y; YASUDA T, 1993, BIOCHEM J, V296, P617, DOI 10.1042/bj2960617; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	46	78	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2610	2616		10.1074/jbc.273.5.2610	http://dx.doi.org/10.1074/jbc.273.5.2610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446563	hybrid			2022-12-27	WOS:000071736600018
J	Gavin, IM; Usachenko, SI; Bavykin, SG				Gavin, IM; Usachenko, SI; Bavykin, SG			Nucleosome structural transition during chromatin unfolding is caused by conformational changes in nucleosomal DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENT MATING LOCI; YEAST HISTONE H4; CORE PARTICLE; PRIMARY ORGANIZATION; IONIC-STRENGTH; SACCHAROMYCES-CEREVISIAE; N-TERMINI; TRANSCRIPTION; REPRESSION; DOMAIN	We have recently reported that certain core histone-DNA contacts are altered in nucleosomes during chromatin unfolding (Usachenko, S. I., Gavin I. M., and Bavykin, S. G. (1996) J. Biol. Chem. 271, 3831-3836), In this work, we demonstrate that these alterations are caused by a conformational change in the nucleosomal DNA, Using zero-length protein-DNA cross linking, we have mapped histone-DNA contacts in isolated core particles at ionic conditions affecting DNA stiffness, which may change the nucleosomal DNA conformation, We found that the alterations in histone-DNA contacts induced by an increase in DNA stiffness in isolated core particles are identical to those observed in nucleosomes during chromatin unfolding. The change in the pattern of micrococcal nuclease digestion of linker histone-depleted chromatin at ionic conditions affecting chromatin compaction also suggests that the stretching of the linker DNA may alter the nucleosomal DNA conformation, resulting in a structural transition in the nucleosome which may play a role in rendering the nucleosome competent for transcription and/or replication.	VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Bavykin, SG (corresponding author), Argonne Natl Lab, Ctr Mechanist Biol & Biotechnol, 9700 S Cass Ave,Bldg 202, Argonne, IL 60439 USA.	sbavykin@everest.bim.anl.gov						ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; AFINSEN CB, 1971, ENZYMES, V4, P177; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BAVYKIN SG, 1985, NUCLEIC ACIDS RES, V13, P3439, DOI 10.1093/nar/13.10.3439; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BazettJones DP, 1996, NUCLEIC ACIDS RES, V24, P321, DOI 10.1093/nar/24.2.321; BEDNAR J, 1995, J CELL BIOL, V131, P1365, DOI 10.1083/jcb.131.6.1365; BELYAVSKY AV, 1980, J MOL BIOL, V139, P519, DOI 10.1016/0022-2836(80)90144-8; BURTON K, 1967, METHODS ENZYMOLOGY A, V12, P222; CHUNG DG, 1985, BIOCHEMISTRY-US, V24, P8028, DOI 10.1021/bi00348a029; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; Czarnota GJ, 1996, J BIOL CHEM, V271, P3677; DAVIES N, 1991, BIOCHIM BIOPHYS ACTA, V1129, P57, DOI 10.1016/0167-4781(91)90212-5; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; EBRALIDSE KK, 1986, FEBS LETT, V194, P69, DOI 10.1016/0014-5793(86)80053-9; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GOULET I, 1988, J MOL BIOL, V200, P253, DOI 10.1016/0022-2836(88)90238-0; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; GUSCHIN DY, 1991, MOL BIOL, V25, P1400; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HIRAI M, 1988, BIOCHEMISTRY-US, V27, P7924, DOI 10.1021/bi00420a051; HOGAN ME, 1987, NATURE, V328, P554, DOI 10.1038/328554a0; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; Lenfant F, 1996, EMBO J, V15, P3974, DOI 10.1002/j.1460-2075.1996.tb00771.x; LIBERTINI LJ, 1982, BIOCHEMISTRY-US, V21, P3327, DOI 10.1021/bi00257a013; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARKY NL, 1991, BIOPOLYMERS, V31, P1543, DOI 10.1002/bip.360311310; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; MIRZABEKOV AD, 1989, METHOD ENZYMOL, V170, P386; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; PRUNELL A, 1979, SCIENCE, V204, P855, DOI 10.1126/science.441739; Pruss D, 1997, METHODS, V12, P36, DOI 10.1006/meth.1997.0445; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; RUIZCARRILLO A, 1979, P NATL ACAD SCI USA, V76, P3284, DOI 10.1073/pnas.76.7.3284; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SHICK VV, 1980, J MOL BIOL, V139, P491, DOI 10.1016/0022-2836(80)90143-6; SIBBET GJ, 1983, EUR J BIOCHEM, V133, P393, DOI 10.1111/j.1432-1033.1983.tb07475.x; STRUCK MM, 1992, J MOL BIOL, V224, P253, DOI 10.1016/0022-2836(92)90588-B; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TRAVERS AA, 1994, CURR BIOL, V4, P659, DOI 10.1016/S0960-9822(00)00148-2; UBERBACHER EC, 1989, J BIOMOL STRUCT DYN, V7, P1; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; Usachenko SI, 1996, J BIOL CHEM, V271, P3831; van Holde KE., 1989, SPRINGER SERIES MOL; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WEISCHET WO, 1979, NUCLEIC ACIDS RES, V6, P1843, DOI 10.1093/nar/6.5.1843; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; WU HM, 1979, BIOCHEMISTRY-US, V18, P3960, DOI 10.1021/bi00585a018; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; ZIVANOVIC Y, 1990, J MOL BIOL, V214, P479, DOI 10.1016/0022-2836(90)90195-R; ZLATANOVA J, 1992, J CELL SCI, V103, P889	78	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2429	2434		10.1074/jbc.273.4.2429	http://dx.doi.org/10.1074/jbc.273.4.2429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442093	hybrid			2022-12-27	WOS:000071595200082
J	Engelward, BP; Allan, JM; Dreslin, AJ; Kelly, JD; Wu, MM; Gold, B; Samson, LD				Engelward, BP; Allan, JM; Dreslin, AJ; Kelly, JD; Wu, MM; Gold, B; Samson, LD			A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID EXCHANGES; CHINESE-HAMSTER CELLS; DNA-POLYMERASE-BETA; ULTRAVIOLET-LIGHT; THYMOCYTE APOPTOSIS; ALKYLATING-AGENTS; S-PHASE; DAMAGE; CYCLE; MOUSE	DNA-damaging agents produce a plethora of cellular responses that include p53 induction, cell cycle arrest, and apoptosis, It is generally assumed that it is the DNA damage produced by these agents that triggers such responses, but there is limited direct evidence to support this assumption, Here, we used DNA alkylation repair proficient and deficient isogenic mouse cell lines to demonstrate that the signal to trigger p53 induction, cell cycle arrest, and apoptosis in response to alkylating agents does emanate from DNA damage. Moreover, we established that 3-methyladenine, a relatively minor DNA lesion produced by most methylating agents (which form mainly 7-methylguanine), can specifically induce sister chromatid exchange, chromatid and chromosome gaps and breaks, S phase arrest, the accumulation of p53, and apoptosis, This study was made possible by the generation of 3-methyladenine DNA glycosylase null mutant cells by targeted homologous recombination and by the chemical synthesis of a methylating agent that almost exclusively produces 3-methyladenine DNA lesions, The combined use of these two experimental tools has defined the biological consequences of 3-methyladenine, a DNA lesion produced by endogenous cellular metabolites, environmental carcinogens, and chemotherapeutic alkylating agents.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Samson, LD (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.		Allan, James/B-4448-2009	Allan, James/0000-0002-7580-5087	NATIONAL CANCER INSTITUTE [R01CA055042, P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES003926] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA55042, CA36727] Funding Source: Medline; NIEHS NIH HHS [P01 ES03926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAN CL, 1993, MUTAT RES, V292, P3, DOI 10.1016/0165-1161(93)90003-I; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BENDER MA, 1973, MUTAT RES, V20, P387, DOI 10.1016/0027-5107(73)90060-2; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; BIANCHINI F, 1993, CARCINOGENESIS, V14, P1677, DOI 10.1093/carcin/14.8.1677; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DASHWOOD RH, 1988, CARCINOGENESIS, V9, P427, DOI 10.1093/carcin/9.3.427; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; DOUBLIE S, 1998, IN PRESS NATURE; Encell L, 1996, CHEM RES TOXICOL, V9, P563, DOI 10.1021/tx9501849; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; EVANS HJ, 1969, PROC R SOC SER B-BIO, V173, P491, DOI 10.1098/rspb.1969.0073; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; ISHII Y, 1980, MUTAT RES, V79, P19, DOI 10.1016/0165-1218(80)90144-5; KAINA B, 1991, CARCINOGENESIS, V12, P1857; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Ljungman M, 1996, ONCOGENE, V13, P823; Longhese MP, 1996, MOL CELL BIOL, V16, P3235; MEYN RE, 1984, PHARMACOL THERAPEUT, V24, P147, DOI 10.1016/0163-7258(84)90032-9; MORRIS SM, 1991, ENVIRON MOL MUTAGEN, V18, P139, DOI 10.1002/em.2850180210; NATARAJAN AT, 1984, CHROMOSOMA, V90, P120, DOI 10.1007/BF00292448; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; PAINTER RB, 1980, MUTAT RES, V70, P337, DOI 10.1016/0027-5107(80)90023-8; PAINTER RB, 1985, MUTAT RES, V145, P63, DOI 10.1016/0167-8817(85)90041-0; PAINTER RB, 1975, RADIAT RES, V64, P648, DOI 10.2307/3574254; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SAVATIER P, 1994, ONCOGENE, V9, P809; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Spratt TE, 1997, BIOCHEMISTRY-US, V36, P13292, DOI 10.1021/bi971253g; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; WATANABE I, 1974, RADIAT RES, V58, P541, DOI 10.2307/3573922; WOLFF S, 1974, MUTAT RES, V25, P73, DOI 10.1016/0165-1218(74)90082-2; YAGI T, 1984, CARCINOGENESIS, V5, P593, DOI 10.1093/carcin/5.5.593; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZHANG Y, 1993, BIOCHEMISTRY-US, V32, P7954, DOI 10.1021/bi00082a017	49	113	116	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5412	5418		10.1074/jbc.273.9.5412	http://dx.doi.org/10.1074/jbc.273.9.5412			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9479003	hybrid			2022-12-27	WOS:000072310400087
J	Hallier, M; Lerga, A; Barnache, S; Tavitian, A; Moreau-Gachelin, F				Hallier, M; Lerga, A; Barnache, S; Tavitian, A; Moreau-Gachelin, F			The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; HUMAN MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATION; ACTIVATION DOMAIN; FACTOR PU.1; FUSION; CHOP; LIPOSARCOMA; INVITRO; SITE	Spi-1/PU.1 is an Ets protein deregulated by insertional mutagenesis during the murine Friend erythroleukemia. The overexpression of the normal protein in a proerythroblastic cell prevents its terminal differentiation. In normal hematopoiesis Spi-1/PU.1 is a transcription factor that plays a key role in normal myeloid and B lymphoid differentiation. Moreover, Spi-1/PU.1 binds RNA and interferes in vitro with the splicing process. Here we report that Spi-1 interacts in vivo with TLS (translocated in liposarcoma), a RNA-binding protein involved in human tumor-specific chromosomal translocations. This interaction appears functionally relevant, since TLS is capable of reducing the abilities of Spi-1/PU.1 to bind DNA and to transactivate the expression of a reporter gene. In addition, we observe that TLS is potentially a splicing factor. It promotes the use of the distal 5' splice site during the E1A pre-mRNA splicing. This effect is counterpoised in vivo by Spi-1. These data suggest that alteration of pre-mRNA alternative splicing by Spi-1 could be involved in the transformation of an erythroblastic cell.	Inst Curie, INSERM, U248, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U248, 26 Rue Ulm, F-75248 Paris 05, France.	framoreau@curie.fr	Hallier, Marc/L-2031-2015					CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; Hackl W, 1996, J MOL BIOL, V264, P843, DOI 10.1006/jmbi.1996.0681; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAYGALLET D, 1995, ONCOGENE, V11, P303; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	23	116	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4838	4842		10.1074/jbc.273.9.4838	http://dx.doi.org/10.1074/jbc.273.9.4838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478924	hybrid			2022-12-27	WOS:000072310400008
J	Sugano, M; Makino, N; Sawada, S; Otsuka, S; Watanabe, M; Okamoto, H; Kamada, M; Mizushima, A				Sugano, M; Makino, N; Sawada, S; Otsuka, S; Watanabe, M; Okamoto, H; Kamada, M; Mizushima, A			Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LIPID TRANSFER PROTEIN; MESSENGER-RNA; FAMILIAL HYPERALPHALIPOPROTEINEMIA; COMBINED HYPERLIPIDEMIA; TRANSGENIC MICE; PLASMA; RECEPTOR; GENE; DEFICIENCY	Cholesteryl ester transfer protein (CETP) is the enzyme that facilitates the transfer of cholesteryl ester from high density lipoprotein (HDL) to apolipoprotein B (apoB)-containing lipoproteins, However, the exact role of CETP in the development of atherosclerosis has not been determined, In the present study, we examined the effect of the suppression of increased plasma CETP by intravenous injection with antisense oligodeoxynucleotides (ODNs) against CETP targeted to the liver on the development of atherosclerosis in rabbits fed a cholesterol diet, The ODNs against rabbit CETP were coupled to asialoglycoprotein (ASOR) carrier molecules, which serve as an important method to regulate liver gene expression, Twenty-two male Japanese White rabbits were used in the experiment, Eighteen animals were fed a standard rabbit chow supplemented with 0.3% cholesterol throughout the experiment for 16 weeks, At 8 weeks, they were divided into three groups (six animals in each group), among which the plasma total and HDL cholesterol concentrations did not significantly change, The central group received nothing, the sense group were injected with the sense ODNs complex, and the antisense group were injected with the antisense ODNs complex, respectively, for subsequent 8 weeks, ASOR poly(L-lysine) ODNs complex were injected via the ear veins twice a week, Four animals were fed a standard rabbit diet for 16 weeks, The total cholesterol concentrations and the CETP mass in the animals injected with antisense ODNs were all significantly decreased in 12 and 16 weeks compared with those injected with sense ODNs and the control animals, The HDL cholesterol concentrations measured by the precipitation assay did not significantly change among the groups fed a cholesterol diet, and triglyceride concentrations did not significantly change in the four groups, However, at the end of the study, when the HDL cholesterol concentrations were measured after the isolation by ultracentrifugation and a column chromotography, they were significantly higher in the animals injected with antisense ODNs than in the animals injected with sense ODNs and in the control animals, A reduction of CETP mRNA and an increase of LDL receptor mRNA in the liver were observed in the animals injected with antisense ODNs compared with those injected with sense ODNs and the control animals, Aortic cholesterol contents and the aortic percentage lesion to total surface area were significantly lower in the animals injected with antisense ODNs than in the animals injected with sense ODNs and in the control animals, These findings showed for the first time that suppression of increased plasma CETP by the injection with antisense ODNs against CETP coupled to ASOR carrier molecules targeted to the liver could thus inhibit the atherosclerosis possibly by decreasing the plasma LDL + very low density lipoprotein (VLDL) cholesterol in cholesterol-fed rabbits.	Kyushu Univ, Med Inst Bioregulat, Dept Bioclimatol & Med, Oita 874, Japan; Japan Tobacco Inc, Cent Pharmaceut Res Inst, Osaka 56911, Japan	Kyushu University; Japan Tobacco Inc.	Sugano, M (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Bioclimatol & Med, 4546 Tsurumihara, Oita 874, Japan.			Mizushima, Atsushi/0000-0002-1256-1919				CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; FOGER B, 1995, J MOL MED, V73, P369; Foger B, 1996, ARTERIOSCL THROM VAS, V16, P1430, DOI 10.1161/01.ATV.16.12.1430; Guerin M, 1996, ARTERIOSCL THROM VAS, V16, P763, DOI 10.1161/01.ATV.16.6.763; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HESLER CB, 1987, J BIOL CHEM, V262, P2275; HIRANO K, 1995, ARTERIOSCL THROM VAS, V15, P1849, DOI 10.1161/01.ATV.15.11.1849; HIRANO KI, 1995, ANN NY ACAD SCI, V748, P599; IKEWAKI K, 1995, J CLIN INVEST, V96, P1573, DOI 10.1172/JCI118196; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; ISHIDA BY, 1987, J LIPID RES, V28, P778; JIANG XC, 1993, J BIOL CHEM, V268, P27406; KATO H, 1989, J BIOL CHEM, V264, P4082; Kinoshita M, 1996, ATHEROSCLEROSIS, V120, P75, DOI 10.1016/0021-9150(95)05684-X; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; McPherson R, 1997, ARTERIOSCL THROM VAS, V17, P203, DOI 10.1161/01.ATV.17.1.203; NAGASHIMA M, 1988, J LIPID RES, V29, P1643; Oliveira HCF, 1997, ARTERIOSCL THROM VAS, V17, P1045, DOI 10.1161/01.ATV.17.6.1045; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; SAITO F, 1984, METABOLISM, V33, P629, DOI 10.1016/0026-0495(84)90061-1; Sugano M, 1996, J BIOL CHEM, V271, P19080, DOI 10.1074/jbc.271.32.19080; SUGANO M, 1986, ARTERIOSCLEROSIS, V6, P237, DOI 10.1161/01.ATV.6.2.237; SUGANO M, 1996, BIOCHIM BIOPHYS ACTA, V127, P123; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1995, J INTERN MED, V237, P5, DOI 10.1111/j.1365-2796.1995.tb01133.x; TATO F, 1995, THROMB VASC BIOL, V15, P112; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; WU GY, 1988, J BIOL CHEM, V263, P14621; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMASHITA S, 1995, ANN NY ACAD SCI, V748, P606; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	34	206	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5033	5036		10.1074/jbc.273.9.5033	http://dx.doi.org/10.1074/jbc.273.9.5033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478952	hybrid			2022-12-27	WOS:000072310400036
J	Tsuga, H; Kameyama, K; Haga, T; Honma, T; Lameh, J; Sadee, W				Tsuga, H; Kameyama, K; Haga, T; Honma, T; Lameh, J; Sadee, W			Internalization and down-regulation of human muscarinic acetylcholine receptor m2 subtypes - Role of third intracellular m2 loop and G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLINERGIC RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; BETA-ARRESTIN; WILD-TYPE; DESENSITIZATION; SEQUESTRATION; MUTANT; BINDING	Internalization and down-regulation of human muscarinic acetylcholine m2 receptors (hm2 receptors) and a hm2 receptor mutant lacking a central part of the third intracellular loop (I3-del m2 receptor) were examined in Chinese hamster ovary (CHO-K1) cells stably expressing these receptors and G protein-coupled receptor kinase 2 (GRK2). Agonist-induced internalization of up to 80-90% of hm2 receptors was demonstrated by measuring loss of [H-3]N-methylscopolamine binding sites from the cell surface, and transfer of [H-3]quinuclidinyl benzilate binding sites from the plasma membrane into the light-vesicle fractions separated by sucrose density gradient centrifugation. Additionally, translocation of hm2 receptors with endocytic vesicles were visualized by immunofluorescence confocal microscopy. Agonist-induced down-regulation of up to 60-70% of hm2 receptors was demonstrated by determining the loss of [H-3]quinuclidinyl benzilate binding sites in the cells. The half-time (t(1/2)) of internalization and down-regulation in the presence of 10(-4) nn carbamylcholine was estimated to be 9.5 min and 2.3 h, respectively. The rates of both internalization and down-regulation of hm2 receptors in the presence of 10(-6) M or lower concentrations of carbamylcholine were markedly increased by coexpression of GRK2. Agonist-induced internalization of I3-del m2 receptors was barely detectable upon incubation of cells for 1 h, but agonist-induced down-regulation of up to 40-50% of I3-del m2 receptors occurred upon incubation with 10(-4) M carbamylcholine for 16 h. However, the rate of down-regulation was lower compared with wild type receptors (t(1/2) = 9.9 versus 2.3 h). These results indicate that rapid internalization of hm2 receptors is facilitated by their phosphorylation with GRK2 and does not occur in the absence of the third intracellular loop, but downregulation of hm2 receptors may occur through both GRK2-facilitating pathway and third intracellular loop-independent pathways.	Natl Inst Ind Hlth, Dept Occupat Dis, Tama Ku, Kanagawa 214, Japan; Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Tokyo 113, Japan; Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA	University of Tokyo; University of California System; University of California San Francisco	Tsuga, H (corresponding author), Natl Inst Ind Hlth, Dept Occupat Dis, Tama Ku, 6-21-1 Nagao, Kanagawa 214, Japan.				NIDA NIH HHS [DA04166] Funding Source: Medline; NIGMS NIH HHS [GM43102] Funding Source: Medline; NIMH NIH HHS [MH00996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004166] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Diviani D, 1996, J BIOL CHEM, V271, P5049; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAGA T, 1994, J NEUROCHEM, V63, P400; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; ISHII K, 1994, J BIOL CHEM, V269, P1125; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MORO O, 1993, J BIOL CHEM, V268, P6862; Nagayama Y, 1996, J BIOL CHEM, V271, P10143, DOI 10.1074/jbc.271.17.10143; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; TSUGA H, 1994, J BIOL CHEM, V269, P32522	37	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5323	5330		10.1074/jbc.273.9.5323	http://dx.doi.org/10.1074/jbc.273.9.5323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478991	hybrid			2022-12-27	WOS:000072310400075
J	Vidal, M; Montiel, JL; Cussac, D; Cornille, F; Duchesne, M; Parker, F; Tocque, B; Roques, BP; Garbay, C				Vidal, M; Montiel, JL; Cussac, D; Cornille, F; Duchesne, M; Parker, F; Tocque, B; Roques, BP; Garbay, C			Differential interactions of the growth factor receptor-bound protein a N-SH3 domain with son of sevenless and dynamin - Potential role in the Ras-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SH3 DOMAIN; MAP KINASE PHOSPHORYLATION; TYROSINE KINASES; GRB2 ADAPTER; BINDING; TRANSDUCTION; PEPTIDE; ASSOCIATION; ENDOCYTOSIS; ACTIVATION	In this paper, we show that the 36-45 surface-exposed sequence WYKAELNGKD of growth factor receptor-bound protein 2 (Grb2) N-SH3 domain inhibits the interaction between Grb2 and a 97-kDa protein identified as dynamin. Moreover, the peptide GPPPQVPSRPNR from dynamin also blocks the binding of dynamin to the proline-rich recognition platform of Grb2. Mutations in the 36-45 motif show that Glu-40 is critical for dynamin recognition. These observations were confirmed by immunoprecipitation experiments, carried out using ER 22 cells. It was also observed that the proline-rich peptide from dynamin was unable to dissociate the Grb2.Sos complex, whereas the proline-rich peptide from Son of sevenless (Sos) inhibited Grb2.dynamin interaction. A time-dependent stimulation of epidermal growth factor receptor overexpressing clone 22 (ER 22) cells by epidermal growth factor resulted in an immediate increase of the Grb2.Sos complex and a concomitant decrease in Grb2.dynamin. This suggests that the recruitment of Grb2.Sos to the membrane, triggered by epidermal growth factor stimulation, activates the Ras-dependent signaling and simultaneously enhances free dynamin levels, leading to both receptor internalization and endocytotic processes.	Univ Paris 05, UFR Sci Pharmaceut & Biol, U266 INSERM URA D1500 CNRS, Dept Pharmacochim Mol & Struct, F-75270 Paris 06, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis; Sanofi France	Roques, BP (corresponding author), Univ Paris 05, UFR Sci Pharmaceut & Biol, U266 INSERM URA D1500 CNRS, Dept Pharmacochim Mol & Struct, 4,Ave de Observ, F-75270 Paris 06, France.		Vidal, Michel/ABA-3396-2020	Montiel Hernandez, Jose Luis/0000-0002-6258-7092; Vidal, Michel/0000-0002-4858-1591				ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BUDAY L, 1995, ONCOGENE, V11, P1327; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; HERMANSON GT, 1992, IMMOBILIZED AFFINITY, V53; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; KELLY RB, 1995, NATURE, V374, P116, DOI 10.1038/374116a0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; LOWE PN, 1994, CELL SIGNAL, V6, P109, DOI 10.1016/0898-6568(94)90067-1; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIKI H, 1994, J BIOL CHEM, V269, P5489; MONTIEL JL, 1997, PROTEIN PEPTIDE LETT, V38, P1389; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Parker F, 1996, MOL CELL BIOL, V16, P2561; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Romero F, 1996, MOL CELL BIOL, V16, P37; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; YANG YS, 1994, EMBO J, V13, P1270, DOI 10.1002/j.1460-2075.1994.tb06379.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	45	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5343	5348		10.1074/jbc.273.9.5343	http://dx.doi.org/10.1074/jbc.273.9.5343			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478994	hybrid			2022-12-27	WOS:000072310400078
J	Yoshioka, K; Matsumura, F; Akedo, H; Itoh, K				Yoshioka, K; Matsumura, F; Akedo, H; Itoh, K			Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; ASCITES HEPATOMA-CELLS; ACTIN STRESS FIBERS; MYOSIN LIGHT-CHAIN; ADP-RIBOSYLATION; PUTATIVE TARGET; SMOOTH-MUSCLE; GENE-PRODUCT; SERINE/THREONINE KINASE; LYSOPHOSPHATIDIC-ACID	We have shown previously that Rho plays a pivotal role in 1-oleoyl-lysophosphatidic acid (LPA)-dependent invasion of rat hepatoma cells (MM1). Herein we made stable transfectants of MM1 expressing active and Botulinum exoenzyme C3 (C3)-sensitive (Val(14)), or active and C3-insensitive (Val(14)/Ile(41)) forms of human RhoA, Both transfectants showed greatly promoted invasive ability in vitro in the absence of LPA as well as in vivo, adherence to the dish with scattered shape, and enhanced phosphorylation level of 20-kDa myosin light chain (MLC20), A specific MLC kinase inhibitor (KT5926) could inhibit their invasion and the phosphorylation level of MLC20, Stable active RhoA transfectants of W1 cells (low invasive counterpart of MM1) also demonstrated promoted invasive ability in, vitro and in vivo, and enhanced phosphorylation level of MLC20. C3 treatment inhibited the invasiveness of the Val(14) RhoA transfectant but not that of the Val(14)/Ile(41) RhoA transfectant. LPA enhanced the invasiveness of both transfectants, and this enhancement was abolished by the C3 treatment, These results suggested that 1) the Rho signaling pathway and actomyosin system were linked in the transmigration of tumor cells, and 2) expressed active RhoA enhanced LPA-induced tumor cell invasion via the activation of endogenous RhoA pathway, indicating a positive feedback mechanism in the activation of RhoA.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biochem, Higashinari Ku, Osaka 537, Japan; Rutgers State Univ, Dept Biochem & Mol Biol, Piscataway, NJ 08854 USA	Osaka Medical Center for Cancer & Cardiovascular Diseases; Rutgers State University New Brunswick	Yoshioka, K (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biochem, Higashinari Ku, 1-3-3 Nakamichi, Osaka 537, Japan.			Matsumura, Fumio/0000-0002-8204-153X; Itoh, Kazuyuki/0000-0002-0761-0499				AKEDO H, 1989, INVAS METAST, V9, P134; AKEDO H, 1986, CANCER RES, V46, P2416; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Gong MC, 1997, J BIOL CHEM, V272, P10704; HIRATA K, 1992, J BIOL CHEM, V267, P8719; IMAMURA F, 1991, JPN J CANCER RES, V82, P493, DOI 10.1111/j.1349-7006.1991.tb01877.x; Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1136, P52, DOI 10.1016/0167-4889(92)90084-O; ITOH K, 1996, MOL BIOL CELL, V7, P234; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MORII N, 1995, METHOD ENZYMOL, V256, P196; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NICOLSON GL, 1989, INVAS METAST, V9, P102; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAUBMAN MB, 1987, J CELL BIOL, V104, P1505, DOI 10.1083/jcb.104.6.1505; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAMAKITA Y, 1996, MOL BIOL CELL, V7, P198; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YOSHIOKA K, 1995, FEBS LETT, V372, P25, DOI 10.1016/0014-5793(95)00937-5; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	55	149	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5146	5154		10.1074/jbc.273.9.5146	http://dx.doi.org/10.1074/jbc.273.9.5146			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478968	hybrid			2022-12-27	WOS:000072310400052
J	Kassam, G; Choi, KS; Ghuman, J; Kang, HM; Fitzpatrick, SL; Zackson, T; Zackson, S; Toba, M; Shinomiya, A; Waisman, DM				Kassam, G; Choi, KS; Ghuman, J; Kang, HM; Fitzpatrick, SL; Zackson, T; Zackson, S; Toba, M; Shinomiya, A; Waisman, DM			The role of annexin II tetramer in the activation of plasminogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT EXOCYTOSIS; ENDOTHELIAL-CELL RECEPTOR; T-PA; EXTRACELLULAR-MATRIX; FIBRIN ENHANCEMENT; CHROMAFFIN CELLS; LYMPHOMA-CELLS; CALPACTIN-I; BINDING; SURFACE	Annexin II tetramer (AIIt) is a major Ca2+-binding protein of endothelial cells which has been shown to exist on both the intracellular and extracellular surfaces of the plasma membrane. In this report, Eve demonstrate that AIIt stimulates the activation of plasminogen by facilitating the tissue plasminogen activator (t-PA)-dependent conversion of plasminogen to plasmin, Fluid-phase AIIt stimulated the rate of activation of [Glu]plasminogen about 341-fold compared with an approximate 6-fold stimulation by annexin II. AIIt bound to [Glu]plasminogen(S741C-fluorescein) with a K-d of 1.26 +/- 0.04 mu M (mean +/- S.D., n = 3) and this interaction resulted in a large conformational change in [Glu]plasminogen. Kinetic analysis established that AIIt produces a large increase of about 190-fold in the k(cat, app) and a small increase in the K-m,K- app which resulted in a 90-fold increase in the catalytic efficiency (k(cat)/K-m) of t-PA for [Glu]plasminogen. AIIt also stimulated the t-PA-dependent activation of [Lys]plasminogen about 28-fold. Furthermore, other annexins such as annexin I, V, or VI did not produce comparable activation of t-PA-dependent conversion of [Glu]plasminogen to plasmin, The stimulation of the activation of [Glu]plasminogen by AIIt was Ca2+-independent and inhibited by epsilon-aminocaproic acid. AIIt bound to human 293 cells potentiated t-PA-dependent plasminogen activation, AIIt that was bound to phospholipid vesicles or heparin also stimulated the activation of [Glu]plasminogen 5- or 11-fold, respectively. Furthermore, immunofluorescence labeling of nonpermeabilized HUVEC revealed a punctated distribution of AIIt subunits on the cell surface, These results therefore identify AIIt as a potent in vitro activator of plasminogen.	Univ Calgary, Fac Med, Dept Med Biochem, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Med Biochem, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			shinomiya, aya/0000-0003-3969-7290; Waisman, David/0000-0002-5097-9662				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Bellagamba C, 1997, J BIOL CHEM, V272, P3195, DOI 10.1074/jbc.272.6.3195; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; Borza DB, 1997, J BIOL CHEM, V272, P5718, DOI 10.1074/jbc.272.9.5718; BURGOYNE RD, 1990, BIOCHEM SOC T, V18, P1101, DOI 10.1042/bst0181101; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; DEVRIES C, 1990, J BIOL CHEM, V265, P13547; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FEARS R, 1990, BIOCHEM J, V266, P693, DOI 10.1042/bj2660693; FISCHER BE, 1992, BLOOD COAGUL FIBRIN, V3, P197; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; HAJJAR KA, 1995, THROMB HAEMOSTASIS, V74, P294; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; Jost M, 1997, J CELL SCI, V110, P221; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; LIJNEN HR, 1990, THROMB HAEMOSTASIS, V64, P61; LIN JJ, 1995, CLIN NEPHROL, V44, P310; LIU L, 1995, BBA-LIPID LIPID MET, V1259, P166, DOI 10.1016/0005-2760(95)00159-A; MAGNUSSON S, 1996, PROTEOLYSIS PHYSL RE, V11, P203; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V748, P86, DOI 10.1016/0167-4838(83)90030-4; NIEUWENHUIZEN W, 1982, EUR J BIOCHEM, V704, P461; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; SAEZ CT, 1995, BIOCHEMISTRY-US, V34, P2496, DOI 10.1021/bi00008a013; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; TRESSLER RJ, 1994, EXP CELL RES, V215, P395, DOI 10.1006/excr.1994.1358; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WRIGHT JF, 1994, BIOCHEM BIOPH RES CO, V198, P983, DOI 10.1006/bbrc.1994.1140; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	48	133	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4790	4799		10.1074/jbc.273.8.4790	http://dx.doi.org/10.1074/jbc.273.8.4790			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468544	hybrid			2022-12-27	WOS:000072115000072
J	Monte, D; DeWitte, F; Hum, DW				Monte, D; DeWitte, F; Hum, DW			Regulation of the human P450scc gene by steroidogenic factor 1 is mediated by CBP/p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E1A-ASSOCIATED PROTEIN P300; CHAIN-CLEAVAGE ENZYME; NUCLEAR RECEPTOR; FACTOR-I; TRANSCRIPTION FACTOR; ADENOVIRUS E1A; GRANULOSA-CELLS; COACTIVATOR CBP; KEY REGULATOR; LEYDIG-CELLS	Regulation of the human CYP11A gene encoding cytochrome P450scc, which catalyzes the first step of steroid synthesis, is regulated by many trans-acting transcription factors including steroidogenic factor 1 (SF-l), Transfection experiments in human adrenal NCI-H295 cells demonstrate regulation of the P450scc gene promoter region that contains several putative SF-1 binding sites, Cotransfection of SF-l with a luciferase reporter construct containing the P450scc gene 5'-flanking region from nucleotides -1676 to +49 increased promoter activity, and deletion of the nucleotide sequence from position -1676 to -1620, which removes a putative cAMP response element (CRE), did not affect the stimulatory response to SF-l, As well, further deletion of the promoter region to nucleotide -110, which contains only one SF-1 binding site, still retained the ability to respond to exogenous SF-1, However, mutation of the remaining site which abolished SF-1 protein/DNA interaction also abrogated any functional response to the factor, All the P450scc reporter constructs which responded to SF-l were further stimulated by exogenous p300 and CREB-binding protein (CBP), suggesting interaction between SF-l and p300/CBP, As well, mutation of the binding site that abrogated the response to SF-l also abolished the response to p300 and CBP, Cotransfection of the adenovirus E1A oncoprotein, which has been shown to interact with p300/CBP and interfere with its function, decreased the stimulatory effect of SF-l and p300/CBP, Cotransfection of a mutated E1A protein, RG2, which does not interact with p300/CBP, did not alter the stimulatory effect of SF-l and p300/CBP on the P450scc promoter, Deletion of the region from amino acid residues 2-67 in E1A, which has been postulated to interact with p300/CBP, also abolished the inhibitory effect of E1A, whereas deletion of the region from residues 120 to 140 had no effect, Two regions of CBP from amino acids 1 to 451 and from 1460 to 1891 were demonstrated to interact with SF-l in vitro, Coexpression of fragments of the p300 protein fused to the VP16 protein in the presence of SF-l and the -110 P450scc reporter construct indicated in vivo the interaction of two regions of p300 with SF-1, thus confirming the in vitro results, Taken together these results indicate that regulation of the human P450scc gene by SF-1 is mediated by p300/CBP, Due to the many putative roles of SF-l to regulate many genes, its interaction with p300/CBP is potentially a key component effecting important physiological processes.	CHUL, Mol Endocrinol Lab, Ctr Rech, St Foy, PQ G1V 4G2, Canada; Univ Laval, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Hum, DW (corresponding author), CHUL, Mol Endocrinol Lab, Ctr Rech, 2705 Boul Laurier, St Foy, PQ G1V 4G2, Canada.			monte, didier/0000-0002-0613-6203				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN CT, 1995, DNA CELL BIOL, V14, P803, DOI 10.1089/dna.1995.14.803; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giuili G, 1997, DEVELOPMENT, V124, P1799; GUO IC, 1994, J BIOL CHEM, V269, P6362; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HANUKOGLU I, 1989, FOLLICULAR DEV OVULA, P233; HATANO O, 1994, DEVELOPMENT, V120, P2787; HONDA S, 1993, J BIOL CHEM, V268, P7494; HUM DW, 1993, ENDOCRINOLOGY, V132, P546, DOI 10.1210/en.132.2.546; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lapointe J, 1996, CANCER RES, V56, P4586; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LeersSucheta S, 1997, J BIOL CHEM, V272, P7960, DOI 10.1074/jbc.272.12.7960; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Parker KL, 1996, TRENDS ENDOCRIN MET, V7, P203, DOI 10.1016/1043-2760(96)00105-1; RAINEY WE, 1994, MOL CELL ENDOCRINOL, V100, P45, DOI 10.1016/0303-7207(94)90277-1; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1990, MOL CELL ENDOCRINOL, V70, pC25, DOI 10.1016/0303-7207(90)90151-W; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; Waterman MR, 1986, CYTOCHROME P450 STRU, P345; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang PL, 1997, MOL ENDOCRINOL, V11, P891, DOI 10.1210/me.11.7.891; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	72	128	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4585	4591		10.1074/jbc.273.8.4585	http://dx.doi.org/10.1074/jbc.273.8.4585			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468515	hybrid			2022-12-27	WOS:000072115000043
J	Furukawa, K; Fritze, CE; Gerace, L				Furukawa, K; Fritze, CE; Gerace, L			The major nuclear envelope targeting domain of LAP2 coincides with its lamin binding region but is distinct from its chromatin interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; INTEGRAL MEMBRANE-PROTEINS; CHICKEN HEPATIC LECTIN; B-RECEPTOR; INNER MEMBRANE; PORE COMPLEX; CDNA CLONING; PHOSPHORYLATION; CHROMOSOMES; CELLS	LAP2 is an integral protein of the inner nuclear membrane which binds lamins and chromosomes and is suggested to have an important role in nuclear envelope organization. In a previous study we identified an internal 76-amino acid region of LAPS which is required for stable targeting of the protein to the nuclear envelope. Here, we have mapped the lamin binding region of LAPS and demonstrate that it coincides with this nuclear envelope targeting domain. In contrast, we found that the portion of LAPS involved in binding to chromosomes resides in a separate region of the protein near its NH2 terminus. The minimal lamin binding region of LAPS is capable of conferring stable nuclear envelope localization when attached to the transmembrane and partial lumenal domains of a protein that shows no nuclear envelope targeting activity. This directly supports the notion that a major mechanism for localization of integral membrane proteins at the inner nuclear membrane involves binding to lamins, which would constrain diffusion through the continuous nuclear envelope/endoplasmic reticulum membrane system.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Gerace, L (corresponding author), Scripps Res Inst, Dept Cell Biol, Mail Drop IMM-10,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							ADAM SA, 1992, METHOD ENZYMOL, V219, P97; AsheryPadan R, 1997, J BIOL CHEM, V272, P2493; Berger R, 1996, GENOME RES, V6, P361, DOI 10.1101/gr.6.5.361; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; BURKE B, 1990, EXP CELL RES, V186, P169, DOI 10.1016/0014-4827(90)90223-W; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DRICKAMER K, 1982, J BIOL CHEM, V257, P5156; DRICKAMER K, 1981, J BIOL CHEM, V256, P5827; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1997, BIOCHEM BIOPH RES CO, V238, P240, DOI 10.1006/bbrc.1997.7235; FURUKAWA K, 1995, EMBO J, V14, P1626, DOI 10.1002/j.1460-2075.1995.tb07151.x; FURUKAWA K, 1993, EMBO J, V12, P97, DOI 10.1002/j.1460-2075.1993.tb05635.x; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOGER TH, 1991, EXP CELL RES, V197, P280, DOI 10.1016/0014-4827(91)90434-V; Lourim David, 1994, Trends in Cell Biology, V4, P314, DOI 10.1016/0962-8924(94)90228-3; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Marshall ICB, 1997, TRENDS CELL BIOL, V7, P69, DOI 10.1016/S0962-8924(96)10047-7; MARTIN L, 1995, J BIOL CHEM, V270, P8822, DOI 10.1074/jbc.270.15.8822; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nikolakaki E, 1997, J BIOL CHEM, V272, P6208, DOI 10.1074/jbc.272.10.6208; PADAN R, 1990, J BIOL CHEM, V265, P7808; POWELL L, 1990, J CELL BIOL, V111, P2225, DOI 10.1083/jcb.111.6.2225; REYNOLDS A, 1993, PROTOCOLS OPINIONS M; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; Yang L, 1997, J CELL BIOL, V139, P1077, DOI 10.1083/jcb.139.5.1077; Yang L, 1997, J CELL BIOL, V137, P1199, DOI 10.1083/jcb.137.6.1199; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; YUAN J, 1991, J BIOL CHEM, V266, P9211	48	99	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4213	4219		10.1074/jbc.273.7.4213	http://dx.doi.org/10.1074/jbc.273.7.4213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461618	hybrid			2022-12-27	WOS:000072048400060
J	Iyer, S; Woo, J; Cornejo, MC; Gao, L; McCoubrey, W; Maines, M; Buelow, R				Iyer, S; Woo, J; Cornejo, MC; Gao, L; McCoubrey, W; Maines, M; Buelow, R			Characterization and biological significance of immunosuppressive peptide D2702.75-84(E -> V) binding protein - Isolation of heme oxygenase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART GRAFT-SURVIVAL; TOXIC LYMPHOCYTES-T; UNCONJUGATED BILIRUBIN; ALLOGRAFT SURVIVAL; CELL RECEPTOR; RAT-LIVER; IN-VITRO; MESSENGER; DOMAIN; BRAIN	This is the first report on peptidic inhibitors of heme oxygenase, Such peptides were originally developed from the immunomodulatory peptide 2702.75-84 which corresponds to amino acid residues 75 to 84 of the alpha(1)-helix of HLA-B2702 (2702.75-84) and has been shown to be immunosuppressive in vitro and in vivo, lit vitro, 2702.75-84 inhibited cytotoxic T-and natural killer cell-mediated target cell lysis, and in vivo peptide therapy resulted in prolongation of heart and skin allograft survival in mice, The peptide was also shown to bind to heat shock protein 70, However, D-enantiomers of 2702.75-84 and derivatives thereof, while still being immunosuppressive, did not bind to heat shock protein 70, This study was designed to identify proteins binding to peptide D2702.75-84(E --> V) (rvnlrialry) consisting of D-amino acids, Compared with 2702.75-84 (RENLRIALRY), glutamic acid residue 76 (E) was replaced with valine (V), Affinity chromatography using immobilized D2702.75-84(E --> V) and mouse and human cell extracts, resulted in the isolation of heme oxygenase-l (HO-1), Peptide D2702.75-84 inhibited HO activity in vitro in a dose dependent manner, Similar to what has been observed with other inhibitors of HO, administration of peptide into mice resulted in an up-regulation of HO-1 mRNA and protein, as well as enzyme activity in liver, spleen and kidney, Other peptides derived from 2702.75-84 with similar immunomodulatory activity displayed similar effects, In contrast, inactive derivatives of 2702.75-84 had no effect on HO activity, Therefore, the immunosuppressive effects of the described immunomodulatory peptides are similar to those of cobalt-protoporphyrin, a known up-regulator of HO-1, Our results suggest that HO-1 modulation may be a novel mechanism of immunomodulation.	SangStat Med Corp, Menlo Park, CA 94025 USA; Univ Rochester, Sch Med, Dept Biochem Biophys & Environm Med, Rochester, NY 14642 USA	University of Rochester	Buelow, R (corresponding author), SangStat Med Corp, 1505 Adams Dr, Menlo Park, CA 94025 USA.				NIEHS NIH HHS [ES03968] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003968] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal A, 1996, TRANSPLANTATION, V61, P93, DOI 10.1097/00007890-199601150-00019; BRIINE B, 1987, MOL PHARMACOL, V32, P497; BUELOW R, 1995, TRANSPLANTATION, V59, P455; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYBERGER C, 1993, TRANSPLANT P, V25, P477; CLAYBERGER C, 1987, NATURE, V330, P763, DOI 10.1038/330763a0; CUTURI MC, 1995, TRANSPLANTATION, V59, P661, DOI 10.1097/00007890-199503150-00003; Degerman E, 1996, BIOCHEM SOC T, V24, P1010, DOI 10.1042/bst0241010; DIAZ JA, 1995, ARCH SURG, V130; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; Gao L, 1996, J HEART LUNG TRANSPL, V15, P78; Haga Y, 1996, BBA-MOL BASIS DIS, V1316, P29, DOI 10.1016/0925-4439(96)00004-X; Haga Y, 1996, DIGEST DIS SCI, V41, P1468, DOI 10.1007/BF02088574; HAGA Y, 1992, CLIN BIOCHEM, V25, P277, DOI 10.1016/0009-9120(92)80033-D; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; KWAK JY, 1991, BIOCHIM BIOPHYS ACTA, V1076, P369, DOI 10.1016/0167-4838(91)90478-I; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1975, J BIOL CHEM, V250, P4171; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1977, J BIOL CHEM, V252, P219; MAINES MD, 1992, HEME OXYGENASE CLIN, P276; NAKAGAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P189, DOI 10.1016/0304-4165(93)90013-X; NISCO S, 1994, J IMMUNOL, V152, P3786; NOESSNER E, 1996, J EXP MED, V183, P339; OLSON CA, 1989, P NATL ACAD SCI USA, V86, P1031, DOI 10.1073/pnas.86.3.1031; PARHAM P, 1987, NATURE, V325, P625, DOI 10.1038/325625a0; Pratt J R, 1996, Transpl Immunol, V4, P72, DOI 10.1016/S0966-3274(96)80041-4; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; Sambrook J., 2002, MOL CLONING LAB MANU; SANO K, 1985, PEDIATR RES, V19, P587, DOI 10.1203/00006450-198506000-00017; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SIGAL LJ, 1994, J IMMUNOL METHODS, V177, P261, DOI 10.1016/0022-1759(94)90164-3; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUN Y, 1990, J BIOL CHEM, V265, P8212; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 1997, TRANSPLANTATION, V64, P1460, DOI 10.1097/00007890-199711270-00015; WOO J, 1995, TRANSPLANTATION, V60, P1156, DOI 10.1097/00007890-199511270-00017; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	47	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2692	2697		10.1074/jbc.273.5.2692	http://dx.doi.org/10.1074/jbc.273.5.2692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446574	hybrid			2022-12-27	WOS:000071736600029
J	Zheng, CH; Xing, Z; Bian, ZC; Guo, CM; Akbay, A; Warner, L; Guan, JL				Zheng, CH; Xing, Z; Bian, ZC; Guo, CM; Akbay, A; Warner, L; Guan, JL			Differential regulation of Pyk2 and focal adhesion kinase (FAK) - The C-terminal domain of FAK confers response to cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; V-SRC; PHOSPHORYLATION; ACTIVATION; INTEGRIN; IDENTIFICATION; PP125(FAK); PAXILLIN; CRK	Pyk2 is a recently described cytoplasmic tyrosine kinase that is related to focal adhesion kinase (FAK) and can be activated by a variety of stimuli that elevate intracellular calcium, in this report, we showed that Pyk2 and FAK tyrosine phosphorylation are regulated differentially by integrin-mediated cell adhesion and soluble factors both in rat aortic smooth muscle cells, which express endogenous Pyk2 and FAK, and in transfected Chinese hamster ovary cells, We also found that Pyk2 is diffusely present throughout the cytoplasm, while FAT( is localized in focal contacts as expected, suggesting that the different localization may account for their differential regulation, By analyzing a chimeric protein contain N-terminal and kinase domains of Pyk2 and C-terminal domain of FAK, we provided evidence that the distinctive C-terminal domains of Pyk2 and FAR were responsible for their differential regulation by integrins and soluble stimuli as well as their subcellular localization, Finally, we correlated FAR, Pyk2, and the chimeric protein binding to talin, but not paxillin, with their regulation by integrins and focal contact localization, These results demonstrate that the distinctive C-terminal domain of Pyk2 and FAK confer their differential regulation by different subcellular localization and association with the cytoskeletal protein talin.	Cornell Univ, Coll Vet Med, Dept Pathol, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Coll Vet Med, Dept Pathol, Canc Biol Labs, Ithaca, NY 14853 USA.		Xing, Zheng/G-8366-2011; Xing, Zheng/O-3137-2015	Xing, Zheng/0000-0002-7288-0268; Xing, Zheng/0000-0002-7288-0268	NCI NIH HHS [T32CA09682] Funding Source: Medline; NIGMS NIH HHS [R01GM52890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; DEVOR BB, 1993, BIOCHEM BIOPH RES CO, V190, P1084, DOI 10.1006/bbrc.1993.1160; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Raja S, 1997, J BIOL CHEM, V272, P10941; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TURNER CE, 1994, J CELL SCI, V107, P1583; VUORI K, 1993, J BIOL CHEM, V268, P21459; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	33	123	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2384	2389		10.1074/jbc.273.4.2384	http://dx.doi.org/10.1074/jbc.273.4.2384			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442086	hybrid			2022-12-27	WOS:000071595200075
J	Kimura, T; Shiina, Y; Sawai, T; Yamaguchi, A				Kimura, T; Shiina, Y; Sawai, T; Yamaguchi, A			Cysteine-scanning mutagenesis around transmembrane segment III of Tn10-encoded metal-tetracycline/H+ antiporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOSE PERMEASE; RESISTANCE PROTEIN; NUCLEOTIDE-SEQUENCE; TRANSPOSON TN10; ACTIVE EFFLUX; H+ ANTIPORTER; RESIDUES; MUTANT; MEMBRANE	Each amino acid in the putative transmembrane helix III and its flanking regions (from Gly-62 to Tyr-98) of the Tn10-encoded metal-tetracycline/H+ antiporter (Tet(B)) was individually replaced with Cys, Out of these 37 cysteine-scanning mutants, the mutants from G62C to R70C and from S92C to Y98C showed high or intermediate reactivity with [C-14]N-ethylmaleimide (NEM) except for the M64C mutant, On the other hand, the mutants from R71C to S91C showed almost no reactivity with NEM except for the P72C mutant, These results confirm that the transmembrane helix III is composed of 21 residues from Arg-71 to Ser-91. The majority of Cys replacement mutants retained high or moderate tetracycline transport activity, Cys replacements for Gly-62, Asp-66, Ser-77, Gly-80, and Asp-84 resulted in almost inactive Tet(B) (less than 3% of the wild-type activity), The Arg-70 --> Cys mutant retained very low activity due to a mercaptide between Co2+ and SH group (Someya, Y., and Yamaguchi, A. (1996) Biochemistry 35, 9385-9391), Three of these six important residues (Ser-77, Gly-80, and Asp-84) are located in the transmembrane helix III and one (Arg-70) is located in the flanking region, These four functionally important residues are located on one side of the helical wheel, Only two of the residual 31 Cys mutants were inactivated by NEM (S65C and L97C), Ser-65 and Leu-97 are located on the cytoplasmic and periplasmic loops, respectively, in the topology of Tet(B), The degree of inactivation of these Cys mutants with SH reagents was dependent on the volume of substituents. In the presence of tetracycline, the reactivity of the S65C mutant with NEM was significantly increased, in contrast, the reactivity of L97C was greatly reduced, indicating that the cytoplasmic and periplasmic loop regions undergo substrate-induced conformational change in the mutually opposite direction.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 567, Japan; Chiba Univ, Fac Pharmaceut Sci, Div Microbial Chem, Chiba 263, Japan; Osaka Univ, Fac Pharmaceut Sci, Osaka 565, Japan	Osaka University; Chiba University; Osaka University	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 567, Japan.		Kimura-Someya, Tomomi/C-4169-2017	Kimura-Someya, Tomomi/0000-0003-2232-1801				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; ECKERT B, 1989, J BIOL CHEM, V264, P11663; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P6408, DOI 10.1021/bi970233b; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P5333, DOI 10.1021/bi953068d; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; Kimura T, 1997, J BIOL CHEM, V272, P580; KIMURA T, 1995, FEBS LETT, V362, P47, DOI 10.1016/0014-5793(95)00205-N; Kimura T, 1997, BIOCHEMISTRY-US, V36, P6941, DOI 10.1021/bi9631879; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SAHINTOTH M, 1994, PROTEIN SCI, V3, P2302, DOI 10.1002/pro.5560031215; SAHINTOTH M, 1994, PROTEIN SCI, V3, P240; SEOL W, 1992, BIOCHEMISTRY-US, V31, P3550, DOI 10.1021/bi00128a032; SOMEYA Y, 1995, BIOCHEMISTRY-US, V34, P7, DOI 10.1021/bi00001a002; Someya Y, 1996, BIOCHEMISTRY-US, V35, P9385, DOI 10.1021/bi961026z; WEITZMAN C, 1995, BIOCHEMISTRY-US, V34, P9374, DOI 10.1021/bi00029a013; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1992, FEBS LETT, V307, P229, DOI 10.1016/0014-5793(92)80773-A; YAMAGUCHI A, 1993, BIOCHEMISTRY-US, V32, P5698, DOI 10.1021/bi00072a027; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAGUCHI A, 1994, J BIOCHEM-TOKYO, V115, P958, DOI 10.1093/oxfordjournals.jbchem.a124445; YAMAGUCHI A, 1993, FEBS LETT, V322, P201, DOI 10.1016/0014-5793(93)81568-K; YAMAGUCHI A, 1995, BIOCHEMISTRY-US, V34, P11800, DOI 10.1021/bi00037a018; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	43	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5243	5247		10.1074/jbc.273.9.5243	http://dx.doi.org/10.1074/jbc.273.9.5243			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478980	hybrid			2022-12-27	WOS:000072310400064
J	Reunanen, N; Westermarck, J; Hakkinen, L; Holmstrom, TH; Elo, I; Eriksson, JE; Kahari, VM				Reunanen, N; Westermarck, J; Hakkinen, L; Holmstrom, TH; Elo, I; Eriksson, JE; Kahari, VM			Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INHIBITS COLLAGEN; MAP KINASE; CELLS; PHOSPHORYLATION; JUN; SUPPRESSION; INDUCTION; AP-1; INTERLEUKIN-1	Inflammatory cytokines tumor necrosis factor-alpha and interleukin-1 trigger the ceramide signaling pathway, initiated by neutral sphingomyelinase-elicited hydrolysis of cell membrane phospholipid sphingomyelin to ceramide, a new lipid second messenger. Here, we show that triggering the ceramide pathway by sphingomyelinase or C-2- and C-6-ceramide enhances collagenase-1 (matrix metalloproteinase-1; MMP-1) gene expression by fibroblasts. C-2-ceramide activates three distinct mitogen-activated protein kinases (MAPKs) in dermal fibroblasts, Le. extracellular signal-regulated kinase 1/2 (ERK1/2), stress-activated protein kinase/Jun N-terminal-kinase (SAPK/JNK), and p38. Stimulation of MMP-1 promoter activity by C-2-ceramide is dependent on the presence of a functional AP-1 cis-element and is entirely inhibited by overexpression of MAPK inhibitor, dual specificity phosphatase CL100 (MAPK phosphatase-1). Activation of MMP-1 promoter by C-2-ceramide is also effectively inhibited by kinase-deficient forms of ERK1/2 kinase (MEK1/2) activator Raf-1, ERK1 and ERK2, SAPK/JNK activator SEK1, or SAPK beta, In addition, ceramide-dependent induction of MMP-1 expression is potently prevented by PD 98059, a selective inhibitor of MEK1 activation, and by specific p38 inhibitor SB 203580. These results show that triggering the ceramide signaling pathway activates MMP-1 gene expression via three distinct MAPK pathways, i.e. ERK1/2, SAPK/JNK and p38, and suggest that targeted modulation of the ceramide signaling pathway may offer a novel therapeutic approach for inhibiting collagenolytic activity, e.g. in inflammatory disorders.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Periodontol, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Dermatol, FIN-20520 Turku, Finland; Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; Abo Akademi University	Kahari, VM (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6, FIN-20520 Turku, Finland.	velkah@utu.fi	Kähäri, Veli-Matti/E-5144-2011; Westermarck, Jukka/AAL-6464-2020; Kahari, Veli-Matti/T-4925-2019; Hakkinen, Lari/B-2228-2016	Kähäri, Veli-Matti/0000-0003-2421-9368; Westermarck, Jukka/0000-0001-7478-3018; Kahari, Veli-Matti/0000-0003-2421-9368; 				ALESSI DR, 1993, ONCOGENE, V8, P2015; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRUDER T, 1993, GENE DEV, V6, P545; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; MAUVIEL A, 1988, FEBS LETT, V236, P47, DOI 10.1016/0014-5793(88)80283-7; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rapala KT, 1996, EXPERIENTIA, V52, P70, DOI 10.1007/BF01922419; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTERMARCK J, 1995, J INVEST DERMATOL, V105, P197, DOI 10.1111/1523-1747.ep12317114; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; YAN MH, 1994, NATURE, V372, P798; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	55	192	199	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5137	5145		10.1074/jbc.273.9.5137	http://dx.doi.org/10.1074/jbc.273.9.5137			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478967	hybrid			2022-12-27	WOS:000072310400051
J	Trybala, E; Bergstrom, T; Spillmann, D; Svennerholm, B; Flynn, SJ; Ryan, P				Trybala, E; Bergstrom, T; Spillmann, D; Svennerholm, B; Flynn, SJ; Ryan, P			Interaction between pseudorabies virus and heparin/heparan sulfate - Pseudorabies virus mutants differ in their interaction with heparin/heparan sulfate when altered for specific glycoprotein C heparin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; FIBROBLAST GROWTH-FACTOR; CELL-SURFACE; LIPOPROTEIN-LIPASE; INITIAL INTERACTION; DIMETHYL-SULFOXIDE; GIII; ADSORPTION; ATTACHMENT; IDENTIFICATION	Cell surface heparan sulfate serves as an initial receptor for a number of herpesviruses including pseudorabies virus (PrV). It has been demonstrated that the heparan sulfate-binding domain of PrV glycoprotein C is composed of three discrete clusters of basic residues corresponding to amino acids 76-RRKPPR-81, 96-HGRKR-100, and 133-RFYRRGRFR-141, respectively, and that these clusters are functionally redundant, i.e. each of them could independently support PrV attachment to cells (Flynn, S. J., and Ryan, P. (1996) J. Virol. 70, 1355-1364). To evaluate the functional significance of each of these clusters we have used PrV mutants in which, owing to specific alterations in glycoprotein C, the heparan sulfate-binding site is dominated by a single specific cluster. These mutants exhibited different patterns of susceptibility to selectively N-, 2-O-, and 6-O-desulfated heparin preparations in virus attachment/infectivity assay. Moreover PrV mutants differed as regard to efficiency of their attachment to and infection of cells pretreated with relatively low amounts of heparan sulfate-degrading enzymes. Furthermore glycoprotein C species, purified from respective mutants, bound heparin oligosaccharide fragments of different minimum size. These differences suggest that specific clusters of basic amino acids of the heparan sulfate-binding domain of glycoprotein C may support PrV binding to different structural features/stretches within the heparan sulfate chain.	Gothenburg Univ, Dept Clin Virol, S-41346 Gothenburg, Sweden; Univ Uppsala, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden; Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Gothenburg; Uppsala University; University of Tennessee System; University of Tennessee Health Science Center	Bergstrom, T (corresponding author), Gothenburg Univ, Dept Clin Virol, Guldhedsgatan 10B, S-41346 Gothenburg, Sweden.			Bergstrom, Tomas/0000-0002-9257-6757; Trybala, Edward/0000-0003-2384-2123				CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COE NE, 1990, ARCH VIROL, V110, P137, DOI 10.1007/BF01310710; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Flynn SJ, 1996, J VIROL, V70, P1355, DOI 10.1128/JVI.70.3.1355-1364.1996; FLYNN SJ, 1993, J VIROL, V67, P2646, DOI 10.1128/JVI.67.5.2646-2654.1993; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HATA A, 1993, J BIOL CHEM, V268, P8447; Herold BC, 1996, J VIROL, V70, P3461, DOI 10.1128/JVI.70.6.3461-3469.1996; HEROLD BC, 1995, VIROLOGY, V206, P1108, DOI 10.1006/viro.1995.1034; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KARGER A, 1995, J VIROL, V69, P3482, DOI 10.1128/JVI.69.6.3482-3489.1995; KARI B, 1993, J GEN VIROL, V74, P255, DOI 10.1099/0022-1317-74-2-255; LIANG XP, 1991, J VIROL, V65, P5553, DOI 10.1128/JVI.65.10.5553-5557.1991; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANN DM, 1994, J BIOL CHEM, V269, P23661; MARTENS G, 1996, J CELL BIOL, V132, P487; METTENLEITER TC, 1990, J VIROL, V64, P278, DOI 10.1128/JVI.64.1.278-286.1990; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; OKAZAKI K, 1991, VIROLOGY, V181, P666, DOI 10.1016/0042-6822(91)90900-V; PEJLER G, 1988, J BIOL CHEM, V263, P5197; ROBBINS A K, 1984, Journal of Molecular and Applied Genetics, V2, P485; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; Trybala E, 1996, VIROLOGY, V218, P35, DOI 10.1006/viro.1996.0163; VANDERPLASSCHEN A, 1993, VIROLOGY, V196, P232, DOI 10.1006/viro.1993.1471; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; WITT DP, 1994, CURR BIOL, V4, P349; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546; ZSAK L, 1991, J VIROL, V65, P4317, DOI 10.1128/JVI.65.8.4317-4324.1991	40	38	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5047	5052		10.1074/jbc.273.9.5047	http://dx.doi.org/10.1074/jbc.273.9.5047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478954	hybrid			2022-12-27	WOS:000072310400038
J	Vaingankar, SM; Martins-Green, M				Vaingankar, SM; Martins-Green, M			Thrombin activation of the 9E3/CEF4 chemokine involves tyrosine kinases including c-src and the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; SMOOTH-MUSCLE CELLS; MICROVASCULAR ENDOTHELIAL-CELLS; PROTEIN ALPHA-SUBUNITS; HUMAN PLATELETS; V-SRC; PHOSPHOINOSITIDE TURNOVER; SIGNALING PATHWAYS; EGF RECEPTOR; TGF-ALPHA	The 9E3/CEF4 gene codes for a chemokine that is highly homologous to human interleukin-8 and melanoma growth-stimulating activity/gro alpha. These chemokines belong to a family of molecular mediators that are importantly involved in inflammation, wound healing, tumor development, and viral entry into cells. On the chorioallantoic membrane the 9E3 protein is chemotactic for monocyte/macrophages and lymphocytes and is angiogenic. In cultured chicken embryo fibroblasts, which have many of the properties of wound fibroblasts, the gene is stimulated by a variety of agents including oncogenes, growth factors, phorbol esters, and thrombin, The strong stimulation of 9E3 by thrombin in culture correlates well with the observation that in young chicks this gene is stimulated to very high levels in fibroblasts upon wounding and remains high throughout wound repair, Activation of 9E3 by thrombin: (i) occurs very rapidly, one minute exposure to thrombin is sufficient to initiate the signals necessary for gene activation; (ii) is independent of mitogenesis; (iii) operates through the proteolytically activated receptor for thrombin; (iv) is mediated by tyrosine kinases, including c-src and the epidermal growth factor (EGF) receptor, rather than Ser/Thr kinases such as protein kinase C and protein kinase A. Inhibition of either c-src or the EGF receptor tyrosine kinase inhibits the stimulation of 9E3 by thrombin. We show here for the first time that activation of the EGF receptor through a cell-surface receptor that does not have tyrosine kinase activity can lead to expression of an immediate early response gene which encodes for a secreted protein, a chemokine. This rapidly activated tyrosine kinase pathway may be a general stress response by which in vivo a localized cell population reacts to emergency situations such as viral infection, wounding, or tumor growth.	Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Martins-Green, M (corresponding author), Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA.	mmgreen@ucracl.ucr.edu			NIGMS NIH HHS [GM48436] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048436] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAFFY G, 1994, J BIOL CHEM, V269, P8483; BARKER K, 1990, MOL CELL BIOL, V10, P3813, DOI 10.1128/MCB.10.7.3813; BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BARKER KA, 1993, J VIROL, V67, P3528, DOI 10.1128/JVI.67.6.3528-3533.1993; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BISSELL MJ, 1977, J SUPRAMOL STR CELL, V6, P1, DOI 10.1002/jss.400060102; Bojovic B, 1996, J BIOL CHEM, V271, P22528, DOI 10.1074/jbc.271.37.22528; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CARVETH HJ, 1992, SEMIN THROMB HEMOST, V18, P126, DOI 10.1055/s-2007-1002417; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; CONSTANTINOU A, 1995, P SOC EXP BIOL MED, V208, P109; COUGHLIN SR, 1992, COLD SPRING HARB SYM, V57, P149, DOI 10.1101/SQB.1992.057.01.019; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROWLEY MR, 1994, J CARDIOVASC PHARM, V23, P806, DOI 10.1097/00005344-199405000-00017; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; ERIKSON RL, 1988, COLD SPRING HARB SYM, V53, P143, DOI 10.1101/SQB.1988.053.01.020; FALET H, 1994, FEBS LETT, V345, P87, DOI 10.1016/0014-5793(94)00414-5; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; GRABHAM P, 1995, J NEUROCHEM, V64, P583; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HEWLETT EL, 1983, INFECT IMMUN, V41, P137, DOI 10.1128/IAI.41.1.137-144.1983; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Iorio P, 1996, FEBS LETT, V381, P244, DOI 10.1016/0014-5793(96)00117-2; ISHII K, 1994, J BIOL CHEM, V269, P1125; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KIM DW, 1994, J CELL PHYSIOL, V160, P573, DOI 10.1002/jcp.1041600321; KIM DW, 1991, J CELL BIOL, V115, P16; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; LAPETINA EG, 1990, FEBS LETT, V268, P400, DOI 10.1016/0014-5793(90)81293-W; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; Lin ZW, 1996, P NATL ACAD SCI USA, V93, P2582, DOI 10.1073/pnas.93.6.2582; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARTINSGREEN M, 1991, CELL REGUL, V2, P739, DOI 10.1091/mbc.2.9.739; MartinsGreen M, 1996, CYTOKINE, V8, P448, DOI 10.1006/cyto.1996.0061; MARTINSGREEN M, 1990, J CELL BIOL, V110, P581, DOI 10.1083/jcb.110.3.581; MARTINSGREEN M, 1992, J CELL SCI, V101, P701; MARTINSGREEN M, 1997, CYTOKINE GROWTH F R, V8, P219; MARTINSGREEN M, 1998, IN PRESS CYTOKINE; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; Molloy CJ, 1996, J CLIN INVEST, V97, P1173, DOI 10.1172/JCI118531; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PRIESCHL EE, 1995, INT ARCH ALLERGY IMM, V107, P475, DOI 10.1159/000237089; QURESHI SA, 1991, ONCOGENE, V6, P995; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SHERRY B, 1991, CURR OPIN IMMUNOL, V3, P56, DOI 10.1016/0952-7915(91)90077-E; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SIEWEKE MH, 1989, CANCER RES, V49, P6419; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STIERNBERG J, 1984, J CELL PHYSIOL, V120, P289, DOI 10.1002/jcp.1041200305; STIERNBERG J, 1993, THROMB HAEMOSTASIS, V70, P158; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; VAINGANKAR S, 1995, MOL BIOL CELL, V6, P84; Vaingankar SM, 1996, MOL BIOL CELL, V7, P52; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; YOSHIMURA M, 1995, J BIOL CHEM, V270, P2298, DOI 10.1074/jbc.270.5.2298; ZIMMERMAN BJ, 1994, AM J PHYSIOL, V267, pH1049, DOI 10.1152/ajpheart.1994.267.3.H1049; ZIMMERMAN GA, 1986, ANN NY ACAD SCI, V485, P349, DOI 10.1111/j.1749-6632.1986.tb34596.x	83	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5226	5234		10.1074/jbc.273.9.5226	http://dx.doi.org/10.1074/jbc.273.9.5226			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478978	hybrid			2022-12-27	WOS:000072310400062
J	Conus, NM; Hemmings, BA; Pearson, RB				Conus, NM; Hemmings, BA; Pearson, RB			Differential regulation by calcium reveals distinct signaling requirements for the activation of Akt and p70(S6k)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; S6 KINASE; PHOSPHATASE INHIBITORS; GROWTH-FACTOR; WORTMANNIN; INSULIN; TARGET; DOMAIN; CA-2+	Activation of the phosphatidylinositol 3-kinase (PI3K) plays an important role in the mitogenic response of many cell types. Recently, two serine/threonine kinases Akt and p70(S6k) have been identified as physiological targets of FI3K. Observations that expression of activated forms elf Akt led to the activation of p70(S6k) implied Akt might mediate mitogenic signaling through activation of p70(S6k). TO clarify the relationship between signaling through these two kinases, we have examined their regulation by various mitogenic stimuli. In this study we have focused on the role of calcium in the regulation of each kinase in Balb/c-3T3 fibroblasts. Depletion of intracellular calcium stores by EGTA pretreatment has no effect on growth factor-induced Akt activation but completely abolishes p70(S6k) stimulation. Increase of intracellular calcium induced by ionomycin or thapsigargin results in a full activation of p70(S6k), whereas little or no activation of Akt is observed. Furthermore, although PI3k in anti-phosphotyrosine immunoprecipitates is only very weakly activated by ionomycin, the calcium-induced stimulation of p70(S6k) is completely inhibited by the specific FISH inhibitor wortmannin. We conclude Akt and p70(S6k) Ii, on separate signaling pathways, Activation of signaling to Akt is insufficient for the activation of p70(S6k), which can be achieved independently of Akt. p70(S6k) requires a separate calcium-dependent and wortmannin-sensitive process that is likely to be independent of type, I-A PI3K family members.	Royal Melbourne Inst Technol, Trescowthick Res Labs, Melbourne, Vic 3000, Australia; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Royal Melbourne Institute of Technology (RMIT); Friedrich Miescher Institute for Biomedical Research	Pearson, RB (corresponding author), Royal Melbourne Inst Technol, Trescowthick Res Labs, Locked Bag 1,A Beckett St, Melbourne, Vic 3000, Australia.		Pearson, Richard Bruce/I-1451-2013	Pearson, Richard Bruce/0000-0001-5919-5090				AHMED NN, 1993, ONCOGENE, V8, P1957; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANE HA, 1991, METHOD ENZYMOL, V200, P269; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SUSA M, 1992, J BIOL CHEM, V267, P6905; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WAHL M, 1993, MOL BIOL CELL, V4, P293, DOI 10.1091/mbc.4.3.293; WELTERS P, 1994, P NATL ACAD SCI USA, V91, P11398, DOI 10.1073/pnas.91.24.11398; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	52	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4776	4782		10.1074/jbc.273.8.4776	http://dx.doi.org/10.1074/jbc.273.8.4776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468542	hybrid			2022-12-27	WOS:000072115000070
J	Forbes, BE; Turner, D; Hodge, SJ; McNeil, KA; Forsberg, G; Wallace, JC				Forbes, BE; Turner, D; Hodge, SJ; McNeil, KA; Forsberg, G; Wallace, JC			Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; SEQUENCE; SERUM; CELLS; MITOGENESIS; COMPLEX; IGFBP-3; CLONING	We have investigated which region(s) of bovine insulin-like growth factor binding protein-2 (bIGFBP-2) interact with insulin-like growth factors (IGFs) using C-terminally truncated forms of bIGFBP-2. Initially to aid in mutant design, we defined the disulfide bonding pattern of bIGFBP-2 C-terminal region using enzymatic digestion, The pattern is Cys(186)-Cys(220), CyS231-CyS242, and Cys(244)-Cys(265). I, addition, cyanogen bromide cleavage of bIGFBP-2 revealed that the N-and C-terminal cysteine-rich domains were not linked by disulfide bonds, Taking the disulfide bonding pattern into consideration, C-terminal truncation mutants were designed and expressed in COS-1 mammalian cells, Following IGF binding assays, a region between residues 222 and 236 was identified as important in IGF binding, Specifically, mutants truncated by 14, 36, and 48 residues from the C terminus bound IGFs to the same extent as wild type (WT) bIGFBP-2. Removal of 63 residues resulted in a greatly reduced (up to 80-fold) ability to bind IGF compared with WT bIGFBP-2. Interestingly this mutant lacked the IGF-II binding preference of WT bIGFBP-2. Residues 236-270 also appeared to play a role in determining IGF binding specificity as their removal resulted in mutants with higher IGF-II binding affinity.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5005, Australia	University of Adelaide	Forbes, BE (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.		, John/AAP-5150-2020; Forbes, Briony/R-1838-2019	Forbes, Briony/0000-0003-4360-9927				ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; Baxter Robert C., 1995, Progress in Growth Factor Research, V6, P215, DOI 10.1016/0955-2235(95)00004-6; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BRINKMAN A, 1991, FEBS LETT, V291, P264, DOI 10.1016/0014-5793(91)81298-M; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CLACKSON T, 1993, PCR PRACTICAL APPROA, P201; FORBES B, 1990, J ENDOCRINOL, V126, P497, DOI 10.1677/joe.0.1260497; FRANCIS GL, 1988, BIOCHEM J, V251, P95, DOI 10.1042/bj2510095; GOCKERMAN A, 1995, CIRC RES, V76, P514, DOI 10.1161/01.RES.76.4.514; GUIDICE LC, 1990, J CLIN ENDOCRINOLOGY, V71, P806; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landale EC, 1995, GROWTH FACTORS, V12, P245, DOI 10.3109/08977199509028963; LEE CY, 1995, ENDOCRINOLOGY, V136, P668, DOI 10.1210/en.136.2.668; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OCRANT I, 1992, ENDOCRINOLOGY, V131, P221, DOI 10.1210/en.131.1.221; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULLER AGP, 1993, GROWTH REGULAT, V3, P32; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; UPTON Z, 1990, J MOL ENDOCRINOL, V5, P77, DOI 10.1677/jme.0.0050077; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WHYATT LM, 1993, MOL CELL BIOL, V13, P7971, DOI 10.1128/MCB.13.12.7971; ZAPF J, 1995, EUR J ENDOCRINOL, V132, P645, DOI 10.1530/eje.0.1320645	31	69	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4647	4652		10.1074/jbc.273.8.4647	http://dx.doi.org/10.1074/jbc.273.8.4647			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468524	hybrid			2022-12-27	WOS:000072115000052
J	Lim, YH; Yoshimura, T; Kurokawa, Y; Esaki, N; Soda, K				Lim, YH; Yoshimura, T; Kurokawa, Y; Esaki, N; Soda, K			Nonstereospecific transamination catalyzed by pyridoxal phosphate-dependent amino acid racemases of broad substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOSTABLE ALANINE RACEMASE; GLUTAMATE RACEMASE; BACILLUS-STEAROTHERMOPHILUS; ESCHERICHIA-COLI; REACTION-MECHANISM; AEROMONAS-CAVIAE; PURIFICATION; GENE; AMINOTRANSFERASE; RACEMIZATION	Pyridoxal 5'-phosphate-dependent amino acid racemases of broad substrate specificity catalyze transamination as a side reaction. We studied the stereospecificities for hydrogen abstraction from C-4' of the bound pyridoxamine 5'-phosphate during transamination from pyridoxamine 5'-phosphate to pyruvate catalyzed by three amino acid racemases of broad substrate specificity. When the enzymes were incubated with (4'S)- or (4'R)-[4'-H-3]pyridoxamine 5'-phosphate in the presence of pyruvate, tritium was released into the solvent from both pyridoxamine 5'-phosphates. Thus, these enzymes abstract a hydrogen nonstereospecifically from C-4' of the coenzyme in contrast to the other pyridoxal 5'-phosphate-dependent enzymes so far studied, which catalyze the stereospecific hydrogen removal. Amino acid racemase of broad substrate specificity from Pseudomonas putida produced D-and L-glutamate from alpha-ketoglutarate through the transamination with L-ornithine. Be cause glutamate does not serve as a substrate for racemization, the enzyme catalyzed the nonstereospecific overall transamination between L-ornithine and alpha-ketoglutarate, The cleavage and formation of the C-H bond at C-4' of the coenzyme and C-2 of the substrate thus occurs nonstereospecifically on both sides of the plane of the coenzyme-substrate complex intermediate, Amino acid racemase of broad substrate specificity is the first example of a pyridoxal enzyme catalyzing nonstereospecific transamination.	Kyoto Univ, Chem Res Inst, Microbial Biochem Lab, Kyoto 611, Japan; Kansai Univ, Fac Engn, Dept Biotechnol, Osaka 564, Japan	Kyoto University; Kansai University	Esaki, N (corresponding author), Kyoto Univ, Chem Res Inst, Microbial Biochem Lab, Kyoto 611, Japan.	esaki@scl.kyoto-u.ac.jp						AHMED SA, 1986, BIOCHEMISTRY-US, V25, P385, DOI 10.1021/bi00350a017; ALBERY WJ, 1986, BIOCHEMISTRY-US, V25, P2572, DOI 10.1021/bi00357a043; ASADA Y, 1981, BIOCHEMISTRY-US, V20, P6881, DOI 10.1021/bi00527a022; AYLING JE, 1968, BIOCHEMISTRY-US, V7, P4532; BAILEY G B, 1970, Federation Proceedings, V29, P857; BESMER P, 1969, CHIMIA, V23, P190; CARDINALE GJ, 1968, BIOCHEMISTRY-US, V7, P3979; CHANG CC, 1982, J BIOL CHEM, V257, P3564; CHOI SY, 1992, J BIOCHEM-TOKYO, V112, P139, DOI 10.1093/oxfordjournals.jbchem.a123853; DUNATHAN HC, 1971, ADV ENZYMOL RAMB, V35, P79; DUNATHAN HC, 1974, P NATL ACAD SCI USA, V71, P3888, DOI 10.1073/pnas.71.10.3888; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; FLOSS HG, 1982, STEREOCHEMISTRY, P161; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3991, DOI 10.1021/bi00066a020; GALLO KA, 1993, BIOCHEMISTRY-US, V32, P3981, DOI 10.1021/bi00066a019; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HENDERSON LL, 1976, BIOCHEM BIOPH RES CO, V68, P793, DOI 10.1016/0006-291X(76)91215-8; INAGAKI K, 1987, AGR BIOL CHEM TOKYO, V51, P173, DOI 10.1080/00021369.1987.10867978; KANDA M, 1989, J BIOCHEM-TOKYO, V105, P653, DOI 10.1093/oxfordjournals.jbchem.a122720; KUO DJ, 1987, BIOCHEMISTRY-US, V26, P7589, DOI 10.1021/bi00398a009; KURAMITSU S, 1985, J BIOCHEM-TOKYO, V97, P993, DOI 10.1093/oxfordjournals.jbchem.a135176; LIM YH, 1993, J BACTERIOL, V175, P4213, DOI 10.1128/JB.175.13.4213-4217.1993; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MARTINEZCARRION M, 1985, TRANSAMINASES, P308; MEHTA PK, 1993, EUR J BIOCHEM, V211, P373, DOI 10.1111/j.1432-1033.1993.tb19907.x; NAKAJIMA N, 1986, AGR BIOL CHEM TOKYO, V50, P2823, DOI 10.1080/00021369.1986.10867827; REYNOLDS K, 1991, J BASIC MICROB, V31, P177, DOI 10.1002/jobm.3620310304; RUNICK G, 1975, BIOCHEMISTRY-US, V14, P4515; SAWADA S, 1994, BIOSCI BIOTECH BIOCH, V58, P807, DOI 10.1271/bbb.58.807; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; SHEN S, 1983, J CHEM SOC CHEM COMM, V82; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; SODA K, 1971, METHODS ENZYMOL    B, V17, P629; SODA K, 1986, COENZYMES COFACTOR B, V1, P223; SUKHAREV.BS, 1971, FEBS LETT, V15, P241, DOI 10.1016/0014-5793(71)80321-6; TANIZAWA K, 1988, BIOCHEMISTRY-US, V27, P1311, DOI 10.1021/bi00404a033; VOET JG, 1973, J BIOL CHEM, V248, P841; WISEMAN JS, 1984, J BIOL CHEM, V259, P8907; YAMAUCHI T, 1992, J BIOL CHEM, V267, P18361; YORIFUJI T, 1971, J BIOL CHEM, V246, P5085; YORIFUJI T, 1971, J BIOL CHEM, V246, P5093; YOSHIMURA T, 1993, J AM CHEM SOC, V115, P3897, DOI 10.1021/ja00063a007; Yoshimura Tohru, 1994, P147, DOI 10.1002/9783527615971.ch8	43	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4001	4005		10.1074/jbc.273.7.4001	http://dx.doi.org/10.1074/jbc.273.7.4001			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461589	hybrid			2022-12-27	WOS:000072048400031
J	Danner, S; Frank, M; Lohse, MJ				Danner, S; Frank, M; Lohse, MJ			Agonist regulation of human beta(2)-adrenergic receptor mRNA stability occurs via a specific AU-rich element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; RNA-BINDING-PROTEIN; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; INDUCED DESTABILIZATION; MAMMALIAN-CELLS; GENE; DEGRADATION; AUUUA; SEQUENCE	Prolonged agonist stimulation of beta(2)-adrenergic receptors results in receptor down-regulation, which is closely associated with a reduction of the corresponding mRNA, an effect mediated in part by changes in mRNA stability. Transfection experiments with human beta(2)-adrenergic receptor cDNAs bearing or lacking the untranslated regions suggested that the essential agonist sensitivity of the mRNA resides within the 3'-untranslated region. The importance of this region was further confirmed in gel shift experiments; cytosolic preparations hom agonist-stimulated DDT1-MF2 smooth muscle cells caused a shift of beta(2)-adrenergic receptor mRNAs containing the 3'-untranslated region. Progressive 3'-terminal truncations of the receptor cDNA led to the identification of an AU-rich element at positions 329-337 of the 3'-untranslated region as the responsible cis-acting element. Substitution of this motif by cytosine residues almost completely abolished mRNA down-regulation and inhibited the formation of the RNA-protein complex. Even though the beta(2)-adrenergic receptor AU-rich element showed two U --> A transitions compared with the recently proposed AU-rich element consensus sequence, it revealed an almost identical destabilizing potency. Fusion of the beta(2)-adrenergic receptor 3' untranslated region to the beta-globin coding sequence dramatically reduced the half-life of the chimeric transcript in an agonist-and cAMP-dependent manner. This suggests that the agonist-induced beta(2)-adrenergic receptor mRNA destabilization is regulated by cAMP-dependent RNA-binding protein(s) via a specific AU-rich element.	Univ Wurzburg, Inst Pharmacol, D-97078 Wurzburg, Germany	University of Wurzburg	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				BAEYENS DA, 1995, J CELL PHYSIOL, V163, P305, DOI 10.1002/jcp.1041630211; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brown CY, 1996, P NATL ACAD SCI USA, V93, P13721, DOI 10.1073/pnas.93.24.13721; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; Danner S, 1997, EUR J PHARMACOL, V331, P73, DOI 10.1016/S0014-2999(97)01022-4; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUANG LY, 1993, J BIOL CHEM, V268, P25769; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAZARWESLEY E, 1991, ENDOCRINOLOGY, V129, P1116, DOI 10.1210/endo-129-2-1116; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MALBON CC, 1988, BIOCHEM BIOPH RES CO, V154, P676, DOI 10.1016/0006-291X(88)90192-1; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; PORT JD, 1992, J BIOL CHEM, V267, P24103; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	36	59	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3223	3229		10.1074/jbc.273.6.3223	http://dx.doi.org/10.1074/jbc.273.6.3223			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452435	hybrid			2022-12-27	WOS:000071822300020
J	Furuta, M; Carroll, R; Martin, S; Swift, HH; Ravazzola, M; Orci, L; Steiner, DF				Furuta, M; Carroll, R; Martin, S; Swift, HH; Ravazzola, M; Orci, L; Steiner, DF			Incomplete processing of proinsulin to insulin accompanied by elevation of des-31,32 proinsulin intermediates in islets of mice lacking active PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN CONVERTASES; BETA-CELL; CONVERSION; RAT; CLEAVAGE; NIDDM; SITE	The prohormone convertases PC2 (SPC2) and PC3/PC1 (SPC3) are the major precursor processing endoproteases in a wide variety of neural and endocrine tissues. Both enzymes are normally expressed in the islet beta cells and participate in proinsulin processing. Recently we generated mice lacking active PC2 due to a disruption of the PC2 gene (Furuta, M., Yano, H., Zhou, A., Rouille, Y., Hoist, J. J., Carroll, R. J., Ravazzola, M., Orci, L., Furuta, H., and Steiner, D. F. (1997) Proc. Natl. Acad. Sci. U.S. A. 94, 6646-6651). Here we report that these PC2 mutant mice have elevated circulating proinsulin, comprising 60% of immunoreactive insulin-like components. Acid ethanol extractable proinsulin from pancreas is also significantly elevated, representing about 35% of total immunoreactive insulin-like components. These increased amounts of proinsulin are mainly stored in secretory granules, giving rise to an altered appearance on electron microscopy. In pulse-chase experiments, the mutant islets incorporate lesser amounts of isotopic amino acids into insulin-related components than normal islets. In both wild-type and mutant islets, proinsulin I was processed more rapidly to insulin, reflecting the preference of both PC2 and PC3 for substrates having a basic amino acid positioned four residues upstream of the cleavage site. The overall half-time for the conversion of proinsulin to insulin is increased approximately 3-fold in the mutant islets and is associated with a 4-5-fold greater elevation of des-31,32 proinsulin, an intermediate that is formed by the preferential cleavage of proinsulin at the B chain-C-peptide junction by PC3 and is C-terminally processed to remove Arg(31) and Arg(32) by carboxypeptidase E. The constitutive release of newly synthesized proinsulin from both mutant and wild-type islets during the first 1-2 h of chase was normal (<2% of total). These results demonstrate that PC2 plays an essential role in proinsulin processing in vivo, but is quantitatively less important in this regard than PC3, and that its absence does not influence the efficient sorting of proinsulin into the regulated secretory pathway.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Geneva, Dept Morphol, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Geneva	Steiner, DF (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave,MC 1028, Chicago, IL 60637 USA.				NIDDK NIH HHS [DK 20595, DK 13914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, P60DK020595, P30DK020595, R01DK013914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; HALES CN, 1996, DIABETES REV, V4, P320; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Kaufmann JE, 1997, DIABETES, V46, P978, DOI 10.2337/diabetes.46.6.978; LERNMARK A, 1976, J CELL BIOL, V71, P606, DOI 10.1083/jcb.71.2.606; LIPKIND G, 1995, J BIOL CHEM, V270, P13277, DOI 10.1074/jbc.270.22.13277; MADSEN OD, 1983, ENDOCRINOLOGY, V113, P2135, DOI 10.1210/endo-113-6-2135; MAXWELL MH, 1978, J MICROSC-OXFORD, V112, P253, DOI 10.1111/j.1365-2818.1978.tb01174.x; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NEERMANARBEZ M, 1994, BIOCHEM J, V300, P57, DOI 10.1042/bj3000057; ORAHILLY S, 1995, NEW ENGL J MED, V333, P1386, DOI 10.1056/NEJM199511233332104; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; OSTREGA D, 1995, DIABETES, V44, P437, DOI 10.2337/diabetes.44.4.437; RHODES CJ, 1994, DIABETES, V43, P511, DOI 10.2337/diabetes.43.4.511; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SIZONENKO S, 1993, DIABETES, V42, P933, DOI 10.2337/diabetes.42.6.933; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Steiner D., 1995, ENDOCRINOLOGY, P1296; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; TAGER HS, 1975, METHODS ENZYMOLOGY; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; WROBLEWSKI VJ, 1993, DIABETES, V42, P1407, DOI 10.2337/diabetes.42.10.1407; YOSHIDA H, 1995, DIABETES, V44, P389, DOI 10.2337/diabetes.44.4.389	29	153	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3431	3437		10.1074/jbc.273.6.3431	http://dx.doi.org/10.1074/jbc.273.6.3431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452465	hybrid			2022-12-27	WOS:000071822300050
J	Bultmann, H; Santas, AJ; Peters, DMP				Bultmann, H; Santas, AJ; Peters, DMP			Fibronectin fibrillogenesis involves the heparin II binding domain of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST-CULTURES; STAPHYLOCOCCUS-AUREUS; EXTRACELLULAR-MATRIX; CELLULAR-FIBRONECTIN; RECEPTOR; LOCALIZATION; SITE; FIBRILS; ANTIBODIES; ADHESION	Fibronectin matrix assembly is thought to involve binding interactions between the amino-terminal I1-5 repeats and the first type III repeat (III1). Here we report that a third site, located within the III12-14 repeats of the carboxyl-terminal heparin II domain of fibronectin, is also involved in fibrillogenesis. Heparin II fragments inhibited fibril formation and binding of I-125-labeled fibronectin and/or 70-kDa fragments to the cell surface, deoxycholate-insoluble matrix, and adsorbed 160-kDa cell adhesion fragments of fibronectin. The inhibitory effects of heparin II fragments were as large or up to 20 times larger than those of a 44-kDa fibronectin fragment containing the III1 repeat. Under physiological conditions, amino-terminal fragments of fibronectin containing the I1-5 repeats interacted preferentially with proteolytically derived heparin II fragments and a recombinant III12-14 peptide both in solution and in solid phase, indicating that matrix assembly may involve direct interactions between I1-5 and III12-14 repeats. Interactions between the I1-5 repeats and 160-kDa fragments containing the III12-14 and III1 repeats could be inhibited by greater than or equal to 90% by either an anti-III13-14 monoclonal antibody (mAb) (IST-S) or an anti-III1 mAb (9D2), suggesting that cooperative interactions between III12-14 and III1 repeats may also promote binding of the I1-5 repeats. Neither mAb IST-2 nor mAb 9D2, alone or in combination, inhibited binding of I-125-labeled 70-kDa fragments to cycloheximide treated cells plated on the 160-kDa substrate, suggesting that additional I1-5 binding sites, independent of the III1 and III12-14 repeats, may be involved in fibrillogenesis.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Peters, DMP (corresponding author), Univ Wisconsin, Dept Pathol, Rm 6590 MSC,1300 Univ Ave, Madison, WI 53706 USA.		Santas, Amy/F-5532-2013	Santas, Amy/0000-0001-8342-9969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047221] Funding Source: NIH RePORTER; NEI NIH HHS [EY0850] Funding Source: Medline; NIGMS NIH HHS [GM47221] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; CARNEMOLLA B, 1987, FEBS LETT, V215, P269, DOI 10.1016/0014-5793(87)80160-6; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DUFOUR S, 1991, EXP CELL RES, V193, P331, DOI 10.1016/0014-4827(91)90104-3; DZAMBA BJ, 1991, J CELL SCI, V100, P605; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HOEKING DC, 1996, J CELL BIOL, V133, P431; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; Hynes R. O., 1989, FIBRONECTINS; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; Mosher DF, 1989, FIBRONECTIN; Peters D. M. P., 1994, EXTRACELLULAR MATRIX, P315; Peters DM, 1996, INVEST OPHTH VIS SCI, V37, P2047; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; Sambrook J., 2002, MOL CLONING LAB MANU; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1	45	84	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2601	2609		10.1074/jbc.273.5.2601	http://dx.doi.org/10.1074/jbc.273.5.2601			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446562	hybrid			2022-12-27	WOS:000071736600017
J	Inoue, Y; Tsujimoto, Y; Kimura, A				Inoue, Y; Tsujimoto, Y; Kimura, A			Expression of the glyoxalase I gene of Saccharomyces cerevisiae is regulated by high osmolarity glycerol mitogen-activated protein kinase pathway in osmotic stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; YAP-1 TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION PATHWAY; TRIOSEPHOSPHATE ISOMERASE; METHYLGLYOXAL SYNTHASE; PLEIOTROPIC DRUG; ELEMENT STRE; TARGET GENE; YEAST; IDENTIFICATION	Methylglyoxal is a cytotoxic metabolite derived from dihydroxyacetone phosphate, an intermediate of glycolysis, Detoxification of methylglyoxal is performed by glyoxalase I, Expression of the structural gene of glyoxalase I (GLO1) of Saccharomyces cerevisiae under several stress conditions was investigated using the GLO1-lacZ fusion gene, and expression of the GLO1 gene was found to be specifically induced by osmotic stress, The Hog1p is one of the mitogen-activated protein kinases (MAPKs) in S. cerevisiae, and both Msn2p and Msn4p are the transcriptional regulators that are thought to be under the control of Hog1p-MAPK. Expression of the GLO1 gene under osmotic stress was completely repressed in hog1 Delta disruptant and was repressed approximately 80 and 50% in msn2 Delta and msn4 Delta disruptants, respectively, A double mutant of the MSN2 and MSN4 gene was unable to induce expression of the GLO1 gene under highly osmotic conditions, Glucose consumption increased approximately 30% during the adaptive period in osmotic stress in the wild type strain, On the contrary, it was reduced by 15% in the hog1 Delta mutant, When the yeast cell is exposed to highly osmotic conditions, glycerol is synthesized as a compatible solute, Glycerol is synthesized from glucose, and a rate-limiting enzyme in glycerol biosynthesis is glycerol-3-phosphate dehydrogenase (GPD1 gene product), which catalyzes reduction of dihydroxyacetone phosphate to glycerol 3-phosphate. Expression of the GPD1 gene is also under the control of Hog1p-MAPK. Methylglyoxal is also synthesized from dihydroxyacetone phosphate; therefore, induction of the GLO1 gene expression by osmotic stress was thought to scavenge methylglyoxal, which in creased during glycerol production for adaptation to osmotic stress.	Kyoto Univ, Food Sci Res Inst, Kyoto 6110011, Japan	Kyoto University	Inoue, Y (corresponding author), Kyoto Univ, Food Sci Res Inst, Kyoto 6110011, Japan.		kimura, akira/D-1215-2010					Alarco AM, 1997, J BIOL CHEM, V272, P19304, DOI 10.1074/jbc.272.31.19304; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; COHEN G, 1988, EUR J BIOCHEM, V176, P159; COOPER RA, 1974, EUR J BIOCHEM, V44, P81, DOI 10.1111/j.1432-1033.1974.tb03459.x; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; FORST SA, 1994, RES MICROBIOL, V145, P363, DOI 10.1016/0923-2508(94)90083-3; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; HOPPER DJ, 1972, BIOCHEM J, V128, P321, DOI 10.1042/bj1280321; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; INOUE Y, 1987, J BIOCHEM-TOKYO, V102, P583, DOI 10.1093/oxfordjournals.jbchem.a122091; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; IYENGAR R, 1981, BIOCHEMISTRY-US, V20, P1223, DOI 10.1021/bi00508a026; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Miller J. H, 1972, EXPT MOL GENETICS; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; NORBECK J, 1997, J BIOL CHEM, V272, P55454; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; RAY S, 1981, J BIOL CHEM, V256, P6230; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; ROGGENKAMP R, 1974, FEBS LETT, V41, P283, DOI 10.1016/0014-5793(74)81230-5; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SHAPIRO R, 1969, BIOCHEMISTRY-US, V8, P238, DOI 10.1021/bi00829a034; SIKORSKI RS, 1989, GENETICS, V122, P19; TSAI PK, 1976, J BIOL CHEM, V251, P364; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; VANDERJAGT DL, 1993, BIOCHEM SOC T, V21, P522, DOI 10.1042/bst0210522; Varela JCS, 1996, MICROBIOL-SGM, V142, P721, DOI 10.1099/00221287-142-4-721; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	53	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2977	2983		10.1074/jbc.273.5.2977	http://dx.doi.org/10.1074/jbc.273.5.2977			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446611	hybrid			2022-12-27	WOS:000071736600066
J	Kone, BC; Higham, SC				Kone, BC; Higham, SC			A novel N-terminal splice variant of the rat H+-K+-ATPase alpha 2 subunit - Cloning, functional expression, and renal adaptive response to chronic hypokalemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE POTASSIUM ABSORPTION; MESSENGER-RNA EXPRESSION; DISTAL COLON; ADENOSINE-TRIPHOSPHATASE; GASTRIC H,K-ATPASE; MOLECULAR-CLONING; BINDING PROTEINS; GENE; SEQUENCES; CDNA	The H+-K+-ATPase of renal collecting duct mediates K+ conservation during chronic hypokalemia, K+ deprivation promotes H+-K+-ATPase alpha 2 (HK alpha 2) gene expression in the medullary collecting duct, the principal site of active K+ reabsorption, suggesting that this isozyme contributes to renal K+ reclamation, We report here that alternative transcriptional initiation and mRNA splicing give rise to distinct N-terminal variants of the HK alpha 2 subunit, Sequence analysis and in vitro translation revealed that HK alpha 2a corresponds to the known HK alpha 2 cDNA (Crowson, M. S., and Shull, G. E. (1992) J. Biol. Chem. 267, 13740-13748), whereas HK alpha 2b represents a novel variant truncated by 108 amino acids at its N terminus, HK alpha 2b mRNA contains a complex 5'-untranslated region with eight upstream open reading frames, features implicated in translational regulation of other genes, Heterologous expression of HK alpha 2b with and without the gastric H+-K+-ATPase beta subunit in HEK 293 cells indicated that this variant encodes a KC uptake mechanism that is relatively Sch 28080-resistant, partially sensitive to ouabain, and appears to require coexpression with the gastric H+-K+-ATPase beta subunit for optimal functional activity, Northern analysis demonstrated that both subtypes (HK alpha 2b > HK alpha 2a) are expressed abundantly in distal colon and modestly in proximal colon and kidney, Moreover, the abundance of the two mRNAs increases coordinately among the renal zones, but not in colon, with chronic K+ deprivation. These results demonstrate the potential for complex control of HK alpha 2 gene expression by transcriptional and posttranscriptional mechanisms not recognized in other members of the Na+-K+-ATPase/H+-K+-ATPase family.	Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Physiol, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System; University of Texas System	Kone, BC (corresponding author), Univ Texas, Sch Med, Dept Internal Med, 6431 Fannin,MSB 4-148, Houston, TX 77030 USA.	bkone@heart.med.uth.tmc.edu			NIDDK NIH HHS [1R01 DK50745, 1R29 DK47981] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050745, R29DK047981] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn KY, 1996, AM J PHYSIOL-RENAL, V271, pF314, DOI 10.1152/ajprenal.1996.271.2.F314; AHN KY, 1996, AM J PHYSIOL, V270, pF577; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BuffinMeyer B, 1997, AM J PHYSIOL-RENAL, V272, pF124, DOI 10.1152/ajprenal.1997.272.1.F124; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DALY SE, 1994, J BIOL CHEM, V269, P23944; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FELDMAN GM, 1997, AM J PHYSIOL, V272, pF59; FOSTER ES, 1986, AM J PHYSIOL, V251, pG619, DOI 10.1152/ajpgi.1986.251.5.G619; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; GRISHIN AV, 1996, AM J PHYSIOL, V271, pC992; Jaisser F, 1996, AM J PHYSIOL-CELL PH, V270, pC679, DOI 10.1152/ajpcell.1996.270.2.C679; Kone BC, 1996, MINER ELECTROL METAB, V22, P349; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuwahara M, 1996, AM J PHYSIOL-RENAL, V270, pF116, DOI 10.1152/ajprenal.1996.270.1.F116; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; Maeda M, 1996, J EXP BIOL, V199, P513; Marsy S, 1996, PFLUG ARCH EUR J PHY, V432, P494, DOI 10.1007/s004240050161; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURAOKA A, 1984, GASTROENTEROLOGY, V106, P145; NEWMAN PR, 1990, DNA CELL BIOL, V9, P749, DOI 10.1089/dna.1990.9.749; OKUSA MD, 1992, AM J PHYSIOL, V262, pF488, DOI 10.1152/ajprenal.1992.262.3.F488; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; REESE MG, 1996, P PAC S BIOC KON HI; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sverdlov VE, 1996, GENOMICS, V32, P317, DOI 10.1006/geno.1996.0125; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALL SM, 1996, AM J PHYSIOL, V270, pR1037; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WINGO CS, 1989, J CLIN INVEST, V84, P361, DOI 10.1172/JCI114165; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YOUNESIBRAHIM M, 1995, AM J PHYSIOL-RENAL, V268, pF1141, DOI 10.1152/ajprenal.1995.268.6.F1141; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111; [No title captured]	53	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2543	2552		10.1074/jbc.273.5.2543	http://dx.doi.org/10.1074/jbc.273.5.2543			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446555	hybrid			2022-12-27	WOS:000071736600010
J	Peter, H; Burkovski, A; Kramer, R				Peter, H; Burkovski, A; Kramer, R			Osmo-sensing by N- and C-terminal extensions of the glycine betaine uptake system BetP of Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCAL-ANESTHETIC TETRACAINE; ESCHERICHIA-COLI; TRANSPORT-SYSTEM; SALMONELLA-TYPHIMURIUM; HYPEROSMOTIC SHIFT; GENE; OSMOREGULATION; EXPRESSION; CELLS; PROU	The major uptake carrier for the compatible solute glycine betaine in Corynebacterium glutamicum is the secondary transport system BetP. It is effectively regulated by the external osmolality both on the level of expression and of activity. BetP carries highly charged domains both at the N and at the C terminus. We investigated the role of these extensions in the regulatory response to hyperosmotic stress. Mutants of the betP gene coding for proteins with truncated N- and C-terminal extensions were expressed in the C. glutamicum betP deletion strain DHP1 and were functionally characterized with respect to regulation of activity. The optimum of activation at 1.3 osmol/kg in wild type was shifted in the recombinant strains to about 2.6 osmol/kg in mutants with deletions in the N-terminal part. Deletions in the C-terminal domain resulted in a complete loss of regulation, The altered response to changes in osmolality led to severe consequences in the cellular adaption to hyperosmotic stress. Whereas in the wild type, the steady state level of glycine betaine accumulation is maintained by activity regulation of the BetP system itself, in the mutant with BetP proteins carrying truncations in the C-terminal domain, the observed steady state betaine accumulation was found to be due to a kinetic balance of unregulated glycine betaine uptake by the modifed BetP and efflux via the mechanosensitive efflux channel for compatible solutes at the same time.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Kramer, R (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.	r.kramer@uni-koeln.de		Burkovski, Andreas/0000-0003-1896-4521				ABE S, 1967, J GEN APPL MICROBIOL, V13, P279, DOI 10.2323/jgam.13.279; BOTTNER M, 1993, BIOPHYS J, V65, P2041, DOI 10.1016/S0006-3495(93)81254-2; CAIRNEY J, 1985, J BACTERIOL, V164, P1218, DOI 10.1128/JB.164.3.1218-1223.1985; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; EIKMANNS BJ, 1994, MICROBIOL-SGM, V140, P1817, DOI 10.1099/13500872-140-8-1817; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; Glaasker E, 1996, J BIOL CHEM, V271, P10060, DOI 10.1074/jbc.271.17.10060; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GROTHE S, 1986, J BACTERIOL, V166, P253, DOI 10.1128/jb.166.1.253-259.1986; HORNBY AP, 1981, BIOCHIM BIOPHYS ACTA, V647, P285, DOI 10.1016/0005-2736(81)90256-X; Kappes RM, 1996, J BACTERIOL, V178, P5071, DOI 10.1128/jb.178.17.5071-5079.1996; KEMPF B, 1995, J BIOL CHEM, V270, P16701, DOI 10.1074/jbc.270.28.16701; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; LAMBERT C, 1995, APPL ENVIRON MICROB, V61, P4334, DOI 10.1128/AEM.61.12.4334-4342.1995; LANDFALD B, 1986, J BACTERIOL, V165, P849, DOI 10.1128/jb.165.3.849-855.1986; LIEBL W, 1989, FEMS MICROBIOL LETT, V65, P299, DOI 10.1016/0378-1097(89)90234-6; LIN YM, 1995, J BACTERIOL, V177, P6874, DOI 10.1128/jb.177.23.6874-6880.1995; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; Maniatis T., 1982, MOL CLONING LAB MANU; MILNER JL, 1988, J BIOL CHEM, V263, P14900; Peter H, 1997, ARCH MICROBIOL, V168, P143, DOI 10.1007/s002030050480; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; Ruffert S, 1997, EUR J BIOCHEM, V247, P572, DOI 10.1111/j.1432-1033.1997.00572.x; SHIMOOKA T, 1992, BIOCHIM BIOPHYS ACTA, V1104, P261, DOI 10.1016/0005-2736(92)90039-O; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YANTZEY PH, 1982, SCIENCE, V217, P1214; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	32	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2567	2574		10.1074/jbc.273.5.2567	http://dx.doi.org/10.1074/jbc.273.5.2567			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446558	hybrid			2022-12-27	WOS:000071736600013
J	Tsuji, Y; Torti, SV; Torti, FM				Tsuji, Y; Torti, SV; Torti, FM			Activation of the ferritin H enhancer, FER-1, by the cooperative action of members of the AP1 and Sp1 transcription factor families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; HEAVY-CHAIN; FACTOR-ALPHA; GENE-EXPRESSION; MESSENGER-RNA; MUSCLE-CELLS; PROMOTER; AP-1; JUN	We have previously reported that the adenovirus E1A oncogene represses the transcription of the H subunit of the mouse ferritin gene, Subsequent analyses defined FER-1, a 37-nucleotide sequence located 4.1 kilobases proximal to the start site of transcription, as the target of E1A-mediated transcriptional repression and as an enhancer of the ferritin H gene, FER-1 is composed of an API-like sequence followed by an element with dyed symmetry. To achieve maximal enhancer activity and transcriptional repression by E1A, both elements were essential, Using gel retardation assays, we now demonstrate that the binding complex for the AP1-like sequence of FER-1 contains JunD, FosB, and ATF1. Furthermore, JunD and FosB were able to activate FER-1 enhancer activity by transient cotransfection with ferritin H-chloramphenicol acetyltransferase reporter constructs, This augmented enhancer activity was inhibited by E1A. In addition, we have defined the minimal sequence in the dyad element of FER-1 required for protein interaction, This was determined to be a C-rich sequence to which Sp1 and Sp3 bind, Experiments with recombinant proteins indicate that members of both transcription factor families simultaneously bind FER-1, Taken together, these results elucidate molecular mechanisms involved in the transcriptional regulation of a pivotal gene in iron metabolism and provide insights into the contribution of the Sp1 family to the activation of AP1-dependent enhancers.	Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University	Tsuji, Y (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.	ytsuji@bgsm.edu			NCI NIH HHS [CA12197] Funding Source: Medline; NIDDK NIH HHS [DK-42412] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042412, R37DK042412] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHAZENBALK GD, 1990, MOL ENDOCRINOL, V4, P1117, DOI 10.1210/mend-4-8-1117; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; IMLER JL, 1988, NUCLEIC ACIDS RES, V16, P3005, DOI 10.1093/nar/16.7.3005; JAIN SK, 1985, J BIOL CHEM, V260, P1762; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; KWAK EL, 1990, GENE, V94, P255, DOI 10.1016/0378-1119(90)90396-9; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIAU G, 1991, J BIOL CHEM, V266, P18819; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MODJTAHEDI N, 1992, EXP CELL RES, V201, P74, DOI 10.1016/0014-4827(92)90349-D; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; TSUJI Y, 1993, J IMMUNOL, V150, P1897; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; Ye JP, 1996, MOL CELL BIOL, V16, P157	38	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2984	2992		10.1074/jbc.273.5.2984	http://dx.doi.org/10.1074/jbc.273.5.2984			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446612	hybrid			2022-12-27	WOS:000071736600067
J	Corey, S; Krapivinsky, G; Krapivinsky, L; Clapham, DE				Corey, S; Krapivinsky, G; Krapivinsky, L; Clapham, DE			Number and stoichiometry of subunits in the native atrial G-protein-gated K(+) channel, I(KACh)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; ACETYLCHOLINE RECEPTORS; NEUROMUSCULAR-JUNCTIONS; VENTRICULAR MYOCYTES; CROSS-LINKING; SHAKER; GIRK1; DROSOPHILA; ACTIVATE; CURRENTS	The G-protein-regulated, inwardly rectifying K(+) (GIRK) channels are critical for functions as diverse as heart rate modulation and neuronal post-synaptic inhibition. GIRK channels are distributed predominantly throughout the heart, brain, and pancreas. In recent years, GIRK channels have received a great deal of attention for their direct G-protein beta gamma (G(beta gamma)) regulation. Native cardiac I(KACh) is composed of GIRK1 and GIRK4 subunits (Krapivinsky, G., Gordon, E. A., Wickman, K. A., Velimirovic, B., Krapivinsky, L., and Clapham, D. E. (1995) Nature 374, 135-141). Here, we examine the quaternary structure of I(KACh) using a variety of complementary approaches. Complete cross-linking of purified atrial I(KACh) protein formed a single adduct with a total molecular weight that was most consistent with a tetramer. In addition, partial cross-linking of purified I(KACh) produced subsets of molecular weights consistent with monomers, dimers, trimers, and tetramers. Within the presumed protein dimers, GIRK1-GIRK1 and GIRK4-GIRK4 adducts were formed, indicating that the tetramer was composed of two GIRK1 and two GIRK4 subunits. This 1:1 GIRK1 to GIRK4 stoichiometry was confirmed by two independent means, including densitometry of both silver-stained and Western-blotted native atrial I(KACh). Similar experimental results could potentially be obtained if GIRK1 and GIRK4 subunits assembled randomly as 2:2 and equally sized populations of 3:1 and 1:3 tetramers. We also show that GIRK subunits may form homotetramers in expression systems, although the evidence to date suggests that GIRK1 homotetramers are not functional. We conclude that the inwardly rectifying atrial K(+) channel, I(KACh), a prototypical GIRK channel, is a heterotetramer and is most likely composed of two GIRK1 subunits and two GIRK4 subunits.	Childrens Hosp, Howard Hughes Med Inst, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Neurosci Program, Rochester, MN 55905 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Mayo Clinic	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Div Cardiovasc, 1309 Enders,320 Longwood Ave, Boston, MA 02115 USA.	clapham@rascal.med.harvard.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428				ARIS JP, 1983, J BIOL CHEM, V258, P4599; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; GAFFNEY BJ, 1985, BIOCHIM BIOPHYS ACTA, V822, P289, DOI 10.1016/0304-4157(85)90012-7; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang DH, 1997, BIOTECHNIQUES, V22, P454, DOI 10.2144/97223bm18; Inanobe A, 1995, BIOCHEM BIOPH RES CO, V217, P1238, DOI 10.1006/bbrc.1995.2901; ITO H, 1995, N-S ARCH PHARMACOL, V351, P610; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; Kennedy ME, 1996, NEUROPHARMACOLOGY, V35, P831, DOI 10.1016/0028-3908(96)00132-3; KOUMI SI, 1994, AM J PHYSIOL, V266, pH1812, DOI 10.1152/ajpheart.1994.266.5.H1812; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LAND BR, 1980, P NATL ACAD SCI-BIOL, V77, P3736, DOI 10.1073/pnas.77.6.3736; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATTHEWSBELLINGER J, 1978, J PHYSIOL-LONDON, V279, P197, DOI 10.1113/jphysiol.1978.sp012340; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; Mourrain P, 1997, P NATL ACAD SCI USA, V94, P10034, DOI 10.1073/pnas.94.19.10034; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	39	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5271	5278		10.1074/jbc.273.9.5271	http://dx.doi.org/10.1074/jbc.273.9.5271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478984	hybrid			2022-12-27	WOS:000072310400068
J	Gan, WN; La Celle, M; Rhoads, RE				Gan, WN; La Celle, M; Rhoads, RE			Functional characterization of the internal ribosome entry site of eIF4G mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCEPHALOMYOCARDITIS VIRUS-RNA; EUKARYOTIC PROTEIN-SYNTHESIS; 5' NONTRANSLATED REGION; TRACT-BINDING-PROTEIN; SYNTHESIS INITIATION FACTOR-EIF-4-GAMMA; CAP-INDEPENDENT TRANSLATION; MESSENGER-RNA; POLIOVIRUS RNA; IN-VITRO; NONCODING REGION	The eIF4 group initiation factors are required for cap-dependent translation initiation. Infection of mammalian cells by picornaviruses results in proteolytic cleavage of one of these factors, eIF4G, which severely restricts cap-dependent initiation but permits cap independent initiation to proceed from an internal ribosome entry site (IRES) in picornaviral RNAs. The first 357 nucleotides (nt) of the 5'-untranslated region of eIF4G mRNA also contains an IRES, Using bicistronic constructs for expression in K562 cells, we have now shown that progressive deletions of the 5'-untranslated region can have either stimulatory or inhibitory effects. Furthermore, a 101-nt segment exhibits full IRES activity, and an 81-nt segment exhibits detectable IRES activity. A polypyrimidine tract (PPT) at the 3' terminus is essential for internal initiation, a property which is characteristic of picornaviral IRESs but not the other host cellular IRESs studied to date. IRES activity does not require sequences beyond 357 nt. Out-of-frame AUGs have no effect on IRES-driven luciferase expression when introduced upstream of the PPT but markedly decrease expression when introduced at sites between the PPT and the authentic initiation codon at nt 369. These results suggest that the ribosomal subunit enters at or near the PPT and then scans downstream for the initiation codon.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Rhoads, RE (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.				NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLIOZ C, 1995, J VIROL, V69, P2214, DOI 10.1128/JVI.69.4.2214-2222.1995; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BORMAN AM, 1994, EMBO J, V13, P3149, DOI 10.1002/j.1460-2075.1994.tb06613.x; Borman AM, 1997, RNA, V3, P186; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BROWN EA, 1994, J VIROL, V68, P1066, DOI 10.1128/JVI.68.2.1066-1074.1994; CHOMCYNSKI P, 1991, CURRENT PROTOCOLS MO; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ETCHISON D, 1985, J VIROL, V54, P634, DOI 10.1128/JVI.54.2.634-638.1985; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; EVSTAFIEVA AG, 1991, NUCLEIC ACIDS RES, V19, P665, DOI 10.1093/nar/19.3.665; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; GLASS MJ, 1993, VIROLOGY, V193, P842, DOI 10.1006/viro.1993.1193; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Kaminski A, 1995, RNA, V1, P924; KAMINSKI A, 1994, EMBO J, V13, P1673, DOI 10.1002/j.1460-2075.1994.tb06431.x; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUGE S, 1989, J MOL BIOL, V207, P175, DOI 10.1016/0022-2836(89)90448-8; KUGE S, 1987, J VIROL, V61, P1478, DOI 10.1128/JVI.61.5.1478-1487.1987; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MADER S, 1995, MOL CELL BIOL, V15, P4990; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; NICHOLSON R, 1991, J VIROL, V65, P5886, DOI 10.1128/JVI.65.11.5886-5894.1991; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; PILIPENKO EV, 1994, J MOL BIOL, V241, P398, DOI 10.1006/jmbi.1994.1516; POYRY T, 1992, J VIROL, V66, P5313; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1994, CURRENT PROTOCOLS MO; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Titus DE, 1991, PROMEGA PROTOCOLS AP; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; WHETTER LE, 1994, J VIROL, V68, P5253, DOI 10.1128/JVI.68.8.5253-5263.1994; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714; ZHANG Y, 1989, J BIOL CHEM, V264, P10679	57	68	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5006	5012		10.1074/jbc.273.9.5006	http://dx.doi.org/10.1074/jbc.273.9.5006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478948	hybrid			2022-12-27	WOS:000072310400032
J	Lee, YJ; Galoforo, SS; Berns, CM; Chen, JC; Davis, BH; Sim, JE; Corry, PM; Spitz, DR				Lee, YJ; Galoforo, SS; Berns, CM; Chen, JC; Davis, BH; Sim, JE; Corry, PM; Spitz, DR			Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASES; HYDROGEN-PEROXIDE; C-FOS; GROWTH; PHOSPHORYLATION; SUPEROXIDE; PATHWAY; ACID; EXPRESSION; METABOLISM	We previously observed that glucose deprivation induces cell death in multidrug-resistant human breast carcinoma cells (MCF-7/ADR), As a follow up we wished to test the hypothesis that metabolic oxidative stress was the causative process or at least the link between causative processes behind the cytotoxicity. In the studies described here, we demonstrate that mitogen-activated protein kinase (MAPK) was activated within 3 min of being in glucose-free medium and remained activated for 3 h, Glucose deprivation for 2-4 h also caused oxidative stress as evidenced by a 3-fold greater steady state concentration of oxidized glutathione and a 3-fold increase in pro-oxidant production, Glucose and glutamate treatment rapidly suppressed MAPK activation and rescued cells from cytotoxicity, Glutamate and the peroxide scavenger, pyruvate, rescued the cells from cell killing as well as suppressed pro-oxidant production, In addition the thiol antioxidant, N-acetyl-L-cysteine, rescued cells from glucose deprivation-induced cytotoxicity and suppressed MAPK activation, These results suggest that glucose deprivation-induced cytotoxicity and alterations in MAPK signal transduction are mediated by oxidative stress in MCF-7/ADR. These results also support the speculation that a common mechanism of glucose deprivation-induced cytotoxicity in mammalian cells may involve metabolic oxidative stress.	William Beaumont Hosp, Dept Radiat Oncol, Res Labs, Royal Oak, MI 48073 USA; William Beaumont Hosp, Dept Clin Pathol, Royal Oak, MI 48073 USA; Washington Univ, Sch Med, Radiat Oncol Ctr, Sect Canc Biol, St Louis, MO 63108 USA	Beaumont Health; Beaumont Health; Washington University (WUSTL)	Lee, YJ (corresponding author), William Beaumont Hosp, Dept Radiat Oncol, Res Labs, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.			Spitz, Douglas/0000-0002-1254-8765	NATIONAL CANCER INSTITUTE [R01CA044550, R37CA044550, R01CA048000] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [CA48000, CA44550] Funding Source: Medline; NHLBI NIH HHS [HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson ME, 1985, HDB METHODS OXYGEN R, P317; AVERILLBATES DA, 1994, ARCH BIOCHEM BIOPHYS, V312, P52, DOI 10.1006/abbi.1994.1279; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CHENG B, 1995, J NEUROSCI, V15, P7095; COHEN JS, 1987, ANN NY ACAD SCI, V508, P216, DOI 10.1111/j.1749-6632.1987.tb32906.x; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P141; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Gupta AK, 1997, MOL CELL BIOCHEM, V170, P23, DOI 10.1023/A:1006890316102; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lee YJ, 1997, J CELL SCI, V110, P681; Liu X, 1997, J BIOL CHEM, V272, P11690, DOI 10.1074/jbc.272.18.11690; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MERRALL NW, 1993, BIOCHEM J, V295, P351, DOI 10.1042/bj2950351; MUINDI JRF, 1986, P AM ASSOC CANC RES, V27, P272; NATH KA, 1995, AM J PHYSIOL, V26, pC227; OBERLEY LW, 1984, J THEOR BIOL, V106, P403, DOI 10.1016/0022-5193(84)90038-9; OBERLEY LW, 1981, MED HYPOTHESES, V7, P21, DOI 10.1016/0306-9877(81)90018-9; OLIVER BL, 1995, P SOC EXP BIOL MED, V210, P162; Pennisi E, 1997, SCIENCE, V275, P1567, DOI 10.1126/science.275.5306.1567; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; STEVENSON MA, 1994, CANCER RES, V54, P12; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Walker J M, 1984, Methods Mol Biol, V1, P57, DOI 10.1385/0-89603-062-8:57; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	42	198	201	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5294	5299		10.1074/jbc.273.9.5294	http://dx.doi.org/10.1074/jbc.273.9.5294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478987	hybrid			2022-12-27	WOS:000072310400071
J	Moallem, E; Kilav, R; Silver, J; Naveh-Many, T				Moallem, E; Kilav, R; Silver, J; Naveh-Many, T			RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA; IN-VITRO; NUCLEOTIDE-SEQUENCE; POSTTRANSCRIPTIONAL REGULATION; EXTRACELLULAR CALCIUM; UNTRANSLATED REGION; PTH SECRETION; RAT; CELLS	Parathyroid hormone (PTH) regulates serum calcium and phosphate levels, which, in turn, regulate PTH secretion and mRNA levels, PTH mRNA levels are markedly increased in rats fed low calcium diets and decreased after low phosphate diets, and this effect is posttranscriptional. Protein-PTH mRNA binding studies, with parathyroid cytosolic proteins, showed three protein-RNA bands, This binding was to the 3'-untranslated region (UTR) of the PTH mRNA and was dependent upon the terminal 60 nucleotides. Parathyroid proteins from hypocalcemic rats showed increased binding, and proteins from hypophosphatemic rats decreased binding, correlating with PTH mRNA levels, There is no parathyroid cell line; however, a functional role was provided by an in vitro degradation assay. Parathyroid proteins from control rats incubated with a PTH mRNA probe led to an intact transcript for 40 min; the transcript was intact with hypocalcemic proteins for 180 min and with hypophosphatemic proteins only for 5 min, A PTH mRNA probe without the 3'-UTR, or just the terminal 60 nucleotides, incubated with hypophosphatemic proteins, showed no degradation at all, indicating that the sequences in the 3'-UTR determine PTH mRNA degradation, Hypocalcemia and hypophosphatemia regulate PTH gene expression post-transcriptionally, This correlates with binding of proteins to the PTR mRNA 3'-UTR, which determines its stability.	Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Silver, J (corresponding author), Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, POB 12000, IL-91120 Jerusalem, Israel.							Agy MB, 1996, VIROLOGY, V217, P158, DOI 10.1006/viro.1996.0103; Almaden Y, 1996, J BONE MINER RES, V11, P970; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CARRAZANA EJ, 1988, MOL CELL BIOL, V8, P2267, DOI 10.1128/MCB.8.6.2267; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; HAWA NS, 1993, J MOL ENDOCRINOL, V10, P43, DOI 10.1677/jme.0.0100043; KEMPER B, 1986, CRIT REV BIOCHEM MOL, V19, P353, DOI 10.3109/10409238609082545; KILAV R, 1995, J CLIN INVEST, V96, P327, DOI 10.1172/JCI118038; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRIKORIAN CR, 1991, J VIROL, V65, P112, DOI 10.1128/JVI.65.1.112-122.1991; KRONENBERG HM, 1979, P NATL ACAD SCI USA, V76, P4981, DOI 10.1073/pnas.76.10.4981; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; NAVEHMANY T, 1992, J CLIN INVEST, V90, P2434, DOI 10.1172/JCI116134; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840; Nielsen PK, 1996, NEPHROL DIAL TRANSPL, V11, P1762; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; SCHMELZER HJ, 1987, NUCLEIC ACIDS RES, V15, P6740, DOI 10.1093/nar/15.16.6740; SILVER J, 1996, PRINCIPLES BONE BIOL; Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701; THEIL EC, 1994, BIOCHEM J, V304, P1; Vadher S, 1996, J BONE MINER RES, V11, P746; VASICEK TJ, 1983, P NATL ACAD SCI-BIOL, V80, P2127, DOI 10.1073/pnas.80.8.2127	29	212	220	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5253	5259		10.1074/jbc.273.9.5253	http://dx.doi.org/10.1074/jbc.273.9.5253			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478982	hybrid			2022-12-27	WOS:000072310400066
J	Park, K; Debyser, Z; Tabor, S; Richardson, CC; Griffith, JD				Park, K; Debyser, Z; Tabor, S; Richardson, CC; Griffith, JD			Formation of a DNA loop at the replication fork generated by bacteriophage T7 replication proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND SYNTHESIS; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; COORDINATED LEADING-STRAND; RNA PRIMER SYNTHESIS; ESCHERICHIA-COLI; GENE-4 PROTEIN; DEOXYRIBONUCLEIC-ACID; PRIMASE-HELICASE; BINDING-PROTEIN; POLYMERASE ACTIVITY	Intermediates in the replication of circular and linear M13 double-stranded DNA by bacteriophage T7 proteins have been examined by electron microscopy. Synthesis generated double-stranded DNA molecules containing a single replication fork with a linear duplex tail, A complex presumably consisting of T7 DNA polymerase and gene 4 helicase/primase molecules was present at the fork together with a variable amount of single-stranded DNA sequestered by gene 2.5 single-stranded DNA binding protein, Analysis of the length distribution of Okazaki fragments formed at different helicase/primase concentrations was consistent with coupling of leading and lagging strand replication, Fifteen to forty percent of the templates engaged in replication have a DNA loop at the replication fork, The loops are fully double-stranded with an average length of similar to 1 kilobase, Labeling with biotinylated dCTP showed that the loops consist of newly synthesized DNA, and synchronization experiments using a linear template with a G-less cassette demonstrated that the loops are formed by active displacement of the lagging strand, A long standing feature of models for coupled leading/lagging strand replication has been the presence of a DNA loop at the replication fork, This study provides the first direct demonstration of such loops.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline; NIGMS NIH HHS [GM 31819] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; EISENBERG S, 1977, P NATL ACAD SCI USA, V74, P3198, DOI 10.1073/pnas.74.8.3198; ENGLER MJ, 1983, J BIOL CHEM, V258, P1197; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBER HE, 1988, CANCER CELL, V6, P11; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15022; KOLODNER R, 1978, J BIOL CHEM, V253, P566; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MODRICH P, 1975, J BIOL CHEM, V250, P5508; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; REGISTER JC, 1986, P NATL ACAD SCI USA, V83, P624, DOI 10.1073/pnas.83.3.624; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	51	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5260	5270		10.1074/jbc.273.9.5260	http://dx.doi.org/10.1074/jbc.273.9.5260			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478983	Green Published, hybrid			2022-12-27	WOS:000072310400067
J	Wang, TH; Wang, HS; Ichijo, H; Giannakakou, P; Foster, JS; Fojo, T; Wimalasena, J				Wang, TH; Wang, HS; Ichijo, H; Giannakakou, P; Foster, JS; Fojo, T; Wimalasena, J			Microtubule-interfering agents activate c-Jun N-terminal kinase stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; OVARIAN-CANCER; GROWTH-INHIBITION; GAMMA-RADIATION; JNK ACTIVATION; TAXOL; P53; PHOSPHORYLATION; PHOSPHATASE; BINDING	The essential cellular functions associated with microtubules have led to a wide use of microtubule-interfering agents in cancer chemotherapy with promising results. Although the most well studied action of microtubule-interfering agents is an arrest of cells at the G(2)/M phase of the cell cycle, other effects may also exist. We have observed that paclitaxel (Taxol), docetaxel (Taxotere), vinblastine, vincristine, nocodazole, and colchicine activate the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signaling pathway in a variety of human cells. Activation of JNK/SAPK by microtubule-interfering agents is dose-dependent and time-dependent and requires interactions with microtubules. Functional activation of the JNKK/SEK1-JNK/SAPK-c-Jun cascade (where JNKK/SEK1 is JNK kinase/SAPK kinase) was demonstrated by activation of a 12-O-tetradecanoylphorbol-13-acetate response element (TRE) reporter construct in a c-Jun dependent fashion. Microtubule-interfering agents also activated both Ras and apoptosis signal-regulating kinase (ASK1) and coexpression of dominant negative Ras and dominant negative apoptosis signal-regulating kinase exerted individual and additive inhibition of JNK/SAPK activation by microtubule-interfering agents. These findings suggest that multiple signal transduction pathways are involved with cellular detection of microtubular disarray and subsequent activation of JNK/SAPK.	Univ Tennessee, Med Ctr, Dept Obstet & Gynecol, Grad Sch Med, Knoxville, TN 37920 USA; Chang Gung Mem Hosp, Chang Gung Med Sch, Dept Obstet & Gynecol, Taipei 10591, Taiwan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Tokyo 170, Japan; NCI, NIH, Div Clin Sci, Med Branch, Bethesda, MD 20892 USA	University of Tennessee System; University of Tennessee Health Science Center; Chang Gung Memorial Hospital; Japanese Foundation for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wimalasena, J (corresponding author), Univ Tennessee, Med Ctr, Dept Obstet & Gynecol, Grad Sch Med, 1924 Alcoa Hwy, Knoxville, TN 37920 USA.	mcf7@msn.com		Ichijo, Hidenori/0000-0002-5005-6438	NCI NIH HHS [CA-68538] Funding Source: Medline; NIAAA NIH HHS [AA-08328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1997, CANCER RES, V57, P130; BONFOCO E, 1995, EXP CELL RES, V218, P189, DOI 10.1006/excr.1995.1147; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Burns Roy G., 1994, Modern Cell Biology, V13, P3; CAMERON MR, 1995, ONCOL RES, V7, P145; Chajry N, 1996, EUR J BIOCHEM, V235, P97, DOI 10.1111/j.1432-1033.1996.00097.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CULIG Z, 1996, 87 ANN M AM ASS CANC, V37, P233; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; Hall A, 1995, GUIDEBOOK SMALL GTPA, P3; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Huschtscha LI, 1996, BRIT J CANCER, V73, P54, DOI 10.1038/bjc.1996.10; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawamura KI, 1996, BRIT J CANCER, V73, P183, DOI 10.1038/bjc.1996.33; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KINGSTON RE, 1995, CURRENT PROTOCOLS MO; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nicolaou KC, 1997, NATURE, V387, P268, DOI 10.1038/387268a0; RAPP UR, 1994, ONCOGENE, V9, P3493; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROWINSKY EK, 1993, MONOGR NATL CANC I, V15, P25; Saunders C, 1997, J BIOL CHEM, V272, P19035, DOI 10.1074/jbc.272.30.19035; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Shore VH, 1997, PLACENTA, V18, P657, DOI 10.1016/S0143-4004(97)90007-2; Suffness Matthew, 1994, In Vivo (Attiki), V8, P867; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TISHLER RB, 1995, CANCER RES, V55, P6021; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wilson Leslie, 1994, Modern Cell Biology, V13, P59; WIMALASENA J, 1991, GYNECOL ONCOL, V41, P56, DOI 10.1016/0090-8258(91)90255-4; Woodgett JR, 1996, PHILOS T R SOC B, V351, P135, DOI 10.1098/rstb.1996.0009; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	66	353	375	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4928	4936		10.1074/jbc.273.9.4928	http://dx.doi.org/10.1074/jbc.273.9.4928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478937	hybrid			2022-12-27	WOS:000072310400021
J	Xing, S; Furminger, TL; Tong, Q; Jhiang, SM				Xing, S; Furminger, TL; Tong, Q; Jhiang, SM			Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; TRANSFORMING ACTIVITY; RET/PTC ONCOGENE; ADAPTER PROTEINS; PROMOTER REGION; PROTOONCOGENE; GENE; ASSOCIATION; EXPRESSION	Gene alterations in the ret proto-oncogene, which encodes a receptor tyrosine kinase, have been found to associate with several human diseases. In this study, we showed that induction of the vgf promoter activity is a good molecular indicator for RET activation in PC12 cells, a rat pheochromocytoma cell line. We demonstrated that all forms of RET oncoprotein, including RET chimeric oncoproteins found in human papillary thyroid carcinomas (RET/PTC) as well as RET oncoproteins found in patients with multiple endocrine neoplasia type 2A and 2B (2A/RET and 2B/RET) can induce vgf promoter activity in PC12 cells. In contrast, a RET mutant found in a patient with Hirschsprung's disease, as well as a RET/PTC1 mutant with deletion of the dimerization domain, failed to induce vgf promoter activity in PC12 cells. We further determined that the signaling events mediated by phosphorylated Tyr(294) and phosphorylated Tyr(451) binding sites are essential for RET/PTC1 to induce vgf promoter activity in PC12 cells. We also showed that RET/PTC1, 2A/RET, and 2B/RET induce ELK-, cAMP-responsive element binding protein (CREB), or JUN-mediated gene expression in PC12 cells, and these three signaling events are mediated by phosphorylated Tyr(294) and phosphorylated Tyr(451) binding sites in RET/PTC1.	Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Grad Program, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Physiol, 302 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NCI NIH HHS [R29 CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; BURRY RW, 1993, J NEUROSCI RES, V36, P241, DOI 10.1002/jnr.490360302; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ITOH F, 1989, Tumor Research, V24, P1; Iwashita T, 1996, ONCOGENE, V12, P481; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; TONG Q, 1995, ONCOGENE, V10, P1781; Tong Q, 1997, J BIOL CHEM, V272, P9043; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Xing SH, 1996, ENDOCRINOLOGY, V137, P1512, DOI 10.1210/en.137.5.1512	41	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4909	4914		10.1074/jbc.273.9.4909	http://dx.doi.org/10.1074/jbc.273.9.4909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478934	hybrid			2022-12-27	WOS:000072310400018
J	Boylan, JM; Gruppuso, PA				Boylan, JM; Gruppuso, PA			Uncoupling of hepatic, epidermal growth factor-mediated mitogen-activated protein kinase activation in the fetal rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; INSULIN; DESENSITIZATION; HEPATOCYTES; GRB2-SOS; CASCADE; 3CH134; STRESS; CELLS	Stimulation of cell proliferation by mitogens involves tyrosine phosphorylation of proteins at the cell membrane by receptor tyrosine kinases. This promotes formation of multi-protein complexes that can activate the small G-protein, Ras. Activation of Ras, in turn, leads to sequential activation of the following three serine-threonine kinases: Raf, extracellular signal-regulated kinase kinase (MEK), and members of the family of mitogen-activated protein (MAP) kinases. Prior studies have shown that intraperitoneal injection of epidermal growth factor (EGF) leads to rapid activation of hepatic MAP kinases in adult rats but not in late gestation (E19) fetal rats (Boylan, J. M., and Gruppuso, P. A. (1996) Cell Growth & Differ. 7, 1261-1269). The present studies were undertaken to determine the mechanism for this "uncoupling" of the MAP kinase pathway. E19 fetal rats and adult male rats were injected with EGF (0.5 mu g/g body weight, intraperitoneally) or with saline. After 15 min, livers were removed and prepared for kinase analyses, EGF injection led to a rapid and marked activation of hepatic Raf and MEK in both fetal and adult rats, whereas MAP kinase activation was minimal in fetal as opposed to adult rats. Examination of the ontogeny of this dissociation of MAP kinase activation from MEK activation showed gradual acquisition of intact signaling as an adult hepatocyte phenotype was attained during the first 4 postnatal weeks. Over this period, MAP kinase content as determined by Western immunoblotting was constant, Recombination experiments using partially purified fetal and adult rat liver MEK and MAP kinase showed intact MAP kinase activation in vitro, indicating that neither enzyme was irreversibly altered in the fetus, In studies using primary cultures of E19 fetal rat hepatocytes, uncoupling of MAP kinase activation from MEK activation could be induced by incubation of fetal hepatocytes for 24 h with a potent fetal hepatocyte mitogen, transforming growth factor-alpha. These findings indicate that a novel negative feedback mechanism for MAP kinase regulation may be active in developing rat hepatocytes.	Rhode Isl Hosp, Dept Pediat, Div Pediat Endocrinol & Metab, Providence, RI 02903 USA; Brown Univ, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Gruppuso, PA (corresponding author), Rhode Isl Hosp, Dept Pediat, Div Pediat Endocrinol & Metab, 593 Eddy St, Providence, RI 02903 USA.	Philip_Gruppuso@brown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD024455] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD011343, P50HD011343] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24455, HD11343] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOYLAN JM, 1994, AM J PHYSIOL-GASTR L, V267, pG1078, DOI 10.1152/ajpgi.1994.267.6.G1078; Boylan JM, 1996, CELL GROWTH DIFFER, V7, P1261; BUDAY L, 1995, ONCOGENE, V11, P1327; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CURRAN TR, 1993, EXP CELL RES, V209, P53, DOI 10.1006/excr.1993.1284; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRUPPUSO PA, 1994, ENDOCRINOLOGY, V134, P769, DOI 10.1210/en.134.2.769; GRUPPUSO PA, 1989, AM J PHYSIOL, V256, pE49, DOI 10.1152/ajpendo.1989.256.1.E49; GRUPPUSO PA, 1995, J CELL BIOCHEM, V58, P65, DOI 10.1002/jcb.240580109; GRUPPUSO PA, 1992, PERINATAL BIOCH, P194; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KRAUTWALD S, 1995, ONCOGENE, V10, P1187; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lipeski LE, 1996, BIOCHEM MOL BIOL INT, V39, P975; NAEYE RL, 1965, PEDIATRICS, V35, P980; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	28	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3784	3790		10.1074/jbc.273.6.3784	http://dx.doi.org/10.1074/jbc.273.6.3784			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452512	hybrid			2022-12-27	WOS:000071822300097
J	Decoster, E; Vanhaesebroeck, B; Boone, E; Plaisance, S; De Vos, K; Haegeman, G; Grooten, J; Fiers, W				Decoster, E; Vanhaesebroeck, B; Boone, E; Plaisance, S; De Vos, K; Haegeman, G; Grooten, J; Fiers, W			Induction of unresponsiveness to tumor necrosis factor (TNF) after autocrine TNF expression requires TNF membrane retention	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA PRECURSOR; CELL-LINE; FACTOR RECEPTORS; RESISTANCE; INHIBITOR; PROTEIN; CYTOTOXICITY; VECTORS; LIGAND; GROWTH	Tumor necrosis factor (TNF) has a specific gene-inducing activity on many cell types and exerts a cytotoxic effect on a number of tumor cell lines. However, several tumor cell types are resistant to TNF-induced effects, and some of these produce TNF. We previously demonstrated that introduction of an exogenous TNF gene in the TNF-sensitive cell line L929sA induced autocrine TNF production and unresponsiveness to the cytotoxic activity of TNF, This resistance required biologically active TNF and was correlated with complete down-modulation of the TNF receptors on the cell surface. We have now characterized this process in more detail. The role of expression of the membrane-bound TNF preform and its subsequent proteolytic processing in the induction of TNF unresponsiveness was investigated. Exchange of the TNF presequence for the signal sequence of interleukin-6 resulted in production of secreted TNF, but not in induction of TNF resistance. On the other hand, expression of non-secretable, membrane-bound TNF generated complete TNF unresponsiveness. To explore whether the requirement for anchoring reflected a specific functional role of the TNF presequence, the latter was replaced by the membrane anchor of trimeric chicken hepatic lectin. Expression of this construct induced complete TNF unresponsiveness. Hence, the role of the TNF presequence in the induction of TNF unresponsiveness only involves its function as a membrane anchor, which permits oligomerization of the TNF molecule into a biologically active homotrimer.	Flanders Interuniv Inst Biotechnol, Mol Biol Lab, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Fiers, W (corresponding author), Flanders Interuniv Inst Biotechnol, Mol Biol Lab, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		De Vos, Kurt/D-8380-2011; Plaisance, Stephane/ABI-6307-2020; Plaisance, Stephane/B-3488-2009	De Vos, Kurt/0000-0003-2161-6309; Plaisance, Stephane/0000-0002-1651-241X; Plaisance, Stephane/0000-0002-1651-241X				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BEYAERT R, 1993, CANCER RES, V53, P2623; CHIACCHIA KB, 1984, J BIOL CHEM, V259, P5440; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; DING AH, 1989, J BIOL CHEM, V264, P3924; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Fiers W, 1995, BIOL THERAPY CANC, P295; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HIMENO T, 1990, CANCER RES, V50, P4941; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LLEONART R, 1990, BIO-TECHNOL, V8, P1263, DOI 10.1038/nbt1290-1263; LUCAS R, 1994, SCIENCE, V263, P814, DOI 10.1126/science.8303299; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; NAKAMURA S, 1991, AGR BIOL CHEM TOKYO, V55, P53, DOI 10.1080/00021369.1991.10870533; OKAMOTO T, 1992, CANCER RES, V52, P5278; PATESTOS NP, 1993, BIOCHIMIE, V75, P1007, DOI 10.1016/0300-9084(93)90153-J; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; RUBIN BY, 1986, J EXP MED, V164, P1350, DOI 10.1084/jem.164.4.1350; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRIGGS D, 1987, P NATL ACAD SCI USA, V84, P6563, DOI 10.1073/pnas.84.18.6563; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEER CJ, 1990, J BIOL CHEM, V265, P3744; STEVENSON FT, 1992, J EXP MED, V176, P1053, DOI 10.1084/jem.176.4.1053; Tang P, 1996, BIOCHEMISTRY-US, V35, P8216, DOI 10.1021/bi952182t; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H	38	14	14	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3271	3277		10.1074/jbc.273.6.3271	http://dx.doi.org/10.1074/jbc.273.6.3271			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452442	hybrid			2022-12-27	WOS:000071822300027
J	Johansson, J; Gudmundsson, GH; Rottenberg, ME; Berndt, KD; Agerberth, B				Johansson, J; Gudmundsson, GH; Rottenberg, ME; Berndt, KD; Agerberth, B			Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; EPITHELIAL-CELLS; PIG INTESTINE; BONE-MARROW; PROTEIN; PR-39; ANTIBIOTICS; NEUTROPHILS; EXPRESSION; DEFENSINS	The influence of ion composition, pH, and peptide concentration on the conformation and activity of the 37-residue human antibacterial peptide LL-37 has been studied. At micromolar concentration in water, LL-37 exhibits a circular dichroism spectrum consistent with a disordered structure. The addition of 15 mM HCO3-, SO42-, or CF3CO2- causes the peptide to adopt a helical structure, with approximately equal efficiency, while 160 mM Cl- is less efficient, A cooperative transition from disordered to helical structure is observed as the peptide concentration is increased, consistent with formation of an oligomer, The extent of alpha-helicity correlates with the antibacterial activity of LL-37 against both Gram-positive and Gram-negative bacteria. Two homologous peptides, FF-33 and SK-29, containing 4 and 8 residue deletions at the N terminus, respectively, require higher concentrations of anions for helix formation and are less active than LL 37 against Escherichia coli D21. Below pH 5, the helical content of LL-37 gradually decreases, and at pH 2 it is entirely disordered, In contrast, the helical structure is retained at pH over 13. The minimal inhibitory concentration of LL-37 against E. coli is 5 mu M, and at 13-25 mu M the peptide is cytotoxic against several eukaryotic cells, In solutions containing the ion compositions of plasma, intracellular fluid, or interstitial fluid, LL-37 is helical, and hence it could pose a danger to human cells upon release. However, in the presence of human serum, the antibacterial and the cytotoxic activities of LL-37 are inhibited.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Agerberth, B (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Doktorsringen 9A3, S-17177 Stockholm, Sweden.		Berndt, Kurt/J-8574-2015; Gudmundsson, Gudmundur H/K-9178-2015	Berndt, Kurt/0000-0002-3049-967X; Gudmundsson, Gudmundur H/0000-0001-5793-0565; Rottenberg, Martin/0000-0003-0514-7434; Johansson, Jan/0000-0002-8719-4703				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; CABIAUX V, 1994, EUR J BIOCHEM, V224, P1019, DOI 10.1111/j.1432-1033.1994.01019.x; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P262; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; FERNLUND P, 1991, LAURELLS KLINISK KEM, P59; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GREENFIELD N, 1969, BIOCHEMISTRY-US, V8, P108; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; HOLTZER ME, 1992, BIOPOLYMERS, V32, P1675, DOI 10.1002/bip.360321209; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; NORDEN MA, 1995, J CLIN MICROBIOL, V33, P1231, DOI 10.1128/JCM.33.5.1231-1237.1995; PANYUTICH A, 1991, AM J RESP CELL MOL, V5, P101, DOI 10.1165/ajrcmb/5.2.101; Popsueva AE, 1996, FEBS LETT, V391, P5, DOI 10.1016/0014-5793(96)00692-8; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SCHLUESENER HJ, 1993, J NEUROIMMUNOL, V47, P199, DOI 10.1016/0165-5728(93)90030-3; Scholtz J. Martin, 1995, P171, DOI 10.1016/B978-012310920-0/50005-X; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Skerlavaj B, 1996, J BIOL CHEM, V271, P28375, DOI 10.1074/jbc.271.45.28375; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TALIAFERRO WH, 1955, J INFECT DIS, V96, P199, DOI 10.1093/infdis/96.3.199; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	37	495	522	0	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3718	3724		10.1074/jbc.273.6.3718	http://dx.doi.org/10.1074/jbc.273.6.3718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452503	hybrid			2022-12-27	WOS:000071822300088
J	Nicol, R; Stavnezer, E				Nicol, R; Stavnezer, E			Transcriptional repression by v-Ski and c-Ski mediated by a specific DNA binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COMPLEX-FORMATION; ONCOGENE ENCODES; PROTEIN; SEQUENCE; CELLS; DOMAIN; ACTIVATION; ENHANCER; FAMILY	The Ski oncoprotein has been shown to bind DNA and activate transcription in conjunction with other cellular factors, Because tumor cells or myogenic cells were used for those studies, it is not clear that those activities of Ski are related to its transforming ability, In this study, we use a nuclear extract of c-ski-transformed cells to identify a specific DNA binding site for Ski with the consensus sequence GTCTAGAC. We demonstrate that both c-Ski and v-Ski in nuclear extracts are components of complexes that bind specifically to this site. By evaluating the features of the sequence that are critical for binding, we show that binding is cooperative. Although Ski cannot bind to this sequence on its own, we use cross-linking with ultraviolet light to show that Ski binds to this site along with several unidentified cellular proteins, Furthermore, we find that Ski represses transcription either through upstream copies of this element or when brought to the promoter by a heterologous DNA binding domain. This is the first demonstration that Ski acts as a repressor rather than an activator and could provide new insights into regulation of gene expression by Ski.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Case Western Reserve University; University System of Ohio; University of Cincinnati	Stavnezer, E (corresponding author), 10900 Euclid Ave, Cleveland, OH 44106 USA.	exs44@po.cwru.edu			NCI NIH HHS [CA-43600] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KELDER B, 1998, IN PRESS GENE AMST; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; LARSEN J, 1992, ONCOGENE, V7, P1903; LARSEN J, 1993, ONCOGENE, V8, P3221; Liang SD, 1996, MOL CELL BIOL, V16, P3773; MERTZ LM, 1994, ANAL BIOCHEM, V221, P160, DOI 10.1006/abio.1994.1392; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SMITH GH, 1986, ANAL BIOCHEM, V156, P17, DOI 10.1016/0003-2697(86)90147-8; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Tarapore P, 1997, NUCLEIC ACIDS RES, V25, P3895, DOI 10.1093/nar/25.19.3895; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WOLFFE AP, 1997, ANTURE, V387, P16; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205; Zhong HL, 1997, J BIOL CHEM, V272, P8402, DOI 10.1074/jbc.272.13.8402; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	48	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3588	3597		10.1074/jbc.273.6.3588	http://dx.doi.org/10.1074/jbc.273.6.3588			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452486	hybrid			2022-12-27	WOS:000071822300071
J	Noguchi, Y; Nakamura, S; Yasuda, T; Kitagawa, M; Kohn, LD; Saito, Y; Hirai, A				Noguchi, Y; Nakamura, S; Yasuda, T; Kitagawa, M; Kohn, LD; Saito, Y; Hirai, A			Newly synthesized Rho A, not Ras, is isoprenylated and translocated to membranes coincident with progression of the G(1) to S phase of growth-stimulated rat FRTL-5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; GDP DISSOCIATION INHIBITOR; COENZYME-A REDUCTASE; REGULATORY PROTEIN; CYCLE PROGRESSION; C-TERMINUS; THYROTROPIN; TRANSITION; EXPRESSION; FARNESYL	Ras and Rho are involved in the regulation of signal transduction events governing cell growth and cell proliferation. Protein prenylation is essential for the activation and/or the translocation of these small GTPases; however, protein geranylgeranylation rather than farnesylation is required for G(1)/S transition. We studied prenylation and translocation of Ras and Rho A during G(1)/S progression in growth-stimulated rat thyroid FRTL-5 cells. Immunoblot analysis revealed that both Ras and Rho A were detected in membrane fractions at G(0). Rho A was eliminated from the membrane fraction during G(1) and was not detected on the membrane at mid-G(1). Translocation of Rho A from the cytoplasm back to the membranes was observed during late G(1) phase. In contrast, Ras remains in the membrane fraction through the cell cycle progression from G(1) to S phase. The immunoprecipitation of Rho A from the membrane fraction demonstrated that newly synthesized Rho A, labeled by pulsing cells with [S-35]methionine and [S-35]cysteine, was geranylgeranylated and associated with the membrane in late G(1). These results indicate that Rho A, not Ras, was eliminated from membrane fraction during G(1) progression and that newly synthesized Rho A is geranylgeranylated and translocated to membranes during G(1)/S progression in growth-stimulated FRTL-5 cells.	Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Chiba 260, Japan; Okayama Univ, Sch Med, Inst Cellular & Mol Biol, Dept Cell Chem, Okayama 700, Japan; Kyusyu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 81282, Japan; NIDDK, Cell Regulat Sect, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	Chiba University; Okayama University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hirai, A (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 1-8-1 Inohana Cho, Chiba 260, Japan.	aizan@med.m.chiba-u.ac.jp						ARAKI S, 1990, J BIOL CHEM, V265, P13007; ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; FARRELL FX, 1993, BIOCHEM J, V289, P349, DOI 10.1042/bj2890349; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hirai A, 1997, J BIOL CHEM, V272, P13; HIRAI A, 1994, J CLIN INVEST, V94, P2215, DOI 10.1172/JCI117583; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; ISOMURA M, 1991, ONCOGENE, V6, P119; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; OLOFSSON B, 1988, ONCOGENE, V3, P321; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OMER CA, 1994, MOL MICROBIOL, V11, P219, DOI 10.1111/j.1365-2958.1994.tb00302.x; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TSAI LH, 1993, ONCOGENE, V8, P1593; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; Vogt A, 1996, ONCOGENE, V13, P1991; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	31	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3649	3653		10.1074/jbc.273.6.3649	http://dx.doi.org/10.1074/jbc.273.6.3649			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452494	hybrid			2022-12-27	WOS:000071822300079
J	Janz, R; Sudhof, TC				Janz, R; Sudhof, TC			Cellugyrin, a novel ubiquitous form of synaptogyrin that is phosphorylated by pp60(c-src)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PROTEIN; NEUROTRANSMITTER RELEASE; TETANUS-TOXIN; SYNAPSIN-I; SYNAPTOPHYSIN; CELLUBREVIN; ASSOCIATION; EXPRESSION; SUBSTRATE; PP60C-SRC	Synaptogyrin is an abundant membrane protein of synaptic vesicles containing four transmembrane re gions and a C-terminal cytoplasmic tail that is tyrosine phosphorylated. We have now identified a novel isoform of synaptogyrin called cellugyrin that exhibits 47% sequence identity with synaptogyrin. In rat tissues, cellugyrin and synaptogyrins are expressed in mirror image patterns, Cellugyrin is ubiquitously present in all tissues tested with the lowest levels in brain tissue, whereas synaptogyrin protein is only detectable in brain. Transfection studies in COS cells demonstrated that both cellugyrin and synaptogyrin are tyrosine phosphorylated in vivo by pp60(c-src), and experiments with recombinant proteins showed that pp60(c-src) phosphorylates the cytoplasmic tails of these proteins in vitro. Cellugyrin and synaptogyrin co-localize when transfected into COS cells but are differentially distributed in brain, the only tissue where both proteins are detectable. Our data suggest that the synaptic vesicle protein synaptogyrin is a specialized version of a ubiquitous protein, cellugyrin, with the two proteins sharing structural similarity but differing in localization. This finding supports the emerging concept of synaptic vesicles as the simplified and specialized form of a generic trafficking organelle. The conserved tyrosine phosphorylation of cellugyrin and synaptogyrins suggests a link between tyrosine phosphorylation via pp60(c-src) and membrane traffic.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.			Janz, Roger/0000-0002-9872-0596				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; LAUBE RE, 1994, DIFFERENTIATION, V56, P163; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINK E, 1993, J BIOL CHEM, V268, P18423; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0	29	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2851	2857		10.1074/jbc.273.5.2851	http://dx.doi.org/10.1074/jbc.273.5.2851			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446595	hybrid			2022-12-27	WOS:000071736600050
J	Kimball, SR; Heinzinger, NK; Horetsky, RL; Jefferson, LS				Kimball, SR; Heinzinger, NK; Horetsky, RL; Jefferson, LS			Identification of interprotein interactions between the subunits of eukaryotic initiation factors eIF2 and eIF2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; POLYPEPTIDE-CHAIN INITIATION; PROTEIN-SYNTHESIS; TRANSLATION INITIATION; RAT-LIVER; FACTOR-II; MECHANISM; PHOSPHORYLATION; PURIFICATION; INHIBITION	Modulation of protein/protein interaction is an important mechanism involved in regulation of translation initiation. Specifically, regulation of the interaction of eIF2 with the guanine nucleotide exchange factor, eIF2B, is a key mechanism for controlling translation under a variety of conditions, Phosphorylation of the alpha-subunit of eIF2 converts the protein into a competitive inhibitor of eIF2B by causing an increase in the binding affinity of eIF2B for eIF2, Consequently, it has been assumed that the a subunit of eIF2 is directly involved in binding to eIF2B, In the present study, eIF2 was found to bind only to the delta- and epsilon-subunits of eIF2B, and eIF2B was shown to bind only to the beta-subunit of eIF2 by far-Western blot analysis, The binding site on eIF2 beta for either the eIF2B holoprotein, or the isolated delta- or epsilon-subunits of eIF2B was shown to be located within approximately 70 amino acids of the C terminus of the protein, Phosphorylation of the alpha-subunit of eIF2 did not promote binding of eIF2B to the isolated subunit, However, it did cause an increase in the affinity of eIF2B for eIF2, Finally, phosphorylation by protein kinase A of the beta-subunit of elF2 in the C-terminal portion of the protein increased the guanine nucleotide exchange activity of eIF2B, whereas phosphorylation by casein kinase II or protein kinase C was without effect.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kimball, SR (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, POB 850, Hershey, PA 17033 USA.				NIDDK NIH HHS [DK07684, DK13499, DK15658] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, T32DK007684, R01DK015658, R01DK013499] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; GOSS DJ, 1984, J BIOL CHEM, V259, P7374; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; KIMBALL SR, 1987, J BIOL CHEM, V262, P2220; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KIMBALL SR, 1989, AM J PHYSIOL, V256, pC28, DOI 10.1152/ajpcell.1989.256.1.C28; KIMBALL SR, 1994, BBA-GEN SUBJECTS, V1201, P473, DOI 10.1016/0304-4165(94)90079-5; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; WELSH GI, 1994, BIOCHEM BIOPH RES CO, V201, P1279, DOI 10.1006/bbrc.1994.1843; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625	16	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3039	3044		10.1074/jbc.273.5.3039	http://dx.doi.org/10.1074/jbc.273.5.3039			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446619	hybrid			2022-12-27	WOS:000071736600074
J	Zhao, M; Schlame, M; Rua, D; Greenberg, ML				Zhao, M; Schlame, M; Rua, D; Greenberg, ML			Cardiolipin synthase is associated with a large complex in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; NUCLEAR-MAGNETIC-RESONANCE; CYTOCHROME-C-OXIDASE; ACYL-CARRIER PROTEIN; SACCHAROMYCES-CEREVISIAE; RADIATION INACTIVATION; HEART-MITOCHONDRIA; MUTANT DEFICIENT; REDUCTASE; MEMBRANE	The phospholipid cardiolipin (CL) is ubiquitous in eucaryotes and is unique in structure, subcellular localization, and potential function, Previous studies have shown that CL is associated with major respiratory complexes in the mitochondrial membrane. To determine whether CL biosynthesis requires the presence of intact respiratory complexes, we measured activity of CL synthase, which catalyzes the synthesis of CL from cytidine diphosphate diacylglycerol and phosphatidylglycerol, in Saccharomyces cerevisiae strains with genetic defects in the oxidative phosphorylation system, Assembly mutants of cytochrome oxidase had significantly reduced CL synthase activity, while assembly mutants of respiratory complex III and the F0F1-ATPase were less inhibited, To obtain further information on the activity of CL synthase, we purified the enzyme and compared the size of the catalytic protein with the functional molecular mass, The enzyme was solubilized by Triton X-100 hom KSCN-extracted mitochondrial membranes of S. cerevisiae, The functional molecular mass of Triton-solubilized CL synthase, determined by radiation inactivation, was 150-240 kDa, indicating that the functional enzyme was a large complex, After partial purification, the enzyme eluted from a Superose 12 gel filtration column with an apparent molecular mass of 70 kDa, CL synthase was further purified by hydroxylapatite and cytidine diphosphate diacylglycerol affinity chromatographies, Mono Q anion exchange FPLC, and preparative gel electrophoresis. These steps led to identification of a 28-kDa protein, which had catalytic activity when eluted from an SDS-polyacrylamide gel, This 28-kDa protein also reacted with an antiserum that inactivated the enzyme, We conclude that yeast CL synthase is a 28-kDa protein, which forms an oligomeric complex whose biogenesis and/or activity is influenced by the assembly of cytochrome oxidase.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037723] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37723] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUREGARD G, 1984, ANAL BIOCHEM, V140, P403, DOI 10.1016/0003-2697(84)90185-4; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; EBLE KS, 1990, J BIOL CHEM, V265, P19434; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; FRY M, 1981, J BIOL CHEM, V256, P1874; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; HIRSCHBERG CB, 1972, P NATL ACAD SCI USA, V69, P506; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P380, DOI 10.1016/0005-2760(72)90052-5; HOSTETLER KY, 1975, BIOCHIM BIOPHYS ACTA, V380, P382, DOI 10.1016/0005-2760(75)90106-X; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P974, DOI 10.1021/bi00650a005; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; PLUSCHKE G, 1978, J BIOL CHEM, V253, P5048; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; SCHLAME M, 1992, METHOD ENZYMOL, V209, P330; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLAME M, 1995, LIPIDS, V30, P633, DOI 10.1007/BF02537000; SPERKAGOTTLIEB CDM, 1988, BIOCHIM BIOPHYS ACTA, V946, P227, DOI 10.1016/0005-2736(88)90397-5; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; WEISS H, 1990, TRENDS BIOCHEM SCI, V15, P178, DOI 10.1016/0968-0004(90)90155-5	36	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2402	2408		10.1074/jbc.273.4.2402	http://dx.doi.org/10.1074/jbc.273.4.2402			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442089	hybrid			2022-12-27	WOS:000071595200078
J	Crawford, CR; Patel, DH; Naeve, C; Belt, JA				Crawford, CR; Patel, DH; Naeve, C; Belt, JA			Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; NITROBENZYLTHIOINOSINE; INHIBITION	Mammalian cells obtain nucleic acid precursors through the de novo synthesis of nucleotides and the salvage of exogenous nucleobases and nucleosides. The first step in the salvage pathway is transport across the plasma membrane, Several transport activities, including equilibrative and concentrative mechanisms, have been identified by their functional properties, We report here the functional cloning of a 2.6-kilobase pair human cDNA encoding the nitrobenzylmercaptopurine riboside (NBMPR)-insensitive, equilibrative nucleoside transporter ei by functional complementation of the transport deficiency in a subline of CEM human leukemia cells, Expression of this cDNA conferred an NBMPR-insensitive, sodium-independent nucleoside transport activity to the cells that exhibited substrate specificity and inhibitor sensitivity characteristic of the ei transporter, The cDNA contained a single open reading frame that encoded a 456-residue protein with 11 potential membrane-spanning regions and two consensus sites for N-glycosylation in the first predicted extracellular loop, The predicted protein was 50% identical to the recently cloned human NBMPR-sensitive, equilibrative nucleoside transporter ENT1 and thus was designated ENT2. Surprisingly, the carboxyl-terminal portion of the ENT2 protein was nearly identical to a smaller protein in the GenBank(TM) data base (human HNP36, 326 residues) that has been identified as a growth factor-induced delayed early response gene of unknown function. Comparison of the ENT2 and HNP36 nucleotide sequences suggested that HNP36 was translated from a second start codon within the ENT2 open reading frame, Transient expression studies with the full-length ENT2 and a 5'-truncated construct that lacks the first start codon (predicted protein 99% identical to HNP36) demonstrated that only the full-length construct conferred uridine transport activity to the cells, These data suggest that the delayed early response gene HNP36 is a truncated form of ENT2 and that the full-length open reading frame of ENT2 is required for production of a functional plasma membrane ei transporter.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Ctr Biotechnol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Belt, JA (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale Ave, Memphis, TN 38105 USA.	judi.belt@stjude.org			NCI NIH HHS [R01-CA55056, P30-CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA055056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARABADJIS PG, 1993, AM J PHYSIOL, V264, pC1246, DOI 10.1152/ajpcell.1993.264.5.C1246; BELT JA, 1988, J BIOL CHEM, V263, P13819; CASS CE, 1995, DRUG TRANSPORT ANTIM; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CHEN SF, 1986, CANCER RES, V46, P5014; CRAWFORD C, 1997, P ANN M AM ASS CANC, V38, P406; CRAWFORD CR, 1990, J BIOL CHEM, V265, P13730; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; HAMMOND JR, 1991, J PHARMACOL EXP THER, V259, P799; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; MECKLINGGILL KA, 1993, J CELL PHYSIOL, V155, P530, DOI 10.1002/jcp.1041550311; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; NORMAN B, 1987, CLIN PHYSIOL, V7, P503, DOI 10.1111/j.1475-097X.1987.tb00192.x; Osses N, 1996, BIOCHEM J, V317, P843, DOI 10.1042/bj3170843; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PATERSON ARP, 1980, MOL PHARMACOL, V18, P40; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; ULLMAN B, 1988, J BIOL CHEM, V263, P12391; WILLIAMS JB, 1995, BIOCHEM BIOPH RES CO, V213, P325, DOI 10.1006/bbrc.1995.2133; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; [No title captured]	26	188	196	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5288	5293		10.1074/jbc.273.9.5288	http://dx.doi.org/10.1074/jbc.273.9.5288			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478986	hybrid			2022-12-27	WOS:000072310400070
J	Sohda, M; Misumi, Y; Yano, A; Takami, N; Ikehara, Y				Sohda, M; Misumi, Y; Yano, A; Takami, N; Ikehara, Y			Phosphorylation of the vesicle docking protein p115 regulates its Association with the Golgi membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT; BINDING; COMPLEX; USO1P; CELLS	The vesicle docking protein p115 was found to be phosphorylated in a cell cycle-specific manner; it was found phosphorylated in interphase but not in mitotic cells, During interphase, however, two forms of p115 were detected in the cells; the phosphorylated form was found exclusively in cytosol, whereas the unphosphorylated form was associated with membranes, mostly of the Golgi complex, The latter form was released from the membranes upon phosphorylation. Mutational analysis revealed that the phosphorylation site of p115 was the Ser(942) residue in the C-terminal acidic domain, A mutant with a single substitution of Ser(942) --> Ata markedly increased its association with the Golgi membrane, Another mutant with Ser(942) --> Asp was able to associate with the membrane, although at a decreased level, indicating that the dissociation of p115 from the membrane is not simply due to the negative charge of phosphorylated Ser(942), Taken together, these results suggest that the phosphorylation of Ser(942) at the C-terminal acidic domain regulates the interaction of p115 with the Golgi membrane, possibly taking part in the regulatory mechanism of vesicular transport.	Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 81480, Japan; Fukuoka Univ, Sch Med, Radioisotope Lab, Jonan Ku, Fukuoka 81480, Japan	Fukuoka University; Fukuoka University	Ikehara, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 81480, Japan.							AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; FEATHERSTONE C, 1985, J CELL BIOL, V101, P2036, DOI 10.1083/jcb.101.6.2036; Haruta T, 1997, BIOCHEM J, V325, P455, DOI 10.1042/bj3250455; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SUPRYNOWICZ FA, 1986, J CELL BIOL, V103, P2073, DOI 10.1083/jcb.103.6.2073; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015	22	43	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5385	5388		10.1074/jbc.273.9.5385	http://dx.doi.org/10.1074/jbc.273.9.5385			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478999	hybrid			2022-12-27	WOS:000072310400083
J	Menard, R; Carmona, E; Takebe, S; Dufour, E; Plouffe, C; Mason, P; Mort, JS				Menard, R; Carmona, E; Takebe, S; Dufour, E; Plouffe, C; Mason, P; Mort, JS			Autocatalytic processing or recombinant human procathepsin L - Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-L; IN-VITRO; CYSTEINE PROTEINASES; CELLS; IDENTIFICATION; PURIFICATION; ACTIVATION; PRECURSOR; PAPAIN; PROPEPTIDE	The autocatalytic processing of procathepsin L was investigated in vitro using purified recombinant proenzyme expressed in Pichia pastoris. Pure intermolecular processing was studied by incubating the mutant procathepsin L (C25S), which cannot autoactivate with a small amount of mature active cathepsin L. The results clearly establish that, contrary to recent reports, intermolecular processing of procathepsin L is possible. The main cleavage sites are located at or near the N terminus of the mature enzyme, in an accessible portion of the proregion, which contains sequences corresponding to the known substrate specificity of cathepsin L. Contrary to procathepsins B, K, and S, autocatalytic processing of procathepsin L can generate the natural mature form the enzyme. A continuous assay using the substrate benzyloxycarbonyl-Phe-Arg 4-methylcoumarinyl-7-amide hydrochloride has also been used to obtain information on the nature of the steps involved in the autocatalytic processing of wild-type procathepsin L. Processing is initiated by decreasing the pH from 8.0 to 5.3. The influence of proenzyme concentration on the rate of processing indicates the existence of both unimolecular and biomolecular steps in the mechanism of processing. The nature of the unimolecular event that triggers processing remains elusive. Circular dichroism and fluorescence measurements indicate the absence of large scale conformational change in the structure of procathepsin L on reduction of pH. However, the bimolecular reaction can be attributed to intermolecular processing of the zymogen.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Shriners Hosp Crippled Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A6, Canada	National Research Council Canada; McGill University; McGill University	Menard, R (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.		Dufour, Eric/T-8774-2019; Dufour, Eric/F-8008-2012	Dufour, Eric/0000-0002-8267-9656				Baker KC, 1996, PROTEIN ENG, V9, P525, DOI 10.1093/protein/9.6.525; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BOUJRAD N, 1995, SCIENCE, V268, P1609, DOI 10.1126/science.7777858; BROMME D, 1993, J BIOL CHEM, V268, P4832; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; Fujishima A, 1997, FEBS LETT, V407, P47, DOI 10.1016/S0014-5793(97)00216-0; Ishidoh K, 1995, BIOCHEM BIOPH RES CO, V217, P624, DOI 10.1006/bbrc.1995.2820; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KOGA H, 1990, J BIOCHEM-TOKYO, V108, P976, DOI 10.1093/oxfordjournals.jbchem.a123324; KOMINAMI E, 1988, FEBS LETT, V231, P225, DOI 10.1016/0014-5793(88)80736-1; MACH L, 1994, J BIOL CHEM, V269, P13030; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACIEWICZ RA, 1988, BIOCHEM SOC T, V16, P1056, DOI 10.1042/bst0161056; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MCDONALD JK, 1995, ARCH BIOCHEM BIOPHYS, V323, P409, DOI 10.1006/abbi.1995.0062; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V263, P107, DOI 10.1016/0003-9861(88)90618-2; Nomura T, 1997, BIOCHEM BIOPH RES CO, V230, P143, DOI 10.1006/bbrc.1996.5905; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SHEAHAN K, 1989, CANCER RES, V49, P3809; SMITH SM, 1989, BIOCHEM J, V262, P931, DOI 10.1042/bj2620931; STORER AC, 1994, METHOD ENZYMOL, V244, P486; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TRABANDT A, 1990, MATRIX, V10, P349, DOI 10.1016/S0934-8832(11)80142-3; VERNET T, 1991, J BIOL CHEM, V266, P21451; YAGEL S, 1989, CANCER RES, V49, P3553; ZABLUDOFF SD, 1990, BIOL REPROD, V43, P25, DOI 10.1095/biolreprod43.1.25	34	123	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4478	4484		10.1074/jbc.273.8.4478	http://dx.doi.org/10.1074/jbc.273.8.4478			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468501	hybrid, Green Published			2022-12-27	WOS:000072115000029
J	Yen, YM; Wong, B; Johnson, RC				Yen, YM; Wong, B; Johnson, RC			Determinants of DNA binding and bending by the Saccharomyces cerevisiae high mobility group protein NHP6A that are important for its biological activities - Role of the unique N terminus and putative intercalating methionine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHISTONE CHROMOSOMAL PROTEIN; SEX-DETERMINING REGION; LINKER HISTONES B4; HMG-BOX; TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; NUCLEOPROTEIN STRUCTURES; DROSOPHILA-MELANOGASTER; ARCHITECTURAL ELEMENTS; SEQUENCE SPECIFICITY	The non-histone proteins 6A/B (NHP6A/B) of Saccharomyces cerevisiae are high mobility group proteins that bind and severely bend DNA of mixed sequence. They exhibit high affinity for linear DNA and even higher affinity for microcircular DNA. The 16-amino acid basic segment located N-terminal to the high mobility group domain is required for stable complex formation on both linear and microcircular DNA. Although mutants lacking the N terminus are able to promote microcircle formation and Hin invertasome assembly at high protein concentrations, they are unable to form stable complexes with DNA, co-activate transcription, and complement the growth defect of Delta nhp6a/b mutants. A basic patch between amino acids 13 and 16 is critical for these activities, and a second basic patch between residues 8 and 10 is required for the formation of monomeric complexes with linear DNA. Mutational analysis suggests that proline 18 may direct the path of the N-terminal arm to facilitate DNA binding, whereas the conserved proline at position 21, tyrosine 28, and phenylalanine 31 function to maintain the tertiary structure of the high mobility group domain. Methionine 29, which may intercalate into DNA, is essential for NHP6A-induced micro-circle formation of 75-bp but not 98-bp fragments in vitro, and for full growth complementation of Delta nhp6a/b mutants in vivo.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Johnson, RC (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM08042, GM38509, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038509, T32GM008042, R01GM038509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1019, DOI 10.1093/nar/23.6.1019; BIANCHI ME, 1991, GENE, V104, P271, DOI 10.1016/0378-1119(91)90261-9; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BONNEANDREA C, 1986, BIOL CELL, V58, P185, DOI 10.1111/j.1768-322X.1986.tb00505.x; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; Farid RS, 1996, TOXICOL APPL PHARM, V141, P532, DOI 10.1006/taap.1996.0319; GE H, 1994, J BIOL CHEM, V269, P17136; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; Hardman CH, 1995, BIOCHEMISTRY-US, V34, P16596, DOI 10.1021/bi00051a007; HAYASHI T, 1989, J BIOCHEM-TOKYO, V105, P577, DOI 10.1093/oxfordjournals.jbchem.a122707; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Johns E.W., 1982, HMG CHROMOSOMAL PROT, P1; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; Kirov NC, 1996, EMBO J, V15, P7079, DOI 10.1002/j.1460-2075.1996.tb01099.x; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KUEHL L, 1984, J CELL BIOL, V99, P648, DOI 10.1083/jcb.99.2.648; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; LOCKER D, 1995, J MOL BIOL, V246, P243, DOI 10.1006/jmbi.1994.0079; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Lu J, 1996, J BIOL CHEM, V271, P33678, DOI 10.1074/jbc.271.52.33678; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; Nightingale K, 1996, EMBO J, V15, P548, DOI 10.1002/j.1460-2075.1996.tb00387.x; OHASHI Y, 1994, MOL CELL BIOL, V14, P2731, DOI 10.1128/MCB.14.4.2731; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; Paull TT, 1996, GENE DEV, V10, P2769, DOI 10.1101/gad.10.21.2769; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; PAVET D, 1997, J MOL BIOL, V266, P66; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Rose MD., 1990, METHODS YEAST GENETI; SCHULMAN IG, 1991, MOL CELL BIOL, V11, P166, DOI 10.1128/MCB.11.1.166; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SIKORSKI RS, 1989, GENETICS, V122, P19; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SREERAMA N, 1993, ANAL BIOCHEM, V209, P33; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Ura K, 1996, EMBO J, V15, P4959, DOI 10.1002/j.1460-2075.1996.tb00876.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vanHoute LPA, 1995, J BIOL CHEM, V270, P30516, DOI 10.1074/jbc.270.51.30516; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WAGNER JP, 1995, J BIOL CHEM, V270, P7394, DOI 10.1074/jbc.270.13.7394; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x	76	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4424	4435		10.1074/jbc.273.8.4424	http://dx.doi.org/10.1074/jbc.273.8.4424			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468494	hybrid			2022-12-27	WOS:000072115000022
J	Black, MW; Boothroyd, JC				Black, MW; Boothroyd, JC			Development of a stable episomal shuttle vector for Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTONOMOUS REPLICATION; DNA; TRANSFORMATION; EXPRESSION; GENE; LEISHMANIA; MARKER	The rapid developments in the molecular genetics of Toxoplasma gondii have far reaching implications in treatment and vaccination strategies far this as well as closely related pathogens such as Plasmodium. Although stable transformation of this parasite through homologous and illegitimate genomic integration has provided many of the tools necessary for genetic analysis, subsequent manipulations of the DNA have proven laborious, This report-describes the selection and subsequent characterization of a Toxoplasma sequence that permits the episomal maintenance of bacterial plasmids in this parasite, This sequence was isolated from the Toxoplasma. genome through selection for episomal stability of a pUC19-based library in the absence of a selectable marker, A 500-base pair fragment was determined to possess the stabilization activity. Transformations of Toxoplasma using vectors possessing this fragment, referred to as EMS (episomal maintenance sequence), demonstrated an elevated stable transformation frequency compared with the vector alone, Mutants deficient in hyploxanthine-xanthine-guanine phosphoribosyltransferase activity were used as a test to see if this gene could be selected from a genomic library using a vector containing the EMS. The success of this test demonstrates the utility of EMS-containing vectors in complementation strategies and the ability of such constructs bearing large? fragments of the Toxoplasma genome to be maintained episomally.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University	Boothroyd, JC (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.			Boothroyd, John C./0000-0001-9719-745X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021423, R01AI021423] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30230, AI 21423] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; Boothroyd John C., 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P211; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; DONALD RGK, 1994, MOL BIOCHEM PARASIT, V63, P243, DOI 10.1016/0166-6851(94)90060-4; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; GODBERG J, 1990, NUCLEIC ACIDS RES, V18, P5515; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KIM K, 1993, CLIN RES, V41, pA209; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; OSSORIO PN, 1991, J MOL BIOL, V222, P525, DOI 10.1016/0022-2836(91)90494-Q; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; PFEFFERKORN ER, 1976, EXP PARASITOL, V36, P365, DOI 10.1016/0014-4894(76)90040-0; PFEFFERKORN ER, 1978, EXP PARASITOL, V44, P26, DOI 10.1016/0014-4894(78)90077-2; PFEFFERKORN ER, 1979, J PARASITOL, V65, P364, DOI 10.2307/3280274; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; ROOS DS, 1993, J BIOL CHEM, V268, P6269; ROOS DS, 1994, METHOD CELL BIOL, V45, P28; Sabin AB, 1941, J AMER MED ASSOC, V116, P801, DOI 10.1001/jama.1941.02820090001001; SIBLEY LD, 1994, P NATL ACAD SCI USA, V91, P5508, DOI 10.1073/pnas.91.12.5508; SOLDATI D, 1995, MOL CELL BIOL, V15, P87, DOI 10.1128/MCB.15.1.87; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; WARE PL, 1987, INFECT IMMUN, V55, P778, DOI 10.1128/IAI.55.3.778-783.1987	23	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3972	3979		10.1074/jbc.273.7.3972	http://dx.doi.org/10.1074/jbc.273.7.3972			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461585	hybrid			2022-12-27	WOS:000072048400027
J	Torella, C; Mattingly, JR; Artigues, A; Iriarte, A; Martinez-Carrion, M				Torella, C; Mattingly, JR; Artigues, A; Iriarte, A; Martinez-Carrion, M			Insight into the conformation of protein folding intermediate(s) trapped by GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; CHAPERONIN GROEL; ALPHA-LACTALBUMIN; ESCHERICHIA-COLI; MASS-SPECTROMETRY; BINDING PROTEIN; CENTRAL CAVITY; PRECURSOR; POLYPEPTIDE; CLEAVAGE	Many aspects of the mechanism by which the GroEL/ES chaperonins mediate protein folding are still unclear, including the amount of structure present in the substrate bound to GroEL. To address this issue we have analyzed the susceptibility to limited proteolysis and to alkylation of cysteine residues of mitochondrial aspartate aminotransferase (mAAT) bound to GroEL. Several regions of the N-terminal portion of GroEL-bound mAAT are highly susceptible to proteolysis, whereas a large core of about 200 residues containing the C-terminal half of the polypeptide chain is protected in the complex, This protection does not extend to the mAAT sulfhydryl groups which in the GroEL-mAAT complex have similar reactivity as in fully unfolded mAAT, These results suggest that the mAAT species bound to GroEL represent folding intermediates with a conformation that is substantially more disorganized than that of the native state. The N-terminal half of the molecule is more flexible and lies exposed at the mouth of the central cavity of GroEL, The more compact C-terminal section of mAAT, which contains residues located at the subunit interface in the native dimer, appears to be hidden in the central cavity of GroEL, Thus, the bulk of the interactions in the GroEL-mAAT complex seems to involve residues from the more compact C-terminal section of the substrate.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA.				NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BEREZOV A, 1994, J BIOL CHEM, V269, P22222; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; DELAURETO PP, 1995, BIOCHEMISTRY-US, V34, P12596, DOI 10.1021/bi00039a015; DOONAN S, 1975, BIOCHEM J, V149, P497, DOI 10.1042/bj1490497d; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Gervasoni P, 1996, P NATL ACAD SCI USA, V93, P12189, DOI 10.1073/pnas.93.22.12189; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTINEZCARRION M, 1990, ANN NY ACAD SCI, V585, P346, DOI 10.1111/j.1749-6632.1990.tb28067.x; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1995, J BIOL CHEM, V270, P1138, DOI 10.1074/jbc.270.3.1138; MATTINGLY JR, 1993, J BIOL CHEM, V268, P3925; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; REYES AM, 1993, J BIOL CHEM, V268, P22281; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; SANDMEIER E, 1980, J BIOL CHEM, V255, P284; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	46	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3915	3925		10.1074/jbc.273.7.3915	http://dx.doi.org/10.1074/jbc.273.7.3915			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461576	hybrid			2022-12-27	WOS:000072048400018
J	Gao, Z; Garbers, DL				Gao, Z; Garbers, DL			Species diversity in the structure of zonadhesin, a sperm-specific membrane protein containing multiple cell adhesion molecule-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; TYROSINE-PHOSPHATASE; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; MAM DOMAIN; RECEPTOR; CLONING; FAMILY; IDENTIFICATION; EXPRESSION	A hallmark of gamete interactions at fertilization is relative or absolute species specificity, A pig sperm protein that binds to the extracellular matrix of the egg in a species-specific manner was recently identified and named zonadhesin (Hardy, D, M,, and Garbers, D, L, (1995) J. Biol. Chen, 270, 26025-26028), We have now cloned a cDNA for mouse zonadhesin (16.4 kb), and it demonstrates a large species variation in the numbers and arrangements of domains, Expression of mouse zonadhesin mRNA is evident only within the testis, and the protein is found exclusively on the apical region of the sperm head, There are 20 partial D-domains, found as tandem repeats, inserted between two of the four full D-domains and an additional partial D-domain, These domains are homologous to the D-domains of von Willebrand factor and alpha-tectorin. A region at the N terminus of the mouse cDNA contains three tandem repeats homologous to MAM domains, These are domains comprised of about 160 amino acids that are present in transmembrane proteins such as the meprins and receptor protein-tyrosine phosphatases, where they appear to function in cell/cell interactions, Additionally, mouse zonadhesin contains a mucin-like domain and a domain homologous to epidermal growth factor (EGF), A putative single transmembrane segment separates a short carboxyl tail from the extracellular region, The existence of MAM, mucin, D-, and EGF domains suggest that mouse zonadhesin functions in multiple cell adhesion processes, where binding to the extracellular matrix of the egg is but one of the functions of this sperm-specific membrane protein.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garbers, DL (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD010254] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10254] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Brown DD, 1996, P NATL ACAD SCI USA, V93, P1924, DOI 10.1073/pnas.93.5.1924; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS C G, 1990, New Biologist, V2, P410; DAVIS LG, 1986, BASIC METHODS MOL BI, P139; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FUJISAWA T, 1991, EUR J BIOCHEM, V196, P673, DOI 10.1111/j.1432-1033.1991.tb15864.x; Gao Z, 1997, GENOMICS, V41, P119, DOI 10.1006/geno.1997.4620; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUM JR, 1994, J BIOL CHEM, V269, P2440; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HARDY DM, 1994, J BIOL CHEM, V269, P19000; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; Joba W, 1997, J BIOL CHEM, V272, P1805, DOI 10.1074/jbc.272.3.1805; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE SL, 1994, BIOTECHNOL APPL BIOC, V19, P31; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MEYER D, 1993, THROMB HAEMOSTASIS, V70, P99; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang HY, 1996, ONCOGENE, V12, P2555; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	36	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3415	3421		10.1074/jbc.273.6.3415	http://dx.doi.org/10.1074/jbc.273.6.3415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452463	hybrid			2022-12-27	WOS:000071822300048
J	Johnson, BD; Schumacher, RJ; Ross, ED; Toft, DO				Johnson, BD; Schumacher, RJ; Ross, ED; Toft, DO			Hop modulates hsp70/hsp90 interactions in protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RETICULOCYTE LYSATE; HEAT-SHOCK PROTEINS; PROGESTERONE-RECEPTOR COMPLEXES; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; HSP90; HSP70; DNAJ; BINDING; GRPE	Hop is a 60-kDa protein characterized by its ability to bind the two chaperones, hsp70 and hsp90. We have tested the function of Hop using an assay for the refolding of denatured firefly luciferase. We show that Hop is involved in the process of refolding thermally denatured firefly luciferase in rabbit reticulocyte lysate. Hop also stimulates refolding by hsp70 and Ydj-1 in a purified refolding system. Hsp90 can also stimulate refolding, and optimal refolding is observed in the presence of both Hop and hsp90. Similar stimulation was observed when Hop was replaced by its yeast homolog Sti1. In assays of the binding of Hop to hsp70 and hsp90, Hop preferentially forms a complex with ADP-bound hsp70, and this process is unaffected by the presence of hsp90. Hop does not alter the ATPase activity or the rate of ADP dissociation of hsp70. Hop also appears to bind to the ADP-bound form of hsp90, blocking the ATP-dependent conversion of hsp90 to a form capable of interacting with p23. Conversely, once p23 is bound to hsp90, Hop binding is diminished. These results confirm that Hop provides a physical link between hsp70 and hsp90 and also indicate that Hop modulates the activities of both of these chaperone proteins.	Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Mayo Clinic; Yale University; Howard Hughes Medical Institute; Yale University	Toft, DO (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	toft@mayo.edu		Ross, Eric/0000-0002-6473-9977	NICHD NIH HHS [HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK 46249] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hofeld J., 1995, CELL, V83, P589; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; PALLEROS DR, 1993, NATURE, V365, P6624; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396	47	281	293	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3679	3686		10.1074/jbc.273.6.3679	http://dx.doi.org/10.1074/jbc.273.6.3679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452498	hybrid			2022-12-27	WOS:000071822300083
J	Luo, YQ; Umegaki, H; Wang, XT; Abe, R; Roth, GS				Luo, YQ; Umegaki, H; Wang, XT; Abe, R; Roth, GS			Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DOMINANT-NEGATIVE MUTANT; CENTRAL-NERVOUS-SYSTEM; X-RAY-MICROANALYSIS; C-JUN; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; PC12 CELLS; MOLECULAR MECHANISMS; SYMPATHETIC NEURONS	Dopamine (DA) is a neurotransmitter, but it also exerts a neurotoxic effect under certain pathological conditions, including age-related neurodegeneration such as Parkinson's disease. By using both the 293 cell line and primary neonatal rat postmitotic striatal neuron cultures, we show here that DA induces apoptosis in a time-and concentration-dependent manner. Concomitant with the apoptosis, DA activates the JNK pathway, including increases in JNK activity, phosphorylation of c-Jun, and subsequent increase in c-Jun protein. This DA-induced JNK activation precedes apoptosis and is persistently sustained during the process of apoptosis. Transient expression of a dominant negative mutant SEK1(Lys --> Arg), an upstream kinase of JNK, prevents both DA-induced JNK activation and apoptosis. A dominant negative c-Jun mutant FLAG Delta 169 also reduces DA-induced apoptotic cell death. Anti-oxidants N-acetylcysteine and catalase, which serve as scavengers of reactive oxygen species generated by metabolic DA oxidation, effectively block DA-induced JNK activation and subsequent apoptosis. Thus, our data suggest that DA triggers an apoptotic death program through an oxidative stress-involved JNK activation signaling pathway. Given the fact that the anti-oxidative defense system declines during aging, this molecular event may be implicated in the age-related striatal neuronal cell loss and age-related dopaminergic neurodegenerative disorders, such as Parkinson's and Huntington's diseases.	NIA, Gerontol Res Ctr, Mol Physiol & Genet Sect, NIH, Baltimore, MD 21224 USA; NIA, Gerontol Res Ctr, Gene Express & Aging Sect, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Luo, YQ (corresponding author), NIA, Gerontol Res Ctr, Mol Physiol & Genet Sect, NIH, 4940 Eastern Ave,4E02, Baltimore, MD 21224 USA.	luoyq@helix.nih.gov						ABAD F, 1995, EUR J PHARM-ENVIRON, V293, P55, DOI 10.1016/0926-6917(95)90018-7; ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; AKIYAMA Y, 1991, J NEUROCHEM, V57, P997, DOI 10.1111/j.1471-4159.1991.tb08249.x; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; Berman SB, 1996, J NEUROCHEM, V67, P593; BOSSI SR, 1993, NEUROREPORT, V4, P73, DOI 10.1097/00001756-199301000-00019; BROWN PH, 1994, ONCOGENE, V9, P791; BUISSON A, 1992, J NEUROCHEM, V59, P1153, DOI 10.1111/j.1471-4159.1992.tb08358.x; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cheng NN, 1996, BRAIN RES, V743, P278, DOI 10.1016/S0006-8993(96)01056-6; COHEN G, 1974, J BIOL CHEM, V249, P2447; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Drukarch B, 1996, J NEUROSCI, V16, P6038; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FILLOUX F, 1991, SYNAPSE, V8, P281, DOI 10.1002/syn.890080406; FORNSTEDT B, 1989, J NEURAL TRANSM-PARK, V1, P279, DOI 10.1007/BF02263482; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN Z, 1989, BRAIN RES, V498, P299, DOI 10.1016/0006-8993(89)91108-6; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; HIRSCH EC, 1991, J NEUROCHEM, V56, P446, DOI 10.1111/j.1471-4159.1991.tb08170.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JELLINGER K, 1992, J NEUROCHEM, V59, P1168, DOI 10.1111/j.1471-4159.1992.tb08362.x; JENNER P, 1993, ACTA NEUROL SCAND, V87, P6; JONSSON G, 1971, PROGR HISTOCHEM CYTO, V2, P299; KASTNER A, 1993, J NEUROCHEM, V61, P1024, DOI 10.1111/j.1471-4159.1993.tb03616.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAI H, 1987, NEUROBIOL AGING, V8, P45, DOI 10.1016/0197-4580(87)90056-X; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; Masserano JM, 1996, MOL PHARMACOL, V50, P1309; MESCO ER, 1992, J NEUROSCI RES, V31, P341, DOI 10.1002/jnr.490310216; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; ODELL SJ, 1991, BRAIN RES, V564, P256, DOI 10.1016/0006-8993(91)91461-9; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; ROTH GS, 1994, ANN NY ACAD SCI, V719, P129, DOI 10.1111/j.1749-6632.1994.tb56824.x; Rubin Lee L., 1994, Current Opinion in Neurobiology, V4, P696, DOI 10.1016/0959-4388(94)90012-4; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539; Shinkai T, 1997, J NEUROSCI RES, V47, P393; Simantov R, 1996, NEUROSCIENCE, V74, P39, DOI 10.1016/0306-4522(96)00102-9; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; TODD RD, 1992, BIOL PSYCHIAT, V31, P794, DOI 10.1016/0006-3223(92)90311-M; VALERIO A, 1994, J NEUROCHEM, V62, P1260; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALKINSHAW G, 1994, NEUROSCIENCE, V63, P975, DOI 10.1016/0306-4522(94)90566-5; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; ZHANG L, 1995, BRAIN RES, V677, P177, DOI 10.1016/0006-8993(95)00197-X; ZilkhaFalb R, 1997, CELL MOL NEUROBIOL, V17, P101, DOI 10.1023/A:1026333222008; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	69	283	291	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3756	3764		10.1074/jbc.273.6.3756	http://dx.doi.org/10.1074/jbc.273.6.3756			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452508	hybrid			2022-12-27	WOS:000071822300093
J	Mayer, B; Pfeiffer, S; Schrammel, A; Koesling, D; Schmidt, K; Brunner, F				Mayer, B; Pfeiffer, S; Schrammel, A; Koesling, D; Schmidt, K; Brunner, F			A new pathway of nitric oxide cyclic GMP signaling involving S-nitrosoglutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLYL CYCLASE; NO-CENTER-DOT; BIOLOGICAL-ACTIVITY; SUPEROXIDE-DISMUTASE; ENDOTHELIAL-CELLS; AQUEOUS-SOLUTION; SYNTHASE; GLUTATHIONE; KINETICS; PEROXYNITRITE	Nitric oxide (NO), a physiologically important activator of soluble guanylyl cyclase (sGC), is synthesized from L-arginine and O-2 in a reaction catalyzed by NO synthases (NOS), Previous studies with purified NOS failed to detect formation of free NO, presumably due to a fast inactivation of NO by simultaneously produced superoxide (O-2(radical anion)). To characterize the products involved in NOS-induced sGC activation, we measured the formation of cyclic 3',5'-guanosine monophosphate (cGMP) by purified sGC incubated in the absence and presence of GSH (1 mM) with drugs releasing different NO-related species or with purified neuronal NOS. Basal sGC activity was 0.04 +/- 0.01 and 0.19 +/- 0.06 mu mol of cGMP x mg(-1) x min(-1) without and with 1 mM GSH, respectively. The NO donor DEA/NO activated sGC in a GSH-independent manner, Peroxynitrite had no effect in the absence of GSH but significantly stimulated the enzyme in the presence of the thiol (3.45 a 0.60 mu mol of cGMP x mg(-1) x min(-1)). The NO/O-2(radical anion) donor SIN-1 caused only a slight accumulation of cGMP in the absence of GSH but was almost as effective as DEA/NO in the presence of the thiol, The profile of sGC activation by Ca2+/calmodulin-activated NOS resembled that of SIN-1; at a maximally active concentration of 200 ng/0.1 ml, NOS increased sGC activity to 1.22 +/- 0.12 and 8.51 +/- 0.88 mu mol of cGMP x mg(-1) x min(-1) in the absence and presence of GSH, respectively, The product of NOS and GSH was identified as the thionitrite GSNO, which activated sGC through Cu+-catalyzed release of free NO. In contrast to S-nitrosation by peroxynitrite, the novel NO/O-2(radical anion)-triggered pathway was very efficient (25-45% GSNO) and insensitive to CO2. Cu+-specific chelators inhibited bradykinin-induced cGMP release from rat isolated hearts but did not interfere with the direct activation of cardiac sGC, suggesting that thionitrites may occur as intermediates of NO/cGMP signaling in mammalian tissues.	Graz Univ, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	University of Graz; Free University of Berlin	Mayer, B (corresponding author), Graz Univ, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	mayer@kfunigraz.ac.at	Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BRUNNER F, 1995, J MOL CELL CARDIOL, V27, P1953, DOI 10.1016/0022-2828(95)90017-9; Butler AR, 1997, ANAL BIOCHEM, V249, P1; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEVION M, 1993, P NATL ACAD SCI USA, V90, P1102, DOI 10.1073/pnas.90.3.1102; CULCASI M, 1994, J BIOL CHEM, V269, P12589; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; Davisson RL, 1996, HYPERTENSION, V28, P354, DOI 10.1161/01.HYP.28.3.354; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Dicks AP, 1996, J CHEM SOC PERK T 2, P481, DOI 10.1039/p29960000481; Dierks EA, 1996, BIOCHEM PHARMACOL, V51, P1593, DOI 10.1016/0006-2952(96)00078-0; Feelisch M., 1989, J CARDIOVASC PHARM, V14, P13; FERRARI R, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90291-5; FREEDMAN JE, 1995, J CLIN INVEST, V96, P394, DOI 10.1172/JCI118047; Friebe A, 1996, NATURE, V382, P120, DOI 10.1038/382120a0; FUKUTO JM, 1993, BIOCHEM BIOPH RES CO, V196, P707, DOI 10.1006/bbrc.1993.2307; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; GORDGE MP, 1995, BRIT J PHARMACOL, V114, P1083, DOI 10.1111/j.1476-5381.1995.tb13317.x; Gordge MP, 1996, BRIT J PHARMACOL, V119, P533, DOI 10.1111/j.1476-5381.1996.tb15704.x; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; Gorren ACF, 1996, ARCH BIOCHEM BIOPHYS, V330, P219, DOI 10.1006/abbi.1996.0247; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Hogg N, 1997, BIOCHEM J, V323, P477, DOI 10.1042/bj3230477; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Hou YC, 1996, BIOCHEM BIOPH RES CO, V228, P88, DOI 10.1006/bbrc.1996.1620; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLUGE I, 1995, SAT S 4 INT BRAIN RE; Lipton SA, 1996, TRENDS PHARMACOL SCI, V17, P186, DOI 10.1016/0165-6147(96)20028-8; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; Mayer Bernd, 1995, P21, DOI 10.1016/B978-012721985-1/50004-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; PACE GW, 1995, FREE RADICAL BIO MED, V19, P523, DOI 10.1016/0891-5849(95)00047-2; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; POU S, 1992, J BIOL CHEM, V267, P24173; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Schultz G., 1984, METHOD ENZYMAT AN, P379; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VENTURINI CM, 1993, J PHARMACOL EXP THER, V266, P1497; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; WINTERBOURN CC, 1990, FREE RADICAL RES COM, V8, P287, DOI 10.3109/10715769009053361; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863	74	172	178	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3264	3270		10.1074/jbc.273.6.3264	http://dx.doi.org/10.1074/jbc.273.6.3264			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452441	hybrid			2022-12-27	WOS:000071822300026
J	White, RR; Kwon, YG; Taing, M; Lawrence, DS; Edelman, AM				White, RR; Kwon, YG; Taing, M; Lawrence, DS; Edelman, AM			Definition of optimal substrate recognition motifs of Ca2+-calmodulin-dependent protein kinases IV and II reveals shared and distinctive features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT MULTIPROTEIN KINASE; GLYCOGEN-SYNTHASE KINASE; ACETYL-COA CARBOXYLASE; PHOSPHORYLATION SITES; MOLECULAR-CLONING; CA-2+ CALMODULIN; STRUCTURAL BASIS; GENE-EXPRESSION; BINDING PROTEIN; RAT-BRAIN	The substrate recognition determinants of Ca2+-calmodulin-dependent protein kinase (CaMK) TV and CaMKII alpha were investigated using peptide substrates modeled on the amino acid sequence encompassing Ser-g of synapsin I, For both kinases, hydrophobic residues (Leu or Phe) at the -5 position, are well tolerated, whereas non-hydrophobic residues (Arg, Ala, or Asp) decrease V-max/K-m,,, by 55- to >4000-fold., At the -3 position, substitution of Ala for Arg leads to decreases of 99- and 343- fold in V-max/K-m,, for CaMKIV and CaMKII alpha, respectively, For both kinases, the nature of the residues occupying the -4, -1, and + 4 positions exerts relatively little influence on phosphorylation kinetics, CaMKIV and CaMKII alpha respond differently to substitutions at the -2 and +1 positions, Substitution of Arg at the -2 position with non-basic residues (Gin or Ala) leads to a-fold decreases in V-max/K-m,,JK, for CaMKIV, but 17-28-fold increases for CaMKII alpha., Additionally, peptides containing Leu, Asp, or Ala at the +1 position are phosphorylated with similar efficiencies by CaMKIV, whereas the Leu-substituted peptide is preferred by CaMKII alpha (by a factor of 5.8-9.7-fold), Thus, CaMKIV and CaMKII alpha preferentially phosphorylate substrates with the motifs: Hyd-X-Arg-X-X-Ser*/Thr*, and Hyd-X-Arg-NB-X-Ser*/Thr*-Hyd, respectively, where Hyd represents a hydrophobic, X any, and NE a non-basic amino acid residue. The different specificities of the two kinases may contribute to their targeting to distinct physiological substrates during Ca2+-dependent cellular events.	SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Chem, Buffalo, NY 14214 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Yeshiva University; Albert Einstein College of Medicine	Edelman, AM (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA.	aedelman@ubmede.buffalo.edu			NIGMS NIH HHS [GM45989] Funding Source: Medline; NINDS NIH HHS [NS24738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024738, R29NS024738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CLARKE PR, 1990, FEBS LETT, V269, P213, DOI 10.1016/0014-5793(90)81157-J; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DOSKELAND AP, 1984, EUR J BIOCHEM, V145, P31, DOI 10.1111/j.1432-1033.1984.tb08518.x; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FINEMESSER RL, 1996, ONCOGENE, V12, P2725; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARDIE DG, 1986, EUR J BIOCHEM, V157, P553, DOI 10.1111/j.1432-1033.1986.tb09702.x; HARDIE DG, 1995, PROTEIN KINASE FACTS, P128; HASHIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41, DOI 10.1016/0003-9861(90)90228-Q; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P347, DOI 10.1111/j.1432-1033.1988.tb14203.x; IKEBE M, 1990, J BIOL CHEM, V265, P8975; IKEBE M, 1990, J BIOL CHEM, V265, P17607; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MARTENSEN TM, 1989, BIOCHEMISTRY-US, V28, P9243, DOI 10.1021/bi00450a002; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOORE S, 1954, J BIOL CHEM, V211, P907; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1983, J BIOL CHEM, V258, P2376; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENOLIKAR S, 1988, BIOCHEM BIOPH RES CO, V151, P1332, DOI 10.1016/S0006-291X(88)80508-4; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SODERLING TR, 1986, BIOCHEM BIOPH RES CO, V139, P1017, DOI 10.1016/S0006-291X(86)80279-0; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; Stewart JM, 1984, SOLID PHASE PEPTIDE; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x	61	114	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3166	3172		10.1074/jbc.273.6.3166	http://dx.doi.org/10.1074/jbc.273.6.3166			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452427	hybrid			2022-12-27	WOS:000071822300012
J	Brushaber, KR; O'Toole, GA; Escalante-Semerena, JC				Brushaber, KR; O'Toole, GA; Escalante-Semerena, JC			CobD, a novel enzyme with L-threonine-O-3-phosphate decarboxylase activity, is responsible for the synthesis of (R)-1-amino-2-propanol O-2-phosphate, a proposed new intermediate in cobalamin biosynthesis in Salmonella typhimurium LT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSG GENE ENCODES; MULTIFUNCTIONAL PROTEIN; HYDROGENOBYRINIC ACID; NUCLEOTIDE LOOP; COENZYME B-12; PURIFICATION; VITAMIN-B12; TRANSDUCTION; RESISTANCE; INSERTION	The cobD gene of Salmonella typhimurium LT2 has been cloned, sequenced, and overexpressed, The overexpressed protein had a molecular mass of similar to 40 kDa, in agreement with the mass predicted by the deduced amino acid sequence (40.8 kDa), Computer analysis of the deduced amino acid sequence of CobD identified a consensus pyridoxal phosphate-binding motif, The role of CobD in cobalamin biosynthesis in this bacterium has been established. CobD was shown to decarboxylate L-threonine O-3-phosphate to yield (R)-1-amino-2-propanol O-2-phosphate. We propose that the latter is a substrate in the reaction catalyzed by the CbiB enzyme proposed to be responsible for the conversion of adenosylcobyric acid to adenosylcobinamide and that the product of the reaction is adenosylcobinamide phosphate, not adenosylcobinamide as previously thought, The implications of these findings are discussed in light of the demonstrated kinase activity of the CobU enzyme (O'Toole, G. A., and Escalante-Semerena, J. C. (1995) J. Biol. Chem. 270, 23560-23569) responsible for the conversion of adenosylcobinamide to adenosylcobinamide phosphate, These findings shed light on the strategy used by this bacterium for the assimilation of exogenous unphosphorylated cobinamide from its environment. To our knowledge, CobD is the first enzyme reported to have L-threonine-O-3-phosphate decarboxylase activity, and computer analysis of its amino acid sequence suggests that it may be a member of a new class of pyridoxal phosphate-dependent decarboxylases.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	jcescala@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040313, R01GM040313, T32GM008349] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040313, GM08349, GM40313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BATTERSBY AR, 1994, SCIENCE, V264, P1551, DOI 10.1126/science.8202709; BLANCHE F, 1993, ANGEW CHEM INT EDIT, V32, P1651, DOI 10.1002/anie.199316511; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; BLANCHE F, 1990, ANGEW CHEM INT EDIT, V29, P884, DOI 10.1002/anie.199008841; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOYLAN SA, 1981, J BIOL CHEM, V256, P1809; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; DEBUSSCHE L, 1992, J BACTERIOL, V174, P7445, DOI 10.1128/jb.174.22.7445-7451.1992; ELLIOTT T, 1988, MOL GEN GENET, V213, P332, DOI 10.1007/BF00339599; ESCALANTESEMERENA JC, 1987, J BACTERIOL, V169, P2251, DOI 10.1128/jb.169.5.2251-2258.1987; Fazzio TG, 1996, J BACTERIOL, V178, P6952, DOI 10.1128/jb.178.23.6952-6959.1996; FORD SH, 1976, ARCH BIOCHEM BIOPHYS, V175, P121, DOI 10.1016/0003-9861(76)90490-2; FORD SH, 1976, BIOCHEM BIOPH RES CO, V72, P1077, DOI 10.1016/S0006-291X(76)80242-2; FORD SH, 1977, BIOCHIM BIOPHYS ACTA, V500, P217, DOI 10.1016/0304-4165(77)90062-9; GALLAGHER SR, 1996, CURRENT PROTOCOLS MO, V2; GOLDMAN BS, 1993, J BACTERIOL, V175, P1457, DOI 10.1128/JB.175.5.1457-1466.1993; GRABAU C, 1992, J BACTERIOL, V174, P2138, DOI 10.1128/JB.174.7.2138-2144.1992; HUFF E, 1959, J BIOL CHEM, V234, P1060; JETER RM, 1984, J BACTERIOL, V159, P206, DOI 10.1128/JB.159.1.206-213.1984; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KELLEY JJ, 1984, J BIOL CHEM, V259, P2124; KRASNA AI, 1957, J BIOL CHEM, V225, P745; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEUBERGER A, 1960, BIOCHIM BIOPHYS ACTA, V41, P164, DOI 10.1016/0006-3002(60)90388-7; OTOOLE GA, 1994, J BIOL CHEM, V269, P26503; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; OTOOLE GA, 1995, J BIOL CHEM, V270, P23560, DOI 10.1074/jbc.270.40.23560; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; REMY E, 1996, 4 EUR S VIT B12 B12, P46; Rondon MR, 1997, PROG NUCLEIC ACID RE, V56, P347, DOI 10.1016/S0079-6603(08)61010-7; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V110, P378, DOI 10.1007/BF00438281; SCOTT AI, 1993, ANGEW CHEM INT EDIT, V32, P1223, DOI 10.1002/anie.199312233; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; SPENCER JB, 1993, FEBS LETT, V335, P57, DOI 10.1016/0014-5793(93)80438-Z; TABOR S, 1990, CURRENT PROTOCOLS MO, V2; TAYLOR RT, 1973, ENZYMES, V9, P121; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WARREN MJ, 1994, BIOCHEM J, V302, P837, DOI 10.1042/bj3020837	44	40	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2684	2691		10.1074/jbc.273.5.2684	http://dx.doi.org/10.1074/jbc.273.5.2684			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446573	hybrid			2022-12-27	WOS:000071736600028
J	Cuvillier, O; Rosenthal, DS; Smulson, ME; Spiegel, S				Cuvillier, O; Rosenthal, DS; Smulson, ME; Spiegel, S			Sphingosine 1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA CONVERTING ENZYME; CD95 FAS/APO-1; ICE/CED-3 PROTEASE; PATHWAY; KINASE; CPP32; BCL-2; SPHINGOMYELINASE; INVOLVEMENT	Ceramide, a sphingolipid generated by the hydrolysis of membrane-associated sphingomyelin, appears to play a role as a gauge of apoptosis. A further metabolite of ceramide, sphingosine 1-phosphate (SPP), prevents ceramide-mediated apoptosis, and it has been suggested that the balance between intracellular ceramide and SPP levels may determine the cell fate (Cuvillier, O., Pirianov, G, Kleuser, B., Vanek, P. G., Coso, O. A., Gut-kind, J. S., and Spiegel, S. (1996) Nature 381, 800-803). Here, we investigated the role of SPP and the protein kinase C activator, phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), in the caspase cascade leading to the proteolysis of poly(ADP-ribose) polymerase (PARP) and lamins. In Jurkat T cells, Fas ligation or addition of exogenous C-2-ceramide induced activations of caspase-3/CPP32 and caspase-7/Mch3 followed by PARP cleavage, effects that can be blocked either by SPP or TPA. Furthermore, both SPP and TPA inhibit the activation of caspase-6/Mch2 and subsequent lamin B cleavage. Ceramide, in contrast to Fas ligation, did not induce activation of caspase-8/FLICE and neither SPP nor TPA were able to prevent this activation. Thus, SPP, likely generated via protein kinase C-mediated activation of sphingosine kinase, suppresses the apoptotic pathway downstream of FLICE but upstream of the executioner caspases, caspase-3, -6, and -7.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 353 Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20007 USA.		CUVILLIER, Olivier/B-2567-2009; Rosenthal, Dean S/J-2360-2014; CUVILLIER, Olivier/S-1631-2019	CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; Rosenthal, Dean/0000-0002-7624-0209	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880, R37GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chmura SJ, 1996, CANCER RES, V56, P2711; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; DUKE RC, 1992, CURRENT PROTOCOLS IM, V2; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Greidinger EL, 1996, FEBS LETT, V390, P299, DOI 10.1016/0014-5793(96)00678-3; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hasegawa J, 1996, CANCER RES, V56, P1713; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	46	235	247	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2910	2916		10.1074/jbc.273.5.2910	http://dx.doi.org/10.1074/jbc.273.5.2910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446602	hybrid			2022-12-27	WOS:000071736600057
J	Goldfarb, AN; Lewandowska, K; Pennell, CA				Goldfarb, AN; Lewandowska, K; Pennell, CA			Identification of a highly conserved module in E proteins required for in vivo helix-loop-helix dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; IN-VIVO; NUCLEAR PHOSPHOPROTEIN; INHIBITORY DOMAIN; CRYSTAL-STRUCTURE; HLH PROTEINS; BHLH DOMAIN; ID-PROTEIN; GENE; MYOD	Basic helix-loop-helix (bHLH) transcription factors often function as heterodimeric complexes consisting of a tissue-specific factor such as SCL/tal or MyoD bound to a broadly expressed E protein. bHLH dimerization therefore appears to represent a key regulatory step in cell lineage determination and oncogenesis. Previous functional and structural studies have indicated that the well defined HLH domain is both necessary and sufficient for dimerization. Most of these studies, however, have employed in vitro systems for analysis of HLH dimerization, and their implications for the requirements for in vivo dimerization remain unclear. Using multiple approaches, we have analyzed bHLH dimerization in intact, living cells and have identified a novel domain in E proteins, domain C, which is required for in vivo dimerization. Domain C, which lies just carboxyl-terminal to helix 2 of the HLH domain, represents the most highly conserved region within E proteins and appears to influence the in vivo conformation of the adjacent HLH domain. These results suggest that HLH dimerization in vivo may represent a complex, regulated process that is distinct from HLH dimerization in vitro.	Case Western Reserve Univ, Sch Med, Inst Pathol, Dept Pathol, Cleveland, OH 44106 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	Case Western Reserve University; University of Minnesota System; University of Minnesota Twin Cities	Goldfarb, AN (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, Dept Pathol, Biomed Res Bldg,Rm 936,10900 Euclid Ave, Cleveland, OH 44106 USA.			Pennell, Christopher/0000-0002-2901-6554	NCI NIH HHS [1 R29 CA7204-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BISHOP P, 1995, J AM CHEM SOC, V117, P8283, DOI 10.1021/ja00136a032; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; Fairman R, 1997, PROTEIN SCI, V6, P175; Ferre d'Amare AR, 1993, NATURE, V363, P38; FINKEL T, 1993, J BIOL CHEM, V268, P5; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GIBSON TJ, 1993, PROTEIN ENG, V6, P41, DOI 10.1093/protein/6.1.41; Goldfarb AN, 1996, J BIOL CHEM, V271, P2683, DOI 10.1074/jbc.271.5.2683; GOLDFARB AN, 1995, BLOOD, V85, P465; GOLDFARB AN, 1992, BLOOD, V80, P2858; GOLDFARB AN, 1994, EXP CELL RES, V214, P481, DOI 10.1006/excr.1994.1285; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Maleki SJ, 1997, BIOCHEMISTRY-US, V36, P6762, DOI 10.1021/bi970262m; Pauza ME, 1997, J IMMUNOL, V158, P3259; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHIRAKATA M, 1995, EMBO J, V14, P1766, DOI 10.1002/j.1460-2075.1995.tb07165.x; SHUE GL, 1994, J BIOL CHEM, V269, P2707; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; Wright WE, 1996, DEV GENET, V19, P131, DOI 10.1002/(SICI)1520-6408(1996)19:2<131::AID-DVG4>3.0.CO;2-A; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	40	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2866	2873		10.1074/jbc.273.5.2866	http://dx.doi.org/10.1074/jbc.273.5.2866			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446597	hybrid			2022-12-27	WOS:000071736600052
J	Schissel, SL; Jiang, XC; Tweedie-Hardman, J; Jeong, TS; Camejo, EH; Najib, J; Rapp, JH; Williams, KJ; Tabas, I				Schissel, SL; Jiang, XC; Tweedie-Hardman, J; Jeong, TS; Camejo, EH; Najib, J; Rapp, JH; Williams, KJ; Tabas, I			Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH - Implications for atherosclerotic lesion development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; APOLIPOPROTEIN-E; MACROPHAGE UPTAKE; AORTIC INTIMA; RECEPTOR; RABBIT; MICE; HYPERCHOLESTEROLEMIA; RETENTION	The subendothelial aggregation and retention of low density lipoprotein (LDL) are key events in atherogenesis, but the mechanisms in vivo are not known. Previous studies have shown that treatment of LDL with bacterial sphingomyelinase (SMase) in vitro leads to the formation of lesion-like LDL aggregates that become retained on extracellular matrix and stimulate macrophage foam cell formation. In addition, aggregated human lesional LDL, but not unaggregated lesional LDL or plasma LDL, shows evidence of hydrolysis by an arterial wall SMase in vivo, and several arterial wall cell types secrete a SMase (S-SMase). S-SMase, however, has a sharp acid pH optimum using a standard in vitro SM-micelle assay. Thus, a critical issue regarding the potential role of S-SMase in atherogenesis is whether the enzyme can hydrolyze lipoprotein-SM, particularly at neutral pH. We now show that S-SMase can hydrolyze and aggregate native plasma LDL at pH 5.5 but not at pH 7.4. Remarkably, LDL modified by oxidation, treatment with phospholipase A(2), or enrichment with apolipoprotein CIII, which are modifications associated with increased atherogenesis, is hydrolyzed readily by S-SMase at pH 7.4. In addition, lipoproteins from the plasma of apolipoprotein E knock-out mice, which develop extensive atherosclerosis, are highly susceptible to hydrolysis and aggregation by S-SMase at pH 7.4; a high SM:PC ratio in these lipoproteins appears to be an important factor in their susceptibility to S-SMase. Most importantly, LDL extracted from human atherosclerotic lesions, which is enriched in sphingomyelin compared with plasma LDL, is hydrolyzed by S-SMase at pH 7.4 10-fold more than same donor plasma LDL, suggesting that LDL is modified in the arterial wall to increase its susceptibility to S-SMase. In summary, atherogenic lipoproteins are excellent substrates for S-SMase, even at neutral pH, making this enzyme a leading candidate for the arterial wall SMase that hydrolyzes LDL-SM and causes subendothelial LDL aggregation.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Gothenburg Univ, Wallenberg Lab Cardiovasc Res, S-41345 Gothenburg, Sweden; Inst Pasteur, F-59019 Lille, France; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Thomas Jefferson Univ, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Columbia University; Columbia University; Columbia University; University of Gothenburg; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jefferson University	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Williams, Kevin Jon/0000-0002-0000-2159	NHLBI NIH HHS [HL57560, HL 21006, HL56984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057560, P50HL021006, P50HL056984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD TY, 1986, BIOCHEMISTRY-US, V25, P4415, DOI 10.1021/bi00363a036; AHMAD TY, 1985, J LIPID RES, V26, P1160; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CALLAHAN JW, 1983, J NEUROSCI RES, V10, P151, DOI 10.1002/jnr.490100205; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; DallingaThie GM, 1997, J CLIN INVEST, V99, P953, DOI 10.1172/JCI119260; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6; ELSAADANI M, 1989, J LIPID RES, V30, P627; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; HOFF HF, 1983, HDB ELECTROPHORESIS, V3, P133; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; IVANDIC B, 1996, CIRCULATION, V94, P152; KAARTINEN M, 1994, ARTERIOSCLER THROMB, V14, P966, DOI 10.1161/01.ATV.14.6.966; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; KREUZER J, 1994, CHEM PHYS LIPIDS, V67-8, P175, DOI 10.1016/0009-3084(94)90137-6; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; MAROUDAS A, 1988, BIOPHYS CHEM, V32, P257, DOI 10.1016/0301-4622(88)87012-1; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; Menkin V, 1934, AM J PATHOL, V10, P193; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PORTMAN OW, 1970, J LIPID RES, V11, P23; PREISS J, 1986, J BIOL CHEM, V261, P8597; PUHL H, 1994, METHOD ENZYMOL, V233, P425; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; Rigoli L, 1995, ACTA DIABETOL, V32, P251, DOI 10.1007/BF00576258; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHNEIDER EG, 1976, BIOCHIM BIOPHYS ACTA, V441, P201, DOI 10.1016/0005-2760(76)90163-6; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHWENKE DC, 1989, ARTERIOSCLEROSIS, V9, P895, DOI 10.1161/01.ATV.9.6.895; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SMITH EB, 1979, ADV EXP MED BIOL, V115, P245; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SRIPADA PK, 1987, J LIPID RES, V28, P710; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; Tsukamoto Y, 1996, J CLIN INVEST, V98, P1930, DOI 10.1172/JCI118994; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	70	256	266	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2738	2746		10.1074/jbc.273.5.2738	http://dx.doi.org/10.1074/jbc.273.5.2738			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446580	hybrid			2022-12-27	WOS:000071736600035
J	Marians, KJ; Hiasa, H; Kim, DR; McHenry, CS				Marians, KJ; Hiasa, H; Kim, DR; McHenry, CS			Role of the core DNA polymerase III subunits at the replication fork - alpha is the only subunit required for processive replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; ONE HOLOENZYME PARTICLE; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; EPSILON-SUBUNIT; SLIDING CLAMPS; THETA-SUBUNIT; BETA-SUBUNIT; PHI-X174-TYPE PRIMOSOME; SALMONELLA-TYPHIMURIUM	The DNA polymerase III holoenzyme is composed of 10 subunits. The core of the polymerase contains the catalytic polymerase subunit, alpha, the proofreading 3' --> 5' exonuclease, epsilon, and a subunit of unknown function, theta. The availability of the holoenzyme subunits in purified form has allowed us to investigate their roles at the replication fork. We show here that of the three subunits in the core polymerase, only alpha is required to form processive replication forks that move at high rates and that exhibit coupled leading-and lagging-strand synthesis in vitro. Taken together with previous data this suggests that the primary determinant of replication fork processivity is the interaction between another holoenzyme subunit, tau, and the replication fork helicase, DnaB.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem Biophys & Genet, Denver, CO 80262 USA	Memorial Sloan Kettering Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Marians, KJ (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM36255, GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R01GM036255, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DEGUEN GE, 1974, J BACTERIOL, V117, P477; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P16371; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LANCY ED, 1989, J BACTERIOL, V171, P5572, DOI 10.1128/jb.171.10.5572-5580.1989; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LIFSICS MR, 1992, J BACTERIOL, V174, P6965, DOI 10.1128/JB.174.21.6965-6973.1992; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1988, J BIOL CHEM, V263, P6570; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WELCH MM, 1982, J BACTERIOL, V152, P351; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P16558; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	58	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2452	2457		10.1074/jbc.273.4.2452	http://dx.doi.org/10.1074/jbc.273.4.2452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442096	hybrid			2022-12-27	WOS:000071595200085
J	Tojo, H; Ichida, T; Okamoto, M				Tojo, H; Ichida, T; Okamoto, M			Purification and characterization of a catalytic domain of rat intestinal phospholipase B/lipase associated with brush border membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; SUBSTRATE-SPECIFICITY; GUINEA-PIG; PANCREATIC LIPASE; MECHANISM; SPLEEN; A(2); LYSOPHOSPHOLIPASE; IDENTIFICATION; SIMILARITY	A brush border membrane-associated phospholipase B/lipase was solubilized from the distal two-thirds of rat small intestine by autolysis during storage at -35 degrees C over 1 month, and then the enzyme was purified to homogeneity and characterized enzymatically and structurally, The purified enzyme exhibited broad substrate specificity including esterase, phospholipase A(2), lysophospholipase, and lipase activities. SDS-gel electrophoretic and reverse-phase high performance liquid chromatographic analyses demonstrated that a single enzyme catalyzes these activities. It preferred hydrolysis at the sn-2 position of diacylphospholipid and diacylglycerol without strict stereoselectivity, whereas it apparently exhibited no positional specificity toward triacylglycerol. Diisopropyl fluorophosphate, an irreversible inhibitor of serine esterases and lipases, inhibited purified enzyme, When the position of enzyme on SDS-gel electrophoresis under the non-reducing conditions was determined by assaying the activity eluted from sliced gels, brush border membrane-associated enzyme corresponded to a similar to 150-kDa protein; autolysis gave a 35-kDa product, in agreement with the results of immunoblot analysis, The purified 35-kDa enzyme consisted of a 14-kDa peptide and a glycosylated 21-kDa peptide. Their NH2-terminal amino acid sequences were determined and found in the second repeat of 161-kDa phospholipase B/lipase with 4-fold tandem repeats of similar to 38 kDa each, which we cloned and sequenced in the accompanying paper (Takemori, H., Zolotaryov, F,, Ting, L., Urbain, T,, Komatsubara, T., Hatano, O., Okamoto, M,, and Tojo, H. (1998) J. Biol. Chem. 273, 2222-2231). These results indicate that the purified enzyme is the catalytic domain derived from the second repeat of brush border membrane-associated phospholipase B/lipase.	Osaka Univ, Sch Med, Dept Mol Physiol Chem, Suita, Osaka 565, Japan	Osaka University	Tojo, H (corresponding author), Osaka Univ, Sch Med, Dept Mol Physiol Chem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	htojo@mr-mbio.med.osaka-u.ac.jp						ALPERS DH, 1994, PHYSL GASTROINTESTIN, V2, P1723; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOLL W, 1993, J BIOL CHEM, V268, P12901; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHO HS, 1993, J BIOL CHEM, V268, P9238; Cohen J.A., 1967, METHODS ENZYMOLOGY, P686; CREER MH, 1985, LIPIDS, V20, P922, DOI 10.1007/BF02534778; CYGLER M, 1994, J AM CHEM SOC, V116, P3180, DOI 10.1021/ja00087a002; FIELD RB, 1983, J BIOL CHEM, V258, P4563; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GIDEZ LI, 1968, J LIPID RES, V9, P794; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; HIDE WA, 1992, J LIPID RES, V33, P167; HILTON S, 1991, J BIOL CHEM, V266, P997; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; INADA M, 1991, EUR J BIOCHEM, V197, P323, DOI 10.1111/j.1432-1033.1991.tb15914.x; JENSEN GL, 1981, ANAL BIOCHEM, V113, P246, DOI 10.1016/0003-2697(81)90073-7; KUUSI T, 1979, MED BIOL, V57, P192; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDS WEM, 1963, J BIOL CHEM, V238, P898; MATTSON FH, 1966, J LIPID RES, V7, P536; PARKIN SM, 1982, BIOCHEM J, V207, P485, DOI 10.1042/bj2070485; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; PIND S, 1989, LIPIDS, V24, P357, DOI 10.1007/BF02535141; Pinkus L M, 1981, Methods Enzymol, V77, P154; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; Sato T, 1997, J BIOL CHEM, V272, P2192; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SHIAU YF, 1987, PHYSL GASTROINTESTIN, P1527; SLOTBOOM AJ, 1970, CHEM PHYS LIPIDS, V4, P15, DOI 10.1016/0009-3084(70)90059-9; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; Takemori H, 1998, J BIOL CHEM, V273, P2222, DOI 10.1074/jbc.273.4.2222; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; THIRSTRUP K, 1994, BIOCHEMISTRY-US, V33, P2748, DOI 10.1021/bi00176a002; TIM TS, 1997, J BIOL CHEM, V272, P2542; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TOJO H, 1991, METHOD ENZYMOL, V197, P390; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOJO H, 1993, J LIPID RES, V34, P837; UPTON C, 1995, TRENDS BIOCHEM SCI, V20, P178, DOI 10.1016/S0968-0004(00)89002-7; VAHOUNY GV, 1964, ARCH BIOCHEM BIOPHYS, V107, P7, DOI 10.1016/0003-9861(64)90262-0; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; Wacker H, 1997, BIOCHEMISTRY-US, V36, P3336, DOI 10.1021/bi962398a; WithersMartinez C, 1996, STRUCTURE, V4, P1363, DOI 10.1016/S0969-2126(96)00143-8	53	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2214	2221		10.1074/jbc.273.4.2214	http://dx.doi.org/10.1074/jbc.273.4.2214			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442064	hybrid			2022-12-27	WOS:000071595200053
J	Brenneisen, P; Wenk, J; Klotz, LO; Wlaschek, M; Briviba, K; Krieg, T; Sies, H; Scharffetter-Kochanek, K				Brenneisen, P; Wenk, J; Klotz, LO; Wlaschek, M; Briviba, K; Krieg, T; Sies, H; Scharffetter-Kochanek, K			Central role of ferrous/ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; MURINE SKIN FIBROBLASTS; FREE-RADICAL REACTIONS; EXPOSURE IN-VITRO; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; GENE-EXPRESSION; OZONE DEPLETION; TRANSCRIPTIONAL ACTIVATION; 5'-FLANKING REGION	Reactive oxygen species (ROS) are important second messengers for the induction of several genes in a variety of physiological and pathological conditions. Ultraviolet B (UVB) irradiation has recently been shown to generate lipid peroxidation products and hydroxyl radicals (HO.) with detrimental long term effects like cancer formation and premature aging of the skin, Here, we addressed the question of whether ferric/ferrous iron via the generation of ROS may mediate the UVB response, finally leading to connective tissue degradation, a hallmark in carcinogenesis and aging. Therefore, we studied the involvement of iron and ROS in the modulation of Jun N-terminal kinase 2 (JNK2) activity, c-jun and c-fos mRNA levels, key signaling steps in the transcriptional control of matrix-degrading metalloprotease (MMP)-1/interstitial collagenase and MMP-3/stromelysin-1 after-UVB irradiation of human dermal fibroblasts in vitro. The iron-driven generation of lipid peroxides and hydroxyl radicals were identified as early events in the downstream signaling pathway of the UVB response leading to a 15-fold increase in JNK2 activity, a 3.5-fold increase in c-jun, to a 6-fold increase in MMP-1, and a 3.8-fold increase in MMP-3 mRNA levels, while virtually no alteration of c-fos mRNA levels were observed. Diminished generation of reactive oxygen species resulted in a significant reduction of JNK2 activity, c-jun, MMP-1, and MMP-3 mRNA levels after WE irradiation compared with UVB-irradiated cells. Collectively, we have identified the iron-driven Fenton reaction and lipid peroxidation as possible central mechanisms underlying signal transduction of the UVB response.	Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Dusseldorf, Inst Physiol Chem 1, D-40225 Dusseldorf, Germany	University of Cologne; Heinrich Heine University Dusseldorf	Scharffetter-Kochanek, K (corresponding author), Univ Cologne, Dept Dermatol, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.		Sies, Helmut/B-7266-2008; Klotz, Lars Oliver/AAC-5051-2019; Sies, Helmut/ABE-7355-2020	Sies, Helmut/0000-0002-1000-3198; Klotz, Lars Oliver/0000-0002-1261-8911; Briviba, Karlis/0000-0003-3338-7515				Aalto K, 1996, TOXICOL LETT, V85, P93, DOI 10.1016/0378-4274(96)03645-4; Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; ALCANTARA O, 1994, BLOOD, V84, P3510; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1985, J CELL BIOCHEM, V29, P351, DOI 10.1002/jcb.240290408; Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; BABBS CF, 1990, FREE RADICAL BIO MED, V8, P471, DOI 10.1016/0891-5849(90)90060-V; BAYREUTHER K, 1992, ARCH GERONTOL GERIAT, P47, DOI 10.1016/S0167-4943(05)80006-8; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BIEMOND P, 1988, FREE RADICAL BIO MED, V4, P185, DOI 10.1016/0891-5849(88)90026-3; BISSETT DL, 1991, PHOTOCHEM PHOTOBIOL, V54, P215, DOI 10.1111/j.1751-1097.1991.tb02009.x; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; Brenneisen P, 1996, PHOTOCHEM PHOTOBIOL, V64, P649, DOI 10.1111/j.1751-1097.1996.tb03119.x; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; BRENNEISEN P, 1994, EXP CELL RES, V211, P219, DOI 10.1006/excr.1994.1081; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; BURDON RH, 1989, FREE RADICAL RES COM, V7, P149, DOI 10.3109/10715768909087937; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CHEESEMAN KH, 1993, DNA FREE RADICALS, P109; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DEAN RT, 1994, FREE RADICAL RES, V20, P83, DOI 10.3109/10715769409147506; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1996, J INVEST DERMATOL, V107, P7; FLEISCHMAJER R, 1981, J INVEST DERMATOL, V76, P400, DOI 10.1111/1523-1747.ep12520933; GAIRE M, 1994, J BIOL CHEM, V269, P2032; Garmyn M, 1997, J PHOTOCH PHOTOBIO B, V37, P125, DOI 10.1016/S1011-1344(96)07340-X; GILCHREST BA, 1989, J AM ACAD DERMATOL, V21, P610, DOI 10.1016/S0190-9622(89)70227-9; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HANTZE MW, 1995, INDUCIBLE GENE EXPRE, V1, P241; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IIZAWA O, 1994, ARCH DERMATOL RES, V286, P47, DOI 10.1007/BF00375843; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON RA, 1992, J PHOTOCH PHOTOBIO B, V14, P345, DOI 10.1016/1011-1344(92)85113-9; Lee SF, 1996, FREE RADICAL BIO MED, V21, P437, DOI 10.1016/0891-5849(96)00040-8; LIN F, 1993, ARCH BIOCHEM BIOPHYS, V300, P714, DOI 10.1006/abbi.1993.1099; LLOYD SA, 1993, LANCET, V342, P1156, DOI 10.1016/0140-6736(93)92130-L; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; MAJMUDAR G, 1994, MOL CARCINOGEN, V9, P17, DOI 10.1002/mc.2940090105; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; MASAKI H, 1995, J DERMATOL SCI, V10, P25, DOI 10.1016/0923-1811(95)93711-9; MELEFORS O, 1993, BLOOD REV, V7, P251, DOI 10.1016/0268-960X(93)90012-S; MELLO AC, 1984, BIOCHIM BIOPHYS ACTA, V781, P56, DOI 10.1016/0167-4781(84)90123-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MINOTTI G, 1992, LIPIDS, V27, P219, DOI 10.1007/BF02536182; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OSHIRO S, 1994, J BIOCHEM-TOKYO, V115, P849, DOI 10.1093/oxfordjournals.jbchem.a124428; Perez S., 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P453; PETERSEN MJ, 1992, J INVEST DERMATOL, V99, P440, DOI 10.1111/1523-1747.ep12616142; PIETARINEN P, 1995, AM J RESP CELL MOL, V13, P434, DOI 10.1165/ajrcmb.13.4.7546773; RIAZULHAQ, 1995, EXP HEMATOL, V23, P428; Sawamura D, 1996, ARCH DERMATOL RES, V288, P628, DOI 10.1007/s004030050115; SCHAICH KM, 1992, LIPIDS, V27, P209, DOI 10.1007/BF02536181; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; SCHARFFETTERKOC.K, 1992, ENV THREAT SKIN, P72; SCHARFFETTERKOCHANEK K, 1993, FEBS LETT, V331, P304, DOI 10.1016/0014-5793(93)80357-Z; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; Slaper H, 1996, NATURE, V384, P256, DOI 10.1038/384256a0; Spear N, 1995, ARCH BIOCHEM BIOPHYS, V324, P111, DOI 10.1006/abbi.1995.9921; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANLENTEN BJ, 1995, J CLIN INVEST, V95, P2104, DOI 10.1172/JCI117898; WLASCHEK M, 1995, J INVEST DERMATOL, V104, P194, DOI 10.1111/1523-1747.ep12612751; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; ZENG LH, 1995, CORNEA, V14, P509	83	178	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5279	5287		10.1074/jbc.273.9.5279	http://dx.doi.org/10.1074/jbc.273.9.5279			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478985	hybrid			2022-12-27	WOS:000072310400069
J	Huang, SS; Huang, JS				Huang, SS; Huang, JS			A pentacosapeptide (CKS-25) homologous to retroviral envelope proteins possesses a transforming growth factor-beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA-2; RECEPTORS; PEPTIDE	CKS-17, a synthetic heptadecapeptide homologous to a conserved domain in retroviral envelope protein p15E, mimics the immunosuppressive properties of p15E in vitro and in vivo, but the mechanisms are not understood. Here we report that a synthetic pentacosapeptide designated CKS-25, a longer version of CKS-17 that contains a functional transforming growth factor-beta(3) (TGF-beta(3)) active-site motif (RXXD), inhibits I-125-labeled TGF-beta(1) (I-125-TGF-beta(1)) binding to cell-surface TGF-beta receptors in cultured epithelial cells. Multiple conjugation of CKS-25 to bovine serum albumin and carbonic anhydrase enhances the I-125-TGF-beta(1) binding inhibitory activity and confers a partial TGF-beta agonist activity (growth inhibition but not transcriptional activation). Since TGF-beta is a potent immunosuppressive factor, these results suggest that the immunosuppressive properties of CKS-17-bovine serum albumin conjugate and p15E are mediated at least in part by their TGF-beta agonist activities.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NCI NIH HHS [CA 38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DENNER J, 1994, AIDS, V8, P1063, DOI 10.1097/00002030-199408000-00005; ELDER JH, 1983, J VIROL, V46, P871, DOI 10.1128/JVI.46.3.871-880.1983; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; HARAGUCHI S, 1995, P NATL ACAD SCI USA, V92, P3611, DOI 10.1073/pnas.92.8.3611; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LIU QJ, 1994, J BIOL CHEM, V269, P9221; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OOSTENDORP RAJ, 1993, CRIT REV ONCOL HEMAT, V14, P189, DOI 10.1016/1040-8428(93)90009-S; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, P410; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	20	7	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4815	4818		10.1074/jbc.273.9.4815	http://dx.doi.org/10.1074/jbc.273.9.4815			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478918	hybrid			2022-12-27	WOS:000072310400002
J	Moestrup, SK; Kozyraki, R; Kristiansen, M; Kaysen, JH; Rasmussen, HH; Brault, D; Pontillon, F; Goda, FO; Christensen, EI; Hammond, TG; Verroust, PJ				Moestrup, SK; Kozyraki, R; Kristiansen, M; Kaysen, JH; Rasmussen, HH; Brault, D; Pontillon, F; Goda, FO; Christensen, EI; Hammond, TG; Verroust, PJ			The intrinsic factor vitamin B-12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-COBALAMIN; YOLK-SAC; BRUSH-BORDER; ENDOCYTOSIS; DOMAIN; SPERMADHESINS; COMPLEXES; CELLS; GP330; MALABSORPTION	The present report shows the molecular characterization of the rat 460-kDa epithelial glycoprotein that functions as the receptor facilitating uptake of intrinsic factor-vitamin B-12 complexes in the intestine and kidney, The same receptor represents also the yolk sac target for teratogenic antibodies causing fetal malformations in rats, Determination of its primary structure by cDNA cloning identified a novel type of peripheral membrane receptor characterized by a cluster of eight epidermal growth factor type domains followed by a cluster of 27 CUB domains, In accordance with the absence of a hydrophobic segment, the receptor could be released from renal cortex membranes by nonenzymatic and nonsolubilizing procedures, The primary structure has no similarity to known endocytic receptors but displays homology to epidermal growth factor and CUB domain proteins involved in fetal development, e.g. the bone morphogenic proteins, Electron microscopic immunogold double labeling of rat yolk sec and renal proximal tubules demonstrated subcellular colocalization with the endocytic receptor megalin, which is expressed in the same epithelia as the 460-kDa receptor, Furthermore, megalin affinity chromatography and surface plasmon resonance analysis revealed a calcium-dependent high affinity binding of the 460-kDa receptor to megalin, which thereby may mediate its vesicular trafficking. Due to the high number of CUB domains, accounting for 88% of the protein mass, we propose the name cubilin for the novel receptor.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Hop Tenon, INSERM, U489, F-75020 Paris, France; Tulane Univ, Med Ctr, New Orleans, LA 70112 USA; Tulane Univ, Astrobiol Ctr, New Orleans, LA 70112 USA; Vet Affairs Med Ctr, New Orleans, LA 70112 USA; Hop Tenon, Dept Biochim, F-75020 Paris, France; Aarhus Univ, Inst Anat, Dept Cell Biol, DK-8000 Aarhus C, Denmark	Aarhus University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Tulane University; Tulane University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Aarhus University	Moestrup, SK (corresponding author), Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark.		Moestrup, Søren Kragh/A-1403-2014; Kozyraki, Renata/G-5321-2017; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Madsen, Mette/0000-0001-7241-6505; Kozyraki, Renata/0000-0001-9779-5898	NIDDK NIH HHS [DK46117] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046117] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beckman DA, 1997, INT J DEV BIOL, V41, P315; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRENT RL, 1961, P SOC EXP BIOL MED, V106, P523, DOI 10.3181/00379727-106-26390; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; Calvete JJ, 1996, BIOL CHEM, V377, P521, DOI 10.1515/bchm3.1996.377.7-8.521; Calvete JJ, 1997, FEBS LETT, V407, P201, DOI 10.1016/S0014-5793(97)00344-X; CHRISTENSEN EI, 1995, EUR J CELL BIOL, V66, P349; COTTER R, 1976, BRIT J HAEMATOL, V34, P477, DOI 10.1111/j.1365-2141.1976.tb03594.x; DAN N, 1994, J BIOL CHEM, V269, P18849; DAVIS C G, 1990, New Biologist, V2, P410; Dias JM, 1997, PROTEIN SCI, V6, P725; DOSTALOVA Z, 1995, BIOL CHEM H-S, V376, P237, DOI 10.1515/bchm3.1995.376.4.237; FYFE JC, 1991, J BIOL CHEM, V266, P4489; GRASBECK R, 1960, ACTA MED SCAND, V167, P289; GUEANT JL, 1995, GASTROENTEROLOGY, V108, P1622, DOI 10.1016/0016-5085(95)90122-1; HAMMOND TG, 1994, AM J PHYSIOL, V266, pF554, DOI 10.1152/ajprenal.1994.266.4.F554; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1997, NAT GENET, V15, P122; IADANATO SP, 1993, BIOCHEM J, V296, P867; IMERSLUND O, 1960, Acta Paediatr Suppl, V49(Suppl 119), P1; JENSEN PH, 1992, FEBS LETT, V29, P129; LEPANSE S, 1995, EUR J CELL BIOL, V67, P120; LePanse S, 1997, EUR J CELL BIOL, V72, P257; LEPANSE S, 1994, AM J PATHOL, V145, P1526; LEUNG CCK, 1982, J EXP MED, V156, P372, DOI 10.1084/jem.156.2.372; Levy D, 1996, Essays Biochem, V31, P49; Llirbat B, 1997, J LIPID RES, V38, P22; LLOYD JB, 1990, TERATOLOGY, V41, P383, DOI 10.1002/tera.1420410404; Menendez M, 1995, EUR J BIOCHEM, V234, P887, DOI 10.1111/j.1432-1033.1995.887_a.x; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; Moestrup SK, 1996, P NATL ACAD SCI USA, V93, P8612, DOI 10.1073/pnas.93.16.8612; NEXO E, 1977, BIOCHIM BIOPHYS ACTA, V494, P395, DOI 10.1016/0005-2795(77)90168-4; NUKJAER A, 1997, EMBO J, V16, P2610; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Romero A, 1996, FEBS LETT, V382, P15, DOI 10.1016/0014-5793(96)00133-0; ROTHENBERG SP, 1968, J CLIN INVEST, V47, P913, DOI 10.1172/JCI105783; SAHALI D, 1988, J EXP MED, V167, P213, DOI 10.1084/jem.167.1.213; SAHALI D, 1993, AM J PATHOL, V142, P1654; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SEETHARAM B, 1981, J BIOL CHEM, V256, P3785; Seetharam B, 1997, J CLIN INVEST, V99, P2317, DOI 10.1172/JCI119411; SEETHARAM B, 1988, J BIOL CHEM, V263, P4443; SEETHARAM B, 1994, ADV T ADDISONS DIS, V2, P393; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; YANG Y, 1985, J CLIN INVEST, V76, P2057, DOI 10.1172/JCI112208	52	206	213	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5235	5242		10.1074/jbc.273.9.5235	http://dx.doi.org/10.1074/jbc.273.9.5235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478979	hybrid			2022-12-27	WOS:000072310400063
J	Remy, E; de Rocquigny, H; Petitjean, P; Muriaux, D; Theilleux, V; Paoletti, J; Roques, BP				Remy, E; de Rocquigny, H; Petitjean, P; Muriaux, D; Theilleux, V; Paoletti, J; Roques, BP			The annealing of tRNA(3)(Lys) to human immunodeficiency virus type 1 primer binding site is critically dependent on the NCp7 zinc fingers structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 NUCLEOCAPSID PROTEIN; MURINE LEUKEMIA-VIRUS; GENOMIC RNA; H-1-NMR; ELEMENTS; RETROVIRUSES; DIMERIZATION; INFECTIVITY; SEQUENCE; PEPTIDES	The nucleocapsid protein NCp7 of the human immunodeficiency virus type 1 contains two zinc fingers of the CX2CX4HX4C type, flanked by several basic residues, and plays a major role in viral infectivity. Thus, NCp7 was shown to promote annealing of the tRNA(3)(Lys) to the primer binding site, a key step in reverse transcription. However; previous in vitro experiments were unable to clarify the role of the zinc fingers in this process, due to nucleic acid aggregation induced by the basic N- and C-terminal domains of NCp7. We show here that deletion of these sequences in (12-53)NCp7 strongly reduces the formation of aggregates and allows a direct visualization of the binary or ternary complexes between NCp7 and nucleic acids by gel electrophoresis. (12-53)NCp7 is able to induce hybridization of the P-33 tRNA(3)(Lys) and the human immunodeficiency virus type 1 viral RNA-(77-257), which contains the primer binding site. Modification of the proximal zinc finger conformation in Cys(23)(12-53)NCp7 led to a large reduction in this hybridization process, while replacement of Trp(37) by Leu in the distal zinc fingers resulted in a complete absence of annealing activity. These data account for the in vivo loss of viral infectivity following these mutations and emphasize the critical role of the structure of the zinc finger domain of NCp7. This could facilitate a rational approach to new antiviral agents directed toward NCp7.	UFR Sci Pharmaceut, CNRS, URA D1500,Dept Pharmacochim Mol & Struct, INSERM,U266,Unite Pharmacochim Mol & Struct, F-75270 Paris 06, France; Inst Gustave Roussy, CNRS, URA 147, Lab Pharmacol & Physicochim Macromol, F-94805 Villejuif, France; Inst Pasteur, Dept Biochim & Genet Mol, CNRS URA 487, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Roques, BP (corresponding author), UFR Sci Pharmaceut, CNRS, URA D1500,Dept Pharmacochim Mol & Struct, INSERM,U266,Unite Pharmacochim Mol & Struct, 4 Ave Observatoire, F-75270 Paris 06, France.							ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERKOWITZ RD, 1994, VIROLOGY, V202, P233, DOI 10.1006/viro.1994.1339; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; COFFIN JM, 1990, RETROVIRIDAE THEIR R, V51, P1437; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GORELICK RJ, 1996, RETROVIRUSES 1996S R, P356; Huang Y, 1997, J VIROL, V71, P4378, DOI 10.1128/JVI.71.6.4378-4384.1997; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Khan R, 1996, NUCLEIC ACIDS RES, V24, P3568, DOI 10.1093/nar/24.18.3568; LAM WC, 1994, BIOCHEMISTRY-US, V33, P10693, DOI 10.1021/bi00201a017; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V21, P831; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; MELY Y, 1991, BIOPOLYMERS, V31, P899, DOI 10.1002/bip.360310709; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; Roques BP, 1997, BIOCHIMIE, V79, P673, DOI 10.1016/S0300-9084(97)83501-8; Stoylov SP, 1997, BIOPOLYMERS, V41, P301, DOI 10.1002/(SICI)1097-0282(199703)41:3&lt;301::AID-BIP5&gt;3.0.CO;2-W; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; VANBEVEREN C, 1984, RNA TUMOR VIRUSES, V2, P559; VERONESE FD, 1987, AIDS RES HUM RETROV, V3, P253, DOI 10.1089/aid.1987.3.253; Yu QA, 1996, J VIROL, V70, P5791, DOI 10.1128/JVI.70.9.5791-5798.1996	36	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4819	4822		10.1074/jbc.273.9.4819	http://dx.doi.org/10.1074/jbc.273.9.4819			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478919	hybrid			2022-12-27	WOS:000072310400003
J	Zhang, LY; Savas, U; Alexander, DL; Jefcoate, CR				Zhang, LY; Savas, U; Alexander, DL; Jefcoate, CR			Characterization of the mouse Cyp1B1 gene - Identification of an enhancer region that directs aryl hydrocarbon receptor-mediated constitutive and induced expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIN-RESPONSIVE ENHANCER; POLYCYCLIC AROMATIC-HYDROCARBONS; NEGATIVE REGULATORY ELEMENT; CELL-SPECIFIC EXPRESSION; STEROIDOGENIC FACTOR-I; HEAT-SHOCK PROTEIN; AH-RECEPTOR; NUCLEAR TRANSLOCATOR; CYTOCHROME-P450 GENE; MUTATIONAL ANALYSIS	Transcriptional activation of the Cyp1B1 gene in rodents is stimulated by both polycyclic hydrocarbons and cAMP. The mouse Cyp1B1 gene structure contains three exons, of which the second nucleotide of exon 2 is the translation start site, Primer extension analysis identified a transcription start domain defining an exon 1 of 371 base pairs, The sequence 1.075 kilobases upstream of the transcription start site showed 11 xenobiotic-responsive elements (XRE) (T(n)GCGTG or GCGTG) that are putative aryl hydrocarbon receptor (AhR)-binding sites and three steroidogenic factor-1 motifs that are associated with cAMP-mediated transcriptional activation of genes, A transiently transfected Cyp1B1-luciferase construct, composed of exon 1 and 1.075 kilobases of 5'-flanking region, was induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; 10.0 +/- 3.0-fold, n = 6) in C3H10T1/2 cells, which exclusively express Cyp1B1. The 90-base pair basal promoter contains two SP-l sites, one SF-l site, and a TATA-like box, TCDD induction and basal expression were dependent on positive regulatory elements present between -1075 and -810. Five XRE motifs localized in the enhancer region were completely conserved between mouse and human CYP1B1 sequences, Similar inductions were seen in Hepa-l cells, which express Cyp1A1 but not Cyp1B1. However, basal Cyp1B1 promoter activities were 4-10-fold higher in C3H10T1/2 cells providing the enhancer region was present, partially reproducing the in vivo cell-specific expression of Cyp1B1. Gel shift experiments established that TCDD stimulates AhR binding to the downstream XRE in the enhancer region, However, oligonucleotides that encompass two other XREs show a high affinity complex of similar size that is evident even without TCDD treatment and that does not contain either the AhR or AhR nuclear translocator, The fourth XRE is immediately adjacent to an E-box, and this oligonucleotide formed a smaller complex that was dependent on this E-box sequence, Negative regulatory sequences have been located between the promoter and TCDD-responsive enhancer regions, Constitutive expression of the Cyp1B1 gene was lost in AhR-deficient cells and was restored by transfected AhR cDNA. Reporter constructs function in a parallel manner, demonstrating the key role of the AhR in constitutive as well as TCDD-induced expression of Cyp1B1 in mouse embryo fibroblasts.	Univ Wisconsin, Med Sci Ctr, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Jefcoate, CR (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	jefcoate@facstaff.wisc.edu			NCI NIH HHS [CA 16265] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016265] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander DL, 1997, CANCER RES, V57, P4498; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; BHATTACHARYYA KK, 1995, J BIOL CHEM, V270, P11595, DOI 10.1074/jbc.270.19.11595; BOUCHER PD, 1993, J BIOL CHEM, V268, P17384; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; BRADLEY JE, 1988, BIOTECHNIQUES, V2, P114; BRAKE PB, 1995, ENDOCRINOLOGY, V136, P5034, DOI 10.1210/en.136.11.5034; CHRISTOU M, 1995, MOL CELL ENDOCRINOL, V115, P41, DOI 10.1016/0303-7207(95)03668-W; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FISHER JM, 1990, J BIOL CHEM, V265, P9676; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUO IC, 1994, J BIOL CHEM, V269, P6362; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; JAIN S, 1994, J BIOL CHEM, V269, P31518; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; JUANG HH, 1995, J BIOL CHEM, V270, P12629, DOI 10.1074/jbc.270.21.12629; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LI H, 1994, J BIOL CHEM, V269, P28098; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NEUHOLD LA, 1986, DNA-J MOLEC CELL BIO, V5, P403, DOI 10.1089/dna.1986.5.403; NOCERA PPD, 1983, P NATL ACAD SCI USA, V80, P7095; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; OTTO S, 1992, ENDOCRINOLOGY, V131, P3067, DOI 10.1210/en.131.6.3067; Parker KL, 1996, TRENDS ENDOCRIN MET, V7, P203, DOI 10.1016/1043-2760(96)00105-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Pollenz RS, 1996, MOL PHARMACOL, V49, P391; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROBERTSON RW, 1994, NUCLEIC ACIDS RES, V22, P1741, DOI 10.1093/nar/22.9.1741; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAS U, 1993, CARCINOGENESIS, V14, P2013, DOI 10.1093/carcin/14.10.2013; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SAVAS U, 1994, MOL PHARMACOL, V45, P1153; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SHEN ZY, 1993, P NATL ACAD SCI USA, V90, P11483, DOI 10.1073/pnas.90.24.11483; SHEN ZY, 1994, DNA CELL BIOL, V13, P763, DOI 10.1089/dna.1994.13.763; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; Tang WM, 1996, J BIOL CHEM, V271, P28324, DOI 10.1074/jbc.271.45.28324; TOUSSAINT C, 1994, J BIOL CHEM, V269, P13318; Walsh AA, 1996, J BIOL CHEM, V271, P22746, DOI 10.1074/jbc.271.37.22746; WATANABE N, 1993, EUR J BIOCHEM, V214, P521, DOI 10.1111/j.1432-1033.1993.tb17950.x; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; WEISINGER G, 1992, J BIOL CHEM, V267, P4508; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; Wo YYP, 1997, J BIOL CHEM, V272, P26702, DOI 10.1074/jbc.272.42.26702	63	115	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5174	5183		10.1074/jbc.273.9.5174	http://dx.doi.org/10.1074/jbc.273.9.5174			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478971	hybrid			2022-12-27	WOS:000072310400055
J	Zhu, XD; Sadowski, PD				Zhu, XD; Sadowski, PD			The role of single-stranded DNA in Flp-mediated strand exchanged	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; 2-MU-M CIRCLE PLASMID; SACCHAROMYCES-CEREVISIAE; TARGET SEQUENCE; HOLLIDAY JUNCTIONS; INTEGRASE FAMILY; BINDING DOMAIN; CHI-STRUCTURES; PROTEIN; LIGATION	The Flp recognition target site contains two inverted 13-base pair (bp) Flp binding sequences that surround an 8-bp core region. Flp recombinase has been shown to carry out strand ligation independently of its ability to execute strand cleavage. Using a synthetic activated DNA substrate bearing a S'-phosphotyrosine group, we have developed an assay to measure strand exchange by Flp proteins. We have shown that wild-type Flp protein was able to catalyze strand exchange using DNA substrates containing 8-bp duplex core sequences. Mutant Flp proteins that are defective in either DNA bending or DNA cleavage were also impaired in their abilities to carry out strand exchange. The inability of these mutant proteins to execute strand exchange could be overcome by providing a DNA substrate containing a single-stranded core sequence. This single-stranded core sequence could be as small as 3 nucleotides. Full activity of mutant Flp proteins in strand exchange was observed when both partner DNAs contained an 8-nucleotide single-stranded core region. Using suicide substrates, we showed that single-stranded DNA is also important for strand exchange reactions where Pip-mediated strand cleavage is required. These results suggest that the ability of Flp to induce DNA bending and strand cleavage may be crucial for strand, exchange. We propose that both DNA bending and strand cleavage may be required to separate the strands of the core region and that single-stranded DNA in the core region might be an intermediate in Pip-mediated DNA recombination.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Sadowski, PD (corresponding author), Univ Toronto, Dept Mol & Med Genet, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	P.Sadowski@utoronto.ca		Zhu, Xu-Dong/0000-0003-1859-3134				ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; AMIN AA, 1989, MOL CELL BIOL, V9, P1987, DOI 10.1128/MCB.9.5.1987; AMIN AA, 1990, J MOL BIOL, V214, P55, DOI 10.1016/0022-2836(90)90146-D; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; DIXON JE, 1995, MOL MICROBIOL, V18, P449, DOI 10.1111/j.1365-2958.1995.mmi_18030449.x; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; DIXON JE, 1993, J MOL BIOL, V234, P522, DOI 10.1006/jmbi.1993.1608; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FUTCHER AB, 1986, J THEOR BIOL, V119, P197, DOI 10.1016/S0022-5193(86)80074-1; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P2320; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1995, J BIOL CHEM, V270, P4042, DOI 10.1074/jbc.270.8.4042; Luetke KH, 1997, NUCLEIC ACIDS RES, V25, P4240, DOI 10.1093/nar/25.21.4240; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; PAN G, 1993, THESIS U TORONTO; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN GH, 1992, J BIOL CHEM, V267, P12397; PAN GH, 1993, J BIOL CHEM, V268, P3683; PAN H, 1991, J BIOL CHEM, V266, P11347; PANIGRAHI GB, 1992, NUCLEIC ACIDS RES, V20, P5927, DOI 10.1093/nar/20.22.5927; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; PROTEAU G, 1986, NUCLEIC ACIDS RES, V14, P4787, DOI 10.1093/nar/14.12.4787; REYNOLDS AE, 1987, MOL CELL BIOL, V7, P3566, DOI 10.1128/MCB.7.10.3566; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; VOLKERT FC, 1986, CELL, V46, P541, DOI 10.1016/0092-8674(86)90879-2; ZHU XD, 1995, J BIOL CHEM, V270, P11646, DOI 10.1074/jbc.270.19.11646; ZHU XD, 1995, J BIOL CHEM, V270, P23044, DOI 10.1074/jbc.270.39.23044	46	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4921	4927		10.1074/jbc.273.9.4921	http://dx.doi.org/10.1074/jbc.273.9.4921			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478936	hybrid			2022-12-27	WOS:000072310400020
J	Bochkareva, E; Frappier, L; Edwards, AM; Bochkarev, A				Bochkareva, E; Frappier, L; Edwards, AM; Bochkarev, A			The RPA32 subunit of human replication protein A contains a single-stranded DNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL DOMAINS; 70-KDA SUBUNIT; COMPLEX; PHOSPHORYLATION; EXPRESSION; POLYMERASE; INITIATION; KINASE; GENES	Replication protein A (RPA) is a conserved nuclear single-stranded DMA (ssDNA)-binding protein, Human RPA (hRPA) comprises three subunits of approximately 70, 32, and 14 kDa (hRPA70, hRPA32 and hRPA14), RPA is known to bind ssDNA through two ssDNA-binding domains in the RPA70 subunit. Here, we demonstrate that the complex of hRPA32 and hRPA14 has an ssDNA-binding domain, Limited proteolysis of the hRPA14.32 complex defined a cars dimes composed of the central region of hRPA32 (amino acids 43-171) and RPA14. The core dimes bound ssDNA with an affinity of approximately 10-50 mu M, which is at least 100-fold more avid than the DNA-binding affinity of the intact dimer. Analysis of the predicted secondary structure of hRPA32 suggests that amino acids 63-150 of hRPA32 form an ssDNA-binding domain similar in structure to each of those in hRPA70, The complex of hRPA14 and hRPA32-(43-171) in turn formed a trimeric complex with the C-terminal region of hRPA70 (amino acids 436-616), The ssDNA-binding affinity of this trimeric complex was 3 to 5-fold higher than hRPA14.32-(43-171) alone, suggesting a role far the C terminus of hRPA70 in ssDNA binding.	Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Frappier, L (corresponding author), Natl Canc Inst, Toronto, ON, Canada.	lori.frappier@utoronto.ca		Edwards, Aled/0000-0002-4782-6016				Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Iftode C, 1997, MOL CELL BIOL, V17, P3876, DOI 10.1128/MCB.17.7.3876; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; Rost B, 1996, METHOD ENZYMOL, V266, P525; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	35	96	100	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3932	3936		10.1074/jbc.273.7.3932	http://dx.doi.org/10.1074/jbc.273.7.3932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461578	hybrid			2022-12-27	WOS:000072048400020
J	Mehta, VB; Connors, L; Wang, HCR; Chiu, IM				Mehta, VB; Connors, L; Wang, HCR; Chiu, IM			Fibroblast variants nonresponsive to fibroblast growth factor 1 are defective in its nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; SIGNAL-TRANSDUCTION; MAP KINASE; FACTOR RECEPTOR; POINT MUTATION; MESODERM INDUCTION; MITOGEN; IMPORT; CELLS	Fibroblast growth factors (FGF) elicit biological effects by binding to high affinity cell-surface receptors and activation of receptor tyrosine kinase. We previously reported that two NIH/3T3 derivatives, NR31 and NR33 (NR cells), express high levels of full-length FGF-1 and exhibit a complete spectrum of transformed phenotype, In the present study, we report that NR cells respond to the mitogenic stimulation of truncated FGF-1 but not to the full-length FGF-1. Incubation of the NR cells with either form of FGF-1 resulted in its binding to cell-surface FGF receptors, activation of mitogen-activated protein (MAP) kinase, and induction of c-fos and c-myc, These data demonstrate that the FGF receptor-mediated, MAP kinase-dependent signaling pathway is not defective in the NR cells. Our data further suggest that the activation of MAP kinase in response to full-length FGF-1 is not sufficient for mitogenesis. Subcellular distribution of exogenously added FGF-1 demonstrated that full-length FGF-1 fails to translocate to the nuclei of NR31 cells, Although the full-length FGF-1 was detected in the nuclear fractions of both NIH/3T3 and NR33 cells, its half-life is much shortened in NR33 than in NIH/3T3 cells, These observations suggest that nonresponsiveness of the two NR cell lines may be due to defectiveness at different steps of nuclear translocation mechanism of FGF-1.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.	chiu.1@osu.edu	Chiu, Ing-Ming/B-1534-2008; Wang, Hwa-Chain/L-5646-2015	Wang, Hwa-Chain/0000-0001-5836-4120	NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047506] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45611] Funding Source: Medline; NIDDK NIH HHS [R01DK47506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, ONCOGENE, V8, P2015; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Patrie KM, 1997, GROWTH FACTORS, V14, P39, DOI 10.3109/08977199709021509; PATRIE KM, 1995, J BIOL CHEM, V270, P29018, DOI 10.1074/jbc.270.48.29018; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SETH A, 1991, J BIOL CHEM, V266, P23521; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; STURGILL TW, 1991, METHOD ENZYMOL, V200, P342; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270	52	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4197	4205		10.1074/jbc.273.7.4197	http://dx.doi.org/10.1074/jbc.273.7.4197			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461616	hybrid			2022-12-27	WOS:000072048400058
J	Mogridge, J; Mah, TF; Greenblatt, J				Mogridge, J; Mah, TF; Greenblatt, J			Involvement of boxA nucleotides in the formation of a stable ribonucleoprotein complex containing the bacteriophage lambda N protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ANTITERMINATION FACTORS; NUSA GENE PROTEIN; ESCHERICHIA-COLI; PHAGE-LAMBDA; RNA-POLYMERASE; ANTI-TERMINATION; RECOGNITION SITE; COLIPHAGE-LAMBDA; NUTL; SEQUENCE	The association of the transcriptional antitermination protein N of bacteriophage lambda with Escherichia coli RNA polymerase depends on nut site RNA (boxA + boxB) in the nascent transcript and the host protein, NusA. This ribonucleoprotein complex can transcribe through Rho dependent and intrinsic termination sites located up to several hundred base pairs downstream of nut. For antitermination to occur farther downstream, this core antitermination complex must be stabilized by the host proteins NusB, NusG, and ribosomal protein S10. Here, we show that the assembly of NusB, NusG, and S10 onto the core complex involves nucleotides 2-7 of lambda boxA (CGCUCUUACACA) and is a fully cooperative process that depends on the presence of all three proteins. This assembly of NusB, NusG, and S10 also requires the carboxyl-terminal region (amino acids 73-107) of N, which interacts directly with RNA polymerase. NusB and S10 assemble in the absence of NusG when lambda boxA is altered at nucleotides 8 and 9 to create a consensus version of boxA (CGCUCUUUAACA). These experiments suggest that multiple protein-protein and protein-RNA interactions are required to convert a core antitermination complex into a complete complex.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Greenblatt, J (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BARON J, 1992, J BACTERIOL, V174, P1983, DOI 10.1128/jb.174.6.1983-1989.1992; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; DAS A, 1984, CELL, V80, P5530; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; DOELLING JH, 1989, NUCLEIC ACIDS RES, V17, P5565, DOI 10.1093/nar/17.14.5565; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GODA Y, 1985, NUCLEIC ACIDS RES, V13, P2569, DOI 10.1093/nar/13.7.2569; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LI J, 1992, J BIOL CHEM, V267, P6012; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MASON SW, 1992, J BIOL CHEM, V267, P19418; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; MOGRIDGE J, 1998, IN PRESS MOL CELL; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; OLSON ER, 1982, CELL, V31, P61, DOI 10.1016/0092-8674(82)90405-6; PATTERSON TA, 1994, J MOL BIOL, V236, P217, DOI 10.1006/jmbi.1994.1131; PELTZ SW, 1985, SCIENCE, V228, P91, DOI 10.1126/science.3156406; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SULLIVAN SL, 1992, J BACTERIOL, V174, P1339, DOI 10.1128/jb.174.4.1339-1344.1992; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; WARD DF, 1983, J MOL BIOL, V168, P73, DOI 10.1016/S0022-2836(83)80323-4; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; WHALEN W A, 1990, New Biologist, V2, P975; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514	37	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4143	4148		10.1074/jbc.273.7.4143	http://dx.doi.org/10.1074/jbc.273.7.4143			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461609	hybrid			2022-12-27	WOS:000072048400051
J	Souri, M; Aoyama, T; Cox, GF; Hashimoto, T				Souri, M; Aoyama, T; Cox, GF; Hashimoto, T			Catalytic and FAD-binding residues of mitochondrial very long chain acyl-coenzyme A dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BETA-OXIDATION ENZYMES; COA DEHYDROGENASE; A DEHYDROGENASE; MOLECULAR-CLONING; PIG-KIDNEY; DEFICIENCY; PURIFICATION; IDENTIFICATION; SITE	Very long-chain acyl-CoA dehydrogenase (VLCAD) is one of four flavoproteins which catalyze the initial step of the mitochondrial beta-oxidation spiral, By sequence comparison with other acyl-CoA dehydrogenases, Glu-422 of VLCAD has been presumed to be the catalytic residue that abstracts the a-proton in the alpha beta-dehydrogenation reaction. Replacing Glu-422 with glutamine (E422Q) caused a loss of enzyme activity by preventing the formation of a charge transfer complex between VLCAD and palmitoyl-CoA. This result provides further evidence for Glu-422 being part of the active site of VLCAD, F418L is a disease-causing mutation in human VLCAD deficiency, Unlike wild-type VLCAD, F418L and F418V contained no bound FAD when expressed at extremely high levels in the baculovirus expression system, Although F418T and F418Y bound FAD at a level similar to that of wild type VLCAD, both showed reduced V-max,, values toward palmitoyl-CoA, most likely due to a decrease in the rate of enzyme-bound FAD reduction, These data suggest that Phe-418 is involved in the binding and subsequent reduction of FAD, FAD-deficient VLCADs (F418L, F418V, and apo-VLCAD) showed increased sensitivity to trypsinization. Loss of FAD may change the folding of VLCAD subunit.	Shinshu Univ, Sch Med, Dept Biochem, Nagano 390, Japan; Childrens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA	Shinshu University; Harvard University; Boston Children's Hospital	Souri, M (corresponding author), Yamagata Univ, Sch Med, Dept Mol Pathobiochem, Iida Nishi 2-2-2, Yamagata 99023, Japan.	msouri@med.id.yamagata-u.ac.jp						Andresen BS, 1996, HUM MOL GENET, V5, P461, DOI 10.1093/hmg/5.4.461; AOYAMA T, 1994, J BIOL CHEM, V269, P19088; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; AOYAMA T, 1995, AM J HUM GENET, V57, P273; AOYAMA T, 1993, BIOCHEM BIOPH RES CO, V191, P1369, DOI 10.1006/bbrc.1993.1368; AOYAMA T, 1994, BIOCHEM BIOPH RES CO, V198, P1113, DOI 10.1006/bbrc.1994.1158; Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; BERTRAND C, 1993, BIOCHIM BIOPHYS ACTA, V1180, P327, DOI 10.1016/0925-4439(93)90058-9; BROSS P, 1990, J BIOL CHEM, V265, P7116; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DJORDJEVIC S, 1994, BIOCHEMISTRY-US, V33, P4258, DOI 10.1021/bi00180a021; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; GHISLA S, 1984, BIOCHEMISTRY-US, V23, P3154, DOI 10.1021/bi00309a008; IKEDA Y, 1985, BIOCHEMISTRY-US, V24, P7192, DOI 10.1021/bi00346a027; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IZAI K, 1992, J BIOL CHEM, V267, P1027; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; NADA MA, 1995, J BIOL CHEM, V270, P530, DOI 10.1074/jbc.270.2.530; OGILVIE I, 1994, NEUROLOGY, V44, P467, DOI 10.1212/WNL.44.3_Part_1.467; SAIJO T, 1995, J BIOL CHEM, V270, P1899, DOI 10.1074/jbc.270.4.1899; Souri M, 1996, AM J HUM GENET, V58, P97; STRAUSS AW, 1995, P NATL ACAD SCI USA, V92, P10496, DOI 10.1073/pnas.92.23.10496; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; THORPE C, 1981, EUR J BIOCHEM, V118, P279; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WIELAND T, 1953, ANGEW CHEM-GER EDIT, V65, P186, DOI 10.1002/ange.19530650706; YAMAGUCHI S, 1993, PEDIATR RES, V34, P111, DOI 10.1203/00006450-199307000-00025	31	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4227	4231		10.1074/jbc.273.7.4227	http://dx.doi.org/10.1074/jbc.273.7.4227			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461620	hybrid			2022-12-27	WOS:000072048400062
J	Davis-Smyth, T; Presta, LG; Ferrara, N				Davis-Smyth, T; Presta, LG; Ferrara, N			Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor placenta growth factor receptor Flt-1 required for binding and structural stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TYROSINE KINASE; FACTOR VEGF; HUMAN CD4; IN-VIVO; ANGIOGENESIS; ANTIBODIES; SITE; VASCULOGENESIS; DETERMINANTS	Flt-1 is one of two receptor tyrosine kinases through which the angiogenic factor vascular endothelial growth factor (VEGF) functions. Placenta growth factor (P1GF) is an additional ligand for Flt-1. The second immunoglobulin-like domain in the extracellular domain of Flt-1 has previously been identified as the region containing the critical ligand-binding determinants, We analyzed the contribution of charged residues within the first three domains of Flt-1 to ligand binding by alanine scanning mutagenesis. Domain 2 residues Arg(159), Glu(208) and His(223)-Arg(224) (together) affect both VEGF and P1GF binding, while Glu(137), Lys(171), His(223), and Arg(224) affect P1GF but not VEGF. Several charged residues, especially Asp(187), are important in maintaining the structural integrity of domain 2. In addition, some residues in domain 3 contribute to binding (Asp(231)) or provide for additional discrimination between ligands (Arg(280)-Asp(283)).	Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Ferrara, N (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, San Francisco, CA 94080 USA.							Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Barleon B, 1997, J BIOL CHEM, V272, P10382; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Binnerts ME, 1996, J BIOL CHEM, V271, P9962, DOI 10.1074/jbc.271.17.9962; BLECHMAN JM, 1993, STEM CELLS, V11, P12; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NANDURI J, 1994, J NEUROSCI RES, V37, P433, DOI 10.1002/jnr.490370402; PARK JE, 1994, J BIOL CHEM, V269, P25646; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0	42	45	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3216	3222		10.1074/jbc.273.6.3216	http://dx.doi.org/10.1074/jbc.273.6.3216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452434	hybrid			2022-12-27	WOS:000071822300019
J	Du, LL; Collins, RN; Novick, PJ				Du, LL; Collins, RN; Novick, PJ			Identification of a Sec4p GTPase-activating protein (GAP) as a novel member of a Rab GAP family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PURIFICATION; HYDROLYSIS; CLONING; BINDING	A yeast open reading frame sharing homology with the two known yeast Rab GTPase-activating proteins (GAPs), Gyp6p and Gyp7p, was found in a data base search. We have named the gene containing this open reading frame GYP1. Recombinant Gyp1p showed GAP activity on Sec4p, increasing both its steady-state rate and single turnover GTPase activity. Gyp1p also stimulated the GTPase activity of several other yeast Rab proteins including Ypt1p, Ypt7p, and Ypt51p but showed no GAP activity on Ypt6p and Ypt32p. Deletion of the GYP1 gene or overexpression of Gyp1p did not alter the growth rate of yeast. However, overexpression of Gyp1p was inhibitory in combination with a subset of secretory mutants including sec4-8 and several ypt1 mutants. This effect is probably due to the increase in GAP activity, which can be observed in a lysate from cells overexpressing Gyp1p. The finding that yeast Rab GAPs share homology with proteins in other species, such as Caenorhabditis elegans and human, suggests the existence of a conserved Rab GAP family.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Yale University	Novick, PJ (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, Sterling Hall Med,POB 208002, New Haven, CT 06520 USA.			Du, Li-Lin/0000-0002-1028-7397	NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; Mallet L, 1996, YEAST, V12, P1351, DOI 10.1002/(SICI)1097-0061(199610)12:13<1351::AID-YEA24>3.0.CO;2-6; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P243, DOI 10.1016/S0968-0004(97)01073-6; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; STAHL B, 1994, J BIOL CHEM, V269, P24770; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TAN TJ, 1991, FEBS LETT, V291, P322, DOI 10.1016/0014-5793(91)81312-V; VOLLMER P, 1995, METHOD ENZYMOL, V257, P118; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	20	69	70	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3253	3256		10.1074/jbc.273.6.3253	http://dx.doi.org/10.1074/jbc.273.6.3253			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452439	hybrid			2022-12-27	WOS:000071822300024
J	Morris, NJ; Ross, SA; Lane, WS; Moestrup, SK; Petersen, CM; Keller, SR; Lienhard, GE				Morris, NJ; Ross, SA; Lane, WS; Moestrup, SK; Petersen, CM; Keller, SR; Lienhard, GE			Sortilin is the major 110-kDa protein in GLUT4 vesicles from adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED MEMBRANE AMINOPEPTIDASE; INSULIN-STIMULATED TRANSLOCATION; RAT ADIPOSE-CELLS; GROWTH FACTOR-II; 3T3-L1 ADIPOCYTES; SUBCELLULAR TRAFFICKING; GLUCOSE TRANSPORTERS; TRANSFERRIN RECEPTORS; SURFACE	Vesicles containing the glucose transporter GLUT4 from rat adipocytes contain a major protein of 110 kDa, We have isolated this protein, obtained the sequences of peptides, and cloned a large portion of its cDNA, This revealed that the protein is sortilin, a novel membrane protein that was cloned in another context from a human source while this work was in progress. Subcellular fractionation of rat and 3T3-L1 adipocytes, together with GLUT4 vesicle isolation, showed that sortilin was primarily located in the low density microsomes in vesicles containing GLUT4, Insulin caused a 1.7-fold increase in the amount of sortilin at the plasma membranes of 3T3-L1 adipocytes, as assessed by cell surface biotinylation, The expression of sortilin in 3T3-L1 cells occurred only upon differentiation. Previous characterization of sortilin has led to the suggestion that it functions to sort lumenal proteins from the trans Golgi. The significance of its insulin stimulated increase at the cell surface and of its expression upon differentiation will require definitive delineation of its function.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Harvard Univ, Dept Mol & Cellular Biol, Harvard Microchem Facil, Cambridge, MA 02138 USA; Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark	Dartmouth College; Harvard University; Aarhus University	Lienhard, GE (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu	Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Morris, Nicholas/0000-0002-8389-7508	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK025336, R56DK025336, R01DK025336, F32DK009401] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09401, DK25336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CORVERA S, 1989, J BIOL CHEM, V264, P10133; Fisher MD, 1996, J BIOL CHEM, V271, P11806, DOI 10.1074/jbc.271.20.11806; FROST SC, 1985, J BIOL CHEM, V260, P2646; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1997, AM J PHYSIOL, V271, pE1; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Morris NJ, 1997, J BIOL CHEM, V272, P9388; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SATOH S, 1993, J BIOL CHEM, V268, P17820; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; YANG J, 1993, J BIOL CHEM, V268, P4600; YANG J, 1992, J BIOL CHEM, V267, P10393	30	116	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3582	3587		10.1074/jbc.273.6.3582	http://dx.doi.org/10.1074/jbc.273.6.3582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452485	hybrid			2022-12-27	WOS:000071822300070
J	Muller, JJ; Thomsen, KK; Heinemann, U				Muller, JJ; Thomsen, KK; Heinemann, U			Crystal structure of barley 1,3-1,4-beta-glucanase at 2.0-angstrom resolution and comparison with Bacillus 1,3-1,4-beta-glucanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCAN ENDOHYDROLASES; ACTIVE-SITE STRUCTURE; ENDO-1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE; STEREOCHEMICAL COURSE; AMINO-ACIDS; REFINEMENT; (1->3,1->4)-BETA-GLUCANASES; LICHENIFORMIS; INACTIVATION; EVOLUTION	Both plants and bacteria produce enzymes capable of degrading the mixed linked beta-glucan of the endosperm cell walls of cereal grains. The enzymes share the specificity for beta-1,4 glycosyl bonds of O-3-substituted glucose units in linear polysaccharides and a similar cleavage mechanism but are unrelated in sequence and tertiary structure, The three-dimensional structure of the 1,3-1,4-beta-glucanase isoenzyme EII from barley was determined from monoclinic crystals at a resolution of 2.0 Angstrom. The protein is folded into a beta alpha(8) barrel structure as has been shown previously (Varghese, J. N,, Garrett, T, P, J,, Colman, P, M,, Chen, L,, Hoj, P, B,, and Fincher, G. B, (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 2785-2789) by diffraction analysis at lower resolution of tetragonal crystals, It contains one N-glycosylation site which is described in detail with the sugar moieties attached to residue Asn(190), The geometry and hydration of the barley 1,3-1,4-beta-glucanase is analyzed; a model beta-glucan fragment is placed into the binding site by molecular dynamics simulation, and the beta-glucan binding grooves of the plant and bacterial enzymes are compared, Their active sites are shown to have a small number of common features in generally dissimilar geometries that serve to explain both the identical substrate specificity and the observed differences in inhibitor binding.	Max Delbruck Ctr Mol Med, Forschungsgrp Kristallog, D-13122 Berlin, Germany; Carlsberg Lab, Dept Physiol, DK-2500 Copenhagen, Denmark; Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin	Muller, JJ (corresponding author), Max Delbruck Ctr Mol Med, Forschungsgrp Kristallog, Robert Rossle Str 10, D-13122 Berlin, Germany.	jjm@mdc-berlin.de	Heinemann, Udo/AAH-4766-2019; Heinemann, Udo/S-3379-2016	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bamforth C. W., 1982, Brewers' Digest, V57, P22; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CHEN L, 1995, BBA-PROTEIN STRUCT M, V1253, P112, DOI 10.1016/0167-4838(95)00157-P; CHEN L, 1993, J BIOL CHEM, V268, P13318; CHEN L, 1995, J BIOL CHEM, V270, P8093, DOI 10.1074/jbc.270.14.8093; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DOAN DNP, 1992, FEBS LETT, V309, P265, DOI 10.1016/0014-5793(92)80786-G; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; HAHN M, 1995, J BIOL CHEM, V270, P3081, DOI 10.1074/jbc.270.7.3081; HAHN M, 1995, EUR J BIOCHEM, V232, P849, DOI 10.1111/j.1432-1033.1995.tb20883.x; HAHN M, 1995, FEBS LETT, V374, P221, DOI 10.1016/0014-5793(95)01111-Q; HARTHILL JE, 1995, PLANT PHYSIOL BIOCH, V33, P9; Heinemann U, 1996, BIOL CHEM, V377, P447; HEINEMANN U, 1995, TRENDS BIOCHEM SCI, V20, P349, DOI 10.1016/S0968-0004(00)89073-8; HOJ PB, 1991, J BIOL CHEM, V266, P11628; HOJ PB, 1995, PLANT J, V7, P367, DOI 10.1046/j.1365-313X.1995.7030367.x; HOJ PB, 1989, J BIOL CHEM, V264, P4939; HOLM L, 1994, PROTEINS, V19, P256, DOI 10.1002/prot.340190309; HUBBARD SJ, 1993, NACCES VERSION 2 1 C; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KEITEL T, 1993, J MOL BIOL, V232, P1003, DOI 10.1006/jmbi.1993.1450; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KLEYWEGT GJ, 1997, IN PRESS METHODS ENZ; KRAULIS JP, 1991, J APPL CRYSTALLOGR, V5, P802; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOGUCHI K, 1992, CARBOHYD RES, V237, P33, DOI 10.1016/S0008-6215(92)84231-G; SATHYANARAYANA BK, 1971, BIOPOLYMERS, V10, P1605, DOI 10.1002/bip.360100914; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	43	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3438	3446		10.1074/jbc.273.6.3438	http://dx.doi.org/10.1074/jbc.273.6.3438			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452466	hybrid			2022-12-27	WOS:000071822300051
J	Olson, DP; Sun, BL; Koenig, RJ				Olson, DP; Sun, BL; Koenig, RJ			Thyroid hormone response element architecture affects corepressor release from thyroid hormone receptor dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL CO-REPRESSOR; ACTIVATION; DOMAIN; IDENTIFICATION; DISSECTION; SEQUENCES; COMPLEX	Thyroid hormone receptors are ligand-modulated transcription factors that can repress or activate transcription depending upon the absence or presence of thyroid hormone and the nature of the hormone response element to which the receptors are bound. The ability of thyroid hormone receptors to repress transcription in the absence of ligand is thought to be due to associations with nuclear hormone receptor corepressors. Ligand binding by the thyroid hormone receptor is believed to dissociate these corepressors and recruit coactivators to promote transcription from target promoters. We hypothesize that variations in response element architecture may influence both the association and dissociation of corepressors from DNA-bound thyroid hormone receptors. Using a chimeric corepressor, we find that ligand alone does not fully relieve corepressor-mediated repression, particularly in the presence of thyroid hormone receptor and its heterodimerization partner, the retinoid X receptor, Interestingly, the steroid receptor coactivator 1 together with ligand is able to mediate full release of corepression, but this relief is dependent upon the architecture of the response element to which the nuclear receptor dimer-corepressor complex is bound. These studies suggest that other cellular factors in addition to ligand may be required for the release of corepressors from thyroid hormone receptor dimers.	Univ Michigan, Med Ctr, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Koenig, RJ (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol & Metab, 1500 W Med Ctr Dr,5560 MSRB 2, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [DK44155] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BRENT G A, 1989, New Biologist, V1, P329; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NGY L, 1997, CELL, V89, P373; OHASHI H, 1991, BIOCHEM BIOPH RES CO, V178, P1167, DOI 10.1016/0006-291X(91)91015-5; Olson DP, 1997, J BIOL CHEM, V272, P9907; ONATE SA, 1995, SCIENCE, V270, P1354; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Williams Graham R., 1995, P217; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458	27	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3375	3380		10.1074/jbc.273.6.3375	http://dx.doi.org/10.1074/jbc.273.6.3375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452457	hybrid			2022-12-27	WOS:000071822300042
J	Yoon, JW; Liu, CZ; Yang, JT; Swart, R; Iannaccone, P; Walterhouse, D				Yoon, JW; Liu, CZ; Yang, JT; Swart, R; Iannaccone, P; Walterhouse, D			GLI activates transcription through a herpes simplex viral protein 16-like activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; CUBITUS-INTERRUPTUS; KRUPPEL FAMILY; GENE; DROSOPHILA; SEQUENCES; BINDING; IDENTIFICATION; EXPRESSION; INITIATION	Three proteins have been identified in mammals, GLI, GLI2, and GLI3, which share a highly conserved zinc finger domain with Drosophila Cubitus interruptus and are believed to function as transcription factors in the vertebrate Sonic hedgehog-Patched signaling pathway, To understand the role GLI plays in the Sonic hedgehog-Patched pathway and mechanisms of GLI-induced transcriptional regulation, we have characterized its transcriptional regulatory properties and contributions of specific domains to transcriptional regulation, We have demonstrated that GLI activates expression of reporter constructs in HeLa cells in a concentration-dependent manner through the GLI consensus binding motif and that a GAL4 binding domain-GLI fusion protein activates reporter expression through the GAIA DNA binding site, GLI-induced transcriptional activation requires the carboxyl-terminal amino acids 1020-1091, which includes an 18-amino acid region highly similar to the alpha-helical herpes simplex viral protein 16 activation domain, including the consensus recognition element for the human TFIID TATA box-binding protein-associated factor TAF(II)31 and conservation of all three amino acid residues believed to contact directly chemically complementary residues in TAF(II)31. The presence of this region in the GLI activation domain provides a mechanism for GLI-induced transcriptional regulation.	Northwestern Univ, Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Sch Med,Div Hematol Oncol, Chicago, IL 60614 USA; Northwestern Univ, Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Sch Med,Dept Pediat, Chicago, IL 60614 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	Walterhouse, D (corresponding author), Northwestern Univ, Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Sch Med,Div Hematol Oncol, Box 30,2300 Childrens Plaza, Chicago, IL 60614 USA.			Liu, Cheng/0000-0002-2219-1018	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028992] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA064395] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64395] Funding Source: Medline; NICHD NIH HHS [HD-28992] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; ARUGA J, 1994, J NEUROCHEM, V63, P1880; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Biesecker LG, 1996, J MED GENET, V33, P585, DOI 10.1136/jmg.33.7.585; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBONO M, 1995, GENE DEV, V9, P155, DOI 10.1101/gad.9.2.155; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Jan E, 1997, EMBO J, V16, P6301, DOI 10.1093/emboj/16.20.6301; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; LIU CZ, 1998, IN PRESS GENE AMST; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Mo R, 1997, DEVELOPMENT, V124, P113; RADKE F, 1995, NUCLEIC ACIDS RES, V23, P2277; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERTS WM, 1989, CANCER RES, V49, P5407; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VORTKAMP A, 1995, DNA CELL BIOL, V14, P629, DOI 10.1089/dna.1995.14.629; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; Yang JT, 1997, MOL MED, V3, P826, DOI 10.1007/BF03401719	35	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3496	3501		10.1074/jbc.273.6.3496	http://dx.doi.org/10.1074/jbc.273.6.3496			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452474	hybrid			2022-12-27	WOS:000071822300059
J	Blagoveshchenskaya, AD; Norcott, JP; Cutler, DF				Blagoveshchenskaya, AD; Norcott, JP; Cutler, DF			Lysosomal targeting of P-selectin is mediated by a novel sequence within its cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GRANULE MEMBRANE-PROTEIN; REGULATED SECRETORY PATHWAY; WEIBEL-PALADE BODIES; DI-LEUCINE MOTIF; INTERNALIZATION SIGNAL; RECEPTOR COMPLEXES; ENDOTHELIAL-CELLS; ACID-PHOSPHATASE; HORSERADISH-PEROXIDASE	Signals controlling the intracellular targeting of many membrane proteins are present as short sequences within their cytoplasmic domains, P-selectin is a type I membrane protein receptor for leukocytes, acting during the inflammation response. Heterologous expression experiments have demonstrated that its 35-residue cytoplasmic tail contains signals for targeting to synaptic-like microvesicles, dense-cored granules, and lysosomes, We have examined the lysosomal targeting information present within the cytoplasmic tail by site-directed mutagenesis of horseradish peroxidase-P-selectin chimeras followed by transient transfection in H.Ep.2 cells. Assaying lysosomal targeting by subcellular fractionation as well as intracellular proteolysis, we have discovered a novel lysosomal targeting signal, KCPL, located within the C1 domain of the cytoplasmic tail, Alanine substitution of this tetrapeptide reduced lysosomal targeting to the level of a tailless horseradish peroxidase-P-selectin chimera, which was previously found to be deficient in both internalization and delivery to lysosomes, A proline residue within this lysosomal targeting signal makes a major contribution to the efficiency of lysosomal targeting, A diaminobenzidine density shift procedure established that chimeras with an inactivated KCPL sequence are present within transferrin-positive compartments, Such a mutant also displays an increased level of expression at the plasma membrane. Our results indicate that the sequence KCPL within the cytoplasmic tail of P-selectin is a structural element that mediates sorting from endosomes to lysosomes.	Univ London Univ Coll, Mol Cell Biol Lab, MRC, London WC1E 6BT, England; Univ London Univ Coll, Dept Biochem, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Cutler, DF (corresponding author), Univ London Univ Coll, Mol Cell Biol Lab, MRC, Gower St, London WC1E 6BT, England.	d.cutler@ucl.ac.uk		Cutler, Daniel/0000-0002-4288-7530	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BONFANTI R, 1989, BLOOD, V73, P1109; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BREMNES B, 1994, J CELL SCI, V107, P2021; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; FUTTER CE, 1989, J CELL SCI, V94, P685; GHOSH RN, 1994, J CELL SCI, V107, P2177; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HAMBURGER SA, 1990, BLOOD, V75, P550; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; KORNILOVA ES, 1992, ONCOGENE, V7, P511; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MASTERSON WJ, 1992, PROTEIN TARGETING PR, P242; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCEVER RP, 1995, AGENT ACTION SUPPL, V47, P117; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1993, STRUCTURE, FUNCTION, AND REGULATION OF MOLECULES INVOLVED IN LEUKOCYTE ADHESION, P135; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; NABI IR, 1993, MOL BIOL CELL, V4, P627, DOI 10.1091/mbc.4.6.627; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Norcott JP, 1996, J CELL BIOL, V134, P1229, DOI 10.1083/jcb.134.5.1229; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SETIADI H, 1995, J BIOL CHEM, V270, P26818, DOI 10.1074/jbc.270.45.26818; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; Subtil A, 1997, J CELL BIOL, V136, P583, DOI 10.1083/jcb.136.3.583; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	63	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2729	2737		10.1074/jbc.273.5.2729	http://dx.doi.org/10.1074/jbc.273.5.2729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446579	hybrid			2022-12-27	WOS:000071736600034
J	Di Cristofano, A; Carpino, N; Dunant, N; Friedland, G; Kobayashi, R; Strife, A; Wisniewski, D; Clarkson, B; Pandolfi, PP; Resh, MD				Di Cristofano, A; Carpino, N; Dunant, N; Friedland, G; Kobayashi, R; Strife, A; Wisniewski, D; Clarkson, B; Pandolfi, PP; Resh, MD			Molecular cloning and characterization of p56(dok-2) defines a new family of RasGAP-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; C-ABL; ELECTROPHORESIS; ACTIVATION; CELLS	Chronic myelogenous leukemia (CML) is a disease characterized by the presence of p210(bcr-abl), a chimeric protein with tyrosine kinase activity. Substrates for p210(bcr-abl) are likely to be involved in the pathogenesis of CML. Here we describe the purification, cDNA cloning, and characterization of a 56-kDa tyrosine phosphorylated protein, p56(dok-2) (Dok-2), from p210(bcr-abl) ex pressing cells, The human dok-2 cDNA encodes a 412-amino acid protein with a predicted N-terminal pleckstrin homology domain as well as several other features of a signaling molecule, including 13 potential tyrosine phosphorylation sites, six PXXP motifs, and the ability to bind to p120(RasGAP). Dok-2 was shown to be 35% identical to p62(dok-1), a recently identified RasGAP binding protein from CML cells, and analysis of the expressed sequence tag data base revealed the presence of at least four additional proteins containing a Dok homology sequence motif. Dok mRNAs were primarily expressed in tissues of hematopoietic origin. These findings strongly suggest that a family of Dok-related proteins exists that bind to RasGAP and may mediate the effects of p210(bcr-abl) in CML.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.	m-resh@ski.mskcc.org	di cristofano, antonio/AAJ-3796-2020; Di Cristofano, Antonio/B-4148-2016	di cristofano, antonio/0000-0003-2537-3228; Resh, Marilyn/0000-0001-6118-9466	NATIONAL CANCER INSTITUTE [P01CA064593] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CLARKSON B, 1993, LEUKEMIA, V7, P1683; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	19	114	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4827	4830		10.1074/jbc.273.9.4827	http://dx.doi.org/10.1074/jbc.273.9.4827			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478921	hybrid			2022-12-27	WOS:000072310400005
J	Hoshino, M; Izumi, T; Shimizu, T				Hoshino, M; Izumi, T; Shimizu, T			Leukotriene D-4 activates mitogen-activated protein kinase through a protein kinase C alpha Raf-1-dependent pathway in human monocytic leukemia THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LUNG; MAP KINASE; SIGNAL TRANSDUCTION; HUMAN NEUTROPHILS; RECEPTOR; PHOSPHORYLATION; WORTMANNIN; ANTAGONIST; EOSINOPHIL; INHIBITION	Leukotriene D-4 (LTD4) is a major lipid mediator involved in inflammatory and allergic disorders including bronchial asthma. Despite its potent biological activity, little is known about the receptor and intracellular signaling pathways. Here we analyzed the signal transduction mechanisms through LTD4 receptors using human monocytic leukemia THP-1 cells. When these cells were stimulated with LTD4, intracellular calcium concentration was increased and mitogen-activated protein kinase (MAP kinase) was activated severalfold, This activation was inhibited by staurosporine or GF109203X treatment or abolished by protein kinase C depletion. Cytosolic protein kinase C alpha was translocated to the membrane, and Raf-l was activated by LTD, treatment in a similar time course. LTD4-induced Raf-l activation was diminished by protein kinase C depletion in the cells. A chemotactic response of THP-1 cells toward LTD, was observed which was inhibited by pertussis toxin (PTX) pretreatment. Thus, LTD4 has at least two distinct signaling pathways in THP-1 cells, a PTX-insensitive mitogen-activated protein kinase activation through protein kinase Ca and Raf-l and a PTX-sensitive chemotactic response. This cellular signaling can explain in part the versatile activities of LTD4 in macrophages under inflammatory and allergic conditions.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.							ALEXANDER SPH, 1997, TRENDS PHARM SCI S, V18, P50; CHAN CC, 1990, EUR J PHARMACOL, V191, P273; CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; DELLAROCCA GJ, 1997, J BIOL CHEM, V272, P19215; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; GOTOH Y, 1994, ONCOGENE, V9, P1891; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HONDA Z, 1994, J BIOL CHEM, V269, P2307; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KRUMP E, 1995, BIOCHEM J, V310, P681, DOI 10.1042/bj3100681; Kuang YN, 1996, J BIOL CHEM, V271, P3975; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; METTERS KM, 1993, J BIOL CHEM, V268, P6487; NAKAGAWA N, 1992, JPN J PHARMACOL, V60, P217, DOI 10.1254/jjp.60.217; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OBATA T, 1992, JPN J PHARMACOL, V60, P227, DOI 10.1254/jjp.60.227; ROCHETTE C, 1993, BIOCHIM BIOPHYS ACTA, V1177, P2383; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; Waga I, 1996, J IMMUNOL METHODS, V190, P71, DOI 10.1016/0022-1759(95)00266-9; WATANABE T, 1990, J BIOL CHEM, V265, P21237; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Yen HH, 1997, J LEUKOCYTE BIOL, V61, P529, DOI 10.1002/jlb.61.4.529; YOKOMIZO T, 1997, NATURE, V387, P6320	34	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4878	4882		10.1074/jbc.273.9.4878	http://dx.doi.org/10.1074/jbc.273.9.4878			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478929	hybrid			2022-12-27	WOS:000072310400013
J	Chaillan-Huntington, CE; Patston, PA				Chaillan-Huntington, CE; Patston, PA			Influence of the P-5 residue on alpha(1)-proteinase inhibitor mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; PROTEINASE-INHIBITORS; REACTIVE LOOP; ALPHA(1)-ANTITRYPSIN; COMPLEX; CHYMOTRYPSIN; ALPHA(1)-ANTICHYMOTRYPSIN; CONFORMATION; SERPIN	The reactive center loop of native alpha(1)-proteinase inhibitor has been reported to be in a helical conformation and in a beta-strand conformation by two different studies. In the beta-strand loop structure the P-5 glutamic acid plays a unique role by stabilizing the loop in the predicted optimal conformation for the interaction with target proteinases and insertion into beta-sheet A. We hypothesize here that disrupting the interactions that stabilize the beta-strand conformation of the loop would result in changes in the inhibitory properties of the serpin. In addition, our earlier studies on reactive center loop mutants of alpha(1)-proteinase inhibitor suggested that the P-5 residue was important in stabilizing the alpha(1)-proteinase inhibitor-proteinase complexes. To address these issues we made mutants of alpha(1)-proteinase inhibitor with glycine, glutamine, or lysine at the P-5 position and measured the rates and stoichiometries of inhibition with trypsin and human neutrophil elastase and the stabilities of the resulting complexes, In most cases the rate of inhibition was reduced by about half and the stoichiometry increased between 2- and 4-fold, The only exception was for trypsin with the lysine variant where the P, was now the favored site of cleavage, These data show that the P-5 Glu is important in maintaining the reactive center loop in a conformation optimal for interaction with the proteinase and for a fast rate of loop insertion. The complexes formed with trypsin and the variant serpins were less stable than that formed with wild-type serpin and resulted in up to 33% regeneration of trypsin activity over a period of 6 days, compared with 17% with wild type, Thus, the P-5 residue of alpha(1)-proteinase inhibitor is important in all steps of the inhibitory mechanism in a manner consistent with the structural role played by this residue in the beta-strand loop structure of native alpha(1)-proteinase inhibitor.	Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci MC 838, Chicago, IL 60612 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Patston, PA (corresponding author), Univ Illinois, Coll Dent, Dept Oral Med & Diagnost Sci MC 838, 801 S Paulina St, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL-49242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049242, R29HL049242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1984, H-S Z PHYSIOL CHEM, V365, P731, DOI 10.1515/bchm2.1984.365.2.731; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; Ciaccia AV, 1997, J BIOL CHEM, V272, P888, DOI 10.1074/jbc.272.2.888; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; Dan JH, 1997, J BIOL CHEM, V272, P8243, DOI 10.1074/jbc.272.13.8243; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Eriksson S, 1996, CHEST, V110, pS237, DOI 10.1378/chest.110.6_Supplement.237S; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; JANIN J, 1990, J BIOL CHEM, V265, P16027; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KWON KS, 1995, BBA-PROTEIN STRUCT M, V1247, P179, DOI 10.1016/0167-4838(94)00224-5; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; ODA K, 1977, BIOCHEM BIOPH RES CO, V76, P1062, DOI 10.1016/0006-291X(77)90964-0; OLSON ST, 1995, J BIOL CHEM, V270, P9717, DOI 10.1074/jbc.270.17.9717; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PATSTON PA, 1994, SEMIN THROMB HEMOST, V20, P410, DOI 10.1055/s-2007-1001929; Patston PA, 1996, FEBS LETT, V383, P87, DOI 10.1016/0014-5793(96)00231-1; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Song HK, 1995, FEBS LETT, V377, P150; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354	31	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4569	4573		10.1074/jbc.273.8.4569	http://dx.doi.org/10.1074/jbc.273.8.4569			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468513	hybrid			2022-12-27	WOS:000072115000041
J	Sidhu, JS; Omiecinski, CJ				Sidhu, JS; Omiecinski, CJ			Protein synthesis inhibitors exhibit a nonspecific effect on phenobarbital-inducible cytochome P450 gene expression in primary rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED INDUCTION; LIVER; CYCLOHEXIMIDE; TRANSCRIPTION; ACTIVATION; CYTOCHROME-P-450B; PHOSPHORYLATION; SUPERINDUCTION; CULTURES; ELEMENT	Previous investigations have indicated that de novo protein synthesis is a critical requirement for phenobarbital (PB) induction, We reexamined this issue in PB-responsive primary rat hepatocyte cultures using a broader array of protein synthesis inhibitors and experimental end points. Anisomycin, cycloheximide, emetine, puromycin, and puromycin aminonucleoside, a negative analog, were evaluated for their respective effects on protein synthesis and the PR-induction process, All of the inhibitors effectively repressed de novo protein synthesis in the cells in a concentration-dependent manner, However, anisomycin only minimally effected PB induction, ascertained though the measure of CYP2B1, CYP2B2, and CYP3A1 mRNA levels, The inactive agent, puromycin aminonucleoside, produced marked repression of the PB induction response, Results from further experiments demonstrated that these protein synthesis inhibitors stimulated rapid and differential phosphorylation of the stress-activated protein kinase/c-Jun kinase (SAP/JNK) pathway, indicating nonselective actions on cellular processes, Puromycin aminonucleoside was without effect on these pathways, despite its efficacy as an inhibitor of PB induction, These results demonstrate that de novo protein synthesis is not a requirement for PB induction, nor is activation of the SAPK/JNK kinase cascade responsible for down-regulating PB responsiveness in primary hepatocytes.	Univ Washington, Dept Environm Hlth, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle	Omiecinski, CJ (corresponding author), Univ Washington, Dept Environm Hlth, 4225 Roosevelt Way NE 100, Seattle, WA 98105 USA.	cjo@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032281] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32281] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGER HJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P204, DOI 10.1016/0003-9861(90)90433-Y; CHIANALE J, 1988, HEPATOLOGY, V8, P327, DOI 10.1002/hep.1840080223; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW SC, 1995, EXP CELL RES, V216, P149, DOI 10.1006/excr.1995.1019; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DOGRA SC, 1993, ARCH BIOCHEM BIOPHYS, V300, P531, DOI 10.1006/abbi.1993.1073; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; HONKAKOSKI P, 1989, ARCH BIOCHEM BIOPHYS, V273, P42, DOI 10.1016/0003-9861(89)90160-4; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; NIMS RW, 1994, J BIOCHEM TOXICOL, V9, P279, DOI 10.1002/jbt.2570090602; Nirodi CS, 1996, ARCH BIOCHEM BIOPHYS, V331, P79, DOI 10.1006/abbi.1996.0285; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; Seglen P., 1976, METHODS BIOL, V13, P433; Shu JY, 1996, ONCOGENE, V13, P2421; Sidhu J. S., 1994, In Vitro Toxicology, V7, P225; SIDHU JS, 1995, J BIOL CHEM, V270, P12762, DOI 10.1074/jbc.270.21.12762; Sidhu JS, 1996, J PHARMACOL EXP THER, V276, P238; Sidhu JS, 1997, J PHARMACOL EXP THER, V282, P1122; SIDHU JS, 1995, PHARMACOGENETICS, V5, P24, DOI 10.1097/00008571-199502000-00003; SIDHU JS, 1993, ARCH BIOCHEM BIOPHYS, V301, P103, DOI 10.1006/abbi.1993.1121; Sommer KM, 1996, PHARMACOGENETICS, V6, P369, DOI 10.1097/00008571-199608000-00012; TEILFELD RM, 1989, DNA NY, V8, P329; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370	30	43	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4769	4775		10.1074/jbc.273.8.4769	http://dx.doi.org/10.1074/jbc.273.8.4769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468541	hybrid			2022-12-27	WOS:000072115000069
J	Broos, J; Hoeve-Duurkens, RT; Robillard, GT				Broos, J; Hoeve-Duurkens, RT; Robillard, GT			A mechanism to alter reversibly the oligomeric state of a membrane-bound protein demonstrated with Escherichia coli EIImtl in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; MANNITOL TRANSPORT PROTEIN; SITE-SPECIFIC MUTAGENESIS; ENZYME-II; PHOSPHORYLATION; PERMEASE; MUTANTS; IIMTL; COMPLEMENTATION; ENZYME-II(MTL)	This paper reports that the aggregation state of a membrane protein can be changed reversibly without the use of chaotropic agents or denaturants by altering the attractive interactions between micelles of polyethylene glycol-based detergents, This has been documented using mannitol permease of Escherichia coli (EIImtl), a protein whose activity is dependent on the dimerization of its membrane-embedded domains, We show that the driving force for the hydrophobic interactions responsible for the dimerization can be decreased by bringing the protein into a less polar environment, This can be done simply and reversibly by increasing the micelle cluster size of the solubilizing detergent since the micropolarity in the micelle decreases upon clustering and is directly related to the cluster size. The micelle cluster size was varied at a fixed temperature by adding sodium phosphate or a second detergent with a distinct clustering behavior, and the changes were quantified by quasi elastic light scattering and by determining the cloud point or demixing temperature (T-d) of the detergent, Maximal EIImtl activity was found when no micelle clustering occurred, but the activity gradually decreased down to 5% of the maximal activity with increasing cluster size, The inactivation was found to be completely reversible, The kinetics of heterodimer formation were also significantly affected by changes in the micelle cluster size as expected, Increasing the cluster size resulted in faster formation of functional heterodimers by increasing the rate of homodimer dissociation. This phenomenon should be generally applicable to controlling the oligomeric state of membrane-bound proteins or even water-soluble proteins if their subunit association is dominated by hydrophobic forces.	Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, GBB, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	g.t.robillard@chem.rug.nl						BOER H, 1994, J BIOL CHEM, V269, P17863; Boer H, 1996, BIOCHEMISTRY-US, V35, P12901, DOI 10.1021/bi9611016; BOER H, 1996, THESIS U GRONINGEN N; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CORTI M, 1981, J PHYS CHEM-US, V85, P1442, DOI 10.1021/j150610a033; CORTI M, 1982, PHYS REV LETT, V48, P1617, DOI 10.1103/PhysRevLett.48.1617; Dijkstra DS, 1996, BIOCHEMISTRY-US, V35, P6628; DOOIJEWAARD G, 1979, BIOCHEMISTRY-US, V18, P2990, DOI 10.1021/bi00581a013; HAYTER JB, 1982, COLLOID POLYM SCI, V260, P1023, DOI 10.1007/BF01451649; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; KomaromyHiller G, 1996, LANGMUIR, V12, P916, DOI 10.1021/la950535j; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10120, DOI 10.1021/bi00495a016; LOLKEMA JS, 1993, J BIOL CHEM, V268, P17844; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; MITCHELL DJ, 1983, J CHEM SOC FARAD T 1, V79, P975, DOI 10.1039/f19837900975; NILSSON PG, 1983, J PHYS CHEM-US, V87, P4756, DOI 10.1021/j100246a041; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5520, DOI 10.1021/bi00415a020; PAS HH, 1987, BIOCHEMISTRY-US, V26, P6689, DOI 10.1021/bi00395a019; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1979, BIOCHEMISTRY-US, V18, P2984, DOI 10.1021/bi00581a012; ROOSSIEN FF, 1986, FEBS LETT, V196, P284, DOI 10.1016/0014-5793(86)80264-2; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; SAIER MH, 1980, J SUPRAMOL STR CELL, V14, P281, DOI 10.1002/jss.400140303; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P4046, DOI 10.1021/bi00362a009; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; WENG QP, 1992, J BIOL CHEM, V267, P19529; ZULAUF M, 1983, J PHYS CHEM-US, V87, P856, DOI 10.1021/j100228a032; ZULAUF M, 1991, CRYSTALLIZATION MEMB, P53	31	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3865	3870		10.1074/jbc.273.7.3865	http://dx.doi.org/10.1074/jbc.273.7.3865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461568	hybrid, Green Published			2022-12-27	WOS:000072048400010
J	Casanueva, OI; Garcia-Huidobro, T; Campos, EO; Aldunate, R; Garrido, J; Inestrosa, NC				Casanueva, OI; Garcia-Huidobro, T; Campos, EO; Aldunate, R; Garrido, J; Inestrosa, NC			A major portion of synaptic basal lamina acetylcholinesterase is detached by high salt- and heparin-containing buffers from rat diaphragm muscle and Torpedo electric organ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-TAILED ACETYLCHOLINESTERASE; EXTRACELLULAR-MATRIX; ASYMMETRIC ACETYLCHOLINESTERASE; NEUROMUSCULAR-JUNCTION; CELLULAR-LOCALIZATION; MOLECULAR-FORMS; CELLS; ASSOCIATION; BINDING; 16S-ACETYLCHOLINESTERASE	Collagen-tailed asymmetric acetylcholinesterase (AChE) forms are believed to be anchored to the synaptic basal lamina via electrostatic: interactions involving proteoglycans. However, it was recently found that in avian and rat muscles, high ionic strength or polyanionic buffers could not detach AChE: from cell-surface clusters and that these buffers solubilized intracellular non-junctional asymmetric AChE rather than synaptic: forms of the enzyme. In the present study, asymmetric AChE forms were specifically solubilized by ionic buffers from sg synaptic basal! lamina-enriched fractions, largely devoid of intracellular material, obtained from the electric organ of Torpedo californica and the end plate regions of rat diaphragm muscle, Furthermore, foci of AChE activity were seen to diminish in size, number, and staining intensity when the rat synaptic basal lamina-enriched preparations were treated with the extraction buffers, Pn the case of Torpedo, almost all the AChE activity was removed from the pure basal lamina sheets. We therefore conclude that a major portion of extracellular collagen-tailed AChE is extractable from rat and Torpedo synaptic basal lamina by high ionic strength and heparin buffers,;although some non-extractable AChE activity remains associated with the junctional regions.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Inestrosa, NC (corresponding author), Catholic Univ Chile, Mol Neurobiol Unit, POB 114-D, Santiago, Chile.			Aldunate, Rebeca/0000-0002-5540-3187				BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BETZ W, 1973, J PHYSIOL-LONDON, V230, P673, DOI 10.1113/jphysiol.1973.sp010211; Bowen DC, 1996, J NEUROCHEM, V66, P2580; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; BRANDAN E, 1984, BIOCHEM J, V221, P415, DOI 10.1042/bj2210415; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; DEPREZ PN, 1995, BBA-PROTEIN STRUCT M, V1252, P53, DOI 10.1016/0167-4838(95)00109-8; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; Eccles JC, 1942, J NEUROPHYSIOL, V5, P211, DOI 10.1152/jn.1942.5.3.211; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FERNANDEZ HL, 1984, NEUROCHEM RES, V9, P1213; GORDON H, 1989, DEV BIOL, V135, P675; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HALL ZW, 1971, NATURE-NEW BIOL, V232, P62, DOI 10.1038/newbio232062a0; INESTROSA NC, 1983, CELL BIOCHEM FUNCT, V1, P41, DOI 10.1002/cbf.290010108; INESTROSA NC, 1984, BIOCHEM J, V217, P377, DOI 10.1042/bj2170377; INESTROSA NC, 1985, J NEUROCHEM, V45, P86, DOI 10.1111/j.1471-4159.1985.tb05478.x; INESTROSA NC, 1981, J NEUROSCI, V1, P1260; INESTROSA NC, 1983, EXP CELL RES, V147, P393, DOI 10.1016/0014-4827(83)90221-5; INESTROSA NC, 1990, J MEMBRANE BIOL, V118, P1, DOI 10.1007/BF01872200; INESTROSA NC, 1982, CELL, V29, P71, DOI 10.1016/0092-8674(82)90091-5; INESTROSA NC, 1988, NERVE MUSCLE CELL TR, P147; INESTROSA NC, 1988, NEUROSCI LETT, V90, P185; INESTROSA NC, 1992, MULTIDISCIPLINARY AP, P51; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KOENIG J, 1979, BIOL CELLULAIRE, V35, P147; LEE SL, 1982, J BIOL CHEM, V257, P2292; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; MENDEZ B, 1984, CELL MOL NEUROBIOL, V4, P125, DOI 10.1007/BF00711000; PERELMAN A, 1990, J BIOL CHEM, V265, P214; PEREZTUR J, 1991, FEBS LETT, V286, P25, DOI 10.1016/0014-5793(91)80932-S; Rossi SG, 1996, J BIOL CHEM, V271, P1979, DOI 10.1074/jbc.271.4.1979; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; Rotundo RL, 1997, J CELL BIOL, V136, P367, DOI 10.1083/jcb.136.2.367; SANES JR, 1979, J CELL BIOL, V83, P357, DOI 10.1083/jcb.83.2.357; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TORRES JC, 1983, FEBS LETT, V154, P265, DOI 10.1016/0014-5793(83)80162-8; VIGNY M, 1983, J BIOL CHEM, V258, P8794; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	42	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4258	4265		10.1074/jbc.273.7.4258	http://dx.doi.org/10.1074/jbc.273.7.4258			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461624	hybrid			2022-12-27	WOS:000072048400066
J	Finn, JP; Edwards, RH				Finn, JP; Edwards, RH			Multiple residues contribute independently to differences in ligand recognition between vesicular monoamine transporters 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINE TRANSPORTER; ENDOCRINE-CELLS; LOCALIZATION; EXPRESSION; CLONING; TETRABENAZINE; SENSITIVITY; INHIBITORS; ISOFORMS; NEURONS	The two closely related vesicular monoamine trans porters (VMATs) 1 and 2 differ substantially in ligand recognition. The neuronal VMAT2 exhibits a higher affinity for monoamine substrates and in particular for histamine as well as a greater sensitivity to the inhibitor tetrabenazine than the nonneuronal VMAT1, The analysis of chimeric transport proteins has previously shown that two major domains, one spanning transmembrane domains (TMDs) 5-8 (TMD5-8) and the other, TMDs 9-12 (TMD9-12), are required for the high affinity interactions characteristic of VMAT2. Using site-directed mutagenesis to replace residues in TMD5-8 of VMAT2 with the equivalent residues from VMAT1, we now show that the sensitivity of VMAT2 to tetrabenazine requires Ala-315, and this interaction occurs independently of the interaction with residues in TMD9-12, The ability to recognize histamine as a substrate depends on Pro-237, and the contribution of TMD9-12 to histamine recognition appears to involve a common mechanism, In contrast, the replacement of many residues in TMD5-8 of VMAT2 with equivalent residues from VMAT1 improves the recognition of both serotonin and tryptamine, and these mutations show a dominant effect on the recognition of both tryptamine and serotonin over mutations in TMD9-12. The results indicate that different ligands interact through distinct mechanisms with the VMATs and that the recognition of each ligand involves multiple, independent interactions with the transport protein.	Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Edwards, RH (corresponding author), Univ Calif San Francisco, Sch Med, Dept Neurol, 3rd & Parnassus St, San Francisco, CA 94143 USA.	edwards@itsa.ucsf.edu						ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Finn JP, 1997, J BIOL CHEM, V272, P16301, DOI 10.1074/jbc.272.26.16301; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERICKEL A, 1995, NEUROPHARMACOLOGY, V34, P1543, DOI 10.1016/0028-3908(95)00148-Y; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1993, GENOMICS, V18, P720, DOI 10.1016/S0888-7543(05)80383-0; PETER D, 1994, J BIOL CHEM, V269, P7231; PETER D, 1995, J NEUROSCI, V15, P6179; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730	15	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3943	3947		10.1074/jbc.273.7.3943	http://dx.doi.org/10.1074/jbc.273.7.3943			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461580	hybrid			2022-12-27	WOS:000072048400022
J	Tsoi, M; Rhee, KH; Bungard, D; Li, XF; Lee, SL; Auer, RN; Lytton, J				Tsoi, M; Rhee, KH; Bungard, D; Li, XF; Lee, SL; Auer, RN; Lytton, J			Molecular cloning of a novel potassium-dependent sodium-calcium exchanger from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; SARCOLEMMAL NA+-CA2+ EXCHANGER; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; MESSENGER-RNAS; SMOOTH-MUSCLE; K+; PHOTORECEPTORS; NEURONS; INITIATION	We have isolated a novel cDNA clone from rat cerebral cortex encoding a protein of 670 amino acids (NCKX2) that has significant similarity to the 1199-amino acid-long Na/Ca-K exchanger of bovine rod outer segment (NCKX1), NCKX2 transcripts are 10.5 kilobase pairs in length and are expressed abundantly in neurons throughout the brain and with much lower abundance in selected other tissues, The predicted topology of the rat NCKX2 protein is very similar to that of bovine NCKX1, beginning with a solitary transmembrane segment (MO), which is removed as a "signal peptide" in bovine NCKX1, an extracellular loop, a cluster of five transmembrane spanning segments (Mi to M5), a long cytoplasmic loop, and a final hydrophobic cluster (M6 to M11), Within the hydrophobic clusters, rat NCKX2 shares 80% identity and 91% similarity with bovine NCKX1, The two larger hydrophilic loops are much shorter in NCKX2 than in NCKX1, accounting largely for the difference in length between the two proteins, and are dissimilar in sequence except for a 32-amino acid stretch with 69% identity in the cytosolic loop. NCKX2 was epitope-tagged in the extracellular domain and was shown to be expressed at the surface of transfected HEK cells. Analysis of NCKX2 function by fluorescent imaging of fura-a-loaded transfected cells demonstrated that NCKX2 is a potassium-dependent sodium/calcium exchanger.	Univ Calgary, Hlth Sci Ctr, Dept Med Biochem, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Neurosci, Calgary, AB T2N 4N1, Canada; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Tsoi, M (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Med Biochem, Rm 2518,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@acs.ucalgary.ca	Auer, Roland/F-6661-2017	Auer, Roland/0000-0001-9044-3419; Lytton, Jonathan/0000-0003-4770-2512				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BREITSCHOPF H, 1996, NONRADIOACTIVE IN SI, P136; Carpenter M.B, 1991, CORE TEXT NEUROANATO; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CONDRESCU M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P198, DOI 10.1016/0005-2736(90)90226-E; DAHAN D, 1991, J BIOL CHEM, V266, P2067; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FRIEDEL U, 1991, BIOCHIM BIOPHYS ACTA, V1061, P247, DOI 10.1016/0005-2736(91)90290-O; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HYRSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35; Juhaszova M, 1996, ANN NY ACAD SCI, V779, P318, DOI 10.1111/j.1749-6632.1996.tb44804.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIMURA M, 1993, J BIOL CHEM, V268, P6874; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lederer WJ, 1996, ANN NY ACAD SCI, V779, P7, DOI 10.1111/j.1749-6632.1996.tb44764.x; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1994, J BIOL CHEM, V269, P17434; LYTTON J, 1992, J BIOL CHEM, V267, P14483; Lytton J, 1996, ANN NY ACAD SCI, V779, P58, DOI 10.1111/j.1749-6632.1996.tb44770.x; MARLIER LNJL, 1993, MOL BRAIN RES, V20, P21, DOI 10.1016/0169-328X(93)90107-Z; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; Navangione A, 1997, BIOPHYS J, V73, P45, DOI 10.1016/S0006-3495(97)78046-9; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Paxinos G., 1996, RAT BRAIN STEREOTAXI; REEVES JP, 1983, J BIOL CHEM, V258, P3178; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; Rispoli G, 1996, ANN NY ACAD SCI, V779, P346, DOI 10.1111/j.1749-6632.1996.tb44806.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHNETKAMP PPM, 1989, PROG BIOPHYS MOL BIO, V54, P1, DOI 10.1016/0079-6107(89)90007-2; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; Schulze DH, 1996, ANN NY ACAD SCI, V779, P46, DOI 10.1111/j.1749-6632.1996.tb44769.x; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; ZEINER M, 1994, BIOTECHNIQUES, V17, P1051	45	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4155	4162		10.1074/jbc.273.7.4155	http://dx.doi.org/10.1074/jbc.273.7.4155			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461611	hybrid			2022-12-27	WOS:000072048400053
J	Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Kharbanda, S; Wang, R; Sung, P; Shinohara, A; Weichselbaum, R; Kufe, D				Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Kharbanda, S; Wang, R; Sung, P; Shinohara, A; Weichselbaum, R; Kufe, D			Regulation of Rad51 function by c-Abl in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEAR TYROSINE KINASE; ESCHERICHIA-COLI RECA; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; STRESS-RESPONSE; STRAND EXCHANGE; P53; REPAIR; GROWTH	The Rad51 protein, a homolog of bacterial RecA, functions in DNA double-strand break repair and genetic recombination. Whereas Rad51 catalyzes ATP-dependent pairing and strand exchange between homologous DNA molecules, regulation of this function is unknown. The c-Abl tyrosine kinase is activated by ionizing radiation and certain other DNA-damaging agents. Here we demonstrate that c-Abl interacts constitutively with Rad51. We show that c-Abl phosphorylates Rad51 on Tyr-54 in vitro. The results also show that treatment of cells with ionizing radiation induces c-Abl dependent phosphorylation of Rad51. Phosphorylation of Rad51 by c-Abl inhibits the binding of Rad51 to DNA and the function of Rad51 in ATP-dependent DNA strand exchange reactions. These findings represent the first demonstration that Rad51 is regulated by phosphorylation and support a functional role for c-Abl in regulating Rad51-dependent recombination in the response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Pharmacol, Boston, MA 02115 USA; Rockefeller Univ, Mass Spectrometry Ctr, New York, NY 10021 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Ctr Mol Med, San Antonio, TX 78245 USA; Osaka Univ, Fac Sci, Dept Biol, Osaka 560, Japan; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Rockefeller University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Osaka University; University of Chicago	Yuan, ZM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Pharmacol, 44 Binney St, Boston, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021; Wang, Rong/A-8721-2009					Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOGA A, 1995, ONCOGENE, V11, P791; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAESHIMA K, 1995, GENE, V160, P195, DOI 10.1016/0378-1119(95)00148-Y; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	40	170	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3799	3802		10.1074/jbc.273.7.3799	http://dx.doi.org/10.1074/jbc.273.7.3799			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461559	hybrid			2022-12-27	WOS:000072048400001
J	Bajzar, L; Nesheim, M; Morser, J; Tracy, PB				Bajzar, L; Nesheim, M; Morser, J; Tracy, PB			Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; PROTEIN-C; PLASMINOGEN-ACTIVATOR; HUMAN-PLASMA; FACTOR-V; PROTHROMBIN ACTIVATION; PROCARBOXYPEPTIDASE-B; CARBOXYPEPTIDASE-U; INACTIVATION; COAGULATION	Thrombin-activable fibrinolysis inhibitor (TAFI) is a recently described plasma zymogen that can be activated by thrombin to an enzyme with carboxypeptidase B-like activity, The enzyme, TAFIa, potently attentuates fibrinolysis, TAFI activation, like protein C activation, is augmented about 1250-fold by thrombomodulin (TM), In this work, the effects of both soluble and cellular forms of TM on TAFI activation-dependent suppression of fibrinolysis were investigated, Soluble TM included in clots formed from purified components, barium citrate-adsorbed plasma, or normal human plasma maximally increased the tissue plasminogen activator-induced lysis time PS-fold, with saturation occurring at 5, 10, and 1 nM TM in the three respective systems. Soluble TM did not effect lysis in the system of purified components lacking TAFI or in plasmas immunodepleted of TAFI, In addition, the antifibrinolytic effect of TM was negated by monoclonal antibodies against either TAFI or TM, The inhibition of fibrinolysis by cellular TM was assessed by forming clots in dialyzed, barium citrate-adsorbed, or normal plasma over cultured human umbilical vein endothelial cells (HUVECs), Tissue plasminogen activator-induced lysis time was increased 2-fold, with both plasmas, in the presence of HUVECs, The antifibrinolytic effect of HUVECs was abolished 66% by specific anti-TAFI or anti-TM monoclonal antibodies, A newly developed functional assay demonstrated that HUVECs potentiate the thrombin-catalyzed. TM-dependent formation of activated TAFI, Thus, endothelial cell TRI, in vitro at least, appears to participate in the regulation of not only coagulation but also fibrinolysis.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Berlex Biosci, Cardiovasc Dept, Richmond, CA 94804 USA	Queens University - Canada; Queens University - Canada; University of Vermont	Nesheim, M (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	nesheimm@post.queensu.ca			NHLBI NIH HHS [HLP01-46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTRUP T, 1991, SEMIN THROMB HEMOST, V17, P161, DOI 10.1055/s-2007-1002606; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; Bajzar L., 1996, Fibrinolysis, V10, P81; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Broze GJ, 1996, BLOOD, V88, P3815, DOI 10.1182/blood.V88.10.3815.bloodjournal88103815; BUTENAS S, 1995, ANAL BIOCHEM, V225, P231, DOI 10.1006/abio.1995.1148; COLLEN D, 1991, BLOOD, V78, P3114; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30, DOI 10.1111/j.1749-6632.1991.tb43689.x; ESMON CT, 1984, SEMIN THROMB HEMOST, V10, P122, DOI 10.1055/s-2007-1004414; FULCHER CA, 1984, BLOOD, V63, P486; GRIFFIN JH, 1984, SEMIN THROMB HEMOST, V10, P162, DOI 10.1055/s-2007-1004419; HEMKER HC, 1993, THROMB HAEMOSTASIS, V70, P617; HOOGENDOORN H, 1990, BLOOD, V75, P2164; ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KODAMA S, 1990, CLIN CHIM ACTA, V192, P191, DOI 10.1016/0009-8981(90)90221-D; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEVIN EG, 1986, THROMB HAEMOSTASIS, V56, P115; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SHATOS MA, 1990, J BIOL CHEM, V265, P20443; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUZUKI K, 1988, J BIOCHEM-TOKYO, V104, P628, DOI 10.1093/oxfordjournals.jbchem.a122523; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TAKAHASHI Y, 1995, THROMB HAEMOSTASIS, V73, P805; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TANS G, 1991, J BIOL CHEM, V266, P21864; VondemBorne PAK, 1997, J CLIN INVEST, V99, P2323, DOI 10.1172/JCI119412; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WANG W, 1994, J BIOL CHEM, V269, P15937	39	96	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2792	2798		10.1074/jbc.273.5.2792	http://dx.doi.org/10.1074/jbc.273.5.2792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446587	hybrid			2022-12-27	WOS:000071736600042
J	Naito, M; Ohara, N; Matsumoto, S; Yamada, T				Naito, M; Ohara, N; Matsumoto, S; Yamada, T			The novel fibronectin-binding motif and key residues of mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-INTERFERON PRODUCTION; BACILLUS CALMETTE-GUERIN; BOVIS-BCG; ALPHA-ANTIGEN; EXTRACELLULAR PROTEINS; PROTECTIVE IMMUNITY; KANSASII INFECTION; SECRETED PROTEIN; IMMUNOGLOBULIN-G; TUBERCULOSIS	The binding motifs of the immunodominant antigen (Ag) alpha-Ag (Ag 85 complex B) of Mycobacterium kansasii for human fibronectin were examined using digested fragments. We defined two fibronectin-binding epitopes on 27 amino acids from 84 to 110 and on 20 amino acids from 211 to 230, The epitopes were almost conserved in the closely related Ag 85 complex of other mycobacteria species. Inhibition of fibronectin binding to intact alpha-Ag molecules was observed with peptide-(84-110), but not with peptide-(211-230). Peptide (84-110) could also inhibit fibronectin binding to all components of the Ag 85 complex of Bacillus Calmette-Guerin (Ag 85A, Ag 85B, and Ag 85C). Further study with synthetic peptides defined 11 residues from 98 to 108 as the minimum motif. Six residues ((98)FEWYYQ(103)) were critical for interacting with fibronectin. The motif revealed no homology to other known prokaryotic and eukaryotic fibronectin-binding proteins. The defined motif of alpha-Ag is novel and unique for mycobacteria.	Nagasaki Univ, Sch Dent, Dept Oral Bacteriol, Nagasaki 852, Japan	Nagasaki University	Naito, M (corresponding author), Nagasaki Univ, Sch Dent, Dept Oral Bacteriol, 1-7-1 Sakamoto, Nagasaki 852, Japan.		OHARA, Naoya/B-2481-2011	NAITO, Mariko/0000-0003-0769-7747; Matsumoto, Sohkichi/0000-0002-6106-7538				ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; ABOUZEID C, 1988, J GEN MICROBIOL, V134, P531; ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; Aung H, 1996, J CLIN INVEST, V98, P1261, DOI 10.1172/JCI118910; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BREATHNACH A, 1995, CLIN INFECT DIS, V20, P812, DOI 10.1093/clinids/20.4.812; CONTENT J, 1991, INFECT IMMUN, V59, P3205, DOI 10.1128/IAI.59.9.3205-3212.1991; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; HUYGEN K, 1988, INFECT IMMUN, V56, P3196, DOI 10.1128/IAI.56.12.3196-3200.1988; HUYGEN K, 1988, SCAND J IMMUNOL, V27, P187, DOI 10.1111/j.1365-3083.1988.tb02338.x; JANICKI BW, 1971, AM REV RESPIR DIS, V104, P602; KITAURA H, 1993, BIOCHEM BIOPH RES CO, V196, P1466, DOI 10.1006/bbrc.1993.2417; MATSUO K, 1990, INFECT IMMUN, V58, P550, DOI 10.1128/IAI.58.2.550-556.1990; MATSUO K, 1988, J BACTERIOL, V170, P3847, DOI 10.1128/jb.170.9.3847-3854.1988; MATSUO K, 1990, INFECT IMMUN, V58, P4049, DOI 10.1128/IAI.58.12.4049-4054.1990; NAGAI S, 1991, INFECT IMMUN, V59, P372, DOI 10.1128/IAI.59.1.372-382.1991; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHARA N, 1993, INFECT IMMUN, V61, P1173, DOI 10.1128/IAI.61.4.1173-1179.1993; OHARA N, 1995, SCAND J IMMUNOL, V41, P433, DOI 10.1111/j.1365-3083.1995.tb03589.x; ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988; PAL PG, 1992, INFECT IMMUN, V60, P4781, DOI 10.1128/IAI.60.11.4781-4792.1992; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; RAMBUKKANA A, 1993, INFECT IMMUN, V61, P1835, DOI 10.1128/IAI.61.5.1835-1845.1993; RATLEDGE C, 1989, BIOL MYCOBACTERIA, V3, P511; RATLIFF TL, 1988, J GEN MICROBIOL, V134, P1307; ROCHE PW, 1994, INFECT IMMUN, V62, P5319, DOI 10.1128/IAI.62.12.5319-5326.1994; SALATA RA, 1991, J LAB CLIN MED, V118, P589; SHAFER RW, 1992, CLIN INFECT DIS, V15, P161, DOI 10.1093/clinids/15.1.161; SNIDER DJ, 1992, NEW ENGL J MED, V32, P703; SUZUKI Y, 1987, J BACTERIOL, V169, P839, DOI 10.1128/jb.169.2.839-843.1987; TAKANO M, 1994, SCAND J IMMUNOL, V40, P165, DOI 10.1111/j.1365-3083.1994.tb03446.x; THOLE JER, 1992, MOL MICROBIOL, V6, P153, DOI 10.1111/j.1365-2958.1992.tb01996.x; TURNEER M, 1988, J CLIN MICROBIOL, V26, P1714, DOI 10.1128/JCM.26.9.1714-1719.1988; WAYNE LG, 1992, CLIN MICROBIOL REV, V5, P1; WEINROTH SE, 1994, CLIN INFECT DIS, V18, P261, DOI 10.1093/clinids/18.2.261; WIKER HG, 1990, AM REV RESPIR DIS, V141, P830, DOI 10.1164/ajrccm/141.4_Pt_1.830; WIKER HG, 1992, SCAND J IMMUNOL, V36, P307, DOI 10.1111/j.1365-3083.1992.tb03104.x; WIKER HG, 1986, INT ARCH ALLER A IMM, V81, P307, DOI 10.1159/000234154; WOLINSKY E, 1992, CLIN INFECT DIS, V15, P1, DOI 10.1093/clinids/15.1.1	42	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2905	2909		10.1074/jbc.273.5.2905	http://dx.doi.org/10.1074/jbc.273.5.2905			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446601	hybrid			2022-12-27	WOS:000071736600056
J	Zhang, F; Anderson, D				Zhang, F; Anderson, D			In vitro selection of bacteriophage phi 29 prohead RNA aptamers for prohead binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-RNA; DNA; DNA-GP3; PRNA	Prohead RNA (pRNA) of the Bacillus subtilis bacteriophage phi 29 is needed for in vitro packaging of DNA-gene product 3 (DNA-gp3). Residues 22-84 of the 174-base pRNA bind the portal vertex of the prohead, the site of DNA packaging, To define the nucleotides of pRNA needed for prohead binding and DNA-gp3 packaging and to seek biologically active variants of pRNA, segments of pRNA were randomized to obtain vast repertoires of RNA molecules, RNA aptamers, ligands best suited for prohead binding, were obtained by multiple rounds of in vitro selection, Evolution of pRNA aptamers was followed by a competition binding assay and nucleotide sequencing, and mutants were tested for DNA-gp3 packaging, Aptamers selected following randomization of the E stem and loop and a part of the C-E loop that were active in DNA-gp3 packaging were invariably wild-type. DNA-gp3 packaging activity also required nucleo tides G(82) and G(83) that form base pairs intermolecularly with C-47 and C-48 to produce a novel hexameric oligomer of pRNA, The only mutant aptamers that retained full DNA-gp(3) packaging activity showed changes of the U residues at positions 81, 84, and 85 of the D loop. Thus, the in vitro selections essentially recapitulated the natural evolution of pRNA.	Univ Minnesota, Dept Oral Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Genet & Cell Biol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Anderson, D (corresponding author), Univ Minnesota, Dept Oral Sci, 18-246 Moos Hlth Sci Tower,515 Delaware St SE, Minneapolis, MN 55455 USA.				NIDCR NIH HHS [DE03606] Funding Source: Medline; NIGMS NIH HHS [GM39931] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE003606, R01DE003606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039931] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1990, J BIOL CHEM, V265, P22365; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; Grimes S, 1997, J MOL BIOL, V266, P901, DOI 10.1006/jmbi.1996.0843; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; LONGEL J, 1992, BIOTECHNIQUES, V13, P604; REID RJD, 1994, J BIOL CHEM, V269, P18656; REID RJD, 1994, J BIOL CHEM, V269, P9084; REID RJD, 1994, J BIOL CHEM, V269, P5157; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WICHITWECHKARN J, 1989, NUCLEIC ACIDS RES, V17, P3459, DOI 10.1093/nar/17.9.3459; WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K; ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	15	17	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2947	2953		10.1074/jbc.273.5.2947	http://dx.doi.org/10.1074/jbc.273.5.2947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446607	hybrid			2022-12-27	WOS:000071736600062
J	Ray, RB; Meyer, K; Steele, R; Shrivastava, A; Aggarwal, BB; Ray, R				Ray, RB; Meyer, K; Steele, R; Shrivastava, A; Aggarwal, BB; Ray, R			Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; IMMUNE-RESPONSES; B VIRUS; REPLICATION; CLEAVAGE; INVITRO; GENOME; DEATH; ALPHA; KILL	Hepatitis C virus (HCV) putative core protein has displayed many intriguing biological properties, Since tumor necrosis factor (TNF) plays an important role in controlling viral infection, in this study the effect of the core protein was investigated on the TNF-alpha induced apoptosis of human breast carcinoma cells (MCF7). RCV core protein when expressed inhibited TNF-alpha-induced apoptotic cell death unlike the control MCF7 cells, as determined by cell viability and DNA fragmentation analysis. Additionally, HCV core protein blocked the TNF-induced proteolytic cleavage of the death substrate poly(ADP-ribose) polymerase from its native 116-kDa protein to the characteristic 85-kDa polypeptide, Results from this study suggest that the HCV core protein plays a role in the inhibition of TNF-alpha-mediated cell death. Thus, the ability of core protein to inhibit the TNF-mediated apoptotic signaling pathway may provide a selective advantage for HCV replication, allowing for evasion of host antiviral defense mechanisms.	St Louis Univ, Hlth Sci Ctr, Div Infect Dis & Immunol, St Louis, MO 63110 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Lab, Houston, TX 77030 USA	Saint Louis University; University of Texas System; UTMD Anderson Cancer Center	Ray, R (corresponding author), St Louis Univ, Hlth Sci Ctr, Div Infect Dis & Immunol, 3635 Vista Ave,FDT-8N, St Louis, MO 63110 USA.		Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [CA52799] Funding Source: Medline; NIAID NIH HHS [AI-45250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052799, R01CA052799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGARWAL BB, 1992, TUMOR NECROSIS FACTO; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Dimitrov T, 1997, J VIROL, V71, P2830, DOI 10.1128/JVI.71.4.2830-2837.1997; FANG JWS, 1994, HEPATOLOGY, V20, P251; Geissler M, 1997, J IMMUNOL, V158, P1231; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Guilhot S, 1996, AM J PATHOL, V148, P801; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hu SM, 1997, J BIOL CHEM, V272, P9621; Jin YD, 1997, J CLIN IMMUNOL, V17, P140, DOI 10.1023/A:1027326415164; Kakumu S, 1997, CLIN EXP IMMUNOL, V108, P138, DOI 10.1046/j.1365-2249.1997.d01-987.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAGGING LM, 1995, J VIROL, V69, P5859, DOI 10.1128/JVI.69.9.5859-5863.1995; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MAJOR ME, 1995, J VIROL, V69, P5798, DOI 10.1128/JVI.69.9.5798-5805.1995; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MESTAN J, 1986, NATURE, V323, P816, DOI 10.1038/323816a0; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; Rudin CM, 1997, ANNU REV MED, V48, P267; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; Shimizu I, 1997, J GASTROENTEROL, V32, P47, DOI 10.1007/BF01213296; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; SMITH GK, 1992, CANCER RES, V52, P4895; Srinivas RV, 1996, VIRUS RES, V45, P87, DOI 10.1016/S0168-1702(96)01361-5; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Totpal K, 1996, J INTERF CYTOK RES, V16, P259, DOI 10.1089/jir.1996.16.259; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	49	199	208	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2256	2259		10.1074/jbc.273.4.2256	http://dx.doi.org/10.1074/jbc.273.4.2256			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442069	hybrid			2022-12-27	WOS:000071595200058
J	Botelho, FM; Edwards, DR; Richards, CD				Botelho, FM; Edwards, DR; Richards, CD			Oncostatin M stimulates c-fos to bind a transcriptionally responsive AP-1 element within the tissue inhibitor of metalloproteinase-1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FIBROBLASTS; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; HEPG2 CELLS; EXPRESSION; PROTEINS; TIMP-1; INTERLEUKIN-6; COLLAGENASE; ACTIVATION	Tissue inhibitor of metalloproteinases-1 (TIMP-1) can be regulated by gp130 cytokines such as IL-6 and oncostatin M (OSM). Polymerase chain reaction deletion analysis of the murine TIMP-1 proximal promoter in chloramphenicol acetyltransferase reporter gene constructs identified an AP-1 element (-59/-53) that allows maximal responsiveness to OSM in HepG2 cells. Fos and Jun nuclear factors bound constitutively to this site as identified by supershift analysis in electrophoretic mobility shift assays, and oncostatin M (but not IL-6) induced an additional "complex 2" that contained c-Fos and JunD. OSM stimulated a rapid and transient increase in c-Fos mRNA and nuclear protein that coincided with complex 2 formation. Phorbol 13-myristate 12-acetate could also induce c-Fos but could not regulate the TIMP-1 reporter gene constructs. Transfection studies also showed that 3'-deletion of sequences downstream of the transcriptional start site (+1/+47) markedly reduced OSM -fold induction. Nuclear factors bound to SP1 and Ets sequences were detected, but were not altered upon OSM stimulation. Although OSM and IL-6 induced STAT (signal transducers and activators of transcription) factors to bind a high affinity Sis-inducible element DNA probe, binding to homologous TIMP-1 promoter sequences was not detected. Thus, OSM (but not IL-6) stimulates c-Fos, which participates in maximal activation of TIMP-1 transcription, likely in cooperation with other factors such as SP1 or as yet unidentified mechanisms involving the +1 to +47 region of the promoter.	McMaster Univ, Hlth Sci Ctr, Dept Pathol, Mol Virol & Immunol Program, Hamilton, ON L8N 3Z5, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Richards, CD (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Pathol, Mol Virol & Immunol Program, Rm 4H17,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Edwards, Dylan R/B-4734-2009	Edwards, Dylan R/0000-0002-3292-2064; Richards, Carl/0000-0002-0081-2231				AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BROWN TJ, 1987, J IMMUNOL, V139, P2977; BROWN TJ, 1990, MOL BIOL CARDIOVASC, V131, P195; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; CAWSTON TE, 1990, BIOCHEM J, V269, P183, DOI 10.1042/bj2690183; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SD, 1987, J CLIN INVEST, V80, P1280, DOI 10.1172/JCI113203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; GEARING DP, 1992, NEW BIOL, V4, P61; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; KUMAR G, 1994, J IMMUNOL, V153, P4436; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURPHY G, 1985, J BIOL CHEM, V260, P3079; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SHIMADA Y, 1992, BLOOD, V79, P2423; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOLDI R, 1994, ONCOGENE, V9, P2253; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; ULISSE S, 1994, ENDOCRINOLOGY, V135, P2479, DOI 10.1210/en.135.6.2479; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	47	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5211	5218		10.1074/jbc.273.9.5211	http://dx.doi.org/10.1074/jbc.273.9.5211			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478976	hybrid			2022-12-27	WOS:000072310400060
J	Joshi, AK; Rangan, VS; Smith, S				Joshi, AK; Rangan, VS; Smith, S			Differential affinity labeling of the two subunits of the homodimeric animal fatty acid synthase allows isolation of heterodimers consisting of subunits that have been independently modified	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAMMARY-GLAND; MULTIFUNCTIONAL ENZYME; MOLECULAR-CLONING; ESCHERICHIA-COLI; ACTIVE-CENTERS; SYNTHETASE; SITE; THIOESTERASE; DOMAIN; CDNA	To explore the domain interactions that are required for catalytic activity of the multifunctional, homodimeric fatty acid synthase (FAS), we have formulated a strategy that allows isolation of modified dimers containing independently mutated subunits, Either a hexahistidine or a FLAG octapeptide tag was incorporated into the FAS at either the amino terminus, within an internal noncatalytic domain, or at the carboxyl terminus, The presence of the tags had no effect on the activity of the wild-type FAS. His-tagged dimers were mixed with FLAG-tagged dimers, and the subunits were randomized to produce a mixture of His-tagged homodimers, FLAG-tagged homodimers, and doubly tagged heterodimers. The doubly tagged heterodimers could be purified to homogeneity by chromatography on an anti-FLAG immunoaffinity column followed by a metal ion chelating column, This procedure for isolation of FAS heterodimers was utilized to determine whether the two centers for fatty acid synthesis in the FAS dimer can function independently of each other, Doubly tagged heterodimers, consisting of one wild-type subunit and one subunit in which the thioesterase activity had been eliminated, either by mutation or by treatment with phenylmethanesulfonyl fluoride, have 50% of the wild-type thioesterase activity and, in the presence of substrates, accumulate a long chain fatty acyl moiety on the modified subunit, thus blocking further substrate turnover at this center, Nevertheless, the ability of the heterodimer to synthesize fatty acids is also 50% of the wild-type FAS, demonstrating that an individual center for fatty acid synthesis has the same activity when paired with either a functional or nonfunctional catalytic center.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Smith, S (corresponding author), Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; CHANG SI, 1990, ACCOUNTS CHEM RES, V23, P363, DOI 10.1021/ar00179a003; CHANG SI, 1988, BIOCHEMISTRY-US, V27, P4753, DOI 10.1021/bi00413a026; HARDIE DG, 1986, MULTIDOMAIN PROTEINS, P229; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; JOSHI AK, 1993, BIOCHEM J, V296, P143, DOI 10.1042/bj2960143; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; JOSHI AK, 1998, IN PRESS BIOCHEMISTR; KUMAR S, 1973, BIOCHEM BIOPH RES CO, V53, P334, DOI 10.1016/0006-291X(73)91438-1; KYUSHIKI H, 1989, BIOCHEM BIOPH RES CO, V164, P434, DOI 10.1016/0006-291X(89)91738-5; LIBERTINI LJ, 1979, ARCH BIOCHEM BIOPHYS, V192, P47, DOI 10.1016/0003-9861(79)90070-5; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MCCARTHY AD, 1982, FEBS LETT, V147, P256, DOI 10.1016/0014-5793(82)81054-5; MIKKELSEN J, 1985, BIOCHEM J, V227, P21, DOI 10.1042/bj2270021; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; POULOSE AJ, 1984, ARCH BIOCHEM BIOPHYS, V230, P117, DOI 10.1016/0003-9861(84)90092-4; POULOSE AJ, 1981, BIOCHEM BIOPH RES CO, V103, P377, DOI 10.1016/0006-291X(81)90463-0; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SINGH N, 1984, J BIOL CHEM, V259, P3605; Smith S, 1975, Methods Enzymol, V35, P65, DOI 10.1016/0076-6879(75)35139-2; Smith S, 1981, Methods Enzymol, V71 Pt C, P181, DOI 10.1016/0076-6879(81)71026-7; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH S, 1985, EUR J BIOCHEM, V152, P547, DOI 10.1111/j.1432-1033.1985.tb09230.x; SMITH S, 1979, ARCH BIOCHEM BIOPHYS, V197, P379, DOI 10.1016/0003-9861(79)90259-5; SMITH S, 1971, J BIOL CHEM, V246, P6428; STERN A, 1982, J BIOL CHEM, V257, P799; STOOPS JK, 1982, J BIOL CHEM, V257, P3230; STOOPS JK, 1981, J BIOL CHEM, V256, P5128; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG YS, 1984, J BIOL CHEM, V259, P3644; Witkowski A, 1996, BIOCHEMISTRY-US, V35, P10569, DOI 10.1021/bi960910m; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; YUAN ZY, 1985, J BIOL CHEM, V260, P3532	36	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4937	4943		10.1074/jbc.273.9.4937	http://dx.doi.org/10.1074/jbc.273.9.4937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478938	hybrid			2022-12-27	WOS:000072310400022
J	Jiang, F; Kelly, BL; Hagopian, K; Greenberg, ML				Jiang, F; Kelly, BL; Hagopian, K; Greenberg, ML			Purification and characterization of phosphatidylglycerolphosphate synthase from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; MIXED MICELLAR ANALYSIS; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEINS; ESCHERICHIA-COLI; PHOSPHATIDYLINOSITOL SYNTHASE; CYTOCHROME-OXIDASE; CONTACT SITES; CARDIOLIPIN; REQUIREMENT	The enzyme CDP-diacylglycerol:sn-glycerol-3-phosphate 3-phosphatidyltransferase (phosphatidylglycerolphosphate synthase; PGPS(4); EC 2.7.8.5) is located in the mitochondrial inner membrane and catalyzes the committed step in the cardiolipin branch of phospholipid synthesis. Previous studies revealed that PGPS is the most highly regulated enzyme in cardiolipin biosynthesis in both Saccharomyces cerevisiae and Schizosaccharomyces pombe, In this work, we report the purification to homogeneity of PGPS from S. pombe, The enzyme was solubilized from the mitochondrial membrane of S. pombe with Triton X-100. The solubilized enzyme, together with the associated detergent and intrinsic lipids, had a molecular mass of 120 kDa, as determined by gel filtration. The enzyme was further purified using salt-induced phase separation, gel filtration, and ionic exchange, hydroxylapatite, and affinity chromatographies, The procedure yielded a homogeneous protein preparation, evidenced by both SDS-polyacrylamide gel electrophoresis (PAGE) and agarose isoelectric focusing under nondenaturing conditions. The purified enzyme had an apparent molecular mass of 60 kDa as determined by SDS-PAGE. The enzyme showed a strong dependence on lipid cofactors for activity in vitro. While both phosphatidic acid and CDP-diacylglycerol appeared to be activators, the most significant activation was observed with cardiolipin, The possible physiological significance of the lipid cofactor effect is discussed, This is the first purification of a eucaryotic PGPS enzyme to date, and the first purification of a phospholipid biosynthetic enzyme from S. pombe.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu			NIGMS NIH HHS [GM37723] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037723] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEDO JC, 1993, ELECTROPHORESIS, V14, P88, DOI 10.1002/elps.1150140116; AMES GFL, 1976, BIOCHEMISTRY-US, V15, P616, DOI 10.1021/bi00648a026; ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; ANTONSSON BE, 1994, BIOCHEM J, V297, P517, DOI 10.1042/bj2970517; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; AWASTHI YC, 1971, BIOCHIM BIOPHYS ACTA, V226, P42, DOI 10.1016/0005-2728(71)90176-9; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1983, CAN J MICROBIOL, V29, P1452, DOI 10.1139/m83-222; CONVERSE CA, 1975, SCIENCE, V189, P469, DOI 10.1126/science.1154021; COUSMINER JJ, 1982, J BACTERIOL, V151, P1372, DOI 10.1128/JB.151.3.1372-1379.1982; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DUTT A, 1985, BIOCHEMISTRY-US, V24, P1074, DOI 10.1021/bi00326a001; EATON BR, 1976, ARCH BIOCHEM BIOPHYS, V176, P604, DOI 10.1016/0003-9861(76)90204-6; ENDO T, 1988, EMBO J, V7, P1153, DOI 10.1002/j.1460-2075.1988.tb02925.x; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; GAYNOR PM, 1991, J BACTERIOL, V173, P6124, DOI 10.1128/jb.173.19.6124-6131.1991; GAYNOR PM, 1992, J BACTERIOL, V174, P5711, DOI 10.1128/JB.174.17.5711-5718.1992; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HAJRA AK, 1968, J BIOL CHEM, V243, P3458; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; HIRABAYASHI T, 1976, BIOCHEMISTRY-US, V15, P5205, DOI 10.1021/bi00669a002; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; KARKHOFFSCHWEIZER RR, 1991, J BACTERIOL, V173, P6132, DOI 10.1128/jb.173.19.6132-6138.1991; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P974, DOI 10.1021/bi00650a005; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P5212, DOI 10.1021/bi00669a003; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; PARISH CR, 1986, ANAL BIOCHEM, V156, P495, DOI 10.1016/0003-2697(86)90284-8; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; RIETVELD A, 1983, EMBO J, V2, P907, DOI 10.1002/j.1460-2075.1983.tb01520.x; RIGHETTI PG, 1979, RECENT DEV CHROMATOG, P1; SANDERMANN H, 1986, PROGR PROTEIN LIPID, P197; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SNOW PM, 1984, J IMMUNOL, V133, P2058; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WARLOW RS, 1990, ELECTROPHORESIS, V11, P53, DOI 10.1002/elps.1150110112; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048	44	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4681	4688		10.1074/jbc.273.8.4681	http://dx.doi.org/10.1074/jbc.273.8.4681			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468529	hybrid			2022-12-27	WOS:000072115000057
J	Ma, TH; Yang, BX; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS				Ma, TH; Yang, BX; Gillespie, A; Carlson, EJ; Epstein, CJ; Verkman, AS			Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; CHIP28; MEMBRANE; RECONSTITUTION; LOCALIZATION; LIPOSOMES; CLONING; PROTEIN; TUBULE	Water channel aquaporin-1 (AQP1) is strongly ex pressed in kidney in proximal tubule and descending limb of Henle epithelia and, in vasa recta endothelia, The grossly normal phenotype in human subjects deficient in AQP1 (Colton null blood group) and in AQP4 knockout mice has suggested that aquaporins (other than the vasopressin-regulated water channel AQP2) may not be important in mammalian physiology, We have generated transgenic mice lacking detectable AQP1. by targeted gene disruption, In kidney proximal tubule membrane vesicles from knockout mice, osmotic water permeability was reduced 8-fold compared with vesicles from wild-type mice, Although the knockout mice were grossly normal In terms of survival, physical appearance, and organ morphology, they became severely dehydrated and lethargic after water deprivation for 36 h, Body weight decreased by 35 +/- 2%, serum osmolality increased to >500 mOsm, and urinary osmolality (657 +/- 59 mOsm) did not change from that before water deprivation. In contrast, wild-type and heterozygous mice remained active after water deprivation, body weight decreased by 20-22%, serum osmolality remained normal (810-330 mOsm), and urine osmolality rose to >2500 mOsm, Urine [Na+] in water-deprived knockout mice was <10 mM, and urine osmolality was slot increased by the V2 agonist DDAVP, The results suggest that AQP1 knockout mice are unable to create a hypertonic medullary interstitium by countercurrent multiplication, AQP1 is thus required for the formation of a concentrated urine by the kidney.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051854, P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51854, HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; Booth A G, 1974, Biochem J, V142, P575; CHOU CL, 1995, AM J PHYSIOL-RENAL, V269, pF70, DOI 10.1152/ajprenal.1995.269.1.F70; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, AM J PHYSIOL, V266, pC893, DOI 10.1152/ajpcell.1994.266.4.C893; JEN JF, 1994, B MATH BIOL, V56, P491, DOI 10.1007/BF02460468; Knepper MA, 1997, AM J PHYSIOL-RENAL, V272, pF3, DOI 10.1152/ajprenal.1997.272.1.F3; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Pallone TL, 1997, AM J PHYSIOL-RENAL, V272, pF587, DOI 10.1152/ajprenal.1997.272.5.F587; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; VERKMAN AS, 1985, AM J PHYSIOL, V248, pF650, DOI 10.1152/ajprenal.1985.248.5.F650; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	24	452	472	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4296	4299		10.1074/jbc.273.8.4296	http://dx.doi.org/10.1074/jbc.273.8.4296			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468475	hybrid			2022-12-27	WOS:000072115000003
J	Patturajan, M; Schulte, RJ; Sefton, BM; Berezney, R; Vincent, M; Bensaude, O; Warren, SL; Corden, JL				Patturajan, M; Schulte, RJ; Sefton, BM; Berezney, R; Vincent, M; Bensaude, O; Warren, SL; Corden, JL			Growth-related changes in phosphorylation of yeast RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TRANSCRIPTION FACTOR TFIIH; CDK-ACTIVATING KINASE; TATA-BINDING PROTEIN; LARGEST SUBUNIT; SACCHAROMYCES-CEREVISIAE; NONPHOSPHORYLATED FORM; HEPTAPEPTIDE REPEAT; SPLICING COMPLEXES; STATIONARY-PHASE	The largest subunit of RNA polymerase II contains a unique C-terminal domain (CTD) consisting of tandem repeats of the consensus heptapeptide sequence Tyr(1)-Ser(2)-Pro(3)-Thr(4)-Ser(5)Pro(6)-Ser(7). Two forms of the largest subunit can be separated by SDS-polyacrylamide gel electrophoresis. The faster migrating form termed IIA contains little or no phosphate on the CTD, whereas the slower migrating II0 form is multiply phosphorylated. CTD kinases with different phosphoryl acceptor specificities are able to convert IIA to II0 in vitro, and different phosphoisomers have been identified in vivo. In this paper we report the binding specificities of a set of monoclonal antibodies that recognize different phosphoepitopes on the CTD. Monoclonal antibodies like H5 recognize phosphoserine in position 2, whereas monoclonal antibodies like H14 recognize phosphoserine in position 5. The relative abundance of these phosphoepitopes changes when growing yeast enter stationary phase or are heat-shocked. These results indicate that phosphorylation of different CTD phosphoacceptor sites are independently regulated in response to environmental signals.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Salk Inst Biol Studies, San Diego, CA 92186 USA; Nexstar Pharmaceut, Boulder, CO 80301 USA; SUNY Buffalo, Dept Sci Biol, Buffalo, NY 14260 USA; Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; Rech Sci Vie & Sante, Quebec City, PQ G1K 7P4, Canada; ENS, F-75230 Paris 05, France	Johns Hopkins University; Salk Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Laval University; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Corden, JL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.			Bensaude, Olivier/0000-0002-0259-6608				Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BREGMAN DB, 1994, J CELL SCI, V107, P387; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; CHABOT B, 1995, NUCLEIC ACIDS RES, V23, P3206, DOI 10.1093/nar/23.16.3206; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Dobbins JR, 1996, INT J PEPT PROT RES, V47, P260; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; HARDING MM, 1992, J MED CHEM, V35, P4658, DOI 10.1021/jm00103a002; KANG ME, 1993, J BIOL CHEM, V268, P25033; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PIPER P, 1990, ANTON LEEUW INT J G, V58, P195, DOI 10.1007/BF00548933; Rickert P, 1996, ONCOGENE, V12, P2631; SCHULTE RJ, UNPUB; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; Seydoux G, 1997, DEVELOPMENT, V124, P2191; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SMITH DB, 1995, CURRENT PROTOCOLS MO, V2; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Steinmetz EJ, 1996, MOL CELL BIOL, V16, P6993, DOI 10.1128/mcb.16.12.6993; STONE N, 1992, J BIOL CHEM, V267, P6353; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; THIBODEAU A, 1991, EXP CELL RES, V195, P145, DOI 10.1016/0014-4827(91)90510-2; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Voellmy R, 1996, EXS, V77, P121; WARREN SL, 1992, J CELL SCI, V103, P381; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WEST ML, 1995, GENETICS, V140, P1223; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; Yuryev A, 1996, GENETICS, V143, P661; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG J, 1991, J BIOL CHEM, V266, P2290; [No title captured]	78	212	212	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4689	4694		10.1074/jbc.273.8.4689	http://dx.doi.org/10.1074/jbc.273.8.4689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468530	hybrid			2022-12-27	WOS:000072115000058
J	Hermesh, O; Kalderon, B; Bar-Tana, J				Hermesh, O; Kalderon, B; Bar-Tana, J			Mitochondria uncoupling by a long chain fatty acyl analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; OXIDATIVE-PHOSPHORYLATION; ENERGY-METABOLISM; OXYGEN-CONSUMPTION; ADP/ATP CARRIER; INNER MEMBRANE; ACIDS; MECHANISM; TRANSPORT; PERMEABILITY	Mitochondria uncoupling by fatty acids in vivo is still questionable, being confounded by their dual role as substrates for oxidation and as putative genuine uncouplers of oxidative phosphorylation, To dissociate between substrate and the uncoupling activity of fatty acids in oxidative phosphorylation, the uncoupling effect was studied here using a nonmetabolizable long chain fatty acyl analogue, beta,beta'-Methyl-substituted hexadecane alpha,omega-dioic acid (MEDICA 16) is reported here to induce in freshly isolated liver cells a saturable oligomycin-insensitive decrease in mitochondrial proton motive force with a concomitant increase in cellular respiration, Similarly, MEDICA 16 induced a saturable decrease in membrane potential, proton gradient, and proton motive force in isolated liver and heart mitochondria accompanied by an increase in mitochondrial respiration, Uncoupling by MEDICA 16 in isolated mitochondria was partially suppressed by added atractyloside. Hence, fatty acids may act as genuine uncouplers of cellular oxidative phosphorylation by interacting with specific mitochondrial proteins, including the adenine nucleotide translocase.	Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Tana, J (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, POB 12272, IL-91120 Jerusalem, Israel.	bartanaj@yam-suff.cc.huji.ac.il						ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; BARTANA J, 1985, J BIOL CHEM, V260, P8404; BERRY MN, 1991, LABORATORY TECHNIQUE, V21, P15; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BRAND MD, 1986, BIOCHEM SOC T, V14, P1200, DOI 10.1042/bst0141200; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; Cho JH, 1997, BIOCHEM J, V324, P971, DOI 10.1042/bj3240971; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; DEBEER LJ, 1974, EUR J BIOCHEM, V47, P591, DOI 10.1111/j.1432-1033.1974.tb03730.x; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; FAHN S, 1966, J BIOL CHEM, V241, P1882; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; HASSINEN I, 1990, BIOCHIM BIOPHYS ACTA, V1019, P73, DOI 10.1016/0005-2728(90)90126-O; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; Hertz R, 1996, BIOCHEM J, V319, P241, DOI 10.1042/bj3190241; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; Jezek P, 1997, FEBS LETT, V408, P161, DOI 10.1016/S0014-5793(97)00334-7; KALDERON B, 1992, ENDOCRINOLOGY, V131, P1629, DOI 10.1210/en.131.4.1629; KALDERON B, 1995, ENDOCRINOLOGY, V136, P3552, DOI 10.1210/en.136.8.3552; KINGSLEYHICKMAN PB, 1990, J BIOL CHEM, V265, P1545; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Krauth J, 1988, DISTRIBUTION FREE ST; Liu GY, 1996, J BIOL CHEM, V271, P25338, DOI 10.1074/jbc.271.41.25338; LUVISETTO S, 1987, BIOCHEMISTRY-US, V26, P7332, DOI 10.1021/bi00397a021; LUVISETTO S, 1990, J BIOENERG BIOMEMBR, V22, P635, DOI 10.1007/BF00809068; Mayorek N, 1997, DIABETES, V46, P1958, DOI 10.2337/diabetes.46.12.1958; Mela L, 1979, Methods Enzymol, V55, P39; NOBES CD, 1990, J BIOL CHEM, V265, P12910; NOBES CD, 1990, J BIOL CHEM, V265, P12903; PIETROBON D, 1987, BIOCHEMISTRY-US, V26, P7339, DOI 10.1021/bi00397a022; PLOMP PJAM, 1985, FEBS LETT, V193, P243, DOI 10.1016/0014-5793(85)80161-7; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; ROTTENBERG H, 1986, BIOCHEMISTRY-US, V25, P1747, DOI 10.1021/bi00355a045; Rottenberg H, 1979, Methods Enzymol, V55, P547; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; SCHOLZ R, 1984, EUR J BIOCHEM, V141, P223, DOI 10.1111/j.1432-1033.1984.tb08179.x; SCHONFELD P, 1988, BIOCHIM BIOPHYS ACTA, V936, P280, DOI 10.1016/0005-2728(88)90003-5; SCHONFELD P, 1990, FEBS LETT, V264, P246, DOI 10.1016/0014-5793(90)80259-L; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SOBOLL S, 1984, EUR J BIOCHEM, V141, P231, DOI 10.1111/j.1432-1033.1984.tb08180.x; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; WOJTCZAK L, 1976, J BIOENERG BIOMEMBR, V8, P293; WOJTCZAK L, 1974, FEBS LETT, V44, P25, DOI 10.1016/0014-5793(74)80298-X	45	59	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3937	3942		10.1074/jbc.273.7.3937	http://dx.doi.org/10.1074/jbc.273.7.3937			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461579	hybrid			2022-12-27	WOS:000072048400021
J	Parenti, A; Morbidelli, L; Cui, XL; Douglas, JG; Hood, JD; Granger, HJ; Ledda, F; Ziche, M				Parenti, A; Morbidelli, L; Cui, XL; Douglas, JG; Hood, JD; Granger, HJ; Ledda, F; Ziche, M			Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase(1/2) activation in postcapillary endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE KINASE; MAP KINASE; PERMEABILITY FACTOR; TUMOR-GROWTH; CELL GROWTH; IN-VITRO; RECEPTOR; BOVINE; DIFFERENTIATION	We recently demonstrated that nitric oxide (NO) significantly contributes to the mitogenic effect of vascular endothelial growth factor (VEGF), suggesting a role for the NO pathway in the signaling cascade following kinase-derivative receptor activation in vascular endothelium. The aim of this study was to investigate the intracellular pathways linked to VEGF/NO-induced endothelial cell proliferation, We assessed the activity of the mitogen-activated protein kinase (MAPK) that is specifically activated by growth factors, extracellular-regulated kinase (ERK1/2), on cultured microvascular endothelium isolated from coronary postcapillary venules, ERK1/2 was immunoprecipitated, and its activity was assessed with an immunocomplex kinase assay. in endothelial cells exposed for 5 min to the NO donor drug sodium nitroprusside at a concentration of 100 mu M, ERK1/2 activity significantly increased. VEGF produced a time-and concentration-dependent activation of ERK1/2. Maximal activity was obtained after 5 min of stimulation at a concentration of 10 ng/ml., The specific MAPK kinase inhibitor PD 98059 abolished ERK1/2 activation and endothelial cell proliferation in a concentration-dependent manner in response to VEGF and sodium nitroprusside. The NO synthase inhibitor N-omega-monomethyl-L-arginine, as well as the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one blocked the activation of ERK1/2 induced by VEGF, suggesting that NO and cGMP contributed to the VEGF-dependent ERK1/2 activation, These results demonstrate for the first time that kinase-derivative receptor activation triggers the NO synthase/guanylate cyclase pathway to activate the MAPK cascade and substantiates the hypothesis that the activation of ERK1/2 is necessary for VEGF-induced endothelial cell proliferation.	Univ Florence, Dept Preclin & Clin Pharmacol, I-50134 Florence, Italy; Case Western Reserve Univ, Sch Med, Div Hypertens, Cleveland, OH 44106 USA; Texas A&M Univ, Hlth Sci Ctr, Microcirculat Res Inst, College Stn, TX 77843 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Physiol, College Stn, TX 77843 USA	University of Florence; Case Western Reserve University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Ziche, M (corresponding author), Univ Florence, Dept Preclin & Clin Pharmacol, Viale Morgagni 65, I-50134 Florence, Italy.	ziche@stat.ds.unifi.it	Morbidelli, Lucia/AAC-7858-2020; Morbidelli, Lucia/K-4053-2016	Morbidelli, Lucia/0000-0001-8148-7049; Parenti, Astrid/0000-0002-7980-6853	NHLBI NIH HHS [HL-21498] Funding Source: Medline; PHS HHS [41618] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021498, R37HL021498] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER H, 1995, J IMMUNOL, V154, P4710; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BREIER G, 1992, DEVELOPMENT, V114, P521; BROCK TA, 1991, AM J PATHOL, V138, P213; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GOTO F, 1993, LAB INVEST, V69, P508; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; PIPILISYNETOS E, 1995, BRIT J PHARMACOL, V116, P1829, DOI 10.1111/j.1476-5381.1995.tb16670.x; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; SCHELLING ME, 1988, AM J PHYSIOL, V254, pH1211, DOI 10.1152/ajpheart.1988.254.6.H1211; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZICHE M, 1993, AM J PHYSIOL, V265, pH569, DOI 10.1152/ajpheart.1993.265.2.H569; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	45	389	404	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4220	4226		10.1074/jbc.273.7.4220	http://dx.doi.org/10.1074/jbc.273.7.4220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461619	hybrid			2022-12-27	WOS:000072048400061
J	Scotto, C; Mely, Y; Ohshima, H; Garin, J; Cochet, C; Chambaz, E; Baudier, J				Scotto, C; Mely, Y; Ohshima, H; Garin, J; Cochet, C; Chambaz, E; Baudier, J			Cysteine oxidation in the mitogenic S100B protein leads to changes in phosphorylation by catalytic CKII-alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; NITRIC-OXIDE; BINDING PROPERTIES; NEURITE EXTENSION; CALCIUM-BINDING; IONS BINDING; BOVINE BRAIN; CELLS; S100-ALPHA-ALPHA; PEROXYNITRITE	The glial-derived calcium-binding protein S100B can be secreted to act as a neurotrophic factor or a mitogen, stimulating proliferation of glial cells, The extracellular S100B activities rely on the oxidation of the protein cysteine residues (Kligman, D., and Marshak, D. R. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 7136-7139; Winningham-Major, F., Staecker, J, L., Barger, S, W., Coats, S., and Van Eldik, L. J. (1989) J. Cell Biol, 109, 3063-3071), Here we show that oxidation of the S100B cysteine residues, Cys-68 and Cys-84, induces a conformational change in the protein structure, unmasking a canonical CKII phosphorylation site located within the typical EF-hand calcium-binding site II beta, Intrasubunit disulfide-bridged S100B monomer and disulfide-bonded S100B dimer are phosphorylated by the catalytic CKII-alpha subunit on Ser-62 with a K-m of 0.5 mu M and a V-max of 10 pmol/min/100 pmol of S100B, Oxidized S100B is the best in vitro CKII-alpha substrate identified so far, Next we show that intrasubunit disulfide-bridged S100B monomer is the most potent S100B species to stimulate [H-3]thymidine uptake by C6 glial cells in culture, In addition, the phosphorylated intrasubunit disulfide-bridged S100B monomer retains apparent mitogenic activity toward C6 glial cells, and hence, P-32-labeled S100B should be a useful probe for characterizing the mechanisms by which extracellular oxidized S100B functions, Finally, we show that formation of intrasubunit disulfide-bridged S100B monomer is stimulated by peroxynitrite anion, suggesting that production of mitogenic S100B species could be enhanced in neuropathology associated with peroxynitrite anion production.	CEN Grenoble, BRCE, Dept Biol Mol & Struct, INSERM U244, F-38054 Grenoble 9, France; CEN Grenoble, BRCE, Dept Biol Mol & Struct, INSERM U244, F-38054 Grenoble, France; CEA, Dept Biol Mol & Struct, F-38054 Grenoble, France; CEN Grenoble, CP, Dept Biol Mol & Struct, Lab Chim Prot, F-38054 Grenoble, France; UFR Sci Pharmaceut, Biophys Lab, F-69372 Lyon, France; Ctr Int Rech Canc, F-69372 Lyon, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; CEA; World Health Organization; International Agency for Research on Cancer (IARC)	Baudier, J (corresponding author), CEN Grenoble, BRCE, Dept Biol Mol & Struct, INSERM U244, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Ohshima, Hiroshi/E-8044-2010; Baudier, Jacques/O-2183-2016	Cochet, Claude/0000-0002-1772-4270; jacques, baudier/0000-0001-8427-4444				Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1986, BIOCHEMISTRY-US, V25, P6934, DOI 10.1021/bi00370a029; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MELY Y, 1990, J NEUROCHEM, V55, P1100, DOI 10.1111/j.1471-4159.1990.tb03111.x; POU S, 1992, J BIOL CHEM, V267, P24173; QUADRONI M, 1994, J BIOL CHEM, V269, P16116; RADI R, 1991, J BIOL CHEM, V266, P4244; REED JW, 1974, J AM CHEM SOC, V96, P1248, DOI 10.1021/ja00811a062; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDTSPANIOL I, 1993, CELL MOL BIOL RES, V39, P761; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SENDTNER M, 1994, CURR BIOL, V4, P1036, DOI 10.1016/S0960-9822(00)00237-2; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Snapes Dr., 1991, GIRLFRENZY; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063	35	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3901	3908		10.1074/jbc.273.7.3901	http://dx.doi.org/10.1074/jbc.273.7.3901			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461574	hybrid			2022-12-27	WOS:000072048400016
J	Fanger, GR; Widmann, C; Porter, AC; Sather, S; Johnson, GL; Vaillancourt, RR				Fanger, GR; Widmann, C; Porter, AC; Sather, S; Johnson, GL; Vaillancourt, RR			14-3-3 proteins interact with specific MEK kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; 14-3-3-PROTEINS; ACTIVATION; RAF-1; PATHWAYS; YEAST; ERK; RAS; PHOSPHORYLATION; ASSOCIATION	MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase) kinases (MEKKs) regulate c-Jun N-terminal kinase and extracellular response kinase pathways. The 14-3-3 zeta and 14-3-3 epsilon isoforms were isolated in a two-hybrid screen for proteins interacting with the N-terminal regulatory domain of MEKK3. 14-3-3 proteins bound both the N-terminal regulatory and C-terminal kinase domains of MEKK3. The binding affinity of 14-3-3 for the MEKK3 N terminus was 90 nM, demonstrating a high affinity interaction. 14-3-3 proteins also interacted with MEKK1 and MEKK2, but not MEKK4. Endogenous 14-3-3 protein and MEKK1 and MEKK2 were similarly distributed in the cell, consistent with their in vitro interactions. MEKK1 and 14-3-3 proteins colocalized using two color digital confocal immunofluorescence. Binding of 14-3-3 proteins mapped to the N-terminal 393 residues of 196-kDa MEKK1. Unlike MEKK2 and MEKK3, the C-terminal kinase domain of MEKK1 demonstrated little or no ability to interact with 14-3-3 proteins. MEKK1, but not MEKK2, -3 or -4, is a caspase-3 substrate that when cleaved releases the kinase domain from the N-terminal regulatory domain. Functionally, caspase-3 cleavage of MEKK1 releases the kinase domain from the N-terminal 14-3-3-binding region, demonstrating that caspases can selectively alter protein kinase interactions with regulatory proteins. With regard to MEKK1, -2 and -3, 14-3-3 proteins do not appear to directly influence activity, but rather function as "scaffolds" for protein-protein interactions.	Univ Arizona, Coll Pharm, Dept Pharmacol Toxicol, Tucson, AZ 85721 USA; Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	University of Arizona; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol Toxicol, Tucson, AZ 85721 USA.	vaillancourt@pharmacy.arizona.edu	Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363	NIDDK NIH HHS [DK37871, DK48845] Funding Source: Medline; NIGMS NIH HHS [GM18643-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048845, R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018643] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Banik U, 1997, J BIOL CHEM, V272, P26219, DOI 10.1074/jbc.272.42.26219; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRINTEN JA, 1994, GENETICS, V138, P609; RAGHAVAN M, 1995, STRUCTURE, V3, P331, DOI 10.1016/S0969-2126(01)00164-2; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; YAN MH, 1994, NATURE, V372, P798; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281	45	132	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3476	3483		10.1074/jbc.273.6.3476	http://dx.doi.org/10.1074/jbc.273.6.3476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452471	hybrid			2022-12-27	WOS:000071822300056
J	Ono, S; Benian, GM				Ono, S; Benian, GM			Two Caenorhabditis elegans actin depolymerizing factor/cofilin proteins, encoded by the unc-60 gene, differentially regulate actin filament dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN SKELETAL-MUSCLE; ACANTHAMOEBA-CASTELLANII; BINDING PROTEINS; ADP-ACTIN; F-ACTIN; COFILIN; PURIFICATION; TROPOMYOSIN; ACTOPHORIN; BRAIN	The Caenorhabditis elegans unc-60 gene encodes two actin depolymerizing factor/cofilin proteins which are implicated in the regulation of actin filament assembly in body wall muscle. We examined the interaction of recombinant UNC-60A and B proteins with actin and found that they differentially regulate actin filament dynamics. Co-pelleting assays with F-actin showed that UNC-60A depolymerized but did not remain bound to F-actin, whereas UNC-60B bound to but did not depolymerize F-actin. In the pH range of 6.8-8.0, the apparent activities of UNC-60A and B did not change although UNC-60A showed greater actin-depolymerizing activity at higher pH. These activities were further confirmed by a light scattering assay and electron microscopy. The effects of these proteins on actin polymerization were quite different. UNC-60A inhibited polymerization in a concentration dependent manner. On the other hand, UNC-60B strongly inhibited the nucleation process but accelerated the following elongation step, However, an excess amount of UNC-60B increased the amount of unpolymerized actin. These results indicate that UNC-60A depolymerizes actin filaments and inhibits actin polymerization, whereas UNC-60B strongly binds to F-actin without depolymerizing it and, through binding to G-actin, changes the rate of actin polymerization depending on the UNC-60B:actin ratio. These data suggest that the two UNC-60 isoforms play differential roles in regulating actin filament dynamics in, vivo.	Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Ono, S (corresponding author), Emory Univ, Dept Pathol, Woodruff Mem Bldg 7007A, Atlanta, GA 30322 USA.		Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398				ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ABE H, 1989, J BIOCHEM-TOKYO, V106, P172, DOI 10.1093/oxfordjournals.jbchem.a122810; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIER MF, 1988, J BIOL CHEM, V263, P817; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COOPER JA, 1986, J BIOL CHEM, V261, P477; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; GIULIANO KA, 1988, BIOCHEMISTRY-US, V27, P8931, DOI 10.1021/bi00425a009; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; HIGASHI S, 1965, J MOL BIOL, V12, P843, DOI 10.1016/S0022-2836(65)80332-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; MABUCHI I, 1983, J CELL BIOL, V97, P1612, DOI 10.1083/jcb.97.5.1612; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MATSUMURA F, 1983, J BIOL CHEM, V258, P6636; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCKIM KS, 1994, MOL GEN GENET, V242, P346, DOI 10.1007/BF00280425; MCKIM KS, 1988, GENETICS, V118, P49; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; Nagaoka R, 1996, J MUSCLE RES CELL M, V17, P463, DOI 10.1007/BF00123362; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; OHSHIMA S, 1989, J BIOCHEM-TOKYO, V105, P855, DOI 10.1093/oxfordjournals.jbchem.a122765; ONO S, 1994, J BIOL CHEM, V269, P15280; Rosenblatt J, 1997, J CELL BIOL, V136, P1323, DOI 10.1083/jcb.136.6.1323; SHIMIZU N, 1986, J BIOCHEM-TOKYO, V99, P751, DOI 10.1093/oxfordjournals.jbchem.a135534; WATERSTON RH, 1980, DEV BIOL, V77, P271, DOI 10.1016/0012-1606(80)90475-3; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410	35	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3778	3783		10.1074/jbc.273.6.3778	http://dx.doi.org/10.1074/jbc.273.6.3778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452511	hybrid			2022-12-27	WOS:000071822300096
J	Satoh, A; Nakanishi, H; Obaishi, H; Wada, M; Takahashi, K; Satoh, K; Hirao, K; Nishioka, H; Hata, Y; Mizoguchi, A; Takai, Y				Satoh, A; Nakanishi, H; Obaishi, H; Wada, M; Takahashi, K; Satoh, K; Hirao, K; Nishioka, H; Hata, Y; Mizoguchi, A; Takai, Y			Neurabin-II/spinophilin - An actin filament-binding protein with one PDZ domain localized at cadherin-based cell-cell adhesion sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; COMPLEX; JUNCTIONS; CATENIN; MODEL	In a preceding paper, we reported a novel actin filament (F-actin)-binding protein, named neurabin, which was specifically expressed in neural tissue and implicated in neurite formation, We purified from rat brain another F-actin-binding protein, which had a domain organization similar to that of neurabin but was ubiquitously expressed, and named it neurabin-II, The original neurabin, renamed neurabin-I, had 1095 amino acids and a calculated M-r of 122,729, whereas neurabin-II had 817 amino acids and a calculated M-r of 89,642. Both neurabin-I and -II had one F-actin-binding domain at the N-terminal region, one PDZ domain at the middle region, a domain known to interact with transmembrane proteins, and domains predicted to form coiled-coil structures at the C-terminal region, Both neurabin-I and -II bound along the sides of F-actin and showed F-actin-cross-linking activity. The subcellular distribution analysis indicated that neurabin-II was enriched at the postsynaptic density fraction in rat brain and the adherens junction fraction in rat liver, Immunofluorescence microscopic analysis revealed that neurabin-II was highly concentrated at the synapse in primary cultured rat hippocampal neurons and at the cadherin-based cell-cell adhesion sites in Madin-Darby canine kidney cells, Neurabin-II turned out to be the same as a recently reported protein phosphatase 1-binding protein named spinophilin, These results suggest that neurabin-II/spinophilin plays an important role in linking the actin cytoskeleton to the plasma membrane.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project, Kobe, Hyogo 65122, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 60601, Japan	Japan Science & Technology Agency (JST); Osaka University; Kyoto University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Osaka 565, Japan.			Nakanishi, Hiroyuki/0000-0002-9765-0266				Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; FRASER AB, 1975, BIOCHEMISTRY-US, V14, P2207, DOI 10.1021/bi00681a025; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Serres M, 1997, EXP CELL RES, V231, P163, DOI 10.1006/excr.1996.3443; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767	30	186	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3470	3475		10.1074/jbc.273.6.3470	http://dx.doi.org/10.1074/jbc.273.6.3470			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452470	hybrid			2022-12-27	WOS:000071822300055
J	Schalinske, KL; Chen, OS; Eisenstein, RS				Schalinske, KL; Chen, OS; Eisenstein, RS			Iron differentially stimulates translation of mitochondrial aconitase and ferritin mRNAs in mammalian cells - Implications for iron regulatory proteins as regulators of mitochondrial citrate utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; SYNTHASE MESSENGER-RNA; RESPONSIVE ELEMENT; TRANSFERRIN RECEPTOR; CYTOSOLIC ACONITASE; RAT HEPATOCYTES; HIGH-AFFINITY; REGION; PHOSPHORYLATION; IDENTIFICATION	Utilization of mRNAs containing iron-responsive elements (IREs) is modulated by iron-regulated RNA-binding proteins (iron regulatory proteins). We examine herein whether iron differentially affects translation of ferritin and mitochondrial aconitase (m-Acon) mRNAs because they contain a similar but not identical IRE in their 5'-untranslated regions. First, we demonstrate that m-Acon synthesis is iron-regulated in mammalian cells. In HL-60 cells, hemin (an iron source) stimulated m-Acon synthesis 3-fold after 4 h compared with cells treated with an iron chelator (Desferal). Furthermore, hemin stimulated m-Acon synthesis 2-4-fold in several cell lines. Second, me show that iron modulates the polysomal association of m-Acon mRNA. We observed m-Acon mRNA in both ribonucleoprotein and polyribosomal fractions of HL-60 cells. Hemin significantly increased the polyribosomal association and decreased the ribonucleoprotein abundance of m-Acon mRNA in HL-60 cells. Third, our results indicate that iron differentially regulates translation of m-Acon and ferritin mRNAs. A dose response to hemin in HL-60 cells elicited a 2-2.4-fold increase in m-Acon synthesis within 5 h compared with untreated cells, whereas ferritin synthesis was stimulated 20-100-fold. We conclude that iron modulates m-Acon synthesis at the translational level and that iron regulatory proteins appear to differentially affect translation of IRE-containing mRNAs.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Eisenstein, RS (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.	eisenste@nutrisci.wisc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047219, R29DK047219] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AISEN P, 1968, BIOCHEM BIOPH RES CO, V32, P220, DOI 10.1016/0006-291X(68)90372-0; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; BAKER E, 1985, AM J PHYSIOL, V248, pG93, DOI 10.1152/ajpgi.1985.248.1.G93; BAKER E, 1981, BRIT J HAEMATOL, V47, P493, DOI 10.1111/j.1365-2141.1981.tb02678.x; BARTON HA, 1990, J BIOL CHEM, V265, P7000; Beaumont C, 1996, J BIOL CHEM, V271, P7923, DOI 10.1074/jbc.271.14.7923; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BEUTLER E, 1959, J CLIN INVEST, V38, P1605, DOI 10.1172/JCI103939; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Chen O. S., 1997, FASEB Journal, V11, pA444; Chen OS, 1997, J NUTR, V127, P238, DOI 10.1093/jn/127.2.238; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; DIX DJ, 1993, J MOL BIOL, V231, P230, DOI 10.1006/jmbi.1993.1278; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EISENSTEIN RS, 1997, METAL IONS GENE REGU, P157; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GROOTVELD M, 1989, J BIOL CHEM, V264, P4417; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HARRIS DC, 1973, BIOCHIM BIOPHYS ACTA, V329, P156, DOI 10.1016/0304-4165(73)90019-6; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOLD EA, 1990, NUCLEIC ACIDS RES, V18, P1819, DOI 10.1093/nar/18.7.1819; MARTIN RB, 1986, J INORG BIOCHEM, V28, P181, DOI 10.1016/0162-0134(86)80081-2; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; OHIRA Y, 1987, AM J PHYSIOL, V253, pC639, DOI 10.1152/ajpcell.1987.253.5.C639; PAGE MA, 1984, AM J PHYSIOL, V246, pG26, DOI 10.1152/ajpgi.1984.246.1.G26; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; SHULL GE, 1982, J BIOL CHEM, V257, P4187; THEIL EC, 1994, BIOCHEM J, V304, P1; Thorp HH, 1996, INORG CHEM, V35, P2773, DOI 10.1021/ic951094u; TREFFRY A, 1979, BIOCHEM J, V181, P709, DOI 10.1042/bj1810709; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	52	66	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3740	3746		10.1074/jbc.273.6.3740	http://dx.doi.org/10.1074/jbc.273.6.3740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452506	hybrid			2022-12-27	WOS:000071822300091
J	Xu, SJ; Wang, YP; Roe, B; Pearson, WR				Xu, SJ; Wang, YP; Roe, B; Pearson, WR			Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER RISK; MAMMALIAN-CELLS; BLADDER-CANCER; HOMOLOGY REQUIREMENTS; NULL GENOTYPE; ALU REPEATS; M1 GSTM1; SUSCEPTIBILITY; SEQUENCES; CLONING	A partial physical map has been constructed of the human class Mu glutathione S-transferase genes on chromosome 1p13.3. The glutathione S-transferase genes in this cluster are spaced about 20 kilobase pairs (kb) apart, and arranged as 5'-GSTM4-GSTM2-GSTM1-GSTM5-3'. This map has been used to localize the end points of the polymorphic GSTM1 deletion, The left repeated region is 5 kb downstream from the 3'-end of the GSTM2 gene and 5 kb upstream from the beginning of the GSTM1 gene; the right repeated region is 5 kb downstream from the 5'-end of the GSTM1 and 10 kb upstream from the 5'-end of the GSTM5 gene. The GSTM1-0 deletion produces a novel 7.4-kb HindIII fragment with the loss of 10.3- and 11.4-kb HindIII fragments. The same novel fragment was seen in 13 unrelated individuals (20 null alleles), suggesting that most GSTM1-0 deletions involve recombinations between the same two regions. We have cloned and sequenced the deletion junction that is produced at the GSTM1-null locus; the 5'- and 5'-flanking regions are more than 99% identical to each other and to the deletion junction sequence over 2.3 kb. Because of the high sequence identity between the left repeat, right repeat, and deletion junction regions, the crossing over cannot be localized within the 2.3-kb region, The 2.3-kb repeated region contains a reverse class IV Alu repetitive element near one end of the repeat.	Univ Virginia, Dept Biochem, Charlottesville, VA 22908 USA; Univ Oklahoma, Dept Chem, Norman, OK 73019 USA	University of Virginia; University of Oklahoma System; University of Oklahoma - Norman	Pearson, WR (corresponding author), Univ Virginia, Dept Biochem, Box 440 Jordan Hall, Charlottesville, VA 22908 USA.	wrp@virginia.edu	Pearson, William/K-4908-2019	Pearson, William/0000-0002-0727-3680	NHGRI NIH HHS [R01 HG00313] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000313] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AYARES D, 1986, P NATL ACAD SCI USA, V83, P5199, DOI 10.1073/pnas.83.14.5199; Batzer MA, 1996, J MOL EVOL, V42, P3, DOI 10.1007/BF00163204; BATZER MA, 1991, GENOMICS, V9, P481, DOI 10.1016/0888-7543(91)90414-A; BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BRITTEN RJ, 1989, P NATL ACAD SCI USA, V86, P3718, DOI 10.1073/pnas.86.10.3718; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COMSTOCK KE, 1993, J BIOL CHEM, V268, P16958; DALY AK, 1993, BRIT MED J, V307, P481, DOI 10.1136/bmj.307.6902.481; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; Heagerty A, 1996, BRIT J CANCER, V73, P44, DOI 10.1038/bjc.1996.8; HEAGERTY AHM, 1994, LANCET, V343, P266, DOI 10.1016/S0140-6736(94)91115-0; HIGGS DR, 1980, NATURE, V284, P632, DOI 10.1038/284632a0; HIRVONEN A, 1993, CARCINOGENESIS, V14, P1479, DOI 10.1093/carcin/14.7.1479; HWU HR, 1986, P NATL ACAD SCI USA, V83, P3875, DOI 10.1073/pnas.83.11.3875; LAFUENTE A, 1995, BRIT J CANCER, V72, P324, DOI 10.1038/bjc.1995.332; LIN HJ, 1994, CARCINOGENESIS, V15, P1077, DOI 10.1093/carcin/15.5.1077; LISKAY RM, 1987, GENETICS, V115, P161; LONDON SJ, 1995, J NATL CANCER I, V87, P1246, DOI 10.1093/jnci/87.16.1246; MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589; METZENBERG AB, 1991, GENETICS, V128, P143; PAN HQ, 1994, GENET ANAL-BIOMOL E, V11, P181; PEARSON WR, 1988, J BIOL CHEM, V263, P13324; PEARSON WR, 1993, AM J HUM GENET, V53, P220; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; ROSS VL, 1993, BIOCHEM J, V294, P373, DOI 10.1042/bj2940373; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCOTT AF, 1984, MOL BIOL EVOL, V1, P371; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SEIDEGARD J, 1990, CARCINOGENESIS, V11, P33, DOI 10.1093/carcin/11.1.33; SINNOTT P, 1990, P NATL ACAD SCI USA, V87, P2107, DOI 10.1073/pnas.87.6.2107; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; SUZUKI T, 1987, ANN HUM GENET, V51, P95, DOI 10.1111/j.1469-1809.1987.tb01051.x; TAYLOR JB, 1991, BIOCHEM J, V274, P587, DOI 10.1042/bj2740587; VNENCAKJONES CL, 1990, SCIENCE, V250, P1745, DOI 10.1126/science.1980158; VORACHEK WR, 1991, P NATL ACAD SCI USA, V88, P4443, DOI 10.1073/pnas.88.10.4443; WALDMAN AS, 1988, MOL CELL BIOL, V8, P5350, DOI 10.1128/MCB.8.12.5350; XU S, 1996, P INT ISSX WORKSH GL, P227; [No title captured]	43	163	173	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3517	3527		10.1074/jbc.273.6.3517	http://dx.doi.org/10.1074/jbc.273.6.3517			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452477	hybrid			2022-12-27	WOS:000071822300062
J	Grigoryev, SA; Woodcock, CL				Grigoryev, SA; Woodcock, CL			Chromatin structure in granulocytes - A link between tight compaction and accumulation of a heterochromatin-associated protein (MENT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLTRANSFERASE; HISTONE H1; NUCLEOSOME; BINDING; CELLS; DNA; CONDENSATION; DOMAIN; STAGE; MODEL	To study the mechanism of heterochromatin formation in vertebrate cells, we isolated nuclei from chicken polymorphonuclear granulocytes and examined the chromatin organization. me found granulocyte chromatin to remain insoluble after nuclease digestion and to be resistant to swelling in low salt/high pH media, Both insolubility and resistance to swelling were lost after washing with 0.3 M NaCl, a procedure that released two abundant tissue-specific proteins from granulocyte nuclei, One of them (42 kDa) is identified as MENT, a protein previously shown to be associated with repressed chromatin from mature chicken erythrocytes. We show that MENT is immunolocalized in granulocyte heterochromatin, where it is one of the most abundant chromatin proteins (similar to 2 molecules/200 base pairs of DNA). MENT is the first nuclear protein structurally related to the serine protease inhibitor family. The other abundant protein is similar to or identical with mim-1, a myeloid-specific protein that is known to be stored in cell granules and to associate with isolated nuclei. MENT (but not mim-1) binds chromatin and free DNA, and, at its physiological protein/DNA ratio, enhances compaction and the reversible Mg2+-dependent self-association of nucleosome arrays. MENT appears to promote the formation of heterochromatin by acting as a "glue" within and between chains of nucleosomes.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Grigoryev, SA (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	sergei@bio.umass.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043786, R55GM051352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43786, GM-51352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; COUTELLE C, 1974, EXP CELL RES, V88, P15, DOI 10.1016/0014-4827(74)90612-0; DAVIES HG, 1975, J CELL SCI, V17, P263; di Padua Mathieu D, 1981, J Cell Biol, V91, P135, DOI 10.1083/jcb.91.1.135; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; ERICKSON PA, 1993, METHOD CELL BIOL, V37, P283, DOI 10.1016/S0091-679X(08)60255-1; ERLANGER BF, 1964, BIOCHEMISTRY-US, V3, P1880, DOI 10.1021/bi00900a015; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; GRIGORYEV SA, 1993, EXP CELL RES, V206, P335, DOI 10.1006/excr.1993.1154; HANSEN JC, 1989, ANAL BIOCHEM, V179, P167, DOI 10.1016/0003-2697(89)90219-4; Harlow E., 1988, ANTIBODIES LAB MANUA, V2nd, P479; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LABHART P, 1981, EUR J CELL BIOL, V25, P19; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOENING UE, 1967, BIOCHEM J, V102, P251, DOI 10.1042/bj1020251; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MISHIMA K, 1991, J BIOCHEM-TOKYO, V110, P388, DOI 10.1093/oxfordjournals.jbchem.a123591; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PrymakowskaBosak M, 1996, P NATL ACAD SCI USA, V93, P10250, DOI 10.1073/pnas.93.19.10250; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; ROWLEY AF, 1988, VERTEBRATE BLOOD CEL, P257; RUIZCARRILLO A, 1980, BIOCHEMISTRY-US, V19, P2544, DOI 10.1021/bi00553a002; SCALA C, 1992, J HISTOCHEM CYTOCHEM, V40, P1799, DOI 10.1177/40.11.1431065; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; van Holde KE., 1989, SPRINGER SERIES MOL; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; VERREAULT A, 1993, COLD SPRING HARB SYM, V58, P15, DOI 10.1101/SQB.1993.058.01.005; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Wolffe A., 1995, CHROMATIN STRUCTURE; WOODCOCK CL, 1997, METHOD CELL BIOL, V53, P167; YAMADA K, 1992, FEBS LETT, V311, P203, DOI 10.1016/0014-5793(92)81102-R; ZLATANOVA J, 1992, J CELL SCI, V103, P889	60	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3082	3089		10.1074/jbc.273.5.3082	http://dx.doi.org/10.1074/jbc.273.5.3082			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446625	hybrid			2022-12-27	WOS:000071736600080
J	Koschak, A; Bugianesi, RM; Mitterdorfer, J; Kaczorowski, GJ; Garcia, ML; Knaus, HG				Koschak, A; Bugianesi, RM; Mitterdorfer, J; Kaczorowski, GJ; Garcia, ML; Knaus, HG			Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; HIGH-CONDUCTANCE; SMOOTH-MUSCLE; RAT-BRAIN; PURIFICATION; LOCALIZATION; INHIBITORS; TERMINALS; BINDING	Five novel peptidyl inhibitors of Shaker type (K(v)1) K+ channels have been purified to homogeneity from venom of the scorpion Centruroides limbatus, The complete primary amino acid sequence of the major component, hongotoxin-1 (HgTX1), has been determined and confirmed after expression of the peptide in Escherichia coli, HgTX1 inhibits I-125-margatoxin binding to rat brain membranes as well as depolarization-induced Rb-86(+) flux through homotetrameric K(v)1.1, K(v)1.2, and K(v)1.3 channels stably transfected in HEK-293 cells, but it displays much lower affinity for K(v)1.6 channels, A HgTX1, double mutant (HgTX1-A19Y/Y37F) was constructed to allow high specific activity iodination of the peptide, HgTX1-A19Y/Y37F and monoiodinated HgTX1-A19Y/Y37F are equally potent in inhibiting I-125-margatoxin binding to rat brain membranes as HgTX1 (IC50 values similar to 0.3 pM), I-125-HgTX1-A19Y/Y37F binds with subpicomolar affinities to membranes derived from HEK-293 cells expressing homotetrameric K(v)1.1, K(v)1.2, and K(v)1.3 channels and to rat brain membranes (K-d values 0.1-0.25 phl, respectively) but with lower affinity to K(v)1.6 channels (K-d 9.6 PM), and it does not interact with either K(v)1.4 or K(v)1.5 channels, Several subpopulations of native K(v)1 subunit oligomers that contribute to the rat brain HgTX1 receptor have been deduced by immunoprecipitation experiments using antibodies specific for K(v)1 subunits, HgTX1, represents a novel and useful tool with which to investigate subclasses of voltage-gated K+ channels and K(v)1 subunit assembly in different tissues.	Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria; Merck Res Labs, Dept Membrane Biochem & Biophys, Rahway, NJ 07065 USA	University of Innsbruck; Merck & Company	Knaus, HG (corresponding author), Univ Innsbruck, Inst Biochem Pharmacol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.	hans.g.knaus@uibk.ac.at						Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KNAUS HG, 1995, BIOCHEMISTRY-US, V34, P13627, DOI 10.1021/bi00041a043; Knaus HG, 1996, J NEUROSCI, V16, P955; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Koschak A, 1997, BIOCHEMISTRY-US, V36, P1943, DOI 10.1021/bi962074m; KOSCHAK A, 1997, BIOPHYS J, V71, pA32; RUSSELL SN, 1994, AM J PHYSIOL-CELL PH, V267, pC1729, DOI 10.1152/ajpcell.1994.267.6.C1729; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; VAZQUEZ J, 1990, J BIOL CHEM, V265, P15564; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588	23	103	119	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2639	2644		10.1074/jbc.273.5.2639	http://dx.doi.org/10.1074/jbc.273.5.2639			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446567	hybrid			2022-12-27	WOS:000071736600022
J	Mucha, A; Cuniasse, P; Kannan, R; Beau, F; Yiotakis, A; Basset, P; Dive, V				Mucha, A; Cuniasse, P; Kannan, R; Beau, F; Yiotakis, A; Basset, P; Dive, V			Membrane type-1 matrix metalloprotease and stromelysin-3 cleave more efficiently synthetic substrates containing unusual amino acids in their P-1 ' positions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; CATALYTIC DOMAIN; STRUCTURAL DETERMINANTS; MOUSE STROMELYSIN-3; PEPTIDE SUBSTRATE; PROGELATINASE-A; GELATINASE; SPECIFICITY; INHIBITOR; ACTIVATION	The influence of the substrate P-1' position on the specificity of two zinc matrix metalloproteases, membrane type-1 matrix metalloprotease (MT1-MMP) and stromelysin-3 (ST3), was evaluated by synthesizing a series of fluorogenic substrates of general formula dansyl-Pro-Leu-Ala-Xaa-Trp-Ala-Arg-NH2, where Xaa in the P-1' position represents unusual amino acids containing either long arylalkyl or alkyl side chains, Our data demonstrate that both MT1-MMP and ST3 cleave substrates containing in their P-1' position unusual amino acids with extremely long side chains more efficiently than the corresponding substrates with natural phenylalanine or leucine amino acids. In this series of substrates, the replacement of leucine by S-para-methoxybenzyl cysteine increased the k(cat)/K-m ratio by a factor of 37 for MT1-MMP and 9 for ST3. The substrate with a S-para-methoxybenzyl cysteine residue in the P-1' position displayed a k(cat)/K-m value of 1.59 10(6) M-1 s(-1) and 1.67 10(4) M-1 s(-1), when assayed with MT1-MMP and ST3, respectively. This substrate is thus one of the most rapidly hydrolyzed substrates so far reported for matrixins, and is the first synthetic peptide efficiently cleaved by ST3. These unexpected results for these two matrixins suggest that extracellular proteins may be cleaved by matrixins at sites containing amino acids with unusual long side chains, like those generated in vivo by some post-translational modifications.	CENS, CEA, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, INSERM, CNRS, F-67404 Illkirch Graffenstaden, France; Univ Athens, Dept Organ Chem, Organ Chem Lab, GR-15771 Athens, Greece	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National & Kapodistrian University of Athens	Dive, V (corresponding author), CENS, CEA, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.	dive@dsvidf.cea.fr		Mucha, Artur/0000-0002-6421-1371				ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; Basset P, 1997, CRIT REV ONCOL HEMAT, V26, P43, DOI 10.1016/S1040-8428(97)00010-3; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Beckett RP, 1996, EXPERT OPIN THER PAT, V6, P1305; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; Esser CK, 1997, J MED CHEM, V40, P1026, DOI 10.1021/jm960465t; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Guerin E, 1997, J BIOL CHEM, V272, P11088; Hagmann WK, 1996, ANNU REP MED CHEM, V31, P231, DOI 10.1016/S0065-7743(08)60463-7; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; MORPHY JR, 1994, BIOORG MED CHEM LETT, V4, P2747, DOI 10.1016/S0960-894X(01)80588-6; MURPHY G, 1993, J BIOL CHEM, V268, P15435; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1997, BIOL CHEM, V378, P151; NETZELARNETT S, 1991, ANAL BIOCHEM, V195, P86, DOI 10.1016/0003-2697(91)90299-9; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; ODONNELL MJ, 1978, TETRAHEDRON LETT, P2641; ODONNELL MJ, 1978, TETRAHEDRON LETT, P4625; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Okada A, 1997, GENE, V185, P187, DOI 10.1016/S0378-1119(96)00615-4; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; ROUYER N, 1994, INVAS METAST, V14, P269; SAHOO SP, 1995, BIOORG MED CHEM LETT, V5, P2441, DOI 10.1016/0960-894X(95)00425-S; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STACK MS, 1989, J BIOL CHEM, V264, P4277; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; STETLERSTEVENSO.WG, 1996, CANC BIOL, V7, P147; STOCKER W, 1990, BIOCHEMISTRY-US, V29, P10418; TAMAKI K, 1995, CHEM PHARM BULL, V43, P1883; TOMCZUK BE, 1995, BIOORG MED CHEM LETT, V5, P343, DOI 10.1016/0960-894X(95)00032-O; WAHL RC, 1994, ANAL BIOCHEM, V219, P383, DOI 10.1006/abio.1994.1284; WAHL RC, 1995, BIOORG MED CHEM LETT, V5, P349, DOI 10.1016/0960-894X(95)00033-P; Welch AR, 1995, ARCH BIOCHEM BIOPHYS, V324, P59, DOI 10.1006/abbi.1995.9929; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119	51	54	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2763	2768		10.1074/jbc.273.5.2763	http://dx.doi.org/10.1074/jbc.273.5.2763			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446583	hybrid			2022-12-27	WOS:000071736600038
J	Ni, AG; Chao, L; Chao, J				Ni, AG; Chao, L; Chao, J			Transcription factor nuclear factor kappa B regulates the inducible expression of the human B-1 receptor gene in inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BRADYKININ RECEPTORS; PHARMACOLOGICAL CHARACTERIZATION; GROWTH-FACTORS; CLONING; ACTIVATION; PROTEIN; DES-ARG9-BRADYKININ; KININS; RNA	Expression of the bradykinin B-1 receptor gene is upregulated in vascular smooth muscle cells (VSMCs) in response to a variety of inflammatory stimuli. We isolated the 5'-flanking region of the human bradykinin B-1 receptor gene and examined its promoter activity by transient transfection analysis. This region (-2582 to +34) showed promoter activity inducible by lipopolysaccharide (LPS), tumor necrosis factor alpha (TNF-alpha), and interleukin-1 beta (IL-1 beta) in VSMCs. Further deletion analysis revealed that constructs containing 111 base pairs of 5'-flanking sequence were sufficient for transcriptional induction. Mutagenesis of a nuclear factor ICE (NF-KB)like site at -64 to -55 abolished most of the LPS, TNF-alpha; and IL-1 beta inducibility, whereas a mutation of a cyclic AMP response element at -50 to -43 markedly reduced the basal promoter activity, and a mutation of the activator protein 1 (AP-1) site at -78 to -72 had minimal effects. Nuclear extracts from LPS, TNF-alpha, and IL-1 beta-treated VSMCs, IL-1 beta-treated human hepatoma HepG(2), and human lung fibroblast IMR-90 cells showed strong. inducible binding activity to the NF-kappa B-like site by gel shift assays. These results demonstrated that NF-kappa B-like nuclear factor was involved in the inducible expression of the human bradykinin B-1 receptor gene during inflammatory processes.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Chao, J (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL 29397, HL 52196] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052196, R01HL029397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin CE, 1997, J BIOL CHEM, V272, P11420; Bachvarov DR, 1995, J PHARMACOL EXP THER, V275, P1623; Bachvarov DR, 1996, GENOMICS, V33, P374, DOI 10.1006/geno.1996.0213; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P439; BATHON JM, 1991, ANNU REV PHARMACOL, V31, P129; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chai KX, 1996, GENOMICS, V31, P51, DOI 10.1006/geno.1996.0008; COGSWELL JP, 1994, J IMMUNOL, V153, P712; DEBLOIS D, 1989, IMMUNOPHARMACOLOGY, V17, P187, DOI 10.1016/0162-3109(89)90047-7; DEBLOIS D, 1988, BRIT J PHARMACOL, V93, P969, DOI 10.1111/j.1476-5381.1988.tb11487.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; GORDON D, 1986, CIRC RES, V59, P633, DOI 10.1161/01.RES.59.6.633; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LEVESQUE L, 1993, BRIT J PHARMACOL, V109, P1254, DOI 10.1111/j.1476-5381.1993.tb13757.x; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIBBY P, 1986, J CLIN INVEST, V78, P1432, DOI 10.1172/JCI112732; MACNEIL T, 1995, BBA-GENE STRUCT EXPR, V1264, P223, DOI 10.1016/0167-4781(95)00152-7; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pesquero JB, 1996, BIOCHEM BIOPH RES CO, V220, P219, DOI 10.1006/bbrc.1996.0384; PESQUERO JB, 1997, KALLIKREIN KININ SYS; REGOLI D, 1980, PHARMACOL REV, V32, P1; Rupniak NMJ, 1997, PAIN, V71, P89, DOI 10.1016/S0304-3959(97)03343-5; Sardi SP, 1997, EUR J PHARMACOL, V321, P33, DOI 10.1016/S0014-2999(96)00927-2; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SMITH JAM, 1995, MOL PHARMACOL, V47, P525; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; Yang XH, 1996, BIOCHEM BIOPH RES CO, V222, P718, DOI 10.1006/bbrc.1996.0810	44	118	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2784	2791		10.1074/jbc.273.5.2784	http://dx.doi.org/10.1074/jbc.273.5.2784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446586	hybrid			2022-12-27	WOS:000071736600041
J	Osterwalder, T; Cinelli, P; Baici, A; Pennella, A; Krueger, SR; Schrimpf, SP; Meins, M; Sonderegger, P				Osterwalder, T; Cinelli, P; Baici, A; Pennella, A; Krueger, SR; Schrimpf, SP; Meins, M; Sonderegger, P			The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE-PROMOTING FACTOR; LONG-TERM POTENTIATION; SERPIN-LIKE PROTEIN; POLYACRYLAMIDE GELS; NERVOUS-SYSTEM; SYNAPSE ELIMINATION; DETECTING PROTEINS; NEURONAL CELLS; MESSENGER-RNA; SCHWANN-CELLS	Neuroserpin is an axonally secreted serine proteinase inhibitor that is expressed in neurons during embryogenesis and in the adult nervous system. To identify target proteinases, we used a eucaryotic expression system based on the mouse myeloma cell line J558L and vectors including a promoter from an Ig-kappa-variable region, an Ig-kappa enhancer, and the exon encoding the Ig-kappa constant region (C kappa) and produced recombinant neuroserpin as a wild-type protein or as a fusion protein with C kappa. We investigated the capability of recombinant neuroserpin to form SDS-stable complexes with, and to reduce the amidolytic activity of, a variety of serine proteinases in vitro. Consistent with its primary structure at the reactive site, neuroserpin exhibited inhibitory activity against trypsin-like proteinases. Although neuroserpin bound and inactivated plasminogen activators and plasmin, no interaction was observed with thrombin. A reactive site mutant of neuroserpin neither formed complexes with nor inhibited the amidolytic activity of any of the tested proteinases. Kinetic analysis of the inhibitory activity revealed neuroserpin to be a slow binding inhibitor of plasminogen activators and plasmin. Thus, we postulate that neuroserpin could represent a regulatory element of extracellular proteolytic events in the nervous system mediated by plasminogen activators or plasmin.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Zurich Hosp, Dept Rheumatol, CH-8091 Zurich, Switzerland; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	University of Zurich; University of Zurich; University Zurich Hospital; Friedrich Miescher Institute for Biomedical Research	Sonderegger, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	pson@bioc.unizh.ch		Baici, Antonio/0000-0002-2980-0541; Cinelli, Paolo/0000-0002-0163-9055; Krueger, Stefan/0000-0001-8739-7052				AKIYAMA H, 1993, NEUROSCI LETT, V164, P233, DOI 10.1016/0304-3940(93)90899-V; BAIRD JL, 1995, J NEUROSCI, V15, P6605; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CHEN ZL, 1995, J NEUROSCI, V15, P5088; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; EATON DL, 1984, J BIOL CHEM, V259, P6241; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Frey U, 1996, J NEUROSCI, V16, P2057; FRIEDMAN GC, 1995, J COMP NEUROL, V360, P658; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GLOOR S, 1986, CELL, V47, P687; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; GUZDEK A, 1990, FEBS LETT, V272, P125, DOI 10.1016/0014-5793(90)80464-T; HANTAI D, 1989, P NATL ACAD SCI USA, V86, P362, DOI 10.1073/pnas.86.1.362; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; ICHINOSE A, 1984, FEBS LETT, V175, P412, DOI 10.1016/0014-5793(84)80779-6; KALDERON N, 1979, P NATL ACAD SCI USA, V76, P5992, DOI 10.1073/pnas.76.11.5992; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; KRYSTOSEK A, 1984, J CELL BIOL, V98, P773, DOI 10.1083/jcb.98.2.773; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; Monard D, 1993, Perspect Dev Neurobiol, V1, P165; MOONEN G, 1982, NATURE, V298, P753, DOI 10.1038/298753a0; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Nakaya N, 1996, MOL BRAIN RES, V42, P293, DOI 10.1016/S0169-328X(96)00133-7; NISHIBORI M, 1995, NEUROSCI LETT, V200, P125, DOI 10.1016/0304-3940(95)12095-L; Nishibori M, 1995, NEUROSCI RES, V24, P47, DOI 10.1016/0168-0102(95)00973-6; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RAO JS, 1993, J NEUROSCI RES, V34, P340, DOI 10.1002/jnr.490340311; RUEGG MA, 1989, EMBO J, V8, P55, DOI 10.1002/j.1460-2075.1989.tb03348.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SEEDS NW, 1996, NEUROSCIENCE, V22; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SONDEREGGER P, 1985, EMBO J, V4, P1395, DOI 10.1002/j.1460-2075.1985.tb03792.x; STOECKLI ET, 1989, EUR J BIOCHEM, V180, P249, DOI 10.1111/j.1432-1033.1989.tb14640.x; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUNECKER A, 1991, EMBO J, V10, P3655, DOI 10.1002/j.1460-2075.1991.tb04932.x; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1997, J NEUROSCI, V17, P543; vanMeijer M, 1996, J BIOL CHEM, V271, P7423, DOI 10.1074/jbc.271.13.7423; WALLEN P, 1983, EUR J BIOCHEM, V132, P681, DOI 10.1111/j.1432-1033.1983.tb07418.x; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	74	111	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2312	2321		10.1074/jbc.273.4.2312	http://dx.doi.org/10.1074/jbc.273.4.2312			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442076	hybrid, Green Accepted			2022-12-27	WOS:000071595200065
J	Bazhenova, EN; Deryabina, YI; Eriksson, O; Zvyagilskaya, RA; Saris, NEL				Bazhenova, EN; Deryabina, YI; Eriksson, O; Zvyagilskaya, RA; Saris, NEL			Characterization of a high capacity calcium transport system in mitochondria of the yeast Endomyces magnusii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDES; SACCHAROMYCES-CEREVISIAE; CA-2+ TRANSPORT; ALLOSTERIC ACTIVATOR; HEART-MITOCHONDRIA; BRAIN MITOCHONDRIA; VACUOLAR MEMBRANE; MATING PHEROMONE	The Ca2+ transport system of Endomyces magnusii mitochondria has been shown previously to be activated by spermine. Here we report it tea be regulated also by low, physiological ADP concentrations, by the intramitochondrial NADH/NAD(+) ratio, and by Ca2+ ions. The combination of all these physiological modulators induced high initial rates of Ca2+ uptake and high Ca2+-buffering capacity of yeast mitochondria, enabling them to lower the medium [Ca2+] to similar to 0.2 mu M. The mechanisms of stimulation by these agents are discussed.	Univ Helsinki, Inst Biomed, Dept Med Chem, FIN-00014 Helsinki, Finland; Russian Acad Sci, Bach Inst Biochem, Lab Biol Oxidat, Moscow 117071, Russia	University of Helsinki; Research Center of Biotechnology RAS; Russian Academy of Sciences	Saris, NEL (corresponding author), Univ Helsinki, Inst Biomed, Dept Med Chem, POB 8, FIN-00014 Helsinki, Finland.	saris@penger.helsinki.fi	Eriksson-Rosenberg, Ove/GVU-6692-2022					AKERMAN KEO, 1983, BIOCHEM BIOPH RES CO, V114, P1176, DOI 10.1016/0006-291X(83)90686-1; BALCAVAG.WX, 1973, BIOCHIM BIOPHYS ACTA, V305, P41, DOI 10.1016/0005-2728(73)90229-6; BAZHENOVA EN, 1998, IN PRESS BIOCH BIOPH; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALVERT CM, 1995, J BIOL CHEM, V270, P7272, DOI 10.1074/jbc.270.13.7272; Fersht A., 1985, ENZYME STRUCTURE MEC; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IIDA H, 1990, J BIOL CHEM, V265, P13391; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; KRONER H, 1988, ARCH BIOCHEM BIOPHYS, V267, P205, DOI 10.1016/0003-9861(88)90024-0; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; LEIKIN YN, 1987, BIOKHIMIYA, V52, P676; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MCCORMACK JG, 1993, BIOCHEM SOC T, V21, P793, DOI 10.1042/bst0210793; MOORE CL, 1971, BIOCHEM BIOPH RES CO, V42, P298, DOI 10.1016/0006-291X(71)90102-1; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P87, DOI 10.1016/0005-2728(90)90010-2; ROTTENBERG H, 1989, FEBS LETT, V247, P483, DOI 10.1016/0014-5793(89)81396-1; SARIS NEL, 1990, J BIOENERG BIOMEMBR, V22, P81, DOI 10.1007/BF00762847; Scarpa A, 1972, Methods Enzymol, V24, P343; Scarpa A, 1979, Methods Enzymol, V56, P301; Sordahl L A, 1978, Ann N Y Acad Sci, V307, P238, DOI 10.1111/j.1749-6632.1978.tb41952.x; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TACHIKAWA T, 1987, AGR BIOL CHEM TOKYO, V51, P1209, DOI 10.1080/00021369.1987.10868161; Tanida I, 1996, FEBS LETT, V379, P38, DOI 10.1016/0014-5793(95)01478-0; TONINELLO A, 1983, BIOCHEM BIOPH RES CO, V111, P792, DOI 10.1016/0006-291X(83)91368-2; VOTYAKOVA TV, 1990, FEBS LETT, V261, P139, DOI 10.1016/0014-5793(90)80655-3; VOTYAKOVA TV, 1993, J BIOENERG BIOMEMBR, V25, P569, DOI 10.1007/BF01108413; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZVJAGILSKAYA RA, 1983, DOKL AKAD NAUK SSSR, V269, P1233; ZVYAGIL'SKAYA R A, 1981, Biokhimiya, V46, P3; ZVYAGILSKAYA RA, 1991, FUNCTIONAL ACTIVITY, V36; ZVYAGILSKAYA RA, 1995, YEAST, V11, pS469; ZVYAGILSKAYA RA, 1996, BIOCHIM BIOPHYS ACTA, V9, P193; ZVYAGILSKAYA RA, 1982, DOKL AKAD NAUK SSSR, V263, P491	42	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4372	4377		10.1074/jbc.273.8.4372	http://dx.doi.org/10.1074/jbc.273.8.4372			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468487	hybrid			2022-12-27	WOS:000072115000015
J	Farah, S; Agazie, Y; Ohan, N; Ngsee, JK; Liu, XJ				Farah, S; Agazie, Y; Ohan, N; Ngsee, JK; Liu, XJ			A rho-associated protein kinase, ROK alpha, binds insulin receptor substrate-1 and modulates insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; XENOPUS-OOCYTE MATURATION; MAP KINASE; IRS-1; PHOSPHORYLATION; ACTIVATION; DISTINCT; TRANSDUCTION; CYTOSKELETON; INVOLVEMENT	Insulin receptor substrate-1 (IRS-1) is physphorylated on multiple tyrosine residues by ligand-activated insulin receptors. These tyrosine phosphorylation sites serve to dock several Src homology 2-containing signaling proteins, In addition, IRS-1 contains a pleckstrin homology domain and a phosphotyrosine binding domain (PTB) implicated in protein-protein and protein-lipid interactions, In a yeast two-hybrid screening using Xenopus IRS-1 (xIRS-1) pleekstrin homology-PTB domains as bait, we identified a Xenopus homolog of Rho-associated kinase alpha (xROK alpha) as a potential xIRS-1-binding protein, The original clone contained. the carboxyl terminus of xROK alpha (xROK-C) including the putative Rho binding domain but lacking the amino-terminal kinase domain. Further analyses in yeast indicated that xROK-C bound to the putative PTB domain of xIRS-1. Binding of xROK-C to xIRS-1 was confirmed in Xenopus oocytes after microinjection of mRNA corresponding to xROK-C. Furthermore, microinjection of xROK-C mRNA inhibited insulin-induced mitogen-activated protein kinase activation with a concomitant inhibition of oocyte maturation. In contrast, microinjection of xROK-C mRNA did not inhibit mitogen-activated protein kinase activation or oocyte maturation induced by progesterone or by microinjection of viral. Ras (v-Ras) mRNA, These results suggest that xROK alpha may play a role in insulin signaling via a direct interaction with xIRS-1.	Ottawa Civic Hosp, Loeb Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa	Liu, XJ (corresponding author), Ottawa Civic Hosp, Loeb Res Inst, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	johne@civich.ottawa.on.ca		Liu, X. Johne/0000-0003-3381-5030				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BORK P, 1995, CELL, V80, P687; CIRCIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514; Craparo A, 1997, J BIOL CHEM, V272, P11663; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; KAVANAUGH WM, 1994, SCIENCE, V266, P819; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAMASAKI H, 1992, J BIOL CHEM, V267, P20953; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	52	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4740	4746		10.1074/jbc.273.8.4740	http://dx.doi.org/10.1074/jbc.273.8.4740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468537	hybrid			2022-12-27	WOS:000072115000065
J	Mesnildrey, S; Agou, F; Karlsson, A; Bonne, DD; Veron, M				Mesnildrey, S; Agou, F; Karlsson, A; Bonne, DD; Veron, M			Coupling between catalysis and oligomeric structure in nucleoside diphosphate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; X-RAY STRUCTURE; CRYSTAL-STRUCTURE; ACTIVE-SITE; NM23 GENE; STABILITY; BINDING; ENZYME; DROSOPHILA; RESOLUTION	A dimeric Dictyostelium nucleoside diphosphate kinase has been stabilized by the double mutation P100S-N150stop which targets residues involved in the trimer interface (Karlsson, A, Mesnildrey S., Xu, Y., Morera, S., Janin, J., and Vernon, M. (1996) J, Biol. Chem. 271, 19928-19934), The reassociation of this dimeric form into a hexamer similar to the wild-type enzyme is induced by the presence of a nucleotide substrate, Equilibrium sedimentation and gel filtration experiments, as well as enzymatic activity measurements, show that reactivation of the enzyme closely parallels its reassociation, A phosphorylatable intermediate with low activity participates ist the association pathway while the dimeric form is shown totally devoid of enzymatic activity, Our results support the hypothesis that different oligomeric species of nucleoside diphosphate kinase are involved in different cellular processes where the enzymatic activity is not required.	Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS URA 1149, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Veron, M (corresponding author), Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, CNRS URA 1149, 25 Rue Dr Roux, F-75724 Paris 15, France.	mveron@pasteur.fr	Karlsson, Anna/E-7945-2018; , AGOU/GXA-2760-2022	Karlsson, Anna/0000-0001-6843-6685				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Giartosio A, 1996, J BIOL CHEM, V271, P17845, DOI 10.1074/jbc.271.30.17845; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; Jaenicke R, 1986, Methods Enzymol, V131, P218; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; LASCU I, 1993, J BIOL CHEM, V268, P20268; Lascu I, 1997, J BIOL CHEM, V272, P15599, DOI 10.1074/jbc.272.25.15599; LASCU I, 1992, J BIOL CHEM, V267, P12775; LASCU I, 1994, J BIOL CHEM, V269, P7046; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; Mesnildrey S, 1997, FEBS LETT, V418, P53, DOI 10.1016/S0014-5793(97)01292-1; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MORERA S, 1994, J MOL BIOL, V243, P373; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Postel EH, 1996, P NATL ACAD SCI USA, V93, P6892, DOI 10.1073/pnas.93.14.6892; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; SEGEL IH, 1975, ENZYME KINETICS, P608; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STURTEVANT AH, 1956, GENETICS, V41, P118; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; Timmons L, 1997, ADV GENET, V35, P207, DOI 10.1016/S0065-2660(08)60451-4; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	37	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4436	4442		10.1074/jbc.273.8.4436	http://dx.doi.org/10.1074/jbc.273.8.4436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468495	Green Published, hybrid			2022-12-27	WOS:000072115000023
J	Spurkland, A; Brinchmann, JE; Markussen, G; Pedeutour, F; Munthe, E; Lea, T; Vartdal, E; Aasheim, HC				Spurkland, A; Brinchmann, JE; Markussen, G; Pedeutour, F; Munthe, E; Lea, T; Vartdal, E; Aasheim, HC			Molecular cloning of a T cell-specific adapter protein (TSAd) containing an Src homology (SH) 2 domain and putative SH3 and phosphotyrosine binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TYROSINE KINASE; CYTOPLASMIC PROTEIN; LYMPHOCYTES-B; EXPRESSION; PEPTIDES; GENE; IDENTIFICATION; HYBRIDIZATION; VIRUS	Adapter proteins link catalytic signaling proteins to cell surface receptors or downstream effector proteins. In this paper, we present the cDNA sequence F2771, isolated from an activated CD8+ T cell cDNA library. The F2771 cDNA encodes a novel putative adapter protein. The predicted amino acid sequence includes an SH2 domain as well as putative SH3 and phosphotyrosine binding interaction motifs, but lacks any known catalytic domains, The expression of the gene is limited to tissues of the immune system and, in particular, activated T cells. The protein expressed by F2771 cDNA in transfected COS cells is localized in the cytoplasm. A polyclonal antiserum raised against an F2771-encoded peptide reacts with a tyrosine-phosphorylated 52-kDa protein expressed in phytohemagglutinin-stimulated peripheral blood mononuclear cells. The gene is localized to chromosome 1q21, a region often found to be aberrant in lymphomas. The T cell-specific expression and the rapid induction of mRNA expression upon receptor binding, as well as the lack of catalytic domains in the presence of protein interaction domains, indicate that the F2771 gene encodes a novel T cell-specific adapter protein (TSAd) involved in the control of T cell activation.	Natl Hosp Norway, Inst Transplantat Immunol, N-0027 Oslo, Norway; Natl Hosp Norway, Inst Immunol & Rheumatol, N-0027 Oslo, Norway; Norwegian Radium Hosp, Dept Immunol, N-0310 Oslo, Norway; Fac Med Nice, CNRS, URA, Nice, France	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Spurkland, A (corresponding author), Natl Hosp Norway, Inst Transplantat Immunol, N-0027 Oslo, Norway.		Spurkland, Anne/L-3369-2019; Munthe, Else/O-3576-2017	Spurkland, Anne/0000-0003-4421-0766; Munthe, Else/0000-0003-3859-1582				Aasheim Hans-Christian, 1996, V69, P115; AASHEIM HC, 1994, BIOTECHNIQUES, V16, P716; BRINCHMANN JE, 1989, J VIROL METHODS, V25, P293, DOI 10.1016/0166-0934(89)90056-6; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Coligan J, 1995, CURRENT PROTOCOLS IM; COOKE M P, 1989, New Biologist, V1, P66; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; FUHLBRIGGE RC, 1987, J IMMUNOL, V138, P3799; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMBERT KN, 1993, NUCLEIC ACIDS RES, V21, P775, DOI 10.1093/nar/21.3.775; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Omri B, 1996, J NEUROCHEM, V67, P1360; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEDEUTOUR F, 1994, GENOMICS, V19, P31, DOI 10.1006/geno.1994.1008; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PRATT JC, 1996, IMMUNOLOGIST, V4, P122; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHANGPENG J, 1995, BLOOD, V85, P203, DOI 10.1182/blood.V85.1.203.bloodjournal851203; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZENNER G, 1995, BIOESSAYS, V17, P967, DOI 10.1002/bies.950171110	49	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4539	4546		10.1074/jbc.273.8.4539	http://dx.doi.org/10.1074/jbc.273.8.4539			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468509	hybrid			2022-12-27	WOS:000072115000037
J	Heikinheimo, L; Somerharju, P				Heikinheimo, L; Somerharju, P			Preferential decarboxylation of hydrophilic phosphatidylserine species in cultured cells - Implications of the mechanism of transport to mitochondria and cellular aminophospholipid species compositions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; HAMSTER OVARY CELLS; RAT-LIVER MITOCHONDRIA; LIPID TRANSFER PROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; PERMEABILIZED ANIMAL-CELLS; PHOSPHOLIPID TRANSFER; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; LIPOPROTEIN SECRETION	In baby hamster kidney and other cultured cells the majority of phosphatidylethanolamine (PE) is synthesized from phosphatidylserine (PS) in a process which involves transport of PS from the endoplasmic reticulum to mitochondria and decarboxylation therein by PS decarboxylase. To study the mechanism of this transport process, we first determined the molecular species composition of PE and PS from baby hamster kidney and Chinese hamster ovary cells. Interestingly, the hydrophilic diacyl molecular species were found to be much more abundant in PE than in PS, suggesting that hydrophilic PS species may be more readily transported to mitochondria than the hydrophobic ones. To study this, me compared the rates of decarboxylation of different PS molecular species in these cells. The cells were pulse labeled with [H-3]serine whereafter the distribution of the labels among PS and PE molecular species was determined by reverse phase high performance liquid chromatography and liquid scintillation counting. The hydrophilic PE species contained relatively much more H-3 label than those of PS, which indicates that they are more readily decarboxylated than the hydrophobic ones. Control experiments showed that differences in [H-3]PS and -PE molecular species profiles are not due to (i) incorporation of H-3 label to some PE species via alternative pathways, (ii) differences in degradation or remodeling among species, or (iii) selective decarboxylation of PS molecular species by the enzyme. Therefore, hydrophilic PS species are indeed decarboxylated faster than the hydrophobic ones. The rate of decarboxylation decreased systematically with hydrophobicity, strongly suggesting that formation of so called activated monomers, i.e. lipid molecules perpendicularly displaced from the membrane (Jones, J. D., and Thompson, T. E. (1990) Biochemistry 29, 1593-1600), is the rate-limiting step in the transport of PS from the endoplasmic reticulum to mitochondria. The formation of activated monomers and thus the rate of transfer is probably greatly enhanced by frequent collisions between the two membranes which tend to be closely associated. The present data also provides a feasible explanation why hydrophilic molecular species in these cells are much more abundant in PE as compared with PS, its immediate precursor.	Univ Helsinki, Dept Med Chem, Inst Biomed, Helsinki 00014, Finland	University of Helsinki	Somerharju, P (corresponding author), Univ Helsinki, Dept Med Chem, Inst Biomed, POB 8, Helsinki 00014, Finland.	pentti.somerharju@helsinki.fi						ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; Allan D, 1996, MOL MEMBR BIOL, V13, P81, DOI 10.3109/09687689609160580; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; ARTHUR G, 1993, BIOCHEM J, V293, P125, DOI 10.1042/bj2930125; BJERVE KS, 1985, BIOCHIM BIOPHYS ACTA, V833, P396, DOI 10.1016/0005-2760(85)90096-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORKENHAGEN L, 1961, J BIOL CHEM, V236, pPC28; CHEN H, 1993, J LIPID RES, V34, P2159; Christie W., 1989, GAS CHROMATOGRAPHY L; COMFURIUS P, 1990, J LIPID RES, V31, P1719; CRAIN RC, 1980, BIOCHIM BIOPHYS ACTA, V620, P37, DOI 10.1016/0005-2760(80)90182-4; DENNIS EA, 1972, J LIPID RES, V13, P263; DERZKO Z, 1980, BIOCHEMISTRY-US, V19, P6050, DOI 10.1021/bi00567a016; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DYGAS A, 1989, ACTA BIOCHIM POL, V36, P131; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; GAIGG B, 1996, BIOCHIM BIOPHYS ACTA, V1234, P214; GURD FRN, 1960, LIPID CHEM, P208; Han XL, 1995, J AM SOC MASS SPECTR, V6, P1202, DOI 10.1016/1044-0305(95)00568-4; HANADA K, 1992, J BIOL CHEM, V267, P23527; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; HOVIUS R, 1992, J BIOL CHEM, V267, P16790; HULLIN F, 1989, J LIPID RES, V30, P1963; JASINSKA R, 1993, BIOCHIM BIOPHYS ACTA, V1152, P161, DOI 10.1016/0005-2736(93)90243-S; JONES JD, 1990, BIOCHEMISTRY-US, V29, P1593, DOI 10.1021/bi00458a034; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KOBAYASHI T, 1991, J CELL BIOL, V113, P235, DOI 10.1083/jcb.113.2.235; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V794, P274, DOI 10.1016/0005-2760(84)90156-5; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MEGLI FM, 1986, BIOCHIM BIOPHYS ACTA, V861, P463, DOI 10.1016/0005-2736(86)90455-4; MENDISHANDAGAMA SMLC, 1995, TISSUE CELL, V27, P483, DOI 10.1016/S0040-8166(05)80056-4; MILLER MA, 1986, J BIOL CHEM, V261, P9753; NICHOLS JW, 1983, J BIOL CHEM, V258, P5368; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P3925, DOI 10.1021/bi00411a006; PATTON GM, 1990, METHOD ENZYMOL, V187, P195; PATTON GM, 1982, J LIPID RES, V23, P190; POWNALL HJ, 1991, BIOCHEMISTRY-US, V30, P5696, DOI 10.1021/bi00237a009; SAMBORSKI RW, 1993, BIOCHIM BIOPHYS ACTA, V1167, P15, DOI 10.1016/0005-2760(93)90211-Q; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SHIAO YJ, 1995, BIOCHEM J, V310, P673, DOI 10.1042/bj3100673; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P13318, DOI 10.1021/bi00211a045; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANCE JE, 1988, BIOCHIM BIOPHYS ACTA, V963, P70, DOI 10.1016/0005-2760(88)90339-6; VANHAREN L, 1992, BIOCHIM BIOPHYS ACTA, V1124, P288; VANHEUSDEN GPH, 1990, J BIOL CHEM, V265, P4105; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WIMLEY WC, 1991, BIOCHEMISTRY-US, V30, P1702, DOI 10.1021/bi00220a036; XU ZL, 1991, J BIOL CHEM, V266, P2143; YOREK MA, 1985, J BIOL CHEM, V260, P2930; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	65	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3327	3335		10.1074/jbc.273.6.3327	http://dx.doi.org/10.1074/jbc.273.6.3327			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452450	hybrid			2022-12-27	WOS:000071822300035
J	Kemppainen, RJ; Behrend, EN				Kemppainen, RJ; Behrend, EN			Dexamethasone rapidly induces a novel Ras superfamily member-related gene in AtT-SO cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITION; PROTEINS; FAMILY; MOTIFS	Differential display was used to identify a new Ras superfamily gene (Dexras1) induced by dexamethasone (Dex) in AtT-20 cells. Treatment of AtT-20 cells with Dex for 30 min resulted in increased mRNA for Dexras1; the highest concentrations appeared after 2 h of treatment, The gene was also identified in mouse heart, brain, liver, and kidney and furthermore was induced in these tissues after Dex treatment, The deduced protein shows regions of homology characteristic of members of the Ras superfamily of small GTPases, Highest homology (36% identity, 57% positives) was found with human Rap-ab, followed closely by a number of other Ras subfamily members, suggesting that Dexras1 is probably a member of the Ras subfamily of GTPases (members include Ras and Rap). Dexras1 is the first Ras superfamily member identified that is induced in response to steroids. The function of this gene is unknown; however, its wide distribution and rapid induction by Dex suggests the possibility of a role in glucocorticoid action in a variety of tissues.	Auburn Univ, Coll Vet Med, Dept Physiol & Pharmacol, Auburn, AL 36849 USA	Auburn University System; Auburn University	Kemppainen, RJ (corresponding author), Auburn Univ, Coll Vet Med, Dept Physiol & Pharmacol, 213 Greene Hall, Auburn, AL 36849 USA.		Behrend, Ellen N/C-3215-2018; Kemppainen, Robert/X-9105-2019	Behrend, Ellen N/0000-0002-5010-2983; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R15DK047975, K08DK002400] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47975, K08 DK02400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLARK TP, 1994, AM J PHYSIOL, V267, pR463, DOI 10.1152/ajpregu.1994.267.2.R463; DelVillar K, 1996, BIOCHEM SOC T, V24, P709; DSilva NJ, 1997, J HISTOCHEM CYTOCHEM, V45, P965, DOI 10.1177/002215549704500706; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; SHIPSTON MJ, 1995, TRENDS ENDOCRIN MET, V6, P261, DOI 10.1016/1043-2760(95)00149-2; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WOODS MD, 1992, ENDOCRINOLOGY, V131, P2873, DOI 10.1210/en.131.6.2873; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	16	133	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3129	3131		10.1074/jbc.273.6.3129	http://dx.doi.org/10.1074/jbc.273.6.3129			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452419	hybrid			2022-12-27	WOS:000071822300004
J	Stanley, P; Hogg, N				Stanley, P; Hogg, N			The I domain of integrin LFA-1 interacts with ICAM-1 domain 1 at residue Glu-34 but not Gln-73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INTERCELLULAR-ADHESION MOLECULE-3; BINDING-SITE; CONTAINS; ALPHA-4-BETA-1; ARRANGEMENT; RECEPTOR; DISTINCT; LIGANDS	Using a solid phase assay, we show that isolated LFA-1 I domain binds ICAM-1 in a Mg2+-dependent manner and is blocked by anti-I domain monoclonal antibodies. This activity mirrors that of the intact receptor (Dransfield, I., Cabanas, C., Craig, A., and Hogg, N. (1992) J. Cell Biob. 116, 219-226) and suggests that the I domain controls divalent cation-dependent receptor function. In ICAM-1, domain 1 residues Glu-34 and Gln-73 have been identified as critical for binding of LFA-1 as an intact receptor (Staunton, D. E., Dustin, M. L., Erickson, H. P., and Springer, T. A. (1990) Cell 61, 243-254). For the first time, we show that isolated I domain binds to domain 1 of ICAM-1 and that this interaction is inhibited partially by mutation of Glu-34 but not by Gln-73. The anti-ICAM-1 monoclonal antibody RR1/1, which maps to Gln-73 (Staunton, D. E., Dustin, M. L., Erickson, H. P., and Springer, T. A. (1990) Cell 61, 243-254), enhances I domain binding, suggesting potential allosteric control or coordinate binding by this region. Finally, I domain binding inhibited by Glu-34 ICAM-1 mutation correlates with divalent cation dependence, indicating that this residue might be in direct contact with the metal ion-dependent adhesion site. Thus, we describe the interaction between the LFA-1 I domain and ICAM-1, an event that controls the function of the intact receptor but includes only part of the complete ligand binding site.	Imperial Canc Res Fund, Leukocyte Adhes Lab, London WC2A 3PX, England	Cancer Research UK	Hogg, N (corresponding author), Imperial Canc Res Fund, Leukocyte Adhes Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.							BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169, DOI 10.1038/nbt0292-169; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Fisher KL, 1997, MOL BIOL CELL, V8, P501, DOI 10.1091/mbc.8.3.501; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GRAVES BJ, 1995, NAT STRUCT BIOL, V2, P181, DOI 10.1038/nsb0395-181; Hogg Nancy, 1994, Trends in Cell Biology, V4, P379, DOI 10.1016/0962-8924(94)90044-2; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LOFTUS JC, 1997, J CLIN INVEST, V99, P23025; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Welply JK, 1996, PROTEINS, V26, P262, DOI 10.1002/(SICI)1097-0134(199611)26:3<262::AID-PROT3>3.0.CO;2-G	30	47	53	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3358	3362		10.1074/jbc.273.6.3358	http://dx.doi.org/10.1074/jbc.273.6.3358			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452454	hybrid			2022-12-27	WOS:000071822300039
J	Antonyak, MA; Moscatello, DK; Wong, AJ				Antonyak, MA; Moscatello, DK; Wong, AJ			Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; EGF RECEPTOR; STRESS; PATHWAY; ERK; JNK; TRANSFORMATION	Epidermal growth factor receptor (EGF) variant type III (EGFRvIII) is a constitutively active, naturally occurring mutation of the EGF receptor that is found in many types of human tumors. When overexpressed in NIH3T3 fibroblasts, EGFRvIII induces transformation by enhancing cell growth and reducing apoptosis, Analysis of downstream signaling pathways has revealed that extracellular signal-regulated kinase activity is down-regulated, raising doubt as to the significance of this pathway in promoting transformation, We investigated whether the c-Jun N-terminal kinase (JNK) pathway was affected by EGFRvIII. NIH3T3 cells expressing EGFRvIII exhibited a high basal level of JNK activity, which was not present in cells overexpressing the normal EGF receptor, Treatment of cells overexpressing EGFRvIII with inhibitors of the EGF receptor or phosphatidylinositol 3-kinase resulted in the down-regulation of JNK activity. Furthermore, the down-regulation of JNK activity was associated with a loss of properties related to transformation, and there was no evidence for JNK activity in the promotion of apoptosis in these cells. These findings implicate constitutive activation of the JNK pathway in transformation by EGFRvIII.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Wong, AJ (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.	a_wong@lac.jci.tju.edu			NCI NIH HHS [CA69495, CA51093] Funding Source: Medline; NIDDK NIH HHS [5-T32-DK07705-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051093, R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Greulich H, 1996, ONCOGENE, V12, P1689; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HARRIS AL, 1992, NATL CANC I MONOGR, V11, P181; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOBAYASHI M, 1997, J BIOL CHEM, V272, P1608; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	42	138	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2817	2822		10.1074/jbc.273.5.2817	http://dx.doi.org/10.1074/jbc.273.5.2817			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446590	hybrid			2022-12-27	WOS:000071736600045
J	Legesse-Miller, A; Sagiv, Y; Porat, A; Elazar, Z				Legesse-Miller, A; Sagiv, Y; Porat, A; Elazar, Z			Isolation and characterization of a novel low molecular weight protein involved in intra-Golgi traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; N-ACETYLGLUCOSAMINE; FUSION PROTEIN; GENE-PRODUCT; YEAST; VESICLES; NSF; PURIFICATION; MEMBRANE	Analysis of the cytosolic requirements for in vitro intra-Golgi transport led to the characterization of three proteins: N-ethylmaleimide-sensitive fusion protein (NSF), soluble NSF attachment protein (SNAP), and p115, all involved in the docking and fusion of transport vesicles to their target membranes, In the course of determining the minimal cytosolic requirements for intra-Golgi transport in vitro, we identified three additional factors that are sufficient to replace crude cytosol, We describe here the purification and characterization of one of these factors, a novel 16-kDa protein, p16, an essential factor for intra-Golgi protein transport, Based on transport activity, this purification procedure resulted in similar to 1,400-fold enrichment of pie to apparent homogeneity. The activity of pie could be observed in the absence of vesicle formation, suggesting that it may participate in the docking and fusion processes.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	bmzevi@weizmann.weizmann.ac.il						BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BLOCK MR, 1992, METHOD ENZYMOL, V219, P300; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mayer T, 1996, J BIOL CHEM, V271, P16097, DOI 10.1074/jbc.271.27.16097; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; ORCI L, 1991, CELL, V64, P1183; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PEREZ M, 1985, J BIOL CHEM, V260, P4671; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SZTUL E, 1993, J BIOL CHEM, V268, P1876; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	34	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3105	3109		10.1074/jbc.273.5.3105	http://dx.doi.org/10.1074/jbc.273.5.3105			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446628	hybrid			2022-12-27	WOS:000071736600083
J	Sugihara, T; Wadhwa, R; Kaul, SC; Mitsui, Y				Sugihara, T; Wadhwa, R; Kaul, SC; Mitsui, Y			A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF 115	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED EXPRESSION; TUMOR-GROWTH; IDENTIFICATION; ANGIOGENESIS; FIBROBLASTS; CELLS; IMMORTALIZATION; FAMILY; INVIVO	Murine immortal fibroblasts express a form of vascular endothelial growth factor (VEGF) that was cloned, characterized and named VEGF 115, It differs from VEGF 120 by 37 amino acids at the carboxyl terminus, VEGF 115-specific sequence reacted to a single transcript in mouse tissues, Reverse transcription-polymerase chain reaction was performed in mouse tissues and in fibroblasts of normal and immortal divisional phenotypes. The data from mouse tissues suggested that VEGF 115 is not a tissue-specific isoform of VEGF 120, whereas a functional relevance with immortalization is indicated from the latter, The novel cDNA was expressed in Escherichia coli, and the His-tagged VEGF 115 (17.2 kDa) thus obtained was recognized by anti-VEGF antibody, A mammalian expression plasmid, pCMV(neo+), encoding for VEGF 115 was transfected to NIH 3T3 cells, and the conditioned medium of stable transfectants was found to have fibroblast growth factor-replacing activity for human umbilical vein endothelial cells. Two independent genomic PI clonings with primers specific for VEGF 164 and VEGF 115, respectively, resulted in isolation of identical P1 clones, We analyzed these three P1 clones on Southern blots with common and specific probes for VEGF 164 and VEGF 115. The results support the hypothesis that VEGF 115 is a new alternatively spliced form of mouse VEGF.	Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Chugai Res Inst Mol Med, Niihari, Ibaraki 30041, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Sugihara, T (corresponding author), Agcy Ind Sci & Technol, Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.		Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				BACIC M, 1995, GROWTH FACTORS, V12, P11, DOI 10.3109/08977199509003209; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KONDO S, 1995, BBA-GEN SUBJECTS, V1243, P195, DOI 10.1016/0304-4165(94)00150-V; KUMAZAKI T, 1993, EXP CELL RES, V205, P396, DOI 10.1006/excr.1993.1103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Sambrook J., 2002, MOL CLONING LAB MANU; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; SUGIHARA T, 1994, BBA-MOL CELL RES, V1224, P365, DOI 10.1016/0167-4889(94)90269-0; TAKAHASHI A, 1994, CANCER RES, V54, P4233; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WHEELER T, 1995, PLACENTA, V16, P289, DOI 10.1016/0143-4004(95)90115-9; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	26	40	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3033	3038		10.1074/jbc.273.5.3033	http://dx.doi.org/10.1074/jbc.273.5.3033			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446618	hybrid			2022-12-27	WOS:000071736600073
J	Ramamoorthy, S; Giovanetti, E; Qian, Y; Blakely, RD				Ramamoorthy, S; Giovanetti, E; Qian, Y; Blakely, RD			Phosphorylation and regulation of antidepressant-sensitive serotonin transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN NOREPINEPHRINE TRANSPORTER; PLACENTAL CHORIOCARCINOMA CELLS; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTER; DEPENDENT REGULATION; XENOPUS-OOCYTES; NITRIC-OXIDE; EXPRESSION; GENE	Antidepressant-sensitive serotonin (5-hydroxytryptamine, 5HT) transporters (SERTs) are responsible for efficient synaptic clearance of extracellular 5HT. Previously (Qian, Y., Galli, A., Ramamoorthy, S., Risso, S., DeFelice, L. J., and Blakely, R. D. (1997) J. Neurosci. 17, 45-47), we demonstrated that protein kinase (PKC)-linked pathways in transfected HEK-293 cells lead to the internalization of cell-surface human (h) SERT protein and a reduction in 5HT uptake capacity. In the present study, we report that PKC activators rapidly, and in a concentration-dependent manner, elevate the basal level of hSERT phosphorylation 5-6-fold. Similarly, protein phosphatase (PP1/PP2A) inhibitors down-regulate 5HT transport and significantly elevate hSERT P-32 incorporation, effects that are additive with those of PKC activators. Moreover, hSERT phosphorylation induced by beta-phorbol 12-myristate 13-acetate is abolished selectively by the PKC inhibitors staurosporine and bisindolymaleimide I, whereas hSERT phosphorylation induced by phosphatase inhibitors is insensitive to these agents at comparable concentrations. Protein kinase A and protein kinase G activators fail to acutely down-regulate 5HT uptake but significantly enhance hSERT phosphorylation. Basal hSERT and okadaic acid-induced phosphorylation were insensitive to chelation of intracellular calcium and Ca2+/calmodulin-dependent protein kinase inhibitors. Together these results reveal hSERT to be a phosphoprotein whose phosphorylation state is likely to be tightly controlled by multiple kinase and phosphatase pathways that may also influence the transporter's regulated trafficking.	Vanderbilt Univ, Sch Med, Dept Pharmacol, MRBII, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, MRBII, Rm 419, Nashville, TN 37232 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07390] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; ANDERSON GM, 1995, SOC NEUR ABSTR, V21; APPARSUNDARAM S, 1996, SOC NEUR ABSTR, V22; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; Barker Eric L., 1995, P321; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Bradley CC, 1997, J NEUROCHEM, V69, P1356; BROWNSTEIN MJ, 1994, RECENT PROG HORM RES, V49, P27; Cook EH, 1997, MOL PSYCHIATR, V2, P247; COOL DR, 1991, J BIOL CHEM, V266, P15750; COREY JL, 1994, J BIOL CHEM, V269, P14759; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fleckenstein AE, 1996, J PHARMACOL EXP THER, V279, P200; Fozzard J., 1989, PERIPHERAL ACTIONS 5; Fuller RW, 1996, ANN NY ACAD SCI, V794, P90, DOI 10.1111/j.1749-6632.1996.tb32512.x; FULLER RW, 1994, LIFE SCI, V55, P163, DOI 10.1016/0024-3205(94)00876-0; GUAN XM, 1988, BRAIN RES BULL, V21, P43, DOI 10.1016/0361-9230(88)90118-9; Heils A, 1996, J NEUROCHEM, V66, P2621; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Huff RA, 1997, J NEUROCHEM, V68, P225; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAUNAY JM, 1994, AM J PHYSIOL, V266, P526; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; MILLER KJ, 1995, SOC NEUR ABSTR, V21; Montgomery Stuart A., 1995, P1043; MYERS CL, 1989, AM J PHYSIOL, V257, pL253, DOI 10.1152/ajplung.1989.257.4.L253; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGLIVIE AD, 1996, LANCET, V347, P731; OSAWA I, 1994, NEUROSCI RES, V19, P287, DOI 10.1016/0168-0102(94)90041-8; POGUN S, 1994, BRAIN RES, V641, P83, DOI 10.1016/0006-8993(94)91818-X; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; QIAN Y, 1995, J NEUROSCI, V15, P1261; QIAN Y, 1995, SOC NEUR ABSTR, V21; QIAN Y, 1996, THESIS EMORY U; Quick MW, 1997, J NEUROSCI, V17, P2967; RAMAMOORTHY JD, 1995, J BIOL CHEM, V270, P17189, DOI 10.1074/jbc.270.29.17189; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMAMOORTHY S, 1998, IN PRESS METHODS ENZ; Reith M E, 1988, NIDA Res Monogr, V88, P23; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; RUDNICK G, 1992, BIOCHEMISTRY-US, V31, P6710, DOI 10.1021/bi00144a010; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Sakai N, 1997, J NEUROCHEM, V68, P2618; SATO K, 1995, J NEUROCHEM, V65, P1967; SHAFQAT S, 1993, MOL ENDOCRINOL, V7, P1517, DOI 10.1210/me.7.12.1517; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STAHL SM, 1977, ARCH GEN PSYCHIAT, V34, P509; TATE CG, 1994, J BIOL CHEM, V269, P26303; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Yura A, 1996, BRAIN RES, V738, P96, DOI 10.1016/0006-8993(96)00762-7	63	243	248	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2458	2466		10.1074/jbc.273.4.2458	http://dx.doi.org/10.1074/jbc.273.4.2458			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442097	hybrid			2022-12-27	WOS:000071595200086
J	Walker, D; Bichet, D; Campbell, KP; De Waard, M				Walker, D; Bichet, D; Campbell, KP; De Waard, M			A beta(4) isoform-specific interaction site in the carboxyl-terminal region of the voltage-dependent Ca2+ channel alpha(1A) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; IDENTIFICATION; CLONING; BRAIN; ALPHA(1)-SUBUNIT; INACTIVATION; DIVERSITY; DOMAIN; MOTIF	The voltage-gated calcium channel beta subunit is a cytoplasmic protein that stimulates activity of the channel-forming subunit, alpha(1), in several ways. Complementary binding sites on alpha(1) and beta have been identified that are highly conserved among isoforms of the two subunits, but this interaction alone does not account for all of the functional effects of the beta subunit. We describe here the characterization in vitro of a second interaction, involving the carboxyl-terminal cytoplasmic domain of alpha(1A) and showing specificity for the beta(4) (and to a lesser extent beta(2a)) isoform. A deletion and chimera approach showed that the carboxyl-terminal region of beta(4), poorly conserved between beta isoforms, contains the interaction site and plays a role in the regulation of channel inactivation kinetics. This is the first demonstration of a molecular basis for the specificity of functional effects seen for different combinations of these two channel components.	Fac Med Nord, Inst Federat Jean Roche, INSERM U464, F-13916 Marseille 20, France; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Howard Hughes Medical Institute; University of Iowa	De Waard, M (corresponding author), Fac Med Nord, Inst Federat Jean Roche, INSERM U464, Bd Pierre Dramard, F-13916 Marseille 20, France.	dewaard.m@jean-roche.univ-mrs.fr	De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889; Bichet, Delphine/0000-0002-9601-089X; Walker, Denise/0000-0003-1534-1679				Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; JAY SD, 1991, J BIOL CHEM, V266, P3287; Klockner U, 1997, AM J PHYSIOL-HEART C, V272, pH1372, DOI 10.1152/ajpheart.1997.272.3.H1372; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Ludwig A, 1997, J NEUROSCI, V17, P1339; Marubio LM, 1996, RECEPTOR CHANNEL, V4, P243; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; SOONG TW, 1993, SCIENCE, V260, P1193; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1991, J BIOL CHEM, V266, P21943; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	38	128	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2361	2367		10.1074/jbc.273.4.2361	http://dx.doi.org/10.1074/jbc.273.4.2361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442082	hybrid			2022-12-27	WOS:000071595200071
J	Nguyen, M; Arkell, J; Jackson, CJ				Nguyen, M; Arkell, J; Jackson, CJ			Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE; 92-KDA GELATINASE; PROGELATINASE-B; ACTIVATION; CELLS; ANGIOGENESIS; STROMELYSIN; IDENTIFICATION; EXPRESSION; PRECURSOR	Human gelatinase B is involved in tissue remodeling and angiogenesis, It is thought to be synthesized and rapidly secreted as an inactive precursor. In this report, we have shown that human endothelial cells accumulate active forms of gelatinase B in the cytosol. Microvascular but not macrovascular endothelial cells dramatically increased the expression of cytosolic gelatinase B in response to phorbol myristate acetate, Western blotting showed that tissue inhibitor of metalloproteinase-l (TIMP1) was also present in the cytosol, Whereas gelatinase B was complexed with TIMP1 in the conditioned medium, it existed as a free enzyme in the cytosol, suggesting that the formation of gelatinase B and TIMP1 complex occurs after their secretion, Immunogold electron microscopy revealed that gelatinase B was localized in secretory vesicles which were especially prominent in invading pseudopodia. In contrast, TIMP1 was found throughout the cytoplasm but was not present in the gelatinase vesicles, The accumulation of intracellular activated gelatinase B, ready for rapid release, may facilitate the migration of microvascular endothelial cells during angiogenesis.	Royal N Shore Hosp, Sutton Rheumatism Res Lab, St Leonards, NSW 2065, Australia	Royal North Shore Hospital	Jackson, CJ (corresponding author), Royal N Shore Hosp, Sutton Rheumatism Res Lab, St Leonards, NSW 2065, Australia.			Jackson, Christopher/0000-0002-9234-9116				Arkona C, 1996, BIOL CHEM, V377, P695, DOI 10.1515/bchm3.1996.377.11.695; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; BENDAYAN M, 1982, J HISTOCHEM CYTOCHEM, V30, P81, DOI 10.1177/30.1.6172469; BOUGHARIOS G, 1994, CLIN CHIM ACTA, V231, P69, DOI 10.1016/0009-8981(94)90255-0; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIDMAN R, 1995, CANCER RES, V55, P2548; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HERRON GS, 1986, J BIOL CHEM, V261, P2810; ITOH Y, 1995, J BIOL CHEM, V270, P16518, DOI 10.1074/jbc.270.28.16518; Jackson CJ, 1997, INT J BIOCHEM CELL B, V29, P1167, DOI 10.1016/S1357-2725(97)00061-7; JACKSON CJ, 1990, J CELL SCI, V96, P257; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KJELDSEN L, 1993, BLOOD, V82, P3183; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	35	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5400	5404		10.1074/jbc.273.9.5400	http://dx.doi.org/10.1074/jbc.273.9.5400			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9479001	hybrid			2022-12-27	WOS:000072310400085
J	Baugh, RJ; Broze, GJ; Krishnaswamy, S				Baugh, RJ; Broze, GJ; Krishnaswamy, S			Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ANTICOAGULANT PEPTIDE; HUMAN FACTOR-VII; COAGULATION INHIBITOR; PROTHROMBINASE COMPLEX; BLOOD-COAGULATION; CELL-SURFACES; STUART FACTOR; ACTIVATION; BINDING; MECHANISM	Tissue factor (TF) pathway inhibitor (TFPI) regulates factor X activation through the sequential inhibition of factor Xa and the VIIa.TF complex, Factor Xa formation was studied in a purified, reconstituted system, at plasma concentrations of factor X and TFPI, saturating concentrations of factor VIIa, and increasing concentrations of TF reconstituted into phosphatidylcholine: phosphatidylserine membranes (TF/PCPS) or PC membranes (TF/PC). The initial rate of factor Xa formation was equivalent in the presence or absence of 2.4 nM TFPI, However, reaction extent was small (<20%) relative to that observed in the absence of TFPI, implying the rapid inhibition of VIIa.TF during factor X activation, Initiation of factor Xa formation using increasing concentrations of TF/PCPS or TF/PC in the presence of TFPI yielded families of progress curves where both initial rate and reaction extent were linearly proportional to the concentration VIIa.TF. These observations were consistent with a kinetic model in which the rate-limiting step represents the initial inhibition of newly formed factor Xa. Numerical analyses of progress curves yielded a rate constant for inhibition of VIIa.TF by Xa.TFPI (>10(8) M-1.s(-1)) that was substantially greater than the value (7.34 +/- 0.8 x 10(6) M-1.s(-1)) directly measured. Thus, VIIa.TF is inhibited at near diffusion-limited rates by Xa.TFPI formed during catalysis which cannot be explained by studies of the isolated reaction, We propose that the predominant inhibitory pathway during factor X activation may involve the initial inhibition of factor Xa either bound to or in the near vicinity of VIIa.TF on the membrane surface. As a result, VIIa.TF inhibition is unexpectedly rapid, and the concentration of active factor Xa that escapes regulation is linearly dependent on the availability of TF.	Emory Univ, Dept Med, Div Hematol Oncol, Atlanta, GA 30322 USA; Washington Univ, Jewish Hosp, Div Hematol, St Louis, MO 63110 USA	Emory University; Barnes-Jewish Hospital; Washington University (WUSTL)	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, 310 Abramson,324 S 34th St, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047465, R01HL034462] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-34462, R01 HL-47465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Bevington P. R, 1969, DATA REDUCTION ERROR; BROZE GJ, 1985, J CLIN INVEST, V76, P937, DOI 10.1172/JCI112093; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1995, ANNU REV MED, V46, P103, DOI 10.1146/annurev.med.46.1.103; CALLANDER NS, 1992, J BIOL CHEM, V267, P876; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DAVID GS, 1972, BIOCHEM BIOPH RES CO, V48, P464, DOI 10.1016/S0006-291X(72)80074-3; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GENTRY R, 1995, BIOPHYS J, V69, P362, DOI 10.1016/S0006-3495(95)79908-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIRARD TJ, 1993, METHOD ENZYMOL, V222, P195; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHE Y, 1994, BIO-TECHNOL, V12, P1119, DOI 10.1038/nbt1194-1119; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LINDHOUT T, 1994, BIOCHEM J, V297, P131, DOI 10.1042/bj2970131; LINDHOUT T, 1995, THROMB HAEMOSTASIS, V74, P910; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MANN KG, 1990, BLOOD, V76, P1; Mason J T, 1978, Ann N Y Acad Sci, V308, P29, DOI 10.1111/j.1749-6632.1978.tb22012.x; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1992, SEMIN HEMATOL, V29, P170; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NOVOTNY WF, 1991, BLOOD, V78, P394; NOVOTNY WF, 1991, BLOOD, V78, P387; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RAO LVM, 1995, BLOOD, V85, P121, DOI 10.1182/blood.V85.1.121.bloodjournal851121; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; WALKER RK, 1994, J BIOL CHEM, V269, P27441; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021	51	174	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4378	4386		10.1074/jbc.273.8.4378	http://dx.doi.org/10.1074/jbc.273.8.4378			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468488	hybrid			2022-12-27	WOS:000072115000016
J	Sharma, B; Iozzo, RV				Sharma, B; Iozzo, RV			Transcriptional silencing of perlecan gene expression by interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; COLON CARCINOMA-CELLS; BASEMENT-MEMBRANES; DOMAIN-III; BINDING; LOCALIZATION; MATRICES; MOLECULE; RECEPTOR	Perlecan, a heparan sulfate proteoglycan of basement membranes and cell surfaces, has been implicated in the control of tumor cell growth and metastasis because of its ability to bind and store growth factors and its activity as an inducer of angiogenesis. Because interferon-gamma (IFN-gamma), a cytokine with known antiproliferative and antitumoral activity, binds with known anti high affinity to the heparan sulfate side chains of perlecan, we investigate the activity of IFN-gamma on perlecan gene expression and cell growth in colon carcinoma cells. We found that IFN-gamma rapidly and efficiently blocked perlecan gene expression with concurrent growth suppression, a phenomenon that was independent of a functional p21(WAF1/CIP1). These effects were transcriptionally mediated, did not require new protein synthesis, and were fully reversible. Moreover, we found these IFN-gamma-induced effects to generalizable because they could be reproduced in a variety of cells with various histogenetic backgrounds. The transcriptional repression of the perlecan gene required intact Stat1 protein, and these effects were likely mediated by Stat1-binding sites in the distal promoter region. Thus, the IFN-gamma-mediated transcriptional repression of perlecan may represent a novel antitumoral effect of this cytokine through which it eliminates a powerful angiogenic stimulus.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, JAH, Philadelphia, PA 19107 USA	Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, JAH, Rm 249,1020 Locust St, Philadelphia, PA 19107 USA.	Iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COHEN IR, 1994, CANCER RES, V54, P5771; COUCHMAN JR, 1995, J HISTOCHEM CYTOCHEM, V43, P955, DOI 10.1177/43.9.7543915; COUCHMAN JR, 1993, CELL SURFACE EXTRACE, P33; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Friedl A, 1997, AM J PATHOL, V150, P1443; GRASSEL S, 1995, MOL CELL BIOCHEM, V145, P61, DOI 10.1007/BF00925714; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; IOZZO RV, 1989, ARCH BIOCHEM BIOPHYS, V269, P239, DOI 10.1016/0003-9861(89)90105-7; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; IOZZO RV, 1998, IN PRESS ANN REV BIO; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LORTAT-JACOB H, 1991, FEBS LETT, V280, P152, DOI 10.1016/0014-5793(91)80225-R; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; Mathiak M, 1997, CANCER RES, V57, P2130; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Praillet C, 1996, FEBS LETT, V387, P109, DOI 10.1016/0014-5793(96)00468-1; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; TIMAR J, 1992, AM J PATHOL, V141, P467; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; WALDMAN T, 1995, CANCER RES, V55, P5187; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079	32	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4642	4646		10.1074/jbc.273.8.4642	http://dx.doi.org/10.1074/jbc.273.8.4642			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468523	hybrid			2022-12-27	WOS:000072115000051
J	Zhang, YL; Yu, NJ; Spremulli, LL				Zhang, YL; Yu, NJ; Spremulli, LL			Mutational analysis of the roles of residues in Escherichia coli elongation factor Ts in the interaction with elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-EF-TU; CRYSTAL-STRUCTURE; COMPLEX	The crystal structure of the Escherichia coli elongation factor (EF)-Tu.Ts complex indicates that there are extensive contacts between EF-Tu and EF-Ts. To determine the importance of these contacts in the interaction between E. coli EF-Ta and EF-Ts, residues in EF-Ts at the interface of these two proteins were mutated, The binding constants governing the interaction of the resulting EF-Ts variants with E, coti EF-Tu were determined, The effects of these mutations on the ability of EF-Ts to stimulate GDP exchange with EF-Tu.GDP and on its ability to stimulate the activity of EF-Tu in polymerization were tested. The results indicate that Arg-12, Met-19, and Met-20 in the N-terminal domain of EF-Ts and His-147 and Lys-166 and/or His-167 in subdomain C of EF-Ts are crucial in the interaction between EF-Tu and EF-Ts. Lys-23, Val-234, Met-235, and the C-terminal helix his are less important, The binding constants of the EF-Ts variants governing their interactions with EF-Tu correlate well with their activities in stimulating GDP exchange with EF-Tu, Mutations prepared in EF-Tu indicate that His-19 and Gln-114 but not Glu-348 in EF-Tu are moderately important for its interaction with EF-Ts.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, Campus Box 3290, Chapel Hill, NC 27599 USA.	Linda_Spremulli@une.edu			NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Clark BFC, 1997, CURR OPIN STRUC BIOL, V7, P110, DOI 10.1016/S0959-440X(97)80014-0; FOX L, 1980, J BIOL CHEM, V255, P6018; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, CURR BIOL, V1, P35; LI XM, 1993, NUCLEIC ACIDS RES, V21, P3745, DOI 10.1093/nar/21.16.3745; MILLER DL, 1970, BIOCHEM BIOPH RES CO, V38, P1016, DOI 10.1016/0006-291X(70)90341-4; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; RAVEL JM, 1969, COLD SPRING HARB SYM, V34, P321, DOI 10.1101/SQB.1969.034.01.039; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; Tsai CJ, 1996, CRIT REV BIOCHEM MOL, V31, P127, DOI 10.3109/10409239609106582; XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243; Xin H., 1997, BIOCHIM BIOPHYS ACTA, V1352, P101; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2; Zhang YL, 1997, J BIOL CHEM, V272, P21956, DOI 10.1074/jbc.272.35.21956	21	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4556	4562		10.1074/jbc.273.8.4556	http://dx.doi.org/10.1074/jbc.273.8.4556			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468511	hybrid, Green Published			2022-12-27	WOS:000072115000039
J	Cao, Y; Stafforini, DM; Zimmerman, GA; McIntyre, TM; Prescott, SM				Cao, Y; Stafforini, DM; Zimmerman, GA; McIntyre, TM; Prescott, SM			Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; SIGNAL TRANSDUCERS; MACROPHAGE LINEAGE; MOUSE MACROPHAGES; INTERFERON-GAMMA; EPITHELIAL-CELLS; SYNTHASE GENE; MYELOID CELLS; DIFFERENTIATION; SECRETION	Platelet-activating factor (PAF) is a potent phospholipid with diverse physiological and pathological actions, and it is inactivated by PAF acetylhydrolase, In this study, we analyzed the tissue distribution of the plasma PAF acetylhydrolase mRNA in humans. We isolated a 3,5-kilobase fragment containing the 5' genomic sequence of the plasma PAF acetylhydrolase gene and fun-ther characterized the promoter activity, We detere mined the transcriptional initiation site by primer extension. We then prepared constructs containing various lengths of 5' genomic fragments fused to a luciferase reporter gene and transfected these constructs into COS-7 cells, We found that there is more than one region in the 1.3-kilobase 5' genomic sequence conferring promoter activity and that a very short 5'-flanking region (72 base pairs) is sufficient for more than 65% of the basal activity. in parallel, we examined the regulation of expression of the PAF acetylhydrolase gene, We found that interferon-gamma (IFN gamma) and lipopolysaccharide (LPS) significantly inhibited synthesis of PAF acetylhydrolase, whereas other cytokines, including IFN alpha, interleukin (IE) 1 alpha, IL4, IL6, tumor necrosis factor-alpha, granulocyte/macrophage colony-stimulating factor, and macrophage colony-stimulating factor, had a smaller or no effect in human monocyte-derived macrophages. Furthermore, transfection of the promoter/reporter construct into macrophage RAW264.7 cells revealed that IFN gamma and LPS decreased the promoter activity by 35% and 50%, respectively, whereas PAF stimulated it by 52% via its receptor, The promoter activity was much lower in monocytic U937 cells compared with the basal level in COS-7 cells, wile the activities in P388DI and RAW264.7 macrophagic cells were considerably higher than the basal level in COS-7 cells. There are multiple regions in the PAF acetylhydrolase promoter that contain responsive elements for signal transducer and activators of transcription-related proteins, and also for myeloid-specific transcription factors. Our data indicate that the opposite of mRNA expression in monocytes versus macrophages is due to inhibition of the promoter activity in the former and activation in the latter cells.	Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Prescott, SM (corresponding author), Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, 15 N 2030 E,Suite 4220, Salt Lake City, UT 84112 USA.	steve.prescott@genetics.utah.edu			NHLBI NIH HHS [1F32HL09775, HL 35828, HL 50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035828, F32HL009775, P50HL050153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI H, 1994, J BIOL CHEM, V269, P24557; Barahmandpour F, 1996, CURR TOP MICROBIOL, V211, P121; BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BAZAN HEP, 1993, P NATL ACAD SCI USA, V90, P8678, DOI 10.1073/pnas.90.18.8678; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; CHAO W, 1990, BIOCHEM J, V292, P617; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; Deng WL, 1996, CELL IMMUNOL, V170, P20, DOI 10.1006/cimm.1996.0129; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HAMILTON TA, 1992, MACROPHAGE PATHOGEN, P83; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; Howard KM, 1997, J BIOL CHEM, V272, P27543, DOI 10.1074/jbc.272.44.27543; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; NARAHARA H, 1993, AM J OBSTET GYNECOL, V169, P531, DOI 10.1016/0002-9378(93)90614-O; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SATOH K, 1993, METABOLISM, V42, P672, DOI 10.1016/0026-0495(93)90231-C; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; SQUINTO SP, 1990, J MOL NEUROSCI, V2, P79, DOI 10.1007/BF02876914; SQUINTO SP, 1989, J NEUROSCI RES, V24, P558, DOI 10.1002/jnr.490240414; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1990, METHOD ENZYMOL, V187, P344; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VENABLE ME, 1993, J LIPID RES, V34, P691; Wang H, 1997, BIOCHEM J, V322, P603, DOI 10.1042/bj3220603; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; YASUDA K, 1992, ENDOCRINOLOGY, V130, P708, DOI 10.1210/en.130.2.708	52	95	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4012	4020		10.1074/jbc.273.7.4012	http://dx.doi.org/10.1074/jbc.273.7.4012			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461591	hybrid			2022-12-27	WOS:000072048400033
J	Gasson, MJ; Kitamura, Y; McLauchlan, WR; Narbad, A; Parr, AJ; Lindsay, E; Parsons, H; Payne, J; Rhodes, MJC; Walton, NJ				Gasson, MJ; Kitamura, Y; McLauchlan, WR; Narbad, A; Parr, AJ; Lindsay, E; Parsons, H; Payne, J; Rhodes, MJC; Walton, NJ			Metabolism of ferulic acid to vanillin - A bacterial gene of the enoyl-SCoA hydratase/isomerase superfamily encodes an enzyme for the hydration and cleavage of a hydroxycinnamic acid SCoA thioester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHRORHIZON CELL-CULTURES; PARA-HYDROXYBENZOIC ACID; BETA-OXIDATION ENZYMES; LARGE ALPHA-SUBUNIT; PARA-COUMARIC ACID; COENZYME-A LYASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MULTIENZYME COMPLEX; ACTIVE-SITE	A gene encoding a novel enoyl-SCoA hydratase/lyase enzyme for the hydration and nonoxidative cleavage of feruloyl-SCoA to vanillin and acetyl-SCoA was isolated and characterized from a strain of Pseudomonas fluorescens. Feruloyl-SCoA is the CoASH thioester of ferulic acid (4-hydroxy-3-methoxy-trans-cinnamic acid), an abundant constituent of plant cell walls and a degradation product of lignin. The gene was isolated by a combination of mutant complementation and biochemical approaches, and its function was demonstrated by heterologous expression in Escherichia coli under the control of a T7 RNA polymerase promoter. The gene product is a member of the enoyl-SCoA hydratase/isomerase superfamily.	Inst Food Res, Norwich Lab, Dept Genet & Microbiol, Norwich NR4 7UA, Norfolk, England; Inst Food Res, Norwich Lab, Dept Biochem, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Walton, NJ (corresponding author), Inst Food Res, Norwich Lab, Dept Genet & Microbiol, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	nicholas.walton@BBSRC.ac.uk						ANDERSON DH, 1989, J BACTERIOL, V171, P6468, DOI 10.1128/jb.171.12.6468-6472.1989; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P14733, DOI 10.1021/bi00253a011; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FRENCH CJ, 1976, PHYTOCHEMISTRY, V15, P564, DOI 10.1016/S0031-9422(00)88979-7; GUHNEMANNSCHAFER K, 1994, EUR J BIOCHEM, V226, P909, DOI 10.1111/j.1432-1033.1994.t01-1-00909.x; HAGEDORN S, 1994, ANNU REV MICROBIOL, V48, P773, DOI 10.1146/annurev.micro.48.1.773; HAGEL P, 1975, FEBS LETT, V59, P120, DOI 10.1016/0014-5793(75)80355-3; HARTLEY RD, 1977, PHYTOCHEMISTRY, V16, P1531, DOI 10.1016/0031-9422(77)84017-X; He XY, 1996, BIOCHEMISTRY-US, V35, P9625, DOI 10.1021/bi960374y; He XY, 1997, BIOCHEMISTRY-US, V36, P11044, DOI 10.1021/bi970901t; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; LOFFELHARDT W, 1975, H-S Z PHYSIOL CHEM, V356, P487, DOI 10.1515/bchm2.1975.356.1.487; LOSCHER R, 1994, PLANT PHYSIOL, V106, P271, DOI 10.1104/pp.106.1.271; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; MULLERNEWEN G, 1993, BIOCHEMISTRY-US, V32, P11405; NARBAD A, 1997, Patent No. 00809; NARBAD A, 1996, Patent No. 96061874; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PREISIGMULLER R, 1994, J BIOL CHEM, V269, P20475; Priefert H, 1997, J BACTERIOL, V179, P2595, DOI 10.1128/JB.179.8.2595-2607.1997; Rabenhorst J, 1996, APPL MICROBIOL BIOT, V46, P470, DOI 10.1007/s002530050846; Rosazza JPN, 1995, J IND MICROBIOL, V15, P457, DOI 10.1007/BF01570016; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO S, 1992, J BIOCHEM-TOKYO, V111, P8, DOI 10.1093/oxfordjournals.jbchem.a123722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNITZLER JP, 1992, PLANTA, V188, P594, DOI 10.1007/BF00197054; SEMLER U, 1987, Z NATURFORSCH C, V42, P1070; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; Shriner R. L., 1942, ORG REACT, V1, P1; STASKAWICZ B, 1987, J BACTERIOL, V169, P5789, DOI 10.1128/jb.169.12.5789-5794.1987; TADASA K, 1977, AGR BIOL CHEM TOKYO, V41, P925, DOI 10.1080/00021369.1977.10862621; TADASA K, 1983, AGR BIOL CHEM TOKYO, V47, P2639, DOI 10.1080/00021369.1983.10866004; TOMS A, 1970, BIOCHEMISTRY-US, V9, P337, DOI 10.1021/bi00804a021; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WHETTEN R, 1995, PLANT CELL, V7, P1001, DOI 10.2307/3870053; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; Wu WJ, 1997, BIOCHEMISTRY-US, V36, P2211, DOI 10.1021/bi962549+; YANG SY, 1995, BIOCHEMISTRY-US, V34, P6441, DOI 10.1021/bi00019a025; YANG SY, 1993, J BIOL CHEM, V268, P6588; YANG XYH, 1991, BIOCHEMISTRY-US, V30, P6788, DOI 10.1021/bi00241a023; YAZAKI K, 1991, PHYTOCHEMISTRY, V30, P2233, DOI 10.1016/0031-9422(91)83620-Z; ZENK MH, 1980, ANAL BIOCHEM, V101, P182, DOI 10.1016/0003-2697(80)90058-5; ZENK MH, 1979, RECENT ADV PHYTOCHEM, V12, P139	50	177	189	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4163	4170		10.1074/jbc.273.7.4163	http://dx.doi.org/10.1074/jbc.273.7.4163			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461612	hybrid			2022-12-27	WOS:000072048400054
J	Noda, T; Ohsumi, Y				Noda, T; Ohsumi, Y			Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; SIGNAL-TRANSDUCTION; MAMMALIAN PROTEIN; VACUOLAR PROTEIN; RAPAMYCIN; PATHWAY; FKBP12-RAPAMYCIN; MECHANISMS	Autophagy is a bulk protein degradation process that is induced by starvation, The control mechanism for induction of autophagy is not well understood, We found that Tor, a phosphatidylinositol kinase homologue, is involved in the control of autophagy in the yeast, Sac charomyces cerevisiae, When rapamycin, an inhibitor of Tor function, is added, autophagy is induced even in cells growing in nutrient-rich medium, A temperature-sensitive tor mutant also leads to induction of autophagy at a nonpermissive temperature. These results indicate that Tor negatively regulates the induction of autophagy, Tor is the first molecule that is identified as a pivotal player in the starvation-signaling pathway of autophagy, Furthermore, we found that a high concentration of cAMP is inhibitory for induction of autophagy, APG gene products are involved in autophagy induced by starvation, Autophagy was not induced in apg mutants in the presence of rapamycin, indicating that the site of action of Tor is upstream of those of Apg proteins, In nutrient-rich medium, Apg proteins are involved also in the transport of aminopeptidase I from the cytosol to the vacuole, Tor may act to switch Apg function between autophagy and transport of aminopeptidase I.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 444, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Nishigonaka 38, Okazaki, Aichi 444, Japan.	yohsumi@nibb.ac.jp	Noda, Takeshi/B-7240-2008; Ohsumi, Yoshinori/C-6449-2009	Noda, Takeshi/0000-0003-3581-7961; Ohsumi, Yoshinori/0000-0003-2384-2166				BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; BAEDET NB, 1996, MOL BIOL CELL, V7, P25; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HOLEN I, 1991, BIOMED BIOCHIM ACTA, V50, P389; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; KOVACS AL, 1981, EXP CELL RES, V133, P431, DOI 10.1016/0014-4827(81)90336-0; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MATSUURA A, 1997, GENE, V192, P240; MEIJER AJ, 1985, EUR J BIOCHEM, V148, P189, DOI 10.1111/j.1432-1033.1985.tb08824.x; MITSUZAWA H, 1993, GENETICS, V135, P321; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Nothwehr SF, 1996, MOL CELL BIOL, V16, P2700; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; SEGLEN PO, 1984, J CELL BIOL, V99, P435, DOI 10.1083/jcb.99.2.435; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; Zheng XF, 1997, P NATL ACAD SCI USA, V94, P3070, DOI 10.1073/pnas.94.7.3070	39	997	1032	1	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3963	3966		10.1074/jbc.273.7.3963	http://dx.doi.org/10.1074/jbc.273.7.3963			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461583	hybrid			2022-12-27	WOS:000072048400025
J	Sekkai, D; Aillet, F; Israel, N; Lepoivre, M				Sekkai, D; Aillet, F; Israel, N; Lepoivre, M			Inhibition of NF-kappa B and HIV-1 long terminal repeat transcriptional activation by inducible nitric oxide synthase 2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; VASCULAR ENDOTHELIAL-CELLS; ANTIMICROBIAL ACTIVITY; VIRAL REPLICATION; GENE-EXPRESSION; IFN-GAMMA; IN-VITRO; TYPE-1; MACROPHAGES	In the human lymphoblastoid T cell line JJhan-5.1, stably transfected with a human immunodeficiency virus-1 long terminal repeat luciferase vector, the level of luciferase activity is dependent on activation of the nuclear factor kappa B (NF-kappa B) transcription factor, Tumor necrosis factor-induced luciferase activity was not modified in JJhan-5.1 cells co-cultivated with murine adenocarcinoma EMT-B cells but was strongly decreased when nitric oxide (NO) synthase 2 expression was induced in these cells, Two NO synthase inhibitors counteracted this inhibitory effect, Tumor necrosis factor-cu binding to JJhan-5.1 cells was not modified after incubation with EMT-6 cells, Viability and protein synthesis in JJhan-5.1 cells were also unchanged, Induction of NF-kappa B DNA binding activity was inhibited when EMT-6 cells expressed NO synthase 2 activity, Aminoguanidine, which completely abolished nitrite production, prevented this inhibition. NF-kappa B activation was also strongly inhibited by S-nitrosoglutathione but was marginally affected by N-(2-aminoethyl)-N-(2-hydroxy-2-nitrosohydrazino)-1,2-ethylenediamine. Taken together, these results indicated that NO-related species, released by EMT-6 effector cells and probably different from NO itself, inhibited NF-kappa B activation in human lymphoblastoid target cells, Consequently, transcriptional activity of a long terminal repeat-driven luciferase gene construct was markedly diminished.	Univ Paris Sud, CNRS, ERS 571, Unite 571, F-91405 Orsay, France; Inst Pasteur, Unite Biol Retrovirus, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lepoivre, M (corresponding author), Univ Paris Sud, CNRS, ERS 571, Unite 571, Bat 430, F-91405 Orsay, France.	michel.lepoivre@bbmpc.u-psud.fr	Lepoivre, Michel/J-8578-2013					AKARID K, 1995, J VIROL, V69, P7001, DOI 10.1128/JVI.69.11.7001-7005.1995; Albina JE, 1995, J LEUKOCYTE BIOL, V58, P643, DOI 10.1002/jlb.58.6.643; ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BAUD L, 1990, J IMMUNOL, V145, P556; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; Chao CC, 1996, GLIA, V16, P276, DOI 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X; CHEN F, 1995, BIOCHEM BIOPH RES CO, V214, P839, DOI 10.1006/bbrc.1995.2363; CHENAIS B, 1994, INT J IMMUNOPHARMACO, V16, P401, DOI 10.1016/0192-0561(94)90028-0; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; ISRAEL N, 1992, J IMMUNOL, V149, P3386; Janabi N, 1996, J IMMUNOL, V157, P2129; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; Liu J, 1996, J IMMUNOL, V157, P3569; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MIRZA UA, 1995, J BIOL CHEM, V270, P17185, DOI 10.1074/jbc.270.29.17185; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sriskandan S, 1996, J IMMUNOL, V156, P2430; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Torre D, 1996, CLIN INFECT DIS, V22, P650, DOI 10.1093/clinids/22.4.650; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980	46	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3895	3900		10.1074/jbc.273.7.3895	http://dx.doi.org/10.1074/jbc.273.7.3895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461573	hybrid			2022-12-27	WOS:000072048400015
J	Batt, DB; Roberts, TM				Batt, DB; Roberts, TM			Cell density modulates protein-tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SWISS 3T3 CELLS; GROWTH-FACTOR; SERINE-PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CROSS-TALK; PAXILLIN; INTEGRIN; SRC; PATHWAYS	The growth of normal cells is arrested at saturating cell density in a process termed contact inhibition. An understanding of how cells communicate their contact with one another is critical for determining how cancers develop and spread. Because the molecular details of how fibroblasts communicate density changes are unclear, we examined cell density itself as a source of signaling events rather than examine specific receptors. A technique was developed to measure tyrosine phosphorylation acutely as a function of cell. density. The tyrosine phosphorylation of a number of proteins was found to be modified in response to cell density. Three of these proteins were identified as Src, paxillin, and focal adhesion kinase (FAK), all of which show an increase in their tyrosine phosphate levels with increasing density. All of these proteins are found in focal adhesions, and both FAK and paxillin are believed to be localized exclusively in focal adhesions. Thus, changing cell density alters tyrosine phosphorylation of focal adhesion components.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Roberts, TM (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.	thomas_roberts@dfci.harvard.edu			NCI NIH HHS [CA43803] Funding Source: Medline; NIGMS NIH HHS [GM18214-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRYANT PJ, 1993, DEVELOPMENT, P239; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; GRADL G, 1995, CURR BIOL, V5, P526, DOI 10.1016/S0960-9822(95)00105-9; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUMBINER BM, 1993, J CELL SCI, P155; HATAI M, 1994, FEBS LETT, V350, P113, DOI 10.1016/0014-5793(94)00745-4; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Leventhal PS, 1996, J BIOL CHEM, V271, P5957, DOI 10.1074/jbc.271.11.5957; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; REBUTBONNETON C, 1993, J CELL SCI, V105, P629; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Saito Y, 1996, BIOCHEM BIOPH RES CO, V224, P23, DOI 10.1006/bbrc.1996.0978; Sakamoto M, 1996, LAB INVEST, V74, P199; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	35	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3408	3414		10.1074/jbc.273.6.3408	http://dx.doi.org/10.1074/jbc.273.6.3408			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452462	hybrid			2022-12-27	WOS:000071822300047
J	Evdokimova, VM; Kovrigina, EA; Nashchekin, DV; Davydova, EK; Hershey, JWB; Ovchinnikov, LP				Evdokimova, VM; Kovrigina, EA; Nashchekin, DV; Davydova, EK; Hershey, JWB; Ovchinnikov, LP			The major core protein of messenger ribonucleoprotein particles (p50) promotes initiation of protein biosynthesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; CYTOPLASMIC MRNP; ESCHERICHIA-COLI; RNA TRANSLATION; SOMATIC-CELLS; RABBIT RETICULOCYTES; BINDING-PROTEINS; MASKING; INHIBITION; FAMILY	The major core protein of cytoplasmic messenger ribonucleoprotein particles (p50) has been shown previously to inhibit protein synthesis in vitro and in vivo, Furthermore, p50 is highly homologous to the Y-box-binding transcription factor family of proteins, binds DNA containing the Y-box motif, and thus may have a dual function in cells as a regulator of both transcription and translation, Here we show that binding or removal of p50 from rabbit reticulocyte lysate by monospecific antibodies to p50 strongly inhibits translation of endogenous and exogenous globin mRNAs as well as prokaryotic beta-galactosidase mRNA in a rabbit reticulocyte cell-free system, Thus, depending on the conditions, p50 not only may act as a translational repressor, but may also be required for protein synthesis, Translation inhibition with anti-p50 antibodies is not a result of mRNA degradation or its functional inactivation, The inhibition does not change the ribosome transit time, and therefore, it does not affect elongation/termination of polypeptide chains. The inhibition with anti-p50 antibodies is followed by a decay of polysomes and accumulation of the 48 S preinitiation complex, These results suggest that p50 participates in initiation of protein biosynthesis, Although uninvolved in the formation of the 48 S preinitiation complex, p50 is necessary either for attachment of the 60 S ribosomal subunit or for previous 5'-untranslated region scanning by the 43 S preinitiation complex.	Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Russian Academy of Sciences; University of California System; University of California Davis	Ovchinnikov, LP (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142292, Moscow Region, Russia.	ovchinn@sun.ipr.serpukhov.su	Ovchinnikov, Lev/L-2397-2015	Nashchekin, Dmitry/0000-0001-7372-0752				ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; AUERBACH S, 1975, BIOCHEM BIOPH RES CO, V63, P149, DOI 10.1016/S0006-291X(75)80023-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; EY PL, 1978, BIOCHEMISTRY-US, V15, P429; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JAIN SK, 1979, FEBS LETT, V97, P84, DOI 10.1016/0014-5793(79)80058-7; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KOZAK M, 1980, CELL, V22, P459, DOI 10.1016/0092-8674(80)90356-6; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MINICH WB, 1990, MOL BIOL REP, V14, P65, DOI 10.1007/BF00360418; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MINICH WB, 1989, FEBS LETT, V257, P257, DOI 10.1016/0014-5793(89)81547-9; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SMAILOV SK, 1990, FEBS LETT, V275, P99, DOI 10.1016/0014-5793(90)81448-W; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Ustinov VA, 1996, BIOCHEMISTRY-MOSCOW+, V61, P414; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	40	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3574	3581		10.1074/jbc.273.6.3574	http://dx.doi.org/10.1074/jbc.273.6.3574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452484	hybrid			2022-12-27	WOS:000071822300069
J	Payne, AS; Gitlin, JD				Payne, AS; Gitlin, JD			Functional expression of the Menkes disease protein reveals common biochemical mechanisms among the copper-transporting P-type ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE GENE; HISTIDINE TREATMENT; IRON UPTAKE; MUTATIONS; YEAST; ENCODES; CELLS; AMPLIFICATION; ORGANIZATION; FIBROBLASTS	Menkes disease is a fatal neurodegenerative disorder of childhood caused by the absence or dysfunction of a putative P-type ATPase encoded on the X chromosome. To elucidate the function of the Menkes disease protein, a plasmid containing the open reading frame of the human Menkes disease gene was constructed and used to transform a strain of Saccharomyces cerevisiae deficient in CCC2, the yeast Menkes/Wilson disease gene homologue. ccc2 Delta yeast are deficient in copper transport into the secretory pathway, and expression of a wild type human Menkes cDNA complemented this defect, as evidenced by the restoration of copper incorporation into the multicopper oxidase Fet3p. Site-directed mutagenesis demonstrated the essential role of four specific amino acids in this process, including a conserved histidine, which is the site of the most common disease mutation in the homologous Wilson disease protein. The expression of Menkes cDNAs with successive mutations of the conserved cysteine residues in the six amino-terminal MXCXXC metal binding domains confirmed the essential role of these cysteine residues in copper transport but revealed that each of these domains is not functionally equivalent. These data demonstrate that the Menkes disease protein functions to deliver copper into the secretory pathway of the cell and that this process involves biochemical mechanisms common to previously characterized members of this P-type ATPase family.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL)	Gitlin, JD (corresponding author), St Louis Childrens Hosp, Dept Pediat, 1 Childrens Pl, St Louis, MO 63110 USA.	gitlin@kidsa1.wustl.edu			NIDDK NIH HHS [DK44464] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044464, R37DK044464] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; CAMAKARIS J, 1980, BIOCHEM GENET, V18, P117, DOI 10.1007/BF00504364; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DANKS DM, 1972, PEDIATRICS, V50, P188; DAS S, 1994, AM J HUM GENET, V55, P883; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GOKA TJ, 1976, P NATL ACAD SCI USA, V73, P604, DOI 10.1073/pnas.73.2.604; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaler SG, 1996, NAT GENET, V13, P21, DOI 10.1038/ng0596-21; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Kuo YM, 1997, HUM MOL GENET, V6, P1043, DOI 10.1093/hmg/6.7.1043; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; ROYCE PM, 1980, BIOCHEM J, V192, P579, DOI 10.1042/bj1920579; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambongi Y, 1997, J BIOCHEM-TOKYO, V121, P1169, DOI 10.1093/oxfordjournals.jbchem.a021711; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Tumer Z, 1997, AM J HUM GENET, V60, P63; Tumer Z, 1996, NAT GENET, V12, P11, DOI 10.1038/ng0196-11; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yang XL, 1997, BIOCHEM J, V326, P897, DOI 10.1042/bj3260897; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	38	134	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3765	3770		10.1074/jbc.273.6.3765	http://dx.doi.org/10.1074/jbc.273.6.3765			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452509	hybrid			2022-12-27	WOS:000071822300094
J	Yu, MH; Zhang, LL; Rishi, AK; Khadeer, M; Inesi, G; Hussain, A				Yu, MH; Zhang, LL; Rishi, AK; Khadeer, M; Inesi, G; Hussain, A			Specific substitutions at amino acid 256 of the sarcoplasmic/endoplasmic reticulum Ca2+ transport ATPase mediate resistance to thapsigargin in thapsigargin-resistant hamster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CA2+-ATPASE; GENE; PHOSPHORYLATION; SITE	High levels of resistance to thapsigargin (TG), a specific inhibitor of intracellular Ca2+ transport ATPases (SERCAs), can be developed in culture by stepwise exposure of mammalian cells to increasing concentrations of TG. We have identified, in two independently selected TG-resistant hamster cell lines of different lineages, mutant forms of SERCA. In the TG-resistant Chinese hamster lung fibroblast cell line DC-3F/TG, a T --> C change at nucleotide 766 introduces a Phe(256) --> Leu alteration within the first cytosolic loop of the SERCA. In contrast, in the TG-resistant Syrian hamster smooth muscle cell line DDT/TG 4 mu M, a T --> C change at nucleotide 767 introduces a Phe(256) --> Ser mutation at that position. When these specific mutations are introduced into a wild-type full-length avian SERCA1 cDNA, transfection experiments reveal that Ca2+ transport function and ATP hydrolytic activity are not altered by such mutations, However, a 4-5-fold resistance to TG inhibition of Ca2+ transport function occurs upon the introduction of either the Phe(256) --> Leu or the Phe(256) --> Ser mutation into wild-type SERCA1, These specific mutations also render the hydrolytic activity of the ATPase resistant to inhibition by TG, Our results not only implicate amino acid 256 in TG-SERCA interactions, but also demonstrate that specific mutations within SERCA can mediate resistance to TG.	Univ Maryland, Greenebaum Canc Ctr, Dept Med, Div Oncol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biol Chem, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Hussain, A (corresponding author), Univ Maryland, Greenebaum Canc Ctr, Dept Med, Div Oncol, 655 W Baltimore St,Bressler Res Bldg,Rm 9-047, Baltimore, MD 21201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL27867] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEDLER JL, 1970, CANCER RES, V30, P1174; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; GUTHEIL JC, 1994, J BIOL CHEM, V269, P7976; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; HUSSAIN A, 1992, ARCH BIOCHEM BIOPHYS, V296, P539, DOI 10.1016/0003-9861(92)90608-Y; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MELERA PW, 1991, SEMINARS CANC BIOL, P245; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; RISHI A, 1992, AM J PHYSIOL, V262, pL566, DOI 10.1152/ajplung.1992.262.5.L566; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sambrook J., 2002, MOL CLONING LAB MANU; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SMITH RG, 1984, J STEROID BIOCHEM, V20, P227; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; YU MH, 1993, CANCER RES, V53, P6031; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	20	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3542	3546		10.1074/jbc.273.6.3542	http://dx.doi.org/10.1074/jbc.273.6.3542			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452480	hybrid			2022-12-27	WOS:000071822300065
J	Firth, SM; Ganeshprasad, U; Baxter, RC				Firth, SM; Ganeshprasad, U; Baxter, RC			Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-LABILE SUBUNIT; TERNARY COMPLEX-FORMATION; I IGF-I; HUMAN FIBROBLASTS; HEPARAN-SULFATE; DNA-POLYMERASE; HUMAN-PLASMA; HUMAN-SERUM; PURIFICATION; IGFBP-3	Among the well defined insulin-like growth factor (IGF)-binding proteins (IGFBPs), IGFBP-3 is characterized by its interaction with an acid-labile glycoprotein (ALS) in the presence of IGFs. To identify the structural determinants on IGFBP-3 required for ligand binding and cell association, five recombinant human IGFBP-3 variants were expressed in Chinese hamster ovary cells: deletions of amino acids 89-264, 89-184, and 185-264, and site specific mutations (228)KGRKR --> MDGEA and (KED)-K-253 --> RGD. The basic carboxyl-terminal region of IGFBP-3 was required for binding to heparin. The deletion variants had greatly decreased IGF binding ability as assessed by ligand blotting and solution binding assays; affinity cross-linking indicated at least a 20-fold decrease in IGF affinity. The RGD mutant had a 4-6-fold reduced affinity for both IGFs, but the MDGEA mutant bound IGF-I with near normal affinity and IGF-II with a 3-fold reduction in affinity, The three deletion variants were incapable of binding ALS; but of the site-specific variants, the MDGEA mutant bound ALS with 90% lower affinity (K-a = 2.5 +/- 0.9 liters/nmol) than seen for RrhIGF-BP-3 (K-a = 24.3 +/- 5.2 liters/nmol), whereas the RGD mutation had no effect on ALS affinity (K-a = 21.7 +/- 4.5 liters/nmol). The ability of IGFBP-3 to associate with the cell surface was lost in variants lacking residues 185-264 and in the (228)KGRKR --> MDGEA mutant. We conclude that residues 228-232 of IGFBP-3 are essential for cell association and are required for normal ALS binding affinity.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Firth, SM (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	sfirth@med.usyd.edu.au	Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				ARAI T, 1994, J BIOL CHEM, V269, P20388; BARRECA A, 1995, J CLIN ENDOCR METAB, V80, P1318, DOI 10.1210/jc.80.4.1318; BAXTER RC, 1990, BIOCHEM J, V271, P773, DOI 10.1042/bj2710773; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; COHEN P, 1993, GROWTH REGULAT, V3, P23; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Drop S.L.S., 1991, MODERN CONCEPTS INSU, P311; FIRTH S, 1996, PROG GROWTH FACTOR R, V6, P223; Fowlkes JL, 1996, J BIOL CHEM, V271, P14676, DOI 10.1074/jbc.271.25.14676; GARGOSKY SE, 1991, J ENDOCRINOL, V131, P491, DOI 10.1677/joe.0.1310491; HASEGAWA T, 1995, GROWTH REGULAT, V5, P151; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Holman SR, 1996, GROWTH REGULAT, V6, P42; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1995, ENDOCRINOLOGY, V136, P668, DOI 10.1210/en.136.2.668; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; MARTIN JL, 1992, GROWTH REGULAT, V2, P88; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MARTIN JL, 1994, CURR OPIN ENDOCRINOL, V1, P16; OH YM, 1993, J BIOL CHEM, V268, P14964; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; ROSENFELD RG, 1994, ACTA PAEDIATR, V83, P154, DOI 10.1111/j.1651-2227.1994.tb13315.x; Russo V. C., 1995, Progress in Growth Factor Research, V6, P329, DOI 10.1016/0955-2235(95)00018-6; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; Yang YWH, 1996, ENDOCRINOLOGY, V137, P4363, DOI 10.1210/en.137.10.4363; ZAPF J, 1988, BIOCHEM BIOPH RES CO, V156, P1187, DOI 10.1016/S0006-291X(88)80758-7; ZAPF J, 1990, J BIOL CHEM, V265, P14892; ZHOU C, 1990, BIOTECHNIQUES, V8, P503	44	118	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2631	2638		10.1074/jbc.273.5.2631	http://dx.doi.org/10.1074/jbc.273.5.2631			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446566	hybrid			2022-12-27	WOS:000071736600021
J	Krebs, B; Griffin, H; Winter, G; Rose-John, S				Krebs, B; Griffin, H; Winter, G; Rose-John, S			Recombinant human single chain Fv antibodies recognizing human interleukin-6 - Specific targeting of cytokine-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; AFFINITY HUMAN-ANTIBODIES; PHAGE DISPLAY LIBRARIES; HUMAN MYELOMA CELLS; RECEPTOR ANTAGONIST; HUMAN IL-6; SYNTHETIC REPERTOIRES; GP130 ACTIVATION; ESCHERICHIA-COLI; AMINO-ACIDS	A human antibody library was displayed on the surface of filamentous bacteriophage and screened for binding to human interleukin-6 (IL-6). Two antibody-bearing phages were selected that bound IL-6. The complementary-determining region 3 loops of the variable heavy chains of these two antibodies differed in length and sequence and recognized two distinct epitopes. One of the single chain Fv fragments isolated (H1) was found to bind human (but not murine) IL-6 with an affinity comparable to that of the human IL-6 receptor. HI also recognized newly synthesized human IL-6 intracellularly, as shown by indirect immunofluorescence. H1 did not neutralize human IL-6, and the H1 epitope was mapped to a region of IL-6 not involved in interactions with IL-6, IL-6 receptor, or the signal-transducing protein gp130. To target IL-6-secreting cells, we then constructed a bispecific antibody fragment (a diabody) comprising H1 and the antigen binding site of the T-cell activating monoclonal antibody OKT3. The diabody led to T-cell-mediated killing of cells secreting IL-6.	Johannes Gutenberg Univ Mainz, Dept Med, Sect Pathophysiol, D-55101 Mainz, Germany; Univ Cambridge, Ctr Prot Engn, MRC, Cambridge CB2 2QH, England	Johannes Gutenberg University of Mainz; University of Cambridge	Rose-John, S (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, Sect Pathophysiol, Obere Zahlbacher Str 63, D-55101 Mainz, Germany.	rose@mzdmza.zdv.uni-mainz.de	Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; Ackermann B, 1997, J INFECT DIS, V175, P1121, DOI 10.1086/516451; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BAUER J, 1991, ANN HEMATOL, V62, P203, DOI 10.1007/BF01729833; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CASTELL J, 1990, EUR J BIOCHEM, V189, P113, DOI 10.1111/j.1432-1033.1990.tb15466.x; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; DEHON FD, 1994, J EXP MED, V180, P2395, DOI 10.1084/jem.180.6.2395; EHLERS M, 1994, J IMMUNOL, V153, P1744; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; EHLERS M, 1996, J INTERFORM CYTOKINE, V16, P599; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Holliger P, 1996, PROTEIN ENG, V9, P299, DOI 10.1093/protein/9.3.299; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; JOHNSON KS, 1996, ANTIBODY ENG; Kallen K J, 1997, Expert Opin Investig Drugs, V6, P237, DOI 10.1517/13543784.6.3.237; KLEIN B, 1991, BLOOD, V78, P1198; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MARKS JD, 1992, J BIOL CHEM, V267, P16007; NEURATH AR, 1992, J EXP MED, V176, P1561, DOI 10.1084/jem.176.6.1561; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WENDLING D, 1993, J RHEUMATOL, V20, P259; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	46	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2858	2865		10.1074/jbc.273.5.2858	http://dx.doi.org/10.1074/jbc.273.5.2858			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446596	hybrid			2022-12-27	WOS:000071736600051
J	Sakatsume, M; Stancato, LF; David, M; Silvennoinen, O; Saharinen, P; Pierce, J; Larner, AC; Finbloom, DS				Sakatsume, M; Stancato, LF; David, M; Silvennoinen, O; Saharinen, P; Pierce, J; Larner, AC; Finbloom, DS			Interferon gamma activation of Raf-1 is Jak1-dependent and p21(ras)-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; SERINE THREONINE KINASE; PROTEIN-TYROSINE KINASE; GENE-EXPRESSION; HUMAN-MONOCYTES; CELL-LINES; RECEPTOR; PHOSPHORYLATION; RAS; BINDING	Signal transduction through the interferon gamma (IFN gamma) receptor involves the formation of a ligand-dependent multimolecular association of receptor chains (alpha and beta), Janus tyrosine kinases (Jak1 and Jak2), and the transcription factor (signal transducers and activators of transcription 1 alpha (STAT1 alpha)) in addition to activation of mitogen-activated protein kinases (MAPK), Interactions between components of the Jak/STAT cascade and the p21(ras)/Raf-1/MAPK cascade are unexplored, Treatment of HeLa cells with IFN gamma resulted in the rapid and transient activation of Raf-1 and MAPK. Parallel activation of cells resulted in essentially no enhancement of p21(ras) activation despite marked enhancement after treatment with epidermal growth factor, In HeLa (E1C3) and fibrosarcoma (U4A) cell lines, both of which are deficient in Jak1 kinase, Raf-1 activation by IFN gamma was absent. Reconstitution of Raf-1 activity was observed only with kinase active Jak1 in both cell lines. In COS cells, transient expression of wild type or kinase-inactive Jak1 coimmunoprecipitated with Raf-1, but activation of Raf-1 activity was only observed in cells expressing kinase-active Jak1. These observations suggest that a kinase-active Jak1 is required for IFN gamma activation of Raf-1 that is p21(ras)-independent.	US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tampere University	Finbloom, DS (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, HFM-505,29 Lincoln Dr, Bethesda, MD 20892 USA.	Finbloom@A1.cbef.fda.gov	Saharinen, Pipsa I/C-9601-2016	Saharinen, Pipsa I/0000-0003-2652-0584				Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CATLING AD, 1994, J BIOL CHEM, V269, P30014; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; FINBLOOM DS, 1985, J IMMUNOL, V135, P300; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994; LOH JE, 1994, MOL CELL BIOL, V14, P2170, DOI 10.1128/MCB.14.3.2170; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; LUONG H, 1994, BIOCHEM J, V299, P799, DOI 10.1042/bj2990799; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MASLINSKI W, 1992, J BIOL CHEM, V267, P15281; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Popik W, 1996, MOL CELL BIOL, V16, P6532; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Sakatsume M, 1996, J IMMUNOL, V156, P4160; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					3021	3026		10.1074/jbc.273.5.3021	http://dx.doi.org/10.1074/jbc.273.5.3021			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446616	hybrid			2022-12-27	WOS:000071736600071
J	Bergelson, S; Klingmuller, U; Socolovsky, M; Hsiao, JG; Lodish, HF				Bergelson, S; Klingmuller, U; Socolovsky, M; Hsiao, JG; Lodish, HF			Tyrosine residues within the intracellular domain of the erythropoietin receptor mediate activation of AP-1 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; SIGNAL-TRANSDUCTION; STAT5 ACTIVATION; CELL-LINE; PHOSPHORYLATION; GENE; PROLIFERATION; INTERACTS; BINDING; JAK2	Binding of erythropoietin (Epo) to the Epo receptor (EpoR) initiates a signaling cascade resulting in tyrosine phosphorylation of several proteins and induction of AP-1 transcription factor(s). While Epo is known to activate c-fos gene expression, the mechanism of AP-1 activation is unknown. Here we show that AP-1 activation by Epo requires tyrosine kinase activity and also de novo protein synthesis. Using a mutant EpoR containing no cytosolic tyrosine residues, and a set of eight mutants containing a single cytosolic tyrosine residue, we show that multiple EpoR tyrosines, thought to activate multiple intracellular signal transduction proteins, can mediate AP-1 activation. An EpoR containing only tyrosine 343 or tyrosine 464 supports a maximal level of AP-1 activation We also show that AP-1 activation does not require maximal STAT5 activation and may occur via a STAT5-independent signaling pathway.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.		Klingmüller, Ursula/G-8477-2013	Klingmüller, Ursula/0000-0001-9845-3099; Socolovsky, Merav/0000-0001-6747-7960	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CURRAN T, 1993, ADV SEC MESS PHOSPH, V28, P271; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LONGMORE GD, 1993, J CELL BIOL, V123, P1305, DOI 10.1083/jcb.123.6.1305; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; NEUMANN D, 1993, J BIOL CHEM, V268, P13639; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rajotte D, 1996, BLOOD, V88, P2906, DOI 10.1182/blood.V88.8.2906.bloodjournal8882906; Shimizu R, 1996, BIOCHEM BIOPH RES CO, V222, P1, DOI 10.1006/bbrc.1996.0688; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TSUDA H, 1994, EUR J HAEMATOL, V52, P73; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	35	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2396	2401		10.1074/jbc.273.4.2396	http://dx.doi.org/10.1074/jbc.273.4.2396			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442088	hybrid			2022-12-27	WOS:000071595200077
J	Huang, XM; Crute, BE; Sun, CH; Tang, YY; Kelley, JJ; Lewis, AF; Hartman, KL; Laue, TM; Speck, NA; Bushweller, JH				Huang, XM; Crute, BE; Sun, CH; Tang, YY; Kelley, JJ; Lewis, AF; Hartman, KL; Laue, TM; Speck, NA; Bushweller, JH			Overexpression, purification, and biophysical characterization of the heterodimerization domain of the core-binding factor beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; HETERONUCLEAR NMR-SPECTROSCOPY; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; BACKBONE DYNAMICS; DNA-BINDING; AML1 GENE; ESCHERICHIA-COLI; RUNT DOMAIN; PROTEIN	Core-binding factors (CBF) are heteromeric transcription factors essential for several developmental processes, including hematopoiesis. CBFs contain a DNA-binding CBF alpha subunit and a non-DNA binding CBF beta subunit that increases the affinity of CBF alpha for DNA. We have developed a procedure for overexpressing and purifying full-length CBF beta as web as a truncated form containing the N-terminal 141 amino acids using a novel glutaredoxin fusion expression system. Substantial quantities of the CBF beta proteins can be produced in this manner allowing for their biophysical characterization. me show that the full-length and truncated forms of CBF beta bind to a CBF alpha.DNA complex with very similar affinities, Sedimentation equilibrium measurements show these proteins to be monomeric. Circular dichroism spectroscopy demonstrates that CBF beta is a mixed alpha/beta protein and NMR spectroscopy shows that the truncated and full-length proteins are structurally similar and suitable for structure determination by NMR spectroscopy.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Univ New Hampshire, Dept Biochem, Durham, NH 03824 USA	Dartmouth College; Dartmouth College; University System Of New Hampshire; University of New Hampshire	Huang, XM (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.		Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368; Bushweller, John/0000-0002-5386-1758	NCI NIH HHS [R01 CA75611, R01 CA/GM 58343] Funding Source: Medline; NIAID NIH HHS [K02 AI01481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058343, R01CA075611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Billeter M, 1995, J BIOMOL NMR, V5, P1; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; Cantor C. R., 1980, BIOPHYSICAL CHEM, P563; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KHARAKOZ DP, 1989, BIOPHYS CHEM, V34, P115, DOI 10.1016/0301-4622(89)80049-3; LAUE TM, 1992, DS835 BECKM INSTR IN; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006; PRESS WH, 1986, NUMERICAL RECIPES AR, P683; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SKLENAR V, 1987, J MAGN RESON, V73, P375, DOI 10.1016/0022-2364(87)90214-9; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; VENABLE RM, 1988, BIOPOLYMERS, V27, P1001, DOI 10.1002/bip.360270609; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WILLIAMSON M P, 1990, Biopolymers, V29, P1423, DOI 10.1002/bip.360291009; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	53	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2480	2487		10.1074/jbc.273.4.2480	http://dx.doi.org/10.1074/jbc.273.4.2480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442100	hybrid			2022-12-27	WOS:000071595200089
J	Khvotchev, M; Sudhof, TC				Khvotchev, M; Sudhof, TC			Developmentally regulated alternative splicing in a novel synaptojanin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL; BINDING; PROTEIN; YEAST	Phosphatidylinositol phosphates (PIPs) perform central functions in signal transduction and membrane traffic. Synaptojanin is a PIP 5-phosphatase that is expressed in a brain-specific and a ubiquitous splice variants and is thought to constitute the major PIP B-phosphatase in mammalian brain (Woscholski, R., Finan, P. M., Radley, E., Totty, N. F., Sterling, A. E., Hsuan, J. J., Waterfield, M. D., and Parker, P. J. (1997) J. Biol. Chem, 272, 9625-9628). me now describe synaptojanin 2, a novel isoform of synaptojanin that, similar to synaptojanin 1, contains an N-terminal SAC1-like sequence and a central 5-phosphatase domain but a distinct, unique C-terminal sequence. Transfection studies demonstrated that synaptojanin 2, like synaptojanin 1, is an active PIP phosphatase. An interesting feature of synaptojanin 1 is the presence of a long open reading frame in the 3' region of the brain mRNA that in non-brain tissues is joined to the coding region by alternative splicing, resulting in a shorter synaptojanin 1 form in brain and a longer form in peripheral tissues (Ramjaun, A. R., and McPherson, P. S. (1996) J. Biol. Chem 271, 24856-24861). Although it exhibits no homology to synaptojanin I in this region, synaptojanin 2 also contains an open reading frame in the 3' region that is subject to alternative splicing. Similar to synaptojanin 1, alternative splicing of synaptojanin 2 is tissue-specific and creates a shorter isoform expressed in brain and a longer form in peripheral tissues. The similar alternative splicing of two homologous proteins in a region of non-homology raises the possibility of evolutionary convergence and supports the significance of the variants. Analysis of mRNAs from three brain regions at different developmental stages revealed that alternative splicing of synaptojanin 2 is a developmentally late event, occurring only after the first postnatal week after the generation of neurons and initial synaptogenesis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.		Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH52804] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; NOVICK P, 1989, GENETICS, V121, P659; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Sambrook J., 2002, MOL CLONING LAB MANU; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Woscholski R, 1997, J BIOL CHEM, V272, P9625	18	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2306	2311		10.1074/jbc.273.4.2306	http://dx.doi.org/10.1074/jbc.273.4.2306			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442075	hybrid			2022-12-27	WOS:000071595200064
J	Takemori, H; Zolotaryov, FN; Ting, L; Urbain, T; Komatsubara, T; Hatano, O; Okamoto, M; Tojo, H				Takemori, H; Zolotaryov, FN; Ting, L; Urbain, T; Komatsubara, T; Hatano, O; Okamoto, M; Tojo, H			Identification of functional domains of rat intestinal phospholipase B/lipase - Its cDNA cloning, expression, and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; LACTASE-PHLORHIZIN HYDROLASE; GUINEA-PIG; TEST MEAL; PROTEIN; BIOSYNTHESIS; ANCHOR; LYSOPHOSPHOLIPASE; GLYCOSIDASES; PURIFICATION	A cDNA encoding a rat intestinal Ca2+-independent phospholipase B/lipase (PLB/LIP) was cloned from an ileac mucosa cDNA library using a probe amplified by polymerase chain reaction based on the purified enzyme's sequence. PLB/LIP consists of an NH2-terminal signal peptide, four tandem repeats of about 350 amino acids each, and a hydrophobic domain near the COOH terminus. The enzyme purified previously was found to be derived from the second repeat part. To examine the function of each domain, the full-length PLB/LIP, individual repeats, and a protein lacking the COOH-terminal hydrophobic stretch were expressed in COS-7 cells. The results showed that the second repeat, but not the other repeats, had all the activities (phospholipase A(2), lysophospholipase, and lipase) found in the purified natural and expressed full-length enzymes, suggesting repeat 2 is a catalytic domain. The full-length enzyme was mainly present in membrane fractions and efficiently solubilized by treatment with 1% Triton X-100, but not with phosphatidylinositol-specific phospholipase C. Deletion of the COOH-terminal hydrophobic stretch caused the secretion of >90% of synthesized PLB/LIP into culture media. These results suggest the hydrophobic domain is not replaced by a glycosylphosphatidylinositol anchor but serves as a membrane anchor directly. A message of the full-length PLB/LIP was abundantly expressed in the ileum and also, in a smaller, but significant amount, in the esophagus and testis. Immunohistochemistry showed that PLB/LIP is localized in brush border membranes of the absorptive cells, Paneth cells, and acrosomes of spermatid, suggesting its roles related and unrelated to intestinal digestion.	Osaka Univ, Sch Med, Dept Mol Physiol Chem, Suita, Osaka 565, Japan; Nara Med Univ, Dept Anat, Shijo, Kashiwara 634, Japan	Osaka University; Nara Medical University	Tojo, H (corresponding author), Osaka Univ, Sch Med, Dept Mol Physiol Chem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	htojo@mr-mbio.med.osaka-u.ac.jp						BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BLACK SM, 1993, ENDOCRINOLOGY, V132, P539, DOI 10.1210/en.132.2.539; BOLL W, 1993, J BIOL CHEM, V268, P12901; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; CARRIERE F, 1993, SCAND J GASTROENTERO, V28, P443, DOI 10.3109/00365529309098247; DIAGNE A, 1987, LIPIDS, V22, P33, DOI 10.1007/BF02534872; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; HATANO O, 1994, DEVELOPMENT, V120, P2787; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; KELLER P, 1995, FEBS LETT, V368, P563, DOI 10.1016/0014-5793(95)00679-4; Kurabuchi S, 1997, CELL TISSUE RES, V288, P485, DOI 10.1007/s004410050834; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MINAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1170, P125; NONAKA Y, 1995, EUR J BIOCHEM, V229, P249, DOI 10.1111/j.1432-1033.1995.tb20462.x; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; PIND S, 1989, LIPIDS, V24, P357, DOI 10.1007/BF02535141; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; Rinderknecht H, 1986, EXOCRINE PANCREAS BI, P163; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; TABOR S, 1990, CURRENT PROTOCOLS S, V11; TATSUMI H, 1990, HISTOCHEMISTRY, V94, P135, DOI 10.1007/BF02440179; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; Tojo H, 1998, J BIOL CHEM, V273, P2214, DOI 10.1074/jbc.273.4.2214; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOJO H, 1993, J LIPID RES, V34, P837; WACKER H, 1992, J BIOL CHEM, V267, P18744	33	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2222	2231		10.1074/jbc.273.4.2222	http://dx.doi.org/10.1074/jbc.273.4.2222			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442065	hybrid			2022-12-27	WOS:000071595200054
J	Rowlinson, SW; Behncken, SN; Rowland, JE; Clarkson, RW; Strasburger, CJ; Wu, Z; Baumbach, W; Waters, MJ				Rowlinson, SW; Behncken, SN; Rowland, JE; Clarkson, RW; Strasburger, CJ; Wu, Z; Baumbach, W; Waters, MJ			Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies - A specific conformational change may be required for full-length receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT MAMMARY-GLAND; PROLACTIN RECEPTOR; BINDING PROTEIN; EXTRACELLULAR DOMAIN; RESPONSE ELEMENTS; EPO RECEPTOR; ERYTHROPOIETIN; DIMERIZATION; ANTAGONISTS; COMPLEX	Signal transduction by the growth hormone receptor (GHR) occurs through growth hormone (GH)-induced dimerization of two GHRs to form a trimeric complex, It is thought that dimerization alone is sufficient for signaling, since monoclonal antibodies (mAbs) against the extracellular domain of the GHR elicit proliferation of FDC-P1 cells transfected with a chimeric receptor comprising the extracellular domain of the GHR and the fibronectin and cytoplasmic domains of the murine granulocyte colony-stimulating factor receptor, We have screened 14 GHR mAbs for proliferative activity against characterized FDC-P1 and BaF-B03 cell lines stably expressing the full-length human, rabbit, or rat GHR, or the chimeric human GHR/granulocyte colony-stimulating factor receptor, and for transactivation of the c-fos promoter and STAT activation. With the chimeric receptor, eight mAbs were able to elicit proliferation, although there was no correlation between inhibition of hormone binding and agonist activity. In contrast, no mAbs were able to act as agonists with the full-length GHR FDC-P1 cell lines, although nine competed with GH for binding, A weak proliferative response was observed in the BaF-B03 cell lines with two of the mAbs (263 and 1C9), and the addition of anti-mouse F(ab)(2) resulted in increased signaling in the hGHR BaF-B03 cell line to a plateau of 28 +/- 4% of the GH maximum for mAb 263. These data could indicate considerable stringency in the ability of mAbs to correctly dimerize the full-length GI-IR. However, the ability of mAb 263 to stimulate a mutant hGHR altered in the F'-G' loop of domain 2 was nearly abolished, concurrent with an increased affinity of this mAb for the receptor. Since the F'-G' loop undergoes a conformational change on GH binding and is necessary for full proliferative signaling, we propose that in addition to promoting receptor dimerization, mAb 263 may induce specific changes in receptor conformation similar to GH, which are required for the biological response.	Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Univ Munich, Klinikum Innenstadt, Med Klin, D-80336 Munich, Germany; Amer Cyanamid Co, Agr Res Ctr, Princeton, NJ 08543 USA	University of Queensland; University of Queensland; University of Munich; American Cyanamid Company	Waters, MJ (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia.		waters, michael j/C-9582-2014; Clarkson, Richard/A-7505-2010	clarkson, richard/0000-0001-7389-8673; Rowland, Jennifer/0000-0003-2313-6106				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BARNARD R, 1989, J ENDOCRINOL, V123, P327, DOI 10.1677/joe.0.1230327; BARNARD R, 1984, ENDOCRINOLOGY, V115, P1805, DOI 10.1210/endo-115-5-1805; BARNARD R, 1986, J RECEPTOR RES, V6, P209, DOI 10.3109/10799898609074811; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; Behncken SN, 1997, J BIOL CHEM, V272, P27077, DOI 10.1074/jbc.272.43.27077; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen CM, 1997, J BIOL CHEM, V272, P5133, DOI 10.1074/jbc.272.8.5133; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DJIANE J, 1985, J BIOL CHEM, V260, P1430; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; ELBERG G, 1990, J BIOL CHEM, V265, P14770; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOBIUS KS, 1992, J MOL ENDOCRINOL, V9, P213, DOI 10.1677/jme.0.0090213; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Kahn C R, 1981, Recent Prog Horm Res, V37, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM L, 1990, HORM METAB RES, V22, P153, DOI 10.1055/s-2007-1004873; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Mellado M, 1997, J BIOL CHEM, V272, P9189; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Rowlinson SW, 1996, ENDOCRINOLOGY, V137, P90, DOI 10.1210/en.137.1.90; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; ROWLINSON SW, 1996, P 10 INT C END SAN F, V2, P334; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; SCHREURS J, 1989, J IMMUNOL, V142, P819; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818; VOLPE R, 1978, CLIN ENDOCRINOL META, V7, P3, DOI 10.1016/S0300-595X(78)80033-4; Wang BS, 1996, MOL CELL ENDOCRINOL, V116, P223, DOI 10.1016/0303-7207(95)03718-7; WATERS MJ, 1990, INT J BIOCHEM, V22, P1089, DOI 10.1016/0020-711X(90)90106-D; WATERS MJ, 1997, HDB PHYSL, V5; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WU Z, 1996, P 10 INT C END SAN F, V2, P338; WU Z, 1996, P 10 INT C END SAN F, V2, P337; XIONG LM, 1992, P NATL ACAD SCI USA, V89, P5356, DOI 10.1073/pnas.89.12.5356	45	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5307	5314		10.1074/jbc.273.9.5307	http://dx.doi.org/10.1074/jbc.273.9.5307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478989	hybrid			2022-12-27	WOS:000072310400073
J	Wells, KM; Abercrombie, RF				Wells, KM; Abercrombie, RF			Luminal Ca2+ protects against thapsigargin inhibition in neuronal endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM POOLS; ADRENAL CHROMAFFIN CELLS; SARCOPLASMIC-RETICULUM; MG-2+-DEPENDENT ATPASE; FUNCTIONAL COMPARISONS; PC12 CELLS; STORES; IDENTIFICATION; PUMPS; CA-2+-ATPASE	Thapsigargin is a specific and potent inhibitor of sarco/endoplasmic reticulum Ca2+-ATPases, However, in whole rat brain microsomes, 1 mu M thapsigargin had no significant effect on the 10-min time course of ATP-dependent Ca2+ uptake in the absence of the luminal Ca2+ chelator oxalate, In contrast, 50 mM oxalate resolved a thapsigargin-sensitive Ca2+ uptake rate (IC50 similar or equal to 1 nM thapsigargin) five times that of a thapsigargin-insensitive rate. This remaining similar to 20% of the total ATP-dependent accumulation was insensitive to thapsigargin (up to 10 mu M), slightly less sensitive to vanadate inhibition, and unresponsive to 5 mu M inositol 1,4,5-trisphosphate or 10 nM caffeine. Measuring both 12-min Ca2+ uptake and initial Ca2+ uptake rates, the apparent thapsigargin sensitivity increased as oxalate concentrations increased from 10 to 50 mM, corresponding to a range of luminal free Ca2+ concentrations of similar to 300 down to 60 nM. Addition of oxalate during steady-state Ca-45 accumulation rapidly resolved the aforementioned thapsigargin sensitivity, These results strongly suggest that luminal Ca2+ may protect a large portion of neuronal endoplasmic reticulum Ca2+ pumps against thapsigargin inhibition, Although high [Ca2+] has been previously shown to protect against thapsigargin inhibition in several reticular membrane preparations, our results suggest that luminal Ca2+ alone is responsible for mediating this effect in neurons.	Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University	Abercrombie, RF (corresponding author), Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA.				NINDS NIH HHS [NS19194] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019194] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIAN JH, 1991, J BIOL CHEM, V266, P8801; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; Caspersen C, 1995, FEBS LETT, V377, P31, DOI 10.1016/0014-5793(95)01304-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; Favre CJ, 1996, J BIOL CHEM, V271, P14925, DOI 10.1074/jbc.271.25.14925; KAPRIELIAN Z, 1989, MOL BRAIN RES, V6, P55, DOI 10.1016/0169-328X(89)90028-4; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MICHAELIS EK, 1983, J BIOL CHEM, V258, P6101; Moore JE, 1996, AM J PHYSIOL-CELL PH, V270, pC628, DOI 10.1152/ajpcell.1996.270.2.C628; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; POULSEN JCJ, 1995, BIOCHEM J, V307, P749, DOI 10.1042/bj3070749; Rooney E, 1996, J BIOL CHEM, V271, P29304, DOI 10.1074/jbc.271.46.29304; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; TANAKA Y, 1993, BIOCHEMISTRY-US, V32, P12062, DOI 10.1021/bi00096a017; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TRIBE RM, 1994, P NATL ACAD SCI USA, V91, P5908, DOI 10.1073/pnas.91.13.5908; VERMA A, 1990, CELL REGUL, V1, P781, DOI 10.1091/mbc.1.10.781; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Wells KM, 1996, AM J PHYSIOL-CELL PH, V271, pC1472, DOI 10.1152/ajpcell.1996.271.5.C1472; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; Witcome M., 1992, BIOCHEM J, V283, P525; WU K, 1995, AM J PHYSIOL, V268, pC775	30	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5020	5025		10.1074/jbc.273.9.5020	http://dx.doi.org/10.1074/jbc.273.9.5020			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478950	hybrid			2022-12-27	WOS:000072310400034
J	Enami, I; Kamo, M; Ohta, H; Takahashi, S; Miura, T; Kusayanagi, M; Tanabe, S; Kamei, A; Motoki, A; Hirano, M; Tomo, T; Satoh, K				Enami, I; Kamo, M; Ohta, H; Takahashi, S; Miura, T; Kusayanagi, M; Tanabe, S; Kamei, A; Motoki, A; Hirano, M; Tomo, T; Satoh, K			Intramolecular cross-linking of the extrinsic 33-kDa protein leads to loss of oxygen evolution but not its ability of binding to photosystem II and stabilization of the manganese cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							33 KDA PROTEIN; 16-KDA PROTEINS; 12-KDA PROTEIN; CALCIUM-IONS; SPINACH; MN; RECONSTITUTION; POLYPEPTIDE; PARTICLES; COMPLEX	The extrinsic 33-kDa protein of photosystem II (PSII) was intramolecularly cross-linked by a zero-length cross-linker, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The resulting cross linked 33-kDa protein rebound to urea/NaCl-washed PSII membranes, which stabilized the binding of manganese as effectively as the untreated 33-kDa protein, In contrast, the oxygen evolution was not restored by binding of the cross-linked protein, indicating that the binding and manganese stabilizing capabilities of the 33-kDa protein are retained but its reactivating ability is lost by intramolecular cross-linking of the protein, From measurements of CD spectra at high temperatures, the secondary structure of the intramolecularly cross-linked 33-kDa protein was found to be stabilized against heat treatment at temperatures 20 degrees C higher than that of the untreated 33-kDa protein, suggesting that structural flexibility of the 33-kDa protein was much decreased by the intramolecular cross-linking, The rigid structure is possibly responsible for the loss of the reactivating ability of the 33-kDa protein, which implies that binding of the 33-kDa protein to PSII is accompanied by a conformational change essential for the reactivation of oxygen evolution. Peptide mapping, N-terminal sequencing, and mass spectroscopic analysis of protease-digested products of the intramolecularly cross-linked 33-kDa protein revealed that cross-linkings occurred between the amino group of Lys(48) and the carboxyl group of Glu(246), and between the carboxyl group of Glu(10) and the amino group of Lys(14). These cross-linked amino acid residues are thus closely associated with each other through electrostatic interactions.	Sci Univ Tokyo, Fac Sci, Dept Biol, Shinjuku Ku, Tokyo 162, Japan	Tokyo University of Science	Enami, I (corresponding author), Sci Univ Tokyo, Fac Sci, Dept Biol, Shinjuku Ku, Kagurazaka 1-3, Tokyo 162, Japan.	enami@rs.noda.sut.ac.jp	Tomo, Tatsuya/K-7680-2012; Kamo, Masaharu/S-1280-2019	Tomo, Tatsuya/0000-0002-9369-1941; Kamo, Masaharu/0000-0001-6791-8754				AKERLUND HE, 1982, BIOCHIM BIOPHYS ACTA, V681, P1, DOI 10.1016/0005-2728(82)90271-7; ANDERSSON B, 1984, BIOCHIM BIOPHYS ACTA, V766, P21, DOI 10.1016/0005-2728(84)90212-3; ANDERSSON B, 1984, FEBS LETT, V168, P113, DOI 10.1016/0014-5793(84)80217-3; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Betts SD, 1996, BBA-BIOENERGETICS, V1274, P135, DOI 10.1016/0005-2728(96)00023-0; Betts SD, 1996, BIOCHEMISTRY-US, V35, P6302, DOI 10.1021/bi953066t; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1994, BIOCHEMISTRY-US, V33, P13712, DOI 10.1021/bi00250a023; CHEN CG, 1995, BIOCHEMISTRY-US, V34, P13511, DOI 10.1021/bi00041a031; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; EATONRYE JJ, 1989, BIOCHIM BIOPHYS ACTA, V977, P219, DOI 10.1016/S0005-2728(89)80075-1; ENAMI I, 1991, BIOCHIM BIOPHYS ACTA, V1060, P224, DOI 10.1016/S0005-2728(09)91010-6; ENAMI I, 1994, BBA-BIOENERGETICS, V1186, P52, DOI 10.1016/0005-2728(94)90134-1; ENAMI I, 1989, BIOCHIM BIOPHYS ACTA, V977, P33, DOI 10.1016/S0005-2728(89)80006-4; ENAMI I, 1994, BBA-BIOENERGETICS, V1185, P75, DOI 10.1016/0005-2728(94)90195-3; Enami I, 1995, BBA-BIOENERGETICS, V1232, P208, DOI 10.1016/0005-2728(95)00122-0; ENAMI L, 1997, BIOCHIM BIOPHYS ACTA, V1320, P17; FRANZEN LG, 1984, BIOCHIM BIOPHYS ACTA, V765, P166, DOI 10.1016/0005-2728(84)90010-0; GHANOTAKIS DF, 1985, PHOTOSYNTH RES, V7, P97, DOI 10.1007/BF00037001; GHANOTAKIS DF, 1984, FEBS LETT, V170, P169, DOI 10.1016/0014-5793(84)81393-9; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; KUWABARA T, 1983, PLANT CELL PHYSIOL, V24, P741, DOI 10.1093/oxfordjournals.pcp.a076571; KUWABARA T, 1986, BIOCHIM BIOPHYS ACTA, V850, P146, DOI 10.1016/0005-2728(86)90019-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIURA K, 1993, BIOCHIM BIOPHYS ACTA, V1172, P357, DOI 10.1016/0167-4781(93)90232-3; Miura T, 1997, J BIOL CHEM, V272, P3788, DOI 10.1074/jbc.272.6.3788; MIYAO M, 1984, FEBS LETT, V168, P118, DOI 10.1016/0014-5793(84)80218-5; MIYAO M, 1985, FEBS LETT, V180, P303, DOI 10.1016/0014-5793(85)81091-7; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MIYAO M, 1986, PHOTOSYNTH RES, V10, P489, DOI 10.1007/BF00118315; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P315, DOI 10.1016/S0005-2728(89)80086-6; MIYAO M, 1987, TOPICS PHOTOSYNTHESI, V9, P289; MOTOKI A, 1992, RES PHOTOSYNTHESIS, V2, P413; OHTA H, 1995, PHOTOSYNTHESIS LIGHT, V2, P361; ONO T, 1984, FEBS LETT, V168, P281, DOI 10.1016/0014-5793(84)80263-X; ONO T, 1984, FEBS LETT, V166, P381, DOI 10.1016/0014-5793(84)80117-9; ONO TA, 1983, FEBS LETT, V164, P255, DOI 10.1016/0014-5793(83)80297-X; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SHEN JR, 1991, PLANT CELL PHYSIOL, V32, P453, DOI 10.1093/oxfordjournals.pcp.a078101; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; Shutova T, 1997, BIOCHEMISTRY-US, V36, P6350, DOI 10.1021/bi963115h; TANAKA S, 1989, BIOCHEMISTRY-US, V28, P7188, DOI 10.1021/bi00444a009; TANAKA S, 1988, PHOTOSYNTH RES, V17, P255, DOI 10.1007/BF00035452; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V1102, P195, DOI 10.1016/0005-2728(92)90100-G; VASS I, 1987, BIOCHIM BIOPHYS ACTA, V892, P224, DOI 10.1016/0005-2728(87)90178-2; XU Q, 1994, BBA-BIOENERGETICS, V1188, P427, DOI 10.1016/0005-2728(94)90065-5	49	61	64	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4629	4634		10.1074/jbc.273.8.4629	http://dx.doi.org/10.1074/jbc.273.8.4629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468521	hybrid			2022-12-27	WOS:000072115000049
J	Gong, WH; Howard, OMZ; Turpin, JA; Grimm, MC; Ueda, H; Gray, PW; Raport, CJ; Oppenheim, JJ; Wang, JM				Gong, WH; Howard, OMZ; Turpin, JA; Grimm, MC; Ueda, H; Gray, PW; Raport, CJ; Oppenheim, JJ; Wang, JM			Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; MULTIPLE LEUKOCYTE RECEPTORS; CHEMOKINE RECEPTORS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; UNIQUE RECEPTORS; MCP3 INTERACTS; RANTES; MIP-1-ALPHA; MIP-1-BETA	Human immunodeficiency virus, type I (HIV-1) cell-type tropism is dictated by chemokine receptor usage: T-cell line tropic viruses use CXCR4, whereas monocyte tropic viruses primarily use CCR5 as fusion coreceptors. CC chemokines macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES (regulated on activation normal T cell expressed and secreted) inhibit CD4/CCR5-mediated HIV-1 cell fusion, MCP-2 is also a member of the CC chemokine subfamily and has the capacity to interact with at least two receptors including CCR-1 and CCR2B. In an effort to further characterize the binding properties of MCP-2 on leukocytes, we observed that MCP-2, but not MCP-1, effectively competed with MIP-1 beta for binding to monocytes, suggesting that MCP-2 may interact with CCR5, As predicted, MCP-2 competitively inhibited MIP-1 beta binding to HEK293 cells stably transfected with CCR5 (CCR5/293 cells). MCP-2 also bound to and induced chemotaxis of CCR5/293 cells with a potency comparable with that of MIP-1 beta. Confocal microscopy indicates that MCP-2 caused remarkable and dose-dependent internalization of CCR5 in CCR5/ 293 cells. Furthermore, MCP-2 inhibited the entry/replication of HIV-1ADA in CCR5/293 cells coexpressing CD4. These results indicated that MCP-2 uses CCR5 as one of its functional receptors and is an additional potent natural inhibitor of HIV-1.	NCI, Frederick Canc Res & Dev Ctr, LMI, DBS, Frederick, MD 21702 USA; SAIC, Intramural Res Support Program, Frederick, MD USA; SAIC, Intramural Res Support Program, Frederick, MD USA; SAIC, Dev Therapeut Program, Frederick, MD USA; ICOS Corp, Bothell, WA 98021 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Icos Corporation	Wang, JM (corresponding author), NCI, Frederick Canc Res & Dev Ctr, LMI, DBS, Bldg 560,Rm 31-19, Frederick, MD 21702 USA.		Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052; Grimm, Michael/0000-0001-9426-3917				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DECOCK B, 1990, BIOCHEM BIOPH RES CO, V167, P904, DOI 10.1016/0006-291X(90)90609-Q; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANCI C, 1995, J IMMUNOL, V154, P6511; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; HOWARD OMZ, 1995, BIOCHEM J, V306, P217, DOI 10.1042/bj3060217; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; OBERLIN E, 1996, NATURE, V382, P333; Oppenheim Joost J., 1996, P187; Proost P, 1996, J LEUKOCYTE BIOL, V59, P67, DOI 10.1002/jlb.59.1.67; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; WANG JM, 1993, J IMMUNOL, V150, P3022; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	31	109	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4289	4292		10.1074/jbc.273.8.4289	http://dx.doi.org/10.1074/jbc.273.8.4289			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468473	hybrid			2022-12-27	WOS:000072115000001
J	Luo, WS; Chu, GX; Sato, Y; Zhou, ZP; Kadambi, VJ; Kranias, EG				Luo, WS; Chu, GX; Sato, Y; Zhou, ZP; Kadambi, VJ; Kranias, EG			Transgenic approaches to define the functional role of dual site phospholamban phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; CARDIAC SARCOPLASMIC-RETICULUM; GUINEA-PIG VENTRICLES; CA-2+ TRANSPORT; MECHANISMS; HEARTS; INHIBITORS; MICE; GENE	Phospholamban is a critical regulator of the sarcoplasmic reticulum Ca2+-ATPase activity and myocardial contractility, Phosphorylation of phospholamban occurs on both Ser(16) and Thr(17) during isoproterenol stimulation, To determine the physiological significance of dual site phospholamban phosphorylation, we generated transgenic models expressing either wild-type or the Ser(16) --> Ala mutant phospholamban in the cardiac compartment of the phospholamban knockout mice. Transgenic lines with similar levels of mutant or wild-type phospholamban were studied in parallel, Langendorff perfusion indicated that the basal hyperdynamic cardiac function of the knockout mouse was reversed to the same extent by reinsertion of either wild-type or mutant phospholamban, However, isoproterenol stimulation was associated with much lower responses in the contractile parameters of mutant phospholamban compared with wild-type hearts, These attenuated responses were due to lack of phosphorylation of mutant phospholamban, assessed in P-32 labelin, a perfusion experiments, The lack of phospholamban phosphorylation in vivo was not due to conversion of Ser(16) to Ala, since the mutated phospholamban form could serve as substrate for the calcium-calmodulin-dependent protein kinase in vitro. These findings indicate that phosphorylation of Ser(16) is a prerequisite for Thr(17) phosphorylation in phospholamban, and prevention of phosphoserine formation results in attenuation of the beta-agonist stimulatory responses in the mammalian heart.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Bethesda Ave,POB 670575, Cincinnati, OH 45267 USA.				NHLBI NIH HHS [HL26057, HL22619, HL52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, R37HL026057, P50HL052318, R01HL026057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSANI RA, 1995, AM J PHYSIOL-HEART C, V268, pH703, DOI 10.1152/ajpheart.1995.268.2.H703; BILEZIKJIAN LM, 1981, CIRC RES, V49, P1356, DOI 10.1161/01.RES.49.6.1356; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; COLYER J, 1991, J BIOL CHEM, V266, P17486; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Hulme JT, 1997, PFLUG ARCH EUR J PHY, V434, P475, DOI 10.1007/s004240050423; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LINDEMANN JP, 1985, J BIOL CHEM, V260, P3122; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; MundinaWeilenmann C, 1996, AM J PHYSIOL-CELL PH, V270, pC107, DOI 10.1152/ajpcell.1996.270.1.C107; MundinaWeilenmann C, 1996, J BIOL CHEM, V271, P33561, DOI 10.1074/jbc.271.52.33561; NAPOLITANO R, 1992, J MOL CELL CARDIOL, V24, P387, DOI 10.1016/0022-2828(92)93193-N; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TALOSI L, 1993, AM J PHYSIOL, V264, pH791; VITTONE L, 1993, MOL CELL BIOCHEM, V124, P33, DOI 10.1007/BF01096379; VITTONE L, 1990, AM J PHYSIOL, V258, pH318, DOI 10.1152/ajpheart.1990.258.2.H318; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Wolska BM, 1996, AM J PHYSIOL-CELL PH, V271, pC391, DOI 10.1152/ajpcell.1996.271.1.C391	27	88	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4734	4739		10.1074/jbc.273.8.4734	http://dx.doi.org/10.1074/jbc.273.8.4734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468536	hybrid			2022-12-27	WOS:000072115000064
J	Venkateswarlu, K; Lamb, DC; Kelly, DE; Manning, NJ; Kelly, SL				Venkateswarlu, K; Lamb, DC; Kelly, DE; Manning, NJ; Kelly, SL			The N-terminal membrane domain of yeast NADPH-cytochrome P450 (CYP) oxidoreductase is not required for catalytic activity in sterol biosynthesis or in reconstitution of CYP activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; P-450 REDUCTASE; CANDIDA-ALBICANS; ERGOSTEROL BIOSYNTHESIS; GENE; 14-ALPHA-DEMETHYLASE; PURIFICATION; KETOCONAZOLE; FLUCONAZOLE; INHIBITION	The disruption of Saccharomyces cerevisiae NADPH-cytochrome P450 oxidoreductase (CPR) gene resulted in a viable strain accumulating approximately 25% of the ergosterol observed in a sterol wild-type parent. The associated phenotypes could be reversed in transformants after expression of native CPR and a mutant lacking the N-terminal 33 amino acids, which localized in the cytosol. This indicated availability of the CPR in each case to function with the monooxygenases squalene epoxidase, CYP51, and CYP61 in the ergosterol biosynthesis pathway. Purification of the cytosolic mutant CPR indicated properties identical to native CPR and an ability to reconstitute ergosterol biosynthesis when added to a cell-free system, as well as to allow reconstitution of activity with purified CYP61, sterol 22-desaturase. This was also observed for purified Candida albicans and human CYP51 in reconstituted systems. The ability of the yeast enzyme to function in a soluble form differed from human CPR, which is shown to be inactive in reconstituting CYP activity.	Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DA, Dyfed, Wales; Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomolec Res, Sheffield S10 2UH, S Yorkshire, England; Sheffields Childrens Hosp, Neonatal Screening Lab, Sheffield S10 2UH, S Yorkshire, England	Aberystwyth University; University of Sheffield; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital	Kelly, SL (corresponding author), Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DA, Dyfed, Wales.		Kanamarlapudi, Venkateswarlu/A-9864-2011	Kanamarlapudi, Venkateswarlu/0000-0002-8739-1483				AOYAMA Y, 1978, ARCH BIOCHEM BIOPHYS, V185, P362, DOI 10.1016/0003-9861(78)90178-9; AOYAMA Y, 1989, J BIOL CHEM, V264, P18502; BLACK SD, 1982, J BIOL CHEM, V257, P5929; DJORDJEVIC S, 1995, P NATL ACAD SCI USA, V92, P3214, DOI 10.1073/pnas.92.8.3214; HATA S, 1987, AGR BIOL CHEM TOKYO, V51, P1349, DOI 10.1080/00021369.1987.10868199; IMAI Y, 1981, J BIOCHEM-TOKYO, V89, P351, DOI 10.1093/oxfordjournals.jbchem.a133209; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; Kelly SL, 1995, FEBS LETT, V377, P217, DOI 10.1016/0014-5793(95)01342-3; Kelly SL, 1997, J BIOL CHEM, V272, P9986, DOI 10.1074/jbc.272.15.9986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb DC, 1997, J BIOL CHEM, V272, P5682, DOI 10.1074/jbc.272.9.5682; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; QUAIL MA, 1993, PHYTOCHEMISTRY, V32, P273, DOI 10.1016/S0031-9422(00)94980-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEVRIOUKOVA IF, 1995, BIOCHIMIE, V77, P562, DOI 10.1016/0300-9084(96)88172-7; SHEN AL, 1989, J BIOL CHEM, V264, P7584; Shyadehi AZ, 1996, J BIOL CHEM, V271, P12445, DOI 10.1074/jbc.271.21.12445; Skaggs BA, 1996, GENE, V169, P105, DOI 10.1016/0378-1119(95)00770-9; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUN G, 1994, GENE, V149, P123; VENKATESWARLU K, 1995, FEMS MICROBIOL LETT, V131, P337, DOI 10.1111/j.1574-6968.1995.tb07797.x; Venkateswarlu K, 1996, ANTIMICROB AGENTS CH, V40, P1382, DOI 10.1128/AAC.40.6.1382; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1981, J BIOL CHEM, V256, P266; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WEETE JD, 1989, ADV LIPID RES, V23, P115; YABUSAKI Y, 1988, J BIOCHEM-TOKYO, V103, P1004, DOI 10.1093/oxfordjournals.jbchem.a122370; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; Yoshida Y, 1988, Curr Top Med Mycol, V2, P388	31	51	56	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4492	4496		10.1074/jbc.273.8.4492	http://dx.doi.org/10.1074/jbc.273.8.4492			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468503	hybrid			2022-12-27	WOS:000072115000031
J	Guo, YL; Baysal, K; Kang, B; Yang, LJ; Williamson, JR				Guo, YL; Baysal, K; Kang, B; Yang, LJ; Williamson, JR			Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; JNK ACTIVATION; IN-VITRO; STRESS; DEATH; PROLIFERATION; SUPPRESSION; FIBROBLASTS; INVITRO; PATHWAY	Rat mesangial cells are normally resistant to tumor necrosis factor-alpha (TNF-alpha)-induced apoptosis, In this report we show that the cells can be made susceptible to the apoptotic effect of TNF-alpha when pretreated with actinomycin D, cycloheximide, or vanadate. c-Jun N-terminal protein kinase (JNK) has been thought to mediate apoptotic processes elicited by some stimuli, but its involvement in TNF-alpha-induced apoptosis has been controversial, JNK activation was investigated under conditions where the mesangial cells were either resistant or susceptible to TNF-alpha-induced apoptosis, TNF-alpha alone stimulated a single transient JNK activity peak, However, when the cells were pretreated with actinomycin D or cycloheximide, TNF-alpha stimulated a second sustained JNK activity peak. When the cells were pretreated with the phosphatase inhibitor vanadate, TNF-alpha-induced JNK activation was greatly prolonged, In all three cases, a sustained JNK activation was associated with the initiation of apoptosis. Our data suggest that a sustained activation of JNK induced by these reagents may be associated with blocking the expression of a phosphatase that inactivates JNK, Further studies reveal that the expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) was induced by TNF-alpha, indicating that MKP-1 may be involved in protecting the cells from apoptosis by preventing a prolonged activation of JNK under normal conditions. Additional studies showed that extracellular signal-regulated protein kinase activation stimulated by TNF-alpha was unlikely to contribute to the resistance of mesangial cells to TNF-alpha cytotoxicity.	Univ Penn, Dept Biochem & Biophys, Goddard Labs 601, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Williamson, JR (corresponding author), Univ Penn, Dept Biochem & Biophys, Goddard Labs 601, Sch Med, 37th & Hamilton Walk, Philadelphia, PA 19104 USA.	johnrwil@mail.med.upenn.edu			NIDDK NIH HHS [DK-48493, DK-15120, DK-07314] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015120, R01DK048493] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal V. R., 1997, CURR BIOL, V7, P94; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; DAVIES M, 1994, KIDNEY INT, V45, P320, DOI 10.1038/ki.1994.41; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; GINES P, 1995, HEPATOLOGY, V22, P1296, DOI 10.1002/hep.1840220440; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GUO YL, 1990, PLANT PHYSIOL, V94, P143, DOI 10.1104/pp.94.1.143; Han YQ, 1997, J BIOL CHEM, V272, P9825; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KREISBERG JI, 1978, KIDNEY INT, V14, P21, DOI 10.1038/ki.1978.86; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEIST M, 1994, J IMMUNOL, V153, P1778; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Liu ZH, 1996, AM J PHYSIOL-CELL PH, V270, pC1595, DOI 10.1152/ajpcell.1996.270.6.C1595; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SKEHAN P, 1995, CELL GROWTH APOPTOSI, P179; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	50	237	241	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4027	4034		10.1074/jbc.273.7.4027	http://dx.doi.org/10.1074/jbc.273.7.4027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461593	hybrid			2022-12-27	WOS:000072048400035
J	Orr, MS; Reinhold, W; Yu, LJ; Schreiber-Agus, N; O'Connor, PM				Orr, MS; Reinhold, W; Yu, LJ; Schreiber-Agus, N; O'Connor, PM			An important role for the retinoblastoma protein in staurosporine-induced G(1) arrest in murine embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; INHIBITOR STAUROSPORINE; POTENT INHIBITOR; G1 PHASE; 2 POINTS; PROGRESSION; CANCER; P21; PHOSPHORYLATION	In this study, we investigated the molecular basis of the ability of staurosporine to induce G(1) arrest in murine embryonic fibroblasts (MEFs), We used MEFs from transgenic mice lacking several negative regulators of the G(1)/S phase transition including cells from mice lacking p53, p21, retinoblastoma (Rb), or p16 genes. We found that p53 function was not essential for staurosporine-induced G(1) arrest. In contrast, MEFs from mice lacking Rb genes showed approximately a 70% reduced capacity to arrest in the G(1) phase following staurosporine treatment, In support of a role for Rb in staurosporine-induced G(1) arrest, rat embryonic fibroblasts stably overexpressing cyclin D1/Cdk4(R24C) exhibited approximately a 50% reduced G(1) arrest response to staurosporine. The role of Rb in determining the degree of staurosporine-induced G(1) arrest did not depend on the function of the cyclin-dependent kinase inhibitors p16 or p21 because MEFs lacking either of these genes were still capable of undergoing G(1) arrest following staurosporine exposure. Our studies provide evidence of an important role for the Rb protein in determining the degree of staurosporine-induced G(1) arrest in the first cell cycle.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 11724 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yeshiva University; Albert Einstein College of Medicine	O'Connor, PM (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D09, Bethesda, MD 20892 USA.	po18c@nih.gov	Reinhold, William/J-6704-2017	Reinhold, William/0000-0001-5513-9323				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1991, CANCER RES, V51, P6304; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MICHIELI P, 1994, CANCER RES, V54, P3391; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR PM, 1993, CANCER RES, V53, P4776; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SCHNIER JB, 1994, CANCER RES, V54, P5959; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TAM SW, 1994, ONCOGENE, V9, P2663; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	36	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3803	3807		10.1074/jbc.273.7.3803	http://dx.doi.org/10.1074/jbc.273.7.3803			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461560	hybrid			2022-12-27	WOS:000072048400002
J	Sims, CE; Allbritton, NL				Sims, CE; Allbritton, NL			Metabolism of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate by the oocytes of Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TRIS-TETRAKISPHOSPHATE PATHWAY; BRUTONS TYROSINE KINASE; SECRETING RINM5F CELLS; HUMAN-PLATELETS; RAT-BRAIN; OVARIAN FOLLICLES; 3-KINASE ACTIVITY; CA2+ RELEASE; TRISPHOSPHATE	The pathway and kinetics of inositol 4,4,5-trisphosphate (IP3) metabolism were measured in Xenopus laevis oocytes and cytoplasmic extracts of oocytes, Degradation of microinjected IP,in intact oocytes was similar to that in the extracts containing comparable concentrations of IP3 ([IP3]). The rate and route of metabolism of IP3 depended on the [IP3] and the intracellular free Ca2+ concentration ([Ca2+]), At low [IP3] (100 nM) and high [Ca2+] (greater than or equal to 1 mu M), IP3 was metabolized predominantly by inositol 1,4,5-trisphosphate 3-kinase (3-kinase) with a half-life of 60 s, As the [IP](3) was increased, inositol polyphosphate 5-phosphatase (5-phosphatase) degraded progressively more IP3. At a [IP3] of 8 mu M or greater, the dephosphorylation of IP3 was the dominant mode of IP3 removal irrespective of the [Ca2+]. At low [IP3] and low [Ca2+] (both less than or equal to 400 nM), the activities of the 5-phosphatase and 5-kinase were comparable. The calculated range of action of IP3 in the oocyte was similar to 300 mu M suggesting that IP3 acts as a global messenger in oocytes. in contrast to IP3 inositol 1,3,4,5-tetrakisphosphate (IP4) was metabolized very slowly. The half-life of IP4 (100 nM) was 20 min and independent of the [Ca2+]. IP4 may act to sustain Ca2+ signals initiated by IP3. The half-life of both IP3 and IP4 in Xenopus oocytes was are order of magnitude or greater than that in small mammalian cells.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Allbritton, NL (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045324] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45324] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIDEN TJ, 1988, BIOCHEM J, V251, P435, DOI 10.1042/bj2510435; BIDEN TJ, 1987, J BIOL CHEM, V262, P3567; BIDEN TJ, 1986, J BIOL CHEM, V261, P1931; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BURGESS GM, 1985, BIOCHEM J, V232, P237, DOI 10.1042/bj2320237; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; CRANK J, 1989, MATH DIFFUSION, P29; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DANIEL JL, 1988, BIOCHEM J, V253, P789, DOI 10.1042/bj2530789; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FERGUSON JE, 1991, EXP CELL RES, V192, P352, DOI 10.1016/0014-4827(91)90052-V; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P511; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1995, BIOCHEM SOC T, V23, P27, DOI 10.1042/bst0230027; JOHANSON RA, 1988, J BIOL CHEM, V263, P7465; KING WG, 1989, J BIOL CHEM, V264, P6070; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LIN AN, 1990, BIOCHEM BIOPH RES CO, V170, P1371, DOI 10.1016/0006-291X(90)90546-Y; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCINTOSH RP, 1990, BIOCHEM J, V268, P141, DOI 10.1042/bj2680141; MCINTOSH RP, 1990, BIOCHEM BIOPH RES CO, V166, P380, DOI 10.1016/0006-291X(90)91956-S; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MORRIS AJ, 1987, BIOCHEM J, V248, P489, DOI 10.1042/bj2480489; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NUCCITELLI R, 1993, DEV BIOL, V158, P200, DOI 10.1006/dbio.1993.1179; PARKER I, 1991, J PHYSIOL-LONDON, V433, P207, DOI 10.1113/jphysiol.1991.sp018422; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SEGEL IH, 1975, BIOCH CALCULATIONS, P225; Shapira Hagit, 1992, Journal of Basic and Clinical Physiology and Pharmacology, V3, P119; SHAYMAN JA, 1988, BIOCHEM BIOPH RES CO, V151, P114, DOI 10.1016/0006-291X(88)90566-9; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SIM SS, 1990, J BIOL CHEM, V265, P10367; SULPICE JC, 1990, METHODS INOSITIDE RE, P45; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WALKER JW, 1987, NATURE, V327, P429; WANG SSH, 1995, J GEN PHYSIOL, V105, P149, DOI 10.1085/jgp.105.1.149; WREGGETT KA, 1987, BIOCHEM J, V245, P933, DOI 10.1042/bj2450933; YAMAGUCHI K, 1987, BIOCHEM J, V244, P787, DOI 10.1042/bj2440787; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	53	81	82	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4052	4058		10.1074/jbc.273.7.4052	http://dx.doi.org/10.1074/jbc.273.7.4052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461597	hybrid			2022-12-27	WOS:000072048400039
J	Aeschlimann, D; Koeller, MK; Allen-Hoffmann, BL; Mosher, DF				Aeschlimann, D; Koeller, MK; Allen-Hoffmann, BL; Mosher, DF			Isolation of a cDNA encoding a novel member of the transglutaminase gene family from human keratinocytes - Detection and identification of transglutaminase gene products based on reverse transcription polymerase chain reaction with degenerate primers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; COAGULATION FACTOR-XIII; AMINO-ACID-SEQUENCE; TISSUE TRANSGLUTAMINASE; CROSS-LINKING; MEMBRANE-PROTEIN; MOLECULAR-CLONING; ERYTHROCYTE PROTEIN-4.2; LAMELLAR ICHTHYOSIS; MESSENGER-RNA	We developed a method using a single set of degenerate oligonucleotide primers for amplification of the conserved active site of transglutaminases by reverse transcription-polymerase chain reaction (RT-PCR) and identification of the PCR products by cleavage with diagnostic restriction enzymes. We demonstrate amplification of tissue transglutaminase (TG(C)), keratinocyte transglutaminase (TG(K)), prostate transglutaminase (TG(P)), the a-subunit of factor XIII, and band 4.2 protein from different human cells or tissues, Analysis of normal human keratinocytes revealed expression of a transglutaminase different from the expected and characterized transglutaminase gene products. A full-length cDNA for the novel transglutaminase (TG(X)) was obtained by anchored PCR. The deduced amino acid sequence encoded a protein with 720 amino acids and a molecular mass of similar to 81 kDa. A comparison of TG(X) to the other members of the gene family revealed that the domain structure and the residues required for enzymatic activity and Ca2+ binding are conserved and showed an overall sequence identity of about 35%. Two transcripts with an apparent size of 2.2 and 2.8 kilobases were detected with a specific probe for TG(X) on Northern blots of human foreskin keratinocyte mRNA, indicating the presence of alternatively spliced mRNAs. cDNA sequencing revealed a shorter TG(X) transcript lacking the sequence homologous to that encoded by exon III of other transglutaminase genes. TG(X) expression increased severalfold when keratinocyte cultures were induced to differentiate by suspension or growth to postconfluency, suggesting that TG(X) contributes to the formation of the cornified envelope.	Univ Wisconsin, Div Orthoped Surg, Clin Sci Ctr F4312, Madison, WI 53792 USA; Univ Wisconsin, Dept Med, Madison, WI 53792 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Aeschlimann, D (corresponding author), Univ Wisconsin, Div Orthoped Surg, Clin Sci Ctr F4312, 600 Highland Ave, Madison, WI 53792 USA.			Aeschlimann, Daniel/0000-0003-0930-7706	NHLBI NIH HHS [HL21644] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; COHEN CM, 1993, SEMIN HEMATOL, V30, P119; Dubbink HJ, 1996, BIOCHEM J, V315, P901, DOI 10.1042/bj3150901; Esposito C, 1996, J BIOL CHEM, V271, P27416, DOI 10.1074/jbc.271.44.27416; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GENTILE V, 1991, J BIOL CHEM, V266, P478; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; HO KC, 1992, J BIOL CHEM, V267, P12660; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; POON MC, 1989, J CLIN INVEST, V84, P787, DOI 10.1172/JCI114237; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RISINGER MA, 1992, J BIOL CHEM, V267, P5680; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; RYBICKI AC, 1994, MAMM GENOME, V5, P438, DOI 10.1007/BF00357005; SCHENKER T, 1996, APOPTOSIS, V1, P126; SOTTILE J, 1989, THROMB HAEMOSTASIS, V62, P1100; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SUNG LPA, 1992, BLOOD, V79, P2763; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; UPCHURCH HF, 1987, IN VITRO CELL DEV B, V23, P795; WERAARCHAKULBOONMARK N, 1992, P NATL ACAD SCI USA, V89, P9804, DOI 10.1073/pnas.89.20.9804; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	57	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3452	3460		10.1074/jbc.273.6.3452	http://dx.doi.org/10.1074/jbc.273.6.3452			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452468	hybrid, Green Accepted			2022-12-27	WOS:000071822300053
J	Matsushita, O; Jung, CM; Minami, J; Katayama, S; Nishi, N; Okabe, A				Matsushita, O; Jung, CM; Minami, J; Katayama, S; Nishi, N; Okabe, A			A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; INDIVIDUAL COLLAGENASES; NUCLEOTIDE-SEQUENCE; SECONDARY-STRUCTURE; III COLLAGENS; CLASS-I; GENE; PURIFICATION; PROPELLER; PROTEINS	gThe Clostridium histolyticum 116-kDa collagenase consists of four segments, S1, S2a, S2b, and S3. A 98-kDa gelatinase, which can degrade denatured but not native collagen, lacks the C-terminal fragment containing a part of S2b and S3. In this paper we have investigated the function of the C-terminal segments using recombinant proteins, Full-length collagenase degraded both native type I collagen and a synthetic substrate, Pz-peptide, while an 88-kDa protein containing only S1 and S2a (S1S2a) degraded only Pt-peptide. Unlike the full-length enzyme, S1S2a did not bind to insoluble type I collagen. To determine the molecular determinant of collagen binding activity, various C-terminal regions were fused to the C terminus of glutathione S-transferase. S3 as well as S2bS3 conferred collagen binding, However, a glutathione S-transferase fusion protein with a region shorter than S3 exhibited reduced collagen binding activity. S3 liberated from the fusion protein also showed collagen binding activity, but not S2aS2b or S2b. S1 had 100% of the Pz-peptidase activity but only 5% of the collagenolytic activity of the full-length collagenase. These results indicate that S1 and S3 are the catalytic and binding domains, respectively, and that S2a and S2b form an interdomain structure.	Kagawa Med Univ, Fac Med, Dept Microbiol, Kagawa 7610793, Japan; Kagawa Med Univ, Fac Med, Dept Endocrinol, Kagawa 7610793, Japan	Kagawa University; Kagawa University	Okabe, A (corresponding author), Kagawa Med Univ, Fac Med, Dept Microbiol, 1750-1 Miki Cho, Kagawa 7610793, Japan.	microbio@kms.ac.jp		Nishi, Nozomu/0000-0001-7050-3226				BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3085, DOI 10.1021/bi00308a036; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3092, DOI 10.1021/bi00308a037; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FRENCH MF, 1992, J PROTEIN CHEM, V11, P83, DOI 10.1007/BF01025095; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Henderson RM, 1996, P NATL ACAD SCI USA, V93, P8756, DOI 10.1073/pnas.93.16.8756; Jin F, 1996, INFECT IMMUN, V64, P230, DOI 10.1128/IAI.64.1.230-237.1996; Jung CM, 1996, MICROBIOL IMMUNOL, V40, P923, DOI 10.1111/j.1348-0421.1996.tb01161.x; KAWAMURA F, 1984, J BACTERIOL, V160, P442, DOI 10.1128/JB.160.1.442-444.1984; Laboratories B.R., 1986, FOCUS, V8, P9; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; MALLYA SK, 1992, J PROTEIN CHEM, V11, P99, DOI 10.1007/BF01025096; MATSUSHITA O, 1994, J BACTERIOL, V176, P149, DOI 10.1128/JB.176.1.149-156.1994; Mayne R., 1987, STRUCTURE FUNCTION C; Mookhtiar K A, 1992, Matrix Suppl, V1, P116; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; PETERKOFSKY B, 1982, METHOD ENZYMOL, V82, P453; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; STEINBRINK DR, 1985, J BIOL CHEM, V260, P2771; TAKEUCHI H, 1992, BIOCHEM J, V281, P703, DOI 10.1042/bj2810703; TRIEUCUOT P, 1991, GENE, V102, P99, DOI 10.1016/0378-1119(91)90546-N; VANWART HE, 1985, BIOCHEMISTRY-US, V24, P6520, DOI 10.1021/bi00344a032; Worthington C.C., 1988, WORTHINGTON ENZYME M; YOSHIHARA K, 1994, J BACTERIOL, V176, P6489, DOI 10.1128/JB.176.21.6489-6496.1994	29	109	117	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3643	3648		10.1074/jbc.273.6.3643	http://dx.doi.org/10.1074/jbc.273.6.3643			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452493	hybrid			2022-12-27	WOS:000071822300078
J	Patel, S; Santra, M; McQuillan, DJ; Iozzo, RV; Thomas, AP				Patel, S; Santra, M; McQuillan, DJ; Iozzo, RV; Thomas, AP			Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SUPPRESSION; INHIBITION; INDUCTION	Several independent lines of evidence have implicated decorin, a small leucine-rich proteoglycan, in the inhibition of cell proliferation. However, the mechanism by which decorin mediates its effect on cell proliferation is unclear. Here we report, for the first time, decorin-mediated increases in intracellular Ca2+ levels of single A431 cells. The effects of decorin persisted in the absence of extracellular Ca2+ but were blocked by AG1478, an epidermal growth factor (EGF)-specific tyrosine kinase inhibitor, and by down-regulation of the EGF receptor. The effects of decorin were not mimicked by the structurally homologous protein, biglycan. Our results indicate a novel action of decorin on the EGF receptor, which results in mobilization of intracellular Ca2+ providing a possible mechanism by which decorin causes growth suppression.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Texas A&M Univ, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Texas A&M University System; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Iozzo, Renato/AAS-1980-2020; Thomas, Andrew/C-6755-2013; Patel, Sandip/O-9591-2015	Thomas, Andrew/0000-0002-9026-7467; Patel, Sandip/0000-0001-7247-2013; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NIDDK NIH HHS [R01 DK38422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADANY R, 1990, J BIOL CHEM, V265, P11389; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MOSCATELLO DK, 1997, IN PRESS J CLIN INVE; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767	24	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3121	3124		10.1074/jbc.273.6.3121	http://dx.doi.org/10.1074/jbc.273.6.3121			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452417	hybrid			2022-12-27	WOS:000071822300002
J	Fushinobu, S; Ohta, T; Matsuzawa, H				Fushinobu, S; Ohta, T; Matsuzawa, H			Homotropic activation via the subunit interaction and allosteric symmetry revealed on analysis of hybrid enzymes of L-lactate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIFIDOBACTERIUM-LONGUM; ASPARTATE TRANSCARBAMOYLASE; LIGAND-BINDING; SITE; MECHANISM	L-Lactate dehydrogenase from Bifidobacterium lon-gum shows homotropic activation by pyruvate as well as heterotropic activation by fructose 1,6-bisphosphate, Hybrid enzymes were produced from the wild-type subunit and a mutant subunit, whose substrate specificity was altered to that of malate dehydrogenase, and separated to analyze the substrate-induced homotropic activation mechanism, Oxamate, a competitive inhibitor of L-lactate dehydrogenase, was used to mimic the substrate-induced activation of the wild-type subunit as "a regulatory subunit," The malate dehydrogenase activity of the mutant subunit as "the catalytic subunit" of the hybrid enzymes was measured, and the activity of the mutant subunit was activated on the addition of oxamate, Thus, we directly observed the inter-subunit homotropic activation transmitted from the wild-type to the mutant subunit, Moreover, "isomeric" hybrid enzymes that have different structural subunit arrangements but identical subunit compositions showed identical kinetic natures, This indicates that the enzyme maintains its subunit symmetry during the allosteric transition.	Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Matsuzawa, H (corresponding author), Univ Tokyo, Dept Biotechnol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.		Wood, David W/B-2992-2012; Fushinobu, Shinya/E-4987-2011	Fushinobu, Shinya/0000-0003-1346-6435				ACKERS GK, 1993, TRENDS BIOCHEM SCI, V18, P385, DOI 10.1016/0968-0004(93)90095-5; BLOOM CR, 1995, J MOL BIOL, V245, P324, DOI 10.1006/jmbi.1994.0027; Dixon M., 1979, ENZYMES, P400; EVENTOFF W, 1977, P NATL ACAD SCI USA, V74, P2677, DOI 10.1073/pnas.74.7.2677; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; Fushinobu S, 1996, J BIOL CHEM, V271, P25611, DOI 10.1074/jbc.271.41.25611; GARVIE EI, 1980, MICROBIOL REV, V44, P106, DOI 10.1128/MMBR.44.1.106-139.1980; GERHART JC, 1962, J BIOL CHEM, V237, P891; Holbrook JJ., 1975, ENZYMES, P191; IWATA S, 1989, AGR BIOL CHEM TOKYO, V53, P3365, DOI 10.1080/00021369.1989.10869841; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; IWATA S, 1993, J MOL BIOL, V230, P21, DOI 10.1006/jmbi.1993.1122; IWATA S, 1989, J BIOCHEM-TOKYO, V106, P558, DOI 10.1093/oxfordjournals.jbchem.a122894; Mattevi A, 1996, CURR OPIN STRUC BIOL, V6, P824, DOI 10.1016/S0959-440X(96)80013-3; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MINOWA T, 1989, GENE, V85, P161, DOI 10.1016/0378-1119(89)90476-9; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OHTA T, 1992, FARADAY DISCUSS, V93, P153, DOI 10.1039/fd9929300153; PERUTZ MF, 1989, MECH COOPERATIVITY A; ROSSMANN MG, 1973, J MOL BIOL, V76, P533, DOI 10.1016/0022-2836(73)90491-9; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; YANG YR, 1980, P NATL ACAD SCI-BIOL, V77, P5187, DOI 10.1073/pnas.77.9.5187; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	23	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2971	2976		10.1074/jbc.273.5.2971	http://dx.doi.org/10.1074/jbc.273.5.2971			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446610	hybrid			2022-12-27	WOS:000071736600065
J	Ikuta, T; Eguchi, H; Tachibana, T; Yoneda, Y; Kawajiri, K				Ikuta, T; Eguchi, H; Tachibana, T; Yoneda, Y; Kawajiri, K			Nuclear localization and export signals of the human aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED TRANSCRIPTION FACTOR; PORE-TARGETING COMPLEX; AMINO-ACID-SEQUENCE; AH-RECEPTOR; PROTEIN IMPORT; DNA-BINDING; DIOXIN RECEPTOR; HUMAN HOMOLOG; IDENTIFICATION; TRANSPORT	The aryl hydrocarbon receptor (Ahr) is a ligand activated transcription factor that binds DNA in the form of a heterodimer with the Ahr nuclear translocator (hypoxia-inducible factor 1 beta). We found in this study that Ahr contains both nuclear localization and export sig nals in the NH2-terminal region. A fusion protein composed of beta-galactosidase and full-length Ahr translocates from the cytoplasm to the nucleus in a ligand-dependent manner. However, a fusion protein lacking the PAS (Per-Ahr nuclear translocator-Sim homology) domain of the Ahr showed strong nuclear localization activity irrespective of the presence or absence of ligand. A minimum bipartite Ahr nuclear localization signal (NLS) consisting of amino acid residues 13-39 was identified by microinjection of fused proteins with glutathione S-transferase-green fluorescent protein, A NLS having mutations in bipartite basic amino acids lost nuclear translocation activity completely, which may explain the reduced binding activity to the NLS receptor, PTAC58. A 21-amino acid peptide (residues 55-75) containing the Ahr nuclear export signal is sufficient to direct nuclear export of a microinjected complex of glutathione S-transferase-Ahr-green fluorescent protein. These findings strongly suggest that Ahr act as a ligand- and signal-dependent nucleocytoplasmic shuttling protein.	Saitama Canc Ctr, Res Inst, Dept Biochem, Ina, Saitama 362, Japan; Osaka Univ, Sch Med, Dept Anat & Cell Biol, Osaka 562, Japan	Osaka University	Kawajiri, K (corresponding author), Saitama Canc Ctr, Res Inst, Dept Biochem, 818 Komuro, Ina, Saitama 362, Japan.	kawajiri@saitama-cc.go.jp	Eguchi, Hiromi/GWC-5633-2022					ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DENISON MS, 1986, J BIOL CHEM, V261, P3987; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FUJIIKURIYAMA Y, 1994, EXP CLIN IMMUNOGENET, V11, P65; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kawajiri K., 1996, CYTOCHROMES P450 MET, P77; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	53	202	204	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2895	2904		10.1074/jbc.273.5.2895	http://dx.doi.org/10.1074/jbc.273.5.2895			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446600	hybrid			2022-12-27	WOS:000071736600055
J	Leong, GM; Wang, KS; Marton, MJ; Blanco, JCG; Wang, IM; Rolfes, RJ; Ozato, K; Segars, JH				Leong, GM; Wang, KS; Marton, MJ; Blanco, JCG; Wang, IM; Rolfes, RJ; Ozato, K; Segars, JH			Interaction between the retinoid X receptor and transcription factor IIB is ligand-dependent in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; PROLIFERATOR-ACTIVATED RECEPTOR; TATA-BINDING PROTEIN; RNA-POLYMERASE-II; FACTOR-TFIIB; NUCLEAR RECEPTOR; BASAL TRANSCRIPTION; ACID RECEPTORS; RXR-ALPHA; PREINITIATION COMPLEX	The retinoid X receptor (RXR) influences gene activation through heterodimeric and homodimeric association with DNA and associates with TATA binding protein, TAF110, and cAMP response element-binding protein-binding protein; yet the molecular mechanisms responsible for gene activation by RXRs remain incompletely defined. Since the general transcription factor IIB (TFIIB) is a common target of sequence-specific transcriptional activators, we suspected that RXR might regulate target genes via an interaction with TFIIB. Coimmunoprecipitation, far Western analysis, and glutathione S-transferase binding studies indicated that murine RXR beta (mRXR beta) was capable of binding to human TFIIB in vitro. Functional analysis with a dual-hybrid yeast system and cotransfection assays revealed the interaction of mRXR beta with TFIIB to be ligand-dependent in vivo. Truncation experiments mapped the essential binding regions to the carboxyl region of mRXR beta (amino acids (aa) 254-389) and two regions in the carboxyl region of TFIIB (aa 178-201 and aa 238-271). Furthermore, the Delta 390-410 mRXR beta mutant bound to TFIIB in vitro but was not active in the dual-hybrid yeast system, suggesting that the extreme carboxyl region of RXR was required for in vivo interaction with TFIIB. These data indicate that interaction of mRXR beta with TFIIB is specific, direct, and ligand-dependent in vivo and suggest that gene activation by RXR involves TFIIB.	NICHHD, Unit Mol Mechanisms Reprod, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Segars, JH (corresponding author), Uniformed Serv Univ Hlth Sci, OSD, Bldg A,Rm 3078,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		Blanco, Jorge/AAW-3752-2020	Blanco, Jorge/0000-0002-6173-0213; Leong, Gary/0000-0001-5763-095X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000636] Funding Source: NIH RePORTER; NICHD NIH HHS [Z01-HD00636] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Blanco JCG, 1996, GENES CELLS, V1, P209, DOI 10.1046/j.1365-2443.1996.d01-229.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HARPER JW, 1993, CELL, V75, P805; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; MEDIN JA, 1994, MOL CELL ENDOCRINOL, V105, P27, DOI 10.1016/0303-7207(94)90032-9; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; NUNEZ SB, 1995, RECENT PROG HORM RES, V50, P409; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; QI JS, 1995, MOL CELL BIOL, V15, P1817; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	89	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2296	2305		10.1074/jbc.273.4.2296	http://dx.doi.org/10.1074/jbc.273.4.2296			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442074	hybrid			2022-12-27	WOS:000071595200063
J	Moir, RD; Lynch, T; Bush, AI; Whyte, S; Henry, A; Portbury, S; Multhaup, G; Small, DH; Tanzi, RE; Beyreuther, K; Masters, CL				Moir, RD; Lynch, T; Bush, AI; Whyte, S; Henry, A; Portbury, S; Multhaup, G; Small, DH; Tanzi, RE; Beyreuther, K; Masters, CL			Relative increase in Alzheimer's disease of soluble forms of cerebral A beta amyloid protein precursor containing the Kunitz protease inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; NEURITIC PLAQUE DENSITY; NORMAL HUMAN-BRAIN; AGED HUMAN BRAIN; TRANSGENIC MICE; RAT-BRAIN; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION; CEREBROSPINAL-FLUID; CULTURED-CELLS	Although a number of studies have examined amyloid precursor protein (APP) mRNA levels in Alzheimer's disease (AD), no clear consensus has emerged as to whether the levels of transcripts for isoforms containing a Kunitz protease inhibitory (KPI)-encoded region are increased or decreased in AD, Here we compare AD and control brain for the relative amounts of APP protein containing KPI to APP protein lacking this domain. APP protein was purified from the soluble subcellular fraction and Triton X-100 membrane pellet extract of one hemisphere of AD (n = 10), normal (n = 7), and neurological control (n = 5) brains, The amount of KPI-containing APP in the purified protein samples was determined using two independent assay methods, The first assay exploited the inhibitory action of KPI-containing APP on trypsin. The second assay employed reflectance analysis of Western blots, The proportion of KPI-containing forms of APP in the soluble subcellular fraction of AD brains is significantly elevated (p < 0.01) compared with controls, Species containing a HPI domain comprise 32-41 and 76-77% of purified soluble APP from control and AD brains, respectively, For purified membrane-associated APP, 72-77 and 65-82% of control and AD samples, respectively, contain a KPI domain. Since KPI-containing species of APP may be more amyloidogenic (Ho, L., Fukuchi, K., and Yonkin, S. G. (1996) J. Biol. Chem. 271, 30929-30934), our findings support an imbalance of isoforms as one possible mechanism for amyloid deposition in sporadic AD.	Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Unit, Boston, MA 02114 USA; Univ Heidelberg, Ctr Mol Biol, D-6900 Heidelberg, Germany	University of Melbourne; Harvard University; Harvard Medical School; Massachusetts General Hospital; Ruprecht Karls University Heidelberg	Masters, CL (corresponding author), Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia.		Bush, Ashley/Y-2457-2019; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007; Moir, Robert D./M-7612-2017	Bush, Ashley/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069; Moir, Robert D./0000-0001-5431-3553; Portbury, Stuart/0000-0002-5470-6100				ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; BAHMANYAR S, 1987, SCIENCE, V237, P77, DOI 10.1126/science.3299701; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; BUSH AI, 1994, J BIOL CHEM, V269, P26618; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CARD JP, 1988, NEURON, V1, P835, DOI 10.1016/0896-6273(88)90131-6; CITRON M, 1993, NEUROBIOL AGING, V14, P571, DOI 10.1016/0197-4580(93)90041-9; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HEASE L, 1994, FEBS LETT, V349, P109; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; HIGGINS GA, 1990, P NATL ACAD SCI USA, V87, P3032, DOI 10.1073/pnas.87.8.3032; HIGGINS LS, 1995, REV NEUROSCIENCE, V6, P87; HIGGINS LS, 1993, ANN NY ACAD SCI, V695, P224, DOI 10.1111/j.1749-6632.1993.tb23056.x; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Ho LB, 1996, J BIOL CHEM, V271, P30929, DOI 10.1074/jbc.271.48.30929; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; HYMAN BT, 1993, MOL BRAIN RES, V18, P253, DOI 10.1016/0169-328X(93)90197-W; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P585, DOI 10.1016/0197-4580(91)90090-7; Johnson D, 1996, CONTROL ENG, V43, P85; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1989, NEUROBIOL AGING, V10, P267, DOI 10.1016/0197-4580(89)90061-4; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; JOHNSON SA, 1996, MOL BRAIN RES, V43, P77; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kawarabayashi T, 1996, NEUROBIOL AGING, V17, P215, DOI 10.1016/0197-4580(95)02061-6; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1453, DOI 10.1016/0006-291X(90)91030-V; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KONIG G, 1991, MOL BRAIN RES, V9, P259, DOI 10.1016/0169-328X(91)90010-U; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; KOO EH, 1990, NEURON, V2, P97; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LEWIS DA, 1988, P NATL ACAD SCI USA, V85, P1691, DOI 10.1073/pnas.85.5.1691; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MITA S, 1989, AM J PATHOL, V134, P1253; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; MORGAN PM, 1995, P NATL ACAD SCI USA, V92, P5341; MOYA KL, 1994, J NEUROCHEM, V63, P1971; NAKAMURA S, 1992, ACTA NEUROPATHOL, V84, P244; Neve RL, 1996, NEUROBIOL AGING, V17, P191, DOI 10.1016/0197-4580(95)02074-8; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OHYAGI Y, 1992, J NEUROL SCI, V111, P33, DOI 10.1016/0022-510X(92)90109-X; OKADA A, 1994, DEMENTIA, V5, P55, DOI 10.1159/000106697; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OYAMA F, 1991, J NEUROPATH EXP NEUR, V50, P560, DOI 10.1097/00005072-199109000-00004; OYAMA F, 1992, J NEUROCHEM, V59, P1117, DOI 10.1111/j.1471-4159.1992.tb08354.x; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1994, J NEUROSCI, V14, P2117; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; SPILLANTINI MG, 1989, MOL BRAIN RES, V6, P143, DOI 10.1016/0169-328X(89)90048-X; TANAKA S, 1989, BIOCHEM BIOPH RES CO, V165, P1406, DOI 10.1016/0006-291X(89)92760-5; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANAKA S, 1992, MOL BRAIN RES, V15, P303, DOI 10.1016/0169-328X(92)90122-R; TANAKA S, 1993, NEUROSCI LETT, V163, P19, DOI 10.1016/0304-3940(93)90219-B; TANZI RE, 1993, MOL BRAIN RES, V18, P246, DOI 10.1016/0169-328X(93)90196-V; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TATEOSTROFF B, 1989, P NATL ACAD SCI USA, V86, P745, DOI 10.1073/pnas.86.2.745; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; ZHAN SS, 1995, CLIN NEUROPATHOL, V14, P142	87	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5013	5019		10.1074/jbc.273.9.5013	http://dx.doi.org/10.1074/jbc.273.9.5013			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478949	hybrid			2022-12-27	WOS:000072310400033
J	Silvestre, JS; Robert, V; Heymes, C; Aupetit-Faisant, B; Mouas, C; Moalic, JM; Swynghedauw, B; Delcayre, C				Silvestre, JS; Robert, V; Heymes, C; Aupetit-Faisant, B; Mouas, C; Moalic, JM; Swynghedauw, B; Delcayre, C			Myocardial production of aldosterone and corticosterone in the rat - Physiological regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RIBONUCLEIC-ACID LEVELS; ANGIOTENSIN-II; MESSENGER-RNAS; CARDIAC FIBROSIS; GENE-EXPRESSION; DIETARY-SODIUM; CYP11B GENES; BIOSYNTHESIS; SYNTHASE	Increasing evidence suggests that mineralo- and glucocorticoids modulate cardiovascular homeostasis via the effects of circulating components generated within the adrenals but also through local synthesis, The aim of this study was to assess the existence of such a steroidogenic system in heart, Using the quantitative reverse transcriptase-polymerase chain reaction, the terminal enzymes of corticosterone and aldosterone synthesis (11 beta-hydroxylase and aldosterone synthase, respectively) were detected in the rat heart, This pathway was shown to be physiologically active, since production of aldosterone, corticosterone, and their precursor, deoxycorticosterone, was detected in both the homogenate and perfusate of isolated rat hearts using radioimmunoassay after Celite column chromatography, Perfusion of angiotensin II or adrenocorticotropin for 3 h increased aldosterone and corticosterone production and decreased deoxycorticosterone, suggesting that aldosterone and corticosterone are formed within the isolated heart from a locally present substrate, Chronic regulation of this intracardiac system was then examined, As in adrenals cardiac 11 beta-hydroxylase and aldosterone-synthase mRNAs were independently regulated by 1 week's treatment with either low sodium and high potassium diet (which increased aldosterone synthase mRNA level only), angiotensin II (which raised level of both mRNAs), or adrenocorticotropin (which stimulated the 11 beta-hydroxylase gene exclusively). Changes in cardiac steroid levels during treatment were not directly related to their plasma levels suggesting independent regulating mechanisms, This study, therefore, provides the first evidence for the existence of an endocrine cardiac steroidogenic system in rat heart and emphasizes its potential physiological and pathological relevance.	Hop Lariboisiere, INSERM, U127, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Delcayre, C (corresponding author), Hop Lariboisiere, INSERM, U127, 41 Bd Chapelle, F-75475 Paris 10, France.	claude.delcayre@inserm.lrb.ap-hop-paris.f	Silvestre, Jean-Sebastien/K-7695-2017; Heymes, Christophe/Y-9368-2019	Silvestre, Jean-Sebastien/0000-0003-3962-2205; Heymes, Christophe/0000-0002-6666-6193				ADLER GK, 1993, ENDOCRINOLOGY, V133, P2235, DOI 10.1210/en.133.5.2235; AGARWAL MK, 1979, J MOL CELL CARDIOL, V11, P115, DOI 10.1016/0022-2828(79)90457-7; AGUILERA G, 1981, ENDOCRINOLOGY, V108, P522, DOI 10.1210/endo-108-2-522; AUPETIT B, 1993, BIOCHIM BIOPHYS ACTA, V752, P73; AUPETITFAISANT B, 1993, J CLIN ENDOCR METAB, V76, P38, DOI 10.1210/jc.76.1.38; BIGLIERI EG, 1987, ANN NY ACAD SCI, V512, P426, DOI 10.1111/j.1749-6632.1987.tb24978.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILLA CG, 1990, CIRC RES, V67, P1355, DOI 10.1161/01.RES.67.6.1355; CAMPBELL SE, 1993, AM J HYPERTENS, V6, P487, DOI 10.1093/ajh/6.6.487; CASEY ML, 1982, ENDOCR REV, V3, P396, DOI 10.1210/edrv-3-4-396; Clyne CD, 1996, ENDOCR RES, V22, P485, DOI 10.1080/07435809609043735; CURNOW KM, 1991, MOL ENDOCRINOL, V5, P1513, DOI 10.1210/mend-5-10-1513; DANSER AHJ, 1994, HYPERTENSION, V24, P37, DOI 10.1161/01.HYP.24.1.37; DELCAYRE C, 1992, AM J PHYSIOL, V263, pH1537, DOI 10.1152/ajpheart.1992.263.5.H1537; DELLABRUNA R, 1995, J HYPERTENS, V13, P763; DellItalia LJ, 1997, J CLIN INVEST, V100, P253, DOI 10.1172/JCI119529; DZAU VJ, 1988, CIRCULATION, V77, P4; Fardella CE, 1996, ANNU REV NUTR, V16, P443, DOI 10.1146/annurev.nu.16.070196.002303; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNDER JW, 1973, ENDOCRINOLOGY, V93, P1300, DOI 10.1210/endo-93-6-1300; HATAKEYAMA H, 1994, J BIOL CHEM, V269, P24316; HAYASHI T, 1991, AM J PHYSIOL, V261, pC106, DOI 10.1152/ajpcell.1991.261.1.C106; HEYMES C, 1994, CIRCULATION, V90, P1328, DOI 10.1161/01.CIR.90.3.1328; HOLLAND OB, 1993, ENDOCRINOLOGY, V132, P2666, DOI 10.1210/en.132.6.2666; Huang MH, 1996, J CLIN INVEST, V98, P1298, DOI 10.1172/JCI118916; HUET M, 1974, LAB INVEST, V30, P154; IKEDA U, 1991, J BIOL CHEM, V266, P12058; KNOX JR, 1969, J ENDOCRINOL, V43, P315, DOI 10.1677/joe.0.0430315; KORICHNEVA I, 1995, J MOL CELL CARDIOL, V27, P2521, DOI 10.1006/jmcc.1995.0239; LINDPAINTNER K, 1990, CIRC RES, V67, P564, DOI 10.1161/01.RES.67.3.564; LOMBES M, 1992, CIRC RES, V71, P503, DOI 10.1161/01.RES.71.3.503; MALEE MP, 1991, P NATL ACAD SCI USA, V88, P4731, DOI 10.1073/pnas.88.11.4731; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; MELLON SH, 1995, J BIOL CHEM, V270, P1643, DOI 10.1074/jbc.270.4.1643; MUKAI K, 1991, BIOCHEM BIOPH RES CO, V180, P1187, DOI 10.1016/S0006-291X(05)81321-X; MUKAI K, 1993, J BIOL CHEM, V268, P9130; NOMURA M, 1993, J BIOCHEM-TOKYO, V113, P144, DOI 10.1093/oxfordjournals.jbchem.a124018; ROBERT V, 1994, HYPERTENSION, V24, P30, DOI 10.1161/01.HYP.24.1.30; ROBERT V, 1995, HYPERTENSION, V26, P971, DOI 10.1161/01.HYP.26.6.971; SHIBATA H, 1991, ENDOCRINOLOGY, V128, P2534, DOI 10.1210/endo-128-5-2534; Takeda Y, 1996, J CLIN ENDOCR METAB, V81, P2797, DOI 10.1210/jc.81.8.2797; TAKEDA Y, 1994, ENDOCRINOLOGY, V135, P2283, DOI 10.1210/en.135.5.2283; TAKEDA Y, 1995, HYPERTENSION, V25, P170, DOI 10.1161/01.HYP.25.2.170; TREMBLAY A, 1991, J BIOL CHEM, V266, P2245; TREMBLAY A, 1992, ENDOCRINOLOGY, V130, P3152, DOI 10.1210/en.130.6.3152; ULLIAN ME, 1992, HYPERTENSION, V20, P67, DOI 10.1161/01.HYP.20.1.67; WALKER BR, 1991, ENDOCRINOLOGY, V129, P3305, DOI 10.1210/endo-129-6-3305; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; YOUNG M, 1994, J CLIN INVEST, V93, P2578, DOI 10.1172/JCI117269; ZHAO HF, 1991, J BIOL CHEM, V266, P583	50	385	402	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4883	4891		10.1074/jbc.273.9.4883	http://dx.doi.org/10.1074/jbc.273.9.4883			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478930	hybrid			2022-12-27	WOS:000072310400014
J	He, ZN; Crist, M; Yen, HC; Duan, XQ; Quiocho, FA; Gimble, FS				He, ZN; Crist, M; Yen, HC; Duan, XQ; Quiocho, FA; Gimble, FS			Amino acid residues in both the protein splicing and endonuclease domains of the PI-SceI intein mediate DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; RECOGNITION; CLEAVAGE	A structure-based model describing the interaction of the two-domain PI-SceI endonuclease with its 31-base pair DNA substrate suggests that the endonuclease domain (domain II) contacts the cleavage site region of the substrate, while the protein splicing domain (domain I) interacts with a distal region that is sufficient for high affinity binding, To support this model, alanine-scanning mutagenesis was used to assemble a set of 49 PI-SceI mutant proteins that were purified and assayed for their DNA binding and cleavage properties, Fourteen mutant proteins were 4- to >500-fold less active than wild-type PI-SceI in cleavage assays, and one mutant (T225A) was 3-fold more active, Alanine substitution at two positions in domain I reduces overall binding >60-fold by perturbing the interaction of PI-SceI with the minimal binding region. Conversely, mutations in domain II have little effect on binding, reduce binding to the cleavage site region only, or affect binding to both regions, Interestingly, substitutions at Lys(301), which is part of the endonucleolytic active site, eliminate binding to the cleavage site region but permit contact with the minimal binding region, This experimental evidence demonstrates that the protein splicing domain as well as the endonuclease domain is involved in binding of a DNA substrate with the requisite length.	Texas A&M Univ, Ctr Macromol Design, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University System; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Gimble, FS (corresponding author), Texas A&M Univ, Ctr Macromol Design, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Wood, David W/B-2992-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280, R29GM050815] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08280, GM50815] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; BROWN BM, 1994, NAT STRUCT BIOL, V1, P164, DOI 10.1038/nsb0394-164; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hwang JS, 1997, J BACTERIOL, V179, P1051, DOI 10.1128/jb.179.4.1051-1058.1997; MUELLER JE, 1993, NUCLEASES, P111; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1712, DOI 10.1021/bi9523926; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123	20	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4607	4615		10.1074/jbc.273.8.4607	http://dx.doi.org/10.1074/jbc.273.8.4607			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468518	hybrid			2022-12-27	WOS:000072115000046
J	Kuniyasu, A; Itagaki, K; Shibano, T; Iino, M; Kraft, G; Schwartz, A; Nakayama, H				Kuniyasu, A; Itagaki, K; Shibano, T; Iino, M; Kraft, G; Schwartz, A; Nakayama, H			Photochemical identification of transmembrane segment IVS6 as the binding region of semotiadil, a new modulator for the L-type voltage-dependent Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BI CALCIUM CHANNELS; SKELETAL-MUSCLE; ALPHA-1 SUBUNIT; 1,4-DIHYDROPYRIDINE SENSITIVITY; PHARMACOLOGICAL PROFILE; MOLECULAR DETERMINANTS; ANTAGONIST; BENZOTHIAZINE; SD-3211; FUMARATE	To identify the binding domain of a new Ca2+ antagonist semotiadil on L-type Ca2+ channels from skeletal muscle, photolabeling was carried out by using an azi dophenyl derivative of [H-3]semotiadil, Photoincorporation was observed in several polypeptides of membrane triad preparations; the only specific photoincorporation was in the alpha 1 subunit of the Ca2+ channel, After solubilization and purification, the photolabeled alpha(1) subunit was subjected to proteolytic and CNBr cleavage followed by antibody mapping, Specific labeling was associated solely with the region of transmembrane segment S6 in repeat IV. Quantitative immunoprecipitation was found in the tryptic and the Lys-C/Glu-C fragments of 6.6 and 6.1 kDa, respectively, Further CNBr cleavage of the Lys-C digests produced two smaller fragments of 3.4 and 1.8 kDa that were included in the tryptic and Lys-C/Glu-C fragments. The smallest labeled fragments were: Tyr(1350)-Met(1366) and Leu(1367)-Met(1381) containing IVS6, a possible pore forming region, The data suggest that semotiadil binds to a region that is overlapped with but not identical to those for phenylalkylamines, dihydropyridines and benzothiazepines. The present study also provides evidence that region IV represents an important component of a binding pocket for Ca2+ antagonists.	Kumamoto Univ, Fac Pharmaceut Sci, Kumamoto 862, Japan; NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; Daiichi Pharmaceut Co Ltd, New Prod Res Labs 2, Edogawa Ku, Tokyo 134, Japan; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA	Kumamoto University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Daiichi Sankyo Company Limited; University of Cincinnati	Nakayama, H (corresponding author), Kumamoto Univ, Fac Pharmaceut Sci, 5-1 Oe Honmachi, Kumamoto 862, Japan.	jin@gpo.kumamoto-u.ac.jp	Itagaki, Kiyoshi/M-5501-2015	Itagaki, Kiyoshi/0000-0002-6033-1122	NHLBI NIH HHS [P01 HL22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; FUJITA M, 1990, J MED CHEM, V33, P1898, DOI 10.1021/jm00169a011; GALIZZI JP, 1986, P NATL ACAD SCI USA, V83, P7513, DOI 10.1073/pnas.83.19.7513; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; KOJICPRODIC B, 1984, HELV CHIM ACTA, V67, P916, DOI 10.1002/hlca.19840670333; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MIYAWAKI N, 1991, LIFE SCI, V48, P1903, DOI 10.1016/0024-3205(91)90222-W; MORI T, 1995, BRIT J PHARMACOL, V116, P1668, DOI 10.1111/j.1476-5381.1995.tb16389.x; NAGAO T, 1973, CHEM PHARM BULL, V21, P92; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NAKAYAMA K, 1994, J CARDIOVASC PHARM, V23, P731, DOI 10.1097/00005344-199405000-00007; NAKAYAMA K, 1992, J CARDIOVASC PHARM, V20, P380, DOI 10.1097/00005344-199209000-00007; Nakayama K, 1996, CARDIOVASC DRUG REV, V14, P97, DOI 10.1111/j.1527-3466.1996.tb00222.x; OTA A, 1993, CHEM PHARM BULL, V41, P1681, DOI 10.1248/cpb.41.1681; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; QAR J, 1988, MOL PHARMACOL, V33, P363; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; WATANABE T, 1993, FEBS LETT, V334, P261, DOI 10.1016/0014-5793(93)80690-V; Watanabe Y, 1996, BIOORG MED CHEM LETT, V6, P1923, DOI 10.1016/0960-894X(96)00338-1	34	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4635	4641		10.1074/jbc.273.8.4635	http://dx.doi.org/10.1074/jbc.273.8.4635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468522	hybrid			2022-12-27	WOS:000072115000050
J	Zimmer, DB; Cornwall, EH; Reynolds, PD; Donald, CM				Zimmer, DB; Cornwall, EH; Reynolds, PD; Donald, CM			S100A1 regulates neurite organization, tubulin levels, and proliferation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OUTGROWTH; FAMILY; BINDING; GAP-43; GENES; OVEREXPRESSION; TRANSFECTION; INVOLVEMENT; MORPHOLOGY	As a first step in determining what cellular processes are regulated by the calcium-modulated protein S100A1 isoform in neurons, the effects of ablated S100A1 expression on neurite organization and microtubule/tubulin levels in PC12 cells were examined. A mammalian expression vector containing the rat S100A1 cDNA in the antisense orientation with respect to a cytomegalovirus promoter was constructed and transfected into PC12 cells, Indirect immunofluorescence microscopy confirmed decreased S100A1 protein levels in all three stable transfectants (pAntisense clones) that expressed exogenous S100A1 antisense mRNA, In response to nerve growth factor, pAntisense clones extended significantly more neurites than control cells (4.01 +/- 0.16 versus 2.93 +/- 0.16 neurites/cell), This increase in neurite number was accompanied by an increase in total alpha-tubulin levels in untreated (4.0 +/- 0.6 versus 1.76 +/- 0.4 ng of alpha-tubulin/mg of total protein) and nerve growth factor-treated pAntisense clones (4.15 +/- 0.4 versus 2.04 +/- 0.5 ng of alpha-tubulin/mg of total protein) when compared with control cells. At high cell densities, pAntisense clones exhibited a significant decrease in anchorage-dependent growth, In soft agar, pAntisense clones formed significantly more colonies (153 +/- 8%) than control cells (116 +/- 5%), However, the pAntisense soft agar colonies were significantly smaller than those observed in control cells (40.6 +/- 3.0 versus 59.5 +/- 1.2 mu m). These data suggest that cell density inhibits both anchorage-independent and -dependent growth of pAntisense clones. In summary, ablation of S100A1 expression in PC12 cells results in increased tubulin levels, altered neurite organization, and decreased cell growth, Thus, S100A1 may directly link the cytoskeleton and calcium signal transduction pathways to cell proliferation.	Univ S Alabama, Dept Pharmacol, Sch Med, Mobile, AL 36688 USA	University of South Alabama	Zimmer, DB (corresponding author), Univ S Alabama, Dept Pharmacol, Sch Med, MSB 3130, Mobile, AL 36688 USA.	dzimmer@jaguar1.usouthal.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030660] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30660] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandt PC, 1996, P NATL ACAD SCI USA, V93, P13843, DOI 10.1073/pnas.93.24.13843; BURKE WJ, 1994, LIFE SCI, V55, pPL313, DOI 10.1016/0024-3205(94)90074-4; CAPPELLETTI G, 1995, CELL BIOL INT, V19, P687, DOI 10.1006/cbir.1995.1118; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; GRIBKOFF VK, 1995, MOL BRAIN RES, V30, P29; Gupta RP, 1997, MOL CHEM NEUROPATHOL, V30, P223, DOI 10.1007/BF02815100; HANEMAAIJER R, 1991, J NEUROSCI RES, V30, P163, DOI 10.1002/jnr.490300117; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; LAKSHMI MS, 1993, ANTICANCER RES, V13, P299; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; MASIAKOWSKI P, 1990, J NEUROSCI RES, V27, P264, DOI 10.1002/jnr.490270304; Meiri KF, 1996, J NEUROBIOL, V29, P213, DOI 10.1002/(SICI)1097-4695(199602)29:2<213::AID-NEU7>3.0.CO;2-D; NIELANDER HB, 1993, NEUROSCI LETT, V162, P46, DOI 10.1016/0304-3940(93)90556-Z; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; Takenaga K, 1997, ONCOGENE, V14, P331, DOI 10.1038/sj.onc.1200820; Tashima K, 1996, J NEUROCHEM, V66, P57; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1; XIE RP, 1995, DEV BRAIN RES, V87, P77, DOI 10.1016/0165-3806(95)00061-H; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zimmer DB, 1996, BBA-MOL CELL RES, V1313, P229, DOI 10.1016/0167-4889(96)00094-8; ZIMMER DB, 1991, BRAIN RES BULL, V27, P157, DOI 10.1016/0361-9230(91)90061-N; ZIMMER DB, 1995, J NEUROCHEM, V64, P2727	32	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4705	4711		10.1074/jbc.273.8.4705	http://dx.doi.org/10.1074/jbc.273.8.4705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468532	hybrid			2022-12-27	WOS:000072115000060
J	Lee, GF; Kelley, RF				Lee, GF; Kelley, RF			A novel soluble tissue factor variant with an altered factor VIIa binding interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOVALENT PHAGE DISPLAY; KUNITZ DOMAIN INHIBITORS; SUBSTRATE RECOGNITION; CRYSTAL-STRUCTURE; FACTOR-X; RESIDUES; COMPLEX; SITE; IDENTIFICATION; SELECTION	Tissue factor (TF) residues Lys(20) and Asp(58) form part of a binding epitope previously shown by alanine scanning to be critical for high affinity interactions with factor VIIa (FVIIa), To explore the possibility of enhancing the affinity of a TF-based antagonist for FVIIa, we created libraries in which residues at 20, 58, and adjacent positions were varied in constructs containing the soluble extracellular domain of TF (sTF) fused to the bacteriophage M13 tail coat protein, TF variants monovalently displayed on phage were then sorted on the basis of binding to FVIIa, Sorting of preliminary libraries, in which position 58 and/or 20 and surrounding residues were randomized, led to the selection of TF proteins of essentially wild-type sequence, Therefore, we devised a strategy wherein TF position 20 was held fixed as alanine and 5 specific residues near to, and including, position 58 were randomized to effectively obtain alternative sequences at this interface, The consensus sequence reached with this library included wild-type residues at positions 61, 62, 65, and 66 but exclusively tryptophan at position 58, Analyses of the soluble K20A,D58W (A20W58) TF protein indicated that it binds FVIIa with an affinity comparable with wild-type sTF but is defective as a cofactor for FVIIa-dependent factor X activation, Further experiments designed to elucidate the mechanism of binding suggest that the new binding interactions involve more than the simple addition of hydrophobic surface area.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Kelley, RF (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.							BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BIETH J, 1974, PROTEINASE INHIBITOR, P463; BROZE GJ, 1994, HAEMOSTASIS THROMBOS, P349; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; Kelley RF, 1997, BLOOD, V89, P3219, DOI 10.1182/blood.V89.9.3219; Kelly CR, 1997, J BIOL CHEM, V272, P17467, DOI 10.1074/jbc.272.28.17467; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee GF, 1997, BIOCHEMISTRY-US, V36, P5607, DOI 10.1021/bi970388j; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Lowman HB., 1991, METHODS COMPANION ME, V3, P205; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANFORD C, 1980, HYDROPHOBIC EFFECT; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; Williams J W, 1979, Methods Enzymol, V63, P437	33	11	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4149	4154		10.1074/jbc.273.7.4149	http://dx.doi.org/10.1074/jbc.273.7.4149			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461610	hybrid			2022-12-27	WOS:000072048400052
J	Niemela, R; Natunen, J; Majuri, ML; Maaheimo, H; Helin, J; Lowe, JB; Renkonen, O; Renkonen, R				Niemela, R; Natunen, J; Majuri, ML; Maaheimo, H; Helin, J; Lowe, JB; Renkonen, O; Renkonen, R			Complementary acceptor and site specificities of Fuc-TIV and Fuc-TVII allow effective biosynthesis of sialyl-TriLex and related polylactosamines present on glycoprotein counterreceptors of selectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MILK FUCOSYL-TRANSFERASE; LEWIS-X; MOLECULAR-CLONING; P-SELECTIN; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; LEUKOCYTE TRAFFICKING; DETERMINES EXPRESSION; CARBOHYDRATE LIGANDS; BETA-GALACTOSIDASE	The P-selectin counterreceptor PSGL-1 is covalently modified by mono alpha 2,3-sialylated, multiply alpha 1,3-fucosylated polylactosamines. These glycans are required for the adhesive interactions that allow this adhesion receptor-counterreceptor pair to facilitate leukocyte extravasation, To begin to understand the biosynthesis of these glycans, we have characterized the acceptor and site specificities of the two granulocyte alpha 1,3-fucosyltransferases, Fuc-TIV and Fuc-TVII, using recombinant forms of these two enzymes and a panel of synthetic polylactosamine-based accepters. We find that Fuc-TIV can transfer fucose effectively to all N-acetyllactosamine (LN) units in neutral polylactosamines, and to the "inner" LN units of alpha 2,3-sialylated accepters but is ineffective in transfer to the distal alpha 2,3-sialylated LN unit in alpha 2,3-sialylated accepters, Fuc-TVII, by contrast, effectively fucosylates only the distal alpha 2,3-sialylated LN unit in alpha 2,3-sialylated accepters and thus exhibits an acceptor site-specificity that is complementary to Fuc-TIV, Furthermore, the consecutive action of Fuc-TIV and Fuc-TVII, in vitro, can convert the long chairs sialoglycan SA alpha 2-3'LN beta 1-3'LN beta 1-3'LN (where SA is sialic acid) into the trifucosylated molecule SA alpha 2-3'Lex beta 1-3'Lex beta 1-3'Lex (where Lex is the trisaccharide Gal beta 1-4(Fuc alpha 1-3)GlcNAc) known to decorate PSGL-1, The complementary in vitro acceptor site-specificities of Fuc-TIV and Fuc-TVII imply that these enzymes cooperate in vivo in the biosynthesis of monosialylated, multifucosylated polylactosamine components of selectin counterreceptors on human leukocytes.	Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Helsinki; University of Helsinki; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Renkonen, R (corresponding author), Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, POB 21, FIN-00014 Helsinki, Finland.				NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKAWA M, 1974, J BIOCHEM, V75, P707, DOI 10.1093/oxfordjournals.jbchem.a130443; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; DEVRIES T, 1994, BIOCHEMISTRY-US, V33, P9937, DOI 10.1021/bi00199a016; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1993, EUR J BIOCHEM, V216, P769, DOI 10.1111/j.1432-1033.1993.tb18197.x; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; Hiraiwa N, 1996, J BIOL CHEM, V271, P31556, DOI 10.1074/jbc.271.49.31556; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; JEZEQUELCUER M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P252, DOI 10.1016/0304-4165(93)90107-J; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P251, DOI 10.1007/BF00731137; JOHNSON PH, 1985, BIOCHEM SOC T, V13, P1119, DOI 10.1042/bst0131119; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEPPANEN A, 1991, BIOCHEMISTRY-US, V30, P9287, DOI 10.1021/bi00102a022; LEY K, 1995, J IMMUNOL, V155, P525; LOWE JB, 1991, J BIOL CHEM, V266, P17467; Maaheimo H, 1997, CARBOHYD RES, V297, P145, DOI 10.1016/S0008-6215(96)00259-5; MAAHEIMO H, 1995, EUR J BIOCHEM, V234, P616, DOI 10.1111/j.1432-1033.1995.616_b.x; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NIEMELA R, 1995, GLYCOCONJUGATE J, V12, P36, DOI 10.1007/BF00731866; Niemela R, 1995, CARBOHYD RES, V279, P331, DOI 10.1016/0008-6215(95)00299-5; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; RABINA J, 1998, IN PRESS CARBOHYDR R; RENKONEN O, 1989, GLYCOCONJUGATE J, V6, P129, DOI 10.1007/BF01047895; RENKONEN O, 1990, BIOCHEM CELL BIOL, V68, P1032, DOI 10.1139/o90-152; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SASAKI K, 1994, J BIOL CHEM, V269, P14730; Seppo A, 1996, GLYCOBIOLOGY, V6, P65, DOI 10.1093/glycob/6.1.65; SEPPO A, 1990, BIOCHEM CELL BIOL, V68, P44, DOI 10.1139/o90-006; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WATKINS WM, 1995, ADV EXP MED BIOL, V376, P83; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732	48	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4021	4026		10.1074/jbc.273.7.4021	http://dx.doi.org/10.1074/jbc.273.7.4021			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461592	hybrid			2022-12-27	WOS:000072048400034
J	Ohkuma, M; Zimmer, T; Iida, T; Schunck, WH; Ohta, A; Takagi, M				Ohkuma, M; Zimmer, T; Iida, T; Schunck, WH; Ohta, A; Takagi, M			Isozyme function of n-alkane-inducible cytochromes P450 in Candida maltosa revealed by sequential gene disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-VECTOR SYSTEM; MULTIGENE FAMILY; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CYP52; IDENTIFICATION; TROPICALIS; YEAST; PURIFICATION; CONSTRUCTION	An n-alkane-assimilating yeast Candida maltosa contains multiple n-alkane-inducible forms of cytochromes P450 (P450alk), which can be assumed to catalyze terminal hydroxylation of n-alkanes in the assimilation pathway. Eight structurally related P450alk genes have been identified, In the present study, the function off four major isoforms of P450alk (encoded by ALK1, ALK2, ALK3, and ALK5 genes) was investigated by sequential gene disruption. Auxotrophic markers used for the selection of disrupted strains were regenerated repeatedly through either mitotic recombination between heterozygous alleles of the diploid genome or directed deletion of the marker gene, to allow sequential gene disruptions within a single strain, The strain depleted of all four isoforms could not utilize n-alkanes for growth, providing direct evidence that P450alk is essential for n-alkane assimilation, Growth properties of a series of intermediate disrupted strains, plasmid-based complementation, and enzyme assays after heterologous expression of single isoforms revealed (i) that each of the four individual isoforms is alone sufficient to allow growth on long chain n-alkane; (ii) that the ALK1-encoding isoform is the mesh; versatile and efficient P450alk form, considering both its enzymatic activity and its ability to confer growth on n-alkanes of different chain length; and (iii) that the ALK5-encoding isoform exhibits a rather narrow substrate specificity and thus cannot support the utilization of short chain n-alkanes.	Univ Tokyo, Lab Cellular Genet, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	University of Tokyo; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Takagi, M (corresponding author), Univ Tokyo, Lab Cellular Genet, Dept Biotechnol, Bunkyo Ku, Tokyo 113, Japan.		Iida, Toshiya/D-2804-2017; Ohkuma, Moriya/A-8100-2011					HIKIJI T, 1989, CURR GENET, V16, P261, DOI 10.1007/BF00422112; HONECK H, 1982, BIOCHEM BIOPH RES CO, V106, P1318, DOI 10.1016/0006-291X(82)91257-8; KAWAI S, 1991, AGR BIOL CHEM TOKYO, V55, P59, DOI 10.1080/00021369.1991.10870559; KELLY R, 1987, MOL CELL BIOL, V7, P199, DOI 10.1128/MCB.7.1.199; KELLY R, 1988, MOL GEN GENET, V214, P24, DOI 10.1007/BF00340174; Masuda Y, 1995, GENE, V167, P157, DOI 10.1016/0378-1119(95)00655-9; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OHKUMA M, 1995, DNA CELL BIOL, V14, P163, DOI 10.1089/dna.1995.14.163; OHKUMA M, 1991, DNA CELL BIOL, V10, P271, DOI 10.1089/dna.1991.10.271; OHKUMA M, 1995, BIOSCI BIOTECH BIOCH, V59, P1328, DOI 10.1271/bbb.59.1328; OHKUMA M, 1993, CURR GENET, V23, P205, DOI 10.1007/BF00351497; OHKUMA M, 1991, AGR BIOL CHEM TOKYO, V55, P1757, DOI 10.1080/00021369.1991.10870878; Ohkuma M, 1995, MOL GEN GENET, V249, P447, DOI 10.1007/BF00287107; PICATAGGIO S, 1992, BIO-TECHNOL, V10, P894, DOI 10.1038/nbt0892-894; PICATAGGIO S, 1991, MOL CELL BIOL, V11, P4333, DOI 10.1128/MCB.11.9.4333; Scheller U, 1996, ARCH BIOCHEM BIOPHYS, V328, P245, DOI 10.1006/abbi.1996.0170; SCHUNCK WH, 1989, BIOCHEM BIOPH RES CO, V161, P843, DOI 10.1016/0006-291X(89)92677-6; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; SCHUNCK WH, 1987, ARCH MICROBIOL, V147, P240, DOI 10.1007/BF00463482; SEGHEZZI W, 1992, DNA CELL BIOL, V11, P767, DOI 10.1089/dna.1992.11.767; TAKAGI M, 1989, AGR BIOL CHEM TOKYO, V53, P2217, DOI 10.1080/00021369.1989.10869646; TAKAGI M, 1986, J BACTERIOL, V167, P551, DOI 10.1128/jb.167.2.551-555.1986; Zimmer T, 1996, BIOCHEM BIOPH RES CO, V224, P784, DOI 10.1006/bbrc.1996.1100; ZIMMER T, 1995, DNA CELL BIOL, V14, P619, DOI 10.1089/dna.1995.14.619	24	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3948	3953		10.1074/jbc.273.7.3948	http://dx.doi.org/10.1074/jbc.273.7.3948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461581	hybrid			2022-12-27	WOS:000072048400023
J	Matsuyama, S; Ueda, T; Crain, PF; McCloskey, JA; Watanabe, K				Matsuyama, S; Ueda, T; Crain, PF; McCloskey, JA; Watanabe, K			A novel wobble rule found in starfish mitochondria - Presence of 7-methylguanosine at the anticodon wobble position expands decoding capability of tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-CODE; TRANSFER-RNA; NUCLEOTIDE-SEQUENCE; MODIFIED NUCLEOSIDES; MASS-SPECTROMETRY; ASCARIS-SUUM; ORGANIZATION; DNA; EVOLUTION; GENOME	In the starfish mitochondrial (mt) genome, codons AGA and AGG (in addition to AGU and AGC) have been considered to be translated as serine. There is, however, only a single candidate mt tRNA gene responsible for translating these codons and it has a GCT anticodon sequence, but guanosine at the first position of the anticodon should base pair only with pyrimidines according to the conventional wobble rule. To solve this enigma, the mt tRNA(GCU)(ser) was purified, and sequence determination in combination with electrospray Liquid chromatography/mass spectrometry revealed that 7-methylguanosine is located at the first position of the anticodon. This is the first case in which a tRNA has been found to have 7-methylguanosine at the wobble position. It is suggested that methylation at N-7 of wobbling guanosine endows the tRNA with the capability of forming base pairs with all four nucleotides, A, U, G, and C, and expands the repertoire of codon-anticodon interaction. This finding indicates that a nonuniversal genetic code in starfish has been generated by base modification in the tRNA anticodon.	Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 113, Japan; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA	University of Tokyo; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.		Ueda, Takuya/K-5217-2014	Ueda, Takuya/0000-0002-7760-8271	NIGMS NIH HHS [GM29812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ASAKAWA S, 1995, GENETICS, V140, P1047; BANKS JF, 1994, ANAL CHEM, V66, P406, DOI 10.1021/ac00075a015; BARRELL BG, 1980, P NATL ACAD SCI-BIOL, V77, P3164, DOI 10.1073/pnas.77.6.3164; CANTATORE P, 1989, J BIOL CHEM, V264, P10965; CLARY DO, 1985, J MOL EVOL, V22, P252, DOI 10.1007/BF02099755; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DEBRUIJN MHL, 1983, NATURE, V304, P234, DOI 10.1038/304234a0; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; HIMENO H, 1987, GENE, V56, P219; JACOBS HT, 1988, J MOL BIOL, V202, P185, DOI 10.1016/0022-2836(88)90452-4; KEITH G, 1995, BIOCHIMIE, V77, P142, DOI 10.1016/0300-9084(96)88118-1; KONDO A, 1996, NUCL ACIDS S SER, V35, P279; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; MARTIN RP, 1990, BIOCHEMISTRY-US, V29, P956, DOI 10.1021/bi00456a016; MORIYA J, 1994, BIOCHEMISTRY-US, V33, P2234, DOI 10.1021/bi00174a033; OKIMOTO R, 1992, GENETICS, V130, P471; OSAWA S, 1989, J MOL EVOL, V29, P202, DOI 10.1007/BF02100203; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; Osawa S., 1995, EVOLUTION GENETIC CO; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; Suzuki T, 1996, FEBS LETT, V381, P195, DOI 10.1016/0014-5793(96)00107-X; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P345; Watanabe Kimitsuna, 1995, P225; WATANABE YI, 1994, J BIOL CHEM, V269, P22902; WINTERMEYER W, 1970, FEBS LETT, V11, P160, DOI 10.1016/0014-5793(70)80518-X; WOLSTENHOLME DR, 1985, GENETICS, V109, P725; YOKOBORI S, 1993, J MOL EVOL, V36, P1, DOI 10.1007/BF02407301	31	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3363	3368		10.1074/jbc.273.6.3363	http://dx.doi.org/10.1074/jbc.273.6.3363			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452455	hybrid			2022-12-27	WOS:000071822300040
J	Medema, JP; Scaffidi, C; Krammer, PH; Peter, ME				Medema, JP; Scaffidi, C; Krammer, PH; Peter, ME			Bcl-x(L) acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; APOPTOTIC CELL-DEATH; PROTEASE; BCL-2; FAS; FAS/APO-1; RECEPTOR; INVOLVEMENT; INTERACTS; DOMAIN	The Bcl-2 family member Bcl-x(L) has often been correlated with apoptosis resistance, We have shown recently that in peripheral human T cells resistance to CD95-mediated apoptosis is characterized by a lack of caspase-8 recruitment to the CD95 death-inducing sig naling complex (DISC) and by increased expression of Bcl-x(L) (Peter, M. E., Kischkel, F. C., Scheuerpflug, C. G., Medema, J. P., Debatin, K.-M., and Krammer, P. H. (1997) Eur. J. Immunol. 27, 1207-1212), This raises the possibility that Bcl-x(L) directly prevents caspase-8 activation by the DISC, To test this hypothesis a cell line in which CD95 signaling was inhibited by overexpression of Bcl-x(L) was used, In these MCF7-Fas-bcl-x(L) cells Bcl-x(L) had no effect on the recruitment of caspase-8 to the DISC, It did not affect the activity of the DISC nor the generation of the caspase-8 active subunits p18 and p10, In contrast, cleavage of a typical substrate for caspase-3-like proteases, poly(ADP-ribose) polymerase, was inhibited in comparison with the control-transfected CD95-sensitive MCF7-Fas cells, To test whether Bcl-x(L) would inhibit active caspase-8 subunits in the cytoplasm, a number of immunoprecipitation experiments were performed, Using monoclonal antibodies directed against different domains of caspase-8, anti-Bcl-x(L) antibodies, or fusion proteins of glutathione S-transferase with different domains of caspase-8, no evidence for a direct or indirect physical interaction between caspase-8 and Bcl-x(L) was found, Moreover, overexpression of Bcl-x(L) did not inhibit the activity of the caspase-8 active subunits p18/p10, Therefore, in this cell line that has become resistant to CD95-induced apoptosis due to overexpression of Bcl-x(L), Bcl-x(L) acts independently and downstream of caspase-8.	German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Peter, ME (corresponding author), German Canc Res Ctr, Tumor Immunol Program, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.peter@dkfz-heidelberg.de	Watzl, Carsten/B-4911-2013	Watzl, Carsten/0000-0001-5195-0995; Peter, Marcus Ernst/0000-0003-3216-036X; Medema, Jan Paul/0000-0003-3045-2924				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bauer MKA, 1997, FEBS LETT, V402, P256, DOI 10.1016/S0014-5793(96)01497-4; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Estoppey S, 1997, CELL DEATH DIFFER, V4, P34, DOI 10.1038/sj.cdd.4400205; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MENON SD, 1995, J BIOL CHEM, V270, P18881; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; PETER ME, 1995, CELL DEATH DIFFER, V2, P163; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V12, P2251; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	40	100	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3388	3393		10.1074/jbc.273.6.3388	http://dx.doi.org/10.1074/jbc.273.6.3388			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452459	hybrid			2022-12-27	WOS:000071822300044
J	Su, TZ; Wang, MH; Syu, LJ; Saltiel, AR; Oxender, DL				Su, TZ; Wang, MH; Syu, LJ; Saltiel, AR; Oxender, DL			Regulation of system A amino acid transport in 3T3-L1 adipocytes by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; SELECTIVE INHIBITOR WORTMANNIN; STIMULATED GLUCOSE-TRANSPORT; HAMSTER OVARY CELLS; PHOSPHOINOSITIDE 3-KINASE; GLYCOGEN-SYNTHASE; GLUT4 TRANSLOCATION; SIGNALING PATHWAYS; GENE-EXPRESSION	The insulin-stimulated uptake of 2-(methylamino) isobutyric acid (MeAIB), a nonmetabolizable substrate for system A, in 3T3-L1 adipocytes was investigated. As cells took on a more adipogenic phenotype, the insulin-stimulated versus the saturable basal MeAIB uptake increased by 5-fold. The induced transport activity showed properties characteristic of system A, with a K-m value of 190 mu M. The half-life of the induced system A activity was independent of de novo mRNA and protein synthesis and was not accelerated by ambient amino acids, therefore, it was mechanistically distinct from the previously described adaptive and hormonal regulation of system A. Inhibition of mitogen-activated protein kinase kinase by PD98059, Ras farnesylation by PD152440 and B581, p70(S6K) by rapamycin, and phosphatidylinositol 3-kinase (PI 3'-K) by wortmannin and LY294002 revealed that only wortmannin and LY294002 inhibited the insulin-induced MeAIB uptake with IC50 values close to that previously reported for inhibition of PI 3'-K. These results suggest that the Ras/mitogen-activated protein kinase and pp70(S6K) insulin signaling pathways are neither required nor sufficient for insulin stimulation of MeAIB uptake, and activation of PI 3'-K or a wortmanninn/LY294002-sensitive pathway may play an important role in regulation of system A transport by insulin in 3T3-L1 cells.	Parke Davis Pharmaceut Res Div, Dept Mol Biol, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA	Pfizer; Pfizer	Su, TZ (corresponding author), Parke Davis Pharmaceut Res Div, Dept Mol Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; BRACY DS, 1986, J BIOL CHEM, V261, P1514; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; COLLARINI EJ, 1987, ANNU REV NUTR, V7, P75, DOI 10.1146/annurev.nu.07.070187.000451; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GRUNFELD C, 1983, ENDOCRINOLOGY, V113, P1763, DOI 10.1210/endo-113-5-1763; HANDLOGTEN ME, 1984, J BIOL CHEM, V259, P3519; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Ho LKF, 1997, BIOCHEM BIOPH RES CO, V235, P130, DOI 10.1006/bbrc.1997.6747; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JONES M, 1994, P NATL ACAD SCI USA, V91, P858, DOI 10.1073/pnas.91.3.858; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KILBERG MS, 1985, CURR TOP CELL REGUL, V25, P133; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MARSHALL S, 1989, J BIOL CHEM, V264, P2037; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; MOFFETT J, 1987, P NATL ACAD SCI USA, V84, P8040, DOI 10.1073/pnas.84.22.8040; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Obata T, 1996, CIRC RES, V79, P1167, DOI 10.1161/01.RES.79.6.1167; OKADA T, 1994, J BIOL CHEM, V269, P3568; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; RUIZMONTASELL B, 1994, P NATL ACAD SCI USA, V91, P9569, DOI 10.1073/pnas.91.20.9569; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Su TZ, 1997, BRAIN RES, V757, P69, DOI 10.1016/S0006-8993(97)00139-X; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TADROS LB, 1993, AM J PHYSIOL, V265, pE135, DOI 10.1152/ajpendo.1993.265.1.E135; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729	58	26	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3173	3179		10.1074/jbc.273.6.3173	http://dx.doi.org/10.1074/jbc.273.6.3173			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452428	hybrid			2022-12-27	WOS:000071822300013
J	Toke, DA; Bennett, WL; Dillon, DA; Wu, WI; Chen, XM; Ostrander, DB; Oshiro, J; Cremesti, A; Voelker, DR; Fischl, AS; Carman, GM				Toke, DA; Bennett, WL; Dillon, DA; Wu, WI; Chen, XM; Ostrander, DB; Oshiro, J; Cremesti, A; Voelker, DR; Fischl, AS; Carman, GM			Isolation and characterization of the Saccharomyces cerevisiae DPP1 gene encoding diacylglycerol pyrophosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLSERINE DECARBOXYLASE; POLYVINYLIDENE DIFLUORIDE; INOSITOL LIPIDS; SHUTTLE VECTORS; NULL ALLELE; YEAST; PROTEIN	Diacylglycerol pyrophosphate (DGPP) is involved in a putative novel lipid signaling pathway, DGPP phosphatase (DGPP phosphohydrolase) is a membrane-associated 34-kDa enzyme from Saccharomyces cerevisiae which catalyzes the dephosphorylation of DGPP to yield phosphatidate (PA) and then catalyzes the dephosphorylation of PA to yield diacylglycerol, Amino acid sequence information derived from DGPP phosphatase was used to identify and isolate the DPP1 (diacylglycerol pyrophosphate phosphatase) gene encoding the enzyme. Multicopy plasmids containing the DPP1 gene directed a 10-fold overexpression of DGPP phosphatase activity in S. cerevisiae. The heterologous expression of the S. cerevisiae DPP1 gene in Sf-9 insect cells resulted in a 500-fold overexpression of DGPP phosphatase activity over that expressed in wild-type S. cerevisiae. DGPP phosphatase possesses a Mg2+-independent PA phosphatase activity, and its expression correlated with the overexpression of DGPP phosphatase activity in S. cerevisiae and in insect cells. DGPP phosphatase was predicted to be an integral membrane protein with six transmembrane-spanning domains. The enzyme contains a novel phosphatase sequence motif found in a superfamily of phosphatases. A dpp1 Delta mutant was constructed by deletion of the chromosomal copy of the DPP1 gene. The dpp1 Delta mutant was viable and did not exhibit any obvious growth defects. The mutant was devoid of DGPP phosphatase activity and accumulated (4-fold) DGPP. Analysis of the mutant showed that the DPP1 gene was not responsible for all of the Mg2+-independent PA phosphatase activity in S. cerevisiae.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08903 USA; Natl Jewish Ctr Immunol & Resp Med, Lord & Taylor Lab Lung Biochem, Denver, CO 80206 USA; Natl Jewish Ctr Immunol & Resp Med, Anna Perahia Adatto Clin Res Ctr, Denver, CO 80206 USA; Univ Rhode Isl, Dept Food Sci & Nutr, W Kingston, RI 02892 USA	Rutgers State University New Brunswick; National Jewish Health; National Jewish Health; University of Rhode Island	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08903 USA.	carman@aesop.rutgers.edu	Oshiro, June/ACF-4163-2022	Oshiro, June/0000-0003-1134-5023; Bennett, Wendy/0000-0001-9828-0706	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453, R29GM049214] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-32453, GM-49214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CULBERTSON MR, 1975, GENETICS, V80, P23; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; EXTON JH, 1990, J BIOL CHEM, V265, P1; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HANSON BA, 1980, J LIPID RES, V21, P309; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Innis MA, 1990, PCR PROTOCOLS GUIDE, P1, DOI [10.1016/0167-7799(90)90215-J, DOI 10.1016/0167-7799(90)90215-J]; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LIN YP, 1989, J BIOL CHEM, V264, P8641; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MICHELL RH, 1992, TRENDS BIOCHEM SCI, V17, P274, DOI 10.1016/0968-0004(92)90433-A; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Reilly D., 1992, BACULOVIRUS EXPRESSI, P109; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Riedel B, 1997, PLANT SCI, V128, P1, DOI 10.1016/S0168-9452(97)00120-9; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Stukey J, 1997, PROTEIN SCI, V6, P469; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	57	100	107	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3278	3284		10.1074/jbc.273.6.3278	http://dx.doi.org/10.1074/jbc.273.6.3278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452443	Green Published, hybrid			2022-12-27	WOS:000071822300028
J	Fushman, D; Najmabadi-Haske, T; Cahill, S; Zheng, J; LeVine, H; Cowburn, D				Fushman, D; Najmabadi-Haske, T; Cahill, S; Zheng, J; LeVine, H; Cowburn, D			The solution structure and dynamics of the pleckstrin homology domain of G protein-coupled receptor kinase 2 (beta-adrenergic receptor kinase 1) - A binding partner of G(beta gamma) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; HIGH-AFFINITY BINDING; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; NMR-SPECTROSCOPY; GAMMA-SUBUNITS; PH DOMAIN; INOSITOL PHOSPHATES; CRYSTAL-STRUCTURE; TYROSINE KINASE; PTB DOMAIN	The solution structure of an extended pleckstrin homology (PII) domain from the beta-adrenergic receptor kinase is obtained by high resolution NMR. The structure establishes that the beta-adrenergic receptor kinase extended PH domain has the same fold and topology as other PH domains, and there are several unique features, most notably an extended C terminal alpha-helix that behaves as a molten helix, and a surface charge polarity that is extensively modified by positive residues in the extended alpha-helix and the C terminus. These observations complement biochemical evidence that the C-terminal portion of this PH domain participates in protein-protein interactions with G(beta gamma) subunits. This suggests that the C-terminal segment of the PH domain may function to mediate protein-protein interactions with the targets of PH domains.	Rockefeller Univ, Lab Phys Biochem, New York, NY 10021 USA; Warner Lambert Parke Davis, Parke Davis Labs, Ann Arbor, MI 48105 USA	Rockefeller University; Pfizer	Cowburn, D (corresponding author), Rockefeller Univ, Lab Phys Biochem, 1230 York Ave, New York, NY 10021 USA.		Cowburn, David/A-8448-2008; Najmabadi, Hossein/P-8182-2017	Cowburn, David/0000-0001-6770-7172; Zheng, Jie/0000-0001-6524-6800	NCRR NIH HHS [RR-00862] Funding Source: Medline; NIGMS NIH HHS [GM-47021] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTOSIEWICZ J, 1995, BIOPHYS J, V69, P1344, DOI 10.1016/S0006-3495(95)80001-9; BARLOW DJ, 1986, BIOPOLYMERS, V25, P1717, DOI 10.1002/bip.360250913; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Chuang TT, 1997, EUR J BIOCHEM, V245, P533, DOI 10.1111/j.1432-1033.1997.00533.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COWBURN D, 1996, SIGNAL TRANSDUCTION, P127; DALVIT C, 1995, J BIOMOL NMR, V5, P306, DOI 10.1007/BF00211757; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Guentert P., 1997, Journal of Molecular Biology, V273, P283; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MORELLI MAC, 1995, FEBS LETT, V358, P193, DOI 10.1016/0014-5793(94)01422-W; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SOMAN KV, 1991, BIOPOLYMERS, V31, P1351, DOI 10.1002/bip.360311202; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHANG P, 1995, STRUCTURE, V3, P1185, DOI 10.1016/S0969-2126(01)00254-4; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zhou MM, 1995, PROG BIOPHYS MOL BIO, V64, P221, DOI 10.1016/S0079-6107(96)00005-3	58	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2835	2843		10.1074/jbc.273.5.2835	http://dx.doi.org/10.1074/jbc.273.5.2835			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446593	hybrid			2022-12-27	WOS:000071736600048
J	Kay, RR				Kay, RR			The biosynthesis of differentiation-inducing factor, a chlorinated signal molecule regulating Dictyostelium development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STALK CELL-DIFFERENTIATION; SLIME-MOLD DICTYOSTELIUM; FATTY-ACID SYNTHASES; AFLATOXIN BIOSYNTHESIS; O-METHYLTRANSFERASES; ESCHERICHIA-COLI; DISCOIDEUM; MORPHOGEN; DIF; ENZYME	Differentiation-inducing factor (DIF)-1 is a chlorinated alkyl phenone released by developing Dictyostelium amoebae, which induces them to differentiate into stalk cells, A biosynthetic pathway for DIF-1 is proposed from labeling, inhibitor, and enzymological experiments, Cells incorporate Cl-36(-) into DIF-1 during development, showing that the chlorine atoms originate from chloride ions; peak incorporation is at the first finger stage, DIF-1 synthesis can be blocked by cerulenin, a polyketide synthase inhibitor, suggesting that it is made from a polyketide, This is most likely the C-12 polyketide (2,4,6-trihydroxyphenyl)-1-hexan-1-one (THPH). Feeding experiments confirm that living cells can convert THPH to DIF-1, Conversion requires both chlorination and methylation of THPH, and enzymatic activities able to do this exist in cell lysates, The chlorinating activity, assayed using Cl-36(-), is stimulated by H2O2 and requires both soluble and particulate components, It is specific for THPH and does not use this compound after O-methylation. The methyltransferase is soluble, uses S-adenosyl-L-methionine as a co-substrate, has a K-m for dichloro-THPH of about 1.1 mu M, and strongly prefers this substrate to close analogues, Both chlorinating and methyltransferase activities increase in development in parallel with DIF-1 production, and both are greatly reduced in a mutant strain that makes little DIF-1, It is proposed that DIF-1 is made by the initial assembly of a C-12 polyketide skeleton, which is then chlorinated and methylated.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Kay, RR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Kay, Robert R/0000-0001-9836-7967				BERKS M, 1990, DEVELOPMENT, V110, P977; BIRCH AJ, 1967, SCIENCE, V156, P202, DOI 10.1126/science.156.3772.202; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROOKMAN JJ, 1982, DEV BIOL, V91, P191, DOI 10.1016/0012-1606(82)90022-7; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; Brown DW, 1996, P NATL ACAD SCI USA, V93, P14873, DOI 10.1073/pnas.93.25.14873; CHANCE K, 1976, J BACTERIOL, V128, P21, DOI 10.1128/JB.128.1.21-27.1976; CHEN YP, 1991, J BIOL CHEM, V266, P23909; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EARLY AE, 1988, DEVELOPMENT, V103, P519; GUITTON MC, 1988, CELL DIFFER DEV, V22, P203, DOI 10.1016/0045-6039(88)90012-7; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; INOKOSHI J, 1994, MOL GEN GENET, V244, P90, DOI 10.1007/BF00280191; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; INSALL R, 1992, EMBO J, V11, P2849, DOI 10.1002/j.1460-2075.1992.tb05352.x; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KAY RR, 1987, METHOD CELL BIOL, V28, P433; KAY RR, 1992, BIOCHEM J, V281, P155, DOI 10.1042/bj2810155; KAY RR, 1983, EUR J BIOCHEM, V136, P51, DOI 10.1111/j.1432-1033.1983.tb07703.x; KAY RR, 1989, DEVELOPMENT, V107, P81; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KHOURI HE, 1988, ARCH BIOCHEM BIOPHYS, V262, P592, DOI 10.1016/0003-9861(88)90410-9; KOPACHIK W, 1983, CELL, V33, P397, DOI 10.1016/0092-8674(83)90421-X; KREUZMAN AJ, 1988, J BIOL CHEM, V263, P15626; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; MADIGAN SJ, 1989, J BACTERIOL, V171, P1492, DOI 10.1128/jb.171.3.1492-1495.1989; Mahanti N, 1996, APPL ENVIRON MICROB, V62, P191, DOI 10.1128/AEM.62.1.191-195.1996; MARTIN JF, 1975, BIOCHIM BIOPHYS ACTA, V411, P186, DOI 10.1016/0304-4165(75)90298-6; MASENTO MS, 1988, BIOCHEM J, V256, P23, DOI 10.1042/bj2560023; MASENTO MS, 1987, THESIS U LONDON LOND; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; MORANDINI P, 1995, BIOCHEM J, V306, P735, DOI 10.1042/bj3060735; MORRIS DR, 1966, J BIOL CHEM, V241, P1763; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; NAYLER O, 1992, EUR J BIOCHEM, V208, P531, DOI 10.1111/j.1432-1033.1992.tb17217.x; Neidleman S.L., 1986, BIOHALOGENATION PRIN; OHagan D., 1991, POLYKETIDE METABOLIT; OHNO H, 1975, J BIOCHEM-TOKYO, V78, P1149, DOI 10.1093/oxfordjournals.jbchem.a131010; Omura S, 1981, Methods Enzymol, V72, P520; ROBERTS G, 1983, FEBS LETT, V159, P13, DOI 10.1016/0014-5793(83)80407-4; Schaap P, 1996, DIFFERENTIATION, V60, P1, DOI 10.1046/j.1432-0436.1996.6010001.x; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; SOBOLEWSKI A, 1983, DIFFERENTIATION, V25, P93; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; TRAYNOR D, 1991, J BIOL CHEM, V266, P5291; VANWAARDE A, 1985, BIOCHIM BIOPHYS ACTA, V836, P27, DOI 10.1016/0005-2760(85)90216-4; WANG M, 1989, DEVELOPMENT, V105, P569; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEISS U, 1980, BIOSYNTHESIS AROMATI; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; YABE K, 1989, APPL ENVIRON MICROB, V55, P2172, DOI 10.1128/AEM.55.9.2172-2177.1989	54	53	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2669	2675		10.1074/jbc.273.5.2669	http://dx.doi.org/10.1074/jbc.273.5.2669			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446571	hybrid			2022-12-27	WOS:000071736600026
J	Fagerstrom, S; Pahlman, S; Nanberg, E				Fagerstrom, S; Pahlman, S; Nanberg, E			Protein kinase C-dependent tyrosine phosphorylation of p130(cas) in differentiating neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HUMAN NEURO-BLASTOMA; NERVE GROWTH-FACTOR; 38 KDA PROTEIN; V-SRC; SIGNAL-TRANSDUCTION; SH3 DOMAINS; 3T3 CELLS; PTP-PEST; CONES	The cell signaling docking protein p130(cas) became tyrosine-phosphorylated in SH-SY5Y human neuroblastoma cells during induced differentiation with 12-O-tetradecanoylphorbol-13-acetate (TPA) and serum or a combination of basic fibroblast growth factor (bFGF) and insulin-like growth factor-I (IGF-I). The differentiating cells develop a neuronal phenotype with neurites and growth cones and sustained activation of protein kinase C (PKC) and pp60(c-src). The TPA-induced p130(cas) phosphorylation increased within 5 min of stimulation and persisted for at least 4 days, whereas bFGF/IGF-I-induced p130(cas) phosphorylation was biphasic, However, the increase in tyrosine phosphorylation of p130(cas) was not restricted to differentiation inducing stimuli. The phosphorylation was blocked by the specific PKC inhibitor GF 109203X, and transient transfection with active PKC-epsilon induced p130(cas) tyrosine phosphorylation, pp60(c-src), known to directly phosphorylate p130(cas) in other cell systems, was not activated after stimulation with TPA or bFGF/IGF-I for up to 30 min, and the initial p130(cas) phosphorylation was resistant to the Src family kinase inhibitor herbimycin A. However, in long term stimulated cells, herbimycin A blocked the induced phosphorylation of p130(cas), Also, overexpression of src induced phosphorylation of p130(cas). p130(cas) protein and phosphorylated p130(cas) were present in growth cones isolated from differentiated SH-SY5Y cells. Inhibition of PKC activity in differentiating cells with GF 109203X leads to a rapid retraction of growth cone filopodia, and p130(cas) phosphorylation decreased transiently (within minutes), Growth cones isolated from these cells were virtually devoid of phosphorylated p130(cas). These data suggest a function for p130(cas) as a PKC downstream target in SH-SY5Y cells and possibly also in their growth cones.	Lund Univ, Hosp MAS, Dept Lab Med, Wallenberg Lab, S-20502 Malmo, Sweden; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden	Lund University; Uppsala University; Uppsala University Hospital	Pahlman, S (corresponding author), Lund Univ, Hosp MAS, Dept Lab Med, Wallenberg Lab, S-20502 Malmo, Sweden.	Sven.Pahlman@medforsk.mas.lu.se						AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnham MR, 1996, ONCOGENE, V12, P2467; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HABIB T, 1994, J BIOL CHEM, V269, P25243; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HELMKE S, 1995, CELL MOTIL CYTOSKEL, V30, P194, DOI 10.1002/cm.970300304; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Keegan K, 1993, Curr Opin Neurobiol, V3, P14, DOI 10.1016/0959-4388(93)90029-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; MARONEY AC, 1995, J NEUROCHEM, V64, P540; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MEYERSON G, 1993, FEBS LETT, V332, P27, DOI 10.1016/0014-5793(93)80475-A; MEYERSON G, 1992, J CELL SCI, V103, P233; MOGI A, 1995, FEBS LETT, V373, P135, DOI 10.1016/0014-5793(95)01014-6; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PAHLMAN S, 1983, CELL DIFFER DEV, V12, P165, DOI 10.1016/0045-6039(83)90006-4; PARROW V, 1995, J NEUROSCI RES, V41, P782, DOI 10.1002/jnr.490410609; PARROW V, 1992, J CELL PHYSIOL, V152, P536, DOI 10.1002/jcp.1041520313; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RUUSALA AI, 1985, DEV BRAIN RES, V18, P27, DOI 10.1016/0165-3806(85)90247-0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259	51	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2336	2343		10.1074/jbc.273.4.2336	http://dx.doi.org/10.1074/jbc.273.4.2336			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442079	hybrid			2022-12-27	WOS:000071595200068
J	Donato, NJ; Perez, M				Donato, NJ; Perez, M			Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; NUCLEOTIDE EXCISION-REPAIR; FAS-MEDIATED APOPTOSIS; KAPPA-B ACTIVATION; CARCINOMA-CELLS; POLY(ADP-RIBOSE) POLYMERASE; SUPPRESSOR GENE; FACTOR-ALPHA; DEATH; PROTEIN	Tumor necrosis factor (TNF)-mediated apoptotic signaling has been characterized by activation of specific protease or protein kinase cascades that regulate the onset of apoptosis, TNF has also been shown to induce oxidative or genotoxic stress in some cell types, and apoptotic potential may be determined by the cellular response to this stress, To determine the role of genotoxic stress in TNF-mediated apoptosis, we examined cellular accumulation of p53 in TNF-treated ME-180 cells selected for apoptotic sensitivity (ME-180S) or resistance (ME-180R) to TNF, Although TNF was able to activate receptor-mediated signaling in either cell line, p53 accumulation was measurable only in apoptotically sensitive ME-180S cells. TNF-induced changes in p53 levels were detected Ih after treatment, and peak levels were measurable 4-8 h after TNF exposure. TNF was unable to induce p21WAF1 in either cell line but affected the stability of this protein in apoptotically responsive ME-180S cells, Evidence of p21WAF1 proteolysis was detected by monitoring the appearance of a 16-kDa immunoblottable p21WAF1 fragment, which became detectable 4 h after TNF addition and increased in content before the onset of DNA fragmentation (16-24 h), The kinetics of p21WAF1 proteolysis closely paralleled those of poly(ADP-ribose) polymerase, suggesting cleavage of p21WAF1. by activation of an apoptotic protease, Pretreatment of ME-180S cells with the apoptotic protease inhibitor YVAD blocked TNF-induced apoptosis and prevented both poly(ADP-ribose) polymerase and p21WAF1 degradation but did not affect p53 induction. These results provide evidence for the early onset of genotoxic stress in cells committed to TNF-mediated apoptosis and for divergence in propagation of this signal in non-responsive cells. In addition, TNF-induced p21WAF1 proteolysis may be mediated by an apoptotic protease and may contribute to the apoptotic process by disrupting p53 signaling, altering cell cycle inhibition, and limiting cellular recovery from genotoxic stress.	Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy & Drug Carriers, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Donato, NJ (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy & Drug Carriers, Box 44,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA48906, CA73018] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073018, R29CA048906, R01CA048906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1990, ONCOGENE, V5, P893; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BELLOMO G, 1992, CANCER RES, V52, P1342; BELLUCCO T, 1995, INTERNET WORLD, V6, P8; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CLARK HM, 1992, J PATHOL, V166, P129, DOI 10.1002/path.1711660208; DARZYNKIEWICZ Z, 1984, CANCER RES, V44, P83; DONATO NJ, 1993, CELL GROWTH DIFFER, V4, P411; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOLSTEIN M, 1991, SCIENCE, V253, P49; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1993, J BIOL CHEM, V268, P10932; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; MCDONNELL TJ, 1995, SEMIN CANCER BIOL, V6, P53, DOI 10.1006/scbi.1995.0007; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NISHIKAWA K, 1994, LYMPHOKINE CYTOK RES, V13, P37; NISHIKAWA K, 1992, CANCER RES, V52, P4758; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Perez M, 1996, J INTERF CYTOK RES, V16, P307, DOI 10.1089/jir.1996.16.307; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; Shih SC, 1996, CANCER RES, V56, P1591; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Stoian I, 1996, BIOCHEM MOL MED, V59, P93, DOI 10.1006/bmme.1996.0072; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang W, 1995, CLIN CANCER RES, V1, P1051; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	57	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					5067	5072		10.1074/jbc.273.9.5067	http://dx.doi.org/10.1074/jbc.273.9.5067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478957	hybrid			2022-12-27	WOS:000072310400041
J	Pummill, PE; Achyuthan, AM; DeAngelis, PL				Pummill, PE; Achyuthan, AM; DeAngelis, PL			Enzymological characterization of recombinant Xenopus DG42, a vertebrate hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; STREPTOCOCCUS-PYOGENES; OLIGODENDROGLIOMA CELLS; SYNTHESIZE HYALURONAN; MOLECULAR-CLONING; GENE; SYNTHETASE; PROTEIN; ACID; IDENTIFICATION	We have characterized the hyaluronan (HA) synthase activity of the Xenopus DG42 gene product in vitro, The recombinant enzyme produced in yeast does not possess a nascent HA chain and, therefore, is an ideal model system for kinetic studies of the synthase's glycosyl transferase activity, The enzymatic rate was optimal from pH 7.6 to 8.1, Only the authentic sugar nucleotide precursors, UDP-glucuronic acid (UDP-GlcA) and UDP-N-acetylglucosamine (UDP-GlcNAc), were utilized to produce a large molecular weight polymer, UDP-glucose or the galactose epimers of the normal substrates did not substitute, The Michaelis constant, K-m, of recombinant DG42 in membranes was 60 +/- 20 and 235 +/- 40 mu M for UDP-GlcA and UDP-GlcNAc, respectively, which is comparable to values obtained previously from membranes derived from vertebrate cells, The apparent energy of activation for HA elongation is about 15 kilocalories/mol. DG42 polymerizes HA at average rates of about 80 to 110 monosaccharides/s in vitro, The resulting HA polysaccharide possessed molecular weights spanning 2 x 10(6)-10(7) Da, corresponding to about 10(4) sugar residues, This is the first report characterizing a defined eukaryotic enzyme that can produce a glycosaminoglycan.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.	Paul-DeAngelis@OUHSC.edu			NIGMS NIH HHS [R01-GM56497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPEL A, 1979, J BIOL CHEM, V254, P2199; ATKINSON EM, 1992, MOL PLANT MICROBE IN, V5, P439, DOI 10.1094/MPMI-5-439; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; DETERMAN HD, 1968, GEL CHROMATOGRAPHY; ISHIMOTO N, 1966, J BIOL CHEM, V241, P2052; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MALINOWSKI NM, 1995, BIOCHEM MOL BIOL INT, V35, P1123; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; NG KF, 1989, J BIOL CHEM, V264, P11776; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945	25	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4976	4981		10.1074/jbc.273.9.4976	http://dx.doi.org/10.1074/jbc.273.9.4976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478944	hybrid			2022-12-27	WOS:000072310400028
J	Gao, MX; Rychlik, W; Rhoads, RE				Gao, MX; Rychlik, W; Rhoads, RE			Cloning and characterization of human eIF4E genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; EUKARYOTIC PROTEIN-SYNTHESIS; CAP-BINDING-PROTEIN; SITE-DIRECTED MUTAGENESIS; RAT EMBRYO FIBROBLASTS; GLOBIN MESSENGER-RNA; TRANSLATION INITIATION; FACTOR EIF-4E; INCREASED EXPRESSION; ELEVATED LEVELS	Two human eukaryotic initiation factor 4E (eIF4E) genes were isolated and characterized from placental and chromosome 4-specific genomic libraries. One of the genes (EIF4E1) contained six introns, but the other gene (EIF4E2) was intronless, flanked by Alu sequences and 14-base pair (bp) direct repeats, and terminated by a short poly(A) stretch, all characteristics of retrotransposons, Numerous additional intronless eIF4E pseudogenes were found, but unlike EIF4E2, all contained premature in-frame stop codons. The entire EIF4E1 gene spanned >50 kilobase pahs, The coding regions of these two genes differed in four nucleotide residues, resulting in two amino acid differences in the predicted proteins, The promoter of EIF4E1 has been characterized previously. The putative promoter of EIF4E2 contained no TATA box but did contain a transcription initiator region (Inr) and numerous other sequence motifs characteristic of regulated promoters. EIF4E2 contained only tyro of the three polyadenylation signals present in EIF4E1. Evidence for transcription of both genes was obtained from primer extension, SI mapping, ribonuclease protection, and reverse transcriptase-polymerase chain reaction experiments, Transcription was found to initiate 19 bp upstream of the translational initiation codon in the case of EIF4E1 and 80 bp in the case of EIF4E2. The two genes were differentially expressed in four human cell lines, Wish, Chang, K562, and HeLa.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Rhoads, RE (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	rrhoad@lsumf.edu			PHS HHS [20818] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; BHANDARI B, 1991, J BIOL CHEM, V266, P7784; BOMMER UA, 1994, CELL MOL BIOL RES, V40, P633; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHOMCYNSKI P, 1991, CURRENT PROTOCOLS MO; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; EDERY I, 1983, J BIOL CHEM, V258, P1398; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GOSS DJ, 1990, BIOCHEMISTRY-US, V29, P5008, DOI 10.1021/bi00473a002; GRAFF JR, 1995, INT J CANCER, V60, P255; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; Hershey JWB, 1996, TRANSLATIONAL CONTRO; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; ISHIDA T, 1991, J CHEM SOC PERK T 1, P1847, DOI 10.1039/p19910001847; JARAMILLO M, 1991, J BIOL CHEM, V266, P10446; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; Methot N, 1996, MOL CELL BIOL, V16, P5328; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; PELLETIER J, 1991, GENOMICS, V10, P1079, DOI 10.1016/0888-7543(91)90203-Q; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Teraoka Y, 1996, BIOCHEM BIOPH RES CO, V228, P704, DOI 10.1006/bbrc.1996.1720; UEDA H, 1991, FEBS LETT, V280, P207, DOI 10.1016/0014-5793(91)80294-D	59	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4622	4628		10.1074/jbc.273.8.4622	http://dx.doi.org/10.1074/jbc.273.8.4622			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468520	hybrid			2022-12-27	WOS:000072115000048
J	Hryciw, DH; Rychkov, GY; Hughes, BP; Bretag, AH				Hryciw, DH; Rychkov, GY; Hughes, BP; Bretag, AH			Relevance of the D13 region to the function of the skeletal muscle chloride channel, ClC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT MYOTONIA-CONGENITA; MOLECULAR-BASIS; MUTATIONS; THOMSEN; GENE	Although hydropathy analysis of the skeletal muscle chloride channel protein, ClC-1, initially predicted 13 potential membrane spanning domains (D1 to D13), later topological studies have suggested that domain D4 is extracellular and that D13, conserved in all eukaryotic ClC channels, is located within the extensive cytoplasmic tail that makes up the carboxyl terminus of the protein, We have examined the effect of deleting D13 (Delta D13) and the function of the carboxyl tail by removing the final 72 (fs923X), 100 (fs895X), 125 (L869X), 398 (N596X), and 420 (Q574X) amino acids from rat ClC-1. Appropriate cDNA constructs were prepared and expressed using the baculovirus Sf9 insect cell system, Patch clamp analysis of chloride currents in Sf9 cells showed that only relatively insubstantial changes could be attributed to the expressed fs923X, fs895X, and Delta D13 mutants compared with wild type rat ClC-1, For N596X and Q574X, however, adequate mRNA could be detected, but neither patch clamp nor polyacrylamide gel electrophoresis showed corresponding protein production, By contrast, expression of L869X. was demonstrable by polyacrylamide gel electrophoresis, but no chloride conductance attributable to it could be detected, Overall, our results indicate that the domain D13 is dispensable, as are the final 100 amino adds, but not the final 125 amino acids or more, of the carboxyl tail. Some essential. region of unknown significance, therefore, appears to reside in the 18 amino acids after D13, from Lys(877) to Arg(894).	Univ S Australia, Sch Pharm & Med Sci, Ctr Adv Biomed Studies, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Physiol, Adelaide, SA 5005, Australia	University of South Australia; University of Adelaide	Bretag, AH (corresponding author), Univ S Australia, Sch Pharm & Med Sci, Ctr Adv Biomed Studies, N Terrace, Adelaide, SA 5000, Australia.		Hryciw, Deanne/P-2642-2019; hughes, bernard p/D-1407-2009	Hryciw, Deanne/0000-0003-1697-8890; Rychkov, Grigori/0000-0002-2788-2977; Hughes, Bernard/0000-0002-4850-6794				Astill DS, 1996, BBA-BIOMEMBRANES, V1280, P178, DOI 10.1016/0005-2736(95)00281-2; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Beck CL, 1996, P NATL ACAD SCI USA, V93, P11248, DOI 10.1073/pnas.93.20.11248; GAUDETTE MF, 1991, NUCLEIC ACIDS RES, V19, P1879, DOI 10.1093/nar/19.8.1879; GEORGE AL, 1994, HUM MOL GENET, V3, P2071; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Lloyd SE, 1997, J CLIN INVEST, V99, P967, DOI 10.1172/JCI119262; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; MEYERKLEINE C, 1995, AM J HUM GENET, V57, P1325; Ponting CP, 1997, J MOL MED-JMM, V75, P160; Possee RD., 1992, BACULOVIRUS EXPRESSI; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; Rychkov GY, 1997, J PHYSIOL-LONDON, V501, P355, DOI 10.1111/j.1469-7793.1997.355bn.x; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x	19	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4304	4307		10.1074/jbc.273.8.4304	http://dx.doi.org/10.1074/jbc.273.8.4304			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468477	hybrid			2022-12-27	WOS:000072115000005
J	Allen, PB; Kwon, YG; Nairn, AC; Greengard, P				Allen, PB; Kwon, YG; Nairn, AC; Greengard, P			Isolation and characterization of PNUTS, a putative protein phosphatase 1 nuclear targeting subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; TYPE-1; PHOSPHORYLATION; IDENTIFICATION; ENCODES; GENE; MECHANISM; AFFINITY; SEQUENCE; MITOSIS	Protein phosphatase 1 (PP1) is found in the cell nucleus and has been implicated in several aspects of nuclear function. We report here the cloning and initial characterization of a novel protein similar to named phosphatase 1 nuclear targeting Subunit (PNUTS). This protein interacts with PP1 in a yeast two-hybrid assay, is found in a stable complex with PP1 in mammalian cell lysates, and exhibits a potent modulation of PP1 catalytic activity toward exogenous substrate in vitro. PNUTS is a ubiquitously expressed protein that exhibits a discreet nuclear compartmentalization and is colocalized with chromatin at distinct phases during mitosis. The subcellular localization of PP1 and the activity toward substrates involved in many aspects of cell physiology have previously been shown to be regulated by association with noncatalytic targeting subunits. The properties of PNUTS are consistent with its role as a targeting subunit for the regulation of nuclear PP1 function.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Hallym Univ, Hallym Acad Sci, Inst Environm & Life Sci, Chunchon 200703, Kangwon Do, South Korea	Rockefeller University; Hallym University	Allen, PB (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	allenp@rockvax.rockefeller.edu		Nairn, Angus/0000-0002-7075-0195	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA010044] Funding Source: Medline; NIMH NIH HHS [MH 40899] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN P, 1988, METHOD ENZYMOL, V159, P390; da Cruz e Silva E.F., 1995, J NEUROSCI, V15, P3375; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DURFEE T, 1993, GENE DEV, V7, P55; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Totaro A, 1996, GENOMICS, V31, P319, DOI 10.1006/geno.1996.0054; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x	38	133	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4089	4095		10.1074/jbc.273.7.4089	http://dx.doi.org/10.1074/jbc.273.7.4089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461602	hybrid			2022-12-27	WOS:000072048400044
J	Trifa, Y; Privat, I; Gagnon, J; Baeza, L; Lerbs-Mache, S				Trifa, Y; Privat, I; Gagnon, J; Baeza, L; Lerbs-Mache, S			The nuclear RPL4 gene encodes a chloroplast protein that co-purifies with the T7-like transcription complex as well as plastid ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; TATA-BINDING PROTEIN; ESCHERICHIA-COLI; COMPLETE SEQUENCE; ANTITERMINATION FACTORS; NUCLEOTIDE-SEQUENCE; GENOME; DNA; SPINACH; OPERON	We have cloned and sequenced the cDNA and the gene coding for plastid ribosomal protein L4 (RPL4) from two higher plant species, spinach and Arabidopsis thaliana. Ribosomal protein L4 is one of the ribosomal proteins far which extraribosomal functions in transcriptional regulation has been demonstrated in prokaryotes, Sequence comparison of the two plant cDNAs and genes shows that the RPL4 gene has acquired a remarkable 3' extension during evolutionary transfer to the nuclear genome. This extension harbors an intron and codes for a glutamic and aspartic acid-rich amino acid sequence that resembles highly acidic C-terminal tails of same transcription factors, Co-purification of ribosomal protein L4 with plastid RNA polymerase and transcription factor CDF2 using different purification protocols as well as the surprising amino acid sequence of the L4 protein make it a likely candidate to play a role in plastid transcriptional regulation.	Univ Grenoble 1, Lab Genet Mol Plantes, F-38041 Grenoble, France; CNRS, F-38041 Grenoble, France; Inst Biol Struct JP Ebel, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Lerbs-Mache, S (corresponding author), Univ Grenoble 1, Lab Genet Mol Plantes, BP 53, F-38041 Grenoble, France.		Gagnon, Jean/C-3136-2008	Gagnon, Jean/0000-0002-0177-824X				Allison LA, 1996, EMBO J, V15, P2802, DOI 10.1002/j.1460-2075.1996.tb00640.x; BAEZA L, 1991, NUCLEIC ACIDS RES, V19, P3577, DOI 10.1093/nar/19.13.3577; BAUMGARTNER BJ, 1993, PLANT PHYSIOL, V101, P781, DOI 10.1104/pp.101.3.781; DESARO FJL, 1995, J MOL BIOL, V252, P189, DOI 10.1006/jmbi.1995.0487; DORNE AM, 1984, MOL GEN GENET, V193, P129, DOI 10.1007/BF00327425; EISERMANN A, 1990, EMBO J, V9, P3981, DOI 10.1002/j.1460-2075.1990.tb07619.x; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; HALLICK RB, 1993, NUCLEIC ACIDS RES, V21, P3537, DOI 10.1093/nar/21.15.3537; HARRAK H, 1995, PLANT PHYSIOL, V108, P685, DOI 10.1104/pp.108.2.685; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; HERMANNLEDENMAT S, 1994, J MOL BIOL, V240, P1; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; INOSTROZA JA, 1992, CELL, V70, P477; IRATNI R, 1994, GENE DEV, V8, P2928, DOI 10.1101/gad.8.23.2928; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; Kudla J, 1996, EMBO J, V15, P7137, DOI 10.1002/j.1460-2075.1996.tb01105.x; LERBS S, 1988, MOL GEN GENET, V211, P459, DOI 10.1007/BF00425701; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; LINDAHL L, 1983, CELL, V33, P241, DOI 10.1016/0092-8674(83)90353-7; MAIER RM, 1995, J MOL BIOL, V251, P614, DOI 10.1006/jmbi.1995.0460; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MOSRIN C, 1990, MOL CELL BIOL, V10, P4737, DOI 10.1128/MCB.10.9.4737; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; Payet D, 1997, J MOL BIOL, V266, P66, DOI 10.1006/jmbi.1996.0782; POSNO M, 1984, CURR GENET, V8, P147, DOI 10.1007/BF00420227; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; SHA YZ, 1995, J MOL BIOL, V245, P474, DOI 10.1006/jmbi.1994.0039; SHI X, 1966, MOL CELL BIOL, V16, P669; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; Stirewalt VL, 1995, PLANT MOL BIOL REP, V13, P327, DOI 10.1007/BF02669186; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Wakasugi T, 1997, P NATL ACAD SCI USA, V94, P5967, DOI 10.1073/pnas.94.11.5967; WAKASUGI T, 1994, P NATL ACAD SCI USA, V91, P9794, DOI 10.1073/pnas.91.21.9794; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648; Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/S0968-0004(96)20011-8; Yoon JB, 1996, MOL CELL BIOL, V16, P1; ZENGEL JM, 1990, P NATL ACAD SCI USA, V87, P2675, DOI 10.1073/pnas.87.7.2675; ZENGEL JM, 1980, CELL, V21, P523, DOI 10.1016/0092-8674(80)90490-0; ZENGEL JM, 1993, NUCLEIC ACIDS RES, V21, P2429, DOI 10.1093/nar/21.10.2429; ZENGEL JM, 1992, GENE DEV, V6, P2655, DOI 10.1101/gad.6.12b.2655	51	36	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3980	3985		10.1074/jbc.273.7.3980	http://dx.doi.org/10.1074/jbc.273.7.3980			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461586	hybrid			2022-12-27	WOS:000072048400028
J	Budinger, GRS; Duranteau, J; Chandel, NS; Schumacker, PT				Budinger, GRS; Duranteau, J; Chandel, NS; Schumacker, PT			Hibernation during hypoxia in cardiomyocytes - Role of mitochondria as the O-2 sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEASURING OXYGEN CONCENTRATION; DOWN-REGULATION; CONTRACTION; ADAPTATION; DEPENDENCE; ISCHEMIA; CELLS; RAT	During myocardial hibernation, decreases in coronary perfusion elicit inhibition of contraction, suggesting that energy demand is attenuated. We previously found an inhibition of contraction and O-2 consumption during hypoxia (3% O-2; PO2 = 20 torr for >2 h) in cardiomyocytes, which was reversible after reoxygenation. This study sought to determine whether mitochondria function as cellular O-2 sensors mediating this response. Embryonic cardiomyocytes were studied under controlled O-2 conditions. Hypoxia produced no acute decrease in mitochondrial potential as assessed using tetramethylrhodamine ethylester (TMRE). Cellular [ATP] was preserved throughout hypoxia, as assessed using the probe Magnesium Green. Thus, ATP synthesis and utilization remained closely coupled. Cells adapted to hypoxia for >2 h exhibited a 4% increase in mitochon drial potential upon reoxygenation, suggesting that a partial inhibition of cytochrome c oxidase had existed. To test whether the oxidase serves as an O-2 sensor, azide was administered (1 mM) to simulate the effects of hypoxia by lowering the V-max of the oxidase. The effects of azide on contraction and mitochondrial potential mimicked the response to hypoxia. We conclude that partial inhibition of cytochrome oxidase during hypoxia allows mitochondria to function as the O-2 sensor mediating the decreases in ATP utilization and O-2 consumption during hypoxia.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Schumacker, PT (corresponding author), Univ Chicago, Dept Med, MC6026,5841 S Maryland Ave, Chicago, IL 60637 USA.			Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL32646, HL35440] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R01HL032646, R55HL032646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI AE, 1995, CIRCULATION, V92, P244, DOI 10.1161/01.CIR.92.2.244; ARAI AE, 1991, CIRC RES, V69, P1458, DOI 10.1161/01.RES.69.6.1458; BARRY WH, 1980, AM J PHYSIOL, V239, pH651, DOI 10.1152/ajpheart.1980.239.5.H651; BUDINGER GRS, 1996, AM J PHYSIOL, V14, pL37; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; Heusch G, 1996, J MOL CELL CARDIOL, V28, P2359, DOI 10.1006/jmcc.1996.0229; ITO BR, 1995, CIRCULATION, V91, P2058, DOI 10.1161/01.CIR.91.7.2058; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; LEE SC, 1993, CARDIOVASC RES, V27, P1542, DOI 10.1093/cvr/27.8.1542; Leyssens A, 1996, J PHYSIOL-LONDON, V496, P111, DOI 10.1113/jphysiol.1996.sp021669; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; MARBAN E, 1991, CIRCULATION, V83, P681, DOI 10.1161/01.CIR.83.2.681; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Opie LH, 1996, J MOL CELL CARDIOL, V28, P2403, DOI 10.1006/jmcc.1996.0233; PETERSEN LC, 1977, BIOCHIM BIOPHYS ACTA, V460, P299, DOI 10.1016/0005-2728(77)90216-X; ROSS J, 1991, CIRCULATION, V83, P1076, DOI 10.1161/01.CIR.83.3.1076; RUMSEY WL, 1990, J BIOL CHEM, V265, P15392; Silverman HS, 1997, CIRC RES, V80, P699, DOI 10.1161/01.RES.80.5.699; WILSON DF, 1988, J BIOL CHEM, V263, P2712	24	123	126	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3320	3326		10.1074/jbc.273.6.3320	http://dx.doi.org/10.1074/jbc.273.6.3320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452449	hybrid			2022-12-27	WOS:000071822300034
J	Henke, B; Girzalsky, W; Berteaux-Lecellier, V; Erdmann, R				Henke, B; Girzalsky, W; Berteaux-Lecellier, V; Erdmann, R			IDP3 encodes a peroxisomal NADP-dependent isocitrate dehydrogenase required for the beta-oxidation of unsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 3-OXOACYL-COA THIOLASE; NUCLEOTIDE-SEQUENCE; CANDIDA-TROPICALIS; TARGETING SIGNAL; SHUTTLE VECTORS; PROTEIN IMPORT; YEAST GENES; OLEIC-ACID; IDENTIFICATION	In Saccharomyces cerevisiae the metabolic degradation of saturated fatty acids is exclusively confined to peroxisomes. In addition to a functional beta-oxidation system, the degradation of unsaturated fatty acids requires auxiliary enzymes, including a Delta 2,Delta 3-enoyl-CoA isomerase and an NADPH-dependent 2,4-dienoyl-CoA reductase. We found both enzymes to be present in yeast peroxisomes. The impermeability of the peroxisomal membrane for pyrimidine nucleotides led to the question of how the NADPH needed by the reductase is regenerated in the peroxisomal lumen. We report the identification and functional analysis of the IDP3 gene product, which is a yeast peroxisomal NADP-dependent isocitrate dehydrogenase. The newly identified peroxisomal protein is homologous to the mitochondrial Idp1p and cytosolic Idp2p, which both are yeast NADP-dependent isocitrate dehydrogenases. Yeast cells lacking Idp3p grow normally on saturated fatty acids, but growth is impaired on unsaturated fatty acids, indicating that the peroxisomal Idp3p is involved in their metabolic utilization. The data presented are consistent with the assumption that peroxisomes of S. cerevisiae contain the enzyme equipment needed for the degradation of unsaturated fatty acids, including an NADP-dependent isocitrate dehydrogenase, a putative constituent of a peroxisomal NADPH-regenerating redox system.	Ruhr Univ Bochum, Inst Physiol Chem, Dept Physiol Chem, D-44780 Bochum, Germany	Ruhr University Bochum	Erdmann, R (corresponding author), Ruhr Univ Bochum, Inst Physiol Chem, Dept Physiol Chem, Univ Str 150, D-44780 Bochum, Germany.	Ralf.Erdmann@rz.ruhr-uni-bochum.de	BERTEAUX-LECELLIER, Veronique/P-6456-2019; Berteaux-Lecellier, Veronique/O-4767-2018	BERTEAUX-LECELLIER, Veronique/0000-0003-2152-6231; Berteaux-Lecellier, Veronique/0000-0003-2152-6231				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel FM, 1988, MOL REPROD DEV; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; COOPER TG, 1969, J BIOL CHEM, V244, P3514; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAIGNANFORNIER B, 1994, MOL GEN GENET, V243, P575, DOI 10.1007/BF00284206; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Erdmann R, 1996, J CELL BIOL, V135, P111, DOI 10.1083/jcb.135.1.111; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P569; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; HARLOW E, 1988, ANTIBODIES; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; Maniatis T., 1982, MOL CLONING LAB MANU; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; OPPERDOES FR, 1988, TRENDS BIOCHEM SCI, V13, P255, DOI 10.1016/0968-0004(88)90158-2; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rottensteiner H, 1996, EMBO J, V15, P2924, DOI 10.1002/j.1460-2075.1996.tb00655.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STOFFEL W, 1965, H-S Z PHYSIOL CHEM, V341, P76, DOI 10.1515/bchm2.1965.341.1.76; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YAMAMOTO S, 1995, ARCH MICROBIOL, V163, P104, DOI 10.1007/BF00381783	53	79	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3702	3711		10.1074/jbc.273.6.3702	http://dx.doi.org/10.1074/jbc.273.6.3702			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452501	hybrid			2022-12-27	WOS:000071822300086
J	O'Handley, SF; Frick, DN; Dunn, CA; Bessman, MJ				O'Handley, SF; Frick, DN; Dunn, CA; Bessman, MJ			Orf186 represents a new member of the Nudix hydrolases, active on adenosine(5 ')triphospho(5 ')adenosine, ADP-ribose, and NADH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; ESCHERICHIA-COLI; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; MUTATOR GENE; MUTT ENZYME; FHIT GENE; PROTEINS; CLONING; PURIFICATION	orf186, a new member of the Nudix hydrolase family of genes, has been cloned and expressed, and the protein has been purified and identified as an enzyme highly specific for compounds of ADP. Its three major substrates are adenosine(5') triphospho(5') adenosine, ADP-ribose, and NADH, all implicated in a variety of cellular regulatory processes, supporting the notion that the function of the Nudix hydrolases is to monitor the concentrations of reactive nucleoside diphosphate derivatives and to help modulate their accumulation during cellular metabolism.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Frick, David/0000-0002-2434-7223; O'Handley, Suzanne/0000-0001-8373-0065; Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1960, J BIOL CHEM, V235, P769; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BAXI MD, 1995, J PHARMACOL TOX MET, V33, P121, DOI 10.1016/1056-8719(94)00127-P; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1990, J BACTERIOL, V172, P2802, DOI 10.1128/jb.172.5.2802-2803.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; Bucala R, 1992, Adv Pharmacol, V23, P1; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CervantesLaurean D, 1996, J BIOL CHEM, V271, P10461, DOI 10.1074/jbc.271.18.10461; Cleland W W, 1979, Methods Enzymol, V63, P103; Fernandez A, 1996, BBA-GEN SUBJECTS, V1290, P121, DOI 10.1016/0304-4165(96)00019-0; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; GLASER L, 1965, BIOCHIM BIOPHYS ACTA, V101, P6, DOI 10.1016/0926-6534(65)90025-4; GURANOWSKI A, 1992, AP4A OTHER DINUCLEOS, P81; Hankin S, 1997, INT J BIOCHEM CELL B, V29, P317, DOI 10.1016/S1357-2725(96)00153-7; HURTADO C, 1987, J BACTERIOL, V169, P1718, DOI 10.1128/jb.169.4.1718-1723.1987; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KAMIYA H, 1995, J BIOL CHEM, V270, P19446, DOI 10.1074/jbc.270.33.19446; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; LAZEWSKA D, 1993, PROTEIN EXPRES PURIF, V4, P45, DOI 10.1006/prep.1993.1007; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MARKHAM R, 1952, BIOCHEM J, V52, P552, DOI 10.1042/bj0520552; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MCCREANOR GM, 1983, BIOCHIM BIOPHYS ACTA, V759, P222, DOI 10.1016/0304-4165(83)90316-1; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P221, DOI 10.1007/BF00928465; McLennan AG., 1992, AP4A OTHER DINUCLEOS; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MOSS J, 1994, MOL CELL BIOCH, V138; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OLIVERA BM, 1989, ADP RIBOSE TRANSFER, P353; RIORDAN JF, 1977, SCIENCE, V195, P884, DOI 10.1126/science.190679; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SONNINO S, 1966, ARCH BIOCHEM BIOPHYS, V116, P26, DOI 10.1016/0003-9861(66)90007-5; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	53	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3192	3197		10.1074/jbc.273.6.3192	http://dx.doi.org/10.1074/jbc.273.6.3192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452430	hybrid			2022-12-27	WOS:000071822300015
J	Muzio, M; Stockwell, BR; Stennicke, HR; Salvesen, GS; Dixit, VM				Muzio, M; Stockwell, BR; Stennicke, HR; Salvesen, GS; Dixit, VM			An induced proximity model for caspase-8 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; SIGNAL-TRANSDUCTION; TNF RECEPTOR; PROTEASE; APOPTOSIS; INHIBITION; DOMAIN	The assembly of the CD-95 (Fas/Apo-1) receptor death-inducing signaling complex occurs in a hierarchical manner; the death domain of CD-95 binds to the corresponding domain in the adapter molecule Fas-associated death domain (FADD) Mort-l, which in turn recruits the zymogen form of the death protease caspase-8 (FLICE/Mach-1) by a homophilic interaction involving the death effector domains. Immediately after recruitment, the single polypeptide FLICE zymogen is proteolytically processed to the active dimeric species composed of large and small catalytic subunits. Since all caspases cleave their substrates after Asp residues and are themselves processed from the single-chain zymogen to the two-chain active enzyme by cleavage at internal Asp residues, it follows that an upstream caspase can process a downstream zymogen. However, since FLICE represents the most apical caspase in the Fas pathway, its mode of activation has been enigmatic. We hypothesized that the FLICE zymogen possesses intrinsic enzymatic activity such that when approximated, it autoprocesses to the active protease. Support for this was provided by (i) the synthesis of chimeric F(pk)3FLICE molecules that can be oligomerized in vivo by the synthetic cell-permeable dimerizer FK1012H2. Cells transfected with F(pk)3FLICE underwent apoptosis after exposure to FR1012H2; (ii) the creation of a nonprocessable zymogen form of FLICE that retained low but detectable protease activity.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Burnham Inst, La Jolla, CA 92037 USA	University of Michigan System; University of Michigan; Harvard University; Howard Hughes Medical Institute; Sanford Burnham Prebys Medical Discovery Institute	Dixit, VM (corresponding author), Genentech Inc, 1 DNA Way, S San Francisco, CA 94080 USA.		Muzio, Marta/J-9360-2018; dixit, vishva m/A-4496-2012; Stockwell, Brent R/AAE-7200-2019	Muzio, Marta/0000-0002-7761-759X; dixit, vishva m/0000-0001-6983-0326; Stockwell, Brent R/0000-0002-3532-3868	NIGMS NIH HHS [GM-52067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	23	837	873	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2926	2930		10.1074/jbc.273.5.2926	http://dx.doi.org/10.1074/jbc.273.5.2926			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446604	hybrid			2022-12-27	WOS:000071736600059
J	Schafer, SL; Lin, RT; Moore, PA; Hiscott, J; Pitha, PM				Schafer, SL; Lin, RT; Moore, PA; Hiscott, J; Pitha, PM			Regulation of type I interferon gene expression by interferon regulatory factor-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; IFN-BETA-GENE; NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; ALPHA PROMOTER REGION; TRANSCRIPTION FACTOR; FACTOR FAMILY; INDUCIBLE GENES; VIRAL INDUCTION; NUCLEAR FACTOR	The genes of the family of interferon (IFN) regulatory factors (IRF) encode DNA binding transcriptional factors that are involved in modulation of transcription of IFN and interferon-induced genes (ISG), The presence of IRF binding sites in the promoter region of IFNA and IFNB genes indicates that IRF factors recognizing these sites play an important role in the virus-mediated induction of these genes, We have described a novel human gene of this family, IRF-3, that is constitutively expressed in a variety of cell types, IRF-3 binds to the interferon-sensitive response element (ISRE) present in the ISG15 gene promoter and activates its transcriptional activity, In the present study, we examined whether IRF-3 can modulate transcriptional activity of IFNA and IFNB promoter regions, Our results demonstrate that IRF-3 can bind to the IRF-like binding sites present in the virus-inducible region of the IFNA4 promoter and to the PRDIII region of the IFNB promoter but cannot alone stimulate their transcriptional activity in the human cell line, 293, However, the fusion protein generated from the IRF-3 binding domain and the RelA(p65) activation domain effectively activates both IFNA4 and IFNB promoters. Cotransfection of IRF-3 and RelA(p65) expression plasmids activates the IFNB gene promoter but not the promoter of IFNA4 gene that does not contain the NF-kB binding site. Surprisingly, activation of the IFNA4 gene promoter by virus and IRF-1 in these cells was inhibited by IRF-3, These data indicate that in 293 cells IRF-3 does not stimulate expression of IFN genes but can cooperate with RelA(p65) to stimulate the IFNB promoter.	Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; McGill Univ, Dept Microbiol & Immunol, Quebec City, PQ H3T 1E2, Canada; Human Genome Sci Inc, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; McGill University; GlaxoSmithKline; Human Genome Sciences Inc	Pitha, PM (corresponding author), Johns Hopkins Univ, Ctr Oncol, 418 N Bond St, Baltimore, MD 21231 USA.	parowe@welchlink.welch.jhu.edu	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503	NCI NIH HHS [CA09071] Funding Source: Medline; NIAID NIH HHS [AI 19737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIAZ MO, 1994, GENOMICS, V22, P540, DOI 10.1006/geno.1994.1427; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; Genin P, 1995, NUCLEIC ACIDS RES, V23, P5055; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIN RT, 1994, J BIOL CHEM, V269, P17542; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANIATIS T, 1992, TRANSCRIPTION REGULA; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PITHA PM, 1995, SEMIN VIROL, V6, P151, DOI 10.1006/smvy.1995.0020; RAJ NBK, 1989, J BIOL CHEM, V264, P11149; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; RONCO LV, 1997, J INTERFERON RES S2, V17, P1; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; RYALS J, 1985, CELL, V41, P495; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEISZ A, 1992, J BIOL CHEM, V267, P25589; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	55	255	259	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2714	2720		10.1074/jbc.273.5.2714	http://dx.doi.org/10.1074/jbc.273.5.2714			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446577	hybrid			2022-12-27	WOS:000071736600032
J	Mattu, TS; Pleass, RJ; Willis, AC; Kilian, M; Wormald, MR; Lellouch, AC; Rudd, PM; Woof, JM; Dwek, RA				Mattu, TS; Pleass, RJ; Willis, AC; Kilian, M; Wormald, MR; Lellouch, AC; Rudd, PM; Woof, JM; Dwek, RA			The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SECRETORY IMMUNOGLOBULIN-A; O-LINKED OLIGOSACCHARIDES; PERFORMANCE LIQUID-CHROMATOGRAPHY; OVINE SUBMAXILLARY MUCIN; HINGE REGION; HEAVY-CHAIN; RHEUMATOID-ARTHRITIS; COMPLEMENT ACTIVATION; MONOCLONAL-ANTIBODY	The human serum immunoglobulins IgG and IgA1 are produced in bone marrow and both interact with specific cellular receptors that mediate biological events. In contrast to IgA1, the glycosylation of IgG has been well characterized, and its interaction with various Fe receptors (Fc gamma Rs) has been well studied. In this paper, we have analyzed the glycosylation of IgA1 and IgA1 Fab and Fc as well as three recombinant IgA1 molecules, including two N-glycosylation mutants. Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr(228), Ser(230), and Ser(232), while O-glycan sites at Thr(228), Thr(236) are partially occupied. Over 90% of the N-glycans in IgA1 were sialylated, in contrast to IgG, where <10% contain sialic acid. This paper contains the first report of Fab glycosylation in IgA1, and (in contrast to IgG: Fab, which contains only N-linked glycans) both N- and O-linked oligosaccharides were identified. Analysis of the N-glycans attached to recombinant IgA1 indicated that the C alpha 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures. Further analysis of these data suggested that processing at one Fc N-glycosylation site affects the other. Neutrophil Fc alpha R binding studies, using recombinant IgA1, indicated that neither the tailpiece region nor the N-glycans in the C alpha 2 domain contribute to IgA1-neutrophil Fc alpha R binding. This contrasts with IgG, where removal of the Fc N-glycans reduces binding to the Fc gamma R. The primary sequence and disulfide bond pattern of IgA1, together with the crystal structures of IgG1 Fc and mouse IgA Fab and the glycan sequencing data, were used to generate a molecular model of IgA1. As a consequence of both the primary sequence and S-S bond pattern, the N-glycans in IgA1 Fc are not confined within the inter-alpha-chain space. The accessibility of the C alpha 2 N-glycans provides an explanation for the increased sialylation and galactosylation of IgA1 Fc over that of IgG Fc N-glycans, which are confined in the space between the two C gamma 2 domains. This also suggests why in contrast to IgG Fc, the IgA1 N-glycans are not undergalactosylated in rheumatoid arthritis.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark; CNRS, CERMAV, F-38041 Grenoble 9, France; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	University of Oxford; University of Dundee; Aarhus University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Oxford	Mattu, TS (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.		Lellouch, Annemarie/E-9905-2014; Pleass, Richard/N-7831-2019; Pleass, Richard J/L-4148-2015; Wormald, Mark R/G-2785-2011	Pleass, Richard/0000-0001-7438-8296; Pleass, Richard J/0000-0001-7438-8296; Wormald, Mark R/0000-0002-4853-2773; Kilian, Mogens/0000-0002-5861-0472	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN AC, 1995, CLIN EXP IMMUNOL, V100, P470; ANDRE PM, 1990, J CLIN LAB ANAL, V4, P115, DOI 10.1002/jcla.1860040208; Atkin JD, 1996, J IMMUNOL, V157, P156; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BASTIAN A, 1992, BIOL CHEM H-S, V373, P1255, DOI 10.1515/bchm3.1992.373.2.1255; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BREWER JW, 1994, J BIOL CHEM, V269, P17338; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CARRAYANNOPOULO.L, 1996, J EXP MED, V183, P1579; CARRAYANNOPOULO.L, 1994, P NATL ACAD SCI USA, V91, P8348; CHANG SC, 1995, THESIS U OXFORD; CHAPLIN MF, 1986, CARBOHYDRATE ANAL PR, P15; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; Chuang PD, 1997, J IMMUNOL, V158, P724; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DELACROIX DL, 1982, IMMUNOLOGY, V47, P383; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; ENDO T, 1995, MOL IMMUNOL, V32, P931, DOI 10.1016/0161-5890(95)00078-S; ENDO T, 1994, MOL IMMUNOL, V31, P1415, DOI 10.1016/0161-5890(94)90157-0; FALLGREENGEBAUER E, 1993, BIOL CHEM H-S, V374, P1023, DOI 10.1515/bchm3.1993.374.7-12.1023; FIELD MC, 1994, BIOCHEM J, V299, P261, DOI 10.1042/bj2990261; FUJIYAMA Y, 1986, MOL IMMUNOL, V23, P147; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FURUKAWA K, 1990, INT IMMUNOL, V2, P105, DOI 10.1093/intimm/2.1.105; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; Gooley AA, 1997, NATURE, V385, P557, DOI 10.1038/385557a0; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUILE GR, 1994, ANAL BIOCHEM, V222, P231, DOI 10.1006/abio.1994.1478; HICKMAN S, 1977, J BIOL CHEM, V252, P4402; INFANTE AJ, 1979, J BIOL CHEM, V254, P9006; ISHIZAKA T, 1986, P NATL ACAD SCI USA, V83, P8323, DOI 10.1073/pnas.83.21.8323; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P393; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P92; JARVIS GA, 1991, J IMMUNOL, V147, P1962; KEHRY MR, 1982, BIOCHEMISTRY-US, V21, P5415, DOI 10.1021/bi00265a006; Kilian M, 1996, APMIS, V104, P321, DOI 10.1111/j.1699-0463.1996.tb00724.x; KILLEEN N, 1987, EMBO J, V6, P4029, DOI 10.1002/j.1460-2075.1987.tb02747.x; KINOSHITA N, 1991, CANCER RES, V51, P5888; KRUGMANN S, 1997, J IMMUNOL, V159, P224; LEATHERBARROW RJ, 1985, MOL IMMUNOL, V22, P407, DOI 10.1016/0161-5890(85)90125-7; LIU YSV, 1979, J BIOL CHEM, V254, P2839; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Lund J, 1996, J IMMUNOL, V157, P4963; MATSUDA H, 1990, MOL IMMUNOL, V27, P571, DOI 10.1016/0161-5890(90)90076-C; MATTU TS, 1996, THESIS U OXFORD; MELLIS SJ, 1983, J BIOL CHEM, V258, P1557; MESTECKY J, 1995, FASEB J, V9, pA74; MORTON HC, 1993, J IMMUNOL, V151, P4743; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; NIKOLOVA EB, 1994, SCAND J IMMUNOL, V39, P275, DOI 10.1111/j.1365-3083.1994.tb03371.x; PADLAN E, 1991, P NATL ACAD SCI USA, V80, P6632; Pao YL, 1996, BIOCHEM BIOPH RES CO, V219, P157, DOI 10.1006/bbrc.1996.0198; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; PATEL TP, 1992, BIOCHEM J, V285, P839, DOI 10.1042/bj2850839; PIERCECRETEL A, 1981, EUR J BIOCHEM, V114, P169, DOI 10.1111/j.1432-1033.1981.tb06188.x; PIERCECRETEL A, 1989, EUR J BIOCHEM, V182, P457, DOI 10.1111/j.1432-1033.1989.tb14853.x; PirieShepherd SR, 1997, J BIOL CHEM, V272, P7408, DOI 10.1074/jbc.272.11.7408; REINHOLDT J, 1990, INFECT IMMUN, V58, P1186, DOI 10.1128/IAI.58.5.1186-1194.1990; RUDD PM, 1994, IMMUNOLOGY, V83, P99; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; RUSSELL MW, 1989, EUR J IMMUNOL, V19, P2243, DOI 10.1002/eji.1830191210; RUSSELL MW, 1989, SCAND J IMMUNOL, V30, P175, DOI 10.1111/j.1365-3083.1989.tb01199.x; SAVVIDOU G, 1981, MOL IMMUNOL, V18, P793, DOI 10.1016/0161-5890(81)90001-8; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SKEA DL, 1988, MOL IMMUNOL, V25, P1, DOI 10.1016/0161-5890(88)90084-3; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; TAKAHASHI N, 1982, P NATL ACAD SCI-BIOL, V79, P2850, DOI 10.1073/pnas.79.9.2850; TAKAYASU T, 1982, BIOCHEM BIOPH RES CO, V105, P1066, DOI 10.1016/0006-291X(82)91078-6; TAO MH, 1989, J IMMUNOL, V143, P2595; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; TORANO A, 1978, P NATL ACAD SCI USA, V75, P966, DOI 10.1073/pnas.75.2.966; TORANO A, 1977, P NATL ACAD SCI USA, V74, P2301, DOI 10.1073/pnas.74.6.2301; TSUCHIYA N, 1989, J RHEUMATOL, V16, P285; WALKER MR, 1989, BIOCHEM J, V259, P1356; WALLICK SC, 1988, J EXP MED, V168, P1099, DOI 10.1084/jem.168.3.1099; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; WORMALD RW, 1997, BIOCHEMISTRY-US, V36, P1370; WRIGHT A, 1993, SPRINGER SEMIN IMMUN, V15, P259; YANG CY, 1979, H-S Z PHYSIOL CHEM, V360, P1919; Youings A, 1996, BIOCHEM J, V314, P621, DOI 10.1042/bj3140621; YOUNG NM, 1990, MOL IMMUNOL, V27, P1083, DOI 10.1016/0161-5890(90)90096-I; ZHANG W, 1994, IMMUNOLOGY, V81, P137; [No title captured]	92	320	353	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2260	2272		10.1074/jbc.273.4.2260	http://dx.doi.org/10.1074/jbc.273.4.2260			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442070	hybrid			2022-12-27	WOS:000071595200059
J	Mellor, H; Flynn, P; Nobes, CD; Hall, A; Parker, PJ				Mellor, H; Flynn, P; Nobes, CD; Hall, A; Parker, PJ			PRK1 is targeted to endosomes by the small GTPase, RhoB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-N; PKN; LOCALIZATION	RhoB has been shown to be an endosomal GTPase both by immunocytochemistry and electron microscopy, however, its role in endocytosis is unknown. Elucidation of the cellular roles of other members of this superfamily of signaling proteins has come with the identification of their downstream partners. We show here that the recently isolated serine/threonine kinase PRK1 is targeted to the endosomal compartment by RhoB. This is established both through immunofluorescence and cell fractionation. PRK1 is shown to interact with activated RhoB in cells and is localized to endosomes through its Rho-binding HR1 domain. Translocation of PRK1 to the endosomal compartment by RhoB is accompanied by a shift in the electrophoretic mobility of the kinase indicative of an accompanying activation.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Univ London Univ Coll, Mol Cell Biol Lab, MRC, Oncogene & Signal Transduct Grp,Canc Res Campaign, London WC1E 6BT, England; Univ London Univ Coll, Dept Biochem, London WC1E 6BT, England	Cancer Research UK; University of London; University College London; University of London; University College London	Mellor, H (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	Mellor, Harry/0000-0003-3894-0623; parker, peter/0000-0002-6218-2933				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; GORVEL JP, 1995, J BIOL CHEM, V270, P2741, DOI 10.1074/jbc.270.6.2741; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Moorman JP, 1996, J IMMUNOL, V156, P4146; Mukai H, 1996, J BIOL CHEM, V271, P9816, DOI 10.1074/jbc.271.16.9816; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; ROBERTSON D, 1995, J HISTOCHEM CYTOCHEM, V43, P471, DOI 10.1177/43.5.7537292; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645	13	98	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	1998	273	9					4811	4814		10.1074/jbc.273.9.4811	http://dx.doi.org/10.1074/jbc.273.9.4811			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YZ939	9478917	hybrid			2022-12-27	WOS:000072310400001
J	Li, JX; Gao, EW; Mendelson, CR				Li, JX; Gao, EW; Mendelson, CR			Cyclic AMP-responsive expression of the surfactant protein-A gene is mediated by increased DNA binding and transcriptional activity of thyroid transcription factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT FETAL LUNG; FACTOR-I TTF-1; PULMONARY SURFACTANT; MESSENGER-RNA; FUNCTIONAL-CHARACTERIZATION; FAMILY MEMBERS; PHORBOL ESTER; SP-A2 GENES; APOPROTEIN; PROMOTER	Surfactant protein (SP)-A gene transcription is stimulated by factors that increase cyclic AMP. In the present study, we observed that three thyroid transcription factor-1 (TTF-1) binding elements (TBEs) located within a 255 base pair region flanking the 5'-end of the baboon SP-A2 (bSP-A2) gene are required for maximal cyclic AMP induction of bSP-A2 promoter activity. We found that TTF-I DNA binding activity was increased in nuclear extracts of pulmonary type II cells cultured in the presence of cyclic AMP. By contrast, the levels of immunoreactive TTF-1 protein were similar in nuclear extracts of control and cyclic AMP-treated type II cells. The incorporation of [P-32]orthophosphate into immunoprecipitated TTF-1 protein also was markedly increased by cyclic AMP treatment. Moreover, exposure of nuclear extracts from cyclic AMP-treated type II cells either to potato acid phosphatase or alkaline phosphatase abolished the cyclic AMP-induced increase in TTF-1 DNA-binding activity. Interestingly, the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), known to activate protein kinase C, also enhanced incorporation of [P-32]orthophosphate into TTF-I protein; however, the DNA binding activity of TTF-I was decreased in nuclear extracts of TPA-treated type II cells, Expression vectors encoding TTF-1 and the catalytic subunit of protein kinase A (PKA-cat) were cotransfected into A549 lung adenocarcinoma cells together with an SPA:human growth hormone fusion gene (255 base pairs of 5'-flanking DNA from the baboon SP-A2 gene. linked to human ,growth hormone, as reporter) containing TBEs, or with a reporter gene construct containing three tandem TBEs fused upstream of the bSP-A2 gene TATA box and the transcription initiation site, Coexpression of TTF-I and PKA-cat increased fusion gene expression 3-4-fold as compared with expression of TTF-I in the absence of PKA-cat, Moreover, the transcriptional! activity of TTF-1 tvas suppressed by cotransfection of a dominant negative form of PKA regulatory subunit RI alpha. We suggest that a PICA-induced increase of TTF-1 phosphorylation and TEE binding activity mediates cyclic AMP-induced expression of the SP-A gene in lung type II cells.	Univ Texas, SW Med Ctr, Dept Biochem, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Obstet Gynecol, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mendelson, CR (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Cecil H & Ida Green Ctr Reprod Biol Sci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Mendelson, Carole Ruth/0000-0003-1696-9791	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL052647] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10-HL-52647] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; Alcorn JL, 1997, AM J RESP CELL MOL, V17, P672, DOI 10.1165/ajrcmb.17.6.2858; AUTEN RL, 1990, AM J RESP CELL MOL, V3, P491, DOI 10.1165/ajrcmb/3.5.491; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1988, J BIOL CHEM, V263, P2939; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CLEMENTS JA, 1976, BIOCH BASIS PULMONAR, P363; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; FISHER JH, 1988, BIOCHIM BIOPHYS ACTA, V950, P338, DOI 10.1016/0167-4781(88)90130-3; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GAO E, 1993, J BIOL CHEM, V268, P19697; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Gao EW, 1996, AM J PHYSIOL-LUNG C, V271, pL617, DOI 10.1152/ajplung.1996.271.4.L617; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; KATYAL SL, 1992, AM J RESP CELL MOL, V6, P446, DOI 10.1165/ajrcmb/6.4.446; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; Kumar AS, 1997, J BIOL CHEM, V272, P20764, DOI 10.1074/jbc.272.33.20764; LAZZARO D, 1991, DEVELOPMENT, V113, P1095; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCCORMICK SM, 1994, AM J PHYSIOL, V266, pL367, DOI 10.1152/ajplung.1994.266.4.L367; MCCORMICK SM, 1994, AM J PHYSIOL, V266, pL354, DOI 10.1152/ajplung.1994.266.4.L354; MENDELSON CR, 1991, ANNU REV PHYSIOL, V53, P415, DOI 10.1146/annurev.ph.53.030191.002215; MENDELSON CR, 1986, J BIOL CHEM, V261, P9938; Michael LF, 1996, MOL ENDOCRINOL, V10, P159, DOI 10.1210/me.10.2.159; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; ODOM MJ, 1987, ENDOCRINOLOGY, V121, P1155, DOI 10.1210/endo-121-3-1155; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Seidner SR, 1996, AM J PHYSIOL-LUNG C, V271, pL609, DOI 10.1152/ajplung.1996.271.4.L609; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SMITH BT, 1977, AM REV RESPIR DIS, V115, P285; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V7, P335, DOI 10.1165/ajrcmb/7.3.335; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082; YOUNG PP, 1996, AM J PHYSIOL, V271, P6287; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	45	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4592	4600		10.1074/jbc.273.8.4592	http://dx.doi.org/10.1074/jbc.273.8.4592			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468516	hybrid			2022-12-27	WOS:000072115000044
J	Srinivasan, A; Li, F; Wong, A; Kodandapani, L; Smidt, R; Krebs, JF; Fritz, LC; Wu, JC; Tomaselli, KJ				Srinivasan, A; Li, F; Wong, A; Kodandapani, L; Smidt, R; Krebs, JF; Fritz, LC; Wu, JC; Tomaselli, KJ			Bcl-x(L) functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; MEDIATED APOPTOSIS; ICE/CED-3 PROTEASE; DEATH; BCL-2; ICE; PATHWAY; INVOLVEMENT; REQUIREMENT; ACTIVATION	Stimulation of the Fas or tumor necrosis factor receptor 1 (TNFR1) cell surface receptors leads to the activation of the death effector protease, caspase-8, and subsequent apoptosis. In some cells, Bcl-x(L) overexpression can inhibit anti-Fas-and tumor necrosis factor (TNF)-alpha-induced apoptosis, To address the effect of Bcl-x(L) on caspase-8 processing, Fas-and TNFR1-mediated apoptosis were studied in the MCF7 breast carcinoma cell line stably transfected with human Fas cDNA (MCF7/F) or double transfected with Fas and human Bcl-x(L) cDNAs (MCF7/FB). Bcl-x(L) strongly inhibited apoptosis induced by either anti-Fas or TNF-alpha. In addition, Bcl-x(L) prevented the change in cytochrome c immunolocalization induced by anti-Fas or TNF-alpha treatment, Using antibodies that recognize the p20 and p10 subunits of active caspase-8, proteolytic processing of caspase-8 was detected in MCF7/F cells following anti-Fas or TNF-alpha, but not during UV-induced apoptosis, In MCF7/FB cells, caspase-8 was processed normally while processing of the downstream caspase-7 was markedly attenuated, Moreover, apoptosis induced by direct microinjection of recombinant, active caspase-8 was completely inhibited by Bcl-x(L). These data demonstrate that Bcl-x(L) can exert an anti-apoptotic function in cells in which caspase-8 is activated, Thus, at least in some cells, caspase-8 signaling in response to Fas or TNFR1 stimulation is regulated by a Bcl-x(L)-inhibitable step.	IDUN Pharmaceut Inc, Cell Biol, La Jolla, CA 92037 USA		Tomaselli, KJ (corresponding author), IDUN Pharmaceut Inc, Cell Biol, 11085 N Torrey Pines Rd,Suite 300, La Jolla, CA 92037 USA.	ktomasel@idun.com						Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HARLOW E, 1988, ANTIBODIES LAB MANUA, P285; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee RK, 1996, INT IMMUNOL, V8, P991, DOI 10.1093/intimm/8.7.991; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MINASCHEK G, 1989, EXP CELL RES, V183, P434, DOI 10.1016/0014-4827(89)90402-3; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	47	151	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	1998	273	8					4523	4529		10.1074/jbc.273.8.4523	http://dx.doi.org/10.1074/jbc.273.8.4523			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YY117	9468507	hybrid			2022-12-27	WOS:000072115000035
J	Howes, R; Wasserman, JD; Freeman, M				Howes, R; Wasserman, JD; Freeman, M			In vivo analysis of argos structure-function - Sequence requirements for inhibition of the Drosophila epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR EGF RECEPTOR; FAINT-LITTLE-BALL; FACTOR-ALPHA; GENE ENCODES; TGF-ALPHA; SIGNAL-TRANSDUCTION; CELL DETERMINATION; SECRETED PROTEIN; HIGH-AFFINITY	The Drosophila Argos protein is the only known extracellular inhibitor of the epidermal growth factor receptor (EGFR), It is structurally related to the activating ligands, in that it is a secreted protein with a single epidermal growth factor (EGF) domain, To understand the mechanism of Argos inhibition, we have investigated which regions of the protein are essential, A series of deletions were made and tested in vivo; furthermore, by analyzing chimeric proteins between Argos and the activating ligand, Spitz (a transforming growth factor-alpha-like factor), we have examined what makes one inhibitory and the other activating, Our results reveal that Argos has structural requirements that differ from all known EGFR activating ligands; domains flanking the EGF domain are essential for its function, We have also defined the important regions of the atypical Argos EGF domain, The extended B-loop is necessary, whereas the C-loop can be replaced with the equivalent Spitz region without substantially affecting Argos function, Comparison of the argos genes from Drosophila melanogaster and the housefly, Musca domestica, supports our structure-function analysis, These studies are a prerequisite for understanding how Argos inhibits the Drosophila EGFR and provide a basis for designing mammalian EGFR inhibitors.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	mf1@mrc-lmb.cam.ac.uk	Wasserman, JD/AAF-8145-2019; Wasserman, Jonathan D/M-4298-2013	Wasserman, JD/0000-0001-7088-8146; Wasserman, Jonathan D/0000-0001-7088-8146; Freeman, Matthew/0000-0003-0410-5451				AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CHERBAS L, 1994, DROSOPHILA MELANOGAS, P161; CHIA CM, 1995, DEVELOPMENT, V121, P299; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Harlow E., 1988, ANTIBODIES LAB MANUA; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hennig W., 1981, INSECT PHYLOGENY; HOEPRICH PD, 1989, J BIOL CHEM, V264, P19086; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOPPE BL, 1992, BIOTECHNIQUES, V12, P679; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOMORIYA A, 1984, P NATL ACAD SCI-BIOL, V81, P1351, DOI 10.1073/pnas.81.5.1351; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; LEE DC, 1995, PHARMACOL REV, V47, P51; LEJEUNE S, 1993, CANCER RES, V53, P3597; LIN YZ, 1991, BIOCHEMISTRY-US, V30, P3310, DOI 10.1021/bi00227a020; Lohmeyer M, 1997, INT J ONCOL, V10, P677; MACIAS A, 1989, ANTICANCER RES, V9, P177; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MATSUNAMI RK, 1990, FEBS LETT, V264, P105, DOI 10.1016/0014-5793(90)80776-F; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; OKANO H, 1992, DIFFERENTIATION, V52, P1, DOI 10.1111/j.1432-0436.1992.tb00494.x; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RAZ E, 1992, DEVELOPMENT, V114, P113; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; vanZoelen EJJ, 1996, PATHOL RES PRACT, V192, P761, DOI 10.1016/S0344-0338(96)80098-7; WADSWORTH SC, 1985, NATURE, V314, P178, DOI 10.1038/314178a0; WILEY LM, 1995, BIOESSAYS, V17, P839, DOI 10.1002/bies.950171005; WOLFF T, 1991, DEVELOPMENT, V113, P841	69	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					4275	4281		10.1074/jbc.273.7.4275	http://dx.doi.org/10.1074/jbc.273.7.4275			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461626	hybrid			2022-12-27	WOS:000072048400068
J	Tsai, AL; Palmer, G; Xiao, GS; Swinney, DC; Kulmacz, RJ				Tsai, AL; Palmer, G; Xiao, GS; Swinney, DC; Kulmacz, RJ			Structural characterization of arachidonyl radicals formed by prostaglandin H synthase-2 and prostaglandin H synthase-1 reconstituted with mangano protoporphyrin IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; HIGHER OXIDATION-STATE; ENDOPEROXIDE SYNTHASE; TYROSYL RADICALS; CYCLOOXYGENASE CATALYSIS; SELECTIVE-INHIBITION; FATTY-ACIDS; PROTEIN; PURIFICATION; LIPOXYGENASE	A tyrosyl radical generated in the peroxidase cycle of prostaglandin H synthase-1 (PGHS-1) can serve as the initial oxidant for arachidonic acid (AA) in the cyclooxygenase reaction, Peroxides also induce radical formation in prostaglandin H synthase-2 (PGHS-2) and in PGHS-1 reconstituted with mangano, protoporphyrin IX (MnPGHS-1), but the EPR spectra of these radicals are distinct from the initial tyrosyl radical in PGHS-1, We have examined the ability of the radicals in PGHS-2 and MnPGHS-1 to oxidize AA, using single-turnover EPR studies. One wide singlet tyrosyl radical with an overall EPR line width of 29-31 gauss (G) was generated by reaction of PGHS-2 with ethyl hydroperoxide. Anaerobic additions of AA to PGHS-2, immediately after formation of this radical led to its disappearance and emergence of an AA radical (AA.) with a 7-line EPR, substantiated by experiments using octadeuterated AA. Subsequent addition of oxygen resulted in regeneration of the tyrosyl radical, In contrast, the peroxide-generated radical (a 21G narrow singlet) in a Y371F PGHS-2 mutant lacking cyclooxygenase activity failed to react with AA. The peroxide-generated radical in MnPGHS-1 exhibited a line width of 36-38G, but was also able to convert AA to an AA. with an EPR spectrum similar to that found with PGHS-2. These results indicate that the peroxide-generated radicals in PGHS-2 and MnPGHS-1 can each serve as immediate oxidants of AA to form the same carbon-centered fatty acid radical that subsequently reacts with oxygen to form a hydroperoxide, The EPR data for the AA-derived radical formed by PGHS-2 and MnPGHS-1 could be accounted for by a planar pentadienyl radical with two strongly interacting beta-protons at C10 of AA. These results support a functional role for peroxide-generated radicals in cyclooxygenase catalysis by both PGHS isoforms and provide important structural characterization of the carbon-centered AA..	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Roche Biosci, Inflammatory Dis Unit, Palo Alto, CA 94304 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University; Roche Holding	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.				NIGMS NIH HHS [GM21337, GM52170, GM44911] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170, R01GM021337, R37GM021337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BASCETTA E, 1982, 4 CHE7 S3C CHE7 C377, P110; DAVIES AG, 1981, J CHEM SOC PERK T 2, P633, DOI 10.1039/p29810000633; DIETZ R, 1988, EUR J BIOCHEM, V171, P821; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HINCHLIFFE A, 1974, J MOL STRUCT, V23, P273, DOI 10.1016/0022-2860(74)85041-6; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; KULMACZ RJ, 1987, PROSTAGLANDINS RELAT, P207; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1992, J BIOL CHEM, V267, P17753; Tsai AL, 1997, J BIOL CHEM, V272, P8885; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	33	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3888	3894		10.1074/jbc.273.7.3888	http://dx.doi.org/10.1074/jbc.273.7.3888			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461572	hybrid			2022-12-27	WOS:000072048400014
J	von Willebrand, M; Williams, S; Saxena, M; Gilman, J; Tailor, P; Jascur, T; Amarante-Mendes, GP; Green, DR; Mustelin, T				von Willebrand, M; Williams, S; Saxena, M; Gilman, J; Tailor, P; Jascur, T; Amarante-Mendes, GP; Green, DR; Mustelin, T			Modification of phosphatidylinositol 3-kinase SH2 domain binding properties by Abl- or Lck-mediated tyrosine phosphorylation at Tyr-688	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; CHRONIC MYELOGENOUS LEUKEMIA; TCR-ZETA-CHAIN; KINASE-ACTIVITY; BCR-ABL; PHILADELPHIA-CHROMOSOME; SIGNAL TRANSDUCTION; CATALYTIC SUBUNIT; INSULIN-RECEPTOR; PROTEIN-KINASE	In cells expressing the oncogenic Bcr-Abl tyrosine kinase, the regulatory p85 subunit of phosphatidylinositol 3-kinase is phosphorylated on tyrosine residues. We report that this phosphorylation event is readily catalyzed by the Abl and Lck protein-tyrosine kinases in vitro, by Bcr-Abl or a catalytically activated Lck-Y505F in cotransfected COS cells, and by endogenous kinases in transfected Jurkat T cells upon triggering of their T cen antigen receptor, Using these systems, we have mapped a major phosphorylation site to Tyr-688 in the C-terminal. SH2 domain of p85. Tyrosine phosphorylation of p85 in vitro or in vivo was not associated with detectable change in the enzymatic activity of the phosphatidylinositol 3-kinase heterodimer, but correlated with a strong reduction in the binding of same, but not all, phosphoproteins to the SH2 domains of p85, This provides tan additional candidate to the list of SH2 domains regulated by tyrosine phosphorylation and mag explain why association of phosphatidylinositol 3-kinase with same cellular ligands is transient or of lower stoichiometry than anticipated.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, Div Cellular Immunol, San Diego, CA 92121 USA	La Jolla Institute for Immunology; La Jolla Institute for Immunology	Mustelin, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA.	tomas_mustelin@liai.org	Mendes, Gustavo P Amarante/C-8187-2012; Green, Douglas R/N-8083-2018	Mendes, Gustavo P Amarante/0000-0002-7851-6205; Green, Douglas R/0000-0002-7332-1417; Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960, R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35603] Funding Source: Medline; NIGMS NIH HHS [GM52735, GM48960] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AmaranteMendes GP, 1997, CELL DEATH DIFFER, V4, P548, DOI 10.1038/sj.cdd.4400276; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; CARRERA AC, 1994, J BIOL CHEM, V269, P19435; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dennehy KM, 1997, EUR J IMMUNOL, V27, P679, DOI 10.1002/eji.1830270316; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EXLEY M, 1994, J BIOL CHEM, V269, P15140; GOLD MR, 1992, J IMMUNOL, V148, P2012; GOTOH A, 1994, LEUKEMIA, V8, P115; HAYASHI H, 1993, J BIOL CHEM, V268, P7107; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HSI ED, 1989, J BIOL CHEM, V264, P10836; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Lee DM, 1996, INT IMMUNOL, V8, P1195, DOI 10.1093/intimm/8.8.1195; LUO K, 1990, ONCOGENE, V5, P921; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Minshall C, 1996, J IMMUNOL, V156, P939; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1994, SRC FAMILY TYROSINE; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; REIF K, 1993, J BIOL CHEM, V268, P10780; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; Williams S, 1997, EUR J BIOCHEM, V245, P84, DOI 10.1111/j.1432-1033.1997.00084.x; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zenner G, 1996, J CELL BIOCHEM, V63, P94, DOI 10.1002/(SICI)1097-4644(199610)63:1<94::AID-JCB8>3.0.CO;2-V; ZHANG WG, 1993, P NATL ACAD SCI USA, V90, P11317, DOI 10.1073/pnas.90.23.11317; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	1998	273	7					3994	4000		10.1074/jbc.273.7.3994	http://dx.doi.org/10.1074/jbc.273.7.3994			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YX516	9461588	hybrid			2022-12-27	WOS:000072048400030
J	Feron, O; Saldana, F; Michel, JB; Michel, T				Feron, O; Saldana, F; Michel, JB; Michel, T			The endothelial nitric-oxide synthase-caveolin regulatory cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PALMITOYLATION; TRANSLOCATION; CELLS; ACYLATION; PROTEIN; M2	Nitric oxide production in the vascular endothelium is promoted by diverse agonists that transiently increase intracellular Ca2+ concentration and activate the endothelial nitric-oxide synthase (eNOS), a Ca2+/calmodulin-dependent enzyme. eNOS is acylated by the fatty acids myristate and palmitate and is targeted thereby to plasmalemmal signal-transducing domains termed caveolae., eNOS enzyme activity is markedly attenuated by its interactions with caveolin, the structural scaffolding protein of caveolae. Fire have discovered that in living cells, the eNOS-caveolin heteromeric complex undergoes cycles of dissociation and re-association modulated by Ca2+-mobilizing agonists. Calcium ionophore A23187 and the muscarinic cholinergic agonist carbachol both promote the dissociation of eNOS from caveolin in cultured cells, associated with translocation of eNOS from caveolae. As [Ca2+](i) returns to basal levels, eNOS reassociates with caveolin, and the inhibited enzyme complex is then restored to caveolae, a process accelerated by palmitoylation of the enzyme. These data establish an eNOS-caveolin regulatory cycle, wherein enzyme activation is modulated by reversible protein-protein interactions controlled by Ca2+/calmodulin and by enzyme palmitoylation. Alterations in this cycle are likely to have an important influence on nitric oxide-dependent signaling in the vascular wall.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Michel, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Cardiovasc, Thorn Bldg 1210A,75 Francis St, Boston, MA 02115 USA.	michel@calvin.bwh.harvard.edu	FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286				BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DUDEK R, 1995, PHARMACOLOGY, V50, P257, DOI 10.1159/000139290; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FUKUDA S, 1995, BRAIN RES, V696, P30, DOI 10.1016/0006-8993(95)00704-T; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; ISHIZAKA N, 1995, PFLUG ARCH EUR J PHY, V429, P426, DOI 10.1007/BF00374159; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SASE K, 1997, TRENDS CARDIOVAS MED, V7, P25; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; VANHOUTTE PM, 1989, HYPERTENSION, V13, P658, DOI 10.1161/01.HYP.13.6.658; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	31	295	302	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3125	3128		10.1074/jbc.273.6.3125	http://dx.doi.org/10.1074/jbc.273.6.3125			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452418	hybrid			2022-12-27	WOS:000071822300003
J	Minegishi, N; Ohta, J; Suwabe, N; Nakauchi, H; Ishihara, H; Hayashi, N; Yamamoto, M				Minegishi, N; Ohta, J; Suwabe, N; Nakauchi, H; Ishihara, H; Hayashi, N; Yamamoto, M			Alternative promoters regulate transcription of the mouse GATA-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; ZINC-FINGER PROTEIN; BETA-GLOBIN GENE; C-MYC; ERYTHROID-DIFFERENTIATION; XENOPUS GATA-2; HEMATOPOIETIC MESODERM; ENDOTHELIAL-CELLS; MESSENGER-RNA; STEM-CELLS	Transcription factor GATA-2 has been shown to be a key regulator in hematopoietic progenitor cells, To elucidate how the expression of the GATA-2 gene is controlled, we isolated the mouse GATA-2 (mGATA-2) gene. Transcription of mGATA-2 mRNAs was found to initiate from two distinct first exons, both of which encode entirely untranslated regions, while the remaining five exons are shared by each of the two divergent mRNAs. Reverse transcriptase-polymerase chain reaction analysis revealed that GATA-2 mRNA initiated at the upstream first exon (IS) in Sca-1(+)/c-kit(+) hematopoietic progenitor cells, whereas mRNA that initiates at the downstream first exon (IG) is expressed in all tissues and cell lines that express GATA-2. While the structure of the IG exon/promoter shows high similarity to those of the Xenopus and human GATA-2 genes, the IS exon/promoter has not been described previously, When we examined the regulation contributing to IS transcription using transient transfection assays, we found that sequences lying between -79 and -61 are critical for the cell type-specific activity of the IS promoter, DNase I footprinting experiments and electrophoretic mobility shift assays demonstrated the binding of transcription factors to this region, These data indicate that the proximal 80 base pair region of IS promoter is important for the generation of cell type-specific expression of mGATA-2 from the IS exon.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan; Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 98077, Japan	University of Tsukuba; University of Tsukuba; Tohoku University	Yamamoto, M (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305, Japan.	masiya@igaku.md.tsukuba.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CROSS MA, 1994, ONCOGENE, V9, P3013; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EMERSON BM, 1984, P NATL ACAD SCI-BIOL, V81, P95, DOI 10.1073/pnas.81.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Fleenor DE, 1996, GENE, V179, P219, DOI 10.1016/S0378-1119(96)00355-1; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Jippo T, 1996, BLOOD, V87, P993, DOI 10.1182/blood.V87.3.993.bloodjournal873993; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEONARD M, 1993, BLOOD, V82, P1071; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Matsuzaki Y, 1997, BLOOD, V89, P853, DOI 10.1182/blood.V89.3.853; Meng AM, 1997, P NATL ACAD SCI USA, V94, P6267, DOI 10.1073/pnas.94.12.6267; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MORRIS JF, 1995, BLOOD, V86, P3640; MOUTHON MA, 1993, BLOOD, V81, P647; NAGAI T, 1994, BLOOD, V84, P1074, DOI 10.1182/blood.V84.4.1074.bloodjournal8441074; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; Onodera K, 1997, J BIOCHEM, V121, P251; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Partington GA, 1997, DEV BIOL, V181, P144, DOI 10.1006/dbio.1996.8432; PERROTTI D, 1995, MOL CELL BIOL, V15, P6075; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PISCHEDDA C, 1995, P NATL ACAD SCI USA, V92, P3511, DOI 10.1073/pnas.92.8.3511; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WALMSLEY ME, 1994, DEVELOPMENT, V120, P2519; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668; ZON LI, 1993, BLOOD, V81, P3234	54	99	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3625	3634		10.1074/jbc.273.6.3625	http://dx.doi.org/10.1074/jbc.273.6.3625			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452491	hybrid			2022-12-27	WOS:000071822300076
J	Ng, FWH; Shore, GC				Ng, FWH; Shore, GC			Bcl-X-L cooperatively associates with the Bap31 complex in the endoplasmic reticulum, dependent on procaspase-8 and Ced-4 adaptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROTEASE	Bap31 is a polytopic integral membrane protein of the endoplasmic reticulum and forms a complex with Bcl-2/Bcl-X-L, and procaspase-8 (Ng, F., W., H.,, Nguyen, M.,, Kwan, T.,, Branton, P., E.,, Nicholson, W., D.,, Cromlish, J., A., and Shore, G., C., (1997) J., Cell Biol. 139, 327-338), In co-transfected human cells, procaspase-8 is capable of interacting with Ced-4, an important adaptor molecule in Caenorhabditis elegans that binds to and activates the C. elegans procaspase, proCed-3., Here, we show that the predicted death effector homology domain within the cytosolic region of Bap31 interacts with Ced-4 and contributes to recruitment of procaspase-8. Bcl-X-L,, which binds directly but weakly to the polytopic transmembrane region of Bap31, indirectly and cooperatively associates with the Bap31 cytosolic domain, dependent on the presence of procaspase-8 and Ced-4. Ced-4 Delta c does not interact with Bcl-X-L but rather displaces it from Bap31, suggesting that an endogenous Ced-4-like adaptor is a normal constituent of the Bap31 complex and is required for stable association of Bcl-X-L, with Bap31 in vivo., These findings indicate that Bap31 is capable of recruiting essential components of a core death regulatory machinery.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	30	77	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3140	3143		10.1074/jbc.273.6.3140	http://dx.doi.org/10.1074/jbc.273.6.3140			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452422	hybrid			2022-12-27	WOS:000071822300007
J	Sleeman, MW; Donegan, NP; Heller-Harrison, R; Lane, WS; Czech, MP				Sleeman, MW; Donegan, NP; Heller-Harrison, R; Lane, WS; Czech, MP			Association of acyl-CoA synthetase-1 with GLUT4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 GLUCOSE-TRANSPORTER; INSULIN-SENSITIVE CELLS; RAT ADIPOSE-CELLS; SUBCELLULAR TRAFFICKING; 3T3-L1 ADIPOCYTES; FATTY-ACIDS; COENZYME-A; PROTEIN; INTERNALIZATION; KINETICS	GLUT4, the glucose transporter present in insulin-sensitive tissues, resides in intracellular vesicular structures and translocates to the cell surface in response to insulin, In an attempt to identify proteins present in these structures, GLUT4-enriched vesicles prepared from rat adipocytes treated with or without insulin were prepared by sucrose velocity gradient centrifugation and immunoadsorbed with anti-GLUT4 antibody, We report here the sequence identification by high performance liquid chromatography-ion trap mass spectrometry of a p75 protein band, long chain acyl-CoA synthetase-l, specifically present in immunoadsorbed GLUT4-containing vesicles but not in vesicles adsorbed by nonimmune serum. Acyl-CoA synthetase activity detected in GLUT4-enriched vesicles prepared by gradient centrifugation from insulin-treated adipocytes was decreased to about the same extent as GLUT4 protein. Additionally, immunoadsorbed GLUT4 vesicles were found to catalyze palmitoylation of proteins when incubated with labeled palmitate, a pathway that requires palmitate esterification with CoA. These data indicate that the insulin-sensitive membrane compartment that sequesters GLUT4 in fat cells contains long chain acyl-CoA synthetase-l and its product fatty acyl-CoA, shown previously to be required for budding and fusion in membrane trafficking processes.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02318 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University	Czech, MP (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.	Michael.Czech@banyan.ummed.edu		Donegan, Niles/0000-0002-8328-2044				CAIN CC, 1992, J BIOL CHEM, V267, P11681; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CORMONT MJ, 1993, ENDOCRINOLOGY, V129, P3343; CZECH MP, 1993, J BIOL CHEM, V268, P9187; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; ICHIHARA K, 1991, J LIPID RES, V32, P1709; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; MANGROO D, 1995, BIOCHEM CELL BIOL, V73, P223, DOI 10.1139/o95-027; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Mastick CC, 1997, ENDOCRINOLOGY, V138, P2391, DOI 10.1210/en.138.6.2391; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SATOH S, 1993, J BIOL CHEM, V268, P17820; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STAGSTED J, 1993, J BIOL CHEM, V268, P22809; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; VOLCHUK A, 1994, BIOCHEM J, V304, P138; YANG J, 1993, J BIOL CHEM, V268, P4600	31	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 6	1998	273	6					3132	3135		10.1074/jbc.273.6.3132	http://dx.doi.org/10.1074/jbc.273.6.3132			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YV427	9452420	hybrid			2022-12-27	WOS:000071822300005
J	Lannert, H; Gorgas, K; Meissner, I; Wieland, FT; Jeckel, D				Lannert, H; Gorgas, K; Meissner, I; Wieland, FT; Jeckel, D			Functional organization of the Golgi apparatus in glycosphingolipid biosynthesis - Lactosylceramide and subsequent glycosphingolipids are formed in the lumen of the late Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GOLGI; ASPARAGINE-LINKED OLIGOSACCHARIDES; INTEGRAL MEMBRANE-PROTEIN; LOW-MOLECULAR-WEIGHT; BREFELDIN-A; GANGLIOSIDE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; GLUCOSYLCERAMIDE SYNTHESIS; LYSOSOMAL-ENZYMES; PLASMA-MEMBRANE	Biosynthesis of plasma membrane sphingolipids involves the coordinate action of enzymes localized to individual compartments of the biosynthetic secretory pathway of proteins. These stations include the endoplasmic reticulum and the Golgi apparatus. Although a precise localization of all the enzymes that synthesize glycosphingolipids has not been achieved to date, it is assumed that the sequence of events in glycosphingolipid biosynthesis resembles that in glycoprotein biosynthesis, i.e. that early reactions occur in early stations (endoplasmic reticulum and cis/medial Golgi) of the pathway, and late reactions occur in late stations (trans Golgi/trans Golgi network). Using truncated analogues of ceramide and glucosylceramide that allow measurement of enzyme activities in intact membrane fractions, we have reinvestigated the localization of individual enzymes involved in glycosphingolipid biosynthesis and for the first time studied the localization of lactosylceramide synthase after partial separation of Golgi membranes as previously described (Trinchera, M., and Ghidoni, R. (1989) J. Biol. Chem. 264, 15766-15769). Here, we show that the reactions involved in higher glycosphingolipid biosynthesis, including lactosylceramide synthesis, all reside in the lumen of the late Golgi compartments from rat liver.	Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany; Univ Heidelberg, Inst Anat & Zellbiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Jeckel, D (corresponding author), Univ Heidelberg, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	CI1@ix.urz.uni-heidelberg.de						BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIEBERICH E, 1989, BIOL CHEM H-S, V370, P809, DOI 10.1515/bchm3.1989.370.2.809; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burger KNJ, 1996, J CELL BIOL, V133, P15, DOI 10.1083/jcb.133.1.15; CAMBRON LD, 1993, BIOCHEM BIOPH RES CO, V193, P585, DOI 10.1006/bbrc.1993.1664; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DATTA SC, 1988, BIOCHEM BIOPH RES CO, V152, P155, DOI 10.1016/S0006-291X(88)80693-4; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1983, P NATL ACAD SCI-BIOL, V80, P3938, DOI 10.1073/pnas.80.13.3938; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FRITZ VMR, 1995, J NEUROCHEM, V65, P1859; Fritz VMR, 1996, J NEUROCHEM, V67, P1393; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HARTELSCHENK S, 1991, EUR J BIOCHEM, V196, P349, DOI 10.1111/j.1432-1033.1991.tb15823.x; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; IBER H, 1992, J NEUROCHEM, V58, P1533, DOI 10.1111/j.1471-4159.1992.tb11375.x; IBER H, 1989, FEBS LETT, V248, P18, DOI 10.1016/0014-5793(89)80423-5; Jaskiewicz E, 1996, GLYCOCONJUGATE J, V13, P213, DOI 10.1007/BF00731496; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KENDLER A, 1992, J NEUROSCI RES, V31, P205, DOI 10.1002/jnr.490310202; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANNERT H, 1994, FEBS LETT, V342, P91, DOI 10.1016/0014-5793(94)80591-1; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MARTINA JA, 1995, J NEUROCHEM, V64, P1274; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOREAU P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P9, DOI 10.1016/0005-2736(93)90332-T; Nakayama J, 1996, J BIOL CHEM, V271, P3684; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; SHERWOOD AL, 1992, J BIOL CHEM, V267, P25328; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; TABAS I, 1979, J BIOL CHEM, V254, P1655; TRINCHERA M, 1990, J BIOL CHEM, V265, P18242; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VANHELVOORT A, 1995, FEBS LETT, V369, P18, DOI 10.1016/0014-5793(95)00616-H; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	81	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2939	2946		10.1074/jbc.273.5.2939	http://dx.doi.org/10.1074/jbc.273.5.2939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446606	hybrid			2022-12-27	WOS:000071736600061
J	Lee, KN; Im, H; Kang, SW; Yu, MH				Lee, KN; Im, H; Kang, SW; Yu, MH			Characterization of a human alpha(1)-antitrypsin variant that is as stable as ovalbumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; REACTIVE CENTER LOOP; HUMAN ALPHA-1-PROTEINASE INHIBITOR; SERPIN-PROTEASE COMPLEXES; CRYSTAL-STRUCTURE; ALPHA(1)-PROTEINASE INHIBITOR; THERMAL-STABILITY; SUICIDE SUBSTRATE; HINGE REGION; SITE LOOP	The metastability of inhibitory serpins (serine proteinase inhibitors) is thought to play a key role in the facile conformational switch and the insertion of the reactive center loop into the central beta-sheet, A-sheet, during the formation of a stable complex between a serpin and its target proteinase, We have examined the folding and inhibitory activity of a very stable variant of human alpha(1)-antitrypsin, a prototype inhibitory serpin, A combination of seven stabilizing single amino acid substitutions of alpha(1)-antitrypsin, designated Multi-7, increased the midpoint of the unfolding transition to almost that of ovalbumin, a non-inhibitory but more stable serpin, Compared with the wild-type alpha(1)-antitrypsin, Multi-7 retarded the opening of A-sheet significantly, as revealed by the retarded unfolding and latency conversion of the native state, Surprisingly, Multi-7 alpha(1)-antitrypsin could form a stable complex with a target elastase with the same kinetic parameters and the stoichiometry of inhibition as the wild type, indicating that enhanced A sheet closure conferred by Multi-7 does not affect the complex formation, It may be that the stability increase of Multi-7 alpha(1)-antitrypsin is not sufficient to influence the rate of loop insertion during the complex formation.	Korea Res Inst Biosci & Biotechnol, Div Prot Engn, Taejon 305600, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Yu, MH (corresponding author), Korea Res Inst Biosci & Biotechnol, Div Prot Engn, Yu Song Ku, 52 Eh Eun Dong, Taejon 305333, South Korea.							AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; AHMAD F, 1976, BIOCHEMISTRY-US, V15, P5168, DOI 10.1021/bi00668a034; Baldwin RL, 1996, FOLD DES, V1, pR1, DOI 10.1016/S1359-0278(96)00003-X; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; CREIGHTON TE, 1992, NATURE, V356, P194, DOI 10.1038/356194a0; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWON KS, 1994, J BIOL CHEM, V269, P9627; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Whisstock J, 1996, PROTEINS, V26, P288, DOI 10.1002/(SICI)1097-0134(199611)26:3<288::AID-PROT5>3.0.CO;2-A; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WRIGHT HT, 1990, J MOL BIOL, V213, P513; WRIGHT HT, 1994, FEBS LETT, V348, P14, DOI 10.1016/0014-5793(94)00568-0; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	51	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2509	2516		10.1074/jbc.273.5.2509	http://dx.doi.org/10.1074/jbc.273.5.2509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446551	hybrid			2022-12-27	WOS:000071736600006
J	Bayewitch, ML; Avidor-Reiss, T; Levy, R; Pfeuffer, T; Nevo, I; Simonds, WF; Vogel, Z				Bayewitch, ML; Avidor-Reiss, T; Levy, R; Pfeuffer, T; Nevo, I; Simonds, WF; Vogel, Z			Differential modulation of adenylyl cyclases I and II by various G(beta) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEINS; CELLS; EXPRESSION; BRAIN; RESPONSIVENESS; PURIFICATION; ACTIVATION; DIVERSITY; CLONING	The accepted dogma concerning the regulation of adenylyl cyclase (AC) activity by G(beta gamma) dimers states that the various isoforms of AC respond differently to the presence of free G(beta gamma) It has been demonstrated that AC I activity is inhibited and AC II activity is stimulated by G(beta gamma) subunits, This result does not address the possible G differences in modulation that may exist among the different G(beta gamma) heterodimers, Six isoforms of G(beta) and 12 isoforms of G(gamma) have been cloned to date, We have established a cell transfection system in which G(beta) and G(gamma) cDNAs were cotransfected with either AC isoform I or II and the activity of these isoforms was determined, We found that while AC I activity was inhibited by both G(beta 1/gamma 2) and G(beta 5/gamma 2) combinations, AC II responded differentially and was stimulated by G(beta 1/gamma 2). This finding demonstrates differential modulatory activity by different combinations of G(beta gamma) on the same AC isoform and demonstrates another level of complexity within the AC signaling system.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Univ Dusseldorf, Dept Physiol Chem 2, D-40225 Dusseldorf, Germany; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	Weizmann Institute of Science; Heinrich Heine University Dusseldorf; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Vogel, Z (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnvogel@weizmann.weizmann.ac.il	Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-06265] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Droste M, 1996, FEBS LETT, V391, P209, DOI 10.1016/0014-5793(96)00735-1; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HELPER JR, 1992, TRENDS BIOCHEM SCI, V17, P383; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM K, 1989, BIOTECHNIQUES, V7, P576; LOPEZILASACA M, 1997, NATURE, V275, P394; PFEUFFER E, 1991, METHOD ENZYMOL, V195, P83; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UEDA N, 1994, J BIOL CHEM, V269, P4388; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	33	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2273	2276		10.1074/jbc.273.4.2273	http://dx.doi.org/10.1074/jbc.273.4.2273			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442071	hybrid			2022-12-27	WOS:000071595200060
